PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Nicasio, AM; Eagye, KJ; Kuti, EL; Nicolau, DP; Kuti, JL				Nicasio, Anthony M.; Eagye, Kathryn J.; Kuti, Effie L.; Nicolau, David P.; Kuti, Joseph L.			Length of Stay and Hospital Costs Associated with a Pharmacodynamic-Based Clinical Pathway for Empiric Antibiotic Choice for Ventilator-Associated Pneumonia	PHARMACOTHERAPY			English	Article						ventilator-associated pneumonia; VAP; clinical pathway; cost analysis; antibiotics	ACQUIRED PNEUMONIA; RESOURCE UTILIZATION; GUIDELINES; THERAPY; IMPACT; OUTCOMES; ADULTS; ICU	Study Objective. To determine hospital costs associated with the use of a clinical pathway implemented in our intensive care units (ICUs) to optimize antibiotic regimen selection for patients with ventilator-associated pneumonia (VAP) compared with costs in a historical control group treated according to prescriber preference. Design. Retrospective cost analysis from the hospital perspective. Setting. Single, tertiary-care medical center. Patients. One hundred sixty-six adults with VAP from the medical, surgical, and neurotrauma ICUs (73 historical control patients [2004-2005] and 93 patients given an empiric antibiotic clinical pathway for VAP [2006-2007]). Measurements and Main Results. The VAN clinical pathway consisted of an ICU-specific three-drug regimen that considered local minimum inhibitory concentration distributions and a pharmacodynamically optimized dosing strategy Hospital cost data were collected and inflated to 2007 according to the consumer price index. The VAP-related length of treatment, hospitalization costs, and antibiotic costs were compared between groups. The median VAP length of treatment was 24 days (interquartile range [IQR] 13-35 days] and 111 days (IQR 7-17 days) for historical and clinical pathway groups, respectively (p<0.001). Daily hospital costs were similar for both cohorts over the first 7 clays, after which costs declined significantly for patients treated with the clinical pathway (p<0.001). When controlling for baseline differences between groups and length of stay before development of VAP, patients treated with the clinical pathway had shorter lengths of ICU stay after VAP, shorter total hospital lengths of stay after VAP, and lower hospital costs after the treatment of VAP. Median total antibiotic costs for individual patients were similar between groups ($535 [1QR $261-998] vs $482 [IQR $222-985] clinical pathway vs control, p=0.45), and the proportion of VAP hospital resources consumed by antibiotics for both groups was low Conclusion. Although aggressive closing of more costly antibiotics was empirically prescribed using the clinical pathway, patients in this group exhibited a shorter duration of treatment, reduced hospital length of stay after VAP, and lower hospital costs without any significant increase in antibiotic expenditures.	[Nicasio, Anthony M.; Eagye, Kathryn J.; Nicolau, David P.; Kuti, Joseph L.] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06102 USA; [Nicolau, David P.] Hartford Hosp, Dept Med, Div Infect Dis, Hartford, CT 06102 USA; [Kuti, Effie L.] Univ Connecticut, Sch Pharm, Storrs, CT USA	Kuti, JL (corresponding author), Hartford Hosp, Ctr Antiinfect Res & Dev, 80 Seymour St, Hartford, CT 06102 USA.	jkuti@harthosp.org					[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Beardsley JR, 2006, CHEST, V130, P787, DOI 10.1378/chest.130.3.787; Chastre J, 2003, JAMA-J AM MED ASSOC, V290, P2588, DOI 10.1001/jama.290.19.2588; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; Eagye KJ, 2009, SEMIN RESP CRIT CARE, V30, P116, DOI 10.1055/s-0028-1119815; Hoffman JM, 2007, AM J HEALTH-SYST PH, V64, P298, DOI 10.2146/ajhp060545; Hoo GWS, 2005, CHEST, V128, P2778, DOI 10.1378/chest.128.4.2778; Ibrahim EH, 2001, CRIT CARE MED, V29, P1109, DOI 10.1097/00003246-200106000-00003; Kollef KE, 2008, CHEST, V134, P281, DOI 10.1378/chest.08-1116; Kuti JL, 2009, SEMIN RESP CRIT CARE, V30, P102, DOI 10.1055/s-0028-1119814; Lancaster JW, 2008, PHARMACOTHERAPY, V28, P852, DOI 10.1592/phco.28.7.852; McKinnon PS, 1997, CLIN INFECT DIS, V24, P57, DOI 10.1093/clinids/24.1.57; Meyer E, 2007, J ANTIMICROB CHEMOTH, V59, P1148, DOI 10.1093/jac/dkm088; Nicasio AM, 2010, J CRIT CARE, V25, P69, DOI 10.1016/j.jcrc.2009.02.014; Nicolau D. P., 1994, Journal of Burn Care and Rehabilitation, V15, P244, DOI 10.1097/00004630-199405000-00008; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Shorr AF, 2008, CRIT CARE MED, V36, P2335, DOI 10.1097/CCM.0b013e31818103ea; Sun HK, 2006, CHEST, V130, P807, DOI 10.1378/chest.130.3.807; Warren DK, 2003, CRIT CARE MED, V31, P1312, DOI 10.1097/01.CCM.0000063087.93157.06	21	24	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-0008	1875-9114		PHARMACOTHERAPY	Pharmacotherapy	MAY	2010	30	5					453	462		10.1592/phco.30.5.453			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	588XD	WOS:000277107000005	20411997				2021-06-18	
J	Ringl, H; Schernthaner, RE; Schueller, G; Balassy, C; Kienzl, D; Botosaneanu, A; Weber, M; Czerny, C; Hajdu, S; Mang, T; Herold, CJ; Schima, W				Ringl, Helmut; Schernthaner, Ruediger E.; Schueller, Gerd; Balassy, Csilla; Kienzl, Daniela; Botosaneanu, Ana; Weber, Michael; Czerny, Christian; Hajdu, Stefan; Mang, Thomas; Herold, Christian J.; Schima, Wolfgang			The Skull Unfolded: A Cranial CT Visualization Algorithm for Fast and Easy Detection of Skull Fractures	RADIOLOGY			English	Article							COMPUTED-TOMOGRAPHY; BRAIN-INJURY; 3D CT; BASE; TRAUMA; CRANIOSYNOSTOSIS; RECONSTRUCTION; POPULATION; DIAGNOSIS; RADIOLOGY	Purpose: To retrospectively assess the rate of detection of skull fractures at cranial computed tomography (CT) achieved with the use of curved maximum intensity projections (MIPs) compared with that achieved by reading transverse sections only. Materials and Methods: The institutional review board approved this research and waived informed consent. A curved thin (3-mm) MIP of the skull cap and a curved thick (50-mm) MIP of the skull base were obtained from the cranial CT data in 200 consecutive patients with head trauma. Four radiologists (two residents without experience in cranial CT and two consultants) independently evaluated all cases. Each radiologist reported findings in 100 patients by using transverse sections only and findings in the other 100 patients by using the unfolded view. The radiologists were blinded to patient names, and patient and group orders were randomized. The results were compared with a standard of reference established by two experts from all prior reading results, all reconstructions, and high-spatial-resolution multiplanar reformats. Logistic regression with repeated measurements was used for statistical analysis. Results: The experts found 63 fractures in 30 patients. When transverse sections only were used, the mean patient-based fracture detection rate was 43% (13 of 30) for inexperienced and 70% (21 of 30) for experienced readers; with curved MIPs, the rates were 80% (24 of 30) and 87% (26 of 30), respectively. Overall sensitivity was higher with curved MIPs (P < .001); specificity was higher with transverse sections (P < .001). Conclusion: Curved MIPs enable a significantly higher fracture detection rate than transverse sections. They also considerably close the experience gap in fracture detection rate between residents and experts. (C) RSNA, 2010	[Ringl, Helmut; Schernthaner, Ruediger E.; Schueller, Gerd; Balassy, Csilla; Kienzl, Daniela; Botosaneanu, Ana; Weber, Michael; Czerny, Christian; Mang, Thomas; Herold, Christian J.; Schima, Wolfgang] Med Univ Vienna, Dept Radiol, A-1090 Vienna, Austria; [Hajdu, Stefan] Med Univ Vienna, Dept Trauma Surg, A-1090 Vienna, Austria	Ringl, H (corresponding author), Med Univ Vienna, Dept Radiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	helmut.ringl@meduniwien.ac.at	Schernthaner, Rudiger/AAG-4584-2021; Weber, Michael/L-9836-2016	Weber, Michael/0000-0002-8507-2219; /0000-0002-1194-1346			ALI QM, 1994, NEURORADIOLOGY, V36, P622, DOI 10.1007/BF00600424; Alkadhi H, 2004, J COMPUT ASSIST TOMO, V28, P378, DOI 10.1097/00004728-200405000-00013; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Chen AR, 2006, WIND STRUCT, V9, P59, DOI 10.12989/was.2006.9.1.059; Chen Jian-yu, 2006, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V28, P16; de Boussard CN, 2006, J TRAUMA, V61, P577, DOI 10.1097/01.ta.0000224901.67930.ce; Fatterpekar GM, 2006, RADIOGRAPHICS, V26, pS117, DOI 10.1148/rg.26si065502; FISHMAN EK, 1991, RADIOLOGY, V181, P321, DOI 10.1148/radiology.181.2.1789832; FISHMAN EK, 1993, RADIOGRAPHICS, V13, P463, DOI 10.1148/radiographics.13.2.8460231; GRODD W, 1987, RADIOLOGE, V27, P502; KLEINBAUM DG, 2002, LOGISTIC REGRESSION, P327; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Medina LS, 2000, AM J NEURORADIOL, V21, P1951; *NIH CLIN EXC, 2007, 56 NICE NIH CLIN EXC; Philipp MO, 2003, EUR J RADIOL, V48, P33, DOI 10.1016/S0720-048X(03)00197-9; Remmler D, 2000, ANN PLAS SURG, V44, P553, DOI 10.1097/00000637-200044050-00015; Rieker O, 1998, ROFO-FORTSCHR RONTG, V169, P490, DOI 10.1055/s-2007-1015325; Ringl H, 2009, EUR RADIOL, V19, P2416, DOI 10.1007/s00330-009-1435-1; Rodt T, 2006, DENTOMAXILLOFAC RAD, V35, P227, DOI 10.1259/dmfr/22989395; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Samii M, 2002, NEUROL RES, V24, P147, DOI 10.1179/016164102101199693; VANNIER MW, 1994, AM J NEURORADIOL, V15, P1861; Xu YM, 1999, SHANGHAI KOU QIANG Y, V8, P153	24	24	24	0	3	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	MAY	2010	255	2					553	562		10.1148/radiol.10091096			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	587FU	WOS:000276976200029	20332373	Bronze			2021-06-18	
J	Pasvogel, AE; Miketova, P; Moore, IM				Pasvogel, Alice E.; Miketova, Petra; Moore, Ida M. (Ki)			Differences in CSF Phospholipid Concentration by Traumatic Brain Injury Outcome	BIOLOGICAL RESEARCH FOR NURSING			English	Article						phospholipids; traumatic brain injury; membrane damage; outcome	HUMAN CEREBROSPINAL-FLUID; FREE FATTY-ACIDS; INTERSTITIAL GLYCEROL; APOPTOSIS	Traumatic brain injury (TBI) is a leading cause of morbidity and mortality. A cascade of events is initiated with TBI that leads to degradation of the membrane lipid bilayer of neurons and neuroglia. The purpose of this study was to (a) describe changes in the cerebrospinal fluid (CSF) phospholipid concentration over time for those who survived and those who died following TBI; and (b) determine whether there were differences in the CSF phospholipid concentration between those who survived and those who died following TBI. Thirty-nine CSF samples were obtained from 10 participants who sustained a TBI. Following extraction, phospholipids were separated and quantified by normal-phase high performance liquid chromatography with ultraviolet detector. For those who died, the highest median concentration was on Day 1 after TBI for lysophosphatidylcholine and on Day 4 after TBI for phosphatidylethanolamine, phosphatidylserine, phosphatidylcholine, and sphingomyelin. For those who survived, the highest median concentration was on Day 1 after TBI for phosphatidylcholine, on Day 3 after TBI for phosphatidylethanolamine and phosphatidylserine, on Day 4 after TBI for sphingomyelin, and on Day 5 after TBI for lysophosphatidylcholine. There were significant differences in the concentrations of phosphatidylethanolamine and phosphatidylserine on Days 1-2 and of phosphatidylethanolamine, phosphatidylcholine, and sphingomyelin on Days 3-4 after TBI between those who survived and died, with the highest concentrations in those who died. These findings provide preliminary evidence of greater disruption of central nervous system membrane phospholipids in participants who died after TBI.	[Pasvogel, Alice E.; Miketova, Petra; Moore, Ida M. (Ki)] Univ Arizona, Coll Nursing, Tucson, AZ 85721 USA	Pasvogel, AE (corresponding author), Univ Arizona, Coll Nursing, 1305 N Martin, Tucson, AZ 85721 USA.	pasvogel@nursing.arizona.edu			Beta Mu Chapter, Sigma Theta Tau International	This study was supported by a grant from Beta Mu Chapter, Sigma Theta Tau International.	CHEN SF, 1985, J CHROMATOGR, V344, P297, DOI 10.1016/S0378-4347(00)82030-7; Farooqui AA, 2006, PHARMACOL REV, V58, P591, DOI 10.1124/pr.58.3.7; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; ILLINGWORTH DR, 1971, J NEUROCHEM, V18, P769, DOI 10.1111/j.1471-4159.1971.tb12006.x; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Koch S, 2001, J LIPID RES, V42, P1143; KUNZ F, 1972, Z NEUROL, V203, P259, DOI 10.1007/BF00316117; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; PARSONS L, 1997, J NEUROTRAUM, V14, P784; Pasvogel AE, 2008, BIOL RES NURS, V10, P113, DOI 10.1177/1099800408323218; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	17	24	24	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1099-8004			BIOL RES NURS	Biol. Res. Nurs.	APR	2010	11	4					325	331		10.1177/1099800409346056			7	Nursing	Nursing	574NF	WOS:000275996100002	20338895				2021-06-18	
J	Bhagia, V; Gilkison, C; Fitts, RH; Zgaljardic, DJ; High, WM; Masel, BE; Urban, RJ; Mossberg, KA				Bhagia, Vinita; Gilkison, Charles; Fitts, Robert H.; Zgaljardic, Dennis J.; High, Walter M., Jr.; Masel, Brent E.; Urban, Randall J.; Mossberg, Kurt A.			Effect of recombinant growth hormone replacement in a growth hormone deficient subject recovering from mild traumatic brain injury: A case report	BRAIN INJURY			English	Article						Closed head injury; hypopituitarism; cognition; oxygen consumption; GH deficiency	QUALITY-OF-LIFE; PITUITARY FUNCTION; BODY-COMPOSITION; GH REPLACEMENT; ADULT PATIENTS; EXERCISE; RELIABILITY; DYSFUNCTION; VELOCITY; GLUCAGON	Objective: To assess the effects of growth hormone (GH) replacement in an individual who sustained mild traumatic brain injury (mTBI) as an adult and was found to have GH deficiency by glucagon stimulation testing. Participant: A 43-year old woman who sustained a mild TBI at age 37 years. She was 6.8 years post-injury when she began supplementation. Intervention: Recombinant human GH (rhGH) subcutaneously per day for 1 year. Main outcome measures: Single fibre muscle function was evaluated from muscle biopsies. Body composition, muscle strength and peak aerobic capacity were also measured. In addition, neuropsychological tests of memory, processing speed and motor dexterity and speed, as well as a self-report depression inventory were administered. All assessments were performed at baseline and after 6 and 12 months of rhGH replacement therapy. Results: Single muscle fibre changes were greatest at 6 months. Body composition showed continuous improvement. Muscle strength improved for knee extension. Peak oxygen consumption increased at 6 months and total work and ventilatory equivalents continued to improve at 12 months. Significant improvements in neuropsychological test performance were not found, with the exception of performance on a test of motor dexterity and speed. Conclusion: rhGH replacement in a subject with GH deficiency after mild TBI improves muscle force production, body composition and aerobic capacity. Reliable improvements on tests of cognition were not found in this subject.	[Bhagia, Vinita; Gilkison, Charles; Zgaljardic, Dennis J.; Urban, Randall J.; Mossberg, Kurt A.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Fitts, Robert H.] Marquette Univ, Milwaukee, WI 53233 USA; [Zgaljardic, Dennis J.; Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA; [High, Walter M., Jr.] Univ Kentucky, Lexington, KY USA	Mossberg, KA (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu		Fitts, Robert/0000-0001-9674-1118	Moody Endowment; National Center for Research Resources, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00073]; USPHSUnited States Department of Health & Human ServicesUnited States Public Health Service; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000071] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000073] Funding Source: NIH RePORTER	This work was partially funded by the generous support of the Moody Endowment. Recombinant growth hormone was supplied by Pfizer, Inc. Studies were conducted on the General Clinical Research Center (GCRC) at the University of Texas Medical Branch at Galveston, funded by grant M01 RR 00073 from the National Center for Research Resources, NIH and USPHS. We gratefully acknowledge Renee Pearcy for editorial assistance.	Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Aimaretti G, 2005, THESCIENTIFICWORLDJO, V5, P777, DOI 10.1100/tsw.2005.100; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020; Beck A.T., 1987, BECK DEPRESSION INVE; Benton AL, 1978, MULTILINGUAL APHASIA; Beshyah SA, 1999, CLIN ENDOCRINOL, V50, P1, DOI 10.1046/j.1365-2265.1999.00682.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Centers for Disease Control Prevention [CDC], 2007, TRAUM BRAIN INJ; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695; Delis DC, 2000, CALIFORNIA VERBAL LE; DELORME TL, 1945, J BONE JOINT SURG, V27, P645; Einaudi S, 2007, CURR OPIN PEDIATR, V19, P465, DOI 10.1097/MOP.0b013e3281ab6eeb; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; GRINDELAND RE, 1994, AM J PHYSIOL, V267, pR316; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; IOM, 2009, GULF WAR HLTH, V7; Ives JC, 2007, J ATHL TRAINING, V42, P431; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; KLOVE H, 1963, MED CLINICS N AM; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LINDERMAN JK, 1994, AM J PHYSIOL, V267, pR365; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; MOSSBERG KA, 2003, BRAIN INJURY, V17, P266; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Osterrieth PA, 1993, CLIN NEUROPSYCHOL, V7, P9; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Reitan RM., 1969, MANUAL ADM NEUROPSYC; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Sesmilo Gemma, 2007, Hormones (Athens), V6, P132; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Widrick JJ, 1998, J APPL PHYSIOL, V85, P1949; Widrick JJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1690; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	48	24	25	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2010	24	3					560	567		10.3109/02699051003601705			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800012	20184413				2021-06-18	
J	Ferguson, A; Duffield, G; Worrall, L				Ferguson, Alison; Duffield, Gemma; Worrall, Linda			Legal decision-making by people with aphasia: critical incidents for speech pathologists	INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS			English	Article						aphasia; speech-language therapy; practice	CLINICAL-PRACTICE; MENTAL-CAPACITY; COMPETENCE	Aims: The research presented in this paper aimed to identify the main issues for speech pathologists when decision-making capacity for legal and related matters arose for their clients with aphasia, and to describe qualitatively the nature of these issues and the practices of the speech pathologists in these situations. Methods: & Procedures: The methodology was informed by the qualitative research paradigm and made use of the semi-structured interview methods developed for the Critical Incident Technique. Nine speech pathologists, with a range of clinical experience between three and 27 years, were interviewed by telephone, with verbatim notes being taken on-line by the interviewer. The speech pathologists described a total of 21 clients (15 male, six female) with acquired neurological communication disorders (including cerebral vascular accident, traumatic brain injury, and tumour) whose care had raised critical incidents for the speech pathologist in relation to legal and related matters. These verbatim notes were qualitatively analysed using NVivo qualitative analysis software. Outcomes & Results: The main incidents related to legal decisions (for example, power of attorney, will-making), as well as decisions involving consent for medical treatment, discharge, accommodation, and business/financial decisions. In all but one of the incidents recounted, the issues centred on a situation of conflict between the person with aphasia and their family, friends or with the multidisciplinary team. The roles taken by the speech pathologists ranged from those expected within a speech pathology scope of practice, such as that of assessor and consultant, to those which arguably present dilemmas and conflict of interest, for example, interpreter, advocate. The assessment practices involved some standardized testing, but this was stressed by all participants to be of lesser importance than informal observations of function. Speech pathologists emphasized the importance of multiple observations, and multimodal means of communication. Conclusions: & Implications: The findings indicate that speech pathologists are currently playing an active role when questions arise regarding capacity for legal and related decision-making by people with aphasia. At the same time, the findings support the need for further research to develop guidelines for practice and to build educational experiences for students and novice clinicians to assist them when they engage with the complex case management issues in this area.	[Ferguson, Alison; Duffield, Gemma] Univ Newcastle, Sch Humanities & Social Sci, Callaghan, NSW 2308, Australia; [Worrall, Linda] Univ Queensland, Sch Speech Pathol & Audiol, St Lucia, Qld, Australia	Ferguson, A (corresponding author), Univ Newcastle, Sch Humanities & Social Sci, 1st Floor,McMullin Bldg, Callaghan, NSW 2308, Australia.	Alison.Ferguson@newcastle.edu.au	Worrall, Linda/D-2579-2010	Worrall, Linda/0000-0002-3283-7038			Bazeley P., 2000, NVIVO QUALITATIVE PR; Bellhouse J, 2001, ADV PSYCHIAT TREATME, V7, P294; BRAZIER M, 1991, PROTECTING VULNERABL, P34; CARNEY T, 1997, ADULT GUARDIANSHIP E; CARNEY T, 1986, HUMAN RIGHTS COMMISS, V2; Chapey R., 2001, LANGUAGE INTERVENTIO, P235; Cherry N. L., 2005, HIGH EDUC RES DEV, V24, P309, DOI DOI 10.1080/07294360500284649; Claremont R., 2005, COLLABORATIVE CONFLI; Collier B., 2005, MENTAL CAPACITY POWE; COOK G, 1985, AM J FORENSIC PSYCH, V3, P10; Critchley M., 1970, APHASIOLOGY, P288; Damico JS, 2003, AM J SPEECH-LANG PAT, V12, P131, DOI 10.1044/1058-0360(2003/060); Darzins P, 2000, WHO CAN DECIDE 6 STE; Davidson B, 2003, APHASIOLOGY, V17, P243, DOI 10.1080/729255457; Denzin N.K., 2001, QUALITATIVE RES, V1, P23, DOI [10.1177/146879410100100102, DOI 10.1177/146879410100100102]; Elman RJ, 2000, APHASIOLOGY, V14, P455, DOI 10.1080/026870300401234; ELMAN RJ, 2005, APHASIA RELATED NEUR, P39; Enderby P, 1994, Med Leg J, V62 ( Pt 2), P70; Ferguson A, 2003, APHASIOLOGY, V17, P965, DOI 10.1080/02687030344000337; FERGUSON A, 2008, STROK 2008 C COMB M; FERGUSON A, 2004, 26 WORLD C INT ASS L; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Ganzini Linda, 2004, J Am Med Dir Assoc, V5, P263; Gardner G., 2001, QUALITATIVE RES, V1, P185; Grisso T, 1998, ASSESSMENT DECISION; Hayes S., 2000, HAYES ABILITY SCREEN; Helm-Estabrooks N, 2002, J COMMUN DISORD, V35, P171, DOI 10.1016/S0021-9924(02)00063-1; HERSH D, 2000, RES REFLECT RENEW, P126; Horner Jennifer, 2003, Seminars in Speech and Language, V24, P263; HUER MB, 2006, ASHA LEADER, V6, P28; Kagan A, 1995, CLIN APHASIOL, V23, P65; Keatinge Diana, 2002, Nurs Health Sci, V4, P33, DOI 10.1046/j.1442-2018.2002.00099.x; Kemppainen JK, 2000, J ADV NURS, V32, P1264, DOI 10.1046/j.1365-2648.2000.01597.x; KERRIDGE I, 2005, ETHICS LAW HLTH PROF; Law Society of New South Wales, 2003, LAW SOC J, V41, P50; Morse JM., 1995, QUALITATIVE RES METH, V2; Mullaly E, 2007, AUST PSYCHOL, V42, P178, DOI 10.1080/00050060601187142; Munoz K., 2005, HEALTH EDUC J, V64, P5, DOI [DOI 10.1177/001789690506400102, 10.1177/001789690506400102]; Nicholson TRJ, 2008, BRIT MED J, V336, P322, DOI 10.1136/bmj.39457.485347.80; Parry J., 2007, MENTAL DISABILITY LA; POUND C, 2000, APHASIA THERAPIES LI; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123; Reid D, 2001, DISABIL SOC, V16, P377, DOI 10.1080/09687590120045941; Richards L., 2000, USING NVIVO QUALITAT; Silverman FH., 1992, LEGAL ETHICAL CONSID; Sinding Christina, 2003, QUALITATIVE RESEARCH, V3, P95, DOI 10.1177/1468794103003001770; SPAR JE, 1992, AM J PSYCHIAT, V149, P169; STREET A, 2001, PRACTICE KNOWLEDGE E, P207; Sturges JE, 2004, QUAL RES, V4, P107, DOI DOI 10.1177/1468794104041110; Sullivan K, 2004, NEUROPSYCHOL REV, V14, P131, DOI 10.1023/B:NERV.0000048180.86543.39; UDELL R, 1980, ARCH PHYS MED REHAB, V61, P374; *UK LAW COMM, 1995, 231 UK LAW COMM, V2008; Verma S, 1997, INT J LAW PSYCHIAT, V20, P35, DOI 10.1016/S0160-2527(96)00021-0; Wagner Lynne C. Brady, 2003, Seminars in Speech and Language, V24, P275; WEBSTER EJ, 1982, CLIN APH C P MIN, P64; Wong JG, 1999, PSYCHOL MED, V29, P437, DOI 10.1017/S0033291798008113; WORRALL L, 2007, AM SPEECH LANG HEAR	57	24	24	0	14	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1368-2822			INT J LANG COMM DIS	Int. J. Lang. Commun. Disord.	MAR	2010	45	2					244	258		10.3109/13682820902936714			15	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	560CH	WOS:000274879000009	22748035				2021-06-18	
J	Munjal, SK; Panda, NK; Pathak, A				Munjal, Sanjay Kumar; Panda, Naresh K.; Pathak, Ashis			Relationship between severity of traumatic brain injury (TBI) and extent of auditory dysfunction	BRAIN INJURY			English	Article						Audiological assessment; head injury; auditory brainstem responses	HEAD-INJURY; EVOKED-POTENTIALS	Objective: To find out the relationship between severity of traumatic brain injury (TBI) and extent of auditory dysfunction Background: Most of the studies have taken the subjects with TBI as one group without taking into account the extent of head injury viz, mild, moderate and severe. Combining all the three groups has resulted in presenting an incomplete picture of auditory deficits following TBI. Methods and procedures: The sample population consisted of 290 subjects with TBI (study group) and 50 otologically normal subjects as controls. The subjects in the study group were further sub-divided into mild (n = 150), moderate (n = 100) and severe (n = 40) TBI. The audiological assessment consisted of pure tone audiometry, speech audiometry, tympanometry, acoustic reflex testing, auditory brainstem response and middle latency response audiometry. Results and conclusions: An association was observed between the extent of auditory dysfunction and severity of TBI. This association was more pronounced for hearing status at high frequencies and ABR/MLR components. ABR Wave V absolute latency and I-V interpeak latency increased with severity of TBI. Amplitude of MLR wave Na and Pa decreased with increasing severity. It is suggested that subjects should be evaluated for hearing difficulties based on their severity of TBI.	[Munjal, Sanjay Kumar; Panda, Naresh K.] Postgrad Inst Med Educ & Res, Dept Otolaryngol Head & Neck Surg, Chandigarh 160012, India; [Pathak, Ashis] Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh 160012, India	Panda, NK (corresponding author), Postgrad Inst Med Educ & Res, Dept Otolaryngol Head & Neck Surg, Chandigarh 160012, India.	npanda59@yahoo.co.in					AGUILAR EA, 1986, OTOLARYNG HEAD NECK, V94, P211, DOI 10.1177/019459988609400214; BARBER HO, 1969, ANN OTO RHINOL LARYN, V78, P239, DOI 10.1177/000348946907800204; Bergemalm PO, 2001, ACTA OTO-LARYNGOL, V121, P724, DOI 10.1080/00016480152583674; FACCO E, 1985, ELECTROEN CLIN NEURO, V62, P332, DOI 10.1016/0168-5597(85)90041-3; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HALL JW, 1982, LARYNGOSCOPE, V92, P883; JERGER J, 1970, ARCHIV OTOLARYNGOL, V92, P311; KITCHENS JL, 1991, J PEDIATR SURG, V26, P992, DOI 10.1016/0022-3468(91)90849-O; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2004, AM J PHYS MED REHAB, V83, P210, DOI 10.1097/01.PHM.0000113402.85460.59; LIDEN G, 1974, ARCH OTOLARYNGOL, V99, P23; Mahapatra AK, 1997, NEUROSCIENCE TODAY, V1, P197; Penn C, 2009, INT J AUDIOL, V48, P135, DOI 10.1080/14992020802635309; SATALOFF R, 2006, OCCUPATIONAL HEARING, P411; SCHUKNECHT HF, 1956, ARCHIV OTOLARYNGOL, V63, P513; VALENTE M, 2008, AUDIOLOGY TREATMENT, P241	16	24	28	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2010	24	3					525	532		10.3109/02699050903516872			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800008	20184409				2021-06-18	
J	Tudor, M; Jandric, I; Marovic, A; Gjurasin, M; Perovic, D; Radic, B; Blagaic, AB; Kolenc, D; Brcic, L; Zarkovic, K; Seiwerth, S; Sikiric, P				Tudor, Mario; Jandric, Ivan; Marovic, Anton; Gjurasin, Miroslav; Perovic, Darko; Radic, Bozo; Blagaic, Alenka Boban; Kolenc, Danijela; Brcic, Luka; Zarkovic, Kamelija; Seiwerth, Sven; Sikiric, Predrag			Traumatic brain injury in mice and pentadecapeptide BPC 157 effect	REGULATORY PEPTIDES			English	Article						Traumatic brain injury; Pentadecapeptide BPC 157; Mice	GASTRIC PENTADECAPEPTIDE; RESTRAINT STRESS; CLINICAL-TRIALS; ACHILLES-TENDON; BPC-157; RAT; ETHANOL; PL-14736; PEPTIDE; WOUNDS	Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide, efficient in inflammatory bowel disease trials (PL 14736), no toxicity reported, improved muscle crush injury. After an induced traumatic brain injury (TBI) in mice by a falling weight, BPC 157 regimens (10.0 mu g, 10.0 ng/kg i.p.) demonstrated a marked attenuation of damage with an improved early outcome and a minimal postponed mortality throughout a 24 h post-injury period. Ultimately, the traumatic lesions (subarachnoidal and intraventricular haemorrhage, brain laceration, haemorrhagic laceration) were less intense and consecutive brain edema had considerably improved. Given prophylactically (30 min before TBI) the improved conscious/unconscious/death ratio in TBI-mice was after force impulses of 0.068 N s, 0.093 N s, 0.113 N s, 0.130 N s, 0.145 N s, and 0.159 N s. Counteraction (with a reduction of unconsciousness, lower mortality) with both mu g- and ng-regimens included the force impulses of 0.068-0.145 N s. A higher regimen presented effectiveness also against the maximal force impulse (0.159 N s). Furthermore, BPC 157 application immediately prior to injury was beneficial in mice subjected to force impulses of 0.093 N s-TBI. For a more severe force impulse (0.130 N s, 0.145 N s, or 0159 N s), the time-relation to improve the conscious/unconscious/death ratio was: 5 min (0.130 N s-TBI), 20 min (0.145 N s-TBI) or 30 min (0.159 N s-TBI). (C) 2009 Elsevier B.V. All rights reserved.	[Sikiric, Predrag] Univ Zagreb, Dept Pharmacol, Fac Med, Zagreb 10000, Croatia; Univ Zagreb, Dept Pathol, Fac Med, Zagreb 10000, Croatia	Sikiric, P (corresponding author), Univ Zagreb, Dept Pharmacol, Fac Med, Salata 11,POB 916, Zagreb 10000, Croatia.	sikiric@mef.hr	Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			Andresen J, 2006, J APPL PHYSIOL, V100, P318, DOI 10.1152/japplphysiol.00937.2005; Aziz Q, 1998, GASTROENTEROLOGY, V114, P559, DOI 10.1016/S0016-5085(98)70540-2; Blagaic AB, 2005, EUR J PHARMACOL, V512, P173, DOI 10.1016/j.ejphar.2005.02.033; Blagaic AB, 2004, EUR J PHARMACOL, V499, P285, DOI 10.1016/j.ejphar.2004.07.112; Boban-Blagaic A, 2006, MED SCI MONITOR, V12, pBR36; Boyd JG, 2002, EUR J NEUROSCI, V15, P613, DOI 10.1046/j.1460-9568.2002.01891.x; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Dobric I, 2007, J PHARMACOL SCI, V104, P7, DOI 10.1254/jphs.FP0061322; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jelovac N, 1999, EUR J PHARMACOL, V379, P19, DOI 10.1016/S0014-2999(99)00486-0; Jelovac N, 1998, BIOL PSYCHIAT, V43, P511, DOI 10.1016/S0006-3223(97)00277-1; Jubran M, 2003, EXP NEUROL, V181, P204, DOI 10.1016/S0014-4886(03)00041-4; Klicek R, 2008, J PHARMACOL SCI, V108, P7, DOI 10.1254/jphs.FP0072161; Krivic A, 2008, INFLAMM RES, V57, P205, DOI 10.1007/s00011-007-7056-8; Krivic A, 2006, J ORTHOP RES, V24, P982, DOI 10.1002/jor.20096; Lovric-Bencic M, 2004, J PHARMACOL SCI, V95, P19, DOI 10.1254/jphs.95.19; MAAS AI, 2005, HEAD INJURY, P406; Maier B, 2007, SHOCK, V27, P610, DOI 10.1097/shk.0b013e31802f9eaf; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; Park CO, 1998, YONSEI MED J, V39, P395, DOI 10.3349/ymj.1998.39.5.395; PEVEC D, 2009, MED SCI MON IN PRESS; Prkacin I, 2001, J PHYSIOLOGY-PARIS, V95, P295, DOI 10.1016/S0928-4257(01)00041-9; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Ruenzi M, 2005, GASTROENTEROLOGY, V128, pA584; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sebecic B, 1999, BONE, V24, P195, DOI 10.1016/S8756-3282(98)00180-X; SEBECIC B, 2008, SURG TODAY, V38, P716; Seiwerth S, 1997, J PHYSIOLOGY-PARIS, V91, P173, DOI 10.1016/S0928-4257(97)89480-6; Seveljevic-Jaran D, 2006, SKIN PHARMACOL PHYS, V19, P266, DOI 10.1159/000093982; Sikiric P., 2006, Inflammopharmacology, V14, P214, DOI 10.1007/s10787-006-1531-7; Sikiric P, 2003, BURNS, V29, P323, DOI 10.1016/S0305-4179(03)00004-4; Sikiric P, 1999, EUR J PHARMACOL, V364, P23, DOI 10.1016/S0014-2999(98)00818-8; SIKIRIC P, 1993, LIFE SCI, V53, pPL291, DOI 10.1016/0024-3205(93)90589-U; Sikiric P, 1999, J PHYSIOLOGY-PARIS, V93, P479, DOI 10.1016/S0928-4257(99)00123-0; SIKIRIC P, 1994, LIFE SCI, V54, pPL63, DOI 10.1016/0024-3205(94)00796-9; Sikiric P, 1996, DIGEST DIS SCI, V41, P1604, DOI 10.1007/BF02087908; Sikiric P, 1997, EUR J PHARMACOL, V332, P23, DOI 10.1016/S0014-2999(97)01033-9; Sikiric P, 1999, J PHYSIOL-PARIS, V93, P505, DOI 10.1016/S0928-4257(99)00119-9; SIKIRIC P, 1993, J PHYSIOL-PARIS, V87, P313, DOI 10.1016/0928-4257(93)90038-U; Skorjanec S, 2009, DIGEST DIS SCI, V54, P46, DOI 10.1007/s10620-008-0332-9; Soares HD, 1995, J NEUROSCI, V15, P8223; Staresinic M, 2006, J ORTHOP RES, V24, P1109, DOI 10.1002/jor.20089; Staresinic M, 2003, J ORTHOP RES, V21, P976, DOI 10.1016/S0736-0266(03)00110-4; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tkalcevic VI, 2007, EUR J PHARMACOL, V570, P212, DOI 10.1016/j.ejphar.2007.05.072; Tohyama Y, 2004, LIFE SCI, V76, P345, DOI 10.1016/j.lfs.2004.08.010; URIST MR, 1996, OSTEOLOGIE, V4, P207; VELJACA M, 1995, J PHARMACOL EXP THER, V272, P417; VELJACA M, 1995, GASTROENTEROLOGY, V108, pA761; VELJACA M, 2003, GUT, V51, pA309; Wood JD, 2004, PHYSIOLOGY, V19, P326, DOI 10.1152/physiol.00034.2004; Xue XC, 2004, CHIN NEW DRUGS J, V12, P602; Xue XC, 2004, WORLD J GASTROENTERO, V10, P1032; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	59	24	24	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-0115	1873-1686		REGUL PEPTIDES	Regul. Pept.	FEB 25	2010	160	1-3					26	32		10.1016/j.regpep.2009.11.012			7	Endocrinology & Metabolism; Physiology	Endocrinology & Metabolism; Physiology	560GL	WOS:000274890000004	19931318				2021-06-18	
J	Bai, CH; Chen, JR; Chiu, HC; Chou, CC; Chau, LY; Pan, WH				Bai, Chyi-Huey; Chen, Jiunn-Rong; Chiu, Hou-Chang; Chou, Chia-Chi; Chau, Lee-Young; Pan, Wen-Harn			Shorter GT repeat polymorphism in the heme oxygenase-1 gene promoter has protective effect on ischemic stroke in dyslipidemia patients	JOURNAL OF BIOMEDICAL SCIENCE			English	Article							CORONARY-ARTERY-DISEASE; TRAUMATIC BRAIN-INJURY; MICROSATELLITE POLYMORPHISM; OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; RISK-FACTORS; RAT-BRAIN; EXPRESSION; BILIRUBIN; ATHEROSCLEROSIS	Background: The microsatellite polymorphism of heme oxygenase (HO)-1 gene promoter has been shown to be associated with the susceptibility to ischemic event, including coronary artery disease (CAD), myocardial infarction, and peripheral vascular disease. We aimed to examine whether the length of (GT)(n) repeats in HO-1 gene promoter is associated with ischemic stroke in people with CAD risk factors, especially low level of HDL. Methods: A total of 183 consecutive firstever ischemic stroke inpatients and 164 non-stroke patients were screened for the length of (GT)(n) repeats in HO-1 promoter. The long (L) and short (S) genotype are defined as the averaged repeat number > 26 and <= 26, respectively. Results: Stroke patients tended to have more proportions of hypertension, diabetics and genotype L, than those of genotype S. Patients with genotype L of HO-1 gene promoter have higher stroke risk in comparison with genotype S especially in dyslipidemia individuals. The significant differences on stroke risk in multivariate odds ratios were found especially in people with low HDL-C levels. Conclusions: Subjects carrying longer (GT)(n) repeats in HO-1 gene promoter may have greater susceptibility to develop cerebral ischemic only in the presence of low HDL-C, suggesting the protective effects in HO-1 genotype S in the process of ischemic stroke, particularly in subjects with poor HDL-C status.	[Chau, Lee-Young; Pan, Wen-Harn] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Bai, Chyi-Huey] Shin Kong WHS Mem Hosp, Cent Lab, Taipei, Taiwan; [Bai, Chyi-Huey] Taipei Med Univ, Sch Publ Hlth, Taipei, Taiwan; [Chen, Jiunn-Rong] Changhua Christian Hosp, Yunlin Branch, Yun Lin Cty, Taiwan; [Chiu, Hou-Chang] Shin Kong WHS Mem Hosp, Dept Neurol, Taipei, Taiwan; [Chou, Chia-Chi] Chang Gung Mem Hosp, Dept Internal Med, Chilung, Taiwan	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.	lyc@ibms.sinica.edu.tw; pan@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Pan, Wen-Harn/F-9972-2010	Chau, Lee-Young/0000-0002-6316-2328; Pan, Wen-Harn/0000-0001-9136-0658	Shin Kong WHS Memorial Hospital [SKH-8302-98-NDR-07]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC95-2314-B341-002]	This study was supported by grants from Shin Kong WHS Memorial Hospital (SKH-8302-98-NDR-07) and the National Science Council (NSC95-2314-B341-002). The greatest appreciation should go to the patients who have been participated this study.	BERG A, 1981, INT J SPORTS MED, V2, P121, DOI 10.1055/s-2008-1034596; Bergeron M, 1997, J CEREBR BLOOD F MET, V17, P647; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Carr FJ, 2002, J CEREBR BLOOD F MET, V22, P767, DOI 10.1097/00004647-200207000-00001; Chalmers J, 2000, Heart Dis, V2, pS13; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Chen YH, 2004, EUR HEART J, V25, P39, DOI 10.1016/j.ehj.2003.10.009; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Dick P, 2005, EUR J CLIN INVEST, V35, P731, DOI 10.1111/j.1365-2362.2005.01580.x; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Exner M, 2001, J ENDOVASC THER, V8, P433, DOI 10.1583/1545-1550(2001)008<0433:HOGPMP>2.0.CO;2; Funk M, 2004, THROMB RES, V113, P217, DOI 10.1016/j.thromres.2004.03.003; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; Ginsberg HN, 2002, CIRCULATION, V106, P2137, DOI 10.1161/01.CIR.0000035280.64322.31; Hoekstra KA, 2004, BIOCHEM CELL BIOL, V82, P351, DOI 10.1139/O04-006; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; Idriss NK, 2008, J AM COLL CARDIOL, V52, P971, DOI 10.1016/j.jacc.2008.06.019; Ishikawa K, 2001, J Atheroscler Thromb, V8, P63; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Kajimura M, 2003, FASEB J, V17, P506, DOI 10.1096/fj.02-0359fje; Kaneda H, 2002, ARTERIOSCL THROM VAS, V22, P1680, DOI 10.1161/01.ATV.0000033515.96747.6F; Kawamura K, 2005, ARTERIOSCL THROM VAS, V25, P155, DOI 10.1161/01.ATV.0000148405.18071.6a; Kimpara T, 1997, HUM GENET, V100, P145, DOI 10.1007/s004390050480; KUTTY RK, 1994, GENOMICS, V20, P513, DOI 10.1006/geno.1994.1213; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Le W, 1999, J NEUROSCI RES, V56, P652; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; Lublinghoff N, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-36; MAINES MD, 1988, FASEB J, V2, P2557; Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058; Morgan L, 2005, BRIT J NEUROSURG, V19, P317, DOI 10.1080/02688690500305456; Morita T, 2005, ARTERIOSCL THROM VAS, V25, P1786, DOI 10.1161/01.ATV.0000178169.95781.49; Nofer JR, 2002, ATHEROSCLEROSIS, V161, P1, DOI 10.1016/S0021-9150(01)00651-7; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; Sheu CC, 2009, INTENS CARE MED, V35, P1343, DOI 10.1007/s00134-009-1504-6; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729	40	24	25	1	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1021-7770	1423-0127		J BIOMED SCI	J. Biomed. Sci.	FEB 23	2010	17								12	10.1186/1423-0127-17-12			8	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	570RS	WOS:000275696300001	20175935	DOAJ Gold, Green Published			2021-06-18	
J	Macrae, D; Pappachan, J; Grieve, R; Parslow, R; Nadel, S; Schindler, M; Baines, P; Fortune, PM; Slavik, Z; Goldman, A; Truesdale, A; Betts, H; Allen, E; Snowdon, C; Percy, D; Broadhead, M; Quick, T; Peters, M; Morris, K; Tasker, R; Elbourne, D				Macrae, Duncan; Pappachan, John; Grieve, Richard; Parslow, Roger; Nadel, Simon; Schindler, Margrid; Baines, Paul; Fortune, Peter-Marc; Slavik, Zdenek; Goldman, Allan; Truesdale, Ann; Betts, Helen; Allen, Elizabeth; Snowdon, Claire; Percy, Deborah; Broadhead, Michael; Quick, Tara; Peters, Mark; Morris, Kevin; Tasker, Robert; Elbourne, Diana			Control of hyperglycaemia in paediatric intensive care (CHiP): study protocol	BMC PEDIATRICS			English	Article							ACUTE MYOCARDIAL-INFARCTION; RESPIRATORY-DISTRESS-SYNDROME; ISCHEMIC BRAIN-DAMAGE; DIABETES-MELLITUS; CLINICAL-TRIALS; INSULIN THERAPY; STRESS HYPERGLYCEMIA; HEAD-INJURY; RISK-FACTOR; GLUCOSE	Background: There is increasing evidence that tight blood glucose (BG) control improves outcomes in critically ill adults. Children show similar hyperglycaemic responses to surgery or critical illness. However it is not known whether tight control will benefit children given maturational differences and different disease spectrum. Methods/Design: The study is an randomised open trial with two parallel groups to assess whether, for children undergoing intensive care in the UK aged <= 16 years who are ventilated, have an arterial line in-situ and are receiving vasoactive support following injury, major surgery or in association with critical illness in whom it is anticipated such treatment will be required to continue for at least 12 hours, tight control will increase the numbers of days alive and free of mechanical ventilation at 30 days, and lead to improvement in a range of complications associated with intensive care treatment and be cost effective. Children in the tight control group will receive insulin by intravenous infusion titrated to maintain BG between 4 and 7.0 mmol/l. Children in the control group will be treated according to a standard current approach to BG management. Children will be followed up to determine vital status and healthcare resources usage between discharge and 12 months post-randomisation. Information regarding overall health status, global neurological outcome, attention and behavioural status will be sought from a subgroup with traumatic brain injury (TBI). A difference of 2 days in the number of ventilator-free days within the first 30 days post-randomisation is considered clinically important. Conservatively assuming a standard deviation of a week across both trial arms, a type I error of 1% (2-sided test), and allowing for non-compliance, a total sample size of 1000 patients would have 90% power to detect this difference. To detect effect differences between cardiac and non-cardiac patients, a target sample size of 1500 is required. An economic evaluation will assess whether the costs of achieving tight BG control are justified by subsequent reductions in hospitalisation costs. Discussion: The relevance of tight glycaemic control in this population needs to be assessed formally before being accepted into standard practice.	[Macrae, Duncan; Betts, Helen] Royal Brompton Hosp, Paediat Intens Care Unit, London SW3 6NP, England; [Pappachan, John] Southampton Univ Hosp NHS Trust, Paediat Intens Care Unit, Southampton SO16 6YD, Hants, England; [Grieve, Richard] Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; [Parslow, Roger] Univ Leeds, Ctr Biostat & Epidemiol, Paediat Epidemiol Grp, Leeds LS2 9JT, W Yorkshire, England; [Nadel, Simon] Imperial Healthcare NHS Trust, Paediat Intens Care Unit, London WC2, England; [Schindler, Margrid] Bristol Royal Hosp Children, Paediat Intens Care Unit, Bristol BS2 8BJ, Avon, England; [Baines, Paul] Alder Hey Childrens Hosp, Paediat Intens Care Unit, Liverpool L12 2AP, Merseyside, England; [Fortune, Peter-Marc] Royal Manchester Childrens Hosp, Paediat Intens Care Unit, Manchester M27 4HA, Lancs, England; [Goldman, Allan] Great Ormond St Childrens Hosp, Cardiac Intens Care Unit, London WC1N 3JH, England; [Truesdale, Ann; Allen, Elizabeth; Percy, Deborah] Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England; [Peters, Mark] Great Ormond St Childrens Hosp, Paediat Intens Care Unit, London WC1 3JH, England; [Morris, Kevin] Birmingham Childrens Hosp NHS Fdn Trust, Paediat Intens Care Unit, Birmingham B4 6NH, W Midlands, England; [Tasker, Robert] Univ Cambridge, Dept Paediat, Cambridge B2 0QQ, England; [Elbourne, Diana] Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HI, England	Macrae, D (corresponding author), Royal Brompton Hosp, Paediat Intens Care Unit, Sydney St, London SW3 6NP, England.	D.macrae@rbht.nhs.uk	Parslow, Roger/AAV-1477-2020; Tasker, Robert C/R-5837-2019; Macrae, Duncan/AAC-9564-2020; Peters, Mark/AAD-7518-2019	Peters, Mark/0000-0003-3653-4808; Grieve, Richard/0000-0001-8899-1301; Tasker, Robert/0000-0003-3647-8113; Macrae, Duncan/0000-0002-7158-6585; Parslow, Roger/0000-0002-3945-5294; Snowdon, Claire/0000-0002-9133-5476			Anderson RE, 1999, STROKE, V30, P160, DOI 10.1161/01.STR.30.1.160; Angus DC, 2005, AM J RESP CRIT CARE, V172, P1358, DOI 10.1164/rccm.2508009; [Anonymous], 2000, N ENGL J MED, V342, P1301; [Anonymous], PAEDIAT INTENSIVE CA; ARDIGO D, 2000, CLIN SCI, V99, P37; Ardigo Diego, 2004, Current Drug Targets - Inflammation and Allergy, V3, P455, DOI 10.2174/1568010042634488; Branco Ricardo G, 2005, Pediatr Crit Care Med, V6, P470, DOI 10.1097/01.PCC.0000161284.96739.3A; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Ceriello A, 2005, EUR HEART J, V26, P328, DOI 10.1093/eurheartj/ehi049; Ceriello A, 2002, DIABETES, V51, P1076, DOI 10.2337/diabetes.51.4.1076; CERIELLO A, 2002, DIABETES, V51, P1938; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; CORNBLATH M, 1990, PEDIATRICS, V85, P834; CURLEY MAQ, 2005, PEDIAT CRIT CARE M S, V6, P150; Curtis L., 2007, UNIT COSTS HLTH SOCI; Das UN, 2002, CRIT CARE, V6, P389; Das UN, 2002, NUTRITION, V18, P526, DOI 10.1016/S0899-9007(02)00767-0; Das UN, 2001, NUTRITION, V17, P409, DOI 10.1016/S0899-9007(01)00518-4; DIETRICH WD, 1993, STROKE, V24, P111, DOI 10.1161/01.STR.24.1.111; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Faustino EV, 2005, J PEDIATR-US, V146, P30, DOI 10.1016/j.jpeds.2004.08.076; Ferrando A A, 1999, Curr Opin Clin Nutr Metab Care, V2, P171, DOI 10.1097/00075197-199903000-00014; Ferrando AA, 1999, ANN SURG, V229, P11, DOI 10.1097/00000658-199901000-00002; Field D, 2005, PEDIATRICS, V115, P926, DOI 10.1542/peds.2004-1209; Furnary Anthony P, 2004, Endocr Pract, V10 Suppl 2, P21; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; Gearhart MM, 2006, AACN ADV CRIT CARE, V17, P50, DOI 10.1097/00044067-200601000-00007; Hall NJ, 2004, J PEDIATR SURG, V39, P898, DOI 10.1016/j.jpedsurg.2004.02.005; HALVERSONSTEELE B, 2004, PEDIATRIC CRITICAL C; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Hoxworth JM, 1999, BRAIN RES, V821, P467, DOI 10.1016/S0006-8993(98)01332-8; *I HEALTHC IMPR, SURV SEPS CAMP; Jenkins KJ, 2002, J THORAC CARDIOV SUR, V123, P110, DOI 10.1067/mtc.2002.119064; Katsura K, 2004, BRAIN RES, V1030, P133, DOI 10.1016/j.brainres.2004.10.007; Lacroix J, 2005, PEDIATR CRIT CARE ME, V6, P126; LANGE P, 1989, EUR RESPIR J, V2, P14; Leteurtre S, 1999, MED DECIS MAKING, V19, P399, DOI 10.1177/0272989X9901900408; Li PA, 1998, BRAIN RES, V804, P36, DOI 10.1016/S0006-8993(98)00651-9; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; McManus LM, 2001, J LEUKOCYTE BIOL, V70, P395; OLIVER MF, 1968, LANCET, V1, P710; Paret G, 1999, J ACCID EMERG MED, V16, P186; PAYMENT B, 2008, HEALTH, P9; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pham TN, 2005, J TRAUMA, V59, P1148, DOI 10.1097/01.ta.0000188933.16637.68; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; Rayner CK, 1999, DIGEST DIS SCI, V44, P279, DOI 10.1023/A:1026642114971; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Russo A, 1999, EUR J CLIN INVEST, V29, P512, DOI 10.1046/j.1365-2362.1999.00487.x; Russo A, 1997, GUT, V41, P494, DOI 10.1136/gut.41.4.494; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vriesendorp TM, 2004, EUR J VASC ENDOVASC, V28, P520, DOI 10.1016/j.ejvs.2004.08.006; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; NHS INFORM STANDARDS	59	24	24	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	FEB 5	2010	10								5	10.1186/1471-2431-10-5			14	Pediatrics	Pediatrics	566UX	WOS:000275399800001	20137090	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Thaler, S; Fiedorowicz, M; Rejdak, R; Choragiewicz, TJ; Sulejczak, D; Stopa, P; Zarnowski, T; Zrenner, E; Grieb, P; Schuettauf, F				Thaler, Sebastian; Fiedorowicz, Michal; Rejdak, Robert; Choragiewicz, Tomasz J.; Sulejczak, Dorota; Stopa, Piotr; Zarnowski, Tomasz; Zrenner, Eberhart; Grieb, Pawel; Schuettauf, Frank			Neuroprotective effects of tempol on retinal ganglion cells in a partial optic nerve crush rat model with and without iron load	EXPERIMENTAL EYE RESEARCH			English	Article						optic nerve crush; neuroprotection; tempol; oxidative stress; peroxynitrite; superoxide dismutase; retinal ganglion cells	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; NITROXIDE TEMPOL; NITRIC-OXIDE; INDUCED NEUROTOXICITY; INDUCED APOPTOSIS; DEATH; INHIBITION; SURVIVAL; DAMAGE	Iron overload can contribute to oxidative stress in many tissues. We studied the effects of pretreatment with iron dextran on RGC loss in a calibrated partial optic nerve crush (PONC) model in rats, along with the protection offered by tempol (4-hydroxy-2,2,6,6-tetramethylpiperidinyl-1-oxyl, a membrane-permeable superoxide dismutase mimetic and free-radical scavenger), in the same experimental paradigm. A total of 40 rats in 6 groups of 5-8 animals each underwent PONC in one eye and sham crush in the other. Animals were pretreated with a single iron dextran load 24 h prior to PONC, and treated with tempol 6 h before and then once daily after PONC. Control animals were treated with PBS. RGC were retrogradely labeled with a fluorescent marker; all data are expressed in percent of the RGC count in the respective sham-treated eye. Immunohistochemistry was performed to visualize 3-nitrotyrosine, a marker of nitroxidative stress. PONC without iron pretreatment resulted in the survival of only 31.4% of labeled RGC after 7 days. Even fewer RGC (12.7%) survived after PONC with iron pretreatment. However, tempo] in doses of 20 mg/kg of body weight (BW) significantly attenuated this effect when given as described above; in the group without iron pretreatment the number of surviving RGC doubled from 31.4% to 62.1%. In the group with iron pretreatment the survival rate of RGC increased even more pronouncedly, from 12.7% without tempol to 46.2% with tempol. Tempol in doses of I mg/kg BW and 5 mg/kg BW showed no significant rescue of RGC. Immunostaining showed nitrotyrosine-positive RGCs in PONC but not in sham-treated eyes and an increase in positive cells after iron load. Tempol treatment reduced nitrotyrosine staining in both the iron and non-iron groups. Our results demonstrate that PONC results in significantly greater RGC damage when iron pretreatment is performed, and that the compound tempol may provide additional protection for RGC in cases of neuronal damage both with and without prior iron treatment. (C) 2009 Elsevier Ltd. All rights reserved.	[Thaler, Sebastian] Univ Tubingen, Ctr Ophthalmol, Div Expt Ophthalmol, D-72076 Tubingen, Germany; [Fiedorowicz, Michal; Rejdak, Robert; Sulejczak, Dorota; Grieb, Pawel] Polish Acad Sci, Med Res Ctr, Warsaw, Poland; [Rejdak, Robert; Choragiewicz, Tomasz J.; Stopa, Piotr; Zarnowski, Tomasz] Med Univ, Tadeusz Krwawicz Chair Ophthalmol, Lublin, Poland; [Rejdak, Robert; Choragiewicz, Tomasz J.; Stopa, Piotr; Zarnowski, Tomasz] Med Univ, Eye Hosp 1, Lublin, Poland	Thaler, S (corresponding author), Univ Tubingen, Ctr Ophthalmol, Div Expt Ophthalmol, Rontgenweg 11, D-72076 Tubingen, Germany.	sebastian.thaler@uni-tuebingen.de	Zarnowski, Tomasz/AAM-6460-2020; Fiedorowicz, Michal/L-1538-2018; Fiedorowicz, Michal/O-9779-2019	Fiedorowicz, Michal/0000-0001-5755-3608; Fiedorowicz, Michal/0000-0001-5755-3608; Zarnowski, Tomasz/0000-0002-6978-7417; Sulejczak, Dorota/0000-0002-1697-8164; Grieb, Pawel/0000-0002-6983-7947	EVI-GENORETEuropean Commission [LSHG-Cr2005-512036]	Supported by the integrated project EVI-GENORET (LSHG-Cr2005-512036). The authors thank Francois Paquet-Durand for valuable comments and Sylvia Bolz and Sandra Bernhard-Kurz for excellent technical assistance. M. Fiedorowicz and T. Choragiewicz received support from the Kerstan Foundation in the form of a research fellowship.	Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; BarPeled O, 1996, P NATL ACAD SCI USA, V93, P8530, DOI 10.1073/pnas.93.16.8530; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Bostanci MO, 2008, NEUROTOXICOLOGY, V29, P130, DOI 10.1016/j.neuro.2007.10.003; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Davalos A, 2000, NEUROLOGY, V54, P1568, DOI 10.1212/WNL.54.8.1568; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Farkas RH, 2004, INVEST OPHTH VIS SCI, V45, P1410, DOI 10.1167/iovs.03-0872; Gariboldi MB, 2006, FREE RADICAL BIO MED, V40, P1409, DOI 10.1016/j.freeradbiomed.2005.12.011; Geiger LK, 2002, NEUROSCIENCE, V109, P635, DOI 10.1016/S0306-4522(01)00493-6; Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776; He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004; Ke Y, 2003, LANCET NEUROL, V2, P246, DOI 10.1016/S1474-4422(03)00353-3; Kikuchi M, 2000, J NEUROSCI, V20, P5037; Koeberle PD, 1999, EXP NEUROL, V158, P366, DOI 10.1006/exnr.1999.7113; Levkovitch-Verbin H, 2000, INVEST OPHTH VIS SCI, V41, P4169; Lipman T, 2006, EUR J PHARMACOL, V549, P50, DOI 10.1016/j.ejphar.2006.08.022; Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170; Maher P, 2005, INVEST OPHTH VIS SCI, V46, P749, DOI 10.1167/iovs.04-0883; Manabe S, 2003, INVEST OPHTH VIS SCI, V44, P385, DOI 10.1167/iovs.02-0187; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; MEHLHORN RJ, 1992, FREE RADICAL RES COM, V17, P157, DOI 10.3109/10715769209068163; Mehta SH, 2004, AM J PHYSIOL-REG I, V286, pR283, DOI 10.1152/ajpregu.00446.2002; Millan M, 2007, STROKE, V38, P90, DOI 10.1161/01.STR.0000251798.25803.e0; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; Monti E, 2001, J CELL BIOCHEM, V82, P271, DOI 10.1002/jcb.1160; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; Ravizza R, 2004, INT J ONCOL, V25, P1817; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Samuni AM, 2003, P NATL ACAD SCI USA, V100, P5390, DOI 10.1073/pnas.0930078100; Schuettauf F, 2000, INVEST OPHTH VIS SCI, V41, P4313; Schuettauf F, 2005, GRAEF ARCH CLIN EXP, V243, P1036, DOI 10.1007/s00417-005-1152-7; Schuettauf F, 2002, VISION RES, V42, P2333, DOI 10.1016/S0042-6989(02)00188-8; Schuettauf F, 2006, EXP EYE RES, V83, P1128, DOI 10.1016/j.exer.2006.05.021; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Souza JM, 2008, FREE RADICAL BIO MED, V45, P357, DOI 10.1016/j.freeradbiomed.2008.04.010; Swanson KI, 2005, INVEST OPHTH VIS SCI, V46, P3737, DOI 10.1167/iovs.05-0155; Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1864, DOI 10.1167/iovs.06-1065; Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490; Thaler S, 2006, MOL VIS, V12, P100; Vaz SM, 2008, P NATL ACAD SCI USA, V105, P8191, DOI 10.1073/pnas.0708211105; Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Zhou XJ, 2000, LAB INVEST, V80, P1905, DOI 10.1038/labinvest.3780200	48	24	25	0	4	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0014-4835	1096-0007		EXP EYE RES	Exp. Eye Res.	FEB	2010	90	2					254	260		10.1016/j.exer.2009.10.013			7	Ophthalmology	Ophthalmology	557AG	WOS:000274639100010	19883642				2021-06-18	
J	Valable, S; Francony, G; Bouzat, P; Fevre, MC; Mahious, N; Bouet, V; Farion, R; Barbier, E; Lahrech, H; Remy, C; Petit, E; Segebarth, C; Bernaudin, M; Payen, JF				Valable, Samuel; Francony, Gilles; Bouzat, Pierre; Fevre, Marie-Cecile; Mahious, Nouara; Bouet, Valentine; Farion, Regine; Barbier, Emmanuel; Lahrech, Hana; Remy, Chantal; Petit, Edwige; Segebarth, Christoph; Bernaudin, Myriam; Payen, Jean-Francois			The impact of erythropoietin on short-term changes in phosphorylation of brain protein kinases in a rat model of traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cerebral edema; EPO (erythropoietin); inhibitors; MAPK (mitogen-activated protein kinase); MAPK activation after brain trauma	FOCAL CEREBRAL-ISCHEMIA; PREVENTS NEURONAL APOPTOSIS; SIGNAL-REGULATED KINASE; NITRIC-OXIDE FORMATION; IN-VIVO; BARRIER PERMEABILITY; AKT PHOSPHORYLATION; EDEMA; NEUROPROTECTION; MICE	We found that recombinant human erythropoietin (rhEPO) reduced significantly the development of brain edema in a rat model of diffuse traumatic brain injury (TBI) (impact-acceleration model). In this study, we investigated the molecular and intracellular changes potentially involved in these immediate effects. Brain tissue nitric oxide (NO) synthesis, phosphorylation level of two protein kinases (extracellular-regulated kinase (ERK)-1/-2 and Akt), and brain water content were measured 1 (H1) and 2 h (H2) after insult. Posttraumatic administration of rhEPO (5,000 IU/kg body weight, intravenously, 30 mins after injury) reduced TBI-induced upregulation of ERK phosphorylation, although it increased Akt phosphorylation at H1. These early molecular changes were associated with a reduction in brain NO synthesis at H1 and with an attenuation of brain edema at H2. Intraventricular administration of the ERK-1/-2 inhibitor, U0126, or the Akt inhibitor, LY294002, before injury showed that ERK was required for brain edema formation, and that rhEPO-induced reduction of edema could involve the ERK pathway. These results were obtained in the absence of any evidence of blood-brain barrier damage on contrast-enhanced magnetic resonance images. The findings of our study indicate that the anti edematous effect of rhEPO could be mediated through an early inhibition of ERK phosphorylation after diffuse TBI. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 361-369; doi: 10.1038/jcbfm.2009.222; published online 7 October 2009	[Payen, Jean-Francois] Univ Grenoble 1, Grenoble Inst Neurosci, INSERM, U836,Equipe 5, F-38042 Grenoble 9, France; [Valable, Samuel; Petit, Edwige; Bernaudin, Myriam] Univ Paris 05, Univ Caen Basse Normandie, Equipe CERVOxy,CI NAPS,UMR 6232, CNRS,CEA, Caen, France; [Francony, Gilles; Bouzat, Pierre; Fevre, Marie-Cecile; Payen, Jean-Francois] Hop Michallon, Dept Anesthesie Reanimat, Grenoble, France; [Bouet, Valentine] Univ Caen Basse Normandie, GMPc, UFR Sci Pharmaceut, Caen, France	Payen, JF (corresponding author), Univ Grenoble 1, Grenoble Inst Neurosci, INSERM, U836,Equipe 5, Site Sante La Tronche,BP 170, F-38042 Grenoble 9, France.	jfpayen@ujf-grenoble.fr	PETIT, Edwige/C-1896-2008; Bernaudin, Myriam/B-7663-2008; valable, samuel/B-7578-2008; Payen, Jean-Francois/L-6667-2014; Lahrech, Hana/M-5229-2018; Bouzat, Pierre/AAC-4105-2019; Barbier, Emmanuel/E-6302-2011; BOUET, Valentine/N-9593-2015; Bouzat, Pierre/L-6881-2014; Remy, Chantal/L-9459-2014	Bernaudin, Myriam/0000-0003-0778-3397; valable, samuel/0000-0003-0355-0270; Bouzat, Pierre/0000-0003-4667-6738; Barbier, Emmanuel/0000-0002-4952-1240; Lahrech, Hana/0000-0003-3843-3410	Institut National de la Sante et de la Recherche Medicale (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm); Institut pour la Recherche sur la Moelle Epiniere et l'Encephale (IRME); Association Francaise contre les Myopathies (AFM)Association Francaise contre les Myopathies; Centre National de la Recherche Scientifique (CNRS)Centre National de la Recherche Scientifique (CNRS); Ligue contre le CancerLigue nationale contre le cancer; Ministere de l'Education, de la Recherche et de la Technologie, France. Epoetin alfa (Eprex); INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission [U836]; Universite Joseph Fourier, Grenoble, France	This study was supported in part by grants from Institut National de la Sante et de la Recherche Medicale (INSERM), Institut pour la Recherche sur la Moelle Epiniere et l'Encephale (IRME), Association Francaise contre les Myopathies (AFM), Centre National de la Recherche Scientifique (CNRS), Ligue contre le Cancer, and Ministere de l'Education, de la Recherche et de la Technologie, France. Epoetin alfa (Eprex) was kindly provided by Janssen-Cilag Division Ortho Biotech, Issy-les-Moulineaux, France. Study support was received from INSERM U836 and Universite Joseph Fourier, Grenoble, France.	Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gahm C, 2005, NEUROSURGERY, V57, P1272, DOI 10.1227/01.NEU.0000187317.32529.06; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Grillon E, 2008, NMR BIOMED, V21, P427, DOI 10.1002/nbm.1206; Gunnarson E, 2009, P NATL ACAD SCI USA, V106, P1602, DOI 10.1073/pnas.0812708106; Huang H, 2009, J INT MED RES, V37, P511, DOI 10.1177/147323000903700227; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kobayashi H, 2008, CLIN EXP PHARMACOL P, V35, P812, DOI 10.1111/j.1440-1681.2008.04925.x; Li Y, 2007, NEUROCHEM RES, V32, P2132, DOI 10.1007/s11064-007-9387-9; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liot G, 2004, EXP NEUROL, V187, P38, DOI 10.1016/j.expneurol.2004.01.002; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; NAGAFUJI T, 1992, NEUROSCI LETT, V147, P159, DOI 10.1016/0304-3940(92)90584-T; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Noguchi K, 2001, BRIT J PHARMACOL, V133, P395, DOI 10.1038/sj.bjp.0704083; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Otani N, 2007, J CLIN NEUROSCI, V14, P42, DOI 10.1016/j.jocn.2005.11.044; Pacary E, 2006, NEURODEGENER DIS, V3, P87, DOI 10.1159/000092098; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Salter M, 1996, J NEUROCHEM, V66, P1683; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Subramaniam S, 2006, NEUROSCIENCE, V138, P1055, DOI 10.1016/j.neuroscience.2005.12.013; Thippeswamy T, 2006, HISTOL HISTOPATHOL, V21, P445, DOI 10.14670/HH-21.445; Valable S, 2003, FASEB J, V17, P443, DOI 10.1096/fj.02-0372fje; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang YK, 2007, J BIOL CHEM, V282, P32453, DOI 10.1074/jbc.M706242200	42	24	27	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2010	30	2					361	369		10.1038/jcbfm.2009.222			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	551TS	WOS:000274233800012	19809465	Bronze, Green Published			2021-06-18	
J	Kalish, H; Phillips, TM				Kalish, Heather; Phillips, Terry M.			Analysis of neurotrophins in human serum by immunoaffinity capillary electrophoresis (ICE) following traumatic head injury"	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						CE; Head trauma; Immunoaffinity; Neurotrophins; Serum	INDUCED FLUORESCENCE DETECTION; NERVE GROWTH-FACTOR; BRAIN-INJURY; MASS-SPECTROMETRY; FACTOR EXPRESSION; UP-REGULATION; RAT-BRAIN; CHILDREN; NEURONS; BDNF	Neurotrophins, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), neutrotrophin-3 (NT-3), neurotrophin-4 (NT-4). anti beta-nerve growth factor (beta-NGF), play an active role in the development. maintenance and survival of cells of the central nervous system (CNS). Previous research has indicated that a decrease in concentrations of these neurotrophins is often associated with cell death and ultimately patient demise. However, much of the research conducted analyses of samples taken directly from the CNS, ie., of samples that are not readily available in clinical trauma centers. In an attempt to obtain a method for evaluating neurotrophins in a more readily accessible matrix, i.e. serum, a precise and accurate immunoaffinity capillary electrophoresis (ICE) method was developed and applied to measure neurotrophins in serum from patients with various degrees of head injury. The five neurotrophins of interest were extracted and concentrated by specific immunochemically immobilized antibodies. bound directly to the capillary wall, and eluted and separated in approximately 10 min. NT-3, BDNF. CNTF and beta-NGF showed a marked decrease in concentration as the severity of the head injury increased: mild versus severe: 91% decrease tot NT-3; 93 % decrease for BDNF; 93 % decrease for CNTF, and a 87% decrease for beta-NGF. This decrease in concentration is consistent with the neuro-protective roles that neurotrophins play in the maintenance and survival of neuronal cells. The results obtained by the ICE method were closely comparable with those generated by a commercially available ELISA method. Published by Elsevier B V.	[Kalish, Heather; Phillips, Terry M.] Natl Inst Biomed Imaging & Bioengn, Ultramicro Immunodiagnost Sect, Lab Bioengn & Phys Sci, NIH, Bethesda, MD USA	Kalish, H (corresponding author), Natl Inst Biomed Imaging & Bioengn, Ultramicro Immunodiagnost Sect, Lab Bioengn & Phys Sci, NIH, Bldg 13,Room 3E42,13 South Dr, Bethesda, MD USA.				National Institute of Biomedical Imaging and Bioengineering, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000018] Funding Source: NIH RePORTER	This research was supported by the Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering, NIH.	Altria KD, 1999, J CHROMATOGR A, V856, P443, DOI 10.1016/S0021-9673(99)00830-4; Benavente F, 2007, ANAL BIOANAL CHEM, V387, P2633, DOI 10.1007/s00216-007-1119-0; Chen HX, 2008, ANAL CHEM, V80, P9583, DOI 10.1021/ac801859e; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Guzman NA, 2008, ELECTROPHORESIS, V29, P3259, DOI 10.1002/elps.200800058; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; Jaworska M, 2009, J PHARMACEUT BIOMED, V50, P90, DOI 10.1016/j.jpba.2009.03.031; Kalish H, 2009, J SEP SCI, V32, P1605, DOI 10.1002/jssc.200900047; Kazanis I, 2004, EXP NEUROL, V186, P221, DOI 10.1016/j.expneurol.2003.12.004; Kim DH, 2005, NEUROCRIT CARE, V3, P71, DOI 10.1385/NCC:3:1:071; Kunnemeyer J, 2009, ELECTROPHORESIS, V30, P1766, DOI [10.1002/elps.2008-00831, 10.1002/elps.200800831]; Lee N, 2005, NEUROSCI LETT, V374, P161, DOI 10.1016/j.neulet.2004.10.048; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Muller A, 2007, BRAIN, V130, P3308, DOI 10.1093/brain/awm257; Pan HC, 2007, J CLIN NEUROSCI, V14, P1089, DOI 10.1016/j.jocn.2006.08.008; Phillips TM, 1997, J CHROMATOGR B, V697, P101, DOI 10.1016/S0378-4347(97)00132-1; Phillips TM, 2004, ELECTROPHORESIS, V25, P1652, DOI 10.1002/elps.200305873; Phillips TM, 2003, BIOMED CHROMATOGR, V17, P182, DOI 10.1002/bmc.240; Phillips TM, 2001, LUMINESCENCE, V16, P145, DOI 10.1002/bio.645.abs; Phillips TM, 1998, ELECTROPHORESIS, V19, P2991, DOI 10.1002/elps.1150191632; PHILLIPS TM, 1992, ANAL TECHNIQUES IMMU; Rost B, 2005, REGUL PEPTIDES, V124, P19, DOI 10.1016/j.regpep.2004.06.024; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Shah JP, 2005, J APPL PHYSIOL, V99, P1977, DOI 10.1152/japplphysiol.00419.2005; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; Weissinger EM, 2009, MINI-REV MED CHEM, V9, P627, DOI 10.2174/138955709788167583; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yokota H, 2005, NEUROSCI LETT, V377, P170, DOI 10.1016/j.neulet.2004.11.093	40	24	27	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232			J CHROMATOGR B	J. Chromatogr. B	JAN 15	2010	878	2			SI		194	200		10.1016/j.jchromb.2009.10.022			7	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	551PG	WOS:000274220900010	19896422	Green Accepted			2021-06-18	
J	Armstrong, E; Ferguson, A				Armstrong, Elizabeth; Ferguson, Alison			Language, meaning, context, and functional communication	APHASIOLOGY			English	Article						Aphasia; Linguistic context; Discourse; Conversation	TRAUMATIC BRAIN-INJURY; LINGUISTIC PERSPECTIVE; CONVERSATION ANALYSIS; APHASIC CONVERSATION; CONNECTED SPEECH; VERB RETRIEVAL; TURN-TAKING; DISCOURSE; ADULTS; ORGANIZATION	Background : In the 1970s Audrey Holland first emphasised the importance of ofunctional communicationo rather than olinguistic accuracyo for individuals with aphasia, noting that they could often ocommunicateo better than they could otalko. Her approach inspired many to explore why and how this could be so, and to look for avenues that tapped everyday communication skills, rather than the person with aphasia's performance on decontextualised language tests. Aims: This paper addresses the kinds of issues that are involved in ofunctional communicationo and specifically addresses the role of language in this endeavour. It aims to highlight language as a set of omeaning-making resourceso rather than as a set of syntactic/semantic constructs that exist outside of the communicator's everyday environment, that have to be mastered before being put into practice and that exist regardless of specific contexts. Main Contribution: The paper discusses language's role in social life in which speakers not only convey information to each other but also maintain social relationships through communication. A taxonomy of the different kinds of social meanings that speakers use to communicate is proposed for use in aphasia research, based on the work of Halliday (1994)those related to conveying ideas and experiences (e.g., vocabulary related to particular experiences, topics), those related to interpersonal relationships (e.g., speech acts, evaluative language devices, exchange structure), and those related to maintaining continuity and coherence across the speaker's discourse (e.g., cohesion). In addition, the systematic relationship existing between language and context and its clinical implications are explored. Conclusions: Language as information is only one form of language use. The paper argues for further consideration in aphasiology of the importance of multiple language uses and their relation to context. It is proposed that regarding language forms from these different perspectives of use will enable clinicians to further address the different aspects of communication required for meaningful and satisfying interactions in everyday social life.	[Armstrong, Elizabeth] Edith Cowan Univ, Perth, WA, Australia; [Ferguson, Alison] Univ Newcastle, Newcastle, NSW 2308, Australia	Armstrong, E (corresponding author), Edith Cowan Univ, Dept Psychol & Social Sci, Joondalup, WA 6027, Australia.	b.armstrong@ecu.edu.au		Armstrong, Elizabeth/0000-0003-4469-1117			Ahlsen E, 2005, CLIN LINGUIST PHONET, V19, P433, DOI 10.1080/02699200400027205; Ahlsen E, 2003, COPENHAGEN WORKING P, V3, P9; Armstrong E, 2005, APHASIOLOGY, V19, P285, DOI 10.1080/02687030444000750; Armstrong E, 2005, CLIN LINGUIST PHONET, V19, P137, DOI 10.1080/02699200410001698599; Armstrong E, 2001, APHASIOLOGY, V15, P1029, DOI 10.1080/02687040143000375; ARMSTRONG E, 2007, CONTINUING DISCOURSE, P383; ARMSTRONG EM, 1991, CLIN LINGUIST PHONET, V5, P39, DOI 10.3109/02699209108985501; Armstrong L, 2007, APHASIOLOGY, V21, P355, DOI 10.1080/02687030600911310; Avent JR, 2003, APHASIOLOGY, V17, P397, DOI 10.1080/02687030244000743; Bastiaanse R, 1998, APHASIOLOGY, V12, P951, DOI 10.1080/02687039808249463; Beeke S, 2008, CLIN LINGUIST PHONET, V22, P317, DOI 10.1080/02699200801918911; Beeke S, 2007, APHASIOLOGY, V21, P256, DOI 10.1080/02687030600911344; Beeke Suzanne, 2007, Seminars in Speech and Language, V28, P136, DOI 10.1055/s-2007-970571; Bird H, 1996, J NEUROLINGUIST, V9, P187, DOI 10.1016/0911-6044(96)00006-1; Borod JC, 2000, NEUROPSYCHOLOGY, V14, P112, DOI 10.1037/0894-4105.14.1.112; Breedin SD, 1998, BRAIN LANG, V63, P1, DOI 10.1006/brln.1997.1923; Butt D., 2000, USING FUNCTIONAL GRA; CARAMAZZA A, 1990, CORTEX, V26, P95, DOI 10.1016/S0010-9452(13)80077-9; Cherney LR, 2008, AM J SPEECH-LANG PAT, V17, P19, DOI 10.1044/1058-0360(2008/003); Christie Frances, 1997, GENRE I SOCIAL PROCE, P3; COELHO CA, 1994, CLIN APHASIOL, V22, P145; Doyle PJ, 2000, APHASIOLOGY, V14, P537, DOI 10.1080/026870300401306; Dronkers NF, 1998, J NEUROLINGUIST, V11, P179, DOI 10.1016/S0911-6044(98)00012-8; Drummond SS, 1995, J NEUROLINGUIST, V9, P47, DOI 10.1016/0911-6044(95)00005-4; EGGINS S, 2004, ANAL CASUAL CONVERSA; Ellis C, 2005, J REHABIL RES DEV, V42, P737, DOI 10.1682/JRRD.2005.02.0026; Fairclough Norman, 2003, ANAL DISCOURSE TEXTU; Ferguson A, 1998, APHASIOLOGY, V12, P1007, DOI 10.1080/02687039808249466; Ferguson A, 2002, J COMMUN DISORD, V35, P11, DOI 10.1016/S0021-9924(01)00071-5; FERGUSON A, 1992, J NEUROLINGUIST, V7, P277, DOI 10.1016/0911-6044(92)90019-S; FERGUSON A, 1994, APHASIOLOGY, V8, P143, DOI 10.1080/02687039408248647; GLINDEMANN R, 1995, TREATMENT APHASIA TH, P90; GOODWIN C, 1995, RES LANG SOC INTERAC, V28, P233, DOI 10.1207/s15327973rlsi2803_4; Goodwin C., 2003, CONVERSATION BRAIN D; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; Halliday M. A. K., 2004, INTRO FUNCTIONAL GRA; Halliday MAK, 1985, LANGUAGE CONTEXT TEX; Halliday Michael A. K., 1976, COHESION ENGLISH; Herbert R, 2008, APHASIOLOGY, V22, P184, DOI 10.1080/02687030701262613; HILLIS AE, 1991, BRAIN, V114, P2081, DOI 10.1093/brain/114.5.2081; Holland A., 1982, CLIN APH P C, P345; Holland A, 1980, COMMUNICATIVE ABILIT; Holland A., 1979, RATIONALE ADULT APHA, P167; HOLLAND AL, 1982, J SPEECH HEAR DISORD, V47, P50, DOI 10.1044/jshd.4701.50; Hopper T, 2002, APHASIOLOGY, V16, P745, DOI 10.1080/02687030244000059; Hunston S., 2000, EVALUATION TEXT AUTH; Jacobs B, 2004, DISABIL REHABIL, V26, P1231, DOI 10.1080/09638280412331280244; Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Kay J, 1996, APHASIOLOGY, V10, P159, DOI 10.1080/02687039608248403; Kim M, 2000, BRAIN LANG, V74, P1, DOI 10.1006/brln.2000.2315; Klippi A., 2003, CONVERSATION BRAIN D, P117; Laakso M, 1999, APHASIOLOGY, V13, P345, DOI 10.1080/026870399402136; Labov William., 1972, LANGUAGE INNER CITY; Lesser R., 1997, CONVERSATION ANAL PR; Lock S, 2001, INT J LANG COMM DIS, V36, P25, DOI 10.3109/13682820109177853; Martin J. R., 2003, WORKING DISCOURSE ME; Martin J. R., 2005, LANGUAGE EVALUATION; Martin N, 2008, APHASIA REHABILITATI; Mayer JF, 2003, APHASIOLOGY, V17, P481, DOI 10.1080/02687030344000148; Mortensen L, 2005, CLIN LINGUIST PHONET, V19, P227, DOI 10.1080/02699200410001698652; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Nickels L, 2002, APHASIOLOGY, V16, P935, DOI 10.1080/02687030244000563; Nickels L., 2002, COGNITIVE NEUROPSYCH; Oelschlaeger ML, 1999, J SPEECH LANG HEAR R, V42, P636, DOI 10.1044/jslhr.4203.636; Perkins L, 1999, APHASIOLOGY, V13, P259, DOI 10.1080/026870399402091; Robson J, 2004, APHASIOLOGY, V18, P917, DOI 10.1080/02687030444000462; Rose S, 2008, IEEE NETWORK, V22, P22, DOI 10.1109/MNET.2008.4476067; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; Sarno M, 1969, FUNCTIONAL COMMUNICA; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SCHEGLOFF EA, 1977, LANGUAGE, V53, P361, DOI 10.2307/413107; Searle John, 1969, SPEECH ACTS; Shadden B., 2007, GROUP TREATMENT NEUR, P111; SHAPIRO LP, 1993, BRAIN LANG, V45, P423, DOI 10.1006/brln.1993.1053; Sherratt S, 2007, APHASIOLOGY, V21, P320, DOI 10.1080/02687030600911401; Simmons-Mackie N, 2007, TOP LANG DISORD, V27, P5, DOI 10.1097/00011363-200701000-00003; Thompson CK, 2003, J SPEECH LANG HEAR R, V46, P591, DOI 10.1044/1092-4388(2003/047); Thompson Geoffrey, 2000, EVALUATION TEXT AUTH, P1; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Ulatowska H, 2006, BRAIN LANG, V99, P61, DOI 10.1016/j.bandl.2006.06.040; Wilcox M. J., 1977, CLIN APHASIOLOGY C P, P166; Youmans G, 2005, APHASIOLOGY, V19, P435, DOI 10.1080/02687030444000877	85	24	24	1	23	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology		2010	24	4					480	496	PII 921463867	10.1080/02687030902775157			17	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	598RU	WOS:000277856700005		Green Published			2021-06-18	
J	Ashwal, S; Wycliffe, ND; Holshouser, BA				Ashwal, Stephen; Wycliffe, Nathaniel D.; Holshouser, Barbara A.			Advanced Neuroimaging in Children with Nonaccidental Trauma	DEVELOPMENTAL NEUROSCIENCE			English	Article						Children; Infants; Nonaccidental trauma; Magnetic resonance imaging; Magnetic resonance spectroscopy; Traumatic brain injury	DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; INFLICTED HEAD-INJURY; HYPOXIC-ISCHEMIC INJURY; PROTON MR SPECTROSCOPY; WHITE-MATTER INJURY; BRAIN-INJURY; YOUNG-CHILDREN; OUTCOME PREDICTION; CORPUS-CALLOSUM	Physical abuse associated with nonaccidental trauma (NAT) affects approximately 144,000 children per year in the USA and, frequently, these injuries affect the developing brain. Most infants with suspected NAT are initially evaluated by skull X-rays and computed tomography to determine whether fractures are present, the severity of the acute injury and the need for urgent neurosurgical intervention. Increasingly, magnetic resonance imaging (MRI) is conducted as it provides additional diagnostic and prognostic information about the extent and nature of the injury. In this review, we examine 4 MRI techniques as they apply to children who present acutely after NAT. Susceptibility-weighted imaging is a 3-D high-resolution MRI technique that is more sensitive than conventional imaging in detecting hemorrhagic lesions that are often associated with diffuse axonal injury (DAI). Magnetic resonance spectroscopy acquires metabolite information reflecting neuronal integrity and function from multiple brain regions and provides a sensitive, noninvasive assessment of neurochemical alterations that offers early prognostic information regarding outcome. Diffusion-weighted imaging (DWI) is based on differences in the diffusion of water molecules within the brain and has been shown to be very sensitive in the early detection of ischemic injury. It is now being used to study the direct effects of traumatic injury as well as those due to secondary ischemia. Diffusion tensor imaging is a form of DWI and allows better evaluation of white matter fiber tracts by taking advantage of the intrinsic directionality (anisotropy) of water diffusion in the human brain. It has been shown to be useful in identifying white matter abnormalities after DAI when conventional imaging appears normal. Although these imaging methods have been studied primarily in adults and children with accidental traumatic brain injury, it is clear that they have the potential to provide additional value in the imaging and clinical evaluation of children with NAT. Copyright (C) 2010 S. Karger AG, Basel	[Ashwal, Stephen] Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Loma Linda, CA 92354 USA; [Wycliffe, Nathaniel D.; Holshouser, Barbara A.] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92354 USA	Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, 11175 Campus St,Room A1120, Loma Linda, CA 92354 USA.	sashwal@llu.edu					Aaen GS, 2010, PEDIATRICS, V125, P295, DOI 10.1542/peds.2008-3312; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ajilogba K, 2006, PEDIATR RADIOL, V36, P1326, DOI 10.1007/s00247-006-0286-z; Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; Alessandri B, 2000, NEUROL RES, V22, P705; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Bammer R, 2009, MAGN RESON IMAGING C, V17, P175, DOI 10.1016/j.mric.2009.01.011; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beitzke D, 2008, EUR J RADIOL, V68, P199, DOI 10.1016/j.ejrad.2008.07.016; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Blitstein MK, 2007, AM J ROENTGENOL, V189, P720, DOI 10.2214/AJR.07.2249; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Carty H, 2002, EUR RADIOL, V12, P2919, DOI 10.1007/s00330-002-1436-9; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Chan YL, 2003, PEDIATR RADIOL, V33, P574, DOI 10.1007/s00247-003-0949-y; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; COLBERT C, 2010, RADIOLOGY IN PRESS; Dan B, 2008, DEV MED CHILD NEUROL, V50, P78; Demaerel P, 2002, EUR RADIOL, V12, P849, DOI 10.1007/s00330-001-1145-9; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; Dolinak D, 2006, ARCH PATHOL LAB MED, V130, P712; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Fernando S, 2008, PEDIATR RADIOL, V38, P827, DOI 10.1007/s00247-007-0729-1; Field AS, 2003, AM J NEURORADIOL, V24, P1461; Foerster BR, 2009, J PEDIATR-US, V154, P573, DOI 10.1016/j.jpeds.2008.09.051; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gill JR, 2009, ARCH PATHOL LAB MED, V133, P619, DOI 10.1043/1543-2165-133.4.619; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Haacke EM, 2007, AM J NEURORADIOL, V28, P316; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jaspan T, 2003, CLIN RADIOL, V58, P44, DOI 10.1053/crad.2002.1094; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Karandikar S., 2004, CHILD ABUSE REV, V13, P178, DOI DOI 10.1002/CAR.850; Kemp AM, 2009, CLIN RADIOL, V64, P473, DOI 10.1016/j.crad.2008.11.011; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Mao H, 2007, J NEUROIMAGING, V17, P292, DOI 10.1111/j.1552-6569.2007.00146.x; McGraw P, 2002, AM J ROENTGENOL, V179, P1515, DOI 10.2214/ajr.179.6.1791515; McKinney AM, 2008, PEDIATR RADIOL, V38, P164, DOI 10.1007/s00247-007-0673-0; McLean MA, 2000, MAGNET RESON MED, V44, P401, DOI 10.1002/1522-2594(200009)44:3<401::AID-MRM10>3.0.CO;2-W; Ment LR, 2009, LANCET NEUROL, V8, P1042, DOI 10.1016/S1474-4422(09)70257-1; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Mukherjee P, 2001, RADIOLOGY, V219, P756, DOI 10.1148/radiology.219.3.r01jn48756; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Nimkin K, 2001, RADIOL CLIN N AM, V39, P843, DOI 10.1016/S0033-8389(05)70314-6; Parizel PM, 2003, PEDIATR RADIOL, V33, P868, DOI 10.1007/s00247-003-1025-3; Pierce MC, 2002, NEUROSURG CLIN N AM, V13, P155, DOI 10.1016/S1042-3680(01)00006-7; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robertson IH, 2008, ARCH PHYS MED REHAB, V89, pS1, DOI 10.1016/j.apmr.2008.10.001; Robertson RL, 2007, PEDIATR RADIOL, V37, P749, DOI 10.1007/s00247-007-0515-0; Rovaris M, 2009, NEUROIMAG CLIN N AM, V19, P37, DOI 10.1016/j.nic.2008.08.001; *ROYAL COLL RAD, 2008, STAND RAD INV SUSP N; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Schuff N, 2001, MAGN RESON MED, V45, P899, DOI 10.1002/mrm.1119; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Slovis T L, 2000, Radiology, V215 Suppl, P805; Soher BJ, 2000, MAGN RESON IMAGING, V18, P1159, DOI 10.1016/S0730-725X(00)00212-5; Stoodley N, 2005, CLIN RADIOL, V60, P22, DOI 10.1016/j.crad.2004.06.023; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Sykova E, 2004, NEUROSCIENCE, V129, P861, DOI 10.1016/j.neuroscience.2004.06.077; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Triulzi F, 2008, NEUROL SCI, V29, pS342, DOI 10.1007/s10072-008-1013-3; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; vanderToorn A, 1996, MAGN RESON MED, V36, P52, DOI 10.1002/mrm.1910360110; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yeo RA, 2006, ADV EXP MED BIOL, V576, P215; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zimmerman RA, 2007, J NEURORADIOLOGY, V34, P109, DOI 10.1016/j.neurad.2007.01.124	129	24	25	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					343	360		10.1159/000316801			18	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900003	20938158				2021-06-18	
J	Mansell, JL; Tierney, RT; Higgins, M; McDevitt, J; Toone, N; Glutting, J				Mansell, Jamie L.; Tierney, Ryan T.; Higgins, Michael; McDevitt, Jane; Toone, Nieka; Glutting, Joseph			Concussive signs and symptoms following head impacts in collegiate athletes	BRAIN INJURY			English	Article						Clinical outcomes; MTBI	SEGMENT DYNAMIC STABILIZATION; FOOTBALL PLAYERS; RECURRENT CONCUSSION; INJURY; EPIDEMIOLOGY	Objective: To evaluate the association between having a previously documented concussion and experiencing concussive signs and symptoms (S&S) following head impacts in collegiate athletes. Methods: Two hundred and one college male football (n = 168) and female women's soccer (n = 33) athletes participated in this retrospective case-control study. Athletes completed a questionnaire and reported if they had been diagnosed with concussion and if they experienced concussive S&S following a head impact during a game or practice in the previous year. Results: Almost 60% (89 of 152) of non-concussed athletes reported experiencing S&S following head impacts in the previous year compared to 80% (39 of 49) of concussed athletes. The Phi coefficient (r = 0.196, p = 0.005) results indicated a significant association between previous history of concussion and the occurrence of S&S following a head impact. Conclusions: A large percentage of non-concussed athletes are experiencing concussive S&S following head impacts during games and practices. Previously concussed athletes, however, report experiencing S&S more frequently following head impacts than their non-concussed counterparts. Although this study is subject to the limitations of a retrospective research design, these findings highlight the need for more diligent surveillance from clinicians, as many concussions are being missed.	[Tierney, Ryan T.; McDevitt, Jane; Toone, Nieka] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Higgins, Michael] Towson Univ, Dept Kinesiol, Towson, MD USA; [Glutting, Joseph] Univ Delaware, Newark, DE USA		jmansell23@gmail.com					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Byard RW, 2009, FORENSIC SCI MED PAT, V5, P36, DOI 10.1007/s12024-008-9063-7; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; GENNARELLI TA, 1982, PHYSL RESPONSE ANGUL; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mansell J, 2005, J ATHL TRAINING, V40, P310; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA	21	24	25	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	9					1070	1074		10.3109/02699052.2010.494589			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	636RH	WOS:000280756700003	20597635				2021-06-18	
J	Ramkumar, NA; Elliott, TR				Ramkumar, Neeta A.; Elliott, Timothy R.			Family caregiving of persons following neurotrauma: Issues in research, service and policy	NEUROREHABILITATION			English	Article						Caregivers; neurotrauma; spinal cord injury; brain injury; rehabilitation	PROBLEM-SOLVING ABILITIES; PUBLIC-HEALTH; BRAIN-INJURY; INTERVENTION; ADJUSTMENT; BEHAVIOR; QUALITY; BURDEN; IMPACT	Family caregivers of persons following neurotrauma function as de facto extensions of our health care system. Their challenges may result in negative consequences for their physical and mental health, which directly impacts the well-being of their care-recipient. In this paper, we survey current practices in providing caregiver support, outline considerations for developing collaborative interventions, and make recommendations for assessing intervention effectiveness consistent with the nature of the adjustment processes among caregivers and care recipients.	[Elliott, Timothy R.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77845 USA	Elliott, TR (corresponding author), Texas A&M Univ, Dept Educ Psychol, 4225 TAMU, College Stn, TX 77845 USA.	telliott@tamu.edu	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD037661] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD37661, R01 HD037661] Funding Source: Medline; NCIPC CDC HHS [R49/CE000191, R49 CE000191] Funding Source: Medline		BERRY JW, 2009, NAT VIOL INJ PREV RE, P11; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; CARTER R, 2008, PREVENTING CHRONIC D, V5, P1; Chwalisz K., 2010, HDB REHABILITATION P, P301; D'Zurilla T. J., 1999, PROBLEM SOLVING THER; *DEP HLTH HUM SERV, 2005, SURG GEN WORKSH WOM; Donelan K, 2001, WOMEN HEALTH ISS, V11, P185, DOI 10.1016/S1049-3867(01)00080-9; Elliott TR, 2009, BEHAV RES THER, V47, P548, DOI 10.1016/j.brat.2009.03.006; Elliott TR, 2009, J CLIN PSYCHOL, V65, P406, DOI 10.1002/jclp.20527; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Gitlin LN, 2003, PSYCHOL AGING, V18, P361, DOI 10.1037/0882-7974.18.3.361; Glass TA, 2006, SOC SCI MED, V62, P1650, DOI 10.1016/j.socscimed.2005.08.044; Hayes AM, 2007, CLIN PSYCHOL REV, V27, P715, DOI 10.1016/j.cpr.2007.01.008; Horowitz A, 1985, Annu Rev Gerontol Geriatr, V5, P194; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Kosciulek JF, 2000, J DISABIL POLICY STU, V11, P82, DOI DOI 10.1177/104420730001100204; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kurylo MF, 2001, J COUNS DEV, V79, P275, DOI 10.1002/j.1556-6676.2001.tb01972.x; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Lollar DJ, 2003, ANNU REV PUBL HEALTH, V24, P195, DOI 10.1146/annurev.publhealth.24.100901.140844; Lollar D, 2008, REHABIL PSYCHOL, V53, P122, DOI 10.1037/0090-5550.53.2.122; Mechanic D, 1998, MILBANK Q, V76, P281, DOI 10.1111/1468-0009.00089; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Sander A. M., 2005, REHABILITATION TRAUM, P156; Sander AM, 2009, J HEAD TRAUMA REHAB, V24, P248, DOI 10.1097/HTR.0b013e3181ad593a; Schulz R, 2009, REHABIL PSYCHOL, V54, P1, DOI 10.1037/a0014932; Shewchuk R, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P553, DOI 10.1037/10361-026; Stull DE, 2008, QUAL LIFE RES, V17, P47, DOI 10.1007/s11136-007-9290-5; Talley RC, 2007, AM J PUBLIC HEALTH, V97, P224, DOI 10.2105/AJPH.2004.059337; U.S Department of Health and Human Services, 2000, HLTH PEOPL 2010; Vitaliano PP, 2004, CURR DIR PSYCHOL SCI, V13, P13, DOI 10.1111/j.0963-7214.2004.01301004.x; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179	38	24	25	0	8	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	27	1					105	112		10.3233/NRE-2010-0585			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	629GA	WOS:000280182000010	20634605	Green Accepted			2021-06-18	
J	Riley, GA; Dennis, RK; Powell, T				Riley, Gerard A.; Dennis, Rebecca K.; Powell, Theresa			Evaluation of coping resources and self-esteem as moderators of the relationship between threat appraisals and avoidance of activities after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Threat; Avoidance; Self-esteem; Coping behaviour	PANIC DISORDER; PROTECTION; EFFICACY; STRESS	It is not uncommon for people after a traumatic brain injury (TBI) to develop anxieties about possible negative outcomes (i.e., threat appraisals) in relation to participating in valued activities. Some respond to this anxiety by avoiding the activities, but others maintain their participation. The present study investigated two factors that may help explain this variation across individuals in their response to threat appraisals - self-esteem and the evaluation of coping resources. Forty-one individuals with a TBI completed the Avoidance and Threat Appraisals Questionnaire, the Rosenberg Self-Esteem Scale and the Coping Resources Questionnaire. The study's hypotheses were supported: Those low in self-esteem, and those with a negative evaluation of their ability to cope with the TBI, were significantly more likely to respond to threat appraisals with avoidance. Those whose injury was more recent and those whose injury was the result of an assault were also more likely to respond with avoidance. The theoretical and therapeutic implications of these results are discussed.	[Riley, Gerard A.; Dennis, Rebecca K.; Powell, Theresa] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England	Riley, GA (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	G.A.Riley@bham.ac.uk	Riley, Gerard Anthony/J-1646-2012; riley, gerard/AAP-1439-2020; Riley, Gerard/A-4328-2008	Riley, Gerard Anthony/0000-0002-1167-8023; Powell, Theresa/0000-0002-3351-9453			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bandura A., 1997, SELF EFFICACY EXERCI; BAUMEISTER RF, 1989, J PERS, V57, P547, DOI 10.1111/j.1467-6494.1989.tb02384.x; Beck AT, 1985, ANXIETY DISORDERS PH; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Casey LM, 2004, CLIN PSYCHOL REV, V24, P529, DOI 10.1016/j.cpr.2004.01.005; Casey LM, 2004, J ANXIETY DISORD, V18, P325, DOI 10.1016/S0887-6185(02)00257-8; CLARK DM, 1986, BEHAV RES THER, V24, P461, DOI 10.1016/0005-7967(86)90011-2; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Ellis-Hill CS, 2000, CLIN REHABIL, V14, P279, DOI 10.1191/026921500671231410; FOLKMAN S, 1984, J PERS SOC PSYCHOL, V46, P839, DOI 10.1037/0022-3514.46.4.839; Goldstein K, 1942, EFFECTS BRAIN INJURY; Heimpel SA, 2006, J PERS, V74, P1293, DOI 10.1111/j.1467-6494.2006.00410.x; HIBBARD MR, 2007, COGNTIVE BEHAV STRAT, P151; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAVETZ S, 1995, BRAIN INJURY, V9, P131, DOI 10.3109/02699059509008186; Lazarus R., 1999, STRESS EMOTION NEW S; Lazarus R.S., 1984, STRESS APPRAISAL COP; Leary MR, 2003, HANDBOOK OF SELF AND IDENTITY, P401; Man DWK, 2003, BRAIN INJURY, V17, P775, DOI 10.1080/0269905031000088577; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Riley GA, 2004, BRAIN INJURY, V18, P871, DOI 10.1080/02699050410001671829; Tabachnik B. G., 2001, USING MULTIVARIATE S; TICE DM, 1991, J PERS SOC PSYCHOL, V60, P711, DOI 10.1037/0022-3514.60.5.711; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Vickery CD, 2008, REHABIL PSYCHOL, V53, P101, DOI 10.1037/0090-5550.53.1.101; White KS, 2006, BEHAV RES THER, V44, P147, DOI 10.1016/j.brat.2005.07.009; WOOD JV, 1994, J PERS SOC PSYCHOL, V67, P713, DOI 10.1037/0022-3514.67.4.713; Wright S., 1995, MEASURES HLTH PSYCHO	36	24	24	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	6					869	882	PII 924820493	10.1080/09602011.2010.503041			14	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	684GB	WOS:000284537300005	20665337				2021-06-18	
J	Singh, S; Hota, D; Prakash, A; Khanduja, KL; Arora, SK; Chakrabarti, A				Singh, Surjit; Hota, Debasish; Prakash, Ajay; Khanduja, Krishan L.; Arora, Sunil K.; Chakrabarti, Amitava			Allopregnanolone, the active metabolite of progesterone protects against neuronal damage in picrotoxin-induced seizure model in mice	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Progesterone; Allopregnanolone picrotoxin; Seizures; Indomethacin; DNA fragmentation; 5-alpha reductase	AMYGDALA-KINDLED SEIZURES; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; HIPPOCAMPAL-NEURONS; CELL-DEATH; ANTICONVULSANT ACTIVITY; GABA(A) RECEPTORS; FEMALE RATS; APOPTOSIS; KAINATE	Progesterone exerts anti-seizure effect against several chemoconvulsants. However, there is no published report on the interaction between progesterone and picrotoxin (M). The present study evaluated the effects of progesterone and its active metabolite, allopregnanolone against PTX-induced seizures, brain lipid peroxidation and DNA fragmentation in male mice. Finasteride, a 5 alpha-reductase inhibitor and indomethacin, an inhibitor of 3 infinity-hydroxysteroid dehydrogenase were assessed against progesterone's effects on PTX-induced seizures, brain lipid peroxidation and DNA fragmentation. M produced clonic-tonic seizures in mice with CD50 and CD97 of 2.4 and 4.0 mg/kg, i.p. respectively. Progesterone significantly countered PTX-induced seizures, with ED50 of 78.30 mg/kg and ED97 of 200 mg/kg. Progesterone antagonized M-induced DNA fragmentation. Finasteride (200 mg/kg) and indomethacin (1 mg/kg) reversed the anti-seizure and anti-DNA fragmentation effects of progesterone. Allopregnanolone, also protected against M-induced seizures and DNA fragmentation. There was no significant change in the brain lipid peroxidation parameters in any of the treatment groups. It may be concluded that progesterone protects against M-induced seizures and DNA fragmentation through its active metabolites allopregnanolone and 5 alpha-pregnan-3,20-dione. However, it appears from the present study that, the neuroprotection with progesterone is primarily on account of allopregnalone. The therapeutic potential of allopregnanolone deserves to be evaluated clinically. (C) 2009 Elsevier Inc. All rights reserved.	[Singh, Surjit; Hota, Debasish; Prakash, Ajay; Chakrabarti, Amitava] Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh 160012, India	Chakrabarti, A (corresponding author), PGIMER, Dept Pharmacol 4046, PN Chuttani Block, Chandigarh 160012, India.	amitavachakrabarti315@yahoo.com		SINGH, SURJIT/0000-0002-8990-3235			Acharya MM, 2005, INDIAN J CLIN BIOCHE, V20, P56, DOI 10.1007/BF02893043; Aggarwal R, 2008, J PHARM PHARMACOL, V60, P731, DOI 10.1211/jpp.60.6.0008; Auger CJ, 2002, J NEUROENDOCRINOL, V14, P561, DOI 10.1046/j.1365-2826.2002.00809.x; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; GIORGI O, 1991, EUR J PHARMACOL, V193, P363, DOI 10.1016/0014-2999(91)90152-G; Guerra-Araiza C, 2003, J NEUROENDOCRINOL, V15, P984, DOI 10.1046/j.1365-2826.2003.01088.x; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; HETMAN M, 1995, EXP NEUROL, V136, P53, DOI 10.1006/exnr.1995.1083; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; Ibanez C, 2003, ENDOCRINOLOGY, V144, P2902, DOI 10.1210/en.2002-0073; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; LANDGREN S, 1987, ACTA PHYSIOL SCAND, V131, P33, DOI 10.1111/j.1748-1716.1987.tb08202.x; Leonhardt SA, 2003, STEROIDS, V68, P761, DOI 10.1016/S0039-128X(03)00129-6; LITCHFIELD ST, 1949, J PHARMACOL EXP THER, V96, P99; Lonsdale D, 2007, NEUROSCI LETT, V411, P147, DOI 10.1016/j.neulet.2006.10.023; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luck H, 1963, METHOD ENZYMAT AN, P885; Mackenzie L, 2002, CLIN NEUROPHYSIOL, V113, P586, DOI 10.1016/S1388-2457(02)00040-8; NICOLETTI F, 1985, EPILEPSIA, V26, P252, DOI 10.1111/j.1528-1157.1985.tb05414.x; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pistritto G, 2009, EXP NEUROL, V217, P302, DOI 10.1016/j.expneurol.2009.03.008; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Reddy DS, 2004, J PHARMACOL EXP THER, V310, P230, DOI 10.1124/jpet.104.065268; Rhodes ME, 2005, EPILEPSY BEHAV, V6, P320, DOI 10.1016/j.yebeh.2005.02.006; Rogawski MA, 2004, EPILEPSY SCI FDN CLI, P319; SAMBROOK J, 2003, MOL CLONING LAB MANU; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SMITH SS, 1987, BRAIN RES, V422, P52, DOI 10.1016/0006-8993(87)90539-7; Velisek L, 2006, MODELS OF SEIZURES AND EPILEPSY, P127, DOI 10.1016/B978-012088554-1/50013-X; Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901; Zhang LX, 1998, MOL BRAIN RES, V55, P198, DOI 10.1016/S0169-328X(97)00316-1	39	24	24	1	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	JAN	2010	94	3					416	422		10.1016/j.pbb.2009.10.003			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	551RK	WOS:000274226500013	19840816				2021-06-18	
J	Babikian, T; Tong, KA; Galloway, NR; Freier-Randall, MC; Obenaus, A; Ashwal, S				Babikian, Talin; Tong, Karen A.; Galloway, Nicholas R.; Freier-Randall, Mary-Catherin; Obenaus, Andre; Ashwal, Stephen			Diffusion-Weighted Imaging Predicts Cognition in Pediatric Brain Injury	PEDIATRIC NEUROLOGY			English	Article							IMPROVES OUTCOME PREDICTION; CLOSED-HEAD INJURY; WHITE-MATTER; AXONAL INJURY; MR; COEFFICIENT; CHILDREN; SPECTROSCOPY; SEVERITY; IMAGES	Apparent diffusion coefficient maps from diffusion-weighted imaging predict gross neurologic outcome in adults with traumatic brain injury. Few studies in children have been reported, and none have used apparent diffusion coefficient maps to predict long-term (>1 year) neurocognitive outcomes. In this study, pooled regional and total brain diffusion coefficients were used to predict long-term outcomes in 17 pediatric brain injury patients. Apparent diffusion coefficient values were grouped into peripheral and deep gray and white matter, posterior fossa, and total brain. Regions of interest excluded areas that appeared abnormal on T-2-weighted images. Apparent diffusion coefficient values from peripheral regions were inversely correlated with cognitive functioning. No significant correlations were apparent between the cognitive scores and apparent diffusion coefficient values for deep tissue or the posterior fossa. Regression analyses suggested that combined peripheral gray and white matter apparent diffusion coefficients explained 42% of the variance in the combined neurocognitive index. Peripheral gray diffusion coefficients alone explained an additional 20% of variance after accounting for clinical variables. These results suggest that obtaining apparent diffusion coefficient values, specifically from peripheral brain regions, may predict long-term outcome after pediatric brain injury. Discrepancies in the literature on this topic, as well as possible explanations, including sampling and clinical considerations, are discussed. (C) 2009 by Elsevier Inc. All rights reserved.	[Babikian, Talin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Tong, Karen A.; Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA USA; [Galloway, Nicholas R.; Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Radiat Med, Loma Linda, CA USA; [Freier-Randall, Mary-Catherin] Loma Linda Univ, Sch Med, Dept Psychol, Loma Linda, CA USA; [Freier-Randall, Mary-Catherin; Obenaus, Andre; Ashwal, Stephen] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA USA	Babikian, T (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,Room C8-746, Los Angeles, CA 90024 USA.	tbabikian@mednet.ucla.edu					Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GILLES EE, 1999, PEDIAT NEUROLOGY PRI, P898; GIZA C, 2006, PEDIAT NEUROLOGY PRI, P1401; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Mukherjee P, 2001, RADIOLOGY, V221, P349, DOI 10.1148/radiol.2212001702; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1034/j.1600-0455.2001.420404.x; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Obenaus A, 2008, NEUROPHARMACOLOGY, V55, P271, DOI 10.1016/j.neuropharm.2008.06.010; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schneider JFL, 2004, NEURORADIOLOGY, V46, P258, DOI 10.1007/s00234-003-1154-2; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Ulug AM, 2002, DEVELOPMENTAL SCI, V5, P286, DOI 10.1111/1467-7687.t01-1-00005; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zheng H, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-5	37	24	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	DEC	2009	41	6					406	412		10.1016/j.pediatrneurol.2009.06.002			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	525PA	WOS:000272227200003	19931161				2021-06-18	
J	Chen, SH; Chang, CY; Chang, HK; Chen, WC; Lin, MT; Wang, JJ; Chen, JCY; Chang, FM				Chen, Sheng-Hsien; Chang, Chia-Yu; Chang, Hsiu-Kang; Chen, Wei-Chun; Lin, Mao-Tsun; Wang, Jhi-Joung; Chen, Jeffrey Cheng-Yu; Chang, Fong-Ming			Premarin stimulates estrogen receptor-alpha to protect against traumatic brain injury in male rats	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; conjugated; estrogen; inflammation; angiogenesis; neurogenesis	CEREBRAL-ARTERY OCCLUSION; BETA-ESTRADIOL PROTECTS; HIPPOCAMPAL-NEURONS; NEUROTROPHIC FACTOR; FLUID PERCUSSION; NERVOUS-SYSTEM; ISCHEMIA; NEUROGENESIS; DAMAGE; EXCITOTOXICITY	Objectives: To establish mechanisms of neuroprotective actions induced by Premarin (an estrogen sulfate) during traumatic brain injury. Design: Chi Mei Medical Center research laboratory. Subjects: Male Sprague-Dawley rats 244 to 268 g. Interventions: Anesthetized rats, immediately after the onset of fluid percussion injury, were divided into three major groups and given the vehicle solution (1 mL/kg of body weight), Premarin (1 mg/kg of body weight), or Premarin (1 mg/kg of body weight) plus the nonselective estrogen receptor-alpha antagonist ICI 182, 780 (0.25 mg/kg of body weight) intravenously and immediately after fluid percussion injury. Measurements and Main Results: Premarin, in addition to inducing pharmacologic levels of estradiol, causes attenuation of fluid percussion injury-induced cerebral infarction and motor and cognitive function deficits. Fluid percussion injury-induced apoptosis (e.g., increased numbers of both terminal deoxynucleotidyl transferase dUTP nick-end labeling-positive and caspase-3-positive cells) as well as activated inflammation (e.g., increased levels of tumor necrosis factor-alpha) was also significantly Premarin-reduced. In peri-ischemic areas of hippocampus, both angiogenesis (e.g., increased numbers of both 5-bromodeoxyuridine-positive endothelial and vascular endothelial growth factor-positive cells) and neurogenesis (e.g., increased numbers of both 5-bromodeoxyuridine/neuronal-specific nuclear protein double-positive and glial cell line-derived neurotrophic factor-positive cells) were Premarin therapy-promoted. In estrogen receptor-a. blockade rats, Premarin therapy had less or no effect on fluid percussion injury-induced behavioral deficits, cerebral infarction and apoptosis, and activated inflammation. Furthermore, Premarin-induced angiogenesis and neurogenesis were estrogen receptor-a blockade-reduced. Conclusions: Our results indicate that pharmacologic levels of Premarin therapy-induced estradiol protect against cortical and hippocampal programmed cell death after fluid percussion injury through mechanisms stimulating estrogen receptor-a in the male rats. (Crit Care Med 2009; 37:3097-3106)	[Chang, Fong-Ming] Natl Cheng Kung Univ, Dept Obstet & Gynecol, Sch Med, Tainan 70101, Taiwan; [Chen, Sheng-Hsien] Chi Mei Med Ctr, Dept Obstet & Gynecol, Tainan, Taiwan; [Chang, Chia-Yu] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Lin, Mao-Tsun; Wang, Jhi-Joung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Chen, Sheng-Hsien; Chang, Chia-Yu] So Taiwan Univ Technol, Dept Biotechnol, Tainan, Taiwan; [Chen, Sheng-Hsien] Taipei Med Univ, Dept Obstet & Gynecol, Taipei, Taiwan; [Chang, Hsiu-Kang; Chen, Wei-Chun] Hlth Banks Biotech Co Ltd, Stem Cell Res Ctr, Taipei, Taiwan; [Chen, Jeffrey Cheng-Yu] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia	Chang, FM (corresponding author), Natl Cheng Kung Univ, Dept Obstet & Gynecol, Sch Med, Tainan 70101, Taiwan.	fchang@mail.ncku.edu.tw			 [NSC 96-2314-B-384006-MY3];  [NSC 97-2321-B-384-001-MY2]	Supported, in part, by grants NSC 96-2314-B-384006-MY3 and NSC 97-2321-B-384-001-MY2.	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Behl C, 1997, MOL PHARMACOL, V51, P535; Cardona-Gomez GP, 2000, J NEUROBIOL, V43, P269, DOI 10.1002/(SICI)1097-4695(20000605)43:3<269::AID-NEU5>3.0.CO;2-D; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen SH, 2006, CRIT CARE MED, V34, P1113, DOI 10.1097/01.CCM.0000205756.04845.15; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; Clark KE, 2000, AM J OBSTET GYNECOL, V183, P12, DOI 10.1067/mob.2000.105200; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Horsburgh K, 2002, J CEREBR BLOOD F MET, V22, P1189; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Maggi A, 2004, ANNU REV PHYSIOL, V66, P291, DOI 10.1146/annurev.physiol.66.032802.154945; Matejuk A, 2001, J NEUROSCI RES, V65, P529, DOI 10.1002/jnr.1183; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002; Paxinos G, 1982, RAT BRAIN STEREOTOXI; PEREZPOLO JR, 1977, LIFE SCI, V21, P1535, DOI 10.1016/0024-3205(77)90211-9; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Shen KH, 2008, SHOCK, V30, P668, DOI 10.1097/SHK.0b013e31817538cb; Shughrue PJ, 2003, NEUROSCIENCE, V116, P851, DOI 10.1016/S0306-4522(02)00790-X; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Togashi H, 1998, NEUROSCI LETT, V240, P53, DOI 10.1016/S0304-3940(97)00918-X; TORANALLERAND CD, 1980, BRAIN RES, V184, P517; Wang Y, 1997, J NEUROSCI, V17, P4341; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wilson ME, 2000, BRAIN RES, V873, P235, DOI 10.1016/S0006-8993(00)02479-3; Wolf D, 2001, HEPATOLOGY, V34, P535, DOI 10.1053/jhep.2001.27218; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Zhang WR, 2002, BRAIN RES, V947, P140, DOI 10.1016/S0006-8993(02)02923-2; Zhang WR, 2001, BRAIN RES, V903, P253, DOI 10.1016/S0006-8993(01)02364-2	45	24	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2009	37	12					3097	3106		10.1097/CCM.0b013e3181bc7986			10	Critical Care Medicine	General & Internal Medicine	529IR	WOS:000272509800014	19789448				2021-06-18	
J	Bouilleret, V; Cardamone, L; Liu, YR; Fang, K; Myers, DE; O'Brien, TJ				Bouilleret, Viviane; Cardamone, Lisa; Liu, Ying Rui; Fang, Ke; Myers, Damian E.; O'Brien, Terence J.			Progressive Brain Changes on Serial Manganese-Enhanced MRI following Traumatic Brain Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						atrophy; manganese-enhanced MRI; plasticity; prognostic; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; IN-VIVO; HEAD-INJURY; TIME-COURSE; SELECTIVE VULNERABILITY; SYNAPTIC REORGANIZATION; POSTTRAUMATIC EPILEPSY; DENTATE GYRUS; MOUSE-BRAIN	Traumatic brain injury (TBI) has a high incidence of long-term morbidity. Manganese-enhanced MRI (MEMRI) provides high contrast structural and functional detail of the brain in-vivo. The study utilized serial MEMRI scanning in the fluid percussion injury (FPI) rat's model to assess long-term changes in the brain following TBI. Rats underwent a left-sided craniotomy and a 3.5 atmosphere FPI pulse (n = 23) or sham procedure (n = 22). MEMRI acquisition was performed at baseline, 1 day, 1 month, and 6 months after FPI. Volume changes and MnCl2 enhancement were measured blindly using region-of-interest analysis and the results analyzed with repeated measures MANOVA. Compared to the shams, FPI animals showed a progressive decrease in brain volume from 1 (right, p = 0.02; left, p = 0.008) to 6 months (right, p = 0.04; left, p = 0.006), with progression over time (F = 7.16, p = 0.00018). Similar changes were found in the cortex and the hippocampus. Conversely, the ventricular volume was increased at 1 (p = 0.02) and 6 months (p = 0.003), with progression over time (F = 7.27, p = 0.0001). There were no differences in thalamic or amygdalae volumes. The severity of the early neuromotor deficits and the T2 signal intensity of the subacute focal lesion were highly predictive of the severity of the long-term hippocampal decrease, and the former was also associated with the degree of neuronal sprouting. Differential MnCl2 enhancement occurred only in the dentate gyrus at 1 month on the side of trauma (p = 0.04). Progressive functional and structural changes occur in specific brain regions post-FPI. The severity of the neuromotor deficit and focal signal changes on MRI subacutely post-injury are predictive of severity of these long-term neurodegenerative changes.	[Bouilleret, Viviane; Cardamone, Lisa; Liu, Ying Rui; Myers, Damian E.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; [Bouilleret, Viviane] CHU Bicetre, ApHp, Dept Neurophysiol & Epilepsy, Paris, France; [Fang, Ke] Howard Florey Inst, Parkville, Vic, Australia; [O'Brien, Terence J.] Royal Melbourne Hosp, Dept Neurol, Parkville, Vic 3050, Australia	O'Brien, TJ (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Clin Sci Bldg,4th Floor Royal Parade, Parkville, Vic 3050, Australia.	obrientj@unimelb.edu.au	Bouilleret, viviane/AAQ-5878-2021; Myers, Damian E/L-5302-2013; O'Brien, Terence J/L-8102-2013	Myers, Damian/0000-0002-7569-9907; O'Brien, Terence/0000-0002-7198-8621	Victorian Government Transport Accident Commission (TAC) [DP0023]	Funding for this project was provided by the Victorian Government Transport Accident Commission (TAC) in the form of a Victorian Neurotrauma Initiative Project grant (DP0023).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alvestad S, 2007, NEUROIMAGE, V38, P57, DOI 10.1016/j.neuroimage.2007.07.027; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bouilleret V, 2009, NEUROIMAGE, V45, P267, DOI 10.1016/j.neuroimage.2008.12.019; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Conti AC, 1998, J NEUROSCI, V18, P5663; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Elmer E, 1997, NEUROREPORT, V8, P1193, DOI 10.1097/00001756-199703240-00027; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Franco-Pons N, 2000, NEUROSCIENCE, V98, P429, DOI 10.1016/S0306-4522(00)00153-6; FREDERICKSON CJ, 1983, BRAIN RES, V273, P335, DOI 10.1016/0006-8993(83)90858-2; Frumberg DB, 2007, BRAIN RES, V1144, P209, DOI 10.1016/j.brainres.2007.01.134; Golarai G, 2001, J NEUROSCI, V21, P8523; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Hsu YH, 2007, BRAIN, V130, P3124, DOI 10.1093/brain/awm207; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kuo YT, 2005, J MAGN RESON IMAGING, V21, P334, DOI 10.1002/jmri.20285; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Longo BM, 1998, EPILEPSY RES, V32, P172, DOI 10.1016/S0920-1211(98)00049-7; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mathern GW, 1998, J NEUROSCI RES, V54, P734, DOI 10.1002/(SICI)1097-4547(19981215)54:6<734::AID-JNR2>3.0.CO;2-P; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nairismagi J, 2006, NEUROIMAGE, V30, P130, DOI 10.1016/j.neuroimage.2005.09.007; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Obenaus A, 2007, EPILEPSIA, V48, P11, DOI 10.1111/j.1528-1167.2007.01237.x; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; REPRESA A, 1993, HIPPOCAMPUS, V3, P257, DOI 10.1002/hipo.450030303; RINK A, 1995, AM J PATHOL, V147, P1575; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Silva AC, 2004, NMR BIOMED, V17, P532, DOI 10.1002/nbm.945; Silva AC, 2008, SCHIZOPHRENIA BULL, V34, P595, DOI 10.1093/schbul/sbn056; Sloviter RS, 2006, J COMP NEUROL, V494, P944, DOI 10.1002/cne.20850; Sloviter RS, 1999, EPILEPSIA, V40, pS34, DOI 10.1111/j.1528-1157.1999.tb00876.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; TAKEDA A, 1994, BRAIN RES, V640, P341, DOI 10.1016/0006-8993(94)91891-0; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Toth Z, 1997, J NEUROSCI, V17, P8106; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; van Raay L, 2009, J NEUROSCI METH, V179, P184, DOI 10.1016/j.jneumeth.2009.01.024; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Watanabe T, 2004, NMR BIOMED, V17, P554, DOI 10.1002/nbm.937; Watanabe T, 2002, MAGN RESON MED, V48, P852, DOI 10.1002/mrm.10276; Yu X, 2005, NAT NEUROSCI, V8, P961, DOI 10.1038/nn1477	74	24	24	2	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1999	2013		10.1089/neu.2009.0943			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600015	19604101				2021-06-18	
J	Shields, BJ; Fernandez, SA; Smith, GA				Shields, Brenda J.; Fernandez, Soledad A.; Smith, Gary A.			Epidemiology of Cheerleading Stunt-Related Injuries in the United States	JOURNAL OF ATHLETIC TRAINING			English	Article						injury surveillance; athletic injuries; collegiate athletes; high school athletes; youth athletes; recreational athletes	HIGH-SCHOOL; HEAD-INJURY; CONCUSSIONS; PREVENTION; SPORTS; RISK	Context. Cheerleading-related injuries are on the rise. To date, no epidemiologic studies of cheerleading stunt-related injuries have been published. Objective: To describe and compare cheerleading stunt-related injuries by type of cheerleading team (All Star, college, high school, middle school, or recreation league) and event (practice, pep rally, athletic event, or cheerleading competition). Design: Prospective injury surveillance study. Setting: Participant exposure and injury data were collected from US cheerleading teams via the Cheerleading RIO (Reporting Information Online) surveillance tool. Patients or Other Participants: Athletes from enrolled cheerleading teams who participated in official, organized cheerleading practices, pep rallies, athletic events, or cheerleading competitions. Main Outcome Measure(s): The numbers, types, and rates of cheerleading stunt-related injuries during a 1-year period (2006-2007) are reported. Results: Stunt-related injuries accounted for 60% (338/567) of the injuries sustained by US cheerleaders who participated in the study and 96% (22/23) of the concussions and closed head injuries (CHIs) reported during the study. Collegiate cheerleaders were more likely to sustain a concussion or CHI than were cheerleaders on other types of teams (P = .02, odds ratio = 3.10, 95% confidence interval = 1.20, 8.06). Most injuries occurred while the cheerleader was spotting or basing another cheerleader (34%, 115/338), and these injuries comprised 32% (51/161) of all stunt-related strains and sprains. Four cheerleaders (1.2%, 4/335) were admitted to the hospital, and 9 cheerleaders (2.7%, 9/335) required surgery. Conclusions: Cheerleading stunts pose an increased risk for injury, especially in terms of sustaining a concussion or CHI. Spotters and bases were most likely to be injured during the performance of cheerleading stunts and were at risk for sustaining strain and sprain injuries. The ankle, lower back, and wrist were the sites most likely to be reinjured while performing cheerleading stunts.	[Shields, Brenda J.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Smith, Gary A.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA	Shields, BJ (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	brenda.shields@nationwidechildrens.org			Research Institute at Nationwide Children's HospitalOhio State University	Funding for this study was provided by the Research Institute at Nationwide Children's Hospital. Debbie Bracewell, Lisa Thompson, and Steve Wedge helped to categorize the cheerleading maneuvers.	*AM ASS CHEERL COA, 2007 2008 AACCA COLL; Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giannone L., 2006, AM ASS CHEERLEADING, P1; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hutchinson MR, 1997, PHYSICIAN SPORTSMED, V25, P83, DOI 10.3810/psm.1997.09.1508; Jacobson BH, 2004, J ORTHOP SPORT PHYS, V34, P261, DOI 10.2519/jospt.2004.34.5.261; Kushner DS, 2001, AM FAM PHYSICIAN, V64, P1007; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Marshall SW, 2007, J ATHL TRAINING, V42, P234; MUELLER FO, 24 NAT CTR CAT SPORT; *NAT ATHL TRAIN AS, SEC SCH OFF STAT; National Athletic Trainers, REC GUID APPR MED CO; National Athletic Trainers Association, 2004, APPR MED CAR SEC SCH; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Proctor MR, 2000, CLIN SPORT MED, V19, P693, DOI 10.1016/S0278-5919(05)70233-7; Schulz MR, 2004, AM J SPORT MED, V32, P396, DOI 10.1177/0363546503261715; Shields BJ, 2006, PEDIATRICS, V117, P122, DOI 10.1542/peds.2005-1139; Shields BJ, 2009, J ATHL TRAINING, V44, P567, DOI 10.4085/1062-6050-44.6.567	23	24	24	1	22	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2009	44	6					586	594		10.4085/1062-6050-44.6.586			9	Sport Sciences	Sport Sciences	522OU	WOS:000272008400004	19911084	Bronze, Green Published			2021-06-18	
J	Larson, MJ; Perlstein, WM				Larson, Michael J.; Perlstein, William M.			Awareness of deficits and error processing after traumatic brain injury	NEUROREPORT			English	Article						attention; awareness; cognitive control; electroencephalogram; error-related negativity; executive; traumatic brain injury	COGNITIVE CONTROL; ANTISACCADE TASK; SEVERE TBI; COMPONENTS; ERP; POTENTIALS; NEGATIVITY; ATTENTION	Severe traumatic brain injury is frequently associated with alterations in performance monitoring, including reduced awareness of physical and cognitive deficits. We examined the relationship between awareness of deficits and electrophysiological indices of performance monitoring, including the error-related negativity and posterior positivity (Pe) components of the scalp-recorded event-related potential, in 16 traumatic brain injury survivors who completed a Stroop color-naming task while event-related potential measurements were recorded. Awareness of deficits was measured as the discrepancy between patient and significant-other ratings on the Frontal Systems Behavior Scale. The amplitude of the Pe, but not error-related negativity, was reliably associated with decreased awareness of deficits. Results indicate that Pe amplitude may serve as an electrophysiological indicator of awareness of abilities and deficits. NeuroReport 20:1486-1490 (C) 2009 Wolters Kluwer Health I Lippincott Williams & Wilkins.	[Larson, Michael J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Larson, Michael J.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Perlstein, William M.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Perlstein, William M.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Perlstein, William M.] Univ Florida, McKnight Brain Inst, Gainesville, FL USA	Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.	michael_larson@byu.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	National Institute of Health (NIH) FellowshipUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F31NS053335]; Evelyn F McKnight Brain Research Grant Program; Florida Brain and Spinal Cord Injury Research Trust Fund; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01 MH01857, R21 MH073076]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH073076, K01MH001857] Funding Source: NIH RePORTER	The study was supported by a National Institute of Health (NIH) Fellowship to M.J.L. (F31NS053335) and grants from the Evelyn F McKnight Brain Research Grant Program, the Florida Brain and Spinal Cord Injury Research Trust Fund, and the National Institute of Health to WMT (K01 MH01857; R21 MH073076).	ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; ARBEL Y, PSYCHOPHYSI IN PRESS; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Endrass T, 2007, EUR J NEUROSCI, V26, P1714, DOI 10.1111/j.1460-9568.2007.05785.x; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Hajcak G, 2003, PSYCHOPHYSIOLOGY, V40, P895, DOI 10.1111/1469-8986.00107; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; O'Connell RG, 2009, NEUROPSYCHOLOGIA, V47, P1149, DOI 10.1016/j.neuropsychologia.2009.01.011; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Shalgi S, 2009, EUR J NEUROSCI, V29, P1522, DOI 10.1111/j.1460-9568.2009.06690.x; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; TEASDALE G, 1974, LANCET, V2, P81; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	25	24	24	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	OCT 28	2009	20	16					1486	1490		10.1097/WNR.0b013e32833283fe			5	Neurosciences	Neurosciences & Neurology	512ZY	WOS:000271292400018	19809369				2021-06-18	
J	Su, ZJ; Han, DD; Sun, B; Qiu, JH; Li, Y; Li, M; Zhang, T; Yang, Z				Su, Zhangjie; Han, Dadong; Sun, Bo; Qiu, Jiaheng; Li, Ying; Li, Mu; Zhang, Tao; Yang, Zhuo			Heat Stress Preconditioning Improves Cognitive Outcome after Diffuse Axonal Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; heat shock protein; heat stress; learning and memory	LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; MORRIS WATER MAZE; SHOCK PRETREATMENT; HIPPOCAMPUS; SCOPOLAMINE; INDUCTION; PROTEIN; MEMORY	This study investigates the influence of heat stress preconditioning on cognitive outcome for rats with diffuse axonal injury (DAI), and attempts to examine the underlying mechanisms. Wistar rats were divided into four groups: rats subjected to heat stress preconditioning 24 h before induction of DAI (n = 10; HSDAI group), a DAI alone group (n = 10), a heat stress alone group (n = 10), and a sham-injury group (n = 10). From day 14 post-injury, the rats' learning abilities and memory were tested using the Morris water maze (MWM) task, followed by long-term potentiation (LTP) recording of the hippocampus. In addition, hematoxylin and eosin staining (H&E) and immunohistochemical staining (IHC) were conducted to determine the presence of brain lesions and expression of heat shock protein 70 (HSP70) at 24 h, and on days 14 and 20 post-injury. The rats in the DAI group displayed impaired MWM performance and attenuated LTP compared to the sham group (p<0.05); the rats in the HSDAI and HS groups showed significant improvement in both MWM and LTP compared with the DAI group (p<0.05), and no significant differences with the sham group (p>0.05). Following injury, retraction balls, shrunken neurons, and HSP70 expression were visible in the brains of rats from the DAI and HSDAI groups; recovery was expedited in the rats belonging to the HSDAI group, as these pathological changes were alleviated, coincident with higher expression of HSP70. The rats' abilities for learning and memory were impaired following DAI; this may be due to the disconnection of brain regions, damage to neurons in the hippocampus, and a decrease in synaptic plasticity. Heat stress preconditioning is able to significantly attenuate this cognitive impairment, possibly mediated by the neuroprotective effect of HSP70.	[Yang, Zhuo] Nankai Univ, Sch Med, Neurophysiol Lab, Tianjin 300071, Peoples R China; [Qiu, Jiaheng; Zhang, Tao] Nankai Univ, Minist Educ, Key Lab Bioact Mat, Coll Life Sci, Tianjin 300071, Peoples R China; [Li, Mu] Tianjin First Cent Hosp, Dept Neurosurg, Tianjin, Peoples R China	Yang, Z (corresponding author), Nankai Univ, Sch Med, Neurophysiol Lab, 94 Weijin Rd, Tianjin 300071, Peoples R China.	zhuoyang@nankai.edu.cn			Municipal Science Foundation Research of Tianjin [06YFJMJC09400]; National Basic Research Program of ChinaNational Basic Research Program of China [2007CB914803]	This work was partly supported by the Municipal Science Foundation Research of Tianjin ( no. 06YFJMJC09400 to Z.Y.), and the National Basic Research Program of China ( no. 2007CB914803 to T.Z.). We thank Dr. Alexander Gerhard for his expert editorial review of this manuscript.	Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Gerges NZ, 2004, J NEUROSCI, V24, P4758, DOI 10.1523/JNEUROSCI.0594-04.2004; Hung CH, 2004, NEUROSCI LETT, V364, P63, DOI 10.1016/j.neulet.2004.02.074; Kelty JD, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0004.2002; Leggio MG, 2006, BRAIN RES BULL, V70, P347, DOI 10.1016/j.brainresbull.2006.06.006; [李峰 Li Feng], 2005, [中华创伤杂志, Chinese Journal of Trauma], V21, P254; LI Y, 2008, CHIN J CONT NEUROL N, V8, P75; Lin YW, 2004, BRAIN RES, V999, P222, DOI 10.1016/j.brainres.2003.11.057; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Myhrer T, 2003, BRAIN RES REV, V41, P268, DOI 10.1016/S0165-0173(02)00268-0; Okada T, 2003, EUR J NEUROSCI, V17, P341, DOI 10.1046/j.1460-9568.2003.02458.x; Pal J, 2006, J NEUROSCI METH, V153, P283, DOI 10.1016/j.jneumeth.2005.11.004; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Sato K, 2002, NEUROSCIENCE, V109, P745, DOI 10.1016/S0306-4522(01)00494-8; SU ZJ, 2008, J BRAIN NERV DIS, V16, P153; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5	23	24	25	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2009	26	10					1695	1706		10.1089/neu.2008.0519			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	507CT	WOS:000270829200008	19785543				2021-06-18	
J	Goverover, Y; Arango-Lasprilla, JC; Hillary, FG; Chiaravalloti, N; DeLuca, J				Goverover, Yael; Arango-Lasprilla, Juan Carlos; Hillary, Frank G.; Chiaravalloti, Nancy; DeLuca, John			Application of the Spacing Effect to Improve Learning and Memory for Functional Tasks in Traumatic Brain Injury: A Pilot Study	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						activities of daily living; brain injuries; cognition disorders; learning; memory	CHILDRENS FREE-RECALL; COGNITIVE REHABILITATION; HEAD-INJURY; REPETITIONS; RECOGNITION; VOCABULARY; RETENTION; MODERATE; MILD; SPEED	Research has indicated that many people with traumatic brain injury (TBI) experience learning and memory difficulties because of impairments in the initial acquisition of information. We examined a strategy, the spacing effect, known to enhance new learning in a laboratory setting in healthy control participants (HCs) and in people with TBI. The spacing effect indicates that information is learned better when presentation trials are distributed over time (spaced presentation) rather than consecutively (massed presentation). In this study, we examined the application of the spacing effect in improving functional tasks. We used a within-subject design and included 10 participants with TBI and 15 HCs. In both the TBI and the HC groups, material learned under the spaced learning condition was recalled better than that learned under massed learning conditions. These results provide initial evidence supporting the use of the spacing effect to improve new learning of functional tasks for people with TBI.	[Goverover, Yael] NYU, Dept Occupat Therapy, Sch Culture Educ & Human Dev, New York, NY 10012 USA; [Goverover, Yael] Kessler Med Rehabil Res & Educ, W Orange, NJ USA; [Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; [Hillary, Frank G.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Chiaravalloti, Nancy] Kessler Fdn Res Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ USA; [DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA	Goverover, Y (corresponding author), NYU, Dept Occupat Therapy, Sch Culture Educ & Human Dev, 35 W 4th St,11th Floor, New York, NY 10012 USA.	yg243@nyu.edu	Hillary, Frank/AAN-8622-2021				Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; BAHRICK HP, 1987, J EXP PSYCHOL LEARN, V13, P344, DOI 10.1037/0278-7393.13.2.344; BAHRICK HP, 1993, PSYCHOL SCI, V4, P316, DOI 10.1111/j.1467-9280.1993.tb00571.x; CAHILL A, 1993, B PSYCHONOMIC SOC, V31, P481; CAMP CJ, 1997, PROSPECTIVE MEMORY T, P311; Cermak LS, 1996, NEUROPSYCHOLOGY, V10, P219; CHALLIS BH, 1993, J EXP PSYCHOL LEARN, V19, P389, DOI 10.1037/0278-7393.19.2.389; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DELIS DC, 2000, DELISKAPLAN EXECUTIV; Delis DC, 1987, CALIFORNIA VERBAL LE; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DEMPSTER FN, 1988, AM PSYCHOL, V43, P627, DOI 10.1037/0003-066X.43.8.627; DEMPSTER FN, 1987, J EDUC PSYCHOL, V79, P162, DOI 10.1037/0022-0663.79.2.162; Dempster FN, 1989, EDUC PSYCHOL REV, V1, P309, DOI 10.1007/BF01320097; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; GLENBERG AM, 1976, J VERB LEARN VERB BE, V15, P1, DOI 10.1016/S0022-5371(76)90002-5; GLENBERG AM, 1980, MEM COGNITION, V8, P528, DOI 10.3758/BF03213772; GLENBERG AM, 1977, J EXP PSYCHOL-HUM L, V3, P282, DOI 10.1037/0278-7393.3.3.282; GLENBERG AM, 1979, MEM COGNITION, V7, P95, DOI 10.3758/BF03197590; GLOVER JA, 1987, J EDUC PSYCHOL, V79, P198, DOI 10.1037/0022-0663.79.2.198; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Goverover Y, 2009, J CLIN EXP NEUROPSYC, V31, P513, DOI 10.1080/13803390802287042; Hall KG, 1995, J MOTOR BEHAV, V27, P299, DOI 10.1080/00222895.1995.9941719; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P49, DOI 10.1076/jcen.25.1.49.13631; Hintzman D. L., 1974, THEORIES COGNITIVE P, p[RL, 77]; Janiszewski C, 2003, J CONSUM RES, V30, P138, DOI 10.1086/374692; JENSEN TD, 1981, B PSYCHONOMIC SOC, V18, P183; Kahana MJ, 2005, PSYCHON B REV, V12, P159, DOI 10.3758/BF03196362; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; MELTON AW, 1970, J VERB LEARN VERB BE, V9, P596, DOI 10.1016/S0022-5371(70)80107-4; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; REA CP, 1985, HUM LEARN, V4, P11; Rohrer D, 2007, CURR DIR PSYCHOL SCI, V16, P183, DOI 10.1111/j.1467-8721.2007.00500.x; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; SHAUGHNESSY JJ, 1972, J VERB LEARN VERB BE, V11, P1, DOI 10.1016/S0022-5371(72)80053-7; Smith A., 1982, SYMBOL DIGIT MODALIT; Sosin DM, 1996, BRAIN INJURY, V10, P47; TOPPINO TC, 1993, B PSYCHONOMIC SOC, V31, P27; TOPPINO TC, 1991, MEM COGNITION, V19, P159, DOI 10.3758/BF03197112; UNDERWOOD BJ, 1970, J VERB LEARN VERB BE, V9, P573, DOI 10.1016/S0022-5371(70)80104-9; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilkinson G.S., 1993, WRAT 3 WIDE RANGE AC; ZECHMEISTER EB, 1980, B PSYCHONOMIC SOC, V15, P41	49	24	24	0	10	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2009	63	5			SI		543	548		10.5014/ajot.63.5.543			6	Rehabilitation	Rehabilitation	493SG	WOS:000269757700004	19785253				2021-06-18	
J	Paci, GM; Sise, MJ; Sise, CB; Sack, DI; Shackford, SR; Kureshi, SA; Osler, TM; Yale, RS; Riccoboni, ST; Peck, KA; O'Reilly, EB				Paci, Gabrielle M.; Sise, Michael J.; Sise, C. Beth; Sack, Daniel I.; Shackford, Steven R.; Kureshi, Sohaib A.; Osler, Turner M.; Yale, Randall S.; Riccoboni, Steven T.; Peck, Kimberly A.; O'Reilly, Eamon B.			Preemptive Craniectomy With Craniotomy: What Role in the Management of Severe Traumatic Brain Injury?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Traumatic brain injury; Craniectomy; Craniotomy	DECOMPRESSIVE CRANIECTOMY; PROPENSITY SCORE	Background: Patients with severe traumatic brain injury (TBI) require aggressive management to prevent secondary brain injury. "Preemptive" craniectomy (CE)-craniectomy performed as a primary procedure in conjunction with craniotomy-has been used as prophylaxis for secondary injury, but the indications and outcomes of craniectomy used for this purpose are not well defined. Methods: To evaluate the role of CE in the management of TBI, we retrospectively reviewed 62 consecutive patients who underwent CE in a 78-month period at our level I trauma center. A cohort of patients who underwent craniotomy only (CO) during this period was compared with the CE group for TBI patterns, indications for operation, and outcomes. Multivariable logistic regression and matched propensity score analysis were used to test the association between CE and survival. The rate of CE was determined by individual neurosurgeons. Results: Of 197 patients with brain injuries who underwent craniotomy, 62 (31.5%) had CE and 135 (68.5%) had CO. Mean age for CE versus CO was 41 years versus 51 years (p < 0.01). Mean admission Glasgow Coma Score was lower in CE versus CO (7.6 vs. 11.8, p < 0.001); Injury Severity Score was higher (30.2 vs. 26.3, p < 0.01). The indication for operation for CE compared with CO was subdural hematoma in 41 (66.1%) versus 87 (64.4%, p = 0.82), epidural hematoma in 2 (3.2%) versus 26 (19.3%, p < 0.0 1), and cerebral contusion or hematoma in 15 (24.2%) versus 8 (5.9%, p < 0.001). Postoperative intracranial pressure was monitored in 48 (77.4%) CE and 44 (32.6%) CO patients (p < 0.001). Intracranial pressure <20 was maintained in 26 (54.2%) after CE and in 31 (70.5%) after CO (p = 0.12). In the CE group, 26 (42%) died compared with 31 (26%, p < 0.01) in the CO group. When adjusted for severity of injury, however, there was no significant difference in mortality between the two groups (p = 0.134). The CE rate obtained by a neurosurgeon varied from 8.6% to 75.0% (p < 0.001). Conclusion: CE was used in patients with more severe injuries, and particularly in those with more severe head injuries. When adjusted for injury severity, CE was not associated with worsened survival, and therefore may reasonably be included in the armamentarium of neurotrauma care. Use of CE by our neurosurgeons, however, varied significantly. These findings underscore the need for practice guidelines based on randomized trials to fully evaluate the role of CE in the management of TBI.	[Paci, Gabrielle M.; Sise, Michael J.; Sise, C. Beth; Sack, Daniel I.; Shackford, Steven R.; Kureshi, Sohaib A.; Osler, Turner M.; Yale, Randall S.; Riccoboni, Steven T.; Peck, Kimberly A.; O'Reilly, Eamon B.] Scripps Mercy Hosp, Div Trauma, San Diego, CA 92103 USA	Sise, MJ (corresponding author), Scripps Mercy Hosp, Div Trauma, 4077 5th Ave, San Diego, CA 92103 USA.	sise.mike@scrippshealth.org		Riccoboni, Steven/0000-0001-6028-9406			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; *CDCP, 2008, TRAUM BRAIN INJ; Cooper P R, 1976, Surg Neurol, V5, P25; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Greenland S., 2008, MODERN EPIDEMIOLOGY, V3rd, P418; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Leuven, 2003, PSMATCH2 STATA MODUL; Marion DW, 2006, NEUROSURGERY, V58, P655; PETERSON SL, 2008, TRAUMA, P871; RORABECK CH, 1984, J BONE JOINT SURG BR, V66, P93; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Saggi B, 1998, J TRAUMA, V45, P597, DOI 10.1097/00005373-199809000-00033; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sauerbrei W, 1999, J R STAT SOC A STAT, V162, P71, DOI 10.1111/1467-985X.00122; Schneider GH, 2002, ACT NEUR S, V81, P77; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Sturmer T, 2006, J CLIN EPIDEMIOL, V59, P437, DOI 10.1016/j.jclinepi.2005.07.004; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Wyrzykowski AD, 2008, TRAUMA, P851	26	24	24	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2009	67	3					531	536		10.1097/TA.0b013e3181b840e8			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	493IL	WOS:000269729900020	19741396				2021-06-18	
J	Togher, L; McDonald, S; Tate, R; Power, E; Rietdijk, R				Togher, Leanne; McDonald, Skye; Tate, Robyn; Power, Emma; Rietdijk, Rachel			Training Communication Partners of People With Traumatic Brain Injury: Reporting the Protocol for a Clinical Trial	BRAIN IMPAIRMENT			English	Article						traumatic brain injury (TBI); communication partner training; cognitive-communication deficits; social skills; rehabilitation	MEASURING PSYCHOSOCIAL RECOVERY; SELF-ESTEEM; HEAD-INJURY; DISCOURSE; SKILLS; CONVERSATION; INFORMATION; ADULTS; REHABILITATION; RELIABILITY	This article reports on the design of a three-arm, nonrandomised controlled trial of interventions targeting social communication skills following traumatic brain injury (TBI) in adult participants. People with severe TBI were allocated to one of the three groups: the TBI group, where only the person with TBI was trained, the JOINT group where both the everyday communication partner (ECP) and the person with TBI were trained together, and a delayed treatment control condition. The trial is comparing whether including everyday communication partners in the training process provide additional benefit when compared to training the person with TBI alone; and additionally, whether training the person with TBI alone is more effective than no training. A range of primary and secondary outcome measures will be used to evaluate outcomes. Publishing the protocol prior to the results of the trial being available has several important benefits (Godlee, 2001). The original hypotheses and intentions of the research are made explicit to ensure that the process of conducting this clinical trial is transparent to readers, and so that comments may be made before results are finalised. It provides the opportunity to outline a detailed description of this intervention and methodology, or to acknowledge changes to methodology, which may assist with eventual clinical application of the intervention. This article also informs the research community of the work that is underway to promote opportunities for collaboration and reduce unnecessary duplication of research. The protocol for this trial has previously been registered on Current Controlled Trials (http://www.controlled-trials.com/ISRCTN57815281).	[Togher, Leanne; Power, Emma; Rietdijk, Rachel] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn] Univ Sydney, Fac Med, No Clin Sch, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia	Togher, L (corresponding author), Natl Hlth & Med Res Council, Canberra, ACT, Australia.	l.togher@usyd.edu.au	McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019; Rietdijk, Rachael/J-6573-2012; Power, Emma/A-9263-2015	McDonald, Skye/0000-0003-0723-6094; Rietdijk, Rachael/0000-0003-4343-4039; Power, Emma/0000-0002-2638-0406; Togher, Leanne/0000-0002-4518-6748	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia	This study was supported by a National Health and Medical Research Council (NH&MRC) project grant.	Adamovich B. B., 1992, SCALES COGNITIVE ABI; Bellon ML, 2006, BRAIN INJURY, V20, P1069, DOI 10.1080/02699050600909813; Benton A., 1994, MULTILINGUAL APHASIA; Blascovich J., 1991, MEASURES PERSONALITY, V1, P115, DOI DOI 10.1016/B978-0-12-590241-0.50008-3; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bute JJ, 2007, HEALTH COMMUN, V21, P235, DOI 10.1080/10410230701307675; Cannizzaro MS, 2002, BRAIN INJURY, V16, P1065, DOI 10.1080/02699050210155230; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; COOPERSMITH S, 1987, SELF ESTEEM INVENTOR; CRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; Creswell J., 2003, RES DESIGN QUALITATI, V2nd edn; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DEMO DH, 1985, J PERS SOC PSYCHOL, V48, P1490, DOI 10.1037/0022-3514.48.6.1490; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Eggins S., 1997, ANAL CASUAL CONVERSA; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Glaser B. G., 1967, DISCOVERY GROUNDED T; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Godlee F, 2001, BMC NEWS VIEWS, V2; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; Heaton R., 1993, WISCONSIN CARD SORTI; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; JUSTICE LM, 2007, EVIDENCE BASED COMMU, V1, P37; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; KILOV A, APHASIOLOGY IN PRESS; Kovarsky D, 2007, TOP LANG DISORD, V27, P50, DOI 10.1097/00011363-200701000-00006; Legg C, 2005, APHASIOLOGY, V19, P559, DOI 10.1080/02687030544000029; *MAA, 1998, TRAIN NEEDS ATT CAR; Macdonald S., 2005, FUNCTIONAL ASSESSMEN; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; McDonald S., 2002, AWARENESS SOCIAL INF; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Meyers J, 1995, REY COMPLEX FIGURE R; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; PRIGATANO G, 1985, HDB CONT REHABILITAT; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; SHAHANI C, 1990, J PERS ASSESS, V54, P276, DOI 10.1207/s15327752jpa5401&2_26; Shelton C, 2007, BRAIN INJURY, V21, P1259, DOI 10.1080/02699050701716935; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; SPSS Inc, 2008, SPSS STAT REL 17 0 1; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate RL, 2004, ARCH PHYS MED REHAB, V85, P538, DOI 10.1016/j.apmr.2003.08.078; TATE RL, 1987, SCAND J REHABIL MED, V19, P19; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; TOGHER L, 1998, COMMUNITY POLI UNPUB; TOGHER L, 2004, BRAIN IMPAIRMENT, V5, P13; TOGHER L, 2001, COMMUNICATION TRAINI; Turner S, 2006, APHASIOLOGY, V20, P483, DOI 10.1080/02687030600589991; VENTOLA E, 1979, J PRAGMATICS, V3, P267, DOI 10.1016/0378-2166(79)90034-1; Visser-Meily JMA, 2004, CLIN REHABIL, V18, P601, DOI 10.1191/0269215504cr776oa; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wedcliffe T, 2001, S Afr J Commun Disord, V48, P77; World Health Organization, 2001, INT CLASS FUNCT DIS; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; Ylvisaker M., 1993, STAFF DEV CLIN INTER, P57; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P303; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	78	24	25	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	SEP	2009	10	2					188	204		10.1375/brim.10.2.188			17	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	488UR	WOS:000269376200005					2021-06-18	
J	Philip, S; Udomphorn, Y; Kirkham, FJ; Vavilala, MS				Philip, Shaji; Udomphorn, Yuthana; Kirkham, Fenella J.; Vavilala, Monica S.			Cerebrovascular Pathophysiology in Pediatric Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	National Summit on Pediatric Disaster and Emergency Services	SEP 11-12, 2008	Los Angeles, CA	Eastern Assoc Surg Trauma, Trauma Assoc Canada, Western Trauma Assoc		Brain injury; Pediatrics; Autoregulation	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; CARBON-DIOXIDE REACTIVITY; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; INTRACRANIAL-PRESSURE; OXIDATIVE-METABOLISM; CO2 REACTIVITY; OXYGEN-CONSUMPTION; PERFUSION-PRESSURE; CHILDREN	Background: Traumatic brain injury (TBI) is the leading cause of traumatic morbidity and mortality in children. Although there is increasing information concerning TBI in adults and experimental animal models, relatively little is known regarding cerebrovascular pathophysiology specific to children. Materials: A review of the pertinent medical literature. Results: Systemic and cerebral hemodynamic factors such as hypotension, hypoxia, hyperglycemia, and fever are associated with poor outcome in pediatric TBI. Similarly, cerebral autoregulation is often impaired after TBI and may adversely affect outcome, especially if systemic hemodynamics are altered. Furthermore, CO2 vasoreactivity may be altered after pediatric TBI and lead to either cerebral ischemia or hyperemia. Conclusions: Understanding the effect of pediatric TBI on the cerebral circulation is needed to potentially develop protocols to improve outcome in this vulnerable population. Specifically, changes in pediatric cerebrovascular physiology and pathophysiology, including CO2 vasoreactivity and pressure autoregulation, must be understood and their mechanism elucidated.	[Philip, Shaji; Udomphorn, Yuthana; Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Kirkham, Fenella J.] UCL Inst Child Hlth, Wolfson Ctr, Neurosci Unit, London, England; [Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Pediat, Seattle, WA 98104 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pediat, Box 359724,325 9th Ave, Seattle, WA 98104 USA.	vavilala@u.washington.edu	Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958			AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; APARICIO JM, 2001, CEREBROVASC DIS, V11, P38; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Biagi L, 2007, J MAGN RESON IMAGING, V25, P696, DOI 10.1002/jmri.20839; BODE H, 1988, PEDIAT APPL TRANSCRA, P1; Bouma GJ, 1998, ACT NEUR S, V71, P272; Brenet O, 1998, ANN FR ANESTH, V17, P227, DOI 10.1016/S0750-7658(98)80004-X; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; HARPER AM, 1965, J NEUROL NEUROSUR PS, V28, P449, DOI 10.1136/jnnp.28.5.449; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hoyert Donna L, 2006, Natl Vital Stat Rep, V54, P1; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Karsli C, 2003, PAEDIATR ANAESTH, V13, P26, DOI 10.1046/j.1460-9592.2003.01017.x; KENNEDY C, 1957, J CLIN INVEST, V36, P1130, DOI 10.1172/JCI103509; KIRKHAM FJ, 1986, ULTRASOUND MED BIOL, V12, P15, DOI 10.1016/0301-5629(86)90139-0; KIRKHAM FJ, 1991, CLIN DEV MED, V113, P283; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; LAM AM, 1995, J CEREBR BLOOD F MET, V15, P714, DOI 10.1038/jcbfm.1995.88; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Lenzi P, 2000, Sleep Res Online, V3, P77; LEON JE, 1991, CAN J ANAESTH, V38, P817, DOI 10.1007/BF03036954; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MADSEN PL, 1991, J APPL PHYSIOL, V70, P2597; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NAKAYAMA DK, 1991, J TRAUMA, V31, P1521, DOI 10.1097/00005373-199111000-00010; Newton CRJC, 1996, PEDIATR NEUROL, V15, P41, DOI 10.1016/0887-8994(96)00115-4; Ng SCP, 2002, ACT NEUR S, V81, P125; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; Ogawa A, 1987, No To Shinkei, V39, P113; OGAWA A, 1989, Neurological Research, V11, P173; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; QUINT SR, 1980, STROKE, V11, P286, DOI 10.1161/01.STR.11.3.286; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Rowney DA, 2002, BRIT J ANAESTH, V88, P357, DOI 10.1093/bja/88.3.357; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; SETTERGREN G, 1980, ACTA PAEDIATR SCAND, V69, P457, DOI 10.1111/j.1651-2227.1980.tb07114.x; SEVERINGHAUS JW, 1967, CIRC RES, V20, P272, DOI 10.1161/01.RES.20.2.272; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; SILVERMAN BW, 1985, J R STAT SOC B, V47, P1; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; STOYKA WW, 1975, CAN ANAESTH SOC J, V22, P275, DOI 10.1007/BF03004836; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Suz P, 2006, J NEUROSURG ANESTH, V18, P5, DOI 10.1097/01.ana.0000189079.26212.37; Thal SC, 2005, CURR OPIN ANESTHESIO, V18, P490, DOI 10.1097/01.aco.0000182561.32680.30; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala Monica S, 2002, Anesthesiol Clin North Am, V20, P247, DOI 10.1016/S0889-8537(01)00012-8; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Vavilala MS, 2003, J NEUROSURG ANESTH, V15, P307, DOI 10.1097/00008506-200310000-00003; Vavilala MS, 2002, ACTA ANAESTH SCAND, V46, P393, DOI 10.1034/j.1399-6576.2002.460411.x; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Visocchi M, 2007, ACTA NEUROCHIR, V149, P347, DOI 10.1007/s00701-006-1102-0; WARD JD, 1995, MANAGEMENT PEDIAT TR, P177; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wintermark M, 2004, PEDIATRICS, V113, P1642, DOI 10.1542/peds.113.6.1642	84	24	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2009	67	2		S			S128	S134		10.1097/TA.0b013e3181ad32c7			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	482OM	WOS:000268898600016	19667845				2021-06-18	
J	Hattori, N; Swan, M; Stobbe, GA; Uomoto, JM; Minoshima, S; Djang, D; Krishnananthan, R; Lewis, DH				Hattori, Naoya; Swan, Megan; Stobbe, Gary A.; Uomoto, Jay M.; Minoshima, Satoshi; Djang, David; Krishnananthan, Ruben; Lewis, David H.			Differential SPECT Activation Patterns Associated with PASAT Performance May Indicate Frontocerebellar Functional Dissociation in Chronic Mild Traumatic Brain Injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						traumatic brain injury; cognitive fatigue; SPECT; activation study; PASAT	SERIAL ADDITION TEST; WORKING-MEMORY; RECOVERY; MODERATE; DISEASE	Patients with mild traumatic brain injury (TBI) often complain of cognitive fatigue during the chronic recovery phase. The Paced Auditory Serial Addition Test (PASAT) is a complex psychologic measure that may demonstrate subtle deficiencies in higher cognitive functions. The purpose of this study was to investigate the brain activation of regional cerebral blood flow (rCBF) with PASAT in patients with mild TBI to explore mechanisms for the cognitive fatigue. Methods: Two groups consisting of 15 patients with mild TBI and 15 healthy control subjects underwent Tc-99m-ethylene cysteine dimer SPECT at rest and during PASAT on a separate day. Cortical rCBF was extracted using a 3-dimensional stereotactic surface projection and statistically analyzed to identify areas of activation, which were compared with PASAT performance scores. Results: Image analysis demonstrated a difference in the pattern of activation between patients with mild TBI and healthy control subjects. Healthy control subjects activated the superior temporal cortex (Brodmann area [BA] 22) bilaterally, the precentral gyrus (BA 9) on the left, and the precentral gyrus (BA 6) and cerebellum bilaterally. Patients with mild TBI demonstrated a larger area of supratentorial activation (BAs 9, 10, 13, and 46) but a smaller area of activation in the cerebellum, indicating frontocerebellar dissociation. Conclusion: Patients with mild TBI and cognitive fatigue demonstrated a different pattern of activation during PASAT. Frontocerebellar dissociation may explain cognitive impairment and cognitive fatigue in the chronic recovery phase of mild traumatic brain injury.	[Hattori, Naoya; Minoshima, Satoshi; Krishnananthan, Ruben; Lewis, David H.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA; [Swan, Megan] Seattle Pacific Univ, Dept Psychol, Seattle, WA 98119 USA; [Stobbe, Gary A.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; [Uomoto, Jay M.] VA Puget Sound Hlth Care Syst, Ctr Polytrauma Care, Dept Neuropsychol, Seattle, WA USA; [Djang, David] Seattle Nucl Med, Dept Nucl Med, Seattle, WA USA	Hattori, N (corresponding author), Univ Washington, Sch Med, Dept Radiol, Box 356113,1959 NE Pacific St, Seattle, WA 98195 USA.	nhattori@u.washington.edu	Uomoto, Jay/AAF-4809-2019; Hattori, Naoya/G-2298-2012; Lewis, David H/AAM-7997-2021; Hattori, Naoya/AAR-6405-2020	Lewis, David H/0000-0003-1927-1073; Minoshima, Satoshi/0000-0002-0043-3047			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM COLL RAD, 2007, ACR PRACT GUID PERF; Audenaert K, 2002, NUCL MED COMMUN, V23, P907, DOI 10.1097/00006231-200209000-00015; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Desmond JE, 2003, NEUROIMAGE, V19, P1510, DOI 10.1016/S1053-8119(03)00102-2; Fos L A, 2000, Appl Neuropsychol, V7, P140, DOI 10.1207/S15324826AN0703_4; Goethals I, 2005, PSYCHIAT RES-NEUROIM, V139, P31, DOI 10.1016/j.pscychresns.2004.09.007; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; HARRINGTON DE, 1993, ARCH PHYS MED REHAB, V74, P579, DOI 10.1016/0003-9993(93)90155-4; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LANE TJ, 1991, AM J MED, V91, P335, DOI 10.1016/0002-9343(91)90150-V; Lazeron RHC, 2003, J NEUROL SCI, V213, P29, DOI 10.1016/S0022-510X(03)00144-8; Lockwood AH, 2004, J INT NEUROPSYCH SOC, V10, P26, DOI 10.1017/S1355617740410145; Lombardi WJ, 2001, NEUROLOGY, V57, P785, DOI 10.1212/WNL.57.5.785; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; SHIFFRIN RM, 1984, PSYCHOL REV, V91, P269, DOI 10.1037/0033-295X.91.2.269; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289	28	24	24	0	3	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	JUL	2009	50	7					1054	1061		10.2967/jnumed.108.060368			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	529VO	WOS:000272547100015	19525460	Bronze			2021-06-18	
J	Jia, YL; Alkayed, N; Wang, RK				Jia, Yali; Alkayed, Nabil; Wang, Ruikang K.			Potential of optical microangiography to monitor cerebral blood perfusion and vascular plasticity following traumatic brain injury in mice in vivo	JOURNAL OF BIOMEDICAL OPTICS			English	Article						Optical microangiography; cerebral blood perfusion; vascular remodeling; traumatic brain injury	FLOW; ANGIOGRAPHY	Optical microanglography (OMAG) is a recently developed imaging modality capable of volumetric imaging of dynamic blood perfusion, down to capillary level resolution, with an imaging depth up to 2.00 mm beneath the tissue surface. We report the use of OMAG to monitor the cerebral blood flow (CBF) over the cortex of mouse brain upon traumatic brain injury (TBI), with the cranium left intact, for a period of two weeks on the same animal. We show the ability of OMAG to repeatedly image 3-D cerebral vasculatures during pre- and post-traumatic phases, and to visualize the changes of regulated CBF and the vascular plasticity after TBI. The results indicate the potential of OMAG to explore the mechanism involved in the rehabilitation of TBI. (C) 2009 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3207121]	[Jia, Yali; Wang, Ruikang K.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA; [Alkayed, Nabil; Wang, Ruikang K.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA	Wang, RK (corresponding author), Oregon Hlth & Sci Univ, Dept Biomed Engn, 3303 SW Bond Ave, Portland, OR 97239 USA.	r.k.wang@bme.ogi.edu	Wang, Ruikang K./L-3889-2019	Wang, Ruikang K./0000-0001-5169-8822; Jia, Yali/0000-0002-2784-1905	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EB009682, R01HL093140, R01DC010201]; American Heart AssociationAmerican Heart Association [0855733G]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL093140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044313, P30NS061800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC010201] Funding Source: NIH RePORTER	This research was supported in part by grants from the National Institutes of Health (Nos. R01EB009682, R01HL093140, and R01DC010201) and the American Heart Association (0855733G).	BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Calamante F, 1999, J CEREBR BLOOD F MET, V19, P701, DOI 10.1097/00004647-199907000-00001; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Guyton C. A., 2006, TXB MED PHYSL, P195; Misgeld T, 2006, NAT REV NEUROSCI, V7, P449, DOI 10.1038/nrn1905; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; Wang RKK, 2007, OPT EXPRESS, V15, P11402, DOI 10.1364/OE.15.011402; Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	10	24	24	0	1	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668	1560-2281		J BIOMED OPT	J. Biomed. Opt.	JUL-AUG	2009	14	4							040505	10.1117/1.3207121			3	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	503MV	WOS:000270540100005	19725710	Bronze, Green Accepted			2021-06-18	
J	Neumann, CR; Brasil, AV; Albers, F				Neumann, Cristina R.; Brasil, Albert V.; Albers, Felix			Risk Factors for Mortality in Traumatic Cervical Spinal Cord Injury: Brazilian Data	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic cervical spinal cord injury; Mortality; Brain trauma	MULTICENTER; SURVIVAL; PATTERNS; SCORE; CARE	Background: Predictive factors for mortality are different among Countries; knowledge of risk factors is important for planning strategies to reduce mortality in trauma. The objective of this study was to identify predictors of death in traumatic cervical spinal cord injury (TSCI) in Brazil. Methods: From 2001 to 2005, 84 patients with clinically detectable TSCI were identified in this retrospective study. For each patient, neurologic and associated injuries, physiologic variables, complications, treatment, and hospital mortality were recorded. Bivariate and multivariate logistic regression analyses were done to identify predictors of mortality. Results: Twenty-two (26.2%) patients died in hospital. Car crash (39%) and falls (37.85) were the most frequent causes of trauma. The causes of death were as follows: neurologic, 8 (36.4%); respiratory, 4 (18.2%); septic complications, 2 (9.1%); venous thrombosis and embolism, 2 (9.1%); and undetermined, 4 (18.2%). Bivariate analysis identified absent neurologic function (risk ratios [RR] 4.5; 95% confidence intervals [CI], 1.6-12.7), high injury severity score (p = 0.001) and low revised trauma score) = 0.001); Glasgow Coma Scale (GCS.) score <9 (RR 47.4; 95% Cl, 5.4-413.2); shock at admission (RR = 2.5; 95% CI, 0.8-7.9); vasopressor use (RR = 25.8; 95% CI, 6.1-109.6); mechanical ventilation (RR = 31.9; 95% CI, 6.6-154.0); acute renal insufficiency (RR = 10.0; 95% CI, 0.98-102.1) as associated with mortality. The mainly independents predictors for mortality were GCS score <9 and vasopressor use. Lowest mortality rate (5.2%) was observed for patients with TSCI alone. Conclusions: GCS score <9, mechanical ventilation, and vasopressor use were predictors of mortality with TCSI, and if these risk factors were absent, we observed low mortality rate.	[Neumann, Cristina R.] Univ Fed Rio Grande do Sul, Sch Med, Dept Social Med, Intensivist Hosp Pronto Socorro Municipal Porto A, Porto Alegre, RS, Brazil; [Brasil, Albert V.] Complexo Hosp Santa Casa, Hosp Pronto Socorro Municipal Porto Alegre, Porto Alegre, RS, Brazil; [Albers, Felix] Hosp Cristo Redentor, Hosp Pronto Socorro Municipal Porto Alegre, Porto Alegre, RS, Brazil	Neumann, CR (corresponding author), 344 Fatima St, BR-90620250 Porto Alegre, RS, Brazil.	cristinaneumann@via-rs.net	neumann, cristina/K-4692-2012				*AM ASS NEUR SURG, 2007, GUID MAN AC CERV SPI; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Claxton AR, 1998, CAN J ANAESTH, V45, P144, DOI 10.1007/BF03013253; Coelho DG, 2000, ARQ NEURO-PSIQUIAT, V58, P1030, DOI 10.1590/S0004-282X2000000600009; DAVERAT P, 1989, J NEUROL NEUROSUR PS, V52, P403, DOI 10.1136/jnnp.52.3.403; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P156; Fisher CG, 2006, SPINE, V31, pS2, DOI 10.1097/01.brs.0000217948.02567.3a; Frankel H L, 1969, Paraplegia, V7, P179; FREITAS PEP, 1990, J BRAS NEUROCIR, V2, P1; Gawryszewski Vilma Pinheiro, 2006, Sao Paulo Med. J., V124, P208, DOI 10.1590/S1516-31802006000400007; Geisler FH, 2001, SPINE, V26, pS58, DOI 10.1097/00007632-200112151-00013; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Geisler FH, 2001, SPINE, V26, pS68, DOI 10.1097/00007632-200112151-00014; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; JAULENT MC, 1999, LOGISTIC REGRESSION; Kannus P, 2007, J GERONTOL A-BIOL, V62, P180, DOI 10.1093/gerona/62.2.180; LEAL FSC, 1997, ARQ BRAS NEUROCIR, V16, P111; Marino RJ, 2002, J SPINAL CORD MED S1, V26, pS50; Martin MJ, 2005, AM J SURG, V190, P836, DOI 10.1016/j.amjsurg.2005.05.051; Martins F, 1998, SPINAL CORD, V36, P574, DOI 10.1038/sj.sc.3100657; *NAT SCISC, 2006, ANN REP MOD SPIN COR; O'Connor PJ, 2005, ARCH PHYS MED REHAB, V86, P37, DOI 10.1016/j.apmr.2004.03.018; *PAN AM HLTH ORG, BAS HLTH IND DAT BRA; Pickett W, 2003, J TRAUMA, V55, P1070, DOI 10.1097/01.TA.0000034228.18541.D1; Robertson A, 2002, J TRAUMA, V53, P5, DOI 10.1097/00005373-200207000-00002; TEASDALE G, 1974, LANCET, V2, P81	28	24	27	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2009	67	1					67	70		10.1097/TA.0b013e3181aa63f3			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	470CZ	WOS:000267953100011	19590310				2021-06-18	
J	Shang, Y; Li, XW; Prasad, PV; Xu, SP; Yao, SL; Liu, D; Yuan, SY; Feng, D				Shang, You; Li, Xingwang; Prasad, Pramod V.; Xu, Sanpeng; Yao, Shanglong; Liu, Dong; Yuan, Shiying; Feng, Dan			Erythropoietin attenuates lung injury in lipopolysaccharide treated rats	JOURNAL OF SURGICAL RESEARCH			English	Article						endotoxin; acute lung injury; inducible nitric oxide synthase; nitric oxide; nitrotyrosine	NITRIC-OXIDE SYNTHASE; RESPIRATORY-DISTRESS-SYNDROME; ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; NEONATAL-RATS; INOS ACTIVITY; KAPPA-B; ENDOTOXIN; MODEL; SHOCK	Background. Erythropoietin (EPO) elicits protective effects in lung ischemia-reperfusion, hyperoxia, acute necrotizing pancreatitis, and some other tissues. In the present study, we investigated the possible protective roles of EPO in the lipopolysaccharide (LPS) induced lung injury. Materials and Methods. Male Sprague-Dawley rats were treated with EPO (3000 U/kg, i.p.) or vehicle (saline), 30 min prior to LPS administration (6 mg/kg, i.v.). Four h following LPS injection, samples of pulmonary tissue were collected. Optical microscopy was performed to examine pathological changes in lungs. Validated methods were used to measure wet/dry ratios (W/D), myeloperoxidase (MPO) activity, malondialdehyde (MDA) concentrations, and nitrite/nitrate (NO2-/NO3-) levels in lungs. Western blotting was performed to study the pulmonary expression of inducible nitric oxide synthase (iNOS) and nitrotyrosine protein. Results. Pretreatment with EPO led to (1) significant attenuation of endotoxemia induced evident lung histologic injury and edema; (2) inhibition of LPS mediated induction in MPO activity and MDA concentration; (3) inhibition of LPS mediated overporduction of pulmonary NO2-/NO3- levels; and (4) marked suppression in endotoxin induced expression of iNOS and nitrotyrosine. Conclusions. This study provides considerable evidence that EPO has an ability to significantly attenuate endotoxin-induced acute lung injury in rats.	[Shang, You; Li, Xingwang; Yao, Shanglong; Liu, Dong; Yuan, Shiying; Feng, Dan] Huazhong Univ Sci & Technol, Dept Anesthesiol & Intens Care Med, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China; [Li, Xingwang] Wenzhou Med Coll, Dept Anesthesiol, Hosp 2, Wenzhou, Peoples R China; [Li, Xingwang; Prasad, Pramod V.] Rockefeller Univ, Ctr Biomed Res, Populat Council, New York, NY USA; [Xu, Sanpeng] Huazhong Univ Sci & Technol, Dept Pathol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Liu, Dong] Lanzhou Gen Hosp PLA, Dept Anesthesiol & Intens Care Med, Lanzhou, Peoples R China	Shang, Y (corresponding author), Huazhong Univ Sci & Technol, Dept Anesthesiol & Intens Care Med, Union Hosp, Tongji Med Coll, 1277 Jiefangdadao, Wuhan 430022, Peoples R China.	shang_you@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30571787]	This work was supported by the National Natural Science Foundation of China (no. 30571787) to SY.	Abdelrahman M, 2004, SHOCK, V22, P63, DOI 10.1097/01.shk.00001276869.21260.9d; Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Cetin H, 2007, CLIN EXP PHARMACOL P, V34, P1181, DOI 10.1111/j.1440-1681.2007.04695.x; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Cuzzocrea S, 2006, CRIT CARE MED, V34, P1168, DOI 10.1097/01.CCM.0000207346.56477.E8; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Ermert M, 2002, LAB INVEST, V82, P425, DOI 10.1038/labinvest.3780436; Fan J, 2001, AM J PHYSIOL-LUNG C, V281, pL1037; Fulkerson WJ, 1996, ARCH INTERN MED, V156, P29, DOI 10.1001/archinte.156.1.29; GHOSH S, 1993, CRIT CARE MED, V21, pS19, DOI 10.1097/00003246-199302001-00005; Grasso G, 2007, DRUG NEWS PERSPECT, V20, P315, DOI 10.1358/dnp.2007.20.5.1120219; Gray KD, 2003, AM J SURG, V186, P526, DOI 10.1016/j.amjsurg.2003.07.010; Guneli E, 2007, MOL MED, V13, P509, DOI 10.2119/2007-00032.Guneli; JELKMANN W, 1992, PHYSIOL REV, V72, P449; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; Koksel O, 2004, PULM PHARMACOL THER, V17, P263, DOI 10.1016/j.pupt.2004.05.002; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; Kristof AS, 1998, AM J RESP CRIT CARE, V158, P1883, DOI 10.1164/ajrccm.158.6.9802100; Lee JH, 2007, J KOREAN MED SCI, V22, P1042, DOI 10.3346/jkms.2008.22.6.1042; Lipsic E, 2006, J AM COLL CARDIOL, V48, P2161, DOI 10.1016/j.jacc.2006.08.031; Liu D, 2005, CRIT CARE MED, V33, P2309, DOI 10.1097/01.CCM.0000183161.81503.7D; Liu SF, 1997, J IMMUNOL, V159, P3976; Liu XM, 2006, LIFE SCI, V78, P2255, DOI 10.1016/j.lfs.2005.09.053; Mikawa K, 2003, ANESTH ANALG, V97, P1751, DOI 10.1213/01.ANE.0000086896.90343.13; Mitra A, 2007, NEPHROL DIAL TRANSPL, V22, P2349, DOI 10.1093/ndt/gfm216; Naidu BV, 2003, J HEART LUNG TRANSPL, V22, P784, DOI 10.1016/S1053-2498(02)00556-9; Ng T, 2003, POSTGRAD MED J, V79, P367, DOI 10.1136/pmj.79.933.367; Numata M, 1998, J IMMUNOL, V160, P3031; Ozer EA, 2005, PEDIATR RES, V58, P38, DOI 10.1203/01.PDR.0000163391.75389.52; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Ozturk E, 2008, PROG NEURO-PSYCHOPH, V32, P81, DOI 10.1016/j.pnpbp.2007.07.016; Parsey MV, 1998, J IMMUNOL, V160, P1007; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699; Sato K, 2002, FASEB J, V16, P1713, DOI 10.1096/fj.02-0331com; Shenkar R, 1999, J IMMUNOL, V163, P954; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Tascilar O, 2007, WORLD J GASTROENTERO, V13, P6172, DOI 10.3748/wjg.13.6172; Wang LF, 2001, BIOCHEM BIOPH RES CO, V283, P694, DOI 10.1006/bbrc.2001.4842; Wu HW, 2006, EUR J CARDIO-THORAC, V29, P902, DOI 10.1016/j.ejcts.2006.02.036; Yang CW, 2003, FASEB J, V17, P1754, DOI 10.1096/fj.02-1191fje; Yidirim E, 2005, J TRAUMA, V58, P1252, DOI 10.1097/01.TA.0000169803.09482.F8; Yildirim E, 2004, J HEART LUNG TRANSPL, V23, P1423, DOI 10.1016/j.healun.2003.10.006; Zhou JL, 2003, WORLD J GASTROENTERO, V9, P1318, DOI 10.3748/wjg.v9.i6.1318	46	24	26	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUL	2009	155	1					104	110		10.1016/j.jss.2008.10.003			7	Surgery	Surgery	463RC	WOS:000267448500027	19285686				2021-06-18	
J	Wang, HE; Weaver, MD; Abo, BN; Kaliappan, R; Fairbanks, RJ				Wang, H. E.; Weaver, M. D.; Abo, B. N.; Kaliappan, R.; Fairbanks, R. J.			Ambulance stretcher adverse events	QUALITY & SAFETY IN HEALTH CARE			English	Article							DESIGNING ERGONOMIC INTERVENTIONS; PATIENT SAFETY; EMS WORKERS	Introduction: Ambulance personnel use wheeled stretchers for moving patients in the out-of-hospital setting. The nature of adverse events and associated injuries occurring during ambulance stretcher operation was characterised. Methods: Data from the United States Food and Drug Administration's Manufacturer and User Facility Device Experience Database (MAUDE) were used. All adverse events involving ambulance stretchers during the years 1996-2005 were identified. The nature of the event, the method of stretcher handling, the individuals injured and the nature of the resulting injuries were identified. Results: There were 671 reported adverse events. The most common adverse events were stretcher collapse (54%; 95% CI 50 to 57%), broken, missing or malfunctioning part (28%; 95% CI 25 to 32%) and dropped stretcher (7%; 95% CI 5 to 9%). Adverse events most commonly occurred during unloading of the stretcher from the ambulance (16%; 13 to 19%). Injuries occurred in 121 events (18%; 95% CI 15 to 21%), most often involving sprains/strains (29%), fractures (16%) and lacerations/avulsions (13%). There were three traumatic brain injuries and three deaths. Patients sustained injuries in 52 events (43%), and ambulance personnel sustained injuries in 64 events (53%). More than one individual sustained injuries in 12 events. Conclusion: Adverse events may occur during ambulance stretcher operation and can result in significant injury to patients and ambulance personnel.	[Wang, H. E.; Weaver, M. D.; Abo, B. N.; Kaliappan, R.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15213 USA; [Fairbanks, R. J.] Univ Rochester, Dept Emergency Med, Rochester, NY USA	Wang, HE (corresponding author), Univ Pittsburgh, Dept Emergency Med, 230 McKee Pl,Suite 400, Pittsburgh, PA 15213 USA.	wanghe@upmc.edu			Agency for Healthcare Research and Quality, Rockville, Maryland, United States of AmericaUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08-HS013628]; Emergency Medicine Patient Safety Foundation (Auburn, CA) through the Society for Academic Emergency Medicine (Lansing, MI); AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS013628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [K08EB009090] Funding Source: NIH RePORTER	HEW is supported by Clinical Scientist Development Award K08-HS013628 from the Agency for Healthcare Research and Quality, Rockville, Maryland, United States of America. RJF is supported by a research training grant from the Emergency Medicine Patient Safety Foundation (Auburn, CA) through the Society for Academic Emergency Medicine (Lansing, MI). This research was independent from the funders.	Burt CW, 2006, ANN EMERG MED, V47, P317, DOI 10.1016/j.annemergmed.2005.12.001; Cone DC, 1998, ANN EMERG MED, V31, P241, DOI 10.1016/S0196-0644(98)70314-2; CULLEN DJ, 1995, JOINT COMM J QUAL IM, V21, P541, DOI 10.1016/S1070-3241(16)30180-8; *DEP PUBL HLTH OFF, 2006, EL WHEEL COT SAF PRA; Gershon R R, 1995, Prehosp Disaster Med, V10, P14; Gosbee J, 2002, QUAL SAF HEALTH CARE, V11, P352, DOI 10.1136/qhc.11.4.352; ISRAELSKI EW, 2006, HDB HUMAN FACTORS ER, P615; Karsh BT, 2007, ANN EMERG MED, V50, P433, DOI 10.1016/j.annemergmed.2007.06.481; Lavender SA, 2007, APPL ERGON, V38, P227, DOI 10.1016/j.apergo.2006.02.005; Lavender SA, 2007, APPL ERGON, V38, P71, DOI 10.1016/j.apergo.2005.12.005; *MHRA MED DEV AG, 2003, DEV B SAF US AMB STR; Samore MH, 2004, JAMA-J AM MED ASSOC, V291, P325, DOI 10.1001/jama.291.3.325; *US DEP TRANSP, 1995, EMT BAS NAT STAND CU; *USFDA, 2008, MAN US FAC DEV EXP D; WANG HE, 2007, ABSTR PREH EM CAR, V11, P96	15	24	24	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1475-3898			QUAL SAF HEALTH CARE	Qual. Saf. Health Care	JUN	2009	18	3					213	216		10.1136/qshc.2007.024562			4	Health Care Sciences & Services	Health Care Sciences & Services	449QI	WOS:000266344700012	19468005				2021-06-18	
J	Morita, K; Lee, MS; Her, S				Morita, Kyoji; Lee, Mi-Sook; Her, Song			Possible Relation of Hemin-Induced HO-1 Expression to the Upregulation of VEGF and BDNF mRNA Levels in Rat C6 Glioma Cells	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Hemin; Glial cells; Neurogenic factor; Angiogenic factor; Brain damage; Cerebral hemorrhage	ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; SMOOTH-MUSCLE-CELLS; OXYGENASE-1 HO-1; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; COMPLETE SEQUENCE; OXIDATIVE STRESS; GENE-EXPRESSION; COBALT CHLORIDE	Glial cells are generally considered to contribute to retaining the integrity of neural function through the protection of neuronal cells against neurodegenerative insults and also expected to play a potential role in the protection of cerebrovascular systems from various toxic insults of hemorrhaged blood, thus proposing a possible implication of glial cells in the recovery of brain function from the damage caused by cerebral hemorrhage. Based on this hypothetical idea, the direct effect of hemin on the expression of genes encoding heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and brain-derived neurotrophic factor (BDNF) in glial cells was examined using rat C6 glioma cells as an in vitro model system. Hemin elevated both HO-1 and VEGF mRNA levels in the glioma cells at the concentration causing no critical damage to the cells, and the elevation of BDNF mRNA levels was also observed by exposing the cells to hemin under the same conditions. Furthermore, the elevation of VEGF and BDNF mRNA levels induced by hemin was blocked by pretreatment of the cells with the agents inhibiting not only HO-1 gene expression but also its enzymatic activity. These pharmacological studies indicate that hemin can induce the enhancement of VEGF and BDNF gene expression probably through the mechanism mediated by HO-1 activity in the glioma cells, proposing the possibility that glial cells are capable of contributing to the recovery of brain function from the damage caused by cerebral hemorrhage through the production of neurogenic and angiogenic factors.	[Morita, Kyoji] Shikoku Univ Sch Hlth Sci, Dept Nursing, Neuropharmacol Lab, Tokushima 7711192, Japan; [Lee, Mi-Sook; Her, Song] Korea Basic Sci Inst, Chuncheon Ctr, Div Bioimaging, Chunchon 200701, South Korea	Morita, K (corresponding author), Shikoku Univ Sch Hlth Sci, Dept Nursing, Neuropharmacol Lab, Tokushima 7711192, Japan.	kmorita@shikoku-u.ac.jp					Andoh Y, 2006, J BIOCHEM, V140, P483, DOI 10.1093/jb/mvj187; Anjos-Ramos L, 2006, VIRCHOWS ARCH, V448, P472, DOI 10.1007/s00428-005-0140-y; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; Bova R, 1998, MOL BRAIN RES, V57, P321, DOI 10.1016/S0169-328X(98)00092-8; Bussolati B, 2006, ANTIOXID REDOX SIGN, V8, P1153, DOI 10.1089/ars.2006.8.1153; Chen-Roetling J, 2006, BIOCHEM BIOPH RES CO, V350, P233, DOI 10.1016/j.bbrc.2006.09.036; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; CUEVAS P, 1994, NEUROL RES, V16, P181; Cuevas P, 1997, NEUROL RES, V19, P254, DOI 10.1080/01616412.1997.11758613; Dulak J, 2002, ANTIOXID REDOX SIGN, V4, P229, DOI 10.1089/152308602753666280; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; EyssenHernandez R, 1996, FEBS LETT, V382, P229, DOI 10.1016/0014-5793(96)00127-5; FAUTZ R, 1991, MUTAT RES, V253, P173, DOI 10.1016/0165-1161(91)90130-Z; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 2005, EXP SUPPL, V94, P209; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633; Gowing G, 2006, GLIA, V53, P331, DOI 10.1002/glia.20288; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Jazwa A, 2006, FREE RADICAL BIO MED, V40, P1250, DOI 10.1016/j.freeradbiomed.2005.11.016; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Kawai T, 2006, NEUROSCIENCE, V141, P1209, DOI 10.1016/j.neuroscience.2006.04.064; Ke ZJ, 2004, NEUROCHEM INT, V45, P361, DOI 10.1016/j.neuint.2003.09.008; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Levy YS, 2002, NEUROTOX RES, V4, DOI 10.1080/1029842021000045624; Loboda A, 2005, CELL MOL BIOL, V51, P347, DOI 10.1170/T637; Lok J, 2007, NEUROCHEM RES, V32, P2032, DOI 10.1007/s11064-007-9342-9; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Marton LS, 2000, AM J PHYSIOL-HEART C, V279, pH2405; Min KJ, 2006, J NEUROSCI, V26, P1880, DOI 10.1523/JNEUROSCI.3696-05.2006; Morita K, 1999, BRAIN RES, V830, P179, DOI 10.1016/S0006-8993(99)01292-5; Morita K, 1999, BRAIN RES, V816, P309, DOI 10.1016/S0006-8993(98)01093-2; Morita K, 2000, CELL BIOL INT, V24, P223, DOI 10.1006/cbir.1999.0494; Morita K, 2006, BRAIN RES, V1085, P49, DOI 10.1016/j.brainres.2006.02.033; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; Pae HO, 2005, ENDOCRINOLOGY, V146, P2229, DOI 10.1210/en.2004-1431; Parfenova H, 2005, AM J PHYSIOL-HEART C, V288, pH2843, DOI 10.1152/ajpheart.01274.2004; Schipper HM, 2006, NEUROBIOL AGING, V27, P252, DOI 10.1016/j.neurobiolaging.2005.01.016; Schipper HM, 2004, FREE RADICAL BIO MED, V37, P1995, DOI 10.1016/j.freeradbiomed.2004.09.015; Schipper HM, 2000, EXP GERONTOL, V35, P821, DOI 10.1016/S0531-5565(00)00148-0; Sehara Y, 2007, BRAIN RES, V1151, P142, DOI 10.1016/j.brainres.2007.01.149; Shrivastava K, 2008, NEUROCHEM INT, V52, P368, DOI 10.1016/j.neuint.2007.07.005; Simard AR, 2007, J COMP NEUROL, V504, P716, DOI 10.1002/cne.21469; Smith SL, 2001, BIOCHEM PHARMACOL, V61, P409, DOI 10.1016/S0006-2952(00)00556-6; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Suzuki H, 1999, J CLIN INVEST, V104, P59, DOI 10.1172/JCI5357; Suzuki M, 2003, BIOCHEM BIOPH RES CO, V302, P138, DOI 10.1016/S0006-291X(03)00114-1; Takahashi M, 2000, NEURON, V28, P461, DOI 10.1016/S0896-6273(00)00125-2; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; Valenzuela MJ, 2007, BRAIN RES REV, V56, P198, DOI 10.1016/j.brainresrev.2007.07.007; Van Bergen P, 1999, FREE RADICAL RES, V31, P631, DOI 10.1080/10715769900301201; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Warner-Schmidt JL, 2008, CURR OPIN PHARMACOL, V8, P14, DOI 10.1016/j.coph.2007.10.013; Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104	58	24	27	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	MAY	2009	38	1					31	40		10.1007/s12031-008-9156-5			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	434AL	WOS:000265247500005	18937073				2021-06-18	
J	Sargin, D; Hassouna, I; Sperling, S; Siren, AL; Ehrenreich, H				Sargin, Derya; Hassouna, Imam; Sperling, Swetlana; Siren, Anna-Leena; Ehrenreich, Hannelore			Uncoupling of Neurodegeneration and Gliosis in a Murine Model of Juvenile Cortical Lesion	GLIA			English	Article						neurotrauma; brain atrophy; erythropoietin; oligodendrocytes; microglia; schizophrenia	TRAUMATIC BRAIN-INJURY; UNBIASED STEREOLOGICAL ESTIMATION; RECOMBINANT-HUMAN-ERYTHROPOIETIN; GLUTAMIC-ACID DECARBOXYLASE; BIPOLAR DISORDER; PREFRONTAL CORTEX; HEAD-INJURY; OPTICAL FRACTIONATOR; ONSET SCHIZOPHRENIA; FUNCTIONAL RECOVERY	A small experimental cryolesion to the right parietal cortex of juvenile mice causes late-onset global brain atrophy with memory impairments, reminiscent of cognitive decline, and progressive brain matter loss in schizophrenia. However, the cellular events underlying this global neurodegeneration are not understood. Here we show, based on comprehensive stereological analysis, that early unilateral lesion causes immediate and lasting bilateral increase in the number of microglia in cingulate cortex and hippocampus, consistent with a chronic low-grade inflammatory process. Whereas the total number of neurons and astrocytes in these brain regions remain unaltered, pointing to a non-gliotic neurodegeneration (as seen in schizophrenia), the subgroup of parvalbumin-positive inhibitory GABAergic interneurons is increased bilaterally in the hippocampus, as is the expression of the GABA-synthesizing enzyme GAD67. Moreover, unilateral parietal lesion causes a decrease in the expression of synapsin1, suggesting impairment of presynaptic functions/neuroplasticity. Reduced expression of the myelin protein cyclic nucleotide phosphodiesterase, reflecting a reduction of oligodendrocytes, may further contribute to the observed brain atrophy. Remarkably, early intervention with recombinant human erythropoietin (EPO), a hematopoietic growth factor with multifaceted neuroprotective properties (intraperitoneal injection of 5000 IU/kg body weight every other day for 3 weeks), prevented all these neurodegenerative changes. To conclude, unilateral parietal lesion of juvenile mice induces a non-gliotic neurodegenerative process, susceptible to early EPO treatment. Although the detailed mechanisms remain to be defined, these profound EPO effects open new ways for prophylaxis and therapy of neuropsychiatric diseases, e.g. schizophrenia. (C) 2008 Wiley-Liss, Inc.	[Sargin, Derya; Hassouna, Imam; Sperling, Swetlana; Ehrenreich, Hannelore] Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Siren, Anna-Leena] Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany	Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Div Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Siren, Anna-Leena/AAE-1374-2019	Siren, Anna-Leena/0000-0002-2217-0081; Ehrenreich, Hannelore/0000-0001-8371-5711	Max-Planck-SocietyMax Planck Society; DFG Center for Molecular Physiology of the Brain (CMPB)German Research Foundation (DFG)	This study has been supported by the Max-Planck-Society as well as by the DFG Center for Molecular Physiology of the Brain (CMPB). DS has a Max-Planck fellowship.	AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; AKBARIAN S, 1995, ARCH GEN PSYCHIAT, V52, P258, DOI 10.1001/archpsyc.1995.03950160008002; Benes FM, 2001, NEUROPSYCHOPHARMACOL, V25, P1, DOI 10.1016/S0893-133X(01)00225-1; Bernstein HG, 2007, ANN NY ACAD SCI, V1096, P120, DOI 10.1196/annals.1397.077; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Blum BP, 2002, INT J NEUROPSYCHOPH, V5, P159, DOI 10.1017/S1461145702002894; Bogerts B, 1999, EUR ARCH PSY CLIN N, V249, P2; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Constantinidis C, 2002, NAT NEUROSCI, V5, P175, DOI 10.1038/nn799; Cullheim S, 2007, BRAIN RES REV, V55, P89, DOI 10.1016/j.brainresrev.2007.03.012; Czeh B, 2005, NEUROPSYCHOPHARMACOL, V30, P67, DOI 10.1038/sj.npp.1300581; Davis KL, 2003, LANCET, V362, P758, DOI 10.1016/S0140-6736(03)14297-3; Dracheva S, 2006, NEUROBIOL DIS, V21, P531, DOI 10.1016/j.nbd.2005.08.012; Ehrenreich H, 2007, MOL PSYCHIATR, V12, P206, DOI 10.1038/sj.mp.4001907; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Ho BC, 2003, ARCH GEN PSYCHIAT, V60, P585, DOI 10.1001/archpsyc.60.6.585; Ho L, 2001, NEUROSCI LETT, V298, P191, DOI 10.1016/S0304-3940(00)01753-5; Hof PR, 2003, BIOL PSYCHIAT, V53, P1075, DOI 10.1016/S0006-3223(03)00237-3; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Karoutzou G, 2008, MOL PSYCHIATR, V13, P245, DOI 10.1038/sj.mp.4002096; Keuker JIH, 2001, BRAIN RES PROTOC, V7, P211, DOI 10.1016/S1385-299X(01)00064-2; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Li WP, 2004, ANN NEUROL, V56, P767, DOI 10.1002/ana.20274; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; McAllister TW, 1998, SEMIN CLIN NEUROPSYC, V3, P211; Miller KR, 2007, NEURON GLIA BIOL, V3, P245, DOI 10.1017/S1740925X08000136; Nagasaka T, 2007, BRAIN TUMOR PATHOL, V24, P1, DOI 10.1007/s10014-006-0209-6; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Pol HEH, 2008, SCHIZOPHRENIA BULL, V34, P354, DOI 10.1093/schbul/sbm168; Rao SG, 2000, J NEUROSCI, V20, P485, DOI 10.1523/JNEUROSCI.20-01-00485.2000; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sugawa M, 2002, NEUROSCI RES, V44, P391, DOI 10.1016/S0168-0102(02)00161-X; Sun Y, 2005, STROKE, V36, P1672, DOI 10.1161/01.STR.0000173406.04891.8c; Suzuki M, 2002, SCHIZOPHR RES, V55, P41, DOI 10.1016/S0920-9964(01)00224-9; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; van Berckel BN, 2008, BIOL PSYCHIAT, V64, P820, DOI 10.1016/j.biopsych.2008.04.025; Vawter MP, 2002, MOL PSYCHIATR, V7, P571, DOI 10.1038/sj.mp.4001158; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Volk DW, 2000, ARCH GEN PSYCHIAT, V57, P237, DOI 10.1001/archpsyc.57.3.237; Wang X, 2002, J NEUROSCI, V22, P9185; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilke M, 2001, NEUROIMAGE, V13, P814, DOI 10.1006/nimg.2001.0751; Xue YQ, 2007, NEUROSCIENCE, V146, P1245, DOI 10.1016/j.neuroscience.2007.02.004; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	61	24	24	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAY	2009	57	7					693	702		10.1002/glia.20797			10	Neurosciences	Neurosciences & Neurology	435VV	WOS:000265372300001	18985736				2021-06-18	
J	Keller, E; Mudra, R; Gugl, C; Seule, M; Mink, S; Frohlich, J				Keller, Emanuela; Mudra, Regina; Gugl, Christoph; Seule, Martin; Mink, Susanne; Frohlich, Juerg			Theoretical evaluations of therapeutic systemic and local cerebral hypothermia	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Hypothermia; Cerebral temperature; Modelling; Simulation	PROMISING TREATMENT MODALITY; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; SUBARACHNOID HEMORRHAGE; MILD HYPOTHERMIA; BLOOD-FLOW; CARDIAC-ARREST; TEMPERATURE; ISCHEMIA; FEVER	Purpose: To simulate cerebral temperature behaviour with hypothermia treatment applying different cooling devices and to find the optimal brain temperature monitoring. Methods: Models based on hourly temperature values recorded in patients with severe aneurysmal subarachnoid hemorrhage, taking MRI data, thermal conductive properties, metabolism and blood flow into account were applied to different scenarios of hypothermia. Results: Systemic hypothermia by endovascular cooling leads to an uniform temperature decrease within the brain tissue. Cooling with head caps lead to 33 degrees C only in the superficial brain while the deep brain remains higher than 36 degrees C. Cooling with neckbands lead to 35.8 degrees C for dry and 32.8 degrees C for wet skin in the deep brain. Conclusions: With head caps temperatures below 36 degrees C cannot be reached in the deep brain tissue, whereas neckbands, covering the carotid triangles, may lead to hypothermic temperatures in the deep brain tissue. Temperature sensors have to be applied at least 2 cm below the cortical surface to give values representative for deep brain tissue. (C) 2009 Elsevier B.V. All rights reserved.	[Keller, Emanuela; Seule, Martin; Mink, Susanne] Univ Zurich Hosp, Dept Neurosurg, Neurointens Care Unit, CH-8091 Zurich, Switzerland; [Mudra, Regina] Swiss Fed Inst Technol, Inst Biomed Engn, CH-8092 Zurich, Switzerland; [Gugl, Christoph; Frohlich, Juerg] Swiss Fed Inst Technol, Lab Electromagnet Fields & Microwave Elect, CH-8092 Zurich, Switzerland	Keller, E (corresponding author), Univ Zurich Hosp, Dept Neurosurg, Neurointens Care Unit, Frauenklin Str 10, CH-8091 Zurich, Switzerland.	Emanuela.keller@usz.ch	Keller, Emanuela/G-4040-2013; Keller, Emanuela/M-2917-2015	Keller, Emanuela/0000-0001-7892-8261; Frohlich, Jurg/0000-0002-5923-3410; Keller, Emanuela, Elisabeth, Sophia/0000-0002-7560-7574			AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BAKER MA, 1982, ANNU REV PHYSIOL, V44, P85, DOI 10.1146/annurev.ph.44.030182.000505; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BIGELOW WG, 1950, AM J PHYSIOL, V160, P125, DOI 10.1152/ajplegacy.1949.160.1.125; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; deDear RJ, 1997, INT J BIOMETEOROL, V40, P141, DOI 10.1007/s004840050035; DEXTER F, 1994, ANN THORAC SURG, V57, P1171, DOI 10.1016/0003-4975(94)91350-1; Diao CG, 2003, ANN BIOMED ENG, V31, P346, DOI 10.1114/1.1554924; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Gasser S, 2003, J NEUROSURG ANESTH, V15, P240, DOI 10.1097/00008506-200307000-00012; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Hegner T, 2001, ACT NEUR S, V77, P131; Karam AM, 2006, ARCH FACIAL PLAST S, V8, P105, DOI 10.1001/archfaci.8.2.105; Keller E, 2000, CRIT CARE MED, V28, P511, DOI 10.1097/00003246-200002000-00037; Konstas AA, 2007, J APPL PHYSIOL, V102, P1329, DOI 10.1152/japplphysiol.00805.2006; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; Mariak Z, 2002, J THERM BIOL, V27, P219, DOI 10.1016/S0306-4565(01)00087-0; MELLERGARD P, 1990, British Journal of Neurosurgery, V4, P31, DOI 10.3109/02688699009000679; Nelson DA, 1998, EUR J APPL PHYSIOL O, V78, P353, DOI 10.1007/s004210050431; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; OLSEN RW, 1985, J BIOMECH ENG-T ASME, V107, P354, DOI 10.1115/1.3138569; PENNES HH, 1948, J APPL PHYSIOL, V1, P93; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; SAFAR P, 1997, TXB NEUROANESTHESIA, P557; Safar PJ, 2002, NEW ENGL J MED, V346, P612, DOI 10.1056/NEJM200202213460811; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Sukstanskii AL, 2007, EUR J APPL PHYSIOL, V101, P41, DOI 10.1007/s00421-007-0452-5; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Wang H, 2006, ACTA NEUROCHIR, V148, P681, DOI 10.1007/s00701-006-0748-y; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Xu XJ, 1999, J APPL PHYSIOL, V86, P265; Zhu L, 2001, MED BIOL ENG COMPUT, V39, P681, DOI 10.1007/BF02345442; Zhu MM, 2006, J APPL PHYSIOL, V101, P1481, DOI 10.1152/japplphysiol.00319.2006	36	24	27	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	APR 15	2009	178	2					345	349		10.1016/j.jneumeth.2008.12.030			5	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	425BG	WOS:000264611400015	19167429				2021-06-18	
J	Maruichi, K; Kuroda, S; Chiba, Y; Hokari, M; Shichinohe, H; Hida, K; Iwasaki, Y				Maruichi, Katsuhiko; Kuroda, Satoshi; Chiba, Yasuhiro; Hokari, Masaaki; Shichinohe, Hideo; Hida, Kazutoshi; Iwasaki, Yoshinobu			Graded model of diffuse axonal injury for studying head injury-induced cognitive dysfunction in rats	NEUROPATHOLOGY			English	Article						animal model; cognitive dysfunction; diffuse axonal injury	TRAUMATIC BRAIN-INJURY; PATHOPHYSIOLOGY; PATHOBIOLOGY	Diffuse axonal injury (DAI) plays a major role in the development of cognitive dysfunction, emotional difficulties and behavioral disturbances in patients following closed head injury, even when they have no definite abnormalities on conventional MRI. This study aimed to develop a highly controlled and reproducible model for DAI that simulates post-traumatic cognitive dysfunction in humans. Sprague-Dawley (SD) rats were subjected to impact acceleration head injury, using a pneumatic impact targeted to a steel disc centered onto their skull. The severity of injury was graded as three levels by adjusting the driving pressure at 60, 70 or 80 pounds per square inch. In vivo MRI was obtained 2 days post-injury. Cognitive function was evaluated using the Morris water maze at 1 and 2 weeks post-injury. HE staining and immunohistochemistry were performed to assess neuronal and axonal damages after 2 weeks. MRI demonstrated that this model induced no gross structural modification in the brain. The degree and duration of cognitive dysfunction were dependent on the force of impact. Histological analysis revealed the force-dependent damage of the neurons and microtubule-associated protein 2-positive axons in the neocortex. Hippocampal damage was much less pronounced and was not linked to cognitive dysfunction. This is the first report that precisely evaluates the threshold of impact energy to lead to neocortical damage and cognitive dysfunction in rodents. This model would be suitable for clarifying the complex mechanisms of post-traumatic brain damage and testing novel therapeutic approaches against post-traumatic cognitive dysfunction due to diffuse axonal damage.	[Kuroda, Satoshi] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Kuroda, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Kita Ku, North 15 West 7, Sapporo, Hokkaido 0608638, Japan.	skuroda@med.hokudai.ac.jp	Shichinohe, Hideo/G-5367-2012; Hokari, Masaaki/G-5395-2012		Ministry of Education, Science and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17390389, 18390387, 19390371]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18390387] Funding Source: KAKEN	This study was supported by Grant-in-aid from the Ministry of Education, Science and Culture of Japan (No. 17390389, No. 18390387 and No. 19390371). The authors deeply thank Yumiko Shinohe for her technical assistance and Miki Shinada for her secretarial work.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2006, ACTA NEUROCHIR WIEN, V148, P93; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; Ellingson Benjamin M., 2005, V41, P86; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Pineda JA, 2001, J NEUROTRAUM, V18, P625, DOI 10.1089/089771501750291864; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Seki T, 2002, NEUROSURGERY, V50, P1075, DOI 10.1097/00006123-200205000-00024; Yano S, 2005, J NEUROTRAUM, V22, P907, DOI 10.1089/neu.2005.22.907; Yano S, 2006, J NEUROTRAUM, V23, P1682, DOI 10.1089/neu.2006.23.1682; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	24	24	24	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-6544	1440-1789		NEUROPATHOLOGY	Neuropathology	APR	2009	29	2					132	139		10.1111/j.1440-1789.2008.00956.x			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	420SU	WOS:000264310300004	18702633				2021-06-18	
J	Frederick, RI; Bowden, SC				Frederick, Richard I.; Bowden, Stephen C.			Evaluating Constructs Represented by Symptom Validity Tests in Forensic Neuropsychological Assessment of Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						forensic neuropsychology; feigned cognitive impairment; malingering assessment; test validation	MIXED GROUP VALIDATION; TOMM; EXAGGERATION	This study uses a new method to summarize diagnostic validity information to explore which constructs are captured by malingering tests. ne Test Validation Summary applies mixed-groups validation to investigate the meaning of test constructs and to estimate test classification characteristics when test validation groups are not "pure" criterion groups (ie, "compliant" vs "malingering"), but members have variable probability of malingering. The method permits the use of tests with relatively low validity to validate tests of greater validity. In our initial analysis, we argue that the Rey 15-Item Memory Test is best construed as an "intention test" (capturing the intention of test takers when taking a test) as opposed to an "effort test." Using the Test Validation Summary and mixed-groups validation, we demonstrate that as an indicator of "intention to feign cognitive impairment," the Rey 15-Item Memory Test has estimated false-positive rate (FPR) = 0.02 and true-positive rate (TPR) = 0.57. We then explore the meaning of failure on the Word Memory Test (WMT), which uses a dichotomous classification of performance as valid or invalid. Although the WMT is commonly referred to as an "effort test," we argue that it likely captures both "intention" and "effort" but collapses this information into a single dichotomous classification of symptom validity. We demonstrate that, as a result of this dichotomous classification process, the WMT likely has a problematic FPR. In our analysis of previously published WMT data, the WMT FPR is estimated at 0.12 when there is no predisposition to perform poorly but rises dramatically and unrealistically as the predisposition to perform poorly increases. We compare these findings to those of the Validity Indicator Profile (VIP), which captures both intent and effort to classify 4 different sorts of response styles in cognitive testing. In our analyses, the VIP demonstrates that FPR = 0 and TPR = 0.86 when the construct being measured is "intent to perform poorly," and reveals that FPR = 0.06 and TPR = 0.63 when the construct being measured is "inconsistent responding" or "poor effort." We were able to demonstrate for the VIP the same "oversensitivity" shown by the WMT when the VIP was interpreted only as a dichotomous classification test. These results indicate that researchers who attempt to generate classification characteristics for malingering tests must carefully consider what constructs are being captured by the test.	[Frederick, Richard I.] US Med Ctr Fed Prisoners, Dept Psychol, Springfield, MO 65807 USA; [Bowden, Stephen C.] Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia	Frederick, RI (corresponding author), US Med Ctr Fed Prisoners, Dept Psychol, 1900 W Sunshine St, Springfield, MO 65807 USA.	rickfrederick@gmail.com	Bowden, Stephen C/C-3726-2012				Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher JN, 1989, MANUAL ADM SCORING M; Cochrane RE, 2001, BEHAV SCI LAW, V19, P565, DOI 10.1002/bsl.454.abs; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; DAWES RM, 1966, PSYCHOL BULL, V66, P63, DOI 10.1037/h0023584; FAUST D, 2003, MALINGERING ILLNESS, P107; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick R. I., 2003, VALIDITY INDICATOR P; Frederick R.I., 1997, VALIDITY INDICATOR P; Frederick R.I., 2003, J FORENSIC NEUROPSYC, V2, P1, DOI [DOI 10.1300/J151v02n03_01, 10.1300/J151v02n03_01, DOI 10.1300/J151V02N03_01]; Frederick R. I, 2002, J FORENSIC NEUROPSYC, V2, P125; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Frederick RI, 2001, NEUROREHABILITATION, V16, P309; Frederick RI, 2000, LAW HUMAN BEHAV, V24, P59, DOI 10.1023/A:1005426803586; Frederick RI, 2000, ARCH CLIN NEUROPSYCH, V15, P281, DOI 10.1016/S0887-6177(99)00002-5; Frederick RI, 2000, BEHAV SCI LAW, V18, P693, DOI 10.1002/bsl.432; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Frederick RI, 2009, ASSESSMENT, V16, P215, DOI 10.1177/1073191108325005; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Graham J. R., 2006, MMPI 2 ASSESSING PER; Green P, 2001, NEUROREHABILITATION, V16, P231; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2003, GREENS WORD MEMORY T; GREEN P, 2000, J FORENSIC NEUROPSYC, V2, P97; Green P., 1996, WORD MEMORY TEST USE; GREEN P, 2007, DETECTION NONCREDIBL; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; O'Bryant SE, 2006, CLIN NEUROPSYCHOL, V20, P533, DOI 10.1080/13854040590967568; Rey A., 1958, LEXAMEN CLINIQUE PSY; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Straus SE., 2005, EVIDENCE BASED MED P, V3rd; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594	39	24	24	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2009	24	2					105	122		10.1097/HTR.0b013e31819b1210			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	427WF	WOS:000264809100005	19333066				2021-06-18	
J	Goverover, Y; Chiaravalloti, N; Gaudino-Goering, E; Moore, N; DeLuca, J				Goverover, Yael; Chiaravalloti, Nancy; Gaudino-Goering, Elizabeth; Moore, Nancy; DeLuca, John			The Relationship Among Performance of Instrumental Activities of Daily Living, Self-Report of Quality of Life, and Self-Awareness of Functional Status in Individuals With Multiple Sclerosis	REHABILITATION PSYCHOLOGY			English	Article						self-awareness; cognitive rehabilitation; multiple sclerosis; outcome measures	TRAUMATIC BRAIN-INJURY; NEUROBEHAVIORAL SYMPTOMS; COGNITIVE DYSFUNCTION; SENILE DEMENTIA; ALZHEIMER-TYPE; DEFICITS; DISABILITY; ASSOCIATION; PERCEPTIONS; METAMEMORY	Objective: To investigate the relationship between self-awareness of functional status and performance of Instrumental Activities of Daily Living (IADL), and self-reports of quality of life (QOL) in persons with multiple sclerosis (MS). Design: A between-groups design, using a correlational approach to examine the relationship between self-awareness of functional status, IADL and QOL. Participants: We studied 47 individuals with clinically definite MS and 26 healthy controls (HCs). Measures: The Functional Behavior Profile was completed by both participants and their informants. Participants' scores were subtracted from those of their informants', and the absolute value was used as the self-awareness/concordance score. The Executive Function Performance Test measured IADL performance; QOL was measured with the Functional Assessment of Multiple Sclerosis. Results: MS participants showed lower levels of self-awareness relative to HCs. Significant correlations were observed between performance of IADL, reports of QOL and self-awareness levels of functional status. However, reports of QOL were not significantly correlated with performance of IADL. Conclusions: The positive association between self-awareness of functional status with IADL performance and QOL reports provides support for the role of awareness in rehabilitation.	[Goverover, Yael] NYU, Steinhardt Sch Culture Educ & Human Dev, Dept Occupat Therapy, New York, NY 10012 USA; [Goverover, Yael; Chiaravalloti, Nancy; Gaudino-Goering, Elizabeth; Moore, Nancy; DeLuca, John] Kessler Med Rehabil Res & Educ Ctr, Keesler AFB, MS USA; [Chiaravalloti, Nancy; DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Dept Neurol & Neurosci, Newark, NJ 07103 USA	Goverover, Y (corresponding author), NYU, Steinhardt Sch Culture Educ & Human Dev, Dept Occupat Therapy, 35 W 4th St,11th Floor, New York, NY 10012 USA.	yg243@nyu.edu					Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Amato MP, 2001, ARCH NEUROL-CHICAGO, V58, P1602, DOI 10.1001/archneur.58.10.1602; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Barker-Collo SL, 2006, ARCH CLIN NEUROPSYCH, V21, P167, DOI 10.1016/j.acn.2005.08.008; BAUM C, 1993, AM J OCCUP THER, V47, P431, DOI 10.5014/ajot.47.5.431; BAUM C, 1993, GERONTOLOGIST, V33, P403, DOI 10.1093/geront/33.3.403; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Baum CM., 2003, TEST MANUAL EXECUTIV; BEATTY WW, 1995, J NEUROLOGIC REHABIL, V9, P67; Beck A.T., 1987, BECK DEPRESSION INVE; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Cella DF, 1996, NEUROLOGY, V47, P129, DOI 10.1212/WNL.47.1.129; Chiaravalloti ND, 2002, ARCH PHYS MED REHAB, V83, P1070, DOI 10.1053/apmr.2002.33729; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DOBLE SE, 1994, ARCH PHYS MED REHAB, V75, P843, DOI 10.1016/0003-9993(94)90107-4; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Finlayson M, 1998, CANADIAN J OCCUPATIO, V65, P299, DOI DOI 10.1177/000841749806500508; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; FITZGERALD JF, 1993, J GERONTOLOGY SOCIAL, V48, P28; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Goverover Y, 2005, ARCH PHYS MED REHAB, V86, P2303, DOI 10.1016/j.apmr.2005.05.016; Goverover Y, 2005, MULT SCLER J, V11, P203, DOI 10.1191/1352458505ms1153oa; Goverover Y, 2004, J CLIN EXP NEUROPSYC, V26, P737, DOI 10.1080/13803390490509321; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Halper June, 2003, J Neurosci Nurs, V35, P70; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; JACOBS JW, 1984, SOURCE BOOK GERIATRI, V2, P50; JACOBS JW, 1984, SOURCE BOOK GERIATRI, V1, P121; Kanner AM, 2005, EPILEPSY BEHAV, V6, P303, DOI 10.1016/j.yebeh.2005.02.008; Katz N., 2007, OCCUPATIONAL THERAPY, V27, P1; KESSLER HR, 1992, INT J NEUROSCI, V62, P17, DOI 10.3109/00207459108999754; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Mansson E, 2004, DISABIL REHABIL, V26, P576, DOI 10.1080/09638280410001684587; Maor Y, 2001, MULT SCLER, V7, P131, DOI 10.1177/135245850100700209; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Middleton LS, 2006, ARCH CLIN NEUROPSYCH, V21, P487, DOI 10.1016/j.acn.2006.06.008; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; PEYSER JM, 1990, ARCH NEUROL-CHICAGO, V47, P94, DOI 10.1001/archneur.1990.00530010120030; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Provinciali L, 1999, ACTA NEUROL SCAND, V100, P156; Randolph JJ, 2004, ARCH CLIN NEUROPSYCH, V19, P259, DOI 10.1016/S0887-6177(03)00026-X; Randolph JJ, 2001, CLIN NEUROPSYCHOL, V15, P357, DOI 10.1076/clin.15.3.357.10278; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Schwartz CE, 1999, SOC SCI MED, V48, P1563, DOI 10.1016/S0277-9536(99)00049-0; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherman TE, 2008, J CLIN EXP NEUROPSYC, V30, P301, DOI 10.1080/13803390701380617; Shevil E, 2006, DISABIL REHABIL, V28, P779, DOI 10.1080/09638280500387013; Tham K, 2001, AM J OCCUP THER, V55, P46, DOI 10.5014/ajot.55.1.46; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Toglia J. P., 2005, COGNITION OCCUPATION, P29	52	24	24	0	8	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2009	54	1					60	68		10.1037/a0014556			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	410WJ	WOS:000263608700007	19618704				2021-06-18	
J	Zhang, Z; Majava, V; Greffier, A; Hayes, RL; Kursula, P; Wang, KKW				Zhang, Z.; Majava, V.; Greffier, A.; Hayes, R. L.; Kursula, P.; Wang, K. K. W.			Collapsin response mediator protein-2 is a calmodulin-binding protein	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Article						CRMP-2; proteolysis; calmodulin; calmodulin-binding protein; oligomerization	TRAUMATIC BRAIN-INJURY; MYELIN BASIC-PROTEIN; MOUSE-BRAIN; NEURONAL POLARITY; CALPAIN; CLEAVAGE; CRMP-2; PROTEOLYSIS; DYNAMICS; GROWTH	Collapsin response mediator protein-2 (CRMP-2) plays a crucial role in axonal guidance and neurite outgrowth during neural development and regeneration. We have studied the interaction between calmodulin (CaM) and CRMP-2 and how Ca(2+)/CaM binding modulates the biological functions of CRMP-2. We have shown that CRMP-2 binds to CaM directly in a Ca(2+)-dependent manner. The CaM binding site of CRMP-2 is proposed to reside in the last helix of the folded domain, and in line with this, a synthesized peptide representing this helix bound to CaM. In addition, CaM binding inhibits a homotetrameric assembly of CRMP-2 and attenuates calpainmediated CRMP-2 proteolysis. Furthermore, a CaM antagonist reduces the number and length of process induced by CRMP-2 overexpression in HEK293 cells. Take together, our data suggest that CRMP-2 is a novel CaM-binding protein and that CaM binding may play an important role in regulating CRMP-2 functions.	[Zhang, Z.; Hayes, R. L.; Wang, K. K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Majava, V.; Greffier, A.; Kursula, P.] Univ Oulu, Dept Biochem, Oulu, Finland; [Hayes, R. L.] Univ Florida, McKnight Brain Inst, Dept Anesthesiol, Gainesville, FL USA; [Wang, K. K. W.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Gainesville, FL USA	Zhang, Z (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12805 Res Dr, Alachua, FL 32615 USA.	zqzhang@banyanbio.com; petri.kursula@oulu.fi; kwang@banyanbio.com	Kursula, Petri/AAF-4563-2020; Kursula, Petri/K-1058-2012	Kursula, Petri/0000-0001-8529-3751; Kursula, Petri/0000-0001-8529-3751; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMD-03-1-0066]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175- 01-A1, R01 NS051431]; Academy of FinlandAcademy of FinlandEuropean Commission; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER	The authors thank Jingxiang Mo for the CRMP- 2 construct and Dr. Nobuhiro Hayashi for the pETCM vector. We wish to thank Drs Andrew K. Ottens, Michael Bubb, Juan A. Martinez and Stephen F. Larner for insightful discussions and editorial assistance. This work was supported by the Department of Defense grant DAMD-03-1-0066, NIH grants R01 NS049175- 01-A1 and R01 NS051431, and by the Academy of Finland. K. K. W. Wang and R. L. Hayes own stock of Banyan Biomarkers Inc., and may benefit financially as a result of the outcome of this research or the work reported in this publication.	Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Berggard T, 2006, J PROTEOME RES, V5, P669, DOI 10.1021/pr050421l; Bretin S, 2005, J COMP NEUROL, V486, P1, DOI 10.1002/cne.20465; Chung MA, 2005, NEUROREPORT, V16, P1647, DOI 10.1097/01.wnr.0000176520.49841.e6; Croall DE, 1996, BBA-PROTEIN STRUCT M, V1298, P276, DOI 10.1016/S0167-4838(96)00138-0; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Fukata Y, 2002, NEUROSCI RES, V43, P305, DOI 10.1016/S0168-0102(02)00062-7; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Gerendasy D, 1999, J NEUROSCI RES, V58, P107, DOI 10.1002/(SICI)1097-4547(19991001)58:1<107::AID-JNR11>3.3.CO;2-7; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Gungabissoon RA, 2003, J HISTOCHEM CYTOCHEM, V51, P411, DOI 10.1177/002215540305100402; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; Ikura M, 2006, P NATL ACAD SCI USA, V103, P1159, DOI 10.1073/pnas.0508640103; Jiang SX, 2007, EUR J NEUROSCI, V26, P801, DOI 10.1111/j.1460-9568.2007.05715.x; JOHNSON GVW, 1991, NEUROCHEM RES, V16, P869, DOI 10.1007/BF00965535; Kawano Y, 2005, MOL CELL BIOL, V25, P9920, DOI 10.1128/MCB.25.22.9920-9935.2005; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; KOSAKI G, 1983, BIOCHEM INT, V6, P767; Krucker T, 2002, J NEUROSCI, V22, P5525; Libich DS, 2003, BIOCHEM BIOPH RES CO, V308, P313, DOI 10.1016/S0006-291X(03)01380-9; Majava V, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-10; Majava V, 2008, FEBS J, V275, P4583, DOI 10.1111/j.1742-4658.2008.06601.x; O'Day DH, 2004, BIOCHEM BIOPH RES CO, V320, P1051, DOI 10.1016/j.bbrc.2004.06.070; Radivojac P, 2006, PROTEINS, V63, P398, DOI 10.1002/prot.20873; Rogemond V, 2008, J BIOL CHEM, V283, P14751, DOI 10.1074/jbc.M708480200; Rosslenbroich V, 2005, EXP CELL RES, V310, P434, DOI 10.1016/j.yexcr.2005.08.005; Sola C, 1999, PROG NEUROBIOL, V58, P207, DOI 10.1016/S0301-0082(98)00082-3; Stenmark P, 2007, J NEUROCHEM, V101, P906, DOI 10.1111/j.1471-4159.2006.04401.x; Tahimic CGT, 2006, BIOCHEM BIOPH RES CO, V340, P1244, DOI 10.1016/j.bbrc.2005.12.132; Touma E, 2007, EUR J NEUROSCI, V26, P3368, DOI 10.1111/j.1460-9568.2007.05943.x; TSUNEKAWA S, 1989, FEBS LETT, V250, P493, DOI 10.1016/0014-5793(89)80783-5; van Dalen JJW, 2003, EUR J NEUROSCI, V18, P13, DOI 10.1046/j.1460-9568.2003.02720.x; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Xia ZG, 2005, NAT REV NEUROSCI, V6, P267, DOI 10.1038/nrn1647; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; ZHANG Z, 2006, CALCIUM BINDING PROT, V1, P125; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078	43	24	24	0	3	BIRKHAUSER VERLAG AG	BASEL	VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND	1420-682X			CELL MOL LIFE SCI	Cell. Mol. Life Sci.	FEB	2009	66	3					526	536		10.1007/s00018-008-8362-1			11	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	402GT	WOS:000263002900014	19151921	Green Accepted			2021-06-18	
J	Alexandersen, A; Dalen, K; Bronnick, K				Alexandersen, Alice; Dalen, Knut; Bronnick, Kolbojrn			Prediction of driving ability after inconclusive neuropsychological investigation	BRAIN INJURY			English	Article						Central nervous system diseases; neuropsychological tests; executive functions; on-road evaluation; automobile driving	TRAUMATIC BRAIN-INJURY; ALZHEIMER-TYPE; DEMENTIA; PERFORMANCE; ATTENTION; COMPETENCE; DRIVERS; FITNESS; RETURN	Objective: The aim of the present study was to investigate the predictive value of neuropsychological tests for on-road evaluation outcome after inconclusive assessment. Methods and procedures: Thirty-five patients were assessed neurologically, neuropsychologically by traditional clinical tests and by on-road evaluation. Simple univariate tests, logistic regression and ROC-curve analysis were used to investigate the predictive power of different neuropsychological tests. Main outcomes and results: Six measures from the California Computerized Assessment Package (CalCAP) and the Digit-Symbol test from Wechsler Adult Intelligence Scale predicted the outcome of the on-road evaluation. A logistic regression analysis showed that a model with two variables from CalCAP and the Digit Symbol test predicted the results of the on-road driving evaluation with an overall accuracy of 84.8%. Conclusions: The findings indicate that the outcome of on-road assessment is most related to cognitive skills such as attention and processing speed in combination with cognitive flexibility.	[Alexandersen, Alice] Stavanger Univ Hosp, Div Med, Dept Phys Med & Rehabil, N-4022 Stavanger, Norway; [Dalen, Knut] Univ Bergen, Dept Biol & Med Psychol, N-5020 Bergen, Norway; [Bronnick, Kolbojrn] Stavanger Univ Hosp, Norwegian Ctr Movement Disorders, N-4022 Stavanger, Norway	Alexandersen, A (corresponding author), Stavanger Univ Hosp, Div Med, Dept Phys Med & Rehabil, Rektor Berntsensgt 12, N-4022 Stavanger, Norway.	alice.alexandersen@sus.no		Bronnick, Kolbjorn/0000-0002-9156-1633			Adler G, 2005, J SAFETY RES, V36, P399, DOI 10.1016/j.jsr.2005.07.005; Barkley RA, 2002, J INT NEUROPSYCH SOC, V8, P655, DOI 10.1017/S1355617702801345; Bieliauskas LA, 2005, BRAIN INJURY, V19, P221, DOI 10.1080/02699050400017213; Brooks DJ, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n04_02; Brooks N, 2005, BRAIN INJURY, V19, P165, DOI 10.1080/02699050410001720004; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Chang L, 2003, ANTIVIR THER, V8, P17; Daigneault G, 2002, J CLIN EXP NEUROPSYC, V24, P221, DOI 10.1076/jcen.24.2.221.993; Duchek JM, 1997, ALZ DIS ASSOC DIS, V11, P48, DOI 10.1097/00002093-199706001-00011; Field A., 2006, DISCOVERING STAT USI; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; HEATON R, 1990, PAR STAFF WCST CV4 W; Hunt LA, 1997, ALZ DIS ASSOC DIS, V11, P13, DOI 10.1097/00002093-199706001-00004; Kakaiya R, 2000, POSTGRAD MED, V107, P229, DOI 10.3810/pgm.2000.03.953; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Lundqvist A, 2008, BRAIN INJURY, V22, P295, DOI 10.1080/02699050801966133; Lundqvist A, 2007, BRAIN INJURY, V21, P1109, DOI 10.1080/02699050701651660; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; *MARK DEP SPSS INC, 1999, SPSS STAT PACK SOC S; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; MCCORMACK PD, 1964, CAN J PSYCHOLOGY, V18, P43, DOI 10.1037/h0083285; Miller E. N., 1990, CALIFORNIA COMPUTERI; *NAT HLTH SERV O N, 1997, GUID US HLTH CERT DR; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Reger MA, 2004, NEUROPSYCHOLOGY, V18, P85, DOI 10.1037/0894-4105.18.1.85; Reitan R.M., 1993, HALSTEADREITAN NEURO; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schanke Anne-Kristine, 1995, Tidsskrift for den Norske Laegeforening, V115, P1349; Schanke Anne-Kristine, 1999, Tidsskrift for den Norske Laegeforening, V119, P954; Schmidt I W, 1996, Appl Neuropsychol, V3, P155, DOI 10.1207/s15324826an0303&4_8; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; Whelihan WM, 2005, ARCH CLIN NEUROPSYCH, V20, P217, DOI 10.1016/j.acn.2004.07.002	41	24	24	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	4					313	321	PII 909310802	10.1080/02699050902788428			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000006	19274519				2021-06-18	
J	Barker-Collo, SL; Wilde, NJ; Feigin, VL				Barker-Collo, Suzanne L.; Wilde, Nancy J.; Feigin, Valery L.			Trends in Head Injury Incidence in New Zealand: A Hospital-Based Study from 1997/1998 to 2003/2004	NEUROEPIDEMIOLOGY			English	Article						Head injury incidence, New Zealand; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; SOCIOECONOMIC-STATUS; ASSOCIATION; CAREGIVERS; SYMPTOMS; DISTRESS; MOTHERS; MAORI; CARE	Traumatic brain injury (TBI) is a leading cause of disability and death in young adults. Globally, the incidence of TBI hospitalizations is estimated at 200-300 people per 100,000 annually. Using a national health database, we examined the incidence of TBI-related hospital discharges ( including 1-day stays) to New Zealand Hospitals from 1997/1998 to 2003/2004. Crude annual hospital-based incidence rates for the total population ranged from 226.9 per 100,000 in 1998/1999 to a high rate of 349.2 in 2002/2003. There was a noticeable increase in rates with the change from ICD-9 to ICD-10 diagnostic codes and there was also disparity in incidence rates according to ethnicity, age and gender. Crude annual hospital-based incidence rates for males and females in Maori (689/100,000 and 302.8/100,000 person-years) and Pacific Island populations (582.6/100,000 and 217.6/100,000 person-years) were much higher than those for the remaining population (435.4/100,000 and 200.9/100,000 person-years), particularly for males. The overall age-standardized hospitalbased incidence rate for 2003/2004 was 342 per 100,000 per year (95% CI = 337-349/100,000), and 458 per 100,000 per year for Maori (95% CI = 438-479/100,000) with Maori males experiencing a peak in incidence between 30 and 34 years of age that was not evidenced for the wider population. Standardized hospital-based incidence rates for the total population and for Maori by age, gender and ICD-10 diagnostic codes are also examined. Copyright (C) 2008 S. Karger AG, Basel	[Barker-Collo, Suzanne L.; Wilde, Nancy J.] Univ Auckland, Dept Psychol, Clin Training Programme, Auckland 1142, New Zealand; [Feigin, Valery L.] Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Rehabil & Occupat Studies, Sch Publ Hlth & Psychol,Natl Res Ctr Stroke Appl, Auckland, New Zealand	Barker-Collo, SL (corresponding author), Univ Auckland, Dept Psychol, Clin Training Programme, Tamaki Campus,Private Bag 92019, Auckland 1142, New Zealand.	s.barker-collo@auckland.ac.nz	Feigin, Valery/AAF-2313-2019	Feigin, Valery L./0000-0002-6372-1740			ALBEDA R, HARMS WAY DOMESTIC V; Bassuk EL, 1996, JAMA-J AM MED ASSOC, V276, P640; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Braver ER, 2003, ACCIDENT ANAL PREV, V35, P295, DOI 10.1016/S0001-4575(01)00106-3; Breslow NE, 1987, DESIGN ANAL COHORT S, V2; Brooks MG, 1996, AM J ORTHOPSYCHIAT, V66, P526, DOI 10.1037/h0080202; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CARADOCDAVIES TH, 1995, NEUROEPIDEMIOLOGY, V14, P199, DOI 10.1159/000109797; CHIU W, 1997, CLIN NEUROL NEUROSUR, V99, P78; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; Malcolm L, 1996, NEW ZEAL MED J, V109, P356; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; *NZ GUID GROUP, 2005, DIAGN AC MAN REH PEO; Ogden JA, 1997, NEW ZEAL J PSYCHOL, V26, P2; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIZZO M, 1996, HEAD INJURY POSTCONC; ROPER P, 1993, HALF WOMEN PUBLIC AS; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Roth J. A., 1993, UNDERSTANDING PREVEN; Shin S, 2007, ANN EMERG MED, V50, pS100, DOI 10.1016/j.annemergmed.2007.06.381; SUTHERLAND HJ, 2002, U OTAGO EC DISCUSSIO, V204; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torner JC, 1996, HEAD INJURY POSTCONC; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Wrightson P, 1998, NEW ZEAL MED J, V111, P99	32	24	24	0	11	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2009	32	1					32	39		10.1159/000170090			8	Public, Environmental & Occupational Health; Clinical Neurology	Public, Environmental & Occupational Health; Neurosciences & Neurology	375RL	WOS:000261130900007	18997476				2021-06-18	
J	Gontkovsky, ST; Russum, P; Stokic, DS				Gontkovsky, Samuel T.; Russum, Paula; Stokic, Dobrivoje S.			Comparison of the CIQ and chart short form in assessing community integration in individuals with chronic spinal cord injury: A pilot study	NEUROREHABILITATION			English	Article						Community integration; Community Integration Questionnaire; Craig Handicap Assessment and Reporting Technique Short Form; spinal cord injuries	TRAUMATIC BRAIN-INJURY; CRAIG HANDICAP ASSESSMENT; REPORTING TECHNIQUE; LIFE SATISFACTION; QUESTIONNAIRE; IMPAIRMENT; VALIDATION; DISABILITY	Objective: To examine the validity of the Community Integration Questionnaire (CIQ) in measuring community integration in persons with chronic spinal cord injury (SCI) through its comparison with the Craig Handicap Assessment and Reporting Technique Short Form (CHART-SF). Design: Correlational analysis. Setting: Tertiary care rehabilitation hospital. Participants: Twenty-eight individuals with chronic SCI who completed the CIQ and CHART-SF during annual follow-up evaluation. Main outcome measures: The CIQ quantifies community integration based on subscales of Home Integration, Social Integration, and Productive Activity. The CHART-SF provides scores of community integration according to subscales of Physical Independence, Cognitive Independence, Mobility, Occupation, Social Integration, and Economic Self-Sufficiency. Results: CIQ Home Integration was significantly correlated with CHART-SF Physical Independence, Cognitive Independence, Mobility, Occupation, and Social Integration (r's= 0.47-0.57). CIQ Social Integration was significantly correlated with CHART-SF Cognitive Independence, Mobility, Occupation, and Social Integration (r's = 0.43-0.77). CIQ Productive Activity was significantly correlated only with CHART-SF Mobility and Occupation (r's = 0.39-0.41). Conclusions: The CIQ may serve as a valid measure for examining community integration in persons with chronic SCI and may be particularly appealing given its relative brevity/simplicity in administration and scoring.	[Gontkovsky, Samuel T.; Russum, Paula; Stokic, Dobrivoje S.] Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, Jackson, MS USA; [Gontkovsky, Samuel T.] Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA	Gontkovsky, ST (corresponding author), Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, Jackson, MS USA.	sgontkovsky@hotmail.com		Stokic, Dobrivoje/0000-0002-1891-5730			Anderson CJ, 2003, DEV MED CHILD NEUROL, V45, P129, DOI 10.1017/S0012162203000239; BRUININKS RH, 1992, RES DEV DISABIL, V13, P463, DOI 10.1016/0891-4222(92)90003-O; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; Dijkers Marcel., 1998, TOP SPINAL CORD INJ, V4, P1, DOI [10.1310/BJJA-2018-45KL-0VTL, DOI 10.1310/BJJA-2018-45KL-0VTL]; Forcheimer M., 1998, TOP SPINAL CORD INJ, V4, P42; Hall KM, 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Kurylo M, 2001, REHABIL PSYCHOL, V46, P247, DOI 10.1037/0090-5550.46.3.247; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McGrew K. S., 1994, CHALLENGES SERVICE S, P65; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Mellick D., 2000, CRAIG HANDICAP ASSES; Morris J, 1986, J HEAD TRAUMA REHAB, V1, P31; Rintala DH, 1998, TOP SPINAL CORD INJ, V4, P1; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SEGAL ME, 1995, AM J PHYS MED REHAB, V74, P276, DOI 10.1097/00002060-199507000-00004; VOGEL LC, 2002, J SPINAL CORD MED, V25, P1006; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	26	24	24	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2009	24	2					185	192		10.3233/NRE-2009-0467			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	436OF	WOS:000265422900009	19339757				2021-06-18	
J	Ma, M; Matthews, BT; Lampe, JW; Meaney, DF; Shofer, FS; Neumar, RW				Ma, Marek; Matthews, Brian T.; Lampe, Joshua W.; Meaney, David F.; Shofer, Frances S.; Neumar, Robert W.			Immediate short-duration hypothermia provides long-term protection in an in vivo model of traumatic axonal injury	EXPERIMENTAL NEUROLOGY			English	Article						Diffuse axonal injury; Trauma; Optic nerve; Brain injury; Hypothermia	POSTTRAUMATIC HYPOTHERMIA; OPTIC-NERVE; MODERATE HYPOTHERMIA; CYTOSKELETAL CHANGES; CALPAIN ACTIVATION; BRAIN-INJURY; DAMAGE; PROTEIN	A prospective, multicenter, randomized trial did not demonstrate improved Outcomes in severe traumatic brain injured patients treated with mild hypothermia [Clifton, G.L., Miller, E.R., Choi, S.C., Levin, H.S., McCauley, S., Smith, K.R., Jr., Muizelaar, J.P., Wagner, F.C., Jr., Marion, D.W., Luerssen, T.G., Chesnut, R.M., Schwartz, M., 2001, Lack of effect of induction of hypothermia after acute brain injury. N. EngI.J. Med. 344, 556-563.]. However, the mean time to target temperature was over 8 h and patient inclusion was based on Glasgow Coma Scale score so brain pathology was likely diverse. There remains significant interest in the benefits of hypothermia after traumatic brain injury (TBI) and, in particular, traumatic axonal injury (TAI). which is believed to significantly contribute to morbidity and mortality of TBI patients. The long-term beneficial effect of mild hypothermia on TAI has not been established. To address this issue, we developed an in vivo rat optic nerve stretch model of TAL Adult male Sprague-Dawley rats underwent unilateral optic nerve stretch at 6, 7 or 8 mm piston displacement. The increased number of axonal swellings and bulbs immunopositive for non-phosphorylated neurofilament (SMI-32) seen four days after injury was statistically significant after 8 mm displacement. Ultrastructural analysis 2 weeks after 8 mm displacement revealed a 45.0% decrease (p<0.0001) in myelinated axonal density in the optic nerve core. There was loss of axons regardless of axon size, Immediate post-injury hypothermia (32 degrees C) for 3 h reduced axonal degeneration ill the core (p = 0.027). There was no differential protection based oil axon size. These results Support further clinical investigation of temporally optimized therapeutic hypothermia after traumatic brain injury. (C) 2008 Elsevier Inc. All rights reserved.	[Ma, Marek; Matthews, Brian T.; Lampe, Joshua W.; Shofer, Frances S.; Neumar, Robert W.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Ma, Marek; Matthews, Brian T.; Lampe, Joshua W.; Neumar, Robert W.] Univ Penn, Ctr Resuscitat Sci, Philadelphia, PA 19104 USA; [Shofer, Frances S.] Univ Penn, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA	Ma, M (corresponding author), Univ Penn, Dept Emergency Med, 3400 Spruce St,Ground Ravdin, Philadelphia, PA 19104 USA.	mamarek@uphs.upen.edu		Lampe, Joshua/0000-0001-6036-535X; Meaney, David/0000-0002-0954-4122	Research Supported by National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055880]; Society of Academic Emergency Medicine institutional Research Grant (RWN); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS055880] Funding Source: NIH RePORTER	Research Supported by National Institutes of Health grant NS055880 (MM) and the Society of Academic Emergency Medicine institutional Research Grant (RWN).	Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 2000, J NEUROSCI, V20, P2825; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hirano Asao, 1995, P49; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; SUGIMOTO T, 1984, EXP BRAIN RES, V54, P266; Sun Xiaochuan, 2002, Chin J Traumatol, V5, P355	37	24	31	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2009	215	1					119	127		10.1016/j.expneurol.2008.09.024			9	Neurosciences	Neurosciences & Neurology	394QM	WOS:000262462300015	18977220	Green Accepted			2021-06-18	
S	Mataric, M; Tapus, A; Winstein, C; Eriksson, J		Gaggioli, A; Keshner, EA; Weiss, PL; Riva, G		Mataric, Maja; Tapus, Adriana; Winstein, Carolee; Eriksson, Jon			Socially Assistive Robotics for Stroke and Mild TBI Rehabilitation	ADVANCED TECHNOLOGIES IN REHABILITATION: EMPOWERING COGNITIVE, PHYSICAL, SOCIAL AND COMMUNICATIVE SKILLS THROUGH VIRTUAL REALITY, ROBOTS, WEARABLE SYSTEMS AND BRAIN-COMPUTER INTERFACES	Studies in Health Technology and Informatics		English	Article; Book Chapter						Socially-Assistive Robotics (SAR); Human-robot interaction (HRI); Robot-assisted rehabilitation; Technology-assisted therapy	INDUCED MOVEMENT THERAPY; UPPER-EXTREMITY; PERSONALITY; RECOVERY	This paper describes an interdisciplinary research project aimed at developing and evaluating effective and user-friendly non-contact robot-assisted therapy, aimed at in-home use. The approach stems from the emerging field of social cognitive neuroscience that seeks to understand phenomena in terms of interactions between the social, cognitive, and neural levels of analysis. This technology-assisted therapy is designed to be safe and affordable, and relies on novel human-robot interaction methods for accelerated recovery of upper-extremity function after lesion-induced hemiparesis. The work is based on the combined expertise in the science and technology of non-contact socially assistive robotics and the clinical science of neurorehabilitation and motor learning, brought together to study how to best enhance recovery after stroke and mild traumatic brain injury. Our approach is original and promising in that it combines several ingredients that individually have been shown to be important for learning and long-term efficacy in motor neurorehabilitation: (1) intensity of task specific training and (2) engagement and self-management of goal-directed actions. These principles motivate and guide the strategies used to develop novel user activity sensing and provide the rationale for development of socially assistive robotics therapy for monitoring and coaching users toward personalized and optimal rehabilitation programs.	[Mataric, Maja] Univ So Calif, Dept Comp Sci, Robot Res Lab, Ctr Robot & Embedded Syst CRES,Interact Lab, Los Angeles, CA 90089 USA; [Winstein, Carolee] Univ So Calif, Div Biokinesiol & Phys Therapy, Sch Dent, Los Angeles, CA 90089 USA; [Mataric, Maja] Univ So Calif, Viterbi Sch Engn, Los Angeles, CA 90089 USA	Mataric, M (corresponding author), Univ So Calif, Dept Comp Sci, Robot Res Lab, Ctr Robot & Embedded Syst CRES,Interact Lab, Los Angeles, CA 90089 USA.	mataric@usc.edu; adriana.tapus@ieee.org; winstein@usc.edu; je@kth.se		Winstein, Carolee/0000-0001-9789-4626			Ada L., 1994, INSIGHTS GRASP REACH, P239; *AM HEART ASS, 2003, HEART DIS STROK STAT; Bandura A., 1969, PRINCIPLES BEHAV MOD; Brewer BR, 2003, P ANN INT IEEE EMBS, V25, P1613, DOI 10.1109/IEMBS.2003.1279676; Broderick JP, 2004, STROKE, V35, P205, DOI 10.1161/01.STR.0000106160.34316.19; Burgar CG, 2000, J REHABIL RES DEV, V37, P663; CARR JH, 1989, PHYSIOTHERAPY, V75, P372; DESROSIERS J, 2003, CLIN REHABIL, P666; Eriksson J, 2005, INT C REHAB ROBOT, P21; EYSENCK HJ, 1991, PERS INDIV DIFFER, V12, P773, DOI 10.1016/0191-8869(91)90144-Z; Feil-Seifer D, 2005, INT C REHAB ROBOT, P465; Fisher BE, 2008, ARCH PHYS MED REHAB, V89, P1221, DOI 10.1016/j.apmr.2008.01.013; Gerkey BP, 2003, PROCEEDINGS OF THE 11TH INTERNATIONAL CONFERENCE ON ADVANCED ROBOTICS 2003, VOL 1-3, P317; Ghahramanlou M, 2001, P AM STROK ASS 26 IN; Hall E.T., 1966, HIDDEN DIMENSION; Hellstrom K, 2003, J REHABIL MED, V35, P202, DOI 10.1080/16501970310000836; Hesse S, 2003, CNS DRUGS, V17, P1093, DOI 10.2165/00023210-200317150-00004; Hesse S, 2003, ARCH PHYS MED REHAB, V84, P915, DOI 10.1016/S0003-9993(02)04954-7; *I MED, 2001, CROSS QUAL CHASM NEW; *INT LAB, INT LAB HUM ROB INT; Kelly-Hayes M, 1998, STROKE, V29, P1274, DOI 10.1161/01.STR.29.6.1274; MATARIC M, 2007, INT J NEUROENGINEERI, V5; Nakajima H, 2003, IEEE SYS MAN CYBERN, P2381; Nakajima H., 2004, J JAPANESE SOC ARTIF, V19, P184; Nass C, 2001, J EXP PSYCHOL-APPL, V7, P171, DOI 10.1037//1076-898X.7.3.171; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; OLSEN TS, 1990, STROKE, V21, P247, DOI 10.1161/01.STR.21.2.247; REINKENSMEYER DJ, 2000, J REHABILITATION RES, V37; Schaechter JD, 2002, NEUROREHAB NEURAL RE, V16, P326, DOI 10.1177/154596830201600403; SMITS H, 2000, HAND RECOVERY STROKE; Tapus A, 2006, P INT S EXP ROB ISER; TAPUS A, 2006, INT J ROBOTICS SOC J, V24, P14; Tapus A., 2007, P NEUR INF PROC SYST; Tapus A, 2008, INTEL SERV ROBOT, V1, P169, DOI 10.1007/s11370-008-0017-4; TAUB EG, 2003, J MED PHYS, V14, P77; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; WATSON MJ, 2008, PHYSIOTHERAPY, V80, P103; Winstein C. J., 2008, STROKE RECOVERY REHA, P267; Winstein CJ, 2004, ARCH PHYS MED REHAB, V85, P620, DOI 10.1016/j.apmr.2003.06.027; Wolf SL, 2008, LANCET NEUROL, V7, P33, DOI 10.1016/S1474-4422(07)70294-6; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	42	24	24	3	10	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0926-9630	1879-8365	978-1-60750-018-6	STUD HEALTH TECHNOL			2009	145						249	262		10.3233/978-1-60750-018-6-249			14	Computer Science, Cybernetics; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Robotics; Rehabilitation	Computer Science; Engineering; Robotics; Rehabilitation	BMC52	WOS:000271844400017	19592798				2021-06-18	
J	McCarter, RJ; Walton, NH; Brooks, DN; Powell, GE				McCarter, Renee J.; Walton, Nigel H.; Brooks, D. Neil; Powell, Graham E.			Effort Testing in Contemporary UK Neuropsychological Practice	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; Symptom validity; Neuropsychology; Survey	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; WORD MEMORY TEST; PSYCHOGENIC NONEPILEPTIC SEIZURES; MMPI-2 VALIDITY SCALES; NEGATIVE RESPONSE BIAS; RELIABLE DIGIT SPAN; CLASSIFICATION ACCURACY; TEST FAILURE; HEAD-INJURY	A survey of members of the British Psychological Society Division of Neuropsychology (N = 588) was conducted via email to ascertain current practice with respect to the use of symptom validity testing (SVT) in clinical and legal neuropsychological assessments. Replies were received from 130 practicing neuropsychologists. Results showed that 59% frequently use SVT in legal assessments, but a minority (15%) employ them in clinical assessments. Practice in the UK is only moderately different to that in North America with respect to frequency of use of SVT, although methods employed showed greater diversity. Favored tests, respondents' justifications for use of SVT and rationales for not using SVT are reported.	[McCarter, Renee J.; Walton, Nigel H.] NPsych Clin Neurosci Partnership, Bristol BS41 9JQ, Avon, England; [Brooks, D. Neil] Milton Keynes, Rehab Walls, London, England; [Powell, Graham E.] Psychol Serv, London, England	McCarter, RJ (corresponding author), NPsych Clin Neurosci Partnership, 133 Long Ashton Rd, Bristol BS41 9JQ, Avon, England.	rjmccarter@npsych.co.uk					Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; BATT K, 2008, J INT NEUROPSYCHO S1, V14, P139; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bianchini K, 2005, ARCH CLIN NEUROPSYCH, V20, P365, DOI 10.1016/j.acn.2004.09.003; Bianchini KJ, 2008, ASSESSMENT, V15, P435, DOI 10.1177/1073191108317341; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini Kevin J, 2004, Spine J, V4, P718, DOI 10.1016/j.spinee.2004.06.007; Bianchini KJ, 2003, CLIN NEUROPSYCHOL, V17, P574, DOI 10.1076/clin.17.4.574.27946; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Bunnage M., 2008, J INT NEUROPSYCHO S1, V14, P138; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher, 1989, MINNESOTA MULTIPHASI; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; Derogatis LR, 1977, SCL 90 R SYMPTOM CHE; Dodrill CB, 2008, EPILEPSIA, V49, P691, DOI 10.1111/j.1528-1167.2007.01457.x; Drane DL, 2006, EPILEPSIA, V47, P1879, DOI 10.1111/j.1528-1167.2006.00611.x; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Eysenck H. J., 1991, MANUAL EYSENCK PERSO; FAUST D, 1988, SCIENCE, V241, P31, DOI 10.1126/science.3291114; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; Faust D, 1988, Arch Clin Neuropsychol, V3, P145, DOI 10.1016/0887-6177(88)90060-1; FAUST D, 1995, NEUROL CLIN, V13, P255; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick RI, 2007, ASSESSMENT, V14, P3, DOI 10.1177/1073191106292009; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; GIOIA GA, 1996, BRIEF BEHAV RATING I; GOUGH HG, 1947, J ABNORM SOC PSYCH, V42, P215, DOI 10.1037/h0063295; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 1996, WORD MEMORY TEST USE; GREEN P, 2007, GREENS NONVERBAL MED; Greve KW, 2008, ARCH CLIN NEUROPSYCH, V23, P341, DOI 10.1016/j.acn.2007.12.001; Greve KW, 2007, CHILD PSYCHIAT HUM D, V37, P307, DOI 10.1007/s10578-006-0036-3; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Greve KW, 2006, NEUROTOXICOLOGY, V27, P940, DOI 10.1016/j.neuro.2006.06.009; Greve KW, 2007, ASSESSMENT, V14, P12, DOI 10.1177/1073191106295095; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; GREVE KW, 2007, CLIN NEUROPSYCHOL, V21, P1; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Iverson GL, 2003, HANDBOOK OF FORENSIC NEUROPSYCHOLOGY, P137; KAPUR N, 1994, J NEUROL NEUROSUR PS, V57, P385, DOI 10.1136/jnnp.57.3.385; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; LORING DW, 1995, ANN N AM M INT NEUR; Meehl P.E., 1954, CLIN VERSUS STAT PRE; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; POWELL G, 2004, CLIN NEUROPSYCHOLOGY; Powell MR, 2004, CLIN NEUROPSYCHOL, V18, P465, DOI 10.1080/1385404049052409; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; RUOCCO AC, 2007, CLIN NEUROPSYCHOL, V26, P1; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; VANDERWERF SP, 2000, NEUROPSYCHIATRY NEUR, V13; WADDELL G, 1980, SPINE, V5, P117, DOI 10.1097/00007632-198003000-00005; Warrington EK., 1984, RECOGNITION MEMORY T	81	24	25	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	6					1050	1066	PII 908983482	10.1080/13854040802665790			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	473BG	WOS:000268178000009	19235633				2021-06-18	
J	Park, BS; Allen, DN; Barney, SJ; Ringdahl, EN; Mayfield, J				Park, Brandon S.; Allen, Daniel N.; Barney, Sally J.; Ringdahl, Erik N.; Mayfield, Joan			Structure of Attention in Children with Traumatic Brain Injury	APPLIED NEUROPSYCHOLOGY			English	Article						adolescents; attention; CPT; children; factor analysis; trail making; traumatic brain injury	CLOSED-HEAD INJURY; SUSTAINED ATTENTION; URBAN CHILDREN; CHILDHOOD; DEFICITS; INFORMATION; RECOVERY; SKILLS; ADOLESCENTS; PERFORMANCE	Traumatic brain injury (TBI) is a common cause of disability among children in the United States, and attention deficits are frequently observed in both the acute and chronic phases of injury. The current study investigated models of attention in children with TBI and examined differential sensitivity of various components of these attention models to the severity of the brain injury. Participants included 151 children and adolescents (mean age 12.9 years, SD=2.6) who had suffered TBI, and 50 normal controls (mean age 12.5 years old, SD=2.2). All children were administered neuropsychological tests of attention as part of a comprehensive neuropsychological battery for brain injury (TBI group) or for the purposes of the current investigation (normal controls). Confirmatory factor analysis (CFA) of the attention tests indicated that a four-factor model of attention composed of Shift, Focus, Encode, and Sustain factors provided the best fit of the TBI group data. Factor scores were subsequently created and used to predict the severity of brain injury. All four factors were sensitive to TBI in that those with TBI performed significantly worse than the controls, but regression analysis indicated that only the Shift and Focus factors were significant predictors of TBI severity. These findings support the utility of a multicomponent model of attention to understand attention deficits resulting from TBI, and may be useful in determining those aspects of attention that are differentially impacted by TBI, in order to assist in assessment and rehabilitation planning.	[Allen, Daniel N.] Univ Nevada, Dept Psychol, Neuropsychol Res Program, Las Vegas, NV 89154 USA; [Mayfield, Joan] Baylor Univ, Dallas, TX USA	Allen, DN (corresponding author), Univ Nevada, Dept Psychol, Neuropsychol Res Program, 4505 Maryland Pkwy, Las Vegas, NV 89154 USA.	daniel.allen@unlv.edu		Allen, Daniel/0000-0003-4868-2242			Allen DN, 1997, SCHIZOPHR RES, V25, P53, DOI 10.1016/S0920-9964(97)00006-6; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V, 2006, J INT NEUROPSYCH SOC, V12, P519, DOI 10.1017/S135561770606067X; *ARM IND TEST BAT, 1994, MAN DIR SCOR; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; Byrne B. M., 1989, PRIMER LISREL; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; *CDCP, 2004, TBI GEN FACT SHEET G; Chan RCK, 2006, BRAIN INJURY, V20, P653, DOI 10.1080/02699050600676974; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Cohen JD, 1997, SCI APPROACHES CONSC; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE, P145; Conners C., 2000, CONNERS CONTINUOUS P; DEJONG R, 1991, PERCEPT PSYCHOPHYS, V50, P333, DOI 10.3758/BF03212226; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Duncan C.C., 2004, COMPREHENSIVE HDB PS, V1, P263; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; Goldstein G, 2001, J AUTISM DEV DISORD, V31, P433, DOI 10.1023/A:1010620820786; Gray J., 2004, CONSCIOUSNESS CREEPI; Harmsen M, 2004, BRAIN INJURY, V18, P787, DOI 10.1080/02699050410001671757; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Kelloway E. K., 1998, USING LISREL STRUCTU; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kline RB., 2016, PRINCIPLES PRACTICE, V4; Korkman M, 2001, DEV NEUROPSYCHOL, V20, P331, DOI 10.1207/S15326942DN2001_2; KREMEN WS, 1992, J NERV MENT DIS, V180, P89, DOI 10.1097/00005053-199202000-00004; Lehnung M, 2003, BRAIN INJURY, V17, P855, DOI 10.1080/0269905031000089369; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Luria A. R, 1973, WORKING BRAIN; Maruyama Geoffrey, 1998, BASICS STRUCTURAL EQ; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A. F., 2002, EVOLUTIONARY NEUROET, P215; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; Mirsky AF, 1999, MENT RETARD DEV D R, V5, P169, DOI 10.1002/(SICI)1098-2779(1999)5:3<169::AID-MRDD2>3.0.CO;2-K; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Pascualvaca DM, 1997, CHILD NEUROPSYCHOL, V3, P13, DOI 10.1080/09297049708401365; POGGE DL, 1994, J CLIN EXP NEUROPSYC, V16, P344, DOI 10.1080/01688639408402645; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Riccio CA, 2002, ARCH CLIN NEUROPSYCH, V17, P235, DOI 10.1016/S0887-6177(01)00111-1; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1998, COMPENDIUM NEUROPSYC; STEINHAUER SR, 1991, ADV NEUROPSYCHIATRY, V1, P169; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1986, BRAIN LANG, V28, P66, DOI 10.1016/0093-934X(86)90091-X; TEASDALE G, 1974, LANCET, V2, P81; TREXLER LE, 1988, BRAIN COGNITION, V8, P291, DOI 10.1016/0278-2626(88)90056-5; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; Wechsler D., 1991, WECHSLER INTELLIGENC; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; ZUBIN J, 1975, EXPT APPROACHES PSYC, P139	70	24	24	0	16	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2009	16	1					1	10	PII 908616865	10.1080/09084280802636371			10	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	406AI	WOS:000263267000001	19205942				2021-06-18	
J	Rutherford, A; Stephens, R; Fernie, G; Potter, D				Rutherford, Andrew; Stephens, Richard; Fernie, Gordon; Potter, Douglas			Do UK university football club players suffer neuropsychological impairment as a consequence of their football (soccer) play?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Concussion; Heading; Head trauma; Neuropsychological impairment; Neuropsychology	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; AMATEUR BOXING LEAD; HEAD-INJURY; SERUM CONCENTRATIONS; BONFERRONI PROCEDURE; BIOCHEMICAL MARKERS; MULTIPLE TESTS; DAMAGE S-100B; CONCUSSION	Male players from football and rugby clubs and sportsmen from a variety of noncontact sports clubs at a UK university were compared on biographical and neuropsychological test measures. A data analysis paradigm was developed and employed to control the inflation of Type 1 error rate due to multiple hypotheses testing. Rugby players sustained most head injuries in their chosen sport, but neuropsychological tests of attention, memory, and executive function provided no evidence of performance impairment attributable to the number of head injuries sustained or the football, rugby, or noncontact sport groups. Footballers' heading frequency was related to the number of football head injuries sustained, but no relationship was detected between footballers' heading frequency and their neuropsychological test performance. Following discussion of pertinent methodological limitations it is concluded that there was no evidence in this dataset of neuropsychological impairment consistent with either mild head injury incidence or football heading frequency. However, a need for further research examining the long-term neuropsychological consequences of such head injuries was identified.	[Rutherford, Andrew] Univ Keele, Sch Psychol, Keele ST5 5BG, Staffs, England; [Fernie, Gordon] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Potter, Douglas] Univ Dundee, Dundee, Scotland	Rutherford, A (corresponding author), Univ Keele, Sch Psychol, Keele ST5 5BG, Staffs, England.	a.rutherford@psy.keele.ac.uk	Stephens, Richard/C-4062-2009	Stephens, Richard/0000-0002-5851-8975	Wellcome TrustWellcome TrustEuropean Commission [054248]	This research was funded by the Wellcome Trust, Grant 054248.	Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Adams J, 2007, CLIN J SPORT MED, V17, P304, DOI 10.1097/JSM.0b013e31803202c8; ANZIL F, 1979, 1 INT C SPORTS MED A, P643; Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Barth J T, 2000, Dent Clin North Am, V44, P67; Barth JT., 1989, MILD HEAD INJURY, P257; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Bernhard G, 2004, STAT PAP, V45, P1, DOI 10.1007/BF02778266; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; CHRISTENSEN PR, 1960, ALTERNATE USES FORM; Cohen J., 2003, APPL MULTIPLE CORREL; Cook T. D., 2002, EXPT QUASIEXPERIMENT; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC; *DEP HLTH, 2008, ALC ADV; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; DUNNETT CW, 1992, J AM STAT ASSOC, V87, P162, DOI 10.2307/2290465; DVORAK J, 2005, BRIT J SPORT MED, V39, P1; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; FIFA, 2006, FIFA BIG COUNT 2006; Fox K, 2004, SPORT LEISURE RESULT; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Golden C., 1978, STROOP COLOR WORD TE; GREEN G, 1996, US FOOTBALL SPORTS M, P191; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOCHBERG Y, 1995, J STAT PLAN INFER, V48, P141, DOI 10.1016/0378-3758(95)00005-T; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Hochberg Y., 1987, MULTIPLE COMP PROCED; HOLLAND BS, 1988, PSYCHOL BULL, V104, P145, DOI 10.1037/0033-2909.104.1.145; Hunt M, 1990, Br J Sports Med, V24, P265; Iverson G L, 2000, Appl Neuropsychol, V7, P247, DOI 10.1207/S15324826AN0704_7; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jaeger RG, 1998, HERPETOLOGICA, V54, pS64; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Kelly JP, 1997, NEUROLOGY, V48, P581; Keppel G, 2004, DESIGN ANAL RES HDB; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; OCARROLL RE, 1987, BRIT J CLIN PSYCHOL, V26, P315, DOI 10.1111/j.2044-8260.1987.tb01367.x; Olejnik S, 1997, J EDUC BEHAV STAT, V22, P389, DOI 10.2307/1165229; Parsons OA, 1998, J STUD ALCOHOL, V59, P180, DOI 10.15288/jsa.1998.59.180; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; Riding RJ, 2003, BRIT J EDUC PSYCHOL, V73, P149, DOI 10.1348/00070990360626912; ROM DM, 1990, BIOMETRIKA, V77, P663, DOI 10.2307/2337008; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Rutherford A, 2005, APPL COGNITIVE PSYCH, V19, P477, DOI 10.1002/acp.1091; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; RUTHERFORD A, 1992, BRIT J MATH STAT PSY, V45, P197, DOI 10.1111/j.2044-8317.1992.tb00988.x; Rutherford A., 2001, INTRO ANOVA ANCOVA G; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; SHAFFER JP, 1986, J AM STAT ASSOC, V81, P826, DOI 10.2307/2289016; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI33, DOI 10.1136/bjsm.2005.019059; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SMITH T, 1995, OCCUPATIONAL HYGIENE, P308; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Washington RL, 2001, PEDIATRICS, V107, P1205; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEIGHTMAN D, 1974, BRIT J SPORT MED, V8, P183; Westfall P, 1999, MULTIPLE COMP MULTIP; Westfall P. H, 1993, RESAMPLING BASED MUL; Wilson, 1991, NATL ADULT READING T; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; ZIMMERMAN P, 1995, TEST ATTENTIONAL PER	94	24	24	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	6					664	681		10.1080/13803390802484755			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	482JV	WOS:000268883300004	19048428				2021-06-18	
J	Donat, CK; Schuhmann, MU; Voiqt, C; Nieber, K; Deuther-Conrad, W; Brust, P				Donat, Cornelius K.; Schuhmann, Martin U.; Voiqt, Cornelia; Nieber, Karen; Deuther-Conrad, Winnie; Brust, Peter			Time-dependent alterations of cholinergic markers after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						CCI; Traumatic brain injury; AChR; vAChT; Cholinergic system; Autoradiography	VESICULAR ACETYLCHOLINE TRANSPORTER; CONTROLLED CORTICAL IMPACT; MUSCARINIC RECEPTOR SUBTYPES; FLUID-PERCUSSION INJURY; RAT-BRAIN; NICOTINIC RECEPTORS; HEAD-INJURY; THALAMIC NUCLEI; BINDING; RELEASE	Traumatic brain injury (TBI) is one of the leading causes of death and disability. Cognitive deficits are believed to be connected with impairments of the cholinergic system. The present study was conducted to evaluate the cholinergic system in a model of focal brain injury with special attention to the time course of posttraumatic events in critical brain regions. Three groups of male Sprague-Dawley rats (post-TBI survival time: 2 h, 24 h and 72 h) were subjected to sham-operation (control) or controlled cortical impact injury. Receptor densities were determined on frozen ipsilateral sagittal brain sections with [H-3]epibatidine (nicotinic acetylcholine receptors) and [H-3]QNB (muscarinic acetylcholine receptors). The density of the vesicular acetylcholine transporter (vAChT) was evaluated with (-) [H-3]vesamicol. Compared to control, vAChT was lowered (up to 50%) at each time point after trauma, with reductions in olfactory tubercle, basal forebrain, motor cortex, putamen, thalamic and hypothalamic areas and the gigantocellular reticular nucleus. Time-dependent reductions of about 20% of nAChR-density in the thalamus, hypothalamus, olfactory tubercle, gigantocellular reticular nucleus and motor cortex were observed post-TBI at 24 and 72 h. The same brain regions showed reductions of mAChR at 24 and 72 h after trauma with additional decreases in the corpus callosurn, basal forebrain and anterior olfactory nucleus. in conclusion, cholinergic markers showed significant time-dependent impairments after TBI. Considering the role of the cholinergic system for cognitive processes in the brain, it seems likely that these impairments contribute to clinically relevant cognitive deficits. (C) 2008 Elsevier B.V. All rights reserved.	[Donat, Cornelius K.; Deuther-Conrad, Winnie; Brust, Peter] Inst Interdisciplinary Isotope Res, D-04318 Leipzig, Germany; [Schuhmann, Martin U.; Voiqt, Cornelia] Univ Leipzig, Dept Neurosurg, Leipzig, Germany; [Nieber, Karen] Univ Leipzig, Inst Pharm, Leipzig, Germany	Donat, CK (corresponding author), Inst Interdisciplinary Isotope Res, Permoserstr 15, D-04318 Leipzig, Germany.	donat@iif-leipzig.de	Deuther-Conrad, Winnie/B-7558-2015	Deuther-Conrad, Winnie/0000-0003-3168-3062; , Peter/0000-0001-5555-7058			ALTAR CA, 1988, SYNAPSE, V2, P486, DOI 10.1002/syn.890020504; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; AUBERT I, 1994, J NEUROSCI, V14, P2476; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BIEGON A, 1989, NEUROBIOL AGING, V10, P305, DOI 10.1016/0197-4580(89)90040-7; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buttermann AE, 1998, TOXICOL LETT, V101, P17, DOI 10.1016/S0378-4274(98)00160-X; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Custers FGJ, 1997, EUR J PHARMACOL, V338, P177, DOI 10.1016/S0014-2999(97)81946-2; Darreh-Shori T, 2004, J NEUROCHEM, V88, P1102, DOI 10.1046/j.1471-4159.2003.02230.x; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Deuther-Conrad W, 2006, SYNAPSE, V59, P201, DOI 10.1002/syn.20232; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donat CK, 2007, BRAIN INJURY, V21, P1031, DOI 10.1080/02699050701630359; EARLEY B, 1995, NEUROCHEM INT, V26, P559, DOI 10.1016/0197-0186(95)00004-R; Fass U, 2000, NEUROREPORT, V11, P931, DOI 10.1097/00001756-200004070-00007; Fujita M, 2003, EUR J NUCL MED MOL I, V30, P1620, DOI 10.1007/S00259-003-1320-0; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; Gill TM, 2000, J NEUROSCI, V20, P4745, DOI 10.1523/JNEUROSCI.20-12-04745.2000; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Gotohda T, 2001, INT J LEGAL MED, V115, P121, DOI 10.1007/s004140000185; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hasselmo ME, 1999, TRENDS COGN SCI, V3, P351, DOI 10.1016/S1364-6613(99)01365-0; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; HUSTVEIT O, 1994, JPN J PHARMACOL, V64, P57, DOI 10.1254/jjp.64.57; Ichikawa T, 1997, J CHEM NEUROANAT, V13, P23, DOI 10.1016/S0891-0618(97)00021-5; Iida Y, 2004, J NUCL MED, V45, P878; IMPERATO A, 1993, EUR J PHARMACOL, V238, P135, DOI 10.1016/0014-2999(93)90518-M; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jett DA, 2002, NEUROTOXICOL TERATOL, V24, P805, DOI 10.1016/S0892-0362(02)00314-8; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kaufer D, 1999, CHEM-BIOL INTERACT, V119, P349, DOI 10.1016/S0009-2797(99)00046-0; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Marutle A, 1998, BRAIN RES, V801, P143, DOI 10.1016/S0006-8993(98)00558-7; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCREE RC, 1995, NEUROIMAGE, V2, P55, DOI 10.1006/nimg.1995.1008; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Moor E, 1998, EUR J PHARMACOL, V359, P119, DOI 10.1016/S0014-2999(98)00642-6; Mortazavi S, 1999, ANESTHESIOLOGY, V90, P1070, DOI 10.1097/00000542-199904000-00021; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perry DC, 2002, J NEUROCHEM, V82, P468, DOI 10.1046/j.1471-4159.2002.00951.x; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Prado VF, 2006, NEURON, V51, P601, DOI 10.1016/j.neuron.2006.08.005; Rothberg BS, 1996, ALCOHOL CLIN EXP RES, V20, P1613, DOI 10.1111/j.1530-0277.1996.tb01706.x; Sabri O, 2008, EUR J NUCL MED MOL I, V35, pS30, DOI 10.1007/s00259-007-0701-1; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; SCHAFER MKH, 1994, J MOL NEUROSCI, V5, P1, DOI 10.1007/BF02736691; Schmanke TD, 2001, DEV BRAIN RES, V131, P127, DOI 10.1016/S0165-3806(01)00248-6; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Scremin OU, 1996, LIFE SCI, V58, P2011, DOI 10.1016/0024-3205(96)00192-0; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Sihver W, 1998, NEUROSCIENCE, V85, P1121, DOI 10.1016/S0306-4522(97)00652-0; Szutowicz A, 2006, METAB BRAIN DIS, V21, P149, DOI 10.1007/s11011-006-9007-4; SZYMUSIAK R, 1995, SLEEP, V18, P478, DOI 10.1093/sleep/18.6.478; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tellez S, 1997, J NEUROCHEM, V68, P778; Tenovuo OS, 2006, CURR DRUG THER, V1, P187, DOI 10.2174/157488506776930932; Terry AV, 2006, NEUROSCIENCE, V140, P1277, DOI 10.1016/j.neuroscience.2006.03.011; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tribollet E, 2004, NEUROSCIENCE, V124, P405, DOI 10.1016/j.neuroscience.2003.09.028; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Vaupel DB, 2007, NEUROIMAGE, V34, P1352, DOI 10.1016/j.neuroimage.2006.10.036; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; WALKER PD, 1993, J NEUROSCI RES, V36, P588, DOI 10.1002/jnr.490360511; WATSON M, 1986, J PHARMACOL EXP THER, V237, P419; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	97	24	26	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 30	2008	1246						167	177		10.1016/j.brainres.2008.09.059			11	Neurosciences	Neurosciences & Neurology	396NE	WOS:000262597600018	18848922				2021-06-18	
J	Clausen, F; Marklund, N; Lewen, A; Hillered, L				Clausen, Fredrik; Marklund, Niklas; Lewen, Anders; Hillered, Lars			The Nitrone Free Radical Scavenger NXY-059 Is Neuroprotective when Administered after Traumatic Brain Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						learning and memory; neuroprotection animal studies; NXY-059; oxidative stress; traumatic brain injury	TERT-BUTYL-NITRONE; FOCAL CEREBRAL-ISCHEMIA; CORTICAL CONTUSION INJURY; SEVERE HEAD-INJURY; FLUID-PERCUSSION; OXIDATIVE DAMAGE; S-PBN; TRAPPING COMPOUND; ARTERY OCCLUSION; NEURONAL INJURY	Reactive oxygen species (ROS) are important contributors to the secondary injury cascade following traumatic brain injury (TBI), and ROS inhibition has consistently been shown to be neuroprotective following experimental TBI. NXY-059, a nitrone free radical trapping compound, has been shown to be neuroprotective in models of ischemic stroke but has not been evaluated in experimental TBI. In the present Study, a continuous 24-h intravenous infusion of NXY-059 or vehicle was initiated 30 min following a severe lateral fluid percussion brain injury (FPI) in adult rats (n=22), and histological and behavioral outcomes were evaluated. Sham-injured animals (n = 22) receiving identical drug infusion were used as controls. Visuospatial learning was evaluated in the Morris water maze at post-injury days 11-14, followed by a probe trial (memory test) at day 18. The animals were sacrificed at day 18, and loss of hemispheric brain tissue was measured in microtubule-associated protein (MAP)-2 stained sections. Brain-injured, NXY-059-treated animals showed a significant reduction of visuospatial learning deficits when compared to the brain-injured, vehicle-treated control animals (p < 0.05). NXY-059-treated animals significantly reduced the loss of hemispheric tissue compared to brain-injured controls (43.0 +/- 11 mm(3) versus 74.4 +/- 19 mm(3), respectively; p < 0.01). The results show that post-injury treatment with NXY-059 significantly attenuated the loss of injured brain tissue and improved cognitive outcome, suggesting a major role for ROS in the pathophysiology of TBI.	[Clausen, Fredrik; Marklund, Niklas; Lewen, Anders; Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden	Clausen, F (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	Fredrik.clausen@neurokir.uu.se		Hillered, Lars/0000-0002-2808-9292; Marklund, Niklas/0000-0002-9797-5626; Clausen, Fredrik/0000-0003-3592-4417			CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; Clausen F, 2005, ACTA NEUROCHIR, V147, P775, DOI 10.1007/s00701-005-0550-2; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clemens JA, 2000, FREE RADICAL BIO MED, V28, P1526, DOI 10.1016/S0891-5849(00)00258-6; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Edenius Charlotte, 2002, J Stroke Cerebrovasc Dis, V11, P34, DOI 10.1053/jscd.2002.123973; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gahm C, 2005, NEUROSURGERY, V57, P1272, DOI 10.1227/01.NEU.0000187317.32529.06; Green AR, 2006, BRAIN RES, V1072, P224, DOI 10.1016/j.brainres.2005.12.035; Hainsworth AH, 2008, J CEREBR BLOOD F MET, V28, P24, DOI 10.1038/sj.jcbfm.9600517; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Hino K, 2005, BRAIN RES, V1053, P77, DOI 10.1016/j.brainres.2005.06.062; Kawamata T, 1997, ACT NEUR S, V70, P191; Kondo T, 1996, NEUROSCI LETT, V215, P103, DOI 10.1016/S0304-3940(96)12954-2; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lyden PD, 2007, STROKE, V38, P2262, DOI 10.1161/STROKEAHA.106.472746; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marshall JWB, 2003, STROKE, V34, P2228, DOI 10.1161/01.STR.0000087790.79851.A8; Marshall JWB, 2003, BRAIN RES, V972, P119, DOI 10.1016/S0006-8993(03)02511-3; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nilsson D, 2007, J CLIN PHARMACOL, V47, P264, DOI 10.1177/0091270006293752; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Papadakis M, 2006, STROKE, V37, P2189, DOI 10.1161/01.STR.0000230598.31774.7a; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Villa RF, 1997, PHARMACOL REV, V49, P99; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Yang Y, 2000, EXP NEUROL, V163, P39, DOI 10.1006/exnr.2000.7364; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; YUE TL, 1992, BRAIN RES, V574, P193, DOI 10.1016/0006-8993(92)90816-R; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x; Zhao ZG, 2001, BRAIN RES, V909, P46, DOI 10.1016/S0006-8993(01)02618-X	64	24	24	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1449	1457		10.1089/neu.2008.0585			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500006	19118455				2021-06-18	
J	Erkonen, G; Lamb, F; Tobias, JD				Erkonen, Gwen; Lamb, Fred; Tobias, Joseph D.			High-dose Dexmedetomidine-induced Hypertension in a Child with Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Dexmedetomidine; Hypertension; Traumatic brain injury	CEREBRAL-BLOOD-FLOW; INTRACRANIAL-PRESSURE; SEDATION; CARE	Introduction Dexmedetomidine is a centrally acting alpha(2)-adrenergic agonist which is currently FDA-approved for the short-term (less than 24 h) sedation of adults during mechanical ventilation. Discussion Given its beneficial physiologic properties, there has been increasing use of this agent in the pediatric population. As with any agent used for sedation in the Pediatric ICU setting, dose escalations may be necessary. Unlike benzodiazepines and opioids, there are limited data regarding the administration of dexmedetomidine above the current package insert dosing recommendations of 0.7 mu g/kg/h. Results We report a 2-year-old child with traumatic brain injury who developed hypertension following the administration of a dexmedetomidine infusion at 4 mu g/kg/h for several hours. Investigation into the etiology of the hypertension was negative and the blood pressure returned to baseline with a decrease in the infusion rate. Conclusion Subsequent to this, no further issues with hypertension were noted.	[Tobias, Joseph D.] Univ Missouri, Dept Anesthesiol, Columbia, MO 65212 USA; [Erkonen, Gwen; Lamb, Fred] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Tobias, Joseph D.] Univ Missouri, Dept Pediat, Columbia, MO 65212 USA	Tobias, JD (corresponding author), Univ Missouri, Dept Anesthesiol, 3W-27G Hlth Sci Ctr,1 Hosp Dr, Columbia, MO 65212 USA.	Tobiasj@health.missouri.edu					Aryan HE, 2006, BRAIN INJURY, V20, P791, DOI 10.1080/02699050600789447; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Chrysostomou C, 2005, PEDIATR CARDIOL, V26, P651, DOI 10.1007/s00246-005-0683-3; Chrysostomou C, 2006, PEDIATR CRIT CARE ME, V7, P126, DOI 10.1097/01.PCC.0000200967.76996.07; Drummond JC, 2008, ANESTHESIOLOGY, V108, P225, DOI 10.1097/01.anes.0000299576.00302.4c; Hammer GB, 2005, PEDIATR ANESTH, V15, P616, DOI 10.1111/j.1460-9592.2005.01656.x; Hammer GB, 2008, ANESTH ANALG, V106, P79, DOI 10.1213/01.ane.0000297421.92857.4e; KARLSSON BR, 1990, ANESTH ANALG, V71, P125; Mason KP, 2008, PEDIATR ANESTH, V18, P403, DOI 10.1111/j.1460-9592.2008.02468.x; Mason KP, 2008, PEDIATR ANESTH, V18, P393, DOI 10.1111/j.1460-9592.2008.02451.x; Mason KP, 2006, ANESTH ANALG, V103, P57, DOI 10.1213/01.ane.0000216293.16613.15; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; Spitzfaden AC, 1999, PEDIATR NEUROSURG, V31, P194, DOI 10.1159/000028861; Talke P, 1997, ANESTH ANALG, V85, P358, DOI 10.1097/00000539-199708000-00021; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Venn RM, 1999, ANAESTHESIA, V54, P1136, DOI 10.1046/j.1365-2044.1999.01114.x; VIRTANEN R, 1988, EUR J PHARMACOL, V150, P9, DOI 10.1016/0014-2999(88)90744-3; Walker J, 2006, J BURN CARE RES, V27, P206, DOI 10.1097/01.BCR.0000200910.76019.CF; Wheeler A, 2005, AM J PAIN MANAGE, V15, P15; ZORNOW MH, 1992, ANESTH ANALG, V75, P232; 2003, PEDIAT CRIT CARE MED, V4, pS34	22	24	25	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2008	9	3					366	369		10.1007/s12028-008-9102-y			4	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	367HC	WOS:000260542100015	18491236				2021-06-18	
J	Narotam, PK; Puri, V; Roberts, JM; Taylon, C; Vora, Y; Nathoo, N				Narotam, Pradeep K.; Puri, Varun; Roberts, John M., Jr.; Taylon, Charles; Vora, Yashail; Nathoo, Narendra			Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation Clinical article	JOURNAL OF NEUROSURGERY			English	Article						acute brain disease; brain tissue oxygen; nicardipine	SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; PROLONGED-RELEASE IMPLANTS; BLOOD-PRESSURE; INTRACEREBRAL HEMORRHAGE; TISSUE OXYGEN; DOUBLE-BLIND; COOPERATIVE ANEURYSM; ISCHEMIC STROKE; TRIAL	Object. Inappropriate sudden blood pressure (BP) reductions may adversely affect cerebral perfusion. This study explores the effect of nicardipine on regional brain tissue O-2 (PbtO(2)) during treatment of acute hypertensive emergencies. Methods. A prospective case-control Study was performed in 30 patients with neurological conditions and clinically elevated BP. All patients had a parenchymal PbtO(2) and intracranial pressure bolt inserted following resuscitation. Using a critical care guide, PbtO(2) was optimized. Intravenous nicardipine (5-15 mg/hour) was titrated to systolic BP < 160 mm Hg, diastolic BP < 90 mm Hg, mean arterial BP (MABP) 90-110 mg/Hg, and PbtO(2) > 20 mm Hg. Physiological parameters-intracranial pressure. PbtO(2), central venous pressure, systolic BP. diastolic BP, MABP, fraction of inspired O-2, and cerebral perfusion pressure (CPP)-were compared before infusion, at 4 hours, and at 8 hours using a t-test. Results. Sixty episodes of hypertension were reported in 30 patients (traumatic brain injury in 13 patients: aneurysmal subarachnoid hemorrhage in 11: intracerebral and intraventricular hemorrhage in 3 and 1, respective]),: arteriovenous malformation in 1; and hypoxic brain injury ill 1). Nicardipine was effective in 87%, of the patients (with intravenous (3 blockers in 4 patients). with a 19.7% reduction in mean 4-hour MABP (115.3 +/- 13.1 mm Hg preinfusion vs 92.9 +/- 11.40 mm Hg after 4 hours of therapy. p < 0.001). No deleterious effect on mean PbtO(2) was recorded (26.74 +/- 15.42 mm Hg preinfusion vs 27.68 +/- 12.51 mm Hg after 4 hours of therapy, p = 0.883) despite significant reduction in CPP. Less dependence oil normobaric hyperoxia was achieved at 8 hours (0.72 +/- 0.299 mm Hg preinfusion vs 0.626 +/- 0.286 mm Hg after 8 hours of therapy, p < 0.01). Subgroup analysis revealed that 12 patients had low pretreatment PbtO(2) (10.30 +/- 6.49 mm Hg), with higher CPP (p < 0.001) requiring, hyperoxia (p = 0.02). In this group, intravenous nicardipine resulted in air 83% improvement in 4- and 8-hour PbtO(2) levels (18.1 +/- 11.33 and respectively: p < 0.01) despite significant red 19.59 +/- 23.68 mm Hg, respectively; p < 0.01) despite significant reductions in both mean MABP (120.6 +/- 16.65 vs 95.8 +/- 8.3 mm Hg, p < 0.001) and CPP (105.00 +/- 20.7 vs 81.2 +/- 15.4 mm Hg, p < 0.001). Conclusions. Intravenous nicardipine is effective for the treatment of hypertensive neurological emergencies and has no adverse effect on PbtO(2). (DOI: 10.317.JNS.2008.109.12.1065)	[Narotam, Pradeep K.; Puri, Varun; Roberts, John M., Jr.; Taylon, Charles; Vora, Yashail; Nathoo, Narendra] Creighton Univ, Med Ctr, Div Neurosurg, Omaha, NE USA	Narotam, PK (corresponding author), Union Hosp Neurosci, 1530 N 7th St,501, Terre Haute, IN 47807 USA.	narotam@mac.com			PDL BioPharma	Dr. Narotam serves as a consultant for Integra Life Sciences. He has no direct financial gain from the sale of Licox or nicardipine (Cardene).; Financial support for this investigator-initiated study, to Dr. Narotam, was provided as an unrestricted research grant by PDL BioPharma.	Ahmed N, 2003, CEREBROVASC DIS, V15, P235, DOI 10.1159/000069498; Ahmed N, 2001, J INTERN MED, V249, P467, DOI 10.1046/j.1365-2796.2001.00831.x; Ahmed N, 2000, STROKE, V31, P1250, DOI 10.1161/01.STR.31.6.1250; ALABADI JA, 1993, NEUROSURGERY, V33, P707, DOI 10.1227/00006123-199310000-00022; Amenta F, 2004, CLIN EXP HYPERTENS, V26, P351, DOI 10.1081/CEH-120034139; Badjatia N, 2004, AM J NEURORADIOL, V25, P819; Bardt TF, 1998, ACT NEUR S, V71, P153; Barth M, 2007, STROKE, V38, P330, DOI 10.1161/01.STR.0000254601.74596.0f; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Cherney D, 2002, J GEN INTERN MED, V17, P937, DOI 10.1046/j.1525-1497.2002.20389.x; Cheung AT, 1999, ANESTH ANALG, V89, P1116, DOI 10.1213/00000539-199911000-00008; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; Denolle T, 2002, FUND CLIN PHARMACOL, V16, P527, DOI 10.1046/j.1472-8206.2002.00110.x; Elliott William J, 2004, J Clin Hypertens (Greenwich), V6, P587, DOI 10.1111/j.1524-6175.2004.03608.x; Fandino J, 2000, J CLIN NEUROSCI, V7, P226, DOI 10.1054/jocn.1999.0202; Filippi R, 2000, NEUROSURG REV, V23, P94; FLAMM ES, 1988, J NEUROSURG, V68, P393, DOI 10.3171/jns.1988.68.3.0393; Fogelholm R, 1997, STROKE, V28, P1396, DOI 10.1161/01.STR.28.7.1396; GABB MR, 1985, BR J CLIN PHARM S, V20, pS67; GROTTA J, 1986, STROKE, V17, P213, DOI 10.1161/01.STR.17.2.213; Haas CE, 2004, AM J HEALTH-SYST PH, V61, P1661, DOI 10.1093/ajhp/61.16.1661; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; HALEY EC, 1993, J NEUROSURG, V78, P537, DOI 10.3171/jns.1993.78.4.0537; HALEY EC, 1993, J NEUROSURG, V78, P548, DOI 10.3171/jns.1993.78.4.0548; Hemphill JC, 2005, NEUROCRIT CARE, V3, P260, DOI 10.1385/NCC:3:3:260; Jarus-Dziedzic K, 2003, ACT NEUR S, V86, P473; Kasuya H, 2005, NEUROSURGERY, V56, P895; Kasuya H, 2002, STROKE, V33, P1011, DOI 10.1161/01.STR.0000014563.75483.22; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kross RA, 2000, ANESTH ANALG, V91, P904, DOI 10.1097/00000539-200010000-00024; Littlejohns L, 2005, AACN ADV CRIT CARE, V16, P501, DOI 10.1097/00044067-200510000-00007; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MASSO JFM, 1990, CLIN THER, V12, P344; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; MUNDO MR, 1990, J CARDIOVASC PHARM, V16, pS16, DOI 10.1097/00005344-199000162-00006; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; NEUTEL JM, 1994, AM J HYPERTENS, V7, P623, DOI 10.1093/ajh/7.7.623; Patel HP, 2005, CURR OPIN PEDIATR, V17, P210, DOI 10.1097/01.mop.0000150769.38484.b3; Powers WJ, 2001, NEUROLOGY, V57, P18, DOI 10.1212/WNL.57.1.18; Qureshi AI, 2006, CRIT CARE MED, V34, P1975, DOI 10.1097/01.CCM.0000220763.85974.E8; Qureshi Adnan I, 2005, J Intensive Care Med, V20, P34, DOI 10.1177/0885066604271619; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; RINKEL GJ, 2002, COCHRANE DB SYST REV, V4, P277; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rose JC, 2004, NEUROCRIT CARE, V1, P287, DOI 10.1385/NCC:1:3:287; ROSENBAUM D, 1991, STROKE, V22, P437, DOI 10.1161/01.STR.22.4.437; ROSENBAUM DM, 1990, ANGIOLOGY, V41, P1017; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sahuquillo J, 2000, REV NEUROLOGIA, V30, P401, DOI 10.33588/rn.3005.99063; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SINGH BN, 1990, AM HEART J, V119, P427, DOI 10.1016/S0002-8703(05)80063-8; Stevens Wendy J, 2004, J Neurosci Nurs, V36, P332; Stiefel MF, 2004, J NEUROSURG, V101, P594, DOI 10.3171/jns.2004.101.4.0594; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Tuncel Meryem, 2003, Am J Cardiovasc Drugs, V3, P21, DOI 10.2165/00129784-200303010-00003; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vaughan CJ, 2000, LANCET, V356, P411, DOI 10.1016/S0140-6736(00)02539-3; WALLIN JD, 1989, ARCH INTERN MED, V149, P2662, DOI 10.1001/archinte.149.12.2662; Yang HJ, 2004, J INT MED RES, V32, P118, DOI 10.1177/147323000403200203	67	24	27	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2008	109	6					1065	1074		10.3171/JNS.2008.109.12.1065			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	376SY	WOS:000261204500017	19035721				2021-06-18	
J	Steigelman, M; Lopez, P; Dent, D; Myers, J; Corneille, M; Stewart, R; Cohn, S				Steigelman, Megan; Lopez, Peter; Dent, Daniel; Myers, John; Corneille, Michael; Stewart, Ronald; Cohn, Stephen			Screening cervical spine MRI after normal cervical spine CT scans in patients in whom cervical spine injury cannot be excluded by physical examination	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	60th Annual Meeting of the Southwestern-Surgical-Congress	MAR 30, 2008	Acapulco, MEXICO	SW Surg Cong		Cervical spine MRI; Cervical spine CT; Obtunded trauma patients; Cervical spine injury	BLUNT TRAUMA; COMPUTED-TOMOGRAPHY; OBTUNDED PATIENTS; CLEARANCE	BACKGROUND: Cervical spine injuries can occur in as many as 10% of patients with blunt trauma with mental status changes from closed head injuries. Despite normal results on cervical spine computed tomography (CT), magnetic resonance imaging (MRI) is often recommended to exclude ligamentous or soft tissue injury. METHODS: A retrospective review was conducted of trauma patients admitted to a level I trauma center from 2002 to 2006, in whom cervical spine injuries could not be excluded by physical examination. All patients with normal results on cervical spine CT followed by cervical spine MRI were included in the analysis. RESULTS: One hundred twenty patients underwent MRI to examine their cervical spines. Seven patients had abnormal MRI findings suggestive of acute traumatic injury. No MRI studies led to operative intervention. Screening MRI increased from 1% of comatose patients in 2002 to 18% in 2006. CONCLUSIONS: The use of MRI in patients with normal results on cervical spine CT does not appear to alter treatment. (C) 2008 Elsevier Inc. All rights reserved.	[Steigelman, Megan; Lopez, Peter; Dent, Daniel; Myers, John; Corneille, Michael; Stewart, Ronald; Cohn, Stephen] Univ Texas Hlth Sci Ctr San Antonio, Div Trauma, San Antonio, TX 78229 USA	Lopez, P (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Div Trauma, San Antonio, TX 78229 USA.	lopez@uthscsa.edu					Ackland HM, 2007, SPINE, V32, P423, DOI 10.1097/01.brs.0000255096.52871.4e; Adams JM, 2006, AM SURGEON, V72, P101; Ajani AE, 1998, ANAESTH INTENS CARE, V26, P487, DOI 10.1177/0310057X9802600502; Barba CA, 2001, J TRAUMA, V51, P652, DOI 10.1097/00005373-200110000-00005; Como JJ, 2007, J TRAUMA, V63, P544, DOI 10.1097/TA.0b013e31812e51ae; Ghanta MK, 2002, AM SURGEON, V68, P563; Grossman MD, 1999, J TRAUMA, V47, P684, DOI 10.1097/00005373-199910000-00012; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Hogan GJ, 2005, RADIOLOGY, V237, P106, DOI 10.1148/radiol.2371040697; Horn EM, 2004, J NEUROSURG-SPINE, V1, P39, DOI 10.3171/spi.2004.1.1.0039; Menaker J, 2008, J TRAUMA, V64, P898, DOI 10.1097/TA.0b013e3181674675; Muchow RD, 2008, J TRAUMA, V64, P179, DOI 10.1097/01.ta.0000238664.74117.ac; Richards PJ, 2005, INJURY, V36, P248, DOI 10.1016/j.injury.2004.07.027; Stassen NA, 2006, J TRAUMA, V60, P171, DOI 10.1097/01.ta.0000197647.44202.de; Tomycz ND, 2008, J TRAUMA, V64, P1258, DOI 10.1097/TA.0b013e318166d2bd	15	24	25	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2008	196	6					857	862		10.1016/j.amjsurg.2008.07.040			6	Surgery	Surgery	388NG	WOS:000262025900015	19095100				2021-06-18	
J	Collins, RC; Kennedy, MC				Collins, Rose C.; Kennedy, Maureen C.			Serving families who have served: Providing family therapy and support in interdisciplinary polytrauma rehabilitation	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						traumatic brain injury; polytrauma; rehabilitation; family support; psychotherapy; family therapy	TRAUMATIC BRAIN-INJURY	Severe polytraumatic injuries sustained in combat operations require intensive rehabilitation and often result in complex, long-term disabilities. Understandably, these significant injuries have a substantial emotional impact on families. In this article, the authors discuss the importance of a family-centered care philosophy, the interdisciplinary team approach, the therapeutic milieu, and two family-systems treatments (medical family therapy and ambiguous loss theory). A case example illustrates the key processes of psychological support and therapy when treating polytrauma patients and their families. (c) 2008 Wiley Periodicals, Inc.	[Collins, Rose C.; Kennedy, Maureen C.] Vet Affairs Med Ctr, Polytrauma Rehabil Ctr, Minneapolis, MN 55417 USA	Collins, RC (corresponding author), Vet Affairs Med Ctr, Polytrauma Rehabil Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA.	Rose.Collins@va.gov					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; BLOCH DA, 1992, MEDICAL FAMILY THERA; Boss P., 2006, LOSS TRAUMA RESILIEN; Boss P., 1999, AMBIGUOUS LOSS LEARN; CAVALLO MM, 2005, TXB TRAUMATIC BRAIN, P533; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Hagen C., 1972, LEVELS COGNITIVE FUN; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; McDaniel S., 1992, MED FAMILY THERAPY B; MUIR C, 1990, REHABILITATION ADULT, P433; Pollack IW, 2005, TXB TRAUMATIC BRAIN, P641; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Williams J.M., 1991, HEAD INJURY FAMILY M, P81	18	24	24	0	1	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	AUG	2008	64	8					993	1003		10.1002/jclp.20515			11	Psychology, Clinical	Psychology	330ES	WOS:000257922900008	18553369				2021-06-18	
J	Statler, KD; Swank, S; Abildskov, T; Bigler, ED; White, HS				Statler, Kimberly D.; Swank, Seth; Abildskov, Tracy; Bigler, Erin D.; White, H. Steve			Traumatic brain injury during development reduces minimal clonic seizure thresholds at maturity	EPILEPSY RESEARCH			English	Article						head injury; controlled cortical impact; seizure threshold; developing rat; rodent	CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; EARLY POSTTRAUMATIC SEIZURES; HEAD-INJURY; STATUS EPILEPTICUS; EPILEPSY; CHILDREN; RAT; MICE; MODEL	Post-traumatic seizures affect 12-35% of children after traumatic brain injury (TBI) and are associated with worse cognitive and functional outcome, even after adjustment for severity of injury. Unfortunately, experimental models of pediatric post-traumatic epilepsy are lacking, and pathogenesis remains poorly understood. We have applied a standard model of TBI in immature rats to determine the effect of TBI on electroconvulsive seizure thresholds later in life. Mate rats underwent controlled cortical impact to left parietal cortex on post-natal day (PND) 16-18. Hindbrain, forebrain, and limbic seizure thresholds were assessed, respectively, by tonic hindlimb extension (THE), minimal. clonic, and partial psychomotor seizure responses during adolescence (PND 34-40) and at maturity (PND 60-63). Post-traumatic seizure thresholds were compared to those obtained in age- and litter-matched sham craniotomy and naive controls. TBI during immaturity had no clear effect on THE seizure thresholds. In contrast, TBI towered minimal. clonic seizure thresholds at maturity (p < 0.05 vs. sham or naive rats), but not during adolescence. Consequently, minimal clonic seizure thresholds increased with age for sham and naive rats but remained similar for TBI rats during adolescence and at maturity. TBI also tended to tower partial psychomotor seizure thresholds, which were determined only during adolescence (p < 0.1 vs. naive). Controlled cortical impact causes both focal cortical injury at the site of impact and ipsilateral hippocampal neuronal death. Since minimal. clonic seizures are mediated by the forebrain, partial psychomotor seizures by the limbic system, and THE seizures by the brainstem, the observed pattern of changes in post-traumatic seizure thresholds is not surprising. The apparent age-dependent effects of TBI, however, are unexpected and likely due to a combination of attenuated maturational increases and progressive epileptogenesis. Additional study is needed to delineate the relative contributions of these processes. Given the sustained reduction in post-traumatic minimal clonic seizure thresholds, controlled cortical impact may hold promise as an experimental model of pediatric post-traumatic epilepsy. (C) 2008 Elsevier B.V. All rights reserved.	[Statler, Kimberly D.; Swank, Seth] Univ Utah, Sch Med, Dept Pediat Crit Care, Salt Lake City, UT 84158 USA; [Bigler, Erin D.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84158 USA; [White, H. Steve] Univ Utah, Coll Pharm, Anticonvulsant Drug Dev Program, Salt Lake City, UT 84158 USA; [Statler, Kimberly D.; White, H. Steve] Univ Utah, Coll Pharm, Dept Pharmacol & Toxicol, Salt Lake City, UT 84158 USA; [Statler, Kimberly D.; Bigler, Erin D.; White, H. Steve] Univ Utah, Inst Brain, Salt Lake City, UT 84158 USA; [Abildskov, Tracy; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Abildskov, Tracy; Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA	Statler, KD (corresponding author), Univ Utah, Sch Med, Dept Pediat Crit Care, POB 581289,295 Chipeta Way, Salt Lake City, UT 84158 USA.	kim.statler@hsc.utah.edu		White, H. Steve/0000-0003-4550-4408	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12-HD 0141001]; Primary Children's Medical Center Foundation; University of Utah Children's Health Research Center; CHRCDA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER	We thank the National Institutes of Health (K12-HD 0141001), the Primary Children's Medical Center Foundation, and the University of Utah Children's Health Research Center for support of this project. Dr. Statler is a CHRCDA awardee, a Primary Children's Medical Center Foundation Scholar, and a University of Utah Pediatric Clinical and Translational Research Scholar.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barton ME, 2001, EPILEPSY RES, V47, P217, DOI 10.1016/S0920-1211(01)00302-3; Ben-Ari Y, 2006, LANCET NEUROL, V5, P1055, DOI 10.1016/S1474-4422(06)70626-3; BROWNING RA, 1981, EPILEPSIA, V22, P583, DOI 10.1111/j.1528-1157.1981.tb04130.x; BROWNING RA, 1985, FED PROC, V44, P2425; BROWNING RA, 1986, LIFE SCI, V39, P857, DOI 10.1016/0024-3205(86)90367-X; Cha BH, 2004, BRAIN DEV-JPN, V26, P394, DOI 10.1016/j.braindev.2003.12.006; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eells JB, 2004, NEUROSCIENCE, V123, P279, DOI 10.1016/j.neuroscience.2003.08.015; Finney DJ., 1971, PROBIT ANAL STAT TRE; FREEMAN FG, 1981, BRAIN RES BULL, V7, P629, DOI 10.1016/0361-9230(81)90109-X; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Golarai G, 2001, J NEUROSCI, V21, P8523; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hopkins RO, 1997, NEUROPSYCHOL REV, V7, P87, DOI 10.1023/B:NERV.0000005946.46506.a9; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; LOSCHER W, 1986, EPILEPSIA, V27, P657, DOI 10.1111/j.1528-1157.1986.tb03592.x; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nishi RA, 2007, J NEUROTRAUM, V24, P674, DOI 10.1089/neu.2006.0204; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Otto JE, 2004, EPILEPSIA, V45, P1009, DOI 10.1111/j.0013-9580.2004.65703.x; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pryce CR, 2003, NEUROSCI BIOBEHAV R, V27, P57, DOI 10.1016/S0149-7634(03)00009-5; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Schweinhardt P, 2003, J NEUROSCI METH, V129, P105, DOI 10.1016/S0165-0270(03)00192-4; SMOTHERMAN WP, 1983, DEV PSYCHOBIOL, V16, P169, DOI 10.1002/dev.420160303; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Toth Z, 1997, J NEUROSCI, V17, P8106; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WOODBURY LA, 1952, ARCH INT PHARMACOD T, V92, P97; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	42	24	24	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	AUG	2008	80	2-3					163	170		10.1016/j.eplepsyres.2008.04.001			8	Clinical Neurology	Neurosciences & Neurology	341QE	WOS:000258728900008	18490145	Green Accepted			2021-06-18	
J	Yang, J; Phillips, G; Xiang, H; Allareddy, V; Heiden, E; Peek-Asa, C				Yang, J.; Phillips, G.; Xiang, H.; Allareddy, V.; Heiden, E.; Peek-Asa, C.			Hospitalisations for sport-related concussions in US children aged 5 to 18 years during 2000-2004	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; CURRENT ISSUES; HEAD-INJURY; MANAGEMENT; RECOVERY; IMPACTS	Objectives: To describe patient and hospital characteristics associated with hospitalisation for a diagnosis of non-fatal sport-related concussion, and to determine factors associated with these hospitalisations. Methods: Children aged 5-18 years with a primary diagnosis of a sport-related concussion in the Nationwide Inpatient Sample (2000-2004) were identified. Length of stay and hospital charges for sport-related concussions were documented. Logistic regression was used to assess the association of patient or hospital characteristics with hospitalisations for sport-related concussion. Results: Between 2000 and 2004, a total of 755 non-fatal paediatric sport-related hospitalisations for concussion were identified. Nationwide, this represents 3712 hospitalisations and over US$29 million total hospital charges, with nearly US$6 million in total hospital charges per year. Over half (52.3%) of patients with concussion experienced loss of consciousness. Over 80% of the patients hospitalised for concussion received no procedures during their average 1.1 day (median 0.8 day) of hospital stay. Older age, but not gender, was associated with increased odds of sport-related hospitalisations for concussion. Non-teaching hospitals or hospitals in rural areas had significantly greater odds of admitting sport-related concussions versus other sport-related traumatic brain injuries compared with teaching or urban hospitals. Conclusions: Management of paediatric sport-related concussions varied, depending on the patient and the hospital. Better guidelines are needed for the identification and management of sport-related concussions. Standardised procedures for hospitals treating concussive injuries may also be warranted.	[Yang, J.; Heiden, E.] Univ Iowa, Dept Community & Behav Hlth, Coll Publ Hlth, Iowa City, IA 52242 USA; [Yang, J.; Allareddy, V.; Heiden, E.; Peek-Asa, C.] Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA 52242 USA; [Phillips, G.] Univ Iowa, Dept Pediat, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Xiang, H.] Ohio State Univ, Ctr Injury Res & Policy, Columbus Childrens Res Inst, Dept Pediat, Columbus, OH 43210 USA; [Phillips, G.; Peek-Asa, C.] Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA	Yang, J (corresponding author), Univ Iowa, Dept Community & Behav Hlth, Coll Publ Hlth, 200 Hawkins Dr,E236 GH, Iowa City, IA 52242 USA.	jingzhen-yang@uiowa.edu	Xiang, Huiyun/E-4335-2011; Yang, Jingzhen/N-4786-2014				Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; *BUR LAB STAT, 2005, INFL RAT INP SERV; *CDCP, 2007, MORTALITY MORBIDITY, V0056; *CDCP NAT CTR INJ, HEADS CONC YOUTH SPO; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P785; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Colorado Medical Society School and Sports Medicine Committee, 1990, COLO MED, V87, P4; Dempsey RL, 2005, INJURY PREV, V11, P91, DOI 10.1136/ip.2004.006205; DICK RW, 1999, NCAA INJURY SURVEILL; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Greenspan AI, 2006, J TRAUMA, V61, P1234, DOI 10.1097/01.ta.0000231558.71696.1a; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HCUP Databases, 2006, HEALTHC COST UT PROJ; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Maxwell RA, 2006, J TRAUMA, V60, P699; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mullins RJ, 2006, J TRAUMA, V60, P691, DOI 10.1097/01.ta.0000210454.92078.89; *NAT CTR INJ PREV, 1997, NEUROLOGY, V48, P581; *NAT FED STAT HIGH, 2004, NFHS 2003 04 HIGH SC; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Yang JZ, 2007, PEDIATRICS, V119, pE813, DOI 10.1542/peds.2006-2140; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	45	24	24	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2008	42	8					664	669		10.1136/bjsm.2007.040923			6	Sport Sciences	Sport Sciences	338UY	WOS:000258536100007	18216159				2021-06-18	
J	Jin, XY; Shen, G; Gao, F; Zheng, XS; Xu, XY; Shen, F; Li, G; Gong, JB; Wen, L; Yang, XF; Bie, XD				Jin, Xiaoying; Shen, Gang; Gao, Feng; Zheng, Xuesheng; Xu, Xiaoyan; Shen, Fang; Li, Gu; Gong, Jiangbiao; Wen, Liang; Yang, Xiaofeng; Bie, Xiaodong			Traditional Chinese drug ShuXueTong facilitates angiogenesis during wound healing following traumatic brain injury	JOURNAL OF ETHNOPHARMACOLOGY			English	Article						ShuXueTong; angiogenesis; traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; STEM-CELLS; INHIBITOR; SU5416; VEGF; MECHANISMS; RECEPTORS	Ethnopharmacological relevance: ShuXueTong injection is a traditional Chinese drug designed to treat the patients of "blood stasis and stagnation (yu xue yu zhi)", including subacute brain trauma. However, the mechanism of the therapeutic effect of ShuXueTong on traumatic brain injury is unknown yet. Aim of the study: We hypothesized that ShuXueTong may promote the brain wound healing by facilitating angiogenesis. Thus this study was designed to explore this hypothesis. Materials and methods: By means of microvessel count, Western blotting, immunocytochemistry, methyl thiazolyl tetrazolium assay and etc., the effect of ShuXueTong on the angiogenesis of brain wound was studied and then its influence on the VEGF/VEGFR-2 pathway were explored. Results: ShuXueTong facilitates angiogenesis in the brain wound and improves the neurological function of the traumatized rats. VEGF expression in the lesion was elevated due to ShuXueTong induction. The in vitro experiment revealed VEGFR-2 and SRF expression in the endothelial cells were enhanced when exposed to ShuXueTong for merely 1 d. Moreover, ShuXueTong promoted the endothelial cell proliferation via the VEGF/VEGFR-2 pathway. Conclusions: The mechanism of the therapeutic effect of ShuXueTong on traumatic brain injury lies at least partly in the enhanced angiogenesis in the lesion. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Jin, Xiaoying; Bie, Xiaodong] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Tradit Chinese Med, Hangzhou 310009, Zhejiang, Peoples R China; [Shen, Gang; Gao, Feng; Zheng, Xuesheng; Xu, Xiaoyan; Shen, Fang; Li, Gu; Gong, Jiangbiao; Wen, Liang; Yang, Xiaofeng] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China	Bie, XD (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Tradit Chinese Med, Hangzhou 310009, Zhejiang, Peoples R China.	xdbie@163.com	shen, fang/G-8439-2011				Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chai JY, 2004, FASEB J, V18, P1264, DOI 10.1096/fj.03-1232fje; CONSTANTINO RSS, 2007, EXP CELL RES, V313, P1561; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fong TAT, 1999, CANCER RES, V59, P99; Li Ai-hua, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P879; Li K. J., 2007, CLIN MED CHINA, V23, P7; LI ZG, 2003, Patent No. 031482813; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; Mendel DB, 2000, CLIN CANCER RES, V6, P4848; Neufeld G, 1999, FASEB J, V13, P9; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang X R, 1994, Zhongguo Zhong Xi Yi Jie He Za Zhi, V14, P349; Zhang Xuan, 2005, Zhongguo Zhong Yao Za Zhi, V30, P1950; Zheng XS, 2007, BRAIN INJURY, V21, P275, DOI 10.1080/02699050701225754; Zheng XS, 2007, CANCER RES, V67, P3691, DOI 10.1158/0008-5472.CAN-06-3912	20	24	27	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-8741			J ETHNOPHARMACOL	J. Ethnopharmacol.	MAY 22	2008	117	3					473	477		10.1016/j.jep.2008.02.033			5	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	310UN	WOS:000256556100014	18417308				2021-06-18	
J	VandeVord, PJ; Leung, LY; Hardy, W; Mason, M; Yang, KH; King, AI				VandeVord, Pamela J.; Leung, Lai Yee; Hardy, Warren; Mason, Matthew; Yang, King H.; King, Albert I.			Up-regulation of reactivity and survival genes in astrocytes after exposure to short duration overpressure	NEUROSCIENCE LETTERS			English	Article						astrocytes; overpressure; reactivity; survival; apoptosis; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; NEURONAL CELL-DEATH; INFLAMMATORY RESPONSE; NEUROTROPHIC FACTOR; CEREBRAL-CORTEX; KINASE PATHWAY; MESSENGER-RNA; EXPRESSION; RATS	Gurdjian et al. proposed decades ago that pressure gradients played a major factor in neuronal injury due to impact. In the late 1950s, their experiments on concussion demonstrated that the principal factor in the production of concussion in animals was the sudden increase of intracranial pressure accompanying head injury. They reported the increase in pressure severity correlated with an increase in 'altered cells' resulting in animal death. More recently, Hardy et al. (2006) demonstrated the presence of transient pressure pulses with impact conditions. These studies indicate that short duration overpressure should be further examined as a mechanism of traumatic brain injury (TBI). In the present study, we designed and fabricated a barochamber that simulated overpressure noted in various head injury studies. We tested the effect of overpressure on astrocytes. Expressions of apoptotic, reactivity and survival genes were examined at 24, 48 and 72 It post-overpressure exposure. At 24 h, we found elevated levels of reactivity and survival gene expression. By 48 h, a decreased expression of apoptotic genes was demonstrated. This study reinforces the hypothesis that transient pressure acts to instigate the cellular response displayed following TBI. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[VandeVord, Pamela J.; Leung, Lai Yee; Hardy, Warren; Mason, Matthew; Yang, King H.; King, Albert I.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA; [VandeVord, Pamela J.] John D Dingell VA Med Ctr, Res & Dev Serv, Detroit, MI 48201 USA	VandeVord, PJ (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48202 USA.	pvord@wayne.edu	VandeVord, Pamela/B-4606-2012; Leung, Lai Yee/H-8204-2013				Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; CHASON JL, 1957, EXP NEUROL, V16, P102; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Gurdjian E S, 1964, Clin Neurosurg, V12, P112; Hardy W.N., 2006, J BIOMECH, V39, pS155; Katano H, 2001, NEUROSCI LETT, V306, P101, DOI 10.1016/S0304-3940(01)01832-8; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; Otani N, 2007, J CLIN NEUROSCI, V14, P42, DOI 10.1016/j.jocn.2005.11.044; Penkowa M, 1999, GLIA, V25, P343; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Smith DH, 1999, J NEUROSCI, V19, P4263; Wen TC, 1998, J EXP MED, V188, P635, DOI 10.1084/jem.188.4.635; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje	32	24	26	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR	2008	434	3					247	252		10.1016/j.neulet.2008.01.056			6	Neurosciences	Neurosciences & Neurology	292YQ	WOS:000255302400002	18342445				2021-06-18	
J	Baker, AJ; Park, E; Hare, GMT; Liu, E; Sikich, N; Mazer, DC				Baker, Andrew J.; Park, Eugene; Hare, Greg M. T.; Liu, Elaine; Sikich, Nancy; Mazer, David C.			Effects of resuscitation fluid on neurologic physiology after cerebral trauma and hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						albumin; electrophysiology; fluid resuscitation; hemorrhage; TBI	EXPERIMENTAL BRAIN INJURY; HEAD-INJURY; TRANSMISSION DAMAGE; TISSUE OXYGEN; HUMAN ALBUMIN; BLOOD-FLOW; HEMODILUTION; RAT; ISCHEMIA; PRESSURE	Background: The current standard of care for fluid resuscitation of hemorrhagic hypotensive patients involves the use of crystalloid solutions. Traumatic brain injury (TBI) is often associated with hemorrhage and hypotension, which can contribute significantly to morbidity and mortality. Guidelines for the choice of fluid resuscitation and the use of red blood cell transfusions are not yet clear in the context of brain injury. Methods: Various fluid resuscitation strategies were evaluated in Sprague-Dawley rats using fresh blood, normal saline, hypertonic saline, and albumin fluid resuscitation protocols. Mean arterial blood pressure (MAP) and cerebral oximetry were assessed in hemorrhaged groups and the mean population spike amplitudes (PSA) from the hippocampus were examined in fluid percussion injured (FPI) animals subject to hemorrhage and fluid resuscitation. Results: MAP in control animals, hemorrhage and hemorrhage + albumin treated groups was 82.4 +/- 1.5 mm Hg, 55.7 +/- 1.5 mm Hg, and 97.0 +/- 3.4 mm Hg, respectively. Arterial PaO2 was higher in albumin-treated animals relative to other fluid alternatives. Regional tissue oxygen tension (PbrO2) levels in hemorrhaged animals reached significantly higher levels in albumin treated group compared with in normal saline and hypertonic saline (p < 0.001, p=0.034, respectively). After FPI+hemorrhage, PSA values in albuminresuscitated animals were significantly higher than in normal saline-resuscitated animals (p=0.012). Conclusions: The results of normal saline resuscitation, relative to other fluid alternatives, suggest that a re-evaluation of current treatment strategies in hemorrhagic hypotensive TBI patients is warranted. Albumin demonstrated the greatest beneficial effects on neurophysiology endpoints over crystalloid alternatives. These data suggests that albumin resuscitation may play an important role in the treatment of hemorrhagic hypotension and TBI.	[Baker, Andrew J.] Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.; Park, Eugene; Hare, Greg M. T.; Liu, Elaine; Sikich, Nancy; Mazer, David C.] St Michaels Hosp, Cara Phelan Ctr Trauma Res, Dept Anesthesia, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Hare, Greg M. T.] Univ Toronto, Dept Physiol, Toronto, ON, Canada	Baker, AJ (corresponding author), Cara Phelan Ctr Trauma Res, 7086 Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca		Mazer, Cyril David/0000-0003-2566-4308			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALDERSON P, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001208.PUB2; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP D; BAVETTA S, 1995, BRAIN INJURY, V9, P635, DOI 10.3109/02699059509008221; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; Berezina TL, 2002, J SURG RES, V102, P6, DOI 10.1006/jsre.2001.6306; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chorny I, 1999, J NEUROSURG ANESTH, V11, P273, DOI 10.1097/00008506-199910000-00008; COLE DJ, 1993, ANESTHESIOLOGY, V78, P335, DOI 10.1097/00000542-199302000-00018; COLE DJ, 1990, AM J PHYSIOL, V259, pH211; COLE DJ, 1990, STROKE, V21, P1333, DOI 10.1161/01.STR.21.9.1333; Cook D, 2004, NEW ENGL J MED, V350, P2294, DOI 10.1056/NEJMe048095; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Dings J, 1998, NEUROL RES, V20, pS71; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; EMLING RH, 1986, CURR STUD HEMATOL BL, P36; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fried E, 1995, J PHYSIOL-LONDON, V489, P557, DOI 10.1113/jphysiol.1995.sp021072; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOLT ME, 1984, BRIT J EXP PATHOL, V65, P231; KAUFMANN MA, 1995, J PHARMACOL EXP THER, V273, P855; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; Kramer MS, 1996, NEUROSURGERY, V38, P355, DOI 10.1097/00006123-199602000-00024; MATSUI T, 1993, NEUROSURGERY, V32, P79, DOI 10.1227/00006123-199301000-00012; MATSUI T, 1993, NEUROSURGERY, V33, P293, DOI 10.1227/00006123-199308000-00017; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; Nicholson JP, 2000, BRIT J ANAESTH, V85, P599, DOI 10.1093/bja/85.4.599; POOLE GV, 1986, CRIT CARE MED, V14, P629, DOI 10.1097/00003246-198607000-00009; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Shen H, 2002, ANESTHESIOLOGY, V96, P142, DOI 10.1097/00000542-200201000-00027; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tian GF, 2000, J NEUROPHYSIOL, V83, P1830; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; Traylor RJ, 1996, ANESTH ANALG, V83, P209, DOI 10.1097/00000539-199608000-00001; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vincent JL, 2004, CRIT CARE MED, V32, P2029, DOI 10.1097/01.CCM.0000142574.00425.E9; WEIL MH, 1979, CRIT CARE MED, V7, P113, DOI 10.1097/00003246-197903000-00006; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	59	24	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2					348	357		10.1097/01.ta.0000245973.71929.db			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	264KV	WOS:000253287100020	18301197				2021-06-18	
J	Schmitter-Edgecombe, M; Rueda, AD				Schmitter-Edgecombe, Maureen; Rueda, Alicia D.			Time estimation and episodic memory following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; DURATION JUDGMENTS; TEMPORAL-LOBE; ATTENTION; PERCEPTION; ORIENTATION; CLOCK	The ability to accurately estimate the passage of time plays an important role in helping to structure daily activities. In this study, we used a prospective verbal time estimation paradigm to investigate time perception in 27 moderate to severe traumatic brain injury (TBI) participants and 27 controls. Verbal time estimations were made for filled intervals both within (i.e., <30 s) and beyond the time frame of working memory. We found that the TBI participants exhibited normal or near-normal estimates of time passage for duration up to 25 s. In contrast, for durations that exceeded working memory, the TBI group perceived less time as having passed than actually had passed as the TBI group significantly underestimated time when compared to controls. This pattern of data was interpreted as being due to episodic memory dysfunction.	[Schmitter-Edgecombe, Maureen; Rueda, Alicia D.] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS47690] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047690] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bauer LO, 2001, DRUG ALCOHOL DEPEN, V63, P87, DOI 10.1016/S0376-8716(00)00195-2; Benton A., 1994, MULTILINGUAL APHASIA; Block, 1996, TIME INTERNAL CLOCKS, V115, P143, DOI DOI 10.1016/S0166-4115(96)80057-4; Block R. A., 1990, COGNITIVE MODELS PSY, P1; Block R.A., 1990, COGNITIVE MODELS PSY, P59; Block RA, 1998, PSYCHOL AGING, V13, P584, DOI 10.1037/0882-7974.13.4.584; Block RA, 1999, DEV REV, V19, P183, DOI 10.1006/drev.1998.0475; BROWN SW, 1985, PERCEPT PSYCHOPHYS, V38, P115, DOI 10.3758/BF03198848; Brown SW, 1997, PERCEPT PSYCHOPHYS, V59, P1118, DOI 10.3758/BF03205526; *CEDR CORP, 1999, SUPERLAB PRO BET VER; Chaston A, 2004, BRAIN COGNITION, V55, P286, DOI 10.1016/j.bandc.2004.02.013; CHURCH RM, 1984, ANN NY ACAD SCI, V423, P566, DOI 10.1111/j.1749-6632.1984.tb23459.x; COHEN BH, 2000, EXPLAINING PSYCHOL S; CURTON ED, 1974, J EXP PSYCHOL, V103, P861, DOI 10.1037/h0037352; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRAISSE P, 1984, ANNU REV PSYCHOL, V35, P1, DOI 10.1146/annurev.ps.35.020184.000245; GERMAN DJ, 1990, NATL COLL ED TEST AD; GIBBON J, 1984, ANN NY ACAD SCI, V423, P52, DOI 10.1111/j.1749-6632.1984.tb23417.x; Gunstad John, 2006, Journal of Integrative Neuroscience, V5, P75, DOI 10.1142/S0219635206001045; Harrington DL, 1998, J NEUROSCI, V18, P1085; HICKS RE, 1976, AM J PSYCHOL, V89, P719, DOI 10.2307/1421469; HICKS RE, 1976, AM J PSYCHOL, V89, P303, DOI 10.2307/1421413; HORNSTEI.AD, 1969, J EXP PSYCHOL, V79, P561, DOI 10.1037/h0026870; JONES MR, 1989, PSYCHOL REV, V96, P459, DOI 10.1037/0033-295X.96.3.459; KIELHOFNER G, 1977, AM J OCCUP THER, V31, P235; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kinsbourne M., 2000, NEUROBEHAV LANGUAGE, P315; Kinsbourne M, 1990, NEUROPSYCHOLOGICAL I, P319, DOI DOI 10.1017/CBO9780511665547.017; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; LEIGH G, 1976, PERCEPT MOTOR SKILL, V43, P899, DOI 10.2466/pms.1976.43.3.899; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lewis PA, 2006, BEHAV PROCESS, V71, P226, DOI 10.1016/j.beproc.2005.12.009; Majdan A, 1996, J CLIN EXP NEUROPSYC, V18, P416, DOI 10.1080/01688639608408998; Mangels JA, 1998, COGNITIVE BRAIN RES, V7, P15, DOI 10.1016/S0926-6410(98)00005-6; MARSHALL MJ, 1989, PERCEPT MOTOR SKILL, V69, P1159, DOI 10.2466/pms.1989.69.3f.1159; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MECK WH, 1984, BEHAV NEUROSCI, V98, P3, DOI 10.1037/0735-7044.98.1.3; Meck WH, 1996, COGNITIVE BRAIN RES, V3, P227, DOI 10.1016/0926-6410(96)00009-2; Meck WH, 2002, BRAIN COGNITION, V48, P195, DOI 10.1006/brcg.2001.1313; MEYERS CA, 1992, NEUROPSY NEUROPSY BE, V5, P28; Mimura M, 2000, J INT NEUROPSYCH SOC, V6, P517, DOI 10.1017/S1355617700655017; Morin C, 2005, COGNITIVE BRAIN RES, V22, P305, DOI 10.1016/j.cogbrainres.2004.09.001; Myers JL., 2003, RES DESIGN STAT ANAL; NICHELLI P, 1993, COGNITIVE BRAIN RES, V1, P87, DOI 10.1016/0926-6410(93)90014-V; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Perbal S, 2001, NEUROREPORT, V12, P939, DOI 10.1097/00001756-200104170-00015; Perbal S, 2000, NEUROCASE, V6, P347, DOI 10.1080/13554790008402782; POLYUKHOV AM, 1989, Z GERONTOL, V22, P79; Rammsayer T, 2001, PSYCHON B REV, V8, P270, DOI 10.3758/BF03196161; Rao SM, 2001, NAT NEUROSCI, V4, P317, DOI 10.1038/85191; RAO SM, 1984, ARCH NEUROL-CHICAGO, V41, P625, DOI 10.1001/archneur.1984.04210080033010; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RICHARDS W, 1973, ACTA PSYCHOL, V37, P279, DOI 10.1016/0001-6918(73)90020-6; SCHNEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; Seri Y, 2002, BRAIN COGNITION, V48, P553, DOI 10.1006/brcg.2001.1416; Sevigny MC, 2003, BRAIN COGNITION, V53, P351, DOI 10.1016/S0278-2626(03)00141-6; SHAW C, 1994, NEUROPSYCHOLOGIA, V32, P857, DOI 10.1016/0028-3932(94)90023-X; Smith A., 1991, SYMBOL DIGIT MODALIT; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; THOMAS EAC, 1975, PERCEPT PSYCHOPHYS, V17, P363, DOI 10.3758/BF03199347; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; VENABLE S D, 1991, Physical and Occupational Therapy in Geriatrics, V9, P31, DOI 10.1300/J148V09N03_04; Venneri A, 1998, BRAIN COGNITION, V37, P169; Wearden J. H, 2004, ACTA NEUROBIOLOGIAE, V64, P313; Wearden JH, 2003, TIME AND MIND II: INFORMATION PROCESSING PERSPECTIVES, P21; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS JM, 1989, J CLIN EXP NEUROPSYC, V11, P713, DOI 10.1080/01688638908400927; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Zachary R.A., 1991, SHIPLEY I LIVING SCA; Zakay D, 1997, CURR DIR PSYCHOL SCI, V6, P12, DOI 10.1111/1467-8721.ep11512604	76	24	24	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2008	30	2					212	223		10.1080/13803390701363803			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	264UY	WOS:000253317100010	18938673				2021-06-18	
J	Ahn, ES; Robertson, CL; Vereczk, V; Hoffman, GE; Fiskum, G				Ahn, Edward S.; Robertson, Courtney L.; Vereczk, Viktoria; Hoffman, Gloria E.; Fiskum, Gary			Normoxic ventilatory resuscitation following controlled cortical impact reduces peroxynitrite-mediated protein nitration in the hippocampus - Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						controlled cortical impact; free radical; hyperoxia; nitrotyrosine; reactive oxygen species; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FREE-RADICAL PRODUCTION; SEVERE HEAD-INJURY; RATS POSSIBLE ROLE; NORMOBARIC HYPEROXIA; TYROSINE NITRATION; INSPIRED OXYGEN; CEREBRAL METABOLISM; 100-PERCENT OXYGEN; LIPID-PEROXIDATION	Object. Ventilatory resuscitation with 100% O-2 after severe traumatic brain injury (TBI) raises concerns about the increased production of reactive oxygen species (ROS). The product of peroxynitrite-meditated tyrosine residue nitration, 3-nitrotyrosine (3-NT), is a marker for oxidative damage to proteins. The authors hypothesized that posttraumatic resuscitation with hyperoxia (100% fraction of inspired oxygen [FiO(2)] concentration) results in increased ROS-induced damage to proteins compared with resuscitation using normoxia (21% FiO(2) concentration). Methods. Male Sprague-Dawley rats underwent controlled cortical impact (CCI) injury and resuscitation with either normoxic or hyperoxic ventilation for I hour (5 rats per group). Twenty-four hours after injury, rat hippocampi were evaluated using 3-NT immunostaining. In a second experiment, animals similarly underwent CCI injury and normoxic or hyperoxic ventilation for 1 hour (4 rats per group). One week after injury, neuronal counts were performed after neuronal nuclei immunostaining. Results. The 3-NT staining was significantly increased in the hippocampi of the hyperoxic group. The normoxic group showed a 51.0% reduction of staining in the CA1 region compared with the hyperoxic group and a 50.8% reduction in the CA3 region (p < 0.05, both regions). There was no significant difference in staining between the injured normoxic group and sham-operated control groups. In the delayed analysis of neuronal survival (neuronal counts), there was no significant difference between the hyperoxic and normoxic groups. Conclusions. In this clinically relevant model of TBI, normoxic resuscitation significantly reduced oxidative damage to proteins compared with hyperoxic resuscitation. Neuronal counts showed no benefit from hyperoxic resuscitation. These findings indicate that hyperoxic ventilation in the early stages after severe TBI may exacerbate oxidative damage to proteins.	[Robertson, Courtney L.; Vereczk, Viktoria; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Anesthesiol Res Labs, Baltimore, MD 21201 USA; [Ahn, Edward S.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Robertson, Courtney L.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Hoffman, Gloria E.] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Anesthesiol Res Labs, 685 W Baltimore St,MSTF 5-34, Baltimore, MD 21201 USA.	gfisk001@umaryland.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS K08 42805] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805] Funding Source: NIH RePORTER		ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HOFFMAN GE, 1992, NEUROPROTOCOLS, V1, P52; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JACKSON RM, 1990, CLIN CHEST MED, V11, P73; JACOBSON I, 1964, SURG GYNECOL OBSTET, V119, P737; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; Liu YB, 1998, STROKE, V29, P1679, DOI 10.1161/01.STR.29.8.1679; Lorch Scott, 2002, Methods Mol Biol, V196, P247; Love S, 1999, BRAIN PATHOL, V9, P119; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; MICKEL HS, 1987, STROKE, V18, P426, DOI 10.1161/01.STR.18.2.426; Nakamura H, 2003, ACT NEUR S, V86, P309; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; SINGER MM, 1970, NEW ENGL J MED, V283, P1473, DOI 10.1056/NEJM197012312832701; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sukoff MH, 2001, J NEUROSURG, V95, P544; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; WATSON RE, 1986, PEPTIDES, V7, P155, DOI 10.1016/0196-9781(86)90076-8; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZWEMER CF, 1994, RESUSCITATION, V27, P159, DOI 10.1016/0300-9572(94)90009-4	50	24	25	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2008	108	1					124	131		10.3171/JNS/2008/108/01/0124			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	248AI	WOS:000252123300018	18173321				2021-06-18	
J	Baguley, IJ; Nott, MT; Slewa-Younan, S				Baguley, Ian J.; Nott, Melissa T.; Slewa-Younan, Shameran			Long-term mortality trends in functionally-dependent adults following severe traumatic-brain injury	BRAIN INJURY			English	Article						Mortality; life expectancy; brain injury; severe disability	SEVERE HEAD-INJURY; LOCKED-IN SYNDROME; LIFE EXPECTANCY; SURVIVAL; DEATH; POPULATION; CARE	Primary objective: To investigate mortality trends in functionally dependent adults following traumatic brain injury (TBI). Methods: Data for 966 consecutive admissions to a specialist TBI rehabilitation service were reviewed. Details for 69 subjects who were functionally dependent at rehabilitation discharge were cross-referenced against the State Government Death Register. The observed mortality rate was compared to an equivalent population sample derived from Australian Life Tables. Results: Twenty-five subjects (36%) were deceased at an average 10.5 years post-injury (SD 5 years; range 1.7-18.8 years). The observed numbers of deaths far exceeded the expected population figure (1.9) for the same period (1989-2007) yielding a standardized mortality rate of 13.2. Mortality trends suggested a bimodal distribution, with more deaths in the first 5 years post-injury followed by no further deaths until 9 years post-injury. Conclusions: Mortality in this functionally-dependent group was significantly associated with age, male sex and degree of disability at discharge. The bimodal distribution of mortality data suggests different contributory mechanisms to early vs. late mortality in this group.	[Baguley, Ian J.; Nott, Melissa T.; Slewa-Younan, Shameran] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia	Baguley, IJ (corresponding author), Brain Injury Rehabil Serv, Res Team Leader, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Nott, Melissa T/M-6778-2018; Baguley, Ian J/K-6878-2013	Nott, Melissa T/0000-0001-7088-5826; Baguley, Ian J/0000-0001-5650-3705			*AUSTR BUR STAT, 2005, 33020 AUSTR BUR STAT; Baguley I, 2000, BRAIN INJURY, V14, P505; BARNES MP, 2008, INT BRAIN INJURY ASS, P1; Brown AW, 2004, NEUROREHABILITATION, V19, P37; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; HAIG AJ, 1994, NEW ENGL J MED, V331, P1380; Haig AJ, 2008, ARCH PHYS MED REHAB, V89, P1005, DOI 10.1016/j.apmr.2008.03.005; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P403; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shavelle RM, 2007, BRAIN INJURY MED PRI, P247; Shavelle RM, 2008, ARCH PHYS MED REHAB, V89, P1005, DOI 10.1016/j.apmr.2008.03.004; Strauss D, 2004, NEUROREHABILITATION, V19, P257; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TATE R, 2003, BRAIN IMPAIR, V4, P82; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WHYTE J, 1994, NEW ENGL J MED, V331, P1381	28	24	25	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					919	925	PII 905450535	10.1080/02699050802448578			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900002	19005883				2021-06-18	
J	Boutin, D; Lassonde, M; Robert, M; Vanassing, P; Ellemberg, D				Boutin, David; Lassonde, Maryse; Robert, Manon; Vanassing, Phetsamone; Ellemberg, Dave			Neurophysiological assessment prior to and following sports-related concussion during childhood: A case study	NEUROCASE			English	Article						concussion; childhood; soccer; neurophysiology; neuropsychology	TRAUMATIC BRAIN-INJURY; SPECTRAL-ANALYSIS; NEUROPSYCHOLOGICAL IMPAIRMENT; HIGH-SCHOOL; CHILDREN; RECOVERY; IMPACT; RETURN; PLAY	The goal of this study was to measure the neurophysiological and cognitive functions of a sport-concussed child and to longitudinally assess the recovery pattern. An 8-year-old girl suffered a concussion while playing soccer. Visual evoked potentials (VEPs) were recorded at 7 weeks pre-injury and 24 h, 7, 22, 32 and 55 weeks post-injury. A neuropsychological assessment performed at 24 h post-injury reveals cognitive impairments, mainly attentional, that resolved within 22 weeks. VEPs and spectral analyses confirm the presence of cortical impairments up to 1 year post-injury, especially affecting vigilance and attention, which were reflected in school performance.	[Ellemberg, Dave] Univ Montreal, Dept Kinesiol, Montreal, PQ H3C 3J7, Canada; [Boutin, David; Lassonde, Maryse; Robert, Manon] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Boutin, David; Lassonde, Maryse; Robert, Manon; Ellemberg, Dave] Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ, Canada; [Lassonde, Maryse; Vanassing, Phetsamone; Ellemberg, Dave] Univ Hosp Ctr Mother Child Ste Justine, Res Ctr, Montreal, PQ, Canada	Ellemberg, D (corresponding author), Univ Montreal, Dept Kinesiol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	dave.ellemberg@umontreal.ca			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	This research was supported by a grant from the Canadian Institutes of Health Research (CIHR) Dave Ellemberg and Maryse Lassonde. Disclosure: The authors report no conflicts of interest.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bertrand O, 2000, INT J PSYCHOPHYSIOL, V38, P211, DOI 10.1016/S0167-8760(00)00166-5; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Csibra G, 2000, SCIENCE, V290, P1582, DOI 10.1126/science.290.5496.1582; Debener S, 2003, NEUROREPORT, V14, P683, DOI 10.1097/00001756-200304150-00005; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Fehr T, 2001, BIOL PSYCHIAT, V50, P108, DOI 10.1016/S0006-3223(01)01122-2; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FISCH BJ, 2000, FISCH SPEHLMANNS 3 R; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kelly JP, 1997, NEUROLOGY, V48, P581; KlOve H, 1963, MED CLIN N AM; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PAPATHANASOPOULOS P, 1994, EUR NEUROL, V34, P268, DOI 10.1159/000117054; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Pointinger H, 2002, BRAIN INJURY, V16, P799, DOI 10.1080/02699050210131911; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Smith A., 1982, SYMBOL DIGIT MODALIT; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P204	53	24	24	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase		2008	14	3					239	248		10.1080/13554790802247543			10	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	337RT	WOS:000258453900003	18654931				2021-06-18	
J	Grinkeviciute, DE; Kevalas, R; Matukevicius, A; Ragaisis, V; Tamasauskas, A				Grinkeviciute, Dovile Evalda; Kevalas, Rimantas; Matukevicius, Algimantas; Ragaisis, Vytautas; Tamasauskas, Arimantas			Significance of intracranial pressure and cerebral perfusion pressure in severe pediatric traumatic brain injury	MEDICINA-LITHUANIA			English	Article						cerebral perfusion pressure; intracranial pressure; decompressive craniotomy; severe head injury	EARLY DECOMPRESSIVE CRANIECTOMY; CRITICAL-CARE MANAGEMENT; CHILDREN; SURVIVAL; OUTCOMES; SYSTEM; AGE	The aim of the study was to evaluate outcome of children after severe traumatic brain injury treated according to intracranial pressure (ICP)-targeted protocol, to define threshold values of peak ICP and minimal cerebral perfusion pressure (CPP)for decompressive osteoplastic craniotomy, and to determine the relationship between ICR, CPP and long-term outcome in these children. All children admitted to Pediatric Intensive Care Unit of Kaunas University of Medicine Hospital after severe head injury from January 2004 to June 2006 and treated according to ICP-targeted protocol for the management of severe head trauma were prospectively included in the study. Raised ICP was defined as a level higher than 20 mmHg. Minimal CPP was considered to be at a level of 40 mmHg. Outcome was defined using Glasgow Outcome Scale (GOS) at discharge from the hospital and after 6 months. Forty-eight patients (32 boys and 16 girls) were included into the study. Favorable outcome (GOS score of 4 and 5) after 6 months was achieved in 43 (89.6%) cases. Mean peak ICP was 24.2 +/- 7.2 mmHg and mean minimal CPP - 53.1 +/- 14.7 mmHg. Decompressive craniotomy was performed in 13 cases. Threshold values of peak ICP and minimal CPP for decompressive craniotomy were 22.5 mmHg (area under the curve, 0.880) and 46.5 mmHg (area under the curve, 0.898), respectively. The differences in peak ICP and minimal CPP in groups of favorable and unfavorable outcomes were not statistically significant. Treating children after severe traumatic brain injury according to the ICP-targeted protocol for the management of severe pediatric traumatic brain injury resulted in a favorable long-term outcome.	[Grinkeviciute, Dovile Evalda; Kevalas, Rimantas] Kaunas Univ Med, Dept Children Dis, LT-50009 Kaunas, Lithuania; [Matukevicius, Algimantas; Tamasauskas, Arimantas] Kaunas Univ Med, Inst Biomed Res, Kaunas, Lithuania; [Ragaisis, Vytautas] Kaunas Univ Med, Dept Neurosurg, Kaunas, Lithuania	Grinkeviciute, DE (corresponding author), Kaunas Univ Med, Dept Children Dis, Eiveniu 2, LT-50009 Kaunas, Lithuania.	dovilgrin@hotmail.com					Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; CHAMBERS IR, 2003, NEUROSURG FOCUS, V15, P1; Chesnut RM, 2007, SURG CLIN N AM, V87, P119, DOI 10.1016/j.suc.2006.09.018; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Figaji AA, 2007, CHILD NERV SYST, V23, P1331, DOI 10.1007/s00381-007-0388-4; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Grinkeviciute Dovile, 2006, Medicina (Kaunas), V42, P278; Grinkeviciute DE, 2007, MEDICINA-LITHUANIA, V43, P861, DOI 10.3390/medicina43110111; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Jennett B, 2005, NEPAL J NEUROSCI, V2, P24; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Mayer SA, 2002, J INTENSIVE CARE MED, V17, P55, DOI 10.1046/j.1525-1489.2002.17201.x; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Mukherjee KK, 2006, SURG NEUROL, V66, P305, DOI 10.1016/j.surneu.2005.12.035; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Polin RS, 2003, CRIT CARE, V7, P409, DOI 10.1186/cc2370; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Reithmeier T, 2005, CHILD NERV SYST, V21, P249, DOI 10.1007/s00381-004-1044-x; ROWLANDS HE, 2007, PAEDIAT CHILD HLTH, V17, P82; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Simma B, 2002, INTENS CARE MED, V28, P1000, DOI 10.1007/s00134-002-1333-3; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; STARKUVIENE S, 2003, CAUSES CONSEQUENCES; TAPE TG, 2007, INTERPRETING DIAGNOS; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Willis CD, 2006, INJURY, V37, P1185, DOI 10.1016/j.injury.2006.07.011	33	24	27	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1010-660X	1648-9144		MEDICINA-LITHUANIA	Med. Lith.		2008	44	2					119	125		10.3390/medicina44020015			7	Medicine, General & Internal	General & Internal Medicine	280IO	WOS:000254419900004	18344664	Other Gold			2021-06-18	
J	Slewa-Younan, S; Baguley, IJ; Heriseanu, R; Cameron, ID; Pitsiavas, V; Mudaliar, Y; Nayyar, V				Slewa-Younan, Shameran; Baguley, Ian J.; Heriseanu, Roxana; Cameron, Ian D.; Pitsiavas, Vicki; Mudaliar, Yugan; Nayyar, Vineet			Do men and women differ in their course following traumatic brain injury? A preliminary prospective investigation of early outcome	BRAIN INJURY			English	Article						traumatic brain injury; sex differences; injury severity; outcome	GENDER-DIFFERENCES; SEX-DIFFERENCES; HEAD-INJURY; MORTALITY; PROGESTERONE; HORMONES; DAMAGE; WORSE	Primary objective: To examine the effect of a patient's sex on measures of outcome in a matched sample of patients admitted for acute traumatic brain injury (TBI). Research design: A prospective multi-centred group comparison study based in metropolitan Sydney, Australia. Methods and procedures: Data was collected on 25 women admitted for treatment following non-penetrating TBI. Forty-five men were then matched with regards to age and injury severity. All subjects met the study criteria of having a moderate-to-severe TBI and aged 50 years old or younger. Exclusion criteria included history of previous head injury, psychiatric disturbance and significant alcohol and/or substance abuse. Data included injury details and physiological and psychometric measures of outcome. Main outcomes and results: Women demonstrated better outcomes as indicated by their Glasgow Outcome Scale scores (adjusted for initial injury severity and age at injury odds ratio [OR] 4.2, 95% CI 1.4-12.7) and having shorter Length of Stay (adjusted OR 9.03, 95% CI 3.13-26.08). Conclusions: Understanding the presence of sex differences in outcome following TBI is an emerging area of research. This study indicated that, after matching for initial injury severity and age at injury, women with severe TBI demonstrate a better early outcome than men.	[Slewa-Younan, Shameran; Baguley, Ian J.; Heriseanu, Roxana] Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia; [Slewa-Younan, Shameran; Baguley, Ian J.; Cameron, Ian D.] Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Pitsiavas, Vicki] Westmead Hosp, Inst Clin Pathol & Med Res, Wentworthville, NSW 2145, Australia; [Mudaliar, Yugan; Nayyar, Vineet] Westmead Hosp, Dept Intens Care Med, Wentworthville, NSW 2145, Australia	Slewa-Younan, S (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	shameran@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Baguley I, 2000, BRAIN INJURY, V14, P505; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; GROSSMAN WF, 1994, J REPROD MED, V39, P738; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; Johannes CB, 1999, SEMIN REPROD ENDOCR, V17, P299; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Maas D, 1997, DRUG AGING, V11, P45, DOI 10.2165/00002512-199711010-00005; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; O'Connor KA, 2001, AM J HUM BIOL, V13, P465, DOI 10.1002/ajhb.1078; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tabachnick BG, 2013, USING MULTIVARIATE S; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; WRIGHT DW, ANN EMERGENCY MED, V49, P391	33	24	24	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					183	191		10.1080/02699050801888808			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600009	18240047				2021-06-18	
J	Tschuor, C; Asmis, LM; Lenzlinger, PM; Tanner, M; Harter, L; Keel, M; Stocker, R; Stover, JF				Tschuor, Christoph; Asmis, Lars M.; Lenzlinger, Philipp M.; Tanner, Martina; Haerter, Luc; Keel, Marius; Stocker, Reto; Stover, John F.			In vitro norepinephrine significantly activates isolated platelets from healthy volunteers and critically ill patients following severe traumatic brain injury	CRITICAL CARE			English	Article							HYDROXYETHYL STARCH SOLUTIONS; P-SELECTIN EXPRESSION; HEMODYNAMIC DEPRESSION; GLUTAMATE UPTAKE; BLOOD-PLATELETS; HEAD-INJURY; VIVO; INFLAMMATION; MECHANISMS; RELEASE	Introduction Norepinephrine, regularly used to increase systemic arterial blood pressure and thus improve cerebral perfusion following severe traumatic brain injury (TBI), may activate platelets. This, in turn, could promote microthrombosis formation and induce additional brain damage. Methods The objective of this study was to investigate the influence of norepinephrine on platelets isolated from healthy volunteers and TBI patients during the first two post-traumatic weeks. A total of 18 female and 18 male healthy volunteers of different age groups were recruited, while 11 critically ill TBI patients admitted consecutively to our intensive care unit were studied. Arterial and jugular venous platelets were isolated from norepinephrine-receiving TBI patients; peripheral venous platelets were studied in healthy volunteers. Concentration-dependent functional alterations of isolated platelets were analyzed by flow cytometry, assessing changes in surface P-selectin expression and platelet-derived microparticles before and after in vitro stimulation with norepinephrine ranging from 10 nM to 100 mu M. The thrombin receptor-activating peptide (TRAP) served as a positive control. Results During the first week following TBI, norepinephrine-mediated stimulation of isolated platelets was significantly reduced compared with volunteers (control). In the second week, the number of P-selectin-and microparticle-positive platelets was significantly decreased by 60% compared with the first week and compared with volunteers. This, however, was associated with a significantly increased susceptibility to norepinephrine-mediated stimulation, exceeding changes observed in volunteers and TBI patients during the first week. This pronounced norepinephrine-induced responsiveness coincided with increased arterio-jugular venous difference in platelets, reflecting intracerebral adherence and signs of cerebral deterioration reflected by elevated intracranial pressure and reduced jugular venous oxygen saturation. Conclusion Clinically infused norepinephrine might influence platelets, possibly promoting microthrombosis formation. In vitro stimulation revealed a concentration-and time-dependent differential level of norepinephrine-mediated platelet activation, possibly reflecting changes in receptor expression and function. Whether norepinephrine should be avoided in the second post-traumatic week and whether norepinephrine-stimulated platelets might induce additional brain damage warrant further investigations.	[Tschuor, Christoph; Tanner, Martina; Stocker, Reto; Stover, John F.] Univ Zurich Hosp, Surg Intens Care Med, CH-8091 Zurich, Switzerland; [Asmis, Lars M.] Univ Zurich Hosp, Inst Clin Hematol, CH-8091 Zurich, Switzerland; [Lenzlinger, Philipp M.; Haerter, Luc; Keel, Marius] Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland	Stover, JF (corresponding author), Univ Zurich Hosp, Surg Intens Care Med, Raemistr 100, CH-8091 Zurich, Switzerland.	john.stover@access.unizh.ch	Asmis, Lars M/H-4011-2019				Akkerman JWN, 2006, SEMIN THROMB HEMOST, V32, P295, DOI 10.1055/s-2006-939442; Aliprandi A, 2005, J CEREBR BLOOD F MET, V25, P513, DOI 10.1038/sj.jcbfm.9600039; Chen G, 2006, ACTA ANAESTH SCAND, V50, P1089, DOI 10.1111/j.1399-6576.2006.01138.x; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; DEIGHTON NM, 1988, J CARDIOVASC PHARM, V12, P332, DOI 10.1097/00005344-198809000-00011; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Gambim MH, 2007, CRIT CARE, V11, DOI 10.1186/cc6133; Gries A, 2001, ACTA ANAESTH SCAND, V45, P449, DOI 10.1034/j.1399-6576.2001.045004449.x; HAMILTON CA, 1987, N-S ARCH PHARMACOL, V335, P534; Hikasa Y, 1998, FUNDAM CLIN PHARM, V12, P498, DOI 10.1111/j.1472-8206.1998.tb00978.x; HOFFMAN B B, 1990, P187; HOLLISTER AS, 1983, J CLIN INVEST, V72, P1498, DOI 10.1172/JCI111106; Holme PA, 1997, ARTERIOSCL THROM VAS, V17, P646, DOI 10.1161/01.ATV.17.4.646; Hsiao G, 2004, EUR J PHARMACOL, V487, P159, DOI 10.1016/j.ejphar.2004.01.026; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Johnston AJ, 2004, INTENS CARE MED, V30, P45, DOI 10.1007/s00134-003-2032-4; JONES CR, 1986, CLIN SCI, V70, P147, DOI 10.1042/cs0700147; Jurk K, 2005, SEMIN THROMB HEMOST, V31, P381, DOI 10.1055/s-2005-916671; Kalsch T, 2007, BASIC RES CARDIOL, V102, P460, DOI 10.1007/s00395-007-0667-y; Kaushansky K, 2005, J CLIN INVEST, V115, P3339, DOI 10.1172/JCI26674; Klinger MHF, 2002, J INTERF CYTOK RES, V22, P913, DOI 10.1089/10799900260286623; LARSSON PT, 1994, CIRCULATION, V89, P1951, DOI 10.1161/01.CIR.89.5.1951; Leytin V, 2002, CRIT CARE MED, V30, P2771, DOI 10.1097/00003246-200212000-00025; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lupia E, 2006, J AM COLL CARDIOL, V48, P2195, DOI 10.1016/j.jacc.2006.04.106; Maeda T, 1997, ACT NEUR S, V70, P102; Mathew JP, 2006, ANN THORAC SURG, V81, P1644, DOI 10.1016/j.athoracsur.2005.12.070; Merten M, 2000, CIRCULATION, V102, P1931, DOI 10.1161/01.CIR.102.16.1931; Michelson AD, 2000, METHODS, V21, P259, DOI 10.1006/meth.2000.1006; Michelson AD, 1996, P NATL ACAD SCI USA, V93, P11877, DOI 10.1073/pnas.93.21.11877; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Offermanns S, 2006, CIRC RES, V99, P1293, DOI 10.1161/01.RES.0000251742.71301.16; Rainesalo S, 2003, NEUROCHEM INT, V43, P389, DOI 10.1016/S0197-0186(03)00026-3; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; SEGAWA H, 1981, ARCH NEUROL-CHICAGO, V38, P265, DOI 10.1001/archneur.1981.00510050031002; Siegel-Axel DI, 2007, SEMIN THROMB HEMOST, V33, P128, DOI 10.1055/s-2007-969025; Thaler U, 2005, ANAESTHESIA, V60, P554, DOI 10.1111/j.1365-2044.2005.04184.x; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tsai CS, 2004, EUR J ANAESTH, V21, P871, DOI 10.1017/S0265021504000213; Vaccaro M, 2007, CEPHALALGIA, V27, P35, DOI 10.1111/j.1468-2982.2006.01234.x; von Hundelshausen P, 2007, CIRC RES, V100, P27, DOI 10.1161/01.RES.0000252802.25497.b7; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005	44	24	27	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	3							R80	10.1186/cc6931			12	Critical Care Medicine	General & Internal Medicine	326CK	WOS:000257635300019	18564410	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Winqvist, S; Luukinen, H; Jokelainen, J; Lehtilahti, M; Nayha, S; Hillbom, M				Winqvist, Satu; Luukinen, Heikki; Jokelainen, Jari; Lehtilahti, Maria; Nayha, Simo; Hillbom, Matti			Recurrent traumatic brain injury is predicted by the index injury occurring under the influence of alcohol	BRAIN INJURY			English	Article						recurrent traumatic brain injury; alcohol drinking; adolescents; young adults	HEAD-INJURY; DRINKING; RISK; POPULATION; EPIDEMIOLOGY; CONSUMPTION; CONCUSSION; PATTERNS; TRENDS; ONSET	Background: Little is known of the role of alcohol intoxication as a risk factor for recurrent traumatic brain injuries (TBI). This study was a population-based longitudinal study to investigate this problem. Methods: The record linkage technique was used and data gathered from the Finnish Hospital Discharge Register, hospital records and by a questionnaire of family characteristics regarding the 12 058 subjects forming the Northern Finland Birth Cohort of 1966. Excluded were TBI subjects injured before the age of 12 years. Results: Of the 236 patients who had survived their first (mainly mild) TBI, 21 had had a recurrent TBI and three of them two recurrent TBIs during the follow-up period (from 1978-2000). An alcohol-related first injury (RR 4.41, 95% CI 1.53-12.70) and urban place of birth (RR 4.39, 95% CI 1.68-11.48) were significant independent predictors of recurrent TBI. A significant positive correlation between the first and recurrent TBIs with respect to alcohol involvement (rs = 0.61, p = 0.003) was observed. Conclusions: A first TBI related to alcohol drinking is predictive of recurrent TBI, which will often similarly be alcohol-related. The risk of recurrent injury seems to extend over several years after the first TBI. To prevent recurrence, efforts should be made to identify those with an alcohol-related first TBI. A brief intervention focused on drinking habits is needed as an immediate preventive measure.	[Winqvist, Satu; Lehtilahti, Maria; Hillbom, Matti] Oulu Univ Hosp, Dept Neurol, FIN-90029 Oys, Finland; [Winqvist, Satu; Lehtilahti, Maria; Hillbom, Matti] Univ Oulu, Dept Neurol, Oulu, Finland; [Luukinen, Heikki; Jokelainen, Jari; Nayha, Simo] Univ Oulu, Dept Publ Hlth Sci & Gen Practice, Oulu, Finland; [Luukinen, Heikki; Jokelainen, Jari; Nayha, Simo] Oulu Univ Hosp, Unit Gen Practice, FIN-90029 Oys, Finland	Winqvist, S (corresponding author), Oulu Univ Hosp, Dept Neurol, FIN-90029 Oys, Finland.	satu.winqvist@oulu.fi		Jokelainen, Jari/0000-0003-4629-0560	Neurology Foundation; Maire Taponen Foundation ( Finland)	This research was supported by the Neurology Foundation and Maire Taponen Foundation ( Finland).	ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BLONDELL RD, 2005, COMPREHENSIVE HDB AL, P321; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P221; Donovan JE, 2007, PREV SCI, V8, P192, DOI 10.1007/s11121-007-0072-7; Drubach D A, 1993, Md Med J, V42, P989; Dunn C, 2003, J TRAUMA, V54, P707, DOI 10.1097/01.TA.0000030625.63338.B2; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; Hingson RW, 2000, JAMA-J AM MED ASSOC, V284, P1527, DOI 10.1001/jama.284.12.1527; HONKANEN R, 1976, ANN CHIR GYNAECOL FE, V65, P287; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; Kraus JF, 1993, HEAD INJURY, P1; LAMMINPAA A, 1990, ACTA PSYCHIAT SCAND, V81, P468, DOI 10.1111/j.1600-0447.1990.tb05483.x; Lintonen T, 2000, HEALTH EDUC RES, V15, P261, DOI 10.1093/her/15.3.261; MAIO RF, 1994, ALCOHOL CLIN EXP RES, V18, P261, DOI 10.1111/j.1530-0277.1994.tb00011.x; McLeod R, 1999, ADDICTION, V94, P1719, DOI 10.1046/j.1360-0443.1999.941117199.x; Pitkanen T, 2005, ADDICTION, V100, P652, DOI 10.1111/j.1360-0443.2005.01053.x; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Vinson DC, 2003, J STUD ALCOHOL, V64, P358, DOI 10.15288/jsa.2003.64.358; Watt K, 2004, ADDICTION, V99, P1262, DOI 10.1111/j.1360-0443.2004.00823.x; WINQVIST S, 2006, J ADOLESCENCE HLTH, V39, P275; Winter T, 2002, ALCOHOL ALCOHOLISM, V37, P330, DOI 10.1093/alcalc/37.4.330; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	32	24	24	0	5	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	10					780	785		10.1080/02699050802339397			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	347MJ	WOS:000259145400008	18787988				2021-06-18	
J	Srinivasan, S; Lim, CCT; Thirugnanam, U				Srinivasan, Sheila; Lim, C. C. Tchoyoson; Thirugnanam, Umapathi			Paroxysmal autonomic instability with dystonia	CLINICAL AUTONOMIC RESEARCH			English	Article						dysautonomia; PAID syndrome; diencephalic seizures	TRAUMATIC BRAIN-INJURY; DIENCEPHALIC SEIZURES; SYMPATHETIC STORMS; CORPUS-CALLOSUM; EPILEPSY; DYSAUTONOMIA; HYPERTHERMIA; HYPOTHERMIA; AGENESIS	Paroxysmal autonomic instability with dystonia, an under-recognized and poorly understood phenomenon of episodic central dysautonomia is associated with various cerebral insults. Treatment options include benzodiazepines, opioids, and gabapentin. Using an illustrative case, we discuss presentation, pathomechanisms, and management of this condition.	[Srinivasan, Sheila; Lim, C. C. Tchoyoson; Thirugnanam, Umapathi] Natl Inst Neurosci, Dept Neuroradiol, Singapore 308433, Singapore; [Lim, C. C. Tchoyoson] Natl Univ Singapore, Dept Diagnost Imaging, Singapore 117548, Singapore	Srinivasan, S (corresponding author), Natl Inst Neurosci, Dept Neuroradiol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	sheila_srinivasan@nni.com.sg		Lim, CC Tchoyoson/0000-0001-9355-6988			Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baumgartner C, 2001, EPILEPTIC DISORD, V3, P103; Benarroch E. E., 1997, CLIN AUTONOMIC DISOR, P17; BENARROCH EE, 1997, CLIN AUTONOMIC DISOR, P421; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; COLICE GL, 1984, AM REV RESPIR DIS, V130, P941; Diesing TS, 2006, MOVEMENT DISORD, V21, P868, DOI 10.1002/mds.20831; FEUERMAN T, 1988, J NEUROSURG, V68, P297, DOI 10.3171/jns.1988.68.2.0297; FOX RH, 1973, BRIT MED J, V2, P693, DOI 10.1136/bmj.2.5868.693; GIROUD M, 1988, CHILD NERV SYST, V4, P252, DOI 10.1007/BF00270925; Goh KYC, 1999, PEDIATR NEUROL, V21, P742, DOI 10.1016/S0887-8994(99)00069-7; HIRAYAMA K, 1994, ARCH NEUROL-CHICAGO, V51, P494, DOI 10.1001/archneur.1994.00540170070018; Penfield W, 1929, ARCH NEURO PSYCHIATR, V22, P358, DOI 10.1001/archneurpsyc.1929.02220020174010; Rey M, 2005, J CARDIOTHOR VASC AN, V19, P654, DOI 10.1053/j.jvca.2005.07.008; ROPEER AH, 1997, CLIN AUTONOMIC DISOR, P791; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SHAPIRO WR, 1969, BRAIN, V92, P423, DOI 10.1093/brain/92.2.423; SPYER KM, 1999, AUTONOMIC FAILURE TX, P46; TALMAN WT, 1985, ANN NEUROL, V18, P1, DOI 10.1002/ana.410180102; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698	23	24	28	1	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0959-9851			CLIN AUTON RES	Clin. Auton. Res.	DEC	2007	17	6					378	381		10.1007/s10286-007-0428-x			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	241FC	WOS:000251641300009	17636370				2021-06-18	
J	Sosnoff, JJ; Broglio, SP; Hillman, CH; Ferrara, MS				Sosnoff, Jacob J.; Broglio, Steven P.; Hillman, Charles H.; Ferrara, Michael S.			Concussion does not impact intraindividual response time variability	NEUROPSYCHOLOGY			English	Article						response time; response variability; mild traumatic brain injury; concussion resolution index	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; RECOVERY; PERFORMANCE; COGNITION; SYMPTOMS; TRACKING; DEFICITS	This investigation examined the effect of concussion on intraindividual variability in 5 processing speed tasks. Forty-four adults, including 22 concussed and 22 healthy age- and gender-matched participants, completed the Headminder Concussion Resolution Index (D. M. Erlanger. D. J. Feldman, K. C. Kutner, & M. McCrea, 2001) twice. The test consists of a series of tasks including 25 trials of simple response time task, 70 trials of cued response time task (CURT), 60 trials each for 2 visual recognition tasks, and 30 trials of symbol scanning task. Concussed participants completed a preinjury baseline assessment and were retested within 48 hours of injury diagnosis. The nonconcussed participants were retested 45 days after initial assessment. Average response time (RT). standard deviation, and response accuracy were calculated for each individual. Overall, concussed individuals had increased RTs across all tasks and were less accurate in the CURT. RT variability for all tasks was elevated in concussed individuals, but controlling for mean RT at follow-up eliminated group differences. These findings indicate that response-time-variability increases in concussed individuals are proportional to processing-time increases. As Such. RT variability is not a unique identifier of cognitive dysfunction following concussion. These results highlight that transient brain injury has significantly different neurobiological consequences than chronic conditions have.	Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA	Sosnoff, JJ (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 s Goodwin Ave,207 Freer Hall, Urbana, IL 61801 USA.	jsosnoff@uiuc.edu	Hillman, Charles/A-4479-2009; Hillman, Charles/AAD-4828-2019; Sosnoff, Jacob/P-3397-2019	Sosnoff, Jacob/0000-0002-0286-9207; Hillman, Charles/0000-0002-3722-5612			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crawford JR, 2006, COGN NEUROPSYCHOL, V23, P877, DOI 10.1080/02643290500538372; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, 2001, CONCUSSION RESOLUTIO; Finkelstein EA., 2006, INCIDENCE EC BURDEN; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hausdorff JM, 2006, EXP AGING RES, V32, P411, DOI 10.1080/03610730600875817; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hultsch D.F., 2004, NEW FRONTIERS COGNIT, P65, DOI DOI 10.1093/ACPROF:OSO/9780198525691.003.0004; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; MacDonald SWS, 2006, TRENDS NEUROSCI, V29, P474, DOI 10.1016/j.tins.2006.06.011; MacDonald SWS, 2003, PSYCHOL AGING, V18, P510, DOI 10.1037/0882-7974.18.3.510; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; NORMAN DA, 1986, CONSCIOUSNESS SELFRE; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stuss DT, 2005, NEUROPSYCHOLOGIA, V43, P396, DOI 10.1016/j.neuropsychologia.2004.06.010; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	38	24	24	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	NOV	2007	21	6					796	802		10.1037/0894-4105.21.6.796			7	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	226EK	WOS:000250570100017	17983293				2021-06-18	
J	Mitchell, P; Gregson, BA; Vindlacheruvu, RR; Mendelow, AD				Mitchell, Patrick; Gregson, Barbara A.; Vindlacheruvu, Raghu R.; Mendelow, A. David			Surgical options in ICH including decompressive craniectomy	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						intracerebral haemorrhage; decompressive craniectomy; ictoliaemorrhagic lesions; surgery	CEREBRAL ARTERIOVENOUS-MALFORMATIONS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; PROSPECTIVE RANDOMIZED TRIAL; GAMMA-KNIFE RADIOSURGERY; HIPPEL-LINDAU-DISEASE; NATURAL-HISTORY; CAVERNOUS MALFORMATIONS	Intracerebral haemorrhage (ICH) accounts for 15 to 20% of strokes. The condition carries a higher morbidity and mortality than occlusive stroke. Despite considerable research effort, no therapeutic modality either medical or surgical has emerged with clear evidence of benefit other than in rare aneurysmal cases. Intracerebral haemorrhages can be divided into those that arise from pre-existing macroscopic vascular lesions-so called "ictohaemorrhagic lesions", and those that do not; the latter being the commoner. Most of the research that has been done on the benefits of surgery has been in this latter group. Trial data available to date precludes a major benefit from surgical evacuation in a large proportion of cases however there are hypotheses of benefit still under investigation, specifically superficial lobar ICH treated by open surgical evacuation, deeper ICH treated with minimally invasive surgical techniques, and decompressive craniectomy. When an ICH arises from an ictohaemorrhagic lesion, therapy has two goals: to treat the effects of the acute haemorrhage and to prevent a recurrence. Three modalities are available for treating lesions to prevent recurrence: stereotactic radiosurgery, endovascular embolisation, and open surgical resection. As with ICH without an underlying lesion there is no evidence to support surgical removal of the haemorrhage in most cases. An important exception is ICHs arising from intracranial aneurysms where there is good evidence to support evacuation of the haematoma as well as repair of the aneurysm. (C) 2007 Elsevier B.V All rights reserved.	Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Mitchell, P (corresponding author), Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	patrick.mitchell@ncl.ac.uk		Gregson, Barbara/0000-0003-4868-9137	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0501444] Funding Source: Medline		Andaluz N, 2002, NEUROSURG CLIN N AM, V13, P385, DOI 10.1016/S1042-3680(02)00006-2; AUER LM, 1989, J NEUROSURG, V70, P530, DOI 10.3171/jns.1989.70.4.0530; BATJER HH, 1990, ARCH NEUROL-CHICAGO, V47, P1103, DOI 10.1001/archneur.1990.00530100071015; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Brown RD, 1996, J NEUROSURG, V85, P29, DOI 10.3171/jns.1996.85.1.0029; BROWN RD, 1988, J NEUROSURG, V68, P352, DOI 10.3171/jns.1988.68.3.0352; Bullock R, 1984, Neurol Res, V6, P184; CHEN X, 1992, ACTA ACAD MED SHANGH, V19, P237; Chen X-C, 2001, CHIN J CLIN NEUROSCI, V4, P365; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1; D'Ambrosio AL, 2005, NEUROSURGERY, V56, P12, DOI 10.1227/01.NEU.0000144820.38439.63; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Detwiler PW, 1998, J NEUROSURG, V89, P167; Ellis TL, 1998, J NEUROSURG, V89, P104, DOI 10.3171/jns.1998.89.1.0104; Figueroa BE, 1998, STROKE, V29, P1202, DOI 10.1161/01.STR.29.6.1202; FOURNIER D, 1991, J NEUROSURG, V75, P228, DOI 10.3171/jns.1991.75.2.0228; FRIEDMAN WA, 1995, J NEUROSURG, V82, P180, DOI 10.3171/jns.1995.82.2.0180; Glasker S, 2005, NEUROSURGERY, V57, P71, DOI 10.1227/01.NEU.0000163250.71951.18; GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18; HAMILTON MG, 1994, NEUROSURGERY, V34, P2; Hattori N, 2004, J NEUROSURG, V101, P417, DOI 10.3171/jns.2004.101.3.0417; HEISKANEN O, 1988, ACTA NEUROCHIR, V90, P81, DOI 10.1007/BF01560559; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Henkes H, 1998, NEUROL RES, V20, P479; HEROS RC, 1990, NEUROSURGERY, V26, P570, DOI 10.1227/00006123-199004000-00003; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Hofmeijer J, 2003, Ned Tijdschr Geneeskd, V147, P2594; Hosseini H, 2003, CEREBROVASC DIS, V16S$, P57; HOUNSFIELD GN, 1980, MED PHYS, V7, P283, DOI 10.1118/1.594709; Hutchinson PJ, 2005, ACTA NEUROCHIR, V147, P1, DOI 10.1007/s00701-004-0400-7; JUVELA S, 1989, J NEUROSURG, V70, P755, DOI 10.3171/jns.1989.70.5.0755; KADER A, 1994, NEUROSURGERY, V34, P801, DOI 10.1227/00006123-199405000-00003; Karlsson B, 2001, INT J RADIAT ONCOL, V49, P1045, DOI 10.1016/S0360-3016(00)01432-2; Kato M, 2005, J NEURO-ONCOL, V72, P267, DOI 10.1007/s11060-004-2244-7; Kato Y, 1997, NEUROL RES, V19, P117; Kirollos RW, 2001, NEUROSURGERY, V49, P1378, DOI 10.1097/00006123-200112000-00015; KONDZIOLKA D, 1995, J NEUROSURG, V83, P825, DOI 10.3171/jns.1995.83.5.0825; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; Kwon Y, 2000, J NEUROSURG, V93, P104, DOI 10.3171/jns.2000.93.supplement_3.0104; Liu HB, 2003, J INCL PHENOM MACRO, V45, P9, DOI 10.1023/A:1023092402944; LUNSFORD LD, 1991, J NEUROSURG, V75, P512, DOI 10.3171/jns.1991.75.4.0512; Makino H, 1979, Acta Neurochir Suppl (Wien), V28, P193; MARAIRE JN, 1995, NEUROSURGERY, V37, P591, DOI 10.1227/00006123-199510000-00001; Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7; MATHEW P, 1995, J NEUROL NEUROSUR PS, V59, P287, DOI 10.1136/jnnp.59.3.287; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MCKISSOCK W, 1961, LANCET, V2, P221; Mendelow A D, 1984, Neurol Res, V6, P189; Mendelow AD, 2005, LANCET, V365, P387; Mitchell P, 2000, BRIT J NEUROSURG, V14, P96; Miyamoto S, 2000, NEUROSURGERY, V46, P589, DOI 10.1097/00006123-200003000-00013; Miyawaki L, 1999, INT J RADIAT ONCOL, V44, P1089, DOI 10.1016/S0360-3016(99)00102-9; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Morgenstern LB, 1998, NEUROLOGY, V51, P1359, DOI 10.1212/WNL.51.5.1359; Munch E, 2000, NEUROSURGERY, V47, P315; Naff NJ, 2004, NEUROSURGERY, V54, P577, DOI 10.1227/01.NEU.0000108422.10842.60; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; NEHLS DG, 1990, NEUROSURGERY, V27, P674, DOI 10.1227/00006123-199011000-00002; Niemann DB, 2003, J NEUROSURG, V99, P843, DOI 10.3171/jns.2003.99.5.0843; *NOV NORD, 2007, STOCK MARK ANN; ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387; PORTER LP, 1999, SPUD TOPICS, V44, P2; Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190; Porter RW, 1999, J NEUROSURG, V90, P50, DOI 10.3171/jns.1999.90.1.0050; Schaller C, 1998, J NEUROL NEUROSUR PS, V65, P547, DOI 10.1136/jnnp.65.4.547; SISTI MB, 1993, J NEUROSURG, V79, P653, DOI 10.3171/jns.1993.79.5.0653; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Spetzler R F, 1978, Clin Neurosurg, V25, P651; Steiger HJ, 2005, ACT NEUR S, V94, P115; STEINER L, 1992, J NEUROSURG, V77, P1, DOI 10.3171/jns.1992.77.1.0001; TAPANINAHO A, 1988, ACTA NEUROCHIR, V91, P21, DOI 10.1007/BF01400522; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Taylor CL, 2004, J NEUROSURG, V100, P810, DOI 10.3171/jns.2004.100.5.0810; Teernstra OPM, 2003, STROKE, V34, P968, DOI 10.1161/01.STR.0000063367.52044.40; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Wanebo JE, 2003, J NEUROSURG, V98, P82, DOI 10.3171/jns.2003.98.1.0082; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; YANG GY, 1994, ACTA NEUROCHIR, P555; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Yu SCH, 2004, AM J NEURORADIOL, V25, P1139; Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833	88	24	29	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2007	261	1-2					89	98		10.1016/j.jns.2007.04.040			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	216JO	WOS:000249874500012	17543995				2021-06-18	
J	Griebenow, M; Casalis, P; Woiciechowsky, C; Majetschak, M; Thomale, UW				Griebenow, Martin; Casalis, Pablo; Woiciechowsky, Christian; Majetschak, Matthias; Thomale, Ulrich-Wilhelm			Ubiquitin reduces contusion volume after controlled cortical impact injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; controlled cortical impact; contusion; neuroprotection; ubiquitin	EXTRACELLULAR UBIQUITIN; CEREBROSPINAL-FLUID; POSSIBLE INVOLVEMENT; EXOGENOUS UBIQUITIN; RESUSCITATION; PERFUSION; INCREASE; CELLS	Recent data suggest that ubiquitin has anti-inflammatory properties and therapeutic potential after severe trauma and brain injuries. However, direct evidence for its neuroprotective effects has not yet been provided. We hypothesized that ubiquitin treatment is neuroprotective, and thus reduces brain edema formation and cortical contusion volume after closed traumatic brain injuries. To test this hypothesis, a focal cortical contusion was induced using a controlled cortical impact (CCI) model in Sprague-Dawley rats. Animals (n = 27) were randomized to either 1.5 mg/kg ubiquitin or vehicle (placebo) intravenously within 5 min after CCI. Blood pressure, arterial blood gases (ABG) and intracranial pressure (ICP) were monitored. Ubiquitin serum and cerebrospinal fluid levels were measured by ELISA. Brain water content was quantified gravimetrically after 24 h and cerebral contusion volume was determined in triphenyltetrazolium-chloride stained brains after 7 days. All animals recovered to normal activity. ICP and cerebral perfusion pressures were normal at the end of the observation period. Ubiquitin serum and CSF levels at 24 h and 7 days after CCI were similar in both groups. With ubiquitin brain water content of the injured hemisphere was slightly lower (n = 6/group; 79.97 +/- 0.29% vs. 81.11 +/- 0.52%; p = 0.08). Cortical contusion volume was significantly lower with ubiquitin (n = 7-8/group; 32.88 +/- 2.1 mm(3) vs. 43.96 +/- 4.56 mm(3); p = 0.025). This study shows that ubiquitin treatment after brain injury has direct neuroprotective effects, as demonstrated by improved brain morphology 7 days after brain injury. In connection with its beneficial effects in our previous studies, these data suggest ubiquitin as a promising candidate protein therapeutic for the treatment of brain injuries.	Humboldt Univ, Virchow Med Ctr, Dept Neurosurg, Berlin, Germany; Univ Miami, Miller Sch Med, Dewitt Daughtry Family Dept Surg, Div Trauma & Surg Crit Care, Miami, FL 33152 USA	Thomale, UW (corresponding author), Humboldt Univ, Virchow Med Ctr, Dept Neurosurg, Berlin, Germany.	uthomale@charite.de		Misch, Martin/0000-0001-5283-5753			Akarsu E, 2001, DIABETES CARE, V24, P100, DOI 10.2337/diacare.24.1.100; ASSEMAN C, 1994, J IMMUNOL METHODS, V173, P93, DOI 10.1016/0022-1759(94)90286-0; Daino H, 2000, BLOOD, V95, P2577; EARLE SA, 2005, TRANSPLANTATION, V138, P31; GARCIACOVARRUBI.L, 2007, AM TRANSPL C SAN FRA; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; KUDO T, 1994, BRAIN RES, V639, P1, DOI 10.1016/0006-8993(94)91757-4; Kurimura M, 1997, Rinsho Shinkeigaku, V37, P963; Majetschak M, 2006, IMMUNOL CELL BIOL, V84, P59, DOI 10.1111/j.1440-1711.2005.01399.x; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Majetschak M, 2004, SURGERY, V135, P536, DOI 10.1016/j.surg.2003.09.006; Majetschak M, 2004, J TRAUMA, V56, P991, DOI 10.1097/01.TA.0000127770.29009.5A; Majetschak M, 2003, BLOOD, V101, P1882, DOI 10.1182/blood-2002-03-0918; MANAKA H, 1992, NEUROSCI LETT, V139, P47, DOI 10.1016/0304-3940(92)90854-Z; OKADA M, 1993, CLIN CHIM ACTA, V220, P135, DOI 10.1016/0009-8981(93)90042-3; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; Patel MB, 2006, J SURG RES, V135, P226, DOI 10.1016/j.jss.2006.04.037; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; Stover JF, 2000, J NEUROTRAUM, V17, P1171, DOI 10.1089/neu.2000.17.1171; Takagi M, 1999, ALCOHOL CLIN EXP RES, V23, p76S, DOI 10.1111/j.1530-0277.1999.tb04539.x; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Thomale UW, 2004, J NEUROTRAUM, V21, P1737	25	24	24	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2007	24	9					1529	1535		10.1089/neu.2007.0306			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	214ZT	WOS:000249777600010	17892413				2021-06-18	
J	Lange, RT; Iverson, GL; Franzen, MD				Lange, Rael T.; Iverson, Grant L.; Franzen, Michael D.			Short-term neuropsychological outcome following uncomplicated mild TBI : Effects of day-of-injury intoxication and pre-injury alcohol abuse	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	23rd Annual Meeting of the National-Academy-of-Neuropsychology	2003	Dallas, TX	Natl Acad Neuropsychol		alcohol intoxication; alcohol abuse; mild TBI; neuropsychological outcome	TRAUMATIC BRAIN-INJURY; SUBSTANCE-ABUSE; HEAD-INJURY; POLYSUBSTANCE ABUSE; ETHANOL; LEVEL; ASSOCIATION; VIOLENCE; MODEL	Research suggests that individuals who are intoxicated at the time of traumatic brain injury (TBI) have worse cognitive outcome compared with those who are sober. Worse outcome in patients with day-ofinjury intoxication might (a) be related to the increased magnitude of brain injury resulting from a variety of negative responses not present following TBI in nonintoxicated individuals, or (b) reflect the effect of pre-injury alcohol abuse that is prevalent in individuals intoxicated at the time of injury. Most studies in this area have focused on patients with moderate to severe TBIs, and on medium- to long-term neuropsychological outcome. The purpose of this study was to examine the relative contributions of day-of-injury intoxication versus pre-injury alcohol abuse on short-term cognitive recovery following mild TBI. Participants were 169 patients with uncomplicated mild TBIs who were assessed on 13 cognitive measures within 7 days postinjury. The prevalence of intoxication at the time of injury was 54.4%. The prevalence of possible pre-injury alcohol abuse was 46.2%. Overall, the results suggest that pre-injury alcohol abuse, compared with day-of-injury alcohol intoxication, had the most influence on short-term neuropsychological outcome from uncomplicated mild TBI. However, the influence of pre-injury alcohol abuse was considered small at best.	Riverview Hosp, British Columbia Mental Hlth & Addict Serv, Res Dept, Coquitlam, BC V3C 4J2, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	Lange, RT (corresponding author), Riverview Hosp, British Columbia Mental Hlth & Addict Serv, Res Dept, Room 124-ADMIN Bldg,Main Floor,2601 Lougheed High, Coquitlam, BC V3C 4J2, Canada.	rlange@bcmhs.bc.ca		Iverson, Grant/0000-0001-7348-9570			Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Altura BM, 1999, ALCOHOL, V19, P119, DOI 10.1016/S0741-8329(99)00025-7; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benton A., 1994, MULTILINGUAL APHASIA; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Biros MH, 1999, ACAD EMERG MED, V6, P1088, DOI 10.1111/j.1553-2712.1999.tb00109.x; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Brandt J., 2001, HOPKINS VERBAL LEARN; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Canadian Institute for Health Information, 2002, ONT TRAUM REG B ALC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; COWIE SE, 2005, DOCUMENTATION SUBSTA; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; Fein G, 1998, ALCOHOL CLIN EXP RES, V22, p196S, DOI 10.1111/j.1530-0277.1998.tb04000.x; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Gururaj G, 2004, J Indian Med Assoc, V102, P157; Gururaj G., 2004, J INDIAN MED ASSOC, V102, P163; Heaton RK, 2004, REVISED COMPREHENSIV; HEINEMANN AW, 1991, ARCH PHYS MED REHAB, V72, P482; Iverson G.L., 2006, BRAIN INJURY MED PRI, P333; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; JERNIGAN T, 1992, IMAGING ALCOHOL RES, P121; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Kongs SK, 2000, WISCONSIN CARD SORTI; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mautes AEM, 2001, ACTA NEUROCHIR, V143, P51, DOI 10.1007/s007010170138; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; Miller Norman S., 1994, P471; Mitrushina M., 1999, HDB NORMATIVE DATA N; Nixon SJ, 1999, PSYCHOL SCI, V10, P181, DOI 10.1111/1467-9280.00130; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reitan R. M., 1992, TRAIL MAKING TEST MA; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; Spreen O., 1998, COMPENDIUM NEUROPSYC; Sullivan EV, 1996, ALCOHOL CLIN EXP RES, V20, P348, DOI 10.1111/j.1530-0277.1996.tb01651.x; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; Zink BJ, 2001, ALCOHOL CLIN EXP RES, V25, P916	67	24	24	0	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2007	21	5					590	598		10.1037/0894-4105.21.5.590			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	205HO	WOS:000249104800008	17784807				2021-06-18	
J	Laudi, S; Donaubauer, B; Busch, T; Kerner, T; Bercker, S; Bail, H; Feldheiser, A; Haas, N; Kaisers, U				Laudi, Sven; Donaubauer, Bernd; Busch, Thito; Kerner, Thoralf; Bercker, Sven; Bail, Hermann; Feldheiser, Aarne; Haas, Norbert; Kaisers, Udo			Low incidence of multiple organ failure after major trauma	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						multiple organ failure; ARDS; major trauma; trauma care; lung protection	RESPIRATORY-DISTRESS-SYNDROME; MECHANICAL VENTILATION; RISK-FACTORS; INFLAMMATORY MEDIATORS; DYSFUNCTION SYNDROME; POLYTRAUMA PATIENTS; BRAIN-INJURY; LUNG INJURY; FRACTURES; MORTALITY	Background: In major trauma patients, multiple organ failure (MCF) is considered a leading cause of death. Acute lung injury is deemed a "pacemaker" of MOF The purpose of this study was to determine if incidence of organ failure and mortality in multiple trauma patients can be reduced by implementation of tung-protective strategies. Methods: All critically ill multiple trauma patients admitted to the ICU of a major trauma center in Berlin, Germany from January 199 to December 2002 were analyzed retrospectively. Patients were ventilated pressure controlled with low tidal volumes and adequate PEEP. Results: n = 287 patients were included. The most frequent injuries were traumatic brain injury (TBI-68%), chest trauma (68%), and lung contusions (55%). Injury severity score (ISS) was 32 +/- 19 (mean +/- standard deviation), polytraumaschluessel (PTS) 34 +/- 19, and APACHE II 14 +/- 7. During their ICU-stay 16 patients died, 9 (56%) from TBI. Single-organ-failure occurred in n = 69 patients (24%, mortality 5%), two-organ-failure in n = 22 (8%, mortality 14%), and MCIF in n = 9 (3%, mortality 13%); one patient died from MOF 14 days after trauma. The number of days on mechanical ventilation increased depending on the number of organs failed (R = 0.618, p < 0.001). Seven patients (2%) fulfilled ARDS criteria for longer than 24 h despite optimized ventilatory settings, one died of irreversible shock. Patients with MOF had a significantly increased ICU-LOS (35 +/- 15 days) compared to patients without organ failure (11 +/- 11 days; p<0.001). Conclusion: The low incidence of MOF in our series of trauma patients suggests that MOF may be prevented in some patients by implementation of lung-protective strategies. The improved outcome was associated with an increased ICU-LOS. (C) 2007 Elsevier Ltd. All. rights reserved.	Univ Leipzig, Fac Med, Dept Anesthesiol & Intens Care Med, D-04103 Leipzig, Germany; Charite Univ Med Ctr, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany; Charite Univ Med Ctr, Dept Trauma & Reconstruct Surg, D-13353 Berlin, Germany	Kaisers, U (corresponding author), Univ Klinikum Leipzig, Klin & Poliklin Anaesthesiol & Intensivtherapie, Liebigstr 20, D-04103 Leipzig, Germany.	udo.kaisers@medizin.uni-leipzig.de	Busch, Thilo/J-8258-2015; bercker, sven/B-9278-2009; Feldheiser, Aarne/AAH-1503-2019	Feldheiser, Aarne/0000-0002-0014-8879			AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Aufmkolk M, 1997, UNFALLCHIRURG, V100, P477, DOI 10.1007/s001130050145; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; DeLong WG, 2004, CLIN ORTHOP RELAT R, P57, DOI 10.1097/01.blo.0000130840.64528.1e; Dereeper E, 1998, RESUSCITATION, V36, P15, DOI 10.1016/S0300-9572(97)00080-4; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Durham RM, 2003, J TRAUMA, V55, P608, DOI 10.1097/01.TA.0000092378.10660.D1; FAIST E, 1983, J TRAUMA, V23, P775, DOI 10.1097/00005373-198309000-00002; Giannoudis PV, 2003, INJURY, V34, P397, DOI 10.1016/S0020-1383(02)00416-3; GORIS RJA, 1982, J TRAUMA, V22, P895, DOI 10.1097/00005373-198211000-00002; Grotz MRW, 2004, INJURY, V35, P1077, DOI 10.1016/j.injury.2004.05.025; Haas N P, 2001, Kongressbd Dtsch Ges Chir Kongr, V118, P421; Hadfield RJ, 2001, RESUSCITATION, V49, P279, DOI 10.1016/S0300-9572(00)00364-6; Hager DN, 2006, CRIT CARE MED, V34, P1554, DOI 10.1097/01.CCM.0000216183.25478.03; Khadaroo RG, 2002, CRIT CARE CLIN, V18, P127, DOI 10.1016/S0749-0704(03)00069-1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Levine JH, 1996, WORLD J SURG, V20, P471, DOI 10.1007/s002689900074; Lewandowski K, 1997, INTENS CARE MED, V23, P819, DOI 10.1007/s001340050418; Michaels AJ, 2004, CRIT CARE CLIN, V20, P83, DOI 10.1016/S0749-0704(03)00099-X; Moore F, 2004, POSTINJURY MULTIPLE, P1397; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Nast-Kolb D, 2001, J TRAUMA, V51, P835, DOI 10.1097/00005373-200111000-00003; Navarrete-Navarro P, 2001, INTENS CARE MED, V27, P1133, DOI 10.1007/s001340100955; Pape HC, 2002, J TRAUMA, V53, P452, DOI 10.1097/00005373-200209000-00010; Ranieri VM, 2000, JAMA-J AM MED ASSOC, V284, P43, DOI 10.1001/jama.284.1.43; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; REGEL G, 1994, UNFALLCHIRURG, V97, P211; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; REGEL G, 1993, UNFALLCHIRURG, V96, P350; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020; Sauaia A, 1998, J TRAUMA, V45, P291, DOI 10.1097/00005373-199808000-00014; SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39; Sauaia A, 1996, WORLD J SURG, V20, P392, DOI 10.1007/s002689900062; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; TRAN DD, 1993, SURGERY, V114, P21	40	24	24	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2007	38	9					1052	1058		10.1016/j.injury.2007.03.020			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	219CG	WOS:000250061700009	17572416				2021-06-18	
J	Proctor, KG; Atapattu, SA; Duncan, RC				Proctor, Kenneth G.; Atapattu, Suresh A.; Duncan, Robert C.			Heart rate variability index in trauma patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						EKG; computed axial tomography; traumatic brain injury; screening test	BRAIN-INJURY; ASSOCIATION; PREDICTOR; MORTALITY; DEATH	Background. Heart rate variability (HRV) changes often reflect autonomic dysfunction with high sensitivity, but the specificity is also low. There are several different methods for measuring HRV, but interpretation is often complex, and the units are not interchangeable. For these reasons, HRV monitoring is not routinely used in many clinical situations. We hypothesized that the specificity of HRV as a screening tool for trauma patients could be improved by controlling some of the confounding influences using multiple logistic regression. Methods: A prospective observational trial with waiver of consent was performed in 243 healthy student volunteers and 257 trauma patients, in the resuscitation bay and intensive care units of a Level I trauma center, who received computed axial tomography (CT) scans of the head as part of the initial work up. Electrocardiogram results were recorded for 5 minutes. HRV was defined by SD of normal R-R intervals (SDNN5) and by root mean square of successive differences of R-R intervals (RMSSD5). A head CT scan was considered positive (+) if there were abnormalities in the parenchyma (diffuse axonal injury or contusion), vasculature (intraparenchymal, subdural, or epidural hemorrhage), and/or structural or bony components (fractures of the face or cranium). Results:. In volunteers, SDNN5 was 73 15 (M +/- SD) milliseconds, compared with 42 22, 31 19, 28 17, and 12 8 milliseconds in, CT(-) patients with no sedation (n = 82), CT(-) with sedation (n = 60), CT(+) with no sedation (n = 55)9 and CT(+) with sedation (n = 60), respectively. The differences between trauma, sedation, and CT categories were significant (all p < 0.001). RMSSD5, differences were similar and also highly significant (all p < 0.001). For both SDNN5 and RMSSD5, in each category, there was wide overlap in the range of values, and strong inverse correlations with heart rate (all p < 0.001). Using multiple logistic regression in a subset with no missing data (n = 194), an index was derived from factors. With a negative predictive value held constant at 0.90, compared with ln(SDNN5) alone, the stepwise addition of heart rate, sedation, age, gender, and blood pressure progressively improved the specificity of the HRV index from 0.56 to 0.77, positive predictive value from 0.55 to 0.68, and efficiency from 0.68 to 0.80. This index was then normalized (0-100 scale) for ease of interpretation. Conclusions. (1) Several factors alter HRV in patients; (2) when HRV was indexed for some of these factors, its specificity and efficiency were improved for predicting a discrete pathologic state in trauma patients, i.e. (+) or (-) cranial CT scans; (3) the algorithm can incorporate other factors to further refine the diagnostic and/or prognostic ability of HRV as a noninvasive clinical tool; (4) this concept should be applicable to any other HRV measurement technique or outcome.	Univ Miami, Miller Sch Med, Ryder Trauma Ctr, Daughtry Family Dept Surg,Div Trauma, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Ryder Trauma Ctr, Daughtry Family Dept Surg,Div Surg Crit Care, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA	Proctor, KG (corresponding author), Univ Miami, Miller Sch Med, Ryder Trauma Ctr, Daughtry Family Dept Surg,Div Trauma, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [14370497] Funding Source: KAKEN		ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Cooke WH, 2006, J TRAUMA, V60, P363, DOI 10.1097/01.ta.0000196623.48952.0e; Duncan RC, 1983, INTRO BIOSTATISTICS; Fathizadeh P, 2004, CRIT CARE MED, V32, P1300, DOI 10.1097/01.CCM.0000127776.78490.E4; Fauchier L, 1998, J AUTONOM NERV SYST, V73, P1, DOI 10.1016/S0165-1838(98)00110-6; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; Grogan EL, 2005, J TRAUMA, V58, P7, DOI 10.1097/01.TA.0000151179.74839.98; Grogan EL, 2004, ANN SURG, V240, P547, DOI 10.1097/01.sla.0000137143.65540.9c; Huikuri HV, 1999, J AM COLL CARDIOL, V34, P1878, DOI 10.1016/S0735-1097(99)00468-4; King ML, 1997, BRAIN INJURY, V11, P445; Lachin J. M., 2000, WILEY SER PROB STAT; LOWENSOHN RI, 1977, LANCET, V1, P626; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; Morris John A Jr, 2005, Adv Surg, V39, P77, DOI 10.1016/j.yasu.2005.04.004; Muhlnickel B, 1991, Anaesthesiol Reanim, V16, P37; Muhlnickel B, 1990, Anaesthesiol Reanim, V15, P342; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; Novak V, 1997, CIRCULATION, V96, P1056; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; Stein PK, 2001, CRIT CARE MED, V29, P1738, DOI 10.1097/00003246-200109000-00014; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	28	24	25	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2007	63	1					33	43		10.1097/01.ta.0000251593.32396.df			11	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	190MI	WOS:000248062600008	17622866				2021-06-18	
J	Shimamura, M; Sato, N; Sata, M; Wakayama, K; Ogihara, T; Morishita, R				Shimamura, Munehisa; Sato, Naoyuki; Sata, Masataka; Wakayama, Kouji; Ogihara, Toshio; Morishita, Ryuichi			Expression of hepatocyte growth factor and c-Met after spinal cord injury in rats	BRAIN RESEARCH			English	Article						spinal cord injury; hepatocyte growth factor; c-Met	FOCAL CEREBRAL-ISCHEMIA; DELAYED NEURONAL DEATH; NEUROTROPHIC FACTOR; GENE-TRANSFER; UP-REGULATION; BRAIN; CELLS; HGF; RECEPTOR; OVEREXPRESSION	Since hepatocyte growth factor (HGF) plays a pivotal role in the development of the central nervous system and pathological conditions, we examined the long-term changes in the mRNA and protein expression of HGF and its receptor c-Met after spinal cord injury (SCI) in rats. HGF mRNA was significantly increased from 7 days after.SCI in the injured segment, and the peak was at 7 days after SCI as assessed by real-time RT-PCR. Importantly, c-met mRNA expression was up-regulated from I day after SCI, and reached a peak at 14 days after SCI. Although up-regulation of HGF and c-met mRNA expression in the injured segment gradually decreased, the increased expression level persisted until 56 days after SCI. Consistent with HGF mRNA expression, HGF protein level was significantly increased mainly in the injured region, which persisted until 56 days after SCI. Immunohistochemistry showed that most of GFAP-positive reactive astrocytes expressed HGF and c-Met both on 14 days and 56 days after SCI. Staining with the mitotic indicator, bromodeoxyuridine (BrdU), revealed that a small number of BrdU-incorporated cells were co-localized with HGF/ GFAP-positive or c-Met/GFAP-positive cells both on 14 and 56 days. These data suggest that HGF and c-Met were up-regulated mainly in the reactive astrocytes around the injured region in the subacute to chronic stage of spinal cord injury. Since HGF plays a critical role in neurotrophic activity, activation of the HGF/c-Met signaling system might be involved in the process of post-traumatic regeneration. (C) 2007 Elsevier B.V. All rights reserved.	Osaka Univ, Grad Sch Med, Dept Clin Gene Therapy, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Med, Dept Adv Clin Sci & Therapeut, Tokyo, Japan; Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 565, Japan	Morishita, R (corresponding author), Osaka Univ, Grad Sch Med, Dept Clin Gene Therapy, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	morishit@cgt.med.osaka-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17689034] Funding Source: KAKEN		BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Hamanoue M, 1996, J NEUROSCI RES, V43, P554, DOI 10.1002/(SICI)1097-4547(19960301)43:5<554::AID-JNR5>3.0.CO;2-H; Hayashi K, 2001, GENE THER, V8, P1167, DOI 10.1038/sj.gt.3301498; Hiebert GW, 2002, J NEUROSCI RES, V69, P160, DOI 10.1002/jnr.10275; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; Ikeda O, 2001, ACTA NEUROPATHOL, V102, P239; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; Kato S, 2003, ACTA NEUROPATHOL, V106, P112, DOI 10.1007/s00401-003-0708-z; Kokuzawa J, 2003, MOL CELL NEUROSCI, V24, P190, DOI 10.1016/S1044-7431(03)00160-X; Machide M, 2000, J BIOL CHEM, V275, P31392, DOI 10.1074/jbc.M002817200; Miyazawa T, 1998, J CEREBR BLOOD F MET, V18, P345, DOI 10.1097/00004647-199804000-00001; Morishita R, 2004, CURR GENE THER, V4, P199; Nagayama T, 2004, BRAIN RES, V999, P155, DOI 10.1016/j.brainres.2003.11.052; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Rush S, 2007, EXP CELL RES, V313, P121, DOI 10.1016/j.yexcr.2006.09.018; Satake K, 2000, NEUROREPORT, V11, P3877, DOI 10.1097/00001756-200011270-00054; Shimamura M, 2006, HYPERTENSION, V47, P742, DOI 10.1161/01.HYP.0000208598.57687.3e; Shimamura M, 2005, J GENE MED, V7, P1468, DOI 10.1002/jgm.793; Shimamura M, 2004, CIRCULATION, V109, P424, DOI 10.1161/01.CIR.0000109496.82683.49; Shimazaki K, 2003, BRAIN RES, V962, P105, DOI 10.1016/S0006-8993(02)03975-6; Sun W, 2002, J NEUROSCI, V22, P6537; Sun W, 2002, MOL BRAIN RES, V103, P36, DOI 10.1016/S0169-328X(02)00168-7; Tai MH, 2003, EXP NEUROL, V183, P508, DOI 10.1016/S0014-4886(03)00130-4; Tsuzuki N, 2001, NEUROL RES, V23, P417, DOI 10.1179/016164101101198659; Tuszynski MH, 1996, EXP NEUROL, V137, P157, DOI 10.1006/exnr.1996.0016; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; YAMADA T, 1994, BRAIN RES, V637, P308, DOI 10.1016/0006-8993(94)91250-5; YAMAGATA T, 1995, BIOCHEM BIOPH RES CO, V210, P231, DOI 10.1006/bbrc.1995.1651; Yan HL, 2002, J NEUROSCI RES, V69, P597, DOI 10.1002/jnr.10323; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	32	24	31	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 2	2007	1151						188	194		10.1016/j.brainres.2007.03.022			7	Neurosciences	Neurosciences & Neurology	172TW	WOS:000246828300019	17425951				2021-06-18	
J	Rafols, JA; Kreipke, CW; Petrov, T				Rafols, Jose A.; Kreipke, Christian W.; Petrov, Theodor			Alterations in cerebral cortex microvessels and the microcirculation in a rat model of traumatic brain injury: a correlative EM and laser Doppler flowmetry study	NEUROLOGICAL RESEARCH			English	Article						brain trauma; cerebral blood flow; ultrastructure; vascular tone	BLOOD-FLOW; AXONAL INJURY; HYPOPERFUSION; ENDOTHELIN-1; HIPPOCAMPUS; EXPRESSION; CONTUSION; PERFUSION; ISCHEMIA	Objectives: We sought to establish the temporal association of fluctuations in cortical cerebral blood flow (CBF) with ultrastructural alterations of microvessels in rat sensorimotor cortex (smCx) following administration of a rodent acceleration impact model of traumatic brain injury (TBI). Methods: Laser Doppler flowmetry (LDF) and electron microscopy (EM) were used in parallel experiments that lasted for up to 48 hours after induction of TBI. Results: Compared to sham-operated control, there was a 37% reduction of cortical CBF between 12 and 24 hours, this reduction remaining unchanged for up to 48 hours post-TBI. Ultrastructural alterations in the lumen and wall of smCx microvessels, including endothelial cell distortion and luminal collapse, were seen at hour 1 and continued up to 48 hours after trauma. Compared to control, there was a 40% decrease in the average microvascular luminal area 4 hours and a trend to recover (21%) by 48 hours after trauma. Smooth muscle (SM) in the wall of reacting microvessels showed evidence of increase contractility that coincided temporally with the decreased perfusion of cortical CBF. Discussion: Based on these observations, it is proposed that TBI causes alterations in the vascular tone of reacting microvessels which leads to prolonged vasoreactivity and restriction of the lumen in many but not all microvessels.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Rafols, JA (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Scott Hall,Room 9312,540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS039860] Funding Source: Medline		Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; ENDELBORGHS K, 2000, J NEUROTRAUM, V17, P667; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GABELLA G, 1976, CELL TISSUE RES, V170, P187; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GOSHGARIAN HG, 1989, J COMP NEUROL, V284, P519, DOI 10.1002/cne.902840404; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; *I LAB AN RES COMM, 1996, NIH PUBL; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MACDONALD RL, 1991, NEUROSURGERY, V29, P544; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; McBeth BD, 2005, ACAD EMERG MED, V12, P483, DOI 10.1197/j.aem.2004.11.028; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PETERS A, 1991, FINE STRUCTURE NERVO, P344; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; PHELPS PC, 1969, AM J ANAT, V125, P399, DOI 10.1002/aja.1001250404; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; Uehara Y, 1990, ULTRASTRUCTURE SMOOT, P237; USHIWATA I, 1990, J NEUROSURG, V73, P82, DOI 10.3171/jns.1990.73.1.0082; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505	40	24	26	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2007	29	4					339	347		10.1179/016164107X204648			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	192PM	WOS:000248214200002	17626728				2021-06-18	
J	Williams, R; Delaney, T; Nelson, E; Gratton, J; Laurent, J; Heath, B				Williams, Robert; Delaney, Thomas; Nelson, Eliot; Gratton, Jennifer; Laurent, Jennifer; Heath, Barry			Speeds associated with skiing and snowboarding	WILDERNESS & ENVIRONMENTAL MEDICINE			English	Article						helmet; traumatic brain injury; head trauma; head injury; skiing; snowboarding; speed; terrain park	HELMET USE; HEAD-INJURIES; SKIERS	Background/Objective.-Traumatic brain injury (TBI) is an important cause of morbidity and mortality in skiing and snowboarding. Although previous studies have advocated the use of a helmet to reduce the incidence of TBI, only a minority of skiers and snowboarders wear helmets. The low use of helmets may be partially due to controversy regarding their effectiveness in a high-speed crash. The protective effect of a ski helmet is diminished at the high speeds a skier or snowboarder can potentially obtain on an open slope. However, ski areas have undergone significant changes in the past decade. Many skiers and snowboarders frequent nontraditional terrain such as gladed areas and terrain parks. Since these areas contain numerous physical obstacles, we hypothesized that skiers and snowboarders would traverse these areas at speeds slow enough to expect a significant protective effect from a helmet. Methods.-Speed data were obtained via radar analysis of 2 groups of expert level skiers and snowboarders traversing a gladed woods trail and terrain park. Results.-A total of 113 observations were recorded. Forty-eight observations were made of 9 skiers and snowboarders in gladed terrain, and 65 observations were conducted of 21 skiers and snowboarders in the terrain park. In 79% of the cases in gladed terrain and 94% of the instances in the terrain park, observed speeds were less than 15 mph. Conclusions.-Skiers and snowboarders navigate nontraditional terrain at speeds slower than on open slopes. At the observed velocities, a helmet would be expected to provide significant help in diminishing the occurrence of TBI. Medical authorities should advocate the use of helmets as an important component of an overall strategy to reduce the incidence of TBI associated with skiing and snowboarding	Vermont Childrens Hosp, Div Pediat Crit Care, Burlington, VT USA; Univ Vermont, Vermont Childrens Hosp, Coll Med, Dept Anesthesia & Pediat, Burlington, VT USA	Williams, R (corresponding author), Vermont Childrens Hosp, Div Pediat Crit Care, Burlington, VT USA.	robert.williams@vtmednet.org					*ASTM, F2040 ASTM; Buller DB, 2003, J TRAUMA, V55, P939, DOI 10.1097/01.TA.0000078694.53320.CA; Corra Stefano, 2004, Inj Control Saf Promot, V11, P281, DOI 10.1080/156609704/233/289788; Hagel B, 2005, ACCIDENT ANAL PREV, V37, P103, DOI 10.1016/j.aap.2004.04.003; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; HEATH B, 2004, 2004 M PED AC SOC SA; Johnson SM, 2001, WILD ENVIRON MED, V12, P244, DOI 10.1580/1080-6032(2001)012[0244:ATACHI]2.0.CO;2; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; Macnab AJ, 2002, INJURY PREV, V8, P324, DOI 10.1136/ip.8.4.324; Made C, 2004, SCAND J MED SCI SPOR, V14, P128, DOI 10.1111/j.1600-0838.2003.00342.x; Nakaguchi H, 2002, J NEUROSURG, V97, P542, DOI 10.3171/jns.2002.97.3.0542; Shealy J. E., 2005, J ASTM INT, V2; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; US Consumer Product Safety Commission, 1999, SKIING HELM EV POT R; Xiang H, 2004, INJURY PREV, V10, P99, DOI 10.1136/ip.2003.004655; Xiang HY, 2005, J TRAUMA, V58, P112, DOI 10.1097/01.TA.0000151270.26634.DD	16	24	24	0	5	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1080-6032			WILD ENVIRON MED	Wildern. Environ. Med.	SUM	2007	18	2					102	105		10.1580/06-WEME-OR-037R1.1			4	Public, Environmental & Occupational Health; Sport Sciences	Public, Environmental & Occupational Health; Sport Sciences	184KU	WOS:000247641100004	17590072	Bronze			2021-06-18	
J	Ward, EC; Green, K; Morton, AL				Ward, Elizabeth C.; Green, Karly; Morton, Ann-Louise			Patterns and predictors of swallowing resolution following adult traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						dysphagia; natural history; swallowing; traumatic brain injury	HEAD-INJURY; DYSPHAGIA	Objective: To examine the patterns of swallowing resolution and outcomes of traumatic brain injury (TBI) patients in an acute care setting and document the risk factors or predictors of resolution of swallowing function. Participants: 117 consecutive TBI patients who had received speech pathology intervention for dysphagia during acute postinjury care. Main outcome measure: Temporal measures relating to pattern of resolution of dysphagia postinjury. Results: 75% of patients were assessed by 2 weeks postinjury, commenced oral intake by 17 days, and ceased supplementation by 3 weeks. By an average of 22 days after admission, 47% had progressed to normal-consistency diet and fluids. Duration to the first swallowing assessment was a predictor for achieving total oral intake and returning to normal intake. There was some preliminary support for severity of CT data and presence/absence of a tracheostomy as predictors for return to normal intake. Conclusion: The current data document the natural history of swallowing resolution and proposes prognostic factors for patients with impaired swallowing following TBI. Establishing clinical parameters that can help predict patterns of swallowing resolution over the course of acute care admission may greatly assist inpatient management and discharge/rehabilitation planning.	Univ Queensland, Div Speech Pathol, Sch Hlth & Rehabil Sci, St Lucia, Qld 4072, Australia; Royal Brisbane & Womens Hosp, Speech Pathol Dept, Brisbane, Qld, Australia	Ward, EC (corresponding author), Univ Queensland, Div Speech Pathol, Sch Hlth & Rehabil Sci, Therapies Bldg, St Lucia, Qld 4072, Australia.	liz.ward@uq.edu.au	Ward, Elizabeth/F-9652-2010	Ward, Elizabeth/0000-0002-2680-8978			COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Halper AS, 1999, J HEAD TRAUMA REHAB, V14, P486, DOI 10.1097/00001199-199910000-00009; LANGMORE S E, 1991, Seminars in Speech and Language, V12, P199, DOI 10.1055/s-2008-1064221; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Reilly S., 2005, ADV SPEECH LANGUAGE, V7, P14; Ward E, 1999, ASIA PACIFIC J SPEEC, V4, P109, DOI DOI 10.1179/136132899805577051; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992	9	24	28	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2007	22	3					184	191		10.1097/01.HTR.0000271119.96780.f5			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	174OH	WOS:000246951100005	17510594				2021-06-18	
J	Ankeny, DP; Popovich, PG				Ankeny, Daniel P.; Popovich, Phillip G.			Central nervous system and non-central nervous system antigen vaccines exacerbate neuropathology caused by nerve injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						autoimmunity; mouse; neuroinflammation; neurotrauma; peripheral nerve injury; T cells	SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; FACIAL MOTOR NUCLEUS; AUTOREACTIVE T-CELLS; INCOMPLETE FREUNDS-ADJUVANT; TUMOR-NECROSIS-FACTOR; IMMUNE SURVEILLANCE; NEURONAL SURVIVAL	Previously, we showed that autoimmune (central nervous system myelin-reactive) T cells exacerbate tissue damage and impair neurological recovery after spinal cord injury. Conversely, independent studies have shown T cell-mediated neuroprotection after spinal cord injury or facial nerve axotomy (FNAx). The antigen specificity of the neuroprotective T cells has not been investigated after FNAx. Here, we compared the neuroprotective capacity of autoimmune and non-autoimmune lymphocytes after FNAx. Prior to axotomy, C57BL/6 mice were immunized with myelin basic protein, myelin oligodendrocyte glycoprotein (MOG) or ovalbumin (a non-self antigen) emulsified in complete Freund's adjuvant (CFA). FNAx mice receiving injections of phosphate-buffered saline (PBS) only (unimmunized) or PBS/CFA emulsions served as controls. At 4 weeks after axotomy, bilateral facial motor neuron counts were obtained throughout the facial motor nucleus using unbiased stereology (optical fractionator). The data show that neuroantigen immunizations and 'generic' lymphocyte activation (e.g. PBS/CFA or ovalbumin/CFA immunizations) exacerbated neuron loss above that caused by FNAx alone. We also found that nerve injury potentiated the effector potential of autoimmune lymphocytes. Indeed, prominent forelimb and hindlimb motor deficits were accompanied by disseminated neuroinflammation and demyelination in FNAx mice receiving subencephalitogenic immunization with MOG. FNAx or neuroantigen (MOG or myelin basic protein) immunization alone did not cause these pathological changes. Thus, irrespective of the antigens used to trigger an immune response, neuropathology was enhanced when the immune system was primed in parallel with nerve injury. These data have important implications for therapeutic vaccination in clinical neurotrauma and neurodegeneration.	Ohio State Univ, Coll Med, Ctr Brain & Spinal Cord Repair, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Inst Behav Med Res, Columbus, OH 43210 USA	Popovich, PG (corresponding author), 333 W 10th Ave,2078 Graves Hall, Columbus, OH 43210 USA.	Phillip.Popovich@osumc.edu	Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI055411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758, R01NS047175] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32 AI55411] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS047175, P30-NS045758] Funding Source: Medline		Aktas O, 2005, NEURON, V46, P421, DOI 10.1016/j.neuron.2005.03.018; ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; Angelov DN, 1998, GLIA, V24, P155; Ankeny DP, 2006, J NEUROCHEM, V99, P1073, DOI 10.1111/j.1471-4159.2006.04147.x; ANTEL JP, 1994, ANN NEUROL, V35, P341, DOI 10.1002/ana.410350315; Bohatschek M, 2004, J COMP NEUROL, V470, P382, DOI 10.1002/cne.20017; Brabb T, 1997, J IMMUNOL, V159, P497; Brisebois M, 2006, J IMMUNOL, V177, P2403, DOI 10.4049/jimmunol.177.4.2403; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Byram SC, 2006, CLIN NEUROSCI RES, V6, P86, DOI 10.1016/j.cnr.2006.06.001; Cabarrocas J, 2003, EUR J IMMUNOL, V33, P1174, DOI 10.1002/eji.200323492; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; CUA DJ, 1995, J IMMUNOL, V155, P4052; Dai XD, 2003, J NEUROSCI, V23, P5846; Dittel BN, 1999, J IMMUNOL, V162, P6392; Dowdell KC, 1999, J NEUROIMMUNOL, V100, P243, DOI 10.1016/S0165-5728(99)00211-8; DSOUZA S, 1995, J NEUROSCI, V15, P7293; Falcone M, 1997, J EXP MED, V185, P901, DOI 10.1084/jem.185.5.901; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Ferri CC, 1998, J NEUROBIOL, V34, P1; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; GENAIN CP, 1994, J CLIN INVEST, V94, P1339, DOI 10.1172/JCI117454; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Gimsa U, 2000, BRAIN PATHOL, V10, P365; Gimsa U, 2001, J NEUROIMMUNOL, V119, P73, DOI 10.1016/S0165-5728(01)00343-5; Giuliani F, 2003, J IMMUNOL, V171, P368, DOI 10.4049/jimmunol.171.1.368; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; Ha GK, 2006, J NEUROIMMUNOL, V172, P1, DOI 10.1016/j.jneuroim.2005.10.012; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI12837; Hayes KC, 2002, J NEUROTRAUM, V19, P753, DOI 10.1089/08977150260139129; Heeger PS, 2000, J IMMUNOL, V164, P5771, DOI 10.4049/jimmunol.164.11.5771; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; Hofstetter HH, 2002, J IMMUNOL, V169, P117, DOI 10.4049/jimmunol.169.1.117; Hottinger AF, 2000, J NEUROSCI, V20, P5587; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; Jones TB, 2004, J NEUROSCI, V24, P3752, DOI 10.1523/JNEUROSCI.0406-04.2004; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Juedes AE, 2000, J IMMUNOL, V164, P419, DOI 10.4049/jimmunol.164.1.419; Kalla R, 2001, J COMP NEUROL, V436, P182; Karpus WJ, 1998, J IMMUNOL, V161, P2667; Kawakami N, 2004, J EXP MED, V199, P185, DOI 10.1084/jem.20031064; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kil K, 1999, J NEUROIMMUNOL, V98, P201, DOI 10.1016/S0165-5728(99)00057-0; Kipnis J, 2002, J NEUROIMMUNOL, V130, P78, DOI 10.1016/S0165-5728(02)00219-9; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; KONNO H, 1990, ACTA NEUROPATHOL, V80, P521, DOI 10.1007/BF00294613; KORBO L, 1990, J NEUROSCI METH, V31, P93, DOI 10.1016/0165-0270(90)90153-7; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; Lake J, 1999, J PATHOL, V187, P259, DOI 10.1002/(SICI)1096-9896(199901)187:2<259::AID-PATH212>3.0.CO;2-H; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; LEE JM, 1955, P SOC EXP BIOL MED, V89, P263; Ling CY, 2006, J NEUROSCI, V26, P731, DOI 10.1523/JNEUROSCI.3502-05.2006; LYMAN WD, 1986, CELL IMMUNOL, V102, P217, DOI 10.1016/0008-8749(86)90340-0; Mariotti R, 2002, EXP NEUROL, V176, P133, DOI 10.1006/exnr.2002.7908; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; McPhail LT, 2004, EXP NEUROL, V188, P331, DOI 10.1016/j.expneurol.2004.04.010; Mendel I, 1996, EUR J IMMUNOL, V26, P2470, DOI 10.1002/eji.1830261030; Meyer AL, 1996, J IMMUNOL, V157, P4230; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MOLLESTON MC, 1993, ADV NEUROL, V59, P337; Neumann H, 2002, TRENDS NEUROSCI, V25, P313, DOI 10.1016/S0166-2236(02)02154-9; Nguyen KB, 1997, J NEUROPATH EXP NEUR, V56, P58, DOI 10.1097/00005072-199701000-00006; Nitsch R, 2004, J NEUROSCI, V24, P2458, DOI 10.1523/JNEUROSCI.4703-03.2004; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Pewe L, 2002, J IMMUNOL, V168, P1547, DOI 10.4049/jimmunol.168.4.1547; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; PHILLIPS MJ, 1995, NEUROPATH APPL NEURO, V21, P189, DOI 10.1111/j.1365-2990.1995.tb01050.x; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1998, NEUROSCIENTIST, V4, P71, DOI 10.1177/107385849800400203; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Raivich G, 1998, J NEUROSCI, V18, P5804; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; Ryan M, 1998, INT IMMUNOL, V10, P651, DOI 10.1093/intimm/10.5.651; SCHMIED M, 1993, AM J PATHOL, V143, P446; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.3.CO;2-3; Serpe CJ, 2003, BRAIN BEHAV IMMUN, V17, P393, DOI 10.1016/S0889-1591(03)00028-X; SGROI D, 1986, J IMMUNOL, V137, P1850; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; VOSKUHL RR, 1993, AUTOIMMUNITY, V15, P137, DOI 10.3109/08916939309043888; Wolf SA, 2002, J NEUROIMMUNOL, V133, P72, DOI 10.1016/S0165-5728(02)00367-3	88	24	24	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	APR	2007	25	7					2053	2064		10.1111/j.1460-9568.2007.05458.x			12	Neurosciences	Neurosciences & Neurology	155UP	WOS:000245604200015	17439492				2021-06-18	
J	Heitger, MH; Jones, RD; Dalrymple-Alford, JC; Frampton, CM; Ardagh, MW; Anderson, TJ				Heitger, Marcus H.; Jones, Richard D.; Dalrymple-Alford, John C.; Frampton, Chris M.; Ardagh, Michael W.; Anderson, Tim J.			Mild head injury - a close relationship between motor function at 1 week post-injury and overall recovery at 3 and 6 months	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						head injury; recovery; motor function; oculomotor; upper-limb visuomotor; prediction of outcome	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYMPTOMS; S-100 PROTEIN MEASUREMENTS; SACCADIC EYE-MOVEMENTS; FOLLOW-UP; NEUROIMAGING FINDINGS; PREDICTIVE-VALUE; MODERATE; DEFICITS; WHIPLASH	Based on previous findings of impaired eye and arm motor control after mild closed head injury (CHI), this study examined whether early eye and arm motor function, and the level of post-injury cerebral dysfunction manifested in motor control, relates systematically to recovery at 3 and 6 months after mild CHI. At 1 week post-injury, we assessed oculomotor function, upper-limb visuomotor performance, and cognitive status in 37 mild CHI patients. Re-examination at 3 and 6 months determined outcome in terms of postconcussional symptoms and performance of everyday tasks, as assessed by the Rivermead Postconcussion Symptoms Questionnaire, the Rivermead Head Injury Follow-up Questionnaire and the SF-36 Health Survey. We then examined the association of early motor function, cognitive status and self-reported health condition with outcome using linear regression. Motor-based regression models explained a high proportion of the variance in outcome (70-89%), with motor function at 1 week being more closely related to outcome at 3 and 6 months than early psychometric assessment (13-32%) or self-reported health status (54-79%). These motor-based models incorporated subcortical/subconscious motor functions alongside motor functions that are subject to volitional control and are primarily mediated by frontal, parietal and temporal cortical brain regions. Early assessment of eye and arm motor function may help in improving accuracy of outcome prediction after mild CHI. Such assessment may assist in the better targeting of early health care intervention and help decrease head-trauma-related morbidity and rehabilitation costs. (c) 2006 Elsevier B.V. All rights reserved.	Van der Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand; Christchurch Hosp, Dept Med Phys & Bioengn, Christchurch, New Zealand; Christchurch Hosp, Emergency Dept, Christchurch, New Zealand; Christchurch Hosp, Dept Neurol, Christchurch, New Zealand; Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand	Heitger, MH (corresponding author), Van der Veer Inst Parkinsons & Brain Res, POB 2682, Christchurch, New Zealand.	marcus.heitger@chmeds.ac.nz		Jones, Richard/0000-0003-2287-3358			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BITTENCOURT PRM, 1981, BRIT J CLIN PHARMACO, V12, P523, DOI 10.1111/j.1365-2125.1981.tb01261.x; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; *CDCP NAT CTR INJ, 1999, TRAUM BRAIN INJ US R; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Enderle JD, 2002, PROG BRAIN RES, V140, P21; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fenton GW, 1996, CLIN ELECTROENCEPHAL, V27, P174; GRONWALL DMA, 1977, PACED AUDITORY SERIA; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JONES RD, 2000, BIOMEDICAL ENG HDB, V149, P1; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; KRAUS JF, 1989, MILD HEAD INJURY, P8; Leigh R.J., 1999, NEUROLOGY EYE MOVEME, V3rd ed.; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell M.R., 2006, SPORTS NEUROPSYCHOLO, P193; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mallinson AI, 1998, AM J OTOL, V19, P809; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Muir S. R., 2003, Australasian Physical & Engineering Sciences in Medicine, V26, P18; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pierrot-Deseilligny C, 2003, PROG BRAIN RES, V142, P3; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; Reitan R M, 1997, Appl Neuropsychol, V4, P16, DOI 10.1207/s15324826an0401_3; Reitan RM, 2003, ARCH CLIN NEUROPSYCH, V18, P11, DOI 10.1016/S0887-6177(01)00177-9; REULEN JPH, 1988, MED BIOL ENG COMPUT, V26, P20, DOI 10.1007/BF02441823; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOLOGI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Smith A., 1973, SYMBOL DIGIT MODALIT; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Thier P, 2002, ANN NY ACAD SCI, V978, P50, DOI 10.1111/j.1749-6632.2002.tb07555.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Umile EM, 1998, BRAIN INJURY, V12, P577; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WARE JE, 2000, HOW SCORE VERSION 2; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; Wrightson P, 1998, NEW ZEAL MED J, V111, P99	76	24	24	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	FEB 15	2007	253	1-2					34	47		10.1016/j.jns.2006.11.007			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	141ZY	WOS:000244619200005	17207818	Green Published			2021-06-18	
J	Chang, TT; Schecter, WP				Chang, Tammy T.; Schecter, William P.			Injury in the elderly and end-of-life decisions	SURGICAL CLINICS OF NORTH AMERICA			English	Article							TRAUMATIC BRAIN-INJURY; BLUNT SPLENIC INJURY; ACTIVATED FACTOR-VII; GERIATRIC TRAUMA; NONOPERATIVE MANAGEMENT; INTRACRANIAL HEMORRHAGE; TRANSTHORACIC ECHOCARDIOGRAPHY; PREEXISTING CONDITIONS; PREINJURY WARFARIN; SURGICAL-PATIENTS	The elderly constitute the fastest growing sector of the population of the United States and geriatric trauma patients are presenting for care with increasing frequency. These patients are challenging particularly because of their vulnerability to severe injury limited physiologic response to stress, and frequent presence of comorbid medical conditions complicating care. Many elderly trauma victims require prolonged intensive care and some fail to improve or succumb despite the best efforts because of the extent of their injuries and their underlying disease. These patients may present profound ethical challenges for trauma surgeons as the goals of care shift from salvage to end-of-life care.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA	Schecter, WP (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Surg, 1001 Potrero Ave,Ward 3A17, San Francisco, CA 94110 USA.	bschect@sfghsurg.ucsf.edu					ABRAMS FR, 1993, NEW ENGL J MED, V328, P975, DOI 10.1056/NEJM199304013281320; [Anonymous], 1968, JAMA, V205, P337; Barone JE, 1999, J TRAUMA, V46, P87, DOI 10.1097/00005373-199901000-00014; Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; Bochicchio GV, 2001, J TRAUMA, V50, P612, DOI 10.1097/00005373-200104000-00004; Cassell J, 2003, CRIT CARE MED, V31, P1551, DOI 10.1097/00003246-200305000-00039; Cocanour CS, 2000, J TRAUMA, V48, P606, DOI 10.1097/00005373-200004000-00005; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Demetriades D, 2002, BRIT J SURG, V89, P1319, DOI 10.1046/j.1365-2168.2002.02210.x; Demetriades D, 2001, J TRAUMA, V51, P754, DOI 10.1097/00005373-200110000-00022; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Epstein CD, 2002, HEART LUNG, V31, P315, DOI 10.1067/mhl.2002.126104; Fakhry SM, 1996, J TRAUMA, V41, P999, DOI 10.1097/00005373-199612000-00010; Fakhry SM, 2001, J TRAUMA, V50, P617; Falimirski ME, 2000, AM SURGEON, V66, P631; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; Fishkind D, 1997, J AM GERIATR SOC, V45, P809, DOI 10.1111/j.1532-5415.1997.tb01506.x; Grossman M, 2003, J TRAUMA, V55, P26, DOI 10.1097/01.TA.0000072109.52351.0D; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Harbrecht BG, 2001, J TRAUMA, V51, P887, DOI 10.1097/00005373-200111000-00010; HART RG, 1995, STROKE, V26, P1471, DOI 10.1161/01.STR.26.8.1471; He W., 2005, 65 US 2005; Henry SM, 2002, J TRAUMA, V53, P15, DOI 10.1097/00005373-200207000-00004; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jacobs DG, 2003, J TRAUMA, V54, P391, DOI 10.1097/01.TA.0000042015.54022.BE; Jensen MB, 2004, EUR J ANAESTH, V21, P700, DOI 10.1017/S0265021504009068; KHOURY AF, 1994, AM HEART J, V127, P1363, DOI 10.1016/0002-8703(94)90057-4; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Knudson MM, 1999, SURG CLIN N AM, V79, P1357, DOI 10.1016/S0039-6109(05)70082-7; KNUDSON MM, 1994, ARCH SURG-CHICAGO, V129, P448; Kong LB, 1996, J AM COLL SURGEONS, V182, P17; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; Koval KJ, 2003, J BONE JOINT SURG AM, V85A, P1380, DOI 10.2106/00004623-200307000-00027; Krause KR, 2000, AM SURGEON, V66, P636; Lavery GG, 2004, CRIT CARE, V8, P433, DOI 10.1186/cc2998; Levy MM, 2004, CRIT CARE CLIN, V20, P541, DOI 10.1016/j.ccc.2004.03.013; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Ma MHM, 1999, J TRAUMA, V46, P168; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; Manasia AR, 2005, J CARDIOTHOR VASC AN, V19, P155, DOI 10.1053/j.jvca.2005.01.023; Mandavia D, 1998, EMERG MED CLIN N AM, V16, P257, DOI 10.1016/S0733-8627(05)70358-8; MARTIN R E, 1990, Emergency Medicine Clinics of North America, V8, P411; Martinowitz U, 2005, J THROMB HAEMOST, V3, P640, DOI 10.1111/j.1538-7836.2005.01203.x; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Morenski John D, 2003, J Intensive Care Med, V18, P211, DOI 10.1177/0885066603254359; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Myers JG, 2000, J TRAUMA, V48, P801, DOI 10.1097/00005373-200005000-00002; O'Brien DP, 2002, SURGERY, V132, P710, DOI 10.1067/msy.2002.127690; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Pande I, 2006, ANN RHEUM DIS, V65, P87, DOI 10.1136/ard.2004.034611; PELLICANE JV, 1992, J TRAUMA, V33, P440, DOI 10.1097/00005373-199209000-00018; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Roudsari BS, 2005, INJURY, V36, P1316, DOI 10.1016/j.injury.2005.05.024; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; SCHECTER WP, 1994, SURG CLIN N AM, V74, P245, DOI 10.1016/S0039-6109(16)46282-1; Schulman AM, 2002, AM SURGEON, V68, P942; SCHULTZ RJ, 1985, J TRAUMA, V25, P309, DOI 10.1097/00005373-198504000-00005; Schurr MJ, 2004, J TRAUMA, V57, P718; Schwartsman R, 1998, Am J Orthop (Belle Mead NJ), V27, P512; Sexson S B, 1987, J Orthop Trauma, V1, P298, DOI 10.1097/00005131-198701040-00005; SHABOT MM, 1995, J TRAUMA, V39, P254, DOI 10.1097/00005373-199508000-00011; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SMITH DP, 1990, SOUTHERN MED J, V83, P171, DOI 10.1097/00007611-199002000-00010; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stricker KH, 2005, ACTA ANAESTH SCAND, V49, P975, DOI 10.1111/j.1399-6576.2005.00702.x; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; VANAALST JA, 1991, J TRAUMA, V31, P1096; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; ZIMMERGEMBECK MJ, 1995, J TRAUMA, V39, P922, DOI 10.1097/00005373-199511000-00017; ZUCKERMAN JD, 1992, CLIN ORTHOP RELAT R, P213	86	24	27	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	FEB	2007	87	1					229	+		10.1016/j.suc.2006.09.010			18	Surgery	Surgery	123NI	WOS:000243302200013	17127130				2021-06-18	
J	Al-Adawi, S; Dorvlo, ASS; Al-Naamani, A; Glenn, MB; Karamouz, N; Chae, HC; Zaidan, ZAJ; Burke, DT				Al-Adawi, Samir; Dorvlo, Atsu S. S.; Al-Naamani, Aziz; Glenn, Mel B.; Karamouz, Nasser; Chae, Heechin; Zaidan, Ziad A. J.; Burke, David T.			The ineffectiveness of the Hospital Anxiety and Depression Scale for diagnosis in an Omani traumatic brain injured population	BRAIN INJURY			English	Article						anxiety; depression; traumatic brain injury; Arabic; Oman	INTERNAL CONSISTENCY; SELF-AWARENESS; OLDER-ADULTS; HAD SCALE; VALIDITY; REHABILITATION; VALIDATION; DISEASE; VERSION; SAMPLE	Background: The rehabilitation of the traumatic brain injury ( TBI) patient is especially challenging in non-western populations as the phenotypic indicators as well as the neurobehavioral assessments for the survivors of brain injury are limited. Objective: The study screened for the prevalence of anxiety and depressive states among patients with TBI and examined the validity of the Hospital Anxiety and Depression Scale ( HADS) to identify TBI patients with comorbid affective dysfunctions, specifically anxiety and depressive disorders, in an Omani population. Methods: Sixty-eight survivors of TBI were screened with the semi-structured, Composite International Diagnostic Interview ( CIDI) and the HADS. A receiver operating characteristics ( ROC) curve was calculated to discriminate the power of the HADS for every possible threshold score. Results: The semi-structured interview revealed the prevalence rate of 57.4% for depressive disorder and 50% for anxiety disorder. The sensitivity ( 53.8%) and specificity 75.9%, gave the best compromise using the cut- off score of 4, suggesting HADS is not a useful screening tool for this particular population. Conclusions: Phenotypic indicators as detected by CIDI revealed that prevalence of affective dysfunctionality is common among this TBI population. Although the HADS is the most widely used screening instrument in other clinical populations, it does not appear to be a reliable resource in identifying depression and anxiety in people with traumatic brain injury in Oman.	Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Behav Sci, Muscat, Oman; Sultan Qaboos Univ, Dept Math & Stat, Muscat, Oman; Harvard Univ, Spaulding Rehabil Hosp, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA	Al-Adawi, S (corresponding author), Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Behav Sci, POB 35,Al Khoudh 123, Muscat, Oman.	adawi@squ.edu.om	Al-Adawi, Samir/A-9663-2016	Al-Adawi, Samir/0000-0002-9858-5582			ABIODUN OA, 1994, BRIT J PSYCHIAT, V165, P669, DOI 10.1192/bjp.165.5.669; Al-Adawi S, 2001, J Sci Res Med Sci, V3, P61; Al-Adawi S, 2004, J NEUROPSYCH CLIN N, V16, P435, DOI 10.1176/appi.neuropsych.16.4.435; Al-Adawi S, 2001, EPILEPSIA, V42, P1476, DOI 10.1046/j.1528-1157.2001.05599.x; Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Al-Adawi S., 2005, JAPANESE J PSYCHOSOM, V45, P933; Al-Lawati J, 2000, J SCI RES MED SCI, V2, P105; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Bolton P, 2001, J NERV MENT DIS, V189, P238, DOI 10.1097/00005053-200104000-00005; Costantini M, 1999, SUPPORT CARE CANCER, V7, P121, DOI 10.1007/s005200050241; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P429, DOI 10.1348/014466501163904; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; ELRUFAIE OEF, 1995, SOC PSYCH PSYCH EPID, V30, P26, DOI 10.1007/BF00784431; ELRUFAIE OEFA, 1987, BRIT J PSYCHIAT, V151, P687, DOI 10.1192/bjp.151.5.687; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Harter M, 2001, DISABIL REHABIL, V23, P737; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Isella V, 2002, MOVEMENT DISORD, V17, P366, DOI 10.1002/mds.10041; JOHNSON G, 1995, ACTA PSYCHIAT SCAND, V91, P252, DOI 10.1111/j.1600-0447.1995.tb09778.x; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kirmayer LJ, 2001, PSYCHIAT CLIN N AM, V24, P465, DOI 10.1016/S0193-953X(05)70241-0; Koss J.D., 1990, TRANSCULT PSYCHIAT R, V27, P5, DOI [10.1177/136346159002700101., DOI 10.1177/136346159002700101]; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lawrence V, 2006, GERONTOLOGIST, V46, P23, DOI 10.1093/geront/46.1.23; LEFF J, 1977, Culture Medicine and Psychiatry, V1, P317; Leung CM, 1999, ACTA PSYCHIAT SCAND, V100, P456, DOI 10.1111/j.1600-0447.1999.tb10897.x; Lisspers J, 1997, ACTA PSYCHIAT SCAND, V96, P281, DOI 10.1111/j.1600-0447.1997.tb10164.x; Lloyd-Williams M, 2001, J PAIN SYMPTOM MANAG, V22, P990, DOI 10.1016/S0885-3924(01)00358-X; MALASI TH, 1991, ACTA PSYCHIAT SCAND, V84, P323, DOI 10.1111/j.1600-0447.1991.tb03153.x; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Mykletun A, 2001, BRIT J PSYCHIAT, V179, P540, DOI 10.1192/bjp.179.6.540; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; Roberts SB, 2001, BRIT J HEALTH PSYCH, V6, P373, DOI 10.1348/135910701169278; Sakamoto N, 2005, INT J PSYCHIAT MED, V35, P191, DOI 10.2190/7WEQ-216D-TVNH-PQJ1; Schnyder U, 2001, AM J RESP CRIT CARE, V164, P653, DOI 10.1164/ajrccm.164.4.2008087; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Simon GE, 1999, NEW ENGL J MED, V341, P1329, DOI 10.1056/NEJM199910283411801; *SPSS CORP, 1999, STAT PACK SOC SCI VE; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Sutcliffe LM, 1998, CLIN REHABIL, V12, P506, DOI 10.1191/026921598672167702; Tang WK, 2004, AGING MENT HEALTH, V8, P397, DOI 10.1080/13607860410001725027; TEASDALE G, 1974, LANCET, V2, P81; Thompson JC, 2002, J NEUROPSYCH CLIN N, V14, P37, DOI 10.1176/appi.neuropsych.14.1.37; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Upadhyaya AK, 1997, INT J GERIATR PSYCH, V12, P35, DOI 10.1002/(SICI)1099-1166(199701)12:1<35::AID-GPS447>3.3.CO;2-8; Viguier D, 2001, BRAIN INJURY, V15, P263; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; World Health Organization, 1993, COMP INT DIAGN INT; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	58	24	24	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	4					385	393		10.1080/02699050701311059			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600004	17487636				2021-06-18	
J	Jumisko, E; Lexell, J; Soderberg, S				Jumisko, Eija; Lexell, Jan; Soderberg, Siv			The experiences of treatment from other people as narrated by people with moderate or severe traumatic brain injury and their close relatives	DISABILITY AND REHABILITATION			English	Article						brain injury; traumatic; relatives; treatment; experiences; interviews	QUALITY-OF-CARE; MISCONCEPTIONS; PERCEPTIONS; DIGNITY; SELF	Purpose. The aim of this study was to describe the treatment from other people as experienced by people with moderate or severe traumatic brain injury (TBI) and their close relatives. Method. Twelve people with moderate or severe TBI and eight of their close relatives were interviewed. The interviews were analysed using thematic content analysis. Results. The results were described by the means of two themes: being excluded and missing confirmation. People with TBI and their close relatives had experiences of being avoided, being ruled by the authorities, being met with distrustfulness and being misjudged. They also searched for answers and longed for the right kind of help. People who listened to them, believed them and tried to understand and help them were appreciated. Conclusions. This study showed a lack of treatment which promotes well-being of the people with TBI and their close relatives. They experienced bad treatment also from authorities. Therefore, we emphasize that authorities should continuously reflect on how to make their practice a place which promotes dignity. Treatment of people with TBI and close relatives may be improved by increased knowledge about TBI, living with it and being a close relative to a person with TBI. This is a challenge to health care and rehabilitation professionals.	Lulea Univ Technol, Dept Hlth Sci, Div Nursing, SE-97187 Lulea, Sweden; Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, S-95187 Lulea, Sweden; Univ Lund Hosp, Dept Rehabil, S-22185 Lund, Sweden	Jumisko, E (corresponding author), Lulea Univ Technol, Dept Hlth Sci, Div Nursing, SE-97187 Lulea, Sweden.	Eija.Jumisko@ltu.se		Lexell, Jan/0000-0001-5294-3332			Andersson S, 2002, J Psychiatr Ment Health Nurs, V9, P285, DOI 10.1046/j.1365-2850.2002.00480.x; ASTROM G, 1995, THESIS UMEA U UMEA, P149; Attree M, 2001, J ADV NURS, V33, P456, DOI 10.1046/j.1365-2648.2001.01689.x; Backhouse M, 1999, AUST OCCUP THER J, V46, P99, DOI DOI 10.1046/J.1440-1630.1999.00183.X; Baxter L. A., 1994, STUDYING INTERPERSON, P239; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; Carson P, 1993, J Neurosci Nurs, V25, P165; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; Corring D J, 1999, Can J Occup Ther, V66, P71; CRISHOLM J, 2001, AXON, V23, P12; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; DELEHANTY R, 1998, J COGNITIVE REHABILI, V16, P14; DOLFE A, 2004, HUR MAN UPPNAR GOTT; Downe-Wamboldt B, 1992, Health Care Women Int, V13, P313; Duff Diane, 2002, Axone, V24, P14; EDLUND M, 2002, THESIS ABO AKAD ABO, P153; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Gallagher A, 2004, NURS ETHICS, V11, P587, DOI 10.1191/0969733004ne744oa; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guba EG, 1989, 4 GENERATION EVALUAT, P294; GUERRIERE D, 1997, J SOC PEDIAT NURSES, V2, P110; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; GUSTAFSSON B, 1994, THEOR MED, V15, P409, DOI 10.1007/BF00993798; Gustafsson B, 2000, J NURSING THEORY, V9, P6; HALLDORSDOTTIR S, 1996, THESIS LINKOPING U L, P198; JUMISKO E, 2005, J NEUROSCIENCE NURSI, V36, P20; Kvale S, 1997, KVALITATIVA FORSKNIN, P306; Lincoln YS., 1985, NATURALISTIC INQUIRY, P416; LOSTRUP KE, 1971, ETHICAL DEMAND, P239; Lovgren G, 1996, SCAND J CARING SCI, V10, P151; Lund M.L., 2001, OCCUP THER INT, V8, P151; Lyons R, 1998, PERSPECTIVES LOSS SO, P137; McMillen A. M., 2002, SCANDINAVIAN J OCCUP, V9, P176, DOI DOI 10.1080/11038120260501208; NADEN D, 2000, INT J HUMAN CARING, V4, P23; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Nordenfelt L, 2004, HEALTH CARE ANAL, V12, P69, DOI 10.1023/B:HCAN.0000041183.78435.4b; Ohlen Joakim, 2004, Res Theory Nurs Pract, V18, P371; Ohman M, 2004, QUAL HEALTH RES, V14, P396, DOI 10.1177/1049732303261692; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Paterson B, 2001, Rehabil Nurs, V26, P48; Paterson J., 2002, REHABILITATION NURSI, V27, P13, DOI [10.1002/j.2048-7940.2002.tb01973.x, DOI 10.1002/J.2048-7940.2002.TB01973.X]; POLIT DF, NURSING RES PRINCIPL, P758; REHNSFELDT A, 1999, THESIS ABO AKAD ABO, P216; Robertson-Malt S, 1999, J ADV NURS, V29, P290, DOI 10.1046/j.1365-2648.1999.00830.x; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Schroder A, 2006, J CLIN NURS, V15, P93, DOI 10.1111/j.1365-2702.2005.01241.x; Schroder A, 2004, SCAND J CARING SCI, V18, P204, DOI 10.1111/j.1471-6712.2004.00271.x; SERIO CD, BRAIN INJ, V11, P1; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Smith J E, 2000, Care Manag J, V2, P27; Soderberg S, 2004, DISABIL REHABIL, V26, P419, DOI 10.1080/09638280410001663111; Soderberg S, 1999, QUAL HEALTH RES, V9, P575, DOI 10.1177/104973299129122090; Sundin K, 2000, SCAND J CARING SCI, V14, P16, DOI 10.1111/j.1471-6712.2000.tb00556.x; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; WALLACE CL, 1995, J ADV NURS, V22, P285, DOI 10.1046/j.1365-2648.1995.22020285.x; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; Wiman E, 2004, J CLIN NURS, V13, P422, DOI 10.1111/j.1365-2702.2004.00902.x	58	24	24	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2007	29	19					1535	1543		10.1080/09638280601055816			9	Rehabilitation	Rehabilitation	220QL	WOS:000250171800007	17852253				2021-06-18	
J	Karunanayaka, PR; Holland, SK; Yuan, W; Altaye, M; Jones, BV; Michaud, LJ; Walz, NC; Wade, SL				Karunanayaka, Prasanna R.; Holland, Scott K.; Yuan, Weihong; Altaye, Mekibib; Jones, Blaise V.; Michaud, Linda J.; Walz, Nicolay Chertkoff; Wade, Shari L.			Neural substrate differences in language networks and associated language-related behavioral impairments in children with TBI: A preliminary fMRI investigation	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; POSITRON EMISSION TOMOGRAPHY; VERBAL WORKING-MEMORY; LONG-TERM OUTCOMES; CLOSED-HEAD-INJURY; EVENT-RELATED FMRI; FUNCTIONAL MRI; SENTENCE COMPREHENSION; TEMPORAL-LOBE; PREFRONTAL CORTEX	The present study examined whether functional MRI (fMRI) can identify changes in the neural substrates of language in young children following traumatic brain injury (TBI). Eight children with TBI (F/M = 3/5, age (Mean +/- SD) = 7.98 +/- 1 years, range = 6-9 years) and a comparison group of nine children with orthopedic injuries (OI) (F/M = 4/5, age (Mean +/- SD) = 7.4 +/- 1 years, range = 6-9 years) participated in an fMRI study of covert verb generation (VG). Results revealed significantly different BOLD signal activation in perisylvian language areas between the groups, after accounting for potential confounders such as verbal fluency and executive function. We also found significant associations between the BOLD signal activation and performance on language-specific neuropsychological tests (NEPSY verbal fluency score, Verbal IQ) and Glasgow Coma Scale (GCS) score. This study suggests that children with TBI have significantly different brain activation patterns in language circuitry compared to children with orthopedic injuries. Although we found clear differences in brain activation between the two groups, conventional MR images showed no evidence of structural abnormalities in five of eight children with TBI. Our study demonstrates the feasibility and potential utility of fMRI as a means of quantifying changes associated with language deficits in future pediatric TBI studies.	[Karunanayaka, Prasanna R.; Holland, Scott K.; Yuan, Weihong; Altaye, Mekibib; Jones, Blaise V.] Cincinnati Childrens Hosp, Med Ctr, Imaging Res Ctr, Dept Radiol,Pediat Neuroimaging Res Consortium, Cincinnati, OH 45229 USA; [Michaud, Linda J.; Walz, Nicolay Chertkoff; Wade, Shari L.] UC Coll Med, Cincinnati, OH USA; [Michaud, Linda J.; Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Behav Med & Psychol, Cincinnati, OH 45229 USA; [Holland, Scott K.; Yuan, Weihong; Jones, Blaise V.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Karunanayaka, PR (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Imaging Res Ctr, Dept Radiol,Pediat Neuroimaging Res Consortium, 3333 Burnet Ave ML 5031, Cincinnati, OH 45229 USA.	Prasana.Karunanayaka@cchmc.org	Altaye, Mekibib/N-5274-2015	Holland, Scott/0000-0003-3719-0875	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038578, R43HD044279] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR 08084, M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD038578, R01-HD38578, R01 HD042729, R01-HD044279, R43 HD044279] Funding Source: Medline		Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; Behrmann M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/j.conb.2004.03.012; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Booth JR, 2000, DEV NEUROPSYCHOL, V18, P139, DOI 10.1207/S15326942DN1802_1; Braver TS, 2001, NEUROIMAGE, V14, P48, DOI 10.1006/nimg.2001.0791; Brizzolara D, 2002, NEUROPSYCHOLOGIA, V40, P620, DOI 10.1016/S0028-3932(01)00158-0; Bullmore ET, 2000, NEUROIMAGE, V11, P289, DOI 10.1006/nimg.2000.0544; Byars AW, 2002, J CHILD NEUROL, V17, P885, DOI 10.1177/08830738020170122201; Cabeza R., 2001, HDB FUNCTIONAL NEURO; Cabeza Roberto, 2000, Current Opinion in Neurology, V13, P415, DOI 10.1097/00019052-200008000-00008; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Caplan D, 2000, HUM BRAIN MAPP, V9, P65; Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chein JM, 2003, J NEUROLINGUIST, V16, P315, DOI 10.1016/S0911-6044(03)00021-6; Chiu CYP, 2005, NEUROREPORT, V16, P883, DOI 10.1097/00001756-200506210-00002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Detre JA, 1998, NEUROLOGY, V50, P926, DOI 10.1212/WNL.50.4.926; Elliot C. D., 1990, INTRO TECHNICAL HDB; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Friederici AD, 2003, CEREB CORTEX, V13, P170, DOI 10.1093/cercor/13.2.170; Friston KJ, 2002, NEUROIMAGE, V16, P513, DOI 10.1006/nimg.2001.1044; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Hallett T L, 1997, Pediatr Rehabil, V1, P219; HART J, 1990, ANN NEUROL, V27, P226, DOI 10.1002/ana.410270303; Hashimoto R, 2002, NEURON, V35, P589, DOI 10.1016/S0896-6273(02)00788-2; Holland SK, 2001, NEUROIMAGE, V14, P837, DOI 10.1006/nimg.2001.0875; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; Inui T, 1998, NEUROREPORT, V9, P3325, DOI 10.1097/00001756-199810050-00032; Jacola LM, 2006, NEUROPEDIATRICS, V37, P46, DOI 10.1055/s-2006-923934; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jung SH, 2005, ARCH PHYS MED REHAB, V86, P2218, DOI 10.1016/j.apmr.2005.04.015; Just MA, 1996, SCIENCE, V274, P114, DOI 10.1126/science.274.5284.114; Karunanayaka PR, 2007, NEUROIMAGE, V34, P349, DOI 10.1016/j.neuroimage.2006.08.028; KINGSTONE RCA, 2001, HDB FUNCTIONAL NEURO; Korkman M, 2001, DEV NEUROPSYCHOL, V20, P331, DOI 10.1207/S15326942DN2001_2; Korkman M, 1998, NEPSY DEV NEUROPSYCH; Kuperberg GR, 2000, J COGNITIVE NEUROSCI, V12, P321, DOI 10.1162/089892900562138; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Liepert J, 2005, STROKE, V36, P2648, DOI 10.1161/01.STR.0000189629.10603.02; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKeown MJ, 1998, HUM BRAIN MAPP, V6, P160, DOI 10.1002/(SICI)1097-0193(1998)6:3<160::AID-HBM5>3.3.CO;2-R; Mechelli A, 2003, J COGNITIVE NEUROSCI, V15, P925, DOI 10.1162/089892903770007317; Morse S, 1999, Pediatr Rehabil, V3, P139; Muller RA, 1998, ARCH NEUROL-CHICAGO, V55, P1113, DOI 10.1001/archneur.55.8.1113; Muzik O, 2000, NEUROIMAGE, V12, P538, DOI 10.1006/nimg.2000.0651; Nakai T, 1999, NEUROSCI LETT, V263, P33, DOI 10.1016/S0304-3940(99)00103-2; Newman AJ, 2001, J PSYCHOLINGUIST RES, V30, P339, DOI 10.1023/A:1010499119393; Ni W, 2000, J COGNITIVE NEUROSCI, V12, P120, DOI 10.1162/08989290051137648; Papanicolaou AC, 2001, J CHILD NEUROL, V16, P241; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Penny WD, 2004, NEUROIMAGE, V22, P1157, DOI 10.1016/j.neuroimage.2004.03.026; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PONER M, 1991, J COGNITIVE NEUROSCI, V3, P303; Price CJ, 2000, J ANAT, V197, P335, DOI 10.1046/j.1469-7580.2000.19730335.x; Pugh KR, 1996, NEUROIMAGE, V4, P159, DOI 10.1006/nimg.1996.0067; RAUSCH R, 1993, ARCH NEUROL-CHICAGO, V50, P812, DOI 10.1001/archneur.1993.00540080023008; Ravizza SM, 2004, NEUROIMAGE, V22, P562, DOI 10.1016/j.neuroimage.2004.01.039; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Sakai KL, 2002, NEURON, V35, P1177, DOI 10.1016/S0896-6273(02)00873-5; Schapiro MB, 2004, NEUROREPORT, V15, P2575, DOI 10.1097/00001756-200412030-00003; Schmithorst VJ, 2006, NEUROIMAGE, V31, P1366, DOI 10.1016/j.neuroimage.2006.01.010; Schmithorst VJ, 2006, NEUROIMAGE, V29, P254, DOI 10.1016/j.neuroimage.2005.07.020; Schmithorst VJ, 2004, MAGN RESON MED, V51, P399, DOI 10.1002/mrm.10706; Schmithorst VJ, 2001, IEEE T MED IMAGING, V20, P535, DOI 10.1109/42.929619; Scott SK, 2000, BRAIN, V123, P2400, DOI 10.1093/brain/123.12.2400; Shaywitz BA, 2007, ANN NEUROL, V61, P363, DOI 10.1002/ana.21093; Solodkin A, 2004, CEREB CORTEX, V14, P1246, DOI 10.1093/cercor/bhh086; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Staudt M, 2001, NEUROLOGY, V57, P122, DOI 10.1212/WNL.57.1.122; Stromswold K, 1996, BRAIN LANG, V52, P452, DOI 10.1006/brln.1996.0024; Szaflarski JP, 2006, ANN NEUROL, V59, P796, DOI 10.1002/ana.20817; Szaflarski JP, 2006, HUM BRAIN MAPP, V27, P202, DOI 10.1002/hbm.20177; Szaflarski JP, 2004, EPILEPSY BEHAV, V5, P244, DOI 10.1016/j.yebeh.2004.01.002; Talairach J., 1988, COPLANAR STEREOTAXIC, P122; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wilke M, 2002, HUM BRAIN MAPP, V17, P48, DOI 10.1002/hbm.10053; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404; Yuan WH, 2006, EPILEPSIA, V47, P593, DOI 10.1111/j.1528-1167.2006.00474.x	94	24	24	1	19	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	5					355	369					15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258HW	WOS:000252860000003	18162699				2021-06-18	
J	Winqvist, S; Jokelainen, J; Luukinen, H; Hillbom, M				Winqvist, Satu; Jokelainen, Jari; Luukinen, Heikki; Hillbom, Matti			Parental alcohol misuse is a powerful predictor for the risk of traumatic brain injury in childhood	BRAIN INJURY			English	Article						alcohol; drinking habits; family history of alcohol misuse; traumatic brain injury; adolescents	SELF-REPORTED DRINKING; HEAD-INJURY; CHILDREN; RELIABILITY; ABUSE; STUDENTS; ONSET	Background: Although the positive relationship between parental alcohol use and children's injuries is well established, it is not known whether parental alcohol misuse is a risk factor for traumatic brain injuries ( TBIs) of their children and whether subjects with childhood TBI have hazardous drinking habits in adolescence. Methods: The authors conducted a longitudinal cohort study at Oulu University Hospital. The cohort consisted of 12 058 subjects born in 1966, of which 207 had sustained TBI before the age of 14 years. Data on parental alcohol problems were obtained from the Finnish Hospital Discharge Register and the adolescents' drinking habits were analysed based on a postal inquiry at the age of 14 years. Results: Parental alcohol misuse (RR 1.99, CI 1.19 - 3.33) and male gender (RR 1.53, CI 1.12 - 2.08) significantly predicted the risk of childhood TBI. Drinking to intoxication at the age of 14 was significantly associated with parental alcohol misuse (RR 1.62, CI 1.34 - 1.96), belonging to a one-parent family (RR 1.80, CI 1.61 - 2.02) and mild TBI (RR 1.67, CI 1.20 - 2.33). Conclusions: It was observed that parental alcohol misuse is a major risk factor for TBI in children and drinking to intoxication is a common drinking pattern of adolescents who have sustained TBI in childhood.	Oulu Univ Hosp, Dept Neurol, FIN-90029 Oys, Finland; Univ Oulu, Dept Neurol, Oulu, Finland; Univ Oulu, Dept Publ Hlth Sci & Gen Practice, Oulu, Finland; Univ Hosp Oulu, Unit Gen Practice, Oulu, Finland	Winqvist, S (corresponding author), Oulu Univ Hosp, Dept Neurol, Box 25, FIN-90029 Oys, Finland.	satu.winqvist@oulu.fi		Jokelainen, Jari/0000-0003-4629-0560			Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BIJUR PE, 1992, JAMA-J AM MED ASSOC, V17, P3166; Bjarnason T, 2003, J STUD ALCOHOL, V64, P200, DOI 10.15288/jsa.2003.64.200; Chalder M, 2006, ALCOHOL ALCOHOLISM, V41, P107, DOI 10.1093/alcalc/agh215; Conners NA, 2004, AM J DRUG ALCOHOL AB, V30, P85, DOI [10.1081/ADA-120029867, 10.1081/ADA-120026258]; Crandall M, 2006, J SURG RES, V133, P7, DOI 10.1016/j.jss.2006.02.027; Dantzer C, 2006, J AM COLL HEALTH, V55, P83, DOI 10.3200/JACH.55.2.83-90; DIKMEN SS, 1995, ANN EMERG MED, V26, P221; Droomers M, 2003, J EPIDEMIOL COMMUN H, V57, P704, DOI 10.1136/jech.57.9.704; Dunn C, 2003, J TRAUMA, V54, P707, DOI 10.1097/01.TA.0000030625.63338.B2; Gruenewald PJ, 2006, J STUD ALCOHOL, V67, P738, DOI 10.15288/jsa.2006.67.738; Hartman CA, 2006, J STUD ALCOHOL, V67, P657, DOI 10.15288/jsa.2006.67.657; HINGSON RW, 2000, JAMA-J AM MED ASSOC, V27, P1527; Johnson TP, 2001, ADDICTION, V96, P1187, DOI 10.1046/j.1360-0443.2001.968118711.x; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Kuendig H, 2006, ALCOHOL ALCOHOLISM, V41, P464, DOI 10.1093/alcalc/agl018; Kuntsche S, 2006, ALCOHOL ALCOHOLISM, V41, pI37, DOI 10.1093/alcalc/agl074; Lintonen T, 2004, ALCOHOL ALCOHOLISM, V39, P362, DOI 10.1093/alcalc/agh071; Lintonen T, 2000, HEALTH EDUC RES, V15, P261, DOI 10.1093/her/15.3.261; Makela P, 2003, J STUD ALCOHOL, V64, P589; Max JE, 1997, BRAIN INJURY, V11, P699; Rantakallio P, 1997, INT J EPIDEMIOL, V26, P837, DOI 10.1093/ije/26.4.837; Ross LT, 2001, SUBST USE MISUSE, V36, P609, DOI 10.1081/JA-100103563; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sosin DM, 1996, BRAIN INJURY, V10, P47; Swan MC, 2004, ALCOHOL RES, V9, P59; Tait RJ, 2005, DRUG ALCOHOL DEPEN, V79, P365, DOI 10.1016/j.drugalcdep.2005.03.016; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Van Zundert RMP, 2006, J FAM PSYCHOL, V20, P456, DOI 10.1037/0893-3200.20.3.456; Villalba-Cota J, 2004, ANN TROP PAEDIATR, V24, P53, DOI 10.1179/027249304225013259; Widom CS, 2001, ALCOHOL RES HEALTH, V25, P52; WINQVIST S, 2006, J ADOLESCENT HEALTH, V39, pE1; Winter T, 2002, ALCOHOL ALCOHOLISM, V37, P330, DOI 10.1093/alcalc/37.4.330	35	24	24	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	10					1079	1085		10.1080/02699050701553221			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600011	17852100				2021-06-18	
J	Harrison, G; Whitley, E; Rasmussen, F; Lewis, G; Dalman, C; Gunnell, D				Harrison, Glynn; Whitley, Elise; Rasmussen, Finn; Lewis, Glyn; Dalman, Christina; Gunnell, David			Risk of schizophrenia and other non-affective psychosis among individuals exposed to head injury: Case control study	SCHIZOPHRENIA RESEARCH			English	Article						schizophrenia; head injury; psychosis; case control	TRAUMATIC BRAIN-INJURY; ASSOCIATION; DISORDER; EPILEPSY	Studies of the risk of schizophrenia and related non-affective psychoses among individuals exposed to head injury have reported conflicting findings. The diagnostic specificity of reported associations remains unclear and the effects of sex, genetic vulnerability and timing of exposures are also uncertain. The authors used a comprehensive range of data derived from the linkage of several Swedish registers to investigate associations of head injury with schizophrenia and other non-affective psychoses. We carried out a nested case control study drawn from a cohort of 785,051 men and women born between 1973 and 1980. After head injury exposure, there was a small increase in the risk (OR 1.37 (CI 1.14-1.66)) of non-schizophrenic, non-affective psychoses but not schizophrenic disorder (OR 1.10 CI 0.82 to 1.47). There was no critical period effect for exposures in early childhood, the association with non-affective psychosis being observed only in those exposed to head injury after age 10. There was no evidence that associations differed in males and females or in those with, and those without, a family history of psychosis. We conclude that it is unlikely that head injury causes schizophrenia. There is a small but significant risk of non-schizophrenic psychotic disorders but this is not associated with early age of injury or family history of psychosis. Further research is needed to clarify the potential roles of social and biological intermediary factors. (c) 2006 Elsevier B.V All rights reserved.	Karolinska Inst, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden; Univ Bristol, Acad Unit Psychiat, Bristol BS6 6JL, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Stockholm Ctr Publ Hlth, S-11891 Stockholm, Sweden	Rasmussen, F (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden.	finn.rasmussen@ki.se	Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245; Dalman, Christina/0000-0002-3579-2357; Rasmussen, Finn/0000-0001-7915-7809; Whitley, Elise/0000-0002-0297-9078			AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; DAVISON D, 1969, BRIT J PSYCHIAT, V4, P113; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Garety PA, 2001, PSYCHOL MED, V31, P189, DOI 10.1017/S0033291701003312; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Gunnell D, 2003, AM J EPIDEMIOL, V158, P291, DOI 10.1093/aje/kwg118; Harrison G, 2003, PSYCHOL MED, V33, P723, DOI 10.1017/S0033291703007591; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Sachdev P, 1998, AM J PSYCHIAT, V155, P325, DOI 10.1176/ajp.155.3.325; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Stata Corporation, 2003, STAT STAT SOFTW REL; Tienari P, 2004, BRIT J PSYCHIAT, V184, P216, DOI 10.1192/bjp.184.3.216; WARDASZKO H, 1966, J NEUROL NEUROSUR PS, V16, P101	20	24	25	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	DEC	2006	88	1-3					119	126		10.1016/j.schres.2006.07.001			8	Psychiatry	Psychiatry	115FJ	WOS:000242719900015	16935470				2021-06-18	
J	Tenovuo, O				Tenovuo, Olli			Pharmacological enhancement of cognitive and behavioral deficits after traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article						cholinergic agents; cognition; dopaminergic agents; psychostimulants; traumatic brain injury	DOUBLE-BLIND; MODAFINIL; ATOMOXETINE; AMANTADINE; PLACEBO; METHYLPHENIDATE; REHABILITATION; FATIGUE; PERFORMANCE; MECHANISMS	Purpose of review To provide the clinician with a reasonable overview of the modern pharmacological alternatives to treat the cognitive and behavioral sequels of traumatic brain injury. Recent findings Original research in this area is sparse and more than half of the articles published on the subject recently have been reviews. Of the three randomized controlled trials, one studied methylphendate (n = 18), one methylphenidate and sertraline (n = 30) and one amantadine (n = 27). All these studies reported beneficial effects on various cognitive measures, but because of the study protocols, the evidence provided may be questioned. The various reviews, uncontrolled studies and case reports suggest that at least psychostimulants, cholinergic agents, dopaminergic agents and antidepressants may be beneficial in treating the cognitive and behavioral symptoms of traumatic brain injury. Summary The clinician trying to ameliorate the cognitive and behavioral symptoms of traumatic brain injury has to make decisions about pharmacotherapy that are still based mainly on clinical experience. Large randomized controlled trials giving high-quality evidence are so far missing. This review discusses the problems facing both the clinician and the scientist treating the cognitive and behavioral sequels of traumatic brain injury. A symptom-based approach is suggested for current practice.	Turku Univ, Dept Neurol, Turku 20521, Finland	Tenovuo, O (corresponding author), Turku Univ, Dept Neurol, POB 52, Turku 20521, Finland.	olli.tenovuo@tyks.fi					Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Apud Jose A, 2006, NeuroRx, V3, P106, DOI 10.1016/j.nurx.2005.12.004; Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406; Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; Bennouna M, 2005, J CLIN PSYCHOPHARM, V25, P505, DOI 10.1097/01.jcp.0000177851.31157.66; Beresford TP, 2005, BRAIN INJURY, V19, P309, DOI 10.1080/02699050410001720121; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; DeMarchi R, 2005, CAN J NEUROL SCI, V32, P4, DOI 10.1017/S0317167100016826; Faraone SV, 2005, J CHILD ADOL PSYCHOP, V15, P664, DOI 10.1089/cap.2005.15.664; Foster DJ, 2006, ARCH PHYS MED REHAB, V87, P216, DOI 10.1016/j.apmr.2005.08.131; Glenn MB, 2002, J HEAD TRAUMA REHAB, V17, P273, DOI 10.1097/00001199-200208000-00002; Glenn MB, 2005, J HEAD TRAUMA REHAB, V20, P51, DOI 10.1097/00001199-200501000-00006; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; Hernandez AV, 2005, NEUROSURGERY, V57, P1244, DOI 10.1227/01.NEU.0000186039.57548.96; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; Lipton Stuart A, 2004, NeuroRx, V1, P101, DOI 10.1007/BF03206570; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Newburn G, 2005, BRAIN INJURY, V19, P149, DOI 10.1080/02699050410001719989; Ondo WG, 2005, J NEUROL NEUROSUR PS, V76, P1636, DOI 10.1136/jnnp.2005.065870; Papakostas GI, 2006, J PSYCHIAT RES, V40, P370, DOI 10.1016/j.jpsychires.2005.04.013; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; Randall DC, 2005, PHARMACOL BIOCHEM BE, V82, P133, DOI 10.1016/j.pbb.2005.07.019; Randall DC, 2005, J PSYCHOPHARMACOL, V19, P647, DOI 10.1177/0269881105056531; Ripley DL, 2006, J HEAD TRAUMA REHAB, V21, P85, DOI 10.1097/00001199-200601000-00010; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Stankoff B, 2005, NEUROLOGY, V64, P1139, DOI 10.1212/01.WNL.0000158272.27070.6A; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Sugden SG, 2006, NEUROREHABILITATION, V21, P3; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo OS, 2006, CURR DRUG THER, V1, P187, DOI 10.2174/157488506776930932; Turner-Stokes L, 2005, CLIN MED, V5, P268, DOI 10.7861/clinmedicine.5-3-268; Tzavara ET, 2006, MOL PSYCHIATR, V11, P187, DOI 10.1038/sj.mp.4001763; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Wu TS, 2005, J EMERG MED, V28, P289, DOI 10.1016/j.jemermed.2004.11.016; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	51	24	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2006	19	6					528	533		10.1097/WCO.0b013e328010944f			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	115XJ	WOS:000242766800004	17102689				2021-06-18	
J	Bochicchio, GV; Bochicchio, K; Nehman, S; Casey, C; Andrews, P; Scalea, TM				Bochicchio, Grant V.; Bochicchio, Kelly; Nehman, Shelley; Casey, Colleen; Andrews, Penny; Scalea, Thomas M.			Tolerance and efficacy of enteral nutrition in traumatic brain-injured patients induced into barbiturate coma	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article							INTRACRANIAL-PRESSURE	Background: There is a paucity of data evaluating the efficacy of nutrition support in traumatic brain-injured patients induced into barbiturate coma for refractory intracranial hypertension. Our objective was to evaluate the efficacy of enteral nutrition in a select group of trauma patients. Methods: Prospective data were collected on severe traumatic brain-injured patients over a 4-year period. Patients were stratified by whether or not they were induced into a barbiturate coma. Barbiturate coma was defined as per American Association of Neurological Surgeons (AANS) guidelines. All patients were initially fed via the enteral route via a nasogastric feeding tube. Patients who did not tolerate feedings within 48 hours started receiving prokinetic,agents. Feeding tolerance was defined as ability to tolerate enteral feedings with < 150 mL of gastric residuals every 6 hours for > 72 hours. Results: Fifty-seven patients were induced into a barbiturate coma. All were victims of blunt-force trauma. Forty-two of 57 (74%) patients were men, with a mean age of 37 +/- 12 years and a mean injury severity score of 24 +/- 10. Thirty-eight of the 57 (67%) patients had an isolated traumatic brain injury. All 57 patients failed enteral nutrition via the nasogastric route after the first 48 hours of nutrition initiation after barbiturate coma was fully achieved by protocol criteria. Prokinetic agents demonstrated no improvement in feeding tolerance after the subsequent 48-72 hours. Of the 12 patients who had a postpyloric feeding tube placed, only 25% tolerated enteral nutrition for > 48 hours. Conclusions: Patients with traumatic brain injury induced into barbiturate coma develop a significant ileus that is refractory to prokinetic agents. Only a marginal improvement is seen when the postpyloric route is obtained. Early parenteral nutrition should be considered in this patient population.	Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, Baltimore, MD 21201 USA	Bochicchio, GV (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Clin & Outcomes Res, Room TIR59,22 S Greene St, Baltimore, MD 21201 USA.	gbochicchio@umm.edu					Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kerwin AJ, 2000, J TRAUMA, V48, P878, DOI 10.1097/00005373-200005000-00011; MAGNUSON B, 1999, NUTR CLIN PRACT, V14, P131; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MILLER C H, 1991, Neurological Research, V13, P117; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Rosenthal RJ, 1997, SURG ENDOSC, V11, P376, DOI 10.1007/s004649900367; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; Wilson RF, 2001, NEUROL RES, V23, P121, DOI 10.1179/016164101101198451	13	24	30	0	6	AMER SOC PARENTERAL & ENTERAL NUTRITION	SILVER SPRING	8630 FENTON STREET SUITE 412, SILVER SPRING, MD 20910 USA	0148-6071			JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	NOV-DEC	2006	30	6					503	506		10.1177/0148607106030006503			4	Nutrition & Dietetics	Nutrition & Dietetics	195XC	WOS:000248444700007	17047175				2021-06-18	
J	Klasner, B; Lumenta, DB; Pruneau, D; Zausinger, S; Plesnila, N				Klaesner, Benjamin; Lumenta, David B.; Pruneau, Didier; Zausinger, Stefan; Plesnila, Nikolaus			Therapeutic window of bradykinin B-2 receptor inhibition after focal cerebral ischemia in rats	NEUROCHEMISTRY INTERNATIONAL			English	Article						focal cerebral ischemia; stroke; kallilcrein-kinin system; bradykinin; kinin receptors; bradykinin B-2 receptor; inhibition; rats	VASOGENIC BRAIN EDEMA; KALLIKREIN-KININ SYSTEM; CLOSED-HEAD TRAUMA; LF 16-0687 MS; REGIONAL-DISTRIBUTION; BINDING-SITES; ANTAGONIST; INJURY; MODEL; MEDIATOR	Following cerebral ischemia bradykinin/kinin B-2 receptors mediate inflammatory responses resulting in edema formation and secondary brain damage. However, the therapeutic window for B-2 receptor inhibition determining its potential clinical use has not been investigated so far. The aim of the current study was therefore to investigate the effect of delayed B-2 receptor inhibition on morphological and functional outcome following experimental stroke. Rats were subjected to 90 min of middle cerebral artery occlusion(MCAo) by an intraluminal filament. Animals received 0.9% NaCl or 1.0 mg/kg/day Anatibant (LF 16-0687 Ms), a selective bradykinin 13, receptor antagonist, for 3 days beginning at different time points after MCAo: 1, 2.5, 4.5, or 6.5 h (n = 10 per group). Neurological recovery was examined daily, infarct volume on day 7 after MCAo. Animal physiology was not influenced by B-2 receptor inhibition. Significant improvement of functional outcome was observed when treatment was delayed up to 4.5 It after ischemia (p < 0.05 versus vehicle). Inhibition of B-2 receptors during ischemia, i.e. when the inhibitor was given I h after MCAo, reduced infarct volume in the basal ganglia and in the cortex by 49% (p < 0.05) and 26% (p < 0.05), resp < ectively. Inhibition of B-2 receptors at later time points (2.5, 4.5, or 6.5 after MCAo) reduced penumbral damage, i.e. cortical infarction, by 19-26% (p < 0.05). In conclusion, the current study shows that the therapeutic window of B-2 receptor inhibition extends for up to 6.5 h after MCAo. Our data therefore suggest that inhibition of kinin B-2 receptors represents a treatment strategy for ischemic stroke which may warrant clinical validation. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Munich, Klinikum Grosshadern, Med Ctr, Dept Neurosurg,Lab Expt Neurosurg, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Med Ctr, Inst Surg Res, D-81377 Munich, Germany; Fournier Pharma, Ctr Rech, Grp Pharmacochim Recepteurs, Daix, France	Plesnila, N (corresponding author), Univ Munich, Klinikum Grosshadern, Med Ctr, Dept Neurosurg,Lab Expt Neurosurg, Marchioninistr 15, D-81377 Munich, Germany.	plesnila@med.uni-muenchen.de	Lumenta, David Benjamin/AAD-5935-2019; Plesnila, Nikolaus/T-7522-2019	Lumenta, David Benjamin/0000-0003-0903-252X; 			Asa I, 2003, J TRAUMA, V54, P881, DOI 10.1097/01.TA.0000046700.45106.4B; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Chalela JA, 2004, CURR OPIN NEUROL, V17, P447, DOI 10.1097/01.wco.0000137536.06986.f9; CHAO J, 1983, J BIOL CHEM, V258, P5173; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; CHOLEWINSKI AJ, 1991, J NEUROCHEM, V57, P1456, DOI 10.1111/j.1471-4159.1991.tb08314.x; CORREA FMA, 1979, P NATL ACAD SCI USA, V76, P1489, DOI 10.1073/pnas.76.3.1489; Couture R, 2001, EUR J PHARMACOL, V429, P161, DOI 10.1016/S0014-2999(01)01318-8; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; GARCIA JH, 1992, J NEUROPATH EXP NEUR, V51, P387, DOI 10.1097/00005072-199207000-00001; GARCIA JH, 1993, AM J PATHOL, V142, P623; GIMPL G, 1992, NEUROSCI LETT, V144, P139, DOI 10.1016/0304-3940(92)90735-P; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HOSLI E, 1993, NEUROREPORT, V4, P159; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; Kamiya T, 1990, Adv Neurol, V52, P543; Kamiya T, 1990, Nihon Ika Daigaku Zasshi, V57, P180; Kaplanski J, 2003, RESUSCITATION, V56, P207, DOI 10.1016/S0300-9572(02)00371-4; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; KARIYA K, 1981, J NEUROCHEM, V36, P2086, DOI 10.1111/j.1471-4159.1981.tb10838.x; KARIYA K, 1982, BIOCHEM BIOPH RES CO, V107, P1461, DOI 10.1016/S0006-291X(82)80163-0; KARIYA K, 1985, J NEUROCHEM, V44, P1892, DOI 10.1111/j.1471-4159.1985.tb07185.x; KLENIEWSKI J, 1980, EXPERIENTIA, V36, P354, DOI 10.1007/BF01952323; Lehmberg J, 2003, J CEREBR BLOOD F MET, V23, P441, DOI 10.1097/01.WCB.0000052280.23292.35; Li DZ, 2003, BRIT J PHARMACOL, V139, P1539, DOI 10.1038/sj.bjp.0705385; Lorenzl S, 1996, EUR J PHARMACOL, V308, P335, DOI 10.1016/0014-2999(96)00375-5; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Noda M, 2003, LIFE SCI, V72, P1573, DOI 10.1016/S0024-3205(02)02449-9; Pan WH, 2001, NEUROSCI LETT, V307, P25, DOI 10.1016/S0304-3940(01)01904-8; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; Pruneau D, 1998, BRIT J PHARMACOL, V125, P365, DOI 10.1038/sj.bjp.0702083; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V33, P104, DOI 10.1016/0162-3109(96)00021-5; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; RELTON JK, 1996, BRIT J PHARMACOL, V120, pC81; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Schwaninger M, 1999, J NEUROCHEM, V73, P1461, DOI 10.1046/j.1471-4159.1999.0731461.x; SCICLI AG, 1984, CLIN EXP HYPERTENS A, V6, P1731, DOI 10.3109/10641968409046068; STEPHENS GJ, 1993, NEUROSCI LETT, V153, P223, DOI 10.1016/0304-3940(93)90327-H; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WHITTLE IR, 1992, ACTA NEUROCHIR, V115, P53, DOI 10.1007/BF01400591; Xia CF, 2004, HYPERTENSION, V43, P452, DOI 10.1161/01.HYP.0000110905.29389.e5; Yong T, 1996, BRAIN INJURY, V10, P385, DOI 10.1080/026990596124395; Zausinger S, 2002, BRAIN RES, V950, P268, DOI 10.1016/S0006-8993(02)03053-6	55	24	26	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	OCT	2006	49	5					442	447		10.1016/j.neuint.2006.02.010			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	080CX	WOS:000240225600003	16624448				2021-06-18	
J	Corbett, SM; Moore, J; Rebuck, JA; Rogers, FB; Greene, CM				Corbett, Stephanie Mallow; Moore, Jesse; Rebuck, Jill A.; Rogers, Frederick B.; Greene, Christopher M.			Survival of propofol infusion syndrome in a head-injured patient	CRITICAL CARE MEDICINE			English	Article						propofol; acidosis; brain injuries; intracranial pressure; catecholamines	METABOLIC-ACIDOSIS; LACTIC-ACIDOSIS; CATECHOLAMINE CARDIOTOXICITY; INTENSIVE-CARE; ADULT; ANESTHESIA; RHABDOMYOLYSIS; DYSFUNCTION; CHILDREN; FAILURE	Objective. To describe the clinical progression of an adult patient with traumatic brain injury who. survived propofol infusion syndrome. Design. Case report. Setting: Tertiary care surgical intensive care unit. Patient. A 21-yr-old male with traumatic brain injury was administered high doses of propofol for sedation and intracranial pressure control combined with vasopressor therapy to maintain cerebral perfusion pressure >60 mmHg. He developed a significant metabolic acidosis with a lactic acid level of 10.9 mmol/L. Interventions: Exploratory laparotomy, discontinuation of propofol infusion. Measurements and Main Results, An exploratory abdominal laparotomy was negative for traumatic injury. During the procedure, the propofol infusion was considered a possible cause and was discontinued. On review, it became apparent that a combination of high-dose propofol and catecholamines were responsible for the lactic acidosis. An echocardiogram revealed severe left ventricular dysfunction and cardiomyopathy, which resolved within 19 days. Conclusions: High-dose propofol should be avoided and alternative agents should be instituted for sedation and intracranial pressure management. The use of catecholamine infusions to maintain cerebral perfusion pressure in the setting of a high-dose propofol infusion may be pharmacologically unsound and may be a triggering factor for propofol infusion syndrome. Identification of the syndrome and discontinuation of propofol resulted in complete reversal of symptoms in the case described.	Univ Vermont, Coll Med, Dept Surg, Div Trauma Crit Care, Burlington, VT 05405 USA; Fletcher Allen Hlth Care, Dept Pharmacotherapy, Burlington, VT USA; Fletcher Allen Hlth Care, Dept Anesthesiol, Burlington, VT USA	Corbett, SM (corresponding author), Univ Vermont, Coll Med, Dept Surg, Div Trauma Crit Care, Burlington, VT 05405 USA.						Akashi YJ, 2002, J ELECTROCARDIOL, V35, P351, DOI 10.1054/jelc.2002.36277; Burow BK, 2004, ANESTHESIOLOGY, V101, P239, DOI 10.1097/00000542-200407000-00035; Cannon ML, 2001, J NEUROSURG, V95, P1053, DOI 10.3171/jns.2001.95.6.1053; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Culp KE, 2004, ANESTH ANALG, V99, P221, DOI 10.1213/01.ane.0000117285.12600.c1; Girard F, 2004, ANESTH ANALG, V99, P573, DOI 10.1213/01.ANE.0000133138.86133.38; Johnson KB, 2004, ANESTHESIOLOGY, V101, P647, DOI 10.1097/00000542-200409000-00013; Kang TM, 2002, ANN PHARMACOTHER, V36, P1453; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kelly DF, 2001, J NEUROSURG, V95, P925, DOI 10.3171/jns.2001.95.6.0925; Koch M, 2004, INTENS CARE MED, V30, P522, DOI 10.1007/s00134-003-2130-3; Kurita T, 2004, ANESTHESIOLOGY, V100, P871, DOI 10.1097/00000542-200404000-00017; Liolios A, 2005, ANESTH ANALG, V100, P1804, DOI 10.1213/01.ANE.0000153017.93666.BF; Machata AM, 2005, J TRAUMA, V58, P643, DOI 10.1097/01.TA.0000159697.03562.D6; Marinella MA, 1996, CHEST, V109, P292, DOI 10.1378/chest.109.1.292; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Rigby-Jones AE, 2002, ANESTHESIOLOGY, V97, P1393, DOI 10.1097/00000542-200212000-00010; RONA G, 1985, J MOL CELL CARDIOL, V17, P291, DOI 10.1016/S0022-2828(85)80130-9; Salengros JC, 2004, ANESTHESIOLOGY, V101, P241, DOI 10.1097/00000542-200407000-00036; Shafer SL, 2004, ANESTHESIOLOGY, V101, P567, DOI 10.1097/00000542-200409000-00002; Stelow EB, 2000, CLIN CHEM, V46, P577; Takizawa D, 2005, CAN J ANAESTH, V52, P463, DOI 10.1007/BF03016523; Vane LA, 2004, ANESTHESIOLOGY, V101, P1136, DOI 10.1097/00000542-200411000-00013; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007	29	24	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2006	34	9					2479	2483		10.1097/01.CCM.0000230238.72846.B3			5	Critical Care Medicine	General & Internal Medicine	077EK	WOS:000240010400028	16791112				2021-06-18	
J	Haber, AH; Fichtenberg, NL				Haber, Adele H.; Fichtenberg, Norman L.			Replication of the Test of Memory Malingering (TOMM) in a traumatic brain injury and head trauma sample	CLINICAL NEUROPSYCHOLOGIST			English	Article							COGNITIVELY INTACT; NORMATIVE DATA; VALIDATION; DEPRESSION	The purpose of the current study was to replicate the clinical validation study of the Test of Memory Malingering (Tombaugh, 19961997). Fifty cases were selected from two different participant pools: medically documented traumatic brain-injury patients and compensation-seeking, mild head trauma cases. Results replicated and expanded those found by Tombaugh and indicated that employing a Trial 2 cutting score of greater than 5 errors provided adequate sensitivity to suboptimal effort while demonstrating remarkable insensitivity to cognitively impaired traumatic brain-injury cases. Use of a lower cutting score (e.g., 2 to 5 errors) is also discussed.	Tampa Gen Hosp, Rehabil Ctr, Tampa, FL 33601 USA; Inst Rehabil Michigan, Detroit, MI USA	Haber, AH (corresponding author), Tampa Gen Hosp, Rehabil Ctr, POB 1289, Tampa, FL 33601 USA.	ahaber@tgh.org					Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Colby F, 2001, NEUROREHABILITATION, V16, P253; Delain SL, 2003, ASSESSMENT, V10, P370, DOI 10.1177/1073191103259156; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Gutheil TG, 2003, J AM ACAD PSYCHIATRY, V31, P6; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Victor TL, 2004, PROF PSYCHOL-RES PR, V35, P373, DOI 10.1037/0735-7028.35.4.373; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481	17	24	24	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2006	20	3					524	532		10.1080/13854040590967595			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	071MT	WOS:000239607000012	16895863				2021-06-18	
J	Sherer, M; Stouter, J; Hart, T; Nakase-Richardson, R; Olivier, J; Manning, E; Yablon, SA				Sherer, Mark; Stouter, Josephine; Hart, Tessa; Nakase-Richardson, Risa; Olivier, Jake; Manning, Edward; Yablon, Stuart A.			Computed tomography findings and early cognitive outcome after traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; computed tomography; neuropsychological outcome	HEAD-INJURY; LESIONS; MILD; SEQUELAE; 1-YEAR	Primary objective: To examine the relationship between CT abnormalities and early neuropsychological outcome following traumatic brain injury (TBI) using quantitative CT analyses, data reduction methods for neuropsychological results and specific hypotheses based on literature review. Research design: Observational, prospective cohort study using acute (emergency) CT data and neuropsychological test data from 89 participants with TBI who were hospitalized for rehabilitation. Methods and procedures: Principal components analysis with varimax rotation was used to reduce data from a standard battery of eight neuropsychological tests administered after clearance of post-traumatic amnesia (1 month post-TBI on average). Bivariate correlations were used to examine relationships of three factors (verbal memory, cognitive processing speed and verbal working memory) to quantitative volumetric analysis of CT scan abnormalities (size, number and location). Specific hypotheses as to CT predictors of poor performance on each factor were tested using multivariable linear regression that included injury severity and demographic variables. Main results: Eighty-nine per cent of participants had some pathology on initial CT. Age, education and time to follow commands (TFC), an index of overall injury severity, were significantly associated with the neuropsychological factors. However, none of the specific hypotheses about CT scan variables and cognitive outcome were strongly supported by the data. There was a trend for any CT abnormality to predict slower speed of processing and for higher number of brain lesions to predict worse memory performance. Conclusions: Despite the precision added by quantitative CT analysis, CT findings did not improve on demographic factors and TFC in predicting early cognitive outcome of TBI. Imaging methods that are more sensitive to white matter integrity may be needed to develop pathophysiologic predictors of TBI outcome.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA	Sherer, M (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org	Olivier, Jake/D-2034-2012	Olivier, Jake/0000-0002-3144-4507			Benton AL, 1983, MULTILINGUAL APHASIA; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; Cihangiroglu M, 2002, NEUROL RES, V24, P7, DOI 10.1179/016164102101199440; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Fiser SM, 1998, AM SURGEON, V64, P1088; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GOLDMANRAKIC PS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P72; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Liu Wei-guo, 2004, Chin J Traumatol, V7, P175; Milner B., 1970, BIOL MEMORY, P29, DOI 10.1016/B978-0-12-564350-4.50011-7; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A., 1982, SYMBOL DIGIT MODALIT; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; Tranel D., 2002, HDB MEMORY DISORDERS; Valadka AB, 1996, NEUROTRAUMA, P119; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; WILBERGER JE, 2000, HEAD INJURY, P27; Young RJ, 2002, NEUROIMAG CLIN N AM, V12, P189, DOI 10.1016/S1052-5149(02)00003-5	34	24	25	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2006	20	10					997	1005		10.1080/02699050600677055			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100001	17046799				2021-06-18	
J	Wright, WL; Geocadin, RG				Wright, Wendy L.; Geocadin, Romergryko G.			Postresuscitative intensive care: Neuroprotective strategies after cardiac arrest	SEMINARS IN NEUROLOGY			English	Article						postresuscitation; cardiopulmonary-cerebral resuscitation (CPCR); cardiac arrest	CEREBRAL-BLOOD-FLOW; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIAL; CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CARDIOPULMONARY-RESUSCITATION; THROMBOLYTIC THERAPY; COMATOSE SURVIVORS; NEUROLOGICAL RECOVERY	Cardiac arrest is a common disease in the United States, and many patients will die as a result of the neurological damage suffered during the anoxic period, or will live in a neurologically debilitated state. When cardiopulmonary-cerebral resuscitation results in the return of spontaneous circulation, intensive care is required to optimize neurological recovery. Such "brain-oriented" therapies include routine care, such as positioning and maintenance of volume status; optimization of cerebral perfusion, with the use of vasopressors if needed; management of increased intracranial pressure with agents such as hypertonic saline; assuring adequate oxygenation and avoiding hypercapnia; aggressive fever control; intensive glucose control, with the use of an insulin drip if needed; and management of seizures if they occur. To date, no neuroprotectant medications have been shown to improve neurological outcome. Induced moderate therapeutic hypothermia is utilized as a neuroprotective maneuver. Future treatment options and-advanced monitoring techniques are also discussed. Further study to optimize neuroprotective strategies when treating patients who survive cardiac arrest is needed.	Emory Univ Hosp, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ Hosp, Dept Neurosurg, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD USA	Wright, WL (corresponding author), Emory Univ Hosp, Dept Neurol, 1365B Clifton Rd,NE,Suite 2200, Atlanta, GA 30322 USA.				NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01-HL-EB 71568] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44-NS-38016] Funding Source: Medline		ARNOLDUS EPJ, 1995, ANN NEUROL, V38, P697, DOI 10.1002/ana.410380427; Ausina A, 1998, ACT NEUR S, V71, P1; Bell DD, 2005, CAN J ANAESTH, V52, P309, DOI 10.1007/BF03016069; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bhardwaj A, 2004, HDB NEUROCRITICAL CA; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; Bottiger B W, 2001, Curr Opin Crit Care, V7, P176; BOTTIGER BW, 1995, CIRCULATION, V92, P2572, DOI 10.1161/01.CIR.92.9.2572; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; Buunk G, 2000, NETH J MED, V57, P106, DOI 10.1016/S0300-2977(00)00059-0; CELESIA GG, 1988, ARCH NEUROL-CHICAGO, V45, P781, DOI 10.1001/archneur.1988.00520310099023; COHAN SL, 1989, STROKE, V20, P761, DOI 10.1161/01.STR.20.6.761; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Eisenburger P, 2001, Curr Opin Crit Care, V7, P184, DOI 10.1097/00075198-200106000-00007; Goh WC, 2002, BRIT J ANAESTH, V88, P719, DOI 10.1093/bja/88.5.719; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; Grubb NR, 2001, HEART, V85, P6, DOI 10.1136/heart.85.1.6; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; HEKMATPANAH J, 1973, NEUROLOGY, V23, P174, DOI 10.1212/WNL.23.2.174; Herlitz J, 2000, EUR HEART J, V21, P1251, DOI 10.1053/euhj.2000.2150; JASTREMSKI M, 1989, JAMA-J AM MED ASSOC, V262, P3427, DOI 10.1001/jama.262.24.3427; Jorgensen EO, 1999, RESUSCITATION, V41, P145, DOI 10.1016/S0300-9572(99)00039-8; KARIMAN K, 1983, J APPL PHYSIOL, V55, P1057; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Koehler R C, 1985, Crit Care Clin, V1, P205; KRAUSE GS, 1986, AM HEART J, V111, P768, DOI 10.1016/0002-8703(86)90114-6; KRUMHOLZ A, 1988, NEUROLOGY, V38, P401, DOI 10.1212/WNL.38.3.401; Krumholz A, 2002, NEUROLOGY, V58, P515, DOI 10.1212/WNL.58.4.515; LEE SK, 1989, RESUSCITATION, V17, P105; Lewis KS, 2004, ANN PHARMACOTHER, V38, P1243, DOI 10.1345/aph.1D211; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; LONGSTRETH WT, 1983, ANN INTERN MED, V98, P588, DOI 10.7326/0003-4819-98-5-588; Longstreth WT, 2002, NEUROLOGY, V59, P506, DOI 10.1212/WNL.59.4.506; LONGSTRETH WT, 1993, NEUROLOGY, V43, P2534, DOI 10.1212/WNL.43.12.2534; LONGSTRETH WT, 2001, NEUROLOGY GEN MED, P151; Mullner M, 1996, STROKE, V27, P59, DOI 10.1161/01.STR.27.1.59; O'Neil BJ, 1996, CARDIAC ARREST SCI P, P84; Parsons MW, 2002, ANN NEUROL, V52, P20, DOI 10.1002/ana.10241; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; Ropper Allan H., 1993, P11; SAFAR P, 1993, ANN EMERG MED, V22, P324, DOI 10.1016/S0196-0644(05)80463-9; Safar P, 1996, CRIT CARE MED, V24, pS3; SAKABE T, 1987, INTENS CARE MED, V13, P256, DOI 10.1007/BF00265114; SCHOLZ KH, 1992, AM J CARDIOL, V69, P724, DOI 10.1016/0002-9149(92)90494-J; Schreiber W, 2002, RESUSCITATION, V52, P63, DOI 10.1016/S0300-9572(01)00432-4; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; STERZ F, 1992, RESUSCITATION, V24, P27, DOI 10.1016/0300-9572(92)90171-8; STERZ F, 1990, STROKE, V21, P1178, DOI 10.1161/01.STR.21.8.1178; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Sundgreen C, 2001, STROKE, V32, P128, DOI 10.1161/01.STR.32.1.128; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANCAMPEN LCMC, 1994, AM J CARDIOL, V73, P953, DOI 10.1016/0002-9149(94)90137-6; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303; Werhahn KJ, 1997, MOVEMENT DISORD, V12, P216, DOI 10.1002/mds.870120212; WIJDICKS EFM, 1994, ANN NEUROL, V35, P239, DOI 10.1002/ana.410350219; Williams LS, 2002, NEUROLOGY, V59, P67, DOI 10.1212/WNL.59.1.67; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; YOUNG GB, 1990, NEUROLOGY, V40, P1843, DOI 10.1212/WNL.40.12.1843; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007; 2000, CIRCULATION S1, V102, P166	65	24	24	0	2	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235			SEMIN NEUROL	Semin. Neurol.	SEP	2006	26	4					396	402		10.1055/s-2006-948320			7	Clinical Neurology	Neurosciences & Neurology	075OX	WOS:000239896200006	16969740				2021-06-18	
J	Bayly, PV; Dikranian, KT; Black, EE; Young, C; Qin, YQ; Labruyere, J; Olney, JW				Bayly, Philip V.; Dikranian, Krikor T.; Black, Erin E.; Young, Chainllie; Qin, Yue- Qin; Labruyere, Joann; Olney, John W.			Spatiotemporal evolution of apoptotic neurodegeneration following traumatic injury to the developing rat brain	BRAIN RESEARCH			English	Article						brain development; apoptosis; axonal injury; biomechanic; caspase-3	ANTERIOR THALAMIC NUCLEI; INFLICTED HEAD-INJURY; FUNCTIONAL RECOVERY; SPATIAL MEMORY; AXONAL INJURY; CELL-DEATH; LESIONS; MODEL; NEUROPATHOLOGY; DEGENERATION	Closed head injury to the developing rat brain causes an acute excitotoxic lesion and axonal disruption at the impact site followed by a delayed pattern of apoptotic damage at various distant sites. Using an electromagnetic impact device to deliver a precisely controlled degree of mechanical deformation to the P7 infant rat skull, we studied the distribution of distant apoptotic lesions and the sequence and time course with which these lesions evolve following relatively mild closed head injury. The first major wave of apoptotic neurodegeneration occurred at 8 h postimpact in the retrosplenial cortex and pre- and parasubiculum. The next major wave occurred in the 16- to 24-h interval and was localized to the anterior thalamic nuclei. A third wave was detected at 36 to 48 h in the mammillary nuclei. We propose that the first and second waves were triggered by injury to a specific fiber tract, the corpus callosum/cingulum bundle that conveys reciprocal connections between the anterior thalamic nuclei and retrosplenial/pre- and parasubicular neurons. This fiber tract passes through a zone of maximum mechanical strain, as measured by tagged MRI. The third wave affecting mammillary neurons occurred because the principal synaptic targets of these neurons are the anterior thalamic neurons that were destroyed in the second wave of degeneration. Prevention of these apoptotic waves of brain damage is a realistic goal in view of the long delay between the impact event and onset of apoptotic degeneration. (c) 2006 Elsevier B.V. All rights reserved.	Washington Univ, St Louis, MO 63130 USA; Washington Univ, St Louis, MO 63130 USA	Bayly, PV (corresponding author), Washington Univ, St Louis, MO 63130 USA.	pvb@me.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R37 HD037100, R01 HD037100, HD 37100] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS045237-02, R21 NS045237-01A1, NS 045237, R21 NS045237] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD037100, R37HD037100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS045237] Funding Source: NIH RePORTER		Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; AGGLETON JP, 1995, BEHAV BRAIN RES, V68, P91, DOI 10.1016/0166-4328(94)00163-A; Aggleton JP, 1996, BEHAV BRAIN RES, V81, P189, DOI 10.1016/S0166-4328(96)89080-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; Dikranian K, 2001, NEUROBIOL DIS, V8, P359, DOI 10.1006/nbdi.2001.0411; Fox S, 1998, INFECT MED, V15, P8; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAZEM A, 1995, BEHAV BRAIN RES, V67, P51, DOI 10.1016/0166-4328(94)00103-M; Mitchell AS, 2002, J NEUROSCI, V22, P1922, DOI 10.1523/JNEUROSCI.22-05-01922.2002; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; Olney JW, 2002, NEUROBIOL DIS, V9, P205, DOI 10.1006/nbdi.2001.0475; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; PRICE JL, 1995, RAT NERVOUS SYSTEM; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; RINK A, 1995, AM J PATHOL, V147, P1575; SHIBATA H, 1993, J COMP NEUROL, V330, P533, DOI 10.1002/cne.903300409; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; SZIKLAS V, 1993, EUR J NEUROSCI, V5, P525, DOI 10.1111/j.1460-9568.1993.tb00518.x; van Groen T, 2002, BEHAV BRAIN RES, V132, P19, DOI 10.1016/S0166-4328(01)00390-4; Wozniak DF, 2004, NEUROBIOL DIS, V17, P403, DOI 10.1016/j.nbd.2004.08.006; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Young CL, 2004, CURR MOL MED, V4, P77, DOI 10.2174/1566524043479158	34	24	25	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 30	2006	1107						70	81		10.1016/j.brainres.2006.05.102			12	Neurosciences	Neurosciences & Neurology	083TN	WOS:000240481200007	16822489	Green Accepted			2021-06-18	
J	Kilmer, RP; Demakis, GJ; Hammond, FM; Grattan, KE; Cook, JR; Kornev, AA				Kilmer, Ryan P.; Demakis, George J.; Hammond, Flora M.; Grattan, Karen E.; Cook, James R.; Kornev, Aleksandr A.			Use of the neuropsychiatric inventory in traumatic brain injury: A pilot investigation	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; assessment; Neuropsychiatric Inventory	COGNITIVE STATUS EXAMINATION; CLOSED-HEAD-INJURY; ALZHEIMERS-DISEASE; PRACTICAL SCALE; FAMILY MEMBERS; SELF-AWARENESS; CAREGIVER; DEMENTIA; DISTURBANCES; CONCORDANCE	Objective: The goal of this investigation was to pilot the Neuropsychiatric Inventory (NPI) among individuals with traumatic brain injury (TBI) and their caregivers, assessing its screen-metric approach. Design and Participants: Using the NPI, caregivers rated neurobehavioral disturbances in 5 1 individuals with moderate-to-severe TBI. The NPI was completed 1 or 2 years after the individuals were injured. Results: Caregivers reported the highest symptom levels for participants on h-ritability/Lability, Apathy, and Agitation/Aggression, and rated greater levels of distress tied to those domains and to Dysphoria. Caregivers endorsing domain screening items endorsed significantly more metric items (vs. screen non-endorsers) within that domain, as would be expected if the screen accurately measured the psychopathology under consideration. In addition, the screen-metric yielded extremely low false-positive rates, although 5 of the 12 domains had elevated false-negative rates. Conclusions: Findings provide preliminary support for the accuracy of the NPI's screen-metric in this population and are consistent with prior work detailing common problematic neurobehavioral consequences of TBI. These results lay groundwork for research and clinical use of this measure in populations with TBI.	Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA	Kilmer, RP (corresponding author), Univ N Carolina, Dept Psychol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	rpkilmer@email.uncc.edu					Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Butcher J. N, 2001, MMPI 2 MINNESOTA MUL; COHEN J, 1908, STAT POWER ANAL BEHA; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Greene J G, 1982, Age Ageing, V11, P121, DOI 10.1093/ageing/11.2.121; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hays W. L., 1988, STATISTICS; Kaufer D, 1998, J NEUROPSYCH CLIN N, V10, P55, DOI 10.1176/jnp.10.1.55; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levy ML, 1996, ARCH NEUROL-CHICAGO, V53, P687, DOI 10.1001/archneur.1996.00550070129021; LEZAK MD, 2003, MAYO PORTLAND ADAPTA; Litvan I, 1996, NEUROLOGY, V47, P1184, DOI 10.1212/WNL.47.5.1184; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P708, DOI 10.1176/appi.ajp.157.5.708; Marcotte TD, 1997, J CLIN EXP NEUROPSYC, V19, P386, DOI 10.1080/01688639708403867; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Mega MS, 1996, NEUROLOGY, V46, P130, DOI 10.1212/WNL.46.1.130; Morey L, 1996, INTERPRETIVE GUIDE P; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Oehlert ME, 1997, J CLIN PSYCHOL, V53, P733, DOI 10.1002/(SICI)1097-4679(199711)53:7<733::AID-JCLP11>3.0.CO;2-M; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; REISBERG B, 1987, J CLIN PSYCHIAT, V48, P9; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009; Yates William R., 1996, P305	43	24	24	0	3	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2006	51	3					232	238		10.1037/0090-5550.51.3.232			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	072OK	WOS:000239682500006					2021-06-18	
J	Lew, HL; Poole, JH; Castaneda, A; Salerno, RM; Gray, M				Lew, Henry L.; Poole, John H.; Castaneda, Annabel; Salerno, Rose Marie; Gray, Max			Prognostic value of evoked and event-related potentials in moderate to severe brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognition; EEG; event-related potentials; evoked potentials; neurology; posttraumatic coma; prognosis; rehabilitation; specificity and sensitivity	PREDICTING OUTCOMES; HEAD-INJURY; EEG	Clinicians are often expected to project patients' clinical outcomes to allow effective planning for future care. This can be a challenge in patients with moderate to severe traumatic brain injury (TBI) who are often unable to participate reliably in clinical evaluations. With recent advances in computer instrumentation and signal processing, evoked potentials and event-related potentials show increasing promise as powerful tools for prognosticating the trajectory of recovery and ultimate outcome from the TBI. Short- and middle-latency evoked potentials can now effectively predict coma outcomes in patients with acute TBI. Long-latency event-related potential components hold promise in predicting recovery of higher order cognitive abilities.	Stanford Univ, VA Palo Alto Hlth Care Syst, Comprehens Rehabil Ctr, PM&R Serv, Palo Alto, CA 94304 USA; Def & Vet Brain Injury Ctr, Palo Alto, CA USA	Lew, HL (corresponding author), Stanford Univ, VA Palo Alto Hlth Care Syst, Comprehens Rehabil Ctr, PM&R Serv, MS-B117,3801 Miranda Ave, Palo Alto, CA 94304 USA.	henrylew@.stanford.edu					Bressler S.L., 2002, HDB BRAIN THEORY NEU, P412; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V38, P55, DOI 10.1016/S0167-8760(00)00130-6; DUNCAN CC, 2005, INT J PSYCHOPHYSIOL; Giaquinto S, 2004, FUNCT NEUROL, V19, P219; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; LEW HL, 2005, NEUROREHABILITATION; LEW HL, IN PRESS J HEAD TRAU; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; Marchand Y, 2002, CLIN NEUROPHYSIOL, V113, P1715, DOI 10.1016/S1388-2457(02)00224-9; Mazzini Letizia, 2004, Phys Med Rehabil Clin N Am, V15, P163, DOI 10.1016/S1047-9651(03)00101-3; MULLIE A, 1988, LANCET, V1, P137; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ozbudak-Demir S, 1999, ARCH PHYS MED REHAB, V80, P252, DOI 10.1016/S0003-9993(99)90134-X; RAPPAPORT M, 1990, CLIN ELECTROENCEPHAL, V21, P188, DOI 10.1177/155005949002100406; Reuter B., 1989, TOPOGRAPHIC BRAIN MA, P192; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Stam CJ, 2003, AM J ELECTRONEUROD T, V43, P211, DOI 10.1080/1086508X.2003.11079444; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Wang JT, 2004, CAN J NEUROL SCI, V31, P438, DOI 10.1017/S0317167100003619; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006	34	24	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2006	21	4					350	360		10.1097/00001199-200607000-00006			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	064SJ	WOS:000239109100006	16915010				2021-06-18	
J	Son, BC; Lee, SW; Choi, ES; Sung, JH; Hong, JT				Son, Byung Chul; Lee, Sang Won; Choi, Eun Seok; Sung, Jae Hoon; Hong, Jae Taek			Motor cortex stimulation for central pain following a traumatic brain injury	PAIN			English	Article						central pain; traumatic brain injury; motor cortex stimulation	POSTSTROKE PAIN; ELECTRICAL-STIMULATION; THALAMIC PAIN; PATIENT; SENSATION; LESION; AREA; PET	Central pain can occur in any lesions along the central nervous system affecting the spinothalamocortical pathway. Although diverse etiologies have been reported to cause central pain, there are few reports on the occurrence and surgical treatment of central pain following a traumatic brain injury (TBI). This paper describes the occurrence of central pain following a severe TBI, in which the diagnosis of central pain was typically delayed due to the patient's decreased ability to express his pain for severe aphasia as a neurological sequela. The severe burning pain, deep pressure-like pain, and deep mechanical allodynia, which presented over the contralateral side to the TBI, were successfully relieved with motor cortex stimulation (MCS). The analgesic effect of stimulation was found to be long lasting and was still present at the 12-month follow up. As shown in this patient, the occurrence of central pain syndrome should be considered by physicians caring for TBI patients, and a comprehensive, systematic study will be needed to determine the prevalence of central pain after a TBI. (c) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea; Catholic Univ Korea, St Marys Hosp, Dept Rehabil, Taejon, South Korea	Son, BC (corresponding author), Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.	sbc@catholic.ac.kr		Hong, Jae Taek/0000-0001-6453-0439			ARMAND J, 1982, PROG BRAIN RES, V57, P329, DOI 10.1016/S0079-6123(08)64136-9; BERTHIER M, 1988, ANN NEUROL, V24, P41, DOI 10.1002/ana.410240109; BIEMOND A, 1956, ARCH NEURO PSYCHIATR, V75, P231, DOI 10.1001/archneurpsyc.1956.02330210011001; Boivi J, 1999, TXB PAIN, P879; BOIVIE J, 1992, SYMP PAIN R, P363; BOIVIE J, 1991, SYMP PAIN R, P65; BONICA JJ, 1991, SYMP PAIN R, P13; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; Craig AD, 1999, J COMP NEUROL, V404, P221; Craig AD, 1996, NATURE, V384, P258, DOI 10.1038/384258a0; Craig AD, 2000, NAT NEUROSCI, V3, P184, DOI 10.1038/72131; DAVIDOFF RA, 1990, NEUROLOGY, V40, P332; Davis KD, 1999, J NEUROPHYSIOL, V81, P1970; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Garcia-Larrea L, 1997, STEREOT FUNCT NEUROS, V68, P141, DOI 10.1159/000099915; H Merskey, 1994, CLASSIFICATION CHRON, P43; Helmchen C, 2002, PAIN, V98, P325, DOI 10.1016/S0304-3959(02)00139-2; Katayama Y, 1998, J NEUROSURG, V89, P585, DOI 10.3171/jns.1998.89.4.0585; Mailis A, 2002, PAIN, V98, P331, DOI 10.1016/S0304-3959(02)00156-2; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Mesulam M. M., 1985, CEREB CORTEX, V4, P179, DOI DOI 10.1007/978-1-4757-9619-3_5; MICHEL D, 1990, REV NEUROL-FRANCE, V146, P405; MYERSON BA, 1993, ACTA NEUROCHIR SUPP, V58, P150; Nguyen JP, 1997, ADV STER F, V12, P54; Nguyen JP, 1999, PAIN, V82, P245, DOI 10.1016/S0304-3959(99)00062-7; PEYRON R, 1995, PAIN, V62, P275, DOI 10.1016/0304-3959(94)00211-V; Ploner M, 1999, PAIN, V81, P211, DOI 10.1016/S0304-3959(99)00012-3; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Saitoh Y, 2000, J NEUROSURG, V92, P150, DOI 10.3171/jns.2000.92.1.0150; Saitoh Y, 2004, J NEUROSURG, V100, P935, DOI 10.3171/jns.2004.100.5.0935; SCHMAHMANN JD, 1992, ARCH NEUROL-CHICAGO, V49, P1032, DOI 10.1001/archneur.1992.00530340048017; Son BC, 2003, J NEUROSURG, V98, P175, DOI 10.3171/jns.2003.98.1.0175; TSUBOKAWA T, 1993, J NEUROSURG, V78, P393, DOI 10.3171/jns.1993.78.3.0393; Tsubokawa T, 1998, TXB STEREOTACTIC FUN, P1547; Vogt BA, 1993, NEUROBIOLOGY CINGULA, P313; WISENDANGER M, 1969, ERGEB PHYSL, V61, P72; Yezierski RL., 2002, SURG MANAGEMENT PAIN, P42; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	38	24	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	JUL	2006	123	1-2					210	216		10.1016/j.pain.2006.02.028			7	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	059PX	WOS:000238745800026	16616421				2021-06-18	
J	Yard, EE; Comstock, RD				Yard, Ellen Elizabeth; Comstock, R. Dawn			Injuries sustained by rugby players presenting to United States emergency departments, 1978 through 2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; epidemiology	UNION FOOTBALL; PROTECTIVE EQUIPMENT; PERFORMANCE PROJECT; EPIDEMIOLOGY; COHORT; PREVENTION; HEADGEAR; LESSONS	Context: Although the United States has nearly 60 000 rugby players, to date no nationally representative rugby injury studies have been conducted. Objective: To describe rugby players with injuries presenting to a representative sample of US emergency departments from 1978 through 2004. Design: Retrospective study. Setting: US Consumer Products Safety Commission's National Electronic Injury Surveillance System. Patients or Other Participants: Rugby players presenting to emergency departments in participating hospitals from October 1, 1978, through December 31, 2004. Main Outcome Measure(s): We reviewed all rugby players with injuries captured by the National Electronic Injury Surveillance System and categorized them by sex, age, injury site, and injury diagnosis. Results: An estimated 236539 rugby players presented to US emergency departments from 1978 through 2004. Injured athletes tended to be male (87.2%) and older than 18 years of age (86.0%). The face (20.5%), shoulder (14.1%), head (11.5%), and ankle (9.1%) were the most frequently injured sites. Strain/sprain (24.3%), laceration (22.1%), fracture (18.7%), and contusion/abrasion (16.6%) were the most common diagnoses. Males presented with more face injuries (injury proportion ratio [IPR] = 2.05, 95% confidence interval [CI] = 1.54-2.72, P < .001) and more lacerations (IPR = 4.23, 95% Cl = 2.87-6.22, P < .001) and dislocations (IPR = 2.17, 95% Cl 1.51-3.13, P < .001). Females presented with more knee injuries (IPR = 1.67, 95% CI = 1.36-2.06, P < .001) and more contusions/abrasions (IPR = 1.48, 95% CI = 1.14-1.92, P < .001) and strains/sprains (IPR = 1.39, 95% = CI 1.16-1.67, P < .001). Those 18 years of age or younger presented with more concussions (IPR = 1.62, 95% CI = 1.06-2.50, P < .001), while those over 18 presented with more lacerations (IPR = 1.83, 95% CI = 1.30-2.57, P < .001). In males, fractures were more common among those. 18 years of age or younger (IPR 1.47, 95% CI = 1.24-1.75 P < .001). Conclusions: Rugby injury patterns in the United States differed by, age and sex. Understanding such patterns should assist certified athletic trainers in developing targeted preventive interventions.	Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA	Yard, EE (corresponding author), Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	YardE@ccri.net					Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Carson JD, 1999, CLIN J SPORT MED, V9, P75, DOI 10.1097/00042752-199904000-00006; Chalmers DJ, 2004, J SCI MED SPORT, V7, P74, DOI 10.1016/S1440-2440(04)80046-X; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; Comstock RD, 2005, CLIN J SPORT MED, V15, P239, DOI 10.1097/01.jsm.0000171288.37293.54; Comstock RD, 2005, J SCI MED SPORT, V8, P101, DOI 10.1016/S1440-2440(05)80030-1; DAVIES JE, 1978, BRIT MED J, V2, P1759, DOI 10.1136/bmj.2.6154.1759; Dietzen C J, 1999, Phys Med Rehabil Clin N Am, V10, P159; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; Gabbett TJ, 2005, J SCI MED SPORT, V8, P111, DOI 10.1016/S1440-2440(05)80031-3; Haylen PT, 2004, MED J AUSTRALIA, V181, P48, DOI 10.5694/j.1326-5377.2004.tb06161.x; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; INGLIS GS, 1981, NEW ZEAL MED J, V94, P349; *INT RUGB BOARD, 2005, MEMB UN US RUGB; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; Levy AS, 1997, AM J SPORT MED, V25, P360, DOI 10.1177/036354659702500315; LEWIS E, 1994, SPORTCARE J, V1, P8; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Marshall SW, 2001, MED SCI SPORT EXER, V33, P2131, DOI 10.1097/00005768-200112000-00024; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; Quarrie KL, 2005, BRIT J SPORT MED, V39, P650, DOI 10.1136/bjsm.2004.016022; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; ROUX CE, 1987, S AFR MED J, V71, P307; RYAN JM, 1992, IRISH MED J, V85, P72; *US CONS PROD SAF, 2005, NEISS SAMPL DES IMPL; *US CONS PROD SAF, 2006, NEISS COD MAN; *US RUGB, 2005, US RUGB GAINS MULT D; Wetzler MJ, 1998, AM J SPORT MED, V26, P177, DOI 10.1177/03635465980260020501	30	24	25	0	6	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2006	41	3					325	331					7	Sport Sciences	Sport Sciences	082ON	WOS:000240396300017	17043702				2021-06-18	
J	Dandona, R; Kumar, GA; Raj, TS; Dandona, L				Dandona, R.; Kumar, G. A.; Raj, T. S.; Dandona, L.			Patterns of road traffic injuries in a vulnerable population in Hyderabad, India	INJURY PREVENTION			English	Article							TRAUMATIC BRAIN-INJURIES; DEVELOPING-COUNTRIES; RECALL; RATES	Objective: To describe patterns of road traffic injuries (RTI) in a vulnerable population-pedestrians and users of motorized two-wheeled vehicles (MTVs)-in Hyderabad, India. Methods: 4019 pedestrians and 4183 MTV drivers provided information on the most recent road traffic crash (RTC) irrespective of the level of injury in the last one year for 17 454 and 17 242 household members, respectively. Crashes in which any household member was involved as a pedestrian or MTV user were analysed. Results: Involvement in an RTC as a pedestrian or MTV user was reported for 1513 (4.4%, 95% CI 4.2 to 4.6%) people in the last one year. In these crashes, the person involved was an MTV user in 1264 (83.5%), aged 21-40 years in 973 (64.3%), and male in 1202 (79.4%). Six (0.4%) people died in RTCs and the cause was collision with a vehicle/person in 1133 (75%) crashes. Among the 1306 people who were injured and survived, 174 (13.3%) were treated as inpatients, 38 (2.9%) could not return fully to routine daily activities, 630 (48.2%) took leave from their regular occupation, and 13 (1%) lost their jobs following injury. Using a three month recall period, the annual incidence per 100 000 population of RTC as a pedestrian or MTV user was 2288 and of non-fatal RTI was 1931, and that of fatal RTI using one year recall period was 17.3 in this population. Conclusions: These findings on how RTI are caused, their type, and outcomes in pedestrians and MTV users can assist in identifying interventions to improve road safety for this vulnerable population in India, and can also be useful for monitoring the effectiveness of such interventions.	Adm Staff Coll India, Hlth Studies Area, Ctr Human Dev, Hyderabad 500082, Andhra Pradesh, India	Dandona, R (corresponding author), Adm Staff Coll India, Hlth Studies Area, Ctr Human Dev, Raj Bhavan Rd, Hyderabad 500082, Andhra Pradesh, India.	rakhi@asci.org.in		Dandona, Rakhi/0000-0003-0926-788X			Aare Magnus, 2003, Inj Control Saf Promot, V10, P131, DOI 10.1076/icsp.10.3.131.14556; Dandona L, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-55; Dandona R, 2004, NATL MED J INDIA, V17, P74; DANDONA R, IN PRESS J SAFETY RE; Dandona Rakhi, 2005, Int J Inj Contr Saf Promot, V12, P167, DOI 10.1080/17457300500088840; Evans Tim, 2003, Inj Control Saf Promot, V10, P11, DOI 10.1076/icsp.10.1.11.14117; Garg N, 2006, SCAND J PUBLIC HEALT, V34, P100, DOI 10.1080/14034940510032149; Ghaffar A, 2004, PUBLIC HEALTH, V118, P211, DOI 10.1016/j.puhe.2003.05.003; GHAFFAR A, 2004, J COLL PHYS SURG PAK, V14, P742; *GOV ANDHR PRAD, CAT WIS VEH STRENGTH; *GOV IND, 2001, POP TOT IND CENS IND; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Hyder AA, 2003, LANCET, V362, P2034, DOI 10.1016/S0140-6736(03)15145-8; Mayou R, 2003, INJURY, V34, P197, DOI 10.1016/S0020-1383(02)00285-1; *MIN ROAD TRANSP H, ROAD ACC IND 1970 20; Mock C, 1999, INT J EPIDEMIOL, V28, P750, DOI 10.1093/ije/28.4.750; Mohan D, 2000, IMECHE CONF TRANS, V2000, P155; Mohan D., 2002, J TRANSPORT INFRASTR, V9, P79; Mohan Dinesh, 2004, J Coll Physicians Surg Pak, V14, P746; Moshiro C, 2005, INJURY PREV, V11, P48, DOI 10.1136/ip.2004.005645; Nantulya Vinand M, 2003, Inj Control Saf Promot, V10, P3, DOI 10.1076/icsp.10.1.3.14109; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; Odero W, 1997, TROP MED INT HEALTH, V2, P445, DOI 10.1046/j.1365-3156.1997.d01-296.x; Odero Wilson, 2003, Inj Control Saf Promot, V10, P53, DOI 10.1076/icsp.10.1.53.14103; OJHA AK, 2002, ROAD ACCIDENTS DELHI; Peden M., 2004, WORLD REPORT ROAD TR; Peden M, 2002, INJURY CHART BOOK GR; Servadei F, 2003, INJURY PREV, V9, P257, DOI 10.1136/ip.9.3.257; Suriyawongpaisal Paibul, 2003, Inj Control Saf Promot, V10, P95, DOI 10.1076/icsp.10.1.95.14110; Umar R, 2002, P 2 WORLD ENG C SAR, P93; Wang Sheng-Yong, 2003, Inj Control Saf Promot, V10, P83, DOI 10.1076/icsp.10.1.83.14105; *WHO, 2002, GLOB BURD DIS PROJ V; Yang LF, 2003, LETT PEPT SCI, V10, P89, DOI 10.1023/B:LIPS.0000032368.82164.a5	33	24	25	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	JUN	2006	12	3					183	188		10.1136/ip.2005.010728			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	049PX	WOS:000238029700012	16751450	Green Published			2021-06-18	
J	Fontela, PS; Tampieri, D; Atkinson, JD; Daniel, SJ; Teitelbaum, J; Shemie, SD				Fontela, Patricia S.; Tampieri, Donatella; Atkinson, Jeffrey D.; Daniel, Sam J.; Teitelbaum, Jeanne; Shemie, Sam D.			Posttraumatic pseudoaneurysm of the intracavernous internal carotid artery presenting with massive epistaxis	PEDIATRIC CRITICAL CARE MEDICINE			English	Article							TRAUMATIC PSEUDOANEURYSM; ANEURYSM; DIAGNOSIS; BLINDNESS; THERAPY	Objectives: To report a case of posttraumatic pseudoaneurysm of the intracavernous internal carotid artery presenting with massive epistaxis and to discuss its pathophysiology and management. Design. Case report and literature review. Setting. Pediatric intensive care unit in a tertiary-care center. Patients and Results: Twelve days after a motor vehicle accident causing a head injury and facial fractures, this patient presented with massive epistaxis due to a pseudoaneurysm of the intracavernous internal carotid artery. Nasal packing was performed and subsequent angiography demonstrated the vascular lesion that had dissected into the sphenoid sinus. Endovascular stent and coil occlusion of the vascular lesion was performed, and the patient's condition improved without any ischemic or thromboembolic sequelae. Conclusion. Posttraumatic aneurysms of the intracavernous internal carotid artery can be associated with delayed and sometimes lethal massive epistaxis. This vascular lesion should be considered in patients with traumatic brain injury presenting with basal skull fractures in the region of the carotid canal or cavernous sinus and/or orbital fractures and compromise of the optical nerves. Knowledge of these risk factors and early diagnosis can minimize the high mortality risk.	Montreal Childrens Hosp, Div Pediat Crit Care, Montreal, PQ H3H 1P3, Canada; Montreal Childrens Hosp, Div Pediat Neurosurg, Montreal, PQ H3H 1P3, Canada; Montreal Childrens Hosp, Div Pediat Otolaryngol, Montreal, PQ H3H 1P3, Canada; McGill Univ, Ctr Hlth, Montreal Neurol Hosp & Inst, Div Radiol, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Montreal Neurol Hosp & Inst, Div Neurol, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Montreal Neurol Hosp & Inst, Div Neurosurg, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Montreal Neurol Hosp & Inst, Div Neurol & Crit Care, Montreal, PQ, Canada	Fontela, PS (corresponding author), Montreal Childrens Hosp, Div Pediat Crit Care, Montreal, PQ H3H 1P3, Canada.		Fontela, Patricia/S-6455-2019; Daniel, Sam J/AAY-6826-2020	Teitelbaum, Jeanne/0000-0002-9834-3882			ARAKI C, 1965, J NEUROSURG, V23, P64, DOI 10.3171/jns.1965.23.1.0064; BURTON R, 1973, MED J AUSTRALIA, V1, P692, DOI 10.5694/j.1326-5377.1973.tb110625.x; Chen DS, 1998, LARYNGOSCOPE, V108, P326, DOI 10.1097/00005537-199803000-00004; GOLEAS J, 1991, ANN OTO RHINOL LARYN, V100, P577, DOI 10.1177/000348949110000711; HAN MH, 1994, LARYNGOSCOPE, V104, P370; HIGASHIDA RT, 1990, J NEUROSURG, V72, P857, DOI 10.3171/jns.1990.72.6.0857; HORNIBROOK J, 1981, AUST NZ J SURG, V51, P206, DOI 10.1111/j.1445-2197.1981.tb05942.x; Jackson F E, 1970, J Trauma, V10, P1158, DOI 10.1097/00005373-197012000-00008; KARAMOSKOS P, 1989, AUST NZ J SURG, V59, P745, DOI 10.1111/j.1445-2197.1989.tb01668.x; KEANE JR, 1972, ARCH OPHTHALMOL-CHIC, V87, P701, DOI 10.1001/archopht.1972.01000020703017; MAURER JJ, 1961, J NEUROSURG, V18, P837, DOI 10.3171/jns.1961.18.6.0837; RENN WH, 1975, J NEUROSURG, V43, P288, DOI 10.3171/jns.1975.43.3.0288; SALMON JH, 1968, J THORAC CARDIOV SUR, V56, P28, DOI 10.1016/S0022-5223(19)42868-7; SHIRAI S, 1977, EUR NEUROL, V15, P212, DOI 10.1159/000114835; SIMPSON RK, 1988, J NEUROSURG, V68, P142, DOI 10.3171/jns.1988.68.1.0142; Wanebo JE, 2004, NEUROSURGERY, V55, P395, DOI 10.1227/01.NEU.0000129549.99061.94; WANG AN, 1986, SURG NEUROL, V25, P77, DOI 10.1016/0090-3019(86)90120-5; WORTHINGTON BS, 1983, AM J NEURORADIOL, V4, P835; Zarins CK, 2004, SABISTON TXB SURG, P1965	19	24	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2006	7	3					260	262		10.1097/01.PCC.0000216418.01278.5E			3	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	087ZL	WOS:000240781200013	16575350				2021-06-18	
J	Liu, JT; Tyan, YS; Lee, YK; Wang, JT				Liu, JT; Tyan, YS; Lee, YK; Wang, JT			Emergency management of epidural haematoma through burr hole evacuation and drainage. A preliminary report	ACTA NEUROCHIRURGICA			English	Article						suction under negative pressure; burr hole drainage; epidural haematoma	EXTRADURAL HEMATOMA; COMPUTERIZED-TOMOGRAPHY; COMATOSE PATIENTS; RESOLUTION	Background. Blood clot evacuation through an osteoplastic craniotomy, a procedure requiring neurosurgical expertise and modern medical facilities, is the accepted method for treatment of a pure traumatic epidural haematoma following closed head injury. In certain emergency situations and/or in less sophisticated settings, however, use of this procedure may not be feasible. The present study was undertaken to ascertain whether placement of a burr hole and drainage under negative pressure constituted a rapid, effective and safe approach to manage patients with simple epidural haematomas. Methods. Thirteen patients suffering from a traumatic epidural haematoma were treated from January, 1999 to October, 2002. Twelve patients presented with skull fracture but no fracture was depressed. Placement of flexible tubes through a burr hole, followed by continuous suction under negative pressure, enabled aspiration of the clot and drainage of the cavity. In 8 cases, the procedure was performed under local anaesthesia with 2% Xylocaine (TM) and with intravenous sedation with propofol as needed. The operative procedure was accomplished within 30min, and the drainage tube was left in place for 3-5 days. CT scans were performed daily from days 1 to 5. Results. In 11 of 13 cases, clots were evacuated successfully and patients regained consciousness within 2 hours. Recoveries occurred without significant sequelae. In the remaining 2 cases, the drainage tube was found to be obstructed by a blood clot such that the haematoma was unaffected. A traditional craniotomy was performed within 8-12 hours, and these 2 patients recovered consciousness within the subsequent 6 hours. Conclusion. Burr hole evacuation followed by drainage under negative pressure is a safe and effective method for emergency management of a pure traumatic epidural haematoma. To assure safety patients given this procedure should be monitored by daily CT scans. Decompressive craniotomy should be performed if consciousness does not improve within several hours.	Chung Shan Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan; Chung Shan Med Univ Hosp, Dept Radiol, Taichung, Taiwan; Chung Shan Med Univ Hosp, Dept Nucleomed, Taichung, Taiwan	Liu, JT (corresponding author), Chung Shan Med Univ Hosp, Dept Neurosurg, 110 Chen Kuo N Rd,Sect 1, Taichung, Taiwan.	cshy654@csh.org.tw					BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; BORZONE M, 1979, SURG NEUROL, V11, P277; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; Firsching R, 1997, NEUROL RES, V19, P257, DOI 10.1080/01616412.1997.11740810; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; Heiskanen O, 1975, Surg Neurol, V4, P23; HOOPER R, 1959, BRIT J SURG, V47, P71, DOI 10.1002/bjs.18004720114; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; JONES NR, 1993, BRIT J NEUROSURG, V7, P465, DOI 10.3109/02688699308995068; KAYE CI, 1985, J CRAN GENET DEV BIO, P259; Malek AM, 1997, PEDIATR NEUROSURG, V26, P160; MARSHALL LF, 1985, NEUROSURGERY, V16, P606; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; REIDER-GROSWASSER I, 1991, Brain Injury, V5, P17, DOI 10.3109/02699059108998507; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SEELIG JM, 1984, NEUROSURGERY, V15, P617, DOI 10.1227/00006123-198411000-00001; WEAVER D, 1981, J NEUROSURG, V54, P248, DOI 10.3171/jns.1981.54.2.0248; Wester K, 1999, NEUROSURGERY, V44, P495, DOI 10.1097/00006123-199903000-00034	22	24	27	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2006	148	3					313	317		10.1007/s00701-005-0723-z			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	018BL	WOS:000235737700017	16437186				2021-06-18	
J	Kaviani, A; Ouriel, K; Kashyap, VS				Kaviani, A; Ouriel, K; Kashyap, VS			Infected carotid pseudoaneurysm and carotid-cutaneous fistula as a late complication of carotid artery stenting	JOURNAL OF VASCULAR SURGERY			English	Article							NECK IRRADIATION; REPAIR; STENOSIS; THERAPY; INJURY; HEAD	Carotid stenosis after neck irradiation is a well-described entity. A 78-year-old mail presented with left eye amaurosis fugax 11 years after radical neck dissection and neck irradiation for mucoepidermoid carcinoma. The patient underwent carotid artery stenting for a high-grade stenosis of the left internal carotid artery. Twenty months after the procedure, a pulsatile neck mass developed with intermittent arterial bleeding. After control of the bleeding, lie underwent resection of the left carotid bifurcation, including the indwelling stent and reconstruction with a saphenous vein interposition graft. A pectoralis myocutaneous flap was used for wound closure. To this case, localized infection of the stented carotid artery led to mycotic degeneration, pseudoaneurysm formation, and erosion to the skill surface. As carotid artery stenting becomes more widely used, previously unreported late complications associated with this procedure are likely to become apparent, and continued close follow-up is warranted.	Cleveland Clin Fdn, Dept Vasc Surg, Cleveland, OH 44195 USA	Kashyap, VS (corresponding author), Cleveland Clin Fdn, Dept Vasc Surg, S40,9500 Euclid Ave, Cleveland, OH 44195 USA.	kashyav@ccf.org		Kashyap, Vikram/0000-0003-1780-979X			Abayomi OK, 2004, ORAL ONCOL, V40, P872, DOI 10.1016/j.oraloncology.2003.12.005; Akiyama Y, 2005, J TRAUMA, V58, P624, DOI 10.1097/01.TA.0000096662.79685.EA; Baril DT, 2004, J VASC SURG, V40, P1024, DOI 10.1016/j.jvs.2004.08.019; Carmody BJ, 1999, J VASC SURG, V30, P1045, DOI 10.1016/S0741-5214(99)70042-X; Cohen James, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P110, DOI 10.1097/00020840-200404000-00010; Ecker Robert D, 2005, Neurosurg Focus, V18, pe8; Houdart E, 2001, STROKE, V32, P118, DOI 10.1161/01.STR.32.1.118; Kashyap VS, 1999, J VASC SURG, V29, P90, DOI 10.1016/S0741-5214(99)70351-4; McCready RA, 2004, J VASC SURG, V40, P1020, DOI 10.1016/j.jvs.2004.07.034; McNeil JD, 2002, J VASC SURG, V36, P187, DOI 10.1067/mva.2002.125020; Rockman CB, 1996, AM J SURG, V172, P191, DOI 10.1016/S0002-9610(96)00150-X; Simental A, 2003, AM J OTOLARYNG, V24, P417, DOI 10.1016/S0196-0709(03)00088-7; Steele SR, 2004, AM J SURG, V187, P594, DOI 10.1016/j.amjsurg.2004.01.014; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	14	24	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	FEB	2006	43	2					379	382		10.1016/j.jvs.2005.10.058			4	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	014PN	WOS:000235492300039	16476618				2021-06-18	
J	Rudehill, S; Muhallab, S; Wennersten, A; von Gertten, C; Al Nimer, F; Sandberg-Nordqvist, AC; Holmin, S; Mathiesen, T				Rudehill, S; Muhallab, S; Wennersten, A; von Gertten, C; Al Nimer, F; Sandberg-Nordqvist, AC; Holmin, S; Mathiesen, T			Autoreactive antibodies against neurons and basal lamina found in serum following experimental brain contusion in rats	ACTA NEUROCHIRURGICA			English	Article						autoantibodies; autoimmunity; B cells; brain injury; rat; T cells	MYELIN BASIC-PROTEIN; INTRACEREBRAL INFLAMMATORY RESPONSE; SPINAL-CORD-INJURY; T-CELLS; POSTOPERATIVE CHANGES; NERVOUS-TISSUE; IMMUNOREACTIVITY; AUTOANTIBODIES; CONSEQUENCES; DEGENERATION	Background. Brain trauma is a risk factor for delayed CNS degeneration which may be attenuated by anti-inflammatory treatment. CNS injuries may cause anti-brain reactivity. This study was undertaken to analyze the pattern of delayed post-traumatic anti-brain immunity in experimental brain contusion. Method. Adult Sprague-Dawley and Lewis rats were subjected to experimental brain contusions. For B-cell investigations, serum was obtained from contused, control and naive rats, and used for immunohistochemistry on slices of rat brains to first detect autoreactive IgG and IgM antibodies in rat serum. Secondly, anti-rat IgG and IgM antibodies were used to search for auto-antibodies already bound to the brain tissue. Double staining with rat-serum and NeuN or anti-GFAP antibody was used to detect anti-neuronal and anti-astrocytic antibodies, respectively. For T-cell reactivity, cells from brains and cervical lymph nodes of rats were used in FACS analysis and elispot with MBP and MOG stimulation. Findings. Anti-vascular basal lamina IgG antibodies were detected at three months in 6/8 rats, following experimental contusion. Anti-neuronal IgG antibodies were detected 2 weeks after experimental contusion and sham surgery, while naive controls were negative. Individual rats showed a prolonged response, or an anti-astrocytic staining. Tissue bound anti-self IgG or IgM was not detected in the brain tissue. Anti-MBP or anti-MOG T-cell responses were not detectable. Conclusions. Experimental brain trauma and to some degree even sham surgery lead to an individually variable pattern of specific anti-brain reactive B-cells, while a T-cell response did not seem to be a consequence of moderate experimental contusion. The mere presence of anti brain-antibodies may be epiphenomenal, but could also be pathogenic for delayed degeneration. It is reasonable to regard the presence of an actual anti-brain reactivity as a potential threat to brain tissue integrity.	Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Med, Ctr Mol Med, Neuroimmunol Unit, S-17176 Stockholm, Sweden	Mathiesen, T (corresponding author), Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, R3 02 KS, S-17176 Stockholm, Sweden.	tiit.mathiesen@ks.se	Nimer, Faiez Al/ABB-9465-2020	Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615; Al Nimer, Faiez/0000-0003-0937-5995			ALLING C, 1980, J NEUROL, V223, P225, DOI 10.1007/BF00313336; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CASTIGLI E, 1995, INT ARCH ALLERGY IMM, V107, P37, DOI 10.1159/000236923; CLAUSEN F, 2005, ACTA NEUROCHIR; Crimando J, 1997, ANN NY ACAD SCI, V823, P303, DOI 10.1111/j.1749-6632.1997.tb48404.x; Cross AH, 2001, J NEUROIMMUNOL, V112, P1, DOI 10.1016/S0165-5728(00)00409-4; Dropcho EJ, 2002, NEUROL CLIN, V20, P85, DOI 10.1016/S0733-8619(03)00055-0; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauss-Wegrzyniak B, 2000, EXP NEUROL, V165, P347, DOI 10.1006/exnr.2000.7469; HOFFMANN SA, 1988, ARTHRITIS RHEUM, V28, P789; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HOYLE NR, 1984, J NEUROSURG, V61, P49, DOI 10.3171/jns.1984.61.1.0049; JENKINSON ML, 1989, BRIT J RHEUMATOL, V28, P86; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; Lopez-Escribano H, 2002, ARTHRITIS RHEUM, V46, P3290, DOI 10.1002/art.10684; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207; Morozov SG, 1996, VOP MED KHIM, V42, P147; Muhallab S, 2001, J NEUROIMMUNOL, V113, P202, DOI 10.1016/S0165-5728(00)00438-0; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Popovic M, 1998, INT J NEUROSCI, V95, P203, DOI 10.3109/00207459809003341; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; RUTTER JV, 1987, GERONTOLOGY, V33, P187, DOI 10.1159/000212874; SEELDRAYERS PA, 1984, ACTA NEUROCHIR, V70, P269, DOI 10.1007/BF01406655; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; SINHA S, 1991, LANCET, V338, P75, DOI 10.1016/0140-6736(91)90073-X; Sjogren M, 2001, MECH AGEING DEV, V122, P1923, DOI 10.1016/S0047-6374(01)00303-7; Stankova I, 1999, PHYSIOL RES, V48, P383; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; THOMAS DGT, 1984, J NEUROL NEUROSUR PS, V47, P173, DOI 10.1136/jnnp.47.2.173; WATERHOUSE DM, 1991, CANCER, V68, P1835, DOI 10.1002/1097-0142(19911015)68:8<1835::AID-CNCR2820680833>3.0.CO;2-N; Weissert R, 1998, J IMMUNOL, V160, P681	38	24	26	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	FEB	2006	148	2					199	205		10.1007/s00701-005-0673-5			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	005WS	WOS:000234856900031	16362182				2021-06-18	
J	Vadeboncoeur, TF; Davis, DP; Ochs, M; Poste, JC; Hoyt, DB; Vilke, GM				Vadeboncoeur, TF; Davis, DP; Ochs, M; Poste, JC; Hoyt, DB; Vilke, GM			The ability of paramedics to predict aspiration in patients undergoing prehospital rapid sequence intubation	JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Emergency-Medical-Services-Physicians	JAN 13-15, 2005	Naples, FL	Natl Assoc Emergency Med Serv Phys		aspiration; prehospital; EMS; paramedics; rapid sequence intubation; airway management; traumatic brain injury; head trauma	ENDOTRACHEAL INTUBATION; TRAUMA PATIENTS; HEAD; PNEUMONIA; HYPOTENSION; FIELD; INDUCTION; INJURY	One of the purported benefits to invasive prehospital airway management is the prevention of aspiration; however, aspiration events may occur before the arrival of prehospital personnel. We explore the timing of aspiration in patients with severe traumatic brain injury (TBI) undergoing paramedic rapid sequence intubation (RSI). Severely head-injured (Glasgow Coma Scale [GCS] score 3-8) adults were prospectively enrolled into the San Diego Paramedic RSI Trial. As part of the prehospital data collection tool, paramedics prospectively assessed for clinical evidence of aspiration before RSI (pre-intubation), aspiration events occurring during RSI (peri-RSI), and regurgitation of vomitus or blood after intubation (post-intubation). Data were abstracted from worksheets used during the RSI procedure, a telephone debriefing by one of the principal investigators immediately after delivery of the patient, and San Diego County prehospital and trauma databases. The incidence of pre-intubation aspiration, peri-RSI aspiration, and post-intubation regurgitation of vomitus or blood were determined. Patients with and without pre-intubation aspiration were compared with regard to pre- and post-intubation hypoxia and the rate of aspiration pneumonia. Logistic regression was used to explore the association between pre-intubation aspiration and various demo-graphic and clinical factors. The results showed that pre-intubation aspiration was noted by paramedics in 72/269 patients in whom complete data were available. Peri-RSI aspiration was reported in one patient; there were no reported cases of post-intubation regurgitation of vomitus or blood. Patients in the pre-intubation aspiration group required more intubation attempts, had a higher incidence of desaturations and lower pre- and post-intubation SaO(2) values, and were more frequently diagnosed with aspiration pneumonia. Pre-intubation aspiration was associated with severe TBI, GCS score of 3, younger age, and the absence of alcohol intoxication despite controlling for age, gender, GCS, Head AIS (Abbreviated Injury Score), and serum ethanol. It is concluded that paramedics seem to be able to accurately assess for aspiration in patients undergoing prehospital RSI. The vast majority of aspiration events seem to occur before the arrival of prehospital personnel. Alteration in consciousness from TBI may carry a higher risk of aspiration than with other causes, such as alcohol intoxication. (c) 2006 Elsevier Inc.	Univ Calif San Diego, Med Ctr, Dept Emergency Med, San Diego, CA 92103 USA; San Diego Cty EMS, San Diego, CA USA; UCSD Muir Coll, San Diego, CA USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA USA	Davis, DP (corresponding author), Univ Calif San Diego, Med Ctr, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.						ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Berrouane Y, 1998, J HOSP INFECT, V40, P275, DOI 10.1016/S0195-6701(98)90303-6; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Cazzadori A, 1997, RESP MED, V91, P193, DOI 10.1016/S0954-6111(97)90038-X; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Doran J V, 1995, Prehosp Disaster Med, V10, P259; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KOCH W, 1874, ARCH KLIN CHIR, V17, P190; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Kramer S P, 1896, Ann Surg, V23, P163, DOI 10.1097/00000658-189601000-00031; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; POLIS A, 1894, REV CHIR, V14, P645; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Sing RF, 1996, ACAD EMERG MED, V3, P41, DOI 10.1111/j.1553-2712.1996.tb03301.x; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Sirvent JM, 2000, INTENS CARE MED, V26, P1369, DOI 10.1007/s001340000611; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; Spaite DW, 2003, ANN EMERG MED, V42, P729, DOI 10.1016/S0196-0644(03)00822-9; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; VILKE GM, 2004, PREHOSP EMERG CARE, V8, P88; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wang HE, 2002, ANN EMERG MED, V40, P168, DOI 10.1067/mem.2002.126370; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Woratyla S P, 1995, Conn Med, V59, P643	42	24	26	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	FEB	2006	30	2					131	136		10.1016/j.jemermed.2005.04.019			6	Emergency Medicine	Emergency Medicine	028GQ	WOS:000236475500001	16567245				2021-06-18	
J	Aikman, J; O'Steen, B; Silver, X; Torres, R; Boslaugh, S; Blackband, S; Padgett, K; Wang, KKW; Hayes, R; Pineda, J				Aikman, J.; O'Steen, B.; Silver, X.; Torres, R.; Boslaugh, S.; Blackband, S.; Padgett, K.; Wang, K. K. W.; Hayes, R.; Pineda, J.			Alpha-II-spectrin after controlled cortical impact in the immature rat brain	DEVELOPMENTAL NEUROSCIENCE			English	Article						spectrin; cerebrospinal fluid; developing brain; pediatric traumatic brain injury; magnetic resonance imaging	SEVERE HEAD-INJURY; CEREBRAL HYPOXIA-ISCHEMIA; APOPTOTIC CELL-DEATH; CASPASE-3 ACTIVATION; CEREBROSPINAL-FLUID; EXPERIMENTAL-MODELS; MU-CALPAIN; NEURONAL APOPTOSIS; COGNITIVE DEFICITS; BREAKDOWN PRODUCTS	Proteolytic processing plays an important role in regulating a wide range of important cellular functions, including processing of cytoskeletal proteins. Loss of cytoskeletal proteins such as spectrin is an important characteristic in a variety of acute central nervous system injuries including ischemia, spinal cord injury and traumatic brain injury (TBI). The literature contains extensive information on the proteolytic degradation of alpha-II-spectrin after TBI in the adult brain. By contrast, there is limited knowledge on the characteristics and relevance of these important processes in the immature brain. The present experiments examine TBI-induced proteolytic processing of alpha-II-spectrin after TBI in the immature rat brain. Distinct proteolytic products resulting from the degradation of the cytoskeletal protein alpha-II-spectrin by calpain and caspase 3 were readily detectable in cortical brain parenchyma and cerebrospinal fluid after TBI in immature rats. Copyright (c) 2006 S. Karger AG, Basel.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Evelyn F & William L McKnight Brain Inst, Gainesville, FL USA; Univ Florida, Ctr Neuroproteom & Biomarkers Res, Dept Psychiat, McKnight Brain Inst, Gainesville, FL USA	Pineda, J (corresponding author), Washington Univ, Sch Med, Dept Pediat, Campus Box 8116,1 Childrens Pl,Suite 5S20, St Louis, MO 63110 USA.	Pineda_J@kids.wustl.edu	Pineda, Jose/W-2806-2019; Silver, Xeve/AAP-3398-2021	Wang, Kevin/0000-0002-9343-6473; Padgett, Kyle/0000-0002-6277-5317	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036992, R01NS052831] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS052831, R01-NS36992] Funding Source: Medline		Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Adelson PD, 1999, EXP TOXICOL PATHOL, V51, P130; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; Blomgren K, 1997, ANN NY ACAD SCI, V825, P104, DOI 10.1111/j.1749-6632.1997.tb48420.x; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; CHAKRABARTI AK, 1993, DEV BRAIN RES, V71, P107, DOI 10.1016/0165-3806(93)90111-M; Cho S, 2003, BRAIN RES, V982, P146, DOI 10.1016/S0006-8993(03)02846-4; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 1999, EXP TOXICOL PATHOL, V51, P172, DOI 10.1016/S0940-2993(99)80091-8; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; FISCHER I, 1991, NEUROCHEM RES, V16, P891, DOI 10.1007/BF00965538; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; GOODMAN SR, 1986, AM J PHYSIOL, V250, pC347; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Ikonomidou C, 2001, BIOCHEM PHARMACOL, V62, P401, DOI 10.1016/S0006-2952(01)00696-7; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; KIMURA F, 1987, J NEUROCYTOL, V16, P649, DOI 10.1007/BF01637657; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kochanek PM, 2006, ANESTH ANALG, V102, P72, DOI 10.1213/01.ANE.0000181101.71587.8A; Kochanek PM, 2001, PEDIATR CLIN N AM, V48, P661, DOI 10.1016/S0031-3955(05)70333-3; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; Levi L, 1998, CHILD NERV SYST, V14, P195, DOI 10.1007/s003810050210; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lu XY, 2000, NEUROSCI LETT, V286, P149, DOI 10.1016/S0304-3940(00)01101-0; MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OSTWALD K, 1993, BRAIN RES, V630, P289, DOI 10.1016/0006-8993(93)90668-D; Pham DL, 2000, ANNU REV BIOMED ENG, V2, P315, DOI 10.1146/annurev.bioeng.2.1.315; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheidler MG, 2000, J TRAUMA, V49, P864, DOI 10.1097/00005373-200011000-00012; SHEPPARD A, 1991, SYNAPSE, V9, P231, DOI 10.1002/syn.890090310; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Verger K, 2000, BRAIN INJURY, V14, P495; Villa PG, 1998, J CELL SCI, V111, P713; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhang J, 2003, DEV BRAIN RES, V142, P105, DOI 10.1016/S0165-3806(03)00057-9; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	84	24	25	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					457	465		10.1159/000094171			9	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600022	16943668				2021-06-18	
J	Guerin, F; Kennepohl, S; Leveille, G; Dominique, A; McKerral, M				Guerin, Fanny; Kennepohl, Stephan; Leveille, Genevieve; Dominique, Aysha; McKerral, Michelle			Vocational outcome indicators in atypically recovering mild TBI: A post-intervention	NEUROREHABILITATION			English	Article; Proceedings Paper	1st International Conference on Vocational Outcomes in Traumatic Brain Injury	APR 14-16, 2005	Vancouver, CANADA			mild traumatic brain injury; post-concussion symptomatology; vocational outcome; prognostic indicators	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; CONCUSSION SYMPTOMS; PREDICTING RETURN; WORK; REHABILITATION; MODERATE	Beyond issues of MTBI etiology, a key question remains the characterization and early identification of those individuals at risk of poor functional outcome. Using a retrospective analysis, the current study aimed at identifying the specific indicators related to return to work in adults with both symptomatic MTBI and functional impacts, having completed a specialized intervention program. In terms of outcome, 59.1% of the cohort (n=110) returned to some form of work-related activity by the end of intervention whereas the rest had not. Three of the sixteen variables studied were retained (logistic regression) as providing unique and significant (p < 0.05) contributions to the prediction outcome model, namely age, number of subjective symptoms and the presence of a public insurance provider. There was also an interaction between the presence of a public insurance provider and referral delay. Overall percentage of cases correctly classified by the model was 70%, positive predictive accuracy was 72.9%, whereas negative predictive accuracy was 65%. Our findings suggest that any studies attempting to assess functional outcome need to take account of the multifactorial nature of MTBI, including not only more objective psychological/physiological variables related to the injury, but also subjective complaints and environmental factors.	Ctr Readaptat Lucie Bruneau, TBI Program, Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ H2H 2N8, Canada; Ctr Interdisciplinary Res Rehabil Greater Montrea, Montreal, PQ, Canada; Univ Montreal, Dept Psychol, Montreal, PQ, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada	McKerral, M (corresponding author), Ctr Readaptat Lucie Bruneau, TBI Program, Ctr Rech Interdisciplinaire Readaptat, 2275 Laurier Ave E, Montreal, PQ H2H 2N8, Canada.	michelle.mckerral@umontreal.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *CDCP, 2003, US STEPS PREV SER PU, P56; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; GUERIN F, 2005, INTERDISCIPLINARY RE, P55; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McKerral M, 2005, J REHABIL MED, V37, P61, DOI 10.1080/16501970510026647; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	38	24	24	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	4					295	303					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	145VU	WOS:000244894700004	17361046				2021-06-18	
J	Huh, JW; Franklin, MA; Widing, AG; Raghupathi, R				Huh, Jimmy W.; Franklin, Michael A.; Widing, Ashley G.; Raghupathi, Ramesh			Regionally distinct patterns of calpain activation and traumatic axonal injury following contusive brain injury in immature rats	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; traumatic axonal injury; calpains; amyloid precursor protein; closed head injury	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; SPECTRIN PROTEOLYSIS; BREAKDOWN; AGE; DEGRADATION; INHIBITION; MECHANISMS; TRANSPORT; CHILDREN	Impact-induced head injury in infants results in acute focal contusions and traumatic axonal injury (TAI) that are associated with chronic holohemispheric cortical and white matter atrophy and may contribute to poor outcome in brain-injured children less than 4 years of age. Contusive brain trauma in postnatal day (PND) 11 or PND 17 rat pups, ages neurologically equivalent to a human infant and toddler, respectively, leads to cortical tissue loss and white matter atrophy which are associated with cognitive deficits. In adult models of brain trauma and in brain-injured humans, acute and sustained activation of the calpain family of calcium-activated neutral proteases has been implicated in neuronal death and TAI. PND 11 or PND 17 rat pups were subjected to closed head injury over the left hemisphere using the controlled cortical impact device and sacrificed at 6 h, 24 h or 3 days. Hemorrhagic contusions and tissue tears in the cortex and white matter were visible at 6 h, and neuronal loss was evident by 3 days. Calpain activation was observed in cell soma and dendrites of injured neurons at 6 h, and in degenerating dendrites and atrophic neurons at 24 h after injury at both ages. Axonal accumulation of amyloid precursor protein, indicative of TAI, was observed in the corpus callosum and lateral aspects of the white matter below the site of impact, and in the thalamus in PND 11 rats only. Intra-axonal calpain activation was observed to a limited extent in the corpus callosum and subcortical white matter tracts in both brain-injured PND 11 and PND 17 rats. Collectively, these results provide evidence that calpain activation may participate in neuronal loss in the injured cortex, but may not contribute to the pathogenesis of TAI following contusive brain trauma in the immature rat. Copyright (c) 2006 S. Karger AG, Basel.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexelmed.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS041561, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS41561] Funding Source: Medline		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; BLOMGREN K, 1995, BRAIN RES, V684, P143, DOI 10.1016/0006-8993(95)00399-B; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen M, 2005, BIOCHEM BIOPH RES CO, V330, P714, DOI 10.1016/j.bbrc.2005.03.029; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobbing J, 1981, SCI F PAEDIATRICS, P744; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kirazov E, 2001, INT J DEV NEUROSCI, V19, P287, DOI 10.1016/S0736-5748(01)00012-0; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SIMAN R, 1990, J NEUROSCI, V10, P2400; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; ZIMMERMAN RA, 1981, J NEURORADIOLOGY, V8, P257	36	24	24	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866			DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					466	476		10.1159/000094172			11	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600023	16943669				2021-06-18	
J	Nolin, P				Nolin, P			Executive memory dysfunctions following mild traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						CVLT; executive functions; memory; mild traumatic brain injury; MTBI; registration; retrieval; storage; verbal learning	VERBAL-LEARNING TEST; HEAD-INJURY; PERFORMANCE; SYMPTOMS; PATTERNS; DEFICITS; MODERATE	Objectives: To explore the contribution of executive dysfunctions to mnemonic problems in adults with mild traumatic brain injury (MTBI). Design: Prospective quasiexperimental between-groups design. Participants: Ninety-nine persons with MTBI were compared to 90 control group participants matched for gender, age, and education. Setting: Two Canadian brain injury rehabilitation programs. Main Outcome Measure: California Verbal Learning Test. Results: Participants with MTBI showed a significant deficit in free recall on the California Verbal Learning Test but performed similarly to the comparison group on the recognition task. Furthermore, the participants with MTBI were less likely to use semantic clustering as a memorizing strategy and made more intrusion errors and false-positive errors on the recognition task. Conclusions: While the scores for the participants with MTBI are only slightly lower than the norm, they demonstrate that MTBI has a negative effect on mnemonic performance. The results are explained in terms of a deficit in registration/retrieval processes rather than a malfunction of the storage processes. This supports the initial hypothesis that executive dysfunctions are detrimental to the quality of mnemonic functions in patients with MTBI.	Univ Quebec Trois Rivieres, Grp Rech Dev Enfant & Famille, Dept Psychol, Trois Rivieres, PQ G9A 5H7, Canada	Nolin, P (corresponding author), Univ Quebec Trois Rivieres, Grp Rech Dev Enfant & Famille, Dept Psychol, CP 500, Trois Rivieres, PQ G9A 5H7, Canada.	Pierre.Nolin@uqtr.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1989, ASSESSMENT CONSEQUEN, V7, P37; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Delis DC, 1987, CALIFORNIA VERBAL LE; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Duchnick JJ, 2002, J CLIN EXP NEUROPSYC, V24, P840, DOI 10.1076/jcen.24.6.840.8405; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, NEUROBEHAVIORAL RECO, P221; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MIDDLETON J, 1989, J CHILD PSYCHOL PSYC, V30, P663, DOI 10.1111/j.1469-7610.1989.tb00780.x; MILLIS S, 1995, PSYCHOL ASSESSMENT, V7, P384; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; Nolin P, 2001, REV NEUROPSYCHOL, V11, P23; NOLIN P, 1999, REV QUEBECOISE PSYCH, V20, P39; Numan B, 2000, J CLIN PSYCHOL, V56, P553, DOI 10.1002/(SICI)1097-4679(200004)56:4<553::AID-JCLP8>3.0.CO;2-Q; Potter DD, 1999, J PSYCHOPHYSIOL, V13, P173, DOI 10.1027//0269-8803.13.3.173; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; VANDERLINDEN M, 1999, NEUROPSYCHOLOGIE TOB; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950; ZAPPALA G, 1992, ARCH CLIN NEUROPSYCH, V7, P145, DOI 10.1016/0887-6177(92)90008-B	41	24	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					68	75		10.1097/00001199-200601000-00007			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300007	16456393				2021-06-18	
J	Wu, D; Shibuya, S; Miyamoto, O; Itano, T; Yamamoto, T				Wu, Di; Shibuya, Sei; Miyamoto, Osamu; Itano, Toshifumi; Yamamoto, Tetsuji			Increase of NG2-positive cells associated with radial glia following traumatic spinal cord injury in adult rats	JOURNAL OF NEUROCYTOLOGY			English	Article							CHONDROITIN-SULFATE PROTEOGLYCAN; CENTRAL-NERVOUS-SYSTEM; PROGENITOR CELLS; NG2 PROTEOGLYCAN; PRECURSOR CELLS; STEM-CELLS; OLIGODENDROGLIAL PROGENITORS; SCAR TISSUE; EXPRESSION; BRAIN	In the CSN including the spinal cord, NG2 proteoglycan is a marker of oligodendrocyte progenitors. To elucidate the dynamics of the endogenous neural stem (progenitor) cells in adult rats with spinal cord injury (SCI), we examined an immunohistochemical analysis of NG2, GFAP, and 3CB2, a specific marker of radial glia (RG). SD rats were divided into a SCI group (n = 25) and a sham-operated group (n = 5). In the injury group, laminectomy was performed at Th11-12 and contusive compression injury was created by applying a weight of 30 g for 10 min. Rats were sacrificed at 24 h, and 1, 4, 8 and 12 weeks post-injury. Frozen 20-mu m sections of tissue 5 and 10 mm rostral and caudal to the epicenter of injury were prepared. Immunohistochemistry was performed using antibodies against NG2, GFAP and 3CB2. At 4 weeks after injury, NG2-positive glial cells arose from below the pial surface as bipolar cells with processes extending throughout the entire white matter. NG2 expression peaked at 4 weeks after injury, showing a 7-fold increase compared to the 24 h after injury. The NG2-positive cells with processes which increased in the white matter of the spinal cord were GFAP-positive and also co-localized with 3CB2 antigen. The pattern of NG2 expression of these cells was temporally and spatially different from the pattern of NG2 expression that accumulated around the hemorrhagic and necrotic epicenter. These results suggest that NG2 positive cells which derived from subpial layer, may have some lineage to RG after SCI in adult rodents.	Kagawa Univ, Dept Neurobiol, Sch Med, Miki, Kagawa 7610793, Japan; Kagawa Univ, Dept Orthopaed Surg, Sch Med, Miki, Kagawa 7610793, Japan	Itano, T (corresponding author), Kagawa Univ, Dept Neurobiol, Sch Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	toshi@kms.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17500432] Funding Source: KAKEN		Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Berry M, 2002, J NEUROCYTOL, V31, P457, DOI 10.1023/A:1025735513560; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; Diers-Fenger M, 2001, GLIA, V34, P213, DOI 10.1002/glia.1055; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Horner PJ, 2000, J NEUROSCI, V20, P2218; Horner PJ, 2002, J NEUROCYTOL, V31, P469, DOI 10.1023/A:1025739630398; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 1999, EXP NEUROL, V160, P333, DOI 10.1006/exnr.1999.7224; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVINE JM, 1993, GLIA, V7, P307, DOI 10.1002/glia.440070406; McKeon RJ, 1999, J NEUROSCI, V19, P10778; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Miyata T, 2001, NEURON, V31, P727, DOI 10.1016/S0896-6273(01)00420-2; Moon LDF, 2002, NEUROSCIENCE, V109, P101, DOI 10.1016/S0306-4522(01)00457-2; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pasterkamp RJ, 2001, EUR J NEUROSCI, V13, P457, DOI 10.1046/j.0953-816X.2000.01398.x; Pouly S, 2001, ACTA NEUROPATHOL, V102, P313; Prada FA, 1995, GLIA, V15, P389, DOI 10.1002/glia.440150404; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Shibuya S, 2003, GLIA, V42, P172, DOI 10.1002/glia.10203; Shibuya S, 2002, NEUROSCIENCE, V114, P905, DOI 10.1016/S0306-4522(02)00323-8; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; WALLACE MC, 1986, NEUROSURGERY, V18, P433; Weiss S, 1996, J NEUROSCI, V16, P7599; Yamamoto S, 2001, EXP NEUROL, V172, P115, DOI 10.1006/exnr.2001.7798	44	24	24	0	4	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	DEC	2005	34	6					459	469		10.1007/s11068-006-8998-4			11	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	073FX	WOS:000239729500009	16902766				2021-06-18	
J	King, DR; Cohn, SM; Proctor, KG				King, DR; Cohn, SM; Proctor, KG			Resuscitation with a hemoglobin-based oxygen carrier after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Japanese-Association-for-Acute-Medicine	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma, Japanese Assoc Acute Med		colloid; hemoglobin-based oxygen carrier (HBOC); intracranial pressure; oxygenation; swine	UNCONTROLLED HEMORRHAGIC-SHOCK; SMALL-VOLUME RESUSCITATION; TISSUE OXYGENATION; IMPROVES SURVIVAL; LIVER TRAUMA; SWINE MODEL; HBOC-201; PRESSURE; HYPOTENSION; VASOPRESSIN	Background. Traumatic brain injury (TBI) remains an exclusionary criterion in nearly every clinical trial involving hemoglobin-based oxygen carriers (HBOCs) for traumatic hemorrhage. Furthermore, most HBOCs are vasoactive, and use of pressors in the setting of hemorrhagic shock is generally contraindicated. The purpose of this investigation was to test the hypothesis that low-volume resuscitation with a vasoactive HBOC (hemoglobin glutamer-200 [bovine], HBOC-301; Oxyglobin, BioPure, Inc., Cambridge, MA) would improve outcomes after severe TBI and hemorrhagic shock. Methods: In Part 1, anesthetized swine received TBI and hemorrhage (30 +/- 2 mL/kg, n = 15). After 30 minutes, lactated Ringer's (LR) solution (n = 5), HBOC (n = 5), or 10 mL/kg of LR + HBOC (n = 5) was titrated to restore systolic blood pressure to >= 100 mm Hg and heart rate (HR) to <= 100 beats/min. After 60 minutes, fluid was given to maintain mean arterial pressure (MAP) at >= 70 nun Hg and heterologous whole blood (red blood cells [RBCs], 10 mL/kg) was transfused. for hemoglobin at <= 5 g/dL. After 90 minutes, mannitol (MAN, 1 g/kg) was given for intracranial pressure >= 20 min Hg, LR solution was given to maintain cerebral perfusion pressure at >= 70 min Hg, and RBCs were given for hemoglobin of <= 5 g/dL. In Part 2, after similar TBI and resuscitation with either LR + MAN + RBCs (n = 3) or HBOC alone (n = 3), animals underwent attempted weaning, extubation, and monitoring for 72 hours. Results: In Part 1, relative to resuscitation with LR + MAN + RBCs, LR + HBOC attenuated intracranial pressure (12 +/- 1 min Hg vs. 33 +/- 6 mm Hg), improved cerebral perfusion pressure in the initial 4 hours (89 +/- 6 nun Hg vs. 60 +/- 3 mm Hg), and improved brain tissue PO2 (34.2 +/- 3.6 min Hg vs. 16.1 +/- 1.6 mm Hg; all p < 0.05). Cerebrovascular reactivity and intracranial compliance were improved with LR + HBOC (p < 0.05) and fluid requirements were reduced (30 +/- 12 vs. 280 +/- 40 mL/kg; p < 0.05). Lactate and base excess corrected faster with LR + HBOC despite a 40% reduction in cardiac index. With HBOC alone and LR + HBOC, MAP and HR rapidly corrected and remained normal during observation; however, with HBOC alone, lactate clearance was slower and systemic oxygen extraction was transiently icreased. In Part 2, resuscitation with HBOC alone allowed all animals to wean and extubate, whereas none in the LR + MAN + RBCs group was able to wean and extubate. At 72 hours, no HBOC animal had detectible neurologic deficits and all had normal hemodynamics. Conclusion: The use of HBOC-301 supplemented by a crystalloid bolus was clearly superior to the standard of care (LR + MAN + RBCs) after TBI. This may represent a new indication for HBOCs. Use of HBOC eliminated the need for RBC transfusions and mannitol. The inherent vasopressor effect of HBOCs, especially when used alone, may misguide initial resuscitation, leading to transient poor global tissue perfusion despite restoration of MAP and HR. This suggests that MAP and HR are inadequate endpoints with HBOC resuscitation. HBOC use alone after TBI permitted early extubation and excellent 72-hour outcomes.	Univ Miami, Sch Med, Ryder Trauma Ctr,Res Inst, Div Trauma & Surg Crit Care,Dewitt Daughtry Famil, Miami, FL 33136 USA	Proctor, KG (corresponding author), Univ Miami, Sch Med, Ryder Trauma Ctr,Res Inst, Div Trauma & Surg Crit Care,Dewitt Daughtry Famil, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu		King, David/0000-0003-1028-1478	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008749] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08749-0] Funding Source: Medline		Cothren CC, 2004, TRANSFUSION MED, V14, P241, DOI 10.1111/j.0958-7578.2004.00502.x; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hare GMT, 2004, ANESTH ANALG, V99, P528, DOI 10.1213/01.ANE.0000136769.65960.D1; JAVID M, 1964, J NEUROSURG, V21, P1059, DOI 10.3171/jns.1964.21.12.1059; Katz LM, 2002, RESUSCITATION, V54, P77, DOI 10.1016/S0300-9572(02)00053-9; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Knudson MM, 2003, J TRAUMA, V54, P242, DOI 10.1097/01.TA.0000037776.28201.75; Lee SK, 2002, ACAD EMERG MED, V9, P969; Levy JH, 2003, EXPERT OPIN BIOL TH, V3, P509, DOI 10.1517/14712598.3.3.509; Malhotra AK, 2004, J TRAUMA, V56, P1049, DOI 10.1097/01.TA.0000127765.75643.66; Malhotra AK, 2003, J TRAUMA, V54, P915, DOI 10.1097/01.TA.0000061000.74343.E1; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Manley GT, 2003, ADV EXP MED BIOL, V530, P311; Manning JE, 2000, SHOCK, V13, P152, DOI 10.1097/00024382-200013020-00010; McNeil JD, 2001, J TRAUMA, V50, P1063, DOI 10.1097/00005373-200106000-00015; Muir W, 2001, J VET PHARMACOL THER, V24, P447, DOI 10.1046/j.1365-2885.2001.0363a.x; Raedler C, 2004, ANESTH ANALG, V98, P1759, DOI 10.1213/01.ANE.0000117150.29361.5A; ROBERTS I, 2003, COCHRANE DB SYST REV, V2; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Sampson JB, 2003, J TRAUMA, V55, P747, DOI 10.1097/01.TA.0000084519.47163.77; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; York GB, 2003, J TRAUMA, V55, P873, DOI 10.1097/01.TA.0000092681.17874.6F	22	24	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2005	59	3					553	560		10.1097/01.ta.0000177711.52191.62			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	014BZ	WOS:000235455000001	16361895				2021-06-18	
J	Clausen, F; Hillered, L				Clausen, F; Hillered, L			Intracranial pressure changes during fluid percussion, controlled cortical impact and weight drop injury in rats	ACTA NEUROCHIRURGICA			English	Article						controlled cortical impact; fluid percussion injury; intra cranial pressure; rat; traumatic brain injury; weight drop injury	TRAUMATIC BRAIN-INJURY; MODEL; ISCHEMIA	Background. In traumatic brain injury research, the fluid percussion injury (FPI) model in the rat is widely used. The injury is graded based on indirect criteria, such as the extracranial pressure wave and/or physiological responses to the injury. We designed this study to investigate if the extracranially monitored pressure in the FPI-device corresponded to the actual intracranial situation. Severe controlled cortical impact (CCI) and severe weight drop injury (WDI) were studied for comparison. Method. We tested the correlation between the extra- and intracranial pressures during severe FPI in rat (2.6-2.9 atm), using pressure probes ( diameter 0.34 mm) with high frequency (500Hz) and high pressure range (1-5 atm). The probes were inserted into either of the lateral ventricles in FPI and in the contralateral lateral ventricle in CCI and WDI to compare the ictal pressure pulses between the models. Findings. FPI showed a time lag between the extracranial, intracranial ipsilateral and intracranial contralateral pressure curves respectively, reflecting the different distances between the pressure source and the individual pressure probes. There was a high degree of correlation (r = 0.994, p < 0.0001) between the extra- and intracranial pressure pulses, once corrected for the time lag. We found no significant differences between the extracranial and the intracranial peak pressure in either ventricle in FPI. In CCI and WDI the contralateral pressure pulses were significantly smaller than in FPI. CCI resulted in higher pressure peaks than WDI, due to higher impact velocity. Conclusions. The extracranial pressure pulse appears to be a good estimate of the intraventricular pressure pulse generated during FPI. Severe CCI and WDI generated intraventricular pressure pulses of much lower magnitude than FPI, explaining the lesser degree of brain stem involvement in the former models.	Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden	Clausen, F (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden.	fredrik.clausen@neurokir.uu.se		Clausen, Fredrik/0000-0003-3592-4417			DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; MATSUSHIMA K, 1995, STROKE, V26, P1052; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER J D, 1987, Neurological Research, V9, P198; MILLER J D, 1987, Neurological Research, V9, P193; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stalhammar D, 1987, Brain Inj, V1, P73, DOI 10.3109/02699058709034448; Tindall G T, 1975, Clin Neurosurg, V22, P332; TOMIDA S, 1987, J CEREBR BLOOD F MET, V7, P773, DOI 10.1038/jcbfm.1987.133; Zwienenberg M, 1999, J NEUROTRAUM, V16, P1095, DOI 10.1089/neu.1999.16.1095	25	24	25	0	4	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUL	2005	147	7					775	780		10.1007/s00701-005-0550-2			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	938AK	WOS:000229972100024	15900397				2021-06-18	
J	Arnbrosini, A; Louin, G; Croci, N; Plotkine, M; Jafarian-Tehrani, M				Arnbrosini, A; Louin, G; Croci, N; Plotkine, M; Jafarian-Tehrani, M			Characterization of a rat model to study acute neuroinflammation on histopathological, biochemical and functional outcomes	JOURNAL OF NEUROSCIENCE METHODS			English	Article						brain injury; lipopolysaccharides; nitric oxide; nitric oxide synthases; myeloperoxidase activity; NeuN; GFAP; neurological score	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; INTRACEREBRAL INJECTION; MICE LACKING; IN-VITRO; LIPOPOLYSACCHARIDE; MICROGLIA; INFLAMMATION; EXPRESSION	Neuroinflammation is one of the events occurring after acute brain injuries. The aim of the present report was to characterize a rat model to study acute neuroinflammation on the histopathological, biochemical and functional outcomes. Lipopolysaccharide (LPS), known as a strong immunostimulant, was directly injected into the hippocampus. The spatiotemporal evolution of inducible NOS (iNOS) and cell death was studied from 6h to 7 days. A perfect time course correlation was observed between iNOS inmunoreactivity and iNOS activity showing an acute, expansive and transient iNOS induction in the hippocampus With a peak at 24 h. It was associated with a marked increase in NO metabolite (NOx) levels, and a high level of myeloperoxidase (MPO) activity. This inflammation precedes a massive cellular loss including at least neurons and astrocytes, and a drop of constitutive NOS activity, restrictive to the ipsilateral hippocampus from 48 h after LPS injection. Moreover, sensorimotor function impairment occurred from 24h to 7 days with a maximum at 24h post-LPS injection. Therefore, we characterized an in vivo model of acute neuroinflammation and neurodegeneration, in relation with a neurological deficit, which may be a powerful tool for mechanistic studies and for further evaluation of the potential neuroprotective, agents. (c) 2004 Elsevier B.V. All rights reserved.	Univ Paris 05, Pharmacokinet Lab, UPRES, EA 2510, F-75270 Paris, France	Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Pharmacokinet Lab, UPRES, EA 2510, 4,Abe Observat, F-75270 Paris, France.	mehrnaz.jafarian@univ-paris5.fr		Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856			Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Batteur-Parmentier S, 2000, J CEREBR BLOOD F MET, V20, P812, DOI 10.1097/00004647-200005000-00007; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Blond D, 2002, BRAIN RES, V958, P89, DOI 10.1016/S0006-8993(02)03473-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Dalmau I, 1998, HIPPOCAMPUS, V8, P458, DOI 10.1002/(SICI)1098-1063(1998)8:5<458::AID-HIPO6>3.3.CO;2-E; Garcion E, 1998, GLIA, V22, P282, DOI 10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Grandati M, 1997, BRIT J PHARMACOL, V122, P625, DOI 10.1038/sj.bjp.0701427; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; Jeohn GH, 2000, MOL BRAIN RES, V79, P32, DOI 10.1016/S0169-328X(00)00082-6; Jeohn GH, 2002, NEUROSCIENCE, V114, P689, DOI 10.1016/S0306-4522(02)00356-1; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Konsman JP, 1999, NEUROSCIENCE, V89, P535, DOI 10.1016/S0306-4522(98)00368-6; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; Matsuoka Y, 1999, NEUROCHEM INT, V34, P91, DOI 10.1016/S0197-0186(98)00053-9; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mirzoeva S, 2002, J MED CHEM, V45, P563, DOI 10.1021/jm015573g; MonteroMenei CN, 1996, BRAIN RES, V724, P55, DOI 10.1016/0006-8993(96)00268-5; Parmentier-Batteur S, 2001, J CEREBR BLOOD F MET, V21, P15, DOI 10.1097/00004647-200101000-00003; Possel H, 2000, GLIA, V32, P51, DOI 10.1002/1098-1136(200010)32:1<51::AID-GLIA50>3.0.CO;2-4; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stern EL, 2000, J NEUROIMMUNOL, V109, P244, DOI 10.1016/S0165-5728(00)00318-0; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; Yamada K, 1999, NEUROSCIENCE, V88, P281, DOI 10.1016/S0306-4522(98)00237-1; Zamora R, 2000, MOL MED, V6, P347, DOI 10.1007/BF03401781; Zhao XR, 2000, BRAIN RES, V872, P215, DOI 10.1016/S0006-8993(00)02459-8	41	24	28	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 15	2005	144	2					183	191		10.1016/j.jbeumeth.2004.11.002			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	934JB	WOS:000229704000005	15910976				2021-06-18	
J	Salomone, JP; Ustin, JS; McSwain, NE; Feliciano, DV				Salomone, JP; Ustin, JS; McSwain, NE; Feliciano, DV			Opinions of trauma practitioners regarding prehospital interventions for critically injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma		emergency medical services; prehospital care; trauma; airway management; intravenous fluid resuscitation; pneumatic antishock garment	EMERGENCY MEDICAL-SERVICES; FLUID RESUSCITATION; PROMPT TRANSPORT; CARE; FIELD; IMMOBILIZATION; STABILIZATION; INTUBATION; PARAMEDICS; SURVIVAL	Background. Significant controversy surrounds the prehospital management of trauma patients. Methods. A questionnaire describing clinical scenarios was mailed to a random sample of 345 trauma practitioners. Results. The 182 trauma practitioners (52.8%) who returned the surveys were predominantly general or trauma surgeons (83.5%) in academic or university practice (68.1%). For a patient with a severe traumatic brain injury, 84.5% of trauma practitioners recommended that emergency medical services personnel attempt intubation at least once when transport time was 20 to 40 minutes. For a with a gunshot wound to the epigastrium in decompensated shock, the majority of trauma practitioners believed that a relatively hypotensive state should be maintained, regardless of transport time. Trauma practitioners (52.2%) have recommended the use of the pneumatic antishock garment for transports of 20 to 40 minutes for patients with an unstable pelvic fracture and decompensated shock. Conclusion. most trauma practitioners believe that emergency medical services providers should attempt intubation for a patient with a severe traumatic brain injury, should treat decompensated shock in a patient with penetrating torso trauma but maintain the patient in a relatively hypotensive state, and should apply and inflate the pneumatic antishock garment for a suspected pelvic fracture accompanied by decompensated shock if the patient is 20 to 40 minutes from a trauma center. The recommendations of trauma practitioners regarding appropriate prehospital care are significantly influenced by the time required for transport to the trauma center.	Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30303 USA; Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70118 USA	Salomone, JP (corresponding author), Emory Univ, Sch Med, Dept Surg, Glenn Mem Bldg,312,69 Jesse Hill Jr Dr,SE, Atlanta, GA 30303 USA.	jsalomo@emory.edu					Ali J, 1997, J TRAUMA, V42, P1018, DOI 10.1097/00005373-199706000-00005; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP P; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BLAISDELL FW, 1985, J TRAUMA, V25, P856, DOI 10.1097/00005373-198509000-00008; BORDER JR, 1983, J TRAUMA, V23, P708, DOI 10.1097/00005373-198308000-00005; CHAN D, 1994, ANN EMERG MED, V23, P48, DOI 10.1016/S0196-0644(94)70007-9; Cornwell EE, 2001, ARCH SURG-CHICAGO, V136, P324, DOI 10.1001/archsurg.136.3.324; Cornwell EE, 2000, ARCH SURG-CHICAGO, V135, P315, DOI 10.1001/archsurg.135.3.315; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; Domeier R M, 1997, Prehosp Emerg Care, V1, P32, DOI 10.1080/10903129708958782; FEERO S, 1995, AM J EMERG MED, V13, P133, DOI 10.1016/0735-6757(95)90078-0; FLINT LM, 1979, ANN SURG, V189, P709, DOI 10.1097/00000658-197906000-00006; Fortune JB, 1997, J TRAUMA, V42, P832, DOI 10.1097/00005373-199705000-00013; GERVIN AS, 1982, J TRAUMA, V22, P443, DOI 10.1097/00005373-198206000-00001; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; IVATURY RR, 1987, J TRAUMA, V27, P1066, DOI 10.1097/00005373-198709000-00019; Jacobson LE, 1996, J TRAUMA, V41, P15, DOI 10.1097/00005373-199607000-00004; JONES SE, 1989, ANN EMERG MED, V18, P244, DOI 10.1016/S0196-0644(89)80405-6; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; LEWIS FR, 1986, J TRAUMA, V26, P804, DOI 10.1097/00005373-198609000-00005; Liberman M, 2003, ANN SURG, V237, P153, DOI 10.1097/00000658-200302000-00001; MATTOX KL, 1989, J TRAUMA, V29, P1104, DOI 10.1097/00005373-198908000-00007; MCSWAIN NE, 1988, ANN EMERG MED, V17, P506, DOI 10.1016/S0196-0644(88)80248-8; MCSWAIN NE, 2003, PHTLS BASIC ADV PREH; OGORMAN M, 1989, J TRAUMA, V29, P84, DOI 10.1097/00005373-198901000-00017; PANTRIDGE JF, 1969, AM J CARDIOL, V24, P666, DOI 10.1016/0002-9149(69)90454-8; PONS PT, 1988, J TRAUMA, V28, P1460, DOI 10.1097/00005373-198810000-00009; ROCKWOOD CA, 1976, J TRAUMA, V16, P299, DOI 10.1097/00005373-197604000-00008; SMITH JP, 1985, J TRAUMA, V25, P65, DOI 10.1097/00005373-198501000-00011; Solomonov E, 2000, CRIT CARE MED, V28, P749, DOI 10.1097/00003246-200003000-00024; Totten V Y, 1999, Prehosp Emerg Care, V3, P347, DOI 10.1080/10903129908958967; TRUNKEY DD, 1984, J TRAUMA, V24, P86, DOI 10.1097/00005373-198401000-00017; WAYNE MA, 1999, PREHOSP EMERG CARE, V3, P377; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	35	24	24	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2005	58	3					509	515		10.1097/01.TA.0000152807.63559.2E			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	906JK	WOS:000227636800019	15761344				2021-06-18	
J	Wennberg, R				Wennberg, R			Effect of ice surface size on collision rates and head impacts at the World Junior Hockey Championships, 2002 to 2004	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						collision; concussion; head impact; hockey; injury; ice surface size	CONCUSSIONS; LEAGUE	Objective: To determine if collision rates and head impacts in elite junior hockey differed between games played on the small North American ice surface (85 ft wide), an intermediate-size Finnish ice surface (94 ft wide), and the large standard international ice surface (100 ft wide). Design: Videotape analysis of all games involving Team Canada from the 2002 (large ice, Czech Republic), 2003 (small ice, Canada), and 2004 (intermediate ice, Finland) World Junior Championships. All collisions were counted and separated into various categories (volitional player/player bodychecks, into boards or open ice, plus accidental/incidental player/boards, player/ice, head/stick, head/puck). Further subdivisions included collisions involving the head directly or indirectly and notably severe head impacts. Results: Small, intermediate, and large ice surface mean collisions/game, respectively, were 295, 258, 222, total collisions; 251, 220, 181, volitional bodychecks; 126, 115, 88, into boards; 125, 106, 93, open ice; 71, 52, 44, total head; 44, 36, 30, indirect head; 26, 16, 13, direct head; and 1.3, 0.5, 0.3, severe head (P < 0.05 for small-intermediate ice and intermediate-large ice differences in total collisions; P < 0.005 for small-large ice difference; P < 0.05 for small-intermediate ice differences in head impacts; P < 0.01 for small-large ice differences in total and severe head impacts). Conclusions: There is a significant inverse correlation between ice size and collision rates in elite hockey, including direct, indirect, and severe head impacts. These findings suggest that uniform usage of the larger international rinks could reduce the risk of injury, and specifically, concussions in elite hockey by decreasing the occurrence of collisions and head impacts.	Univ Toronto, Toronto Western Hosp, Div Neurol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada	Wennberg, R (corresponding author), Univ Toronto, Toronto Western Hosp, Div Neurol, 399 Bathurst St,5W444, Toronto, ON M5T 2S8, Canada.	r.wennberg@utoronto.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Marchie A, 2003, CAN MED ASSOC J, V169, P124; Watson RC, 1997, CLIN J SPORT MED, V7, P192, DOI 10.1097/00042752-199707000-00007; Wennberg R, 2004, CAN J NEUROL SCI, V31, P373, DOI 10.1017/S0317167100003474; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596	5	24	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2005	15	2					67	72		10.1097/01.jsm.0000152712.27968.fe			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	943CF	WOS:000230328800005	15782049				2021-06-18	
J	Tomita, M; Holman, BJ; Santoro, CP; Santoro, TJ				Tomita, Michiyo; Holman, Brita J.; Santoro, Christopher P.; Santoro, Thomas J.			Astrocyte production of the chemokine macrophage inflammatory protein-2 is inhibited by the spice principle curcumin at the level of gene transcription	JOURNAL OF NEUROINFLAMMATION			English	Article								Background: In neuropathological processes associated with neutrophilic infiltrates, such as experimental allergic encephalitis and traumatic injury of the brain, the CXC chemokine, macrophage inflammatory protein-2 (MIP-2) is thought to play a pivotal role in the induction and perpetuation of inflammation in the central nervous system (CNS). The origin of MIP-2 in inflammatory disorders of the brain has not been fully defined but astrocytes appear to be a dominant source of this chemokine. Curcumin is a spice principle in, and constitutes approximately 4 percent of, turmeric. Curcumin's immunomodulating and antioxidant activities suggest that it might be a useful adjunct in the treatment of neurodegenerative illnesses characterized by inflammation. Relatively unexplored, but relevant to its potential therapeutic efficacy in neuroinflammatory syndromes is the effect of curcumin on chemokine production. To examine the possibility that curcumin may influence CNS inflammation by mechanisms distinct from its known anti-oxidant activities, we studied the effect of this spice principle on the synthesis of MIP-2 by astrocytes. Methods: Primary astrocytes were prepared from neonatal brains of CBA/CaJ mice. The cells were stimulated with lipopolysaccharide in the presence or absence of various amount of curcumin or epigallocatechin gallate. MIP-2 mRNA was analyzed using semi-quantitative PCR and MIP-2 protein production in the culture supernatants was quantified by ELISA. Astrocytes were transfected with a MIP-2 promoter construct, pGL3-MIP-2, and stimulated with lipopolysaccharide in the presence or absence of curcumin. Results: The induction of MIP-2 gene expression and the production of MIP-2 protein were inhibited by curcumin. Curcumin also inhibited lipopolysaccharide-induced transcription of the MIP-2 promoter reporter gene construct in primary astrocytes. However MIP-2 gene induction by lipopolysaccharide was not inhibited by another anti-oxidant, epigallocatechin gallate. Conclusion: Our results indicate that curcumin potently inhibits MIP-2 production at the level of gene transcription and offer further support for its potential use in the treatment of inflammatory conditions of the CNS.	[Tomita, Michiyo; Santoro, Thomas J.] Univ N Dakota, Sch Med & Hlth Sci, Dept Med, Grand Forks, ND 58201 USA; [Holman, Brita J.] Boston Univ, Chestnut Hill, MA 02467 USA; [Santoro, Christopher P.] Loyola Univ, Chicago, IL 60626 USA; [Santoro, Thomas J.] Fargo VA Med Ctr, Res Serv, Fargo, ND 58102 USA	Tomita, M (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Med, 501 North Columbia Rd, Grand Forks, ND 58201 USA.	mtomita@medicine.nodak.edu; bjholman@bu.edu; csantor@luc.edu; tsantoro@medicine.nodak.edu			Arthritis Foundation	This study was, in part, supported by the North Central Chapter of the Arthritis Foundation.	Ambegaokar SS, 2003, NEUROENDOCRINOL LETT, V24, P469; Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; Diab A, 1999, INFECT IMMUN, V67, P2590, DOI 10.1128/IAI.67.5.2590-2601.1999; FRANZOSO G, 1994, J EXP MED, V180, P1445, DOI 10.1084/jem.180.4.1445; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; HUANG MT, 1988, CANCER RES, V48, P5941; Kang BY, 1999, EUR J PHARMACOL, V384, P191, DOI 10.1016/S0014-2999(99)00690-1; Kang BY, 1999, BRIT J PHARMACOL, V128, P380, DOI 10.1038/sj.bjp.0702803; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Lim GP, 2001, J NEUROSCI, V21, P8370; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Nygardas PT, 2000, EUR J IMMUNOL, V30, P1911, DOI 10.1002/1521-4141(200007)30:7<1911::AID-IMMU1911>3.0.CO;2-E; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Otto VI, 2002, J NEUROCHEM, V80, P824, DOI 10.1046/j.0022-3042.2001.00748.x; Pan MH, 2000, BIOCHEM PHARMACOL, V60, P1665, DOI 10.1016/S0006-2952(00)00489-5; Pousset F, 2001, J NEUROCHEM, V79, P726, DOI 10.1046/j.1471-4159.2001.00569.x; Santoro T, 1995, GENOMICS, V30, P558, DOI 10.1006/geno.1995.1277; SANTORO TJ, 1988, J EXP MED, V167, P1713, DOI 10.1084/jem.167.5.1713; Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744; Sreejayan Rao M. N., 1997, J PHARM PHARMACOL, V49, P105; SREEJAYAN RMN, 1994, J PHARM PHARMACOL, V46, P1013; Tomita M, 2002, PHYTOTHER RES, V16, P36, DOI 10.1002/ptr.834; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200	25	24	26	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.		2005	2								8	10.1186/1742-2094-2-8			7	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	V29PC	WOS:000208759300008		DOAJ Gold, Green Published			2021-06-18	
J	Svendsen, HA; Teasdale, TW; Pinner, M				Svendsen, HA; Teasdale, TW; Pinner, M			Subjective experience in patients with brain injury and their close relatives before and after a rehabilitation programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SELF-AWARENESS; HEAD-INJURY; FAMILY; PERFORMANCE; DYSFUNCTION; RECOVERY; OUTCOMES	This study reports results from 143 adult patients with cerebrovascular accident, traumatic brain injury or other acquired brain injury who underwent a neuropsychologically-based post-acute rehabilitation programme. Immediately pre- and post-programme, patients, as well as close relatives, completed the European Brain Injury Questionnaire (EBIQ) regarding patient symptoms, together with the impact of injury on the relative. Results for the three groups of patients were compared to those of 64 control subjects without brain injury. There were three major findings. First, significantly higher levels of symptoms were found in the patient groups at pre-programme evaluation, compared to the control group.Within the patient groups there were comparatively few differences between the self-reports of the patients and the reports of their relatives. Second, the patients showed significantly reduced levels of symptoms post-programme, both in their self-reports and in their relatives' reports. These levels remained however above those of the control group. Third, the reported impact of the injury to the patient upon their relatives was significantly reduced post-programme. Thus, this study further documents that patient symptoms, and the impact of these on close relatives, may be broadly reduced, but perhaps not eliminated, as a result of neuropsychological rehabilitation.	Univ Copenhagen, Ctr Rehabil Brain Injury, DK-2300 Copenhagen S, Denmark; Univ Copenhagen, Dept Psychol, DK-1168 Copenhagen, Denmark	Svendsen, HA (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	aaby@cfh.ku.dk					ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Bond M R, 1975, Ciba Found Symp, P141; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N., 1984, CLOSED HEAD INJURY P; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHRISTENSEN AL, 1988, NEUROPSYCHOL REHABIL, P115; ELSASS P, 1993, SUNDHEDSPSYKOLOGI; ENGBERG A, 1995, ACTA NEUROLOGICA S S, V164; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fleminger S, 1999, NEUROPSYCHOL REHABIL, V9, P225, DOI 10.1080/096020199389338; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; HOWELL DC, 2001, FUNDAMENTAL STAT BEH; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teasdale T W, 1995, Appl Neuropsychol, V2, P116; Teasdale TW, 1997, BRIT MED J, V315, P569; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TREXLER LE, 1996, AMBULANTE TEILSTATIO, P25; Voogt RD, 1998, NEUROREHABILITATION, V11, P107, DOI 10.1016/S1053-8135(98)00015-8; Wade DT, 1992, MEASUREMENT NEUROLOG; Willer B, 2001, BRAIN DAM B, P47; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	47	24	24	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	DEC	2004	14	5					495	515		10.1080/09602010343000318			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	863AY	WOS:000224533800002					2021-06-18	
J	Foster, M; Tilse, C; Fleming, J				Foster, M; Tilse, C; Fleming, J			Referral to rehabilitation following traumatic brain injury: practitioners and the process of decision-making	SOCIAL SCIENCE & MEDICINE			English	Article						traumatic brain injury; rehabilitation; professional decision-making; Australia	SEVERE HEAD-INJURY; HEALTH-CARE; PRACTICAL ISSUES; DISCHARGE; CHILDREN; TRANSITION; HOSPITALS; PROVISION; SERVICES; OUTCOMES	The study aimed to examine the factors influencing referral to rehabilitation following traumatic brain injury (TBI) by using social problems theory as a conceptual model to focus on practitioners and the process of decision-making in two Australian hospitals. The research design involved semi-structured interviews with 18 practitioners and observations of 10 team meetings, and was part of a larger study on factors influencing referral to rehabilitation in the same settings. Analysis revealed that referral decisions were influenced primarily by practitioners' selection and their interpretation of clinical and non-clinical patient factors. Further, practitioners generally considered patient factors concurrently during an ongoing process of decision-making, with the combinations and interactions of these factors forming the basis for interpretations of problems and referral justifications. Key patient factors considered in referral decisions included functional and tracheostomy status, time since injury, age, family, place of residence and Indigenous status. However, rate and extent of progress, recovery potential, safety and burden of care, potential for independence and capacity to cope were five interpretative themes, which emerged as the justifications for referral decisions. The subsequent negotiation of referral based on patient factors was in turn shaped by the involvement of practitioners. While multi-disciplinary processes of decision-making were the norm, allied health professionals occupied a central role in referral to rehabilitation, and involvement of medical, nursing and allied health practitioners varied. Finally, the organizational pressures and resource constraints, combined with practitioners' assimilation of the broader efficiency agenda were central factors shaping referral. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia; Griffith Univ, Res Ctr Clin Pract Innovat, Bundall, Qld 9726, Australia; Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4072, Australia	Tilse, C (corresponding author), Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia.	tilsec@social.uq.edu.au	Tilse, Cheryl/AAH-2155-2019; Fleming, Jennifer M/B-4436-2011; Tilse, Cheryl/A-1266-2008	Tilse, Cheryl/0000-0001-5596-9132			Abbott A, 1988, SYSTEM PROFESSIONS E; *AIWH, 1998, HLTH RUR REM AUSTR A; Banja J, 1999, BRAIN INJURY, V13, P745, DOI 10.1080/026990599121142; Baumann E. A., 1989, IMAGES ISSUES TYPIFY, P55; BEST J, 1987, SOC PROBL, V34, P101, DOI 10.1525/sp.1987.34.2.03a00010; Best J., 1993, RECONSIDERING SOCIAL, P129; BEST J, 1995, IMAGES ISSUES TYPIFY, P3; Blades DA, 1997, J REHABIL, V63, P35; Caplan A, 1997, J HEAD TRAUMA REHAB, V12, P29, DOI 10.1097/00001199-199702000-00006; Cavestri R, 1997, ITAL J NEUROL SCI, V18, P9, DOI 10.1007/BF02106224; CHABOYER W, 2003, INTENSIVE CRITICAL C; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; CLARK DO, 1994, J APPL GERONTOL, V13, P267, DOI 10.1177/073346489401300304; CLARK JA, 1991, SOC SCI MED, V32, P853, DOI 10.1016/0277-9536(91)90241-4; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Dillingham TR, 1998, ARCH PHYS MED REHAB, V79, P279, DOI 10.1016/S0003-9993(98)90007-7; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DOMBOVY M, 1996, BRAIN INJURY, V11, P305; Draper M., 1999, HLTH POLICY MARKET S, P131; DUCHENE PA, 1995, J HEAD TRAUMA REHAB, V12, P91; Eker C, 2000, BRAIN INJURY, V14, P605; Fabiano RJ, 1998, J REHABIL, V64, P9; FINCH J, 1999, INTERIM REPORT STATE; Foster M, 2000, BRAIN INJURY, V14, P1035; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; FOSTER M, 2001, THESIS U QUEENSLAND; Foster RL, 1997, ADV NURS SCI, V20, P1; Foster-Barber A, 2002, MENT RETARD DEV D R, V8, P20, DOI 10.1002/mrdd.10009; Freidson E, 1986, PROFESSIONAL POWERS; Fyffe C, 1996, Aust J Rural Health, V4, P232, DOI 10.1111/j.1440-1584.1996.tb00216.x; GRIFFIN SD, 1993, ARCH PHYS MED REHAB, V74, P1087, DOI 10.1016/0003-9993(93)90066-J; Griffiths L., 1994, QUALITATIVE HLTH RES, V4, P385; HAIG AJ, 1995, ARCH PHYS MED REHAB, V76, P341, DOI 10.1016/S0003-9993(95)80659-8; Hancock L., 1999, HLTH POLICY MARKET S, P87; HARRISON S, 1995, BRIT MED BULL, V51, P885, DOI 10.1093/oxfordjournals.bmb.a073003; Hensher M, 1999, BRIT MED J, V319, P845, DOI 10.1136/bmj.319.7213.845; Hill TP, 1996, SOC SCI MED, V43, P783, DOI 10.1016/0277-9536(96)00123-2; Holstein JA, 1993, RECONSIDERING SOCIAL, P151; Hughes D, 1997, SOC SCI MED, V44, P589, DOI 10.1016/S0277-9536(96)00207-9; Humphreys J, 1999, Aust J Rural Health, V7, P60, DOI 10.1046/j.1440-1584.1999.00217.x; HUNTER DJ, 1995, BRIT MED BULL, V51, P876, DOI 10.1093/oxfordjournals.bmb.a073002; IRVINE DH, 1995, BRIT MED BULL, V51, P842, DOI 10.1093/oxfordjournals.bmb.a072999; Jan S, 1996, AUST NZ J PUBL HEAL, V20, P9, DOI 10.1111/j.1467-842X.1996.tb01326.x; Jones H P, 1995, J Rural Health, V11, P122, DOI 10.1111/j.1748-0361.1995.tb00405.x; Keigher SM, 1997, HEALTH SOC WORK, V22, P149, DOI 10.1093/hsw/22.2.149; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Mason J., 1996, QUALITATIVE RES; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McKinlay W W, 1987, Brain Inj, V1, P3, DOI 10.3109/02699058709034438; MCKINNEY MM, 1993, HEALTH SERV RES, V28, P459; McMillan T. M., 1993, CLIN REHABIL, V7, P346; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Patford J., 1999, AUSTR SOCIAL WORK, V52, P3, DOI 10.1080/03124079908414103; Patton M.Q., 2002, QUALITATIVE RES EVAL; Potthoff S, 1997, HEALTH CARE FINANC R, V19, P47; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; SCHWARTZ CG, 1983, PSYCHIATRY, V46, P333, DOI 10.1080/00332747.1983.11024208; Sherman SE, 2000, J GEN INTERN MED, V15, P2; Swerissen H, 1997, HLTH POLICY FINANCIN, P13; Tennier LD, 1997, SOC WORK HEALTH CARE, V26, P41, DOI 10.1300/J010v26n01_03; Teram E, 1999, HUM RELAT, V52, P263, DOI 10.1023/A:1016988903857; TOBIS JS, 1982, SCAND J REHABIL MED, V14, P83; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Tuzman L, 1992, Health Soc Work, V17, P299; Unsworth C A, 1997, Pediatr Rehabil, V1, P207; Walker WC, 1996, BRAIN INJURY, V10, P65; WILLIAMS S, 1995, AUSTR OCCUPATIONAL T, V42, P143; WRAY LA, 1992, GENERATION, V16, P31; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	71	24	24	1	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	NOV	2004	59	9					1867	1878		10.1016/j.socscimed.2004.02.017			12	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	852CZ	WOS:000223734100008	15312921				2021-06-18	
J	Van den Heuvel, C; Donkin, JJ; Finnie, JW; Blumbergs, PC; Kuchel, T; Koszyca, B; Manavis, J; Jones, NR; Reilly, PL; Vink, R				Van den Heuvel, C; Donkin, JJ; Finnie, JW; Blumbergs, PC; Kuchel, T; Koszyca, B; Manavis, J; Jones, NR; Reilly, PL; Vink, R			Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; cyclosporin-A; head injury model; immunocytochemistry; RT-PCR; sheep; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NERVE GROWTH-FACTOR; ALZHEIMERS-DISEASE; SECRETED FORMS; UP-REGULATION; BETA-PROTEIN; MESSENGER-RNA; KINASE-C; AXONAL DAMAGE; CELL-SURFACE	The aim of these studies was to assess and quantitate the effects of cyclosporin-A (CyA) on brain APP messenger RNA and neuronal perikaryal APP antigen expression following controlled focal head impact in sheep. Impact results in a significant increase in both APP mRNA and neuronal perikaryal APP antigen expression. Post-traumatic administration of CyA (intrathecal 10 mg/kg) resulted in a reduction in APP mRNA and neuronal perikaryal antigen expression. At 2 h postinjury, CyA treatment caused a statistically significant (p < 0.05) 1.3 +/- 0.1-fold decrease in APP mRNA in the central gray matter of impacted sheep compared to untreated impacted sheep. A more profound reduction in APP mRNA synthesis (1.6 +/- 0.2 fold) was evident at 6 h (P < 0.05). The mean percentage brain area with APP immunoreactive neuronal perikarya at 6 h post-injury was 94.5% in untreated impacted animals, 10.0% in CyA-treated impacted animals, 5.5% in untreated non-impacted animals, and 6% in CyA-treated non-impacted controls. These results demonstrate that CyA has a downregulatory effect on increased APP expression caused by TBI.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia; IMVS, Vet Div, Adelaide, SA, Australia; Royal Adelaide Hosp, Dept Neurosurg, Adelaide, SA, Australia	Van den Heuvel, C (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; , Corinna/0000-0003-0664-8935			Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Caputi A, 1997, J NEUROCHEM, V68, P2523; CLARRIS HJ, 1994, J NEUROSCI RES, V38, P248, DOI 10.1002/jnr.490380303; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DOYLE E, 1990, NEUROSCI LETT, V115, P97, DOI 10.1016/0304-3940(90)90524-D; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GITTER BD, 1995, EUR J PHARM-MOLEC PH, V289, P439, DOI 10.1016/0922-4106(95)90152-3; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; JIN LW, 1994, J NEUROSCI, V14, P5461; Johnson D, 1997, EDN, V42, P94; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lee RKK, 2000, ANN NY ACAD SCI, V920, P261; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1999, J NEUROCHEM, V73, P532, DOI 10.1046/j.1471-4159.1999.0730532.x; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MOYA KL, 1994, DEV BIOL, V161, P597, DOI 10.1006/dbio.1994.1055; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; OHSAWA I, 1995, BIOCHEM BIOPH RES CO, V213, P52, DOI 10.1006/bbrc.1995.2097; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Parks JK, 2001, J NEUROCHEM, V76, P1050, DOI 10.1046/j.1471-4159.2001.00112.x; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pyrzynska B, 2001, NEUROCHEM INT, V38, P409, DOI 10.1016/S0197-0186(00)00105-4; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Seo JH, 2001, BIOL PSYCHIAT, V49, P240, DOI 10.1016/S0006-3223(00)01124-0; SLACK BE, 1993, ANN NY ACAD SCI, V695, P128, DOI 10.1111/j.1749-6632.1993.tb23040.x; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Takahashi T, 2001, J INVEST DERMATOL, V117, P605, DOI 10.1046/j.0022-202x.2001.01452.x; TREJO J, 1994, J BIOL CHEM, V269, P21682; Van den Heuvel C, 2000, J NEUROTRAUM, V17, P1041, DOI 10.1089/neu.2000.17.1041; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van den Heuvel C, 2000, J CLIN NEUROSCI, V7, P140; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	54	24	24	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1562	1572		10.1089/0897715042441783			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800004	15684649				2021-06-18	
J	Vink, R; Donkin, JJ; Cruz, MI; Nimmo, AJ; Cernak, L				Vink, R; Donkin, JJ; Cruz, MI; Nimmo, AJ; Cernak, L			A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats	JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION			English	Article						brain trauma; brain Mg; inflammation; functional outcome; rats; substance P-antagonist	NEUROKININ; EDEMA	Objective: Magnesium (Mg) deficiency has been shown to increase substance P release and induce a pro-inflammatory response that can be attenuated with the administration of a substance P-antagonist. Neurogenic inflammation has also been implicated in traumatic brain injury (TBI), a condition where brain intracellular free magnesium (Mg-f) decline is known to occur and has been correlated with functional outcome. We therefore examined whether a substance P antagonist restores brain intracellular free magnesium concentration following TBI. Methods: Male, adult Sprague-Dawley rats were injured using. the Cernak impact acceleration model of diffuse TBI. At 30 min after injury, animals were administered either 0.25 mg/kg i.v. n-acetyl tryptophan or equal volume saline. Prior to and 4 h after induction of injury, phosphorus magnetic resonance spectra were acquired using a 7-tesla magnet interfaced with a Broker console. Mgf was calculated from the chemical shift of the beta ATP. Before injury, Mgf was 0.51 +/- 0.05 mM (SEM). Results: By 4 hr after injury, Mgf had significantly declined to 0.27 +/- 0.02 mM in saline treated rats. In contrast, rats treated with n-acetyl tryptophan had a Mgf of 0.47 +/- 0.06 mM at 4 h after injury, which was not significantly different from preinjury values. There were no significant differences in pH between the treatment groups. Conclusion: It seems that any beneficial effect of a substance P antagonist on functional outcome following TBI may be related to improvement in brain Mg homeostasis induced by the compound.	Univ Adelaide, Dept Pathol, Adelaide, SA, Australia; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia; Georgetown Univ, Dept Neurosci, Washington, DC USA	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA, Australia.	Robert.vink@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X; Nimmo, Alan/0000-0002-0718-7934			Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bereiter DA, 1998, NEUROSCIENCE, V83, P525, DOI 10.1016/S0306-4522(97)00433-8; CERNAK I, 2004, IN PRESS NEUROBIOL D; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; Hasenohrl RU, 2000, NEUROPEPTIDES, V34, P272, DOI 10.1054/npep.2000.0824; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Hokfelt T, 2001, J INTERN MED, V249, P27, DOI 10.1046/j.0954-6820.2000.00773.x; HUSTON JP, 1995, BEHAV BRAIN RES, V66, P117, DOI 10.1016/0166-4328(94)00132-Y; Kramer JH, 1997, J MOL CELL CARDIOL, V29, P97, DOI 10.1006/jmcc.1996.0255; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Murck H, 2002, NUTR NEUROSCI, V5, P375, DOI 10.1080/1028415021000039194; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Parker D, 1998, J NEUROSCI, V18, P4800; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; VINK R, 2000, REST NEUROL NEUROSCI, V16, P164; VINK R, 2002, EXPERT OPIN INV DRUG, V11, P1; WALSH DT, 1995, BRIT J PHARMACOL, V114, P1343, DOI 10.1111/j.1476-5381.1995.tb13354.x	23	24	24	0	1	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0731-5724	1541-1087		J AM COLL NUTR	J. Am. Coll. Nutr.	OCT	2004	23	5					538S	540S		10.1080/07315724.2004.10719398			3	Nutrition & Dietetics	Nutrition & Dietetics	863AF	WOS:000224531900019	15466960				2021-06-18	
J	Wirz, SA; Morale, MC; Marchetti, B; Barr, AM; Sotgiu, S; Rosati, G; Pugliatti, M; Sanna, MV; Giliberto, O; Bartfai, T; Conti, B				Wirz, SA; Morale, MC; Marchetti, B; Barr, AM; Sotgiu, S; Rosati, G; Pugliatti, M; Sanna, MV; Giliberto, O; Bartfai, T; Conti, B			High frequency of TNF alleles -238A and -376A in individuals from northern Sardinia	CYTOKINE			English	Article						association; malaria; polymorphism; Sardinia; TNF	ALPHA PROMOTER POLYMORPHISM; SEVERE MALARIAL ANEMIA; MULTIPLE-SCLEROSIS; DIABETES-MELLITUS; GENE POLYMORPHISMS; CEREBRAL MALARIA; REGION; SUSCEPTIBILITY; ASSOCIATION; INFECTION	The G to A single nucleotide polymorphisms (SNPs), at position -376, -308 and -238 in the promoter of the tumor necrosis factor alpha (TNF) gene, have been independently correlated with numerous diseases. Alleles TNF-376A and TNF-238A are normally found throughout the world with very low frequencies. We investigated the frequency of these SNPs in Sicilian subjects hospitalized after traumatic brain injury and in three groups of subjects from northern Sardinia: healthy subjects and individuals with multiple sclerosis or ischemic stroke. While no significant difference was found between healthy and disease subjects, the frequency of TNF-376A and TNF-238A was elevated up to 10 times in Sardinia compared to Sicily and other populations throughout the world. These elevated frequencies may be the result of genetic drift or of selective pressure on TNF itself or on neighboring genes, including the HLA. Malaria, endemic to Sardinia until the end of the 1940s, and the bubonic plague, are among the possible causes of selection. These findings indicate that Sardinia is an ideal location to further elucidate the correlation between TNF or HLA polymorphisms and diseases, including multiple sclerosis and type-l diabetes, present with an unusually high frequency and co-morbidity in Sardinia. (C) 2004 Elsevier Ltd. All rights reserved.	Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, La Jolla, CA 92037 USA; OASI, Dipartimento Neurofarmacol, IRCCS, I-94018 Troina, EN, Italy; Univ Sassari, Ist Clin Neurol, I-07100 Sassari, Italy; Univ Cagliari, Dipartimento Stor Geog & Artist, I-09124 Cagliari, Italy; Osped Catania, Div Neurochirurg, I-95100 Catania, Italy	Conti, B (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, 10550 N Torrey Pines Rd,SR307, La Jolla, CA 92037 USA.	bconti@scripps.edu	Morale, Maria Concetta/D-5847-2017; Marchetti, Bianca Maria/K-4623-2016; sotgiu, stefano/M-1011-2017	Morale, Maria Concetta/0000-0003-0624-7234; Marchetti, Bianca Maria/0000-0002-9287-8448; Conti, Bruno/0000-0002-9185-5201; Barr, Alasdair/0000-0002-3407-1574			Ackerman H, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r24; Bayley JP, 2001, CYTOKINE, V14, P316, DOI 10.1006/cyto.2001.0902; Braun N, 1996, NEUROSCI LETT, V215, P75, DOI 10.1016/S0304-3940(96)12920-7; Brinkman B M, 1995, J Inflamm, V46, P32; Brinkman BMN, 1997, BRIT J RHEUMATOL, V36, P516; Contu L, 1998, TISSUE ANTIGENS, V52, P452, DOI 10.1111/j.1399-0039.1998.tb03072.x; DALFONSO S, 1994, IMMUNOGENETICS, V39, P150; DAlfonso S, 1996, TISSUE ANTIGENS, V47, P551, DOI 10.1111/j.1399-0039.1996.tb02598.x; Fernandes JAM, 2002, AUTOIMMUNITY, V35, P377, DOI 10.1080/0891693021000021549; Fernandez-Arquero M, 1999, NEUROLOGY, V53, P1361, DOI 10.1212/WNL.53.6.1361; Gourley IS, 2002, J INFECT DIS, V186, P1007, DOI 10.1086/342947; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; HAMANN A, 1995, BIOCHEM BIOPH RES CO, V211, P833, DOI 10.1006/bbrc.1995.1887; Hohler T, 1998, CLIN EXP IMMUNOL, V111, P579; Hohler T, 1998, J MED VIROL, V54, P173, DOI 10.1002/(SICI)1096-9071(199803)54:3<173::AID-JMV5>3.0.CO;2-2; Hohlfeld R, 1997, BRAIN, V120, P865, DOI 10.1093/brain/120.5.865; Kaluza W, 2000, J INVEST DERMATOL, V114, P1180, DOI 10.1046/j.1523-1747.2000.00001.x; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Kroeger KR, 1996, BIOCHEM MOL BIOL INT, V40, P43; Marrosu MG, 2002, LANCET, V359, P1461, DOI 10.1016/S0140-6736(02)08431-3; McDermott MF, 2001, CELL MOL BIOL, V47, P619; McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; Morse HR, 1999, CYTOKINE, V11, P789, DOI 10.1006/cyto.1999.0491; Pugliatti M, 2002, NEUROLOGY, V58, P277, DOI 10.1212/WNL.58.2.277; Repo H, 2002, SCAND J RHEUMATOL, V31, P355, DOI 10.1080/030097402320817086; SANNA MV, IN PRESS IGIENE MODE; Sashio H, 2002, IMMUNOGENETICS, V53, P1020, DOI 10.1007/s00251-001-0423-7; SINISCALCO M, 1961, NATURE, V190, P1179, DOI 10.1038/1901179a0; Stephens LA, 1999, ENDOCRINOLOGY, V140, P3219, DOI 10.1210/en.140.7.3219; Wahlgren M, 1999, NAT GENET, V22, P120, DOI 10.1038/9621; Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195	34	24	28	0	0	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666	1096-0023		CYTOKINE	Cytokine	MAY 21	2004	26	4					149	154		10.1016/j.cyto.2004.02.006			6	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	827KM	WOS:000221898400002	15149631				2021-06-18	
J	Fisher, AJ; Donnelly, SC; Pritchard, G; Dark, JH; Corris, PA				Fisher, AJ; Donnelly, SC; Pritchard, G; Dark, JH; Corris, PA			Objective assessment of criteria for selection of donor lungs suitable for transplantation	THORAX			English	Article							LIBERALIZATION; INTERLEUKIN-8	Background: Donor organ shortage severely limits lung transplantation as a therapeutic option, yet many potential donor lungs are deemed unsuitable by clinical selection criteria. Methods: Of 39 consecutive potential donor lungs, 14 were accepted and 25 excluded by clinical selection criteria. All were evaluated prospectively by clinical assessment, bronchoscopy, and bronchoalveolar lavage (BAL) to evaluate objectively the discrimination of pulmonary infection and injury. Results: Accepted donors were significantly younger than those excluded ( mean (SD) age 36.7 (15.3) years v 49.5 (13.2) years; p = 0.009, unpaired t test) and were more likely to have suffered traumatic brain death (50% v 20%; p = 0.07, Fisher's exact test). Oxygenation (PaO2: FiO(2)) was higher in accepted donors than in excluded donors (median (range) 63.2 (48 - 82.5) kPa v 43.1 (7.7 - 71.7) kPa; p = 0.0001, Mann-Whitney test). Positive formal BAL culture was more frequent in accepted donors (75%) than in those excluded (43%; p = 0.1, Fisher's exact test). There was no significant difference in the percentage and concentration of neutrophils in BAL fluid between accepted and excluded donors ( median (range) 37.9 (0 - 96.9)% and 44.6 (0 - 1190) x 10(3)/ ml v 36 (1 - 98.1)% and 46 (0.2 - 1457) x10(3)/ml), nor in the BAL fluid concentration of tumour necrosis factor-alpha (140 (0 - 340) pg/ml v 160 (0 - 760) pg/ml) or interleukin 8 (810 (33 - 17 600) pg/ml v 540 (0 - 15 110) pg/ml). Conclusion: Current selection criteria are poor discriminators of pulmonary injury and infection and lead to the exclusion of potentially usable donor lungs.	Newcastle Univ, Freeman Hosp, Dept Cardiopulm Transplantat & Immunobiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Newcastle Univ, Freeman Hosp, Transplantat Res Grp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Univ Coll Dublin, Conway Inst, Dublin 2, Ireland; St Vincents Hosp, Dept Med & Therapeut, Dublin 4, Ireland	Corris, PA (corresponding author), Freeman Rd Hosp, Dept Thorac Med, High Heaton, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	paul.corris@ncl.ac.uk	Fisher, Andrew J/A-2160-2012	Donnelly, Seamas/0000-0001-7145-1843			Anyanwu AC, 2002, HEART, V87, P449, DOI 10.1136/heart.87.5.449; Aziz TM, 2002, ANN THORAC SURG, V73, P1599, DOI 10.1016/S0003-4975(02)03420-3; Bhorade SM, 2000, J HEART LUNG TRANSPL, V19, P1199, DOI 10.1016/S1053-2498(00)00215-1; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Fisher AJ, 1998, THORAX, V53, P818, DOI 10.1136/thx.53.10.818; Fisher AJ, 2001, AM J RESP CRIT CARE, V163, P259, DOI 10.1164/ajrccm.163.1.2005093; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; Grover FL, 1997, AM J SURG, V173, P523, DOI 10.1016/S0002-9610(97)00004-4; KRON IL, 1993, ANN SURG, V217, P518, DOI 10.1097/00000658-199305010-00012; Pierre AF, 2002, J THORAC CARDIOV SUR, V123, P421, DOI 10.1067/mtc.2002.120345; SHUMWAY SJ, 1994, ANN THORAC SURG, V57, P92, DOI 10.1016/0003-4975(94)90371-9; Starnes VA, 1999, ANN THORAC SURG, V68, P2279, DOI 10.1016/S0003-4975(99)01155-8; SUNDARESAN S, 1995, J THORAC CARDIOV SUR, V109, P1075, DOI 10.1016/S0022-5223(95)70190-7; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; Trulock EP, 1997, AM J RESP CRIT CARE, V155, P789, DOI 10.1164/ajrccm.155.3.9117010; *UKTSSA, 1996, CARD ORG TRANSPL AUD; Ware LB, 2002, LANCET, V360, P619, DOI 10.1016/S0140-6736(02)09774-X; Weill D, 2002, J HEART LUNG TRANSPL, V21, P555, DOI 10.1016/S1053-2498(01)00415-6; Weill D, 2002, CHEST, V121, P2029, DOI 10.1378/chest.121.6.2029; Winton T L, 1992, Semin Thorac Cardiovasc Surg, V4, P79	20	24	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376	1468-3296		THORAX	Thorax	MAY 1	2004	59	5					434	437		10.1136/thx.2003.007542			4	Respiratory System	Respiratory System	815WQ	WOS:000221072800015	15115876	Green Published, Bronze			2021-06-18	
J	Meade, MA; Taylor, LA; Kreutzer, JS; Marwitz, JH; Thomas, V				Meade, MA; Taylor, LA; Kreutzer, JS; Marwitz, JH; Thomas, V			A preliminary study of acute family needs after spinal cord injury: Analysis and implications	REHABILITATION PSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; ACUTE-CARE PERIOD; EMOTIONAL-REACTIONS; QUALITY; LIFE; MARRIAGES; OUTCOMES; PATIENT; STAFF	Objective: To address the paucity of research on family needs following spinal cord injury (SCI). Study Design: Prospective cross-sectional design. Setting: Inpatient SCI rehabilitation unit within a Level I trauma center. Participants: Family members of 17 inpatients with SCI. Main Outcome Measure: Family Needs Questionnaire (FNQ). Results: Eighteen of the 40 FNQ needs were rated as important or very important by 100% of the respondents. Health Information Needs were rated as most important and Instrumental Support Needs as least important. Involvement With Care Needs were most often met, whereas Emotional Support Needs were most often unmet. Conclusions: The FNQ is a promising measure of family members' needs after SCI and treatment planning and program evaluation tool. Findings affirm that family education is important during rehabilitation.	Virginia Commonwealth Univ, Med Ctr, Div Rehabil Psychol & Neuropsychol, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Med Ctr, Div Rehabil Psychol & Neuropsychol, Dept Phys Med & Rehabil, POB 980542, Richmond, VA 23298 USA.	jskreutz@hsc.vcu.edu					Campbell C H, 1988, Rehabil Nurs, V13, P320; Chan RCK, 2000, DISABIL REHABIL, V22, P764, DOI 10.1080/09638280050200269; Chan RCK, 2000, SPINAL CORD, V38, P687, DOI 10.1038/sj.sc.3101085; CLEVELAND M, 1980, FAM RELAT, V29, P558, DOI 10.2307/584472; Devivo Michael J., 1995, P289; DEVIVO MJ, 1995, ARCH PHYS MED REHAB, V76, P130, DOI 10.1016/S0003-9993(95)80022-0; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P156; Eastwood EA, 1999, ARCH PHYS MED REHAB, V80, P1457, DOI 10.1016/S0003-9993(99)90258-7; ELGHATIT AZ, 1976, ARCH PHYS MED REHAB, V57, P470; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; Engli M, 1993, J Neurosci Nurs, V25, P78; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Gill M, 1999, Crit Care Nurs Q, V22, P1; Hart G, 1981, Rehabil Nurs, V6, P11; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreuter M, 2000, SPINAL CORD, V38, P2, DOI 10.1038/sj.sc.3100933; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MOLTER NC, 1979, HEART LUNG, V8, P323; Moules S, 1999, BRAIN INJURY, V13, P983; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Stanton G M, 1984, J Neurosurg Nurs, V16, P253; Stebbins P, 1998, J REHABIL, V64, P15; Sullivan J, 1990, Crit Care Nurs Clin North Am, V2, P407; TRIESCHMANN RB, 1980, SPINAL CORD INJURIES; TUCKER S, 1987, TOP ACUTE CARE TRAUM, V1, P86; Vargo F., 1984, J APPL REHABIL COUNS, V15, P28; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; WELLER DJ, 1977, SOC WORK HEALTH CARE, V3, P7, DOI 10.1300/J010v03n01_02; WELLER DJ, 1977, SOC WORK HEALTH CARE, V2, P369, DOI 10.1300/J010v02n04_01; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; WOLFER JA, 1970, NURS RES, V19, P402, DOI 10.1097/00006199-197009000-00005	38	24	24	0	5	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2004	49	2					150	155		10.1037/0090-5550.49.2.150			6	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	819BS	WOS:000221288800009					2021-06-18	
J	Jiang, JY; Liang, YM; Luo, QZ; Zhu, C				Jiang, JY; Liang, YM; Luo, QZ; Zhu, C			Effect of mild hypothermia on brain dialysate lactate after fluid percussion brain injury in rodents	NEUROSURGERY			English	Article						lactate; microdialysate; mild hypothermia; traumatic brain injury	EXCITATORY AMINO-ACIDS; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; GLUCOSE-UTILIZATION; ENERGY-METABOLISM; RAT; MICRODIALYSIS; ACCUMULATION; HYPOXIA; RELEASE	OBJECTIVE: To investigate the effects of mild hypothermia on brain microdialysate lactate after fluid percussion traumatic brain injury (TBI) in rats. METHODS: Brain dialysate lactate before and after fluid percussion brain injury (2.1 +/- 0.2 atm) was measured in rats with preinjury mild hypothermia (32degreesC), postinjury mild hypothermia (32degreesC), injury normothermia (37degrees), and the sham control group. Mild hypothermia (32degreesC) was induced by partial immersion in a water bath (0degreesC) under general anesthesia and maintained for 2 hours. RESULTS: In the normothermia TBI group, brain extracellular fluid lactate increased from 0.311 +/- 0.03 to 1.275 +/- 0.08 mmol/L within 30 minutes after TBI (P < 0.01) and remained at a high level (0.546 +/- 0.05 mmol/L) (P < 0.01) at 2 hours after injury. In the postinjury mild hypothermic group, brain extracellular fluid lactate increased from 0.303 +/- 0.03 to 0.875 +/- 0.05 mmol/L at 15 minutes after TBI (P < 0.01) and then gradually decreased to 0.316 +/- 0.04 mmol/L at 2 hours after TBI (P > 0.05). In the preinjury mild hypothermic group, brain extracellular fluid lactate remained at normal levels after injury (P > 0.05). CONCLUSION: The cerebral extracellular fluid lactate level increases significantly after fluid percussion brain injury. Preinjury mild hypothermia completely inhibits the cerebral lactate accumulation, and early postinjury mild hypothermia significantly blunts the increase of cerebral lactate level after fluid percussion injury.	Shanghai Med Univ 2, Dept Neurosurg, Renji Hosp, Shanghai 200001, Peoples R China	Jiang, JY (corresponding author), Shanghai Med Univ 2, Dept Neurosurg, Renji Hosp, Shanghai 200001, Peoples R China.	jiangiyb@online.sh.cn					ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GARDINER M, 1982, J CEREBR BLOOD F MET, V2, P429, DOI 10.1038/jcbfm.1982.49; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAGERDAL M, 1979, ACTA ANAESTH SCAND, V23, P89; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; Hayashi N, 1997, NEUROCHEMISTRY, P97; Hayashi N, 2000, BRAIN HYPOTHERMIA: PATHOLOGY, PHARMACOLOGY, AND TREATMENT OF SEVERE BRAIN INJURY, P121; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KALIMO H, 1981, ACTA NEUROPATHOL, V7, P135; KATAYAMA Y, 1992, BRAIN RES, V584, P329, DOI 10.1016/0006-8993(92)90916-W; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; Myers R E, 1979, Adv Neurol, V26, P195; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON CS, J NEUROTRAUMA, V7, P1; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	44	24	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAR	2004	54	3					713	717		10.1227/01.NEU.0000109535.58429.49			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	802FN	WOS:000220149500053	15028148				2021-06-18	
J	Moran, C; Gillon, G				Moran, C; Gillon, G			Language and memory profiles of adolescents with traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD INJURY; WORKING MEMORY; INDIVIDUAL-DIFFERENCES; LINGUISTIC HUMOR; COMPREHENSION; CHILDREN; TRANSPARENCY; EXPLANATION; PERFORMANCE; FAMILIARITY	The performance of adolescents who suffered a traumatic brain injury in childhood, on language comprehension tasks with varying working memory demands, was examined. It was hypothesized that adolescents with a traumatic brain injury would perform more poorly than their non-injured peers, particularly on those tasks with high working memory demands. A case study design allowed for both group and intra-participant comparisons. A battery of language comprehension and working memory tasks was administered to six adolescents aged 12-16 years. Their performance was compared with six individually age-matched peers with typical development and to the normative data of the standardized tests. Intra-participant performance was examined by comparing results across language tasks that varied in working memory demands. Analysis revealed that individuals with traumatic brain injury performed poorly compared with their age-matched peers. However, the pattern of listening comprehension impairment differed across individuals and marked variability within the comprehension profiles for some individuals with traumatic brain injury was evident. Language comprehension tasks with high working memory demands generally posed the most difficulty for individuals with traumatic brain injury.	Univ Canterbury, Fac Sci, Dept Speech & Language Therapy, Christchurch 1, New Zealand	Moran, C (corresponding author), Univ Canterbury, Fac Sci, Dept Speech & Language Therapy, Private Bag 4800, Christchurch 1, New Zealand.	c.moran@spth.canterbury.ac.nz		Gillon, Gail/0000-0001-9501-8147			DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Docking K, 1999, BRAIN INJURY, V13, P953; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Frank EM, 1997, J MED SPEECH-LANG PA, V5, P97; HAMMILL DD, 1994, TEST ADOLESCENT ADUL; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; HOOVER WA, 1990, READ WRIT, V2, P127, DOI 10.1007/BF00401799; JORDAN FM, 1995, APHASIOLOGY, V9, P23, DOI 10.1080/02687039508248686; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P729, DOI 10.1080/026990596123990; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; KING J, 1991, J MEM LANG, V30, P580, DOI 10.1016/0749-596X(91)90027-H; MCDOWELL L, 1992, ANTIPODE, V24, P56, DOI 10.1111/j.1467-8330.1992.tb00428.x; MIYAKE A, 1995, COGNITIVE NEUROPSYCH, V12, P651, DOI 10.1080/02643299508252012; MORAN CA, 2002, THESIS; Nippold M., 1998, LATER LANGUAGE DEV S; NIPPOLD MA, 1993, J SPEECH HEAR RES, V36, P728, DOI 10.1044/jshr.3604.728; NIPPOLD MA, 1988, J SPEECH HEAR RES, V31, P466, DOI 10.1044/jshr.3103.466; NIPPOLD MA, 1995, J SPEECH HEAR RES, V38, P426, DOI 10.1044/jshr.3802.426; *NZ COUNC ED RES, 1994, PROGR ACH TESTS; Secord, 1989, TEST LANGUAGE COMPET; SEMEL W, 1995, CLIN EVALUATION LANG; STOLTZFUS ER, 1996, WORKING MEMORY HUMAN; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 1999, LANG SPEECH HEAR SER, V30, P132, DOI 10.1044/0161-1461.3002.132; Turkstra LS, 1998, J SPEECH LANG HEAR R, V41, P137, DOI 10.1044/jslhr.4101.137; TURKSTRA LS, 1995, BRAIN INJURY, V5, P329; TURNER ML, 1989, J MEM LANG, V28, P127, DOI 10.1016/0749-596X(89)90040-5; Warr-Leeper G.A., 1989, LANGUAGE, V20, P420, DOI [10.1044/0161-1461.2004.420, DOI 10.1044/0161-1461.2004.420]; Wechsler D., 1997, WMS 3 WECHSLER MEMOR	34	24	24	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2004	18	3					273	288		10.1080/02699050310001617415			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900004	14726286				2021-06-18	
J	Strauss, KI; Narayan, RK; Raghupathi, R				Strauss, KI; Narayan, RK; Raghupathi, R			Common patterns of bcl-2 family gene expression in two traumatic brain injury models	NEUROTOXICITY RESEARCH			English	Article						apoptosis; mRNA measurement; cerebral cortex; hippocampus; traumatic brain injury; animal models; gene expression patterns	CONTROLLED CORTICAL IMPACT; APOPTOTIC CELL-DEATH; HUMAN HEAD-INJURY; ALZHEIMERS-DISEASE; GLOBAL-ISCHEMIA; TRANSGENIC MICE; RAT-BRAIN; NEURONAL APOPTOSIS; COGNITIVE DEFICITS; APOLIPOPROTEIN-E	Cell death/survival following traumatic brain injury (TBI) may be a result of alterations in the intracellular ratio of death and survival factors. Bcl-2 family genes mediate both cell survival and the initiation of cell death. Using lysate RNase protection assays, mRNA expression of the anti-cell death genes Bcl-2 and Bcl-X-L, and the pro-cell death gene Bax, was evaluated following experimental brain injuries in adult male Sprague-Dawley rats. Both the lateral fluid-percussion (LFP) and the lateral controlled cortical impact (LCI) models of TBI showed similar patterns of gene expression. Anti-cell death bcl-2 and bcL-X-L mRNAs were attenuated early and tended to remain depressed for at least 3 days after injury in the cortex and hippocampus ipsilateral to injury. Pro-cell death bax mRNA was elevated in these areas, usually following the decrease in anti-cell death genes. These common patterns of gene expression suggest an important role for Bcl-2 genes in cell death and survival in the injured brain. Understanding the regulation of these genes may facilitate the development of new therapeutic strategies for a condition that currently has no proven pharmacologic treatments.	Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Drexel Univ, MCP Hahnemann Med Coll, Philadelphia, PA 19104 USA	Strauss, KI (corresponding author), Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA.	kstrauss@uc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038654] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038654, R01 NS038654-03] Funding Source: Medline		ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DeBilbao F, 1996, NEUROSCIENCE, V71, P1111, DOI 10.1016/0306-4522(95)00505-6; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gillardon F, 1996, BRAIN RES, V739, P244, DOI 10.1016/S0006-8993(96)00829-3; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Graham DI, 1999, ACT NEUR S, V73, P89; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hassouna I, 1996, NEUROSCI LETT, V204, P85, DOI 10.1016/0304-3940(96)12323-5; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; Irving EA, 1996, NEUROSCI LETT, V213, P189; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Liu B, 2003, ENVIRON HEALTH PERSP, V111, P1065, DOI 10.1289/ehp.6361; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PALKOVITS M, 1973, BRAIN RES, V59, P449, DOI 10.1016/0006-8993(73)90290-4; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RINK A, 1995, AM J PATHOL, V147, P1575; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; STRAUSS KI, 1993, MOL BRAIN RES, V20, P229, DOI 10.1016/0169-328X(93)90045-Q; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	58	24	27	0	2	F P GRAHAM PUBLISHING CO	MOUNTAIN HOME	PO BOX 370, MOUNTAIN HOME, TN 37684 USA	1029-8428			NEUROTOX RES	Neurotox. Res.		2004	6	4					333	342		10.1007/BF03033444			10	Neurosciences	Neurosciences & Neurology	880OH	WOS:000225798600012	15545017	Green Accepted			2021-06-18	
J	Rooker, S; Jorens, PG; Van Reempts, J; Borgers, M; Verlooy, J				Rooker, S; Jorens, PG; Van Reempts, J; Borgers, M; Verlooy, J			Continuous measurement of intracranial pressure in awake rats after experimental closed head injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						traumatic brain injury; closed head injury; rats; long-term measurement; intracranial pressure	TRAUMATIC BRAIN INJURY; EXPERIMENTAL-MODEL; AUTOREGULATION	The present study validates a method for continuous measurement of intracranial pressure (ICP) in freely moving rats after experimental induction of impact-acceleration injury. Rats subjected to either mild or moderate trauma were individually placed in a Bas-Ratturn(R) system, equipped with a sensor that synchronously turns the cage in response to the locomotor activity of the animal. In this way correct probe positioning is permanently assured and damage due to coiling is avoided. The evolution of ICP and mean arterial blood pressure (MABP) in injured rats was compared with that of a non-traumatized sham group. Since the animals regained consciousness after surgery, interference of anaesthesia on these sensitive parameters should be minimised. The results showed that immediately after induction of neurotrauma, ICP was significantly higher in traumatized rats (sham: 7.7 +/- 0.5 mmHg; mild trauma: 10.4 +/- 10.7 mmHg; moderate trauma: 14.9 +/- 2.4 mmHg; P < 0.05). Regression analysis showed a stable ICP up to 3 h post-insult for all three conditions. From 4h onwards till the end of the experiment at 10h post-insult, a significant increase in ICP was seen for sham-operated and mildly traumatized rats (16.1 +/- 3.4 and 30.5 +/- 6.9 mmHg, respectively; P < 0.05), but not for moderately traumatized rats (47.3 +/- 11.9 mmHg). The method allows observation of ICP for a critical period up to 3 h. As such the method can be regarded as clinically relevant to study early pathological aspects of intracranial hypertension and to define a therapeutic window for pharmacological intervention after traumatic brain injury (TBI). (C) 2003 Elsevier B.V. All rights reserved.	Univ Antwerp Hosp, UZA, Dept Neurosurg, B-2650 Edegem, Belgium; Univ Antwerp Hosp, Dept Intens Care Med, Edegem, Belgium; Janssen Res Fdn, Dept Life Sci, B-2340 Beerse, Belgium	Rooker, S (corresponding author), Univ Antwerp Hosp, UZA, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	servanrooker@belgacom.net	Rooker, Servan/AAD-4316-2020				Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock RM, 2000, J NEUROTRAUM, V17, P449; De Mulder G, 2000, ACT NEUR S, V76, P409; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GUILLAUME J, 1951, MANOMETRIC INTRACRAN, V59, P953; LEE JG, 1994, ANESTH ANALG, V79, P58; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Rooker S, 2002, J NEUROSCI METH, V119, P83, DOI 10.1016/S0165-0270(02)00183-8; Van Reempts J, 2000, NEUROSCI RES COMMUN, V26, P161, DOI 10.1002/1520-6769(200005/06)26:3<161::AID-NRC4>3.0.CO;2-N; VANREEMPTS J, 1994, HISTOL HISTOPATHOL, V9, P185; VANREEMPTS J, 1990, CEREBRAL ISCHEMIA RE, P235	17	24	25	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	DEC 30	2003	131	1-2					75	81		10.1016/S0165-0270(03)00233-4			7	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	759EM	WOS:000187725400009	14659826				2021-06-18	
J	Arciniegas, DB; Harris, SN; Brousseau, KM				Arciniegas, DB; Harris, SN; Brousseau, KM			Psychosis following traumatic brain injury	INTERNATIONAL REVIEW OF PSYCHIATRY			English	Article							HEAD-INJURY; TARDIVE-DYSKINESIA; BIPOLAR DISORDER; SCHIZOPHRENIA; REHABILITATION; HALOPERIDOL; PSYCHOPATHOLOGY; PHENOMENOLOGY; RISPERIDONE; OLANZAPINE	Psychosis is a relatively infrequent but potentially serious and debilitating consequence of traumatic brain injury (TBI), and one about which there is considerable scientific uncertainty and disagreement. There are several substantial clinical, epidemiological, and neurobiological differences between the post-traumatic psychoses and the primary psychotic disorders. The recognition of these differences may facilitate identification and treatment of patients whose psychosis is most appropriately regarded as post-traumatic. In the service of assisting psychiatrists and other mental health clinicians in the diagnosis and treatment of persons with post-traumatic psychoses, this article will review post-traumatic psychosis, including definitions relevant to describing the clinical syndrome, as well as epidemiologic, neurobiological, and neurogenetic factors attendant to it. An approach to evaluation and treatment will then be offered, emphasizing identification of the syndrome of post-traumatic psychosis, consideration of the differential diagnosis of this condition, and careful selection and administration of treatment interventions.	Univ Colorado, Hlth Sci Ctr, Neuropsychiat Serv, Dept Psychiat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurol, Behav Neurol Sect, Denver, CO 80262 USA; Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA	Arciniegas, DB (corresponding author), Univ Colorado, Hlth Sci Ctr, Neuropsychiat Serv, Dept Psychiat, Campus Box C268-68,4200 E 9th Ave, Denver, CO 80262 USA.	David.Arciniegas@UCHSC.edu	Arciniegas, David/A-3792-2009				AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Arciniegas David B., 2001, Curr Treat Options Neurol, V3, P347, DOI 10.1007/s11940-001-0039-0; Arciniegas DB, 2001, BRAIN INJURY, V15, P649, DOI 10.1080/02699050010019800; ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P167; BRACKEN P, 1987, BRIT J PSYCHIAT, V150, P690, DOI 10.1192/bjp.150.5.690; BUCKLEY P, 1993, AM J PSYCHIAT, V150, P146; Burke JG, 1999, J PSYCHIATR NEUROSCI, V24, P456; Callaghan JT, 1997, J CLIN PHARMACOL, V37, P971, DOI 10.1002/j.1552-4604.1997.tb04272.x; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; CUMMINGS JL, 1985, BRIT J PSYCHIAT, V146, P184, DOI 10.1192/bjp.146.2.184; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; CUMMINGS JL, 1992, NEUROPSY NEUROPSY BE, V5, P144; CUTTING J, 1987, BRIT J PSYCHIAT, V151, P324, DOI 10.1192/bjp.151.3.324; Davison K, 1969, CURRENT PROBLEMS NEU, P113; De Mol J, 1982, Encephale, V8, P17; Edwards-Lee T, 2000, BEHAVIOR AND MOOD DISORDERS IN FOCAL BRAIN LESIONS, P419; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Feinstein A, 1998, J NEUROPSYCH CLIN N, V10, P448, DOI 10.1176/jnp.10.4.448; Flaum M, 2000, DIAGNOSTIC STAT MANU, P297; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; GOETHE KE, 1984, PSYCHIAT ANN, V14, P540, DOI 10.3928/0048-5713-19840701-11; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hillbom E., 1960, ACTA PSYCHIATRICA S, VS142, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LIEBERMAN JA, 1989, J CLIN PSYCHIAT, V50, P329; Lyketsos CG, 1996, PSYCHOSOMATICS, V37, P407, DOI 10.1016/S0033-3182(96)71527-X; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; McAllister TW, 2002, NEUROREHABILITATION, V17, P357; McAllister TW, 1998, SEMIN CLIN NEUROPSYC, V3, P211; MCKENNA PJ, 1985, AM J PSYCHIAT, V142, P895; MICHALS ML, 1993, J CLIN PSYCHOPHARM, V13, P198; NIZAMIE SH, 1988, ACTA PSYCHIAT SCAND, V77, P637, DOI 10.1111/j.1600-0447.1988.tb05181.x; NORQUIST GS, 2000, COMPREHENSIVE TXB PS, V1, P1010; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; Purdon SE, 2000, ARCH GEN PSYCHIAT, V57, P249, DOI 10.1001/archpsyc.57.3.249; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; RIESS H, 1987, J CLIN PSYCHIAT, V48, P29; ROSEBUSH P, 1989, AM J PSYCHIAT, V146, P717; Ruff RM, 1999, BRAIN INJURY, V13, P943; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sachdev P, 2001, J NEUROL NEUROSUR PS, V70, P708; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; SANDEL ME, 1993, BRAIN INJURY, V7, P77, DOI 10.3109/02699059309008159; Schreiber S, 1998, INT CLIN PSYCHOPHARM, V13, P273, DOI 10.1097/00004850-199811000-00006; SHAPIRO LB, 1939, ILLINOIS MED J, V76, P250; Silver Jonathan M., 1994, P631; Smeltzer Donald J., 1994, P251; Stanislav SW, 1997, BRAIN INJURY, V11, P335, DOI 10.1080/026990597123494; TEASDALE G, 1974, LANCET, V2, P81; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trimble M R, 1991, Adv Neurol, V55, P143; Trzepacz Paula T., 1994, P189; VINCENT FM, 1986, NEUROSURGERY, V18, P190, DOI 10.1227/00006123-198602000-00013; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; Wilkinson R, 1999, BRAIN INJURY, V13, P1025; WOLF B, 1989, COMPR PSYCHIAT, V30, P534, DOI 10.1016/0010-440X(89)90084-9; YASSA R, 1984, PSYCHOSOMATICS, V25, P852, DOI 10.1016/S0033-3182(84)72946-X; YASSA R, 1984, PSYCHOSOMATICS, V25, P135, DOI 10.1016/S0033-3182(84)73083-0	71	24	26	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0954-0261	1369-1627		INT REV PSYCHIATR	Int. Rev. Psych.	NOV	2003	15	4					328	340		10.1080/09540260310001606719			13	Psychiatry	Psychiatry	739UD	WOS:000186364100005	15276954				2021-06-18	
J	Felderhoff-Mueser, U; Buhrer, C; Groneck, P; Obladen, M; Bartmann, P; Heep, A				Felderhoff-Mueser, U; Buhrer, C; Groneck, P; Obladen, M; Bartmann, P; Heep, A			Soluble Fas (CD95/Apo-1), soluble Fas ligand, and activated caspase 3 in the cerebrospinal fluid of infants with posthemorrhagic and nonhemorrhagic hydrocephalus	PEDIATRIC RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; NEURODEGENERATION FOLLOWING TRAUMA; PROGRAMMED CELL-DEATH; DEVELOPING RAT-BRAIN; TNF-ALPHA; MEDIATED APOPTOSIS; DOWN-REGULATION; IFN-GAMMA; IN-VITRO; EXPRESSION	Hydrocephalus may result in loss of tissue associated with neuronal degeneration, axonal damage, and reactive gliosis. The soluble form of the anti-apoptotic regulator Fas (sFas) and the pro-apoptotic factors soluble FasL (sFasL) and activated caspase 3 were studied in the cerebrospinal fluid of infants with hydrocephalus. Fifteen preterm infants with posthemorrhagic hydrocephalus undergoing serial reservoir puncture and seven term or near-term infants with nonhemorrhagic hydrocephalus and shunt surgery were included in the study. Twenty-four age-matched patients with lumbar puncture for the exclusion of meningitis served as controls. Elevated levels of sFas were observed in infants with posthemorrhagic hydrocephalus [median (range), 131 ng/mL (51-279 ng/mL)] and in nonhemorrhagic hydrocephalus [127 ng/mL (35-165 ng/mL)]. sFas concentrations were highest in a subgroup of eight patients with posthemorrhagic hydrocephalus developing periventricular leukomalacia [164 ng/mL (76-227 ng/mL)]. In contrast, in 24 control infants, sFas was low, in 15 cases below detection limit (0.5 ng/mL) and in nine cases, 24 ng/mL (20-43 ng/mL). sFasL and activated caspase 3 did not differ from control infants in all groups of patients. Increased intrathecal release of sFas in the cerebrospinal fluid of infants with hydrocephalus may serve as an indicator of brain injury from progressive ventricular dilatation.	Childrens Hosp, Dept Neonatol, Charite, D-13353 Berlin, Germany; Cologne Childrens Hosp, Dept Neonatol, D-50735 Cologne, Germany; Univ Bonn, Dept Neonatol, D-53113 Bonn, Germany	Felderhoff-Mueser, U (corresponding author), Childrens Hosp, Dept Neonatol, Charite, Augustenburger Pl, D-13353 Berlin, Germany.		Felderhoff-Muser, Ursula/AAU-9682-2020				Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Choi C, 1999, J IMMUNOL, V162, P1889; Ciusani E, 1998, J NEUROIMMUNOL, V82, P5, DOI 10.1016/S0165-5728(97)00177-X; Del Bigio MR, 1998, EXP NEUROL, V154, P157, DOI 10.1006/exnr.1998.6922; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; DSOUZA S, 1996, J EXP MED, V184, P2362; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Felderhoff-Mueser U, 2001, ARCH DIS CHILD, V84, P369, DOI 10.1136/adc.84.4.369; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; FUKUMIZU M, 1995, PEDIATR NEUROL, V13, P230, DOI 10.1016/0887-8994(95)00183-G; GOPINATH G, 1979, J NEUROL SCI, V43, P333, DOI 10.1016/0022-510X(79)90013-3; HARRIS NG, 1994, CHILD NERV SYST, V10, P293, DOI 10.1007/BF00335166; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Heep A, 2002, ARCH DIS CHILD-FETAL, V87, pF34, DOI 10.1136/fn.87.1.F34; Heep A, 2001, CHILD NERV SYST, V17, P47, DOI 10.1007/s003810000363; Hentze H, 2001, BIOCHEM BIOPH RES CO, V283, P1111, DOI 10.1006/bbrc.2001.4918; Hochhaus F, 2001, BMC Pediatr, V1, P2, DOI 10.1186/1471-2431-1-2; HUGHES DPM, 1995, J EXP MED, V182, P1395, DOI 10.1084/jem.182.5.1395; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; LEVENE MI, 1981, ARCH DIS CHILD, V56, P900, DOI 10.1136/adc.56.12.900; Matsuki Y, 2002, CELL DEATH DIFFER, V9, P626, DOI 10.1038/sj.cdd.4401016; Miyan JA, 1998, EUR J PEDIATR SURG, V8, P43, DOI 10.1055/s-2008-1071253; Mogi M, 1996, NEUROSCI LETT, V220, P195, DOI 10.1016/S0304-3940(96)13257-2; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakashima K, 1999, J NEUROTRAUM, V16, P143, DOI 10.1089/neu.1999.16.143; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sabri F, 2001, J NEUROIMMUNOL, V114, P197, DOI 10.1016/S0165-5728(00)00424-0; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Tarkowski E, 1999, STROKE, V30, P321, DOI 10.1161/01.STR.30.2.321; Tullberg M, 1998, NEUROLOGY, V50, P1122, DOI 10.1212/WNL.50.4.1122; Van Landeghem FKH, 2002, PEDIATR RES, V51, P129, DOI 10.1203/00006450-200202000-00003; Volpe JJ, 2001, NEUROLOGY NEWBORN, P428; Yang JT, 1999, CLIN BIOCHEM, V32, P673, DOI 10.1016/S0009-9120(99)00077-6	43	24	24	0	1	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	NOV	2003	54	5					659	664		10.1203/01.PDR.0000084114.83724.65			6	Pediatrics	Pediatrics	736GJ	WOS:000186162800006	12867600	Bronze			2021-06-18	
J	Fukui, S; Fazzina, G; Amorini, AM; Dunbar, JG; Marmarou, A				Fukui, S; Fazzina, G; Amorini, AM; Dunbar, JG; Marmarou, A			Differential effects of atrial natriuretic peptide on the brain water and sodium after experimental cortical contusion in the rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						atrial natriuretic peptide; cyclic GMP; intraperitoneal administration; controlled cortical impact; brain edema; brain sodium concentration	ARGININE-VASOPRESSIN; EDEMA FORMATION; BARRIER; INJURY; PERMEABILITY; TRANSPORT; HEART; MECHANISMS; DIFFUSION; ISCHEMIA	Atrial natriuretic peptide (ANP) plays an important role in the regulation of water and sodium in the body via cyclic GMP (cGMP) pathway. Although ANP has been shown to be protective in cerebral ischemia or intracerebral hemorrhage, its role in traumatic brain injury (TBI) has yet to be elucidated. We herein assessed ANP effects on brain water and sodium in TBI. Controlled cortical impact (3 nun depth, 6 m/sec) was used to induce an experimental cortical contusion in rats. Continuous administration of ANP 0.2 (n = 6) or 0.7 mug/kg/24 h (n = 6), cGMP analogue (8-Bromo-cGMP) 0.1 (n = 5) or 0.3 mg/kg/24 h (n = 5), or vehicle (n = 6) was begun 15 minutes after injury, using a mini-osmotic pump implanted into the peritoneal cavity. At 24 hours after injury, ANP significantly exacerbated brain edema in the injured hemisphere in a dose-dependent manner while it reduced brain sodium concentrations in both hemispheres. These ANP effects could be mimicked by a cGMP analogue. In the second series (n = 20), BBB integrity was assessed by evaluating the extravasation of Evans blue dye. ANP or cGMP analogue significantly worsened BBB disruption in the injured hemisphere at 24 hours after injury. These findings suggest that ANP administration exacerbates brain edema after the experimental cortical contusion in rats, possibly because of an increase in the BBB permeability via cGMP pathway, whereas it reduces brain sodium levels.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 950508, Richmond, VA 23298 USA.			AMORINI, Angela Maria/0000-0003-3525-9955	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587, R56NS019235, R01NS019235] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 19235] Funding Source: Medline		Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bhasin RR, 2002, ACTA NEUROCHIR SUPPL, V81, P249; Chi OZ, 1999, MICROVASC RES, V58, P35, DOI 10.1006/mvre.1999.2152; Dijkhuizen RM, 1999, J CEREBR BLOOD F MET, V19, P341, DOI 10.1097/00004647-199903000-00012; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ennis SR, 1996, J NEUROCHEM, V66, P756; ERMISCH A, 1991, BRAIN RES, V554, P209, DOI 10.1016/0006-8993(91)90191-W; GRAMMAS P, 1991, BRAIN RES, V562, P93, DOI 10.1016/0006-8993(91)91191-3; IBARAGI M, 1989, J NEUROCHEM, V53, P1802, DOI 10.1111/j.1471-4159.1989.tb09246.x; Jin XH, 2001, HYPERTENSION, V38, P309, DOI 10.1161/01.HYP.38.3.309; Levin ER, 1998, NEW ENGL J MED, V339, P321; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Mitaka C, 2002, CRIT CARE MED, V30, P1570, DOI 10.1097/00003246-200207000-00029; Mizuno O, 2001, AM J CARDIOL, V88, P863, DOI 10.1016/S0002-9149(01)01893-8; NAKAO N, 1990, NEUROSURGERY, V27, P39, DOI 10.1227/00006123-199007000-00005; NARUSE S, 1991, STROKE, V22, P61, DOI 10.1161/01.STR.22.1.61; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; PRICHARD BNC, 1991, ACTA CARDIOL, V46, P309; ROSENBERG GA, 1993, NEUROSCI LETT, V160, P117, DOI 10.1016/0304-3940(93)90927-D; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; ROSENBERG GA, 1995, STROKE, V26, P874, DOI 10.1161/01.STR.26.5.874; Sarker MH, 2002, J PHYSIOL-LONDON, V540, P209, DOI 10.1113/jphysiol.2001.012912; Singh S, 2002, CRIT CARE MED, V30, P2575, DOI 10.1097/00003246-200211000-00028; STEARDO L, 1987, SCIENCE, V235, P470, DOI 10.1126/science.2879355; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; VIGNE P, 1992, BIOCHEM BIOPH RES CO, V183, P640, DOI 10.1016/0006-291X(92)90530-X; Walther T, 2002, J HYPERTENS, V20, P785, DOI 10.1097/00004872-200205000-00001; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wright EM, 2000, ANN NY ACAD SCI, V915, P54; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658	34	24	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2003	23	10					1212	1218		10.1097/01.WCB.0000088762.02615.30			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	729DD	WOS:000185755500011	14526231	Bronze			2021-06-18	
J	Heimann, A; Takeshima, T; Alessandri, B; Noppens, R; Kempski, O				Heimann, A; Takeshima, T; Alessandri, B; Noppens, R; Kempski, O			Effects of hypertonic/hyperoncotic treatment after rat cortical vein occlusion	CRITICAL CARE MEDICINE			English	Article						cerebral ischemia; hypertonic solution; hydroxyethyl starch; cerebral blood flow; microcirculation	CEREBRAL-BLOOD-FLOW; SMALL-VOLUME RESUSCITATION; 7.5-PERCENT SODIUM-CHLORIDE; TRAUMATIC BRAIN INJURY; HYPERTONIC SALINE; HEMORRHAGIC-SHOCK; INTRACRANIAL HYPERTENSION; ALBUMIN THERAPY; FOCAL ISCHEMIA; INFARCT VOLUME	Objective: To examine the effects of hypertonic/hyperoncotic treatment on physiologic variables and regional cerebral blood flow and to test its neuroprotective efficiency in a model of permanent venous ischemia. Design: Randomized prospective study. Setting. University research institute. Subjects. Adult male Wistar rats, weighing 359 +/- 54 g (n = 38). Interventions. Rats were subjected to photochemical occlusion of two adjacent cortical veins. A randomized infusion with vehicle (0.9% NaCl), 10% hydroxyethyl starch 200000 (HES), or 7.5% saline plus 10% hydroxyethyl starch 200000 (HHES) was started 30 mins after two-vein occlusion. Effects on physiologic variables and regional cerebral blood flow (assessed by laser Doppler flowmetry) were studied up to 120 mins after two-vein occlusion. Two days after occlusion, the brains were removed for histologic evaluation. Measurements and Main Results. After occlusion, regional cerebral blood flow decreased by 50%, significantly in all groups (from 47.3 +/- 3 to 22.2 +/- 2.2 laser Doppler units). In the vehicle and HES groups, regional cerebral blood flow further decreased to 12.9 +/- 1.9 and 17.8 +/- 2.3 laser Doppler units, respectively. HHES improved regional cerebral blood flow significantly to 27.3 +/- 3.5 laser Doppler units, particularly by reducing no-flow/low-flow areas and reducing infarct size. onclusion: We found that HHES reduced infarct size as a consequence of an improved regional cerebral blood flow and reduced no-flow/low-flow areas in the tissue at risk in the two-vein occlusion model.	Johannes Gutenberg Univ Mainz, Inst Neurosurg Pathophysiol, Mainz, Germany	Heimann, A (corresponding author), Johannes Gutenberg Univ Mainz, Inst Neurosurg Pathophysiol, Mainz, Germany.			Heimann, Axel/0000-0003-2510-3228			Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bhardwaj A, 2000, STROKE, V31, P1694, DOI 10.1161/01.STR.31.7.1694; BITTERMAN H, 1987, CIRC SHOCK, V21, P271; CHAN R, 1983, INT J MICROCIRC, V2, P297; DEFELIPPE J, 1980, LANCET, V2, P1002; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Fischer M, 1996, RESUSCITATION, V32, P227, DOI 10.1016/0300-9572(96)00953-7; GUNNAR W, 1988, SURGERY, V103, P398; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; HARTL R, 1995, SHOCK, V3, P274; Heimann A, 1999, BRAIN RES, V838, P210, DOI 10.1016/S0006-8993(99)01740-0; HEIMANN A, 1994, J CEREBR BLOOD F MET, V14, P1100, DOI 10.1038/jcbfm.1994.144; Hossmann KA, 1997, SHOCK, V8, P95, DOI 10.1097/00024382-199708000-00004; Huh PW, 1998, BRAIN RES, V804, P105, DOI 10.1016/S0006-8993(98)00674-X; Jonas J, 2000, SHOCK, V14, P24, DOI 10.1097/00024382-200014010-00005; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; KEMPSKI O, 1995, INT J MICROCIRC, V15, P37, DOI 10.1159/000178947; Kempski O, 1996, ACT NEUR S, V66, P114; KREIMEIER U, 1988, BAILLIERE CLIN ANAES, V2, P545, DOI 10.1016/S0950-3501(88)80006-0; KREIMEIER U, 1990, CIRC SHOCK, V32, P83; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; Mazzoni MC, 1995, INT J MICROCIRC, V15, P265, DOI 10.1159/000179028; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629; MESSMAR K, 1989, RESUSCITATION, pS51; Nakase H, 1996, J CEREBR BLOOD F MET, V16, P720, DOI 10.1097/00004647-199607000-00024; Nakase H, 1997, J NEUROSURG, V87, P307, DOI 10.3171/jns.1997.87.2.0307; NAKASE H, 1995, NEUROSURGERY BALTIMO, V37, P1; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; Otsuka H, 2000, EXP NEUROL, V162, P201, DOI 10.1006/exnr.1999.7326; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; RIZOLI SB, 2002, YB INTENSIVE CARE EM, P446; SCHURER L, 1992, EUR SURG RES, V24, P1, DOI 10.1159/000129183; Soehle M, 2001, J NEUROSCI METH, V110, P91, DOI 10.1016/S0165-0270(01)00422-8; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; STRECKER U, 1993, INT CONGR SER, V1031, P63; TODA N, 1993, AM J PHYSIOL, V265, pH929; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664	40	24	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2003	31	10					2495	2501		10.1097/01.CCM.0000084893.44650.CB			7	Critical Care Medicine	General & Internal Medicine	733LZ	WOS:000186003100012	14530757				2021-06-18	
J	O'Bryant, SE; Palav, A; McCaffrey, RJ				O'Bryant, SE; Palav, A; McCaffrey, RJ			A review of symptoms commonly associated with menopause: Implications for clinical neuropsychologists and other health care providers	NEUROPSYCHOLOGY REVIEW			English	Article; Proceedings Paper	Annual Convention of the New-York-State-Psychology-Association	2001	ALBANY, NY	NY State Psychol Assoc		base rates; symptoms of menopause; neuropsychology of menopause	PSYCHOLOGICAL SYMPTOMS; ESTROGEN REPLACEMENT; NATURAL MENOPAUSE; WOMENS-HEALTH; COMPLAINTS; TRANSITION; ATTITUDES; THERAPY; SMOKING; AGE	Menopause is a process, either naturally or medically induced, that occurs in nearly all women at some point in life. Some of the most commonly reported symptoms associated with menopause are hot flushes/flashes, fatigue, headaches, irritability, insomnia, and depression. These symptoms overlap with symptoms commonly reported in Traumatic Brain Injury (TBI) as well as postconcussive syndrome. This overlap between symptoms commonly associated with menopause and neuropsychological conditions makes it necessary to have the base rates of these symptoms and conditions available. The purpose of the present review was to consolidate the clinical literature Oil the most Commonly reported menopausal symptoms and to calculate the base rates associated with these symptoms.	SUNY Albany, Dept Psychol, Albany, NY 12222 USA; Brown Med Sch, Mem Hosp Rhode Isl, Pawtucket, RI USA	McCaffrey, RJ (corresponding author), SUNY Albany, Dept Psychol, Social Sci 112, Albany, NY 12222 USA.	RJMCCAFFREY@aol.com		O'Bryant, Sid/0000-0003-0582-5266			ABRAHAM S, 1994, MATURITAS, V20, P121, DOI 10.1016/0378-5122(94)90007-8; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anarte MT, 1998, MATURITAS, V29, P203, DOI 10.1016/S0378-5122(98)00017-6; AVIS NE, 1991, MATURITAS, V13, P65, DOI 10.1016/0378-5122(91)90286-Y; Coope J, 1996, MATURITAS, V23, P159, DOI 10.1016/0378-5122(95)00971-X; DENNERSTEIN L, 1978, MATURITAS, V1, P55, DOI 10.1016/0378-5122(78)90010-5; DENNERSTEIN L, 1993, MED J AUSTRALIA, V159, P232, DOI 10.5694/j.1326-5377.1993.tb137821.x; Dennerstein L, 1996, MATURITAS, V23, P147, DOI 10.1016/0378-5122(95)00970-1; ELWOOD RW, 1993, CLIN PSYCHOL REV, V13, P409, DOI 10.1016/0272-7358(93)90012-B; FACCHINETTI F, 1987, POSTMENOPAUSAL HORMO, P67; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GREENE JG, 1976, J PSYCHOSOM RES, V20, P425, DOI 10.1016/0022-3999(76)90005-2; HAGSTAD A, 1986, ACTA OBSTET GYN SCAN, P59; Halbreich U, 1997, NEUROLOGY, V48, pS16, DOI 10.1212/WNL.48.5_Suppl_7.16S; HARTMANN BW, 1995, GYNECOL ENDOCRINOL, V9, P247, DOI 10.3109/09513599509160453; HIGH RV, 1994, SOC BEHAV PERSONAL, V22, P347, DOI 10.2224/sbp.1994.22.4.347; HOLTE A, 1991, MATURITAS, V13, P193, DOI 10.1016/0378-5122(91)90194-U; Holte A, 1998, MATURITAS, V29, P5, DOI 10.1016/S0378-5122(98)00023-1; HUNTER M, 1986, MATURITAS, V8, P217, DOI 10.1016/0378-5122(86)90029-0; INDIRA SN, 1980, IND J CLIN PSYCHOL, V7, P125; JASZMANN L, 1969, Medical Gynaecology and Sociology, V4, P268; JICK H, 1977, LANCET, V1, P1354; Kaufert P, 1998, MENOPAUSE, V5, P197; Kuh DL, 1997, BRIT J OBSTET GYNAEC, V104, P923, DOI 10.1111/j.1471-0528.1997.tb14352.x; Langs G, 2000, J AFFECT DISORDERS, V58, P43, DOI 10.1016/S0165-0327(99)00097-X; LAURITZEN C, 1990, MATURITAS, V12, P199, DOI 10.1016/0378-5122(90)90004-P; MATTHEWS KA, 1990, J CONSULT CLIN PSYCH, V58, P345, DOI 10.1037/0022-006X.58.3.345; MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; NERI I, 1993, MATURITAS, V17, P31, DOI 10.1016/0378-5122(93)90121-W; NEUGARTEN BL, 1965, PSYCHOSOM MED, V27, P266, DOI 10.1097/00006842-196505000-00009; NEWTON MICHAEL, 1964, SOUTHERN MED J, V57, P1309; NOTMAN MT, 1984, PSYCHIAT ANN, V14, P448, DOI 10.3928/0048-5713-19840601-10; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P765, DOI 10.1016/S0002-9378(12)90816-9; Perz JM, 1997, WOMEN HEALTH, V25, P53, DOI 10.1300/J013v25n01_04; Porter M, 1996, BRIT J OBSTET GYNAEC, V103, P1025, DOI 10.1111/j.1471-0528.1996.tb09555.x; PUGH MB, 2000, STEDMANS MED DICT; REKERS H, 1992, MATURITAS, V15, P101, DOI 10.1016/0378-5122(92)90244-X; Robinson G, 1996, J NERV MENT DIS, V184, P453, DOI 10.1097/00005053-199608000-00001; RORER LG, 1982, J CONSULT CLIN PSYCH, V50, P419, DOI 10.1037/0022-006X.50.3.419; Seshadri S, 2001, ARCH NEUROL-CHICAGO, V58, P435, DOI 10.1001/archneur.58.3.435; SUKWATANA P, 1991, MATURITAS, V13, P217, DOI 10.1016/0378-5122(91)90196-W; VONMUHLEN DG, 1995, MATURITAS, V22, P71, DOI 10.1016/0378-5122(95)00917-A; *WHO, 1981, RES MEN RES WHO SCI; Wijma K, 1997, J BEHAV THER EXP PSY, V28, P251, DOI 10.1016/S0005-7916(97)00030-X	46	24	24	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1040-7308	1573-6660		NEUROPSYCHOL REV	Neuropsychol. Rev.	SEP	2003	13	3					145	152		10.1023/A:1025573529407			8	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	728BA	WOS:000185694300002	14584909				2021-06-18	
J	Crago, BR; Nelson, LA; Davis, M; Arnold, L; Thrasher, JD				Crago, BR; Nelson, LA; Davis, M; Arnold, L; Thrasher, JD			Psychological, neuropsychological, and electrocortical effects of mixed mold exposure	ARCHIVES OF ENVIRONMENTAL HEALTH			English	Article						dose-response relationship; neuropsychological testing; Symptom Checklist-90-R; quantitative electroencephalograph; toxic encephalopathy; toxic mold	AMERICAN ACADEMY; HYPERSENSITIVITY PNEUMONITIS; STACHYBOTRYS CHARTARUM; QUANTITATIVE EEG; NEUROLOGY; MYCOTOXICOSIS; DEPRESSION; OUTBREAK; INJURY; HEALTH	The authors assessed the psychological, neuropsychological, and electrocortical effects of human exposure to mixed colonies of toxigenic molds. Patients (N = 182) with confirmed mold-exposure history completed clinical interviews, a symptom checklist (SCL-90-R), limited neuropsychological testing, quantitative electroencephalogram (QEEG) with neurometric analysis, and measures of mold exposure. Patients reported high levels of physical, cognitive, and emotional symptoms. Ratings on the SCL-90-R were "moderate" to "severe," with a factor reflecting situational depression accounting for most of the variance. Most of the patients were found to suffer from acute stress, adjustment disorder, or post-traumatic stress. Differential diagnosis confirmed an etiology of a combination of external stressors, along with organic metabolically based dysregulation of emotions and decreased cognitive functioning as a result of toxic or metabolic encephalopathy. Measures of toxic mold exposure predicted QEEG measures and neuropsychological test performance. QEEG results included narrowed frequency bands and increased power in the alpha and theta bands in the frontal areas of the cortex. These findings indicated a hypoactivation of the frontal cortex, possibly due to brainstem involvement and insufficient excitatory input from the reticular activating system. Neuropsychological testing revealed impairments similar to mild traumatic brain injury. In comparison with premorbid estimates of intelligence, findings of impaired functioning on multiple cognitive tasks predominated. A dose-response relationship between measures of mold exposure and abnormal neuropsychological test results and QEEG measures suggested that toxic mold causes significant problems in exposed individuals. Study limitations included lack of a comparison group, patient selection bias, and incomplete data sets that did not allow for comparisons among variables.	Neurobehav Hlth Serv, Tucson, AZ 85712 USA; Progress Hlth Care Grp, Benson, AZ USA; Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA; ImmunTox LLC, Benson, AZ USA; Sam 1 Trust, Alto, NM USA	Crago, BR (corresponding author), Neurobehav Hlth Serv, 5363 E Pima St,Suite 100, Tucson, AZ 85712 USA.	bcbrain1@msn.com					Anyanwu Ebere, 2002, Int J Adolesc Med Health, V14, P67; Anyanwu Ebere C, 2003, ScientificWorldJournal, V3, P281; AUGER P, 2001, BIOAEROSOLS FUNGI MY, P131; Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Baldo Juliana V, 2002, Appl Neuropsychol, V9, P193, DOI 10.1207/S15324826AN0904_1; CALLENDER TJ, 1993, ENVIRON RES, V60, P295, DOI 10.1006/enrs.1993.1039; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; Croft WA, 2002, J ENVIRON BIOL, V23, P301; Delis DC, 2001, DELISKAPLAN EXECUTIV; Derogatis L.R., 1994, SCL 90 R ADM SCORING, V3rd; Ebbehoj NE, 2002, INDOOR AIR, V12, P273, DOI 10.1034/j.1600-0668.2002.02141.x; ELLIOTT CL, 1992, J ABNORM PSYCHOL, V101, P572, DOI 10.1037/0021-843X.101.3.572; Fan LL, 2002, CURR OPIN PEDIATR, V14, P323, DOI 10.1097/00008480-200206000-00008; FLANNIGAN B, 1991, J APPL BACTERIOL, V70, pS61; Gordon W. A., 1999, BIOAEROSOLS FUNGI MY, P94; Gray MR, 2003, ARCH ENVIRON HEALTH, V58, P410; Gunnbjornsdottir MI, 2003, RESP MED, V97, P302, DOI 10.1053/rmed.2002.1389; HARTMANN DE, 1995, NEUROPSYCHOLOGICAL T; HEBBEN N, 2002, ESSENTIALS NEUROPSYC; Heuser G, 1998, TOXICOL IND HEALTH, V14, P813, DOI 10.1177/074823379801400604; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543, DOI 10.1289/ehp.02110543; Johanning E, 1996, INT ARCH OCC ENV HEA, V68, P207; JOHN ER, 1977, FUNCTIONAL NEUROSCIE, V2; Johnstone J., 2003, Journal of Neurotherapy, V7, P31, DOI 10.1300/J184v07n03_02; Kilburn K.H., 2002, EUR J ONCOL, V7, P197; Kurup VP, 2000, MICROBES INFECT, V2, P1101, DOI 10.1016/S1286-4579(00)01264-8; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; *NXLINK LTD, 2001, NXLINK NEUR AN SYST; Patel AM, 2001, J ALLERGY CLIN IMMUN, V108, P661; Persson R, 2000, NEUROTOXICOLOGY, V21, P667; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Rosen I, 1997, DEMENT GERIATR COGN, V8, P110, DOI 10.1159/000106615; SANFORD J, 1995, INTERMEDIATE VISUAL; Savilahti R, 2000, ARCH ENVIRON HEALTH, V55, P405, DOI 10.1080/00039890009604038; Schore A. N., 1994, AFFECT REGULATION OR; Seuri M, 2000, INDOOR AIR, V10, P138, DOI 10.1034/j.1600-0668.2000.010003138.x; *STATS INC, 1984, STAT 6 0 WIND; Thatcher RW, 2003, CLIN ELECTROENCEPHAL, V34, P39, DOI 10.1177/155005940303400203; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; VANSWEDEN B, 1993, ELECTROENCEPHALOGRAP, P643; Ziem G, 1997, ENVIRON HEALTH PERSP, V105, P417, DOI 10.2307/3433348; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	45	24	24	0	6	HELDREF PUBLICATIONS	WASHINGTON	1319 EIGHTEENTH ST NW, WASHINGTON, DC 20036-1802 USA	0003-9896			ARCH ENVIRON HEALTH	Arch. Environ. Health	AUG	2003	58	8					452	463		10.3200/AEOH.58.8.452-463			12	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	833FT	WOS:000222322600001	15259424				2021-06-18	
J	Schallert, T; Woodlee, MT				Schallert, T; Woodlee, MT			Brain-dependent movements and cerebral-spinal connections: Key targets of cellular and behavioral enrichment in CNS injury models	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article; Proceedings Paper	Conference on Translational Research in Spinal Cord Injury	APR 03, 2003	MIAMI, FL			exercise; forced-use therapy; motor enrichment; Parkinson's disease; plasticity; neurotrophic factors; spinal cord; stroke; traumatic brain injury	BILATERAL CUTANEOUS STIMULATION; FUNCTIONAL RECOVERY; STRUCTURAL EVENTS; CORTICAL DAMAGE; MESSENGER-RNA; DORSAL COLUMN; LIMB-USE; RATS; MOTOR; CORD	One of the most difficult problems in experimental and clinical neurology is how to facilitate recovery of the ability to walk voluntarily. Local spinal mechanisms, descending input from the brain, and ascending sensory feedback to the brain are required for non-treadmill, self-initiated stepping. In evaluating the integrity of axons connecting the brain and spinal cord in neural injury models, the selection of behavioral tests may be at least as important as the histological procedures, if not more so. A comprehensive and clinically meaningful test battery should include assessments of brain-dependent movement capacity. Behavioral enrichment procedures that prominently encourage self-initiation of stepping have been used to facilitate plasticity and motor function after brain or spinal cord injury. Progressive degeneration characteristic of parkinsonian models can be slowed or halted altogether by forced exercise and limb use. Behavioral interventions may work partly because the animal adopts alternative behavioral strategies to compensate for impaired performance. However, mounting evidence suggests that motor rehabilitation can also promote restoration of function or prevent slow degeneration of tissue by engaging constitutively available mechanisms that protect, repair, rewire, or reactivate cells.	Univ Texas, Inst Neurosci, Dept Psychol, Austin, TX 78712 USA; Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Human Growth & Dev, Ann Arbor, MI 48109 USA	Schallert, T (corresponding author), Univ Texas, Inst Neurosci, Dept Psychol, Seay Bldg, Austin, TX 78712 USA.	Tschall@umich.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 23979-14] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023979] Funding Source: NIH RePORTER		Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; BACHYRITA P, 2000, CEREBRAL REORGANIZAT, P357; Barbeau H, 2003, NEUROREHAB NEURAL RE, V17, P3, DOI 10.1177/0888439002250442; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bittner GD, 2000, NEUROSCIENTIST, V6, P88, DOI 10.1177/107385840000600207; Bunge MB, 2002, PROG BRAIN RES, V137, P275; Cenci MA, 2002, NAT REV NEUROSCI, V3, P574, DOI 10.1038/nrn877; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cohen AD, 2003, J NEUROCHEM, V85, P299, DOI 10.1046/j.1471-4159.2003.01657.x; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; DeBow SB, 2003, STROKE, V34, P1021, DOI 10.1161/01.STR.0000063374.89732.9F; Diener PS, 1998, J NEUROSCI, V18, P763; DIETRICH WD, 1990, STROKE, V21, P147; Dobkin BH, 1999, NEUROREHAB NEURAL RE, V13, P157, DOI 10.1177/154596839901300301; EDGERTON VR, 2002, INJURY DECREASES BDN; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FINGER S, 1982, BRAIN DAMAGE RECOVER, P257; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; GOLANI I, 1979, BRAIN RES, V164, P237, DOI 10.1016/0006-8993(79)90019-2; Goldstein LB, 1998, RESTORATIVE NEUROLOGY, P241; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; HAYCOCK JW, 1977, PSYCHOPHARMACOLOGY, V54, P21, DOI 10.1007/BF00426535; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Karhunen H, 2003, PHARMACOL BIOCHEM BE, V74, P663, DOI 10.1016/S0091-3057(02)01053-5; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Kim D, 2001, NEUROREHAB NEURAL RE, V15, P141, DOI 10.1177/154596830101500207; KLEIM JA, 2003, IN PRESS NEUROCHEM R; KOLB B, 1988, BEHAV BRAIN RES, V28, P259, DOI 10.1016/0166-4328(88)90129-5; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Liu Y, 1999, J NEUROSCI, V19, P4370; MARSHALL JF, 1974, J COMP PHYSIOL PSYCH, V86, P375, DOI 10.1037/h0035941; McKenna JE, 1999, J NEUROSCI, V19, P1885; MOROZ IA, 2002, EFFECTS FORCED LIMB; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; Rossignol S, 2000, CURR OPIN NEUROBIOL, V10, P708, DOI 10.1016/S0959-4388(00)00151-3; SCHALLERT T, 1988, ANN NY ACAD SCI, V515, P108, DOI 10.1111/j.1749-6632.1988.tb32972.x; SCHALLERT T, 1984, BEHAV NEUROSCI, V98, P518; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHALLERT T, 1983, PHARMACOL BIOCHEM BE, V18, P753, DOI 10.1016/0091-3057(83)90019-9; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schallert T, 2000, CONT NEUROS, P131; SCHALLERT T, 1978, SCIENCE, V199, P1461, DOI 10.1126/science.564552; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; SCHALLERT T, 1985, DEV PSYCHOBIOL, V18, P501, DOI 10.1002/dev.420180607; SCHALLERT T, 2003, PHYS MED REHAB CLIN, V14, P1; SCHALLERT T, 1998, CEREBROVASC DIS, P611; SCHALLERT T, 1988, ANN NY ACAD SCI, V515, P108; Schallert T, 2002, PHARM CEREBRAL ISCHE; Schallert T, 1992, J NEUR TRANSPLANT PL, V3, P332, DOI DOI 10.1155/NP.1992.332; SCHRIMSHER GW, 1993, EXP NEUROL, V120, P264, DOI 10.1006/exnr.1993.1060; Selzer ME, 1999, NEUROREHAB NEURAL RE, V13, P155; SMITH JL, 1980, J NEUROPHYSIOL, V43, P612; Soblosky JS, 2001, BEHAV BRAIN RES, V119, P1, DOI 10.1016/S0166-4328(00)00328-4; Stoltz S, 1999, BEHAV BRAIN RES, V106, P127, DOI 10.1016/S0166-4328(99)00100-X; TAKAYUKI T, 2003, J NEUROSCI, V23, P3432; Teitelbaum P., 1983, HDB BEHAVIORAL NEURO, V6, P23; Tillerson JL, 2002, J NEUROSCI, V22, P6790; Tillerson JL, 2001, J NEUROSCI, V21, P4427, DOI 10.1523/JNEUROSCI.21-12-04427.2001; TILLERSON JL, 2003, IN PRESS NEUROSCIENC; WHISHAW IQ, 1977, ELECTROEN CLIN NEURO, V42, P389, DOI 10.1016/0013-4694(77)90175-4; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744	70	24	24	0	4	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	JUL-AUG	2003	40	4		1			9	17		10.1682/JRRD.2003.08.0009			9	Rehabilitation	Rehabilitation	712ZK	WOS:000184829300003	15077644	Bronze			2021-06-18	
J	Teasdale, TW; Engberg, AW				Teasdale, TW; Engberg, AW			Cognitive dysfunction in young men following head injury in childhood and adolescence: a population study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; SECULAR TRENDS; CHILDREN; CONCUSSION; ABILITIES	Objectives: To examine the prevalence of cognitive dysfunction among young men who had suffered a head injury during childhood or adolescence, in particular focusing upon the effects of age and the severity of the injury. Methods: By cross linkage of Danish national registers for hospital admissions and the draft board, 3091 young men were identified who had been injured before age 18 and tested at age 18 or shortly thereafter: 970 had suffered a single concussion and were in hospital for one day only; 521 had two concussions at separate times and were in hospital for one day only on each occasion; 961 had a cranial fracture; and 639 had a cerebral lesion. For all of these, scores on the draft board's cognitive screening test were obtained, dichotomised as dysfunctional or non-dysfunctional. Prevalences of dysfunctional scores were compared with population base rates (about 20% of all Danish men appearing before the draft board had a score classified as dysfunctional). Results: For young men who had suffered a single concussion, cranial fracture, or cerebral lesion before 12 years of age, resulting in less than 12 days of hospital admission (n = 376), rates of cognitive dysfunction did not exceed those in the general population (odds ratios < 1.4, NS), but the odds ratios became significant and > 1.4 where the injury occurred after age 11. For those with a cerebral lesion resulting in over 11 days of hospital admission (n = 263), all odds ratios were significant and greater than or equal to 2.0, irrespective of age at injury. For cases of two concussions, all odds ratios were > 1.4 but were not significant for all age groupings. Conclusions: For milder forms of single head injury before age 12 there is no evidence of enduring cognitive dysfunction. The apparent effect at later ages may reflect predisposing psychosocial factors. For more serious injury, and for cases with two concussions, the effect is marked and not clearly related to age. For the former, this suggests enduring neurological effects of the injury; for the latter, where the effect is unrelated to time between injuries, predisposing factors may again play a role.	Univ Copenhagen, Dept Psychol, DK-2300 Copenhagen S, Denmark; Copenhagen Univ Hosp, Div Neurol Rehabil, Hvidovre, Denmark	Teasdale, TW (corresponding author), Univ Copenhagen, Dept Psychol, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	tom.teasdale@psy.ku.dk					Andersen TF, 1999, DAN MED BULL, V46, P263; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Finger S, 1999, J Hist Neurosci, V8, P269, DOI 10.1076/jhin.8.3.269.1824; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Green A, 1996, DAN MED BULL, V43, P464; GRONWALL D, 1975, LANCET, V2, P995; Halperin JM, 1998, J AM ACAD CHILD PSY, V37, P575, DOI 10.1097/00004583-199806000-00007; HART K, 1988, J CLIN PSYCHOL, V44, P780, DOI 10.1002/1097-4679(198809)44:5<780::AID-JCLP2270440519>3.0.CO;2-1; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Marschark M, 2000, J HEAD TRAUMA REHAB, V15, P1227, DOI 10.1097/00001199-200012000-00004; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; MORTENSEN EL, 1989, SCAND J PSYCHOL, V30, P315, DOI 10.1111/j.1467-9450.1989.tb01094.x; Nybo T, 1999, BRAIN INJURY, V13, P759; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE TW, 1994, SCAND J PSYCHOL, V35, P328, DOI 10.1111/j.1467-9450.1994.tb00957.x; Teasdale TW, 2000, INTELLIGENCE, V28, P115, DOI 10.1016/S0160-2896(99)00034-3; Teasdale TW, 1997, BRIT MED J, V315, P569; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; Webb C, 1996, BRAIN INJURY, V10, P303, DOI 10.1080/026990596124476; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	29	24	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2003	74	7					933	936		10.1136/jnnp.74.7.933			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	690JB	WOS:000183543800024	12810783	Bronze, Green Published			2021-06-18	
J	Iino, M; Nakatome, M; Ogura, Y; Fujimura, H; Kuroki, H; Inoue, H; Ino, Y; Fujii, T; Terao, T; Matoba, R				Iino, M; Nakatome, M; Ogura, Y; Fujimura, H; Kuroki, H; Inoue, H; Ino, Y; Fujii, T; Terao, T; Matoba, R			Real-time PCR quantitation of FE65 a beta-amyloid precursor protein-binding protein after traumatic brain injury in rats	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						real-time PCR; diffuse axonal injury; FE65; beta-APP; NSE	DIFFUSE AXONAL INJURY; NEURON-SPECIFIC ENOLASE; INTERLEUKIN-1-BETA MESSENGER-RNA; POLYMERASE-CHAIN-REACTION; FLUID-PERCUSSION MODEL; CLOSED-HEAD INJURY; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; ALTERED EXPRESSION; APOLIPOPROTEIN-E	In cases of traumatic brain injury (TBI) in which the patient survived for only a short period of time and was without macroscopic changes at autopsy, it is difficult to diagnose TBI. To detect early diagnostic markers of diffuse axonal injury (DAI), real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in an experimental head trauma model of rat was chosen. The beta-amyloid precursor protein (beta-APP) is a well-known diagnostic marker of DAI which can be detected by immunolabeling as early as 1.5 h after injury. beta-APP has a binding protein, FE65, which is expressed in the brain of Alzheimer's disease patients along with beta-APP, but no involvement with brain injury has been reported. Neuron-specific enolase (NSE) is also a useful marker of DAI. We found that FE65 expression increased dramatically as early as 30 min after injury and decreased after peaking 1 h post-injury, although NSE showed no significant changes. These results suggest that real-time PCR of FE65 mRNA is useful for the diagnosis of DAI in forensic cases.	Osaka Univ, Dept Legal Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Neurol, Grad Sch Med, Osaka, Japan	Iino, M (corresponding author), Osaka Univ, Dept Legal Med, Grad Sch Med, 2-2 F3 Yamadaoka, Suita, Osaka 5650871, Japan.	iino@legal.med.osaka-u.ac.jp	Iino, Morio/N-9135-2013				AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1984, LANCET, V2, P1420; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Aldape K, 2002, BRAIN PATHOL, V12, P54; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bodjarian N, 1997, NEUROREPORT, V8, P3951, DOI 10.1097/00001756-199712220-00020; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; COCHRAN E, 1991, AM J PATHOL, V139, P485; Delatour B, 2001, AM J PATHOL, V158, P1585, DOI 10.1016/S0002-9440(10)64113-2; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Ermekova KS, 1998, ADV EXP MED BIOL, V446, P161; ESPOSITO F, 1990, DEV NEUROSCI-BASEL, V12, P373, DOI 10.1159/000111865; FAN L, 1995, MOL BRAIN RES, V30, P125; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gotohda T, 2001, INT J LEGAL MED, V115, P121, DOI 10.1007/s004140000185; Graham DI, 1997, BRAIN PATHOL, V7, P1285; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; HATFIELD RH, 1992, BRAIN RES, V577, P249, DOI 10.1016/0006-8993(92)90280-M; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hu QB, 1998, HUM GENET, V103, P295, DOI 10.1007/s004390050820; Hu QB, 2000, J NEUROSCI RES, V60, P73, DOI 10.1002/(SICI)1097-4547(20000401)60:1<73::AID-JNR8>3.0.CO;2-S; IMAJO T, 1984, AM J FOREN MED PATH, V5, P217, DOI 10.1097/00000433-198409000-00005; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; Ishida K, 2000, FORENSIC SCI INT, V113, P127, DOI 10.1016/S0379-0738(00)00252-8; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Lambert JC, 2000, NEUROSCI LETT, V293, P29, DOI 10.1016/S0304-3940(00)01477-4; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; Li X, 2000, BRAIN RES PROTOC, V5, P211, DOI 10.1016/S1385-299X(00)00015-5; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARANGOS PJ, 1978, BRAIN RES, V150, P117, DOI 10.1016/0006-8993(78)90657-1; Marmarou A, 1990, Adv Neurol, V52, P233; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MURRAY GI, 1993, J CLIN PATHOL, V46, P993, DOI 10.1136/jcp.46.11.993; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; Nogami M, 1998, FORENSIC SCI INT, V94, P97, DOI 10.1016/S0379-0738(98)00060-7; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; Orihara Y, 2000, Nihon Hoigaku Zasshi, V54, P361; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Orihara Y, 2002, INT J LEGAL MED, V116, P92, DOI 10.1007/s00414-001-0265-8; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schreiber SS, 1999, EXP NEUROL, V159, P329, DOI 10.1006/exnr.1999.7147; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; STRICH SJ, 1961, LANCET, V2, P443; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; Wang XK, 2000, J NEUROSCI RES, V59, P238, DOI 10.1002/(SICI)1097-4547(20000115)59:2<238::AID-JNR10>3.0.CO;2-G; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	87	24	30	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	JUN	2003	117	3					153	159		10.1007/s00414-003-0370-y			7	Medicine, Legal	Legal Medicine	701AQ	WOS:000184143700004	12707777				2021-06-18	
J	Langeluddecke, PM; Lucas, SK				Langeluddecke, PM; Lucas, SK			Wechsler Adult Intelligence Scale - Third edition findings in relation to severity of brain injury in litigants	CLINICAL NEUROPSYCHOLOGIST			English	Article							WAIS-III; SHORT FORMS; PERFORMANCE; DYSFUNCTION; VALIDITY	WAIS-III findings were reported for 150 litigants, classified into three groups according to severity of traumatic brain injury (TBI), and a general population control group. There was a significant "dose response" relationship between TBI severity and all Index/IQ scores. Effect size was greatest for the Processing Speed Index (PSI). Between group differences were significant on all subtests except Information and Digit Span. Effect sizes were greatest for Digit Symbol, Symbol Search, Similarities, and Picture Arrangement. Relative to the control group, there was a significant difference for the Severe and Extremely Severe TBI groups on all IQ/Index scores and most subtests. The Moderate TBI group differed significantly on one Index (the PSI) and none of the subtests. Clinical implications of the findings are discussed in relation to the utility of the WAIS-III in assessing the cognitive sequelae of TBI, the use of current WAIS-III IQ scores to assess intelligence - memory discrepancies, WAIS-III short forms, and estimation of premorbid intelligence.	Westmead Hosp, Dept Med Psychol, Westmead, NSW 2145, Australia	Langeluddecke, PM (corresponding author), Suite 1003,37 Bligh St, Sydney, NSW, Australia.	langeluddecke@bigpond.com					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2002, ASSESSMENT, V9, P17, DOI 10.1177/1073191102009001003; Axelrod BN, 2001, ARCH CLIN NEUROPSYCH, V16, P293, DOI 10.1016/S0887-6177(00)00048-2; Basso MR, 2002, CLIN NEUROPSYCHOL, V16, P57, DOI 10.1076/clin.16.1.57.8329; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2002, PSYCHOL ASSESSMENT, V14, P360, DOI 10.1037//1040-3590.14.3.360; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; FOX DD, 1994, ARCH CLIN NEUROPSYCH, V9, P211, DOI 10.1016/0887-6177(94)90026-4; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Hawkins KA, 2002, ARCH CLIN NEUROPSYCH, V17, P49, DOI 10.1016/S0887-6177(00)00099-8; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson H, 1992, NATL ADULT READING T; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; Psychological Corporation, 2001, WECHSL TEST AD READ; Rey A, 1964, EXAMEN CLIN PSYCHOL; Ringe WK, 2002, ASSESSMENT, V9, P254, DOI 10.1177/1073191102009003004; Ryan JJ, 1998, J PSYCHOEDUC ASSESS, V16, P315, DOI 10.1177/073428299801600403; Sattler J. M., 1999, ASSESSMENT CHILDRE S; Schoenberg MR, 2002, CLIN NEUROPSYCHOL, V16, P426, DOI 10.1076/clin.16.4.426.13913; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; SPSS, 2001, STAT PACK SOC SCI; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	37	24	25	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	2003	17	2					273	284		10.1076/clin.17.2.273.16499			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	734PF	WOS:000186065200017	13680435				2021-06-18	
J	Lu, J; Moochhala, S; Shirhan, M; Ng, KC; Tan, MH; Teo, AL; Ling, EA				Lu, J; Moochhala, S; Shirhan, M; Ng, KC; Tan, MH; Teo, AL; Ling, EA			Nitric oxide induces macrophage apoptosis following traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						lateral fluid percussive brain injury; inducible NO synthase; transferase d-UTP nick-end labeling; caspase-3; aminoguanidine; rat	CLOSED-HEAD INJURY; CNS INJURY; EXPRESSION; PATHWAYS; SYNTHASE	This study examined the apoptotic mechanisms of macrophages following a lateral fluid percussive brain injury. A marked induction of inducible NO synthase (iNOS) immunoexpression was observed in brain macrophages in the subarachnoid space and lateral ventricles ipsilateral to the injury. Numerous apoptotic macrophages occurred in the same region 7 days after the injury as shown by in situ terminal transferase d-UTP nick-end labeling (TUNEL) and caspase-3 immunohistochemistry. Double immunofluorescence staining showed that only a small number of TUNEL positive cells were iNOS positive; many TUNEL positive cells, however, were observed in the vicinity of iNOS positive cells. Administration of aminoguanidine resulted in a marked reduction of apoptotic cells in the lesioned area suggesting that overproduction of NO is linked to diminution of brain macrophages by apoptosis. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.	Def Sci & Technol Agcy, Def Med Res Inst, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 119260, Singapore	Lu, J (corresponding author), Def Sci & Technol Agcy, Def Med Res Inst, 18 Med Dr,01-06,MD2, Singapore 117597, Singapore.			MOOCHHALA, SHABBIR/0000-0003-4521-3192			Castillo J, 2000, STROKE, V31, P852, DOI 10.1161/01.STR.31.4.852; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; KAUR C, 1987, J ANAT, V154, P215; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Messmer UK, 1998, EUR J PHARMACOL, V349, P333, DOI 10.1016/S0014-2999(98)00189-7; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	16	24	27	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAR 20	2003	339	2					147	150		10.1016/S0304-3940(03)00003-X			4	Neurosciences	Neurosciences & Neurology	652ZW	WOS:000181411600015	12614916				2021-06-18	
J	Albrecht, RM; Malik, S; Kingsley, DD; Hart, B				Albrecht, RM; Malik, S; Kingsley, DD; Hart, B			Severity of cervical spine ligamentous injury correlates with mechanism of injury, not with severity of blunt head trauma	AMERICAN SURGEON			English	Article; Proceedings Paper	45th Annual Meeting of the Midwest-Surgical-Association	AUG 11-14, 2002	MACKINAC ISL, MI	Midwest Surg Assoc			DYNAMIC FLUOROSCOPY; ASSOCIATION; RISK	Clearance of the cervical spine (CS) in obtunded trauma patients in an intensive care unit is problematic. Patients with no osseous injuries have potential unstable extradural supportive soft tissue injury. Evaluation of the supporting structures involves dynamic fluoroscopy or MRI both of which have inherent risks and convenience issues. Defining which of these patients are at highest risk for severe supportive structure injury may improve resource utilization for CS clearance. The purpose of this study was to evaluate clinical factors that may predict the probability of CS supportive soft tissue injury in patients with traumatic brain injury. Patients who sustained traumatic brain injury with intracranial. pathology, absence of CS osseous injury, and a limited cervical spine MRI within 72 hours of injury were included. Potential clinical predictors included the severity of the traumatic brain injury defined by the Abbreviated Injury Severity Score for the cerebrum and initial Glasgow Coma Scale, the Injury Severity Score (ISS), mechanism of injury, and high versus low-velocity mechanism. Severity of soft tissue/ligament injury was graded by MRI findings. One hundred twenty-five patients met the study criteria; 81 had negative MRI findings and in 44 the MRI study was positive for potentially unstable injuries. High-velocity mechanisms of injury and ISS-not the severity of the traumatic brain injury or initial Glasgow Coma Scale score-were statistically significant predictors of severe CS supportive soft tissue injuries. Obtunded blunt trauma patients who have been involved in high-velocity-mechanism incidents and have high ISS are at greatest risk for extradural supportive soft tissue CS injuries. These patients should either remain in CS immobilization until clinical evaluation can be completed or undergo further evaluation of their supportive soft tissue structures by MRI or fluoroscopic flexion/extension.	Univ Oklahoma, Dept Surg, Oklahoma City, OK 73104 USA; Univ New Mexico, Dept Surg, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Radiol, Albuquerque, NM 87131 USA	Albrecht, RM (corresponding author), Univ Oklahoma, Dept Surg, 920 Stanton L Young Blvd,WP 2140, Oklahoma City, OK 73104 USA.						Albrecht RM, 2001, WORLD J SURG, V25, P1089, DOI 10.1007/s00268-001-0063-y; [Anonymous], 2002, NEUROSURGERY S, V50, pS30; BAYLESS P, 1989, AM J EMERG MED, V7, P139, DOI 10.1016/0735-6757(89)90125-3; Benzel EC, 1996, J NEUROSURG, V85, P824, DOI 10.3171/jns.1996.85.5.0824; Blackmore CC, 1999, RADIOLOGY, V211, P759, DOI 10.1148/radiology.211.3.r99jn22759; Cox M W., 2001, Curr Surg, V58, P96, DOI 10.1016/S0149-7944(00)00441-4; D'Alise MD, 1999, J NEUROSURG, V91, P54, DOI 10.3171/spi.1999.91.1.0054; DAVIS JW, 1995, J TRAUMA, V39, P435; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; Davis JW, 2001, J TRAUMA, V50, P1044, DOI 10.1097/00005373-200106000-00011; HILLS MW, 1993, J TRAUMA, V34, P549, DOI 10.1097/00005373-199304000-00011; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; MIRVIS SE, 1996, RADIOLOGY ACUTE CERV, P114; OMALLEY KF, 1988, J TRAUMA, V28, P1476, DOI 10.1097/00005373-198810000-00013; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; Patton JH, 2000, AM SURGEON, V66, P326; ROTH BJ, 1994, ARCH SURG-CHICAGO, V129, P643; Sees DW, 1998, J TRAUMA, V45, P768, DOI 10.1097/00005373-199810000-00026; Velmahos GC, 1996, J TRAUMA, V40, P768, DOI 10.1097/00005373-199605000-00015; WILLIAMS J, 1992, ANN EMERG MED, V21, P719, DOI 10.1016/S0196-0644(05)82786-6	21	24	24	0	5	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	MAR	2003	69	3					261	265					5	Surgery	Surgery	659LG	WOS:000181777700028	12678485				2021-06-18	
J	Kay, AD; Petzold, A; Kerr, M; Keir, G; Thompson, EJ; Nicoll, JAR				Kay, AD; Petzold, A; Kerr, M; Keir, G; Thompson, EJ; Nicoll, JAR			Cerebrospinal fluid apolipoprotein E concentration decreases after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						Alzheimer's disease; apolipoprotein E; cerebrospinal fluid; S100B; traumatic brain injury	INCREASED NEURONAL DAMAGE; ENTORHINAL CORTEX LESION; CENTRAL NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; E POLYMORPHISM; MOUSE MODEL; HEAD-INJURY; NEUROBIOCHEMICAL MARKERS; APOE IMMUNOREACTIVITY; AMYLOID DEPOSITION	The APOE epsilon4 allele has been associated with unfavorable outcome after several types of acute brain injury, yet the biological mechanisms underlying this observation are poorly understood. Postmortem and experimental brain injury studies suggest the presence of increased amounts of apolipoprotein E (apoE) within the neuropil after acute brain injury. We assayed the concentration of apolipoprotein E in the cerebrospinal fluid (CSF) of non-injured controls and patients with traumatic brain injury (TBI) to determine whether differences exist, and if these differences correlate with injury severity and clinical outcome. CSF apoE and S100B, a marker of injury severity, were measured by enzyme linked immunosorbant assay. CSF was sampled from 27 traumatic brain injury patients (mean age 32, median 25, range 16-65 years) within 3 days of injury, and 28 controls (mean age 40, median 37, range 19-73 years). The TBI patients all had a Glasgow Coma Score (GCS) of less than eight (i.e., severe head injury). Clinical outcome was determined using the Glasgow Outcome Score (GOS). The average concentration of apoE in the CSF of controls was 12.4 mg/L (95% CI: 10.5-14.3 mg/L) and in TBI patients was 3.7 mg/L (95% CI: 2.1-4.1 mg/L; Mann-Whitney: p < 0.0001). In contrast, the concentration of S100B in the CSF of TBI patients was significantly higher than that of controls (Mann-Whitney: p < 0.0001). We speculate that apoE is retained within the parenchyma of the central nervous system in response to injury where in view of previous data, it may have a protective role.	Univ Glasgow, Inst Neurol Sci, So Gen Hosp, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; Univ London, Inst Neurol & Neurosurg, Dept Neuroimmunol, London, England; Univ Pittsburgh, Ctr Nursing Res, Pittsburgh, PA USA; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton SO9 5NH, Hants, England	Kay, AD (corresponding author), Univ Glasgow, Inst Neurol Sci, So Gen Hosp, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.		Petzold, Axel/C-1090-2009; Nicoll, James/I-9253-2017	Petzold, Axel/0000-0002-0344-9749; Nicoll, James/0000-0002-9444-7246			Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Baskin F, 1997, J NEUROL SCI, V148, P15, DOI 10.1016/S0022-510X(96)05335-X; Carlin C, 2000, J NEUROPATH EXP NEUR, V59, P361, DOI 10.1093/jnen/59.5.361; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Kargman DE, 1998, ATHEROSCLEROSIS, V139, P391, DOI 10.1016/S0021-9150(98)00085-9; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LUXTON RW, 1989, CLIN CHEM, V35, P1731; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; Nicoll JAR, 2001, NEUROREPORT, V12, P695, DOI 10.1097/00001756-200103260-00016; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Starck M, 2000, CELL BIOCHEM FUNCT, V18, P9, DOI 10.1002/(SICI)1099-0844(200001/03)18:1<9::AID-CBF841>3.0.CO;2-X; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THOMPSON EJ, 1990, ANN CLIN BIOCHEM, V27, P425, DOI 10.1177/000456329002700503; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	42	24	25	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					243	250		10.1089/089771503321532824			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500002	12820678				2021-06-18	
J	Keenan, MA; Fuller, DA; Whyte, J; Mayer, N; Esquenazi, A; Fidler-Sheppard, R				Keenan, MA; Fuller, DA; Whyte, J; Mayer, N; Esquenazi, A; Fidler-Sheppard, R			The influence of dynamic polyelectromyography in formulating a surgical plan in treatment of spastic elbow flexion deformity	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; elbow; electromyography; rehabilitation; surgery	UPPER-LIMB SPASTICITY; BOTULINUM-TOXIN	Objective: To determine the influence of motor-control analysis with dynamic electromyography on surgical planning in patients with spastic elbow flexion deformity. Design: Prospective observational design. Setting: A Traumatic Brain Injury Model Systems-affiliated specialty referral center for the evaluation and treatment of mobility problems associated with neurologic injury and disease. Participants: Twenty-one patients with spastic elbow flexion deformity. Interventions: Two surgeons each formulated a detailed surgical plan for each individual muscle-tendon unit. Patients then underwent motor-control analysis in which kinetic and polyelectromyographic data were collected by using a standard protocol. Each surgeon formulated another surgical plan after independently reviewing the laboratory study. Main Outcome Measures: The frequency of change and degree of agreement in the surgical plans after review of the laboratory data were used as measures of the effect of the laboratory studies. Results: Fifty-seven percent of the surgical plans were changed after the motor-control study. The frequency of change did not differ by clinical experience. There was a trend toward higher agreement between surgeons after the study than before. Conclusions: Detailed electromyographic motor-control analysis alters surgical planning for patients with spastic elbow flexion deformity. Clinical assessment alone does not accurately identify the muscles responsible for the deformity or dysfunction. More clinical experience does not result in greater accuracy. Motor-control analysis produces higher agreement between surgeons in planning surgery.	Thomas Jefferson Univ, Sch Med, Albert Einstein Med Ctr, Mossrehab Hosp,Inst Mobil Evaluat & Treatment, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Sch Med, Moss Rehabil Res Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Sch Med, Dept Rehabil Med, Philadelphia, PA 19107 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Hosp, Dept Orthopaed Surg, Camden, NJ 08103 USA	Keenan, MA (corresponding author), Univ Penn, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.		Keenan, Mary Ann/ABB-1551-2020	Whyte, John/0000-0002-4381-1474			Bae DS, 2001, J PEDIATR ORTHOPED, V21, P580, DOI 10.1097/00004694-200109000-00005; Bhakta BB, 1996, J NEUROL NEUROSUR PS, V61, P30, DOI 10.1136/jnnp.61.1.30; Friedman A, 2000, AM J PHYS MED REHAB, V79, P53, DOI 10.1097/00002060-200001000-00012; Fuller DA, 2002, FOOT ANKLE INT, V23, P738, DOI 10.1177/107110070202300810; HISEY MS, 1998, OPERATIVE HAND SURG, P287; Keenan MA, 1996, J HEAD TRAUMA REHAB, V11, P57, DOI 10.1097/00001199-199608000-00008; KEENAN MAE, 1990, J HAND SURG-AM, V15A, P607, DOI 10.1016/S0363-5023(09)90023-5; KEENAN MAE, 1990, J HAND SURG-AM, V15A, P340, DOI 10.1016/0363-5023(90)90120-G; LEE GA, 2001, CHAPMANS ORTHOPAEDIC, P3201; MCDAID P, 2001, CHAPMANS ORTHOPAEDIC, P1809; MEALS RA, 1988, J BONE JOINT SURG AM, V70A, P1081, DOI 10.2106/00004623-198870070-00017; MITAL MA, 1979, J BONE JOINT SURG AM, V61, P515, DOI 10.2106/00004623-197961040-00005; Panizza M, 2000, FUNCT NEUROL, V15, P147; REIMERS J, 1990, CLIN ORTHOP RELAT R, P35; SHERK HH, 1977, CLIN ORTHOP RELAT R, P151; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306	16	24	24	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					291	296		10.1053/apmr.2003.50099			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700021	12601663				2021-06-18	
J	O'Bryant, SE; Hilsabeck, RC; Fisher, JM; McCaffrey, RJ				O'Bryant, SE; Hilsabeck, RC; Fisher, JM; McCaffrey, RJ			Utility of the trail making test in the assessment of malingering in a sample of mild traumatic brain injury litigants	CLINICAL NEUROPSYCHOLOGIST			English	Article							VERBAL-LEARNING TEST; HEAD-INJURY; PERFORMANCE	The Trail Making Test (TMT) is one of the most commonly administered tests in neuropsychological assessments. It has been shown to be a valid indicator of brain damage due to traumatic brain injury (TBI), as well as a number of other neuropathological conditions. TMT error and ratio scores have been suggested as possible markers of malingering. The present study examined the utility of various TMT scores as malingering measures in 94 TBI litigants. Litigants were divided into those suspected of (n=27) and those not suspected of malingering (n=67) based on scores obtained on the Test of Memory Malingering and/or the Rey 15-Item Test. TMT errors did not discriminate between suspected and nonsuspected malingerers: however, the overall level of performance on the TMT was suppressed in suspected malingerers. The TMT ratio score was significantly lower in litigants suspected of malingering, although the clinical utility of this ratio is minimal. Results of the present study suggest using caution when interpreting TMT scores as markers of malingering in TBI litigants.	SUNY Albany, Albany, NY 12222 USA; Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79409 USA; Brain Injury Consultants Inc, Fairport, NY USA; Albany Psychol Associates, Albany, NY USA	McCaffrey, RJ (corresponding author), SUNY Albany, Dept Psychol, 1400 Washington Ave, Albany, NY 12222 USA.	rm188@albany.edu	Hilsabeck, Robin/ABC-5093-2020	O'Bryant, Sid/0000-0003-0582-5266			Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; Iverson GL, 2000, J CLIN EXP NEUROPSYC, V22, P191, DOI 10.1076/1380-3395(200004)22:2;1-1;FT191; King JH, 1998, J CLIN EXP NEUROPSYC, V20, P603, DOI 10.1076/jcen.20.5.603.1124; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Rasmusson DX, 1998, CLIN NEUROPSYCHOL, V12, P169, DOI 10.1076/clin.12.2.169.2005; REITAN RM, 1993, HEALSTEAD REITAN NEU; Rey A, 1964, EXAMEN CLIN PSYCHOL; Ruff RM, 1999, STUD NEUROPSYCHOL DE, P315; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; SILBERFARB PM, 1980, AM J PSYCHIAT, V137, P597; STARKSTEIN SE, 1988, J NEUROL NEUROSUR PS, V51, P1259, DOI 10.1136/jnnp.51.10.1259; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245	22	24	26	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2003	17	1					69	74		10.1076/clin.17.1.69.15624			6	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	707XM	WOS:000184535300006	12854012				2021-06-18	
J	Benjamins, JA; Nedelkoska, L; George, EB				Benjamins, JA; Nedelkoska, L; George, EB			Protection of mature oligodendrocytes by inhibitors of caspases and calpains	NEUROCHEMICAL RESEARCH			English	Article						apoptosis; calpains; caspases; kainate; oligodendroglia; staurosporine	CELL-DEATH; MOUSE OLIGODENDROCYTES; DEMYELINATING DISEASES; APOPTOTIC PATHWAYS; MEMBRANE SHEETS; WHITE-MATTER; RAT-BRAIN; ACTIVATION; EXCITOTOXICITY; CALCIUM	Mature mouse oligodendrocytes (OLs) are susceptible to death in demyelinating diseases such as multiple sclerosis and in brain injury following neurotrauma, ischemia, or stroke. To understand mechanisms leading to death of mature OLs and develop strategies for protection, we utilized cultures of mature mouse OLs to investigate the role of caspases and calpains in OL cell death mediated by different mechanisms. The agents used were (i) staurosporine, which induces apoptotic death via inhibition of protein kinases; (ii) kainate, which activates non-NMDA glutamate receptors; (iii) thapsigargin, which releases intracellular calcium stores; and (iv) SNAP, which releases active NO species and causes necrotic cell death. Inhibitors blocking primary effector caspases (including caspase 3), the FAS (death receptor)-mediated initiator caspases (including caspase 8), and stress-induced caspases (including caspase 9), were tested for their protective effects. Inhibition of caspases 3, 8, and 9 each robustly protected OLs following insult with staurosporine, thapsigargin, or kainate when added at optimal times. The time of addition of the inhibitors for maximal protection varied with the agent, from 1 h of preincubation before addition of staurosporine to 6 h after addition of kainate. Much less protection was seen for the NO generator SNAP under any condition. The role of calcium in OL death in each model was investigated by chelating extracellular Ca++ with EGTA, and by inhibiting the Ca++-activated calpain proteases. Calcium chelation did not protect against staurosporine, but decreased OL death initiated by kainate, thapsigargin, or NO. The calpain inhibitors PD150606 and calpain inhibitor I protected from cell death initiated by staurosporine, kainate, and thapsigargin, but not from cell death initiated by the NO donor SNAP.	Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA	Benjamins, JA (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, 421 E Canfield Ave, Detroit, MI 48201 USA.	joyce.benjamins@wayne.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS13143] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS013143] Funding Source: NIH RePORTER		Alberdi E, 2002, NEUROBIOL DIS, V9, P234, DOI 10.1006/nbdi.2001.0457; BENJAMINS JA, 1994, NEUROCHEM RES, V19, P631, DOI 10.1007/BF00971340; Benjamins JA, 1996, NEUROCHEM RES, V21, P471, DOI 10.1007/BF02527712; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; BOTTENSTEIN JE, 1986, P NATL ACAD SCI USA, V83, P1955, DOI 10.1073/pnas.83.6.1955; Boullerne AI, 2001, J NEUROSCI RES, V63, P124, DOI 10.1002/1097-4547(20010115)63:2<124::AID-JNR1004>3.0.CO;2-C; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; DYER CA, 1990, J CELL BIOL, V111, P625, DOI 10.1083/jcb.111.2.625; Feng GP, 2002, AM J PHYSIOL-GASTR L, V282, pG825, DOI 10.1152/ajpgi.00467.2001; Fern R, 2000, J NEUROSCI, V20, P34, DOI 10.1523/JNEUROSCI.20-01-00034.2000; Follett PL, 2000, J NEUROSCI, V20, P9235; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gu CH, 1999, J NEUROSCI, V19, P3043; Itoh T, 2000, GLIA, V31, P165, DOI 10.1002/1098-1136(200008)31:2<165::AID-GLIA80>3.0.CO;2-#; Jamin N, 2001, EXP NEUROL, V172, P17, DOI 10.1006/exnr.2001.7752; Kavanaugh B, 2000, J NEUROSCI RES, V60, P725; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Liu W, 2001, BRAIN RES, V916, P239, DOI 10.1016/S0006-8993(01)03006-2; Lopez E, 2000, MOL BRAIN RES, V85, P61, DOI 10.1016/S0169-328X(00)00235-7; Matute C, 2001, TRENDS NEUROSCI, V24, P224, DOI 10.1016/S0166-2236(00)01746-X; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; Matute C, 1999, ADV EXP MED BIOL, V468, P97; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McColl KS, 1998, MOL CELL ENDOCRINOL, V139, P229, DOI 10.1016/S0303-7207(98)00051-3; MITROVIC B, 1995, NEUROSCIENCE, V65, P531, DOI 10.1016/0306-4522(94)00491-M; Moore JD, 2002, BRIT J PHARMACOL, V135, P1069, DOI 10.1038/sj.bjp.0704538; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; OKA A, 1993, J NEUROSCI, V13, P1441; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Sanchez-Gomez MV, 1999, NEUROBIOL DIS, V6, P475, DOI 10.1006/nbdi.1999.0264; Single B, 2001, EXP CELL RES, V262, P8, DOI 10.1006/excr.2000.5059; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Studzinski DM, 2001, J NEUROSCI RES, V66, P691, DOI 10.1002/jnr.10003; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003; Werner P, 2000, ADV RES NEURODEGENER, V8, P375; Yoshioka A, 2000, J NEUROCHEM, V74, P633, DOI 10.1046/j.1471-4159.2000.740633.x; Yoshioka A, 1998, J NEUROCHEM, V70, P2416; Yoshioka A, 2000, BRAIN RES, V854, P207, DOI 10.1016/S0006-8993(99)02359-8; Yoshioka A, 1996, J NEUROSCI RES, V46, P427; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	50	24	24	0	2	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JAN	2003	28	1					143	152		10.1023/A:1021612615554			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	626GJ	WOS:000179863200015	12587672				2021-06-18	
J	Haldorsen, T; Waterloo, K; Dahl, A; Mellgren, SI; Davidsen, PE; Molin, PK				Haldorsen, T; Waterloo, K; Dahl, A; Mellgren, SI; Davidsen, PE; Molin, PK			Symptoms and cognitive dysfunction in patients with the late whiplash syndrome	APPLIED NEUROPSYCHOLOGY			English	Article						late whiplash syndrome; symptoms; rivermead post-concussion symptoms questionnaire; cognitive dysfunction	MINOR HEAD-INJURY; COMMON WHIPLASH; CEREBRAL SYMPTOMS; FOLLOW-UP; NECK	The aim of the study was to record the severity of symptoms in patients with the late whiplash syndrome and to assess how the symptom load affected the performance on a simple psychometric test. The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) with an additional question on neck pain, modified RPQ (mRPQ), and the Short Test of Mental Status (STMS) were applied on 40 chronic whiplash patients. Symptoms reported by the whiplash group were compared to those of 50 normal controls. The patients scored significantly higher than the controls on all symptoms listed in the mRPQ. The most frequent symptoms reported by the whiplash group were neck pain, headache, "taking longer to think, "forgetfulness, poor concentration, and fatigue. Total score of STMS was significantly lower (p = .0001) in the patients. There was a statistically significant association (p. 0001) between the total scores of mRPQ and STMS indicating that a high symptom load is associated with a poor performance on STMS. The study illustrates that various symptoms, in addition to neck and head pain, may have an impact on cognitive functions when evaluated by an easily administrated test like STMS.	Univ Tromso Hosp, Dept Neurol, N-9038 Tromso, Norway; Univ Tromso, Dept Psychol, Tromso, Norway	Haldorsen, T (corresponding author), Univ Tromso Hosp, Dept Neurol, N-9038 Tromso, Norway.	nevrtoh@unn.no		Molin, Pal Kristian/0000-0002-3319-4177			BALLA JI, 1982, CULT MED PSYCHIAT, V6, P191, DOI 10.1007/BF00051428; BARRETT K, 1995, J ACCID EMERG MED, V12, P173; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; EVANS RW, 1996, NEUROLOGY TRAUMA, P439; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Karlsborg M, 1997, ACTA NEUROL SCAND, V95, P65, DOI 10.1111/j.1600-0404.1997.tb00071.x; Kessels RPC, 1998, ACTA NEUROL SCAND, V97, P188; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; KOKMEN E, 1987, MAYO CLIN PROC, V62, P281, DOI 10.1016/S0025-6196(12)61905-3; MOSS NEG, 1994, CLIN REHABIL, V8, P149; OLSNES BT, 1989, ACTA NEUROL SCAND, V80, P584, DOI 10.1111/j.1600-0404.1989.tb03931.x; RADANOV BP, 1994, J NEUROL NEUROSUR PS, V57, P486, DOI 10.1136/jnnp.57.4.486; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Schmand B, 1998, J NEUROL NEUROSUR PS, V64, P339, DOI 10.1136/jnnp.64.3.339; Smed A, 1997, ACTA NEUROL SCAND, V95, P73, DOI 10.1111/j.1600-0404.1997.tb00072.x; SPITZER WO, 1995, SPINE, V20, pS1; Waterloo K, 1997, EUR J NEUROL, V4, P171, DOI 10.1111/j.1468-1331.1997.tb00323.x	23	24	24	0	6	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	3					170	175		10.1207/S15324826AN1003_06			6	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	780NL	WOS:000189387500006	12890644				2021-06-18	
J	Sarno, S; Erasmus, LP; Lipp, B; Schlaegel, W				Sarno, S; Erasmus, LP; Lipp, B; Schlaegel, W			Multisensory integration after traumatic brain injury: a reaction time study between pairings of vision, touch and audition	BRAIN INJURY			English	Article							POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD-INJURY; SUPERIOR COLLICULUS; POSTERIOR PARIETAL; SPATIAL ATTENTION; CORTEX; HUMANS; RECOGNITION; MECHANISMS; INHIBITION	Traumatic brain injury (TBI) frequently results in deficits in attention and speed of information processing. In order to disentangle the influence of sensory-specific factors and the role of cross-modal integration from the supra-modal aspects of cognitive slowing, the present reaction time (RT) study was designed. Simple and choice RT to pairings of visual, auditory and tactile stimuli were measured in 35 TBI patients and 35 matched controls. Results proved a strong influence of sensory-specific and cross-modal factors in the RTs. The tactile modality was more difficult to integrate with the visual and the auditory modality, rather than the visual and the auditory modalities between them. TBI patients showed prolonged simple and choice RTs throughout all tasks, but their difficulty with integrating the tactile modality was disproportionately higher in comparison to controls.	Therapiezentrum Burgau, D-89331 Burgau, Germany	Sarno, S (corresponding author), Therapiezentrum Burgau, Dr Friedl Str 1, D-89331 Burgau, Germany.						Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Banati RB, 2000, NEUROPSYCHOLOGIA, V38, P115, DOI 10.1016/S0028-3932(99)00074-3; Bertelson P, 2000, PERCEPT PSYCHOPHYS, V62, P321, DOI 10.3758/BF03205552; Bremmer F, 2001, NEURON, V29, P287, DOI 10.1016/S0896-6273(01)00198-2; Calvert GA, 1999, NEUROREPORT, V10, P2619, DOI 10.1097/00001756-199908200-00033; Calvert GA, 2001, NEUROIMAGE, V14, P427, DOI 10.1006/nimg.2001.0812; Downar J, 2000, NAT NEUROSCI, V3, P277; Foxe JJ, 2000, COGNITIVE BRAIN RES, V10, P77, DOI 10.1016/S0926-6410(00)00024-0; Giard MH, 1999, J COGNITIVE NEUROSCI, V11, P473, DOI 10.1162/089892999563544; Gron G, 1996, J CLIN EXP NEUROPSYC, V18, P406, DOI 10.1080/01688639608408997; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Jiang W, 2001, J NEUROPHYSIOL, V85, P506; KAAS JH, 1990, HUMAN NERVOUS SYSTEM, P813; KAWASHIMA R, 1995, P NATL ACAD SCI USA, V92, P5969, DOI 10.1073/pnas.92.13.5969; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Macaluso E, 2000, SCIENCE, V289, P1206, DOI 10.1126/science.289.5482.1206; Macaluso E, 2000, J NEUROPHYSIOL, V83, P3062; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Massaro DW, 1999, TRENDS COGN SCI, V3, P310, DOI 10.1016/S1364-6613(99)01360-1; McDonald JJ, 2000, NATURE, V407, P906, DOI 10.1038/35038085; MCGURK H, 1976, NATURE, V264, P746, DOI 10.1038/264746a0; MEREDITH MA, 1986, J NEUROPHYSIOL, V56, P640; Miller E, 1970, Cortex, V6, P121; Muller SV, 2002, ARCH PHYS MED REHAB, V83, P115, DOI 10.1053/apmr.2002.27472; Niemann H, 1996, NEUROPSYCHOL REV, V6, P11, DOI 10.1007/BF01875418; REGAN D, 1983, OPHTHALMOLOGY, V90, P1192; Sarno S, 2000, VISION RES, V40, P3029, DOI 10.1016/S0042-6989(00)00137-1; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Spence C, 2000, EXP BRAIN RES, V134, P42, DOI 10.1007/s002210000442; Stein BE, 1996, PROG BRAIN RES, V112, P289; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tassinari G, 1996, NEUROPSYCHOLOGIA, V34, P235, DOI 10.1016/0028-3932(95)00085-2; URBANTSCHITSCH V, 1880, PFLUGERS ARCH GESAMT, V42; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wallace MT, 1996, J NEUROPHYSIOL, V76, P1246; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Xing J, 2000, J COGNITIVE NEUROSCI, V12, P601, DOI 10.1162/089892900562363; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	40	24	25	1	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	5					413	426		10.1080/0269905031000070161			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	660MQ	WOS:000181837300005	12745713				2021-06-18	
J	Tuzgen, S; Tanriover, N; Uzan, M; Tureci, E; Tanriverdi, T; Gumustas, K; Kuday, C				Tuzgen, S; Tanriover, N; Uzan, M; Tureci, E; Tanriverdi, T; Gumustas, K; Kuday, C			Nitric oxide levels in rat cortex, hippocampus, cerebellum, and brainstem after impact acceleration head injury	NEUROLOGICAL RESEARCH			English	Article						nitric oxide; severe head injury; impact acceleration model	SMOOTH-MUSCLE; L-ARGININE; SYNTHASE EXPRESSION; CEREBRAL-ARTERIES; ISCHEMIA; PATHWAY; PATHOPHYSIOLOGY; NITRATE; MODELS; TRAUMA	Nitric oxide (NO) is a potential mediator of secondary brain injury in the settings of cerebral ischemia and inflammation. Traumatic brain injury (TBI) alters the levels of stable end products of NO metabolism. We investigated these changes and attempted to identify brain regions that were unique with regard to NO production in the period immediately after TBI. The experiment involved assaying nitrite-nitrate concentrations in the rat cortex, cerebellum, hippocampus, and brainstem after impact-acceleration head injury, Five rats comprised the sham-operated (control) group, five sustained mild head injury (MHI), and five sustained severe head injury (SHI). There was a uniform decline in the tissue concentrations of NO metabolites in all four brain regions in both injured groups. There were no significant differences in the concentrations of NO metabolites among the various sites tested in the MHI group; however, there appeared to be a relationship between degree of decline in NO levels and amount of trauma sustained by a given region in the SHI group. In these rats, NO dropped to the lowest levels in the brain region where the direct trauma was most severe. The results suggest that nitrite-nitrate levels in these four brain regions fall below normal in the first 5min after impact trauma. This decrease may, in part, be related to reduced activity of all nitric oxide synthase isoforms, which would cause a drop in the levels of NO metabolites. We believe that this decline may be linked to, and may even cause, the global decrease in cerebral blood flow that occurs in the initial stages of TBI. [Neurol Res 2003; 25: 31-34].	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Anesthesiol, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Biochem, Istanbul, Turkey	Uzan, M (corresponding author), POB 5, TR-34301 Istanbul, Turkey.	uzan@istanbul.edu.tr	Tanriverdi, Taner/C-9003-2019; Tuzgen, Saffet/AAD-7881-2021; Gumustas, Mustafa Koray/AAC-9427-2021; Uzan, Mustafa/D-6571-2019; Tanriover, Necmettin/AAD-3212-2020	Gumustas, Mustafa Koray/0000-0002-0745-0640; Tanriover, Necmettin/0000-0001-7628-9443; Uzan, Mustafa/0000-0001-7214-380X; Tuzgen, Saffet/0000-0002-0490-1506			Albina J E, 1995, New Horiz, V3, P46; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOODMAN JC, 1995, J NEUROTRAUM, V12, P971; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JACOB TD, 1993, J TRAUMA, V35, P590, DOI 10.1097/00005373-199310000-00015; KAJITA Y, 1994, J NEUROSURG, V80, P476, DOI 10.3171/jns.1994.80.3.0476; Kanwar S, 1995, New Horiz, V3, P93; KIM N, 1993, J CLIN INVEST, V91, P437, DOI 10.1172/JCI116220; Love S, 1999, BRAIN PATHOL, V9, P119; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MISRA M, 1998, CNS ANN M; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; RENGASAMY A, 1991, J PHARMACOL EXP THER, V259, P310; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SKAMOTO KI, 1997, J NEUROTRAUM, V14, P349; SUZUKI S, 1995, J NEUROSURG, V83, P862, DOI 10.3171/jns.1995.83.5.0862; SUZUKI Y, 1993, STROKE, V24, P1049, DOI 10.1161/01.STR.24.7.1049; Tsutsui M, 1996, CIRC RES, V79, P336, DOI 10.1161/01.RES.79.2.336; VISSER JJ, 1994, ANN INTERN MED, V120, P345, DOI 10.7326/0003-4819-120-4-199402150-00023; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WAHL M, 1993, ACTA NEUROCHIR, P3	34	24	24	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JAN	2003	25	1					31	34		10.1179/016164103101201085			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	637TU	WOS:000180530500006	12564123				2021-06-18	
J	Tator, CH				Tator, CH			Strategies for recovery and regeneration after brain and spinal cord injury	INJURY PREVENTION			English	Article; Proceedings Paper	6th World Conference on Injury Prevention and Control	MAY 12-15, 2002	MONTREAL, CANADA				NEURAL TISSUE-TRANSPLANTATION; COMA DATA-BANK; HEAD-INJURY; STEM-CELLS; NEUROLOGICAL RECOVERY; NEUROTROPHIC FACTOR; APOLIPOPROTEIN-E; METHYLPREDNISOLONE; REPAIR; TRIAL	Current knowledge of the epidemiology and pathophysiology of neurotrauma and the key clinical and experimental strategies for promoting recovery and regeneration after brain and spinal cord trauma are reviewed. Brief overviews of the epidemiology and pathophysiology of neurotrauma are presented, and the key experimental and clinical treatments for the promotion of recovery and regeneration after brain and spinal cord trauma are discussed.	Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto, ON, Canada	Tator, CH (corresponding author), Toronto Western Hosp, Room 4W-433,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.on.ca					Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; *ASS ASI, 1992, STAND NEUR FUNCT CLA; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; Brunelli GA, 2001, J RECONSTR MICROSURG, V17, P631, DOI 10.1055/s-2001-18873; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Darlington C, 2000, Curr Opin Investig Drugs, V1, P375; David S, 2002, NEUROSCIENTIST, V8, P33, DOI 10.1177/107385840200800108; Dietz V., 2001, Neural Plasticity, V8, P83, DOI 10.1155/NP.2001.83; Fehlings MG, 1999, J NEUROSURG, V91, P1, DOI 10.3171/spi.1999.91.1.0001; Fehlings MG, 2001, SPINE, V26, pS101, DOI 10.1097/00007632-200112151-00017; FEHLINGS MG, 1988, SPINAL CORD DYSFUNCT, P3; GARTON H, 2001, CLIN TRIALS NEUROLOG, P77; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; Graham DI, 1999, ACT NEUR S, V73, P89; HANSEBOUT RR, 1982, EARLY MANAGEMENT ACU, P181; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; JENNETT B, 1977, LANCET, V1, P878; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kmietowicz Z, 1999, BRIT MED J, V318, P1441, DOI 10.1136/bmj.318.7196.1441; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; Kraus JF, 1993, HEAD INJURY, P1; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Namiki J, 1999, J NEUROPATH EXP NEUR, V58, P489, DOI 10.1097/00005072-199905000-00008; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT TRAUM REG, 2001, INJ STAT CAN 1998 99; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Penn RD, 1997, NEUROSURGERY, V40, P94, DOI 10.1097/00006123-199701000-00021; Potter PJ, 1998, J NEUROTRAUM, V15, P837, DOI 10.1089/neu.1998.15.837; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Povlishock JT., 1996, NEUROTRAUMA, P1325; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; Schwab ME, 1996, PHYSIOL REV, V76, P319; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Stover S., 1995, SPINAL CORD INJURY C; TATOR CH, 1995, PARAPLEGIA, V33, P254, DOI 10.1038/sc.1995.58; Tator CH, 1998, NEUROSURGERY, V42, P696, DOI 10.1097/00006123-199804000-00007; TATOR CH, 2001, BLUE BOOK PRACT NEUR, V25, P99; Tator CH, 1996, NEUROSURGERY, P2847; Tator CH, 1995, CONT MANAGEMENT SPIN, P9; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Vaccaro AR, 1997, SPINE, V22, P2609, DOI 10.1097/00007632-199711150-00006; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; Weiss S, 1996, J NEUROSCI, V16, P7599; Wirth ED, 2001, J NEUROTRAUM, V18, P911, DOI 10.1089/089771501750451839; 2002, NEUROSURGERY, V50, pS1	65	24	24	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	DEC	2002	8			4			IV33	IV36		10.1136/ip.8.suppl_4.iv33			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	656FA	WOS:000181597100010	12460955	Bronze, Green Published			2021-06-18	
J	Hillary, FG; Steffener, J; Biswal, BB; Lange, G; DeLuca, J; Ashburner, J				Hillary, FG; Steffener, J; Biswal, BB; Lange, G; DeLuca, J; Ashburner, J			Functional magnetic resonance imaging technology and traumatic brain injury rehabilitation: Guidelines for methodological and conceptual pitfalls	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						fMRI; methodology; rehabilitation; TBI	EVENT-RELATED FMRI; CEREBRAL-BLOOD-FLOW; WORKING-MEMORY; SUSCEPTIBILITY ARTIFACTS; DETECTING ACTIVATIONS; SPATIAL NORMALIZATION; PREFRONTAL CORTEX; MRI; SIGNAL; OXYGENATION	Objectives: To illuminate the current methodological and conceptual pitfalls inherent in conducting functional magnetic resonance imaging (fMRI) research with individuals who have sustained traumatic brain injury (TBI) and to discuss appropriate remedies. The aim is describe fMRI research, its limitations, and how to best use this technology to examine TBI. Discussion: The topics discussed in this article include issues regarding signal detection, brain activation measurement, head movement, and sources of signal artifact. issues surrounding data interpretation and the importance of analyzing the brain as a connected neural network is also discussed. Finally, problems with spatial normalization when examining individuals with TBI are reviewed. Conclusions: To date, there is a scarcity of research applying fMRI technology to the study of TBI. However, because it is a noninvasive procedure with high availability in hospital settings across the country; the next decade of TBI research will likely include a proliferation of this form of investigation. At this time, much work is needed to better understand how to optimally use this technology to examine the effects of TBI on behavior. For fMRI to enhance TBI research it will be imperative to establish valid research protocols and reliable methods of data interpretation.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England	Hillary, FG (corresponding author), 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.		Hillary, Frank/AAN-8622-2021; Ashburner, John/I-3757-2013	Ashburner, John/0000-0001-7605-2518			Aguirre GK, 2002, NEUROIMAGE, V15, P488, DOI 10.1006/nimg.2001.0990; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Barth M, 1999, MAGN RESON IMAGING, V17, P321, DOI 10.1016/S0730-725X(98)00191-X; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Biswal B, 1996, MAGNET RESON MED, V35, P107, DOI 10.1002/mrm.1910350114; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Buckner RL, 1998, NEUROIMAGE, V7, P163, DOI 10.1006/nimg.1998.0328; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P14878, DOI 10.1073/pnas.93.25.14878; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Clare S, 1999, MAGNET RESON MED, V42, P1117; Cordes D, 2000, AM J NEURORADIOL, V21, P1636; Cordes D, 2000, MAGN RESON IMAGING, V18, P1055, DOI 10.1016/S0730-725X(00)00199-5; D'Esposito M, 1999, PSYCHOL BULL, V125, P155, DOI 10.1037/0033-2909.125.1.155; D 'Esposito M, 2000, SEMIN NEUROL, V20, P487, DOI 10.1055/s-2000-13182; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Deichmann R, 2002, NEUROIMAGE, V15, P120, DOI 10.1006/nimg.2001.0985; Derbyshire SWG, 1997, PAIN, V73, P431, DOI 10.1016/S0304-3959(97)00138-3; Diemling M, 1997, MAGN RESON IMAGING, V15, P753, DOI 10.1016/S0730-725X(97)00030-1; Drevets WC, 2000, PROG BRAIN RES, V126, P413; Dunn JF, 1999, MAGNET RESON MED, V41, P850, DOI 10.1002/(SICI)1522-2594(199904)41:4<850::AID-MRM27>3.0.CO;2-L; EVANS AC, 1994, NATO ADV SCI INST SE, V264, P263; EVANS AC, 1993, P IEEE NUCL SCI S ME, P1813; Fox PT, 1995, HUM BRAIN MAPP, V3, P161, DOI 10.1002/hbm.460030302; FRAHM J, 1994, NMR BIOMED, V7, P45, DOI 10.1002/nbm.1940070108; Fredrikson M, 1997, J CLIN PSYCHIAT, V58, P16; Freire L, 2001, NEUROIMAGE, V14, P709, DOI 10.1006/nimg.2001.0869; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Fuster JM, 2001, NEURON, V30, P319, DOI 10.1016/S0896-6273(01)00285-9; George MS, 1997, J NEUROPSYCH CLIN N, V9, P55; Goldman-Rakic P, 2000, NEUROIMAGE, V11, P451, DOI 10.1006/nimg.2000.0575; Gorno-Tempini ML, 2002, NEUROIMAGE, V15, P136, DOI 10.1006/nimg.2001.0967; HAJNAL JV, 1994, MAGN RESON MED, V31, P289; HEDERA P, 1995, INVEST RADIOL, V30, P625, DOI 10.1097/00004424-199511000-00001; HOROWITZ AL, 1995, MRI PHYSICS RADIOLOG; Ishii K, 2001, J NUCL MED, V42, P548; Jansma JM, 2001, J COGNITIVE NEUROSCI, V13, P730, DOI 10.1162/08989290152541403; Jezzard P, 1999, HUM BRAIN MAPP, V8, P80, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<80::AID-HBM2>3.0.CO;2-C; Jezzard P, 1996, NEUROIMAGE, V4, pS63, DOI 10.1006/nimg.1996.0056; Kraus J. F., 1999, REHABILITATION ADULT, P3; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Krings T, 1999, AM J NEURORADIOL, V20, P1907; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Lindauer U, 2001, NEUROIMAGE, V13, P988, DOI 10.1006/nimg.2000.0709; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; Manoach DS, 2000, BIOL PSYCHIAT, V48, P99, DOI 10.1016/S0006-3223(00)00227-4; MANOACH DS, 2000, BIOL PSYCHIAT, V15, P48; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; MAZZIOTTA JC, 1995, NEUROIMAGE, V2, P89, DOI 10.1006/nimg.1995.1012; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McIntosh A. R., 1994, Human Brain Mapping, V2, P2; MCINTOSH AR, 1992, NATO ADV SCI I D-BEH, V68, P219; MINOSHIMA S, 1993, J NUCL MED, V34, P322; National Institutes of Health, 1998, REH PERS TRAUM BRAIN, V16, P1; Nemeroff CB, 1999, AM J PSYCHIAT, V156, P671; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Ojemann JG, 1997, NEUROIMAGE, V6, P156, DOI 10.1006/nimg.1997.0289; PAPANICOLAOU AC, 1998, FUNDAMENTALS FUNCTIO; Parrish TB, 2000, MAGNET RESON MED, V44, P925, DOI 10.1002/1522-2594(200012)44:6<925::AID-MRM14>3.0.CO;2-M; Pollmann S, 2000, HUM BRAIN MAPP, V9, P26, DOI 10.1002/(SICI)1097-0193(2000)9:1<26::AID-HBM3>3.3.CO;2-U; RAICHLE ME, 1991, J CEREB BLOOD FLO S2, V11, pS364; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rosenthal M, 2000, HDB REHABILITATION P; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Seto E, 2001, NEUROIMAGE, V14, P284, DOI 10.1006/nimg.2001.0829; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Song AW, 1999, MAGN RESON MED, V42, P631, DOI 10.1002/(SICI)1522-2594(199910)42:4<631::AID-MRM3>3.0.CO;2-#; Song AW, 2001, MAGNET RESON MED, V46, P407, DOI 10.1002/mrm.1205; Talairach J., 1988, COPLANAR STEREOTAXIC; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; TURNER R, 1991, MAGNET RESON MED, V22, P159, DOI 10.1002/mrm.1910220117; Whyte J, 1998, REHABILITATION MED P, P1191	75	24	24	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2002	17	5					411	430		10.1097/00001199-200210000-00004			20	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	610DD	WOS:000178944700004	12802252				2021-06-18	
J	Ohhashi, G; Tani, S; Murakami, S; Kamio, M; Abe, T; Ohtuki, J				Ohhashi, G; Tani, S; Murakami, S; Kamio, M; Abe, T; Ohtuki, J			Problems in health management of professional boxers in Japan	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; CONCUSSION; SEQUELAE; SPORTS; GUIDELINES; SYMPTOMS; BRAIN	Objective: To investigate whether the incidence of boxing accidents is higher in Japan than in other countries. Method: A nationwide survey of boxers was conducted. Results: A total of 632 boxers responded. Most Japanese boxers were relatively mature when they started boxing (mean starting age of 19.2 years). A high percentage of boxers was found three weight divisions higher than previously reported. Many boxers stated that losing weight was not a big problem. It was found that a punch that turns the head can cause serious physical damage, and it was clarified that only a simple punch, rather than accumulated damage from multiple punches, can cause cerebral concussion. Severe shock causing retrograde amnesia is very rare after a fight and disappears relatively quickly. Many additional symptoms are related to damage to the hearing organs, such as hearing difficulties, tinnitus, and vertigo, but these symptoms also resolve quickly. Many boxers experience memory disturbance, not just after a fight but in daily life. Conclusion: The approach to boxing has become more oriented towards the method of practice and scientific training, rather than psychological factors, which used to be emphasised.	Jikei Univ, Sch Med, Dept Neurol Surg, Minato Ku, Tokyo 1058461, Japan; Nihon Univ, Sch Med, Dept Emergency & Crit Care Med, Tokyo 102, Japan	Ohhashi, G (corresponding author), Jikei Univ, Sch Med, Dept Neurol Surg, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.						Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; *BAS MAG CO, 2000, JAP BOX YB 2000; *BAS MAG CO, 1990, JAP BOX YB 1990; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1995, BOXING MED, P19; ENZENAUER RW, 1994, JAMA-J AM MED ASSOC, V272, P1821, DOI 10.1001/jama.1994.03520230031028; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fiore DC, 1996, JAMA-J AM MED ASSOC, V276, P954; GRONWALL D, 1975, LANCET, V2, P995; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Leclerc S, 1999, BRIT J SPORT MED, V33, P426, DOI 10.1136/bjsm.33.6.426; LUNDBERG GD, 1994, JAMA-J AM MED ASSOC, V271, P1790, DOI 10.1001/jama.271.22.1790; LUNDBERG GD, 1985, AM J FOREN MED PATH, V6, P192, DOI 10.1097/00000433-198509000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; OCONNOR F, 1991, MIL MED, V156, P391; Pearn J, 1998, J PAEDIATR CHILD H, V34, P311, DOI 10.1046/j.1440-1754.1998.00231.x; Ryan AJ, 1998, CLIN SPORT MED, V17, P155, DOI 10.1016/S0278-5919(05)70070-3; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Sawauchi S, 1996, NEUROL SURG TOKYO, V24, P905; SCHMIDTOLSEN S, 1990, AM J SPORT MED, V18, P98, DOI 10.1177/036354659001800117; SWARTZBERG D, 1995, JAMA-J AM MED ASSOC, V274, P784, DOI 10.1001/jama.1995.03530100018006; TANI S, 1994, 1994 INT C REC ADV N, P1065; TANI S, 2001, J JAPANESE SOC CLIN, V19, P413; Warburton N, 1998, J MED ETHICS, V24, P56, DOI 10.1136/jme.24.1.56	33	24	27	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT	2002	36	5					346	352		10.1136/bjsm.36.5.346			7	Sport Sciences	Sport Sciences	602RN	WOS:000178518400009	12351332	Green Published, Bronze			2021-06-18	
J	Yeiser, EC; Vanlandingham, JW; Levenson, CW				Yeiser, EC; Vanlandingham, JW; Levenson, CW			Moderate zinc deficiency increases cell death after brain injury in the rat	NUTRITIONAL NEUROSCIENCE			English	Article						apoptosis; CNS; macrophages; microglia; trauma; TUNEL	GROWTH-INHIBITORY FACTOR; CENTRAL-NERVOUS-SYSTEM; NEURONAL DEATH; STAB WOUNDS; MONOCLONAL-ANTIBODIES; CEREBRAL-ISCHEMIA; APOPTOSIS; MICROGLIA; MECHANISMS; SUPPLEMENTATION	Zinc supplementation has been used clinically to reduce Zn losses and protein turnover in patients suffering from traumatic brain injury. Despite the known role of zinc in cell survival and integrity, the influence of zinc status on central nervous system wound healing in the weeks and months after brain injury has not been addressed. In this investigation, we examined cell death after unilateral cortical stab wounds in adult rats (n = 5 per group) that were provided diets containing adequate zinc (30 mg Zn/kg diet), supplemental zinc (180 mg/kg), or moderately deficient zinc (5 mg/kg). Four weeks following the brain injury there was a 1.82-2.65-fold increase in terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick-end labeling (TUNEL)-positive cells with DNA fragmentation at the site of injury in animals receiving a moderately zinc deficient diet compared to animals receiving a zinc-adequate or supplemented diet (p0.05). Examination of the nuclear morphology of these cells suggested the presence of both apoptosis and necrosis. Immunohistochemistry showed that the TUNEL-positive cells expressed both ED-1 and OX-42, identifying them as microglia/macrophages. Thus it appears that adequate zinc status may be necessary to minimize the amount of neuroimmune cell death after brain injury.	Florida State Univ, Biomed Res Facil 237, Program Neurosci, Tallahassee, FL 32306 USA; Florida State Univ, Dept Nutr Food & Exercise Sci, Tallahassee, FL 32306 USA	Levenson, CW (corresponding author), Florida State Univ, Biomed Res Facil 237, Program Neurosci, Tallahassee, FL 32306 USA.			Levenson, Cathy W/0000-0003-4463-3136	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R29DK050472] Funding Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK50472] Funding Source: Medline		Bagchi M, 2001, MOL CELL BIOCHEM, V221, P49, DOI 10.1023/A:1010946517651; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Conti AC, 1998, J NEUROSCI, V18, P5663; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Falchuk KH, 1998, MOL CELL BIOCHEM, V188, P41, DOI 10.1023/A:1006808119862; FAURE H, 1991, BIOL TRACE ELEM RES, V30, P37, DOI 10.1007/BF02990340; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; Fraker PJ, 1997, P SOC EXP BIOL MED, V215, P229, DOI 10.3181/00379727-215-44132; FREDERICKSON CJ, 1983, BRAIN RES, V273, P335, DOI 10.1016/0006-8993(83)90858-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Fukamachi Y, 1998, BIOCHEM BIOPH RES CO, V246, P364, DOI 10.1006/bbrc.1998.8621; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HOZUMI I, 1990, BRAIN RES, V534, P291, DOI 10.1016/0006-8993(90)90142-X; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; Hozumi I, 1996, BRAIN RES, V741, P197, DOI 10.1016/S0006-8993(96)00912-2; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lees GJ, 1998, BRAIN RES, V799, P108, DOI 10.1016/S0006-8993(98)00483-1; LEVENSON CW, 1994, ANAL BIOCHEM, V221, P243, DOI 10.1006/abio.1994.1408; Libonati JP, 2000, NUTR NEUROSCI, V3, P425, DOI 10.1080/1028415X.2000.11747342; Manev H, 1997, EXP NEUROL, V146, P171, DOI 10.1006/exnr.1997.6510; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; MCINTOSH TK, 1990, ACT NEUR S, V51, P329; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Rains TM, 1998, PHYSIOL BEHAV, V65, P473, DOI 10.1016/S0031-9384(98)00182-6; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; RINK A, 1995, AM J PATHOL, V147, P1575; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WILCOX BJ, 1995, J COMP NEUROL, V359, P573, DOI 10.1002/cne.903590405; Yeiser EC, 1999, NEUROSCI LETT, V277, P75, DOI 10.1016/S0304-3940(99)00825-3; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403; ZALEWSKI PD, 1991, BIOCHEM INT, V24, P1093	50	24	25	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1028-415X			NUTR NEUROSCI	Nutr. Neurosci.	OCT	2002	5	5					345	352		10.1080/1028415021000033811			8	Neurosciences; Nutrition & Dietetics	Neurosciences & Neurology; Nutrition & Dietetics	603FT	WOS:000178548700006	12385597				2021-06-18	
J	Wilson, MS; Hamm, RJ				Wilson, MS; Hamm, RJ			Effects of fluoxetine on the 5-HT1A receptor and recovery of cognitive function after traumatic brain injury in rats	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; serotonin; 5-HT; 5-HT1A; fluoxetine; learning; Morris water maze; rats	FLUID-PERCUSSION MODEL; EXTRACELLULAR RELEASE; SEROTONIN RECEPTOR; MOTOR RECOVERY; MESSENGER-RNA; IN-VITRO; IMPAIRMENT; WAY-100635; ANTAGONIST; PREVENTS	Objective: This study examined the effects of chronic administration of fluoxetine, a selective serotonin reuptake inhibitor, on cognitive performance and 5-HT1A receptor immunoreactivity following traumatic brain injury. Design: Rats received a moderate severity of lateral fluid percussive injury or sham injury 24 hr after surgical preparation. Fluoxetine or vehicle was administered chronically on postinjury days 1-15. Motor performance and Morris water maze performance were assessed on postinjury days 1-5 and 11-15, respectively. Results: Results indicated that chronic fluoxetine treatment did not affect motor or maze performance. Injured groups showed significantly higher 5-HT1A receptor immunoreactivity on postinjury day 15 than sham-injured rats, and fluoxetine treatment did not alter 5-HT1A receptor immunoreactivity. Conclusions: These results indicate that chronic postinjury fluoxetine administration did not influence the recovery of motor or Morris water maze performance following lateral fluid percussive injury. They also indicate that injury-induced changes in the 5-HT1A receptor may contribute to traumatic brain injury-induced cognitive deficits.	Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA	Hamm, RJ (corresponding author), Virginia Commonwealth Univ, Dept Psychol, POB 842018, Richmond, VA 23284 USA.						Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; ALTMAN HJ, 1988, NEUROBIOL AGING, V9, P627, DOI 10.1016/S0197-4580(88)80124-6; Boast C, 1999, NEUROBIOL LEARN MEM, V71, P259, DOI 10.1006/nlme.1998.3886; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; BRILEY M, 1990, PHARMACOPSYCHIATRY, V23, P75, DOI 10.1055/s-2007-1014538; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Carli M, 1997, BRAIN RES, V774, P167, DOI 10.1016/S0006-8993(97)81700-3; Carli M, 1999, NEUROPHARMACOLOGY, V38, P1165, DOI 10.1016/S0028-3908(99)00038-6; CARLI M, 1992, BRIT J PHARMACOL, V105, P720, DOI 10.1111/j.1476-5381.1992.tb09045.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duman RS, 1998, BIOL PSYCHIAT, V44, P324, DOI 10.1016/S0006-3223(98)00031-6; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; GLOBUS MYT, 1992, STROKE, V23, P1595, DOI 10.1161/01.STR.23.11.1595; Gould E, 1999, NEUROPSYCHOPHARMACOL, V21, pS46, DOI 10.1038/sj.npp.1395369; HALL H, 1981, EUR J PHARMACOL, V70, P393, DOI 10.1016/0014-2999(81)90172-2; Harder JA, 2000, NEUROPHARMACOLOGY, V39, P547, DOI 10.1016/S0028-3908(99)00179-3; Helsley S, 1998, PROG NEURO-PSYCHOPH, V22, P1179, DOI 10.1016/S0278-5846(98)00068-2; Hilton G, 1994, Orthop Nurs, V13, P25, DOI 10.1097/00006416-199407000-00006; HOVDA DA, 1983, SOC NEUR ABSTR, V9, P1001; HUNTER AJ, 1989, BIOCHEM SOC T, V17, P79, DOI 10.1042/bst0170079; KMIECIAKKOLADA K, 1987, POL J PHARMACOL PHAR, V39, P47; Liang KC, 1998, CHINESE J PHYSIOL, V41, P33; MCENTEE WJ, 1991, PSYCHOPHARMACOLOGY, V103, P143, DOI 10.1007/BF02244194; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MENESES A, 1995, PHARMACOL BIOCHEM BE, V52, P341, DOI 10.1016/0091-3057(95)00102-3; Meneses A, 1999, NEUROBIOL LEARN MEM, V71, P207, DOI 10.1006/nlme.1998.3866; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NIBUYA M, 1995, J NEUROSCI, V15, P7539; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; Pappius HM, 1995, NEUROCHEM RES, V20, P1311, DOI 10.1007/BF00992506; PERUCHE B, 1994, J NEURAL TRANSM-PARK, V8, P73, DOI 10.1007/BF02250918; RICHELSON E, 1984, PSYCHOPHARMACOL BULL, V20, P213; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SIRVIO J, 1994, PROG NEUROBIOL, V43, P363, DOI 10.1016/0301-0082(94)90060-4; SLOAN R L, 1992, Brain Injury, V6, P315, DOI 10.3109/02699059209034945; STARK P, 1985, J CLIN PSYCHIAT, V46, P7; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; Vaidya VA, 1997, J NEUROSCI, V17, P2785; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273	44	24	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY	2002	81	5					364	372		10.1097/00002060-200205000-00009			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	543XX	WOS:000175129200007	11964577				2021-06-18	
J	Schulman, J; Sacks, J; Provenzano, G				Schulman, J; Sacks, J; Provenzano, G			State level estimates of the incidence and economic burden of head injuries stemming from non-universal use of bicycle helmets	INJURY PREVENTION			English	Article							TRAUMATIC BRAIN INJURY; SAFETY HELMETS; UNITED-STATES; RETURN; DEATHS; WORK	Objective: To develop national and state level estimates for preventable bicycle related head injuries (BRHIs) and associated direct and indirect health costs from the failure to use bicycle helmets. Methods: Information on the effectiveness and prevalence of use of bicycle helmets was combined to estimate the avoidable fraction, that is, the proportion of BRHIs that could be prevented through the use of bicycle helmets. The avoidable fraction multiplied by the expected number of BRHIs gives an estimate of the number of preventable cases. Direct and indirect health costs are estimated from a social perspective for the number of preventable BRHIs to assess potential cost savings that would be achieved if all riders wore helmets. Results: Approximately 107 000 BRHIs could have been prevented in 1997 in the United States. These preventable injuries and deaths represent an estimated $81 million in direct and $2.3 billion in indirect health costs. Estimates range from 200 preventable BRHIs and $3 million in health costs in Wyoming (population 480 000) to 13 700 preventable BRHIs and $320 million in health costs in California (population 32.3 million). Conclusions: A number of successful approaches to increasing bicycle helmet use exist, including mandatory use laws and community based programs. The limited use of these strategies may be related to the fact that too little information is available to state agencies about the public health and economic burden of these preventable injuries. In conjunction with information on program costs, our estimates,, can assist state planners in better quantifying the number of preventable BRHIs and the costs and benefits of helmet promotion programs.	Ctr Publ Hlth Res & Evaluat, Battelle Mem Inst, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Uniintent Injury Prevent, Atlanta, GA USA	Schulman, J (corresponding author), Ctr Publ Hlth Res & Evaluat, Battelle Mem Inst, 2971 Flowers Rd,Suite 233, Atlanta, GA 30341 USA.						[Anonymous], 1995, MMWR Recomm Rep, V44, P1; Bolen JR, 1998, ARCH FAM MED, V7, P72, DOI 10.1001/archfami.7.1.72; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; *CONS PROD SAF COM, 1994, NAT EL INJ SURV SYST; Consumer Products Safety Commission, 1998, CONSUMER PRODUCT SAF, V3, P4; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; GINSBERG GM, 1994, AM J PUBLIC HEALTH, V84, P653, DOI 10.2105/AJPH.84.4.653; GOLD MR, 1996, COST EFFECTIVENESS G; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; *HEALTHC COST UT P, 1994, HCUP 3 NAT INP SAMPL; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Kopjar B, 2000, PREV MED, V30, P401, DOI 10.1006/pmed.2000.0645; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; MILLER TR, 1995, DATABOOK NONFATAL IN; *NAT CTR HLTH STAT, 1993, VIT STAT MORT DAT MU; PROVENZANO G, 1997, LIT REV COSTS BICYCL; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVARA FP, 1996, JAMA-J AM MED ASSOC, V267, P1968; Sacks J J, 1996, Inj Prev, V2, P258, DOI 10.1136/ip.2.4.258; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; SCHULMAN J, 1998, PREVENTABLE INJURIES; Sosin DM, 1996, PEDIATRICS, V98, P868; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28; WINTERBOTTOM C, 1995, STATE LEVEL DATABOOK; WOLTERS C, 1997, LIT REV EFFECTIVENES; 1994, FED REG         0624, V59	32	24	24	0	4	B M J PUBLISHING INC	SAN FRANCISCO	221 MAIN ST, PO BOX 7690, SAN FRANCISCO, CA 94120-7690 USA	1353-8047			INJ PREV	Inj. Prev.	MAR	2002	8	1					47	52		10.1136/ip.8.1.47			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	654LE	WOS:000181497700011	11928974	Bronze, Green Published			2021-06-18	
J	Ohman, J; Braakman, R; Legout, V				Ohman, J; Braakman, R; Legout, V		Traumatic Brain Injury Study Grp	Repinotan (BAY x 3702): A 5HT(1A) agonist in traumatically brain injured patients	JOURNAL OF NEUROTRAUMA			English	Article						5HT(1A) agonist; intracranial pressure; preliminary GOS scores; repinotan; safety; severe traumatic brain injury	SEVERE HEAD-INJURY; GUIDELINES; MANAGEMENT; COMA	Repinotan is a high-affinity, selective, full agonist of the 5HT(1A)-receptor subtype with neuroprotective properties. This paper presents the results of a randomized, double-blind, placebo-controlled study examining the safety and tolerability of three different doses of repinotan in patients with severe traumatic brain injury. Sixty patients were enrolled to receive repinotan (0.5, 1.25, or 2.50 mg/day) or placebo, by continuous Lv. infusion for 7 days. Repinotan treatment had no apparent adverse effects on intracranial pressure, hemodynamic parameters or laboratory parameters. No seizures occurred during treatment, and the incidence and severity of adverse events was as expected for this indication. No serious adverse events were considered related to drug treatment, with the possible exception of one case of inappropriate ADH secretion. No further safety concerns were raised during the 3 months following treatment. On a descriptive basis, the proportion of patients having good outcome or moderate disability (Glasgow Outcome Scale) was somewhat greater in repinotan-treated patients (60%) than in placebo (50%).	Helsinki Univ Hosp, Dept Neurosurg, FIN-00170 Helsinki, Finland; Bayer Pharma, Puteaux La Defense, France	Ohman, J (corresponding author), Helsinki Univ Hosp, Dept Neurosurg, Unioninkatu 38, FIN-00170 Helsinki, Finland.			Ohman, Juha/0000-0002-6592-1367			BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; Bullock MR, 1996, J NEUROTRAUM, V13, P643; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; De Vry Jean, 1997, Drugs of the Future, V22, P341; DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Dunn L T, 1997, Expert Opin Investig Drugs, V6, P1511, DOI 10.1517/13543784.6.10.1511; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; HORVATH E, 1997, SOC NEUR ABSTR, V23, P745; HORVATH E, 1997, J NEUROTRAUM, V14, P800; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; Jennett BFrankowskiR, 1990, HDB CLIN NEUROLOGY, V13, P1; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; RELLING MV, 1989, CLIN PHARMACY, V8, P852	23	24	25	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2001	18	12					1313	1321		10.1089/08977150152725614			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	504RE	WOS:000172869000002	11780862				2021-06-18	
J	Uzan, M; Tanriover, N; Bozkus, H; Gumustas, K; Guzel, O; Kuday, C				Uzan, M; Tanriover, N; Bozkus, H; Gumustas, K; Guzel, O; Kuday, C			Nitric oxide (NO) metabolism in the cerebrospinal fluid of patients with severe head injury - Inflammation as a possible cause of elevated NO metabolites	SURGICAL NEUROLOGY			English	Article						inflammation; interleukin; nitric oxide; severe head injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; ENDOTHELIAL-CELLS; SMOOTH-MUSCLE; L-ARGININE; SUBARACHNOID HEMORRHAGE; NITRATE CONCENTRATIONS; SYNTHASE EXPRESSION; INTERLEUKIN-8 GENE; CYTOKINES	BACKGROUND This article investigates nitric oxide (NO) metabolism following severe head injury (SHI). We wished to clarify the alterations of NO metabolism end products that is associated with SHI, and to delineate the role of inflammation in this process. METHODS In a prospective study, we simultaneously measured the concentrations of NO metabolites and interleukin-8 (IL-8) in the ventricular cerebrospinal fluid (CSF of 11 patients who had suffered SHI. The CSF concentrations of nitrite (NO2-) and nitrate (NO3-) combined, and of IL-8 were measured during the following four time periods post-trauma: 6 to 10, 20 to 28, 40 to 56, and 64 to 74 hours. Levels were measured using the corresponding kits. RESULTS Compared to the ventricular CSF control values, all of our SHI patients had significantly elevated CSF levels of NO2- plus NO3- (NO2- + NO3-) and IL-8 during all periods tested. CSF NO2- + NO3- and IL-8 concentrations reached their maximums simultaneously at 20 to 28 hours following trauma (Spearman's rank correlation = 0.609, p < 0.05), and NO2- + NO3- levels were significantly higher wthan those measured at 6 to 10, 40 to 56, and 64 to 74 hours. [Nitrite-nitrate concentrations: 6-10 hours: 19.22 +/- 6.75, 20-28 hours: 25 +/- 6.2 mumol/l, 40-56 hours: 19.82 +/- 4.47, and 64-74 hours: 19.72 +/- 4.61 mumol/l, (p < 0.05). IL-8 concentrations: 6-10 hours: 3,232 +/- 2,976.2, 20-28 hours: 3,458.45 +/- 3,048 pg/mL, 40-56 hours: 2,616.41 +/- 2,539.21, 64-74 hours: 1,388.88 +/- 1,216.7 pg/ mL, (p < 0.001).]. This simultaneous surge in NO2- + NO3- and IL-8 in the initial 24 hours post-traumatic indicated that inflammation secondary to SHI increased the rate of NO metabolism, resulting in higher levels of metabolites in the CSF CONCLUSION In patients with SHI, CSF concentrations of the dominant metabolites of NO are elevated in the first 3 days after trauma. A similar concurrent spike in the CSF level of IL-8, a marker of acute inflammatory response, can also be demonstrated, These data indicate that the predominant cause of the higher CSF NO2- + NO3- concentrations observed in SHI is most likely inflammation. (C) 2001 by Elsevier Science Inc.	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Biochem, Istanbul, Turkey; Amer Hosp, Dept Neurosurg, Vehbi Koc Fdn, Istanbul, Turkey; Bruni Biochem Lab, Istanbul, Turkey	Uzan, M (corresponding author), POB 5,Cerrahpasa, TR-34301 Istanbul, Turkey.		Uzan, Mustafa/D-6571-2019; Gumustas, Mustafa Koray/AAC-9427-2021; Tanriover, Necmettin/AAD-3212-2020	Gumustas, Mustafa Koray/0000-0002-0745-0640; Tanriover, Necmettin/0000-0001-7628-9443; Uzan, Mustafa/0000-0001-7214-380X			Albina J E, 1995, New Horiz, V3, P46; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bednar MM, 1999, STROKE, V30, P887, DOI 10.1161/01.STR.30.4.887; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GHAJAR JB, 1996, AANS ANN M POST; GOODMAN JC, 1995, J NEUROTRAUM, V12, P971; Groeneveld PHP, 1997, CYTOKINE, V9, P138, DOI 10.1006/cyto.1996.0147; Horner H. C., 1992, Society for Neuroscience Abstracts, V18, P173; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iwata S, 1999, NEUROSURGERY, V45, P24, DOI 10.1097/00006123-199907000-00006; JACOB TD, 1993, J TRAUMA, V35, P590, DOI 10.1097/00005373-199310000-00015; KAJITA Y, 1994, J NEUROSURG, V80, P476, DOI 10.3171/jns.1994.80.3.0476; Kanwar S, 1995, New Horiz, V3, P93; KOMAKI G, 1992, AM J PHYSIOL, V262, pE246; KOSSMANN MC, 1999, J CEREB BLOOD FLOW M, V17, P280; Love S, 1999, BRAIN PATHOL, V9, P119; MCCALL TB, 1991, EUR J IMMUNOL, V21, P2523, DOI 10.1002/eji.1830211032; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NITTA T, 1992, NEUROSURG REV, V15, P203, DOI 10.1007/BF00345934; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Rise IRR, 1998, J NEUROSURG, V89, P448, DOI 10.3171/jns.1998.89.3.0448; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SCHNEEMANN M, 1993, IMMUNOL LETT, V35, P159, DOI 10.1016/0165-2478(93)90085-G; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SUZUKI S, 1995, J NEUROSURG, V83, P862, DOI 10.3171/jns.1995.83.5.0862; Suzuki Y, 1997, NEUROSURGERY, V41, P807, DOI 10.1097/00006123-199710000-00008; SUZUKI Y, 1993, STROKE, V24, P1049, DOI 10.1161/01.STR.24.7.1049; TADA M, 1993, J NEURO-ONCOL, V16, P25, DOI 10.1007/BF01324831; Thompson BG, 1996, J NEUROSURG, V84, P71, DOI 10.3171/jns.1996.84.1.0071; Tsutsui M, 1996, CIRC RES, V79, P336, DOI 10.1161/01.RES.79.2.336; Villarete LH, 1997, SHOCK, V7, P29, DOI 10.1097/00024382-199701000-00003; VILLARETE LH, 1995, BIOCHEM BIOPH RES CO, V211, P671, DOI 10.1006/bbrc.1995.1864; VISSER JJ, 1994, ANN INTERN MED, V120, P345, DOI 10.7326/0003-4819-120-4-199402150-00023; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WAHL M, 1993, ACTA NEUROCHIR, P3; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WONG HR, 1995, CRIT CARE MED, V23, P835, DOI 10.1097/00003246-199505000-00010	55	24	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	DEC	2001	56	6					350	356		10.1016/S0090-3019(01)00633-4			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	510HB	WOS:000173201700001	11755960				2021-06-18	
J	Lambri, M; Djurovic, V; Kibble, M; Cairns, N; Al-Sarraj, S				Lambri, M; Djurovic, V; Kibble, M; Cairns, N; Al-Sarraj, S			Specificity and sensitivity of beta APP in head injury	CLINICAL NEUROPATHOLOGY			English	Article						head injury; axonal damage; beta APP; hypoxia; ischemia	AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; DIAGNOSIS; NEUROPATHOLOGY; BRAIN	Introduction: beta -amyloid precursor protein (beta APP) expression has been found in traumatic brain injury, hypoxia, ischemia and infection which affect axonal transport. Although beta APP is a sensitive marker for detecting axonal damage, it has become non-specific for a particular type of injury. The aim of this study was to identify a difference in the pattern, distribution and intensity of beta APP expression in head injury compared to hypoxic/ischemic insults. Materials and methods: Thirteen primary head injury and 12 primary hypoxic/ischemic cases were selected. The anterior and posterior parts of corpus callosum, internal capsule (basal ganglia), middle cerebellar peduncles (cerebellum) and pons were examined and stained immunohistochemically for beta APP antibody. A computerized system of image analysis was used to examine the intensity (strength of staining) and density (area fraction) of beta APP. Results: Significant differences were observed in the overall intensity and density of beta APP expression (p < 0.05) and in all 5 brain regions in cases of head injury compared to the hypoxic/ischemic group (p < 0.05). Positive staining for beta APP was found in all regions in all cases of head injury, however, 4 out of 12 cases of hypoxia/ischemia were positive for beta APP. One case expressed positivity in all 5 regions, 2 cases exhibited positivity in the pons alone, with only 1 case exhibiting immunoreactivity in the posterior corpus callosum and internal capsule. Differences in the pattern of beta APP expression identified a predominantly granular pattern with a dirty background seen in hypoxia/ischemia, while fusiform swellings, beaded and thick filaments with clear background were observed in head injury. Conclusion: There are differences in the pattern, distribution and intensity of beta APP in head injury compared to hypoxia/ischemia. These could be due to pathophysiological differences. The results may be helpful in differentiating head injury from hypoxia in medicolegal cases.	Kings Coll London Hosp, Inst Psychiat, Dept Neuropathol, London, England; Kings Coll London, Guys Hosp, Dept Forens Med, London WC2R 2LS, England	Al-Sarraj, S (corresponding author), Inst Psychiat, Dept Neuropathol, Denmark Hill, London SE5 8AF, England.	S.Alsarraj@iop.kcl.ac.uk					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; FERREIRA A, 1993, J NEUROSCI, V13, P3112; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526	19	24	25	1	2	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	NOV-DEC	2001	20	6					263	271					9	Clinical Neurology; Pathology	Neurosciences & Neurology; Pathology	496BT	WOS:000172375500006	11758782				2021-06-18	
J	Watanabe, S; Hoffman, JR; Craik, RL; Hand, PJ; Croul, SE; Reivich, M; Greenberg, JH				Watanabe, S; Hoffman, JR; Craik, RL; Hand, PJ; Croul, SE; Reivich, M; Greenberg, JH			A new model of localized ischemia in rat somatosensory cortex produced by cortical compression	STROKE			English	Article						cerebral blood flow; cerebral ischemia; neuronal plasticity; stroke, experimental; somatosensory cortex; rats	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; ARTERY OCCLUSION; BLOOD-FLOW; MOTOR RECOVERY; INFARCT SIZE; STROKE; REPRESENTATION; PLASTICITY	Background and Purpose-Because of its precise connectivity and functional specificity, the rat whisker-barrel system offers an excellent opportunity to study experience-dependent neuroplasticity. However, data are lacking regarding the neuroplasticity of this system after cerebral ischemia. The purpose of the present study was to develop a reproducible model for the production of ischemia/reperfusion of the posteromedial barrel subfield (PMBSF) in the rat, which is the visible representation of the large whiskers on the opposite face. Methods-Focal cortical ischemia was induced in male Sprague-Dawley rats (n = 40) by slowly compressing the intact dura (maximum 0.05 mm/s) with a 4- or 5-mm-diameter brass cylinder equipped with a laser-Doppler probe, combined with ipsilateral common carotid artery occlusion. The microvascular blood flow of PMBSF during compression ischemia was maintained at 18% to 20% of baseline flow for 1 hour. The total infarction volume was measured by 2,3,5-triphenyltetrazolium chloride staining at several reperfusion times, and pathological examination was performed on hematoxylineosin-stained sections. Results-The infarct volumes were 36.5 +/- 9.2 (n = 9), 40.7 +/- 7.7 (n = 7), and 36.6 +/- 6.4 mm(3) (n = 5) at 24 hours, 72 hours, and 7 days after ischemia, respectively, with no significant differences among these values. There was no evidence of damage to white matter or to deep gray matter and no evidence of hemorrhage. The topographic distribution of the damaged tissue was in good agreement with that of PMBSF. Conclusions-This stroke model produces a highly consistent cortical infarct in PMBSF and can facilitate the study of behavioral, functional, and structural consequences after cerebral ischemia/reperfusion in the rat somatosensory Cortex.	Univ Penn, Cerebrovasc Res Ctr, Dept Neurol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Arcadia Univ, Dept Biol, Glenside, PA USA; Arcadia Univ, Dept Phys Therapy, Glenside, PA USA; Med Coll Penn & Hahnemann Univ, Dept Pathol, Philadelphia, PA USA	Greenberg, JH (corresponding author), Univ Penn, Cerebrovasc Res Ctr, Dept Neurol, Sch Med, 415 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA.	greenberg@cvrc.med.upenn.edu	Craik, Rebecca L/J-8325-2017; Hoffman, John/ABH-8001-2020	Craik, Rebecca L/0000-0003-4816-1439; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-33785] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033785] Funding Source: NIH RePORTER		BARONE FC, 1991, BRAIN RES BULL, V26, P285, DOI 10.1016/0361-9230(91)90240-K; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Browning JL, 1996, J NEUROTRAUM, V13, P583, DOI 10.1089/neu.1996.13.583; Carel C, 2000, J CEREBR BLOOD F MET, V20, P478, DOI 10.1097/00004647-200003000-00006; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DERESKI MO, 1993, ACTA NEUROPATHOL, V85, P327; DIAMOND ME, 1993, P NATL ACAD SCI USA, V90, P2082, DOI 10.1073/pnas.90.5.2082; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FOX K, 1994, J NEUROSCI, V14, P7665; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GROME JJ, 1988, J CEREBR BLOOD F MET, V8, P89, DOI 10.1038/jcbfm.1988.11; HAMADA J, 1995, J CEREBR BLOOD F MET, V15, P779, DOI 10.1038/jcbfm.1995.98; HATASHITA S, 1990, STROKE, V21, P582, DOI 10.1161/01.STR.21.4.582; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kawaguchi K, 1997, BRAIN RES, V749, P131, DOI 10.1016/S0006-8993(96)01311-X; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Markarian GZ, 1996, NEUROSURGERY, V38, P542; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miyazaki H, 1999, LIFE SCI, V64, P869, DOI 10.1016/S0024-3205(99)00011-9; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; PERSSON L, 1989, STROKE, V20, P641, DOI 10.1161/01.STR.20.5.641; RICE FL, 1995, BARREL CORTEX RODENT, P1; RUBINO GJ, 1988, STROKE, V19, P870, DOI 10.1161/01.STR.19.7.870; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schiene K, 1999, J NEUROL SCI, V162, P6, DOI 10.1016/S0022-510X(98)00292-5; Staiger JF, 2000, NEUROSCIENCE, V99, P7, DOI 10.1016/S0306-4522(00)00166-4; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; WEI L, 1995, STROKE, V26, P1459, DOI 10.1161/01.STR.26.8.1459; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WELKER C, 1974, J COMP NEUROL, V158, P437, DOI 10.1002/cne.901580405; WELKER C, 1976, J COMP NEUROL, V166, P173, DOI 10.1002/cne.901660205; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Zhang L, 2000, J NEUROL SCI, V174, P141, DOI 10.1016/S0022-510X(00)00268-9	53	24	29	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	NOV	2001	32	11					2615	2623		10.1161/hs1101.097384			9	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	490PG	WOS:000172059800030	11692026	Bronze, Green Published			2021-06-18	
J	Kieslich, M; Marquardt, G; Galow, G; Lorenz, R; Jacobi, G				Kieslich, M; Marquardt, G; Galow, G; Lorenz, R; Jacobi, G			Neurological and mental outcome after severe head injury in childhood: a long-term follow-up of 318 children	DISABILITY AND REHABILITATION			English	Article							EVOKED-POTENTIALS; RISK-FACTORS; PREDICTION	Purpose: Identification of prognostic risk factors in paediatric head injury. Method: Long-term follow-up of 318 children with severe head injuries with a mean follow-up period of 8 years and 9 months. The neurological and mental outcome was classified by the Glasgow Outcome Scale and the Frankfurt Mental Outcome Scale. Results: Prognostic risk factors were a primary post-traumatic vigilance disturbance longer than 24 hours, less than seven points on the Glasgow Coma Scale, an increased intracranial pressure with cerebral perfusion pressure below 50 mmHg, age at accident younger than 2 years, physical abuse and the development of post-traumatic epilepsy. Conclusions: The infant brain is more vulnerable to lasting deficits and is more prone to post-traumatic seizure development. Post-traumatic epilepsy itself causes a deterioration in outcome because of the developmental disturbance at epilepsy onset and often unfavourable course. Physically abused children with their often multiple and repeated head injuries are predestined for poor outcome.	Univ Frankfurt, Dept Paediat, D-6000 Frankfurt, Germany; Univ Frankfurt, Dept Neurosurg, D-6000 Frankfurt, Germany	Kieslich, M (corresponding author), Univ Frankfurt, Dept Paediat, D-6000 Frankfurt, Germany.						DUSSER A, 1989, ELECTROEN CLIN NEURO, V73, P85, DOI 10.1016/0013-4694(89)90187-9; Gjerris F, 1986, Acta Neurochir Suppl (Wien), V36, P155; GORDON NS, 1983, NEUROPEDIATRICS, V14, P3, DOI 10.1055/s-2008-1059545; HANS P, 1989, J NEUROSURG, V71, P54, DOI 10.3171/jns.1989.71.1.0054; HENDRICK EB, 1968, J TRAUM, V8, P547; JACOBI G, 1988, KLIN PADIATR, V200, P359, DOI 10.1055/s-2008-1033735; JACOBI G, 1983, EXTR PAEDIAT, V7, P275; JENNETT B, 1973, DEV MED CHILD NEUROL, V15, P56; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT WB, 1975, LANCET, V325, P480; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; KIESLICH M, 1995, LANCET, V345, P187, DOI 10.1016/S0140-6736(95)90188-4; KRETSCHMER H, 1983, NEUROPEDIATRICS, V14, P176, DOI 10.1055/s-2008-1059574; LANGECOSACK H, 1973, HIRNTRAUMA KINDES JU; OTTAVIANI F, 1986, ELECTROEN CLIN NEURO, V65, P196, DOI 10.1016/0168-5597(86)90054-7; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; ROBERTS AH, 1976, P ROY SOC MED, V1, P137; RUIJS MBM, 1993, NEUROPEDIATRICS, V24, P307, DOI 10.1055/s-2008-1071562; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; Shokunbi T, 1994, West Afr J Med, V13, P38; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784	25	24	25	2	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	OCT	2001	23	15					665	669					5	Rehabilitation	Rehabilitation	481AN	WOS:000171496300003	11720116				2021-06-18	
J	Radanov, BP; Di Stefano, G; Augustiny, KF				Radanov, BP; Di Stefano, G; Augustiny, KF			Symptomatic approach to posttraumatic headache and its possible implications for treatment	EUROPEAN SPINE JOURNAL			English	Article						head trauma; whiplash injury; chronic posttraumatic headache; migraine; tension headache	TENSION-TYPE HEADACHE; TRAUMATIC BRAIN INJURY; CERVICOGENIC HEADACHE; WHIPLASH INJURY; MIGRAINE; PATHOPHYSIOLOGY; MECHANISMS; RECOVERY; SPECT; PAIN	We investigated 112 patients (mean age 39.5+/-10.5 years, 59% women (n=66)] with chronic posttraumatic headache following cranio-cervical acceleration/deceleration trauma after an average time interval of 2.5+/-1.9 years from trauma. Headache following minor head injury or whiplash is one of the most prominent problems in neurotraumatology. Previous research is inconclusive regarding the symptomatic approach of this type of headache. Details of the phenomenology of posttraumatic headache in the previous literature are inconclusive. This may lead to inappropriate treatment strategies, because recent advances in therapy of different headache types may be neglected. Patients were investigated at the outpatient service of the Department of Psychiatry. Headache was analyzed according to its principal location, laterality, projection, quality, precipitation or aggravation and possible additional symptoms. For this analysis, headache was diagnosed according to the classification of the International Headache Society. The results showed that 42 patients (37%) had tension-type headache, 30 (27%) were identified as suffering from migraine, whereas 20 patients (18%) had cervicogenic headache. An additional 18% of patients suffered from headache that did not fulfill criteria of a particular category. In 104 patients (93%), neck pain was associated in time with headache. Each of the diagnosed headache types in this study may require specific treatment strategies based upon empirical studies of non-traumatic headache types. For these reasons a detailed analysis of headache following cranio-cervical acceleration/deceleration trauma is necessary.	Univ Bern, Inselspital, Dept Psychiat, CH-3010 Bern, Switzerland	Radanov, BP (corresponding author), Univ Bern, Inselspital, Dept Psychiat, CH-3010 Bern, Switzerland.						Adams MA, 1998, WHIPLASH INJURIES CU, P13; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bendtsen L, 1996, J NEUROL NEUROSUR PS, V61, P285, DOI 10.1136/jnnp.61.3.285; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLAU JN, 1994, HEADACHE, V34, P88, DOI 10.1111/j.1526-4610.1994.hed3402088.x; BOVIM G, 1992, PAIN, V51, P43, DOI 10.1016/0304-3959(92)90007-X; Brault JR, 1998, ARCH PHYS MED REHAB, V79, P72, DOI 10.1016/S0003-9993(98)90212-X; ESSELMAN PC, 1995, BRAIN INJURY, V9, P17; EVANS RW, 1992, NEUROL CLIN, V10, P815; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goadsby PJ, 1997, PAIN, V73, P23, DOI 10.1016/S0304-3959(97)00074-2; Haas DC, 1997, NEUROLOGY, V48, P1735, DOI 10.1212/WNL.48.6.1735; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; *HEAD CLASS COMM I, 1998, CEPHALALGIA S7, V8; Hobson DE, 1997, HEADACHE, V37, P253, DOI 10.1046/j.1526-4610.1997.3704253.x; ICHISE M, 1994, J NUCL MED, V35, P217; Jensen R, 1996, CEPHALALGIA, V16, P175, DOI 10.1046/j.1468-2982.1996.1603175.x; Lord SM, 1996, SPINE, V21, P1737, DOI 10.1097/00007632-199608010-00005; MEYER S, 1998, WHIPLASH INJURIES CU, P95; MOSKOWITZ MA, 1993, NEUROLOGY, V43, P16; OMMAYA K, 1975, HDB CLIN NEUROLOGY, P67; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Penning L, 1992, Eur Spine J, V1, P13, DOI 10.1007/BF00302136; RADANOV BP, 1993, BRIT MED J, V307, P652, DOI 10.1136/bmj.307.6905.652; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; SAPER JR, 1997, HEADACHE S1, V37, P1; Schellhas KP, 1996, SPINE, V21, P300, DOI 10.1097/00007632-199602010-00009; SHEA M, 1991, J BIOMECH, V24, P95, DOI 10.1016/0021-9290(91)90354-P; SILBERSTEIN SD, 1994, NEUROLOGY, V44, P6; Sternberg PE, 1997, NEUROLOGY, V48, P1735; STURZENEGGER M, 1995, J NEUROL, V242, P443, DOI 10.1007/BF00873547; TRELEAVEN J, 1994, CEPHALALGIA, V14, P273, DOI 10.1046/j.1468-2982.1994.1404273.x; Wallis BJ, 1997, PAIN, V73, P15, DOI 10.1016/S0304-3959(97)00060-2; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915	36	24	26	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0940-6719			EUR SPINE J	Eur. Spine J.	OCT	2001	10	5					403	407		10.1007/s005860000227			5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	487FQ	WOS:000171863300006	11718194	Green Published			2021-06-18	
J	Basso, A; Previgliano, I; Duarte, JM; Ferrari, N				Basso, A; Previgliano, I; Duarte, JM; Ferrari, N			Advances in management of neurosurgical trauma in different continents	WORLD JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; BRAIN INJURY; EPIDEMIOLOGY; GUIDELINES; TRIAL	Neurotrauma is a major public health problem. The incidence varies from 67 to 317 per 100,000 and mortality rates are in the range of near 1% for minor injury, 18% for mild injury, and 48% for severe head injury. It is the main cause of death and disability in people under 40 years old. Several problems appear when outcome measurements, rehabilitation programs and treatment options are considered: In order to solve these problems a worldwide campaign is outlined. It focuses on epidemiology, prevention, education, treatment, rehabilitation, social reinsertion, and outcome measurements. The goals of such a program are to take into account realities in both developed and developing countries, to develop worldwide acceptable programs and guidelines, and to test those guidelines and programs and diminish mortality and morbidity, improving quality of life. We describe the concept of Centers of Excellence and an educational program, Advanced Brain Life Support. Such a program is a moral obligation because mortality and morbidity tend to decrease in Centers of Excellence.	Buenos Aires Univ Hosp, Dept Neurosurg, RA-1111 Buenos Aires, DF, Argentina; Antartida Private Hosp, Dept Neurosci, RA-1424 Buenos Aires, DF, Argentina; Antartida Private Hosp, Crit Care Unit, RA-1424 Buenos Aires, DF, Argentina	Basso, A (corresponding author), Buenos Aires Univ Hosp, Dept Neurosurg, Ayacucho 1342, RA-1111 Buenos Aires, DF, Argentina.			Duarte, Juan Manuel/0000-0003-0408-0178			Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; de Sousa R M, 1996, Rev Esc Enferm USP, V30, P484; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; JENNETT B, 1977, Lancet, V2, P696; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1997, HEAD INJURY PATHOPHY, P440; JERVARATNAM DR, 1996, BRIT MED J, V312, P944; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Study Group on Head Injury of the Italian Society for Neurosurgery, 1996, J NEUROSURG SCI, V40, P11; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; TORNER IC, 1996, HEAD INJURY POSTCONC, P19; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; YOUNGSU J, 1997, NO SHINKEI GEKA, V25, P529	30	24	25	0	0	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	SEP	2001	25	9					1174	1178					5	Surgery	Surgery	471NB	WOS:000170934500015	11571955				2021-06-18	
J	Sahlas, DJ				Sahlas, DJ			Functional neuroanatomy in the pre-hippocratic era: Observations from the Iliad of Homer	NEUROSURGERY			English	Article						history of medicine; ancient; Homer; nervous system; neuroanatomy; trauma		OBJECTIVE: To describe observations of neurological significance made in the Iliad of Homer and to interpret these relative to pre-Hippocratic concepts of health and disease in Ancient Greece. METHODS: English translations of the Iliad were analyzed for references of neurological significance, and the Homeric Creek was subsequently reviewed for accuracy. Findings are discussed in the context of ancient Creek ideas regarding anatomy and physiology, early descriptions and conceptualizations of the nervous system, ancient Creek theories concerning illness and disease, and the practice of medicine in the pre-Hippocratic era. RESULTS: Descriptions of injuries sustained by soldiers fighting in the Trojan War represent some of the earliest case histories of neurotrauma. Passages in the Iliad describe immediate death after penetrating head trauma with injury to the brain or the brainstem, make reference to clinical signs of brain injury, and mention neurological signs and symptoms after damage to the spinal cord, brachial plexus, and peripheral nerves. CONCLUSION: The Iliad of Homer contains many descriptions of traumatic injury to the nervous system and provides us with 3000-year-old references to some of the basic principles of functional neuroanatomy.	McGill Univ, Montreal Neurol Hosp, Ctr Hlth, Montreal, PQ H3A 2B4, Canada	Sahlas, DJ (corresponding author), McGill Univ, Montreal Neurol Hosp, Ctr Hlth, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.						Adams F., 1886, GENUINE WORKS HIPPOC; BEASLEY AW, 1972, CLIN ORTHOP RELAT R, P10; BEYE CR, 1993, ANCIENT EPIC POETRY, P1; DERENNE JP, 1994, EUR RESPIR J, V7, P2234, DOI 10.1183/09031936.94.07122234; Frolich H, 1879, MILITAR MED HOMERS; FRONIMOPOULOS J, 1990, DOC OPHTHALMOL, V74, P125; Godquin B, 1990, Chirurgie, V116, P136; Knox B., 1990, ILIAD, P3; MCHENRY LC, 1969, HIST NEUROLOGY, P3; METTLER CC, 1947, HIST MED CORRELATIVE; METTLER FA, 1945, RES PUBL ASSOC RES N, V24, P1; Mumford DB, 1996, J PSYCHOSOM RES, V41, P139, DOI 10.1016/0022-3999(96)00091-8; MURRAY AT, 1999, ILIAD HOMER BOOKS 13, V2; MURRAY AT, 1995, ODYSSEY HOMER BOOKS, V1; MURRAY AT, 1999, ILIAD HOMER BOOKS 1, V2; SPILLANE JD, 1981, DOCTRINE NERVES CHAP, P7; Stahl W, 1966, Zahnarztl Prax, V17, P60; STEVENS LA, 1971, EXPLORERS BRAIN, P10; WALKER AE, 1951, HIST NEUROLOGICAL SU, P364; WALKER AE, 1951, HIST NEUROLOGICAL SU, P396; Walshe T M, 1997, J Hist Neurosci, V6, P72	21	24	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUN	2001	48	6					1352	1357		10.1097/00006123-200106000-00037			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	433XG	WOS:000168785500097	11383741				2021-06-18	
J	Cardenas, DD; Haselkorn, JK; McElligott, JM; Gnatz, SM				Cardenas, DD; Haselkorn, JK; McElligott, JM; Gnatz, SM			Bibliography of cost-effectiveness practices in physical medicine and rehabilitation: AAPM&R white paper	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; cerebrovascular accident; cost effective; rehabilitation; spinal cord injuries	SPINAL-CORD-INJURY; OUTPATIENT TREATMENT; EARLY INTERVENTION; LEG ISCHEMIA; HEAD-INJURY; LOW-BACK; STROKE; HIP; BENEFITS; PROGRAM	Cost-effectiveness studies attempt to determine the ratio of costs to outcomes of a particular intervention or treatment and to compare a standard intervention with an alternative intervention to determine if the alternative is more cost effective. The goal is to establish priorities for the resources allocation and to decide among alternative interventions for the same medical condition. The global process of rehabilitation does not usually lend itself to cost-effective analysis (due to the complex set of treatments provided) but rather to specific interventions and specific aspects of outcome. The American Academy of Physical Medicine and Rehabilitation has published a cost effectiveness annotated bibliography on the Internet (http://www.aapmr.org/memphys/cebfinala.htm) that identifies 132 studies in the literature that meet specified criteria and are related to the field of rehabilitation. This White Paper attempts to interpret and synthesize the studies in that bibliography that relate to stroke, spinal cord injury (SCI), orthopedic conditions, pain syndromes, amputations, and traumatic brain injury (TBI). Most studies support the cost effectiveness of care for stroke and SCI in dedicated units or centers rather than in a general medical unit. Studies also support back programs and revascularization procedures in limb ischemia. Studies in TBI underscore the significant financial resources for the care of these patients as well as the potential benefit from rehabilitation services even in the most severely injured. Further high quality research in this area is needed.	Univ Washington, Dept Rehabil Med, Seattle, WA USA; Pitt Cty Mem Hosp, Rehabil Ctr, Grimesland, NC USA; Vet Hlth Adm, Grimesland, NC USA; Univ Med Ctr Eastern Carolina Pitt Cty, Grimesland, NC USA; Univ Missouri, Dept Phys Med & Rehabil, Columbia, MO USA	Cardenas, DD (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA USA.	dianamac@u.washington.edu					Ankjaer-Jensen A, 1994, Ugeskr Laeger, V156, P647; APELQVIST J, 1995, FOOT ANKLE INT, V16, P388, DOI 10.1177/107110079501600702; BACH JR, 1994, CHEST, V105, P1538, DOI 10.1378/chest.105.5.1538; BAKKER C, 1994, J RHEUMATOL, V21, P264; Botel U, 1997, SPINAL CORD, V35, P40, DOI 10.1038/sj.sc.3100345; BROWN KC, 1992, SPINE, V17, P1224, DOI 10.1097/00007632-199210000-00016; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; CAMERON ID, 1994, J CLIN EPIDEMIOL, V47, P1307, DOI 10.1016/0895-4356(94)90136-8; CARDENAS DD, 1998, CRIT REV PHYS REHABI, V10, P359; CICALA RS, 1989, CLIN J PAIN, V5, P223, DOI 10.1097/00002508-198909000-00005; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CZYRNY JJ, 1994, AM J PHYS MED REHAB, V73, P353, DOI 10.1097/00002060-199409000-00009; DACRE JE, 1989, ANN RHEUM DIS, V48, P322, DOI 10.1136/ard.48.4.322; DINKEL R, 1984, AKTUEL RHEUMATOL, V9, P149, DOI 10.1055/s-2008-1048134; Dunn K L, 1994, Rehabil Nurs, V19, P334; Durance J P, 1989, Int Disabil Stud, V11, P127; Eneroth M, 1996, ACTA ORTHOP SCAND, V67, P459, DOI 10.3109/17453679608996668; Falconer J A, 1993, QRB Qual Rev Bull, V19, P8; FALCONER JA, 1993, QRB QUAL REV B, V19, P142; FORSTER DP, 1994, BRIT MED J, P485; Friedlieb O P, 1994, Am J Med Qual, V9, P24, DOI 10.1177/0885713X9400900105; Goossens MEJB, 1998, HEALTH ECON, V7, P39, DOI 10.1002/(SICI)1099-1050(199802)7:1<39::AID-HEC323>3.0.CO;2-S; Gupta S K, 1988, Eur J Vasc Surg, V2, P151, DOI 10.1016/S0950-821X(88)80067-7; HAMMEL JM, 1992, ARCH PHYS MED REHAB, V73, P683; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1989, ARCH NEUROL-CHICAGO, V46, P1098, DOI 10.1001/archneur.1989.00520460084017; HELEWA A, 1989, ARTHRITIS RHEUM, V32, P1505, DOI 10.1002/anr.1780321203; HELEWA A, 1990, ARTHRITIS RHEUM, V33, P1751; Hertel R, 1996, J ORTHOP TRAUMA, V10, P223, DOI 10.1097/00005131-199605000-00001; HOLLINGWORTH W, 1993, BRIT MED J, V307, P903, DOI 10.1136/bmj.307.6909.903; Holloway RG, 1999, STROKE, V30, P1340, DOI 10.1161/01.STR.30.7.1340; HUI E, 1995, STROKE, V26, P1616, DOI 10.1161/01.STR.26.9.1616; Hull RD, 1997, ARCH INTERN MED, V157, P298, DOI 10.1001/archinte.157.3.298; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; JONSSON B, 1991, SCAND J RHEUMATOL, V20, P351, DOI 10.3109/03009749109096811; Jorgensen H S, 1996, Ugeskr Laeger, V158, P4894; JORGENSEN HS, 1997, UGESKRIFT LAEGER, V159, P2570; JORGENSEN HS, 1997, UGESKRIFT LAEGER, V159, P965; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; KALRA L, 1994, STROKE, V25, P912; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Kristiansen I S, 1997, Tidsskr Nor Laegeforen, V117, P2619; KRISTIANSEN IS, 1997, TIDSSKR NOR LAEGEFOR, V117, P3557; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Midha M, 1998, SPINAL CORD, V36, P190, DOI 10.1038/sj.sc.3100532; Moller G, 1992, Int J Technol Assess Health Care, V8, P93; Munin MC, 1998, JAMA-J AM MED ASSOC, V279, P847, DOI 10.1001/jama.279.11.847; NANCE P, 1995, CAN J NEUROL SCI, V22, P22, DOI 10.1017/S0317167100040452; NATHAN PA, 1993, J HAND SURG-AM, V18A, P1044, DOI 10.1016/0363-5023(93)90401-N; Nordstrom DCE, 1996, SCAND J RHEUMATOL, V25, P200, DOI 10.3109/03009749609069988; OAKES DD, 1990, ARCH PHYS MED REHAB, V71, P637; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P117, DOI 10.1097/00002060-199006000-00003; PETITTI DB, 1994, MONOGRAPHS EPIDEMIOL, V24; PINZUR MS, 1988, ORTHOPEDICS, V11, P1051; PRINCE JM, 1995, ARCH PHYS MED REHAB, V76, P919, DOI 10.1016/S0003-9993(95)80067-0; RAVIOLA CA, 1988, ARCH SURG-CHICAGO, V123, P495; Ryden L A, 1988, J Community Health, V13, P222, DOI 10.1007/BF01324234; SHVARTZMAN L, 1992, SPINE, V17, P176, DOI 10.1097/00007632-199202000-00010; SIKORSKI JM, 1993, MED J AUSTRALIA, V159, P23, DOI 10.5694/j.1326-5377.1993.tb137698.x; SIKORSKI JM, 1993, MED J AUSTRALIA, V159, P708, DOI 10.5694/j.1326-5377.1993.tb138095.x; Skargren EI, 1997, SPINE, V22, P2167, DOI 10.1097/00007632-199709150-00015; SMURAWSKA LT, 1994, STROKE, V25, P1628, DOI 10.1161/01.STR.25.8.1628; STODDART GL, 1980, CLIN INVEST MED, V3, P245; SVENSSON M, 1991, HEALTH POLICY, V19, P197, DOI 10.1016/0168-8510(91)90008-L; TATOR CH, 1993, PARAPLEGIA, V31, P700, DOI 10.1038/sc.1993.112; TRAHEY PJ, 1991, AM J OCCUP THER, V45, P397, DOI 10.5014/ajot.45.5.397; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; *US PREV HLTH SCI, 1996, GUID CLIN PREV SERV; VERVERELI PA, 1995, CLIN ORTHOP RELAT R, P208; WEST M, 1991, ARCH PHYS MED REHAB, V72, P127; WESTBROOK L, 1990, CLIN J PAIN, V6, P32, DOI 10.1097/00002508-199003000-00006; Wielink G, 1997, EUR UROL, V31, P441; YASSI A, 1995, OCCUP MED-OXFORD, V45, P209, DOI 10.1093/occmed/45.4.209	75	24	25	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2001	82	5					711	719		10.1053/apmr.2001.24814			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	429RR	WOS:000168531200029	11346857				2021-06-18	
J	Stebbins, P; Pakenham, KI				Stebbins, P; Pakenham, KI			Irrational schematic beliefs and psychological distress in caregivers of people with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							SOCIAL SUPPORT; FAMILY NEEDS; HEAD-INJURY; STRESS; INVENTORY; PATIENT; HEALTH	Objective: To investigate the relation between irrational schematic beliefs and psychological distress in caregivers of persons with traumatic brain injury (TBI). Design: Cross-sectional mail survey. Participants: One hundred sixteen caregivers of persons with TBI living in the Australian states of Victoria and Queensland who were members of community support groups and brain injury associations. Measures: The Irrational Beliefs Inventory, Brief Symptom Inventory, income satisfaction, degree of personality and behavior change in the TBI individual, and injury severity. Results: Hierarchical regression analyses showed that after controlling for the effects of characteristics of the caregiving situation and the individual with TBI, greater adherence to irrational beliefs was related to higher levels of global psychological distress. Specifically, irrational beliefs related to Worrying were associated with all areas of psychological distress. Conclusion: Results support the cognitive theory proposal that irrational beliefs play an important role in the adaptation to TBI caregiving. Findings suggest the inclusion of cognitive therapy strategies in interventions for caregivers.	Univ Queensland, Sch Psychol, Behav Res & Therapy Ctr, Brisbane, Qld 4072, Australia	Pakenham, KI (corresponding author), Univ Queensland, Sch Psychol, Behav Res & Therapy Ctr, Brisbane, Qld 4072, Australia.		Pakenham, Kenneth/A-9973-2008	Pakenham, Kenneth/0000-0002-8653-4593			Abrams M., 1994, BRIT J GUID COUNS, V22, P39; Beck J.S., 1995, COGNITIVE THERAPY BA; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Ellis A., 1975, NEW GUIDE RATIONAL L; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Frosch S, 1997, BRAIN INJURY, V11, P891; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HARRAN SM, 1991, J RATION-EMOT COGN-B, V9, P265; Howlett B, 1994, J RATION-EMOT COGN-B, V12, P205, DOI DOI 10.1007/BF02354548; JACOBS H, 1989, TRAUMATIC BRAIN INJU, P425; Jones R. G., 1969, DISS ABSTR INT B, V29, P4379; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Koopmans P. C., 1994, EUROPEAN J PSYCHOL A, V10, P15; Kosciulek JF, 1997, BRAIN INJURY, V11, P821, DOI 10.1080/026990597123034; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lazarus R.S., 1984, STRESS APPRAISAL COP; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LICHTENBERG JW, 1992, J COUNS DEV, V71, P157, DOI 10.1002/j.1556-6676.1992.tb02191.x; MCNAUGHTON ME, 1995, J NERV MENT DIS, V183, P78, DOI 10.1097/00005053-199502000-00003; MUIR C, 1984, BEHAV ASSESSMENT REH, P89; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Panting A., 1972, REHABILITATION, V38, P33; PERLESZ A, 1992, AUSTR NZ J FAMILY TH, V13, P145, DOI DOI 10.1002/J.1467-8438.1992.TB00910.X; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Selye H., 1974, STRESS DISTRESS; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SHORKEY CT, 1977, EDUC PSYCHOL MEAS, V37, P527, DOI 10.1177/001316447703700232; Stebbins P, 1998, J REHABIL, V64, P15; STEBBINS P, 1997, THESIS DEAKIN U MELB; STEBBINS P, 1997, AUSTR J REHABILITATI, V3, P30; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; Willer B S, 1993, NeuroRehabilitation, V3, P40, DOI 10.3233/NRE-1993-3206; Zanetti O, 1998, INT J GERIATR PSYCH, V13, P358, DOI 10.1002/(SICI)1099-1166(199806)13:6<358::AID-GPS772>3.0.CO;2-J	42	24	25	0	11	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2001	46	2					178	194		10.1037/0090-5550.46.2.178			17	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	472DX	WOS:000170969200006					2021-06-18	
J	Danet, M; Raymond, J; Roy, D				Danet, M; Raymond, J; Roy, D			Distal superior cerebellar artery aneurysm presenting with cerebellar infarction: Report of two cases	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC ANEURYSM; FALSE ANEURYSM; INJURY; NERVE; BRAIN	We report two cases of aneurysm of the distal branches of the superior cerebellar artery presenting with cerebellar infarction, In both cases, the diagnosis required close correlation of the findings from different imaging techniques, as catheter angiography failed to opacify the lesions. In one patient endovascular parent vessel occlusion was performed, whereas in the second patient the aneurysm thrombosed spontaneously, We describe the clinical and radiologic presentation of these aneurysms and discuss their pathogenesis, diagnosis, and treatment.	CHUM, Notre Dame Hosp, Dept Radiol, Montreal, PQ H2L 4M1, Canada	Roy, D (corresponding author), CHUM, Notre Dame Hosp, Dept Radiol, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.		Raymond, Jean/D-3940-2011				AGOSTINIS C, 1992, NEUROLOGY, V42, P457, DOI 10.1212/WNL.42.2.457; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BOZBOGA M, 1996, ACTA NEUROCHIR, V138, P1913; Chaloupka JC, 1996, AM J NEURORADIOL, V17, P1338; COCKRILL HH, 1977, J NEUROSURG, V46, P377, DOI 10.3171/jns.1977.46.3.0377; COLLINS TE, 1992, NEUROSURGERY, V30, P258, DOI 10.1227/00006123-199202000-00020; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; GACS G, 1983, J NEUROSURG, V58, P63, DOI 10.3171/jns.1983.58.1.0063; Jackson MR, 1997, J TRAUMA, V43, P159, DOI 10.1097/00005373-199707000-00041; MABUCHI S, 1992, NEUROSURGERY, V30, P284, DOI 10.1227/00006123-199202000-00027; OBrien D, 1997, ARCH PHYS MED REHAB, V78, P883, DOI 10.1016/S0003-9993(97)90205-7; OIATT JH, 1992, J NEUROSURG, V77, P799; PAPO I, 1977, SURG NEUROL, V7, P15; Piepgras D. G., 1993, BRAIN SURG, P1083; Proust F, 1997, J NEUROSURG, V87, P950, DOI 10.3171/jns.1997.87.6.0950; QUATTROCCHI KB, 1990, NEUROSURGERY, V27, P476, DOI 10.1227/00006123-199009000-00025; Stoodley MA, 1998, NEUROSURG CLIN N AM, V9, P549; YOSHIMOTO T, 1979, CEREBRAL ANEURYSMS, P14	18	24	26	0	1	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2001	22	4					717	720					4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	423CA	WOS:000168156800024	11290485				2021-06-18	
J	Stoffel, M; Rinecker, M; Plesnila, N; Eriskat, J; Baethmann, A				Stoffel, M; Rinecker, M; Plesnila, N; Eriskat, J; Baethmann, A			Role of nitric oxide in the secondary expansion of a cortical brain lesion from cold injury	JOURNAL OF NEUROTRAUMA			English	Article						aminoguanidine; cerebral contusion; lesion growth; L-arginine; N-G-nitro-L-arginine; nitric oxide synthase; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; L-ARGININE; MESSENGER MOLECULE; IMPACT INJURY; RAT; SYNTHASE; EDEMA; AMINOGUANIDINE; INHIBITION; MODEL	We have investigated the role of nitric oxide (NO) as mediator of the secondary growth of a traumatic cortical necrosis. For this purpose, a highly standardized focal lesion of the brain was induced in 46 Sprague-Dawley rats by cold injury. Twenty-four hours later-the timepoint of maximal lesion spread-the animals were sacrificed and brains were removed for histomorphometry of the maximal necrosis area and volume. The animals were divided into five experimental groups. Group I received the NO donor L-arginine as i.v. bolus 10 min prior to trauma (300 mg/kg body weight; n = 10) and a second bolus of the same dosage intraperitoneally 1 h after trauma. Group II (n = 10)-serving as control of group I-was infused with an i.v. bolus of 1 mL/kg isotonic saline 10 min prior to and a subsequent bolus i.p. 1 h after trauma. Group III (n = 8) received 100 mg/kg b.w. of the inducible NOS (iNOS) inhibitor aminoguanidine (AG) 1 h before and 8 1 1 after trauma by intraperitoneal route. Group IV was administered with the nitric oxide synthase (NOS) inhibitor N-G-nitro-L-arginine (L-NNA; 100 mg/kg b.w., i.p.; n = 8); group V-the controls of group III and IV-was administered with isotonic saline (1 mL/kg b.w, i.p.; n = 10) 1 h before and 8 h after trauma. In the control group with i.v./i.p. sham treatment (II), the focal lesion led to a cortical necrosis with a maximum area of 3.1 +/- 0.3 mm(2) and a lesion volume of 5.7 +/- 0.5 mm(3) at 24 h after trauma. In animals with administration of L-arginine, the focal lesion had a maximum area of 3.1 +/- 0.3 mm(2) and a volume of 5.3 +/- 0.5 mm3. Hence, the NO donor did not affect the secondary growth of necrosis. Animals with i.p. sham treatment (group V) had a maximal lesion area of 3.6 +/- 0.2 mm(2) and lesion volume of 6.2 +/- 0.4 mm(3). Administration of aminoguanidine afforded significant attenuation of the lesion growth. Accordingly, the maximal area of necrosis spread only to 2.8 +/- 0.2 mm(2) with a volume of 4.5 +/- 0.5 mm(3), respectively, at 24 h after trauma (p < 0.01 vs group V). On the other hand, administration of L-NNA did not influence the maximal lesion area (3.7 +/- 0.2 mm(2)) or lesion volume (6.5 +/- 0.5 mm(3)) evolving at 24 h after trauma. Thus, neither the enhancement of the formation of NO by L-arginine nor gross inhibition of the synthesis of NO by L-NNA did affect the secondary spread of the necrosis from a focal trauma. The marked attenuation of the posttraumatic necrosis growth by the iNOS inhibitor aminoguanidine strongly indicates an important role of iNOS product in this phenomenon. These findings, thus, demonstrate that the expansion of a primary necrotic focal lesion is a secondary process which can be therapeutically inhibited. Thereby, the growth of a focal tissue necrosis from trauma is clearly identified as a manifestation of secondary brain damage. This information is deemed important for the better understanding of the pathophysiology of traumatic brain injury and for the targeted development of specific treatment modalities.	Univ Bonn, Dept Neurosurg, D-53105 Bonn, Germany; Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-8000 Munich, Germany	Stoffel, M (corresponding author), Univ Bonn, Dept Neurosurg, Sigmund Freud Str 25, D-53105 Bonn, Germany.	michael.stoffel@meb.uni-bonn.de	Plesnila, Nikolaus/T-7522-2019				BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Cockroft KM, 1996, STROKE, V27, P1393, DOI 10.1161/01.STR.27.8.1393; DALKARA T, 1994, AM J PHYSIOL, V267, pH678; DALKARA T, 1994, NEUROPHARMACOLOGY, V33, P1447, DOI 10.1016/0028-3908(94)90048-5; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DAWSON DA, 1992, NEUROSCI LETT, V142, P151, DOI 10.1016/0304-3940(92)90361-A; Dawson T.M., 1995, NEUROSCIENTIST, V1, P7; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; EGGERT HR, 1985, NEUROSURGERY, V16, P443, DOI 10.1227/00006123-198504000-00001; ERISKAT J, 1994, ACTA NEUROCHIR, P425; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Gahm C, 2000, NEUROSURGERY, V46, P169; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KOENIG H, 1989, J NEUROCHEM, V52, P101, DOI 10.1111/j.1471-4159.1989.tb10903.x; LINDSBERG PJ, 1991, J CEREBR BLOOD F MET, V11, P88, DOI 10.1038/jcbfm.1991.10; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIPTON SA, 1997, CEREBROVASC DIS, P210; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAGAFUJI T, 1992, NEUROSCI LETT, V147, P159, DOI 10.1016/0304-3940(92)90584-T; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; PLESNILA N, 1997, J CEREB BLOOD FLOW M, V17, pS73; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Southan GJ, 1996, BRIT J PHARMACOL, V117, P619, DOI 10.1111/j.1476-5381.1996.tb15236.x; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stoffel M, 1997, J NEUROTRAUM, V14, P339, DOI 10.1089/neu.1997.14.339; TRIFILETTI RR, 1992, EUR J PHARMACOL, V218, P197, DOI 10.1016/0014-2999(92)90168-4; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UYLINGS HBM, 1986, J NEUROSCI METH, V18, P19, DOI 10.1016/0165-0270(86)90111-1; VONHOF S, 1997, THESIS L MAXIMILIANS; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WYRWICH W, 1997, THESIS L MAXIMILIANS; YAMAMOTO S, 1992, J CEREBR BLOOD F MET, V12, P717, DOI 10.1038/jcbfm.1992.102	47	24	24	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					425	434		10.1089/089771501750171010			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000006	11336443				2021-06-18	
J	Grundy, PL; Patel, N; Harbuz, MS; Lightman, SL; Sharples, PM				Grundy, PL; Patel, N; Harbuz, MS; Lightman, SL; Sharples, PM			Glucocorticoids modulate the NGF mRNA response in the rat hippocampus after traumatic brain injury	BRAIN RESEARCH			English	Article						traumatic brain injury; fluid percussion; NGF; adrenalectomy; glucocorticoid; hippocampus	NERVE GROWTH-FACTOR; FLUID-PERCUSSION INJURY; MESSENGER-RNA; HEAD-INJURY; BASAL FOREBRAIN; NEUROTROPHIN EXPRESSION; EXCITOTOXIC LESIONS; CHOLINERGIC NEURONS; ADRENAL-STEROIDS; CELL LOSS	Nerve growth factor (NGF) expression in the rat hippocampus is increased after experimental traumatic brain injury (TBI) and is neuroprotective. Glucocorticoids are regulators of brain neurotrophin levels and are often prescribed following TBI. The effect of adrenalectomy (ADX) and corticosterone (CORT) replacement on the expression of NGF mRNA in the hippocampus after TBI has not been investigated to date. We used fluid percussion injury and in situ hybridisation to evaluate the expression of NGF mRNA in the hippocampus 4 h after TBI in adrenal-intact or adrenalectomised rats (with or without CORT replacement). TBI increased expression of NGF mRNA in sham-ADX rats, but not in ADX rats. Furthermore. CORT replacement in ADX rats restored the increase in NGF mRNA induced by TBI. These findings suggest that glucocorticoids have an important role in the induction of hippocampal NGF mRNA after TBI. (C) 2001 Elsevier Science B.V. All rights reserved.	Frenchay Hosp, Acad Ctr, Dept Neurosurg, Neurosurg Res Grp, Bristol BS16 1LE, Avon, England; Univ Bristol, Univ Res Ctr Neuroendocrinol, Bristol BS15 4UB, Avon, England; Univ Bristol, Div Child Hlth, Bristol BS8 1TH, Avon, England	Grundy, PL (corresponding author), Frenchay Hosp, Acad Ctr, Dept Neurosurg, Neurosurg Res Grp, Room 1, Bristol BS16 1LE, Avon, England.	p.l.grundy@bristol.ac.uk		Lightman, Stafford/0000-0002-8546-9646			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; BENGZON J, 1993, NEUROSCIENCE, V53, P433, DOI 10.1016/0306-4522(93)90207-V; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BURKE MA, 1994, EXP NEUROL, V130, P178, DOI 10.1006/exnr.1994.1197; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CONRAD CD, 1995, HIPPOCAMPUS, V5, P1, DOI 10.1002/hipo.450050103; DEKKER AJ, 1992, NEUROSCIENCE, V48, P111, DOI 10.1016/0306-4522(92)90342-Y; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FOLLESA P, 1993, MOL PHARMACOL, V43, P132; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; HARBUZ MS, 1989, J ENDOCRINOL, V122, P705, DOI 10.1677/joe.0.1220705; JACOBSON L, 1989, ENDOCRINOLOGY, V124, P2144, DOI 10.1210/endo-124-5-2144; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LARKFORS L, 1987, J NEUROSCI RES, V18, P525, DOI 10.1002/jnr.490180404; LAUTERBORN J, 1995, NEUROSCIENCE, V68, P363, DOI 10.1016/0306-4522(95)00150-H; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LI YW, 1995, J NEUROSCI, V15, P2888; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LINDHOLM D, 1994, ANN NY ACAD SCI, V746, P195; Lindsay E A, 1989, Am J Health Promot, V3, P11, DOI 10.4278/0890-1171-3.3.11; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCEWEN BS, 1994, ANN NY ACAD SCI, V746, P134; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mocchetti I, 1996, J NEUROSCI, V16, P2141; MUFSON EJ, 1994, J COMP NEUROL, V341, P507, DOI 10.1002/cne.903410407; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCULLY JL, 1995, MOL BRAIN RES, V31, P158; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Shi BT, 2000, EXP NEUROL, V162, P257, DOI 10.1006/exnr.2000.7360; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SUN FY, 1993, NEUROPSYCHOPHARMACOL, V8, P219, DOI 10.1038/npp.1993.24; TAKEDA A, 1993, NEUROSCIENCE, V55, P23, DOI 10.1016/0306-4522(93)90451-K; WHITELEY T, 1999, THESIS U NEWCASTLE U; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613	41	24	29	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 23	2001	892	2					386	390		10.1016/S0006-8993(00)03258-3			5	Neurosciences	Neurosciences & Neurology	403BJ	WOS:000167022400020	11172788				2021-06-18	
J	Wildburger, R; Zarkovic, N; Leb, G; Borovic, S; Zarkovic, K; Tatzber, F				Wildburger, R; Zarkovic, N; Leb, G; Borovic, S; Zarkovic, K; Tatzber, F			Post-traumatic changes in insulin-like growth factor type 1 and growth hormone in patients with bone fractures and traumatic brain injury	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						bone fractures; traumatic brain injury; growth hormone; insulin-like growth factor type 1; heterotopic; ossifications	SEVERE HEAD-INJURY; ENHANCED OSTEOGENESIS; FACTOR-I; IGF-I; CALLUS FORMATION; RATS; EXPRESSION; DENSITY; VITRO; LINK	The aim of the study was to determine whether changes in serum levels of growth hormone (GH) and insulin-like growth factor type 1 (IGF-1) are related to the phenomenon of enhanced osteogenesis in patients with bone fracture combined with traumatic brain injury (TBI), which would also suggest their involvement in posttraumatic stress and their applicability in the promotion of bone fracture healing. GH values were increased during the initial post-traumatic period in all patients (those with bone fractures or TBI alone or combined injury associated with enhanced osteogenesis), declining to normal values afterwards. However, a further increase in GH was only observed in patients with combined injury overlapping with the time of clinically manifested enhanced osteogenesis. Serum levels of IGF-1 were above normal throughout the study period (14 weeks) in patients with TBI only, but not if TBI was combined with bone fractures followed by enhanced osteogenesis. In these patients IGF-1 values increased gradually during fracture healing, as was also the case in patients with bone fractures alone. Thus, different patterns of post-traumatic changes in both GH and IGF-1 were seen in patients with TBI or bone fractures in comparison to those with combined injury, indicating the involvement of these substances in the posttraumatic stress response and in the phenomenon of enhanced osteogenesis in patients with bone fractures and TBI.	Graz Univ, Clin Traumatol, Dept Traumatol, A-8036 Graz, Austria; Graz Univ, Dept Med, A-8036 Graz, Austria; Rudjer Boskovic Inst, Dept Mol Med, Zagreb, Croatia; KBC Rebro, Fac Med, Dept Neuropathol, Zagreb, Croatia; Univ Vienna, Inst Nucl Med, EliTec GMBH, Vienna, Austria	Wildburger, R (corresponding author), Graz Univ, Clin Traumatol, Dept Traumatol, Auenbruggerpl 7A, A-8036 Graz, Austria.		Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			ANDREW JG, 1993, CALCIFIED TISSUE INT, V53, P97, DOI 10.1007/BF01321886; BAGI C, 1995, BONE, V16, P559, DOI 10.1016/8756-3282(95)00078-R; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; CALANDRIELLO B, 1964, Bull Hosp Joint Dis, V25, P170; CANALIS E, 1992, CALCIFIED TISSUE INT, V53, P90; Collins D, 1998, BONE, V23, P13, DOI 10.1016/S8756-3282(98)00066-0; CONOVER CA, 1992, J CLIN ENDOCR METAB, V74, P1355, DOI 10.1210/jc.74.6.1355; DEJERINE MME, 1918, ANN MED, V5, P497; Dore S, 1997, TRENDS NEUROSCI, V20, P326; EHRNBERG A, 1995, ACTA ORTHOP SCAND, V64, P562; Eming SA, 1996, J INVEST DERMATOL, V107, P113, DOI 10.1111/1523-1747.ep12298351; FERRACCIOLI G, 1994, J RHEUMATOL, V21, P1332; Gianotti L, 1998, J ENDOCRINOL INVEST, V21, P115, DOI 10.1007/BF03350325; GILPIN DA, 1994, ANN SURG, V220, P19, DOI 10.1097/00000658-199407000-00004; Hedner E, 1996, J BONE MINER RES, V11, P1952; Jeevanandam M, 1996, NUTRITION, V12, P777, DOI 10.1016/S0899-9007(96)00220-1; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; Nguyen TT, 1996, ANN SURG, V223, P14, DOI 10.1097/00000658-199601000-00004; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; PETERSEN SR, 1995, J TRAUMA, V39, P295, DOI 10.1097/00005373-199508000-00018; Raff T, 1997, CHIRURG, V68, P995, DOI 10.1007/s001040050309; RAISZ LG, 1993, PHYSL PHARM BONE, P229; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; Sell S, 1998, CALCIFIED TISSUE INT, V62, P51, DOI 10.1007/s002239900394; Sherrard RM, 1997, NEUROREPORT, V8, P3225, DOI 10.1097/00001756-199710200-00008; SMITH R, 1987, J BONE JOINT SURG BR, V69, P518; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; Sugimoto T, 1997, J BONE MINER RES, V12, P1272, DOI 10.1359/jbmr.1997.12.8.1272; THALLER SR, 1993, ANN PLAS SURG, V31, P429, DOI 10.1097/00000637-199311000-00007; THALLER SR, 1993, ANN PLAS SURG, V31, P421, DOI 10.1097/00000637-199311000-00006; Trippel SB, 1996, J BONE JOINT SURG AM, V78A, P1272, DOI 10.2106/00004623-199608000-00020; Unneberg K, 1997, EUR J SURG, V163, P779; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WILDBURGER R, 1992, ZBL CHIR, V117, P515; Wildburger R, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P305; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; Wildburger R, 1996, UNFALLCHIRURG, V99, P17; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Wildburger R, 2000, WIEN KLIN WOCHENSCHR, V112, P798; WILDBURGER R, 1995, MED SCI RES, V223, P219; WILDBURGER R, 2000, ERSATZ ERGANZUNGSMET, P370	43	24	32	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0043-5325			WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB 15	2001	113	3-4					119	126					8	Medicine, General & Internal	General & Internal Medicine	405BB	WOS:000167136400010	11253737				2021-06-18	
J	Voller, B; Auff, E; Schnider, P; Aichner, F				Voller, B; Auff, E; Schnider, P; Aichner, F			To do or not to do? Magnetic resonance imaging in mild traumatic brain injury	BRAIN INJURY			English	Article							DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; VEGETATIVE STATE; CONCUSSION; MRI; DIAGNOSIS; LESIONS; HUMANS; SPECT; CT	Clinical quantification of mild traumatic brain injury (MTBI) patients should be based on Glasgow coma scale (GCS) score, duration of loss of consciousness (LOC) and post-traumatic amnesia (PTA). In addition, a short practicable neuropsychological test might be useful in detecting minor memory and attentional deficits. MRI appears to be the most sensitive imaging method for assessing MTBI so far, but information regarding a visualized lesion is not usually utilized in the classification of MTBI. Magnetic resonance imaging (MRI) should, therefore, play a major role in any MTBI classification scheme. An appropriate MRI protocol has to be chosen using at least T-1 weighted, T-2 weighted, proton density and gradient-echo (GRE) sequence images, all in at least two planes, in order to detect and classify all lesions precisely. Owing to the fact that acute lesions may be missed, it is advisable to perform MRI in the first 2 weeks following trauma. Further research is necessary to clarify the relationship between chronic symptoms after MTBI and MRI abnormalities. It may, thus, be possible to provide optimal strategies for emergency department management, to define a group of patients with a need for acute and rehabilitative intervention after MTBI, and to predict their outcome.	OO Landes Nervenklin Wagner Jauregg, Dept Neurol, A-4021 Linz, Austria; Univ Vienna, Dept Neurorehabil, A-1010 Vienna, Austria	Aichner, F (corresponding author), OO Landes Nervenklin Wagner Jauregg, Dept Neurol, Wagner Jauregg Weg 15, A-4021 Linz, Austria.	franz.aichner@wj.lkh.ooe.gv.at		Voller, Bernhard/0000-0001-5809-874X			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 1990, HDB CLIN NEUROLOGY, P43; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; Barzo P, 1997, ACT NEUR S, V70, P243; Beauchamp NJ, 1999, RADIOLOGY, V212, P307, DOI 10.1148/radiology.212.2.r99au16307; COBURN TH, 1989, MILD HEAD INJURY, P37; DOEZEMA D, 1991, ANN EMERG MED, V20, P449; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1994, RADIOLOGY, V191, P1; Goodman JC, 1999, TRAUMATIC BRAIN INJU, P143; JENKINS A, 1986, LANCET, V2, P445; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Schoenhuber R, 1983, J Neurosurg Sci, V27, P157; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Umile EM, 1998, BRAIN INJURY, V12, P577; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wiesmann M, 1998, RADIOLOGE, V38, P645, DOI 10.1007/s001170050405; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WRIGHTSON P, 1989, MILD HEAD INJURY, P246; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	42	24	24	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2001	15	2					107	115		10.1080/026990501458344			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	398BG	WOS:000166733800003	11260761				2021-06-18	
J	Manasse, NJ; Hux, K; Rankin-Erickson, JL				Manasse, NJ; Hux, K; Rankin-Erickson, JL			Speech recognition training for enhancing written language generation by a traumatic brain injury survivor	BRAIN INJURY			English	Article							LEARNING-DISABILITIES; VERBAL IMPAIRMENT; STUDENTS; TECHNOLOGY	Impairments in motor functioning, language processing, and cognitive status may impact the written language performance of traumatic brain injury (TBI) survivors. One strategy to minimize the impact of these impairments is to use a speech recognition system. The purpose of this study was to explore the effect of mild dysarthria and mild cognitive-communication deficits secondary to TBI on a 19-year-old survivor's mastery and use of such a system-specifically, Dragon NaturallySpeaking(R). Data included the % of the participant's words accurately perceived by the system over time, the participant's accuracy over time in using commands for navigation and error correction, and quantitative and qualitative changes in the participant's written texts generated with and without the use of the speech recognition system. Results showed that Dragon NaturallySpeaking(R) was similar to 80% accurate in perceiving words spoken by the participant, and the participant quickly and easily mastered all navigation and error correction commands presented. Quantitatively, the participant produced a greater amount of text using traditional word processing and a standard keyboard than using the speech recognition system. Minimal qualitative differences appeared between writing samples. Discussion of factors that may have contributed to the obtained results and that may affect the generalization of the findings to other TBI survivors is provided.	Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders, Lincoln, NE 68583 USA	Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders, 318E Barkley Mem Ctr, Lincoln, NE 68583 USA.		Hux, Karen/AAQ-2078-2020				ALWANG G, 1998, PC MAGAZINE, V17, P199; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; COLEMAN C L, 1991, AAC (Augmentative and Alternative Communication), V7, P34, DOI 10.1080/07434619112331275663; De la Paz S, 1999, LEARN DISABILITY Q, V22, P173, DOI 10.2307/1511284; HIGGINS EL, 1995, LEARN DISABILITY Q, V18, P159, DOI 10.2307/1511202; Hux K, 1996, INTERV SCH CLIN, V31, P158, DOI 10.1177/105345129603100305; HUX K, IN PRESS AUGMENTATIV; MacArthur CA, 1996, J LEARN DISABIL, V29, P344, DOI 10.1177/002221949602900403; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; WOODCOCK RW, 1989, WEOODCOCKJOHNSON TES; Yorkston K.M., 1996, SENTENCE INTELLIGIBI; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; YOUDIN M, 1980, MED PROG TECHNOL, V7, P139	14	24	24	0	5	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2000	14	11					1015	1034					20	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	373UC	WOS:000165306800007	11104141				2021-06-18	
J	Schmitter-Edgecombe, M; Nissley, HM				Schmitter-Edgecombe, M; Nissley, HM			Effects of divided attention on automatic and controlled components of memory after severe closed-head injury	NEUROPSYCHOLOGY			English	Article							PROCESS-DISSOCIATION PROCEDURE; TRAUMATIC BRAIN INJURY; WORD-STEM COMPLETION; IMPLICIT MEMORY; EXPLICIT MEMORY; UNCONSCIOUS INFLUENCES; HUNTINGTONS-DISEASE; TESTS; PERFORMANCE; FRAMEWORK	The relation between attention available at encoding and automatic and consciously controlled aspects of memory was investigated using the process-dissociation procedure. Twenty-four severely closed-head injured (CHI) participants (> 1 year postinjury) and 24 matched controls studied word lists in full- and divided-attention conditions. Recall cued with word stems was tested. In contrast to consciously controlled memory, the CHI group did not perform more poorly than the controls in estimates of automatic memory. Furthermore, for both groups, the divided-attention manipulation reduced the controlled estimates of memory, whereas automatic influences remained invariant. These results suggest that automatic memory processes may remain partially immune to the deleterious effects of severe CHI or show recovery by 1 year postinjury. They also indicate that automatic memory processes do not require additional attentional resources following severe CHI.	Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03 HD35838] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD035838] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AURENBACH SH, 1987, J HEAT TRAUMA REHABI, V1, P1; BADDELEY AD, 1969, BRIT J PSYCHOL, V60, P51, DOI 10.1111/j.2044-8295.1969.tb01175.x; BADDELEY AD, 1974, RECENT ADV LEARNING, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BARTZ WH, 1970, J EXP PSYCHOL, V84, P380, DOI 10.1037/h0029100; BASSILI JN, 1989, Q J EXP PSYCHOL-A, V41, P439, DOI 10.1080/14640748908402375; BENNET B, 1965, BRIT J PSYCHOL, V56, P413; BLAXTON TA, 1989, J EXP PSYCHOL LEARN, V15, P657, DOI 10.1037/0278-7393.15.4.657; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, CORTEX, V11, P329; BUCHNER A, 1995, J EXP PSYCHOL GEN, V124, P137, DOI 10.1037/0096-3445.124.2.137; CERMAK LS, 1992, BRAIN COGNITION, V20, P367, DOI 10.1016/0278-2626(92)90027-J; Cowan N, 1996, J EXP PSYCHOL GEN, V125, P195, DOI 10.1037/0096-3445.125.2.195; CURRAN T, 1995, J EXP PSYCHOL LEARN, V21, P531, DOI 10.1037/0278-7393.21.3.531; Curran T, 1997, J EXP PSYCHOL LEARN, V23, P496, DOI 10.1037/0278-7393.23.2.496; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dodson CS, 1996, J EXP PSYCHOL GEN, V125, P181, DOI 10.1037/0096-3445.125.2.181; Engle R.W., 1999, MODELS WORKING MEMOR, P102, DOI DOI 10.1017/CBO9781139174909.007; FAHY JF, 1995, J INT NEUROPSYCH SOC, V1, P183; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GRAF P, 1994, EUR J COGN PSYCHOL, V6, P113, DOI 10.1080/09541449408520139; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Hamann SB, 1996, J EXP PSYCHOL LEARN, V22, P933; Hay JF, 1996, J EXP PSYCHOL LEARN, V22, P1323, DOI 10.1037/0278-7393.22.6.1323; HEINDEL WC, 1990, BRAIN COGNITION, V13, P282, DOI 10.1016/0278-2626(90)90053-Q; Hintzman DL, 1997, J EXP PSYCHOL LEARN, V23, P511, DOI 10.1037/0278-7393.23.2.511; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P505, DOI 10.1037/0278-7393.23.2.505; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JACOBY LL, 1989, J EXP PSYCHOL GEN, V118, P115, DOI 10.1037/0096-3445.118.2.115; Jacoby LL, 1998, J EXP PSYCHOL LEARN, V24, P3, DOI 10.1037/0278-7393.24.1.3; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; Jacoby LL, 1997, CARN S COGN, P13; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P484, DOI 10.1037/0278-7393.23.2.484; JERNIGAN TL, 1993, NEUROPSYCHOLOGY, V7, P14, DOI DOI 10.1037/0894-4105.7.1.14; JOORDENS S, 1996, J EXPT PSYCHOL GEN, V122, P462; Kucera H, 1967, COMPUTATIONAL ANAL P; LEVIN HS, 1988, SCAND J REHABIL MED, P33; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; McKone E, 1997, MEM COGNITION, V25, P352, DOI 10.3758/BF03211291; Mulligan NW, 1997, J EXP PSYCHOL LEARN, V23, P280, DOI 10.1037/0278-7393.23.2.280; Mulligan NW, 1998, J EXP PSYCHOL LEARN, V24, P27, DOI 10.1037/0278-7393.24.1.27; Mulligan NW, 1996, MEM COGNITION, V24, P453, DOI 10.3758/BF03200934; Mulligan NW, 1997, MEM COGNITION, V25, P11, DOI 10.3758/BF03197281; NISSEN M, 1986, J HEAD TRAUMA REHAB, V1, P13; PERRUCHET P, 1989, MEM COGNITION, V17, P77, DOI 10.3758/BF03199559; RANDOLPH C, 1991, J CLIN EXP NEUROPSYC, V13, P479, DOI 10.1080/01688639108401065; REEDER KP, 1994, ARCH CLIN NEUROPSYCH, V9, P491, DOI 10.1016/0887-6177(94)90040-X; ROEDIGER HL, 1992, J EXP PSYCHOL LEARN, V18, P1251, DOI 10.1037/0278-7393.18.6.1251; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; ROEDIGER HL, 1994, NEUROPSYCHOLOGY, V8, P284, DOI DOI 10.1037/0894-4105.8.2.284; Sattler JM, 1988, ASSESSMENT CHILDREN; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Schmitter-Edgecombe M, 1999, MEM COGNITION, V27, P512, DOI 10.3758/BF03211545; Schmitter-Edgecombe M, 1996, J Int Neuropsychol Soc, V2, P111; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; SMITH ER, 1988, J EXP SOC PSYCHOL, V24, P490, DOI 10.1016/0022-1031(88)90048-0; Spreen O, 1969, NEUROSENSORY CTR COM; SQUIRE LR, 1992, J EXP PSYCHOL LEARN, V18, P106, DOI 10.1037/0278-7393.18.1.106; SRINIVAS K, 1990, J MEM LANG, V29, P389, DOI 10.1016/0749-596X(90)90063-6; SteMarie DM, 1996, CLIN NEUROPSYCHOL, V10, P25, DOI 10.1080/13854049608406660; TEASDALE G, 1974, LANCET, V2, P81; TOTH JP, 1994, J EXP PSYCHOL LEARN, V20, P290, DOI 10.1037/0278-7393.20.2.290; VAKIL E, 1994, J CLIN EXP NEUROPSYC, V16, P539, DOI 10.1080/01688639408402665; Vakil E, 1997, J Int Neuropsychol Soc, V3, P327; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Wagner AD, 1997, J EXP PSYCHOL LEARN, V23, P305, DOI 10.1037/0278-7393.23.2.305; Watt S, 1999, NEUROPSYCHOLOGY, V13, P338, DOI 10.1037/0894-4105.13.3.338; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1981, WAIS R MANUAL WECHSL; Yonelinas AP, 1996, J EXP PSYCHOL GEN, V125, P422, DOI 10.1037/0096-3445.125.4.422	74	24	24	0	1	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2000	14	4					559	569					11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	363HZ	WOS:000089831000008	11055258				2021-06-18	
J	Henry-Feugeas, MC; Azouvi, P; Fontaines, A; Denys, P; Bussels, B; Maaz, F; Samson, Y; Schouman-Claeys, E				Henry-Feugeas, MC; Azouvi, P; Fontaines, A; Denys, P; Bussels, B; Maaz, F; Samson, Y; Schouman-Claeys, E			MRI analysis of brain atrophy after severe closed-head injury: relation to clinical status	BRAIN INJURY			English	Article							CT-SCAN; VOLUME	The purpose of this study was to determine the clinical correlates of supratentorial ventricular dilations and of corpus callosal atrophy at the subacute stage after a severe closed-head injury (CHI). Thirty-three CHI patients underwent MRI 2 months or more after injury. Morphometric measures were compared to clinical data (coma score, coma duration and Glasgow Outcome Scale). There were numerous significant correlations between clinical data and mid-third ventricle and frontal hems measurements. Fewer significant correlations were found with the lateral ventricle bodies and the corpus callosal body. There was no significant correlation with the posterior part of the corpus callosum and of the ventricles. Corpus callosum atrophy correlated significantly with anterior and deep ventricular dilatation. In conclusion, the best indicator of clinical status was ventriculomegaly, and particularly third ventricle enlargement, which probably reflects the extent of both anterior and deep white matter lesions.	Hop Bichat Claude Bernard, Dept Radiol, F-75877 Paris 18, France; Raymond Poincare Hosp, Garches, France; CEA, Serv Hosp Frederic Joliot, F-91406 Orsay, France	Henry-Feugeas, MC (corresponding author), Hop Bichat Claude Bernard, Dept Radiol, 46 Rue Henri Huchard, F-75877 Paris 18, France.		samson, yves/C-5647-2013	samson, yves/0000-0002-8080-1427			ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Azouvi P., 1993, ANN READAPTATION MED, V36, P1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; ENDO M, 1991, NEURORADIOLOGY, V33, P269; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GOMORI JM, 1984, NEURORADIOLOGY, V26, P21, DOI 10.1007/BF00328197; JENNETT B, 1995, LANCET, V345, P480; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PENN RD, 1978, ANN NEUROL, V3, P216, DOI 10.1002/ana.410030306; REIDERGROSWASSE.I, 1992, AM J ROENTGENOL, V160, P147; TALAIRACH J, 1967, ATLAS ANATOMIE STERE; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZATZ LM, 1983, PSYCHIAT RES, V8, P207, DOI 10.1016/0165-1781(83)90064-1	17	24	24	0	1	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2000	14	7					597	604					8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	335AV	WOS:000088220600001	10914642				2021-06-18	
J	Panizza, M; Castagna, I; di Summa, A; Saibene, L; Grioni, G; Nilsson, J				Panizza, M; Castagna, I; di Summa, A; Saibene, L; Grioni, G; Nilsson, J			Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX)	FUNCTIONAL NEUROLOGY			English	Article						ashworth; botulinum toxin; spasticity; task score; upper limb	TRAUMATIC BRAIN INJURY; UPPER EXTREMITY SPASTICITY; RECIPROCAL INHIBITION; FOREARM MUSCLES; STROKE PATIENTS; DOUBLE-BLIND; DYSTONIA; TRIAL	Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks. In order to study the usefulness of botulinum toxin type A (BTX) as a therapy for spasticity, we studied 15 patients affected by spasticity secondary to stroke. Tests included: clinical evaluation of tone (Ashworth scale); active angles of extension and flexion at elbow and wrist; Hmax/Mmax ratio from flexor carpi radialis (FCR); H-reflex presynaptic inhibition from FCR during vibration; Task score: and video recording. Patients were injected with BTX into one or more muscles with total doses not exceeding 200 International Units (IU). The rests were performed immediately prior to injection and repeated 2 weeks afterwards. Furthermore, in eight patients, testing was also performed one month after BTX injection. Between two weeks and one month after BTX there were no statistically significant differences. A statistically significant difference in the Task and Ashworth scores before and after treatment emerged (p<0.0014), but only 6 patients showed a clear improvement in motor performance. Overall, we observed an improvement in the angle of active extension and flexion at the wrist and elbow. There were no significant changes in the Hmax/Mmax ratio and the H-reflex presynaptic inhibition during vibration. All the patients reported a subjective improvement. The results suggest that subjective benefits can be gained from the use of BTX in patients affected by spasticity, and that the degree of motor improvement seems to depend on the motor recovery obtained before treatment.	IRCCS, Rehabil Inst Castel Goffredo, Salvatore Maugeri Fdn, Lab Clin Neurophysiol, I-46042 Castel Goffredo, MN, Italy			Grioni, Giuseppe/AAC-1927-2020; CASTAGNA, MARISA/AAA-6279-2021	Grioni, Giuseppe/0000-0002-0281-891X; CASTAGNA, MARISA/0000-0002-0888-9612			Bhakta BB, 1996, J NEUROL NEUROSUR PS, V61, P30, DOI 10.1136/jnnp.61.1.30; BURGEN ASV, 1949, J PHYSIOL-LONDON, V109, P10, DOI 10.1113/jphysiol.1949.sp004364; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; DUTTON JJ, 1988, OPHTHALMOLOGY, V95, P1529; Girlanda P, 1997, NEUROREPORT, V8, P3039, DOI 10.1097/00001756-199709290-00008; GRACIES JM, 1997, MUSCLE NERVE       S, V6, pS61; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; JANKOVIC J, 1990, NEUROLOGY, V40, P277, DOI 10.1212/WNL.40.2.277; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; Lance J., 1980, SPASTICITY DISORDERE; Palmer DT, 1998, AM J PHYS MED REHAB, V77, P348, DOI 10.1097/00002060-199807000-00020; Pavesi G, 1998, J NEUROL NEUROSUR PS, V64, P419, DOI 10.1136/jnnp.64.3.419; PIERROTDESEILLI.E, 1999, SPASTICITY MECH TREA, V1, P1; PRIORI A, 1995, BRAIN, V118, P801, DOI 10.1093/brain/118.3.801; Reiter F, 1998, ARCH PHYS MED REHAB, V79, P532, DOI 10.1016/S0003-9993(98)90068-5; Sampaio C, 1997, CLIN REHABIL, V11, P3, DOI 10.1177/026921559701100102; SCOTT AB, 1973, INVEST OPHTH VISUAL, V12, P924; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; VANERMENGEM E, 1979, REV INFECT DIS, V1, P701; Watanabe Y, 1998, DISABIL REHABIL, V20, P62, DOI 10.3109/09638289809166055; Wilson DJ, 1997, BRAIN INJURY, V11, P157, DOI 10.1080/026990597123610; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	25	24	28	2	2	C I C-EDIZIONI INT SRL	ROME	CORSO TRIESTE, 42, 00198 ROME, ITALY	0393-5264	1971-3274		FUNCT NEUROL	Funct. Neurol.	JUL-SEP	2000	15	3					147	155					9	Clinical Neurology	Neurosciences & Neurology	365CB	WOS:000089929900002	11062843				2021-06-18	
J	Watanabe, Y; Shiel, A; Asami, T; Taki, K; Tabuchi, K				Watanabe, Y; Shiel, A; Asami, T; Taki, K; Tabuchi, K			An evaluation of neurobehavioural problems as perceived by family members and levels of family stress 1-3 years following traumatic brain injury in Japan	CLINICAL REHABILITATION			English	Article							HEAD-INJURY; RELATIVES; SCALE	Objective: To ascertain the proportion of patients with traumatic brain injury (TBI) admitted to a Japanese district hospital and to evaluate the levels of stress and anxiety In families living with those TBI patients Design: A retrospective study of patients admitted to hospital from April 1995 to March 1997 and a questionnaire study of family members of survivors. Setting and subjects: All patients referred or transferred to the Emergency Department a? the Saga Medical School Hospital, Japan with a primary diagnosis of TBI were studied. Family members living with TBI patients were sent questionnaires. Main outcome measures: The Barthel index, the Patient Competency Rating Scale, the modified Caregiver Strain Index and the Hospital Anxiety and Depression Scale. Results. There were 34 patients who required hospitalization for care relating to TBI. Of these, nine family members took part in the questionnaire study. Three carers reported fairly high levels of stress and another three carers were considered to be at risk of anxiety and depression. There was a tendency for family members who reported that patients had difficulties in performing behavioural tasks to have higher levels of stress themselves. Conclusion: These preliminary results showed that family members experienced certain levels of stress and were also at risk of anxiety and depression. The Impact of TBI on families as well as patients should receive more attention.	Saga Med Sch, Dept Orthopaed Surg, Saga 8498501, Japan; Univ Southampton, Rehabil Res Unit, Southampton, Hants, England; Saga Med Sch, Dept Emergency Med, Saga 8498501, Japan; Saga Med Sch, Dept Neurosurg, Saga 8498501, Japan	Watanabe, Y (corresponding author), Saga Med Sch, Dept Orthopaed Surg, 5-1-1 Nabeshima, Saga 8498501, Japan.						BARNES M, 1998, REHABILITATION TRAUM; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; Engli M, 1993, J Neurosci Nurs, V25, P78; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kunishio Katsuzo, 1993, Neurologia Medico-Chirurgica, V33, P824, DOI 10.2176/nmc.33.824; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; MIZUOCHI K, 1994, RINSHO RIHEBIRITESHO, P153; *NAT HEAD INJ FDN, 1997, BRAIN INJURY, V11, P821; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OHASHI M, 1992, RINSHO RIHABIRITESHO, V1, P511; Ohta T, 1974, No Shinkei Geka, V2, P623; PRIGATANO GP, 1997, NEUROPSYCHIATR NEURO, V6, P43; PRIGATANO GP, 1986, NEUROPSYCOLOGICAL RE; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wade D T, 1988, Int Disabil Stud, V10, P64; WATANABE Y, 1999, JAPANESE J REHABILIT, V36, P180; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	24	24	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	APR	2000	14	2					172	177		10.1191/026921500666833742			6	Rehabilitation	Rehabilitation	297QX	WOS:000086095100009	10763794				2021-06-18	
J	Levin, HS; Song, J; Scheibel, RS; Fletcher, JM; Harward, HN; Chapman, SB				Levin, HS; Song, J; Scheibel, RS; Fletcher, JM; Harward, HN; Chapman, SB			Dissociation of frequency and recency processing from list recall after severe closed head injury in children and adolescents	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE LESIONS; TEMPORAL-ORDER; MEMORY; INFORMATION; JUDGMENTS; MODEL	To investigate judgment of the frequency and recency of events relative to word list recall in children following closed head injury (CHI), 124 children and adolescents, including 79 severe CHI patients (mean age at test = 13.2 years), 27 mild CHI cases (mean age at test = 12.1 years), and 18 uninjured comparison subjects (mean age = 12.8 years) were studied. The mean postinjury interval was 63.6 months for the severe and 46.7 months for the mild CHI groups. The experimental tasks included estimation of the frequency of presentation of words and designs and recency judgment to select the most recently presented of two stimuli on verbal (words) and nonverbal (faces) tasks. To compare frequency and recency judgments to performance on a task which has been shown to be sensitive to CHI severity and age at test, verbal recall was tested using the California Verbal Learning Test-Children's Version. Severity of CHI (group) affected verbal recall across trials and after delays, but had no effect on estimating frequency and isolated effects on judgment of recency. Age was also primarily related to verbal recall. A subgroup of severe CHI patients with frontal lesions was impaired on delayed recall. The results are discussed in relation to previous research on the effects of CHI on processing the frequency and recency of events.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Texas, Callier Ctr Commun Disorders, Dallas, TX 75235 USA	Levin, HS (corresponding author), PM&R Res Off, 1333 Moursund Ave,Room A205, Houston, TX 77030 USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR02558] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		AGRESTI A, 1994, CATEGORICAL DATA ANA; BIJUR PE, 1990, PEDIATRICS, V86, P337; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; COLTHEART M, 1981, Q J EXP PSYCHOL-A, V33, P497, DOI 10.1080/14640748108400805; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; DELIS D, 1994, CALIFORNIA VERBAL LE; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Fuster J, 1989, PREFRONTAL CORTEX; GOLDMANRAKIC PS, 1987, COGNITIVE NEUROCHEMI, P90; GOLDSTEIN D, 1983, AM J PSYCHOL, V96, P229, DOI 10.2307/1422814; HASHER L, 1984, AM PSYCHOL, V39, P1372, DOI 10.1037/0003-066X.39.12.1372; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HUNKIN NM, 1993, CORTEX, V29, P485, DOI 10.1016/S0010-9452(13)80255-9; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; Kucera H, 1967, COMPUTATIONAL ANAL P; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; McCullagh P., 1989, GEN LINEAR MODELS; MILNER B, 1991, NEUROPSYCHOLOGIA, V29, P601, DOI 10.1016/0028-3932(91)90013-X; MILNER B, 1982, PHILOS T R SOC B, V298, P211, DOI 10.1098/rstb.1982.0083; MOSCOVITCH M, 1992, J COGNITIVE NEUROSCI, V4, P257, DOI 10.1162/jocn.1992.4.3.257; PAIVIO A, 1968, J EXP PSYCHOL, V76, P1, DOI 10.1037/h0025327; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SHIMAMURA AP, 1990, NEUROPSYCHOLOGIA, V28, P803, DOI 10.1016/0028-3932(90)90004-8; SMITH ML, 1988, NEUROPSYCHOLOGIA, V26, P297, DOI 10.1016/0028-3932(88)90082-6; TEASDALE G, 1974, LANCET, V2, P81; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; Wechsler D., 1974, MANUAL WECHSLER INTE; Wheeler M A, 1995, J Int Neuropsychol Soc, V1, P525; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	34	24	24	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2000	22	1					1	15		10.1076/1380-3395(200002)22:1;1-8;FT001			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	287BE	WOS:000085484000001	10649541				2021-06-18	
J	Sherrill-Pattison, S; Donders, J; Thompson, E				Sherrill-Pattison, S; Donders, J; Thompson, E			Influence of demographic variables on neuropsychological test performance after traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							CLOSED-HEAD INJURY; COMPREHENSIVE NORMS; CLINICAL UTILITY; EDUCATION; AGE; RECOVERY; REITAN	The validity of correcting for demographic variables when considering neuropsychological test scores was evaluated in a sample of 136 patients with traumatic brain injury (TBI) who had been screened carefully for premorbid or comorbid confounding factors. When considered in concert with neurological variables, age and education accounted for a significant proportion of the variance in raw scores on the Category Test and the Trail Making Test in the complete sample. Gender did not affect level of test performance. Correcting neuropsychological test scores for demographic variables did not significantly alter their success in identifying patients with severe TBI, but did lead to greater accuracy when classifying individuals with mild-moderate TBI. This investigation concluded that norms that consider the demographic background of the individual are likely to reflect more accurately the neuropsychological status of patients with TBI than interpretations that are based exclusively on raw data.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; Adler Sch Profess Psychol, Chicago, IL USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BORNSTEIN RA, 1988, DEV NEUROPSYCHOL, V4, P17, DOI 10.1080/87565648809540386; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P345, DOI 10.1080/13854049708400463; DEFILIPPIS NA, 1987, BOOKLET CATEGORY TES; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fastenau PS, 1996, J CLIN EXP NEUROPSYC, V18, P444; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P906, DOI 10.1076/jcen.20.6.906.1104; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton RK, 1996, J CLIN EXP NEUROPSYC, V18, P449, DOI 10.1080/01688639608409001; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LECKLITER IN, 1989, J CLIN PSYCHOL, V45, P484, DOI 10.1002/1097-4679(198907)45:4<484::AID-JCLP2270450402>3.0.CO;2-L; MARTIN TA, IN PRESS REHABILITAT; Moses JA, 1999, ARCH CLIN NEUROPSYCH, V14, P445, DOI 10.1016/S0887-6177(98)00030-4; Reitan R M, 1997, Appl Neuropsychol, V4, P16, DOI 10.1207/s15324826an0401_3; Reitan R.M., 1993, HALSTEADREITAN NEURO; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P151, DOI 10.1080/13854049508401597; ShuttleworthJordan AB, 1997, CLIN NEUROPSYCHOL, V11, P205, DOI 10.1080/13854049708407053; TEASDALE G, 1974, LANCET, V2, P81; Vanderploeg RD, 1997, CLIN NEUROPSYCHOL, V11, P210, DOI 10.1080/13854049708407054; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205	30	24	24	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2000	14	4					496	503		10.1076/clin.14.4.496.7196			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	398CD	WOS:000166737600006	11262719				2021-06-18	
J	Byard, RW; Koszyca, B; James, R				Byard, RW; Koszyca, B; James, R			Crossbow suicide: Mechanisms of injury and neuropathologic findings	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						crossbow; suicide; axonal injury; amyloid precursor protein	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; AXONAL INJURY; GUNSHOT WOUNDS; ARROW WOUNDS; MARKER	Crossbow injuries are rarely reported events in modern times. Two cases of death due to self-inflicted crossbow injuries to the head are reported in 2 men aged 18 and 27 years, respectively. Despite relatively low velocity and concussive force, the sharpness and propulsion force of crossbow bolts may be sufficient to enable penetration of the skull at short range. Due to the relatively low concussive force of the crossbow bolt, however, death may not be instantaneous but may occur from intraparenchymal cerebral damage sometime thereafter. Detailed neuropathologic evaluation of such cases may therefore demonstrate "red cell" hypoxic injury, as well as axonal injury, not limited to the region of the missile tract, but widely distributed, even to the point of extensive brain stem involvement. These changes may result from primary mechanical deformation at the time of injury, from secondary hypoxic damage, or from a combination of both factors. Immunohistochemical staining of brains for amyloid precursor protein to delineate more clearly the pattern of axonal damage may assist in determining the extent of injury in such cases.	Univ Adelaide, Forens Sci Ctr, Adelaide, SA, Australia	Byard, RW (corresponding author), State Forens Sci Ctr, 21 Divett Pl, Adelaide, SA 5000, Australia.			Byard, Roger/0000-0002-0524-5942			Alessi F J, 1976, J La State Med Soc, V128, P231; Besler K, 1998, INT J LEGAL MED, V111, P88, DOI 10.1007/s004140050121; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CLAYDON SM, 1993, MED SCI LAW, V33, P349, DOI 10.1177/002580249303300414; DOWNS JCU, 1994, J FORENSIC SCI, V39, P428; Foley V., 1985, SCI AM, V252, P80; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Karger B, 1998, J TRAUMA, V45, P495, DOI 10.1097/00005373-199809000-00011; Koszyca B, 1998, J NEUROTRAUM, V15, P675, DOI 10.1089/neu.1998.15.675; OPESKIN K, 1994, AM J FOREN MED PATH, V15, P14, DOI 10.1097/00000433-199403000-00004; Payne-Gallwey R., 1995, BOOK CROSSBOW; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RANDALL B, 1989, J FORENSIC SCI, V34, P579; ROGERS C, 1990, J FORENSIC SCI, V35, P886; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Taupin JM, 1998, J FORENSIC SCI, V43, P205; 1797, ENCY BRITANNICA, V3, P488; 1797, ENCY BRITANNICA, V2, P211	19	24	24	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-7910			AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	1999	20	4					347	353		10.1097/00000433-199912000-00007			7	Medicine, Legal; Pathology	Legal Medicine; Pathology	267AC	WOS:000084331600007	10624928				2021-06-18	
J	Fujii, T; Yamadori, A; Endo, K; Suzuki, K; Fukatsu, R				Fujii, T; Yamadori, A; Endo, K; Suzuki, K; Fukatsu, R			Disproportionate retrograde amnesia in a patient with herpes simplex encephalitis	CORTEX			English	Article						amnesia; retrograde amnesia; anterograde amnesia; hippocampus; medial temporal lobe	ENDURING MEMORY IMPAIRMENT; ABNORMAL FORGETTING RATE; CLOSED-HEAD INJURY; EPISODIC MEMORY; DEFICIT; CONSOLIDATION; ANTEROGRADE; RETRIEVAL; RECOVERY; SYSTEMS	We describe a patient who developed a severe but temporally limited retrograde amnesia coupled with a relatively mild anterograde amnesia following herpes simplex encephalitis. The patient showed a profound retrograde amnesia for autobiographical events extending for about 10 years prior to the disease onset. Her knowledge about public events and famous persons was also impaired for this period. An MRI and SPECT demonstrated bilateral medial temporal pathology. This case represents a further instance of a relatively focal retrograde amnesia following brain damage. We review other reported cases with focal retrograde amnesia and consider theoretical and neuroanatomical accounts for the present case. Two factors may account for her amnesic patterns: a partial disruption of the store for premorbid binding codes (i.e., information that multimodal feature representations occurred synchronously); along with a relative preservation of the encoding process required to develop new synchronous codes.	Tohoku Univ, Grad Sch Med, Div Disabil Sci, Sect Neuropsychol,Aoba Ku, Sendai, Miyagi 9808575, Japan; Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON, Canada	Fujii, T (corresponding author), Tohoku Univ, Grad Sch Med, Div Disabil Sci, Sect Neuropsychol,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.						ANDREWS E, 1982, CORTEX, V18, P441, DOI 10.1016/S0010-9452(82)80041-5; Calabrese P, 1996, J NEUROL NEUROSUR PS, V61, P304, DOI 10.1136/jnnp.61.3.304; Carlesimo GA, 1998, CORTEX, V34, P449, DOI 10.1016/S0010-9452(08)70767-6; DallaBarba G, 1997, CORTEX, V33, P143, DOI 10.1016/S0010-9452(97)80010-X; DALLASALA S, 1996, METHOD MADNESS CASE, P209; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DeRenzi E, 1997, NEUROPSYCHOLOGIA, V35, P781, DOI 10.1016/S0028-3932(97)00018-3; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; DOBBS AR, 1989, PSYCHOL AGING, V4, P500, DOI 10.1037/0882-7974.4.4.500; Evans JJ, 1996, NEUROCASE, V2, P1; Fukatsu R, 1998, NEUROLOGY, V50, P539, DOI 10.1212/WNL.50.2.539; Fukatsu R, 1994, Rinsho Shinkeigaku, V34, P777; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; HOKKANEN L, 1995, PSYCHOL MED, V25, P203, DOI 10.1017/S0033291700028245; Hunkin N, 1997, CASE STUDIES NEUROPS, P63; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; Ishihara K, 1997, Rinsho Shinkeigaku, V37, P509; Kapur N, 1997, MEMORY, V5, P115, DOI 10.1080/741941152; KAPUR N, 1989, CORTEX, V25, P387, DOI 10.1016/S0010-9452(89)80053-X; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; Kapur N, 1996, J COGNITIVE NEUROSCI, V8, P416, DOI 10.1162/jocn.1996.8.5.416; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; Kopelman M. D., 1990, AUTOBIOGRAPHICAL MEM; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; LUCCHELLI F, 1995, BRAIN, V118, P167, DOI 10.1093/brain/118.1.167; Maravita A, 1995, CORTEX, V31, P653, DOI 10.1016/S0010-9452(13)80018-4; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; Mattioli F, 1996, CORTEX, V32, P121, DOI 10.1016/S0010-9452(96)80021-9; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; Reed JM, 1998, J NEUROSCI, V18, P3943; RempelClower NL, 1996, J NEUROSCI, V16, P5233; ROMANCAMPOS G, 1980, CORTEX, V16, P509, DOI 10.1016/S0010-9452(80)80053-0; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; Rubin DC, 1998, P NATL ACAD SCI USA, V95, P5413, DOI 10.1073/pnas.95.9.5413; Squire LR, 1996, P NATL ACAD SCI USA, V93, P13515, DOI 10.1073/pnas.93.24.13515; Starkstein SE, 1997, NEUROCASE, V3, P105, DOI 10.1093/neucas/3.2.105; STRACCIARI A, 1994, CORTEX, V30, P459, DOI 10.1016/S0010-9452(13)80341-3; STUSS DT, 1988, BRAIN COGNITION, V8, P21, DOI 10.1016/0278-2626(88)90036-X; TEYLER TJ, 1986, BEHAV NEUROSCI, V100, P147, DOI 10.1037/0735-7044.100.2.147; YONEDA Y, 1994, EUR NEUROL, V34, P243, DOI 10.1159/000117051; YONEDA Y, 1992, EUR NEUROL, V32, P340, DOI 10.1159/000116857; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	50	24	24	0	5	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	DEC	1999	35	5					599	614		10.1016/S0010-9452(08)70822-0			16	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	275TL	WOS:000084836200001	10656630				2021-06-18	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Brain free magnesium concentration is predictive of motor outcome following traumatic axonal brain injury in rats	MAGNESIUM RESEARCH			English	Article						magnesium; neurotrauma; magnetic resonance; brain trauma	INTRACELLULAR FREE MAGNESIUM; CLOSED-HEAD INJURY; METABOLISM; NEURONS; SPECTROSCOPY; RECEPTORS; BLOCKADE; DECREASE; MODEL	A number of studies have supported a role for brain free magnesium as an important secondary injury factor in the development of neurologic deficits following traumatic brain injury. Despite this, few studies have characterised free magnesium changes in diffuse models of brain injury relevant to clinical trauma, and none have critically examined the association between brain free magnesium concentration and degree of neurologic deficit following graded trauma. In the present study, a combination of nuclear magnetic resonance spectroscopy and rotarod motor function tests were used to characterise the relationship between brain free magnesium concentration and neurologic motor function following graded traumatic axonal brain injury in rats. Induction of moderate or severe impact-acceleration induced traumatic brain injury resulted in a profound decline (p < 0.01) in brain free magnesium concentration that persisted for a minimum of 4 days postrauma in both injury groups. Posttraumatic rotarod deficits assessed on a daily basis after injury were linearly correlated with brain free magnesium concentration measured in the same animals immediately after the motor tests were performed (r = 0.87; p < 0.001). These results suggest that brain free magnesium declines following graded diffuse axonal brain injury and that the concentration of the ion after trauma may be a prognostic indicator of motor outcome following.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	Vink, R (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ANDERSON D, 1994, NEUROBIOLOGY CENTRAL; Bara M, 1984, MAGNESIUM, V3, P212; BIRCH NJ, 1993, MAGNESIUM CELL; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fearnside MR, 1997, HEAD INJURY PATHOPHY, P3; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; ISHIGE M, 1987, J NEUROSURG, V6, P848; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MULLINS PGM, 1995, NEUROREPORT, V6, P1633, DOI 10.1097/00001756-199508000-00011; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SMITH BF, 1993, INT HIST REV, V15, P211; Suzuki M, 1997, GEN PHARMACOL, V28, P119, DOI 10.1016/S0306-3623(96)00148-6; TERASAKI M, 1985, P NATL ACAD SCI USA, V82, P7324, DOI 10.1073/pnas.82.21.7324; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; Vink R, 1996, J NEUROCHEM, V66, P2477; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	42	24	26	0	0	JOHN LIBBEY & CO LTD	LONDON	13 SMITHS YARD, SUMMERLEY ST, LONDON SW18 4HR, ENGLAND	0953-1424			MAGNESIUM RES	Magnes. Res.	DEC	1999	12	4					269	277					9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	264ZB	WOS:000084212800004	10612084				2021-06-18	
J	Laatsch, L; Pavel, D; Jobe, T; Lin, Q; Quintana, JC				Laatsch, L; Pavel, D; Jobe, T; Lin, Q; Quintana, JC			Incorporation of SPECT imaging in a longitudinal cognitive rehabilitation therapy programme	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; RECOVERY	In this clinical study, five consecutive referrals to a cognitive rehabilitation therapy (CRT) programme were followed in a longitudinal protocol involving a resting SPECT and neuropsychological evaluation at pre-treatment, post-treatment, and post non-treatment intervals. All clients had acquired brain injury and initially demonstrated neuropsychological deficits and various degrees of hypoperfusion on SPECT. Statistical Parametric Mapping (SPM) was used to evaluate change in successive SPECT images. Following CRT, all clients were able to return to productive employment or schooling. Examination of the neuropsychological testing results revealed significant improvement in performance following CRT which were generally maintained during the non-treatment period. SPM analysis of the SPECT data revealed that, in a majority of cases, most of the significant increases in relative cerebral blood flow redistribution were seen during the treatment period, rather than the non-treatment period. The results suggest that, even in individuals who are more than 2 years post-brain damage, relative increases in rCBF can be demonstrated following individualized CRT and that most of these changes can be related to improvements on neuropsychological tests.	Univ Illinois, Coll Med, Chicago, IL 60612 USA	Laatsch, L (corresponding author), Univ Illinois, Coll Med, 901 S Wolcott Ave,Room W-130, Chicago, IL 60612 USA.						BACHYRITA P, 1992, J NEURO REHAB, V6, P191; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; BOLGER JF, 1980, CLIN NEUROPSYCHOLOGY, V4, P66; BRACY OE, 1994, SOFT TOOLS COGNITIVE; Brown L., 1990, TEST NONVERBAL INTEL; CHOCA J, 1993, ADAPTIVE COMPUTERIZE; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Christensen C K, 1987, J Diabet Complications, V1, P45, DOI 10.1016/S0891-6632(87)80079-X; COSTA DC, 1994, NEW TRENDS NUCL NEUR; DELIS D, 1987, CALIFORNIA VERBAL LE; ELLE P, 1985, LANCET, V2, P50; FIRSTON K, 1995, HUMAN BRAIN MAPPING, V1, P214; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GIANUTSOS R, 1996, COMPUTER PROGRAMS CO, V7; GOLDEN C, 1978, STROOP TEST; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton R. K, 1981, WISCONSIN CARD SORTI; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; KNOPMAN DS, 1984, ANN NEUROL, V15, P530, DOI 10.1002/ana.410150604; Laatsch L, 1997, BRAIN INJURY, V11, P851; LAATSCH L, 1983, COGNITIVE REHABILITA, V1, P15; LAATSCH L, 1985, COGNITIVE REHABILITA; Luria A. R., 1981, WORKING BRAIN; MEYERS T, 1995, REY COMPLEX FIGURE T; PANTANO P, 1992, INT J NEUROSCI, V66, P153; PARENTE M, 1996, RETRAINING COGNITION; PAVEL D, 1996, RADIOLOGY, P201; PAVEL DG, 1997, J NUCL MED S, V38, P280; Umile EM, 1998, BRAIN INJURY, V12, P577; Wechsler D., 1987, WECHSLER MEMORY SCAL; WECHSLER D, 1987, WECSHLER ADULT INTEL	32	24	26	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1999	13	8					555	570		10.1080/026990599121304			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200001	10901685				2021-06-18	
J	Stover, JF; Pleines, UE; Morganti-Kossmann, MC; Stocker, R; Kossmann, T				Stover, JF; Pleines, UE; Morganti-Kossmann, MC; Stocker, R; Kossmann, T			Thiopental attenuates energetic impairment but fails to normalize cerebrospinal fluid glutamate in brain-injured patients	CRITICAL CARE MEDICINE			English	Article						barbiturate coma; cerebrospinal fluid; electroencephalogram; glutamate; hypoxanthine; intracranial pressure; lactate; thiopental; traumatic brain injury	EXCITATORY AMINO-ACIDS; SEVERE HEAD-INJURY; CORTICAL ACTIVITY; RAT; ISCHEMIA; RELEASE; ANESTHETICS; ACCUMULATION; MECHANISMS; INHIBITOR	Objectives: Brain-injured patients are susceptible to secondary brain damage related to decreased cerebral perfusion pressure associated with edema formation and increased intracranial pressure (ICP). Whenever conventional therapy fails to reduce elevated ICP, barbiturate coma represents an additional intervention that may control ICP. In patients suffering from severe traumatic brain injury, cerebrospinal fluid levels of glutamate, hypoxanthine, and lactate were measured during barbiturate coma and correlated to electroencephalographic recordings and ICP. Design: Prospective, descriptive study. Setting: Ten-bed surgical intensive care unit in a university hospital. Patients: Twenty-one patients with severe traumatic brain injury (Glasgow Coma Scale score less than or equal to 9); 11 required barbiturate coma because of refractory intracranial hypertension, and 10 were manageable with continuous administration of fentanyl and midazolam. Interventions: Thiopental was administered continuously for increased ICP within the first 24 hrs after trauma and adjusted to the burst-suppression pattern (four to six bursts per minute) on continuous electroencephalographic monitoring. Measurements and Main Results: Glutamate and hypoxanthine were analyzed using high-performance liquid chromatography, whereas lactate was measured enzymatically. Patients requiring thiopental presented with significantly higher ICP, glutamate, and hypoxanthine levels than patients receiving fentanyl and midazolam (p < .05). Within the first 24 hrs, thiopental significantly reduced cerebrospinal fluid glutamate and hypoxanthine levels in all patients, i.e., the burst-suppression pattern was successfully induced (p < .001). Interestingly, in five patients cerebrospinal fluid glutamate increased to initial values again despite unchanged neuronal activity. In these patients, ICP, hypoxanthine, and lactate remained significantly elevated compared with the six patients with steadily decreasing cerebrospinal fluid glutamate, hypoxanthine, lactate, and ICP values (p < .02). Conclusions: Barbiturate coma does not unequivocally preserve energetic stability despite successful suppression of neuronal activity. Despite the use of barbiturate coma in patients with refractory intracranial hypertension, persistent release or impaired uptake of glutamate may be associated with continuous anaerobic metabolism, as shown by increases in cerebrospinal fluid hypoxanthine and lactate levels.	Univ Zurich Hosp, Div Trauma Surg, Dept Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Surg Res, CH-8091 Zurich, Switzerland	Stover, JF (corresponding author), Charite Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			Amakawa K, 1996, ANESTHESIOLOGY, V85, P1422, DOI 10.1097/00000542-199612000-00024; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BALCAR VJ, 1978, BIOCHEM PHARMACOL, V27, P2955, DOI 10.1016/0006-2952(78)90214-9; BARKER JL, 1977, J PHYSL, V280, P355; BICKLER PE, 1995, ANESTHESIOLOGY, V83, P1233, DOI 10.1097/00000542-199512000-00014; BIEBUYCK JF, 1993, ANESTHESIOLOGY, V78, P615; CARLA V, 1992, NEUROSCI LETT, V146, P21, DOI 10.1016/0304-3940(92)90162-Z; DAGANI F, 1987, J NEUROCHEM, V49, P1229, DOI 10.1111/j.1471-4159.1987.tb10015.x; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DeWitt D S, 1995, New Horiz, V3, P376; EBLING WF, 1991, J PHARMACOKINET BIOP, V19, P123, DOI 10.1007/BF01073865; HAGBERG H, 1986, NEUROSCI LETT, V68, P311, DOI 10.1016/0304-3940(86)90508-2; HANSSON E, 1994, NEUROSCIENCE, V63, P1057, DOI 10.1016/0306-4522(94)90572-X; Ito T, 1996, LIFE SCI, V59, P169, DOI 10.1016/0024-3205(96)00199-3; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KIMELBERG HK, 1989, MOL CHEM NEUROPATHOL, V11, P1, DOI 10.1007/BF03160036; LEVIN SD, 1984, J NEUROL NEUROSUR PS, V47, P730, DOI 10.1136/jnnp.47.7.730; Lukatch HS, 1996, ANESTHESIOLOGY, V84, P1425, DOI 10.1097/00000542-199606000-00019; MADL JE, 1993, J NEUROSCI, V13, P4429; McIntosh TK, 1996, LAB INVEST, V74, P315; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P315, DOI 10.1097/00000542-197009000-00008; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; MUELLER RA, 1988, CELL MOL NEUROBIOL, V8, P235, DOI 10.1007/BF00711249; NEHLS DG, 1987, ANESTHESIOLOGY, V66, P453, DOI 10.1097/00000542-198704000-00002; NELSON SR, 1968, J NEUROCHEM, V15, P1271, DOI 10.1111/j.1471-4159.1968.tb05904.x; NICOLL RA, 1975, P NATL ACAD SCI USA, V72, P1460, DOI 10.1073/pnas.72.4.1460; NICOLL RA, 1975, NATURE, V258, P625, DOI 10.1038/258625a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORDBY HK, 1984, ACTA NEUROCHIR, V72, P157, DOI 10.1007/BF01406868; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OLNEY JW, 1986, NEUROSCI LETT, V68, P29, DOI 10.1016/0304-3940(86)90224-7; Phillis JW, 1997, BRAIN RES, V758, P9, DOI 10.1016/S0006-8993(97)00155-8; STOCKER R, 1995, INTEGRATED APPROACH, P196; Stover JF, 1997, NEUROSCI LETT, V238, P25, DOI 10.1016/S0304-3940(97)00840-9; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; Stover JF, 1998, EUR NEUROL, V39, P223, DOI 10.1159/000007938; TORP R, 1991, NEUROSCIENCE, V41, P433, DOI 10.1016/0306-4522(91)90339-P; Wilberger J E, 1995, New Horiz, V3, P469; WONG EHF, 1991, ANNU REV PHARMACOL, V31, P401; YOSHIDA S, 1983, J NEUROCHEM, V40, P1278, DOI 10.1111/j.1471-4159.1983.tb13567.x; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	45	24	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	1999	27	7					1351	1357		10.1097/00003246-199907000-00028			7	Critical Care Medicine	General & Internal Medicine	224NZ	WOS:000081906300019	10446831				2021-06-18	
J	Mattioli, F; Miozzo, A; Vignolo, LA				Mattioli, F; Miozzo, A; Vignolo, LA			Confabulation and delusional misidentification a four year follow-up study	CORTEX			English	Article						confabulation; misidentification; autobiographical memory; closed head injury; frontal lobe; temporal lobe	FRONTAL-LOBE DYSFUNCTION; RETRIEVAL; INJURY	We describe a patient, AZ, who showed, in addition to an amnesic syndrome which eventually improved, longstanding confabulation and delusional misidentification following bilateral frontal and right temporal post-traumatic lesions. Confabulation appeared in personal recollections and on long-term verbal memory testing. Misidentification concerned mainly his wife and house. During the four year follow-up AZ's confabulation progressively shrinked so as to become restricted to verbal memory tasks. By contrast, misidentification persisted. General semantic memory was unimpaired throughout, while performance on frontal tests was initially poor and partly improved in time. We argue that confabulation and misidentification, though often intermingled and occurring after similar lesion pattern, should be considered as different neuropsychological entities.	Univ Brescia, Neurol Clin, Neuropsychol Lab, I-25125 Brescia, Italy	Mattioli, F (corresponding author), Univ Brescia, Neurol Clin, Neuropsychol Lab, Spedali Civili, I-25125 Brescia, Italy.						Alexander I., 1979, COMPUTERS DIGITAL TE, V2, P29; BADDELEY AD, 1986, AUTOBIOGRAPHICAL MEM; BENSON DF, 1976, NEUROLOGY, V26, P147, DOI 10.1212/WNL.26.2.147; Capgras Joseph, 1923, B SOC CLIN MED MENTA, P6; Conway MA, 1996, NEUROCASE, V2, P325; Dalla Barba G, 1997, NEUROCASE, V3, P425, DOI 10.1093/neucas/3.6.425; DallaBarba G, 1997, CORTEX, V33, P563, DOI 10.1016/S0010-9452(08)70237-5; DALLABARBA G, 1993, CORTEX, V29, P567, DOI 10.1016/S0010-9452(13)80281-X; DALLABARBA G, 1993, COGN NEUROPSYCHOL, V10, P1; Elliott ML, 1996, BRAIN INJURY, V10, P703, DOI 10.1080/026990596123972; Feinberg TE, 1997, BEHAV NEUROLOGY NEUR; FISHER RS, 1995, J CLIN EXPT NEUROPSY, V17, P209; HAYMAN MA, 1977, BRIT J PSYCHIAT, V130, P68, DOI 10.1192/bjp.130.1.68; JOHNSON M, 1997, TRENDS COGNITIVE NEU, V2, P137; JOHNSON MK, 1991, AWARENESS DEFICIT BR; KAPUR N, 1980, J NEUROL NEUROSUR PS, V43, P461, DOI 10.1136/jnnp.43.5.461; KAPUR N, 1988, J NEUROL NEUROSUR PS, V51, P579, DOI 10.1136/jnnp.51.4.579; Kopelman MD, 1995, NEUROCASE, V1, P71, DOI 10.1080/13554799508402348; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; MARIANI C, 1991, J NEUROL, V238, P395, DOI 10.1007/BF00319859; Moscovitch M, 1997, NEUROPSYCHOLOGIA, V35, P1017, DOI 10.1016/S0028-3932(97)00028-6; MOSCOVITCH M, 1989, VARIETIES MEMORY CON; Pick A, 1903, BRAIN, V26, P242, DOI 10.1093/brain/26.2.242; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; Second College, 1982, AM HERITAGE DICT; SPINNLER H, 1987, ITALIAN J NEUROLOGIC, V89, P1837; WEINSTEIN EA, 1969, HDB CLIN NEUROLOGY	27	24	25	0	1	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	JUN	1999	35	3					413	422		10.1016/S0010-9452(08)70809-8			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	219WG	WOS:000081630400008	10440078				2021-06-18	
J	Rothoerl, RD; Woertgen, C; Holzschuh, M; Metz, C; Brawanski, A				Rothoerl, RD; Woertgen, C; Holzschuh, M; Metz, C; Brawanski, A			Rapid evaluation of S-100 serum levels. Case report and comparison to previous results	BRAIN INJURY			English	Article							NEURON-SPECIFIC ENOLASE; ISCHEMIC BRAIN-DAMAGE; CREATINE-KINASE BB; CEREBROSPINAL-FLUID; HEAD-INJURY; PROTEIN; INCREASES; STROKE; NSE; CSF	The aim of this case report is to describe the time course of S-100 serum levels of a patient, after severe head injury, whose blood sample could be drawn very soon after injury. The results were compared to a group of patients in which a correlation between S-100 serum levels and outcome after traumatic brain injury could be demonstrated. Blood samples were taken on admission (mean 2.3 hours), 6, 12 and 24 hours after trauma and then every 24 hours up until and including the fifth day. The outcome was estimated on discharge using the Glasgow Outcome Scale. The S-100 serum level of the patient described in the case report with a favourable outcome had initially risen to 10.0 mu g/l and showed a rapid decline. In the previous group, patients with unfavourable outcome had a S-100 serum level of 7 mu g/l mean concerning the fuse probe (after 2.3 hours mean) compared to 1.5 mu g/l mean (after 2.23 hours mean) in patients with favourable outcome (p < 0.05). In comparison to the literature, there seems to be differences regarding the enzyme liberation in stroke and head injury. Therefore, S-100 serum levels need to be interpreted with regard to collection time and underlying pathology.	Univ Regensburg, Dept Neurosurg, D-8400 Regensburg, Germany; Univ Regensburg, Dept Anesthesiol, D-8400 Regensburg, Germany	Rothoerl, RD (corresponding author), Univ Regensburg Klinikum, Dept Neurosurg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.						BARONE FC, 1993, BRAIN RES, V623, P77, DOI 10.1016/0006-8993(93)90012-C; CUNNINGHAM RT, 1991, EUR J CLIN INVEST, V21, P497, DOI 10.1111/j.1365-2362.1991.tb01401.x; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HAY E, 1984, J NEUROL NEUROSUR PS, V47, P724, DOI 10.1136/jnnp.47.7.724; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; JENNETT B, 1975, LANCET, V1, P480; KRUSE A, 1991, ACTA NEUROCHIR, V110, P106, DOI 10.1007/BF01400675; MARANGOS PJ, 1979, J NEUROCHEM, V33, P319, DOI 10.1111/j.1471-4159.1979.tb11735.x; MARSHALL LF, 1991, J NEUROSURG, V75, pS15; MISSLER U, 1995, EUR J CLIN CHEM CLIN, V33, P743; NARA T, 1988, AM J DIS CHILD, V142, P173, DOI 10.1001/archpedi.1988.02150020075032; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PRANGE HW, 1994, Z KARDIOL, V83, P127; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; TEASDALE G, 1974, LANCET, V2, P81; VAAGENES P, 1986, ARCH NEUROL-CHICAGO, V43, P357, DOI 10.1001/archneur.1986.00520040043017; WOERTGEN C, 1997, ZENTRALBLATT NEUROCH, V17; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	19	24	26	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1999	13	5					387	391					5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	200LE	WOS:000080541100008	10367150				2021-06-18	
J	Kerrigan, DCC; Bang, MS; Burke, DT				Kerrigan, DCC; Bang, MS; Burke, DT			An algorithm to assess stiff-legged gait in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; stiff-legged gait; traumatic brain injury	CONTRALATERAL SHOE-LIFT; CEREBRAL-PALSY; IMMOBILIZED KNEE; RELIABILITY; MANAGEMENT; WALKING	Spastic paretic stiff-legged gait Is a frequently encountered gait problem in patients with traumatic brain injury, as well as in many other patients with upper motor neuron disease. Formerly, spasticity of the quadriceps was considered to be the sole cause of stiff-legged gait. Quantitative gait analysis, however, may implicate hip flexor weakness or poor ankle mechanics as the cause of stiff-legged gait. We discuss the use of an algorithm to evaluate stiff-legged gait in traumatic brain injury using a quantitative gait analysis system such that the specific etiology of stiff-legged gait can be identified and can serve as the basis of a treatment plan.	Harvard Univ, Sch Med, Spaulding Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Ctr Rehabil Sci, Boston, MA USA; Seoul Natl Univ, Coll Med, Dept Rehabil Med, Seoul, South Korea	Kerrigan, DCC (corresponding author), Harvard Univ, Sch Med, Spaulding Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.		Bang, Moon Suk/J-5501-2012				Abdulhadi HM, 1996, ARCH PHYS MED REHAB, V77, P670, DOI 10.1016/S0003-9993(96)90006-4; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Frigo C, 1998, MED BIOL ENG COMPUT, V36, P179, DOI 10.1007/BF02510740; GAGE JR, 1993, CLIN ORTHOP RELAT R, P126; Gage JR, 1989, SEMIN ORTHOP, V4, P72; HARRIS GF, 1994, ARCH PHYS MED REHAB, V75, P216; Kerrigan DC, 1998, GAIT POSTURE, V7, P117, DOI 10.1016/S0966-6362(97)00040-4; KERRIGAN DC, 1994, AM J PHYS MED REHAB, V73, P421, DOI 10.1097/00002060-199411000-00007; KERRIGAN DC, 1991, AM J PHYS MED REHAB, V70, P294; Kerrigan DC, 1997, ARCH PHYS MED REHAB, V78, P1085; KERRIGAN DC, 1998, REHABILITATION MED P; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P489, DOI 10.1097/01241398-199307000-00013; KREBS DE, 1985, PHYS THER, V65, P1027, DOI 10.1093/ptj/65.7.1027; LAGE KJ, 1995, MED SCI SPORT EXER, V27, P8; MURRAY M P, 1984, Journal of Orthopaedic Research, V2, P272, DOI 10.1002/jor.1100020309; OLNEY SJ, 1991, ARCH PHYS MED REHAB, V72, P309; Perry J, 1992, GAIT ANAL NORMAL PAT; Piazza SJ, 1996, J BIOMECH, V29, P723, DOI 10.1016/0021-9290(95)00144-1; SAUNDERS JBDM, 1953, J BONE JOINT SURG AM, V35-A, P543, DOI 10.2106/00004623-195335030-00003; SUTHERLAND DH, 1990, J PEDIATR ORTHOPED, V10, P433; SUTHERLAND DH, 1978, DEV MED CHILD NEUROL, V20, P807; TREANOR WJ, 1969, CLIN ORTHOP RELAT R, P14; WATERS RL, 1979, J BONE JOINT SURG AM, V61, P927, DOI 10.2106/00004623-197961060-00022; WINTER DA, 1995, BEHAV BRAIN RES, V67, P111, DOI 10.1016/0166-4328(94)00154-8; Winter DA., 1991, BIOMECHANICS MOTOR C	25	24	24	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1999	14	2					136	145		10.1097/00001199-199904000-00004			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	187DN	WOS:000079771800004	10191372				2021-06-18	
J	McHenry, MA				McHenry, MA			Aerodynamic, acoustic, and perceptual measures of nasality following traumatic brain injury	BRAIN INJURY			English	Article							LISTENER JUDGMENTS; HYPERNASALITY; FLOW	Data were obtained from 31 subjects who had incurred a traumatic brain injury (TBI). Two expert listeners judged nasality using direct magnitude estimation with a referent. They rated samples of the first sentence of the Rainbow Passage, played backwards, with all pauses removed. Sensitivity was good for nasalance, velopharyngeal airway resistance, and velopharyngeal orifice area, indicating that these measures would accurately identify an individual as nasal. Specificity was reduced, and was adequate only for nasalance. The reduced specificity was due to a high number of false positives, i.e. perceived nasality in the absence of objective corroboration. Analysis of the false positives revealed that a slow speaking rate could mislead a listener's perception of nasality. Overall, for individuals with dysarthria following TBI, the measure of nasalance may most accurately reflect listener perception of nasality.	Galveston Inst Human Commun, Transit Learning Community, Galveston, TX 77550 USA	McHenry, MA (corresponding author), Galveston Inst Human Commun, Transit Learning Community, 1528 PO St, Galveston, TX 77550 USA.						BARLOW S M, 1989, Journal of Voice, V3, P283, DOI 10.1016/S0892-1997(89)80050-5; BARLOW SM, 1991, J COMPUTER USERS SPE, V7, P211; BERRY RC, 1972, J SPEECH HEAR RES, V15, P185, DOI 10.1044/jshr.1501.185; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Counihan D T, 1970, Cleft Palate J, V7, P261; DALSTON RM, 1991, CLEFT PALATE-CRAN J, V28, P184, DOI 10.1597/1545-1569(1991)028<0184:UONAAD>2.3.CO;2; DALSTON RM, 1986, CLEFT PALATE J, V23, P108; DELOREY RM, 1993, AM SPEECH LANG HEAR; EBEL RL, 1951, PSYCHOMETRIKA, V16, P407; ENGEN T, 1971, WOODWORTH SCHLOSBERG, P47; Fairbanks G., 1960, VOICE ARTICULATION D, V, 2nd ed; FLETCHER SG, 1972, J SPEECH HEAR DISORD, V37, P329, DOI 10.1044/jshd.3703.329; FLETCHER SG, 1978, DIAGNOSING SPEECH DI; HARDIN MA, 1992, CLEFT PALATE-CRAN J, V29, P346, DOI 10.1597/1545-1569(1992)029<0346:CBNSAL>2.3.CO;2; KARNELL MP, 1995, CLEFT PALATE-CRAN J, V32, P145, DOI 10.1597/1545-1569(1995)032<0145:NDOHAT>2.3.CO;2; Kent R. D., 1992, ACOUSTIC ANAL SPEECH; McHenry M., 1997, AM J SPEECH-LANG PAT, V6, P55; McHenry MA, 1998, ARCH PHYS MED REHAB, V79, P545, DOI 10.1016/S0003-9993(98)90071-5; McHenry MA, 1996, DISORDERS MOTOR SPEE, P229; NELLIS JL, 1992, CLEFT PALATE-CRAN J, V29, P157, DOI 10.1597/1545-1569(1992)029<0157:CONALJ>2.3.CO;2; SCHIAVETTI N, 1981, J SPEECH HEAR RES, V24, P441, DOI 10.1044/jshr.2403.441; SEAVER EJ, 1991, J SPEECH HEAR RES, V34, P715, DOI 10.1044/jshr.3404.715; SNODGRAS JG, 1975, EXPT SENSORY PSYCHOL, P18; Southwood M. H., 1996, J MED SPEECH-LANG PA, V4, P13; *SPSS INC, 1994, SPSS WIND REL 6 1; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; Titze I.R., 1994, PRINCIPLES VOICE PRO; WARREN D W, 1964, Cleft Palate J, V16, P52; Watterson Thomas, 1993, Journal of Communication Disorders, V26, P13, DOI 10.1016/0021-9924(93)90013-Z; Yorkston K., 1984, COMPUTERIZED ASSESSM; Zajac DJ, 1998, AM J SPEECH-LANG PAT, V7, P95, DOI 10.1044/1058-0360.0703.95	31	24	25	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1999	13	4					281	290		10.1080/026990599121656			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	186RH	WOS:000079742400007	10230529				2021-06-18	
J	Blackard, DO; Jensen, RL; Ebben, WP				Blackard, DO; Jensen, RL; Ebben, WP			Use of EMG analysis in challenging kinetic chain terminology	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article							LOWER-EXTREMITY; BIOMECHANICAL ANALYSIS; REHABILITATION; EXERCISE; KNEE; PERFORMANCE; EXTENSION; INJURY	Purpose: The purpose of this study was to compare mean integrated electromyographic values (EMG(int)) during biomechanically comparable closed kinetic chain/fixed external load, open kinetic chain/moveable no load, and moveable external load exercises. Methods: EMG(int) were obtained for the pectoralis major (PM) and the long head of the triceps (T) during absorption and force phases of three biomechanically comparable exercises: the push-up (PU); the bench press-load (BP-L); and the bench press-no load (BP-NL) equated to the closed kinetic chain/fixed external load; moveable external load; and open kinetic chain/moveable no load conditions respectively. A force plate was used to equate load for the PU and BP-L exercises. Ten males (24 +/- 4.4 yr) participated in the three randomly ordered exercises. A pronated, closed grip was used for all exercises. The mean integrated EMG values from three isometric maximal voluntary contractions were used to determine a reference EMG (EMG(MVC)) for each muscle. Normalized EMG values (NEMG) were determined by EMG(int)/EMG(MVC) and analyzed by one-factor repeated measures ANOVA for each muscle (PM and T) during each phase (absorption and force). Results: There was no significant difference (P > 0.05) between the equivalently loaded, different boundary exercises (PU and BP). Statistical significance (P < 0.05) was determined between the differently loaded, equivalent boundary exercises (BP and BP-NL) as well as the differently loaded, different boundary exercises (PU and BP-NL). Conclusions: Results from this study support the theory that activities of similar biomechanical motions and mass of loading, regardless of the boundary condition, have comparable EMG values of primary muscle groups. In addition, this study suggests external load is more important than boundary condition in describing human activity.	No Michigan Univ, US Olymp Educ Ctr Sports Med, Marquette, MI 49855 USA; No Michigan Univ, Dept Hlth Phys Educ & Recreat, Marquette, MI 49855 USA; Marquette Univ, Dept Strength & Conditioning, Milwaukee, WI 53233 USA	Blackard, DO (corresponding author), No Michigan Univ, US Olymp Educ Ctr Sports Med, Meyland Hall, Marquette, MI 49855 USA.	dblackar@nmu.edu					DAVIES GJ, 1995, J SPORT REHABIL, V4, P1; DeCarlo M., 1992, ISOKINET EXERC SCI, V2, P24; DILLMAN CJ, 1994, J SPORT REHABIL, V3, P228, DOI DOI 10.1123/JSR.3.3.228; GOULD JA, 1990, ORTHOPAEDIC SPORTS P, P77; Graham Victoria L., 1993, Journal of Athletic Training, V28; GRAY GW, 1992, FITNESS MANAGE, V8, P31; GRAY GW, 1989, CHAIN REACTION SUCCE, P1; Howell S M, 1993, Am J Sports Med, V21, P632, DOI 10.1177/036354659302100427; KELSEY DD, 1994, J ORTHOP SPORT PHYS, V19, P218, DOI 10.2519/jospt.1994.19.4.218; LAFREE J, 1995, J SPORT REHABIL, V4, P99; LEE HWM, 1994, J MANUAL MANIPULATIV, V2, P133; LUTZ GE, 1993, J BONE JOINT SURG AM, V75A, P732, DOI 10.2106/00004623-199305000-00014; PALMITIER RA, 1991, SPORTS MED, V11, P402, DOI 10.2165/00007256-199111060-00005; PANARIELLO RA, 1991, NATL STRENGTH COND A, V13, P29; PICCIANO AM, 1993, J ORTHOP SPORT PHYS, V18, P553, DOI 10.2519/jospt.1993.18.4.553; PODESTA L, 1990, CLIN ORTHOP RELAT R, P262; Rivera JE, 2010, J SPORT REHABIL, V3, DOI 10.1123/jsr.3.2.154; ROSENTHAL MD, 1994, J SPORT REHABIL, V3, P218; RUBINSTEIN RA, 1994, AM J SPORT MED, V22, P324, DOI 10.1177/036354659402200305; SAWYERR AM, 1991, ALIMENT PHARM THERAP, V5, P1; SETO JL, 1994, CLIN SPORT MED, V13, P695; SHELBOURNE KD, 1990, AM J SPORT MED, V18, P292, DOI 10.1177/036354659001800313; SHELBOURNE KD, 1994, SPORTS MED, V17, P132, DOI 10.2165/00007256-199417020-00005; SMIDT GL, 1973, J BIOMECH, V6, P79, DOI 10.1016/0021-9290(73)90040-7; STEINDLER A, 1973, KINESIOLOGY HUMAN BO, V63, P436; Stone Jennifer A., 1993, Journal of Athletic Training, V28, P34; White D M, 1993, Am J Sports Med, V21, P633, DOI 10.1177/036354659302100429; WORRELL TW, 1993, J ORTHOP SPORT PHYS, V18, P646, DOI 10.2519/jospt.1993.18.6.646; YACK HJ, 1993, AM J SPORTS MED, V21, P632	29	24	26	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	MAR	1999	31	3					443	448		10.1097/00005768-199903000-00014			6	Sport Sciences	Sport Sciences	176ME	WOS:000079154500014	10188750				2021-06-18	
J	Kolakowsky-Hayner, SA; Kishore, R				Kolakowsky-Hayner, SA; Kishore, R			Caregiver functioning after traumatic injury	NEUROREHABILITATION			English	Article						caregiver functioning; traumatic brain injury; traumatic spinal cord injury; brief symptom inventory; family assessment device	FAMILY ASSESSMENT DEVICE; BRAIN INJURY; MCMASTER MODEL; HEAD-INJURY; FOLLOW-UP; DISTRESS; RELATIVES; SYMPTOMS; SAMPLE; IMPACT	Objectives: Investigate pervasiveness of unhealthy family functioning and psychological distress among primary caregivers of 28 adult outpatients with traumatic injuries. Describe caregiver functioning and psychological distress in caregivers of persons with traumatic brain injury and caregivers of persons with a traumatic spinal cord injury. Determine similarities and differences between the two populations. Study Design: Caregivers completed self-report measures including the Brief Symptom Inventory (BSI) and Family Assessment Device (FAD). Data were matched on respondent's gender, patient's age at injury, ethnicity, and marital status. Descriptive statistics were compiled for all variables. Independent samples t-tests and chi squares were computed to test for between group differences. Results: Similarities found between groups with regard to severity and mechanism of injury. Caregivers exhibited the highest levels of unhealthy functioning with regard to communication skills. Highest levels of healthy functioning were noted with regard to behavioral control. Almost 75% of caregivers reported elevated stress levels. Primary caregivers of persons with SCI report significantly (t(25) = 2.619, p = .015) more stress secondary to phobic anxiety than caregivers of persons with TBI. Conclusion: Previous research demonstrates that the BSI and FAD are valuable clinical tools. Current results suggest they are inappropriate for significantly distinguishing between SCI and TBI caregiver samples.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kolakowsky-Hayner, SA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	sakolako@hsc.vcu.edu	Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909			Alfano D P, 1994, Appl Neuropsychol, V1, P57, DOI 10.1207/s15324826an0101&2_10; BEEBER BJ, 1992, REHABILITATION NURSI, V17, P332; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N, 1984, CLOSED HEAD INJURY P, P123; Canning RD, 1996, J PEDIATR PSYCHOL, V21, P735, DOI 10.1093/jpepsy/21.5.735; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marshall J, 1998, FASEB J, V12, pA179; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199303000-00010, 10.1097/00001199-199303000-00010]; Panting A., 1972, REHABILITATION, V38, P33; Pelletier P M, 1994, Appl Neuropsychol, V1, P38, DOI 10.1207/s15324826an0101&2_8; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	35	24	25	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		1999	13	1					27	33					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	244UT	WOS:000083069700005					2021-06-18	
J	Mazzini, L; Pisano, F; Zaccala, M; Miscio, G; Gareri, F; Galante, M				Mazzini, L; Pisano, F; Zaccala, M; Miscio, G; Gareri, F; Galante, M			Somatosensory and motor evoked potentials at different stages of recovery from severe traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; CENTRAL CONDUCTION TIME; PROGNOSTIC VALUE; COMATOSE PATIENTS; PARIETAL COMPONENTS; RATING-SCALE; SENSORIMOTOR; DISABILITY; RESPONSES; SEP	Objective: To detect changes of somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs) at different stages of recovery from severe brain injury and to determine whether they can be used to predict late functional outcome. Design: Correlational study on a prospective cohort. Setting: Brain injury rehabilitation center. Patients: Twenty-seven consecutively sampled patients with severe traumatic brain injury referred to the inpatient intensive rehabilitation unit of primary care in a university-based system. Main Outcome Measures: (1) Glasgow Outcome Scale, Disability Rating Scale, and Functional Independence Measure: (2) SEPs and MEPs from upper limbs (ULs) and lower limbs (LLs). Outcome was assessed at 6 and 12 months after trauma. Correlations were computed with the nonparametric test of Spearman-Rank. Results: Both SEPs and MEPs showed dynamic changes (p < .02 for N20, p < .05 for N30, P40, and N45), with a trend toward a progressive normalization. N30 was more frequently abnormal than N20. SEPs from LLs were more frequently and more persistently abnormal than those from ULs. Clinical and functional outcome was strongly correlated with the degree of abnormality of SEPs from LLs (p < .002), whereas only mild relationships were found with SEPs from ULs. Both SEPs and MEPs showed a high negative predictive value (83% for N30 and 83% for P40), but only SEPs from LLs also had a high positive predictive value (72% for P40). Sensitivity was 88% both for N30 and P40. Specificity was 50% for N30 and 70% for P40). Conclusion: SEPs from LLs can be very useful in monitoring the postacute phase of traumatic brain injury and in identifying patients who require further intensive rehabilitation. MEPs may be of questionable value. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Fdn Salvatore Maugeri, IRCCS, Ctr Med Veruno, Med Ctr Rehabil,Dept Phys Therapy, I-28010 Veruno, No, Italy; Fdn Salvatore Maugeri, IRCCS, Dept Neurol, Med Ctr Rehabil,Dept Phys Therapy, I-28010 Veruno, No, Italy	Mazzini, L (corresponding author), Fdn Salvatore Maugeri, IRCCS, Ctr Med Veruno, Med Ctr Rehabil,Dept Phys Therapy, I-28010 Veruno, No, Italy.		Mazzini, Letizia/AAA-2262-2021				Altman D. G., 1990, PRACTICAL STAT MED R; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; DESMEDT JE, 1987, ELECTROEN CLIN NEURO, V68, P1, DOI 10.1016/0168-5597(87)90065-7; FACCO E, 1991, ELECTROEN CLIN NEURO, V80, P469, DOI 10.1016/0168-5597(91)90128-K; FACCO E, 1989, ELECTROEN CLIN NEURO, V73, P552, DOI 10.1016/0013-4694(89)90265-4; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENBERG RP, 1982, J NEUROSURG, V56, P1, DOI 10.3171/jns.1982.56.1.0001; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HOULDEN DA, 1992, J TRAUMA, V33, P244, DOI 10.1097/00005373-199208000-00014; JENNETT B, 1975, LANCET, V1, P480; KEREN O, 1994, BRAIN INJURY, V8, P239, DOI 10.3109/02699059409150976; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; MAUGUIERE F, 1983, BRAIN, V106, P271, DOI 10.1093/brain/106.2.271; NAU HE, 1988, NEUROCHIRURGIA, V31, P170; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; TEASDALE G, 1974, LANCET, V2, P81; VECCHIO TJ, 1966, NEW ENGL J MED, V274, P1171, DOI 10.1056/NEJM196605262742104; YING Z, 1992, J NEUROL NEUROSUR PS, V55, P470, DOI 10.1136/jnnp.55.6.470; ZENTNER J, 1988, EEG-EMG-Z ELEK ELEKT, V19, P267; ZENTNER J, 1994, NEUROL RES, V16, P89; ZENTNER J, 1992, NEUROSURGERY, V31, P429, DOI 10.1227/00006123-199209000-00007	31	24	24	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1999	80	1					33	39		10.1016/S0003-9993(99)90304-0			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	155XZ	WOS:000077973000005	9915369				2021-06-18	
J	Fuhrer, MJ; Keith, RA				Fuhrer, MJ; Keith, RA			Facilitating patient learning during medical rehabilitation - A research agenda	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						learning; patient education; medical rehabilitation		Although patient learning is widely acknowledged to be an integral part of many medical rehabilitation practices, it has been the subject of little systematic research. A workshop conducted August 18 to 19, 1997, was organized by the National Center for Medical Rehabilitation Research (National Institute of Child Health and Human Development, National Institutes of Health) and several co-sponsoring organizations to formulate recommendations concerning learning-oriented rehabilitation practices. The recommendations and their supporting rationale are summarized in the topic areas of motor learning and control, cognitive learning, recovery of functioning, generalization and transfer of training, and applications for patients with strokes, traumatic brain injury, amputations, and infants and children.	NICHHD, Natl Ctr Med Rehabil Res, NIH, Rockville, MD 20852 USA; Casa Colina Hosp, Pomona, CA USA	Fuhrer, MJ (corresponding author), NICHHD, Natl Ctr Med Rehabil Res, NIH, Bldg 6100,Room 2A03,6100 Execut Blvd, Rockville, MD 20852 USA.						HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; *NAT I CHILD HLTH, 1993, RES PLAN NAT CTR MED; Wade DT, 1996, J NEUROL NEUROSUR PS, V61, P242, DOI 10.1136/jnnp.61.3.242	3	24	24	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	1998	77	6					557	561		10.1097/00002060-199811000-00022			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	147RZ	WOS:000077487100017	9862546				2021-06-18	
J	Choi, SC; Marmarou, A; Bullock, R; Nichols, JS; Wei, X; Pitts, LH				Choi, SC; Marmarou, A; Bullock, R; Nichols, JS; Wei, X; Pitts, LH		Amer Brain Injury Consortium Study Grp	Primary end points in phase III clinical trials of severe head trauma: DRS versus GOS	JOURNAL OF NEUROTRAUMA			English	Article						Disability Rating Scale; Glasgow Outcome Scale; outcome; traumatic brain injury	DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; BRAIN INJURY; RECOVERY	The most commonly used primary end point in phase III clinical trials of severe head trauma is the Glasgow Outcome Scale (GOS), usually dichotomized to favorable (good) and unfavorable (poor) outcomes. The alternative endpoints include the Disability Rating Scale (DRS) with a 31-point scale, The purpose of this study was to compare DRS and GOS using the data collected from two completed clinical trials organized by the American Brain Injury Consortium and two pharmaceutical companies, The two outcome scales were examined and compared in terms of the correlation between the two scales, sensitivity, and p values between the differences between two arms of the trials. There was no indication that the DRS was more sensitive or advantageous relative to the dichotomized or four-category GOS, In addition, the highly significant correlation between the two outcome scales (r = 0.95; p < 0.0001) could not justify the DRS as an end point. The other problems with the DRS include the difficulty of determining the clinically meaningful difference in designing trials, The study suggested that the GOS is a better primary end point than DRS.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; St Anthony Hosp, Dept Neurosurg, Denver, CO USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Choi, SC (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Box 980032, Richmond, VA 23298 USA.						CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DANIEL WW, 1995, BIOSTATISTICS; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Ingelfinger JA, 1983, BIOSTATISTICS CLIN M; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE GM, 1997, 4 INT NEUR S SEOUL K	8	24	25	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1998	15	10					771	776		10.1089/neu.1998.15.771			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	132LW	WOS:000076632400002	9814633				2021-06-18	
J	Dunn-Meynell, AA; Hassanain, M; Levin, BE				Dunn-Meynell, AA; Hassanain, M; Levin, BE			Norepinephrine and traumatic brain injury: a possible role in post-traumatic edema	BRAIN RESEARCH			English	Article						head trauma; catecholamine; contusion; cerebral edema; somatosensory cortex	SENSORIMOTOR CORTEX INJURY; CEREBRAL BLOOD-FLOW; RAT-BRAIN; NEURONAL DAMAGE; BEAM-WALKING; NORADRENALINE; RECOVERY; ISCHEMIA; IDAZOXAN; PERMEABILITY	Unilateral cerebral contusion is associated with an early (30 min) increase in norepinephrine (NE) turnover followed by a later (6-24 h) depression of turnover which is bilateral and widespread throughout the brain. Blockade of NE function during the first few hours after traumatic brain injury (TBI) impedes subsequent recovery of function without enlarging the size of the lesion. The current studies were carried out to characterize further the timing of the switch from increased to decreased NE turnover and to investigate the pathogenesis of the delayed recovery of function associated with blocking NE function. Adult male rats had unilateral somatosensory cortex contusions made with a 5 mm diameter impact piston. They were killed after 2 h and their brains analyzed for NE turnover by HPLC with electrochemical detection. In general, NE turnover (the ratio of 3-methoxy-4-hyroxyphenylglycol to NE levels) had returned to sham-lesion control levels in most brain regions by 2 h after either left or right sided contusions. The only exceptions were a persistent 87% increase at the lesion site after right-sided contusions and 22% and 32% increases in the contralateral cerebellum after right- and left-sided contusions, respectively. Blockade of alpha(1)-adrenoceptors by treatment with prazosin (3 mg/ kg, i.p.) 30 min prior to TBI produced edema in the striatum and hippocampus at 24 h which was not seen saline-treated rats nor in rats where NE reuptake was blocked with desmethylimipramine (DMI; 10 mg/kg, i.p.). DMI increased edema at the lesion site at 24 h, however. These data suggest that the early increase in NE release following unilateral cerebral contusion is protective and that this may act to stabilize the blood-brain barrier in areas adjacent to the injury site. Drugs that interfere with this enhanced noradrenergic function might enhance the damage caused by TBI. (C) 1998 Elsevier Science B.V. All rights reserved.	Va Med Ctr, Neurol Serv 127C, E Orange, NJ 07018 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Newark, NJ 07103 USA	Levin, BE (corresponding author), Va Med Ctr, Neurol Serv 127C, E Orange, NJ 07018 USA.						BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; DunnMeynell AA, 1997, J NEUROTRAUM, V14, P43, DOI 10.1089/neu.1997.14.43; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; GINSBERG MD, 1985, BRAIN RES, V337, P59, DOI 10.1016/0006-8993(85)91609-9; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; Goldstein LB, 1997, RESTOR NEUROL NEUROS, V11, P55, DOI 10.3233/RNN-1997-111206; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GUSTAFSON I, 1991, EXP BRAIN RES, V86, P555; GUSTAFSON I, 1989, J CEREBR BLOOD F MET, V9, P171, DOI 10.1038/jcbfm.1989.25; GUSTAFSON I, 1990, J CEREBR BLOOD F MET, V10, P885, DOI 10.1038/jcbfm.1990.145; HARIK SI, 1984, ANN NEUROL, V15, P568, DOI 10.1002/ana.410150609; HEILIG M, 1990, J NEURAL TRANSM-GEN, V79, P193, DOI 10.1007/BF01245130; HIAKALA H, 1987, J NEUROCHEM, V49, P1033; IDA Y, 1982, NEUROBIOL AGING, V3, P233, DOI 10.1016/0197-4580(82)90044-6; KAMISAKI Y, 1992, EUR J PHARMACOL, V217, P57, DOI 10.1016/0014-2999(92)90511-2; LAWTHO D, 1993, EUR J NEUROSCI, V5, P1494, DOI 10.1111/j.1460-9568.1993.tb00217.x; LEVIN BE, 1983, BRAIN RES, V289, P205, DOI 10.1016/0006-8993(83)90021-5; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; MOURADIAN RD, 1991, BRAIN RES, V546, P83, DOI 10.1016/0006-8993(91)91162-T; NISHINO K, 1991, NEUROSCIENCE, V43, P361, DOI 10.1016/0306-4522(91)90300-D; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; ROBINSON RG, 1980, BRAIN RES, V188, P63, DOI 10.1016/0006-8993(80)90557-0; SCHANBERG SM, 1968, BIOCHEM PHARMACOL, V17, P247, DOI 10.1016/0006-2952(68)90330-4; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; WESTERINK BHC, 1984, J NEUROCHEM, V42, P934, DOI 10.1111/j.1471-4159.1984.tb12694.x	33	24	25	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 3	1998	800	2					245	252		10.1016/S0006-8993(98)00524-1			8	Neurosciences	Neurosciences & Neurology	107YP	WOS:000075238800008	9685666				2021-06-18	
J	Ghirnikar, RS; Lee, YL; Li, JD; Eng, LF				Ghirnikar, RS; Lee, YL; Li, JD; Eng, LF			Chemokine inhibition in rat stab wound brain injury using antisense oligodeoxynucleotides	NEUROSCIENCE LETTERS			English	Article						blood-brain barrier; chemokines; inflammation; macrophage; trauma	MONOCYTE CHEMOATTRACTANT PROTEIN-1; CENTRAL-NERVOUS-SYSTEM; GRANULOMA-FORMATION; EXPRESSION; LOCALIZATION; MACROPHAGES; PEPTIDE-1	Traumatic injury to the central nervous system (CNS) results in the breakdown of the blood-brain barrier and recruitment of hematogenous cells at the site of injury. The role of chemokines in this process has been well recognized and they have been regarded as promising targets for development of anti-inflammatory therapies. The expression of monocyte chemoattractant protein (MCP-1), in particular, has been closely linked to macrophage infiltration following trauma in rat brain. In this study we determined whether inhibition of MCP-1 following stab wound injury would reduce macrophage infiltration. Stab wound injured Sprague-Dawley rats were infused with MCP-1 sense or antisense oligonucleotides using an Alzet miniosmotic pump (1 mu l/h for 3 days). Three days following injury, widespread gliosis was observed in both groups of rats as judged by glial fibrillary acidic protein (GFAP) immunoreactivity. Immunohistochemistry showed significantly less staining for MCP-1 in antisense treated animals. In addition, the number of macrophages were reduced by 30% in the antisense compared to the sense treated animals (P < 0.05). These results demonstrate that modulation of MCP-1 expression in stab wound injury directly affects monocytic infiltration and provide a basis for MCP-1 inhibition as a therapeutic strategy for controlling inflammatory events of traumatic brain injury. (C) 1998 Elsevier Science Ireland Ltd.	VAPA Hlth Care Syst, Dept Pathol, Palo Alto, CA 94304 USA; Stanford Univ, Med Ctr, Sch Med, Stanford, CA 94305 USA	Eng, LF (corresponding author), VAPA Hlth Care Syst, Dept Pathol, 3801 Miranda Ave, Palo Alto, CA 94304 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-11632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS011632] Funding Source: NIH RePORTER		Berman JW, 1996, J IMMUNOL, V156, P3017; BRYSCH W, 1994, CELL MOL NEUROBIOL, V14, P557, DOI 10.1007/BF02088837; CHENSUE SW, 1995, AM J PATHOL, V146, P130; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FLORY CM, 1993, LAB INVEST, V69, P396; FUENTES ME, 1995, J IMMUNOL, V155, P5769; GHIRNIKAR RS, 1996, NEUROSCI RES, V46, P727; GHIRNIKAR RS, 1997, NEUROCHEM RES, V23, P333; Glabinski AR, 1996, J IMMUNOL, V156, P4363; GLABINSKI AR, 1995, INT J DEV NEUROSCI, V13, P153, DOI 10.1016/0736-5748(95)00017-B; JONES ML, 1992, J IMMUNOL, V149, P2147; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; SCHMOUDER RL, 1993, KIDNEY INT, V44, P43, DOI 10.1038/ki.1993.211; Sozzani S, 1996, Prog Drug Res, V47, P53; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410; TANI M, 1994, BRAIN PATHOL, V4, P135, DOI 10.1111/j.1750-3639.1994.tb00824.x; Wada T, 1996, FASEB J, V10, P1418	17	24	27	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	MAY 8	1998	247	1					21	24		10.1016/S0304-3940(98)00268-7			4	Neurosciences	Neurosciences & Neurology	ZP138	WOS:000073720200006	9637400				2021-06-18	
J	Lipton, JM; Catania, A; Delgado, R				Lipton, JM; Catania, A; Delgado, R			Peptide modulation of inflammatory processes within the brain	NEUROIMMUNOMODULATION			English	Article						alpha-MSH; melanocortins; brain; inflammation; melanocortin receptors; TNF-alpha; nitric oxide; microglia; astrocyte	TUMOR-NECROSIS-FACTOR; MELANOCYTE-STIMULATING HORMONE; FACTOR-ALPHA; MOLECULAR-CLONING; ANTIINFLAMMATORY DRUGS; MELANOCORTIN RECEPTOR; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; EXPRESSION; INJURY	It is clear that inflammatory processes contribute to neurodegenerative disease, stroke, closed head injury, encephalitis, and other CNS disorders. These inflammatory processes are marked by local increases in cytokines, in particular tumor necrosis factor-alpha (TNF-alpha). It is important to control such CNS inflammation in order to preserve neural function. The neuroimmunomodulatory peptide alpha-melanocyte-stimulating hormone (alpha-MSH) has been shown to modulate peripheral inflammation by acting on melanocortin receptors in host cells (macrophages, neutrophils) to inhibit production of such proinflammatory agents. Our results indicate that alpha-MSH likewise acts directly within the brain to modulate local inflammation. To determine if microglia are involved in anti-inflammatory responses to alpha-MSH within the brain, murine cells were tested; they produced TNF-alpha and nitric oxide in response to challenge, and production of both was reduced by alpha-MSH. In tests on human astrocytes, both alpha-MSH (1-13) and alpha-MSH (11-13) reduced TNF-alpha. Ischemia/reperfusion in the posterior circulation in dogs causes inflammatory reactions and disturbance of function, estimated from decreases in auditory-evoked potentials. These deficits were reduced by administering alpha-MSH systemically during reperfusion, moreso when the peptide was given during both ischemia and reperfusion. The results indicate that, much as for inflammation in the periphery, alpha-MSH modulates brain inflammatory responses mediated by proinflammatory agents.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Osped Maggiore, IRCCS, Div Internal Med 3, Milan, Italy	Lipton, JM (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA.	james.lipton@email.swmed.edu		Catania, Anna/0000-0002-8261-7973; Delgado Hernandez, Rene/0000-0001-7051-7871	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS10046] Funding Source: Medline		AIRAGHI L, 1995, AM HEART J, V130, P204, DOI 10.1016/0002-8703(95)90430-1; Aisen PS, 1996, MOL CHEM NEUROPATHOL, V28, P83, DOI 10.1007/BF02815208; ASSPGLOU K, 1997, J IMMUNOL, V158, P438; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Breitner JCS, 1996, ANNU REV MED, V47, P401; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; Catania A, 1996, PEPTIDES, V17, P675, DOI 10.1016/0196-9781(96)00037-X; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; Chiao H, 1996, J CLIN INVEST, V97, P2038, DOI 10.1172/JCI118639; Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272; DULDERIAN SJ, 1995, J PEDIATR, V125, P872; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GLIMAKER M, 1993, J INFECT DIS, V167, P882, DOI 10.1093/infdis/167.4.882; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; HUH SK, 1997, J NEUROSURG, V40, P132; KIMBERLIN DW, 1995, IMMUNOL INVEST, V24, P775, DOI 10.3109/08820139509060705; KOKA P, 1995, J NEUROIMMUNOL, V57, P179, DOI 10.1016/0165-5728(94)00184-P; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LABBE O, 1994, BIOCHEMISTRY-US, V33, P4543, DOI 10.1021/bi00181a015; Lassmann H, 1997, J NEURAL TRANSM-SUPP, P183; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; LIPTON JM, IN PRESS ANN NY ACAD; MASON MJ, 1989, J IMMUNOL, V142, P1646; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; McGeer PL, 1996, ANN NY ACAD SCI, V777, P213, DOI 10.1111/j.1749-6632.1996.tb34421.x; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; RAINE CS, 1994, ANN NEUROL S, V36, P61; Rajora N, 1997, J NEUROSCI, V17, P2181; Rajora N, 1996, J LEUKOCYTE BIOL, V59, P248; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SELMAJ KW, 1995, NEUROLOGY, V45, pS44, DOI 10.1212/WNL.45.6_Suppl_6.S44; SKAPER SD, 1995, J NEUROCHEM, V64, P266; STAR RA, 1995, P NATL ACAD SCI USA, V92, P8016, DOI 10.1073/pnas.92.17.8016; TARLOW MJ, 1993, NEUROPATH APPL NEURO, V19, P324, DOI 10.1111/j.1365-2990.1993.tb00447.x; Tatro JB, 1996, NEUROIMMUNOMODULAT, V3, P259, DOI 10.1159/000097281; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; WILSON JF, 1988, PSYCHOPHARMACOLOGY, V96, P262; Wong KY, 1997, NEUROIMMUNOMODULAT, V4, P37; WOODROOFE MN, 1993, CYTOKINE, V5, P583, DOI 10.1016/S1043-4666(05)80008-0; XIA Y, 1995, NEUROREPORT, V6, P2193, DOI 10.1097/00001756-199511000-00022; YEUNG MC, 1995, AIDS, V9, P137, DOI 10.1097/00002030-199509020-00004	50	24	26	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401			NEUROIMMUNOMODULAT	Neuroimmunomodulation	MAY-AUG	1998	5	3-4					178	183		10.1159/000026335			6	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	118EV	WOS:000075826200008	9730684				2021-06-18	
J	Schwartz, ML; Carruth, F; Binns, MA; Brandys, C; Moulton, R; Snow, WG; Stuss, DT				Schwartz, ML; Carruth, F; Binns, MA; Brandys, C; Moulton, R; Snow, WG; Stuss, DT			The course of post-traumatic amnesia: Three little words	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	3rd International Neurotrauma Symposium	1995	TORONTO, CANADA				HEAD-INJURY; PRACTICAL SCALE	Objective: To provide a simple means of "real time" recognition of emergence from post-traumatic amnesia (PTA). Methods: Ninety-one patients with traumatic brain injury (PBI); 53 minor (GCS 13-15), 19 moderate (GCS 9-12), 18 seven (GCS 3-8), Twenty-seven control subjects treated at two regional trauma units for their acute phase and followed in a hospital-based research institute were studied prospectively. Subjects were examined repeatedly following injury with the Galveston Orientation and Amnesia Test (GOAT) and tests of their ability to learn and retain new information. Word triplets balanced for concreteness and frequency were presented. Immediate and 24-hour recall were tested. If 24-hour recall was imperfect, recognition was tested by presenting the 3 target words and 6 distracters, The target words were then re-presented and recall was tested the next day. The time intervals to first perfect recognition and first free perfect recall were compared with the patients' first GOAT score of 75 or greater on 2 successive days. Simple line drawings of common objects were also presented to the subjects using an identical paradigm, The outcome measures were GOAT, 3-word recognition and recall, 3 picture recognition and recall. Results: For all categories of head injury severity, the median interval to perfect free recall of words followed the achievement GOAT criterion by a significant interval. The mean GOAT scores for perfect 3-word recall and recognition corresponding to minor, moderate and severe injuries were 97, 90 and 88, and 97, 76 and 68 respectively, The recognition and recall of pictures preceded the recognition and recall of words by approximately 1 day. Conclusions: The orientation measures of the GOAT that contain material that the patient knew prior to injury obscure the determination of recovery of continuous memory and should be tested separately. Three-word recall which is simpler to administer than the GOAT is a more reliable measure of emergence from PTA. For patients who are dysphasic or who do not share a common language with the examiner, 3-picture recognition and recall may substitute for word recognition and recall.	Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Surg Neurosurg, Toronto, ON, Canada; Univ Toronto, Dept Psychol & Med Neurol, Toronto, ON, Canada	Schwartz, ML (corresponding author), 2075 Bayview Ave,Suite A129, Toronto, ON M4N 3M5, Canada.		Binns, Malcolm/AAQ-9195-2020	Binns, Malcolm/0000-0001-9998-6612			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P432; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KONDZIOLKA D, 1989, J TRAUMA, V29, P730, DOI 10.1097/00005373-198906000-00005; Lawless J.F., 1982, STAT MODELS METHODS; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; PAIVIO A, 1968, J EXP PSYCH MONO 2 S, V76; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Symonds CP, 1943, LANCET, V1, P7; TEASDALE G, 1974, LANCET, V2, P81	19	24	25	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	1998	25	2					108	116		10.1017/S0317167100033709			9	Clinical Neurology	Neurosciences & Neurology	ZM688	WOS:000073565900003	9604131	Bronze			2021-06-18	
J	McIntosh, A; Dowdell, B; Svensson, N				McIntosh, A; Dowdell, B; Svensson, N			Pedal cycle helmet effectiveness: A field study of pedal cycle accidents	ACCIDENT ANALYSIS AND PREVENTION			English	Article						pedal cyclist; helmets; head injury; accidents	BICYCLE	The paper describes a study of pedal cycle accidents focussing on helmet effectiveness. Only accidents in which a helmet was worn and received an impact were studied. Cases were collected from hospital accident and emergency units, through the police and via direct contact. Forty-two cases, all helmeted were examined. There were four fatal accidents; all four involved a collision with a motor vehicle. Nine cases experienced a head injury of AIS severity greater than or equal to 2, although there were no skull fractures. Helmet impacts tended to be close to the rim anterio-laterally. The majority of non-fatal (ATS greater than or equal to 2) head injury cases received a helmet impact to the anterio-lateral rim, which corresponds to the temporal/parietal region of the head. This site received directly only 25% of the impacts, and of these impacts, 75% produced head injuries of at least AIS=2. Soft-shell helmets tended to disintegrate on impact, and although only a single impact occurred, a helmet should remain intact to provide protection during second impacts. There was. general increase in the percentage of subjects injured or killed in accidents that involved a second vehicle compared to single vehicle accidents, 54% to 44%, respectively. This trend was stronger with cars travelling at greater than 30 km/h. (C) 1998 Elsevier Science Ltd. All rights reserved.	Univ New S Wales, Dept Safety Sci, Dept Safety & Sci, Sydney, NSW 2052, Australia; Rd & Traff Author, Sydney, NSW, Australia	McIntosh, A (corresponding author), Univ New S Wales, Dept Safety Sci, Dept Safety & Sci, Sydney, NSW 2052, Australia.						*AUSTR BUR STAT, 1989, 45051 BIC US SAF NSW; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; GALE A, 1985, PLAST RUB PROC APPL, V5, P101; *I TRANSP STUD, 1993, SURV LAW COMPL HELM; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh AS, 1993, P 37 STAPP CAR CRASH; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; THIBAULT L, 1989, 807480 HS US DEP TRA; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WILLIAMS M, 1989, PROTECTIVE PERFORMAN	10	24	24	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAR	1998	30	2					161	168		10.1016/S0001-4575(97)00089-4			8	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	YQ463	WOS:000071390200003	9450120				2021-06-18	
J	Whyte, J; Fleming, M; Polansky, M; Cavallucci, C; Coslett, HB				Whyte, J; Fleming, M; Polansky, M; Cavallucci, C; Coslett, HB			The effects of visual distraction following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						attention; arousal; brain injury; reaction time	CLOSED-HEAD INJURY; ATTENTION; SEQUELAE; SCALE; COMA	Clinical assessments of individuals with traumatic brain injury (TBI) typically report attentional difficulties, with distractibility prominent among these complaints. However, laboratory-based measures have often failed to find disproportionate distraction among patients with TBI, as compared to control participants. In this experiment, we tested 21 patients hospitalized for rehabilitation following recent TBI and 21 demographically comparable control subjects on a visual reaction time go-no-go task in which the target was preceded or followed by a brightly colored moving visual stimulus, appearing above the target location. Early distracters actually served as warning stimuli, improving accuracy and speed for both participant groups. Distracters occurring at or shortly after the time of target presentation had no significant impact on accuracy or response bias in either group, but did produce slowing of RT that was significantly greater for patients than for controls. The distracter that produced maximal slowing occurred 100 ms after the presentation of the target or foil. Repeated testing sessions led to reduction in the impact of the distracter and loss of the group difference in RT impact. The degree of RT slowing induced by distraction was modestly related to injury severity, as measured by the current score on the Disability Rating Scale, and the time until the patient first followed verbal commands. There was also a trend of greater RT slowing among individuals with focal orbitofrontal lesions, as assessed on neuroimaging studies. These results document a greater susceptibility to extraneous visual distraction among patients with TBI in comparison to controls. The fact that this difference appears only in the RT domain, and is greatest when the distracter follows the target, suggests that the primary impact of visual distracters is on response preparation and execution rather than target detection.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA; Allegheny Univ Hlth Sci, Dept Clin & Hlth Psychol, Philadelphia, PA 19102 USA; Allegheny Univ Hlth Sci, Sch Publ Hlth, Philadelphia, PA 19102 USA; Temple Univ, Hlth Sci Ctr, Sch Med, Dept Neurol, Philadelphia, PA 19140 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS27715] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS027715] Funding Source: NIH RePORTER		CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; DENCKER SJ, 1958, ACTA PSYCHIAT N S122, V33, P5; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kewman D G, 1988, Brain Inj, V2, P131, DOI 10.3109/02699058809150937; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; Miller E, 1970, Cortex, V6, P121; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Van Zomeren A. H., 1981, REACTION TIME ATTENT; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	21	24	24	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	1998	4	2					127	136		10.1017/S1355617798001271			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	103EY	WOS:000075146200004	9529822				2021-06-18	
J	Fearnside, M; McDougall, P				Fearnside, M; McDougall, P			Moderate head injury: A system of neurotrauma care	AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY			English	Article; Proceedings Paper	Annual Scientific Meeting of the Royal-Australasian-College-of-Surgeons	MAY 07-15, 1997	BRISBANE, AUSTRALIA	Royal Australasian Coll Surgeons		computed tomography; delayed intracranial haematoma; head injury; intracranial pressure; moderate head injury; outcome	ACUTE BRAIN INJURY; SEVERITY SCORE; MEMORY; SCALE; MANAGEMENT; PRESSURE; TRAUMA; COMA	Background: The aim of the present study was to determine those factors which contribute to a poor outcome and to propose a management plan that is complementary to trauma systems in common use. Methods: A prospective study of 110 consecutive patients with moderate head il?jury (post-resuscitation Glasgow Coma Scale (GCS) 9-13) was carried out. Results: A total of 75% of the patients sustained multisystem trauma. generally of minor or moderate grade according to the Abbreviated Injury Scale (AIS). However, the death rate increased with the severity of the injury as measured by the Injury Severity Score (ISS). The initial cranial computed tomography (CT) scan was abnormal in 61% and no patient with a normal scan developed a delayed intracranial haematoma or neurological worsening. Those patients who developed a delayed intracerebral haematoma had a worse outcome. Sixteen patients underwent craniotomy fur haematoma. The intracranial pressure (ICP) was measured selectively in 20 patients and exceeded 20 mmHg in half, requiring treatment, Nine patients died, four as a result of head injury and all those had an intracranial haematoma. As a group, those who died were older and had a higher ISS. Conclusions: A plan for care of patients with moderate head Injury is proposed, complementary to the Early Management of Severe Trauma (EMST) protocol and the Neurosurgical Society of Australasia guidelines for neurotrauma management in rural and remote locations.	Univ Sydney, Dept Surg, Sydney, NSW 2006, Australia; Westmead Hosp, Dept Neurosurg, Westmead, NSW 2145, Australia	Fearnside, M (corresponding author), POB 34, Westmead, NSW 2145, Australia.	Michael_Fearnside@compuserve.com					*ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOWERS SA, 1980, NEUROSURGERY, V6, P237; Bullock Ross, 1993, Journal of Emergency Medicine, V11, P23; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS259; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LABATO R, 1991, J NEUROSURG, V75, P256; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; *NEUR SOC AUSTR, 1992, MAN AC NEUR RUR REM; OSLER T, 1993, AM J SURG, V165, pS43, DOI 10.1016/S0002-9610(05)81206-1; REILLY PL, 1975, LANCET, V2, P375; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RING IT, 1986, AUST NZ J SURG, V56, P557, DOI 10.1111/j.1445-2197.1986.tb07099.x; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; *ROYAL AUSTR COLL, 1992, EARL MAN SEV TRAUM M; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TEASDALE G, 1974, LANCET, V2, P81; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6	38	24	26	0	1	BLACKWELL SCIENCE	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0004-8682			AUST NZ J SURG	Aust. N. Z. J. Surg.	JAN	1998	68	1					58	64		10.1111/j.1445-2197.1998.tb04638.x			7	Surgery	Surgery	YQ084	WOS:000071346700014	9440458				2021-06-18	
J	Bednar, MM; Gross, CE; Howard, DB; Lynn, M				Bednar, MM; Gross, CE; Howard, DB; Lynn, M			Neutrophil activation in acute human central nervous system injury	NEUROLOGICAL RESEARCH			English	Article						stroke; trauma; subarachnoid hemorrhage; central nervous system injury; neutrophil; chemiluminescence	CEREBRAL-ARTERY OCCLUSION; ISCHEMIC CELL-DAMAGE; TRANSPORT INHIBITOR L-644,711; SECONDARY BRAIN INJURY; MONOCLONAL-ANTIBODY; RABBIT MODEL; POLYMORPHONUCLEAR LEUKOCYTES; THROMBOEMBOLIC STROKE; REPERFUSION INJURY; ADHESION MOLECULES	The hypothesis that neutrophil activation exacerbates brain injury in acute stroke is currently receiving wide acceptance. However, the temporal relationship of neutrophil activation to the ischemic event in clinical states is not clear. Therefore, this study was undertaken to examine human neutrophil activation by the technique of luminol-dependent chemiluminescence in both acute bland and hemorrhagic stroke. Patients (bland, n = 18; hemorrhagic, n = 16) were entered into this study within six hours of the ictus. These results were compared to other clinical central nervous system insults: subarachnoid hemorrhage (n = 11), spinal trauma (n = 9) and isolated closed head injury (n = 19). All subjects were sampled upon presentation to the emergency room and 0.5, 1, 2, 3, 4 and 5 days following the event Neutrophil activation, as determined by luminol-dependent chemiluminescence, was evident at day I following the ictus in the bland stroke group (p < 0.05), although this trend was not demonstrated for hemorrhagic stroke. Patients suffering a closed head injury demonstrated greater initial neutrophil activation with values being significantly lower than baseline at days 0.5 (p = 0.01) and 1 (p = 0.05). No significant change was demonstrated for the groups with spinal trauma or subarachnoid hemorrhage. These results support a role for neutrophil activation during various central nervous system insults and provide a temporal framework for considering drug therapy directed at transient suppression of neutrophil function.	Univ Vermont, Div Neurosurg, Burlington, VT 05405 USA; Univ Vermont, Gen Clin Res Ctr, Burlington, VT USA	Bednar, MM (corresponding author), Univ Vermont, Div Neurosurg, Given D319, Burlington, VT 05405 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR109] Funding Source: Medline		BARONE FC, 1992, STROKE, V23, P1337, DOI 10.1161/01.STR.23.9.1337; Bednar, 1995, J Thromb Thrombolysis, V1, P179, DOI 10.1007/BF01062576; BEDNAR M, 1985, CIRC RES, V57, P131, DOI 10.1161/01.RES.57.1.131; BEDNAR M M, 1992, Neurological Research, V14, P53; BEDNAR MM, 1991, STROKE, V22, P44, DOI 10.1161/01.STR.22.1.44; Bednar MM, 1996, NEUROL RES, V18, P171; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; BOWES MP, 1995, NEUROLOGY, V45, P815, DOI 10.1212/WNL.45.4.815; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK WM, 1994, STROKE, V25, P1411, DOI 10.1161/01.STR.25.7.1411; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FASSBENDER K, 1995, STROKE, V26, P1361, DOI 10.1161/01.STR.26.8.1361; GROGAARD B, 1989, J CEREBR BLOOD F MET, V9, P500, DOI 10.1038/jcbfm.1989.73; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KOHUT JJ, 1992, STROKE, V23, P93, DOI 10.1161/01.STR.23.1.93; LESLIE JB, 1985, J NEUROSURG, V63, P659, DOI 10.3171/jns.1985.63.5.0659; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; Penix Laroy, 1996, Stroke, V27, P177; SIMPSON PJ, 1990, CIRCULATION, V81, P226, DOI 10.1161/01.CIR.81.1.226; VERMES I, 1988, STROKE, V19, P631, DOI 10.1161/01.STR.19.5.631; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WILSON JT, 1995, J TRAUMA, V39, P473; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	34	24	25	0	0	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	DEC	1997	19	6					588	592					5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ZC204	WOS:000072552000005	9427957				2021-06-18	
J	Zasler, ND				Zasler, ND			Prognostic indicators in medical rehabilitation of traumatic brain injury: A commentary and review	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; EARLY INTERVENTION; PREDICTION; RECOVERY; CONSCIOUSNESS; ABNORMALITIES; EQUATIONS; SYSTEM; LENGTH; SCALE	The National Information System (NIS) project is developing consensus opinion regarding a proposed structural framework for the prognostic data to be collected as part of this proposed multicenter research effort on severe traumatic brain injury (TBI). This article provide a brief history of the process, examines challenges facing rehabilitation research in this particular area, discusses reasons for identifying prognostic data within the research context of the NIS project, and describes methodologies for use of mathematical models in predicting outcome from TBI. The literature regarding prognostic parameters in severe TBI is briefly reviewed, utilizing three broad parameter categorizations: preinjury, injury, and postinjury. The implications of this research and directions for further study within the NIS project are discussed. (C) 1997 by the American Congress of Rehabilitation Medicine.	NATL NEUROREHABIL CONSORTIUM INC,RICHMOND,VA; CONCUSS CARE CTR VIRGINIA LTD,RICHMOND,VA; TREE LIFE LLC,RICHMOND,VA							ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; BANJA J, 1994, ARCH PHYS MED REHAB, V75, pS19; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BONTKE CF, 1996, NEUROTRAUMA, P841; BORN JD, 1988, ACTA NEUROCHIR, V9, P1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1996, NEUROTRAUMA, P779; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; ENAS GG, 1982, THESIS VIRGINIA COMM; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FELDMAN Z, 1996, NEUROTRAUMA, P805; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GOLDSTEIN FC, 1986, J CLIN EXP NEUROPSYC, V8, P405, DOI 10.1080/01688638608401330; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; HEISKANEN O, 1973, ACTA CHIR SCAND, V139, P605; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1979, NEUROSURGERY, V4, P282; JENNETT B, 1992, PROGNOSIS NEUROLOGIC, P85; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pS1; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; KATZ DI, 1995, ARCH PHYS MED REHAB, V76, P592; KATZ DI, 1989, NEUROLOGY, V39, P798; KATZ DI, 1993, ARCH PHYS MED REHAB, V74, P661; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MACK A, 1989, TBI STAR PM R, P13; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; MYSIW WJ, 1996, MED REHABILITATION T, P53; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; Rappaport M, 1996, MED REHABILITATION T, P271; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; TEASDALE G, 1974, LANCET, V2, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Torner James C., 1996, P19; VOLLMER DG, 1991, NEUROSURGERY, V75, pS37; WHYTE J, 1994, AM J PHYS MED REHAB, V73, P428, DOI 10.1097/00002060-199411000-00008; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7	55	24	25	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1997	78	8		4			S12	S16		10.1016/S0003-9993(97)90150-7			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	XR538	WOS:A1997XR53800003	9270483				2021-06-18	
J	Kendall, E; Shum, D; Halson, D; Bunning, S; Teh, M				Kendall, E; Shum, D; Halson, D; Bunning, S; Teh, M			The assessment of social problem-solving ability following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							SEVERE HEAD-INJURY; SUBSEQUENT LEVEL; COLLEGE-STUDENTS; COMPETENCE; SKILLS; ADULTS	Objective: To investigate the nature of social problem-solving deficits following TBI using the D'Zurilla and Goldfried(14) model of social problem solving, which consists of four social problem-solving skills that traditionally have been assessed by self-report inventory. To overcome the problems associated with self-report following TBI, the current study developed a video task for the assessment of social problem solving. Design: Cohort study. Participants: The study involved 15 community-dwelling individuals with TBI caused by motor vehicle accidents who volunteered to be involved in the study. A matched control sample without psychiatric or neurologic conditions consisted of 15 members of a community group who also volunteered to assist. Main Outcome Measures: Two measures were used, the Social Problem-Solving Inventory(17) and a problem-solving video vignette task designed specifically for the study. Both instruments assessed the components of the model-namely, problem definition and goal formulation, solution generation, decision making, and solution implementation and verification. Results: Individuals with TBI were impaired relative to the control sample in their ability to recognize and define social problems and to generate a range of solutions. However, these differences emerged only when using the video task. Correlations between the video task and the self-report scales were nonsignificant for both groups. Conclusions: Current social problem-solving training may lack validity due to an inappropriate focus on the later stages rather than the early stages of problem solving, when the major deficits following TBI tend to occur. In addition, the difficulties associated with self-report assessment following TBI can be overcome by using the video task.	GRIFFITH UNIV,SCH APPL PSYCHOL,NEUROPSYCHOL UNIT,NATHAN,QLD 4111,AUSTRALIA	Kendall, E (corresponding author), GRIFFITH UNIV,CTR STRATEG HUMAN SERV REHABIL,SCH APPL PSYCHOL,NATHAN,QLD 4111,AUSTRALIA.		kendall, elizabeth/F-5065-2013; Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262; Kendall, Elizabeth/0000-0003-2399-1460			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BELLACK AS, 1994, J ABNORM PSYCHOL, V103, P371, DOI 10.1037/0021-843X.103.2.371; CASTLES EE, 1986, AM J MENT RETARD, V91, P35; D'Zurilla T. J., 1990, PYCSHOLOGICAL ASSESS, V2, P156, DOI DOI 10.1037/1040-3590.2.2.156; DZURILLA TJ, 1992, COGNITIVE THER RES, V16, P589, DOI 10.1007/BF01175144; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; DZURILLA TJ, 1991, J PERS SOC PSYCHOL, V61, P841, DOI 10.1037/0022-3514.61.5.841; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; GILES GM, 1993, BRAIN INJURY REHABIL; HEPPNER PP, 1990, HDB SOCIAL CLIN PSYC; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Marsh NV, 1990, NEUROPSYCHOLOGY, V4, P13, DOI 10.1037/0894-4105.4.1.13; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; SPIERS MV, 1994, BRAIN INJURY, V8, P463, DOI 10.3109/02699059409150998; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VONCRAMON DY, 1990, COGNITIVE REHABILITA; VONCRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; VONCRAMON DY, 1992, NEUROPSYCHOLOGICAL R; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	24	24	24	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1997	12	3					68	78		10.1097/00001199-199706000-00007			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XC699	WOS:A1997XC69900007					2021-06-18	
J	Ekman, R; Schelp, L; Welander, G; Svanstrom, L				Ekman, R; Schelp, L; Welander, G; Svanstrom, L			Can a combination of local, regional and national information substantially increase bicycle-helmet wearing and reduce injuries? Experiences from Sweden	ACCIDENT ANALYSIS AND PREVENTION			English	Article						program evaluation; bicycle helmets; bicycle-related injuries; injury prevention	SWEDISH MUNICIPALITY; CHILDREN; CAMPAIGN; HEAD	Is it possible to substantially reduce the incidence of injuries related to cycling through the provision of information on helmet wearing? This issue has been investigated in Skaraborg County, Sweden, where 90 percent of all pre-school children now use bicycle helmets. For children under 15, there was an average annual decrease in all bicycle-related injuries of 3.1 percent, equivalent to a decrease of 48 percent over the study period, 1978-93 (for head injuries, 59%). Sweden as a whole showed a reduction of 32 percent in bicycle-related injuries (head injuries, 43%). In Skaraborg, children have been the target of helmet-wearing programs at local and regional levels since 1982, and at national level since 1987. The elderly have not been targeted in helmet-wearing programs; currently, they scarcely wear helmets at all, and showed a significant increase in their injury rate over the period (4.7% annually). The number of concussions sustained by helmet-wearers is estimated to be one-third fewer than that of non-wearers. Comparisons with Australia and some parts of the U.S.A. indicate that, despite the significant decrease in Skaraborg, greater effects might be achievable if information is supplemented by compulsory-helmet-wearing legislation. (C) 1997 Elsevier Science Ltd.	SKARABORG INST,DIV PUBL HLTH,SKOVDE,SWEDEN; NATL INST PUBL HLTH,STOCKHOLM,SWEDEN	Ekman, R (corresponding author), KAROLINSKA INST,DEPT PUBL HLTH SCI,DIV SOCIAL MED,S-17283 SUNDBYBERG,SWEDEN.						BJORNSTIG U, 1992, J TRAUMA, V33, P887; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; CASS DT, 1989, AUST NZ J SURG, V59, P719, DOI 10.1111/j.1445-2197.1989.tb01664.x; COTE TR, 1992, PEDIATRICS, V89, P1216; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; EKMAN R, 1991, SWEDISH BICYCLE HELM; *FORS, 1992, ROAD FAT STAT AUSTR; LEICESTER P, 1991, GR91 ROAD SAF DIV; LEKANDER T, 1994, COMMUNICATION; LIND MG, 1986, ACTA CHIR SCAND S, V531; *NAT SWED BOARD CO, 1992, 19923 KOVFS; *NAT SWED BOARD CO, 1992, 19922 KOVFS; NOLEN S, 1995, BICYCLE HELMET USAGE; OTT L, 1984, INTRO STATISTICAL ME; RIVARA FP, 1994, PEDIATRICS, V93, P567; SCHEIDT PC, 1992, PEDIATRICS, V89, P1248; SCHELP L, 1990, PUBLIC HEALTH, V104, P55, DOI 10.1016/S0033-3506(05)80346-4; SCHELP L, 1988, SOC SCI MED, V26, P1087, DOI 10.1016/0277-9536(88)90183-9; SIMPSON AHRW, 1988, BRIT MED J, V296, P1161, DOI 10.1136/bmj.296.6630.1161-a; *STAT SWED, 1995, OFF STAT SWED CAUS D; Svanstrom L, 1995, Inj Prev, V1, P169, DOI 10.1136/ip.1.3.169; Svanstrom L., 1996, INT J CONSUMER SAFET, V3, P1; *SWED NAT BOARD HL, 1989, KLASS REG OL; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; THULIN H, 1991, 72 TFB VTI; THULIN H, 1995, COMMUNICATION; *UN, 1993, STAT ROAD TRAFF ACC; WAHLBERG T, 1995, LAKARTIDNINGEN, V92, P7; WELANDER G, 1994, C ROAD SAF EUR STRAT; *WHO, 1992, WHO HELM IN, V1; *WHO, 1995, WHO HELM IN, V4	31	24	24	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAY	1997	29	3					321	328		10.1016/S0001-4575(96)00086-3			8	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	XD126	WOS:A1997XD12600007	9183470				2021-06-18	
J	Hoane, MR; Raad, C; Barth, TM				Hoane, MR; Raad, C; Barth, TM			Non-competitive NMDA antagonists and anti-oxidant drugs reduce striatal atrophy and facilitate recovery of function following lesions of the rat cortex	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						secondary brain damage; sensorimotor behavior; neuroprotection; glutamate; recovery of function; magnesium chloride; MK-801; PEN	METHYL-D-ASPARTATE; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; CENTRAL NERVOUS-SYSTEM; MOUSE CENTRAL NEURONS; TERT-BUTYL-NITRONE; GLUTAMATE NEUROTOXICITY; RETROSPLENIAL CORTEX; SENSORIMOTOR CORTEX; POSTERIOR CINGULATE	Following brain injury there is an excessive release of glutamate, a reduction in levels of cellular Mg++, and the generation of oxygen free radicals. These processes may contribute to the severity of the behavioral impairments seen following brain injury by leading to secondary neuronal degeneration. The present experiment investigates the relative effects of three drugs (MK-801, an NMDA antagonist; magnesium chloride, an NMDA antagonist; and N-tert-butyl-alpha-phenylnitrone (PBN), an anti-oxidant and free radical scavenger) which disrupt different aspects of the pathophysiological process, in reducing these impairments. Direct comparisons of these drugs may determine if one treatment is more effective than another, or if one is detrimental. In addition, the effects of combination treatments including PBN and MK-801 or MgCl2, were examined. These combination treatment were aimed at the possibility of potentiating the beneficial effects observed after administration of these agents alone. Rats received unilateral electrolytic lesions of the somatic sensorimotor cortex followed by a regimen of MK-801 (1 mg/kg), MgCl2 (1 mmol/kg), PBN (100 mg/kg), MK-801 + PEN (1 mg/kg, 100 mg/kg), MgCl2, + PBN (1 mmol/kg, 100 mg/kg), or saline (1 ml/kg) beginning 15 min following injury. Rats were tested on several sensorimotor tasks (i.e. forelimb placing and foot-fault) for 43 days following the cortical lesions. Rats receiving any of the single or combination drug treatments showed a significant facilitation of recovery on the sensorimotor tasks compared to saline control rats. On one behavioral test (i.e. foot-fault) there was a significant further enhancement of the recovery by combination treatments compared to the single treatment groups. These data are consistent with the idea that excessive release of glutamate, reduction in Mg++ levels, and free radical generation contribute to the severity of the behavioral impairments following cortical injury, and that arresting these processes results in a facilitation of behavioral recovery. Anatomical analysis showed that all drug treatments decreased the amount of atrophy seen in the ipsilateral striatum. (C) 1997 Elsevier Science Ireland Ltd.	TEXAS CHRISTIAN UNIV, DEPT PSYCHOL, FT WORTH, TX 76129 USA; TEXAS CHRISTIAN UNIV, PROGRAM NEUROSCI, FT WORTH, TX 76129 USA				Hoane, Michael/0000-0001-7779-2657			Aikawa J.W., 1981, MAGNESIUM ITS BIOL S, P21; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; AUER RN, 1994, ACTA NEUROPATHOL, V87, P1; Bara M, 1984, MAGNESIUM, V3, P212; BARTH TM, 1990, STROKE, V21, P153; BARTH TM, 1994, BEHAV NEUROSCI, V108, P818, DOI 10.1037/0735-7044.108.4.818; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BIELENBERG GW, 1991, BRAIN RES, V552, P338, DOI 10.1016/0006-8993(91)90101-Z; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1988, PHARM APPROACHES TRE; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; FIX AS, 1995, BRAIN RES, V696, P194, DOI 10.1016/0006-8993(95)00842-E; FOSTER AC, 1987, NEUROSCI LETT, V76, P307, DOI 10.1016/0304-3940(87)90420-4; GARFINKEL L, 1985, Magnesium, V4, P60; GILL R, 1987, J NEUROSCI, V7, P3343; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GRAHAM DI, 1989, CEREBROVASC DIS, P65; GUNTHER T, 1984, MAGNESIUM-B, V6, P77; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HARA H, 1993, BRAIN RES, V618, P251, DOI 10.1016/0006-8993(93)91273-U; Hoane M. R., 1995, Society for Neuroscience Abstracts, V21, P172; Hoane M. R., 1994, Society for Neuroscience Abstracts, V20, P1430; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOSOKAWA S, 1985, BRAIN RES, V343, P8, DOI 10.1016/0006-8993(85)91152-7; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; MARTINEZARIZALA A, 1990, EXP NEUROL, V108, P232, DOI 10.1016/0014-4886(90)90128-F; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; McCulloch J, 1993, Acta Neurochir Suppl (Wien), V57, P73; MCDONALD JW, 1990, NEUROSCIENCE, V36, P589, DOI 10.1016/0306-4522(90)90002-L; MCDONALD JW, 1989, BRAIN RES, V490, P33, DOI 10.1016/0006-8993(89)90427-7; MCDONALD JW, 1990, SYNAPSE, V6, P179, DOI 10.1002/syn.890060210; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; MCDONALD JW, 1989, EXP NEUROL, V106, P289, DOI 10.1016/0014-4886(89)90162-3; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1989, CEREBROVASC DIS, P47; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PERUCHE B, 1993, PROG NEURO-PSYCHOPH, V17, P21, DOI 10.1016/0278-5846(93)90032-N; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; SAPONJIC RM, 1995, RESTOR NEUROL NEUROS, V8, P205, DOI 10.3233/RNN-1995-8406; SCHALLERT T, 1990, STROKE, V21, P143; SCHALLERT T, 1990, CAN J PSYCHOL, V44, P276, DOI 10.1037/h0084244; SCHALLERT T, 1984, BEHAV NEUROSCI, V98, P518; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Sen S., 1993, Society for Neuroscience Abstracts, V19, P636; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAMURA A, 1990, BRAIN RES, V510, P154, DOI 10.1016/0006-8993(90)90744-V; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VILLABLANCA JR, 1976, EXP NEUROL, V53, P289, DOI 10.1016/0014-4886(76)90072-8; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; von Monakow C, 1969, MOOD STATES MIND; WATKINS JC, 1989, NMDA RECEPTOR, P1; YUE TL, 1992, BRAIN RES, V574, P193, DOI 10.1016/0006-8993(92)90816-R	81	24	24	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	APR	1997	11	1-2					71	82					12	Neurosciences	Neurosciences & Neurology	XB752	WOS:A1997XB75200008	21551530				2021-06-18	
J	McPherson, KM; Pentland, B				McPherson, KM; Pentland, B			Disability in patients following traumatic brain injury - Which measure?	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						disability; measurement; head injury	FUNCTIONAL ASSESSMENT SCALES; REHABILITATION	Head injury results in a wide range of functional sequelae. Thus, measuring solely physical aspects of functioning may fail to highlight the actual level of disability. This study compares a commonly used measure of physical disability, the Barthel Index, with three recently devised measures - the OPCS Scales of Disability, the Functional Independence Measure (FIM) and Functional Assessment Measure (FIM + FAM). Fifty-four head-injured subjects were assessed following discharge-from an in-patient rehabilitation unit utilizing each measure. The majority of subjects had no detectable disability according to the Barthel Index. In contrast, only four subjects (7%) attained maximal scores for independence with the OPCS scale; two (4%) with the FIM and only one subject (2%) with the FIM + FAM. This reflected the nature of the disabilities in activities such as intellectual functioning, communication, behaviour and wider aspects of mobility measured by the OPCS, FIM and FIM + FAM but not in the Barthel Index. The relationship between all measures was significant (Spearman ranked correlations P < 0.001) but correlations were greater between OPCS, FIM and FIM + FAM than with the Barthel. The results of this study would support considering the use of scales other than the Barthel Index when describing disability following traumatic head injury.	UNIV EDINBURGH,REHABIL STUDIES UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND				McPherson, Kathryn/0000-0003-1240-8882; McPherson, Kath/0000-0003-0487-8497			APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1207; Chau N, 1994, Disabil Rehabil, V16, P63; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Frattali C M, 1993, Disabil Rehabil, V15, P1; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GRANGER CV, 1995, INT J TECHNOL ASSESS, V11, P262, DOI 10.1017/S0266462300006875; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin J, 1988, PREVALENCE DISABILIT; MCPHERSON K, 1993, CLIN REHABIL, V7, P105; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; PENTLAND B, 1994, HLTH B, V52, P438; ROY CW, 1988, INT J REHABIL RES, V11, P67, DOI 10.1097/00004356-198803000-00010; Wade DT, 1992, MEASUREMENT NEUROLOG; WELLWOOD I, 1995, AGE AGEING, V24, P54, DOI 10.1093/ageing/24.1.54; World Health Organization, 1980, INT CLASS IMP DIS HA	26	24	24	0	2	CHAPMAN HALL LTD	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	MAR	1997	20	1					1	10		10.1097/00004356-199703000-00001			10	Rehabilitation	Rehabilitation	WN631	WOS:A1997WN63100001	9089011				2021-06-18	
J	Leonard, JR; Grady, MS; Lee, ME; Paz, JC; Westrum, LE				Leonard, JR; Grady, MS; Lee, ME; Paz, JC; Westrum, LE			Fluid percussion injury causes disruption of the septohippocampal pathway in the rat	EXPERIMENTAL NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; NERVE GROWTH-FACTOR; MEDIAL SEPTUM; DIAGONAL BAND; CHOLINE-ACETYLTRANSFERASE; ALZHEIMERS-DISEASE; HIPPOCAMPAL-FORMATION; HEAD-INJURY; LONG-TERM; NEURONS	Fluid percussion injury (FPI) causes memory deficits, loss of hippocampal neurons, and basal forebrain cholinergic immunoreactivity in rats. Basal forebrain septohippocampal projections terminate in specific hippocampal regions. The purpose of this study was to examine the effects of FPI on the septohippocampal pathway (SHP). Halothane-anesthetized rats received either a sham injury or a parasagittal FPI. To characterize the anatomical effects of FPI on the SHP, silver stains were performed on brains of animals at 1, 5, and 10 days following FPI and were compared to sham-injured preparations. To characterize the effects of FPI on retrograde transport in the SHP, a separate group of FPI and sham-injured animals with survival times of 2, 5, and 10 days received bilateral WGA-HRP injections into the hippocampal formation 24 h prior to sacrifice. Argyrophilic CA3 neurons were present 1 day following FPI. Five days following FPI, terminal degeneration was present in the inner third of the molecular layer of the dentate gyrus bilaterally that was not present 1 day after injury. Fiber and terminal degeneration was not observed in the basal forebrain until 10 days after FPI. WGA-HRP-labeled septal neurons decreased significantly (P < 0.05) ipsilateral to injury in animals sacrificed 5 and 10 days following FPI but not 2 days after injury. This investigation demonstrated that FPI produces focal injury in the hippocampal formation. In addition, the appearance of terminal degeneration in the dentate molecular layer correlated with the significant reduction in axonal transport 5 days following injury. This correlation illustrates the secondary processes that structurally damage the SHP up to 10 days after injury. (C) 1997 Academic Press.	UNIV WASHINGTON, DEPT NEUROL SURG, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT RESTORAT DENT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PSYCHOL, SEATTLE, WA 98195 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30305] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030305] Funding Source: NIH RePORTER		AMARAL DG, 1985, J COMP NEUROL, V240, P37, DOI 10.1002/cne.902400104; ARENDT T, 1985, NEUROSCIENCE, V14, P1, DOI 10.1016/0306-4522(85)90160-5; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55; BRIONI JD, 1990, BRAIN RES, V522, P227, DOI 10.1016/0006-8993(90)91465-S; CLARKE DJ, 1985, BRAIN RES, V360, P349, DOI 10.1016/0006-8993(85)91253-3; DAVIES P, 1976, LANCET, V2, P1403; de Olmos JS, 1981, NEUROANATOMICAL TRAC, P117; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; GAYKEMA RPA, 1991, NEUROSCIENCE, V43, P349, DOI 10.1016/0306-4522(91)90299-4; GIVENS BS, 1990, BEHAV NEUROSCI, V104, P849, DOI 10.1037/0735-7044.104.6.849; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; GONATAS NK, 1979, J HISTOCHEM CYTOCHEM, V27, P728, DOI 10.1177/27.3.90065; GONATAS NK, 1973, J CELL BIOL, V59, P436, DOI 10.1083/jcb.59.2.436; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; HALPERIN JJ, 1975, BRAIN RES, V100, P253, DOI 10.1016/0006-8993(75)90482-5; HARRELL LE, 1987, BEHAV NEUROSCI, V101, P644, DOI 10.1037/0735-7044.101.5.644; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HJORTHSIMONSEN A, 1972, J COMP NEUROL, V144, P215, DOI 10.1002/cne.901440206; HJORTHSIMONSEN A, 1977, J COMP NEUROL, V174, P591, DOI 10.1002/cne.901740404; KISS J, 1990, NEUROSCIENCE, V36, P61, DOI 10.1016/0306-4522(90)90351-4; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin H., 1987, HEAD INJURY, P442; LEWIS PR, 1967, BRAIN, V90, P521, DOI 10.1093/brain/90.3.521; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MESULAM MM, 1978, J HISTOCHEM CYTOCHEM, V26, P106, DOI 10.1177/26.2.24068; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; RAISMAN G, 1965, BRAIN, V88, P963, DOI 10.1093/brain/88.5.963; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SENUT MC, 1989, NEUROSCIENCE, V30, P385, DOI 10.1016/0306-4522(89)90260-1; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SWANSON LW, 1980, BRAIN RES, V197, P207, DOI 10.1016/0006-8993(80)90446-1; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SWANSON LW, 1977, J COMP NEUROL, V172, P49, DOI 10.1002/cne.901720104; VONEIDA TJ, 1981, ANAT REC, V201, P91, DOI 10.1002/ar.1092010112; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WITTER MP, 1993, HIPPOCAMPUS, V3, P33; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	54	24	25	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	1997	143	2					177	187		10.1006/exnr.1996.6366			11	Neurosciences	Neurosciences & Neurology	WM449	WOS:A1997WM44900001	9056381				2021-06-18	
J	McKindley, DS; Boucher, BA; Hess, MM; Rodman, JH; Feler, C; Fabian, TC				McKindley, DS; Boucher, BA; Hess, MM; Rodman, JH; Feler, C; Fabian, TC			Effect of acute phase response on phenytoin metabolism in neurotrauma patients	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article							TUMOR-NECROSIS-FACTOR; ADULT HUMAN HEPATOCYTES; C-REACTIVE PROTEIN; PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC SEIZURES; HEPATIC DRUG-METABOLISM; SEVERE HEAD-INJURY; CYTOCHROME-P-450 ENZYMES; CLINICAL-PHARMACOLOGY; INTERLEUKIN-1 IL-1	The purpose of this prospective study was to correlate measures of the acute phase response, associated therapeutic interventions, and other clinical variables with the process of altered drug metabolism previously observed in patients with severe neurotrauma. Nine patients with severe head injury (Glasgow Coma Scale less than or equal to 8) requiring intravenous phenytoin were included in the study. A loading dose of phenytoin was followed by daily maintenance doses. Serial blood samples were taken after the loading dose and every even-numbered study day for 10 to 14 days for measurement of total and unbound concentrations of phenytoin, interleukin-1 beta, interleukin-6 (IL-6), tumor necrosis factor alpha, alpha(1)-acid-glycoprotein, C-reactive protein, and albumin. Time-invariant and time-variant Michaelis-Menten models were fit to the phenytoin concentration-time data. Protein intake was closely monitored. The mean (+/- SEM) unbound fraction of phenytoin increased from 0.17 +/- 0.02 on day 1 to 0.24 +/- 0.04 on day 10 (P < 0.05). The time-variant model was superior in describing the concentration-time data of unbound phenytoin in eight of nine patients. Mean (+/- SEM) pharmacokinetic parameter estimates for unbound phenytoin were: V-max(Delta) = 605 +/- 92 mg/day, V-max(B) = 149 +/- 26.3 mg/day, k(ind) = 0.013 +/- 0.004 hr(-1). Interleukin-6 was the only cytokine with significant concentration changes over time; it was inversely correlated with V-max,V-t. Peak concentrations of interleukin-6 also proved to be inversely correlated with V-max(B). The daily amount of protein administered was significantly correlated with V-max,V-t. Significant alterations in the metabolism of phenytoin occur after severe neurotrauma. The etiology of these changes is probably multifaceted. These results suggest that low initial phenytoin V-max may be explained by the presence of interleukin-6. An increase in oxidative metabolism that correlated with nutritional protein administration was observed later in these patients.	UNIV TENNESSEE, DEPT CLIN PHARM SURG & NEUROSURG, MEMPHIS, TN USA	McKindley, DS (corresponding author), UNIV RHODE ISL, DEPT PHARM PRACTICE, 144 FOGARTY HALL, KINGSTON, RI 02881 USA.						ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; ANDERSON KE, 1979, CLIN PHARMACOL THER, V26, P493, DOI 10.1002/cpt1979264493; AULITZKY WE, 1994, DRUGS, V48, P667, DOI 10.2165/00003495-199448050-00002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEAL SL, 1983, J PHARMACOKINET BIOP, V11, P641, DOI 10.1007/BF01059062; BOUCHER BA, 1988, CLIN PHARMACOL THER, V44, P675, DOI 10.1038/clpt.1988.211; BOUCHER BA, 1991, CLIN PHARMACOL THER, V50, P487, DOI 10.1038/clpt.1991.173; BOUCHER BA, 1987, CLIN PHARMACY, V6, P881; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CHEN YL, 1992, BIOCHEM PHARMACOL, V44, P137, DOI 10.1016/0006-2952(92)90047-M; CHUICKSHANK AM, 1990, CLIN SCI, V79, P161; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; DARGENIO DZ, 1979, COMPUT PROG BIOMED, V9, P115, DOI 10.1016/0010-468X(79)90025-4; DELERS F, 1989, BIOCHEM BIOPH RES CO, V161, P81, DOI 10.1016/0006-291X(89)91563-5; DICKINSON RG, 1985, THER DRUG MONIT, V7, P283, DOI 10.1097/00007691-198507030-00008; FAGAN TC, 1987, CLIN PHARMACOL THER, V41, P402, DOI 10.1038/clpt.1987.48; GHEZZI P, 1986, INFECT IMMUN, V54, P837, DOI 10.1128/IAI.54.3.837-840.1986; GHEZZI P, 1986, BIOCHEM BIOPH RES CO, V136, P316, DOI 10.1016/0006-291X(86)90912-5; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRIFFETH LK, 1983, DRUG METAB DISPOS, V11, P517; GRIFFETH LK, 1984, DRUG METAB DISPOS, V12, P588; GUO Y, 1990, CLIN IMMUNOL IMMUNOP, V54, P361, DOI 10.1016/0090-1229(90)90050-Z; JUAN D, 1986, CLIN PHARMACOL THER, V40, P187, DOI 10.1038/clpt.1986.162; KAPPAS A, 1976, CLIN PHARMACOL THER, V20, P643; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRISHNASWAMY K, 1984, BRIT J CLIN PHARMACO, V17, P139, DOI 10.1111/j.1365-2125.1984.tb02328.x; LUDDEN TM, 1977, CLIN PHARMACOL THER, V21, P287; Markowsky SJ, 1996, ANN PHARMACOTHER, V30, P443, DOI 10.1177/106002809603000501; MARTIN E, 1977, J PHARMACOKINET BIOP, V5, P579, DOI 10.1007/BF01059685; MAWER GE, 1974, BRIT J CLIN PHARMACO, V1, P163, DOI 10.1111/j.1365-2125.1974.tb00226.x; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MOSHAGE HJ, 1988, BIOCHEM BIOPH RES CO, V155, P112, DOI 10.1016/S0006-291X(88)81056-8; OHZATO H, 1992, SURGERY, V111, P201; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; POUS C, 1990, DRUG METAB DISPOS, V18, P467; RENTON KW, 1976, BIOCHEM BIOPH RES CO, V73, P343, DOI 10.1016/0006-291X(76)90713-0; Roberts P R, 1995, New Horiz, V3, P506; SCHLUTER B, 1991, J TRAUMA, V31, P1663, DOI 10.1097/00005373-199112000-00017; SHEDLOFSKY SI, 1987, LIFE SCI, V40, P2331, DOI 10.1016/0024-3205(87)90506-6; SLAUGHTER RL, 1995, ANN PHARMACOTHER, V29, P619, DOI 10.1177/106002809502900612; SUJITA K, 1990, BIOCHEM BIOPH RES CO, V168, P1217, DOI 10.1016/0006-291X(90)91158-O; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; THOMPSON PJ, 1983, BRIT J CLIN PHARMACO, V16, P267, DOI 10.1111/j.1365-2125.1983.tb02160.x; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; VESELL ES, 1979, CLIN PHARMACOL THER, V26, P275; WERMELING DP, 1987, DRUG INTEL CLIN PHAR, V21, P459, DOI 10.1177/106002808702100517; YAMADA Y, 1990, ANN NY ACAD SCI, V587, P351, DOI 10.1111/j.1749-6632.1990.tb00176.x; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010; YUEN GJ, 1983, RES COMMUN CHEM PATH, V42, P355	56	24	24	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	FEB	1997	37	2					129	139		10.1002/j.1552-4604.1997.tb04771.x			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	WK569	WOS:A1997WK56900007	9055139				2021-06-18	
J	Ikeda, Y; Teramoto, A; Nakagawa, Y; Ishibashi, Y; Yoshii, T				Ikeda, Y; Teramoto, A; Nakagawa, Y; Ishibashi, Y; Yoshii, T			Attenuation of cryogenic induced brain oedema by arginine vasopressin release inhibitor RU51599	ACTA NEUROCHIRURGICA			English	Article						brain oedema; arginine vasopressin; cryogenic injury; kappa opioid	OPIOID RECEPTOR AGONIST; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; FOCAL CEREBRAL-ISCHEMIA; EDEMA; INJURY; RATS; PROTECTION; U-50488H; CATS	Centrally released arginine vasopressin (AVP) has been implicated in the regulation of the brain water content and is elevated in the cerebrospinal fluid of patients with ischaemic and traumatic brain injuries. The protective effect of RU51599, which is a selective kappa opioid agonist as an AVP release inhibitor, on brain oedema was examined. Male Wistar rats, weighing 300 to 400 g each, were used. The cortical cryogenic injury was produced by application of a previously prepared metal probe cooled with dry ice to the dura of the right patietal region. Animals were separated into three groups. Group 1: sham operated rats without lesion production. Group 2: saline-treated rats with lesion production. Group 3: RU51599-treated rats with lesion production. In Group 3, rats were treated with RU51599 (0.1-3 mg/kg) at 30 minutes before lesion production, 1 hour, 2 hours, and 4 hours after lesion production. After 6 hours, animals were decapitated and brain water contents were measured using the dry-wet weight method. The extent of blood brain barrier (BBB) disruption was determined by assessment of Evans blue uptake based on extraction from tissue using dimethylformamide. The primary injured infarcted area was determined by 2,3,5-triphenyltetrazolium chloride (TTC) staining. Sodium and potassium contents in serum and brain tissue were measured using atomic absorption spectrophotometry. The antagonism of naloxone against protective effects of RU51599 on cryogenic induced brain oedema and on antinociceptive effects in acetic-acid treated animals was examined. Statistical analysis was performed using Dunnett-test and U-test following Kruskal-Wallis test. RU 51599 significantly reduced the brain water contents on the injured side and the contralateral non-injured side (p < 0.01) after 4 administration of 1 and 3 mg/kg. RU51599 neither significantly inhibited BBB disruption nor reduced the primary injured infarcted area. RU51559 significantly increased brain sodium and potassium contents in the injured brain and also increased serum sodium levels (p < 0.01). Naloxone antagonized the anti-oedema effects and antinociceptive effects of RU51599. These findings indicate that the AVP release inhibitor, RU51599 posssibly mediated by opioid receptors, has a potential protective effect on cryogenic-induced brain oedema and that centrally released AVP plays an important role in the progression of vasogenic brain oedema.	Nippon Med Sch, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan; Expt Biomed Res Inc, Ibaraki, Osaka, Japan	Ikeda, Y (corresponding author), Nippon Med Sch, Dept Neurosurg, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 113, Japan.						BASKIN DS, 1994, STROKE, V25, P2047, DOI 10.1161/01.STR.25.10.2047; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; DICKINSON LD, 1992, J CEREBR BLOOD F MET, V12, P681, DOI 10.1038/jcbfm.1992.93; DOCZI T, 1984, NEUROSURGERY, V14, P436, DOI 10.1227/00006123-198404000-00008; DOCZI TP, 1995, ACTA NEUROCHIR, V132, P87, DOI 10.1007/BF01404853; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FARACI FM, 1988, CIRC RES, V63, P373, DOI 10.1161/01.RES.63.2.373; Furui Tomoo, 1993, Neurologia Medico-Chirurgica, V33, P133, DOI 10.2176/nmc.33.133; GUENIAU C, 1995, J CEREB FLOW METAB S, V15, pS383; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAMON G, 1994, J AM SOC NEPHROL, V5, P272; IKEDA Y, 1994, ACTA NEUROCHIR, P119; ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198; KUSUMOTO K, 1992, BRAIN RES, V576, P147, DOI 10.1016/0006-8993(92)90621-F; LASZLO FA, 1995, ACTA NEUROCHIR, V133, P122, DOI 10.1007/BF01420062; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1994, AM J PHYSIOL, V267, pR665; NAGAO S, 1994, ACTA NEUROCHIR, P502; OISO Y, 1988, NEUROENDOCRINOLOGY, V48, P658, DOI 10.1159/000125078; RAICHLE ME, 1978, BRAIN RES, V143, P191, DOI 10.1016/0006-8993(78)90766-7; REEDER RF, 1986, J NEUROSURG, V64, P941, DOI 10.3171/jns.1986.64.6.0941; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; SILVIA RC, 1987, BRAIN RES, V403, P52, DOI 10.1016/0006-8993(87)90121-1; SORENSEN PS, 1985, J NEUROL NEUROSUR PS, V48, P50, DOI 10.1136/jnnp.48.1.50; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X	25	24	25	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1997	139	12					1173	1179		10.1007/BF01410978			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	YM860	WOS:000071108900032	9479424				2021-06-18	
J	Lazar, L; Erez, I; Gutermacher, M; Katz, S				Lazar, L; Erez, I; Gutermacher, M; Katz, S			Brain concussion produces transient hypokalemia in children	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	29th Annual Meeting of the Pacific-Association-of-Pediatric-Surgeons	MAY 12-15, 1996	SINGAPORE, SINGAPORE	Pacific Assoc Pediat Surgeons		brain concussion; hypokalemia	HEAD-INJURY; CATECHOLAMINES; POTASSIUM	Hyperglycemia and hypokalemia caused by catecholamine discharge have been reported to occur in patients after severe head trauma. The aim of this prospective study was to evaluate whether a similar neuroendocrine and metabolic response is found in children after minor head trauma such as brain concussion (Glasgow Coma Scale (GCS) greater than or equal to 13). One hundred fifty patients aged 2 to 14 years (average, 6 years) were divided into three groups (n = 50 in each group), Group 1 included patients admitted to the emergency department for brain concussion (Glasgow Coma Scale (GCS) greater than or equal to 13); group 2 included patients admitted for fractures of long bones without head injury; and group 3 were control patients electively admitted for hernia repair. All patients had complete physical and neurological examinations. Complete blood count and blood chemistry were obtained on admission. All blood tests were repeated at 6, 12, and 24 hours in patients belonging to group 1. An electrocardiogram was obtained in selected patients and catecholamine levels were measured in some patients. Statistical analysis was performed using analysis of variance (ANOVA). Serum potassium and sodium levels in patients with brain concussion (group 1) were 3.6 +/- 0.6 and 136 +/- 3 mEq/L, respectively and were significantly lower (P < 0.01) than those in patients belonging to group 2, 4 +/- 0.4 and 138 +/- 3, respectively, and the controls (group 3), 4.2 +/- 0.5 and 140 +/- 2, respectively Serum glucose revel was 124 +/- 34 and 118 +/- 32 mg% in groups 1 and 2 and was significantly higher than that of the controls (group 3), 90 +/- 23 mg%. There was no correlation between serum electrolytes and GCS. No electrocardiogram changes or elevation of serum catecholamines were found. Hypokalemia resolved spontaneously within 24 hours. All patients recovered without neurological sequalae. Transient hypokalemia frequently occurs in children even with minor head trauma. This hypokalemia resolves spontaneously, without treatment and within 24 hours. Copyright (C) 1997 by W.B. Saunders Company	MEIR HOSP,DEPT PEDIAT SURG,SAPIR MED CTR,IL-44281 KEFAR SAVA,ISRAEL							BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; CLAUSEN T, 1983, ACTA MED SCAND S, V672, P111; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CRUICKSHANK JM, 1974, BRIT HEART J, V36, P697; EPSTEIN FH, 1983, NEW ENGL J MED, V309, P1450, DOI 10.1056/NEJM198312083092308; PENTELENYI T, 1979, INJURY, V10, P201, DOI 10.1016/0020-1383(79)90009-3; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; POMERANZ S, 1989, ACTA NEUROCHIR, V97, P62, DOI 10.1007/BF01577741	9	24	25	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	JAN	1997	32	1					88	90		10.1016/S0022-3468(97)90102-0			3	Pediatrics; Surgery	Pediatrics; Surgery	WE275	WOS:A1997WE27500025	9021578				2021-06-18	
J	Simpson, DM				Simpson, DM			Clinical trials of botulinum toxin in the treatment of spasticity	MUSCLE & NERVE			English	Article							UPPER EXTREMITY SPASTICITY; DOUBLE-BLIND	Botulinum toxin has been tested as a treatment for spasticity resulting from cerebral palsy multiple sclerosis, traumatic brain injury, spinal cord injury, and stroke. The results of 18 studies are reviewed in this article. In both open label and double-blind, placebo-controlled trials, botulinum toxin has proven to be an effective measure for reduction of focal spasticity Improvements have been documented in tone reduction, range of motion, hygiene, autonomic dysreflexia, gait pattern, positioning, and other criteria, though not all criteria tested showed improvement in all studies. In none of the studies were there significant adverse effects. Future trials may be improved by refinement of several design parameters, including patient selection, treatment timing, and selection of dose and injection site. (C) 1997 John Wiley & Sons, Inc.	Mt Sinai Med Ctr, Dept Neurol, New York, NY 10019 USA; Mt Sinai Med Ctr, Dept Clin Neurophysiol, New York, NY 10019 USA	Simpson, DM (corresponding author), Mt Sinai Med Ctr, Dept Neurol, 1 Gustave L Levy Pl, New York, NY 10019 USA.						[Anonymous], 1990, Neurology, V40, P1332; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Benecke R, 1994, THERAPY BOTULINUM TO, P557; BOHLEGA S, 1995, MOVEMENT DISORD, V10, P399; BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364; Chutorian A, 1994, INT PEDIAT S1, V9, P35; CHUTORIAN A, 1995, MOVEMENT DISORD, V10, P364; Corry IS, 1997, DEV MED CHILD NEUROL, V39, P185; COSGROVE AP, 1992, BR J SURG B, V74, P135; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DENGLER R, 1992, J NEUROL, V239, P375; DYKSTRA DD, 1990, ARCH PHYS MED REHAB, V71, P24; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; JABBARI B, 1995, MOVEMENT DISORD, V10, P379; Koman LA, 1994, THERAPY BOTULINUM TO, P511; LANDAU WM, 1974, ARCH NEUROL-CHICAGO, V31, P217; MEMIN B, 1992, REV NEUROL, V148, P212; PIERSON SH, 1997, MUSCLE NERVE S6, V20, pS36; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; Takenaga S, 1995, Rinsho Shinkeigaku, V35, P251; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939; YOUNG RR, 1989, NEW ENGL J MED, V320, P1553, DOI 10.1056/NEJM198906083202310; YOUNG RR, 1994, NEUROLOGY, V44, P512	25	24	27	0	0	JOHN WILEY & SONS INC	NEW YORK	605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0148-639X			MUSCLE NERVE	Muscle Nerve		1997				6			S169	S175					7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	YQ157	WOS:000071354200011	9826988				2021-06-18	
J	SmithKnapp, K; Corrigan, JD; Arnett, JA				SmithKnapp, K; Corrigan, JD; Arnett, JA			Predicting functional independence from neuropsychological tests following traumatic brain injury	BRAIN INJURY			English	Article							ASSESSMENT SCALES	The relationship between impairment, measured by the Halstead-Reitan Neuropsychological Test Battery (HRNTB), and disability, measured by the Functional Independence Measure (FIM), was investigated in 164 subjects completing acute, inpatient rehabilitaton following traumatic brain injury. Exploratory factor analysis of the FIM supported a two-factor model of disability, with 13 items loading on a motor disability factor and five items loading on a cognitive disability factor. HRNTB findings and injury-related variables were predictive of motor disability, as five variables accounted for 39-44% of the variance in FIM Motor scores. Contrary to expectations, the relationship with cognitive disability was comparable to, but did not exceed, that for motor disability, as only 29-40% of the variance in FIM Cognitive scores was accounted for. The WAIS-R Comprehension subtest was the single best predictor of cognitive disability, accounting for 20% of variance, and suggesting that the FIM Cognitive subscale is measuring social-cognitive ability, as intended by its authors. Results are discussed in terms of the relationships among impairment and disability, including the need to further scrutinize the operationalization of these constructs as they relate to cognitive functions.	MED COLL OHIO,DEPT PHYS MED & REHABIL,TOLEDO,OH 43699; OHIO STATE UNIV,DEPT PHYS MED & REHABIL,COLUMBUS,OH 43210			Corrigan, John D./E-2921-2011				BENYISHA.Y, 1970, J CONSULT CLIN PSYCH, V34, P436, DOI 10.1037/h0029366; Committee on Trauma Research CoLS National Research Council and the IOM, 1985, INJ AM CONT PUBL HLT; *CTR FUNCT ASS RES, 1990, GUID US UN DAT SET M; DAHLBERG C, 1990, P AM SPINAL INJURY A, P23; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; FRANZEN MD, 1989, REALIABILITY VALIDIT; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; FUHRER MJ, 1987, REHABILITATION OUTCO, P1; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1992, AM J PHYS MED REHAB, V71, P108, DOI 10.1097/00002060-199204000-00009; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 1991, PREDICTION REHABILIT; HEVERN VW, 1980, CLIN NEUROPSYCHOLOGY, V2, P49; JARVIS PE, 1984, HALSTEAD REITAN TEST; Jastak S, 1984, WIDE RANGE ACHIEVEME; KLOVE H, 1974, CLIN NEUROPSYCHOLOGY, P211; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MCCUE M, 1990, REHABIL PSYCHOL, V35, P91; PULLICINO P, 1992, STROKE, V222, P919; REITAN RM, 1973, ANN CONV AM PSYCH AS; Reitan RM., 1985, HALSTEAD REITAN NEUR; Robbins D. E., 1989, RELIABILITY VALIDITY, P91; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; Sattler J.M., 1988, ASSESSMENT CHILDRENS, V3rd; WAGNER KA, 1987, REHABILITATION OUTCO, P19; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; World Health Organization, 1980, INT CLASS IMP DIS HA	34	24	24	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1996	10	9					651	661		10.1080/026990596124070			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VB635	WOS:A1996VB63500003	8853868				2021-06-18	
J	Franzen, MD; Paul, D; Iverson, GL				Franzen, MD; Paul, D; Iverson, GL			Reliability of alternate forms of the trail making test	CLINICAL NEUROPSYCHOLOGIST			English	Article								Initial research in a limited sample of 15 closed-head-injury patients indicated reasonable reliability for alternate forms of the Trail Making Test, Parts A and B, called Form C and D, respectively. The present study examined the reliability of these alternate forms in a larger and more heterogeneous sample of 192 subjects with neurologic, psychiatric, or substance abuse diagnoses. The two forms correlated significantly, and there were no significant differences in mean scores for the two forms. The results indicate adequate reliability, although separate cut-off values for Form C may be necessary due to a nonsignificant tendency for scores on Form C to be lower than for the Trail Making Test, Part A.	MED COLL PENN & HAHNEMANN UNIV,DEPT PSYCHIAT & ANI,PHILADELPHIA,PA; W VIRGINIA UNIV,MORGANTOWN,WV 26506				Iverson, Grant/0000-0001-7348-9570			Berg R., 1987, SCREENING BRAIN IMPA; CHARTER RA, 1987, INT J CLIN NEUROPSYC, V9, P28; DESROSIERS G, 1987, INT J CLIN NEUROPSYC, V9, P162; DYE OA, 1979, PRECEPTUAL MOTOR SKI, V48, P206; Heaton R.K., 1991, COMPREHENSIVE NORMS; KELLAND DZ, 1994, CLIN NEUROPSYCHOL, V8, P295, DOI 10.1080/13854049408404136; Lewis RF., 1979, MANUAL REPEATABLE CO; LEZAK MD, 1982, 5 EUR C INT NEUR SOC; MATARAZZO JD, 1974, J NERV MENT DIS, V158, P37, DOI 10.1097/00005053-197401000-00006; MCCRACKEN LM, 1992, PSYCHOL ASSESSMENT, V4, P235, DOI DOI 10.1037//1040-3590.4.2.235; Reitan M., 1985, HALSTEAD REITAN NEUR; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM	12	24	24	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	1996	10	2					125	129		10.1080/13854049608406672			5	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	UM880	WOS:A1996UM88000001					2021-06-18	
J	Patrick, CW; Kukreti, S; McIntire, LV				Patrick, CW; Kukreti, S; McIntire, LV			Quantitative effects of peripheral monocytes and nerve growth factor on CNS neural morphometric outgrowth parameters in vitro	EXPERIMENTAL NEUROLOGY			English	Article							3-DIMENSIONAL CELL-CULTURES; BLOOD MONONUCLEAR-CELLS; NEURITE OUTGROWTH; TRAUMATIC INJURY; MAMMALIAN BRAIN; NTERA-2 CELLS; NEURONS; LINE; INHIBITION; PHAGOCYTES	Wound healing of the central nervous system (CNS) is a complex process involving interactions between cells from both the vascular and the neural environments, extracellular matrix proteins, and a cocktail of agonistic and antagonistic bioactive molecules. Vascular cells, particularly peripheral monocytes and macrophages, are believed to play an important role in organizing and mediating CNS tissue reactions subsequent to penetrating injuries that compromise the blood-brain barrier. Although many investigators have studied the effect of macrophages and microglia (resident brain macrophages) on neural outgrowth, little is known regarding monocyte effects. We have combined tissue culture, video microscopy, and digital image processing and analysis to quantify morphometric parameters of neurons exposed to monocyte secretory products in vitro. The experimental system developed is simple in design but provides a quantitative understanding of cellular function and molecular mechanisms and has the ability to both study processes of graded complexity and relate cellular function to overall systems behavior. We evaluate the efficacy of the experimental model developed by measuring morphometric parameters of human neural cells (hNT cell line) in the presence of nerve growth factor (NGF). Results suggest that monocyte-conditioned media (MCM) increases neuron outgrowth parameters, such as neuritic output, mean arbor output, neurite branching, and effective cell diameter. Moreover, we show that the bioactive factor present in MCN is not IL-1 and the activity of the factor with respect to neural outgrowth is between that of 10 and 100 ng/ml NGF. (C) 1996 Academic Press, Inc.		Patrick, CW (corresponding author), RICE UNIV, COX LAB BIOMED ENGN, INST BIOSCI & BIOENGN, HOUSTON, TX 77251 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37-HL-18672] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [O01-NS-22237] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL018672] Funding Source: NIH RePORTER		AEBISCHER P, 1989, J NEUROSCI, V9, P3590; ANDREESEN R, 1990, J LEUKOCYTE BIOL, V47, P490; ARAUJO DM, 1993, BRAIN RES, V600, P49, DOI 10.1016/0006-8993(93)90400-H; BEATY CE, 1993, J CONTROL RELEASE, V24, P15, DOI 10.1016/0168-3659(93)90165-2; BENNETT S, 1992, J IMMUNOL METHODS, V153, P201, DOI 10.1016/0022-1759(92)90323-L; BRODKEY JA, 1993, EXP NEUROL, V123, P251, DOI 10.1006/exnr.1993.1158; BROSNAN CF, 1993, ADV NEUROL, V59, P349; BUETTNER HM, 1991, DEV BIOL, V145, P266, DOI 10.1016/0012-1606(91)90125-M; CHAMAK B, 1994, J NEUROSCI RES, V38, P221, DOI 10.1002/jnr.490380213; CHULUYAN HE, 1993, J CLIN INVEST, V92, P2768, DOI 10.1172/JCI116895; CUNHA A, 1993, BRAIN RES, V631, P39; DINARELLO CA, 1994, FASEB J, V8, P1314; FISHER M, 1993, J NEUROL SCI, V119, P189, DOI 10.1016/0022-510X(93)90133-J; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GIULIAN D, 1993, STROKE S1, V24, P84; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Greene L.A., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HARDY M, 1994, J NEUROCHEM, V63, P482; HIRKA G, 1991, J VIROL, V65, P2732, DOI 10.1128/JVI.65.5.2732-2735.1991; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KREWSON CE, 1994, BIOTECHNOL BIOENG, V43, P555, DOI 10.1002/bit.260430704; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LYNCH EA, 1994, J IMMUNOL, V153, P300; MORGAN B, 1989, J NEUROSCI RES, V23, P41, DOI 10.1002/jnr.490230106; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; PATRICK CW, 1995, BLOOD, V85, P168, DOI 10.1182/blood.V85.1.168.bloodjournal851168; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; POUTSIAKA DD, 1991, BLOOD, V78, P1275; RECALDE HR, 1984, J IMMUNOL METHODS, V69, P71, DOI 10.1016/0022-1759(84)90278-3; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; RUDGE JS, 1989, EXP NEUROL, V103, P1, DOI 10.1016/0014-4886(89)90180-5; SALTZMAN WM, 1992, ANN NY ACAD SCI, V665, P259, DOI 10.1111/j.1749-6632.1992.tb42590.x; STRIJBOS PJLM, 1995, J NEUROSCI, V15, P3468; THORPE LW, 1987, J NEUROSCI RES, V17, P128, DOI 10.1002/jnr.490170206; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.ne.12.030189.000535; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WOODROOFE MN, 1993, CYTOKINE, V5, P583, DOI 10.1016/S1043-4666(05)80008-0; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	48	24	24	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	1996	138	2					277	285		10.1006/exnr.1996.0066			9	Neurosciences	Neurosciences & Neurology	UF078	WOS:A1996UF07800011	8620926				2021-06-18	
J	Shum, D; Sweeper, S; Murray, R				Shum, D; Sweeper, S; Murray, R			Performance on verbal implicit and explicit memory tasks following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						explicit memory; implicit memory; level of processing; traumatic brain injury	CLOSED-HEAD-INJURY; RETENTION; SURVIVORS	The study aimed to ascertain if implicit memory is preserved after traumatic brain injury (TBI). It used two explicit memory tasks (graphemic-cued recall and semantic-cued recall) and two implicit memory tasks (word-fragment completion and general knowledge) to compare the performance of 16 individuals with severe, long-term TBI, and 16 matched controls. In addition, it examined the effect of level of processing on memory-task performance. It was found that individuals with TBI performed significantly more poorly on the two explicit memory tasks but not the two implicit memory tasks. Moreover, it was found that these individuals did not benefit as much from deep processing of memory materials as the matched controls. Implications of these Endings for developing memory training programs are discussed.	GRIFFITH UNIV,SCH APPL PSYCHOL,NATHAN,QLD 4111,AUSTRALIA	Shum, D (corresponding author), GRIFFITH UNIV,NEUROPSYCHOL UNIT,NATHAN,QLD 4111,AUSTRALIA.		Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			BLAXTON TA, 1992, MEM COGNITION, V20, P549, DOI 10.3758/BF03199587; BRANDT J, 1992, NEUROPSYCHOLOGY MEMO; CHALLIS BH, 1992, J EXP PSYCHOL LEARN, V18, P595, DOI 10.1037/0278-7393.18.3.595; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; GARDINER JM, 1988, J EXP PSYCHOL LEARN, V14, P495, DOI 10.1037/0278-7393.14.3.495; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; GLISKY EL, 1989, HDB NEUROPSYCHOLOGY; GLISKY EL, 1992, J HEAD TRAUMA REHAB, V7, P1; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Levin H., 1989, HDB NEUROPSYCHOLOGY; MAPOU RL, 1992, HDB HEAD TRAUMA; MASSON MEJ, 1992, J EXP PSYCHOL GEN, V121, P145, DOI 10.1037/0096-3445.121.2.145; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; PARKIN AJ, 1993, NEUROPSYCHOLOGY AMNE; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; SCHACTER DL, 1992, AM PSYCHOL, V47, P559, DOI 10.1037/0003-066X.47.4.559; Sholberg M. M., 1989, INTRO COGNITIVE REHA; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; WARRINGT.EK, 1970, NATURE, V228, P628, DOI 10.1038/228628a0; WARRINGTON EK, 1968, NATURE, V217, P972, DOI 10.1038/217972a0; Wilson B.A., 1992, CLIN MANAGEMENT MEMO, V2nd; WILSON BA, 1992, NEUROPSYCHOLOGY MEMO	25	24	24	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1996	11	2					43	53		10.1097/00001199-199604000-00005			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UD674	WOS:A1996UD67400005					2021-06-18	
J	Wilde, MC; Boake, C; Sherer, M				Wilde, MC; Boake, C; Sherer, M			Do recognition-free recall discrepancies detect retrieval deficits in closed-head injury? An exploratory analysis with the California verbal learning test	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	22nd Annual Meeting of the International-Neuropsychological-Society	FEB 02-05, 1994	CINCINNATI, OH	Int Neuropsychol Soc			HUNTINGTONS-DISEASE; MEMORY; ALZHEIMERS	The present study examined the validity of the Recognition Discriminability-Long Delay Free Recall discrepancy from the California Verbal Learning Test (CVLT) as a sign of retrieval deficits in closed-head injury (CHI). Discrepancy and nondiscrepancy groups who differed in their Recognition Discriminability performance but were equated on Long-Delay Free Recall were compared on indices hypothesized to reveal performance patterns consistent with retrieval deficits. Results showed that the discrepancy group produced fewer intrusions. The two groups did not differ in their consistency of recall or relative degree of benefit from semantic cuing. Additional analysis using a discrepancy group with normal Recognition Discriminability scores but abnormal Long-Delay Free Recall performance did not alter these results. The hypotheses were not supported when patients with language deficits were excluded. The findings did not support the use of this discrepancy from the CVLT as a marker for retrieval deficits in CHI.	BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,INST REHABIL & RES,HOUSTON,TX; UNIV TEXAS,HLTH SCI CTR,DEPT PHYS MED & REHABIL,HOUSTON,TX							Benton A, 1988, MULTILINGUAL APHASIA; BRANDT J, 1992, J CLIN EXP NEUROPSYC, V14, P773, DOI 10.1080/01688639208402862; BUTTERS N, 1986, CORTEX, V22, P11, DOI 10.1016/S0010-9452(86)80030-2; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1993, CLIN NEUROPSYCHOL, V7, P250, DOI 10.1080/13854049308401897; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; CROSSON B, 1993, NEUROPSYCHOLOGY, V7, P193, DOI DOI 10.1037/0894-4105.7.2.193; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1991, PSYCHOL ASSESSMENT, V3, P19, DOI DOI 10.1037/1040-3590.3.1.19; Fridlund A, 1987, CVLT RES EDITION ADM; GRANHOLM E, 1988, BRAIN COGNITION, V7, P335, DOI 10.1016/0278-2626(88)90007-3; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MASSMAN PJ, 1990, J CLIN EXP NEUROPSYC, V12, P729, DOI 10.1080/01688639008401015; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; TULVING E, 1987, NEUROBEHAVIORAL RECO, P341; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	20	24	24	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1995	17	6					849	855		10.1080/01688639508402434			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	TM776	WOS:A1995TM77600005	8847391				2021-06-18	
J	KRAUS, JF; PEEK, C				KRAUS, JF; PEEK, C			THE IMPACT OF 2 RELATED PREVENTION STRATEGIES ON HEAD-INJURY REDUCTION AMONG NONFATALLY INJURED MOTOR CYCLE RIDERS, CALIFORNIA, 1991-1993	JOURNAL OF NEUROTRAUMA			English	Article						ACCIDENT PREVENTION; TRAFFIC ACCIDENTS; TRAUMA; LEGISLATION; EPIDEMIOLOGY	LAW; FATALITIES; HELMETS; COSTS	Although the traumatic injury death rate in the United States decreased during the last 20 years, the percent of all injury deaths attributable to brain injuries has remained steady. Head injuries are a leading cause of injury among motorcycle riders in crashes, and the helmet is an effective measure to reduce these injuries. To reduce the burden and cost of motorcycle injuries, many states have increased helmet use by introducing mandatory helmet legislation. This report presents evidence on the effects of the motorcycle helmet and helmet use legislation-two interrelated prevention strategies which decrease traumatic brain injury among motorcycle riders. Nonfatally injured motorcyclists were included if they crashed between January 1, 1991 and December 31, 1993 and were treated in one of 18 hospitals in 10 California counties. Medical records for all injured motorcyclists admitted to these 18 hospitals and those treated in the emergency department and released in eight of these hospitals were individually reviewed. Complete lists of injury diagnoses for each rider were coded according to the 1990 Abbreviated Injury Severity Scale by trained clinical staff. Before the universal helmet law was introduced (when only a third of injured riders wore helmets) 38.2% of riders sustained head injuries. When helmet use increased to over 85% of injured riders following the law, less than 25% of riders sustained head injuries. Both the severity and the number of head injuries per individual rider decreased after the mandatory helmet use law led to increased helmet use. Riders wearing helmets suffered fewer skull fractures, fewer intracranial injuries, had less frequent and shorter periods of loss of consciousness, more favorable GCS scores, and shorter hospital stays. Mandatory motorcycle helmet use laws are an effective mechanism to increase helmet use among riders and thus prevent head and brain injuries resulting from motorcycle crashes.		KRAUS, JF (corresponding author), UNIV CALIF LOS ANGELES,SCH PUBL HLTH,SO CALIF INJURY PREVENT RES CTR,10833 LECONTE AVE,LOS ANGELES,CA 90095, USA.						[Anonymous], 1990, ABBREVIATED INJURY S; CAIRNS H, 1941, BRIT MED J, V2, P465; Carey V, 1994, Aust J Public Health, V18, P25; DRYSDALE WF, 1975, J TRAUMA, V15, P99, DOI 10.1097/00005373-197502000-00003; EVANS L, 1991, ACCIDENT ANAL PREV, V23, P165, DOI 10.1016/0001-4575(91)90046-8; EVANS L, 1990, ACCIDENT ANAL PREV, V22, P167, DOI 10.1016/0001-4575(90)90067-U; FAYON A, 1976, P BIOMECHANICS INJUR; FLEMING NS, 1992, MED CARE, V30, P832, DOI 10.1097/00005650-199209000-00007; HURT HH, 1981, P AM ASS AUTOMOTIVE; KRANTZ KPG, 1985, INJURY, V16, P253; KRAUS JF, 1995, AM J PUBLIC HEALTH, V85, P96, DOI 10.2105/AJPH.85.1.96; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LOEB PD, 1993, ACCIDENT ANAL PREV, V25, P189, DOI 10.1016/0001-4575(93)90059-6; LUNA GK, 1981, WESTERN J MED, V135, P89; MCSWAIN NE, 1990, J TRAUMA, V30, P1189, DOI 10.1097/00005373-199010000-00002; MCSWAIN NE, 1984, DOTHS806760 NAT HIGH; MCSWAIN NE, 1984, DTN22782C05086; Mounce N., 1992, REINSTATED COMPREHEN; MUELLEMAN RL, 1992, ANN EMERG MED, V21, P266, DOI 10.1016/S0196-0644(05)80886-8; ROBERSTON L, 1992, INJURY EPIDEMIOLOGY; RUTLEDGE R, 1991, 35TH P ASS ADV AUT M; SARKAR S, 1995, J TRAUMA, V38, P242, DOI 10.1097/00005373-199502000-00017; SOSIN D, UNPUB; WAGENAAR AC, 1990, ACCIDENT ANAL PREV, V22, P253, DOI 10.1016/0001-4575(90)90017-F; WATSON GS, 1980, AM J PUBLIC HEALTH, V70, P579, DOI 10.2105/AJPH.70.6.579; ZADOR PL, 1993, AM J PUBLIC HEALTH, V83, P661, DOI 10.2105/AJPH.83.5.661; 1991, GAORCED91170; 1980, REPORT C EFFECT MOTO; 1994, TRAFFIC SAFETY FACTS; 1994, 1993 ANN REP FAT INJ; 1994, JAMA-J AM MED ASSOC, V272, P1535	32	24	24	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					873	881		10.1089/neu.1995.12.873			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600011	8594214				2021-06-18	
J	LOKEN, WJ; THORNTON, AE; OTTO, RL; LONG, CJ				LOKEN, WJ; THORNTON, AE; OTTO, RL; LONG, CJ			SUSTAINED ATTENTION AFTER SEVERE CLOSED-HEAD INJURY	NEUROPSYCHOLOGY			English	Article							DYSFUNCTION	Sustained attention was assessed in 20 patients with severe closed head injury (CHI) and 20 normal matched controls. Participants were presented with a visual continuous performance task (CPT) with 3 levels of complexity. Performance was assessed by examining response latencies and error rates. Across all levels of complexity, the CHI patients demonstrated a vigilance decrement, whereas the performance of the matched controls was stable across time. The vigilance decrement was not differentially affected by the manipulation of task complexity in the CHI patients. However, findings suggest that the overall vigilance performance of CHI patients was differentially affected by increasing the complexity of the task.	UNIV MEMPHIS, MEMPHIS, TN USA; BRAINTREE REHABIL HOSP, BRAINTREE, MA USA				Thornton, Allen/0000-0002-9942-0122			BOND MR, 1983, REHABILITATION HEAD, P219; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BUCHSBAUM MS, 1987, PSYCHOPHARMACOLOGY 3, P783; BUCHTEL HA, 1987, NEUROBEHAVIORAL RECO, P372; BUCK L, 1966, PSYCHOL BULL, V65, P291, DOI 10.1037/h0023207; COHEN RM, 1987, LIFE SCI, V40, P2031, DOI 10.1016/0024-3205(87)90295-5; Conkey RC, 1938, ARCH PSYCHOL, P5; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Davies D.R., 1982, PSYCHOL VIGILANCE; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRONWALL D, 1974, LANCET, V2, P605; LEVIN HS, 1988, SCAND J REHABIL MED, P33; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOKEN WJ, 1992, ARCH CLIN NEUROPSYCH, V8, P245; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PARASURAMAN R, 1984, VARIETIES ATTENTION, P243; Parasuraman R., 1977, VIGILANCE THEORY OPE, P559; Posner M. I., 1987, NEUROPSYCHOL REHABIL, P182; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SCHEIBEL AB, 1980, RETICULAR FORMATION, P55; Seashore SH, 1941, J EXP PSYCHOL, V29, P342, DOI 10.1037/h0061571; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Wickens C.D., 1992, ENG PSYCHOL HUMAN PE, VSecond; WILKINS AJ, 1987, NEUROPSYCHOLOGIA, V25, P359, DOI 10.1016/0028-3932(87)90024-8; WOOD RL, 1988, J LEARN DISABIL, V21, P327, DOI 10.1177/002221948802100603	33	24	24	0	1	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	1995	9	4					592	598		10.1037/0894-4105.9.4.592			7	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	TA644	WOS:A1995TA64400017					2021-06-18	
J	BANDAK, FA				BANDAK, FA			ON THE MECHANICS OF IMPACT NEUROTRAUMA - A REVIEW AND CRITICAL SYNTHESIS	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		IMPACT; TBI; COMPUTATIONAL; DAI; HEMATOMA; CONTUSIONS; VASCULAR		A computational modeling technique for the simulation of head impact mechanics is proposed as a tool for the study of traumatic brain injury (TBI), The capabilities, limitations, and consequently the utilities of this technique are discussed in light of the current computing and imaging technologies and their prospective advancement, A significant portion of the mechanics, relevant to head impact simulation, has been incorporated into this computational technique resulting in automated devices that ease the technical burden of biomechanical analysis of TBI mechanisms, A brief exposition of the concepts utilized in these devices is given and their basis in experiment is discussed.	GEORGE WASHINGTON UNIV,SCH ENGN & APPL SCI,WASHINGTON,DC 20052	BANDAK, FA (corresponding author), US DEPT TRANSPORTAT,NATL HIGHWAY TRAFF SAFE ADM,WASHINGTON,DC 20590, USA.						BANDAK FA, 1995, J NEUROTRAUM, V12, P679, DOI 10.1089/neu.1995.12.679; BANDAK FA, 1995, UNPUB EXPT COMPUTATI; CHAN PC, 1995, UNPUB INFLUENCE SUBA; CHAN RKC, 1986, WIN ANN M AN; DIMASI F, 1991, AUTO TRAFFIC SAFETY, V1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1987, 31ST P STAPP CAR CRA, P564; HALLQUIST J, 1994, 1018 LIV SOFTW TECHN; Holbourn AHS, 1943, LANCET, V2, P438; LILLES DR, 1978, J COMP PHYS, V26, P390; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; MEANEY DF, 1990, 1990 P IRCOBI C LYON, V11, P215; Melvin J.W., 1993, ACCIDENTAL INJURY BI, P268; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1968, J BIOMECH; OMMAYA AK, 1969, ACCIDENT PATHOLOGY; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P63; THIBAULT LE, 1982, ADV BIOENGINEERING	25	24	24	1	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					635	649		10.1089/neu.1995.12.635			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000015	8683615				2021-06-18	
J	GOLDING, EM; VINK, R				GOLDING, EM; VINK, R			EFFICACY OF COMPETITIVE VS NONCOMPETITIVE BLOCKADE OF THE NMDA CHANNEL FOLLOWING TRAUMATIC BRAIN INJURY	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						NMDA ANTAGONIST; MAGNESIUM; MAGNETIC RESONANCE; PHOSPHORUS MRS; DEXTROMETHORPHAN; CGS-19755	VOLTAGE-DEPENDENT BLOCK; D-ASPARTATE RECEPTORS; MAGNETIC-RESONANCE; FREE MAGNESIUM; ACTIVATED CHANNELS; CALCIUM; NEURONS; GLUTAMATE; DAMAGE; MG-2+	N-methyl-D-aspartate (NMDA) receptor antagonists have been demonstrated widely to be neuroprotective in cerebral ischemia, hypoxia, and traumatic brain injury. However, although noncompetitive NMDA antagonists have typically proven efficacious under all of these conditions, competitive antagonists have not been shown to be beneficial following moderate traumatic brain injury. The present study has used phosphorus magnetic resonance spectroscopy ([P-31]MRS) to examine the effects of the competitive antagonist cis-4-(phosphonomethyl) piperidine-2-carboxylic acid (CGS-19755) and the noncompetitive antagonist dextromethorphan on biochemical outcome following fluid percussion-induced traumatic brain injury in rats. Five minutes prior to induction of moderate (2.8 +/- 0.2 atm) fluid percussion brain injury, animals received either CGS-19755 (10 mg/kg iv), dextromethorphan (10 mg/kg iv), or equal volume saline vehicle. [P-31]MRS spectra were then acquired for 4 h post-trauma and intracellular pH, free magnesium concentration, cytosolic phosphorylation potential, and oxidative capacity determined. Both CGS-19755-treated animals and saline treated controls demonstrated significant and sustained declines in intracellular free magnesium concentration and bioenergetic status following trauma. In contrast, administration of dextromethorphan significantly attenuated free magnesium decline and improved bioenergetic state during the post-traumatic monitoring period. These results suggest that the neuroprotective actions of NMDA antagonists following traumatic brain injury are associated with attenuation of free magnesium decline and that such actions seem to be preferentially medicated by noncompetitive blockers.	JAMES COOK UNIV N QUEENSLAND,DIV BIOCHEM & HUMAN PHYSIOL,TOWNSVILLE,QLD 4811,AUSTRALIA			Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; BOLGER GT, 1986, PHARMACOL BIOCHEM BE, V24, P417, DOI 10.1016/0091-3057(86)90534-4; BRAAKMAN R, 1993, J NEUROTRAUMA S, V10, pS85; CARPENTER CL, 1988, BRAIN RES, V439, P372, DOI 10.1016/0006-8993(88)91497-7; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1986, FED PROC, V45, P2915; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1989, INTENSIVE CARE EMERG, V9, P14; GARFINKEL L, 1984, BIOCHEMISTRY-US, V23, P3547, DOI 10.1021/bi00310a025; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; JOHNSON JW, 1990, BIOPHYS J, V57, P1085, DOI 10.1016/S0006-3495(90)82626-6; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NIOKA S, 1990, J APPL PHYSIOL, V68, P2527; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PEARSON HA, 1993, NEUROPHARMACOLOGY, V32, P1171, DOI 10.1016/0028-3908(93)90011-Q; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; TAKIZAWA S, 1991, J CEREBR BLOOD F MET, V11, P786, DOI 10.1038/jcbfm.1991.136; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, J NEUROTRAUMA, V5, P365; VINK R, 1991, MAGNESIUM EXCITABLE, P695; YOUNG W, 1992, CENTRAL NERVOUS SYST, P9; ZEEVALK GD, 1991, J PHARMACOL EXP THER, V257, P870	51	24	24	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07012	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	FEB-APR	1995	24	2-3					137	150		10.1007/BF02962139			14	Neurosciences; Pathology	Neurosciences & Neurology; Pathology	QX448	WOS:A1995QX44800004	7632318				2021-06-18	
J	JOHNSTONE, B; FRANK, RG				JOHNSTONE, B; FRANK, RG			NEUROPSYCHOLOGICAL ASSESSMENT IN REHABILITATION - CURRENT LIMITATIONS AND APPLICATIONS	NEUROREHABILITATION			English	Article						NEUROPSYCHOLOGICAL EVALUATION; REHABILITATION PSYCHOLOGY; CONSTRUCT VALIDITY; ECOLOGICAL VALIDITY	CLOSED-HEAD-INJURY; VISUAL ORGANIZATION TEST; CARD SORTING TEST; TEST-PERFORMANCE; BRAIN INJURY; BATTERY; LURIA; VALIDITY; HOOPER; DYSFUNCTION	Neuropsychological assessment is a standard procedure for rehabilitation patients with cognitive dysfunction. However, the use of neuropsychological evaluations in rehabilitation settings is limited as the most commonly used measures were originally developed for diagnostic purposes with an emphasis on localization/lateralization of lesions and description of brain-behavior relationships. As a result, the functional (versus diagnostic) utility of neuropsychological evaluations is questionable at best. Furthermore, neuropsychological evaluation in rehabilitation settings will continue to be of limited utility as long as INS-APA Division 40 guidelines continue to emphasize training in neurologic and neuroanatomic factors, with minimal attention to rehabilitation issues and resources. Several factors necessitate the use of neuropsychological evaluations for functional rather than diagnostic purposes, including advances in neuroradiological evaluation, the growth of rehabilitation facilities given increased survival rates for brain injured patients, and an associated greater need for psychological services for these patients. Suggestions are offered for improving the functional utility of neuropsychological evaluations, as well as more effective ways to train neuropsychologists in rehabilitation issues and interventions.		JOHNSTONE, B (corresponding author), UNIV MISSOURI,SCH MED,DEPT PHYS MED & REHABIL,501 RRC,COLUMBIA,MO 65212, USA.			Johnstone, Brick/0000-0001-8845-9649			ADAMS KM, 1980, J CONSULT CLIN PSYCH, V48, P511, DOI 10.1037/0022-006X.48.4.511; ALBERTS MJ, 1992, STROKE, V23, P663, DOI 10.1161/01.STR.23.5.663; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Barkley R. A., 1994, ADHD REPORT, V2, P1; BENNETT TL, 1988, COGNITIVE REHABILITA, V6, P18; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bigler E D, 1991, Arch Clin Neuropsychol, V6, P113, DOI 10.1016/0887-6177(91)90028-8; BLIEBERG J, 1992, PHYSICAL MED REHABIL; BOLL TJ, 1981, HDB CLIN NEUROPSYCHO; BORNSTEIN RA, 1988, CLIN NEUROPSYCHOL, V2, P107, DOI DOI 10.1080/13854048808520093; BORNSTEIN RA, 1988, ARCH CLIN NEUROPSYCH, V2, P15; BOYD JL, 1981, J CONSULT CLIN PSYCH, V49, P15, DOI 10.1037/0022-006X.49.1.15; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Chelune G. J, 1986, NEUROPSYCHOLOGY HDB, P489; COSTA L, 1988, CLIN NEUROPSYCHOL, V2, P3; DELIS DC, 1983, J CONSULT CLIN PSYCH, V51, P396; DODRILL CB, 1984, J CONSULT CLIN PSYCH, V52, P520, DOI 10.1037/0022-006X.52.4.520; Dunn E J, 1990, Arch Clin Neuropsychol, V5, P103, DOI 10.1016/0887-6177(90)90032-K; ERICKSON RC, 1986, J CLIN EXP NEUROPSYC, V8, P257, DOI 10.1080/01688638608401317; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FITZ AG, 1992, ARCH CLIN NEUROPSYCH, V7, P243, DOI 10.1016/0887-6177(92)90166-K; FRANK RG, 1990, AM PSYCHOL, V45, P757, DOI 10.1037/0003-066X.45.6.757; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GOLDEN C, 1981, HDB CLIN NEUROPSYCHO; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; Hartman D E, 1991, Arch Clin Neuropsychol, V6, P147, DOI 10.1016/0887-6177(91)90030-D; HARTMAN DE, 1988, ARCH CLIN NEUROPSYCH, V3, P299; HAUT M, 1992, STATE ART REV PHYSIC; Heaton R. K, 1981, WISCONSIN CARD SORTI; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Heilbronner R. L., 1989, CLIN NEUROPSYCHOL, V3, P250; HEINRICHS RW, 1990, PROF PSYCHOL-RES PR, V21, P171, DOI 10.1037/0735-7028.21.3.171; Hooper, 1983, HOOPER VISUAL ORG TE; Hooper H.E., 1958, HOOPER VISUAL ORG TE; Johnston M. V., 1992, NEUROREHABILITATION, V2, P72; KANE RL, 1989, J CLIN EXPT NEUROPSY, V4, P589; Kaplan E., 1988, CLIN NEUROPSYCHOLOGY, P125; Kaplan E, 1983, HOLISTIC DEV PSYCHOL, P143; KAZMARK P, 1992, BRAIN INJURY, V6, P213; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KREUTZER JS, 1990, COMMUNITY INTEGRATIO, P49; LEUNG P, 1990, REHABIL PSYCHOL, V35, P157; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEWIS GP, 1979, J CONSULT CLIN PSYCH, V47, P1003, DOI 10.1037/0022-006X.47.6.1003; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Loring D W, 1991, Arch Clin Neuropsychol, V6, P167; LORING DW, 1989, CLIN NEUROPSYCHOL, V3, P59, DOI DOI 10.1080/13854048908404077; Lynch W. J., 1990, REHABILITATION ADULT, P310; MALEC EA, 1991, NEUROPSYCHOLOGY, V5, P29, DOI DOI 10.1037/0894-4105.5.1.29; MAPOU RL, 1988, J CLIN EXP NEUROPSYC, V10, P271, DOI 10.1080/01688638808408241; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCSWEENY AJ, 1985, J CLIN EXP NEUROPSYC, V7, P281, DOI 10.1080/01688638508401260; MILBERG WP, 1986, NEUROPSYCHOLOGICAL A, P65; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; Paolo A. M., 1994, CLIN NEUROPSYCHOL, V8, P112; PARKER HJ, 1990, REHABIL PSYCHOL, V35, P239, DOI 10.1037/0090-5550.35.4.239; Parsons O A, 1991, Arch Clin Neuropsychol, V6, P105, DOI 10.1016/0887-6177(91)90027-7; PRIGATANO G, 1986, NEUROPSYCHOLOGOCAL R; PUENTE AE, 1992, ARCH CLIN NEUROPSYCH, V7, P297, DOI 10.1016/0887-6177(92)90024-H; Putnam S, 1990, CLIN NEUROPSYCHOL, V4, P199, DOI DOI 10.1080/13854049008401906; Reitan R M, 1989, Arch Clin Neuropsychol, V4, P385, DOI 10.1016/0887-6177(89)90029-2; REITAN RM, 1988, CLIN NEUROPSYCHOL, V2, P33; ROBBINS DE, 1989, RELIABILITY VALIDITY; ROSENTHAL M, 1992, NEUROREHABILITATION, V2, P1; ROTH DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; Rourke B P, 1991, Arch Clin Neuropsychol, V6, P1, DOI 10.1016/0887-6177(91)90017-4; ROUSSEAUX M, 1992, STROKE, V23, P511, DOI 10.1161/01.STR.23.4.511; SEIDEL WT, 1994, CLIN NEUROPSYCHOL, V8, P59, DOI 10.1080/13854049408401543; SHERER M, 1991, J CLIN EXP NEUROPSYC, V13, P741, DOI 10.1080/01688639108401087; SHESLOW R, 1990, WIDE RANGE ASSESSMEN; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SPIERS PA, 1981, J CONSULT CLIN PSYCH, V49, P331, DOI 10.1037/0022-006X.49.3.331; STAMBROOK M, 1983, J CLIN NEUROPSYCHOL, V5, P247, DOI 10.1080/01688638308401173; STERNE DM, 1973, J CLIN PSYCHOL, V29, P212, DOI 10.1002/1097-4679(197304)29:2<212::AID-JCLP2270290217>3.0.CO;2-S; TAMKIN AS, 1984, J CLIN PSYCHOL, V40, P1459, DOI 10.1002/1097-4679(198411)40:6<1459::AID-JCLP2270400633>3.0.CO;2-3; TAMKIN AS, 1985, J CLIN PSYCHOL, V41, P660, DOI 10.1002/1097-4679(198509)41:5<660::AID-JCLP2270410512>3.0.CO;2-B; TELLIER A, 1991, J CLIN EXP NEUROPSYC, V13, P105; TERAYAMA Y, 1991, SURG NEUROL, V36, P335, DOI 10.1016/0090-3019(91)90021-Z; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; WANG PL, 1977, PERCEPT MOTOR SKILL, V45, P723, DOI 10.2466/pms.1977.45.3.723; WEHMAN P, 1988, REHABIL COUNS BULL, V31, P298; WEHMAN P, 1989, BRAIN INJURY, V4, P397; *WI U, 1985, 12TH I REH ISS REH T; WILSON BA, 1987, REHAB MEMORY; 1987, CLIN NEUROPSYCHOL, V1, P29; 1992, DIV 22 NEWSLETT, V19, P7	88	24	24	0	5	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	FEB	1995	5	1					75	86		10.1016/1053-8135(94)00106-5			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RJ879	WOS:A1995RJ87900007	24525461				2021-06-18	
J	Buxbaum, LJ; Schwartz, MF; Coslett, HB; Carew, TG				Buxbaum, LJ; Schwartz, MF; Coslett, HB; Carew, TG			Naturalistic action and praxis in callosal apraxia	NEUROCASE			English	Article						callosal disconnection; ideational apraxia; apraxic agraphia; naturalistic action	DISCONNECTION SYNDROME; IDEATIONAL APRAXIA; MECHANISMS; PATIENT	We report a subject who, subsequent to closed head injury, demonstrated a severe left hand ideational apraxia and apraxic agraphia, consistent with callosal disconnection syndrome. In contrast to the left hand, performance of the right hand was unimpaired on traditional tests of gesture to command, sight of object, and with actual object use, but proved deficient on tests of spatial and constructional ability. We examined the consequences of these hand-specific deficits for the performance of naturalistic action tasks. The patient made errors with each hand; however, the right hand performed more poorly than the left hand. In addition, the types of errors made by each hand differed in a manner consistent with the results of neuropsychological testing and indicative of disconnection phenomena. We suggest that unlike gesture, naturalistic action requires the contribution of the specialized abilities of each hemisphere, integrated across callosal structures. Traditional testing of gesture may underestimate the right hemisphere's capacity for action programming.	TEMPLE UNIV, SCH MED, PHILADELPHIA, PA 19140 USA; MOSS REHABIL RES INST, PHILADELPHIA, PA 19141 USA							ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BENTON AL, 1985, CLIN NEUROPSYCHOLOGY, V2, P151; BOLDRINI P, 1992, CORTEX, V28, P135, DOI 10.1016/S0010-9452(13)80172-4; De Renzi E., 1982, DISORDERS SPACE EXPL; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1982, BRAIN, V105, P301, DOI 10.1093/brain/105.2.301; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; Foundas A L, 1995, J Int Neuropsychol Soc, V1, P62; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GESCHWIND N, 1962, NEUROLOGY, V12, P675, DOI 10.1212/WNL.12.10.675; Goldstein K., 1948, LANGUAGE LANGUAGE DI; GRAFFRADFORD NR, 1987, NEUROLOGY, V37, P100, DOI 10.1212/WNL.37.1.100; Heilman K. M., 1993, INT J CLIN NEUROPSYC, P141; HEILMAN KM, 1984, BRAIN, V107, P519, DOI 10.1093/brain/107.2.519; LEIGUARDA R, 1989, BRAIN, V112, P1019, DOI 10.1093/brain/112.4.1019; Liepmann H, 1900, MON PSYCHIATR NEUROL, V8, P15; Liepmann H, 1908, J PSYCHOL NEUROL, V10, P214; LORING DW, 1989, NEUROPSYCHOLOGIA, V27, P811, DOI 10.1016/0028-3932(89)90005-5; MAYER NH, 1990, NEUROPSYCHOLOGY EVER; Morlaas J., 1928, CONTRIBUTION ETUDE A; OCHIPA C, 1992, BRAIN, V115, P1061, DOI 10.1093/brain/115.4.1061; POECK K, 1980, CORTEX, V16, P273, DOI 10.1016/S0010-9452(80)80062-1; POECK K, 1983, J NEUROL, V230, P1, DOI 10.1007/BF00313591; RAPCSAK SZ, 1993, BRAIN COGNITION, V23, P181, DOI 10.1006/brcg.1993.1054; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROTHI LJG, 1984, BRAIN COGNITION, V18, P35; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; VOLPE BT, 1982, NEUROLOGY, V32, P645, DOI 10.1212/WNL.32.6.645; WATSON RT, 1983, BRAIN, V106, P391, DOI 10.1093/brain/106.2.391; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; ZAIDEL D, 1977, NEUROPSYCHOLOGIA, V15, P193, DOI 10.1016/0028-3932(77)90028-8	31	24	24	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase		1995	1	1					3	17		10.1080/13554799508402342			15	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	TY680	WOS:A1995TY68000002					2021-06-18	
J	WINKLER, T; SHARMA, HS; STALBERG, E; OLSSON, Y; NYBERG, F				WINKLER, T; SHARMA, HS; STALBERG, E; OLSSON, Y; NYBERG, F			OPIOID RECEPTORS INFLUENCE SPINAL-CORD ELECTRICAL-ACTIVITY AND EDEMA FORMATION FOLLOWING SPINAL-CORD INJURY - EXPERIMENTAL-OBSERVATIONS USING NALOXONE IN THE RAT	NEUROSCIENCE RESEARCH			English	Article						NALOXONE; SPINAL CORD EVOKED POTENTIALS; EDEMA; SPINAL CORD TRAUMA; OPIOID PEPTIDES; EPIDURAL SPACE	DORSAL HORN NEURONS; IMPROVES NEUROLOGIC RECOVERY; RADIOIMMUNOASSAY TECHNIQUE; PARA-CHLOROPHENYLALANINE; EVOKED-POTENTIALS; TRAUMATIC INJURY; BRAIN INJURY; INHIBITION; MECHANISMS; DYNORPHIN	The possibility that opioid peptides participate in alteration of spinal cord conduction following trauma to the cord was investigated in a rat model using a pharmacological approach. Spinal cord injury was produced in urethane anesthetized animals by a longitudinal incision into the right dorsal horn of T10-11 segments (2 mm deep and 5 mm long). Spinal cord evoked potentials (SCEP) were recorded epidurally from the T9 (rostral) and T12 (caudal) segments after stimulation of the ipsilateral tibial and sural nerves at the ankle. SCEP from both rostral and caudal segments consisted of a small positive peak followed by a high negative peak. Infliction of trauma in untreated rats resulted in an immediate depression of the rostral maximal negative peak (MNP) amplitude. This depression was long-lasting. Later, a significant increase in the latency of the rostral MNP amplitude occurred. Naloxone was administered in a high dosage (10 mg/kg, i.p.) to block mu-, delta- and kappa-opioid receptors 30 min before injury. This drug treatment inhibited the immediate post-injury decrease of the rostral MNP amplitude without any significant effect on latency changes. Measurement of water content in the traumatized spinal cord segment showed a significant reduction in the drug treated animals 5 h after trauma (71.46 +/- 0.54) as compared with untreated controls (74.65 +/- 0.76). However, 1 mg or 5 mg/kg dosages of the drug were not effective in reducing the SCEP changes or edema after injury. These results strongly suggest that blockade of kappa-opioid receptors with high doses of naloxone is important in reduction of trauma induced alteration of SCEP and edema formation in spinal cord injury.	UNIV UPPSALA HOSP, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN; UNIV UPPSALA HOSP, DEPT CLIN NEUROPHYSIOL, S-75185 UPPSALA, SWEDEN; BIOMED CTR, DEPT PHARMACEUT BIOSCI, S-75124 UPPSALA, SWEDEN							BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BASKIN DS, 1993, J SPINAL DISORD, V6, P38; BENZEL EC, 1992, J SPINAL DISORD, V5, P75, DOI 10.1097/00002517-199203000-00009; BENZEL EC, 1990, NEUROSURGERY, V27, P597, DOI 10.1227/00006123-199010000-00016; BJORKLUND A, 1990, HDB CHEM NEUROANAT 2, V9; BJORKLUND A, 1990, HDB CHEM NEUROANAT 1, V9; Black P, 1991, J NEUROTRAUM, V8, P157, DOI 10.1089/neu.1991.8.157; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; DANGELO CM, 1973, J NEUROSURG, V38, P332, DOI 10.3171/jns.1973.38.3.0332; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; DUGGAN AW, 1984, PHARMACOL REV, V35, P220; DUGGAN AW, 1993, HDB EXP PHARM, V104, P731; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1984, EUR J PHARMACOL, V103, P115, DOI 10.1016/0014-2999(84)90196-1; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1982, NEUROLOGY, V32, P677, DOI 10.1212/WNL.32.6.677; FADEN AI, 1985, NEUROLOGY, V35, P1311, DOI 10.1212/WNL.35.9.1311; FADEN AI, 1993, HDB EXP PHARM, V104, P325; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; FITZGERALD M, 1980, PAIN, V9, P293, DOI 10.1016/0304-3959(80)90044-5; Gibson S. J., 1986, IMMUNOCYTOCHEMISTRY, P360; HERRERO JF, 1993, BRIT J PHARMACOL, V110, P303, DOI 10.1111/j.1476-5381.1993.tb13809.x; HOKFELT T, 1978, PSYCHOPHARMACOLOGY G, P39; HOMMA S, 1984, FUNDAMENTALS CLIN AP; HYLDEN JLK, 1991, PAIN, V44, P187, DOI 10.1016/0304-3959(91)90136-L; JONES SL, 1990, BRAIN RES, V532, P160, DOI 10.1016/0006-8993(90)91756-7; KIM JP, 1987, EUR J PHARMACOL, V138, P133, DOI 10.1016/0014-2999(87)90349-9; KRUMINS SA, 1986, ANN NEUROL, V19, P498, DOI 10.1002/ana.410190514; LIPTON SA, 1993, CURR OPIN NEUROL NEU, V6, P588; MACDONALD RL, 1978, SCIENCE, V199, P1449, DOI 10.1126/science.204015; MARTIN WR, 1983, PHARMACOL REV, V35, P283; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MEANS ED, 1987, HDB SPINAL CORD, V5, P19; MISRA AL, 1978, FACTORS AFFECTING AC, P297; MOORE SD, 1994, J NEUROSCI, V14, P809; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; OLSSON Y, 1994, IN PRESS PROGR BRAIN, V104; PARSONS CG, 1989, BRIT J PHARMACOL, V98, P533, DOI 10.1111/j.1476-5381.1989.tb12627.x; SALZMAN SK, 1990, NEURAL MONITORING PR; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; SHARMA HS, 1992, NEUROSCI RES, V14, P195; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; SHARMA HS, 1994, REG PEPT S, V1, pS91; SHARMA HS, 1995, IN PRESS PROG BRAIN, V104; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; VINK R, 1991, AM J PHYSIOL, V261, pR1527; WILLIS WD, 1984, FUNDAMENTALS CLIN AP, P3; YAKSH TL, 1993, HDB EXPT PHARM, V104, P53; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	53	24	25	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	NOV	1994	21	1					91	101		10.1016/0168-0102(94)90072-8			11	Neurosciences	Neurosciences & Neurology	QB913	WOS:A1994QB91300010	7708296				2021-06-18	
J	KURTH, SM; BIGLER, ED; BLATTER, DD				KURTH, SM; BIGLER, ED; BLATTER, DD			NEUROPSYCHOLOGICAL OUTCOME AND QUANTITATIVE IMAGE-ANALYSIS OF ACUTE HEMORRHAGE IN TRAUMATIC BRAIN INJURY - PRELIMINARY FINDINGS	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; DEGENERATIVE CHANGES; COMPUTED-TOMOGRAPHY; INTELLIGENCE; LESIONS; SCAN	The effect on neuropsychological outcome of the number of acute haemorrhages, lesion volume, and lesion location in traumatic brain injury (TBI) was evaluated. Haemorrhagic lesion volume was associated with severity of injury. However, the number of petechial haemorrhages was not reliably associated with any of the clinical outcome measures. Likewise, despite the use of detailed morphometric methods to quantify volume, the acute lesion size did not significantly relate to neuropsychological sequelae. Furthermore, brain quadrant localization methods did not enhance outcome prediction. These results are discussed in the context of acute lesion analysis contrasted with chronic TBI-induced neuropathological changes associated with neuropsychological outcome.	LDS HOSP,SALT LAKE CITY,UT							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BERROL S, 1986, J HEAD INJURY REHABI, V1; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler E D, 1991, Arch Clin Neuropsychol, V6, P113, DOI 10.1016/0887-6177(91)90028-8; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; GUILBURD LL, 1990, NEUROSURGERY, V27, P428; Heaton R.K., 1991, COMPREHENSIVE NORMS; HOLLIDAY PO, 1982, NEUROSURGERY, V10, P25, DOI 10.1227/00006123-198201000-00005; JERNIGAN TL, 1990, ARCH NEUROL-CHICAGO, V47, P27, DOI 10.1001/archneur.1990.00530010035015; KIMURA D, 1983, CAN J PSYCHOL, V37, P19, DOI 10.1037/h0080696; Kolb B., FUNDAMENTALS HUMAN N; KURTZKE JF, 1982, NEUROLOGY, V32, P1207, DOI 10.1212/WNL.32.11.1207; LEIFER D, 1990, NEUROLOGY, V40, P911, DOI 10.1212/WNL.40.6.911; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEZAK M, NEUROPSYCHOLOGICAL A; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; OPPENHEIM JS, 1992, POSTGRAD MED, V91, P261; RAVEN RM, 1960, GUIDE PROGRESSIVE MA; Reitan RM., 1985, HALSTEAD REITAN NEUR; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; TURKHEIMER E, 1990, NEUROPSYCHOLOGIA, V28, P1011, DOI 10.1016/0028-3932(90)90136-C; TURKHEIMER E, 1990, J CLIN EXP NEUROPSYC, V12, P549, DOI 10.1080/01688639008401001; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; WECHSLER D, 1975, AM PSYCHOL, V30, P135, DOI 10.1037/h0076868; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; YEO R, 1983, CLIN NEUROPSYCHOL, V45, P1983; 1990, JAVA JANDEL VIDEO AN	41	24	24	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					489	500		10.3109/02699059409151001			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200001	7527266				2021-06-18	
J	LUZ, JGC; DIMASE, F				LUZ, JGC; DIMASE, F			INCIDENCE OF DENTOALVEOLAR INJURIES IN-HOSPITAL EMERGENCY ROOM PATIENTS	ENDODONTICS & DENTAL TRAUMATOLOGY			English	Article						DENTAL TRAUMA; EPIDEMIOLOGY, ORAL; TRAUMATIC INJURIES		A retrospective survey over one year of a hospital emergency room population, seen at an oral and maxillofacial surgery clinic, found 271 patients (4.6% of the total population) with dentoalveolar injuries. A very large number of injuries occurred to children between the ages of 0 and 5 years (42.1%), and there was a significant number of injured patients in the adult population (19.1%). The ratio of male to female was 1.9:1. The leading cause of injury was falls (59.8%). The largest number of injuries was seen during summer. The diagnoses were lateral luxation (27.3%), concussion (17.3%), exarticulation (14.3%), tooth fracture (12.5%), intrusive luxation (11.1%), fracture of alveolar process (7.4%), extrusive luxation (3.7%), and cases with more than one diagnosis (6.3%). Most of the involved teeth were maxillary central incisors, in both dentitions.		LUZ, JGC (corresponding author), UNIV SAO PAULO,DEPT ORAL & MAXILLOFACIAL SURG,R DUARTE DE AZEVEDO 284,S 22,BR-02036021 SAO PAULO,BRAZIL.		Luz, Joao/K-2265-2017					0	24	26	0	6	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0109-2502			ENDOD DENT TRAUMATOL	Endod. Dent. Traumatol.	AUG	1994	10	4					188	190					3	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	PE008	WOS:A1994PE00800006	7995251				2021-06-18	
J	YOUNG, WF; ROSENWASSER, RH; VASTHARE, US; TUMA, RF				YOUNG, WF; ROSENWASSER, RH; VASTHARE, US; TUMA, RF			PRESERVATION OF POSTCOMPRESSION SPINAL-CORD FUNCTION BY INFUSION OF HYPERTONIC SALINE	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						SPINAL CORD; TRAUMA; BLOOD FLOW; HYPERTONIC SALINE	HEMORRHAGIC-SHOCK; BLOOD-FLOW; INJURY; ISCHEMIA; TRAUMA; RAT; RESUSCITATION; NECROSIS; BRAIN	We tested the hypothesis that the administration of hypertonic saline, following traumatic injury to the spinal cord, could enhance blood flow to the cord and preserve function. Rats were used as the experimental model. Direct compression of the spinal cord for a period of 10 min was done to produce the injury. Somatosensory evoked potentials (SSEPs) and spinal cord blood flow were measured using a laser Doppler flow meter throughout the experiment. Comparisons of the blood flow values and SSEPs were made among four different groups of animals. The control group received no fluid resuscitation after injury. A second group received a bolus injection of isotonic saline (0.5 ml/100 g) as an i.v. infusion over a period of 1 min. A third group received a bolus infusion of 7.5% NaCl (0.5 ml/100 g) over a period of 1 min. The final group received 4 ml/100 g of 0.9% NaCl over a period of 10 min. The administration of hypertonic saline significantly reduced spinal cord vascular resistance during the first 10 min after infusion. During the first 30 min after the removal of compression, spinal cord blood flow was greater in the hypertonic saline group than in the other three groups. The hypertonic saline group had a reactive hyperemia whereas the flow in the other groups remained at or below control values. Beginning 10 min after injury and for the remainder of the 1-h observation period, the latency of the cortical peak of the SSEP in the group receiving hypertonic saline was significantly shorter than in any of the other three groups. These results indicate that the administration of hypertonic saline enhances blood flow and preserves spinal cord conduction following traumatic injury to the spinal cord.	TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR,SCH MED,DEPT NEUROSURG, CEREBROVASC LAB, PHILADELPHIA, PA 19140 USA			ROSENWASSER, ROBERT H/L-2482-2014				Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; AMES A, 1968, AM J PATHOL, V52, P437; BAUE AE, 1967, J TRAUM, V7, P743, DOI 10.1097/00005373-196709000-00012; COLLINS WF, 1983, PARAPLEGIA, V21, P204, DOI 10.1038/sc.1983.34; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DOHRMANN GJ, 1971, J NEUROSURG, V35, P263, DOI 10.3171/jns.1971.35.3.0263; DOPPMAN JL, 1979, J NEUROSURG, V51, P201, DOI 10.3171/jns.1979.51.2.0201; FISCHER EG, 1977, STROKE, V8, P36, DOI 10.1161/01.STR.8.1.36; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; KRAMER GC, 1989, ROLE HEMODILUTION OP, P89; MAZZONI MC, 1990, CIRC SHOCK, V31, P407; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; Nemecek S, 1978, Adv Neurol, V20, P395; NERLICH M, 1983, CIRC SHOCK, V10, P179; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P460, DOI 10.1111/j.1600-0404.1988.tb03688.x; OSTERHOLM JL, 1972, J NEUROSURG, V36, P386, DOI 10.3171/jns.1972.36.4.0386; OSTERHOLM JL, 1972, J NEUROSURG, V36, P395, DOI 10.3171/jns.1972.36.4.0395; PROUGH DS, 1991, ANESTH ANALG, V73, P736; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; SANDLER AN, 1976, J NEUROSURG, V45, P660, DOI 10.3171/jns.1976.45.6.0660; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TOCHAESILVA M, 1986, CIRC SHOCK, V19, P165; TUMA RF, 1989, ROLE HEMODILUTION OP; VASTHARE US, 1990, SURG NEUROL, V33, P261, DOI 10.1016/0090-3019(90)90046-R; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664; WALLACE MC, 1986, NEUROSURGERY, V18, P433	29	24	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	1994	6	2					122	127					6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	NC363	WOS:A1994NC36300008	8012171				2021-06-18	
J	LIU, SL; LYETH, BG; HAMM, RJ				LIU, SL; LYETH, BG; HAMM, RJ			PROTECTIVE EFFECT OF GALANIN ON BEHAVIORAL DEFICITS IN EXPERIMENTAL TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							RAT VENTRAL HIPPOCAMPUS; CENTRAL NERVOUS-SYSTEM; PHOSPHOINOSITIDE TURNOVER; ACETYLCHOLINE-RELEASE; NEURONS; STIMULATION	The magnitude of behavioral deficits in traumatic brain injury (TBI) has been shown to be partly related to alterations in the balance between excitatory and inhibitory neurotransmitter release. Previous studies have demonstrated that extracellular excitatory neurotransmitter concentrations dramatically increase following experimental TBI. We examined the effects of a neuromodulatory peptide, galanin (GAL), on behavioral morbidity, as measured by sensory motor and memory performance tasks, associated with experimental TBI in the rat. A single intraventricular injection of GAL (1.0 mug, n = 8 or 10.0 mug, n = 10) or cerebrospinal fluid (CSF) vehicle (n = 10) was administered 5 minutes prior to central fluid percussion TBI in rats. Performance on sensory motor tasks was assessed prior to injury and for 5 days after TBI with beam-balance, beam-walking, and rotarod tasks. Memory performance was assessed on days 11-15 after TBI with the Morris water maze. TBI produced significant motor and memory deficits in the CSF-treated group. GAL-treated rats had significantly less magnitude of deficits compared to CSF-treated rats on beam-balance, beam-walking, and rotarod performance. The 1.0 mug GAL dose produced slightly greater protection than the 10.0 mug GAL dose. Neither GAL dose affected body weight loss or Morris water maze performance. These results suggest that the physiologic effects of GAL may reduce certain components of TBI morbidity, possibly by modulating neuronal excitability.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,BOX 693 MCV STN,RICHMOND,VA 23298				Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, P01NS012587, P50NS012587] Funding Source: NIH RePORTER		BENARI Y, 1989, EUR J PHARMACOL, V165, P331, DOI 10.1016/0014-2999(89)90732-2; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUTAR P, 1989, EUR J PHARMACOL, V164, P355, DOI 10.1016/0014-2999(89)90477-9; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FISONE G, 1987, P NATL ACAD SCI USA, V84, P7339, DOI 10.1073/pnas.84.20.7339; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELANDER T, 1986, J COMP NEUROL, V248, P475, DOI 10.1002/cne.902480404; MERCHENTHALER I, 1993, PROG NEUROBIOL, V40, P711, DOI 10.1016/0301-0082(93)90012-H; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NORDSTROM O, 1987, NEUROSCI LETT, V73, P21, DOI 10.1016/0304-3940(87)90024-3; PALAZZI E, 1991, J NEUROCHEM, V56, P739, DOI 10.1111/j.1471-4159.1991.tb01986.x; PALAZZI E, 1988, EUR J PHARMACOL, V148, P479, DOI 10.1016/0014-2999(88)90133-1; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PARSONS RL, 1991, NEUROSCIENCE, V43, P647, DOI 10.1016/0306-4522(91)90323-G; PRAMANIK A, 1992, BRAIN RES, V574, P317, DOI 10.1016/0006-8993(92)90832-T; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; Seifert W, 1983, NEUROBIOLOGY HIPPOCA, P405; SKOFITSCH G, 1985, PEPTIDES, V6, P509, DOI 10.1016/0196-9781(85)90118-4; SUNDSTROM E, 1988, NEUROSCI LETT, V88, P331, DOI 10.1016/0304-3940(88)90233-9; TSUDA K, 1989, HYPERTENSION, V14, P81, DOI 10.1161/01.HYP.14.1.81	31	24	24	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1994	11	1					73	82		10.1089/neu.1994.11.73			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	NC365	WOS:A1994NC36500004	7515444				2021-06-18	
J	LEEDHAM, CS; BLOOD, CG; NEWLAND, C				LEEDHAM, CS; BLOOD, CG; NEWLAND, C			A DESCRIPTIVE ANALYSIS OF WOUNDS AMONG UNITED-STATES MARINES TREATED AT 2ND-ECHELON FACILITIES IN THE KUWAITI THEATER OF OPERATIONS	MILITARY MEDICINE			English	Article								Medical data from 120 U.S. Marine Corps trauma admissions to second-echelon facilities during Operation Desert Shield/Storm were examined. Sixty-five percent of the admissions occurred between February 22 and February 28, the time frame corresponding to the ground war and the preliminary mobilization period. Penetrating wounds were the most prevalent types of injury, followed by lacerations, open fractures, and closed fractures. The most frequent anatomical regions sustaining injuries were the leg, head, hand, and arm. Fragments were the causative agent of 63% of the admissions that had this variable recorded, while gunfire was the cause in 20% of the cases. The median injury-to-admission interval increased from 0.67 hours in the non-ground war period to 4.41 during the ground war.	USN,HLTH RES CTR,MED INFORMAT SYST & OPERAT RES DEPT,POB 85122,SAN DIEGO,CA 92186								0	24	25	0	0	ASSN MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814	0026-4075			MIL MED	Milit. Med.	AUG	1993	158	8					508	512					5	Medicine, General & Internal	General & Internal Medicine	LT492	WOS:A1993LT49200012	8414070				2021-06-18	
J	FADEN, AI; LABROO, VM; COHEN, LA				FADEN, AI; LABROO, VM; COHEN, LA			IMIDAZOLE-SUBSTITUTED ANALOGS OF TRH LIMIT BEHAVIORAL DEFICITS AFTER EXPERIMENTAL BRAIN TRAUMA	JOURNAL OF NEUROTRAUMA			English	Article							THYROTROPIN-RELEASING-HORMONE; SPINAL-CORD INJURY; INTRACELLULAR FREE MG-2+; CARDIOVASCULAR-SYSTEM; NEUROLOGIC RECOVERY; PROLACTIN-RELEASE; DOSE-RESPONSE; RATS; HYPOTENSION; PEPTIDES	Treatment with thyrotropin releasing hormone (TRH) or TRH analogues improves outcome after experimental brain or spinal cord trauma. TRH analogues with modifications at the N-terminal position of the tripeptide are effective, whereas analogues with modifications of the C-terminal residue are not. Imidazole-substituted TRH analogues, which modify the middle amino acid (histidine) of the tripeptide, have more recently been developed but have not been evaluated in models of central nervous system (CNS) trauma. In the present studies two imidazole-substituted analogues-4(5)-NO2(Im)TRH and 2,4 diiodo(Im)TRH-are shown to improve behavioral recovery following fluid percussion-induced traumatic brain injury (TBI) in rats. Because 4(5)-NO2(Im)TRH has little endocrine activity and 2,4 diiodo(Im)TRH has minimal cardiovascular effects, these experiments support the hypothesis that the neuroprotective actions of TRH analogues are independent of their endocrine or autonomic actions.	NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD; ZYMOGENET INC,SEATTLE,WA	FADEN, AI (corresponding author), GEORGETOWN UNIV,MED CTR,MED DENT BLDG,NW 101,3900 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR306634-02] Funding Source: Medline		ARIAS MJ, 1987, SURG NEUROL, V28, P335, DOI 10.1016/0090-3019(87)90054-1; BASSIRI RM, 1973, J CLIN INVEST, V52, P1616, DOI 10.1172/JCI107339; FADEN AI, 1985, NEUROLOGY, V35, P1331, DOI 10.1212/WNL.35.9.1331; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1988, PHYSL BASIS FUNCTION, P531; FEUERSTEIN G, 1984, NEUROPEPTIDES, V4, P303, DOI 10.1016/0143-4179(84)90004-0; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; FUKUDA N, 1979, FOLIA PHARM JAPAN, V75, P3221; HASHIMOTO T, 1989, Japanese Journal of Pharmacology, V49, p312P; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; KOSKINEN LOD, 1989, ANN NY ACAD SCI, P353; LABROO VM, 1987, NEUROPEPTIDES, V10, P29, DOI 10.1016/0143-4179(87)90086-2; LABROO VM, 1983, BIOCHEM BIOPH RES CO, V113, P581, DOI 10.1016/0006-291X(83)91765-5; LABROO VM, 1990, TETRAHEDRON LETT, V31, P5705, DOI 10.1016/S0040-4039(00)97937-1; LABROO VM, 1989, PEPTIDES CHEM STRUCT, P127; LABROO VM, 1985, PEPTIDES STRUCTURE F, P703; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; METCALF G, 1982, BRAIN RES REV, V4, P389, DOI 10.1016/0165-0173(82)90012-1; PAAKKARI I, 1990, PEPTIDES, V11, P939, DOI 10.1016/0196-9781(90)90013-U; Salzman S K, 1987, Cent Nerv Syst Trauma, V4, P181; SIREN AL, 1986, NEUROPEPTIDES, V8, P63, DOI 10.1016/0143-4179(86)90066-1; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1989, BIOCHEM BIOPH RES CO, V165, P913, DOI 10.1016/S0006-291X(89)80053-1; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	36	24	24	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SUM	1993	10	2					101	108		10.1089/neu.1993.10.101			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LM056	WOS:A1993LM05600002	8411214				2021-06-18	
J	XU, BN; YABUKI, A; MISHINA, H; MIYAZAKI, M; MAEDA, M; ISHII, S				XU, BN; YABUKI, A; MISHINA, H; MIYAZAKI, M; MAEDA, M; ISHII, S			PATHOPHYSIOLOGY OF BRAIN-SWELLING AFTER ACUTE EXPERIMENTAL BRAIN COMPRESSION AND DECOMPRESSION	NEUROSURGERY			English	Article						BRAIN EDEMA; BRAIN SWELLING; CEREBRAL ISCHEMIA; DECOMPRESSION; TRAUMA	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; ACUTE SUBDURAL-HEMATOMA; COMATOSE PATIENTS; COMPUTERIZED-TOMOGRAPHY; EDEMA; METABOLISM; BIOMECHANICS; CHILDREN; MANAGEMENT	GLOBAL ISCHEMIA WAS created by controlled expansion of an epidural balloon for 25 minutes in Group A (six cats) and for minutes in Group B (six cats). The alterations of intracranial pressure, arteriovenous oxygen content difference, cerebral metabolic rate of oxygen, cerebral blood flow, and electroencephalogram were observed until brain death or 24 hours' survival with normal intracranial pressure. The animals were then killed for brain histological examination. In four other cats, a 2% solution of Evans blue dye (4 mg/kg) was injected intravenously-immediately after deflation-resulting in 25 minutes of global ischemia. Two other cats received 5 minutes of global ischemia. The cats were killed 1 hour later. Abrupt swelling occurred in Group A, and no swelling was found in Group B. A transient absolute hyperemia was found immediately after deflation in both groups. The cerebral blood flow and cerebral metabolic rate of oxygen decreased markedly with low arteriovenous oxygen content difference and flat electroencephalogram in Group A, compared with gradual recovery of cerebral blood flow and cerebral metabolic rate of oxygen with high arteriovenous oxygen content difference and reappearance of electroencephalogram activity in Group B. The extravasation of Evans blue was observed on the compressed cerebral hemisphere, thalamus, hypothalamus, and brain stem in swelling animals and only on the compressed hemisphere in nonswelling animals. Histologically, the damage and congestive dilation of capillary, degeneration, and necrosis of neuronal and glial cell were found prominently on the hypothalamus and brain stem in the swelling group. There was no obvious alteration observed in the nonswelling group. This study showed that there was a close relationship between duration of compressive global ischemia and occurrence of brain swelling. it was postulated that damage of the hypothalamus and brain stem, probably caused by distortion and ischemia during brain compression, might be responsible for the vasomotor paralysis to increase cerebral blood volume. Our study suggests that, in postdecompressive acute swelling, severe cerebral ischemia is the basic feature, and damage of the control center for the vasomotor area, such as the hypothalamus and brain stem, is pathophysiological.	CHINESE PEOPLES LIBERAT ARMY GEN HOSP, DEPT NEUROSURG, 28 FU XING RD, BEIJING 100853, PEOPLES R CHINA; JUNTENDO UNIV, DEPT NEUROSURG, TOKYO 113, JAPAN; JUNTENDO UNIV, CTR CASUALTY, TOKYO 113, JAPAN							BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BULLOCK R, 1985, J NEUROSURG, V63, P64, DOI 10.3171/jns.1985.63.1.0064; CHIANG J, 1968, AM J PATHOL, V52, P455; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FUJIMOTO T, 1976, DYNAMICS BRAIN EDEMA, P171; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HATASHITA S, 1988, STROKE, V19, P91, DOI 10.1161/01.STR.19.1.91; Hossman K, 1976, DYNAMICS BRAIN EDEMA, P219; ISHII S, 1965, HEAD INJURY, P276; JENNETT B, 1981, BRAIN EDEMA, P61; JENNETT B, 1981, MANAGEMENT HEAD INJU, P153; KLATZO I, 1976, BRAIN EDEMA, P554; KOBRINE AI, 1977, J NEUROSURG, V46, P256, DOI 10.3171/jns.1977.46.2.0256; KUROIWA T, 1989, J NEUROSURG, V70, P73, DOI 10.3171/jns.1989.70.1.0073; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LONG DM, 1982, CLIN NEUR, V29, P174; MAEDA M, 1986, INTRACRANIAL PRESSUR, V6, P151; Marmarou A, 1980, Adv Neurol, V28, P345; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MILLER JD, 1973, J NEUROSURG, V39, P186, DOI 10.3171/jns.1973.39.2.0186; MILLER JD, 1982, CLIN NEUR, V29, P162; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; NUMOTO M, 1970, J NEUROSURG, V33, P381, DOI 10.3171/jns.1970.33.4.0381; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pasztor E, 1973, STROKE, V4, P556, DOI 10.1161/01.STR.4.4.556; PLUM F, 1963, ARCH NEUROL-CHICAGO, V9, P563, DOI 10.1001/archneur.1963.00460120013001; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; WAGA S, 1979, SURG NEUROL, V11, P191; WEINSTEIN JD, 1967, SURG FORUM, V18, P430; YOSHINO E, 1985, J NEUROSURG, V63, P830, DOI 10.3171/jns.1985.63.6.0830	43	24	29	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	1993	32	2					289	296		10.1227/00006123-199302000-00019			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KL520	WOS:A1993KL52000019	8437667				2021-06-18	
J	CUCCINIELLO, B; MARTELLOTTA, N; NIGRO, D; CITRO, E				CUCCINIELLO, B; MARTELLOTTA, N; NIGRO, D; CITRO, E			CONSERVATIVE MANAGEMENT OF EXTRADURAL HEMATOMAS	ACTA NEUROCHIRURGICA			English	Article						HEAD INJURY; EXTRADURAL HEMATOMA; COMPUTERIZED TOMOGRAPHY; SPONTANEOUS RESOLUTION	EPIDURAL HEMATOMAS; SPONTANEOUS RESOLUTION; HEAD-INJURY; TOMOGRAPHY	The personal experiences with a series of 57 conservatively treated extradural haematomas (EDH) are presented and the criteria for conservative management outlined. Main preconditions are absence of neurological deficit, close clinical supervision and repeated CT check-ups.		CUCCINIELLO, B (corresponding author), SAN CARLO BASILICATA GEN HOSP,DEPT NEUROSURG,I-85100 POTENZA,ITALY.						AOKI N, 1988, J NEUROSURG, V68, P149, DOI 10.3171/jns.1988.68.1.0149; BENMOUSSA H, 1992, NEUROCHIRURGIE, V38, P42; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; CORDOBES F, 1980, ACTA NEUROCHIR, V53, P275, DOI 10.1007/BF02074800; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; DEVRIES J, 1981, NEURORADIOLOGY, V22, P167, DOI 10.1007/BF00346762; ERICSON K, 1981, ACTA RADIOL DIAGN, V22, P513, DOI 10.1177/028418518102200501; Guillermain P., 1986, ADV NEUROTRAUMATOLOG, V1, P2; ILLINGWORTH R, 1983, J NEUROL NEUROSUR PS, V46, P558, DOI 10.1136/jnnp.46.6.558; JACKSON JJ, 1950, J NEUROSURG, V7, P444; JENNETT B, 1981, MANAGEMENT HEAD INJU, P153; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; LECLERCQ TA, 1979, R I MED J, V62, P97; Lindenberg R., 1977, RADIOLOGY SKULL BRAI, V3, P3049; MCLAURIN RL, 1964, J NEUROSURG, V21, P364, DOI 10.3171/jns.1964.21.5.0364; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MORLEY JB, 1970, J NEUROL NEUROSUR PS, V33, P679, DOI 10.1136/jnnp.33.5.679; PAGNI CA, 1968, EMATOMA EXTRADURALE, P1; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; POZZATI E, 1984, NEUROSURGERY, V14, P724, DOI 10.1227/00006123-198406000-00012; SERVADEI F, 1988, J NEUROL NEUROSUR PS, V51, P526, DOI 10.1136/jnnp.51.4.526; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; TAPIERO B, 1984, HEMATOMES EXTRA DURA, P213; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE G, 1979, BRIT MED J, V1, P1793, DOI 10.1136/bmj.1.6180.1793-a; TOCHIO H, 1984, NEUROSURGERY, V15, P96, DOI 10.1227/00006123-198407000-00018; TROWBRIDGE WV, 1954, AMA ARCH SURG, V69, P824, DOI 10.1001/archsurg.1954.01270060066009; WEAVER D, 1981, J NEUROSURG, V54, P248, DOI 10.3171/jns.1981.54.2.0248; ZANDER E, 1974, ADV TECHNICAL STANDA, V1, P121; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	34	24	25	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1993	120	1-2					47	52		10.1007/BF02001469			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KJ107	WOS:A1993KJ10700009	8434517				2021-06-18	
J	SWEENEY, JE				SWEENEY, JE			NONIMPACT BRAIN INJURY - GROUNDS FOR CLINICAL-STUDY OF THE NEUROPSYCHOLOGICAL EFFECTS OF ACCELERATION FORCES	CLINICAL NEUROPSYCHOLOGIST			English	Article							MINOR HEAD-INJURY; CEREBRAL CONCUSSION; REACTION-TIME; SEQUELAE; SYMPTOMS; WHIPLASH; RECOVERY	Individuals subjected to acceleration forces in motor vehicle accidents often exhibit the postconcussive syndrome and, upon examination, neuropsychological impairment. Brain injury and particular variables relating to nonimpact intracranial brain movement are reviewed. Brain injury in man can occur through exposure to acceleration forces without direct impact to the head or loss of consciousness. Hence, there are clear grounds for the neuropsychological study of victims of acceleration forces. Moreover, as with mild head injury, adequate regard for the variables of age, previous head injury, premorbid adaptive ability, socioeconomic status, motivation, and test sensitivity may assist in clarifying the specific problems in adaptation encountered by this clinical population. Clinical experience suggests that acceleration forces adversely affect attention (especially at older age levels), learning, and conceptual flexibility.								ALVES WM, 1985, CENTRAL NERVOUS SYST, P255; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1989, ASSESSMENT BEHAV CON, P37; CAFFEY J, 1974, PEDIATRICS, V54, P396; Cook J B, 1972, Scand J Rehabil Med, V4, P27; CRONHOLM B, 1958, ACTA CHIR SCAND, V113, P263; Denker P., 1944, NY STATE J MED, V44, P379; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; FISHER CM, 1982, NEUROLOGY, V32, P667, DOI 10.1212/WNL.32.6.667; FRANKEL CJ, 1959, JAMA-J AM MED ASSOC, V169, P216, DOI 10.1001/jama.1959.03000200014004; GAY JR, 1953, JAMA-J AM MED ASSOC, V152, P1698, DOI 10.1001/jama.1953.03690180020006; GENNARELLI TA, 1990, NEUROLOGICAL SURGERY, P1953; Goggio AF, 1941, J NEUROL PSYCHIATRY, V4, P11, DOI 10.1136/jnnp.4.1.11; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hathaway S. R., 1989, MINNESOTA MULTIPHASI; Hathaway Starke, 1967, MINNESOTA MULTIPHASI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Hirsch A. E., 1970, IMPACT INJURY CRASH, P352; Holbourn AHS, 1944, J NEUROSURG, V1, P190, DOI 10.3171/jns.1944.1.3.0190; Holbourn AHS, 1943, LANCET, V2, P438; JACOBSON SA, 1969, LATE EFFECTS HEAD IN, P35; KARZMARK P, 1985, J CLIN EXP NEUROPSYC, V7, P412, DOI 10.1080/01688638508401273; KOZOL HL, 1946, ARCH NEUROLOGY PSYCH, V53, P358; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MARSHALL LF, 1989, MILD HEAD INJURY, P226; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MILLER H, 1969, LATE EFFECTS HEAD IN, P429; Munro D., 1938, CRANIO CEREBRAL INJU; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1969, LANCET, V2, P237; OMMAYA AK, 1969, J NEUROSURG, V30, P25, DOI 10.3171/jns.1969.30.1.0025; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1966, HEAD INJURY, P260; PANG D, 1989, ASSESSMENT BEHAV CON, P1; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; REITAN R M, 1955, AMA Arch Neurol Psychiatry, V73, P28; Reitan RM, 1988, TRAUMATIC BRAIN INJU, VII; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; TORRES F, 1961, ARCH NEUROL-CHICAGO, V5, P40; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VOGT AT, 1977, PERCEPT MOTOR SKILL, V45, P607, DOI 10.2466/pms.1977.45.2.607; Wechsler D., 2008, WECHSLER ADULT INTEL; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554; WOOTEN AJ, 1983, J CLIN PSYCHOL, V39, P392, DOI 10.1002/1097-4679(198305)39:3<392::AID-JCLP2270390313>3.0.CO;2-H; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; 1865, GAZETTE MED, V20, P500; 1865, GAZETTE MED, V20, P463; 1865, GAZETTE MED, V20, P314; 1865, GAZETTE MED, V20, P226; 1865, GAZETTE MED, V20, P254; 1865, GAZETTE MED, V20, P382; 1865, GAZETTE MED, V20, P396	68	24	24	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV	1992	6	4					443	457		10.1080/13854049208401870			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	KC737	WOS:A1992KC73700007					2021-06-18	
J	WANI, MA; TANDON, PN; BANERJI, AK; BHATIA, R				WANI, MA; TANDON, PN; BANERJI, AK; BHATIA, R			COLLET-SICARD SYNDROME RESULTING FROM CLOSED HEAD-INJURY - CASE-REPORT	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article								A 67-year-old man developed paralysis of the right ninth, tenth, eleventh, and twelfth cranial nerves (Collet-Sicard syndrome) after sustaining a closed head injury. Plain x-ray films of the skull revealed two linear fractures of the occipital bone (one of them probably traversing through the right occipital condyle) and a prominent soft-tissue shadow in the region of the nasopharynx, suggestive of a skull base fracture. The patient was managed conservatively. This is the only case of unilateral multiple caudal cranial nerve palsies (IX through XII), seen by us over a 20-year period, from among more than 5,000 moderate to significant head injuries.	STEGLITZ MED CTR,DEPT SURG NEUROL,W-1000 BERLIN 45,GERMANY; ALL INDIA INST MED SCI,NEW DELHI 110016,INDIA							BOLENDER N, 1978, AM J ROENTGENOL, V131, P729, DOI 10.2214/ajr.131.4.729; Collet FJ, 1915, LYON MED, V124, P121; DANIELS DL, 1983, AM J NEURORADIOL, V4, P1227; DICHIRO GD, 1964, J NEUROSURG, V21, P447, DOI 10.3171/jns.1964.21.6.0447; FISHBONE H, 1976, HDB CLIN NEURODLOGY, V24, P179; FROWEIN RA, 1978, NEUROSURG REV, V1, P147; GARDNERTHORPE C, 1970, BR MEKD J, V1, P405; GRUNDY DJ, 1984, SPINE, V9, P339, DOI 10.1097/00007632-198405000-00002; HARDIDNGESMITH J, 1980, J BONE JOINT SURG AM, V63, P1170; HASHIMOTO T, 1988, NEUROSURGERY, V3, P367; MOHANTY KH, 1973, J NEUROSURG, V8, P86; PALATUCCI DM, 1974, JAMA-J AM MED ASSOC, V229, P24, DOI 10.1001/jama.1974.03230390016009; Pollock LJ, 1920, ARCH NEURO PSYCHIATR, V4, P517, DOI 10.1001/archneurpsyc.1920.02180230040004; SBUMM P, 1974, ARCH KLIN EXP OHR, V205, P348; Sicard J.A., 1917, MARSEILLE MED, V53, P385; SPENCER JA, 1984, NEUROSURGERY, V15, P101, DOI 10.1227/00006123-198407000-00019	16	24	24	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	1991	31	10					1437	1439		10.1097/00005373-199110000-00025			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	GM785	WOS:A1991GM78500025	1942161				2021-06-18	
J	STAMBROOK, M; MOORE, AD; PETERS, LC; ZUBEK, E; MCBEATH, S; FRIESEN, IC				STAMBROOK, M; MOORE, AD; PETERS, LC; ZUBEK, E; MCBEATH, S; FRIESEN, IC			HEAD-INJURY AND SPINAL-CORD INJURY - DIFFERENTIAL-EFFECTS ON PSYCHOSOCIAL FUNCTIONING	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SCALE; LIFE	Closed-head injury (CHI) and spinal cord injury (SCI) cause significant permanent alterations in life style, social-role functioning, and psychological status. While the cognitive effects of CHI are well known, there have been questions concerning the psychosocial sequelae from CHI, and whether they are unique to this disability group rather than representing general effects of a life-threatening medical emergency with permanent life-altering consequences. This issue was examined with samples of ambulatory moderate (n = 31) and severe (n = 17) CHI patients and wheelchair-dependent SCI (n = 24) patients. Results indicate that there were no significant differences between the groups on pre- and post injury demographic factors. However, while the moderate CHI and SCI groups were equivalent on many indicators of psychosocial outcome, the severe CHI group was more depressed, angry and hostile, and confused and bewildered. As well, wives of the severe CHI patients rated their husbands as more belligerent, negative, helpless, suspicious, withdrawn and retarded, and with more general psychopathology than did wives of moderate CHI or wives of SCI patients. Implications of these findings for preventative psychosocial rehabilitation are discussed.	UNIV MANITOBA,DEPT PSYCHIAT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT MED,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT PSYCHOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV VICTORIA,DEPT PSYCHOL,VICTORIA V8W 2Y2,BC,CANADA; SOC MANITOBANS DISABIL INC,WINNIPEG,MANITOBA,CANADA	STAMBROOK, M (corresponding author), HLTH SCI CLIN RES CTR,NEUROPSYCHOL RES UNIT,MS 779,820 SHERBROOK ST,WINNIPEG R3A 1M9,MANITOBA,CANADA.						BERGNER M, 1976, COPING ADAPTATION, P127; BLISHEN BR, 1967, CAN REV SOCIOL ANTHR, V4, P41; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Brooks N., 1984, CLOSED HEAD INJURY P; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; EISENBERG HM, 1987, NEUROBEHAVIORAL RECO, P13; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KLONOFF PS, 1986, NEUROSURGERY, V9, P735; Levin HS, 1989, MILD HEAD INJURY; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; McNair DM, 1971, EITS MANUAL PROFILE; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; TEASDALE G, 1974, LANCET, V2, P81	19	24	24	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	1991	13	4					521	530		10.1080/01688639108401068			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	GL617	WOS:A1991GL61700006	1918283				2021-06-18	
J	LEE, JP; WANG, ADJ				LEE, JP; WANG, ADJ			POSTTRAUMATIC BASAL GANGLIA HEMORRHAGE - ANALYSIS OF 52 PATIENTS WITH EMPHASIS ON THE FINAL OUTCOME	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SEVERE HEAD-INJURY; COMPUTED TOMOGRAPHY; PROGNOSIS; HEMATOMA; LESIONS; COMA; CT	A series of 52 patients suffering post-traumatic basal ganglia hemorrhage (BGH) after closed head injury is reviewed. Post-traumatic BGH was associated with other intracranial lesions in most cases. The outcome in this series is rather good, with 53.8% of patients having a functional survival. Radiologically, the post-traumatic intraventricular hemorrhage (IVH) and brainstem hemorrhage usually coexisted with a poor outcome. Old age (> 60), abnormal pupil reaction, impaired oculocephalic response, and abnormal motor response to pain stimuli are reliable clinical hallmarks for poor prognosis.	CHANG GUNG MED COLL, DEPT SURG, DIV NEUROSURG, TAIPEI, TAIWAN	LEE, JP (corresponding author), CHANG GUNG MEM HOSP, DEPT SURG, DIV NEUROSURG, 199 TUNG HWA N RD, TAIPEI 10591, TAIWAN.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Borovich B, 1975, Surg Neurol, V3, P25; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Courville CB, 1940, ARCH SURG-CHICAGO, V41, P1; CROMPTON MR, 1971, LANCET, V1, P669; DEMERINO VJ, 1976, AM J ROENTGENOL, V126, P765; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; FRENCH BN, 1977, SURG NEUROL, V7, P171; Gennarelli T. A., 1987, HEAD INJURY, P108; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GEORGE B, 1981, ACTA NEUROCHIR, V59, P35, DOI 10.1007/BF01411189; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; JAMIESON KG, 1972, J NEUROSURG, V37, P528, DOI 10.3171/jns.1972.37.5.0528; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; LANGFITT TW, 1968, AM J PHYSIOL, V215, P90; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MEYER JS, 1971, NEUROLOGY, V21, P247, DOI 10.1212/WNL.21.3.247; MOSBERG WH, 1959, J NEUROSURG, V16, P209, DOI 10.3171/jns.1959.16.2.0209; PAGNI CA, 1973, J NEUROSURG SCI, V17, P289; Stewart W A, 1973, Surg Neurol, V1, P303; TEASDALE G, 1974, LANCET, V2, P81; TSAI FY, 1980, AM J NEURORADIOL, V1, P23; VAPALAHTI M, 1971, BMJ-BRIT MED J, V3, P404, DOI 10.1136/bmj.3.5771.404; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	28	24	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1991	31	3					376	380		10.1097/00005373-199103000-00011			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	FD246	WOS:A1991FD24600010	2002524				2021-06-18	
J	PANIAK, CE; SHORE, DL; ROURKE, BP				PANIAK, CE; SHORE, DL; ROURKE, BP			RECOVERY OF MEMORY AFTER SEVERE CLOSED HEAD-INJURY - DISSOCIATIONS IN RECOVERY OF MEMORY PARAMETERS AND PREDICTORS OF OUTCOME	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV WINDSOR,DEPT PSYCHOL,WINDSOR N9B 3P4,ONTARIO,CANADA							Bond M R, 1975, Ciba Found Symp, P141; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1974, T NEW YORK ACAD SCI, V36, P721, DOI 10.1111/j.2164-0947.1974.tb01606.x; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Buschke H., 1984, NEUROPSYCHOLOGY MEMO, P33; EGAN JP, 1975, SIGNAL DETECTION THE; Flavell J H, 1970, Adv Child Dev Behav, V5, P181, DOI 10.1016/S0065-2407(08)60467-X; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HASHER IM, 1979, J EXPT PSYCHOL GENER, V80, P356; HULICKA IM, 1967, J GERONTOL, V22, P46; HULTSCH DF, 1971, DEV PSYCHOL, V4, P338, DOI 10.1037/h0030990; Jennett B, 1981, MANAGEMENT HEAD INJU; KOHL D, 1985, MEMORY DYSFUNCTIONS, V444, P460; KRAEMER HC, 1983, PSYCHOL BULL, V94, P367, DOI 10.1037/0033-2909.94.2.367; LEVIN HS, 1985, SEMIN NEUROL, V5, P221, DOI 10.1055/s-2008-1041519; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1979, CHILDS BRAIN, V5, P282; LEVIN HS, 1976, J PEDIATR PSYCHOL, V1, P38; LORING DW, 1987, J CLIN EXP NEUROPSYC, V9, P340, DOI 10.1080/01688638708405055; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; PAIVIO A, 1968, J EXP PSYCHOL, V76, P1, DOI 10.1037/h0025327; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; SHORE D, 1981, FEB M INT NEUR SOC P; SMITH AD, 1977, DEV PSYCHOL, V13, P326, DOI 10.1037/0012-1649.13.4.326; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; Thorndike EL., 1944, TEACHERS WORD BOOK 3; Van Zomeren A. H., 1981, REACTION TIME ATTENT	29	24	24	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1989	11	5					631	644		10.1080/01688638908400921			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AX358	WOS:A1989AX35800004	2808654				2021-06-18	
J	COLQUHOUN, IR; BURROWS, EH				COLQUHOUN, IR; BURROWS, EH			THE PROGNOSTIC-SIGNIFICANCE OF THE 3RD VENTRICLE AND BASAL CISTERNS IN SEVERE CLOSED HEAD-INJURY	CLINICAL RADIOLOGY			English	Article									SOUTHAMPTON GEN HOSP,WESSEX NEUROL CTR,DEPT NEURORADIOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND							BRUCE DA, 1979, CHILD BRAIN, V5, P174; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; JENNETT B, 1975, LANCET, V1, P480; KISHORE PRS, 1981, AM J ROENTGENOL, V137, P829, DOI 10.2214/ajr.137.4.829; MENDELOW AD, 1983, BRIT J SURG, V70, P641, DOI 10.1002/bjs.1800701102; MURPHY A, 1983, INTRACRANIAL PRESSUR, V5, P562; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; TABADDOR K, 1982, SURG NEUROL, V18, P212, DOI 10.1016/0090-3019(82)90395-0; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691	10	24	24	0	0	BLACKWELL SCIENCE LTD	OXFORD	OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL	0009-9260			CLIN RADIOL	Clin. Radiol.	JAN	1989	40	1					13	16		10.1016/S0009-9260(89)80006-6			4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	R9919	WOS:A1989R991900005	2784083				2021-06-18	
J	CROSSON, B; BUENNING, W				CROSSON, B; BUENNING, W			AN INDIVIDUALIZED MEMORY RETRAINING PROGRAM AFTER CLOSED-HEAD INJURY - A SINGLE-CASE STUDY	JOURNAL OF CLINICAL NEUROPSYCHOLOGY			English	Article									BERT NASH MENTAL HLTH CTR,LAWRENCE,CA	CROSSON, B (corresponding author), VET ADM MED CTR,PSYCHOL SERV 183,OKLAHOMA CITY,OK 73104, USA.		Crosson, Bruce A/L-3128-2013				BADDELEY AD, 1973, NEUROPSYCHOLOGIA, V11, P159, DOI 10.1016/0028-3932(73)90003-1; Benton A. L., 1975, TEST FACIAL RECOGNIT; BENTON AL, 1975, JUDGMENT LINE ORIENT; BINDER L M, 1980, Journal of Clinical Neuropsychology, V2, P71, DOI 10.1080/01688638008403782; CARTER L, 1980, CLIN NEUROPSYCHOLOGY, V2, P109; CERMAK L S, 1975, Cortex, V11, P163; CERMAK LS, 1976, NEUROPSYCHOLOGIA, V14, P311, DOI 10.1016/0028-3932(76)90025-7; CROVITZ HF, 1979, CORTEX, V15, P225, DOI 10.1016/S0010-9452(79)80027-1; CROVITZ HF, 1979, CORTEX, V15, P131, DOI 10.1016/S0010-9452(79)80013-1; DRUDGE OW, 1981, AUG M AM PSYCH ASS L; GASPARRINI B, 1979, Journal of Clinical Neuropsychology, V1, P137, DOI 10.1080/01688637908414447; GIANUTSOS R, 1981, Journal of Clinical Neuropsychology, V3, P143, DOI 10.1080/01688638108403119; GIANUTSOS R, 1980, J REHABIL, V46, P36; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; GIANUTSOS R, INT REHABILITATION M; Jennett B, 1981, MANAGEMENT HEAD INJU; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; JONESGOTMAN M, 1978, NEUROPSYCHOLOGIA, V16, P61, DOI 10.1016/0028-3932(78)90043-X; KALSBEEK WD, 1980, J NEUROSURGERY S, V53, P19; KNIGHT RG, 1980, PSYCHOL BULL, V88, P753; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; PATTEN BM, 1972, ARCH NEUROL-CHICAGO, V26, P25, DOI 10.1001/archneur.1972.00490070043006; Russell E. W., 1981, HDB CLIN NEUROPSYCHO, P287; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; RYAN C, 1980, J STUD ALCOHOL, V41, P437, DOI 10.15288/jsa.1980.41.437; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; VICTOR M, 1971, WERNICKEKORSAKOFF SY; WARRINGTON EK, 1971, NEUROPSYCHOLOGIA, V9, P67, DOI 10.1016/0028-3932(71)90063-7	31	24	24	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0165-0475			J CLIN NEUROPSYCHOL			1984	6	3					287	301		10.1080/01688638408401219			15	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	TD295	WOS:A1984TD29500004	6470166				2021-06-18	
J	BROWN, WJ; CANTY, T; VERITY, MA; YOSHIDA, N				BROWN, WJ; CANTY, T; VERITY, MA; YOSHIDA, N			EXPERIMENTAL CONCUSSION - ULTRASTRUCTURAL AND BIOCHEMICAL CORRELATES	AMERICAN JOURNAL OF PATHOLOGY			English	Article																BODIAN D, 1964, B JOHNS HOPKINS HOSP, V114, P13; BOWSHER D, 1970, J ANAT, V106, P23; BOWSHER D, 1971, BRAIN RES, V28, P443, DOI 10.1016/0006-8993(71)90055-2; BRECKENRIDGE BM, 1962, J NEUROCHEM, V9, P383, DOI 10.1111/j.1471-4159.1962.tb09464.x; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; CHASON JL, 1957, J NEUROPATH EXP NEUR, V16, P102, DOI 10.1097/00005072-195701000-00012; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DOW RS, 1945, J NEUROPHYSIOL, V8, P161; DROCHMANS P, 1962, J ULTRA MOL STRUCT R, V6, P141, DOI 10.1016/S0022-5320(62)90050-3; EVANS JP, 1944, RES PUBL ASS NERV ME, V24, P254; FRIEDE R, 1958, BIOPHYSICS CONCUSS 2, P58; FRIEDE RL, 1960, J NEUROPATH EXP NEUR, V19, P266, DOI 10.1097/00005072-196004000-00007; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; Gray E G, 1966, Int Rev Cytol, V19, P111, DOI 10.1016/S0074-7696(08)60566-5; GRAY EG, 1961, J PHYSIOL-LONDON, V157, P581, DOI 10.1113/jphysiol.1961.sp006744; GRAY EG, 1959, J ANAT, V93, P420; GRILLO MA, 1966, PHARMACOL REV, V18, P387; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; Groat RA, 1944, AM J PHYSIOL, V141, P0117; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; IBRAHIM MZM, 1970, AM J PATHOL, V60, P403; KARNOVSKY MJ, 1961, J BIOPHYS BIOCHEM CY, V11, P729, DOI 10.1083/jcb.11.3.729; Kerr SE, 1936, J BIOL CHEM, V116, P9; KIRKPATRICK JB, 1968, J COMP NEUROL, V132, P189, DOI 10.1002/cne.901320110; KLATZO I, 1961, J NEUROPATH EXP NEUR, V20, P459, DOI 10.1097/00005072-196120040-00001; KOENIG H, 1945, STAIN TECHNOL, V20, P13, DOI 10.3109/10520294509107124; Kuffer S. W., 1966, Ergebnisse der Physiologie, V57, P1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAXWELL DS, 1965, J CELL BIOL, V25, P141, DOI 10.1083/jcb.25.2.141; MCILWAIN H, 1952, BIOCHEM J, V52, P289, DOI 10.1042/bj0520289; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; REVEL JP, 1964, J HISTOCHEM CYTOCHEM, V12, P104, DOI 10.1177/12.2.104; RHINES R, 1946, AM J PHYSIOL, V146, P344; ROLLESTON FS, 1967, BIOCHEM J, V104, P524, DOI 10.1042/bj1040524; SHIMIZU N, 1958, NATURE, V181, P781, DOI 10.1038/181781a0; SOTELO C, 1968, J CELL BIOL, V36, P151, DOI 10.1083/jcb.36.1.151; STRICH SJ, 1961, LANCET, V2, P443; TAKAGAKI G, 1968, J NEUROCHEM, V15, P903, DOI 10.1111/j.1471-4159.1968.tb11632.x; VENABLE JH, 1965, J CELL BIOL, V25, P407, DOI 10.1083/jcb.25.2.407; VERITY MA, 1969, BIOCHEM PHARMACOL, V18, P327, DOI 10.1016/0006-2952(69)90210-X; VERITY MA, 1963, J LAB CLIN MED, V62, P846; VESCO C, 1968, J NEUROCHEM, V15, P81, DOI 10.1111/j.1471-4159.1968.tb06177.x; WARD JW, 1948, J NEUROPHYSIOL, V11, P59; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; WINDLE W. F., 1944, TRANS AMER NEUROL ASSOC, V70, P117; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; WOLFE LS, 1962, J NEUROCHEM, V9, P213, DOI 10.1111/j.1471-4159.1962.tb11862.x; WOOLLEY DE, 1963, P SOC EXP BIOL MED, V114, P571; YAMAMOTO T, 1963, J CELL BIOL, V16, P159, DOI 10.1083/jcb.16.1.159	54	24	24	0	0	AMER SOC INVESTIGATIVE PATHOLOGY, INC	BALTIMORE	428 EAST PRESTON ST, BALTIMORE, MD 21202-3993	0002-9440			AM J PATHOL	Am. J. Pathol.		1972	67	1					41	&					0	Pathology	Pathology	M3066	WOS:A1972M306600003	5045878				2021-06-18	
J	DILLON, H; LEOPOLD, RL				DILLON, H; LEOPOLD, RL			CHILDREN AND POST-CONCUSSION SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																BOCHNER AK, 1957, H LMP; COURVILLE CB, 1953, COMMOTIO CEREBRI; DENCKER SJ, 1960, ARCH GEN PSYCHIAT, V2, P569; FABIAN AA, 1956, J NERV MENT DIS, V123, P428, DOI 10.1097/00005053-195605000-00002; HARRIS P, 1956, ARCH DIS CHILD, V32, P488; PETERSON BH, 1956, MED J AUST, V1, P689; ROWBOTHAM GF, 1954, BRIT MED J, V1, P726, DOI 10.1136/bmj.1.4864.726; SELLEY I, 1958, ACTA PSYCHIAT SCAND, V33, P209; WECHSLER IS, 1958, TEXTBOOK CLINICAL NE	9	24	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.		1961	175	2					86	&		10.1001/jama.1961.03040020012003			0	Medicine, General & Internal	General & Internal Medicine	3293B	WOS:A19613293B00007	13722906				2021-06-18	
J	DOMBRAIN, A				DOMBRAIN, A			TRAUMATIC OR CONCUSSION CHRONIC GLAUCOMA	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article																DOMBRAIN A, 1945, T OPHTHALMOL SOC AUS, V5, P116; DOMBRAIN A, 1946, T OPHTHAL SOC AUST, V6, P129; DOMBRAIN AW, 1944, MED J AUSTR, V2, P112; DUKEELDER WS, 1940, TXB OPHTHALMOLOGY, V3, P3300; POSNER A, 1948, AM J OPHTHALMOL, V31, P915, DOI 10.1016/0002-9394(48)92521-5; REESE AB, 1944, AM J OPHTHALMOL, V27, P1193	6	24	24	2	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161			BRIT J OPHTHALMOL	Br. J. Ophthalmol.		1949	33	8					495	500		10.1136/bjo.33.8.495			6	Ophthalmology	Ophthalmology	XW290	WOS:A1949XW29000005	18135478	Green Published, Bronze			2021-06-18	
J	Barrow, DW; Rhoads, HT				Barrow, DW; Rhoads, HT			Blast concussion injury	JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																Fulton J. F., 1942, NEW ENGL J MED, V226, P1; Gates R., 1943, U S NAVAL MED BULL, V41, P12; Hadfield G, 1941, BRIT MED J, V1941, P77, DOI 10.1136/bmj.1.4176.77; Krohn PL, 1942, LANCET, V1, P252; Logan DD, 1939, BRIT MED J, V2, P864, DOI 10.1136/bmj.2.4112.864; MCMULLIN JJA, 1943, US NAV M B, V41, P1; OREILLY JN, 1941, BRIT MED J, V2, P423; PALMA J, 1943, BRIT MED J, V41, P3; Stewart OW, 1941, LANCET, V1, P172; Sutherland GA, 1940, LANCET, V2, P641; Wilson J V, 1943, Br Med J, V1, P470; Wilson JV, 1943, LANCET, V1, P257; 1941, P ROY SOC MED, V34, P171	13	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0002-9955			J AMER MED ASSOC	J. Am. Med. Assoc.	MAY-AUG	1944	125						900	902		10.1001/jama.1944.02850310020006			3	Medicine, General & Internal	General & Internal Medicine	V24NU	WOS:000201658200164					2021-06-18	
J	Capizzi, A; Woo, J; Verduzco-Gutierrez, M				Capizzi, Allison; Woo, Jean; Verduzco-Gutierrez, Monica			Traumatic Brain Injury An Overview of Epidemiology, Pathophysiology, and Medical Management	MEDICAL CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; TBI; Head injury; Acquired brain injury; Concussion; Disorders of consciousness	GALVESTON ORIENTATION; CONSCIOUSNESS; DISORDERS; DIAGNOSIS	Traumatic brain injury (TBI) is an acquired insult to the brain from an external mechanical force that may result in temporary or permanent impairment. The goal of this article is to provide a general review of the epidemiology, pathophysiology and medical management of adult patients with TBI for providers practicing outside the field of physical medicine and rehabilitation. The medical and rehabilitation management of moderate to severe TBI is the focus of this article, with a brief discussion of the management of mild injuries.	[Capizzi, Allison] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Phys Med & Rehabil, 1333 Moursund St, Houston, TX 77030 USA; [Woo, Jean] Baylor Coll Med, H Ben Taub Dept Phys Med & Rehabil, 7200 Cambridge St, Houston, TX 77030 USA; [Verduzco-Gutierrez, Monica] Univ Texas Hlth Sci Ctr Houston, Brain Injury & Stroke Programs, Dept Phys Med & Rehabil, McGovern Med Sch,TIRR Mem Hermann Hosp, 1333 Moursund St, Houston, TX 77030 USA	Verduzco-Gutierrez, M (corresponding author), Univ Texas Hlth Sci Ctr Houston, Brain Injury & Stroke Programs, Dept Phys Med & Rehabil, McGovern Med Sch,TIRR Mem Hermann Hosp, 1333 Moursund St, Houston, TX 77030 USA.	Monica.verduzco-gutierrez@uth.tmc.edu		Verduzco-Gutierrez, Monica/0000-0003-0964-5908			[Anonymous], 2017, MEDICARE BENEFIT POL; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Centers for Disease Control and Prevention, 2014, SURV REP TRAUM BRAIN; Cifu D., 2016, BRADDOMS PHYS MED RE, P964; Compton E, 2018, NURS CLIN N AM, V53, P459, DOI 10.1016/j.cnur.2018.05.003; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cuccurullo SJ, 2010, PHYS MED REHABILITAT, P49; Dixon KJ, 2017, PHYS MED REH CLIN N, V28, P215, DOI 10.1016/j.pmr.2016.12.001; Eapen B, 2018, REHABILITATION TRAUM; Eapen BC, 2017, PHYS MED REH CLIN N, V28, P245, DOI 10.1016/j.pmr.2016.12.003; Fins Joseph J, 2012, Virtual Mentor, V14, P221, DOI 10.1001/virtualmentor.2012.14.3.stas1-1203; Giacino JT, 2018, NEUROLOGY, V91, P450, DOI 10.1212/WNL.0000000000005926; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Hammond FM, 2019, J NEUROTRAUM, V36, P1136, DOI 10.1089/neu.2018.5954; Jackson George L, 2008, N C Med J, V69, P43; Kalra ID, 2017, J HEAD TRAUMA REHAB, V32, pE61, DOI 10.1097/HTR.0000000000000359; Kapoor D, 2014, SINGAP MED J, V55, pE123, DOI 10.11622/smedj.2013264; Katz DI, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P2; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Magee DJ, 2014, ORTHOPEDIC PHYS ASSE, P84; McCrea MA, 2017, PHYS MED REH CLIN N, V28, P271, DOI 10.1016/j.pmr.2016.12.005; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Oberholzer M, 2019, MED SCI, V7, P1; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Tapia RN, 2017, PHYS MED REH CLIN N, V28, P287, DOI 10.1016/j.pmr.2016.12.006; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468	31	23	23	9	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0025-7125	1557-9859		MED CLIN N AM	Med. Clin. N. Am.	MAR	2020	104	2					213	+		10.1016/j.mcna.2019.11.001			27	Medicine, General & Internal	General & Internal Medicine	KR5JE	WOS:000517653900005	32035565				2021-06-18	
J	O'Keeffe, E; Kelly, E; Liu, YZ; Giordano, C; Wallace, E; Hynes, M; Tiernan, S; Meagher, A; Greene, C; Hughes, S; Burke, T; Kealy, J; Doyle, N; Hay, A; Farrell, M; Grant, GA; Friedman, A; Veksler, R; Molloy, MG; Meaney, JF; Pender, N; Camarillo, D; Doherty, CP; Campbell, M				O'Keeffe, Eoin; Kelly, Eoin; Liu, Yuzhe; Giordano, Chiara; Wallace, Eugene; Hynes, Mark; Tiernan, Stephen; Meagher, Aidan; Greene, Chris; Hughes, Stephanie; Burke, Tom; Kealy, John; Doyle, Niamh; Hay, Alison; Farrell, Michael; Grant, Gerald A.; Friedman, Alon; Veksler, Ronel; Molloy, Michael G.; Meaney, James F.; Pender, Niall; Camarillo, David; Doherty, Colin P.; Campbell, Matthew			Dynamic Blood-Brain Barrier Regulation in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; blood-brain barrier dysfunction; MRI	ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; CONCUSSION; DISRUPTION; ENCEPHALOPATHY; DYSFUNCTION; PATHOLOGY; HEALTH; YOUTH	Whereas the diagnosis of moderate and severe traumatic brain injury (TBI) is readily visible on current medical imaging paradigms (magnetic resonance imaging [MRI] and computed tomography [CT] scanning), a far greater challenge is associated with the diagnosis and subsequent management of mild TBI (mTBI), especially concussion which, by definition, is characterized by a normal CT. To investigate whether the integrity of the blood-brain barrier (BBB) is altered in a high-risk population for concussions, we studied professional mixed martial arts (MMA) fighters and adolescent rugby players. Additionally, we performed the linear regression between the BBB disruption defined by increased gadolinium contrast extravasation on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on MRI and multiple biomechanical parameters indicating the severity of impacts recorded using instrumented mouthguards in professional MMA fighters. MMA fighters were examined pre-fight for a baseline and again within 120 h post-competitive fight, whereas rugby players were examined pre-season and again post-season or post-match in a subset of cases. DCE-MRI, serological analysis of BBB biomarkers, and an analysis of instrumented mouthguard data, was performed. Here, we provide pilot data that demonstrate disruption of the BBB in both professional MMA fighters and rugby players, dependent on the level of exposure. Our data suggest that biomechanical forces in professional MMA and adolescent rugby can lead to BBB disruption. These changes on imaging may serve as a biomarker of exposure of the brain to repetitive subconcussive forces and mTBI.	[O'Keeffe, Eoin; Campbell, Matthew] Trinity Coll Dublin, Smurfit Inst Genet, Lincoln Pl Gate, Dublin 2, Ireland; [Kelly, Eoin] St James Hosp, Hlth Care Ctr, Dept Neurol, Hosp 5, Dublin, Ireland; [Liu, Yuzhe; Giordano, Chiara] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Hynes, Mark] Personal Hlth, Dublin, Ireland; [Tiernan, Stephen; Meagher, Aidan] Technol Univ Dublin, Dept Mech Engn, Dublin, Ireland; [Tiernan, Stephen] Beaumont Hosp, Dept Psychol, Dublin, Ireland; [Burke, Tom] Trinity Coll Dublin, Acad Unit Neurol, Inst Biomed Sci, Dublin, Ireland; [Farrell, Michael] Beaumont Hosp, Dept Neuropathol, Dublin, Ireland; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA USA; [Friedman, Alon; Veksler, Ronel] Ben Gur Univ Negev, Zlotowski Ctr Neurosci, Dept Cognit & Brain Sci, Beer Sheva, Israel; [Friedman, Alon] Dalhousie Univ, Dept Med Neurosci, Halifax, NS, Canada; [Molloy, Michael G.] Univ Coll Cork, Dept Med, Cork, Ireland; [Meaney, James F.] St James Hosp, Dept Radiol, Dublin, Ireland; [Meaney, James F.] St James Hosp, CAMI, Dublin, Ireland	Campbell, M (corresponding author), Trinity Coll Dublin, Smurfit Inst Genet, Lincoln Pl Gate, Dublin 2, Ireland.	Matthew.Campbell@tcd.ie	Burke, Tom/AAH-8963-2020; Kealy, John/A-6515-2010	Burke, Tom/0000-0002-6563-1597; Greene, Chris/0000-0003-4192-9433; Kealy, John/0000-0002-0503-4379; , Alon/0000-0003-4780-8456; Doherty, Colin/0000-0002-8869-8567; Tiernan, Stephen/0000-0002-0658-7557	Science Foundation Ireland (SFI)Science Foundation Ireland [12/YI/B2614, 11/PI/1080]; Health Research Board of Ireland (HRB); BrightFocus FoundationBrightFocus Foundation; St James' Hospital Foundation; Ellen Mayston Bates Bequest at the Trinity Foundation; SFIScience Foundation Ireland [16/RC/3948]; European Regional Development fundEuropean Commission; Canada Institute for Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	This work was supported by grants from Science Foundation Ireland (SFI; 12/YI/B2614 and 11/PI/1080), The Health Research Board of Ireland (HRB), the BrightFocus Foundation, and the St James' Hospital Foundation with support to E.K. from the Ellen Mayston Bates Bequest at the Trinity Foundation. The Campbell lab at TCD is also supported by an SFI Centres grant supported, in part, by a research grant from SFI under grant number 16/RC/3948 and co-funded under the European Regional Development fund by FutureNeuro industry partners. Work in the laboratory of A.F. is supported by the Canada Institute for Health Research (CIHR; to A.F.).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Doherty CP, 2019, CLIN NEUROPATHOL, V38, P14, DOI 10.5414/NP301131; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Greene C, 2018, MOL PSYCHIATR, V23, P2156, DOI 10.1038/mp.2017.156; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Iacono D, 2017, PHYS MED REH CLIN N, V28, P301, DOI 10.1016/j.pmr.2016.12.007; Johnson VE, 2018, ACTA NEUROPATHOL, V135, P711, DOI 10.1007/s00401-018-1824-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Koerte IK, 2017, J NEUROTRAUM, V34, P2389, DOI 10.1089/neu.2016.4960; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Lynall RC, 2017, J NEUROTRAUM, V34, P2684, DOI 10.1089/neu.2017.5032; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; Menard C, 2017, NAT NEUROSCI, V20, P1752, DOI 10.1038/s41593-017-0010-3; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Pardridge William M, 2005, NeuroRx, V2, P3; Prasad P, 2008, STAPP CAR C, V52, P187; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Smith DH, 2019, NAT REV NEUROL, V15, P179, DOI 10.1038/s41582-018-0114-8; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Veksler R, 2014, ARCH MED RES, V45, P646, DOI 10.1016/j.arcmed.2014.11.016; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	39	23	23	3	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2020	37	2					347	356		10.1089/neu.2019.6483		NOV 2019	10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	JZ2YM	WOS:000495443500001	31702476				2021-06-18	
J	Kerr, ZY; Chandran, A; Nedimyer, AK; Arakkal, A; Pierpoint, LA; Zuckerman, SL				Kerr, Zachary Y.; Chandran, Avinash; Nedimyer, Aliza K.; Arakkal, Alan; Pierpoint, Lauren A.; Zuckerman, Scott L.			Concussion Incidence and Trends in 20 High School Sports	PEDIATRICS			English	Article							COLLEGIATE FOOTBALL PLAYERS; HEALTH-CARE UTILIZATION; TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; UNITED-STATES; RECURRENT CONCUSSION; GENDER-DIFFERENCES; SEX-DIFFERENCES; EPIDEMIOLOGY; RATES	This epidemiological study uses sports injury surveillance data to describe concussion incidence and trends in high school sports during the 2013-2014 to 2017-2018 academic years. BACKGROUND: Ongoing monitoring of concussion rates and distributions is important in assessing temporal patterns. Examinations of high school sport-related concussions need to be updated. This study describes the epidemiology of concussions in 20 high school sports during the 2013-2014 to 2017-2018 school years. METHODS: In this descriptive epidemiology study, a convenience sample of high school athletic trainers provided injury and athlete exposure (AE) data to the National High School Sports-Related Injury Surveillance Study (High School Reporting Information Online). Concussion rates per 10 000 AEs with 95% confidence intervals (CIs) and distributions were calculated. Injury rate ratios and injury proportion ratios examined sex differences in sex-comparable sports (soccer, basketball, baseball and softball, cross country, track, and swimming). We also assessed temporal trends across the study period. RESULTS: Overall, 9542 concussions were reported for an overall rate of 4.17 per 10 000 AEs (95% CI: 4.09 to 4.26). Football had the highest concussion rate (10.40 per 10 000 AEs). Across the study period, football competition-related concussion rates increased (33.19 to 39.07 per 10 000 AEs); practice-related concussion rates decreased (5.47 to 4.44 per 10 000 AEs). In all sports, recurrent concussion rates decreased (0.47 to 0.28 per 10 000 AEs). Among sex-comparable sports, concussion rates were higher in girls than in boys (3.35 vs 1.51 per 10 000 AEs; injury rate ratio = 2.22; 95% CI: 2.07 to 2.39). Also, among sex-comparable sports, girls had larger proportions of concussions that were recurrent than boys did (9.3% vs 6.4%; injury proportion ratio = 1.44; 95% CI: 1.11 to 1.88). CONCLUSIONS: Rates of football practice-related concussions and recurrent concussions across all sports decreased. Changes in concussion rates may be associated with changes in concussion incidence, diagnosis, and management. Future research should continue to monitor trends and examine the effect of prevention strategies.	[Nedimyer, Aliza K.] Univ North Carolina Chapel Hill, Human Movement Sci Curriculum, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Chandran, Avinash] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Chandran, Avinash; Nedimyer, Aliza K.] Univ North Carolina Chapel Hill, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA; [Arakkal, Alan] Univ Colorado Denver, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA; [Pierpoint, Lauren A.] Steadman Philippon Res Inst, Vail, CO USA; [Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA; [Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Sports Concuss Ctr, Nashville, TN 37212 USA	Kerr, ZY (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2 RR025754]; National Federation of High School Associations; National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack	This report represents data collection from High School Reporting Information Online. These data were provided by Dr R. Dawn Comstock of the Colorado School of Public Health and the University of Colorado School of Medicine. High School Reporting Information Online was funded in part by the Centers for Disease Control and Prevention (grants R49/CE000674-01 and R49/CE001172-01) and the National Center for Research Resources (award KL2 RR025754). The authors also acknowledge the research funding contributions of the National Federation of High School Associations, National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the funding organizations.	Baker DR, 2018, AM J SPORT MED, V46, P396, DOI 10.1177/0363546517738742; Brenner JS, 2015, PEDIATRICS, V136, pe1419; Brett BL, 2018, SPORTS MED-OPEN, V4, DOI 10.1186/s40798-018-0121-8; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Comstock RD, 2018, CONVENIENCE SAMPLE S; Covassin T, 2018, AM J SPORT MED, V46, P2270, DOI 10.1177/0363546518780225; Currie DW, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2447; de Courten-Myers GM, 1999, J NEUROPATH EXP NEUR, V58, P217; Esposito G, 1996, J NUCL MED, V37, P559; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Green L., 2014, LEGAL PERSPECTIVES R; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harvey HH, 2015, J LAW MED ETHICS, V43, P87, DOI 10.1111/jlme.12225; Jones B., 2015, STATES ADOPT PLANS L; Jones CM, 2017, SPORTS MED, V47, P943, DOI 10.1007/s40279-016-0619-5; Kerr ZY, 2021, CLIN J SPORT MED, V31, pE21, DOI 10.1097/JSM.0000000000000697; Kerr ZY, 2018, J ATHL TRAINING, V53, P738, DOI 10.4085/1062-6050-144-17; Kerr ZY, 2017, AM J PREV MED, V53, P914, DOI 10.1016/j.amepre.2017.05.017; Kerr ZY, 2017, NEUROL CLIN, V35, P409, DOI 10.1016/j.ncl.2017.03.001; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Lombardi NJ, 2016, ORTHOPEDICS, V39, pE944, DOI 10.3928/01477447-20160623-10; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; National Federation of State High School Associations, 2020, PART STAT; National Federation of State High School Associations, 2018, RUL REV HIGH SCH VOL; O'Connor KL, 2017, J ATHL TRAINING, V52, P175, DOI 10.4085/1062-6050-52.1.15; Pfaller AY, 2019, AM J SPORT MED, V47, P2294, DOI 10.1177/0363546519860120; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; The Aspen Institute: Project Play, 2018, STAT PLAY 2018 TREND; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; United States Census Bureau, 2009, CENS REG US; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Wiebe DJ, 2018, JAMA-J AM MED ASSOC, V320, P2035, DOI 10.1001/jama.2018.14165; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Yang JZ, 2017, AM J PUBLIC HEALTH, V107, P1916, DOI 10.2105/AJPH.2017.304056; Yard EE, 2009, J ATHL TRAINING, V44, P645, DOI 10.4085/1062-6050-44.6.645; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	48	23	23	1	16	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2019	144	5							e20192180	10.1542/peds.2019-2180			13	Pediatrics	Pediatrics	JK2MP	WOS:000494681400023	31615955	Bronze			2021-06-18	
J	Wu, JX; Cai, N; Chen, WJ; Wang, HH; Wang, GT				Wu, Jixiu; Cai, Nian; Chen, Wenjie; Wang, Huiheng; Wang, Guotian			Automatic detection of hardhats worn by construction personnel: A deep learning approach and benchmark dataset	AUTOMATION IN CONSTRUCTION			English	Article						Construction sites safety; Hardhat wearing detection; Computer vision; Convolutional neural network; Reverse progressive attention	TRAUMATIC BRAIN-INJURIES; IDENTIFICATION	Hardhats play an essential role in protecting construction individuals from accidents. However, wearing hardhats is not strictly enforced among workers due to all kinds of reasons. To enhance construction sites safety, the majority of existing works monitor the presence and proper use of hardhats through multi-stage data processing, which come with limitations on adaption and generalizability. In this paper, a one-stage system based on convolutional neural network is proposed to automatically monitor whether construction personnel are wearing hardhats and identify the corresponding colors. To facilitate the study, this work constructs a new and publicly available hardhat wearing detection benchmark dataset, which consists of 3174 images covering various on-site conditions. Then, features from different layers with different scales are fused discriminately by the proposed reverse progressive attention to generate a new feature pyramid, which will be fed into the Single Shot Multibox Detector (SSD) to predict the final detection results. The proposed system is trained by an end-to-end scheme. The experimental results demonstrate that the proposed system is effective under all kinds of on-site conditions, which can achieve 83.89% mAP (mean average precision) with the input size 512 x 512.	[Wu, Jixiu; Cai, Nian; Chen, Wenjie; Wang, Huiheng] Guangdong Univ Technol, Sch Informat Engn, Guangzhou 510006, Guangdong, Peoples R China; [Wang, Guotian] Face Intelligent Technol Co Ltd, Guangzhou 510032, Guangdong, Peoples R China	Cai, N (corresponding author), Guangdong Univ Technol, Sch Informat Engn, Guangzhou 510006, Guangdong, Peoples R China.	cainian@gdut.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61001179, 61471132]; Key Project of Industry-University-Research Collaborative Innovation in Guangzhou, China [201802020010, 201802020007]	This work was in part supported by the National Natural Science Foundation of China (Grant Nos. 61001179 and 61471132) and the Key Project of Industry-University-Research Collaborative Innovation in Guangzhou, China (Nos. 201802020010 and 201802020007).	Bureau of Labor Statistics, 2017, NUMB RAT FAT WORK IN; Colantonio A, 2009, BRAIN INJURY, V23, P873, DOI 10.1080/02699050903036033; Dollar P, 2014, IEEE T PATTERN ANAL, V36, P1532, DOI 10.1109/TPAMI.2014.2300479; Dong S, 2015, ICCREM 2015: ENVIRONMENT AND THE SUSTAINABLE BUILDING, P204; Fang Q, 2018, AUTOMAT CONSTR, V85, P1, DOI 10.1016/j.autcon.2017.09.018; Green L, 2012, GARY TOMINACK REAL T; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; Howard A.G., 2017, 170404861 ARXIV; Iandola Forrest, 2017, 2017 International Conference on Hardware/Software Codesign and System Synthesis (CODES+ISSS), DOI 10.1145/3125502.3125606; Jia YQ, 2014, PROCEEDINGS OF THE 2014 ACM CONFERENCE ON MULTIMEDIA (MM'14), P675, DOI 10.1145/2647868.2654889; Karen S., 2015, INTERNATIONAL CONFER; Kelm A, 2013, AUTOMAT CONSTR, V36, P38, DOI 10.1016/j.autcon.2013.08.009; Konda S, 2016, AM J IND MED, V59, P212, DOI 10.1002/ajim.22557; Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386; Li H., 2018, BRIT MACH VIS C BMVC; Li J, 2017, 2017 NINTH INTERNATIONAL CONFERENCE ON ADVANCED COMPUTATIONAL INTELLIGENCE (ICACI), P201, DOI 10.1109/ICACI.2017.7974509; Li K, 2017, IEEE ANN INT CONF CY, P617, DOI 10.1109/CYBER.2017.8446080; Lin TY, 2017, PROC CVPR IEEE, P936, DOI 10.1109/CVPR.2017.106; Liu W, 2016, LECT NOTES COMPUT SC, V9905, P21, DOI 10.1007/978-3-319-46448-0_2; MHURD (the Ministry of Housing and Urban-Rural Development), 2017, SHORT REP FAT ACC CH; Mneymneh BE, 2019, J COMPUT CIVIL ENG, V33, DOI 10.1061/(ASCE)CP.1943-5487.0000813; Mneymneh BE, 2018, FRONT ENG MANAG, V5, P227, DOI 10.15302/J-FEM-2018071; Park MW, 2016, AUTOMAT CONSTR, V72, P129, DOI 10.1016/j.autcon.2016.08.039; Park MW, 2015, J CONSTR ENG M, V141, DOI 10.1061/(ASCE)CO.1943-7862.0000974; Park MW, 2012, AUTOMAT CONSTR, V28, P15, DOI 10.1016/j.autcon.2012.06.001; Redmon J., 2018, ARXIV180402767; Ren Shaoqing, 2017, IEEE Trans Pattern Anal Mach Intell, V39, P1137, DOI 10.1109/TPAMI.2016.2577031; Rubaiyat AM, 2016, 2016 IEEE/WIC/ACM INTERNATIONAL CONFERENCE ON WEB INTELLIGENCE WORKSHOPS (WIW 2016), P135, DOI [10.1109/WIW.2016.10, 10.1109/WIW.2016.045]; Shan Du, 2011, 2011 3rd International Conference on Computer Research and Development (ICCRD 2011), P25, DOI 10.1109/ICCRD.2011.5763846; Shrestha K., 2015, J CONSTRUCTION ENG, V2015, P1; Wang R. J., 2018, INT C LEARN REPR WOR; Wu H, 2018, COMPUT IND, V100, P267, DOI 10.1016/j.compind.2018.03.037; Zhang H, 2019, J CONSTR ENG M, V145, DOI 10.1061/(ASCE)CO.1943-7862.0001629; Zhang XN, 2018, PROC CVPR IEEE, P714, DOI 10.1109/CVPR.2018.00081; Zhu Z., 2015, 5 INT CONSTR SPEC C, P1, DOI [10.14288/1.0076342, DOI 10.14288/1.0076342]	35	23	23	4	25	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0926-5805	1872-7891		AUTOMAT CONSTR	Autom. Constr.	OCT	2019	106								102894	10.1016/j.autcon.2019.102894			7	Construction & Building Technology; Engineering, Civil	Construction & Building Technology; Engineering	JA8YG	WOS:000488136600043					2021-06-18	
J	Harris, TC; de Rooij, R; Kuhl, E				Harris, Taylor C.; de Rooij, Rijk; Kuhl, Ellen			The Shrinking Brain: Cerebral Atrophy Following Traumatic Brain Injury	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Cerebral atrophy; Neurodegeneration; Computational simulation; Finite element modeling	ALZHEIMERS-DISEASE; WHITE-MATTER; HEAD-INJURY; VOLUME; ENCEPHALOPATHY; PREDICTS; SEGMENTATION; MORPHOMETRY; DYSFUNCTION; CONCUSSION	Cerebral atrophy in response to traumatic brain injury is a well-documented phenomenon in both primary investigations and review articles. Recent atrophy studies focus on exploring the region-specific patterns of cerebral atrophy; yet, there is no study that analyzes and synthesizes the emerging atrophy patterns in a single comprehensive review. Here we attempt to fill this gap in our current knowledge by integrating the current literature into a cohesive theory of preferential brain tissue loss and by identifying common risk factors for accelerated atrophy progression. Our review reveals that observations for mild traumatic brain injury remain inconclusive, whereas observations for moderate-to-severe traumatic brain injury converge towards robust patterns: brain tissue loss is on the order of 5% per year, and occurs in the form of generalized atrophy, across the entire brain, or focal atrophy, in specific brain regions. The most common regions of focal atrophy are the thalamus, hippocampus, and cerebellum in gray matter and the corpus callosum, corona radiata, and brainstem in white matter. We illustrate the differences of generalized and focal gray and white matter atrophy on emerging deformation and stress profiles across the whole brain using computational simulation. The characteristic features of our atrophy simulations-a widening of the cortical sulci, a gradual enlargement of the ventricles, and a pronounced cortical thinning-agree well with clinical observations. Understanding region-specific atrophy patterns in response to traumatic brain injury has significant implications in modeling, simulating, and predicting injury outcomes. Computational modeling of brain atrophy could open new strategies for physicians to make informed decisions for whom, how, and when to administer pharmaceutical treatment to manage the chronic loss of brain structure and function.	[Harris, Taylor C.; de Rooij, Rijk; Kuhl, Ellen] Stanford Univ, Stanford, CA 94305 USA	Kuhl, E (corresponding author), Stanford Univ, Stanford, CA 94305 USA.	ekuhl@stanford.edu	Kuhl, Ellen/G-4444-2011	Kuhl, Ellen/0000-0002-6283-935X	Stanford Graduate FellowshipStanford University; Bio-X IIP Seed Grant Molecular Mechanisms of Chronic Traumatic Encephalopathy; National Science Foundation GrantNational Science Foundation (NSF) [CMMI 1727268]	We acknowledge the support of Alexander Zollner and Johannes Weickenmeier for creating the finite element models and the illustration by Lucy Reading. This study was supported by the Stanford Graduate Fellowship to Rijk de Rooij and by the Bio-X IIP Seed Grant Molecular Mechanisms of Chronic Traumatic Encephalopathy and the National Science Foundation Grant CMMI 1727268 Understanding Neurodegeneration Across the Scales to Ellen Kuhl.	Ahmadzadeh H, 2015, BIOPHYS J, V109, P2328, DOI 10.1016/j.bpj.2015.09.010; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; BOWEN DM, 1983, J NEUROCHEM, V41, P266, DOI 10.1111/j.1471-4159.1983.tb11838.x; Budday S, 2017, ACTA BIOMATER, V48, P319, DOI 10.1016/j.actbio.2016.10.036; Budday S, 2014, SCI REP-UK, V4, DOI 10.1038/srep05644; Burton EJ, 2004, BRAIN, V127, P791, DOI 10.1093/brain/awh088; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Cole JH, 2018, BRAIN, V141, P822, DOI 10.1093/brain/awx354; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALPAN GJ, 1992, NEUROLOGY, V42, P2125, DOI 10.1212/WNL.42.11.2125; de Rooij R, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00144; de Rooij R, 2018, J MECH PHYS SOLIDS, V112, P563, DOI 10.1016/j.jmps.2017.12.011; de Rooij R, 2018, BIOPHYS J, V114, P201, DOI 10.1016/j.bpj.2017.11.010; Deng XQ, 2014, J MECH MED BIOL, V14, DOI 10.1142/S0219519414400028; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fahlstedt M, 2015, J BIOMECH, V48, P1331, DOI 10.1016/j.jbiomech.2015.02.057; Finkenstein EA, 2006, INCIDENCE EC BURDEN; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Gooijers J, 2016, NEUROREHAB NEURAL RE, V30, P603, DOI 10.1177/1545968315613448; Goriely A, 2015, ADV APPL MECH, V48, P79, DOI 10.1016/bs.aams.2015.10.002; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Horstemeyer M. F., 2018, PHYS MOTIVATED MECH; Horstemeyer MF, 1999, INT J SOLIDS STRUCT, V36, P5029, DOI 10.1016/S0020-7683(98)00239-X; Hua X, 2008, NEUROIMAGE, V43, P458, DOI 10.1016/j.neuroimage.2008.07.013; Irimia A, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00530; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KUHL DE, 1982, ANN NEUROL, V12, P425, DOI 10.1002/ana.410120504; Kuo C, 2017, J NEUROTRAUM, V34, P3198, DOI 10.1089/neu.2016.4893; Ledig C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188152; Lehericy S, 2007, EUR RADIOL, V17, P347, DOI 10.1007/s00330-006-0341-z; Leunissen I, 2014, CORTEX, V51, P67, DOI 10.1016/j.cortex.2013.10.009; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Losseff NA, 1996, BRAIN, V119, P2009, DOI 10.1093/brain/119.6.2009; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Purohit DP, 2011, J ALZHEIMERS DIS, V24, P187, DOI 10.3233/JAD-2010-101698; Ruet A, 2018, J NEUROTRAUM, V35, P1552, DOI 10.1089/neu.2017.5242; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Spitz G, 2013, BRAIN COGNITION, V83, P34, DOI 10.1016/j.bandc.2013.06.007; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Taylor DA, 2013, MMWR-MORBID MORTAL W, V66, P1; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Turner RC, 2016, BRAIN INJURY, V30, P1279, DOI 10.1080/02699052.2016.1193631; van den Bedem H, 2017, CURR OPIN BIOMED ENG, V1, P23, DOI 10.1016/j.cobme.2017.02.003; Waller A, 1850, PHILOS T R SOC LOND, V140, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021, 10.1098/rstl.1850.0021]; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Weickenmeier J, 2018, J MECH BEHAV BIOMED, V84, P88, DOI 10.1016/j.jmbbm.2018.04.009; Weickenmeier J, 2017, COMPUT METHOD APPL M, V314, P180, DOI 10.1016/j.cma.2016.08.011; Weickenmeier J, 2016, ACTA BIOMATER, V42, P265, DOI 10.1016/j.actbio.2016.07.040; Weickenmeier J, 2018, PHYS REV LETT, V121, DOI 10.1103/PhysRevLett.121.158101; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	69	23	23	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	SEP	2019	47	9			SI		1941	1959		10.1007/s10439-018-02148-2			19	Engineering, Biomedical	Engineering	JD1MH	WOS:000489738300008	30341741	Green Published, Other Gold			2021-06-18	
J	Leddy, JJ; Haider, MN; Hinds, AL; Darling, S; Willer, BS				Leddy, John J.; Haider, Mohammad N.; Hinds, Andrea L.; Darling, Scott; Willer, Barry S.			A Preliminary Study of the Effect of Early Aerobic Exercise Treatment for Sport-Related Concussion in Males	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						exercise treatment; relative rest; concussion; adolescent; symptoms	POSTCONCUSSION SYNDROME; SLEEP QUALITY; HIGH-SCHOOL; RECOVERY; SYMPTOMS; RELIABILITY; REHABILITATION; CHILDREN; BRAIN; PARTICIPATION	Objective: To study the effect of early prescribed aerobic exercise versus relative rest on rate of recovery in male adolescents acutely after sport-related concussion (SRC). Design: Quasi-experimental design. Setting: University sports medicine centers. Participants: Exercise group (EG, n = 24, 15.13 +/- 1.4 years, 4.75 +/- 2.5 days from injury) and rest group (RG, n = 30, 15.33 +/- 1.4 years, 4.50 +/- 2.1 days from injury). Interventions: Exercise group performed a progressive program of at least 20 minutes of daily subthreshold aerobic exercise. Rest group was prescribed relative rest (no structured exercise). Both groups completed daily online symptom reports (Postconcussion Symptom Scale) for 14 days. Main Outcome Measures: Days to recovery after treatment prescription. Recovery was defined as return to baseline symptoms, exercise tolerant, and judged recovered by physician examination. Results: Recovery time from initial visit was significantly shorter in EG (8.29 +/- 3.9 days vs 23.93 +/- 41.7 days, P = 0.048). Mixed-effects linear models showed that all symptom clusters decreased with time and that there was no significant interaction between treatment group and time. No EG participants experienced delayed recovery (>30 days), whereas 13% (4/30) of RG participants experienced delayed recovery. Conclusions: These preliminary data suggest that early subthreshold aerobic exercise prescribed to symptomatic adolescent males within 1 week of SRC hastens recovery and has the potential to prevent delayed recovery.	[Leddy, John J.; Haider, Mohammad N.; Hinds, Andrea L.; Darling, Scott] SUNY Buffalo, UBMD Orthopaed & Sports Med, Buffalo, NY USA; [Haider, Mohammad N.] SUNY Buffalo, Dept Neurosci, Buffalo, NY USA; [Willer, Barry S.] SUNY Buffalo, Dept Psychiat, Buffalo, NY USA	Leddy, JJ (corresponding author), UBMD Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu			The Ralph C. Wilson Foundation; Program for Understanding Childhood Concussion and Stroke; Robert Rich Family Foundation; Buffalo Sabres Foundation; National Football League Charities; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094444] Funding Source: NIH RePORTER	The authors thank The Ralph C. Wilson Foundation, Program for Understanding Childhood Concussion and Stroke, The Robert Rich Family Foundation, The Buffalo Sabres Foundation, the National Football League Charities, and the National Institutes of Health for their financial support.	[Anonymous], 2013, R LANG ENV STAT COMP; ARAI Y, 1989, AM J PHYSIOL, V256, pH132; Balasundaram AP, 2017, SCAND J MED SCI SPOR, V27, P2002, DOI 10.1111/sms.12844; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Borg G., 1998, BORGS PERCEIVED EXER; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Chrisman SPD, 2017, NEUROREHABILITATION, V40, P493, DOI 10.3233/NRE-161436; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Dimeo F, 2001, BRIT J SPORT MED, V35, P114, DOI 10.1136/bjsm.35.2.114; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; El-Sheikh M, 2013, J SLEEP RES, V22, P282, DOI 10.1111/jsr.12019; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griffin EW, 2011, PHYSIOL BEHAV, V104, P934, DOI 10.1016/j.physbeh.2011.06.005; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guiney H, 2015, NEUROPSYCHOLOGY, V29, P1, DOI 10.1037/neu0000124; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Haider MN, 2017, BR J SPORTS MED; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hinds A, 2016, J NEUROL NEUROPHYSIO, P7, DOI [DOI 10.4172/2155-9562.1000388, 10.4172/2155-9562.1000388]; Hinds Andrea, 2016, Concussion, V1, pCNC15, DOI 10.2217/cnc-2016-0002; Joyce AS, 2015, MED SCI SPORT EXER, V47, P1119, DOI 10.1249/MSS.0000000000000534; Kappus RM, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-015-0046-6; Kline CE, 2013, SLEEP, V36, P1279, DOI 10.5665/sleep.2946; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Leddy J, 2017, J ATHL TRAINING, V52, P299, DOI 10.4085/1062-6050-51.11.08; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2018, CLIN J SPORT MED, V28, P13, DOI 10.1097/JSM.0000000000000431; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P273, DOI 10.1080/87565641.2015.1067706; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Matuszak JM, 2016, SPORTS HEALTH, V8, P260, DOI 10.1177/1941738116641394; McCarty CA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0459; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Merritt VC, 2015, J CLIN EXP NEUROPSYC, V37, P764, DOI 10.1080/13803395.2015.1060950; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; Oliveira NL, 2014, AM HEART J, V167, P753, DOI 10.1016/j.ahj.2014.02.001; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Schwandt M, 2012, J HEAD TRAUMA REHAB, V27, P99, DOI 10.1097/HTR.0b013e31820e6858; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Vega SR, 2006, BRAIN RES, V1121, P59, DOI 10.1016/j.brainres.2006.08.105; Yang PY, 2012, J PHYSIOTHER, V58, P157, DOI 10.1016/S1836-9553(12)70106-6; Youngstedt SD, 2005, CLIN SPORT MED, V24, P355, DOI 10.1016/j.csm.2004.12.003	54	23	24	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2019	29	5					353	360		10.1097/JSM.0000000000000663			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	KG1HH	WOS:000509692100002	30239422	Green Accepted			2021-06-18	
J	Hirad, AA; Bazarian, JJ; Merchant-Borna, K; Garcea, FE; Heilbronner, S; Paul, D; Hintz, EB; van Wijngaarden, E; Schifitto, G; Wright, DW; Espinoza, TR; Mahon, BZ				Hirad, Adnan A.; Bazarian, Jeffrey J.; Merchant-Borna, Kian; Garcea, Frank E.; Heilbronner, Sarah; Paul, David; Hintz, Eric B.; van Wijngaarden, Edwin; Schifitto, Giovanni; Wright, David W.; Espinoza, Tamara R.; Mahon, Bradford Z.			A common neural signature of brain injury in concussion and subconcussion	SCIENCE ADVANCES			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; WHITE-MATTER; AXONAL INJURY; HEAD IMPACTS; PROFESSIONAL FOOTBALL; PLAYER; DAMAGE; COMA	The midbrain is biomechanically susceptible to force loading from repetitive subconcussive head impacts (RSHI), is a site of tauopathy in chronic traumatic encephalopathy (CTE), and regulates functions (e.g., eye movements) often disrupted in concussion. In a prospective longitudinal design, we demonstrate there are reductions in midbrain white matter integrity due to a single season of collegiate football, and that the amount of reduction in midbrain white matter integrity is related to the amount of rotational acceleration to which players' brains are exposed. We then replicate the observation of reduced midbrain white matter integrity in a retrospective cohort of individuals with frank concussion, and further show that variance in white matter integrity is correlated with levels of serum-based tau, a marker of blood-brain barrier disruption. These findings mean that noninvasive structural MRI of the midbrain is a succinct index of both clinically silent white matter injury as well as frank concussion.	[Hirad, Adnan A.; Bazarian, Jeffrey J.; Merchant-Borna, Kian] Univ Rochester, Dept Emergency Med, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA; [Hirad, Adnan A.] Univ Rochester, Dept Clin & Translat Sci, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA; [Garcea, Frank E.; Mahon, Bradford Z.] Univ Rochester, Ctr Visual Sci, 601 Elmwood Ave, Rochester, NY 14642 USA; [Garcea, Frank E.] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Heilbronner, Sarah] Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA; [Heilbronner, Sarah] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; [Paul, David; Mahon, Bradford Z.] Univ Rochester, Med Ctr, Dept Neurosurg, 601 Elmwood Ave, Rochester, NY 14642 USA; [Hintz, Eric B.] San Antonio Mil Med Ctr, Div Neurosurg, San Antonio, TX 78234 USA; [van Wijngaarden, Edwin] Univ Rochester, Dept Publ Hlth Sci, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA; [Schifitto, Giovanni; Mahon, Bradford Z.] Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave, Rochester, NY 14642 USA; [Wright, David W.; Espinoza, Tamara R.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; [Mahon, Bradford Z.] Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; [Mahon, Bradford Z.] Carnegie Mellon Univ, Carnegie Mellon Neurosci Inst, Pittsburgh, PA 15213 USA; [Mahon, Bradford Z.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA	Hirad, AA (corresponding author), Univ Rochester, Dept Emergency Med, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.; Hirad, AA (corresponding author), Univ Rochester, Dept Clin & Translat Sci, Med Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.; Mahon, BZ (corresponding author), Univ Rochester, Ctr Visual Sci, 601 Elmwood Ave, Rochester, NY 14642 USA.; Mahon, BZ (corresponding author), Univ Rochester, Med Ctr, Dept Neurosurg, 601 Elmwood Ave, Rochester, NY 14642 USA.; Mahon, BZ (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave, Rochester, NY 14642 USA.; Mahon, BZ (corresponding author), Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA.; Mahon, BZ (corresponding author), Carnegie Mellon Univ, Carnegie Mellon Neurosci Inst, Pittsburgh, PA 15213 USA.; Mahon, BZ (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA.	adnan_hirad@urmc.rochester.edu; bmahon@andrew.cmu.edu	Paul, David/AAZ-8514-2020	Paul, David/0000-0002-3517-8787; Hirad, Adnan/0000-0002-0601-7423; BAZARIAN, JEFFREY/0000-0001-7100-3805; van Wijngaarden, Edwin/0000-0001-7583-4630; Merchant-Borna, Kian/0000-0002-6643-1597	NFL Charities; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 HD064754, R01 MH099921, R21NS076176, R01NS089609, R01EY028535, T32 GM007356, R01MH118257]; National Institute of Nursing Research Intramural Research Program; U.S. Army Rapid Innovation Fund [W911NF-11-R-0017]; University of Rochester via the NIH/National Center for Advancing Translational Sciences [UL1 TR002001]; BWF-IIMP; University of Rochester Center for Visual Science (NIH) [5T32EY007125-24]; Moss Rehabilitation Research Institute [NIH T32HD007425]; University of Rochester Clinical and Translational Science Institute [CTSI TL1 TR000096];  [TL1 TR002000]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR002000, UL1TR002001] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [T32EY007125, R01EY028535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH099921, R01MH118257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089609] Funding Source: NIH RePORTER	This study was supported by funds from the NFL Charities (www.nflcharities-org.ezpminer.urmc.rochester.edu/) and NIH K24 HD064754 to J.J.B., National Institute of Nursing Research Intramural Research Program, U.S. Army Rapid Innovation Fund (W911NF-11-R-0017) to D.W.W., NIH grant R01 MH099921 to G.S., and NIH grants R21NS076176, R01NS089609, and R01EY028535 to B.Z.M. A.A.H. is a trainee in the Medical Scientist Training Program funded by NIH T32 GM007356. Further support for A.A.H. was provided by University of Rochester UL1 TR002001 via the NIH/National Center for Advancing Translational Sciences, BWF-IIMP Pilot Project, and a predoctoral training grant to the Clinical & Translational Sciences Institute (TL1 TR002000). F.E.G. was supported by a University of Rochester Center for Visual Science predoctoral training fellowship (NIH training grant 5T32EY007125-24) and a Moss Rehabilitation Research Institute postdoctoral training fellowship (NIH T32HD007425). S.H. was supported, in part, by NIH grant R01MH118257. D.P. was supported by a grant from the University of Rochester Clinical and Translational Science Institute (CTSI TL1 TR000096). The opinions in this manuscript do not constitute endorsement by the Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information contained therein. More generally, no funders had a role in the study design, data collection, data analysis, decision to publish, or preparation of the manuscript.	Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chang L, 2012, J IMMUNOL METHODS, V378, P102, DOI 10.1016/j.jim.2012.02.011; Chernoff BL, 2018, J COGNITIVE NEUROSCI, V30, P752, DOI 10.1162/jocn_a_01244; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davenport EM, 2016, J NEUROTRAUM, V33, P2133, DOI 10.1089/neu.2015.4267; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Garcea FE, 2017, CURR BIOL, V27, P2684, DOI 10.1016/j.cub.2017.07.051; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Hernandez F, 2019, BIOMECH MODEL MECHAN, V18, P631, DOI 10.1007/s10237-018-01106-0; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; McKee AC, 2016, NEUROSURG CLIN N AM, V27, P529, DOI 10.1016/j.nec.2016.05.009; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Narayana Ponnada A, 2017, Concussion, V2, pCNC35, DOI 10.2217/cnc-2016-0028; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Omalu B, 2018, NEUROSURGERY, V82, P237, DOI 10.1093/neuros/nyx536; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Rostowsky KA, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00948; Seghier ML, 2008, MAGN RESON IMAGING, V26, P594, DOI 10.1016/j.mri.2007.10.010; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Ventura RE, 2016, J NEUROL SCI, V361, P79, DOI 10.1016/j.jns.2015.12.010; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	50	23	23	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	2375-2548			SCI ADV	Sci. Adv.	AUG	2019	5	8							eaau3460	10.1126/sciadv.aau3460			11	Multidisciplinary Sciences	Science & Technology - Other Topics	IR9WX	WOS:000481798400001	31457074	DOAJ Gold, Green Published			2021-06-18	
J	Bieniek, KF; Blessing, MM; Heckman, MG; Diehl, NN; Serie, AM; Paolini, MA; Boeve, BF; Savica, R; Reichard, RR; Dickson, DW				Bieniek, Kevin F.; Blessing, Melissa M.; Heckman, Michael G.; Diehl, Nancy N.; Serie, Amanda M.; Paolini, Michael A., II; Boeve, Bradley F.; Savica, Rodolfo; Reichard, R. Ross; Dickson, Dennis W.			Association between contact sports participation and chronic traumatic encephalopathy: a retrospective cohort study	BRAIN PATHOLOGY			English	Article						chronic traumatic encephalopathy; contact sports; football; tau; traumatic brain injuries	MEDICAL-RECORDS-LINKAGE; HIGH-SCHOOL FOOTBALL; DIAGNOSIS; PATHOLOGY; EVENTS; RISK	Chronic traumatic encephalopathy is a debilitating neurodegenerative disorder associated with repetitive traumatic brain injuries often sustained through prior contact sport participation. The frequency of this disorder in a diverse population, including amateur athletes, is unknown. Primary historical obituary and yearbook records were queried for 2566 autopsy cases in the Mayo Clinic Tissue Registry resulting in identification of 300 former athletes and 450 non-athletes. In these cases, neocortical tissue was screened for tau pathology with immunohistochemistry, including pathology consistent with chronic traumatic encephalopathy, blinded to exposure or demographic information. Using research infrastructure of the Rochester Epidemiology Project, a comprehensive and established medical records-linkage system of care providers in southern Minnesota and western Wisconsin, medical diagnostic billing codes pertaining to head trauma, dementia, movement disorders, substance abuse disorders and psychiatric disorders were recorded for cases and controls in a blinded manner. A total of 42 individuals had pathology consistent with, or features of, chronic traumatic encephalopathy. It was more frequent in athletes compared to non-athletes (27 cases versus 15 cases) and was largely observed in men (except for one woman). For contact sports, American football had the highest frequency of chronic traumatic encephalopathy pathology (15% of cases) and an odds ratio of 2.62 (P-value = 0.005). Cases with chronic traumatic encephalopathy pathology had higher frequencies of antemortem clinical features of dementia, psychosis, movement disorders and alcohol abuse compared to cases without chronic traumatic encephalopathy pathology. Understanding the frequency of chronic traumatic encephalopathy pathology in a large autopsy cohort with diverse exposure backgrounds provides a baseline for future prospective studies assessing the epidemiology and public health impact of chronic traumatic encephalopathy and sports-related repetitive head trauma.	[Bieniek, Kevin F.; Serie, Amanda M.; Dickson, Dennis W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Bieniek, Kevin F.] UT Hlth San Antonio, Long Sch Med, Dept Pathol & Lab Med, San Antonio, TX 78229 USA; [Blessing, Melissa M.; Paolini, Michael A., II; Reichard, R. Ross] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Heckman, Michael G.; Diehl, Nancy N.] Mayo Clin, Div Biomed Stat & Informat, Jacksonville, FL 32224 USA; [Boeve, Bradley F.; Savica, Rodolfo] Mayo Clin, Dept Neurol, Rochester, MN USA; [Savica, Rodolfo] Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN USA	Bieniek, KF (corresponding author), UT Hlth San Antonio, Glenn Biggs Inst Alzheimers & Neurodegenerat Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	bieniek@uthscsa.edu	Blessing, Melissa/AAZ-1340-2020	Blessing, Melissa/0000-0002-4014-4426; Bieniek, Kevin/0000-0003-4922-864X	National Institute on Aging of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG034676]; Florida Department of Health Ed and Ethel Moore Alzheimer's Disease Research Program [7AZ08]; Mayo Clinic Younkin Scholars Program on Synaptic Biology and Memory; Mayo Clinic Alzheimer's Disease Research Center Pilot Project Grant; National Institutes on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG062348]	The authors would foremost like to thank the patients and their families for their selfless act of brain donation, without which this study would not be possible. The authors would like to thank Drs. Walter Rocca and Caterina Giannini for study access to the Rochester Epidemiology Project database and the Mayo Clinic Tissue Registry archives. This study was made possible using the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health (R01-AG034676). The content is solely the responsibility of the authrs and does not necessarily represent the official views of the National Institutes of Health. We are also grateful for the training and data retrieval support of Barb Abbott, Kaitlin Schwartz and Gary Larson as well as histologic support of Linda Rousseau and Ariston Librero. This study was funded through grant support by the Florida Department of Health Ed and Ethel Moore Alzheimer's Disease Research Program (#7AZ08; KFB), Mayo Clinic Younkin Scholars Program on Synaptic Biology and Memory (KFB), Mayo Clinic Alzheimer's Disease Research Center Pilot Project Grant (KFB) and the National Institutes on Aging (R01-AG062348; KFB, DWD). All study authors declare no conflicts of interest.	Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Darby A, 2015, J NEUROPATH EXP NEUR, V74, P615; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Iverson GL, 2018, J ALZHEIMERS DIS, V61, P17, DOI 10.3233/JAD-170654; Janssen PHH, 2017, MAYO CLIN PROC, V92, P66, DOI 10.1016/j.mayocp.2016.09.004; Koga S, 2016, J NEUROPATH EXP NEUR, V75, P963, DOI 10.1093/jnen/nlw073; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Mahar I, 2017, NEUROSCI BIOBEHAV R, V83, P622, DOI 10.1016/j.neubiorev.2017.08.023; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130507; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan W, 2015, NEUROLOGY, V85, P1504, DOI 10.1212/WNL.0000000000001893; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; National Collegiate Athletic Association, 2018, NCAA SPORTS SPONS PA; National Council of Youth Sports, 2008, NCYS REP TRENDS PART; National Federation of State High School Associations, 2018, 2017 2018 HIGH SCH A; Noy S, 2016, J NEUROPATH EXP NEUR, V75, P1145, DOI 10.1093/jnen/nlw092; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Reams N, 2016, JAMA NEUROL, V73, P743, DOI 10.1001/jamaneurol.2015.5015; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; Rocca WA, 2012, MAYO CLIN PROC, V87, P1202, DOI 10.1016/j.mayocp.2012.08.012; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; St Sauver JL, 2012, INT J EPIDEMIOL, V41, P1614, DOI 10.1093/ije/dys195; St Sauver JL, 2012, MAYO CLIN PROC, V87, P151, DOI 10.1016/j.mayocp.2011.11.009; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Walt GS, 2018, J NEUROPATH EXP NEUR, V77, P1091, DOI 10.1093/jnen/nly092	33	23	23	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	JAN	2020	30	1					63	74		10.1111/bpa.12757		JUL 2019	12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	QI0GP	WOS:000474105500001	31199537	Green Published, Other Gold			2021-06-18	
J	Honan, CA; McDonald, S; Tate, R; Ownsworth, T; Togher, L; Fleming, J; Anderson, V; Morgan, A; Catroppa, C; Douglas, J; Francis, H; Wearne, T; Sigmundsdottir, L; Ponsford, J				Honan, Cynthia A.; McDonald, Skye; Tate, Robyn; Ownsworth, Tamara; Togher, Leanne; Fleming, Jennifer; Anderson, Vicki; Morgan, Angela; Catroppa, Cathy; Douglas, Jacinta; Francis, Heather; Wearne, Travis; Sigmundsdottir, Linda; Ponsford, Jennie			Outcome instruments in moderate-to-severe adult traumatic brain injury: recommendations for use in psychosocial research	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; psychosocial; outcome assessment; remediation; research; recommendations	INTERNATIONAL CLASSIFICATION; NEUROPSYCHOLOGICAL OUTCOMES; SHORT-TERM; SCALE; DISABILITY; QUALITY; HEALTH; RELIABILITY; PERCEPTION; AWARENESS	Background: Traumatic brain injury (TBI) can reduce psychosocial functioning, causing relationship, family, and employment difficulties. The present study by Moving Ahead: Centre for Research Excellence (CRE) in Brain Recovery aimed to identify a set of adult outcome instruments for moderate-to-severe TBI psychosocial research. Procedure: A review of 115 instruments (identified through nomination, literature search, and international expert opinion) was conducted over a 15-month period. Eleven psychosocial areas were examined: Global Outcome, Communication, Social Cognition, Behavioural and Executive Function, Other Neuropsychological Functioning, Psychological Status, TBI-related Symptoms, Activities and Participation, Support and Relationships, Sense of Self, and Health-related Quality of Life. Individual instruments were considered against selection guidelines, and specific measures that best met the guidelines were identified as core (common across all studies), supplemental (dependent on study type) or emerging. Results: The final recommendations, organised in accordance with the World Health Organisation's International Classification of Functioning taxonomy, comprised 56 instruments for use in early recovery, outcome, and intervention studies. Conclusion: These recommendations provide a coherent framework along with identified outcome instruments to guide psychosocial research in moderate-to-severe TBI. Adherence to the recommendations will enable data-pooling and comparison across studies and research settings facilitating consistent measurement across the lifespan.	[Honan, Cynthia A.] Univ Tasmania, Sch Med, Dept Psychol, Newnham, Australia; [Honan, Cynthia A.; McDonald, Skye; Tate, Robyn; Ownsworth, Tamara; Togher, Leanne; Fleming, Jennifer; Anderson, Vicki; Morgan, Angela; Catroppa, Cathy; Douglas, Jacinta; Francis, Heather; Wearne, Travis; Sigmundsdottir, Linda; Ponsford, Jennie] Moving Ahead Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia; [McDonald, Skye; Wearne, Travis] Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn; Sigmundsdottir, Linda] Univ Sydney, Sydney Med Sch, Northern Clin Sch, Sydney, NSW, Australia; [Tate, Robyn; Sigmundsdottir, Linda] John Walsh Ctr Rehabil Studies, Sydney, NSW, Australia; [Ownsworth, Tamara] Griffith Univ, Sch Appl Psychol, Brisbane, Qld, Australia; [Togher, Leanne] Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia; [Fleming, Jennifer] Univ Queensland, Fac Hlth & Behav Sci, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia; [Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Murdoch Childrens Res Inst, Psychol Sci & Paediat, Melbourne, Vic, Australia; [Morgan, Angela] Univ Melbourne, Murdoch Childrens Res Inst, Ctr Neurosci Speech, Melbourne, Vic, Australia; [Douglas, Jacinta] La Trobe Univ, Dept Community & Clin Allied Hlth, Sch Allied Hlth, Melbourne, Vic, Australia; [Francis, Heather] Macquarie Univ, Fac Human Sci, Dept Psychol, Sydney, NSW, Australia; [Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia	McDonald, S (corresponding author), Moving Ahead Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia.; McDonald, S (corresponding author), Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	Togher, Leanne/AAC-7083-2019; Fleming, Jennifer/AAH-5108-2020; Douglas, Jacinta M/C-2380-2009; McDonald, Skye/G-4118-2014; Honan, Cynthia/O-6332-2017; Morgan, Angela/J-5235-2017	Francis, Heather/0000-0002-7223-7782; Fleming, Jennifer/0000-0002-5603-2410; Anderson, Vicki/0000-0001-5233-3147; McDonald, Skye/0000-0003-0723-6094; Honan, Cynthia/0000-0001-5735-4270; Wearne, Travis/0000-0002-7565-9163; Morgan, Angela/0000-0003-1147-7405; Togher, Leanne/0000-0002-4518-6748; Ownsworth, Tamara/0000-0003-1835-7094; Douglas, Jacinta/0000-0003-0940-6624	National Health and Medical Research Council (NHMRC) Centre for Research Excellence grant for the period 2012-2017	The Moving Ahead CRE is funded by the National Health and Medical Research Council (NHMRC) Centre for Research Excellence grant for the period 2012-2017.	Andelic N, 2016, J NEUROTRAUM, V33, P95, DOI 10.1089/neu.2014.3844; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A., 1976, MULTILINGUAL APHASIA; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Bickenbach J., 2012, ICF CORE SETS MANUAL; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Burgess P.W., 1996, DYSEXECUTIVE QUESTIO; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Carter R, 2015, REHABILITATION RES P; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cieza A, 2002, J REHABIL MED, V34, P205, DOI 10.1080/165019702760279189; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coetzer R., 2001, PSYCHIAT B, V25, P421, DOI DOI 10.1192/pb.25.11.421; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Davis M.H, 1980, J PERS SOC PSYCHOL, V10, P85; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Drummond AER, 1994, BR J OCCUP THER, V57, P414, DOI DOI 10.1177/030802269405701102; Enderby P., 2008, FDA 2 FRENCHAY DYSAR, V2nd; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Fitts W. H., 1997, TENNESSE SELF CONCEP; Fleming JM, 1996, BRAIN INJURY, V10, P1; Forslund MV, 2013, ACTA NEUROL SCAND, V128, P220, DOI 10.1111/ane.12130; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hays SJ, 2004, APHASIOLOGY, V18, P693, DOI 10.1080/02687030444000183; Honan CA, 2016, CLIN NEUROPSYCHOL, V30, P243, DOI 10.1080/13854046.2015.1136691; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Kaplan E., 1983, BOSTON NAMING TEST; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kertesz A., 2007, W APHASIA BATTERY RE; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Law M., 2014, CANADIAN OCCUPATIONA; Laxe S, 2012, CLIN NEUROL NEUROSUR, V114, P645, DOI 10.1016/j.clineuro.2011.12.038; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lubben J., 2004, SOCIAL NETWORKS SOCI, P20; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; Malec J., 2008, MANUAL MAYO PORTLAND; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2012, BRAIN IMPAIR, V13, P256, DOI 10.1017/BrImp.2012.21; McMillan TM, 2013, J NEUROTRAUM, V30, P970, DOI 10.1089/neu.2012.2703; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Oddy M, 2008, J CLIN EXP NEUROPSYC, V30, P568, DOI 10.1080/13803390701555598; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Rey A, 1964, EXAMEN CLIN PSYCHOL; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Roebuck-Spencer T., 2012, FORENSIC NEUROPSYCHO, P260; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Roth R., 2005, BRIEF A BEHAV RATING; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schmidt M., 1996, REY AUDITORY VERBAL; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Shipley W. C., 2009, SHIPLEY 2 MANUAL; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tate R., 2011, MANUAL SYDNEY PSYCHO; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; Tate R. L., 2010, COMPENDIUM TESTS SCA; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; Tate RL, 2013, NEUROREHABILITATION, V32, P729, DOI 10.3233/NRE-130898; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tellez N, 2005, MULT SCLER J, V11, P198, DOI 10.1191/1352458505ms1148oa; Tulsky DS, 2016, J HEAD TRAUMA REHAB, V31, P40, DOI 10.1097/HTR.0000000000000131; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Weiss DS, 1996, IMPACT EVENTS SCALE, P399; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; World Health Organisation, 2004, WHODAS 2 TRAIN MAN G; World Health Organization, 2013, US ICF PRACT MAN US; World Health Organization, 2001, INT CLASS FUNCT DIS; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	89	23	23	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL 3	2019	29	6					896	916		10.1080/09602011.2017.1339616			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	HU3MB	WOS:000465176100004	28671050				2021-06-18	
J	Jost, WH; Friedman, A; Michel, O; Oehlwein, C; Slawek, J; Bogucki, A; Ochudlo, S; Banach, M; Pagan, F; Flatau-Baque, B; Csikos, J; Cairney, CJ; Blitzer, A				Jost, Wolfgang H.; Friedman, Andrzej; Michel, Olaf; Oehlwein, Christian; Slawek, Jaroslaw; Bogucki, Andrzej; Ochudlo, Stanislaw; Banach, Marta; Pagan, Fernando; Flatau-Baque, Birgit; Csikos, Janos; Cairney, Claire J.; Blitzer, Andrew			SIAXI Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea	NEUROLOGY			English	Article							BOTULINUM-TOXIN-A; PARKINSONS-DISEASE; NONMOTOR SYMPTOMS; CONTROLLED-TRIAL; INJECTION; PREVALENCE; MANAGEMENT; BURDEN; IMPACT; PALSY	Objective This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of chronic sialorrhea due to Parkinson disease (PD), atypical parkinsonism, stroke, or traumatic brain injury (TBI). Methods Adult patients with PD (70.7%), atypical parkinsonism (8.7%), stroke (19.0%), or TBI (2.7%) were randomized (2: 2: 1) to double-blind treatment with placebo (n = 36), or total doses of incobotulinumtoxinA 75U(n = 74) or 100U(n = 74), in a single treatment cycle. The coprimary endpoints were change in unstimulated salivary flow rate from baseline to week 4, and patients' Global Impression of Change Scale score at week 4. Adverse events were recorded throughout. Results A total of 184 patients were randomized. Both incobotulinumtoxinA dose groups showed reductions in mean unstimulated salivary flow rate at week 4, with a significant difference vs placebo in the incobotulinumtoxinA 100 U group (p = 0.004). Patients' Global Impression of Change Scale scores also improved at week 4, with a significant difference vs placebo in the incobotulinumtoxinA 100Ugroup (p = 0.002). A lasting effectwas observed at week 16 post injection. The most frequent treatment-related adverse events in the incobotulinumtoxinA 75 U and 100 U groups were dry mouth (5.4% and 2.7% of patients) and dysphagia (2.7% and 0.0% of patients). Conclusions IncobotulinumtoxinA 100 U is an effective and well-tolerated treatment of chronic sialorrhea in adults.	[Jost, Wolfgang H.] Parkinson Klin Ortenau, Wolfach, Germany; [Friedman, Andrzej] Med Univ Warsaw, Fac Hlth Sci, Dept Neurol, Warsaw, Poland; [Michel, Olaf] Vrije Univ Brussel, Univ Hosp Brussels, Dept Otorhinolaryngol, Brussels, Belgium; [Oehlwein, Christian] Neurol Outpatient Clin Parkinsons Dis & Deep Brai, Gera, Germany; [Slawek, Jaroslaw] Med Univ Gdansk, Dept Neurol Psychiat Nursing, Gdansk, Poland; [Slawek, Jaroslaw] St Adalbert Hosp, Dept Neurol, Gdansk, Poland; [Bogucki, Andrzej] Med Univ Lodz, Dept Extrapyramidal Dis, Lodz, Poland; [Ochudlo, Stanislaw] Med Univ Silesia, Dept Neurol, Katowice, Poland; [Ochudlo, Stanislaw] Med Univ Silesia, Stroke Unit, Katowice, Poland; [Banach, Marta] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland; [Pagan, Fernando] Georgetown Univ Hosp, Dept Neurol, Washington, DC 20007 USA; [Flatau-Baque, Birgit; Csikos, Janos] Merz Pharmaceut GmbH, Frankfurt, Germany; [Cairney, Claire J.] Complete Med Commun, Glasgow, Lanark, Scotland; [Blitzer, Andrew] Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, 630 W 168th St, New York, NY 10032 USA; [Blitzer, Andrew] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Blitzer, Andrew] NY Ctr Voice & Swallowing Disorders, New York, NY USA	Jost, WH (corresponding author), Parkinson Klin Ortenau, Wolfach, Germany.	w.jost@parkinson-klinik.de	Michel, Olaf/B-3673-2012	Michel, Olaf/0000-0003-4289-5693; Slawek, Jaroslaw/0000-0001-6816-0877	Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany	This study was supported by Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.	Bagheri H, 1999, CLIN NEUROPHARMACOL, V22, P213; Banfi P, 2015, RESP CARE, V60, P446, DOI 10.4187/respcare.02856; Bhatia KP, 1999, J NEUROL NEUROSUR PS, V67, P697, DOI 10.1136/jnnp.67.5.697; Castelnovo G, 2013, MOVEMENT DISORD, V28, pS167; Chinnapongse R, 2012, MOVEMENT DISORD, V27, P219, DOI 10.1002/mds.23929; Clifford T, 1995, Gerodontology, V12, P99, DOI 10.1111/j.1741-2358.1995.tb00138.x; Costa J, 2008, J NEUROL, V255, P545, DOI 10.1007/s00415-008-0738-5; Erkkinen MG, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a033118; Guidubaldi A, 2011, MOVEMENT DISORD, V26, P313, DOI 10.1002/mds.23473; Hockstein NG, 2004, AM FAM PHYSICIAN, V69, P2628; Huss K., 2008, NEUROPEDIATRICS, V39; Intiso D, 2012, NEUROREHABILITATION, V31, P117, DOI 10.3233/NRE-2012-0781; Isaacson S, 2017, NEUROLOGY; Jackson CE, 2009, MUSCLE NERVE, V39, P137, DOI 10.1002/mus.21213; Jost WH, 1999, MOVEMENT DISORD, V14, P1057, DOI 10.1002/1531-8257(199911)14:6<1057::AID-MDS1033>3.0.CO;2-4; Jost WH, 2016, J NEURAL TRANSM, V123, P51, DOI 10.1007/s00702-015-1416-2; Kalf JG, 2009, J NEUROL, V256, P1391, DOI 10.1007/s00415-009-5098-2; Kalf JG, 2007, J NEUROL, V254, P1227, DOI 10.1007/s00415-007-0508-9; Kalf JG, 2011, ARCH PHYS MED REHAB, V92, P1152, DOI 10.1016/j.apmr.2011.02.011; Ko SH, 2013, ANN REHABIL MED-ARM, V37, P796, DOI 10.5535/arm.2013.37.6.796; Kossmehl P., 2007, 4 ANN C INT SOC PHYS; Lagalla G, 2006, MOVEMENT DISORD, V21, P704, DOI 10.1002/mds.20793; Lagalla G, 2009, J NEUROL, V256, P563, DOI 10.1007/s00415-009-0085-1; Leibner J, 2010, PARKINSONISM RELAT D, V16, P475, DOI 10.1016/j.parkreldis.2009.12.003; Lipp A, 2003, NEUROLOGY, V61, P1279, DOI 10.1212/WNL.61.9.1279; Mazlan M, 2015, TOXINS, V7, P3758, DOI 10.3390/toxins7093758; McGeachan Alexander J, 2017, Pract Neurol, V17, P96, DOI 10.1136/practneurol-2016-001515; Mcgeachan AJ, 2015, AMYOTROPH LAT SCL FR, V16, P108, DOI 10.3109/21678421.2014.951942; Merz Pharmaceuticals LLC, 2018, HIGHL PRESCR INF XEO; Narayanaswami P, 2016, PARKINSONISM RELAT D, V30, P73, DOI 10.1016/j.parkreldis.2016.07.001; Ou RW, 2015, PARKINSONISM RELAT D, V21, P211, DOI 10.1016/j.parkreldis.2014.12.004; Ozdilek B, 2012, J NEUROPSYCH CLIN N, V24, P478, DOI 10.1176/appi.neuropsych.11100315; Parkes J, 2010, DEV MED CHILD NEUROL, V52, P1113, DOI 10.1111/j.1469-8749.2010.03765.x; Porta M, 2001, J NEUROL NEUROSUR PS, V70, P538, DOI 10.1136/jnnp.70.4.538; Restivo DA, 2018, TOXINS, V10, DOI 10.3390/toxins10020055; Rodriguez Abarca F, 2012, REV MEX NEUROCI, V13, P111; Seppi K, 2011, MOVEMENT DISORD, V26, pS42, DOI 10.1002/mds.23884; South A, 2011, MOVEMENT DISORD, V26, pS140; Srivanitchapoom P, 2014, PARKINSONISM RELAT D, V20, P1109, DOI [10.1016/j.parkreldis.2014.08.013, 10.1016/S1353-8020(13)70029-4]; Thomas-Stonell N, 1988, Dysphagia, V3, P73, DOI 10.1007/BF02412423	40	23	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 23	2019	92	17					E1982	E1991		10.1212/WNL.0000000000007368			10	Clinical Neurology	Neurosciences & Neurology	IQ4ZP	WOS:000480760800006	30918101	Green Published, Other Gold			2021-06-18	
J	Siddiqi, SH; Trapp, NT; Hacker, CD; Laumann, TO; Kandala, S; Hong, X; Trillo, L; Shahim, P; Leuthardt, EC; Carter, AR; Brody, DL				Siddiqi, Shan H.; Trapp, Nicholas T.; Hacker, Carl D.; Laumann, Timothy O.; Kandala, Sridhar; Hong, Xin; Trillo, Ludwig; Shahim, Pashtun; Leuthardt, Eric C.; Carter, Alexandre R.; Brody, David L.			Repetitive Transcranial Magnetic Stimulation with Resting-State Network Targeting for Treatment-Resistant Depression in Traumatic Brain Injury: A Randomized, Controlled, Double-Blinded Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						depression; fMRI; rTMS; TBI	FUNCTIONAL CONNECTIVITY; MAJOR DEPRESSION; RTMS; METAANALYSIS; DISORDER; DEFAULT; TRIAL; ORGANIZATION; INDIVIDUALS; DYSFUNCTION	Repetitive transcranial magnetic stimulation (rTMS) has demonstrated antidepressant efficacy but has limited evidence in depression associated with traumatic brain injury (TBI). Here, we investigate the use of rTMS targeted with individualized resting-state network mapping (RSNM) of dorsal attention network (DAN) and default mode network (DMN) in subjects with treatment-resistant depression associated with concussive or moderate TBI. The planned sample size was 50 with first interim analysis planned at 20, but only 15 were enrolled before the study was terminated for logistical reasons. Subjects were randomized to 20 sessions of bilateral rTMS (4000 left-sided excitatory pulses, 1000 right-sided inhibitory pulses) or sham. Treatment was targeted to the dorsolateral prefrontal cluster with maximal difference between DAN and DMN correlations based on resting-state functional magnetic resonance imaging with individualized RSNM. Mean improvement in the primary outcome, Montgomery-Asberg Depression Rating Scale (MADRS), was 56% +/- 14% (n = 9) with active treatment and 27% +/- 25% (n = 5) with sham (Cohen's d = 1.43). One subject randomized to sham withdrew before starting treatment. There were no seizures or other significant adverse events. MADRS improvement was inversely correlated with functional connectivity between the right-sided stimulation site and the subgenual anterior cingulate cortex (sgACC; r = -0.68, 95% confidence interval 0.03-0.925). Active treatment led to increased sgACC-DMN connectivity (d = 1.55) and increased sgACC anti-correlation with the left- and right-sided stimulation sites (d = -1.26 and -0.69, respectively). This pilot study provides evidence that RSNM-targeted rTMS is feasible in TBI patients with depression. Given the dearth of existing evidence-based treatments for depression in this patient population, these preliminarily encouraging results indicate that larger controlled trials are warranted.	[Siddiqi, Shan H.] McLean Hosp, Dept Neurol, Belmont, MA 02178 USA; [Shahim, Pashtun; Brody, David L.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, NIH, Traumat Brain Injury Res Grp, Bethesda, MD 20814 USA; [Siddiqi, Shan H.; Laumann, Timothy O.; Kandala, Sridhar; Trillo, Ludwig] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Hacker, Carl D.; Leuthardt, Eric C.] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO USA; [Hong, Xin; Carter, Alexandre R.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Trapp, Nicholas T.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA	Siddiqi, SH (corresponding author), McLean Hosp, Div Neurotherapeut, 115 Mill St, Belmont, MA 02478 USA.	shan.siddiqi@mgh.harvard.edu	Siddiqi, Shan/ABA-6482-2020	Siddiqi, Shan/0000-0002-0967-9289; Trapp, Nicholas/0000-0003-0287-2964; Laumann, Timothy/0000-0002-0428-427X			[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Awiszus F., 2011, CEREB CORTEX, P1; Brunoni AR, 2017, JAMA PSYCHIAT, V74, P143, DOI 10.1001/jamapsychiatry.2016.3644; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Bullmore ET, 1999, IEEE T MED IMAGING, V18, P32, DOI 10.1109/42.750253; Caeyenberghs K., 2016, NEUROIMAGE; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Choi KS, 2015, JAMA NEUROL, V72, P1252, DOI 10.1001/jamaneurol.2015.2564; Connolly K Ryan, 2012, J Clin Psychiatry, V73, pe567, DOI 10.4088/JCP.11m07413; Dougherty DD, 2003, J NEUROSURG, V99, P1010, DOI 10.3171/jns.2003.99.6.1010; Dowson AJ, 2001, CURR MED RES OPIN, V17, P298, DOI 10.1185/030079901753403207; Eche Julien, 2012, Front Psychiatry, V3, P13, DOI 10.3389/fpsyt.2012.00013; Fann JR, 2017, J HEAD TRAUMA REHAB, V32, P332, DOI 10.1097/HTR.0000000000000322; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fitzgerald PB, 2009, NEUROPSYCHOPHARMACOL, V34, P1255, DOI 10.1038/npp.2008.233; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Fox MD, 2013, NEUROIMAGE, V66, P151, DOI 10.1016/j.neuroimage.2012.10.082; Fox MD, 2012, BIOL PSYCHIAT, V72, P595, DOI 10.1016/j.biopsych.2012.04.028; Gao W, 2012, HUM BRAIN MAPP, V33, P192, DOI 10.1002/hbm.21204; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; George MS, 2010, ARCH GEN PSYCHIAT, V67, P507, DOI 10.1001/archgenpsychiatry.2010.46; Glasser MF, 2016, NATURE, V536, P171, DOI 10.1038/nature18933; Gordon E.M., 2016, NEUROIMAGE, P146; Gordon EM, 2016, CEREB CORTEX, V26, P288, DOI 10.1093/cercor/bhu239; Gordon EM, 2015, CEREB CORTEX, V25, P336, DOI 10.1093/cercor/bht229; GREENLAND S, 1987, J CHRON DIS, V40, pS17, DOI 10.1016/S0021-9681(87)80005-X; Hacker CD, 2013, NEUROIMAGE, V82, P616, DOI 10.1016/j.neuroimage.2013.05.108; Han K, 2016, J INT NEUROPSYCH SOC, V22, P263, DOI 10.1017/S1355617715001393; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kaiser RH, 2015, JAMA PSYCHIAT, V72, P603, DOI 10.1001/jamapsychiatry.2015.0071; Khedr EM, 2005, NEUROLOGY, V65, P466, DOI 10.1212/01.wnl.0000173067.84247.36; Klein E, 1999, ARCH GEN PSYCHIAT, V56, P315, DOI 10.1001/archpsyc.56.4.315; Klomjai W, 2015, ANN PHYS REHABIL MED, V58, P208, DOI 10.1016/j.rehab.2015.05.005; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Laumann TO, 2015, NEURON, V87, P657, DOI 10.1016/j.neuron.2015.06.037; Lee Megan H, 2016, Top Magn Reson Imaging, V25, P11, DOI 10.1097/RMR.0000000000000075; Li N, 2014, J NEUROTRAUM, V31, P395, DOI 10.1089/neu.2013.3059; Liston C, 2014, BIOL PSYCHIAT, V76, P517, DOI 10.1016/j.biopsych.2014.01.023; Liu BS, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0342-4; Mansur CG, 2005, NEUROLOGY, V64, P1802, DOI 10.1212/01.WNL.0000161839.38079.92; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Mueller S, 2013, NEURON, V77, P586, DOI 10.1016/j.neuron.2012.12.028; Muller MJ, 2003, J AFFECT DISORDERS, V77, P255, DOI 10.1016/S0165-0327(02)00120-9; Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005; Perera T, 2016, BRAIN STIMUL, V9, P336, DOI 10.1016/j.brs.2016.03.010; Philip NS, 2018, BIOL PSYCHIAT, V83, P263, DOI 10.1016/j.biopsych.2017.07.021; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Reti IM, 2015, BRAIN INJURY, V29, P789, DOI 10.3109/02699052.2015.1009168; Salsman JM, 2013, NEUROLOGY, V80, pS76, DOI 10.1212/WNL.0b013e3182872e11; Sasaki N, 2014, BRAIN INJURY, V28, P1682, DOI 10.3109/02699052.2014.947626; Scheid R, 2010, DTSCH ARZTEBL INT, V107, P199, DOI 10.3238/arztebl.2010.0199; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shen XY, 2017, J AFFECT DISORDERS, V211, P65, DOI 10.1016/j.jad.2016.12.058; Shin SS, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00015; Siddiqi S.H., 2016, OPEN SCI FRAMEWORK; Siegel JS, 2017, CEREB CORTEX, V27, P4492, DOI 10.1093/cercor/bhw253; Slotnick SD, 2017, COGN NEUROSCI-UK, V8, P150, DOI 10.1080/17588928.2017.1319350; SVRAKIC DM, 1993, ARCH GEN PSYCHIAT, V50, P991; Tulsky DS, 2017, REHABIL PSYCHOL, V62, P413, DOI 10.1037/rep0000174; van der Horn HJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171031; Wang DH, 2015, NAT NEUROSCI, V18, P1853, DOI 10.1038/nn.4164; Weigand A, 2018, BIOL PSYCHIAT, V84, P28, DOI 10.1016/j.biopsych.2017.10.028; Xie CL, 2015, NEUROL SCI, V36, P1751, DOI 10.1007/s10072-015-2345-4; Yesavage J.A., 2018, JAMA PSYCHIAT	70	23	23	3	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2019	36	8					1361	1374		10.1089/neu.2018.5889			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HS4DK	WOS:000463812000014	30381997	Green Published			2021-06-18	
J	Balan, I; Beattie, MC; O'Buckley, TK; Aurelian, L; Morrow, AL				Balan, Irina; Beattie, Matthew C.; O'Buckley, Todd K.; Aurelian, Laure; Morrow, A. Leslie			Endogenous Neurosteroid (3 alpha,5 alpha)3-Hydroxypregnan-20-one Inhibits Toll-like-4 Receptor Activation and Pro-inflammatory Signaling in Macrophages and Brain	SCIENTIFIC REPORTS			English	Article							CORTICOTROPIN-RELEASING-FACTOR; STEROID-HORMONE METABOLITES; OF-CONCEPT TRIAL; NEUROACTIVE STEROIDS; PROGESTERONE METABOLITE; ETHANOL-CONSUMPTION; NEGATIVE SYMPTOMS; ALCOHOL-DRINKING; GENE-EXPRESSION; GROWTH-FACTOR	The endogenous neurosteroid (3 alpha,5 alpha)3-hydroxypregnan-20-one (3 alpha,5 alpha-THP, allopregnanolone) has protective activity in animal models of alcoholism, depression, traumatic brain injury, schizophrenia, multiple sclerosis, and Alzheimer's disease that is poorly understood. Because these conditions involve proinflammatory signaling through toll-like receptors (TLRs), we examined the effects of 3 alpha,5 alpha-THP, and pregnenolone on TLR4 activation in both the periphery and the central nervous system (CNS). We used monocytes/macrophages (RAW264.7) as a model of peripheral immune signaling and studied innately activated TLR4 in the ventral tegmental area (VTA) of selectively bred alcohol-preferring (P) rats. LPS activated the TLR4 pathway in RAW264.7 cells as evidenced by increased levels of p-TAK1, TRAF6, NF-kappa B p50, phospho-NF-kappa B-p65, pCREB, HMGB1, and inflammatory mediators, including MCP-1 and TNF alpha. Both 3 alpha,5 alpha-THP and pregnenolone (0.5-1.0 mu M) substantially (similar to 80%) inhibited these effects, indicating pronounced inhibition of TLR4 signaling. The mechanism of inhibition appears to involve blockade of TLR4/MD-2 protein interactions in RAW246.7 cells. In VTA, 3 alpha,5 alpha-THP (15 mg/kg, IP) administration reduced TRAF6 (similar to 20%), CRF (similar to 30%), and MCP-1 (similar to 20%) levels, as well as TLR4 binding to GABAA receptor a2 subunits (similar to 60%) and MyD88 (similar to 40%). The data suggest that inhibition of proinflammatory neuroimmune signaling underlies protective effects of 3 alpha,5 alpha-THP in immune cells and brain, apparently involving blocking of protein-protein interactions that initiate TLR4-dependent signaling. Inhibition of pro-inflammatory TLR4 activation represents a new mechanism of 3 alpha,5 alpha-THP action in the periphery and the brain.	[Balan, Irina; Aurelian, Laure] Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA; [Beattie, Matthew C.; O'Buckley, Todd K.; Morrow, A. Leslie] Univ N Carolina, Dept Psychiat & Pharmacol, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27515 USA	Aurelian, L (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA.; Morrow, AL (corresponding author), Univ N Carolina, Dept Psychiat & Pharmacol, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27515 USA.	LAurelian@som.umaryland.edu; morrow@med.unc.edu		O'Buckley, Todd/0000-0001-8723-734X; Balan, Irina/0000-0002-2299-6115	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01-AA020935, R01-AA024095, R01-AA021261]; Bowles Ctr for Alcohol Studies; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA024095, U24AA015512] Funding Source: NIH RePORTER	This work was supported by NIH grants U01-AA020935, R01-AA024095 (ALM), R01-AA021261 (LA) and the Bowles Ctr for Alcohol Studies (ALM).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Alfonso-Loeches S, 2016, NEUROCHEM RES, V41, P193, DOI 10.1007/s11064-015-1760-5; Alfonso-Loeches S, 2010, J NEUROSCI, V30, P8285, DOI 10.1523/JNEUROSCI.0976-10.2010; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Aurelian L, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.72; Balan I, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8040072; Balan I, 2018, BRAIN BEHAV IMMUN, V69, P139, DOI 10.1016/j.bbi.2017.11.008; Beattie MC, 2017, ADDICT BIOL, V22, P318, DOI 10.1111/adb.12326; Bhattacharya A, 2016, PSYCHOPHARMACOLOGY, V233, P1623, DOI 10.1007/s00213-016-4214-0; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P11, DOI 10.2174/156720506775697160; Bsibsi M, 2010, J IMMUNOL, V184, P6929, DOI 10.4049/jimmunol.0902419; Carlson SL, 2013, J PHARMACOL EXP THER, V345, P317, DOI 10.1124/jpet.112.201954; Chandrashekaran IR, 2018, FEBS LETT, V592, P179, DOI 10.1002/1873-3468.12953; Chattopadhyay S, 2014, CYTOKINE GROWTH F R, V25, P533, DOI 10.1016/j.cytogfr.2014.06.002; Cochet F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112318; Cook JB, 2014, J NEUROSCI, V34, P5824, DOI 10.1523/JNEUROSCI.4733-13.2014; CRAWLEY JN, 1986, BRAIN RES, V398, P382, DOI 10.1016/0006-8993(86)91500-3; Crews FT, 2011, BRAIN BEHAV IMMUN, V25, pS4, DOI 10.1016/j.bbi.2011.03.003; Crews FT, 2017, NEUROPHARMACOLOGY, V122, P56, DOI 10.1016/j.neuropharm.2017.01.031; Crews FT, 2017, PSYCHOPHARMACOLOGY, V234, P1483, DOI 10.1007/s00213-017-4560-6; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dedic N, 2018, CURR MOL PHARMACOL, V11, P4, DOI 10.2174/1874467210666170302104053; DEVAUD LL, 1995, ALCOHOL CLIN EXP RES, V19, P350, DOI 10.1111/j.1530-0277.1995.tb01514.x; Faraz M, 2018, J BIOL CHEM, V293, P3421, DOI 10.1074/jbc.M117.807487; Fox HC, 2013, PSYCHONEUROENDOCRINO, V38, P1532, DOI 10.1016/j.psyneuen.2012.12.022; Fu HQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106331; Gondre-Lewis MC, 2016, STRESS, V19, P235, DOI 10.3109/10253890.2016.1160280; HARRISON NL, 1987, J PHARMACOL EXP THER, V241, P346; Quadros IMH, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00134; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; He J, 2008, EXP NEUROL, V210, P349, DOI 10.1016/j.expneurol.2007.11.017; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Irwin RW, 2014, PROG NEUROBIOL, V113, P40, DOI 10.1016/j.pneurobio.2013.08.004; June HL, 2015, NEUROPSYCHOPHARMACOL, V40, P1549, DOI 10.1038/npp.2015.4; Kanes S, 2017, LANCET, V390, P480, DOI 10.1016/S0140-6736(17)31264-3; Keller CA, 2004, J NEUROSCI, V24, P5881, DOI 10.1523/JNEUROSCI.1037-04.2004; Kim SJ, 2017, BMB REP, V50, P55, DOI 10.5483/BMBRep.2017.50.2.011; Kokate TG, 1996, NEUROPHARMACOLOGY, V35, P1049, DOI 10.1016/S0028-3908(96)00021-4; Koob GF, 2014, NEUROPHARMACOLOGY, V76, P370, DOI 10.1016/j.neuropharm.2013.05.024; Lacagnina MJ, 2017, NEUROPSYCHOPHARMACOL, V42, P156, DOI 10.1038/npp.2016.121; Laing JM, 2010, J NEUROCHEM, V112, P662, DOI 10.1111/j.1471-4159.2009.06475.x; Lawrimore CJ, 2017, ALCOHOL CLIN EXP RES, V41, P939, DOI 10.1111/acer.13368; Leclercq S, 2012, BRAIN BEHAV IMMUN, V26, P911, DOI 10.1016/j.bbi.2012.04.001; Lee JW, 2017, J CHROMATOGR B, V1065, P14, DOI 10.1016/j.jchromb.2017.09.002; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Liu JA, 2011, P NATL ACAD SCI USA, V108, P4465, DOI 10.1073/pnas.1019020108; Lowery-Gionta EG, 2012, J NEUROSCI, V32, P3405, DOI 10.1523/JNEUROSCI.6256-11.2012; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Maroso M, 2011, J INTERN MED, V270, P319, DOI 10.1111/j.1365-2796.2011.02431.x; Maroso M, 2011, NEUROTHERAPEUTICS, V8, P304, DOI 10.1007/s13311-011-0039-z; Marx CE, 2007, BIOL PSYCHIAT, V61, p13S; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Mayfield J, 2017, NEUROPSYCHOPHARMACOL, V42, P376, DOI 10.1038/npp.2016.177; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; Milivojevic V, 2016, PSYCHONEUROENDOCRINO, V65, P44, DOI 10.1016/j.psyneuen.2015.12.008; Morita N, 2017, FEBS LETT, V591, P1732, DOI 10.1002/1873-3468.12693; Morrow AL, 2007, PHARMACOL THERAPEUT, V116, P1, DOI 10.1016/j.pharmthera.2007.04.003; MORROW AL, 1987, EUR J PHARMACOL, V142, P483, DOI 10.1016/0014-2999(87)90094-X; Morrow AL, 2001, BRAIN RES REV, V37, P98, DOI 10.1016/S0165-0173(01)00127-8; Noorbakhsh F, 2014, FRONT CELL NEUROSCI, V8, P1, DOI 10.3389/fncel.2014.00134; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; OWENS MJ, 1992, BRAIN RES, V573, P353, DOI 10.1016/0006-8993(92)90788-B; Pandey SC, 2012, BRIT J PHARMACOL, V165, P1316, DOI 10.1111/j.1476-5381.2011.01695.x; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pascual M, 2017, ADDICT BIOL, V22, P1829, DOI 10.1111/adb.12461; Pascual M, 2011, BRAIN BEHAV IMMUN, V25, pS80, DOI 10.1016/j.bbi.2011.02.012; Patchev V.K., 1996, BRAIN SOURCE TARGET, P93; Patchev VK, 1996, NEUROPSYCHOPHARMACOL, V15, P533, DOI 10.1016/S0893-133X(96)00096-6; PATCHEV VK, 1994, NEUROSCIENCE, V62, P265, DOI 10.1016/0306-4522(94)90330-1; PAUL SM, 1992, FASEB J, V6, P2311; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Phillips TJ, 2015, GENES BRAIN BEHAV, V14, P98, DOI 10.1111/gbb.12189; Porcu P, 2014, PSYCHOPHARMACOLOGY, V231, P3257, DOI 10.1007/s00213-014-3564-8; Porcu P, 2010, ALCOHOL CLIN EXP RES, V34, P432, DOI 10.1111/j.1530-0277.2009.01123.x; Poulopoulos A, 2009, NEURON, V63, P628, DOI 10.1016/j.neuron.2009.08.023; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Qin LY, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-10; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Sanada T, 2008, J BIOL CHEM, V283, P33858, DOI 10.1074/jbc.M806923200; Sato S, 2016, MICROBIOL IMMUNOL, V60, P382, DOI 10.1111/1348-0421.12381; Sawle P, 2005, BRIT J PHARMACOL, V145, P800, DOI 10.1038/sj.bjp.0706241; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; Silva E, 2007, INTENS CARE MED, V33, P1829, DOI 10.1007/s00134-007-0748-2; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; Stell BM, 2003, P NATL ACAD SCI USA, V100, P14439, DOI 10.1073/pnas.2435457100; Thomson CA, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-73; Tsatsanis C, 2006, J IMMUNOL, V176, P1869, DOI 10.4049/jimmunol.176.3.1869; VanDoren MJ, 2000, J NEUROSCI, V20, P1982; Vartanian KB, 2010, TRANSL STROKE RES, V1, P252, DOI 10.1007/s12975-010-0033-5; Walter TJ, 2017, ALCOHOL CLIN EXP RES, V41, P2066, DOI 10.1111/acer.13511; Whitman BA, 2013, ALCOHOL CLIN EXP RES, V37, P2086, DOI 10.1111/acer.12189; Winkler Z, 2017, BEHAV BRAIN RES, V334, P119, DOI 10.1016/j.bbr.2017.07.023; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107	100	23	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 4	2019	9								1220	10.1038/s41598-018-37409-6			14	Multidisciplinary Sciences	Science & Technology - Other Topics	HK0UA	WOS:000457616300109	30718548	DOAJ Gold, Green Published			2021-06-18	
J	Dai, WY; Wang, XG; Teng, HL; Li, C; Wang, B; Wang, J				Dai, Wangying; Wang, Xingguo; Teng, Honglin; Li, Chi; Wang, Bin; Wang, Jing			Celastrol inhibits microglial pyroptosis and attenuates inflammatory reaction in acute spinal cord injury rats	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Celastrol; Pyroptosis; Spinal cord injury; Microglia	TRAUMATIC BRAIN; IN-VITRO; C-JUN; ACTIVATION; INFLAMMASOMES; CASPASE-1; INFECTION; PROTECTS; RECEPTOR; DISEASE	Pyroptosis pathway is closely related to inflammation. However, Celastrol effect on pyroptosis pathway after spinal cord injury (SCI) are poorly understood. We studied the anti-inflammatory and neuroprotective effects of Celastrol on acute spinal cord injury in rats, and its anti-inflammatory effects on lipopolysaccharide (LPS)/ATPinduced microgliosis. Our results show that Celastrol can improve the recovery of hindlimb motor function after SCI in Sprague-Dawley (SD) rats, and reduce the cavity area of spinal cord injury along with the neuronal loss. Celastrol simultaneously reduced the activation of microglia (especially M1 microglia) in the spinal cord, inhibited the pyroptosis-related proteins (NLRP3 ASC Caspase-1 GSDMD), reduced the release of TNF-alpha IL-1 beta and IL-18 inflammatory factors, and increased the release of IL10 cytokines. In vitro studies showed that Celastrol reduced the toxicity resulting from the administration of LPS with ATP to BV-2 cells, inhibited the pyroptosis-related proteins (NLRP3 Caspase-1 GSDMD), and inhibited the release of corresponding inflammatory factors. Finally, Celastrol can inhibit the expression of NF kappa B/p-p65 in vitro and in vivo. Our results show that Celastrol can attenuate the inflammatory response of the spinal cord after SCI, which is associated with inhibition of microglial activation and pyroptosis pathway. Further study to explore the use of Celastrol to treat SCI is warranted.	[Dai, Wangying; Wang, Xingguo; Teng, Honglin; Li, Chi; Wang, Bin; Wang, Jing] Wenzhou Med Univ, Affiliated Hosp 1, Dept Spine Surg, Wenzhou 325035, Peoples R China	Wang, J (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Spine Surg, Wenzhou 325035, Peoples R China.	wjspine@163.com			Medical and Health Technology Project of Zhejiang Province [2018KY124]	This study was supported by Medical and Health Technology Project of Zhejiang Province (2018KY124).	Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bowes AL, 2014, J NEUROTRAUM, V31, P1753, DOI 10.1089/neu.2014.3429; Cascao R, 2012, AUTOIMMUN REV, V11, P856, DOI 10.1016/j.autrev.2012.02.022; Cheng P, 2014, NEUROPHARMACOLOGY, V85, P408, DOI 10.1016/j.neuropharm.2014.06.004; Cheng S, 2018, VALPROIC ACID ATTENU, P1; DiSabato DJ, 2016, J NEUROCHEM, V139, P136, DOI 10.1111/jnc.13607; Faust K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-109; Gaudet AD, 2018, NEUROTHERAPEUTICS, V15, P554, DOI 10.1007/s13311-018-0630-7; Grabowski GA, 2017, SEMIN PEDIATR NEUROL, V24, P207, DOI 10.1016/j.spen.2017.08.005; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Jung HW, 2007, EXP MOL MED, V39, P715, DOI 10.1038/emm.2007.78; Kannaiyan R, 2011, APOPTOSIS, V16, P1028, DOI 10.1007/s10495-011-0629-6; Kanneganti TD, 2006, J BIOL CHEM, V281, P36560, DOI 10.1074/jbc.M607594200; Kim EA, 2015, NEUROTOXICOLOGY, V51, P198, DOI 10.1016/j.neuro.2015.10.013; Konieczny J, 2014, NEUROTOX RES, V26, P255, DOI 10.1007/s12640-014-9477-9; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Lee SW, 2018, J NEUROTRAUM, V35, P1681, DOI 10.1089/neu.2017.5530; Letellier E, 2010, IMMUNITY, V32, P240, DOI 10.1016/j.immuni.2010.01.011; Li G, 2016, BIOMATERIALS, V83, P233, DOI 10.1016/j.biomaterials.2015.11.059; Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543; Li J, 2011, SPINAL CORD, V49, P777, DOI 10.1038/sc.2011.8; Li YH, 2012, BRAIN RES, V1464, P8, DOI 10.1016/j.brainres.2012.04.054; Lin CW, 2016, NEUROSCI BULL, V32, P137, DOI 10.1007/s12264-016-0017-x; Liu JL, 2015, CELL, V161, P999, DOI 10.1016/j.cell.2015.05.011; Liu W, 2018, J DENT RES, V97, P1391, DOI 10.1177/0022034518775036; Liu W, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1083-y; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Mortazavi MM, 2015, CLIN ANAT, V28, P27, DOI 10.1002/ca.22432; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Okada S, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0026-1; Paris D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-17; Pinna GF, 2004, BIOCHEM BIOPH RES CO, V322, P778, DOI 10.1016/j.bbrc.2004.07.186; Pirhonen J, 1999, J IMMUNOL, V162, P7322; Poniatowski LA, 2017, MOL NEUROBIOL, V54, P2167, DOI 10.1007/s12035-016-9787-4; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Salminen A, 2010, BIOCHEM BIOPH RES CO, V394, P439, DOI 10.1016/j.bbrc.2010.03.050; Shi FS, 2013, J NEUROIMMUNOL, V260, P121, DOI 10.1016/j.jneuroim.2013.04.016; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Slowik A, 2018, J STEROID BIOCHEM, V183, P18, DOI 10.1016/j.jsbmb.2018.05.003; Vande Walle L, 2016, CURR BIOL, V26, pR568, DOI 10.1016/j.cub.2016.02.019; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wang WF, 2018, J PHARM PHARMACOL, V70, P81, DOI 10.1111/jphp.12835; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Xu S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1183-8; Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009; Yang HB, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00044; You TT, 2017, ACS CHEM NEUROSCI, V8, P2381, DOI 10.1021/acschemneuro.7b00065; Yuan JY, 2016, CELL, V167, P1693, DOI 10.1016/j.cell.2016.11.047; Yuan SY, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00683	52	23	28	2	37	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	JAN	2019	66						215	223		10.1016/j.intimp.2018.11.029			9	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	HI1SQ	WOS:000456225700024	30472522				2021-06-18	
J	Van Stan, JH; Dijkers, MP; Whyte, J; Hart, T; Turkstra, LS; Zanca, JM; Chen, C				Van Stan, Jarrad H.; Dijkers, Marcel. P.; Whyte, John; Hart, Tessa; Turkstra, Lyn S.; Zanca, Jeanne M.; Chen, Christine			The Rehabilitation Treatment Specification System: Implications for Improvements in Research Design, Reporting, Replication, and Synthesis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Meta-analysis as topic; Methods; Outcome assessment (health care); Rehabilitation; Therapeutics; Translational medical research	TRAUMATIC BRAIN-INJURY; VOICE DISORDERS; BLACK-BOX; STROKE; INTERVENTIONS; EXERCISE; THERAPY; EXPLANATION; OUTCOMES; ADULTS	Despite significant advances in measuring the outcomes of rehabilitation interventions, little progress has been made in specifying the therapeutic ingredients and processes that cause measured changes in patient functioning. The general approach to better clarifying the process of treatment has been to develop reporting checklists and guidelines that increase the amount of detail reported. However, without a framework instructing researchers in how to describe their treatment protocols in a manner useful to or even interpretable by others, requests for more detail will fail to improve our understanding of the therapeutic process. In this article, we describe how the Rehabilitation Treatment Specification System (RTSS) provides a theoretical framework that can improve research intervention reporting and enable testing and refinement of a protocol's underlying treatment theories. The RTSS framework provides guidance for researchers to explicitly state their hypothesized active ingredients and targets of treatment as well as for how the individual ingredients in their doses directly affect the treatment targets. We explain how theory-based treatment specification has advantages over checklist approaches for intervention design, reporting, replication, and synthesis of evidence in rehabilitation research. A complex rehabilitation intervention is used as a concrete example of the differences between an RTSS-based specification and the Template for Intervention Description and Replication checklist. The RTSS's potential to advance the rehabilitation field can be empirically tested through efforts to use the framework with existing and newly developed treatment protocols. (C) 2018 by the American Congress of Rehabilitation Medicine	[Van Stan, Jarrad H.] Harvard Med Sch, Boston, MA USA; [Van Stan, Jarrad H.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, 11th Fl,1 Bowdoin Sq, Boston, MA 02114 USA; [Van Stan, Jarrad H.] Massachusetts Gen Hosp, Inst Hlth Profess, Charlestown, MA USA; [Dijkers, Marcel. P.] Wayne State Univ, Detroit, MI USA; [Dijkers, Marcel. P.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Whyte, John; Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Turkstra, Lyn S.] McMaster Univ, Hamilton, ON, Canada; [Zanca, Jeanne M.] Kessler Fdn, W Orange, NJ USA; [Chen, Christine] Texas Womens Univ, Denton, TX USA	Van Stan, JH (corresponding author), Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, 11th Fl,1 Bowdoin Sq, Boston, MA 02114 USA.	jvanstan@mgh.harvard.edu		Whyte, John/0000-0002-4381-1474; Turkstra, Lyn/0000-0002-6948-6921	Patient Centered Outcomes Research InstitutePatient-Centered Outcomes Research Institute - PCORI [ME-1403-14083]; National Institutes of Health (NIH) National Institute on Deafness and Other Communication Disorders and Office of Behavioral and Social Sciences Research [R21 DC016124, OD016124]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R21DC016124] Funding Source: NIH RePORTER	We thank the members of our Advisory Board, Mary Ferraro, PhD, OTR/L and Andrew Packel, PT, NCS, who provided valuable feedback on the concepts presented here. The contents of this article were developed under contract number ME-1403-14083 from the Patient Centered Outcomes Research Institute awarded to John Whyte at Moss Rehabilitation Research Institute and grant numbers R21 DC016124 and OD016124 from the National Institutes of Health (NIH) National Institute on Deafness and Other Communication Disorders and Office of Behavioral and Social Sciences Research awarded to Jarrad Van Stan at Massachusetts General Hospital. All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee. The article's contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Binder EF, 2004, JAMA-J AM MED ASSOC, V292, P837, DOI 10.1001/jama.292.7.837; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Campbell KL, 2012, BRIT J SPORT MED, V46, P909, DOI [10.1136/bjsm.2010.082719, 10.1136/bjsports-2010-082719]; Carlaw C, 2012, DYSPHAGIA, V27, P297, DOI 10.1007/s00455-011-9366-9; Chang SM, 2012, METHODS GUIDE MED TE; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; DeJong G, 2004, ARCH PHYS MED REHAB, V85, P678, DOI 10.1016/j.apmr.2003.06.033; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1269, DOI 10.1016/j.apmr.2008.11.021; Devan D, 2014, J HAND THER, V27, P325, DOI 10.1016/j.jht.2014.02.005; Dijkers M, 2002, AM J PHYS MED REHAB, V81, P21, DOI 10.1097/00002060-200201000-00005; Dijkers MP, 2015, ARCH PHYS MED REHAB, V96, P1170, DOI 10.1016/j.apmr.2015.01.017; Goedert KM, 2020, NEUROPSYCHOL REHABIL, V30, P32, DOI 10.1080/09602011.2018.1448287; Hart T, 2019, ARCH PHYS MED REHAB, V100, P172, DOI 10.1016/j.apmr.2018.09.109; Hart T, 2017, J HEAD TRAUMA REHAB, V32, P319, DOI 10.1097/HTR.0000000000000316; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Hayward KS, 2015, CLIN REHABIL, V29, P1234, DOI 10.1177/0269215514565395; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1055/s-0041-111066, 10.1136/bmj.g1687]; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2015, ARCH PHYS MED REH S8, V96; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P563, DOI 10.1080/09602011.2012.676284; Jack K, 2010, MANUAL THER, V15, P220, DOI 10.1016/j.math.2009.12.004; JOHNSONLAIRD PN, 1980, COGNITIVE SCI, V4, P71, DOI 10.1207/s15516709cog0401_4; Joosten EAG, 2008, PSYCHOTHER PSYCHOSOM, V77, P219, DOI 10.1159/000126073; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kragel PA, 2018, NEURON, V99, P257, DOI 10.1016/j.neuron.2018.06.009; Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6; Neil-Sztramko SE, 2019, BRIT J SPORT MED, V53, P504, DOI 10.1136/bjsports-2017-098389; Page P, 2017, INT J SPORTS PHYS TH, V12, P297; Patti F, 2010, PATIENT PREFER ADHER, V4, P1; Phillips AC, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0759-1; Powell LE, 2012, NEUROPSYCHOL REHABIL, V22, P85, DOI 10.1080/09602011.2011.640466; ROY N, 1993, J VOICE, V7, P242, DOI 10.1016/S0892-1997(05)80333-9; Roy N, 2003, J SPEECH LANG HEAR R, V46, P670, DOI 10.1044/1092-4388(2003/053); Roy N, 2012, INT J SPEECH-LANG PA, V14, P419, DOI 10.3109/17549507.2012.686119; Slade SC, 2016, BRIT J SPORT MED, V50, P1428, DOI 10.1136/bjsports-2016-096651; Sliwa JA, 2002, AM J PHYS MED REHAB, V81, P126, DOI 10.1097/00002060-200202000-00009; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; Tiedemann A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1380-7; Wade DT, 2009, CLIN REHABIL, V23, P291, DOI 10.1177/0269215509103551; Waterschoot FPC, 2014, PAIN, V155, P179, DOI 10.1016/j.pain.2013.10.006; Whiteneck G, 2009, J SPINAL CORD MED, V32, P251, DOI 10.1080/10790268.2009.11760779; Whyte J, 2014, ARCH PHYS MED REHA S, V95; Whyte J, 2019, ARCH PHYS MED REHAB, V100, P156, DOI 10.1016/j.apmr.2018.09.111; Whyte J, 2014, ARCH PHYS MED REHAB, V95, pS17, DOI 10.1016/j.apmr.2013.02.029; Winstein CJ, 2003, NEUROREHAB NEURAL RE, V17, P137, DOI 10.1177/0888439003255511; Zbogar D, 2017, SPINAL CORD, V55, P172, DOI 10.1038/sc.2016.129	48	23	23	3	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2019	100	1					146	155		10.1016/j.apmr.2018.09.112			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HH8HP	WOS:000455972800019	30267666	Green Accepted			2021-06-18	
J	Liu, L; Urch, B; Szyszkowicz, M; Evans, G; Speck, M; Van Huang, A; Leingartner, K; Shutt, RH; Pelletier, G; Gold, DR; Brook, JR; Pollitt, KG; Silverman, FS				Liu, Ling; Urch, Bruce; Szyszkowicz, Mieczyslaw; Evans, Greg; Speck, Mary; Van Huang, Angela; Leingartner, Karen; Shutt, Robin H.; Pelletier, Guillaume; Gold, Diane R.; Brook, Jeffrey R.; Pollitt, Krystal Godri; Silverman, Frances S.			Metals and oxidative potential in urban particulate matter influence systemic inflammatory and neural biomarkers: A controlled exposure study	ENVIRONMENT INTERNATIONAL			English	Article							CONCENTRATED AMBIENT PARTICLES; EMERGENCY-ROOM VISITS; AIR-POLLUTION; BIOLOGICAL CONSTITUENTS; LIPID-PEROXIDATION; BLOOD-PRESSURE; FINE; STRESS; COARSE; RISK	Background: Oxidative stress and inflammation are considered to be important pathways leading to particulate matter (PM)-associated disease. In this exploratory study, we examined the effects of metals and oxidative potential (OP) in urban PM on biomarkers of systemic inflammation, oxidative stress and neural function. Methods: Fifty-three healthy non-smoking volunteers (mean age 28 years, twenty-eight females) were exposed to coarse (2.5-10 mu m, mean 213 mu g/m(3)), fine (0.15-2.5 mu m, 238 mu g/m(3)), and/or ultrafine concentrated ambient PM (< 0.3 mu m, 136 mu g/m(3)). Exposures lasted 130 min, separated by >= 2 weeks. Metal concentrations and OP (measured by ascorbate and glutathione depletion in synthetic airway fluid) in PM were analyzed. Blood and urine samples were collected pre-exposure, and 1-h and 21-h post exposure for assessment of biomarkers. We used mixed-regression models to analyze associations adjusting for PM size and mass concentration. Results: Results for metals were expressed as change (%) from daily pre-exposure biomarker levels after exposure to a metal at a level equivalent to the mean concentration. Exposure to various metals (silver, aluminum, barium, copper, iron, potassium, lithium, nickel, tin, and/or vanadium) was significantly associated with increased levels of various blood or urinary biomarkers. For example, the blood inflammatory marker vascular endothelia growth factor (VEGF) increased 5.3% (95% confidence interval: 0.3%, 10.2%) 1-h post exposure to nickel; the traumatic brain injury marker ubiquitin C-terminal hydrolase L1 (UCHL1) increased 11% (1.2%, 21%) and 14% (0.3%, 29%) 1-h and 21-h post exposure to barium, respectively; and the systemic stress marker cortisol increased 1.5% (0%, 2.9%) and 1.5% (0.5%, 2.8%) 1-h and 21-h post exposure to silver, respectively. Urinary DNA oxidation marker 8-hydroxy-deoxy-guanosine increased 14% (6.4%, 21%) 1-h post exposure to copper; urinary neural marker vanillylmandelic acid increased 29% (3%, 54%) 1-h post exposure to aluminum; and urinary cortisol increased 88% (0.9%, 176%) 1-h post exposure to vanadium. Results for OP were expressed as change (%) from daily pre-exposure biomarker levels after exposure to ascorbate-related OP at a level equivalent to the mean concentration, or for exposure to glutathione-related OP at a level above the limit of detection. Exposure to ascorbate-or glutathione-related OP was significantly associated with increased inflammatory and neural biomarkers including interleukin-6, VEGF, UCHL1, and S100 calcium-binding protein B in blood, and malondialdehyde and 8-hydroxy-deoxy-guanosine in urine. For example, UCHL1 increased 9.4% (1.8%, 17%) in blood 21-h post exposure to ascorbate-related OP, while urinary malondialdehyde increased 19% (3.6%, 35%) and 8-hydroxydeoxy- guanosine increased 24% (2.9%, 48%) 21-h post exposure to ascorbate-and glutathione-related OP, respectively. Conclusion: Our results from this exploratory study suggest that metal constituents and OP in ambient PM may influence biomarker levels associated with systemic inflammation, oxidative stress, perturbations of neural function, and systemic physiological stress.	[Liu, Ling; Szyszkowicz, Mieczyslaw; Leingartner, Karen; Shutt, Robin H.; Pelletier, Guillaume] Hlth Canada, Hlth Environm & Consumer Safety Branch, PL 0201A,101 Tunneys Pasture Driveway, Ottawa, ON K1A 0K9, Canada; [Urch, Bruce; Evans, Greg; Speck, Mary; Brook, Jeffrey R.; Silverman, Frances S.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Occupat & Environm Hlth, Toronto, ON, Canada; [Urch, Bruce; Evans, Greg; Van Huang, Angela; Brook, Jeffrey R.; Silverman, Frances S.] SOCAAR, Toronto, ON, Canada; [Gold, Diane R.] Harvard Med Sch, Channing Lab, Brigham & Womens Hosp, Boston, MA USA; [Brook, Jeffrey R.] Environm & Climate Change Canada, Toronto, ON, Canada; [Silverman, Frances S.] Univ Toronto, Dept Med, Div Occupat Med, Toronto, ON, Canada; [Silverman, Frances S.] Univ Toronto, Dept Med, Div Respirol, Toronto, ON, Canada; [Pollitt, Krystal Godri] Yale Univ, Environm Hlth Sci, New Haven, CT USA; [Silverman, Frances S.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada	Liu, L (corresponding author), Hlth Canada, Hlth Environm & Consumer Safety Branch, PL 0201A,101 Tunneys Pasture Driveway, Ottawa, ON K1A 0K9, Canada.	ling.liu@canada.ca	Szyszkowicz, Mieczyslaw/N-2490-2019	Godri Pollitt, Krystal/0000-0001-7332-2228; Szyszkowicz, Mieczyslaw/0000-0001-7022-3267; Pelletier, Guillaume/0000-0002-4200-4515	Health Canada's Clean Air Regulatory Agenda; U.S. EPAUnited States Environmental Protection Agency [RD-83241601]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 ES005605]; Environment and Climate Change Canada; AllerGen Networks of Centres of Excellence; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES005605] Funding Source: NIH RePORTER	This work was supported by Health Canada's Clean Air Regulatory Agenda, U.S. EPA RD-83241601, NIH Grant P30 ES005605, Environment and Climate Change Canada, and AllerGen Networks of Centres of Excellence. Infrastructure for concentrated ambient particle exposure facility was provided by SOCAAR through funding from the Canada Foundation for Innovation. The contents of this publication are solely the responsibility of the grantee and do not necessarily represent the official views of the funding agencies. The funding agencies do not endorse the purchase of any commercial products or services mentioned in the publication.	Anderson JL, 1998, J AM COLL CARDIOL, V32, P35, DOI 10.1016/S0735-1097(98)00203-4; Ayres JG, 2008, INHAL TOXICOL, V20, P75, DOI 10.1080/08958370701665517 ; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Bates JT, 2015, ENVIRON SCI TECHNOL, V49, P13605, DOI 10.1021/acs.est.5b02967; Behbod B, 2013, OCCUP ENVIRON MED, V70, P761, DOI 10.1136/oemed-2013-101498; Bell Michelle L, 2012, Res Rep Health Eff Inst, P5; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Borm PJA, 2007, OCCUP ENVIRON MED, V64, P73, DOI 10.1136/oem.2006.029090; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Cakmak S, 2014, ENVIRON POLLUT, V189, P208, DOI 10.1016/j.envpol.2014.03.004; Chen LC, 2009, INHAL TOXICOL, V21, P1, DOI [10.1080/08958370802105405, 10.1080/08958370802105405 ]; Clarke RW, 2000, ENVIRON HEALTH PERSP, V108, P1179, DOI 10.2307/3434831; Crobeddu B, 2017, ENVIRON POLLUT, V230, P125, DOI 10.1016/j.envpol.2017.06.051; Daher N, 2014, SCI TOTAL ENVIRON, V470, P417, DOI 10.1016/j.scitotenv.2013.09.104; FRANKENHAEUSER M, 1986, PHARMACOL BIOCHEM BE, V24, P1521, DOI 10.1016/0091-3057(86)90478-8; Fukuda M, 1996, PSYCHIAT RES, V63, P7, DOI 10.1016/0165-1781(96)02527-9; Gurgueira SA, 2002, ENVIRON HEALTH PERSP, V110, P749, DOI 10.1289/ehp.02110749; Haberzettl P, 2012, ENVIRON HEALTH PERSP, V120, P848, DOI 10.1289/ehp.1104206; Haynes WG, 1996, CIRCULATION, V93, P1860, DOI 10.1161/01.CIR.93.10.1860; Huang YCT, 2003, INHAL TOXICOL, V15, P327, DOI 10.1080/08958370304460; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; Kelly Frank, 2011, Res Rep Health Eff Inst, P73; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Lippmann Morton, 2013, Res Rep Health Eff Inst, P5; Liu L, 2017, ENVIRON INT, V101, P89, DOI 10.1016/j.envint.2017.01.010; Liu L, 2015, ENVIRON HEALTH PERSP, V123, P534, DOI 10.1289/ehp.1408387; Maikawa CL, 2016, ENVIRON HEALTH PERSP, V124, P1616, DOI 10.1289/EHP175; Moylan S, 2013, NEUROSCI BIOBEHAV R, V37, P573, DOI 10.1016/j.neubiorev.2013.02.003; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nishimoto N, 2006, NAT CLIN PRACT RHEUM, V2, P619, DOI 10.1038/ncprheum0338; PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S; Pollitt KJG, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0173-5; Rastogi N, 2012, AEROSOL SCI TECH, V46, P1015, DOI 10.1080/02786826.2012.686674; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schaumann F, 2004, AM J RESP CRIT CARE, V170, P898, DOI 10.1164/rccm.200403-423OC; Strak M, 2012, ENVIRON HEALTH PERSP, V120, P1183, DOI 10.1289/ehp.1104389; Subramanian M, 2016, NATURE, V534, P166, DOI 10.1038/534166a; Tonne C, 2012, EPIDEMIOLOGY, V23, P486, DOI 10.1097/EDE.0b013e31824e613e; Weichenthal S, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0129-9; Weichenthal S, 2016, ENVIRON RES, V146, P92, DOI 10.1016/j.envres.2015.12.013; Weichenthal SA, 2016, AM J RESP CRIT CARE, V194, P577, DOI 10.1164/rccm.201512-2434OC; Weichenthal SA, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-40; Wu S, 1996, J ANAL ATOM SPECTROM, V11, P287, DOI 10.1039/ja9961100287; Yang A, 2016, OCCUP ENVIRON MED, V73, P154, DOI 10.1136/oemed-2015-103175; Yang A, 2015, ENVIRON HEALTH PERSP, V123, P1187, DOI 10.1289/ehp.1408916; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhong J, 2015, HYPERTENSION, V66, P509, DOI 10.1161/HYPERTENSIONAHA.115.05342; Zhou JA, 2011, ENVIRON HEALTH PERSP, V119, P461, DOI 10.1289/ehp.1002613	48	23	23	2	30	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0160-4120	1873-6750		ENVIRON INT	Environ. Int.	DEC	2018	121		2				1331	1340		10.1016/j.envint.2018.10.055			10	Environmental Sciences	Environmental Sciences & Ecology	HE2CS	WOS:000453083000033	30420132	Other Gold, Green Accepted			2021-06-18	
J	Haarbauer-Krupa, J; Lee, AH; Bitsko, RH; Zhang, XJ; Kresnow-Sedacca, MJ				Haarbauer-Krupa, Juliet; Lee, Akilah Heggs; Bitsko, Rebecca H.; Zhang, Xinjian; Kresnow-Sedacca, Marcie-jo			Prevalence of Parent-Reported Traumatic Brain Injury in Children and Associated Health Conditions	JAMA PEDIATRICS			English	Article							PSYCHIATRIC-DISORDERS; BEHAVIOR PROBLEMS; EARLY-CHILDHOOD; UNITED-STATES; ADOLESCENTS; OUTCOMES; CARE; US; DISABILITY; RECOVERY	IMPORTANCE Traumatic brain injury (TBI) in children results in a high number of emergency department visits and risk for long-term adverse effects. OBJECTIVES To estimate lifetime prevalence of TBI in a nationally representative sample of US children and describe the association between TBI and other childhood health conditions. DESIGN, SETTING, AND PARTICIPANTS Data were analyzed from the 2011-2012 National Survey of Children's Health, a cross-sectional telephone survey of US households with a response rate of 23%. Traumatic brain injury prevalence estimates were stratified by sociodemographic characteristics. The likelihood of reporting specific health conditions was compared between children with and without TBI. Age-adjusted prevalence estimates were computed for each state. Associations between TBI prevalence, insurance type, and parent rating of insurance adequacy were examined. Data analysis was conducted from February 1, 2016, through November 1, 2017. MAIN OUTCOMES AND MEASURES Lifetime estimate of TBI in children, associated childhood health conditions, and parent report of health insurance type and adequacy. RESULTS The lifetime estimate of parent-reported TBI among children was 2.5%(95% CI, 2.3%-2.7%), representing over 1.8 million children nationally. Children with a lifetime history of TBI were more likely to have a variety of health conditions compared with those without a TBI history. Those with the highest prevalence included learning disorders (21.4%; 95% CI, 18.1%-25.2%); attention-deficit/hyperactivity disorder (20.5%; 95% CI, 17.4%-24.0%); speech/language problems (18.6%; 95% CI, 15.8%-21.7%); developmental delay (15.3%; 95% CI, 12.9%-18.1%); bone, joint, or muscle problems (14.2%; 95% CI, 11.6%-17.2%); and anxiety problems (13.2%; 95% CI, 11.0%-16.0%). States with a higher prevalence of childhood TBI were more likely to have a higher proportion of children with private health insurance and higher parent report of adequate insurance. Examples of states with higher prevalence of TBI and higher proportion of private insurance included Maine, Vermont, Pennsylvania, Washington, Montana, Wyoming North Dakota, South Dakota, and Colorado. CONCLUSIONS AND RELEVANCE A large number of US children have experienced a TBI during childhood. Higher TBI prevalence in states with greater levels of private insurance and insurance adequacymay suggest an underrecognition of TBI among children with less access to care. For more comprehensive monitoring, health care professionals should be aware of the increased risk of associated health conditions among children with TBI.	[Haarbauer-Krupa, Juliet] Ctr Dis Control & Prevent, Div Unintent Injury, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS-F62, Atlanta, GA 30341 USA; [Lee, Akilah Heggs] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA; [Bitsko, Rebecca H.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA; [Zhang, Xinjian; Kresnow-Sedacca, Marcie-jo] Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Atlanta, GA 30341 USA	Haarbauer-Krupa, J (corresponding author), Ctr Dis Control & Prevent, Div Unintent Injury, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS-F62, Atlanta, GA 30341 USA.	jhaarbauerkrupa@cdc.gov					Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bramlett Matthew D, 2017, Vital Health Stat 1, P1; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, TRAUM BRAIN INJ CONC; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; DeNavas-Walt C., 2012, US CENSUS BUREAU CUR; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fabio A, 2017, J HLTH DISPAR RES PR, V10, P107; Faul M, TRAUMATIC BRAIN INJU; Glang A, 2008, NEUROREHABILITATION, V23, P477; Haarbauer-Krupa J, 2017, J HEAD TRAUMA REHAB, V32, P367, DOI 10.1097/HTR.0000000000000287; Hansen G, 2015, SAGE OPEN MED, V3, DOI 10.1177/2050312115573817; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Iverson GL, 2016, J NEUROTRAUM, V33, P2077, DOI 10.1089/neu.2014.3424; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Max JE, 2015, J NEUROPSYCH CLIN N, V27, P112, DOI 10.1176/appi.neuropsych.13080190; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Pastor PN, 2006, AMBUL PEDIATR, V6, P38, DOI 10.1016/j.ambp.2005.07.002; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Schell A, 2016, OTOLARYNG HEAD NECK, V154, P175, DOI 10.1177/0194599815609114; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schootman M, 2000, BRAIN INJURY, V14, P373; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Taylor HG, 2015, J HEAD TRAUMA REHAB, V30, P302, DOI 10.1097/HTR.0000000000000106; Vaaramo K, 2014, J NEUROL NEUROSUR PS, V85, P598, DOI 10.1136/jnnp-2012-304457; Waissbluth S, 2016, INT J PEDIATR OTORHI, V84, P106, DOI 10.1016/j.ijporl.2016.02.034; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007	35	23	23	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	NOV	2018	172	11					1078	1086		10.1001/jamapediatrics.2018.2740			9	Pediatrics	Pediatrics	GZ2LO	WOS:000449215800022	30264150	Green Published, Bronze			2021-06-18	
J	Jha, RM; Elmer, J; Zusman, BE; Desai, S; Puccio, AM; Okonkwo, DO; Park, SY; Shutter, LA; Wallisch, JS; Conley, YP; Kochanek, PM				Jha, Ruchira M.; Elmer, Jonathan; Zusman, Benjamin E.; Desai, Shashvat; Puccio, Ava M.; Okonkwo, David O.; Park, Seo Young; Shutter, Lori A.; Wallisch, Jessica S.; Conley, Yvette P.; Kochanek, Patrick M.			Intracranial Pressure Trajectories: A Novel Approach to Informing Severe Traumatic Brain Injury Phenotypes*	CRITICAL CARE MEDICINE			English	Article						intracranial pressure trajectory; traumatic brain injury; group based trajectory modeling; ABCC8; sulfonylurea receptor 1	SINGLE NUCLEOTIDE POLYMORPHISMS; CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; ISCHEMIC-STROKE; CARDIAC-ARREST; SEVERE TBI; HYPERTENSION; EDEMA; TRIAL	Objectives: Intracranial pressure in traumatic brain injury is dynamic and influenced by factors like injury patterns, treatments, and genetics. Existing studies use time invariant summary intracranial pressure measures thus potentially losing critical information about temporal trends. We identified longitudinal intracranial pressure trajectories in severe traumatic brain injury and evaluated whether they predicted outcome. We further interrogated the model to explore whether ABCC8 polymorphisms (a known cerebraledema regulator) differed across trajectory groups. Design: Prospective observational cohort. Setting: Single-center academic medical center. Patients: Four-hundred four severe traumatic brain injury patients. Interventions: None. Measurements and Main Results: We used group-based trajectory modeling to identify hourly intracranial pressure trajectories in days 0-5 post traumatic brain injury incorporating risk factor adjustment (age, sex, Glasgow Coma Scale 6score, craniectomy, primary hemorrhage pattern). We compared 6-month outcomes (Glasgow Outcome Scale, Disability Rating Scale, mortality) and ABCC8 tag-single-nucleotide polymorphisms associated with cerebral edema (rs2237982, rs7105832) across groups. Regression models determined whether trajectory groups predicted outcome. A six trajectory group model best fit the data, identifying cohorts differing in initial intracranial pressure, evolution, and number/proportion of spikes greater than 20mm Hg. There were pattern differences in age, hemorrhage type, and craniectomy rates. ABCC8 polymorphisms differed across groups. GOS (p = 0.006), Disability Rating Scale (p = 0.001), mortality (p < 0.0001), and rs2237982 (p = 0.035) differed across groups. Unfavorable outcomes were surprisingly predicted by both low intracranial pressure trajectories and sustained intracranial hypertension. Intracranial pressure variability differed across groups (p < 0.001) and may reflect preserved/impaired intracranial elastance/compliance. Conclusions: We employed a novel approach investigating longitudinal/dynamic intracranial pressure patterns in traumatic brain injury. In a risk adjusted model, six groups were identified and predicted outcomes. If validated, trajectory modeling may be a first step toward developing a new, granular approach for intracranial pressure phenotyping in conjunction with other phenotyping tools like biomarkers and neuroimaging. This may be particularly relevant in light of changing traumatic brain injury demographics toward the elderly.	[Jha, Ruchira M.; Elmer, Jonathan; Shutter, Lori A.; Wallisch, Jessica S.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Jha, Ruchira M.; Elmer, Jonathan; Desai, Shashvat; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Zusman, Benjamin E.; Puccio, Ava M.; Okonkwo, David O.; Shutter, Lori A.] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Jha, Ruchira M.; Wallisch, Jessica S.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Jha, Ruchira M.; Conley, Yvette P.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA; [Elmer, Jonathan] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA; [Park, Seo Young] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Park, Seo Young] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesia, Pittsburgh, PA USA	Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.; Jha, RM (corresponding author), Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA.	jharm3@upmc.edu	Desai, Shashvat/AAM-2615-2021; Shutter, Lori A/G-2957-2013	Conley, Yvette/0000-0002-1784-6067; Shutter, Lori/0000-0002-1390-0628; Wallisch, Jessica/0000-0002-7908-9479	National Institutes of Health (NIH) National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); National Center for Advancing Translational Science; UPP Foundation award; University of Pittsburgh School of Medicine Dean's Faculty Advancement Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146, KL2TR001856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS097629, K23NS101036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342, R00NR013176] Funding Source: NIH RePORTER	We are grateful to the following institutions for their grant support: the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Center for Advancing Translational Science, UPP Foundation award, and University of Pittsburgh School of Medicine Dean's Faculty Advancement Award.	Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Chesnut R, 2014, NEUROCRIT CARE, V21, P64, DOI 10.1007/s12028-014-0048-y; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Elmer J, 2016, NEUROCRIT CARE, V25, P415, DOI 10.1007/s12028-016-0263-9; Feldmann H, 1979, Acta Neurochir Suppl (Wien), V28, P74; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Jha RM, 2017, LANCET NEUROL, V16, P578, DOI 10.1016/S1474-4422(17)30225-9; Jha RM, 2017, NEUROCRIT CARE, V26, P213, DOI 10.1007/s12028-016-0309-z; Jha Ruchira M, 2017, Crit Care Med, V45, pe255, DOI 10.1097/CCM.0000000000002079; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Nagin D., 2005, GROUP BASED MODELING; Nielson JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169490; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Rivera-Lara L, 2017, CRIT CARE MED, V45, P695, DOI 10.1097/CCM.0000000000002251; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Sajobi TT, 2017, STROKE, V48, P105, DOI 10.1161/STROKEAHA.116.014456; Sheth KN, 2016, LANCET NEUROL, V15, P1160, DOI 10.1016/S1474-4422(16)30196-X; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Stein DM, 2013, NEUROCRIT CARE, V18, P332, DOI 10.1007/s12028-013-9832-3; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wallisch J, 2016, CRIT CARE MED, V44; Weaver SM, 2014, BRAIN IMAGING BEHAV, V8, P420, DOI 10.1007/s11682-012-9197-9	39	23	24	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2018	46	11					1792	1802		10.1097/CCM.0000000000003361			11	Critical Care Medicine	General & Internal Medicine	GW5XM	WOS:000447016100025	30119071	Green Accepted			2021-06-18	
J	Hammond, FM; Giacino, JT; Richardson, RN; Sherer, M; Zafonte, RD; Whyte, J; Arciniegas, DB; Tang, XY				Hammond, Flora M.; Giacino, Joseph T.; Richardson, Risa Nakase; Sherer, Mark; Zafonte, Ross D.; Whyte, John; Arciniegas, David B.; Tang, Xinyu			Disorders of Consciousness due to Traumatic Brain Injury: Functional Status Ten Years Post-Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; cognition; consciousness disorders; minimally conscious state; prognosis; rehabilitation outcome; vegetative state	RECOVERY; REHABILITATION; OUTCOMES; POPULATION; ADMISSION; HEALTH	Few studies have assessed the long-term functional outcomes of patients with a disorder of consciousness due to traumatic brain injury (TBI). This study examined functional status during the first 10 years after TBI among a cohort with disorders of consciousness (i.e., coma, vegetative state, minimally conscious state). The study sample included 110 individuals with TBI who were unable to follow commands prior to inpatient rehabilitation and for whom follow-up data were available at 1, 2, 5, and 10 years post-injury. The sample was subdivided into those who demonstrated command-following early (before 28 days post-injury) versus late ( 28 days post-injury or never). Functional Independence Measure (FIM) at 1, 2, 5, and 10 years following TBI was used to measure functional outcomes. Measureable functional recovery occurred throughout the 10-year period, with more than two thirds of the sample achieving independence in mobility and self-care, and about one quarter achieving independent cognitive function by 10 years. Following commands prior to 28 days was associated with greater functional independence at all outcome time-points. Multi-trajectory modeling of recovery of three FIM subscales (self-care, mobility, cognition) revealed four distinct prognostic groups with different temporal patterns of change on these subscales. More than half the sample achieved near-maximal recovery by 1 year post-injury, while the later command-following subgroups recovered over longer periods of time. Significant late functional decline was not observed in this cohort. Among a cohort of patients unable to follow commands at the time of inpatient rehabilitation, a substantial proportion achieved functional independence in self-care, mobility, and cognition. The proportion of participants achieving functional independence increased between 5 and 10 years post-injury. These findings suggest that individuals with disorders of consciousness may benefit from ongoing functional monitoring and updated care plans for at least the first decade after TBI.	[Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, 4141 Shore Dr, Indianapolis, IN 46254 USA; [Giacino, Joseph T.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Richardson, Risa Nakase] Univ S Florida, Hlth Serv Res & Dev Serv, Ctr Innovat Disabil & Rehabil Res, Tampa, FL USA; [Richardson, Risa Nakase] Univ S Florida, Def & Vet Brain Injury Ctr, James A Haley Vet Hosp, Tampa, FL USA; [Sherer, Mark] Univ S Florida, Coll Med, Tampa, FL USA; [Zafonte, Ross D.] Harvard Med Sch, Spaulding Rehabil Hosp, Massachusetts Gen Hosp, Brigham & Womens Hosp,Dept Phys Med & Rehabil, Boston, MA USA; [Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Arciniegas, David B.] Univ Colorado, Sch Med, Marcus Inst Brain Hlth, Dept Neurol,Ctr Mental Hlth, Gunnison, CO USA; [Arciniegas, David B.] Univ Colorado, Sch Med, Marcus Inst Brain Hlth, Dept Psychiat,Ctr Mental Hlth, Gunnison, CO USA; [Tang, Xinyu] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA	Hammond, FM (corresponding author), Indiana Univ Sch Med, Dept Phys Med & Rehabil, 4141 Shore Dr, Indianapolis, IN 46254 USA.	flora.hammond@rhin.com	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR), a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS) [DPTBI17000014, 90DP0036, 90DRTB0002, 90DPTB0011, 90DP0039]; Department of Veterans AffairsUS Department of Veterans Affairs; Department of Health and Human Services (National Institute on Disability, Independent Living, and Rehabilitation Research); VHA Central Office VA TBI Model System Program of Research; General Dynamics Health Solutions from the Defense and Veterans Brain Injury Center within the Defense Health Agency [W91YTZ-13-C-0015]; U.S. Department of Veterans Affairs Health Services Research and Development COIN grantUS Department of Veterans Affairs [1 I50 HX001233-01]	The contents of this publication were developed under grants from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR; grant numbers, DPTBI17000014; 90DP0036 and 90DRTB0002; 90DPTB0011, 90DP0039), which is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS).; The Polytrauma Rehabilitation Center Traumatic Brain Injury (TBI) Model System collaboration is funded through an Interagency Agreement between the Department of Veterans Affairs and the Department of Health and Human Services (National Institute on Disability, Independent Living, and Rehabilitation Research). This research is sponsored by VHA Central Office VA TBI Model System Program of Research, and Subcontract from General Dynamics Health Solutions (W91YTZ-13-C-0015) from the Defense and Veterans Brain Injury Center within the Defense Health Agency, and U.S. Department of Veterans Affairs Health Services Research and Development COIN grant (1 I50 HX001233-01; CINDRR).	Bogner JA, 2017, J HEAD TRAUMA REHAB, V32, pE1, DOI 10.1097/HTR.0000000000000291; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Deguise E, 2008, J HEAD TRAUMA REHAB, V23, P294, DOI 10.1097/01.HTR.0000336842.53338.f4; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fins Joseph J, 2012, Virtual Mentor, V14, P221, DOI 10.1001/virtualmentor.2012.14.3.stas1-1203; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Greenwald BD, 2015, J NEUROTRAUM, V32, P1883, DOI 10.1089/neu.2014.3454; Hammond F, 2009, J NEUROTRAUM, V26, pA83; Institute of Medicine, 2009, GULF WAR HLTH, V7; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Nagin DS, 2018, STAT METHODS MED RES, V27, P2015, DOI 10.1177/0962280216673085; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1855, DOI 10.1016/j.apmr.2012.10.041	23	23	23	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2019	36	7					1136	1146		10.1089/neu.2018.5954		OCT 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HR6CL	WOS:000447718700001	30226400	Other Gold			2021-06-18	
J	Burstein, B; Upton, JE; Terra, HF; Neuman, MI				Burstein, Brett; Upton, Julia E. M.; Terra, Heloisa Fuzaro; Neuman, Mark I.			Use of CT for Head Trauma: 2007-2015	PEDIATRICS			English	Article							COMPUTED-TOMOGRAPHY USE; EMERGENCY-DEPARTMENT; UNITED-STATES; RADIATION-EXPOSURE; PREDICTION RULES; DECISION RULE; CHILDREN; INJURY; PECARN; VALIDATION	In this study, we used a nationwide US sample to evaluate the trend in CT neuroimaging for children with head injuries presenting to EDs. BACKGROUND AND OBJECTIVES:International efforts have been focused on identifying children at low risk of clinically important traumatic brain injury in whom computed tomography (CT) neuroimaging can be avoided. We sought to determine if CT use for pediatric head trauma has decreased among US emergency departments (EDs).METHODS:This was a cross-sectional analysis of the National Hospital Ambulatory Care Medical Survey database of nationally representative ED visits from 2007 to 2015. We included children <18 years of age evaluated in the ED for head injury. Survey weighting procedures were used to estimate the annual proportion of children who underwent CT neuroimaging and to perform multivariable logistic regression.RESULTS:There were an estimated 14.3 million pediatric head trauma visits during the 9-year study period. Overall, 32% (95% confidence interval [CI]: 29%-35%) of children underwent CT neuroimaging with no significant annual linear trend (P trend = .50). Multivariate analysis similarly revealed no difference by year (adjusted odds ratio [aOR]: 1.02; 95% CI: 0.97-1.07) after adjustment for patient- and ED-level covariates. CT use was associated with age 2 years (aOR: 1.51; 95% CI: 1.13-2.01), white race (aOR: 1.43; 95% CI: 1.10-1.86), highest triage acuity (aOR: 8.24 [95% CI: 4.00-16.95]; P < .001), and presentation to a nonteaching (aOR: 1.47; 95% CI: 1.05-2.06) or nonpediatric (aOR: 1.53; 95% CI: 1.05-2.23) hospital.CONCLUSIONS:CT neuroimaging did not decrease from 2007 to 2015. Findings suggest an important need for quality improvement initiatives to decrease CT use among children with head injuries.	[Burstein, Brett] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Div Pediat Emergency Med,Dept Pediat, 1001 Decarie Blvd, Montreal, PQ H4C 3J1, Canada; [Burstein, Brett; Upton, Julia E. M.; Terra, Heloisa Fuzaro] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA; [Upton, Julia E. M.] Univ Toronto, Dept Pediat, Div Immunol & Allergy, Toronto, ON, Canada; [Upton, Julia E. M.] Hosp Sick Children, Toronto, ON, Canada; [Terra, Heloisa Fuzaro] Virginia Commonwealth Univ, Sch Dent, Richmond, VA USA; [Neuman, Mark I.] Harvard Univ, Harvard Med Sch, Dept Pediat, Div Emergency Med, Boston, MA 02115 USA; [Neuman, Mark I.] Boston Childrens Hosp, Boston, MA USA	Burstein, B (corresponding author), McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Div Pediat Emergency Med,Dept Pediat, 1001 Decarie Blvd, Montreal, PQ H4C 3J1, Canada.	brett.burstein@mail.mcgill.ca	Upton, Julia/T-7425-2019				Babl FE, 2017, LANCET, V389, P2393, DOI 10.1016/S0140-6736(17)30555-X; Bender JM, 2014, J CLIN LAB ANAL, V28, P349, DOI 10.1002/jcla.21692; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bulas D, 2009, PEDIATR RADIOL, V39, P112, DOI 10.1007/s00247-008-1101-9; Dayan PS, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2709; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Fortin EM, 2016, EMERG RADIOL, V23, P597, DOI 10.1007/s10140-016-1424-z; Goldwasser T, 2015, EUR J EMERG MED, V22, P413, DOI 10.1097/MEJ.0000000000000201; Goske MJ, 2008, AM J ROENTGENOL, V190, P273, DOI 10.2214/AJR.07.3526; Goske Marilyn J, 2008, J Am Coll Radiol, V5, P1200, DOI 10.1016/j.jacr.2008.06.007; Green Lawrence W, 2014, Front Public Health Serv Syst Res, V3, P3; Hoyle JD, 2014, PEDIATR EMERG CARE, V30, P1, DOI 10.1097/PEC.0000000000000059; Ide K, 2017, ACAD EMERG MED, V24, P308, DOI 10.1111/acem.13129; Image Gently Alliance, CAMP OV; Jennings RM, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1349; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Larson DB, 2011, RADIOLOGY, V259, P793, DOI 10.1148/radiol.11101939; Lin MP, 2017, ACAD EMERG MED, V24, P668, DOI 10.1111/acem.13167; Lodwick DL, 2015, PEDIATRICS, V136, pE1212, DOI 10.1542/peds.2015-1671; Lorton F, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0287-3; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Marin JR, 2014, ACAD EMERG MED, V21, P987, DOI 10.1111/acem.12458; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Marr AL., 2004, CENTRAL NERVOUS SYST; Melnick ER, 2015, ACAD EMERG MED, V22, P1474, DOI 10.1111/acem.12824; Miescier MJ, 2017, PEDIATR EMERG CARE, V33, P156, DOI 10.1097/PEC.0000000000000500; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180; Natale JE, 2012, ARCH PEDIAT ADOL MED, V166, P732, DOI 10.1001/archpediatrics.2012.307; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Slovis TL, 2002, PEDIATR RADIOL, V32, P217, DOI 10.1007/s00247-002-0669-8; Stanley RM, 2014, J PEDIATR-US, V165, P1201, DOI 10.1016/j.jpeds.2014.08.008; Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403	38	23	23	0	0	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2018	142	4							e20180814	10.1542/peds.2018-0814			8	Pediatrics	Pediatrics	GZ0EU	WOS:000449034300025	30181120	Bronze			2021-06-18	
J	Di Pietro, V; Porto, E; Ragusa, M; Barbagallo, C; Davies, D; Forcione, M; Logan, A; Di Pietro, C; Purrello, M; Grey, M; Hammond, D; Sawlani, V; Barbey, AK; Belli, A				Di Pietro, Valentina; Porto, Edoardo; Ragusa, Marco; Barbagallo, Cristina; Davies, David; Forcione, Mario; Logan, Ann; Di Pietro, Cinzia; Purrello, Michele; Grey, Michael; Hammond, Douglas; Sawlani, Vijay; Barbey, Aron K.; Belli, Antonio			Salivary MicroRNAs: Diagnostic Markers of Mild Traumatic Brain Injury in Contact-Sport	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						concussion; mild traumatic brain injury; biomarkers; saliva; microRNA	FIBRILLARY ACIDIC PROTEIN; IN-VITRO MODEL; TEMPORAL WINDOW; INTRACRANIAL LESIONS; BIOMARKERS; SERUM; CONCUSSION; RNA; VULNERABILITY; REGULATORS	Concussion is difficult to diagnose, particularly when symptoms are atypical or late in presenting. An accurate and timely initial assessment is crucial for clinical management. Cerebral spinal fluid (CSF) and blood markers of traumatic brain injury show promising results but their clinical applicability in concussion has significant limitations. In the study, we explored saliva as a new source of biomarkers of concussion. Saliva samples of concussed players were collected after 48-72 h from concussion and analyzed by high-throughput technologies. A discovery group of 10 concussed rugby professional and semiprofessional athletes and 10 non-concussed matched controls was used for the analysis of 92 inflammatory proteins by the Proseek-Multiplex-Inflammation technology. In addition, saliva samples of 6 concussed and 6 non-concussed athletes were used to screen 800 human microRNAs (miRNAs) by the Nanostring Technology. The results were then validated by RT-qPCR in an enlarged cohort (validation group) comprising 22 concussed athletes. Results showed, no significant variations of the 65 inflammatory proteins detected in saliva between groups but 5 microRNAs, miR-27b-3p (p=0.016), let-7i-5p (p=0.001), miR-142-3p (p=0.008), miR-107 (p=0.028), miR-135b-5p (p=0.017) significantly upregulated in concussed athletes. Univariate ROC curve analysis showed that the differentially expressed miRNAs could be considered good classifiers of concussion. Further analyses showed significant correlation between these microRNAs and Reaction Time component of the ImPACT concussion assessment tool. In addition, biocomputation analysis predicted the involvement of these microRNAs in important biological processes that might be related to trauma, such as response to hypoxia, cell death, neurogenesis, axon repair and myelination. Ease of access and non-invasiveness of saliva samples make these biomarkers particularly suitable for concussion assessment.	[Di Pietro, Valentina; Porto, Edoardo; Logan, Ann; Belli, Antonio] Univ Birmingham, Inst Inflammat & Ageing, Neurotrauma & Ophthalmol Res Grp, Birmingham, W Midlands, England; [Di Pietro, Valentina; Porto, Edoardo; Davies, David; Forcione, Mario; Hammond, Douglas; Sawlani, Vijay; Belli, Antonio] Queen Elizabeth Hosp, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England; [Di Pietro, Valentina; Barbey, Aron K.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL USA; [Ragusa, Marco; Barbagallo, Cristina; Di Pietro, Cinzia; Purrello, Michele] Univ Catania, Dept Biomed Sci & Biotechnol, Sect Biol & Genet G Sichel, BioMol Genome & Complex Syst BioMed Unit BMGS, Catania, Italy; [Ragusa, Marco] IRCCS Associaz Oasi Maria SS, Inst Res Mental Retardat & Brain Aging, Troina, Italy; [Grey, Michael] Univ East Anglia, Sch Sport & Exercise, Norwich, Norfolk, England	Di Pietro, V (corresponding author), Univ Birmingham, Inst Inflammat & Ageing, Neurotrauma & Ophthalmol Res Grp, Birmingham, W Midlands, England.; Di Pietro, V (corresponding author), Queen Elizabeth Hosp, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England.; Di Pietro, V (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL USA.	v.dipietro@bham.ac.uk	Ragusa, Marco/D-7691-2010; Belli, Antonio/I-3799-2015; Barbey, Aron/L-7312-2015; Forcione, Mario/K-2852-2018	Ragusa, Marco/0000-0002-4282-920X; Belli, Antonio/0000-0002-3211-9933; Barbey, Aron/0000-0002-6092-0912; Porto, Edoardo/0000-0002-1442-9137; Forcione, Mario/0000-0002-4045-8011	National Institute for Health Research (NIHR), Midlands Neuroscience Training and Research Fund; British Medical Association; Department Research Plan of University of Catania	This study was funded by the National Institute for Health Research (NIHR), Midlands Neuroscience Training and Research Fund and by the British Medical Association. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was also funded by 2016/2018 Department Research Plan of University of Catania (2 degrees line of intervention).	Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721-5732.2005; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Bi YJ, 2009, J CELL PHYSIOL, V218, P467, DOI 10.1002/jcp.21639; Bonne NJ, 2012, GENOME MED, V4, DOI 10.1186/gm383; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Burbelo PD, 2012, ORAL DIS, V18, P121, DOI 10.1111/j.1601-0825.2011.01863.x; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Cirnigliaro M, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00250; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Devic I, 2011, BRAIN, V134, DOI 10.1093/brain/awr015; Di Pietro V, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00429; Di Pietro V, 2017, J NEUROTRAUM, V34, P1948, DOI 10.1089/neu.2016.4857; Di Pietro V, 2015, NEUROCHEM RES, V40, P991, DOI 10.1007/s11064-015-1554-9; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gaetz M, 2017, MED HYPOTHESES, V102, P130, DOI 10.1016/j.mehy.2017.03.023; Gauthier BR, 2006, NAT MED, V12, P36, DOI 10.1038/nm0106-36; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Hicks SD, 2018, J NEUROTRAUM, V35, P64, DOI 10.1089/neu.2017.5111; Johnson JJ, 2018, JAMA PEDIATR, V172, P65, DOI 10.1001/jamapediatrics.2017.3884; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Li MA, 2012, BIOESSAYS, V34, P670, DOI 10.1002/bies.201200019; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Ludwig N, 2016, NUCLEIC ACIDS RES, V44, P3865, DOI 10.1093/nar/gkw116; Maroon JC, 2014, PROG NEUROL SURG, V28, P1, DOI 10.1159/000358746; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Mitoh Y, 2004, BRAIN RES, V999, P62, DOI 10.1016/j.brainres.2003.11.053; Mitra B, 2017, J CLIN NEUROSCI, V38, P37, DOI 10.1016/j.jocn.2016.12.009; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nylen K, 2006, NEUROSCI LETT, V404, P132, DOI 10.1016/j.neulet.2006.05.029; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Park NJ, 2006, CLIN CHEM, V52, P988, DOI 10.1373/clinchem.2005.063206; Ragusa M, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/4723193; Ragusa M, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00051; Ragusa M, 2015, CANCER BIOL THER, V16, P1387, DOI 10.1080/15384047.2015.1046021; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shi M, 2011, J ALZHEIMERS DIS, V27, P299, DOI 10.3233/JAD-2011-110731; Szafranskil K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00087; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vallelunga A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00156; Vos BC, 2018, CLIN J SPORT MED, V28, P91, DOI 10.1097/JSM.0000000000000432; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Yang T, 2016, J NEUROCHEM, V137, P122, DOI 10.1111/jnc.13534; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	60	23	23	1	19	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	AUG 20	2018	11								290	10.3389/fnmol.2018.00290			13	Neurosciences	Neurosciences & Neurology	GQ9XY	WOS:000442156900001	30177873	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Silverberg, ND; Panenka, WJ; Iverson, GL				Silverberg, Noah D.; Panenka, William J.; Iverson, Grant L.			Fear Avoidance and Clinical Outcomes from Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adaptation; psychological; brain concussion; cohort studies; fear; post-concussion symptoms	COMMON DATA ELEMENTS; INTERNATIONAL CLASSIFICATION; CORE SETS; HEALTH; DISABILITY; RECOMMENDATIONS; FRAMEWORK; ICF	Characterizing psychological factors that contribute to persistent symptoms after mild traumatic brain injury (MTBI) can inform early intervention. To determine whether fear avoidance, a known risk factor for chronic disability after musculoskeletal injury, is associated with worse clinical outcomes from MTBI, adults were recruited from four outpatient MTBI clinics and assessed at their first clinic visit (mean= 2.7, standard deviation= 1.5 weeks post -injury) and again four to five months later. Of 273 patients screened, 102 completed the initial assessment, and 87 returned for the outcome assessment. The initial assessment included a battery of questionnaires that measure activity avoidance and associated fears. Endurance, an opposite behavior pattern, was measured with the Behavioral Response to Illness Questionnaire The multi -dimensional outcome assessment included measures of post -concussion symptoms (British Columbia Postconcussion Symptom Inventory), functional disability (World Health Organization Disability Assessment Schedule -12 2.0), return to work status, and psychiatric complications (MINI Neuropsychiatric Interview). A single component was retained from principal components analysis of the six avoidance subscales. In generalized linear modeling, the avoidance composite score predicted symptom severity (95% confidence interval [CI] for B =1.22-6.33) and disability (95% CI for B = 2.16-5.48), but not return to work (95% CI for B = -0.68-0.24). The avoidance composite was also associated with an increased risk for depression (odds ratio [OR] =1.76, 95% CI= 1.02-3.02) and anxiety disorders (OR= 1.89, 95% CI= 1.16-3.19). Endurance behavior predicted the same outcomes, except for depression. In summary, avoidance and endurance behavior were associated with a range of adverse clinical outcomes from MTBI. These may represent early intervention targets.	[Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Rehabil Res Program, GF Strong Rehab Ctr, Vancouver, BC, Canada; [Panenka, William J.] Univ British Columbia, British Columbia Neuropsychiat Program, Dept Psychiat, Vancouver, BC, Canada; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] A Red Sox Fdn, Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA	Silverberg, ND (corresponding author), Univ British Columbia, Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570; Panenka, William/0000-0001-7143-6512			Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chalmers I, 2009, LANCET, V374, P86, DOI 10.1016/S0140-6736(09)60329-9; Cieza A, 2004, J REHABIL MED, V36, P9, DOI 10.1080/16501960410015353; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Donovan J, 2014, CHIROPR MAN THER, V22, DOI 10.1186/s12998-014-0038-3; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Ellis MJ, 2017, CLIN J SPORT MED, V27, P179, DOI 10.1097/JSM.0000000000000305; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Laxe S, 2013, BRAIN INJURY, V27, P379, DOI 10.3109/02699052.2012.750757; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; Stucki G, 2005, AM J PHYS MED REHAB, V84, P733, DOI 10.1097/01.phm.0000179521.70639.83; Sveen U, 2013, DISABIL REHABIL, V35, P749, DOI 10.3109/09638288.2012.707741; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	23	23	23	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2018	35	16					1864	1873		10.1089/neu.2018.5662			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GQ2YY	WOS:000441527400004	29665736				2021-06-18	
J	Yuan, J; Wang, DF; Liu, Y; Chen, XJ; Zhang, HL; Shen, F; Liu, X; Fu, JQ				Yuan, Jia; Wang, Difen; Liu, Ying; Chen, Xianjun; Zhang, Hailing; Shen, Feng; Liu, Xu; Fu, Jiangquan			Hydrogen-rich water attenuates oxidative stress in rats with traumatic brain injury via Nrf2 pathway	JOURNAL OF SURGICAL RESEARCH			English	Article						Hydrogen-rich water; Nrf2 pathway; Traumatic brain injury; Oxidative stress	ANTIOXIDANT ENZYMES; SALINE PROTECTS; SYSTEM; MODEL; HIPPOCAMPUS; MECHANISMS; APOPTOSIS; TARGETS; DAMAGE; ROLES	Background: Several studies have recently found that oxidative stress plays a pivotal role in the pathogenesis of traumatic brain injury (TBI) and may represent a target in TBI treatment. Hydrogen-rich water was recently shown to exert neuroprotective effects in various neurological diseases through its antioxidant properties. However, the mechanisms underlying its effects in TBI are not clearly understood. The purpose of our study was to evaluate the neuroprotective role of hydrogen-rich water in rats with TBI and to elucidate the possible mechanisms underlying its effects. Materials and methods: The TBI model was constructed according to the modified Feeney weight-drop method. In part 1 of the experiment, we measured oxidative stress levels by observing the changes in catalase (CAT), glutathione peroxidase (GPx), and malondialdehyde (MDA) expressions. We also evaluated nuclear factor erythroid 2-related factor 2 (Nrf2) levels to determine the role of the protein in the neuroprotective effects against TBI. In part 2, we verified the neuroprotective effects of hydrogen-rich water in TBI and observed its effects on Nrf2. All the experimental rats were divided into sham group, TBI group, and TBI + hydrogen-rich water-treated (TBI + HW) group. We randomly chose 20 rats from each group and recorded their 7-d survival rates. Modified neurological severity scores were recorded from an additional six rats per group, which were then sacrificed 24 h after testing. Spectrophotometry was used to measure GPx, CAT, and MDA levels, whereas western blotting, reverse transcription polymerase chain reaction, and immunohistochemistry were used to measure the expression of Nrf2 and downstream factors like heme oxygenase 1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1). Results: GPx and CAT activity was significantly decreased, and MDA content was increased in the TBI group compared with the sham group at 6 h after TBI. MDA content peaked at 24 h after TBI. Nrf2 nucleoprotein levels were upregulated in the TBI group compared with the sham group and peaked at 24 h after TBI; however, no significant changes in Nrf2 mRNA levels were noted after TBI. Hydrogen-rich water administration significantly increased 7-d survival rates, reduced neurologic deficits, and lowered intracellular oxidative stress levels. Moreover, hydrogen-rich water caused Nrf2 to enter the cell nucleus, which resulted in increases in the expression of downstream factors such as HO-1 and NQO1. Conclusions: Our results indicate that hydrogen-rich water has neuroprotective effects against TBI by reducing oxidative stress and activating the Nrf2 pathway. (C) 2018 Elsevier Inc. All rights reserved.	[Yuan, Jia; Wang, Difen; Liu, Ying; Chen, Xianjun; Zhang, Hailing; Shen, Feng; Liu, Xu; Fu, Jiangquan] Guizhou Med Univ, Dept Crit Care Med, Affiliated Hosp, Guiyi Rd 28, Guiyang 550004, Guizhou, Peoples R China	Wang, DF (corresponding author), Guizhou Med Univ, Dept Crit Care Med, Affiliated Hosp, Guiyi Rd 28, Guiyang 550004, Guizhou, Peoples R China.	DifenWang123@163.com	SHEN, Feng/AAQ-8531-2020		High-level Personnel of Special Support Program [TZJF-2011-25]; Science & Technology Department [SY [2010] 3079]; Key Specialty Construction of Clinical Projects in Guizhou Province [[2011] 52]; National Key Specialty Construction of Clinical Projects in China [[2011] 170]	This work was supported by grants from the High-level Personnel of Special Support Program (No. TZJF-2011-25), the Science & Technology Department (No. SY [2010] 3079), and the Key Specialty Construction of Clinical Projects (No. [2011] 52) in Guizhou Province, as well as the National Key Specialty Construction of Clinical Projects (No. [2011] 170) in China. The authors thank the Clinical Research Center of the Affiliated Hospital of Guizhou Medical University for their support during the experiment.	Arent AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723060; Baird L, 2011, ARCH TOXICOL, V85, P241, DOI 10.1007/s00204-011-0674-5; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cui T, 2015, CELL BIOCHEM BIOPHYS, V71, P595, DOI 10.1007/s12013-014-0239-3; Dash B, 2012, GENE, V501, P144, DOI 10.1016/j.gene.2012.04.015; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding H, 2017, NEUROCHEM RES, V42, P337, DOI 10.1007/s11064-016-2077-8; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dohi K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108034; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fujita K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007247; Gao YY, 2017, AM J TRANSL RES, V9, P887; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Iketani M, 2017, SHOCK, V48, P85, DOI 10.1097/SHK.0000000000000810; Ji XT, 2012, J SURG RES, V178, pE9, DOI 10.1016/j.jss.2011.12.038; Kawamura T, 2013, AM J PHYSIOL-LUNG C, V304, pL646, DOI 10.1152/ajplung.00164.2012; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Li J, 2010, BRAIN RES, V1328, P152, DOI 10.1016/j.brainres.2010.02.046; Liu Y, 2017, INT J CLIN EXP PATHO, V10, P3807; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Manaenko A, 2013, CRIT CARE MED, V41, P1266, DOI 10.1097/CCM.0b013e31827711c9; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Nagata K, 2009, NEUROPSYCHOPHARMACOL, V34, P501, DOI 10.1038/npp.2008.95; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Shen MH, 2014, MED GAS RES, V4, DOI 10.1186/2045-9912-4-17; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Sun Y, 2017, CNS NEUROL DISORD-DR, V16, P326, DOI 10.2174/1871527316666170102120211; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Tanaka N, 2011, BRAIN RES, V1370, P246, DOI 10.1016/j.brainres.2010.11.010; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wang C, 2011, NEUROSCI LETT, V491, P127, DOI 10.1016/j.neulet.2011.01.022; Wang F, 2011, J SURG RES, V167, pE339, DOI 10.1016/j.jss.2010.11.005; Wang L, 2017, BIOSCIENCE REP, V37, P1; Wang Z, 2014, CLIN INTERV AGING, V9, P1, DOI [10.1186/1556-276X-9-643, 10.2147/CIA.S41356]; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu G, 2016, MED SCI MONITOR, V22, P2161, DOI 10.12659/MSM.896568; Xie Q, 2014, MOL MED REP, V10, P1143, DOI 10.3892/mmr.2014.2283; Yang CH, 2009, BRAIN RES, V1282, P133, DOI 10.1016/j.brainres.2009.05.009; Yang YY, 2012, MED SCI MONITOR, V18, pBR144, DOI 10.12659/MSM.882616; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yilmaz N, 2007, BRAIN RES, V1164, P132, DOI 10.1016/j.brainres.2007.06.017; Zhang DQ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/731932; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003	44	23	25	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	AUG	2018	228						238	246		10.1016/j.jss.2018.03.024			9	Surgery	Surgery	GK8TB	WOS:000436499700033	29907217				2021-06-18	
J	Elbin, RJ; Sufrinko, A; Anderson, MN; Mohler, S; Schatz, P; Covassin, T; Mucha, A; Collins, MW; Kontos, AP				Elbin, R. J.; Sufrinko, Alicia; Anderson, Morgan N.; Mohler, Samantha; Schatz, Philip; Covassin, Tracey; Mucha, Anne; Collins, Michael W.; Kontos, Anthony P.			Prospective Changes in Vestibular and Ocular Motor Impairment After Concussion	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						brain; human movement system; sport; VOMS; youth	SPORT-RELATED CONCUSSION; SCREENING VOMS; BASE-LINE; RECOVERY-TIME; HIGH-SCHOOL; RELIABILITY; CHILDREN; STATEMENT; OUTCOMES; PERFORMANCE	Background and Purpose: The utility of prospective changes on the Vestibular/Ocular Motor Screening (VOMS) assessment are unknown, and 2 methods of scoring are published in the literature. Total scores are the total symptom scores for each VOMS component, and change scores are the difference between the pretest total symptom score and component total symptom scores. This study documented prospective changes in vestibular and ocular motor impairments and symptoms in high school athletes with concussion using the total and change scoring methods and compared the percentage of scores over clinical cutoffs using the total and change scoring methods for the VOMS. Methods: Sixty-three athletes (15.53 1.06 years) completed the VOMS at baseline (ie, preinjury), 1 to 7 days, and 8 to 14 days after concussion. A series of repeated-measures multivariate analyses of variance were conducted on total and change scores. A 2-way repeated-measures analysis of variance was performed on the near-point convergence distance. A series of (2) analyses compared scores exceeding clinical cutoffs between the total and change scoring methods. Results: Total scoring revealed impairments (Wilks = 0.39, F-16,F-47 = 4.54, P < 0.001, (2) = 0.61) on all VOMS components at 1 to 7 and 8 to 14 days compared to baseline. Change scoring revealed postinjury impairments compared with baseline (Wilks = 0.58, F-14,F-49 = 2.52, P = 0.009, (2) = 0.42) on all components at 1 to 7 days; however, impairments at 8 to 14 days were revealed only for the vertical vestibular oculomotor reflex and vestibular motor sensitivity components. Total scoring identified significantly more scores over cutoffs at 1 to 7 days ((2)(1,63) = 5.97, P = 0.02) compared with change scores. Discussion and Conclusions: Both total and change scoring methods on the VOMS are useful for identifying impairments following concussion. Video Abstract available for more insights from the authors (see Supplemental Digital Content 1, http://links.lww.com/JNPT/A230)	[Elbin, R. J.; Mohler, Samantha] Univ Arkansas, Off Sport Concuss Res, Dept Hlth Human Performance & Recreat, 155 Stadium Dr, Fayetteville, AR 72701 USA; [Sufrinko, Alicia; Mucha, Anne; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, Dept Orthoped Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Anderson, Morgan N.; Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Mucha, Anne] UPMC Ctr Rehabil Serv, Pittsburgh, PA USA	Elbin, RJ (corresponding author), Univ Arkansas, Off Sport Concuss Res, Dept Hlth Human Performance & Recreat, 155 Stadium Dr, Fayetteville, AR 72701 USA.	rjelbin@uark.edu			NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01 DC012332] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER		Akin FW, 2003, J REHABIL RES DEV, V40, P415, DOI 10.1682/JRRD.2003.09.0415; Anzalone AJ, 2017, AM J SPORT MED, V45, P474, DOI 10.1177/0363546516668624; Asken BM, 2017, CLIN NEUROPSYCHOL, V31, P138, DOI 10.1080/13854046.2016.1246672; Barth JT, 1989, MILD HEAD INJURY SPO; BOWER CM, 1995, ARCH OTOLARYNGOL, V121, P911; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T, 2010, OPEN ACCESS J SPORTS, V1, P55; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Custer A, 2016, J ATHL TRAINING, V51, P136, DOI 10.4085/1062-6050-51.2.12; Elbin RJ, 2016, MED SCI SPORT EXER, V48, P525, DOI 10.1249/01.mss.0000486580.32473.21; Eviatar L, 1986, Pediatr Neurol, V2, P61, DOI 10.1016/0887-8994(86)90058-5; Gaikwad SB, 2018, J NEUROL PHYS THER, V42, P72, DOI 10.1097/NPT.0000000000000216; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Herdman SJ, 1998, AM J OTOL, V19, P790; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kemper AR, 2004, OPTOMETRY VISION SCI, V81, P7, DOI 10.1097/00006324-200401000-00003; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murray DA, 2017, BRIT J SPORT MED, V51, P442, DOI 10.1136/bjsports-2016-096081; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Riina N, 2005, ARCH OTOLARYNGOL, V131, P996, DOI 10.1001/archotol.131.11.996; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Schatz P, 2014, ARCH CLIN NEUROPSYCH, V29, P625, DOI 10.1093/arclin/acu041; Sufrinko AM, 2017, CLIN J SPORT MED, V27, P133, DOI 10.1097/JSM.0000000000000324; Yorke AM, 2017, SPORTS HEALTH, V9, P174, DOI 10.1177/1941738116678411; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720	37	23	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JUL	2018	42	3			SI		142	148		10.1097/NPT.0000000000000230			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GL1OM	WOS:000436873100005	29864101	Green Accepted, Bronze			2021-06-18	
J	Hoshi, Y; Okabe, K; Shibasaki, K; Funatsu, T; Matsuki, N; Ikegaya, Y; Koyama, R				Hoshi, Yutaka; Okabe, Kohki; Shibasaki, Koji; Funatsu, Takashi; Matsuki, Norio; Ikegaya, Yuji; Koyama, Ryuta			Ischemic Brain Injury Leads to Brain Edema via Hyperthermia-Induced TRPV4 Activation	JOURNAL OF NEUROSCIENCE			English	Article						brain edema; hyperthermia; ischemia; TRPV4	TARGETED TEMPERATURE MANAGEMENT; FOCAL CEREBRAL-ISCHEMIA; NEURONAL EXCITABILITY; CELL-VOLUME; ION-CHANNEL; HYPOTHERMIA; ASTROCYTES; PERMEABILITY; MODULATION; INDUCTION	Brain edema is characterized by an increase in net brain water content, which results in an increase in brain volume. Although brain edema is associated with a high fatality rate, the cellular and molecular processes of edema remain largely unclear. Here, we developed an in vitro model of ischemic stroke-induced edema in which male mouse brain slices were treated with oxygen-glucose deprivation (OGD) to mimic ischemia. We continuously measured the cross-sectional area of the brain slice for 150 min under macroscopic microscopy, finding that OGD induces swelling of brain slices. OGD-induced swelling was prevented by pharmacologically blocking or genetically knocking out the transient receptor potential vanilloid 4 (TRPV4), a member of the thermosensitive TRP channel family. Because TRPV4 is activated at around body temperature and its activation is enhanced by heating, we next elevated the temperature of the perfusate in the recording chamber, finding that hyperthermia induces swelling via TRPV4 activation. Furthermore, using the temperature-dependent fluorescence lifetime of a fluorescent-thermosensitive probe, we confirmed that OGD treatment increases the temperature of brain slices through the activation of glutamate receptors. Finally, we found that brain edema following traumatic brain injury was suppressed in TRPV4-deficient male mice in vivo. Thus, our study proposes a novel mechanism: hyperthermia activates TRPV4 and induces brain edema after ischemia.	[Hoshi, Yutaka; Matsuki, Norio; Ikegaya, Yuji; Koyama, Ryuta] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Chem Pharmacol, Tokyo 1130033, Japan; [Okabe, Kohki; Funatsu, Takashi] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Bioanalyt Chem, Tokyo 1130033, Japan; [Okabe, Kohki] JST, PRESTO, Kawaguchi, Saitama 3320012, Japan; [Shibasaki, Koji] Gunma Univ, Grad Sch Med, Dept Mol & Cellular Neurobiol, Maebashi, Gunma 3718514, Japan; [Ikegaya, Yuji] Natl Inst Informat & Commun Technol, Ctr Informat & Neural Networks, Suita, Osaka 5650871, Japan	Koyama, R (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Chem Pharmacol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	rkoyama@mol.f.u-tokyo.ac.jp	Shibasaki, Koji/U-8674-2018; Funatsu, Takashi/Q-1404-2015	Shibasaki, Koji/0000-0003-2330-1749; Funatsu, Takashi/0000-0002-9656-8308; Ikegaya, Yuji/0000-0003-2260-8191	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [17H03988, 15H0300]; Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17H05738, 15H05931, 15H05934]; Brain Science Foundation	This work was supported in part by Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (B) 17H03988 to R.K. and 15H0300 to K.S., Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research on Innovation Area "Dynamic Regulation of Brain Function by Scrap & Build System" 17H05738 to R.K. and "Thermal Biology" 15H05931 to K.O. and 15H05934 to K.S., and the Brain Science Foundation to R.K.	ABE K, 1988, J CEREBR BLOOD F MET, V8, P436, DOI 10.1038/jcbfm.1988.81; Adeva MM, 2012, NEUROCHEM INT, V61, P166, DOI 10.1016/j.neuint.2012.05.007; Aiyagari V, 2002, NEUROLOGIST, V8, P152, DOI 10.1097/00127893-200205000-00002; Bardutzky J, 2007, STROKE, V38, P3084, DOI 10.1161/STROKEAHA.107.490193; Belkacemi T, 2017, GLIA, V65, P1535, DOI 10.1002/glia.23180; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Bernal W, 2013, J HEPATOL, V59, P74, DOI 10.1016/j.jhep.2013.02.010; BETZ AL, 1994, J CEREBR BLOOD F MET, V14, P29, DOI 10.1038/jcbfm.1994.5; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Butenko O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039959; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Dwyer BE, 1996, MOL BRAIN RES, V38, P251, DOI 10.1016/0169-328X(95)00341-O; Evans SS, 2015, NAT REV IMMUNOL, V15, P335, DOI 10.1038/nri3843; Everaerts W, 2010, PROG BIOPHYS MOL BIO, V103, P2, DOI 10.1016/j.pbiomolbio.2009.10.002; Fenton RA, 2010, CELL MOL LIFE SCI, V67, P829, DOI 10.1007/s00018-009-0218-9; Furman CS, 2003, P NATL ACAD SCI USA, V100, P13609, DOI 10.1073/pnas.2235843100; Pascual MG, 2011, NEUROREHABILITATION, V29, P353, DOI 10.3233/NRE-2011-0712; Gota C, 2009, J AM CHEM SOC, V131, P2766, DOI 10.1021/ja807714j; Guler AD, 2002, J NEUROSCI, V22, P6408; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hayashi T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117677; Heinrich C, 2014, STEM CELL REP, V3, P1000, DOI 10.1016/j.stemcr.2014.10.007; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; Hill JK, 1999, BRAIN RES, V820, P45, DOI 10.1016/S0006-8993(98)01140-8; Hirayama Y, 2015, J NEUROSCI, V35, P3794, DOI 10.1523/JNEUROSCI.4218-14.2015; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; Honkaniemi J, 1996, J CEREBR BLOOD F MET, V16, P557, DOI 10.1097/00004647-199607000-00005; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Jie PH, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00141; Jo AO, 2015, J NEUROSCI, V35, P13525, DOI 10.1523/JNEUROSCI.1987-15.2015; Kauer JA, 2009, TRENDS NEUROSCI, V32, P215, DOI 10.1016/j.tins.2008.12.006; Khan M, 2017, NEURAL REGEN RES, V12, P696, DOI 10.4103/1673-5374.206632; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Lipski J, 2006, BRAIN RES, V1077, P187, DOI 10.1016/j.brainres.2006.01.016; Lu KT, 2017, J NEUROCHEM, V140, P718, DOI 10.1111/jnc.13920; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mizuno A, 2003, AM J PHYSIOL-CELL PH, V285, pC96, DOI 10.1152/ajpcell.00559.2002; Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206; MOSER EI, 1994, J NEUROSCI, V14, P4458; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Okabe K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1714; Paczynski RP, 2000, STROKE, V31, P1702, DOI 10.1161/01.STR.31.7.1702; Polderman KH, 2015, THER HYPOTHERMIA TEM, V5, P73, DOI 10.1089/ther.2014.0031; Rakers C, 2017, GLIA, V65, P1550, DOI 10.1002/glia.23183; RITCHIE JM, 1957, J PHYSIOL-LONDON, V136, P80, DOI 10.1113/jphysiol.1957.sp005744; Rungta RL, 2015, CELL, V161, P610, DOI 10.1016/j.cell.2015.03.029; Ryskamp DA, 2014, J NEUROSCI, V34, P15689, DOI 10.1523/JNEUROSCI.2540-14.2014; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; SCHIFF SJ, 1985, BRAIN RES, V345, P279, DOI 10.1016/0006-8993(85)91004-2; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Shen J, 2019, J CEREBR BLOOD F MET, V39, P1501, DOI 10.1177/0271678X18769515; Shibasaki K, 2007, J NEUROSCI, V27, P1566, DOI 10.1523/JNEUROSCI.4284-06.2007; Shibasaki K, 2016, J ANESTH, V30, P1014, DOI 10.1007/s00540-016-2225-y; Shibasaki K, 2015, PFLUG ARCH EUR J PHY, V467, P2495, DOI 10.1007/s00424-015-1726-0; Shibasaki K, 2014, J BIOL CHEM, V289, P14470, DOI 10.1074/jbc.M114.557132; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Takayama Y, 2014, FASEB J, V28, P2238, DOI 10.1096/fj.13-243436; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; Tucker B, 2017, J EMERG MED, V53, P18, DOI 10.1016/j.jemermed.2017.02.010; Vardjan N, 2016, ADRENERGIC ACTIVATIO, P1034; Veenith TV, 2016, JAMA NEUROL, V73, P542, DOI 10.1001/jamaneurol.2016.0091; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; White JPM, 2016, PHYSIOL REV, V96, P911, DOI 10.1152/physrev.00016.2015	71	23	23	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 20	2018	38	25					5700	5709		10.1523/JNEUROSCI.2888-17.2018			10	Neurosciences	Neurosciences & Neurology	GK1NB	WOS:000435883500005	29793978	Green Published, Bronze			2021-06-18	
J	Meconi, A; Wortman, RC; Wright, DK; Neale, KJ; Clarkson, M; Shultz, SR; Christie, BR				Meconi, Alicia; Wortman, Ryan C.; Wright, David K.; Neale, Katie J.; Clarkson, Melissa; Shultz, Sandy R.; Christie, Brian R.			Repeated mild traumatic brain injury can cause acute neurologic impairment without overt structural damage in juvenile rats	PLOS ONE			English	Article							SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; CLOSED-HEAD-INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; HYPERPHOSPHORYLATED TAU; POSTCONCUSSION SYNDROME; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; OXIDATIVE STRESS	Repeated concussion is becoming increasingly recognized as a serious public health concern around the world. Moreover, there is a greater awareness amongst health professionals of the potential for repeated pediatric concussions to detrimentally alter the structure and function of the developing brain. To better study this issue, we developed an awake closed head injury (ACHI) model that enabled repeated concussions to be performed reliably and reproducibly in juvenile rats. A neurological assessment protocol (NAP) score was generated immediately after each ACHI to help quantify the cumulative effects of repeated injury on level of consciousness, and basic motor and reflexive capacity. Here we show that we can produce a repeated ACHI (4 impacts in two days) in both male and female juvenile rats without significant mortality or pain. We show that both single and repeated injuries produce acute neurological deficits resembling clinical concussion symptoms that can be quantified using the NAP score. Behavioural analyses indicate repeated ACHI acutely impaired spatial memory in the Barnes maze, and an interesting sex effect was revealed as memory impairment correlated moderately with poorer NAP score performance in a subset of females. These cognitive impairments occurred in the absence of motor impairments on the Rotarod, or emotional changes in the open field and elevated plus mazes. Cresyl violet histology and structural magnetic resonance imaging (MRI) indicated that repeated ACHI did not produce significant structural damage. MRI also confirmed there was no volumetric loss in the cortex, hippocampus, or corpus callosum of animals at 1 or 7 days post-ACHI. Together these data indicate that the ACHI model can provide a reliable, high throughput means to study the effects of concussions in juvenile rats.	[Meconi, Alicia; Wortman, Ryan C.; Neale, Katie J.; Clarkson, Melissa; Shultz, Sandy R.; Christie, Brian R.] Univ Victoria, Div Med Sci, Victoria, BC, Canada; [Wright, David K.; Shultz, Sandy R.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Wright, David K.; Shultz, Sandy R.] Monash Univ, Dept Neurosci, Melbourne, Vic, Australia; [Shultz, Sandy R.] Univ Melbourne, Dept Med, Parkville, Vic, Australia; [Christie, Brian R.] Univ British Columbia, Ctr Brain Hlth, Vancouver, BC, Canada; [Christie, Brian R.] Univ British Columbia, Program Neurosci, Vancouver, BC, Canada; [Christie, Brian R.] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC, Canada	Christie, BR (corresponding author), Univ Victoria, Div Med Sci, Victoria, BC, Canada.; Christie, BR (corresponding author), Univ British Columbia, Ctr Brain Hlth, Vancouver, BC, Canada.; Christie, BR (corresponding author), Univ British Columbia, Program Neurosci, Vancouver, BC, Canada.; Christie, BR (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC, Canada.	brain64@uvic.ca	Christie, Brian/AAF-3766-2019	Christie, Brian/0000-0002-6830-0160	NSERCNatural Sciences and Engineering Research Council of Canada (NSERC); CFICanada Foundation for Innovation; Australian NHMRCNational Health and Medical Research Council of Australia; CIHR/NSERC graduate fellowships	This development of this model was supported by funding from NSERC and CFI to BRC. MRI investigations by SS were supported by the Australian NHMRC. AM, RCW, and MC were supported by CIHR/NSERC graduate fellowships.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brocardo PS, 2012, NEUROPHARMACOLOGY, V62, P1607, DOI 10.1016/j.neuropharm.2011.10.006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clough M, 2018, J NEUROTRAUM, V35, P730, DOI 10.1089/neu.2017.5204; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davis GA, 2017, BRIT J SPORT MED, V51, P859, DOI 10.1136/bjsports-2017-097492; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Ding JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063850; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Erlanger DM, 2015, BRAIN INJURY, V29, P171, DOI 10.3109/02699052.2014.965211; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flower O, 2012, EMERG MED INT, V2012, DOI 10.1155/2012/637171; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Gilliland J, EPIDEMIOLOGIC PROFIL, DOI [10.1097/TA.0b013e3182aafdf5, DOI 10.1097/TA.0B013E3182AAFDF5]; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hawley DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030222; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Hsieh TH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178186; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; List J, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00228; Luo YW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11458-9; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2017, BRIT J SPORT MED, V47; McCrory P, 2017, BRIT J SPORT MED, V51, P877, DOI 10.1136/bjsports-2016-097393; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Ricciardi MC, 2017, J NEUROTRAUM, V34, P23, DOI 10.1089/neu.2015.4338; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenfeld CS, 2014, JOVE-J VIS EXP, DOI 10.3791/51194; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; TEASDALE G, 1974, LANCET, V2, P81; Tkachenko N, 2016, PEDIATR NEUROL, V57, P46, DOI 10.1016/j.pediatrneurol.2015.12.019; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; White ER, 2017, J NEUROTRAUM, V34, P1111, DOI 10.1089/neu.2016.4638; Wilde EA, 2015, BRAIN IMAGING BEHAV, V9, P367, DOI 10.1007/s11682-015-9444-y; Wright AD, 2017, BRIT J SPORT MED, V51, DOI [10.1136/bjsports-2016-097270.96, DOI 10.1136/BJSPORTS-2016-097270.96]; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Xiong KL, 2014, BRAIN IMAGING BEHAV, V8, P487, DOI 10.1007/s11682-013-9288-2; Xiong Y, 2013, ANIMAL MODELS TRAUMA, V18, P1199; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	92	23	23	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2018	13	5							e0197187	10.1371/journal.pone.0197187			24	Multidisciplinary Sciences	Science & Technology - Other Topics	GF1VY	WOS:000431724900053	29738554	DOAJ Gold, Green Published			2021-06-18	
J	Anuncibay-Soto, B; Perez-Rodriguez, D; Santos-Galdiano, M; Font-Belmonte, E; Ugidos, IF; Gonzalez-Rodriguez, P; Regueiro-Purrinos, M; Fernandez-Lopez, A				Anuncibay-Soto, Berta; Perez-Rodriguez, Diego; Santos-Galdiano, Maria; Font-Belmonte, Enrique; Ugidos, Irene F.; Gonzalez-Rodriguez, Paloma; Regueiro-Purrinos, Marta; Fernandez-Lopez, Arsenio			Salubrinal and robenacoxib treatment after global cerebral ischemia. Exploring the interactions between ER stress and inflammation	BIOCHEMICAL PHARMACOLOGY			English	Article						COX-2 inhibitor; Salubrinal; Blood-brain barrier; Microglia; Inflammation; ER stress	ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B; CYCLOOXYGENASE-2 INHIBITORS; BIDIRECTIONAL REGULATION; ALZHEIMERS-DISEASE; RODENT MODEL; CELL-DEATH	Background Blood reperfusion of the ischemic tissue after stroke promotes increases in the inflammatory response as well as accumulation of unfolded/misfolded proteins in the cell, leading to endoplasmic reticulum (ER) stress. Both Inflammation and ER stress are critical processes in the delayed death of the cells damaged after ischemia. The aim of this study is to check the putative synergic neuroprotective effect by combining anti-inflammatory and anti-ER stress agents after ischemia. Methods: The study was performed on a two-vessel occlusion global cerebral ischemia model. Animals were treated with salubrinal one hour after ischemia and with robenacoxib at 8 h and 32 h after ischemia. Parameters related to the integrity of the blood brain barrier (BBB), such as matrix metalloproteinase 9 and different cell adhesion molecules (CAMs), were analyzed by qPCR at 24 h and 48 h after ischemia. Microglia and cell components of the neurovascular unit, including neurons, endothelial cells and astrocytes, were analyzed by immunofluorescence after 48 h and seven days of reperfusion. Results: Pharmacologic control of ER stress by salubrinal treatment after ischemia, revealed a neuroprotective effect over neurons that reduces the transcription of molecules involved in the impairment of the BBB. Robenacoxib treatment stepped neuronal demise forward, revealing a detrimental effect of this anti-inflammatory agent. Combined treatment with robenacoxib and salubrinal after ischemia prevented neuronal loss and changes in components of the neurovascular unit and microglia observed when animals were treated only with robenacoxib. Conclusion Combined treatment with anti-ER stress and anti-inflammatory agents is able to provide enhanced neuroprotective effects reducing glial activation, which opens new avenues in therapies against stroke.	[Anuncibay-Soto, Berta; Perez-Rodriguez, Diego; Santos-Galdiano, Maria; Font-Belmonte, Enrique; Ugidos, Irene F.; Gonzalez-Rodriguez, Paloma; Fernandez-Lopez, Arsenio] Univ Leon, Inst Biomed, Dept Biol Celular, Leon, Spain; [Regueiro-Purrinos, Marta] Univ Leon, Dept Cirugia Med & Anat Vet, Leon, Spain	Fernandez-Lopez, A (corresponding author), Univ Leon, Area Biol Celular, Inst Biomed, Leon, Spain.	aferl@unileon.es	Fernandez-Lopez, Arsenio/E-1280-2011; Rodriguez, Paloma Gonzalez/AAO-4519-2020	Fernandez-Lopez, Arsenio/0000-0001-5557-2741; Rodriguez, Paloma Gonzalez/0000-0002-3962-6858; Perez Rodriguez, Diego/0000-0003-4903-3914; Santos Galdiano, Maria/0000-0002-9918-8319; Fernandez Ugidos, Irene/0000-0002-3727-0544	MINECO [BIO2013-49006-C2-2-R, RTC-2015-4094-1]; University of Leon [EDU/529/2017]; Junta de Castilla y LeonJunta de Castilla y Leon [EDU/529/2017, EDU/346/2013, EDU/310/2015]; Neural Therapies	This study was supported by MINECO (reference BIO2013-49006-C2-2-R and RTC-2015-4094-1), which also supports Berta Anuncibay-Soto and Maria Santos-Galdiano by fellowships. Enrique Font is supported by the University of Leon (EDU/529/2017). Diego Perez Rodriguez, Paloma Gonzalez-Rodriguez and Irene F Ugidos has a grant from Junta de Castilla y Leon (EDU/346/2013; EDU/310/2015; EDU/529/2017). We also thank Neural Therapies for additional financial support.	Abbott NJ, 2013, J INHERIT METAB DIS, V36, P437, DOI 10.1007/s10545-013-9608-0; Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Aid S, 2011, BIOCHIMIE, V93, P46, DOI 10.1016/j.biochi.2010.09.009; Anuncibay-Soto B, 2016, J NEUROCHEM, V138, P295, DOI 10.1111/jnc.13651; Anuncibay-Soto B, 2014, AGE, V36, DOI 10.1007/s11357-014-9703-7; Barreda-Manso MA, 2017, J CELL PHYSIOL, V232, P1501, DOI 10.1002/jcp.25655; Baron R, 2014, AGING CELL, V13, P584, DOI 10.1111/acel.12210; Berezowski V., 2012, INT J CELL BIOL, V2012, P1; Cai XH, 2014, EXP NEUROL, V257, P148, DOI 10.1016/j.expneurol.2014.04.029; Cairns JA, 2007, CAN J CARDIOL, V23, P125, DOI 10.1016/S0828-282X(07)70732-8; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Candelario-Jalil E, 2008, CURR PHARM DESIGN, V14, P1401, DOI 10.2174/138161208784480216; da Fonseca ACC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00362; Castro CC, 2014, NEUROL RES, V36, P198, DOI 10.1179/1743132813Y.0000000286; Choi SH, 2009, TRENDS PHARMACOL SCI, V30, P174, DOI 10.1016/j.tips.2009.01.002; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Feng L, 2017, ENVIRON SCI POLLUT R, V24, P11683, DOI 10.1007/s11356-017-8773-3; Fiebich BL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00260; FitzGerald GA, 2001, CLIN EXP RHEUMATOL, V19, pS31; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; Hasnain SZ, 2012, IMMUNOL CELL BIOL, V90, P260, DOI 10.1038/icb.2011.112; Huang YC, 2013, ACTA PHARMACOL SIN, V34, P6, DOI 10.1038/aps.2012.178; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; King JN, 2009, J VET PHARMACOL THER, V32, P1, DOI 10.1111/j.1365-2885.2008.00962.x; KIRINO T, 1985, PROG BRAIN RES, V63, P39; Kitamura M, 2009, ANTIOXID REDOX SIGN, V11, P2353, DOI [10.1089/ars.2008.2391, 10.1089/ARS.2008.2391]; KOUDSTAAL PJ, 1993, STROKE, V24, P219, DOI 10.1161/01.STR.24.2.219; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Llorente IL, 2015, NEUROSCIENCE, V292, P118, DOI 10.1016/j.neuroscience.2015.02.040; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23; De los Reyes LM, 2014, BIOMEDICA, V34, P366, DOI [10.7705/biomedica.v34i3.2191, 10.1590/S0120-41572014000300007]; Nakajima S, 2013, FREE RADICAL BIO MED, V65, P162, DOI 10.1016/j.freeradbiomed.2013.06.020; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Patrono C, 2016, BRIT J CLIN PHARMACO, V82, P957, DOI 10.1111/bcp.13048; Patrono C, 2016, CURR CARDIOL REP, V18, DOI 10.1007/s11886-016-0702-4; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Rom S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0729-x; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Roumie CL, 2008, STROKE, V39, P2037, DOI 10.1161/STROKEAHA.107.508549; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Schwab C, 2008, J ALZHEIMERS DIS, V13, P359; Szekely CA, 2010, CNS NEUROL DISORD-DR, V9, P132, DOI 10.2174/187152710791012026; Taylor S, 2010, METHODS, V50, pS1, DOI 10.1016/j.ymeth.2010.01.005; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; Ugidos IF, 2017, BBA-BIOMEMBRANES, V1859, P1648, DOI 10.1016/j.bbamem.2017.03.009; Vieira M, 2014, NEUROBIOL DIS, V68, P26, DOI 10.1016/j.nbd.2014.04.002; Walker FR, 2014, BRAIN BEHAV IMMUN, V37, P1, DOI 10.1016/j.bbi.2013.12.010; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xin Q, 2014, NEUROCHEM INT, V68, P18, DOI 10.1016/j.neuint.2014.02.001; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yilmaz G, 2010, NEUROMOL MED, V12, P193, DOI 10.1007/s12017-009-8074-1; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhu H, 2012, J NEUROCHEM, V120, P574, DOI 10.1111/j.1471-4159.2011.07550.x	62	23	23	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	MAY	2018	151						26	37		10.1016/j.bcp.2018.02.029			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GE3FO	WOS:000431099400004	29499167				2021-06-18	
J	Kho, AR; Choi, BY; Lee, SH; Hong, DK; Lee, SH; Jeong, JH; Park, KH; Song, HK; Choi, HC; Suh, SW				Kho, A. Ra; Choi, Bo Young; Lee, Song Hee; Hong, Dae Ki; Lee, Sang Hwon; Jeong, Jeong Hyun; Park, Kyoung-Ha; Song, Hong Ki; Choi, Hui Chul; Suh, Sang Won			Effects of Protocatechuic Acid (PCA) on Global Cerebral Ischemia-Induced Hippocampal Neuronal Death	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						global ischemia; neuron death; protocatechuic acid; oxidative stress; blood-brain barrier; microglial activation	TRAUMATIC BRAIN-INJURY; ADHESIVE REMOVAL TEST; IN-VIVO; ARTERY OCCLUSION; PHENOLIC-COMPOUNDS; BARRIER BREAKDOWN; INDUCED NEUROTOXICITY; RADICAL PRODUCTION; OXIDATIVE STRESS; NADPH OXIDASE	Global cerebral ischemia (GCI) is one of the main causes of hippocampal neuronal death. Ischemic damage can be rescued by early blood reperfusion. However, under some circumstances reperfusion itself can trigger a cell death process that is initiated by the reintroduction of blood, followed by the production of superoxide, a blood-brain barrier (BBB) disruption and microglial activation. Protocatechuic acid (PCA) is a major metabolite of the antioxidant polyphenols, which have been discovered in green tea. PCA has been shown to have antioxidant effects on healthy cells and anti-proliferative effects on tumor cells. To test whether PCA can prevent ischemia-induced hippocampal neuronal death, rats were injected with PCA (30 mg/kg/day) per oral (p.o) for one week after global ischemia. To evaluate degenerating neurons, oxidative stress, microglial activation and BBB disruption, we performed Fluoro-Jade B (FJB), 4-hydroxynonenal (4HNE), CD11b, GFAP and IgG staining. In the present study, we found that PCA significantly decreased degenerating neuronal cell death, oxidative stress, microglial activation, astrocyte activation and BBB disruption compared with the vehicle-treated group after ischemia. In addition, an ischemia-induced reduction in glutathione (GSH) concentration in hippocampal neurons was recovered by PCA administration. Therefore, the administration of PCA may be further investigated as a promising tool for decreasing hippocampal neuronal death after global cerebral ischemia.	[Kho, A. Ra; Choi, Bo Young; Lee, Song Hee; Hong, Dae Ki; Lee, Sang Hwon; Suh, Sang Won] Hallym Univ, Dept Physiol, Coll Med, Chunchon 24252, South Korea; [Jeong, Jeong Hyun] Hallym Univ, Dept Med Sci, Coll Med, Chunchon 24252, South Korea; [Park, Kyoung-Ha] Hallym Univ, Med Ctr, Div Cardiovasc Dis, Anyang 14068, South Korea; [Song, Hong Ki; Choi, Hui Chul] Hallym Univ, Coll Med, Neurol, Chunchon 24252, South Korea	Suh, SW (corresponding author), Hallym Univ, Dept Physiol, Coll Med, Chunchon 24252, South Korea.	rnlduadkfk136@hallym.ac.kr; bychoi@hallym.ac.kr; sshlee@hallym.ac.kr; zxnm01220@gmail.com; bluesea3616@naver.com; jd1422@hanmail.net; pkhmd@naver.com; hksong0@hanmail.net; dohchi@naver.com; swsuh@hallym.ac.kr		Choi, Bo Young/0000-0002-9579-3503; Hong, Dae-Ki/0000-0003-3769-3456	Brain Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2017R1D1A3B03028830, NRF-2017M3C7A1028937]; Hallym University Research Fund [HRF-201801-014]	This work was support by Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2017R1D1A3B03028830) to K.H.P. and (NRF-2017M3C7A1028937) to S.W.S. This study was also supported by Hallym University Research Fund (HRF-201801-014).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Adefegha SA, 2016, BIOMED PHARMACOTHER, V83, P559, DOI 10.1016/j.biopha.2016.07.017; Adefegha SA, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1408-6; Ali SM, 1996, MOL BRAIN RES, V38, P37, DOI 10.1016/0169-328X(95)00301-8; An LJ, 2006, FOOD CHEM TOXICOL, V44, P436, DOI 10.1016/j.fct.2005.08.017; Aoyama K, 2012, INT J MOL SCI, V13, P12017, DOI 10.3390/ijms130912017; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; AUER RN, 1984, DIABETES, V33, P1090, DOI 10.2337/diabetes.33.11.1090; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; Bouet V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Britschgi M, 2007, INT REV NEUROBIOL, V82, P205, DOI 10.1016/S0074-7742(07)82011-3; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Choi BY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102070; Cueva C, 2012, LETT APPL MICROBIOL, V54, P557, DOI 10.1111/j.1472-765X.2012.03248.x; Dalkara T, 2011, ACTA NEUROPATHOL, V122, P1, DOI 10.1007/s00401-011-0847-6; Das Kusal K., 2001, Journal of Basic and Clinical Physiology and Pharmacology, V12, P187; DIRNAGL U, 1995, J CEREBR BLOOD F MET, V15, P929, DOI 10.1038/jcbfm.1995.118; Dvoriantchikova G, 2009, EUR J NEUROSCI, V30, P175, DOI 10.1111/j.1460-9568.2009.06814.x; Foster M, 2010, ANTIOXID REDOX SIGN, V13, P1549, DOI 10.1089/ars.2010.3111; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; Freret T, 2006, BEHAV NEUROSCI, V120, P1285, DOI 10.1037/0735-7044.120.6.1285; Freret T, 2009, BEHAV NEUROSCI, V123, P224, DOI 10.1037/a0014157; Guan S, 2009, TOXICOL IN VITRO, V23, P201, DOI 10.1016/j.tiv.2008.11.008; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hua Jin-shuang, 2008, J Tradit Chin Med, V28, P289; Kakkar Sahil, 2014, ISRN Pharmacol, V2014, P952943, DOI 10.1155/2014/952943; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kazlowska K, 2010, J ETHNOPHARMACOL, V128, P123, DOI 10.1016/j.jep.2009.12.037; Khan AK, 2015, ACTA POL PHARM, V72, P643; Kho AR, 2017, AMINO ACIDS, V49, P367, DOI 10.1007/s00726-016-2370-5; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee SH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122510; Lee SH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010187; Liu CL, 2002, FOOD CHEM TOXICOL, V40, P635, DOI 10.1016/S0278-6915(02)00002-9; Liu WL, 2016, LIFE SCI, V151, P313, DOI 10.1016/j.lfs.2016.01.045; Liu WH, 2010, J AGR FOOD CHEM, V58, P10247, DOI 10.1021/jf102379n; Miyamoto N, 2014, NEUROSCI LETT, V573, P40, DOI 10.1016/j.neulet.2014.05.005; Muley MM, 2013, LIFE SCI, V93, P51, DOI 10.1016/j.lfs.2013.05.020; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; Neumann JT, 2013, CURR DRUG TARGETS, V14, P20; Ohana E, 2009, J BIOL CHEM, V284, P17677, DOI 10.1074/jbc.M109.007203; RUTH RE, 1988, ACTA NEUROPATHOL, V76, P380, DOI 10.1007/BF00686975; Safonova O. A., 2016, Eksperimental'naya i Klinicheskaya Farmakologiya, V79, P23; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shi GF, 2006, NEUROSCI LETT, V403, P206, DOI 10.1016/j.neulet.2006.02.057; Sifat AE, 2017, AAPS J, V19, P957, DOI 10.1208/s12248-017-0091-7; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; Ste-Marie L, 2000, CAN J NEUROL SCI, V27, P152; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511; Sun N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.299; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Wan L, 2015, J ETHNOPHARMACOL, V165, P118, DOI 10.1016/j.jep.2015.02.027; Woodruff TM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-11; Yamasaki S, 2007, J CELL BIOL, V177, P637, DOI 10.1083/jcb.200702081; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Yuksel M, 2017, ULUS TRAVMA ACIL CER, V23, P1, DOI 10.5505/tjtes.2016.20165; Zhang HN, 2010, NEUROSCI LETT, V474, P99, DOI 10.1016/j.neulet.2010.03.016; Zhang L, 2000, J NEUROL SCI, V174, P141, DOI 10.1016/S0022-510X(00)00268-9; Zhang YJ, 2011, J ETHNOPHARMACOL, V136, P129, DOI 10.1016/j.jep.2011.04.023; Zhang ZJ, 2015, FREE RADICAL BIO MED, V84, P331, DOI 10.1016/j.freeradbiomed.2015.02.030	69	23	23	0	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	MAY	2018	19	5							1420	10.3390/ijms19051420			19	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	GJ4BO	WOS:000435297000156	29747437	DOAJ Gold, Green Published			2021-06-18	
J	Moran, RN; Covassin, T; Elbin, RJ; Gould, D; Nogle, S				Moran, Ryan N.; Covassin, Tracey; Elbin, R. J.; Gould, Dan; Nogle, Sally			Reliability and Normative Reference Values for the Vestibular/Ocular Motor Screening (VOMS) Tool in Youth Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; baseline testing; vestibular; ocular motor; athletes	CONCUSSION; OCULOMOTOR; PLAYERS; SPORTS	Background: The Vestibular/Ocular Motor Screening (VOMS) measure is a newly developed vestibular and ocular motor symptom provocation screening tool for sport-related concussions. Baseline data, psychometric properties, and reliability of the VOMS are needed to further understand the applications of this tool, especially in the youth population, where research is scarce. Purpose: To establish normative data and document the internal consistency and false-positive rate of the VOMS in a sample of nonconcussed youth athletes. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A total of 423 youth athletes (male = 278, female = 145) between the ages of 8 and 14 years completed baseline VOMS screening before the start of their respective sport seasons. Internal consistency was measured with Cronbach alpha and inter-item correlations. Results: Approximately 60% of youth athletes reported no symptom provocation on baseline VOMS assessment, with 9% to 13% scoring over the cutoff levels (score of >= 2 for any individual VOMS symptom, near point convergence distance of >= 5 cm). The VOMS displayed a high internal consistency (Cronbach alpha = .97) at baseline among youth athletes. Conclusion: The current findings provide preliminary support for the implementation of VOMS baseline assessment into clinical practice, due to a high internal consistency, strong relationships between VOMS items, and a low false-positive rate at baseline in youth athletes.	[Moran, Ryan N.; Covassin, Tracey; Elbin, R. J.; Gould, Dan; Nogle, Sally] Michigan State Univ, E Lansing, MI 48824 USA; [Moran, Ryan N.] Univ Alabama, Dept Hlth Sci, Athlet Training Res Lab, 478 Russell Hall,Box 870311, Tuscaloosa, AL 35487 USA; [Covassin, Tracey; Nogle, Sally] Michigan State Univ, Dept Kinesiol, Sports Injury Res Lab, E Lansing, MI 48824 USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Fayetteville, AR 72701 USA; [Gould, Dan] Michigan State Univ, Inst Study Youth Sports, E Lansing, MI 48824 USA	Moran, RN (corresponding author), Univ Alabama, Dept Hlth Sci, Athlet Training Res Lab, 478 Russell Hall,Box 870311, Tuscaloosa, AL 35487 USA.	rnmoran@ches.ua.edu			Michigan State University College of Education; Michigan State University Graduate School	This study was funded by the Michigan State University College of Education and Graduate School dissertation award. The funding was used for participant reimbursement for participation.	Broglio S, 2004, J ATHL TRAINING, V49, P245; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; Ciuffreda KJ, 2011, OPTOMETRY, V82, P61, DOI 10.1016/j.optm.2010.11.011; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Li C, 2006, J PEDIAT, V171, P240; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Moore D. S, 2013, BASIC PRACTICE STAT, V6th; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; O'Reilly RC, 2010, OTOL NEUROTOL, V31, P1441, DOI 10.1097/MAO.0b013e3181f20673; Riina N, 2005, ARCH OTOLARYNGOL, V131, P996, DOI 10.1001/archotol.131.11.996; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Seidman DH, 2015, J NEUROL SCI, V356, P97, DOI 10.1016/j.jns.2015.06.021; Vernau BT, 2015, DEV NEUROPSYCHOL, V40, P7, DOI 10.1080/87565641.2014.971955; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906	22	23	23	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2018	46	6					1475	1480		10.1177/0363546518756979			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	GF7IB	WOS:000432140700025	29513549				2021-06-18	
J	Howell, DR; Stillman, A; Buckley, TA; Berkstresser, B; Wang, F; Meehan, WP				Howell, David R.; Stillman, Alexandra; Buckley, Thomas A.; Berkstresser, Brant; Wang, Francis; Meehan, William P., III			The utility of instrumented dual-task gait and tablet-based neurocognitive measurements after concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Postural control; Locomotion; Neurocognitive test; Mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; SPORT CONCUSSION; SINGLE-TASK; HIGH-SCHOOL; MANAGEMENT; ATTENTION; RECOVERY; METAANALYSIS; ADOLESCENTS	Objectives: Quantitative and non-invasive measurements acquired by neurocognitive or gait evaluations are useful concussion management components. Emerging technology has allowed for the development of portable and objective tests which may be potentially useful across many settings where evaluations take place. Our aim was to examine the association between instrumented dual-task gait and tablet-based neurocognitive outcome variables with an acute concussion. Design: A total of 59 collegiate athletes were identified and tested within 5 days of concussion (n = 18, 50% female, 20 +/- 1 years of age) or as a part of a baseline examination (n = 41, 29% female, 19 +/- 1 years of age). Methods: Participants completed an instrumented dual-task gait evaluation and a tablet-based neurocognitive evaluation. Outcome variables were compared with t-tests, and a multivariable logistic regression model was constructed to identify the association between the presence of a concussion and test performance. Results: Compared with controls, participants with concussion reported significantly more severe symptoms (PCSS = 19.1 +/- 15.2 vs. 4.1 +/- 6.3; p < 0.001), walked significantly slower during dual-task conditions (87.7 +/- 10.4 cm/s vs. 98.1 +/- 15.4 cm/s; p = 0.01), and responded with significantly slower simple reaction times (305.2 +/- 32.4 ms vs. 275.4 +/- 22.1 ms; p < 0.001). After adjusting for the effect of potential confounding variables, these three variables (more severe symptoms, slower walking speed, and slower reaction time) remained independently associated with concussion (adjusted odds ratios = 1.181, 0.916, and 1.043, respectively). Conclusions: Relatively simple quantitative measurements of dual-task gait and reaction time may be useful and portable clinical tests in the multifaceted assessment of concussion. (C) 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Howell, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Howell, David R.; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Stillman, Alexandra] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Berkstresser, Brant; Wang, Francis] Harvard Univ, Hlth Serv, Cambridge, MA 02138 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat & Orthoped Surg, Boston, MA USA	Howell, DR (corresponding author), Univ Colorado, Sch Med, Childrens Hosp Colorado, Sports Med Ctr, 13123 E 16th Ave,8060, Aurora, CO 80045 USA.; Howell, DR (corresponding author), Univ Colorado, Sch Med, Dept Orthoped, 13123 E 16th Ave,8060, Aurora, CO 80045 USA.	David.Howell2@childrens.harvard.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Howell, David/0000-0002-2955-0191			Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Borges A, 2017, INT J SPORTS PHYS TH, V12, P381; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.0.CO;2-K; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2011, PM&R, V3, pS445, DOI 10.1016/j.pmrj.2011.08.009; Hocking DR, 2014, RES DEV DISABIL, V35, P203, DOI 10.1016/j.ridd.2013.10.005; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2017, J SCI MED SPORT, V20, P622, DOI 10.1016/j.jsams.2016.11.020; Howell DR, 2017, GAIT POSTURE, V54, P284, DOI 10.1016/j.gaitpost.2017.03.034; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Langner R, 2013, PSYCHOL BULL, V139, P870, DOI 10.1037/a0030694; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Sawyer Q, 2016, J ATHL TRAINING, V51, P739, DOI 10.4085/1062-6050-51.12.01; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Woods DL, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00595; Yasen AL, 2017, MED SCI SPORT EXER, V49, P1066, DOI 10.1249/MSS.0000000000001217; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720	31	23	23	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	APR	2018	21	4					358	362		10.1016/j.jsams.2017.08.004			5	Sport Sciences	Sport Sciences	GB5DL	WOS:000429082500007	28919121				2021-06-18	
J	Hood, KN; Zhao, J; Redell, JB; Hylin, MJ; Harris, B; Perez, A; Moore, AN; Dash, PK				Hood, Kimberly N.; Zhao, Jing; Redell, John B.; Hylin, Michael J.; Harris, Brynn; Perez, Alec; Moore, Anthony N.; Dash, Pramod K.			Endoplasmic Reticulum Stress Contributes to the Loss of Newborn Hippocampal Neurons after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						context fear discrimination; dendritic shortening; loss of hippocampal newborn neurons; memory impairment; traumatic brain injury	UNFOLDED PROTEIN RESPONSE; DENTATE GYRUS; PATTERN SEPARATION; ADULT NEUROGENESIS; GENE-EXPRESSION; CYTOCHROME-C; ER STRESS; CELL LOSS; DEATH; MEMORY	Adult hippocampal neurogenesis has been shown to be required for certain types of cognitive function. For example, studies have shown that these neurons are critical for pattern separation, the ability to store similar experiences as distinct memories. Although traumatic brain injury (TBI) has been shown to cause the loss of newborn hippocampal neurons, the signaling pathway(s) that triggers their death is unknown. Endoplasmic reticulum (ER) stress activates the PERK-eIF2 alpha pathway that acts to restore ER function and improve cell survival. However, unresolved/intense ER stress activates C/EBP homologous protein (CHOP), leading to cell death. We show that TBI causes the death of hippocampal newborn neurons via CHOP. Using CHOP KO mice, we show that loss of CHOP markedly reduces newborn neuron loss after TBI. Injured CHOP mice performed significantly better in a context fear discrimination task compared with injured wild-type mice. In contrast, the PERK inhibitor GSK2606414 exacerbated doublecortin cell loss and worsened contextual discrimination. Administration of guanabenz (which reduces ER stress) to injured male rats reduced the loss of newborn neurons and improved one-trial contextual fear memory. Interestingly, we also found that the surviving newborn neurons in brain-injured animals had dendritic loss, which was not observed in injured CHOPKO mice or in animals treated with guanabenz. These results indicate that ER stress plays a key role in the death of newborn neurons after TBI. Further, these findings indicate that ER stress can alter dendritic arbors, suggesting a role for ER stress in neuroplasticity and dendritic pathologies.	[Hood, Kimberly N.; Zhao, Jing; Redell, John B.; Hylin, Michael J.; Harris, Brynn; Perez, Alec; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hylin, Michael J.] Southern Illinois Univ, Dept Psychol, Life Sci 2 6502, Carbondale, IL 62901 USA	Dash, PK (corresponding author), Univ Texas Houston, Med Sch, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019	Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS090935, NS088298, NS087149]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088298, R01NS087149, R01NS090935] Funding Source: NIH RePORTER	This work was supported by NIH Grants NS090935, NS088298 and NS087149 to P.K.D. We thank Jacilyn MacGowan for maintaining the animal colonies and genotyping, and Dr. Mark Maynard for critical reading of the paper.	Ambrogini P, 2004, BRAIN RES, V1017, P21, DOI 10.1016/j.brainres.2004.05.039; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Crespillo-Casado A, 2017, ELIFE, V6, DOI 10.7554/eLife.26109; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash PK, 2000, NEUROREPORT, V11, P2811, DOI 10.1097/00001756-200008210-00040; Dash PK, 2015, J NEUROTRAUM, V32, P1608, DOI 10.1089/neu.2014.3772; Denny CA, 2012, HIPPOCAMPUS, V22, P1188, DOI 10.1002/hipo.20964; Drew MR, 2010, BEHAV NEUROSCI, V124, P446, DOI 10.1037/a0020081; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI 10.1089/neu.2008-0744; Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189; HALL ED, 1993, RES P ARNMD, V71, P81; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hotamisligil GS, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a006072; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kheirbek MA, 2012, NAT NEUROSCI, V15, P1613, DOI 10.1038/nn.3262; Kheirbek MA, 2012, J NEUROSCI, V32, P8696, DOI 10.1523/JNEUROSCI.1692-12.2012; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Liu CL, 2012, J GERIATR CARDIOL, V9, P258, DOI 10.3724/SP.J.1263.2012.02292; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McClelland JL, 1996, HIPPOCAMPUS, V6, P654; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Niibori Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2261; Opendak M, 2015, TRENDS COGN SCI, V19, P151, DOI 10.1016/j.tics.2015.01.001; Osier N, 2016, METHODS MOL BIOL, V1462, P177, DOI 10.1007/978-1-4939-3816-2_11; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Plumpe T, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-77; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sun D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00095; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Van Der Vlies D, 2003, ANTIOXID REDOX SIGN, V5, P381, DOI 10.1089/152308603768295113; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wek RC, 2007, ANTIOXID REDOX SIGN, V9, P2357, DOI 10.1089/ars.2007.1764; Yassa MA, 2011, TRENDS NEUROSCI, V34, P515, DOI 10.1016/j.tins.2011.06.006; YU CCW, 1992, HISTOCHEM J, V24, P121, DOI 10.1007/BF01047461; Zhao YH, 2016, STEM CELLS, V34, P1263, DOI 10.1002/stem.2310; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	64	23	24	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 28	2018	38	9					2372	2384		10.1523/JNEUROSCI.1756-17.2018			13	Neurosciences	Neurosciences & Neurology	FX8PM	WOS:000426357200019	29386258	Green Published, Bronze			2021-06-18	
J	Parola, A; Berardinelli, L; Bosco, FM				Parola, Alberto; Berardinelli, Laura; Bosco, Francesca M.			Cognitive abilities and theory of mind in explaining communicative pragmatic disorders in patients with schizophrenia	PSYCHIATRY RESEARCH			English	Article						Pragmatics; Communication disorders; Executive functioning; Theory of mind; Mindreading; Schizophrenia	TRAUMATIC BRAIN-INJURY; IMPAIRMENT; COMPREHENSION; COMPLEXITY; CHILDREN; PEOPLE	Patients with schizophrenia usually show an impairment in their communicative-pragmatic performance; they also have difficulties in cognitive functioning and Theory of Mind (ToM). In the literature it has been proposed that ToM and cognitive deficits have a role in explaining the communicative-pragmatic difficulties of patients with schizophrenia. However, the exact interplay of these functions is still not completely clear. The present research investigates the relationship between communicative-pragmatic, ToM and cognitive impairments (i.e. general intelligence, selective attention, speed processing and EF-working memory, inhibition and flexibility-) in a sample of 26 individuals with schizophrenia and matched controls. The linguistic and extralinguistic scales of the Assessment Battery of Communication (ABaCo), and a series of ToM and cognitive tasks were administered to patients and healthy controls. The results showed that individuals with schizophrenia performed less well than controls in all the tasks investigated. However, a hierarchical regression analysis showed that only ToM, and not cognitive functions, seems to be a predictive variable of patients' performance. Finally, a Fisher's exact test showed that there was not a stable significant relationship between ToM or EF and pragmatic impairment.	[Parola, Alberto; Bosco, Francesca M.] Univ Turin, Dept Psychol, Ctr Cognit Sci, Turin, Italy; [Berardinelli, Laura] ASL Citta Torino, Dept Mental Hlth, Turin, Italy; [Bosco, Francesca M.] Inst Neurosci, Turin, Italy	Bosco, FM (corresponding author), Dipartimento Psicol, Via Po 14, I-10123 Turin, Italy.	Francesca.bosco@unito.it	Parola, alberto/AAK-3748-2020; bosco, francesca marina/B-6746-2013	bosco, francesca marina/0000-0001-6101-8587; PAROLA, ALBERTO/0000-0002-6039-0907	MIUR: Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN)Ministry of Education, Universities and Research (MIUR); Project 'The interpretative brain: Understanding and promoting pragmatic abilities across lifespan and in mental illness' [201577HA9M]; MIUR: Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN)Ministry of Education, Universities and Research (MIUR); Project 'The interpretative brain: Understanding and promoting pragmatic abilities across lifespan and in mental illness' [201577HA9M]	The research was funded by MIUR: Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN) 2017. Project 'The interpretative brain: Understanding and promoting pragmatic abilities across lifespan and in mental illness' project code 201577HA9M.	Abu-akel A., 2000, PSYCHOL MED, V303, P735; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andreasen N.C., 1985, CONTROVERSIES SCHIZO, P199; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; Arcara G, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00070; Bambini V, 2016, COMPR PSYCHIAT, V71, P106, DOI 10.1016/j.comppsych.2016.08.012; Bara BG., 2010, COGNITIVE PRAGMATICS; Bazin N, 2005, SCHIZOPHR RES, V77, P75, DOI 10.1016/j.schres.2005.01.020; Bloom P, 2000, COGNITION, V77, pB25, DOI 10.1016/S0010-0277(00)00096-2; Bosco F. M., 2016, FRONT PSYCHOL, V7, DOI DOI https://doi.org/10.3389/fpsyg.2016.00566; Bosco FM, 2017, CORTEX, V94, P73, DOI 10.1016/j.cortex.2017.06.010; Bosco FM, 2017, BRAIN LANG, V168, P73, DOI 10.1016/j.bandl.2017.01.007; Bosco FM, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00021; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2014, CONSCIOUS COGN, V24, P84, DOI 10.1016/j.concog.2014.01.003; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Bosco FM, 2009, CONSCIOUS COGN, V18, P306, DOI 10.1016/j.concog.2008.06.006; Bosia M., 2015, STUDI ITALIANI LINGU, VXLIV; Brizio A, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01011; Brune M, 2005, SCHIZOPHR RES, V75, P233, DOI 10.1016/j.schres.2004.11.006; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Champagne-Lavau Maud, 2009, Cogn Neuropsychiatry, V14, P217, DOI 10.1080/13546800903004114; Champagne-Lavau M, 2010, J NEUROLINGUIST, V23, P285, DOI 10.1016/j.jneuroling.2009.08.009; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Corcoran R, 1997, SCHIZOPHR RES, V24, P319, DOI 10.1016/S0920-9964(96)00117-X; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Corcoran Rhiannon, 2003, Cogn Neuropsychiatry, V8, P223, DOI 10.1080/13546800244000319; Cummings L., 2017, RES CLIN PRAGMATICS; Del-Monte J, 2013, PSYCHIAT RES, V210, P29, DOI 10.1016/j.psychres.2013.05.034; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Edwards J, 2002, CLIN PSYCHOL REV, V22, P789, DOI 10.1016/S0272-7358(02)00130-7; Eisenberg DP, 2010, NEUROPSYCHOPHARMACOL, V35, P258, DOI 10.1038/npp.2009.111; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frith C. D., 1988, SCHIZOPHRENIA MAJOR, P172; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Frith CD., 1992, COGN NEUROPSYCHOL; Frith R C, 1996, Cogn Neuropsychiatry, V1, P305, DOI 10.1080/135468096396460; Gabbatore I, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/1612078; Gavilan JM, 2011, J NEUROLINGUIST, V24, P54, DOI 10.1016/j.jneuroling.2010.07.006; Giora R, 2002, J PRAGMATICS, V34, P487, DOI 10.1016/S0378-2166(01)00045-5; Green MF, 2015, NAT REV NEUROSCI, V16, P620, DOI 10.1038/nrn4005; Haas MH, 2015, J PSYCHOLINGUIST RES, V44, P469, DOI 10.1007/s10936-014-9298-2; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Harrington Leigh, 2005, Cogn Neuropsychiatry, V10, P249, DOI 10.1080/13546800444000056; Honan CA, 2015, BRAIN LANG, V150, P69, DOI 10.1016/j.bandl.2015.08.007; Huber W., 1983, AACHENER APHASIE TES; Jang G, 2013, NEUROIMAGE, V81, P61, DOI 10.1016/j.neuroimage.2013.05.027; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Key-DeLyria SE, 2016, AM J SPEECH-LANG PAT, V25, DOI 10.1044/2015_AJSLP-14-0111; Kupper Z, 2010, SCHIZOPHR RES, V121, P90, DOI 10.1016/j.schres.2010.03.032; Langdon R, 2002, MIND LANG, V17, P68, DOI 10.1111/1468-0017.00189; Lavelle M, 2013, SCHIZOPHRENIA BULL, V39, P1150, DOI 10.1093/schbul/sbs091; Levinson S.C., 1983, PRAGMATICS; Linscott RJ, 2005, SCHIZOPHR RES, V75, P225, DOI 10.1016/j.schres.2004.10.007; Marini A, 2008, SCHIZOPHR RES, V105, P144, DOI 10.1016/j.schres.2008.07.011; Mazza M, 2001, SCHIZOPHR RES, V47, P299, DOI 10.1016/S0920-9964(00)00157-2; Mazza M, 2008, PSYCHOPATHOLOGY, V41, P254, DOI 10.1159/000128324; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; Meilijson SR, 2004, J SPEECH LANG HEAR R, V47, P695, DOI 10.1044/1092-4388(2004/053); Merrill AM, 2017, PSYCHIAT RES, V249, P172, DOI 10.1016/j.psychres.2016.12.051; Mittal VA, 2011, SCHIZOPHR RES, V130, P164, DOI 10.1016/j.schres.2011.05.007; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mo SL, 2008, PSYCHIAT RES, V157, P21, DOI 10.1016/j.psychres.2006.04.002; Moro A, 2015, NEUROPSYCHOLOGIA, V79, P147, DOI 10.1016/j.neuropsychologia.2015.10.030; Mossaheb N, 2014, COMPR PSYCHIAT, V55, P928, DOI 10.1016/j.comppsych.2013.12.021; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nichols S., 2003, MINDREADING; Parola A, 2016, J NEUROLINGUIST, V39, P10, DOI 10.1016/j.jneuroling.2015.12.003; PERNER J, 1989, CHILD DEV, V60, P689, DOI 10.1111/j.1467-8624.1989.tb02749.x; Pesciarelli F, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00799; Pickup GJ, 2008, PSYCHOPATHOLOGY, V41, P206, DOI 10.1159/000125554; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Rapp AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074224; Rapp AM, 2012, NEUROIMAGE, V63, P600, DOI 10.1016/j.neuroimage.2012.06.022; Raven JC, 1956, COLOURED PROGR MATRI; Reichenberg A, 2007, PSYCHOL BULL, V133, P833, DOI 10.1037/0033-2909.133.5.833; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sacco K, 2008, J COGN SCI, V9, P111; Sarfati Y, 1999, PSYCHOL MED, V29, P613, DOI 10.1017/S0033291799008326; Schettino A, 2010, NEUROPSYCHOLOGIA, V48, P1032, DOI 10.1016/j.neuropsychologia.2009.11.030; Spinnler H., 1987, ITAL J NEUROL SCI, V6, P8; Sponheim SR, 2003, SCHIZOPHR RES, V65, P117, DOI 10.1016/S0920-9964(02)00525-X; Tan EJ, 2014, COMPR PSYCHIAT, V55, P693, DOI 10.1016/j.comppsych.2013.10.016; Tavano A, 2008, SCHIZOPHR RES, V102, P53, DOI 10.1016/j.schres.2008.02.008; Tenyi T, 2002, PSYCHOPATHOLOGY, V35, P25, DOI 10.1159/000056212; Thoma P, 2006, NEUROSCI BIOBEHAV R, V30, P1182, DOI 10.1016/j.neubiorev.2006.09.001; Thoma P, 2009, PSYCHIAT RES, V170, P132, DOI 10.1016/j.psychres.2009.01.026; Tirassa M, 2006, COGN SYST RES, V7, P128, DOI 10.1016/j.cogsys.2006.01.002; Varga E, 2014, J NEUROLINGUIST, V29, P1, DOI 10.1016/j.jneuroling.2014.01.001; Varga E, 2013, BRAIN LANG, V126, P231, DOI 10.1016/j.bandl.2013.05.017; Weickert TW, 2000, ARCH GEN PSYCHIAT, V57, P907, DOI 10.1001/archpsyc.57.9.907; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5	94	23	23	0	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	FEB	2018	260						144	151		10.1016/j.psychres.2017.11.051			8	Psychiatry	Psychiatry	FV8RU	WOS:000424855300022	29195166				2021-06-18	
J	Pervez, M; Kitagawa, RS; Chang, TR				Pervez, Mubashir; Kitagawa, Ryan S.; Chang, Tiffany R.			Definition of Traumatic Brain Injury, Neurosurgery, Trauma Orthopedics, Neuroimaging, Psychology, and Psychiatry in Mild Traumatic Brain Injury	NEUROIMAGING CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury (TBI); Neurotrauma; Concussion; Trauma orthopedics; Traumatic brain injury imaging; Postconcussion syndrome	CHRONIC SUBDURAL-HEMATOMA; HEAD-INJURY; INTRACRANIAL HYPERTENSION; DECOMPRESSIVE CRANIECTOMY; HYPERTONIC SALINE; CONTROLLED-TRIAL; SKULL FRACTURE; CONCUSSION; MANAGEMENT; RESUSCITATION	Traumatic brain injury (TBI) disrupts the normal function of the brain. This condition can adversely affect a person's quality of life with cognitive, behavioral, emotional, and physical symptoms that limit interpersonal, social, and occupational functioning. Although many systems exist, the simplest classification includes mild, moderate, and severe TBI depending on the nature of injury and the impact on the patient's clinical status. Patients with TBI require prompt evaluation and multidisciplinary management. Aside from the type and severity of the TBI, recovery is influenced by individual patient characteristics, social and environmental factors, and access to medical and rehabilitation services.	[Pervez, Mubashir] Univ Connecticut, Sch Med, Dept Neurol, Jefferson Bldg,Suite 607,80 Seymour St,POB 5037, Hartford, CT 06112 USA; [Kitagawa, Ryan S.; Chang, Tiffany R.] Mem Hermann Texas Med Ctr, Mischer Neurosci Inst, Vivian L Smith Dept Neurosurg, 6431 Fannin St MSB 7-154, Houston, TX 77030 USA	Pervez, M (corresponding author), Univ Connecticut, Sch Med, Dept Neurol, Jefferson Bldg,Suite 607,80 Seymour St,POB 5037, Hartford, CT 06112 USA.	mubashir.pervez@hhchealth.org					Adhiyaman V, 2002, POSTGRAD MED J, V78, P71, DOI 10.1136/pmj.78.916.71; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Almandoz JED, 2010, RADIOLOGY, V255, P570, DOI 10.1148/radiol.10091565; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRAAKMAN R, 1972, J NEUROL NEUROSUR PS, V35, P395, DOI 10.1136/jnnp.35.3.395; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Congress of Neurological Surgeon, 1966, CLIN NEUROSURG, V12, P386; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Coronado VG, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Davis DP, 2008, RESUSCITATION, V76, P333, DOI 10.1016/j.resuscitation.2007.08.004; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DURWARD QJ, 1983, J NEUROSURG, V59, P938, DOI 10.3171/jns.1983.59.6.0938; Esposito DP, 2009, NEUROSURG QUART, V19, P249, DOI 10.1097/WNQ.0b013e3181bd1d53; Fattahi TT, 2003, J CRANIOFAC SURG, V14, P240, DOI 10.1097/00001665-200303000-00020; Fox JL, 2010, CAN J EMERG MED, V12, P355; Frieden TR., TRAUMATIC BRAIN INJU, DOI [10.3171/2009.10.JNS091500, DOI 10.3171/2009.10.JNS091500]; Gennarelli TA, HEAD LESION; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Golfinos JG, 2000, HEAD INJURY, P155; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Irie F, 2011, J TRAUMA, V71, P847, DOI 10.1097/TA.0b013e3182032c9a; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; John R, 2014, ANAEST INTENS CARE M, V15, P161, DOI 10.1016/j.mpaic.2014.01.010; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Marr AL., 2004, CENTRAL NERVOUS SYST; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Martland HS, 1943, THER INT DIS, V3, P291; McCrory P, 2017, BR J SPORTS MED; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; MILLER JD, 1968, LANCET, V2, P991; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Oddo M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1294-5; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2; Rust T, 2006, J CLIN NEUROSCI, V13, P823, DOI 10.1016/j.jocn.2004.12.013; Shutter LA, 2016, NEW ENGL J MED, V375, P1183, DOI 10.1056/NEJMe1609722; Sim YW, 2012, J KOREAN NEUROSURG S, V52, P234, DOI 10.3340/jkns.2012.52.3.234; Staal JA, 2007, DEV NEUROBIOL, V67, P1831, DOI 10.1002/dneu.20552; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Takeuchi Satoru, 2013, Acta Neurochir Suppl, V118, P135, DOI 10.1007/978-3-7091-1434-6_24; Teale EA, 2014, BMJ-BRIT MED J, V348, pg1682; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; Tubbs RS, 2010, J NEUROSURG, V112, P186, DOI 10.3171/2008.8.JNS08241; Wasserman JR, KOENIGSBERG RA DIFFU, DOI [10.1007/3-540-27660-2_104, DOI 10.1007/3-540-27660-2_104]; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zhao X, 2008, J NEUROTRAUM, V25, P104, DOI 10.1089/neu.2007.0351	66	23	23	0	39	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1052-5149	1557-9867		NEUROIMAG CLIN N AM	Neuroimaging Clin. N. Am.	FEB	2018	28	1					1	+		10.1016/j.nic.2017.09.010			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FR3UA	WOS:000418990900003	29157846				2021-06-18	
J	Zhou, Y; Cai, W; Zhao, ZL; Hilton, T; Wang, M; Yeon, J; Liu, W; Zhang, FY; Shi, FD; Wu, XP; Thiagarajan, P; Li, M; Zhang, JN; Dong, JF				Zhou, Yuan; Cai, Wei; Zhao, Zilong; Hilton, Tristan; Wang, Min; Yeon, Jason; Liu, Wei; Zhang, Fangyi; Shi, Fu-Dong; Wu, Xiaoping; Thiagarajan, Perumal; Li, Min; Zhang, Jianning; Dong, Jing-fei			Lactadherin promotes microvesicle clearance to prevent coagulopathy and improves survival of severe TBI mice	BLOOD			English	Article							TRAUMATIC BRAIN-INJURY; APOPTOTIC CELLS; PROCOAGULANT ACTIVITY; HUMAN-MILK; PHOSPHATIDYLSERINE; SURFACE; PHAGOCYTOSIS; COAGULATION; EXPOSURE; PROTEIN	Coagulopathy is common in patients with traumatic brain injury (TBI) and predicts poor clinical outcomes. We have shown that brain-derived extracellular microvesicles, including extracellular mitochondria, play a key role in the development of TBI-induced coagulopathy. Here, we further show in mouse models that the apoptotic cell-scavenging factor lactadherin, given at a single dose of 400 mu g/kg 30 minutes before (preconditioning) or 30 minutes after cerebral fluid percussion injury, prevented coagulopathy as defined by clotting time, fibrinolysis, intravascular fibrin deposition, and microvascular bleeding of the lungs. Lactadherin also reduced cerebral edema, improved neurological function, and increased survival. It achieved these protective effects by enhancing the clearance of circulating microvesicles through phosphatidylserine-mediated phagocytosis. Together, these results identify the scavenging system for apoptotic cells as a potential therapeutic target to prevent TBI-induced coagulopathy and improve the outcome of TBI.	[Zhou, Yuan; Zhao, Zilong; Liu, Wei; Shi, Fu-Dong; Zhang, Jianning] Tianjin Inst Neurol, Tianjin, Peoples R China; [Zhou, Yuan; Zhao, Zilong; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin, Peoples R China; [Zhou, Yuan; Hilton, Tristan; Yeon, Jason; Liu, Wei; Wu, Xiaoping; Dong, Jing-fei] Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA; [Cai, Wei; Wang, Min; Li, Min] Lanzhou Univ, Inst Pathol, Sch Basic Med Sci, Lanzhou, Gansu, Peoples R China; [Zhang, Fangyi] Univ Washington, Sch Med, Dept Neurosurg, Seattle, WA USA; [Shi, Fu-Dong] Tianjin Med Univ, Dept Neurol, Gen Hosp, Tianjin, Peoples R China; [Shi, Fu-Dong] St Josephs Hosp, Barrow Neurol Inst, Dept Neurol, Phoenix, AZ USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Thiagarajan, Perumal] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX USA; [Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin, Peoples R China.; Dong, JF (corresponding author), Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.; Li, M (corresponding author), Lanzhou Univ, Inst Pathol, Sch Basic Med Sci, Lanzhou, Gansu, Peoples R China.	limin@lzu.edu.cn; jianningzhang@hotmail.com; jfdong@psbc.org	Zhao, Zilong/AAZ-2196-2020		National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS087296]; National Institutes of Health, National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL119391]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81271361, 81271359, 81672399]; Biomedical Laboratory Research and Development Award from the Department of Veterans Affairs [BX000502]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000502] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke grant NS087296 and National Institutes of Health, National Heart, Lung, and Blood Institute grant HL119391 (J.-f.D.); Natural Science Foundation of China State Key Program Grant 81330029 (J.Z.) and Research Grants 81271361, 81271359 (J.N.Z.),and 81672399 (M.L.); and the Biomedical Laboratory Research and Development Award BX000502 from the Department of Veterans Affairs (P.T.).	Andersen MH, 2000, BIOCHEMISTRY-US, V39, P6200, DOI 10.1021/bi992221r; Andersen MH, 1997, BIOCHEMISTRY-US, V36, P5441, DOI 10.1021/bi963119m; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Couto JR, 1996, DNA CELL BIOL, V15, P281, DOI 10.1089/dna.1996.15.281; Dasgupta SK, 2008, TRANSFUSION, V48, P2370, DOI 10.1111/j.1537-2995.2008.01841.x; Dasgupta SK, 2005, HAEMATOLOGICA, V90, P1267; Dasgupta SK, 2009, BLOOD, V113, P1332, DOI 10.1182/blood-2008-07-167148; DINI L, 1995, J CELL SCI, V108, P967; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; FOX JEB, 1991, J BIOL CHEM, V266, P13289; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; LAROCCA D, 1991, CANCER RES, V51, P4994; Maani CV, 2009, CURR OPIN ANESTHESIO, V22, P255, DOI 10.1097/ACO.0b013e32832922be; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; NAG S, 1984, ACTA NEUROPATHOL, V63, P276, DOI 10.1007/BF00687333; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Owens AP, 2011, CIRC RES, V108, P1284, DOI 10.1161/CIRCRESAHA.110.233056; SAHAGUN G, 1990, AM J PHYSIOL, V259, pH162; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; Shi JL, 2003, BLOOD, V101, P2628, DOI 10.1182/blood-2002-07-1951; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; SIMIONESCU N, 1981, J CELL BIOL, V90, P605, DOI 10.1083/jcb.90.3.605; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wu F, 2017, SHOCK, V48, P340, DOI 10.1097/SHK.0000000000000832; Zhao ZL, 2016, BLOOD, V127, P2763, DOI [10.1182/blood-2015-12688838, 10.1182/blood-2015-12-688838]; Zhu JJ, 2018, J CEREBR BLOOD F MET, V38, P1979, DOI 10.1177/0271678X17726062	37	23	26	1	9	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	FEB 1	2018	131	5					563	572		10.1182/blood-2017-08-801738			10	Hematology	Hematology	FV1QA	WOS:000424338300013	29162596	Green Published, Bronze			2021-06-18	
J	Bailey, KC; Soble, JR; O'Rourke, JJF				Bailey, K. Chase; Soble, Jason R.; O'Rourke, Justin J. F.			Clinical utility of the Rey 15-Item Test, recognition trial, and error scores for detecting noncredible neuropsychological performance in a mixed clinical sample of veterans	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance Validity Assessment; Rey 15-Item Test; Test of Memory Malingering (TOMM); veterans; psychometrics	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; MEMORY MALINGERING TOMM; SCREENING MEASURE; SPECIFICITY; SEVERITY; NAN	Objective: This cross-sectional study examined the Rey 15-Item Test (RFIT), Recognition Trial, and Error Scores for identifying noncredible performance in a mixed clinical veteran sample compared to another widely used validity measure, the Test of Memory Malingering (TOMM). Method: Sixty-two veterans who completed the RFIT (Recall/Recognition Trials), TOMM, and Word Memory Test (WMT) during clinical evaluation were included. Using the WMT as the criterion, 71% (N = 44) were classified as valid and 29% (N = 18) as invalid. Results: Among valid participants, 25% failed the RFIT Recall, whereas 78% of invalid participants passed (sensitivity: 22%; specificity: 75%; diagnostic odds ratio [DOR]: .86). The Recognition Trial increased sensitivity to 39% for identifying invalid performance, but 25% of valid participants still scored below cut-off (specificity: 75%; DOR: 1.91). RFIT Recall and Recognition Trial logistic regression and receiver operating characteristic (ROC) analyses were nonsignificant, with respective classification accuracies of 71 and 72.6% and areas under the curve (AUCs) of .52 and .55. RFIT Error Scores also failed to differentiate validity groups. In contrast, TOMM had stronger psychometric properties (sensitivity: 50%; specificity: 97.7%; DOR: 43; classification accuracy: 82.3%; AUC: .91). Moreover, RFIT Recall and Recognition failure rates were 14 and 22% greater, respectively, among those with cognitive impairment, whereas 95% of those with impairment and 100% without passed the TOMM. Conclusion: Despite frequent use among VA neuropsychologists, the RFIT displayed limited ability to detect noncredible performance and misclassified a large percentage of valid participants in this mixed clinical veteran sample, suggesting limited utility with this population.	[Bailey, K. Chase; Soble, Jason R.; O'Rourke, Justin J. F.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA; [O'Rourke, Justin J. F.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA	Bailey, KC (corresponding author), South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA.	Kenneth.Bailey2@va.gov		Bailey, Kenneth/0000-0002-5389-5229			American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Benedict R., 1997, BRIEF VISUOSPATIAL M; Boone K. B., 2002, DOT COUNTING TEST MA; Boone K. B., 2007, ASSESSMENT FEIGNED C, P29; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Brewin B., 2012, NATL J; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Dandachi-FitzGerald B, 2016, PSYCHIAT RES, V239, P47, DOI 10.1016/j.psychres.2016.02.061; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Flaherty JM, 2015, BRAIN INJURY, V29, P1630, DOI 10.3109/02699052.2015.1075249; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Griffin GAE, 1996, PSYCHOL ASSESSMENT, V8, P383; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hill BD, 2013, ARCH CLIN NEUROPSYCH, V28, P640, DOI 10.1093/arclin/act045; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Love CM, 2014, ASSESSMENT, V21, P618, DOI 10.1177/1073191114528028; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; National Center for Veterans Analysis and Statistics, 2015, US VET EL TRENDS STA; Nitch S. R., 2007, ASSESSMENT FEIGNED C, P29; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Pearson, 2009, ADV CLIN SOL WAIS 4; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rey A, 1964, EXAMEN CLIN PSYCHOL; Russo AC, 2012, ARCH CLIN NEUROPSYCH, V27, P840, DOI 10.1093/arclin/acs090; Sawyer RJ, 2017, CLIN NEUROPSYCHOL, V31, P207, DOI 10.1080/13854046.2016.1245787; Shamieh E., 1996, THESIS; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Soble JR, 2016, ARCH CLIN NEUROPSYCH, V31, P79, DOI 10.1093/arclin/acv084; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Spiegel E., 2007, THESIS; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wolfson D., 1993, HALSTEAD REITAN NEUR; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730	43	23	23	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2018	32	1					119	131		10.1080/13854046.2017.1333151			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	GD3XB	WOS:000430436000010	28555516				2021-06-18	
J	Caccese, JB; Buckley, TA; Tierney, RT; Rose, WC; Glutting, JJ; Kaminski, TW				Caccese, Jaclyn B.; Buckley, Thomas A.; Tierney, Ryan T.; Rose, William C.; Glutting, Joseph J.; Kaminski, Thomas W.			Sex and age differences in head acceleration during purposeful soccer heading	RESEARCH IN SPORTS MEDICINE			English	Article						Concussion; mild traumatic brain injury; head acceleration; pediatrics	YOUTH SOCCER; IMPACT; PLAYERS; EXPOSURE; INJURIES	Differences in head-neck segment mass, purposeful heading technique, and cervical strength and stiffness may contribute to differences in head accelerations across sex and age. The purpose of this study was to compare head acceleration across sex and age (youth [12-14 years old], high school and collegiate) during purposeful soccer heading. One-hundred soccer players (42 male, 58 female, 17.1 +/- 3.5 years, 168.5 +/- 20.3 cm, 61.5 +/- 13.7 kg) completed 12 controlled soccer headers at an initial ball velocity of 11.2 m/s. Linear and rotational accelerations were measured using a triaxial accelerometer and gyroscope and were transformed to the head centre-of-mass. A MANOVA revealed a significant multi-variate main effect for sex (Pillai's Trace = .165, F(2,91) = 11.868, p < .001), but not for age (Pillai's Trace = .033, F(4,182) = 0.646, p = .630). Peak linear and rotational accelerations were higher in females (40.9 +/- 13.3 g; 3279 +/- 1065 rad/s(2)) than males (27.6 +/- 8.5 g, 2219 +/- 823 rad/s(2)). These data suggest that under controlled soccer heading conditions, females may be exposed to higher head accelerations than males.	[Caccese, Jaclyn B.; Buckley, Thomas A.; Rose, William C.; Kaminski, Thomas W.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Caccese, Jaclyn B.; Buckley, Thomas A.; Rose, William C.; Kaminski, Thomas W.] Univ Delaware, Biomech & Movement Sci Interdisciplinary Program, Newark, DE 19716 USA; [Tierney, Ryan T.] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Glutting, Joseph J.] Univ Delaware, Sch Educ, Newark, DE USA	Caccese, JB (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA.; Caccese, JB (corresponding author), Univ Delaware, Biomech & Movement Sci Interdisciplinary Program, Newark, DE 19716 USA.	jcaccese@udel.edu	Buckley, Thomas A/B-7525-2016; Caccese, Jaclyn B./AAH-4571-2020	Buckley, Thomas A/0000-0002-0515-0150; Caccese, Jaclyn B./0000-0003-2329-3603	Brain Injury Association of Delaware under the Pediatric Track Concussion Advocacy Grant	This work was supported by the Brain Injury Association of Delaware under the Pediatric Track Concussion Advocacy Grant	Babbs C F, 2001, ScientificWorldJournal, V1, P281; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Bretzin A. C., 2016, SPORTS HEALTH, V9, P168; Caccese JB, 2016, INTERNATIONAL RESEARCH IN SCIENCE AND SOCCER II, P133; Caccese JB, 2016, RES SPORTS MED, V24, P407, DOI 10.1080/15438627.2016.1230549; Caccese JB, 2016, SPORTS MED, V46, P1591, DOI 10.1007/s40279-016-0544-7; Catenaccio E, 2016, RES SPORTS MED, V24, P416, DOI 10.1080/15438627.2016.1234472; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Federation Internationale de Football Association (FIFA), 2007, FIFA BIG COUNT 2006, V31, P3; Ford PR, 2012, J SPORT SCI, V30, P1653, DOI 10.1080/02640414.2012.701762; Funk J, 2009, 2009010251 SAE, DOI [10.4271/2009-01-0251, DOI 10.4271/2009-01-0251]; Grinberg LT, 2016, J ALZHEIMERS DIS, V54, P169, DOI 10.3233/JAD-160312; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Higgins MJ, 2009, P I MECH ENG P-J SPO, V223, P117, DOI 10.1243/17543371JSET15; Irick E., 2015, NCAA SPORTS SPONSORS; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lynall RC, 2016, MED SCI SPORT EXER, V48, P1772, DOI 10.1249/MSS.0000000000000951; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Reynolds BB, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117701708; Seacrist T, 2012, J BIOMECH, V45, P99, DOI 10.1016/j.jbiomech.2011.09.016; Tarnutzer A. A., 2016, BRIT J SPORTS MED; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Yang YT, 2016, JAMA PEDIATR, V170, P413, DOI 10.1001/jamapediatrics.2016.0338; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029	31	23	23	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1543-8627	1543-8635		RES SPORTS MED	Res. Sports Med.		2018	26	1					64	74		10.1080/15438627.2017.1393756			11	Sport Sciences	Sport Sciences	GA8NC	WOS:000428596000006	29067816				2021-06-18	
J	Fernandes, FAO; Tchepel, D; de Sousa, RJA; Ptak, M				Fernandes, Fabio A. O.; Tchepel, Dmitri; Alves de Sousa, Ricardo J.; Ptak, Mariusz			Development and validation of a new finite element human head model: Yet another head model (YEAHM)	ENGINEERING COMPUTATIONS			English	Article						Finite element analysis; Biomechanics; Brain modelling; Finite element head model; Head trauma	TRAUMATIC BRAIN-INJURY; MECHANICAL-PROPERTIES; IN-VIVO; TISSUE; STRAIN; DEFORMATION; COMPRESSION; PREDICTORS; BEHAVIOR; DESIGN	Purpose Currently, there are some finite element head models developed by research groups all around the world. Nevertheless, the majority are not geometrically accurate. One of the problems is the brain geometry, which usually resembles a sphere. This may raise problems when reconstructing any event that involves brain kinematics, such as accidents, affecting the correct evaluation of resulting injuries. Thus, the purpose of this study is to develop a new finite element head model more accurate than the existing ones. Design/methodology/approach In this work, a new and geometrically detailed finite element brain model is proposed. Special attention was given to sulci and gyri modelling, making this model more geometrically accurate than currently available ones. In addition, these brain features are important to predict specific injuries such as brain contusions, which usually involve the crowns of gyri. Findings The model was validated against experimental data from impact tests on cadavers, comparing the intracranial pressure at frontal, parietal, occipital and posterior fossa regions. Originality/value As this model is validated, it can be now used in accident reconstruction and injury evaluation and even as a design tool for protective head gear.	[Fernandes, Fabio A. O.; Tchepel, Dmitri; Alves de Sousa, Ricardo J.] Univ Aveiro, Dept Mech Engn, Ctr Mech Technol & Automat, TEMA, Aveiro, Portugal; [Ptak, Mariusz] Wroclaw Univ Technol, Dept Mech Engn, Wroclaw, Poland	Fernandes, FAO (corresponding author), Univ Aveiro, Dept Mech Engn, Ctr Mech Technol & Automat, TEMA, Aveiro, Portugal.	fabiofernandes@ua.pt; dmitritchepel@ua.pt; rsousa@ua.pt; mariusz.ptak@pwr.edu.pl	Ptak, Mariusz/B-1493-2013; Fernandes, Fabio A.O./H-2680-2012; de Sousa, Ricardo Alves/E-4405-2010	Ptak, Mariusz/0000-0001-8081-8336; Fernandes, Fabio A.O./0000-0001-9751-8807; de Sousa, Ricardo Alves/0000-0002-5848-6424	Portuguese Foundation for Science and Technology (FCT)Portuguese Foundation for Science and Technology [SFRH/BD/91292/2012]	The authors are grateful to the Portuguese Foundation for Science and Technology (FCT), which financially supported this work, through the scholarship SFRH/BD/91292/2012. The authors also acknowledge Dr Alfredo Calheiros from the Hospital Geral de Santo Antonio, Porto, for providing the medical images and Professors Paula Martins, Silvia Francesco (University of Aveiro) and Teresa Magalhaes (University of Porto) for the fruitful discussions.	ABAQUS, 2010, 6 10 DOC; [Anonymous], 2003, OS US MAN; [Anonymous], 2012, MESHM MAN; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Bilston LE, 2011, BIOL MED PHYS BIOMED, P69, DOI 10.1007/978-1-4419-9997-9_4; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Chinn B., 2009, TECHNICAL RESPONSE U; Cignoni P., 2008, ERCIM NEWS, V73, P45, DOI [10.2312/LocalChapterEvents/ItalChap/ItalianChapConf2008/129-136, DOI 10.2312/L0CALCHAPTEREVENTS/ITALCHAP/ITALIANCHAPC0NF2008/129-136]; Claessans M., 1997, P 41 STAPP CAR CRASH, P315, DOI DOI 10.4271/973338; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Cotton RT, 2015, COMPUTER METHODS BIO, V19, P1; Deck C., 2009, P 7 EUR LS DYNA C; deSouzaNeto EA, 1996, INT J SOLIDS STRUCT, V33, P3277, DOI 10.1016/0020-7683(95)00259-6; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fernandes FAO, 2017, PROCEDIA MANUF, V13, P227, DOI 10.1016/j.promfg.2017.09.055; Fernandes FAO, 2017, PROCEDIA MANUF, V13, P219, DOI 10.1016/j.promfg.2017.09.052; Fernandes FAO, 2015, MATER DESIGN, V82, P335, DOI 10.1016/j.matdes.2015.06.004; Fernandes FAO, 2013, ACCIDENT ANAL PREV, V56, P1, DOI 10.1016/j.aap.2013.03.011; Fernandes F. A. O., 2013, P IRCOBI C GOTH, P431; Fernandes FAO, 2015, P I MECH ENG H, V229, P592, DOI 10.1177/0954411915592906; Fernandes FAO, 2013, STRUCT ENG MECH, V48, P661, DOI 10.12989/sem.2013.48.5.661; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P112; HARDY CH, 1973, J APPL MECH-T ASME, V40, P838, DOI 10.1115/1.3423172; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hosey R. R., 1982, FINITE ELEMENTS BIOM, P379; Joldes GR, 2009, COMMUN NUMER METH EN, V25, P827, DOI 10.1002/cnm.1185; KHALIL TB, 1977, J BIOMECH, V10, P119, DOI 10.1016/0021-9290(77)90075-6; KHALIL TB, 1982, P 26 STAPP CAR CRASH, P87; Kleiven S., 2002, THESIS; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Meaney D.F., 1990, INT C BIOM IMP; Miller K, 2011, BIOL MED PHYS BIOMED, P111, DOI 10.1007/978-1-4419-9997-9_6; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Miller R.T., 1998, STAPP CAR CRASH J, P155; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Nahum A.M., 1976, 20 STAPP CAR CRASH C, P2638; Nahum AM., 1977, P 21 STAPP CAR CRASH, P339, DOI [10.4271/770922., DOI 10.4271/770922]; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ogden R., 1997, NONLINEAR ELASTIC DE; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Ptak M, 2017, INT J IMPACT ENG, V106, P238, DOI 10.1016/j.ijimpeng.2017.04.014; Ptak M., 2017, LECT NOTES MECH ENG; Rashid B., 2012, P ASME 2012 INT MECH, P9; Rashid B, 2012, J MECH BEHAV BIOMED, V14, P113, DOI 10.1016/j.jmbbm.2012.04.005; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Ruan J, 2001, Stapp Car Crash J, V45, P395; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Sauren A. A. H. J., 1993, P INT IRCOBI C BIOM, P241; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tchepel D., 2016, REFERENCE MODULE MAT; Tchepel D., 2016, WHAT ARE FORENSIC SC, P3542; Tchepel D, 2016, BRAIN INJURY, V30, P516; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Tse Kwong Ming, 2014, AM J ENG TECHNOLOGY, V1, P28; van Dommelen JAW, 2011, STUD MECHANOBIOL TIS, V3, P41, DOI 10.1007/8415_2010_16; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Yang J, 2011, COMPUTATIONAL BIOMEC; Yang KH, 2011, BIOL MED PHYS BIOMED, P91, DOI 10.1007/978-1-4419-9997-9_5; Zhang JY, 2011, J BIOMECH, V44, P391, DOI 10.1016/j.jbiomech.2010.10.024; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; 2011, BIOMECHANICS BRAIN, P1	81	23	23	0	7	EMERALD GROUP PUBLISHING LTD	BINGLEY	HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND	0264-4401	1758-7077		ENG COMPUTATION	Eng. Comput.		2018	35	1					477	496		10.1108/EC-09-2016-0321			20	Computer Science, Interdisciplinary Applications; Engineering, Multidisciplinary; Mathematics, Interdisciplinary Applications; Mechanics	Computer Science; Engineering; Mathematics; Mechanics	GA2QM	WOS:000428168600025					2021-06-18	
J	Holzmacher, JL; Reynolds, C; Patel, M; Maluso, P; Holland, S; Gamsky, N; Moore, H; Acquista, E; Carrick, M; Amdur, R; Hancock, H; Metzler, M; Dunn, J; Sarani, B				Holzmacher, Jeremy L.; Reynolds, Cassandra; Patel, Mayur; Maluso, Patrick; Holland, Seth; Gamsky, Nathaniel; Moore, Henry; Acquista, Elizabeth; Carrick, Matthew; Amdur, Richard; Hancock, Heather; Metzler, Michael; Dunn, Julie; Sarani, Babak			Platelet transfusion does not improve outcomes in patients with brain injury on antiplatelet therapy	BRAIN INJURY			English	Article						Traumatic brain injury; brain injury; closed head injury	TRAUMATIC INTRACRANIAL HEMORRHAGE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; EMERGENCY-DEPARTMENT; PREINJURY WARFARIN; CLOPIDOGREL USE; AGENTS; MORTALITY; IMPACT; RISK	Introduction: Platelet dysfunction following traumatic brain injury (TBI) is associated with worse outcomes. The efficacy of platelet transfusion to reverse antiplatelet medication (APM) remains unknown. Thrombelastography platelet mapping (TEG-PM) assesses platelet function. We hypothesize that platelet transfusion can reverse the effects of APM but does not improve outcomes following TBI.Methods: An observational study at six US trauma centres was performed. Adult patients on APM with CT evident TBI after blunt injury were enrolled. Demographics, brain CT and TEG-PM results before/after platelet transfusion, length of stay (LOS), and injury severity score (ISS) were abstracted.Results: Sixty six patients were enrolled (89% aspirin, 50% clopidogrel, 23% dual APM) with 23 patients undergoing platelet transfusion. Transfused patients had significantly higher ISS and admission CT scores. Platelet transfusion significantly reduced platelet inhibition due to aspirin (76.030.2% to 52.7 +/- 31.5%, p<0.01), but had a non-significant impact on clopidogrel-associated inhibition (p=0.07). Platelet transfusion was associated with longer length of stay (7.8vs. 3.5days, p<0.01), but there were no differences in mortality.Conclusion: Platelet transfusion significantly decreases platelet inhibition due to aspirin but is not associated with change in outcomes in patients on APM following TBI.	[Holzmacher, Jeremy L.; Maluso, Patrick; Gamsky, Nathaniel; Amdur, Richard; Sarani, Babak] George Washington Univ, Dept Surg, Ctr Trauma & Crit Care, Washington, DC USA; [Reynolds, Cassandra] East Carolina Univ, Dept Surg, Brody Sch Med, Greenville, NC USA; [Patel, Mayur] Vanderbilt Univ, Dept Surg,Surg Serv,Gen Surg Sect, Div Trauma Emergency Gen Surg & Surg Crit Care,Me, Sect Surg Sci,Vanderbilt Brain Inst,Vanderbilt Ct, Nashville, TN 37240 USA; [Patel, Mayur] Vanderbilt Univ, Med Ctr,Dept Neurosurg,Gen Surg Sect, Div Trauma Emergency Gen Surg & Surg Crit Care,Su, Sect Surg Sci,Vanderbilt Brain Inst,Vanderbilt Ct, Nashville, TN 37240 USA; [Patel, Mayur] Vanderbilt Univ, Med Ctr,Dept Hearing & Speech Sci,Gen Surg Sect, Div Trauma Emergency Gen Surg & Surg Crit Care,Su, Sect Surg Sci,Vanderbilt Brain Inst,Vanderbilt Ct, Nashville, TN 37240 USA; [Patel, Mayur] US Dept Vet Affairs, Med Ctr, Tennessee Valley Healthcare Syst, Nashville, TN USA; [Holland, Seth; Hancock, Heather] San Antonio Mil Med Ctr, Dept Surg, Ft Sam Houston, TX USA; [Moore, Henry] Carle Fdn Hosp, Dept Surg, Urbana, IL USA; [Acquista, Elizabeth] Univ North Carolina Chapel Hill, Dept Surg, Chapel Hill, NC USA; [Carrick, Matthew] Med Ctr Plano, Dept Surg, Plano, TX USA; [Metzler, Michael; Dunn, Julie] Med Ctr Rockies, Dept Surg, Loveland, CO USA	Sarani, B (corresponding author), George Washington Univ, Dept Surg, 2150 Penn Ave NW,Suite 6B, Washington, DC 20037 USA.	bsarani@mfa.gwu.edu	Amdur, Richard/AAE-5345-2019		NCATSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445]; Vanderbilt Faculty Research Scholars Program; National Institutes of Health NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111]; NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445, UL1TR002243] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484] Funding Source: NIH RePORTER	Funding was provided by NCATS UL1TR000445 for REDCap (all authors), Vanderbilt Faculty Research Scholars Program (mbp); National Institutes of Health NHLBI R01HL111111 (mbp) and NIGMS R01GM120484(mbp).	Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Bonville DJ, 2011, SURGERY, V150, P861, DOI 10.1016/j.surg.2011.07.070; Briggs A, 2015, J SURG RES, V193, P802, DOI 10.1016/j.jss.2014.08.016; Downey DM, 2009, AM SURGEON, V75, P1100; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Ives C, 2012, J AM COLL SURGEONS, V215, P496, DOI 10.1016/j.jamcollsurg.2012.06.005; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Major J, 2009, EMERG MED J, V26, P871, DOI 10.1136/emj.2008.068643; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Narum S, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0094-1; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Peck KA, 2011, J TRAUMA, V71, P1600, DOI 10.1097/TA.0b013e31823b9ce1; Sirajuddin S, 2016, J TRAUMA ACUTE CARE, V81, P328, DOI 10.1097/TA.0000000000001057; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e	24	23	23	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	3					325	330		10.1080/02699052.2018.1425804			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FU3PV	WOS:000423764700006	29341793	Green Accepted			2021-06-18	
J	Kumar, RG; Juengst, SB; Wang, ZS; Dams-O'Connor, K; Dikmen, SS; O'Neil-Pirozzi, TM; Dahdah, MN; Hammond, FM; Felix, ER; Arenth, PM; Wagner, AK				Kumar, Raj G.; Juengst, Shannon B.; Wang, Zhensheng; Dams-O'Connor, Kristen; Dikmen, Sureyya S.; O'Neil-Pirozzi, Therese M.; Dahdah, Marie N.; Hammond, Flora M.; Felix, Elizabeth R.; Arenth, Patricia M.; Wagner, Amy K.			Epidemiology of Comorbid Conditions Among Adults 50 Years and Older With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aging; brain injuries; comorbidity; epidemiology	SYSTEMS NATIONAL DATABASE; SUBSTANCE USE DISORDERS; MODEL SYSTEMS; INPATIENT REHABILITATION; UNITED-STATES; OUTCOMES; HEALTH; CARE; AGE; REPRESENTATIVENESS	Objectives: Aging individuals with traumatic brain injury (TBI) experience multiple comorbidities that can affect recovery from injury. The objective of this study was to describe the most commonly co-occurring comorbid conditions among adults 50 years and older with TBI. Setting: Level I Trauma centers. Participants: Adults 50 years and older with moderate/severe TBI enrolled in the TBI-Model Systems (TBI-MS) from 2007 to 2014 (n = 2134). Design: A TBI-MS prospective cohort study. Main Measures: International Classification of Disease-9th Revision codes collapsed into 45 comorbidity categories. Comorbidity prevalence estimates and trend analyses were conducted by age strata (50-54, 55-64, 65-74, 75-84, = 85 years). A dimension reduction method, Treelet Transform, classified clusters of comorbidities that tended to co-occur. Results: The 3 most commonly occurring comorbid categories were hypertensive disease (52.6/100 persons), other diseases of the respiratory system (51.8/100 persons), and fluid component imbalances (43.7/100 persons). Treelet Transform classified 3 clusters of comorbid codes, broadly classified as (1) acute medical diseases/infections, (2) chronic conditions, and (3) substance abuse disorders. Conclusion: This study provides valuable insight into comorbid conditions that co-occur among adults 50 years and older with TBI and provides a foundation for future studies to explore how specific comorbidities affect TBI recovery.	[Kumar, Raj G.; Juengst, Shannon B.; Wang, Zhensheng; Arenth, Patricia M.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA; [Kumar, Raj G.; Wang, Zhensheng] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Commun Sci & Disorders, Boston, MA 02115 USA; [O'Neil-Pirozzi, Therese M.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Dahdah, Marie N.] Baylor Scott & White Hlth Med Ctr, Plano, TX USA; [Dahdah, Marie N.] Baylor Inst Rehabil, Dallas, TX USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Felix, Elizabeth R.] Univ Miami, Dept Phys Med & Rehabil, Miami, FL USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Felix, Elizabeth/AAD-6356-2021; Juengst, Shannon B/AAC-5891-2019	Juengst, Shannon/0000-0003-4709-545X; Felix, Elizabeth/0000-0002-6239-715X	NIDILRRUnited States Department of Health & Human Services [90DP0041, 90DP0045, 90DP0046, 90DP0038-03-00]; NIH/NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1 K01 HD07465101A1]	The authors acknowledge NIDILRR Grant 90DP0041 (R.G.K., A.K.W., S.B.J., P.M.A., Z.W.) (University of Pittsburgh); NIDILRR Grant 90DP0045 (M.D.); NIDILRR Grant 90DP0046 (E.R.F.) (University of Miami); NIDILRR 90DP0038-03-00, NIH/NICHD 1 K01 HD07465101A1 (K.D-O) (Icahn School of Medicine at Mount Sinai). Kristen Dams-O'Connor, PhD, serves as a consultant to the Brain Injury Association of America and Craig Hospital and provides clinical expert testimony in forensic cases. Marie Dahdah, PhD, receives some project from the Ginger Murchison Foundation.	Beard JR, 2015, LANCET, V385, P658, DOI 10.1016/S0140-6736(14)61461-6; BLACKBURN H, 2007, DEV MODERN EPIDEMIOL, P71; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; Cappellini MD, 2015, SEMIN HEMATOL, V52, P261, DOI 10.1053/j.seminhematol.2015.07.006; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; CDC, PERC DISTR TBI REL H; Centers for Disease Control and Prevention, 2013, STAT AG HLTH AM 2013; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Crownover J, 2012, CURR GERIATR REP, V1, P149, DOI 10.1007/s13670-012-0021-6; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P122, DOI 10.1097/HTR.0000000000000012; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Dams-O'Connor K, 2016, J AM GERIATR SOC, V64, P844, DOI 10.1111/jgs.14014; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Failla MD, 2014, NEUROREHAB NEURAL RE; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Fulop T, 2016, REV INVEST CLIN, V68, P84; Golub A, 2013, SUBST USE MISUSE, V48, P811, DOI 10.3109/10826084.2013.796988; Gorst-Rasmussen A, 2011, TT TREELET TRANSFORM; Gorst-Rasmussen A, 2011, AM J EPIDEMIOL, V173, P1097, DOI 10.1093/aje/kwr060; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Hamirudin AH, 2016, ARCH GERONTOL GERIAT, V62, P9, DOI 10.1016/j.archger.2015.09.007; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2015, J NEUROTRAUM, V32, P1893, DOI 10.1089/neu.2014.3353; Hsiao KY, 2015, INJURY, V46, P859, DOI 10.1016/j.injury.2014.11.025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Karpur A, 2013, GUIDE TRAUMATIC BRAI; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Kesinger MR, 2016, ARCH PHYS MED REHABI; Kumar RG, 2015, BRAIN BEHAV IMMUN; Lecours A, 2012, J HEAD TRAUMA REHAB, V27, P379, DOI 10.1097/HTR.0b013e31823b2385; Nacionales DC, 2015, J IMMUNOL, V195, P2396, DOI 10.4049/jimmunol.1500984; Olson-Madden JH, 2012, J HEAD TRAUMA REHAB, V27, P370, DOI 10.1097/HTR.0b013e318268d496; Ortman JM., 2014, AGING NATION OLDER P, P25; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; SAVITEER SM, 1988, AM J MED, V84, P661, DOI 10.1016/0002-9343(88)90101-5; Schutte C, 2010, INT J NEUROSCI, V120, P551, DOI 10.3109/00207454.2010.494789; Smith S. M., 2012, BMJ, V345; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2012, J NEUROTRAUM, V29, P1864, DOI 10.1089/neu.2011.2284; Thompson HJ, 2012, RES GERONTOL NURS, V5, P17, DOI 10.3928/19404921-20111206-02; Tuglus C, 2008, ANN APPL STAT, V2, P489, DOI 10.1214/08-AOAS137F; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586	55	23	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2018	33	1					15	24		10.1097/HTR.0000000000000273			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GB0QS	WOS:000428752300010	28060201				2021-06-18	
J	Sufrinko, A; McAllister-Deitrick, J; Elbin, RJ; Collins, MW; Kontos, AP				Sufrinko, Alicia; McAllister-Deitrick, Jamie; Elbin, R. J.; Collins, Michael W.; Kontos, Anthony P.			Family History of Migraine Associated With Posttraumatic Migraine Symptoms Following Sport-Related Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion recovery; migraine history; neurocognitive testing; ocular motor; sport-related concussion; vestibular	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; RISK; EPIDEMIOLOGY; PREVALENCE; HEADACHE; CHILDREN; RECOVERY; ADOLESCENTS; SPECIFICITY	Objective: To determine whether family history of migraine increased the likelihood of posttraumatic migraine (PTM) symptom presentation in adolescents following concussion, and examine the influence of family history of migraine and PTM on postinjury outcomes. Setting: Outpatient concussion clinic. Participants: A total of 153 patients with concussion (103 males and 50 females) aged 15.72 +/- 1.48 years (range 12-18 years). Design: Cross-sectional, observational study of patients presenting for initial evaluation 4.72 +/- 3.05 days (range 1-14) postinjury. Main Measures: Computerized neurocognitive testing, symptom report, and vestibular/oculomotor screening. Results: Patients with a family history of migraine were 2.6 times (odds ratio = 2.60, confidence interval = 1.35-5.02, P = .003) more likely to present with PTM compared with patients without a family history. Results of multivariate analyses of covariance, controlling for concussion history, revealed significant main effects for PTM on (1) Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT)/Post-Concussion Symptom Scale (PCSS) (F = 15.43, P < .001) and (2) Vestibular/OcularMotor Screening (VOMS) (F = 8.52, P < .001). There was no main effect for family history of migraine on ImPACT/PCSS (P = .22) and VOMS (P = .83) or interaction between family history of migraine and PTM on ImPACT/PCSS (P = .84) and VOMS (P = .52). Conclusion: Family history of migraine is associated with PTM symptoms following sport-related concussion, suggesting a genetic predisposition for migraine may serve as a catalyst or trigger for onset of PTM. However, only presence of PTM, rather than family history ofmigraine, was related to worse neurocognitive and vestibular/oculomotor outcomes.	[Sufrinko, Alicia; McAllister-Deitrick, Jamie; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Off Sport Concuss Res, Fayetteville, AR 72701 USA	Sufrinko, A (corresponding author), Univ Pittsburgh, Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15221 USA.	sufrinkoam@upmc.edu			National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	This research was supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) to Dr Kontos.	Abu-Arafeh I, 2010, DEV MED CHILD NEUROL, V52, P1088, DOI 10.1111/j.1469-8749.2010.03793.x; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Bisdorff A, 2014, CURR OPIN NEUROL, V27, P105, DOI 10.1097/WCO.0000000000000061; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T., 2014, ATHLETIC TRAINING SP, V6, DOI [DOI 10.3928/19425864-20140916-01, https://doi.org/10.3928/19425864-20140916-01]; Dieterich M, 1999, J NEUROL, V246, P883, DOI 10.1007/s004150050478; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Elbin R, 2015, PERSPECT NEUROPHYSIO, V25, P4, DOI DOI 10.1044/NNSLD25.1.4; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Gasparini CF, 2013, CURR GENOMICS, V14, P300, DOI 10.2174/13892029113149990007; Genizi J, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0625-x; Genizi J, 2013, J HEADACHE PAIN, V14, P1, DOI 10.1186/1129-2377-14-54; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Heyer GL, 2016, CEPHALALGIA, V36, P309, DOI 10.1177/0333102415590240; Immediate Post-Concussion Assessment Testing (ImPACT&REG;) Test, 2011, IMPACT APPL TECHN MA; Kontos AP, 2016, BRAIN IMAGING BEHAV, V10, P594, DOI 10.1007/s11682-015-9412-6; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lempert T, 2012, J VESTIBUL RES-EQUIL, V22, P167, DOI 10.3233/VES-2012-0453; Lipton RB, 2005, AM J MED, V118, p3S, DOI 10.1016/j.amjmed.2005.01.014; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lu SR, 2000, CEPHALALGIA, V20, P479, DOI 10.1046/j.1468-2982.2000.00076.x; McCrory P, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.014860; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Merikangas KR, 2013, HEADACHE, V53, P230, DOI 10.1111/head.12038; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; RUSSELL MB, 1995, BRIT MED J, V311, P541, DOI 10.1136/bmj.311.7004.541; Sandel N, 2014, ARCH CLIN NEUROPSYCH, V29, P584; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Singer AB, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0533-5; Singman Eric L, 2014, Am Orthopt J, V64, P112, DOI 10.3368/aoj.64.1.112; Stewart WF, 2008, CEPHALALGIA, V28, P1170, DOI 10.1111/j.1468-2982.2008.01666.x; Stewart WF, 1997, ANN NEUROL, V41, P166, DOI 10.1002/ana.410410207; Wober-Bingol C, 2013, CURR PAIN HEADACHE R, V17, P341, DOI 10.1007/s11916-013-0341-z	48	23	23	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2018	33	1					7	14		10.1097/HTR.0000000000000315			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GB0QS	WOS:000428752300009	28520665	Green Accepted			2021-06-18	
J	Berkner, J; Meehan, WP; Master, CL; Howell, DR				Berkner, Justin; Meehan, William P., III; Master, Christina L.; Howell, David R.			Gait and Quiet-Stance Performance Among Adolescents After Concussion-Symptom Resolution	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; dual-task gait; symptom recovery	TRAUMATIC BRAIN-INJURY; DUAL-TASK GAIT; EXTREMITY MUSCULOSKELETAL INJURY; SPORTS-RELATED CONCUSSION; ERROR SCORING SYSTEM; NEUROCOGNITIVE PERFORMANCE; POSTURAL STABILITY; BALANCE CONTROL; COGNITIVE TASK; YOUNG-ADULTS	Context: Concussions affect a large number of US athletes each year. Returning an athlete to activity once self-reported symptoms have resolved can be problematic if unrecognized neurocognitive and balance deficits persist. Pairing cognitive and motor tasks or cognitive and quiet-stance tasks may allow clinicians to detect and monitor these changes postconcussion. Objective: To prospectively examine adolescent athletes' gait and quiet-stance performance while concurrently completing a cognitive task acutely after concussion and after symptom resolution. Design: Case-control study. Setting: Sport concussion clinic. Patients or Other Participants: Thirty-seven athletes (age = 16.2 +/- 3.1 years; 54% female) were diagnosed with a concussion, and their performance was compared with that of a group of 44 uninjured control participants (age = 15.0 +/- 2.0 years; 57% female). Intervention: Participants diagnosed with a concussion completed a symptom inventory and single-and dual-task gait and quiet-stance evaluations within 21 days of injury and then again after symptom resolution. Gait and postural-control measurements were quantified using an inertial sensor system and analyzed using multivariate analyses of covariance. Main Outcome Measure(s): Post-Concussion Symptom Scale, single-task and dual-task gait measures, quiet-stance measures, and cognitive task performance. Results: At the initial postinjury examination, single-task gait stride length (1.16 +/- 0.14 versus 1.25 +/- 0.13 m, P = .003) and dual-task gait stride length (1.02 +/- 0.13 m versus 1.10 +/- 0.13 m, P = .011) for the concussion group compared with the control group, respectively, were shorter. After symptom resolution, no single-task gait differences were found, but the concussion group demonstrated slower gait velocity (0.78 +/- 0.15 m/s versus 0.92 +/- 0.14 m/ s, P = .005), lower cadence (92.5 +/- 12.2 steps/min versus 99.3 +/- 7.8 steps/min, P= .001), and a shorter stride length (0.99 +/- 0.15 m versus 1.10 +/- 0.13 m, P = .003) during dual-task gait than the control group. No between-groups differences were detected during quiet stance at either time point. Conclusions: Acutely after concussion, single-task and dual-task stride-length alterations were present among youth athletes compared with a control group. Although single-task gait alterations were not detected after symptom resolution, dual-task gait differences persisted, suggesting that dual-task gait alterations may persist longer after concussion than single-task gait or objective quiet-stance alterations. Dual-task gait assessments may, therefore, be a useful component in monitoring concussion recovery after symptom resolution.	[Berkner, Justin] Univ New England, Biddeford, ME USA; [Meehan, William P., III; Howell, David R.] Boston Childrens Hosp, Micheli Ctr Sports Injury Prevent, Div Sports Med, Waltham, MA USA; [Master, Christina L.] Univ Penn, Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA; [Howell, David R.] Univ Colorado, Childrens Hosp Colorado, Ctr Sports Med, Sch Med,Dept Orthoped, 13123 East 16th Ave B060, Aurora, CO 80045 USA	Howell, DR (corresponding author), Univ Colorado, Childrens Hosp Colorado, Ctr Sports Med, Sch Med,Dept Orthoped, 13123 East 16th Ave B060, Aurora, CO 80045 USA.	David.Howell@childrenscolorado.org		Master, Christina/0000-0002-6717-4270			Broglio SP, 2007, J ATHL TRAINING, V42, P504; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2016, GAIT POSTURE, V49, P176, DOI 10.1016/j.gaitpost.2016.07.008; Howell DR, 2016, PHYSICIAN SPORTSMED, V44, P304, DOI 10.1080/00913847.2016.1197763; Howell DR, 2016, ACTA PAEDIATR, V105, pE426, DOI 10.1111/apa.13486; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mancini M, 2016, GAIT POSTURE, V43, P125, DOI 10.1016/j.gaitpost.2015.08.015; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170	29	23	23	0	24	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	DEC	2017	52	12					1089	1095		10.4085/1062-6050-52.11.23			7	Sport Sciences	Sport Sciences	FR9BQ	WOS:000419368900001	29154694	Green Published, Bronze			2021-06-18	
J	Zhang, J; Peng, F; Liu, Z; Luan, JL; Liu, XM; Fei, C; Heng, XY				Zhang, Jian; Peng, Fei; Liu, Zhuang; Luan, Jinli; Liu, Xingming; Fei, Chang; Heng, Xueyuan			Cranioplasty with autogenous bone flaps cryopreserved in povidone iodine: a long-term follow-up study	JOURNAL OF NEUROSURGERY			English	Article						autogenous bone flaps; cranioplasty; follow-up; bone resorption; surgical technique	TRAUMATIC BRAIN-INJURY; METHYL-METHACRYLATE CRANIOPLASTY; DECOMPRESSIVE CRANIECTOMY; AUTOLOGOUS BONE; CLINICAL ARTICLE; RISK-FACTORS; RECONSTRUCTION; FROZEN; GRAFT; RESORPTION	OBJECTIVE The aim of this study was to investigate the long-term therapeutic efficacy of cranioplasty with autogenous bone flaps cryopreserved in povidone iodine and explore the risk factors for bone resorption. METHODS Clinical data and follow-up results of 188 patients (with 211 bone flaps) who underwent cranioplasty with autogenous bone flaps cryopreserved in povidone-iodine were retrospectively analyzed. Bone flap resorption was classified into 3 types according to CT features, including bone flap thinning (Type I), reduced bone density (Type II), and osteolysis within the flaps (Type III). The extent of bone flap resorption was graded as mild, moderate, or severe. RESULTS Short-term postoperative complications included subcutaneous or extradural seroma collection in 19 flaps (9.0%), epidural hematoma in 16 flaps (7.6%), and infection in 8 flaps (3.8%). Eight patients whose flaps became infected and had to be removed and 2 patients who died within 2 years were excluded from the follow-up analysis. For the remaining 178 patients and 201 flaps, the follow-up duration was 24-122 months (mean 63.1 months). In 93 (46.3%) of these 201 flaps, CT demonstrated bone resorption, which was classified as Type I in 55 flaps (59.1%), Type II in 11 (11.8%), and Type III in 27 (29.0%). The severity of bone resorption was graded as follows: no bone resorption in 108 (53.7%) of 201 flaps, mild resorption in 66 (32.8%), moderate resorption in 15 (7.5%), and severe resorption in 12 (6.0%). The incidence of moderate or severe resorption was higher in Type III than in Type I (p = 0.0008). The grading of bone flap resorption was associated with the locations of bone flaps (p = 0.0210) and fragmentation (flaps broken into 2 or 3 fragments) (p = 0.0009). The incidence of bone flap collapse due to bone resorption was higher in patients who underwent ventriculoperitoneal (VP) shunt implantation than in those who did not (p = 0.0091). CONCLUSIONS Because of the low incidence rates of infection and severe bone resorption, the authors conclude that cranioplasty with autogenous bone flaps cryopreserved in povidone-iodine solution is safe and effective. The changes characteristic of bone flap resorption became visible on CT scans about 2 months after cranioplasty and tended to stabilize at about 18 months postoperatively. The bone resorption of autogenous bone flap may be classified into 3 types. The rates of moderate and severe resorption were much higher in Type III than in Type I. The grade of bone flap resorption was associated with bone flap locations. Fragmented bone flaps or those implanted in patients treated with VP shunts may have a higher incidence of bone flap collapse due to bone resorption.	[Zhang, Jian; Fei, Chang; Heng, Xueyuan] Linyi Peoples Hosp, Dept Neurosurg, Linyi, Peoples R China; [Peng, Fei; Liu, Zhuang; Luan, Jinli; Liu, Xingming] Weifang Med Univ, Dept Neurosurg, Weifang, Shandong, Peoples R China; [Peng, Fei] Peoples Hosp Xuchang, Dept Neurosurg, Xuchang, Henan, Peoples R China	Zhang, J (corresponding author), Peoples Hosp Linyi City, Dept Neurosurg, Linyi 276000, Shandong, Peoples R China.	honest20699@126.com			Projects of Medical and Health Technology Development Program in Shandong province [2009HW019]; Shandong Province Health Department	This study was supported by the Projects of Medical and Health Technology Development Program in Shandong province (Item Number: 2009HW019 to Chang Fei). We are especially thankful for funds from the Shandong Province Health Department. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrzejak S, 2005, ACTA NEUROCHIR, V147, P973, DOI 10.1007/s00701-005-0581-8; Artico M, 2003, SURG NEUROL, V60, P71, DOI 10.1016/S0090-3019(03)00031-4; Asano Y, 1993, No To Shinkei, V45, P1145; Bhaskar IP, 2014, WORLD NEUROSURG, V82, pE531, DOI 10.1016/j.wneu.2013.01.013; Bhaskar IP, 2011, ANZ J SURG, V81, P137, DOI 10.1111/j.1445-2197.2010.05584.x; Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Brommeland T, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0155-6; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Chen TM, 2008, J TRAUMA, V65, P1321, DOI 10.1097/TA.0b013e3181574edf; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; Fiorot JA, 2008, ARQ NEURO-PSIQUIAT, V66, P204, DOI 10.1590/S0004-282X2008000200012; Garusi C, 2001, MICROSURG, V21, P131, DOI 10.1002/micr.1024; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Greene AK, 2007, PLAST RECONSTR SURG, V120, P1603, DOI 10.1097/01.prs.0000282106.75808.af; HANCOCK DO, 1963, J NEUROSURG, V20, P983, DOI 10.3171/jns.1963.20.11.0983; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Im SH, 2012, J KOREAN NEUROSURG S, V52, P396, DOI 10.3340/jkns.2012.52.4.396; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Kim H, 2013, ACTA NEUROCHIR, V155, P2171, DOI 10.1007/s00701-013-1877-8; KOBAYASHI S, 1987, NEUROSURGERY, V21, P751, DOI 10.1227/00006123-198711000-00032; KREUZ FP, 1951, J BONE JOINT SURG AM, V33-A, P863, DOI 10.2106/00004623-195133040-00005; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; Krishnan P, 2006, NEUROL INDIA, V54, P291; Kurokawa Y, 1995, JPN J NEUROSURG TOKY, V4, P128; Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0; ODOM GL, 1952, J NEUROSURG, V9, P606, DOI 10.3171/jns.1952.9.6.0606; Ozaki F., 1994, J WAKAYAMA MED SOC, V45, P217; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Rajendra Prasad B, 2009, J Emerg Trauma Shock, V2, P89, DOI 10.4103/0974-2700.50742; Sahoo N, 2010, J CRANIOFAC SURG, V21, P79, DOI 10.1097/SCS.0b013e3181c3ba58; Saringer W, 2002, ACTA NEUROCHIR, V144, P1193, DOI 10.1007/s00701-002-0995-5; Schwarz F, 2016, J NEUROSURG, V124, P710, DOI 10.3171/2015.4.JNS159; Sorour M, 2014, ACTA NEUROCHIR, V156, P207, DOI 10.1007/s00701-013-1800-3; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Wang JC, 2012, J CRANIOFAC SURG, V23, P1802, DOI 10.1097/SCS.0b013e318271012a; Yamashita K, 1992, KEISEI GEKA, V35, P1073; Zins JE, 2010, J CRANIOFAC SURG, V21, P1755, DOI 10.1097/SCS.0b013e3181c34675	43	23	25	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2017	127	6					1449	1456		10.3171/2016.8.JNS16204			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FO5KM	WOS:000416895700030	28186447				2021-06-18	
J	Li, J; Chen, SX; Zhao, ZK; Luo, YH; Hou, YH; Li, H; He, LM; Zhou, LB; Wu, WT				Li, Jing; Chen, Shuangxi; Zhao, Zhikai; Luo, Yunhao; Hou, Yuhui; Li, Heng; He, Liumin; Zhou, Libing; Wu, Wutian			Effect of VEGF on Inflammatory Regulation, Neural Survival, and Functional Improvement in Rats following a Complete Spinal Cord Transection	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						spinal cord transection; locomotor function; vascular endothelial growth factor; MAPK signaling; neural circuitry	ENDOTHELIAL GROWTH-FACTOR; PROMOTE NEURONAL SURVIVAL; TRAUMATIC BRAIN-INJURY; STEM-CELLS; AXONAL REGENERATION; SIGNALING PATHWAY; LOCOMOTOR RECOVERY; OXIDATIVE STRESS; RATING-SCALE; LESION SITE	After complete transection of the thoracic spinal segment, neonatal rats exhibit spontaneous locomotor recovery of hindlimbs, but this recovery is not found in adult rats after similar injury. The potential mechanism related to the difference in recovery of neonatal and adult rats remains unknown. In this study, 342 animals were analyzed. The vascular endothelial growth factor (VEGF) level in spinal segments below injury sites was significantly higher in postnatal day 1 rats (P1) compared with 28-day-old adult rats (P28) following a complete T9 transection. VEGF administration in P28 rats with T9 transection significantly improved the functional recovery; by contrast, treatment with VEGF receptor inhibitors in P1 rats with T9 transection slowed down the spontaneous functional recovery. Results showed more neurons reduced in the lumbar spinal cord and worse local neural network reorganization below injury sites in P28 rats than those in P1 rats. Transynaptic tracing with pseudorabies virus and double immunofluorescence analysis indicated that VEGF treatment in P28 rats alleviated the reduced number of neurons and improved their network reorganization. VEGF inhibition in neonates resulted in high neuronal death rate and deteriorated network reorganization. In in vivo studies, T9 transection induced less increase in the number of microglia in the spinal cord in P1 animals than P28 animals. VEGF treatment reduced the increase in microglial cells in P28 animals. VEGF administration in cultured spinal motoneurons prevented lipopolysaccharide (LPS)-induced neuronal death and facilitated neurite growth. Western blots of the samples of lumbar spinal cord after spinal transection and cultured spinal motoneurons showed a lower level of Erk1/2 phosphorylation after the injury or LPS induction compared with that in the control. The phosphorylation level increased after VEGF treatment. In conclusion, VEGF is a critical mediator involved in functional recovery after spinal transection and can be considered a potential target for clinical therapy.	[Li, Jing; Chen, Shuangxi; Zhao, Zhikai; Luo, Yunhao; Hou, Yuhui; Zhou, Libing; Wu, Wutian] Jinan Univ, Minist Educ CNS Regenerat Collaborat Joint Lab, Guangdong Hongkong Macau Inst CNS Regenerat, Guangzhou, Guangdong, Peoples R China; [Li, Jing] Hubei Univ Med, Inst Basic Med Sci, Dept Anat, Shiyan, Peoples R China; [Li, Heng; Wu, Wutian] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [He, Liumin] Jinan Univ, Coll Life Sci & Technol, Dept Biomed Engn, Key Lab Biomat,Guangdong Higher Educ Inst, Guangzhou, Guangdong, Peoples R China; [Wu, Wutian] Restem Biotechnol Co Ltd, Suzhou, Peoples R China	Wu, WT (corresponding author), Jinan Univ, Minist Educ CNS Regenerat Collaborat Joint Lab, Guangdong Hongkong Macau Inst CNS Regenerat, Guangzhou, Guangdong, Peoples R China.; Wu, WT (corresponding author), Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China.; Wu, WT (corresponding author), Restem Biotechnol Co Ltd, Suzhou, Peoples R China.	wtwu@hku.hk		Zhou, Libing/0000-0002-8975-5228	National Basic Research Program of China (973 Program)National Basic Research Program of China [2014CB542205]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81641047]	This work was supported by National Basic Research Program of China (973 Program, 2014CB542205) and the National Natural Science Foundation of China (81641047).	Alam M, 2017, EXP NEUROL, V291, P141, DOI 10.1016/j.expneurol.2017.02.006; Andrews EM, 2012, EXP NEUROL, V235, P174, DOI 10.1016/j.expneurol.2011.09.008; Araujo MR, 2017, EXP NEUROL, V294, P45, DOI 10.1016/j.expneurol.2017.04.009; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Beazley-Long N, 2013, AM J PATHOL, V183, P918, DOI 10.1016/j.ajpath.2013.05.031; Benedito R, 2012, NATURE, V484, P110, DOI 10.1038/nature10908; BERNSTEIN DR, 1981, NEUROSCI LETT, V26, P55, DOI 10.1016/0304-3940(81)90425-0; Bhuiyan MIH, 2015, NEUROSCIENCE, V290, P90, DOI 10.1016/j.neuroscience.2015.01.025; Bisicchia E, 2017, MOL NEUROBIOL, V54, P4896, DOI 10.1007/s12035-016-0031-z; Chen S, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00021; Chen T, 2017, NEURAL REGEN RES, V12, P433, DOI 10.4103/1673-5374.202947; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Choo AM, 2008, EXP NEUROL, V212, P490, DOI 10.1016/j.expneurol.2008.04.038; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Dulin JN, 2015, J NEUROSCI, V35, P13860, DOI 10.1523/JNEUROSCI.2599-15.2015; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Guo JS, 2007, SPINAL CORD, V45, P15, DOI 10.1038/sj.sc.3101943; Gwak SJ, 2017, BIOMATERIALS, V121, P155, DOI 10.1016/j.biomaterials.2017.01.003; Han Q, 2015, EXP NEUROL, V267, P194, DOI 10.1016/j.expneurol.2015.03.008; Hase T, 2002, J NEUROTRAUM, V19, P267, DOI 10.1089/08977150252807009; Hase T, 2002, EUR J NEUROSCI, V15, P969, DOI 10.1046/j.1460-9568.2002.01932.x; He WW, 2016, NATURE, V532, P402, DOI 10.1038/nature16499; Herrera JJ, 2009, J NEUROTRAUM, V26, P995, DOI [10.1089/neu.2008.0779, 10.1089/neu.2008-0779]; Hu JL, 2017, NEURAL REGEN RES, V12, P525, DOI 10.4103/1673-5374.205080; Hwang WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02439; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9; Kawabori M, 2015, METAB BRAIN DIS, V30, P381, DOI 10.1007/s11011-014-9531-6; Keefe KM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030548; Khaibullina AA, 2004, DEV BRAIN RES, V148, P59, DOI 10.1016/j.devbrainres.2003.09.022; Kitayama M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025234; Lai BQ, 2016, BIOMATERIALS, V109, P40, DOI 10.1016/j.biomaterials.2016.08.005; Lang BT, 2015, NATURE, V518, P404, DOI 10.1038/nature13974; Leach MK, 2011, JOVE-J VIS EXP, DOI 10.3791/2389; Lee H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6514; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Merrill MJ, 2005, J NEUROSURG, V103, P853, DOI 10.3171/jns.2005.103.5.0853; Mukhamedshina YO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151745; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nicola FD, 2017, BRAIN RES, V1663, P95, DOI 10.1016/j.brainres.2017.03.015; Oh JS, 2012, NEUROREPORT, V23, P174, DOI 10.1097/WNR.0b013e32834f4f3a; Park SS, 2012, CYTOTHERAPY, V14, P584, DOI 10.3109/14653249.2012.658913; Patel BN, 2002, J NEUROSCI, V22, P6578; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Qi C, 2014, J NEUROSCI, V34, P4494, DOI 10.1523/JNEUROSCI.3647-13.2014; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Rossi SL, 2009, CURR OPIN BIOTECH, V20, P552, DOI 10.1016/j.copbio.2009.09.008; Rossignol S, 2006, PHILOS T R SOC B, V361, P1647, DOI 10.1098/rstb.2006.1889; Rossignol S, 2011, ANNU REV NEUROSCI, V34, P413, DOI 10.1146/annurev-neuro-061010-113746; Saban MR, 2008, AM J PHYSIOL-RENAL, V295, pF60, DOI 10.1152/ajprenal.00618.2007; Sanchez A, 2010, NEUROPEPTIDES, V44, P323, DOI 10.1016/j.npep.2010.04.002; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; Seiler S, 2017, BRAIN RES, V1668, P56, DOI 10.1016/j.brainres.2017.05.015; Shen ZL, 2017, NEUROCHEM RES, V42, P2336, DOI 10.1007/s11064-017-2251-7; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Skirgaudas M, 1996, NEUROSURGERY, V39, P537, DOI 10.1097/00006123-199609000-00021; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Stenudd M, 2015, JAMA NEUROL, V72, P235, DOI 10.1001/jamaneurol.2014.2927; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Tillakaratne NJK, 2010, NEUROSCIENCE, V166, P23, DOI 10.1016/j.neuroscience.2009.12.010; Wakabayashi Y, 2001, SPINE, V26, P1215, DOI 10.1097/00007632-200106010-00009; Wang HY, 2015, BIOCHEM BIOPH RES CO, V464, P453, DOI 10.1016/j.bbrc.2015.06.146; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Willerslev-Olsen M, 2015, BRAIN, V138, P589, DOI 10.1093/brain/awu399; Xia X, 2014, MOL BIOL REP, V41, P6827, DOI 10.1007/s11033-014-3568-9; Xu JP, 2017, BRAIN RES, V1670, P32, DOI 10.1016/j.brainres.2017.06.012; Xu S, 2015, NEUROSCI LETT, V589, P31, DOI 10.1016/j.neulet.2015.01.015; Yin X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038381; Yuan QJ, 2006, NEUROREPORT, V17, P711, DOI 10.1097/01.wnr.0000214390.35480.1a; Yuan QJ, 2013, NEUROSCI BULL, V29, P509, DOI 10.1007/s12264-013-1356-5; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895; Zeng X, 2015, BIOMATERIALS, V53, P184, DOI 10.1016/j.biomaterials.2015.02.073; Zhang J, 2014, J NEUROSCI, V34, P5184, DOI 10.1523/JNEUROSCI.4129-13.2014; Zhou ZP, 2016, NEUROSCIENCE, V329, P193, DOI 10.1016/j.neuroscience.2016.05.019	81	23	23	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	NOV 29	2017	11								381	10.3389/fncel.2017.00381			16	Neurosciences	Neurosciences & Neurology	FO0NQ	WOS:000416442000001	29238292	DOAJ Gold, Green Published			2021-06-18	
J	Su, WS; Wu, CH; Chen, SF; Yang, FY				Su, Wei-Shen; Wu, Chun-Hu; Chen, Szu-Fu; Yang, Feng-Yi			Transcranial ultrasound stimulation promotes brain-derived neurotrophic factor and reduces apoptosis in a mouse model of traumatic brain injury	BRAIN STIMULATION			English	Article						Ultrasound; Traumatic brain injury; Neurotrophic factor; BDNF; Apoptosis	INTENSITY PULSED ULTRASOUND; BLOOD-BRAIN; HEAD-INJURY; FOCUSED ULTRASOUND; CELL-DEATH; RAT MODEL; BDNF; INCREASES; NEUROPROTECTION; PERMEABILITY	Background: The protein expressions of brain-derived neurotrophic factor (BDNF) can be elevated by transcranial ultrasound stimulation in the rat brain. Objective: The purpose of this study was to investigate the effects and underlying mechanisms of BDNF enhancement by low-intensity pulsed ultrasound (LIPUS) on traumatic brain injury (TBI). Methods: Mice subjected to controlled cortical impact injury were treated with LIPUS in the injured region daily for a period of 4 days. Western blot analysis and immunohistochemistry were performed to assess the effects of LIPUS. Results: The results showed that the LIPUS treatment significantly promoted the neurotrophic factors BDNF and vascular endothelial growth factor (VEGF) at day 4 after TBI. Meanwhile, LIPUS also enhanced the phosphorylation of Tropomyosin-related kinase B (TrkB), Akt, and cAMP-response element binding protein (CREB). Furthermore, treatment with LIPUS significantly decreased the level of cleaved caspase-3. The reduction of apoptotic process was inhibited by the anti-BDNF antibody. Conclusions: In short, post-injury LIPUS treatment increased BDNF protein levels and inhibited the progression of apoptosis following TBI. The neuroprotective effects of LIPUS may be associated with enhancements of the protein levels of neurotrophic factors, at least partially via the TrkB/Akt-CREB signaling pathway. (C) 2017 Elsevier Inc. All rights reserved.	[Su, Wei-Shen; Yang, Feng-Yi] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei, Taiwan; [Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol & Biophys, Taipei, Taiwan; [Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, 45 Cheng Hsin St, Taipei 11221, Taiwan; [Yang, Feng-Yi] Natl Yang Ming Univ, Biophoton & Mol Imaging Res Ctr, Taipei, Taiwan	Chen, SF (corresponding author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, 45 Cheng Hsin St, Taipei 11221, Taiwan.; Yang, FY (corresponding author), Natl Yang Ming Univ, Sch Biomed Sci & Engn, Dept Biomed Imaging & Radiol Sci, 155,Sec 2,Li Nong St, Taipei 11221, Taiwan.	szufuchen@yahoo.com.tw; fyyang@ym.edu.tw	WU, CHUN-HU/P-3958-2018	WU, CHUN-HU/0000-0001-6851-7936	Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST 105-2221-E-010-003, MOST 104-2314-B-010-003-MY3, 101-2314-B-350-001-MY3]; Veterans General Hospitals University System of Taiwan Joint Research Program [VGHUST106-G7-6-1]; Cheng Hsin General Hospital Foundation [CY10622, CY10418, CHGH103-34]; Taiwan Ministry of Education's Aim for the Top University Plan	This study was supported by grants from the Ministry of Science and Technology of Taiwan (no. MOST 105-2221-E-010-003, MOST 104-2314-B-010-003-MY3, and 101-2314-B-350-001-MY3), the Veterans General Hospitals University System of Taiwan Joint Research Program (#VGHUST106-G7-6-1), the Cheng Hsin General Hospital Foundation (no. CY10622, CY10418 and CHGH103-34), and the Taiwan Ministry of Education's Aim for the Top University Plan.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Chen CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115694; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Clark RSB, 1999, FASEB J, V13, P813; Dalecki D, 2004, ANNU REV BIOMED ENG, V6, P229, DOI 10.1146/annurev.bioeng.6.040803.140126; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FRY WJ, 1968, J ACOUST SOC AM, V44, P919, DOI 10.1121/1.1911230; Fulmer CG, 2014, J NEUROSCI, V34, P8186, DOI 10.1523/JNEUROSCI.4267-13.2014; Gavrilov LR, 1996, ULTRASOUND MED BIOL, V22, P179, DOI 10.1016/0301-5629(96)83782-3; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hanawa K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104863; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang SL, 2017, RADIOLOGY, V282, P113, DOI 10.1148/radiol.2016160095; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Jeon SJ, 2011, NEUROSCI RES, V69, P214, DOI 10.1016/j.neures.2010.11.008; Krasovitski B, 2011, P NATL ACAD SCI USA, V108, P3258, DOI 10.1073/pnas.1015771108; Lin WT, 2015, SCI REP-UK, V5, DOI 10.1038/srep09671; Liu SH, 2017, CEREB CORTEX, V27, P3152, DOI 10.1093/cercor/bhw169; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Pandya CD, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0047-9; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Su WS, 2015, ONCOTARGET, V6, P42290, DOI 10.18632/oncotarget.5978; ter Haar G, 2007, PROG BIOPHYS MOL BIO, V93, P111, DOI 10.1016/j.pbiomolbio.2006.07.005; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Wang ZT, 2013, J MOL NEUROSCI, V49, P409, DOI 10.1007/s12031-012-9908-0; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Xia P, 2015, ULTRASOUND MED BIOL, V41, P1690, DOI 10.1016/j.ultrasmedbio.2015.01.014; Yang FY, 2015, BRAIN STIMUL, V8, P465, DOI 10.1016/j.brs.2014.11.017; Yang FY, 2014, NEUROIMAGE, V90, P93, DOI 10.1016/j.neuroimage.2013.12.033; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje	42	23	26	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	NOV-DEC	2017	10	6					1032	1041		10.1016/j.brs.2017.09.003			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FL2UE	WOS:000414074400003	28939348				2021-06-18	
J	Tulsky, DS; Carlozzi, NE; Holdnack, J; Heaton, RK; Wong, A; Goldsmith, A; Heinemann, AW				Tulsky, David S.; Carlozzi, Noelle E.; Holdnack, James; Heaton, Robert K.; Wong, Alex; Goldsmith, Arielle; Heinemann, Allen W.			Using the NIH Toolbox Cognition Battery (NIHTB-CB) in Individuals With Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						TBI; traumatic brain injury; cognitive assessment; neuropsychological assessment; psychometrics	MEASURING EPISODIC MEMORY; PROCESSING SPEED TEST; NEUROPSYCHOLOGICAL ASSESSMENT; BEHAVIORAL FUNCTION; EXECUTIVE FUNCTION; HEAD-INJURY; CRITERION VALIDITY; SCALE-4TH EDITION; COMPOSITE SCORES; COMPLICATED MILD	Purpose/Objective: The NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery (NIHTB-CB) is a common data element for use in individuals with traumatic brain injury (TBI). This study evaluates its sensitivity and specificity in distinguishing individuals with complicated mild, moderate, or severe TBI, and provides support for the construct validity of the NIHTB-CB in individuals with TBI. Research Method: One hundred eighty-two individuals with TBI (n = 83 complicated mild/moderate; n = 99 severe) completed the NIHTB-CB and neuropsychological criterion measures. Complete data were obtained on 158 participants. A control sample of 158 individuals without known neurological impairment was extracted from the NIHTB-CB normative sample. Multivariate analyses of variance determined the sensitivity of the NIHTB-CB measures to TBI and injury severity (complicated mild/ moderate TBI, severe TBI, and controls) on the demographically corrected NIHTB-CB composite scores and seven subtests. A descriptive analysis of the sensitivity of each subtest was conducted. Finally, correlations between NIHTB-CB measures and criterion tests assessed convergent and discriminant validity. Results: Multivariate analyses indicated that there was a main effect for group (complicated mild/ moderate vs. severe vs. controls) for fluid scores in the NIHTB-CB as opposed to only marginally significant results for the verbal scores. Moderate to strong relationships were found between the NIHTB-CB measures and their corresponding neuropsychological measures (convergent validity), whereas much smaller correlations were found between measures of different cognitive domains (discriminant validity). Conclusions: Findings provide evidence of construct validity and the clinical utility of the NIHTB-CB in individuals with TBI.	[Tulsky, David S.; Holdnack, James] Univ Delaware, Ctr Hlth Assessment Res & Translat, Newark, DE 19713 USA; [Tulsky, David S.] Univ Delaware, Dept Phys Therapy, Newark, DE 19713 USA; [Tulsky, David S.] Univ Delaware, Dept Psychol & Brain Sci, Newark, DE 19713 USA; [Carlozzi, Noelle E.] Univ Michigan, Ctr Clin Outcomes Dev & Applicat CODA, Ann Arbor, MI 48109 USA; [Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Holdnack, James] Pearson Assessment, San Antonio, TX USA; [Heaton, Robert K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Wong, Alex] Washington Univ, Program Occupat Therapy, St Louis, MO USA; [Wong, Alex] Washington Univ, Dept Neurol, St Louis, MO USA; [Goldsmith, Arielle; Heinemann, Allen W.] Shirley Ryan AbilityLab, Ctr Rehabil Outcomes Res, Chicago, IL USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Evanston, IL 60208 USA	Tulsky, DS (corresponding author), Univ Delaware, STAR Hlth Sci, 540 South Coll Ave, Newark, DE 19713 USA.	dtulsky@udel.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Wong, Alex/0000-0002-4423-2685; Tulsky, David/0000-0002-4335-4509	National Institute on Disability, Independent Living, and Research Rehabilitation grant [H133B090024]; Office of Behavioral and Social Sciences Research, National Institutes of Health [HHS-N-260-2006-00007-C]; Institutional Development Award (IDeA) from NIH, National Institute of General Medical Sciences [U54-GM104941]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH062512] Funding Source: NIH RePORTER	Support was provided by the National Institute on Disability, Independent Living, and Research Rehabilitation grant H133B090024 (PI: Allen W. Heinemann). The Blueprint for Neuroscience Research. The Office of Behavioral and Social Sciences Research, National Institutes of Health, supported the collection of the adult norming sample under contract HHS-N-260-2006-00007-C (PI: Richard C. Gershon). Salary support for Dr. Holdnack was provided by an Institutional Development Award (IDeA) from the NIH, National Institute of General Medical Sciences, Grant U54-GM104941 (PI: Binder-Macleod). We thank their talented and dedicated research staff: Ana Miskovic, Sara Jerousek, Sue Tucker, Jessica Dashner, Cathy Crawley, Ben Aziz, Julie Grech, Livia Vanden Belt, and Angela Miciura.	Akshoomoff N, 2013, MONOGR SOC RES CHILD, V78, P119, DOI 10.1111/mono.12038; Bauer PJ, 2013, MONOGR SOC RES CHILD, V78, P34, DOI 10.1111/mono.12033; Baughman RW, 2006, J NEUROSCI, V26, P10329, DOI 10.1523/JNEUROSCI.3979-06.2006; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Carlozzi NE, 2015, ARCH CLIN NEUROPSYCH, V30, P359, DOI 10.1093/arclin/acv031; Carlozzi NE, 2015, CLIN NEUROPSYCHOL, V29, P21, DOI 10.1080/13854046.2015.1005677; Carlozzi NE, 2014, J INT NEUROPSYCH SOC, V20, P630, DOI 10.1017/S1355617714000319; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Carlozzi NE, 2013, MONOGR SOC RES CHILD, V78, P88, DOI 10.1111/mono.12036; Casaletto KB, 2015, J INT NEUROPSYCH SOC, V21, P378, DOI 10.1017/S1355617715000351; Cohen J., 2003, APPL MULTIPLE CORREL; Corey DM, 1998, J GEN PSYCHOL, V125, P245, DOI 10.1080/00221309809595548; Crowe SF, 2013, J CLIN EXP NEUROPSYC, V35, P298, DOI 10.1080/13803395.2013.771616; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2014, J INT NEUROPSYCH SOC, V20, P611, DOI 10.1017/S1355617714000460; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2016, ARCH CLIN NEUROPSYCH, V31, P29, DOI 10.1093/arclin/acv048; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Donders J, 2012, ARCH CLIN NEUROPSYCH, V27, P440, DOI 10.1093/arclin/acs043; Fisher R., 1958, STAT METHODS RES WOR; Gershon RC, 2014, J INT NEUROPSYCH SOC, V20, P642, DOI 10.1017/S1355617714000411; Gershon RC, 2013, MONOGR SOC RES CHILD, V78, P49, DOI 10.1111/mono.12034; Gershon RC, 2013, NEUROLOGY, V80, pS2, DOI 10.1212/WNL.0b013e3182872e5f; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Heaton R.K., 2009, NEUROPSYCHOLOGICAL A, P127; Heaton RK, 2014, J INT NEUROPSYCH SOC, V20, P588, DOI 10.1017/S1355617714000241; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Holdnack J., 2006, WISC 4 ADV CLIN INTE, P201; Iverson GL, 2013, PRACT RESOUR MENT, P485, DOI 10.1016/B978-0-12-386934-0.00010-9; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P497, DOI 10.1080/01688638508401281; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Magasi S, 2017, REHABIL PSYCHOL, V62, P455, DOI 10.1037/rep0000191; Merkley TL, 2013, J INT NEUROPSYCH SOC, V19, P899, DOI 10.1017/S135561771300074X; Mungas D, 2014, J INT NEUROPSYCH SOC, V20, P579, DOI 10.1017/S1355617714000307; Mungas D, 2013, MONOGR SOC RES CHILD, V78, P103, DOI 10.1111/mono.12037; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sinclair KL, 2013, J CLIN EXP NEUROPSYC, V35, P210, DOI 10.1080/13803395.2012.762340; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; TEASDALE G, 1974, LANCET, V2, P81; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tulsky DS, 2014, J INT NEUROPSYCH SOC, V20, P599, DOI 10.1017/S135561771400040X; Tulsky DS, 2013, MONOGR SOC RES CHILD, V78, P70, DOI 10.1111/mono.12035; Tulsky DS, 2003, PSYCHOL ASSESSMENT, V15, P149, DOI 10.1037/1040-3590.15.2.149; Weintraub S, 2014, J INT NEUROPSYCH SOC, V20, P567, DOI 10.1017/S1355617714000320; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wright MJ, 2014, J CLIN EXP NEUROPSYC, V36, P268, DOI 10.1080/13803395.2014.884543; Zelazo PD, 2014, J INT NEUROPSYCH SOC, V20, P620, DOI 10.1017/S1355617714000472; Zelazo PD, 2013, MONOGR SOC RES CHILD, V78, P16, DOI 10.1111/mono.12032	60	23	23	0	5	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2017	62	4					413	424		10.1037/rep0000174			12	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	FT1CK	WOS:000422871400002	29265862	Green Accepted, Bronze			2021-06-18	
J	Galvagno, SM; Fox, EE; Appana, SN; Baraniuk, S; Bosarge, PL; Bulger, EM; Callcut, RA; Cotton, BA; Goodman, M; Inaba, K; O'Keeffe, T; Schreiber, MA; Wade, CE; Scalea, TM; Holcomb, JB; Stein, DM				Galvagno, Samuel M., Jr.; Fox, Erin E.; Appana, Savitri N.; Baraniuk, Sarah; Bosarge, Patrick L.; Bulger, Eileen M.; Callcut, Rachel A.; Cotton, Bryan A.; Goodman, Michael; Inaba, Kenji; O'Keeffe, Terence; Schreiber, Martin A.; Wade, Charles E.; Scalea, Thomas M.; Holcomb, John B.; Stein, Deborah M.		PROPPR Study Grp	Outcomes after concomitant traumatic brain injury and hemorrhagic shock: A secondary analysis from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios trial	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; hemorrhagic shock; resuscitation; trauma	DAMAGE-CONTROL RESUSCITATION; COMBAT CASUALTY CARE; FRESH-FROZEN PLASMA; LARGE ANIMAL-MODEL; CRITICALLY-ILL; CLINICAL-TRIAL; SERUM LACTATE; BASE EXCESS; COAGULOPATHY; TRANSFUSION	BACKGROUND: Often the clinician is faced with a diagnostic and therapeutic dilemma in patients with concomitant traumatic brain injury (TBI) and hemorrhagic shock (HS), as rapid deterioration from either can be fatal. Knowledge about outcomes after concomitant TBI and HS may help prioritize the emergent management of these patients. We hypothesized that patients with concomitant TBI and HS (TBI + HS) had worse outcomes and required more intensive care compared with patients with only one of these injuries. METHODS: This is a post hoc analysis of the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. TBI was defined by a head Abbreviated Injury Scale score greater than 2. HS was defined as a base excess of -4 or less and/or shock index of 0.9 or greater. The primary outcome for this analysis was mortality at 30 days. Logistic regression, using generalized estimating equations, was used to model categorical outcomes. RESULTS: Six hundred seventy patients were included. Patients with TBI + HS had significantly higher lactate (median, 6.3; interquartile range, 4.7-9.2) compared with the TBI group (median, 3.3; interquartile range, 2.3-4). TBI + HS patients had higher activated prothrombin times and lower platelet counts. Unadjusted mortality was higher in the TBI + HS (51.6%) and TBI (50%) groups compared with the HS (17.5%) and neither group (7.7%). Adjusted odds of death in the TBI and TBI + HS groups were 8.2 (95% confidence interval, 3.4-19.5) and 10.6 (95% confidence interval, 4.8-23.2) times higher, respectively. Ventilator, intensive care unit-free and hospital-free days were lower in the TBI and TBI + HS groups compared with the other groups. Patients with TBI + HS or TBI had significantly greater odds of developing a respiratory complication compared with the neither group. CONCLUSION: The addition of TBI to HS is associated with worse coagulopathy before resuscitation and increased mortality. When controlling for multiple known confounders, the diagnosis of TBI alone or TBI+ HS was associated with significantly greater odds of developing respiratory complications. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.)	[Galvagno, Samuel M., Jr.] Univ Maryland, Dept Anesthesiol, Div Crit Care Med,Sch Med, Med Ctr,Program Trauma,R Adams Cowley Shock Traum, 22 South Greene St,T3N08, Baltimore, MD 21201 USA; [Fox, Erin E.] Univ Texas Hlth Sci Ctr Houston, Div Acute Care Surg, Dept Surg, Ctr Translat Injury Res CeTIR, Houston, TX 77030 USA; [Appana, Savitri N.] Univ Texas Hlth Sci Ctr Houston, Dept Biostat, Houston, TX 77030 USA; [Baraniuk, Sarah] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA; [Bosarge, Patrick L.] Univ Alabama Birmingham, Sch Med, Dept Surg, Div Acute Care Surg, Birmingham, AL 35294 USA; [Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Bulger, Eileen M.] Harborview Med Ctr, Dept Trauma, Seattle, WA USA; [Callcut, Rachel A.] Univ Calif San Francisco, Div Gen Surg, San Francisco, CA 94143 USA; [Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, Div Acute Care Surg, Dept Surg, Houston, TX 77030 USA; [Goodman, Michael] Univ Cincinnati, Dept Surg, Sch Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA; [Inaba, Kenji] Univ Southern Calif, Keck Sch Med, Dept Surg, Los Angeles, CA USA; [O'Keeffe, Terence] Univ Arizona, Sch Med, Tucson, AZ USA; [Schreiber, Martin A.] Oregon Hlth & Sci Univ, Sch Med Portland, Div Trauma Crit Care & Acute Care Surg, Portland, OR 97201 USA; [Wade, Charles E.; Holcomb, John B.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX USA; [Scalea, Thomas M.] Univ Maryland, Sch Med, Program Trauma Francis X Kelly, Baltimore, MD 21201 USA; [Stein, Deborah M.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Stein, Deborah M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Dept Surg,Program Trauma, Baltimore, MD 21201 USA	Galvagno, SM (corresponding author), Univ Maryland, Dept Anesthesiol, Div Crit Care Med,Sch Med, Med Ctr,Program Trauma,R Adams Cowley Shock Traum, 22 South Greene St,T3N08, Baltimore, MD 21201 USA.	sgalvagno@anes.umm.edu	INABA, KENJI/AAC-8532-2020; Wong, Monica D/D-9016-2017	Wong, Monica D/0000-0001-7041-9518; Stein, Deborah/0000-0003-3683-3963; Galvagno, Samuel/0000-0001-5563-4092; holcomb, john/0000-0001-8312-9157	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [K01ES026834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50GM038529] Funding Source: NIH RePORTER; CIHRCanadian Institutes of Health Research (CIHR) [CRR-120612] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01 HL077863] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [K01 ES026834] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50 GM038529] Funding Source: Medline		Alali Aziz S, 2014, J Trauma Acute Care Surg, V76, P70, DOI 10.1097/TA.0b013e3182a8fd6a; Angus DC, 2010, CRIT CARE MED, V38, P527, DOI 10.1097/CCM.0b013e3181c0259d; Arora Shubhangi, 2014, J Emerg Trauma Shock, V7, P25, DOI 10.4103/0974-2700.125635; Baraniuk S, 2014, INJURY, V45, P1287, DOI 10.1016/j.injury.2014.06.001; Bogert JN, 2016, J INTENSIVE CARE MED, V31, P177, DOI 10.1177/0885066614558018; Caputo ND, 2015, AM J EMERG MED, V33, P1134, DOI 10.1016/j.ajem.2015.04.085; Chang R, 2017, SURGERY, V161, P538, DOI 10.1016/j.surg.2016.08.023; Clark DE, 2013, PHYS THER, V93, P186, DOI 10.2522/ptj.20110417; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; Da Luz LT, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0518-9; Dekker SE, 2016, J SURG RES, V205, P147, DOI 10.1016/j.jss.2016.06.023; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; Pinto FCG, 2015, ARQ NEURO-PSIQUIAT, V73, P499, DOI 10.1590/0004-282X20150039; Halaweish I, 2015, J AM COLL SURGEONS, V220, P809, DOI 10.1016/j.jamcollsurg.2015.01.057; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Hu Y, 2015, J SURG RES, V195, P284, DOI 10.1016/j.jss.2015.01.038; Hunt H, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010438.pub2; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Lee K, 2012, CRIT CARE RES PRAC, V2012, P1; Leung LY, 2016, J TRAUMA ACUTE CARE, V81, P860, DOI 10.1097/TA.0000000000001206; Leung LY, 2016, METHODS MOL BIOL, V1462, P445, DOI 10.1007/978-1-4939-3816-2_25; Leung LY, 2013, J NEUROTRAUM, V30, P1288, DOI 10.1089/neu.2012.2715; Liou DZ, 2014, AM SURGEON, V80, P994; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; Park M, 2008, BRAZ J MED BIOL RES, V41, P241; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Perl VJU, 2016, J TRAUMA ACUTE CARE, V80, P568, DOI 10.1097/TA.0000000000000960; Proctor Julie L, 2015, J Trauma Acute Care Surg, V79, pS101, DOI 10.1097/TA.0000000000000742; Shrestha B, 2015, J TRAUMA ACUTE CARE, V78, P336, DOI 10.1097/TA.0000000000000514; Sillesen M, 2017, J AM COLL SURGEONS, V224, P49, DOI 10.1016/j.jamcollsurg.2016.09.015; Sillesen M, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0046-2; Singhal R, 2005, EUR J VASC ENDOVASC, V30, P263, DOI 10.1016/j.ejvs.2005.04.003; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Undurraga Perl VJ, 2016, J TRAUMA ACUTE CARE, V80, P74; Whiting P, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19580; Yuan Q, 2016, J NEUROTRAUM, V33, P1279, DOI 10.1089/neu.2015.4205; Yumoto T, 2014, J INTENSIVE CARE, V2, DOI 10.1186/s40560-014-0054-3; Zhu HJ, 2016, INJURY, V47, P2131, DOI 10.1016/j.injury.2016.07.028	46	23	23	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2017	83	4					668	674		10.1097/TA.0000000000001584			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	FH8PN	WOS:000411460500016	28930959	Green Accepted			2021-06-18	
J	Spaite, DW; Hu, CC; Bobrow, BJ; Chikani, V; Barnhart, B; Gaither, JB; Denninghoff, KR; Adelson, PD; Keim, SM; Viscusi, C; Mullins, T; Rice, AD; Sherrill, D				Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Adelson, P. David; Keim, Samuel M.; Viscusi, Chad; Mullins, Terry; Rice, Amber D.; Sherrill, Duane			Association of Out-of-Hospital Hypotension Depth and Duration With Traumatic Brain Injury Mortality	ANNALS OF EMERGENCY MEDICINE			English	Article							SEVERE HEAD-INJURY; BLOOD-PRESSURE; PROGNOSTIC VALUE; HYPOXIA; INSULTS; SEVERITY; RESUSCITATION; MANAGEMENT; HYPOXEMIA; CHILDREN	Study objective: Out-of-hospital hypotension has been associated with increased mortality in traumatic brain injury. The association of traumatic brain injury mortality with the depth or duration of out-of-hospital hypotension is unknown. We evaluated the relationship between the depth and duration of out-of-hospital hypotension and mortality in major traumatic brain injury. Methods: We evaluated adults and older children with moderate or severe traumatic brain injury in the preimplementation cohort of Arizona's statewide Excellence in Prehospital Injury Care study. We used logistic regression to determine the association between the depth-duration dose of hypotension (depth of systolic blood pressure <90 mm Hg integrated over duration [minutes] of hypotension) and odds of inhospital death, controlling for significant confounders. Results: There were 7,521 traumatic brain injury cases included (70.6% male patients; median age 40 years [interquartile range 24 to 58]). Mortality was 7.8% (95% confidence interval [CI] 7.2% to 8.5%) among the 6,982 patients without hypotension (systolic blood pressure >= 90 mm Hg) and 33.4% (95% CI 29.4% to 37.6%) among the 539 hypotensive patients(systolic blood pressure <90 mm Hg). Mortality was higher with increased hypotension dose: 0.01 to 14.99 mm Hg-minutes 16.3%; 15 to 49.99 mm Hg-minutes 28.1%; 50 to 141.99 mm Hg-minutes 38.8%; and greater than or equal to 142 mm Hg-minutes 50.4%. Log(2) (the logarithm in base 2) of hypotension dose was associated with traumatic brain injury mortality (adjusted odds ratio 1.19 [95% CI 1.14 to 1.25] per 2-fold increase of dose). Conclusion: In this study, the depth and duration of out-of-hospital hypotension were associated with increased traumatic brain injury mortality. Assessments linking out-of-hospital blood pressure with traumatic brain injury outcomes should consider both depth and duration of hypotension.	[Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Keim, Samuel M.; Viscusi, Chad; Rice, Amber D.] Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ 85004 USA; [Adelson, P. David] Univ Arizona, Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Adelson, P. David] Univ Arizona, Coll Med, Dept Child Hlth Neurosurg, Phoenix, AZ USA; [Spaite, Daniel W.; Bobrow, Bentley J.; Gaither, Joshua B.; Denninghoff, Kurt R.; Keim, Samuel M.; Viscusi, Chad; Rice, Amber D.] Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ USA; [Hu, Chengcheng; Sherrill, Duane] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA; [Bobrow, Bentley J.; Chikani, Vatsal; Mullins, Terry] Arizona Dept Hlth Serv, Bur EMS & Trauma Syst, Phoenix, AZ 85007 USA	Spaite, DW (corresponding author), Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ 85004 USA.; Spaite, DW (corresponding author), Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ USA.	dan@aemrc.arizona.edu	Adelson, David/W-2083-2019	Chikani, Vatsal/0000-0003-0904-7887	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award R01NS071049. The University of Arizona receives funding from the NIH supporting the Excellence in Prehospital Injury Care study. This includes support for the following authors: Drs. Spaite, Bobrow, Gaither, Denninghoff, Adelson, Viscusi, and Sherrill and Mssrs. Chikani and Barnhart.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bobrow BJ, 2013, ANN EMERG MED, V62, P47, DOI 10.1016/j.annemergmed.2012.12.020; Brenner M, 2012, J TRAUMA ACUTE CARE, V72, P1135, DOI 10.1097/TA.0b013e31824af90b; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chesnut RM, 2000, J NEUROTRAUM, V17, P199; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Franschman G, 2011, J TRAUMA, V71, P826, DOI 10.1097/TA.0b013e31820cebf0; GENTLEMAN D, 1992, INT SURG, V77, P297; Haddad Samir, 2005, Middle East Journal of Anesthesiology, V18, P45; Hannan EL, 2005, J TRAUMA, V58, P244, DOI 10.1097/01.TA.0000141995.44721.44; HILL DA, 1993, AUST NZ J SURG, V63, P604, DOI 10.1111/j.1445-2197.1993.tb00466.x; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JEFFREYS RV, 1981, LANCET, V2, P459; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MAYER TA, 1985, ANN EMERG MED, V14, P1178, DOI 10.1016/S0196-0644(85)81025-8; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Newgard CD, 2013, J AM COLL SURGEONS, V216, P147, DOI 10.1016/j.jamcollsurg.2012.08.017; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pencina MJ, 2011, STAT MED, V30, P11, DOI 10.1002/sim.4085; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; R Core Team, 2018, R LANG ENV STAT COMP; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SEELIG JM, 1986, INTRACRANIAL PRESSUR, P675; Shutter LA, 2008, ANN EMERG MED, V51, pS37, DOI 10.1016/j.annemergmed.2007.11.013; Spaite DW, 2017, JAMA SURG, V152, P360, DOI 10.1001/jamasurg.2016.4686; Spaite DW, 2017, ANN EMERG MED, V69, P62, DOI 10.1016/j.annemergmed.2016.08.007; Spaite DW, 2014, ACAD EMERG MED, V21, P818, DOI 10.1111/acem.12411; Spaite DW, 1993, PREHOSP DISASTER MED, V8, pS35; Stassen W, 2014, SAMJ S AFR MED J, V104, P424, DOI [10.7196/SAMJ.7494, 10.7196/samj.7494]; Stewart KE, 2011, INJURY, V42, P934, DOI 10.1016/j.injury.2010.05.033; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Wood S., 2017, GEN ADDITIVE MODELS, V2nd ed.; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x; YEH KC, 1978, J PHARMACOKINET BIOP, V6, P79, DOI 10.1007/BF01066064	54	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	OCT	2017	70	4					522	530		10.1016/j.annemergmed.2017.03.027			9	Emergency Medicine	Emergency Medicine	FJ7VM	WOS:000412967800014	28559036	Green Accepted			2021-06-18	
J	Li, JR; Donangelo, I; Abe, K; Scremin, O; Ke, SJ; Li, F; Milanesi, A; Liu, YY; Brent, GA				Li, Jianrong; Donangelo, Ines; Abe, Kiyomi; Scremin, Oscar; Ke, Sujie; Li, Feng; Milanesi, Anna; Liu, Yan-Yun; Brent, Gregory A.			Thyroid hormone treatment activates protective pathways in both in vivo and in vitro models of neuronal injury	MOLECULAR AND CELLULAR ENDOCRINOLOGY			English	Article						Controlled cortical injury (CCI); Thyroid hormone; Deiodinase; HIF-1 alpha; HIF-2 alpha; Hypoxia-responsive genes; Thyroid hormone responsive genes	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; NEUROBLASTOMA-CELLS; GENE-EXPRESSION; GROWTH-FACTOR; NEUROGENESIS; RECEPTOR; PROLIFERATION; PATHOPHYSIOLOGY; OVEREXPRESSION	Thyroid hormone plays an important role in brain development and adult brain function, and may influence neuronal recovery after Traumatic Brain Injury (TBI). We utilized both animal and cell culture models to determine the effects of thyroid hormone treatment, post TBI or during hypoxia, on genes important for neuronal survival and neurogenesis. We show that TBI in rats is associated with a reduction in serum thyroxine (T4) and triiodothyronine (T3). A single dose of levothyroxine (T4), one hour after injury, increased serum T4 and normalized serum T3 levels. Expression of genes important for thyroid hormone action in the brain, MCT8 and Type 2 deiodinase (Dio2) mRNA, diminished after injury, but were partially restored with T4 treatment. mRNA from the Type 3 deiodinase (Dio3) gene, which inactivates T4 to reverse T3 (Gamma T3), was induced 2.7 fold by TBI, and further stimulated 6.7-fold by T4 treatment. T4 treatment significantly increased the expression of mRNA from Bcl2, VEGFA, Sox2 and neurotrophin, genes important for neuronal survival and recovery. The cortex, compared to the hippo campus and cerebellum, sustained the greatest injury and had the most significant change in gene expression as a result of injury and the greatest response to T4 treatment. We utilized hypoxia to study the effect of neuronal injury in vitro. Neuroblastoma cells were exposed to reduced oxygen tension, 0.2%, and were compared to cells grown at control oxygen levels of 21%. T3 treatment significantly increased hypoxia inducible factor (HIF)-2 alpha protein, but not HIF-1 alpha. In a hypoxia time course exposure, expression of hypoxia-mediated genes (VEGF, Enolase, HIF2 alpha, c-Jun) peaked at least 8 h earlier with T3-treatment, compared to cells grown without T3. The early induction of these genes may promote cellular growth after injury. After hypoxic injury, T3 induced mRNA expression of the genes, KLF9 and hairless, important for T3-mediated brain function. The findings from both in vitro and in vivo studies support a role of thyroid hormone in activating pathways important for neuronal protection and promotion of neuronal recovery after injury. Published by Elsevier Ireland Ltd.	[Li, Jianrong; Donangelo, Ines; Abe, Kiyomi; Ke, Sujie; Li, Feng; Milanesi, Anna; Liu, Yan-Yun; Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Endocrinol Div, Mol Endocrinol Lab,VA Greater Angeles Healthcare, Los Angeles, CA 90095 USA; [Scremin, Oscar; Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; [Li, Jianrong] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China	Liu, YY; Brent, GA (corresponding author), VA Greater Los Angeles Healthcare Syst, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	yyl@ucla.edu; gbrent@mednet.ucla.edu	Abe, Kiyomi/AAM-6036-2021		United States Veteran Administration Merit Review; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08 DK097295]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08DK097295] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003665] Funding Source: NIH RePORTER	This work is supported by the United States Veteran Administration Merit Review to GAB and NIH K08 DK097295 to AM.	Acosta S, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-12; Alonso-Merino E, 2016, P NATL ACAD SCI USA, V113, pE3451, DOI 10.1073/pnas.1506113113; Anderson GW, 2008, CEREBELLUM, V7, P60, DOI 10.1007/s12311-008-0021-4; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bernal J, 2007, NAT CLIN PRACT ENDOC, V3, P249, DOI 10.1038/ncpendmet0424; Bowyer JF, 2012, JOVE-J VIS EXP, DOI 10.3791/4285; Brent GA, 2012, J CLIN INVEST, V122, P3035, DOI 10.1172/JCI60047; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Cayrol F, 2015, BLOOD, V125, P841, DOI 10.1182/blood-2014-07-587337; Chatonnet F, 2013, P NATL ACAD SCI USA, V110, pE766, DOI 10.1073/pnas.1210626110; Crupi R, 2013, PHARMACOL RES, V70, P80, DOI 10.1016/j.phrs.2012.12.009; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dentice M, 2014, CELL METAB, V20, P1038, DOI 10.1016/j.cmet.2014.10.009; Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795; Farwell AP, 2013, CURR OPIN ENDOCRINOL, V20, P478, DOI 10.1097/01.med.0000433069.09294.e8; Fauquier T, 2011, DEV BIOL, V356, P350, DOI 10.1016/j.ydbio.2011.05.657; Fournier NM, 2012, BEHAV BRAIN RES, V227, P440, DOI 10.1016/j.bbr.2011.04.022; Garry PS, 2015, EXP NEUROL, V263, P235, DOI 10.1016/j.expneurol.2014.10.017; Genovese T, 2013, BRAIN RES, V1513, P92, DOI 10.1016/j.brainres.2013.03.001; Gereben B, 2008, ENDOCR REV, V29, P898, DOI 10.1210/er.2008-0019; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hagihara Hideo, 2009, J Vis Exp, DOI 10.3791/1543; Huang SA, 2008, NAT CLIN PRACT ENDOC, V4, P148, DOI 10.1038/ncpendmet0727; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Koibuchi N, 2003, CEREBELLUM, V2, P279, DOI 10.1080/14734220310011920; Kovalevich J, 2013, METHODS MOL BIOL, V1078, P9, DOI 10.1007/978-1-62703-640-5_2; Lebrun C, 2013, MOL CELL NEUROSCI, V54, P9, DOI 10.1016/j.mcn.2012.11.010; Lin JZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052407; Liu F, 2009, J NEUROSCI, V29, P5075, DOI 10.1523/JNEUROSCI.0201-09.2009; Liu YY, 2002, ENDOCRINOLOGY, V143, P2664, DOI 10.1210/en.143.7.2664; Luidens MK, 2010, VASC PHARMACOL, V52, P142, DOI 10.1016/j.vph.2009.10.007; Magnoni S, 2012, CRIT CARE MED, V40, P1785, DOI 10.1097/CCM.0b013e318246bd45; Mayer S, 2014, J CLIN INVEST, V124, P1987, DOI 10.1172/JCI70324; McAllister RM, 2005, J ENDOCRINOL, V185, P111, DOI 10.1677/joe.1.06022; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; O'Driscoll C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012911; Pizzi M, 2009, FEBS J, V276, P27, DOI 10.1111/j.1742-4658.2008.06767.x; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rovet JF, 2014, ENDOCR DEV, V26, P26, DOI 10.1159/000363153; Sadana P, 2015, J NEUROL SCI, V354, P37, DOI 10.1016/j.jns.2015.04.042; Salvatore D, 2014, NAT REV ENDOCRINOL, V10, P206, DOI 10.1038/nrendo.2013.238; Sarnico I, 2009, INT REV NEUROBIOL, V85, P351, DOI 10.1016/S0074-7742(09)85024-1; Schoenmakers N, 2013, BBA-GEN SUBJECTS, V1830, P4004, DOI 10.1016/j.bbagen.2013.03.018; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Serfozo Z, 2008, NEUROCHEM RES, V33, P569, DOI 10.1007/s11064-007-9480-0; Simonides WS, 2008, J CLIN INVEST, V118, P975, DOI 10.1172/JCI32824; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Taylor SR, 2013, J NEUROSURG-PEDIATR, V12, P545, DOI 10.3171/2013.8.PEDS13154; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vieira HLA, 2011, PROG NEUROBIOL, V93, P444, DOI 10.1016/j.pneurobio.2011.01.007; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolahan SM, 2017, NEUROCRIT CARE, V26, P239, DOI 10.1007/s12028-016-0313-3; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yen CC, 2006, J MOL ENDOCRINOL, V36, P9, DOI 10.1677/jme.1.01911	61	23	26	0	26	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0303-7207			MOL CELL ENDOCRINOL	Mol. Cell. Endocrinol.	SEP 5	2017	452	C					120	130		10.1016/j.mce.2017.05.023			11	Cell Biology; Endocrinology & Metabolism	Cell Biology; Endocrinology & Metabolism	EZ5YF	WOS:000404794900012	28549992				2021-06-18	
J	Hao, P; Duan, HM; Hao, F; Chen, L; Sun, M; Fan, KS; Sun, YE; Williams, D; Yang, ZY; Li, XG				Hao, Peng; Duan, Hongmei; Hao, Fei; Chen, Lan; Sun, Min; Fan, Kevin S.; Sun, Yi Eve.; Williams, David; Yang, Zhaoyang; Li, Xiaoguang			Neural repair by NT3-chitosan via enhancement of endogenous neurogenesis after adult focal aspiration brain injury	BIOMATERIALS			English	Article						Aspiration brain injury; Endogenous neurogenesis; Chitosan; NT3; Functional recovery; Microenvironment	FUNCTIONAL RECOVERY; STEM-CELLS; CEREBRAL-CORTEX; MOTOR CORTEX; HEAD-INJURY; NEURONS; NEUROTROPHIN-3; PROLIFERATION; MIGRATION; TRKC	The latent regenerative potential of endogenous neural stem progenitor cells (NSCs) in the adult mammalian brain has been postulated as a likely source for neural repair. However, the inflammatory and inhibitory microenvironment after traumatic brain injury (TBI) prohibits NSCs from generating new functional neurons to restore brain function. Here we report a biodegradable material, chitosan, which, when loaded with neurotrophin-3 (NT3) and injected into the lesion site after TBI, effectively engaged endogenous NSCs to proliferate and migrate to the injury area. NSCs differentiate and mature into functional neurons, forming nascent neural networks that further integrate into existing neural circuits to restore brain function. Three main actions of NT3-chitosan, i.e., pro-neurogenesis, anti -inflammation, and pro-revascularization, elicit significant regeneration after TBI. Our study suggests that through creating an optimal microenvironment, endogenous NSCs are capable of executing neural repair, thus widening the therapeutic strategies to treat TBI and perhaps stroke or other neurological conditions. (C) 2017 Published by Elsevier Ltd.	[Hao, Peng; Duan, Hongmei; Hao, Fei; Chen, Lan; Sun, Min; Yang, Zhaoyang; Li, Xiaoguang] Capital Med Univ, Sch Basic Med Sci, Dept Neurobiol, Beijing 100069, Peoples R China; [Sun, Yi Eve.] Tongji Univ, Sch Med, Dept Regenerat Med, Shanghai 200065, Peoples R China; [Sun, Yi Eve.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Li, Xiaoguang] Beihang Univ, Sch Biol Sci & Med Engn, Dept Biomed Engn, Beijing 100191, Peoples R China; [Fan, Kevin S.] Univ Calif Santa Barbara, Dept Comp Engn, Santa Barbara, CA 93106 USA; [Williams, David] Wake Forest Inst Regenerat Med, Winston Salem, NC 27101 USA	Yang, ZY; Li, XG (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Neurobiol, Beijing 100069, Peoples R China.	wack_lily@163.com; lxgchina@sina.com		Duan, Hongmei/0000-0003-2261-2182; hao, peng/0000-0002-8509-8232	State Key Program of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31130022, 31320103903, 31670988, 31271371]; International Cooperation in Science and Technology Project of the Ministry of Science and Technology of China [2014DFA30640]; National Ministry of Education Special Fund for Excellent Doctoral Dissertation [201356]; Special Fund for Excellent Doctoral Dissertation of Beijing [20111000601]; Special Funds for Beijing Base Construction & Talent Cultivation [Z171100002217066]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K12532] Funding Source: KAKEN	We thank Xiaomin Xu for his assistance in some data analyses. This work was supported by the State Key Program of the National Natural Science Foundation of China (Grants 31130022, 31320103903, 31670988 & 31271371), the International Cooperation in Science and Technology Project of the Ministry of Science and Technology of China (Grant 2014DFA30640), the National Ministry of Education Special Fund for Excellent Doctoral Dissertation (Grant 201356), the Special Fund for Excellent Doctoral Dissertation of Beijing (Grant 20111000601), and the Special Funds for Beijing Base Construction & Talent Cultivation (Grant Z171100002217066).	Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Coskun V, 2008, P NATL ACAD SCI USA, V105, P1026, DOI 10.1073/pnas.0710000105; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Cristofaro B, 2010, ARTERIOSCL THROM VAS, V30, P1143, DOI 10.1161/ATVBAHA.109.205468; Diaz F, 2013, J NEUROSCI, V33, P6278, DOI 10.1523/JNEUROSCI.5885-12.2013; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; Duan HM, 2015, P NATL ACAD SCI USA, V112, P13360, DOI 10.1073/pnas.1510176112; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gonzalez CLR, 2004, EUR J NEUROSCI, V20, P3442, DOI 10.1111/j.1460-9568.2004.03751.x; Henion PD, 1995, DEV BIOL, V172, P602, DOI 10.1006/dbio.1995.8054; Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Ibrahim S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21793; Ihrie RA, 2011, NEURON, V70, P674, DOI 10.1016/j.neuron.2011.05.004; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Lawrie G, 2007, BIOMACROMOLECULES, V8, P2533, DOI 10.1021/bm070014y; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Luo YP, 2015, CELL, V161, P1175, DOI 10.1016/j.cell.2015.04.001; Magavi SS, 2000, NATURE, V405, P951; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mo LH, 2010, BIOMATERIALS, V31, P2184, DOI 10.1016/j.biomaterials.2009.11.078; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NARHI LO, 1993, J BIOL CHEM, V268, P13309; Ohira K, 2011, CELL MOL LIFE SCI, V68, P1645, DOI 10.1007/s00018-010-0552-y; Oka H, 1999, J NEUROSCI METH, V93, P61, DOI 10.1016/S0165-0270(99)00113-2; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Riedel G, 1999, NAT NEUROSCI, V2, P898; Saha B, 2013, STEM CELL RES, V11, P965, DOI 10.1016/j.scr.2013.06.006; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Takeo C, 2003, BIOCHEM BIOPH RES CO, V305, P400, DOI 10.1016/S0006-291X(03)00770-8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; Villasana LE, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0056-15.2015; Wang JM, 2011, BIOMATERIALS, V32, P7454, DOI 10.1016/j.biomaterials.2011.06.036; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7; Yalvac ME, 2016, GENE THER, V23, P95, DOI 10.1038/gt.2015.67; Yang JX, 2014, MOL THER, V22, P440, DOI 10.1038/mt.2013.241; Yang ZY, 2015, P NATL ACAD SCI USA, V112, P13354, DOI 10.1073/pnas.1510194112; Yang ZY, 2010, BIOMATERIALS, V31, P4846, DOI 10.1016/j.biomaterials.2010.02.015; Yonemori F, 1999, J CEREBR BLOOD F MET, V19, P483, DOI 10.1097/00004647-199905000-00002; Zhang WD, 2000, HIPPOCAMPUS, V10, P512, DOI 10.1002/1098-1063(2000)10:5<512::AID-HIPO2>3.0.CO;2-M; Zhang YQ, 2012, CELLS TISSUES ORGANS, V195, P313, DOI 10.1159/000327724	58	23	25	2	54	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	SEP	2017	140						88	102		10.1016/j.biomaterials.2017.04.014			15	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	FB2KY	WOS:000405973900009	28641124				2021-06-18	
J	Wallace, J; Covassin, T; Nogle, S; Gould, D; Kovan, J				Wallace, Jessica; Covassin, Tracey; Nogle, Sally; Gould, Daniel; Kovan, Jeffrey			Concussion Knowledge and Reporting Behavior Differences Between High School Athletes at Urban and Suburban High Schools	JOURNAL OF SCHOOL HEALTH			English	Article						concussion knowledge; reporting behaviors; adolescent health; urban health; suburban health	TRAUMATIC BRAIN-INJURY; RECURRENT CONCUSSION; FOOTBALL PLAYERS; TEST-SCORES; AMERICAN; SPORT; YOUTH; ASSOCIATION; STATEMENT; RISK	BACKGROUNDWe determined differences in knowledge of concussion and reporting behaviors of high school athletes attending urban and suburban high schools, and whether a relationship exists between underreporting and access to an athletic trainer in urban schools. METHODSHigh school athletes (N = 715) from 14 high schools completed a validated knowledge of concussion survey consisting of 83 questions. The independent variable was school type (urban/suburban). We examined the proportion of athletes who correctly identified signs and symptoms of concussion, knowledge of concussion and reasons why high school athletes would not disclose a potential concussive injury across school classification. Data were analyzed using descriptive, non-parametric, and inferential statistics. RESULTSAthletes attending urban schools have less concussion knowledge than athletes attending suburban schools (p < .01). Athletes attending urban schools without an athletic trainer have less knowledge than urban athletes at schools with an athletic trainer (p < .01) There was no significant relationship between reporting percentage and school type (p = .73); however, significant relationships exist between AT access at urban schools and 10 reasons for not reporting. CONCLUSIONConcussion education efforts cannot be homogeneous in all communities. Education interventions must reflect the needs of each community.	[Wallace, Jessica] Youngstown State Univ, Kinesiol & Sport Sci Dept, Beeghly Ctr 307L, 1 Univ Plaza, Youngstown, OH 44555 USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, 105 IM Circle, E Lansing, MI 48824 USA; [Nogle, Sally] Michigan State Univ, Dept Athlet, 105 IM Circle, E Lansing, MI 48824 USA; [Gould, Daniel] Michigan State Univ, Dept Kinesiol, 308 W Circle Dr, E Lansing, MI 48824 USA; [Kovan, Jeffrey] Michigan State Univ, Dept Radiol, Sports Med, 4660 South Hagadom Rd,Suite 420, E Lansing, MI 48824 USA	Wallace, J (corresponding author), Youngstown State Univ, Kinesiol & Sport Sci Dept, Beeghly Ctr 307L, 1 Univ Plaza, Youngstown, OH 44555 USA.	Jwallace02@ysu.edu; covassin@msu.edu; nogle@ath.msu.edu; drgould@msu.edu; Jeff.kovan@ht.msu.edu			Pentecost Foundation; Blue Cross Blue Shield of Michigan Foundation	Funding for the project was provided by the Pentecost Foundation and the Blue Cross Blue Shield of Michigan Foundation.	Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Borden BP, 2007, AM J SPORTS MED, V35, P1075; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cournoyer J, 2014, J ATHL TRAINING, V49, P654, DOI 10.4085/1062-6050-49.3.34; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HANNAWAY J, 1993, EDUC ADMIN QUART, V29, P164, DOI 10.1177/0013161X93029002004; Herbers JE, 2012, EDUC RESEARCHER, V41, P366, DOI 10.3102/0013189X12445320; Ickovics JR, 2014, J SCHOOL HEALTH, V84, P40, DOI 10.1111/josh.12117; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2013, J ATHL TRAINING, V48, P483, DOI 10.4085/1062-6050-48.4.04; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Register-Mihalik JK, 2009, ATHL TRAIN SPORTS HL, V1, P227; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Sandy J, 2010, EDUC ECON, V18, P297, DOI 10.1080/09645290903465713; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; US Department of Education Institute of Education Sciences, CHILDR LIV POV; WATSON BC, 1989, J NEGRO EDUC, V58, P309, DOI 10.2307/2295664; WAYSON WW, 1972, URBAN EDUC, V7, P109, DOI 10.1177/004208597200700202; Willie CV, 2001, URBAN EDUC, V36, P461, DOI 10.1177/0042085901364002	35	23	23	1	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4391	1746-1561		J SCHOOL HEALTH	J. Sch. Health	SEP	2017	87	9					665	674		10.1111/josh.12543			10	Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health	Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health	FC8IW	WOS:000407086000004	28766322				2021-06-18	
J	Jin, T; Wang, P; Hitchens, TK; Kim, SG				Jin, Tao; Wang, Ping; Hitchens, T. Kevin; Kim, Seong-Gi			Enhancing sensitivity of pH-weighted MRI with combination of amide and guanidyl CEST	NEUROIMAGE			English	Article						CEST; Amide; Guanidyl; pH; APT; Stroke	EXCHANGE SATURATION-TRANSFER; NUCLEAR OVERHAUSER ENHANCEMENT; ACUTE CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; TRANSFER APT MRI; PROTON-TRANSFER; MAGNETIZATION-TRANSFER; TISSUE PH; INTRACELLULAR PH; LACTIC-ACIDOSIS	Amide-proton-transfer weighted (APTw) MRI has emerged as a non-invasive pH-weighted imaging technique for studies of several diseases such as ischemic stroke. However, its pH-sensitivity is relatively low, limiting its capability to detect small pH changes. In this work, computer simulations, protamine phantom experiments, and in vivo gas challenge and experimental stroke in rats showed that, with judicious selection of the saturation pulse power, the amide-CEST at 3.6 ppm and guanidyl-CEST signals at 2.0 ppm changed in opposite directions with decreased pH. Thus, the difference between amide-CEST and guanidyl-CEST can enhance the pH measurement sensitivity, and is dubbed as pH(enh). Acidification induced a negative contrast in APTw, but a positive contrast in pHenh. In vivo experiments showed that pHenh can detect hypercapnia-induced acidosis with about 3-times higher sensitivity than APTw. Also, pHenh slightly reduced gray and white matter contrast compared to APTw. In stroke animals, the CEST contrast between the ipsilateral ischemic core and contralateral normal tissue was -1.85 +/- 0.42% for APTw and 3.04 +/- 0.61% (n = 5) for pHenh, and the contrast to noise was 2.9 times higher for pHenh than APTw. Our results suggest that pHenh can be a useful tool for non-invasive pH-weighted imaging.	[Jin, Tao; Wang, Ping] Univ Pittsburgh, Dept Radiol, 3025 E Carson St,Room 156, Pittsburgh, PA 15260 USA; [Jin, Tao] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA; [Hitchens, T. Kevin] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA; [Kim, Seong-Gi] Inst Basic Sci, Ctr Neurosci Imaging Res, Suwon, South Korea; [Kim, Seong-Gi] Sungkyunkwan Univ, Dept Biomed Engn, Suwon, South Korea	Jin, T (corresponding author), Univ Pittsburgh, Dept Radiol, 3025 E Carson St,Room 156, Pittsburgh, PA 15260 USA.	taj6@pitt.edu	Jin, Tao/D-5101-2009; Kim, Seong-Gi/A-2691-2008		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EB003324, P30-NS076405, P30-CA047904]; Institute for Basic Science in Korea [IBS-R015-D1]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA047904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB003324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS076405] Funding Source: NIH RePORTER	We thank Kristy Hendrich for maintaining the 9.4 T system. This work is supported by NIH grants EB003324, P30-NS076405 and P30-CA047904, and the Institute for Basic Science in Korea (IBS-R015-D1).	Anderson RE, 1999, STROKE, V30, P160, DOI 10.1161/01.STR.30.1.160; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Autio JA, 2014, J CEREBR BLOOD F MET, V34, P768, DOI 10.1038/jcbfm.2014.16; BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; BERECZKI D, 1993, METAB BRAIN DIS, V8, P125, DOI 10.1007/BF00996926; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gerweck LE, 1996, CANCER RES, V56, P1194; Guo YK, 2016, NEUROIMAGE, V141, P242, DOI 10.1016/j.neuroimage.2016.07.025; Heo HY, 2016, MAGN RESON MED, V75, P137, DOI 10.1002/mrm.25581; Hua J, 2007, MAGN RESON MED, V58, P786, DOI 10.1002/mrm.21387; Jin T, 2013, P INT SOC MAGN RESON, V21, P2528; Jin T, 2013, MAGN RESON MED, V69, P760, DOI 10.1002/mrm.24315; Jin T, 2012, MAGN RESON MED, V68, P1056, DOI 10.1002/mrm.24449; Jin T, 2011, MAGN RESON MED, V65, P1448, DOI 10.1002/mrm.22721; Jin T, 2010, NEUROIMAGE, V51, P1378, DOI 10.1016/j.neuroimage.2010.03.047; Jokivarsi KT, 2007, MAGN RESON MED, V57, P647, DOI 10.1002/mrm.21181; Jones CK, 2013, NEUROIMAGE, V77, P114, DOI 10.1016/j.neuroimage.2013.03.047; Jones CK, 2012, MAGN RESON MED, V67, P1579, DOI 10.1002/mrm.23141; Koizumi JYY, 1986, JPN J STROKE, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; LAXER KD, 1992, EPILEPSIA, V33, P618, DOI 10.1111/j.1528-1157.1992.tb02337.x; Lee JK, 2013, SOCIAL MEDIA AND STRATEGIC COMMUNICATIONS, P3; Li H, 2015, NMR BIOMED, V28, P200, DOI 10.1002/nbm.3243; Liepinsh E, 1996, MAGNET RESON MED, V35, P30, DOI 10.1002/mrm.1910350106; Liu DP, 2013, MAGN RESON MED, V70, P1070, DOI 10.1002/mrm.24560; Lu J, 2009, NEUROIMAGE, V45, P1126, DOI 10.1016/j.neuroimage.2008.11.037; Magnotta VA, 2012, P NATL ACAD SCI USA, V109, P8270, DOI 10.1073/pnas.1205902109; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McVicar N, 2014, J CEREBR BLOOD F MET, V34, P690, DOI 10.1038/jcbfm.2014.12; Mori S, 1998, MAGNET RESON MED, V40, P36, DOI 10.1002/mrm.1910400105; MORRISON C, 1995, J MAGN RESON SER B, V108, P103, DOI 10.1006/jmrb.1995.1111; Narvainen J, 2010, J MAGN RESON, V207, P242, DOI 10.1016/j.jmr.2010.09.004; NISHIMURA M, 1989, J APPL PHYSIOL, V66, P2181; PEEK KE, 1989, METAB BRAIN DIS, V4, P261, DOI 10.1007/BF00999772; Pouwels PJW, 1999, PEDIATR RES, V46, P474, DOI 10.1203/00006450-199910000-00019; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; REHNCRONA S, 1985, ANN EMERG MED, V14, P770, DOI 10.1016/S0196-0644(85)80055-X; SAKO K, 1985, STROKE, V16, P828, DOI 10.1161/01.STR.16.5.828; Scheidegger R, 2011, MAGN RESON MED, V66, P1275, DOI 10.1002/mrm.22912; Sheth VR, 2012, MAGN RESON MED, V67, P760, DOI 10.1002/mrm.23038; Song XL, 2012, MAGN RESON MED, V68, P1074, DOI 10.1002/mrm.23312; Sun PZ, 2007, J CEREBR BLOOD F MET, V27, P1129, DOI 10.1038/sj.jcbfm.9600424; Sun PZ, 2012, NEUROIMAGE, V60, P1, DOI 10.1016/j.neuroimage.2011.11.091; Sun PZ, 2011, MAGN RESON MED, V66, P1042, DOI 10.1002/mrm.22894; Sun PZ, 2011, J CEREBR BLOOD F MET, V31, P1743, DOI 10.1038/jcbfm.2011.23; TANNOCK IF, 1989, CANCER RES, V49, P4373; Tee YK, 2014, NMR BIOMED, V27, P1019, DOI 10.1002/nbm.3147; Tietze A, 2014, NMR BIOMED, V27, P163, DOI 10.1002/nbm.3048; TOMLINSON FH, 1993, STROKE, V24, P435, DOI 10.1161/01.STR.24.3.435; WAGNER KR, 1992, J CEREBR BLOOD F MET, V12, P213, DOI 10.1038/jcbfm.1992.31; Warach S, 2001, STROKE, V32, P2460; Ward KM, 2000, J MAGN RESON, V143, P79, DOI 10.1006/jmre.1999.1956; Xu JD, 2014, MAGN RESON MED, V71, P1798, DOI 10.1002/mrm.24850; Zaiss M, 2017, MAGN RESON MED, V77, P196, DOI 10.1002/mrm.26100; Zaiss M, 2011, J MAGN RESON, V211, P149, DOI 10.1016/j.jmr.2011.05.001; Zhou JY, 2003, NAT MED, V9, P1085, DOI 10.1038/nm907; Zong XP, 2014, MAGN RESON MED, V71, P118, DOI 10.1002/mrm.24639; Zu ZL, 2013, MAGN RESON MED, V69, P637, DOI 10.1002/mrm.24284	60	23	23	1	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	AUG 15	2017	157						341	350		10.1016/j.neuroimage.2017.06.007			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FG6WU	WOS:000410539800028	28602944	Green Accepted			2021-06-18	
J	Cheng, YJ; Wei, YX; Yang, WL; Song, YY; Shang, HB; Cai, Y; Wu, ZB; Zhao, WG				Cheng, Yijun; Wei, Yongxu; Yang, Wenlei; Song, Yaying; Shang, Hanbing; Cai, Yu; Wu, Zhebao; Zhao, Weiguo			Cordycepin confers neuroprotection in mice models of intracerebral hemorrhage via suppressing NLRP3 inflammasome activation	METABOLIC BRAIN DISEASE			English	Article						Intracerebral hemorrhage; Neuroinflammation; NLRP3 inflammasome; Cordycepin; Neuronal death; HMGB1	ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; FOCAL ISCHEMIA; CELL-DEATH; RAT MODEL; EXPRESSION; MILITARIS; PROTECTS; 3-DEOXYADENOSINE; PATHOGENESIS	Neuroinflammation has been recognized as a major contributor to brain injury caused by intracerebral hemorrhage (ICH). Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome acts as an important mediator of inflammatory response in various inflammation-related diseases including hemorrhagic insults. Cordycepin has recently been shown to possess anti-inflammatory effect; however, its role and the possible underlying mechanisms in ICH remain unclear. This study was designed to investigate the neuroprotective effect of cordycepin in mice models of ICH and to elucidate the underlying molecular mechanisms. ICH was induced in male ICR mice by injecting autologous blood infusion stereotactically. Cordycepin was then given intraperitoneally (i.p.) at 30 min after ICH induction. The results demonstrated that NLRP3 inflammasome was activated and exacerbated the inflammatory progression after ICH. Cordycepin treatment significantly alleviated neurological deficits, brain edema, and perihematomal tissue damage following ICH. These changes were accompanied by downregulated NLRP3 inflammasome components expression and a reduction of production and release of inflammasome substrates interleukin-1beta (IL-1 beta) and interleukin-18 (IL-18). Furthermore, cordycepin ameliorated neuronal death in the perihematomal regions, accompanied by a large reduction in the expression of high-mobility group protein B 1 (HMGB1) post-ICH. In conclusion, this study provides in vivo evidence that cordycepin confers neuroprotective effect in the models of ICH, possibly through the suppression of NLRP3 inflammasome activation.	[Cheng, Yijun; Wei, Yongxu; Yang, Wenlei; Shang, Hanbing; Wu, Zhebao; Zhao, Weiguo] Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Neurosurg, Sch Med, Shanghai 200025, Peoples R China; [Song, Yaying] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Neurol, Shanghai 200025, Peoples R China; [Cai, Yu] Shanghai Jiao Tong Univ, Sch Med, North Rui Jin Hosp, Dept Neurosurg, Shanghai 201800, Peoples R China	Wu, ZB; Zhao, WG (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Neurosurg, Sch Med, Shanghai 200025, Peoples R China.; Cai, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, North Rui Jin Hosp, Dept Neurosurg, Shanghai 201800, Peoples R China.	caiyu10746@sina.com; wuzhebao@aliyun.com; ruijinsjwk@qq.com	Wu, Zhe Bao/AAH-8078-2020	Wu, Zhe Bao/0000-0002-1611-8228	Natural Science Fund from Science and Technology Commission of Shanghai Municipality [14ZR1426000, 16ZR14212000]	This research was supported by the Natural Science Fund (No. 14ZR1426000; 16ZR14212000) from the Science and Technology Commission of Shanghai Municipality.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Bauernfeind F, 2011, CELL MOL LIFE SCI, V68, P765, DOI 10.1007/s00018-010-0567-4; Cai ZL, 2013, EUR J PHARMACOL, V714, P249, DOI 10.1016/j.ejphar.2013.05.049; Cao GS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091418; Cha JY, 2013, FOOD CHEM TOXICOL, V60, P52, DOI 10.1016/j.fct.2013.07.033; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Chang W, 2008, EUR J PHARMACOL, V597, P64, DOI 10.1016/j.ejphar.2008.08.030; Chen LS, 2008, BRIT J HAEMATOL, V140, P682, DOI 10.1111/j.1365-2141.2007.06955.x; Cheng ZY, 2011, EUR J PHARMACOL, V664, P20, DOI 10.1016/j.ejphar.2011.04.052; Chiu GS, 2012, J NEUROSCI, V32, P13945, DOI 10.1523/JNEUROSCI.0704-12.2012; Choi YH, 2014, DRUG DES DEV THER, V8, P1941, DOI 10.2147/DDDT.S71957; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Duan XC, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1203285; Ellis A, 2016, BRAIN BEHAV IMMUN, V58, P348, DOI 10.1016/j.bbi.2016.08.004; Fann DYW, 2013, AGEING RES REV, V12, P941, DOI 10.1016/j.arr.2013.09.004; Feng L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0409-2; Geldhoff M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-358; GLAZER RI, 1978, CANCER RES, V38, P2233; Hwang IK, 2008, PLANTA MED, V74, P114, DOI 10.1055/s-2008-1034277; Jiang W, 2016, J SURG RES, V203, P331, DOI 10.1016/j.jss.2016.02.041; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Krafft PR, 2014, BEHAV BRAIN RES, V264, P151, DOI 10.1016/j.bbr.2014.01.052; Lamkanfi M, 2010, J IMMUNOL, V185, P4385, DOI 10.4049/jimmunol.1000803; Lammerding L, 2016, NEUROENDOCRINOLOGY, V103, P460, DOI 10.1159/000439435; Lebeaupin C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.248; Li B, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyv112; Li Y, 2015, PHARMACOL RES, V99, P101, DOI 10.1016/j.phrs.2015.05.012; Liu H, 2013, J NANOMATER, V2013, P3; Ma L, 2015, NUTR RES, V35, P431, DOI 10.1016/j.nutres.2015.04.011; Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070; Meng XF, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0212-5; Nakamura K, 2015, J PHARMACOL SCI, V127, P53, DOI 10.1016/j.jphs.2014.09.001; Nguemeni C, 2015, J NEUROSCI METH, V242, P72, DOI 10.1016/j.jneumeth.2015.01.005; Olatunji OJ, 2016, BIOMED PHARMACOTHER, V81, P7, DOI 10.1016/j.biopha.2016.03.009; Olsen I, 2016, J ALZHEIMERS DIS, V54, P45, DOI 10.3233/JAD-160197; Ribo M, 2006, CURR NEUROL NEUROSCI, V6, P17, DOI 10.1007/s11910-996-0004-0; Rynkowski MA, 2008, NAT PROTOC, V3, P122, DOI 10.1038/nprot.2007.513; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Shao LW, 2016, ONCOL LETT, V12, P995, DOI 10.3892/ol.2016.4706; SHIGEURA HT, 1965, J BIOL CHEM, V240, P806; Shin Seulmee, 2009, Immune Netw, V9, P255, DOI 10.4110/in.2009.9.6.255; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Wali Jibran A, 2013, Cells, V2, P266, DOI 10.3390/cells2020266; Wang BJ, 2005, FOOD CHEM TOXICOL, V43, P543, DOI 10.1016/j.fct.2004.12.008; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Williams A, 2010, CURR OPIN IMMUNOL, V22, P34, DOI 10.1016/j.coi.2010.01.004; Wu HY, 2007, PHYTOMEDICINE, V14, P43, DOI 10.1016/j.phymed.2006.11.005; Xiao L, 2012, FREE RADICAL RES, V46, P174, DOI 10.3109/10715762.2011.647688; Yang XF, 2015, INT IMMUNOPHARMACOL, V26, P401, DOI 10.1016/j.intimp.2015.04.017; Yang Z, 2015, MOL IMMUNOL, V65, P267, DOI 10.1016/j.molimm.2014.12.018; Yuan BQ, 2015, J NEUROIMMUNOL, V287, P71, DOI 10.1016/j.jneuroim.2015.08.002; Yuan J, 2016, BRAIN RES BULL, V127, P171, DOI 10.1016/j.brainresbull.2016.09.010; Yue K, 2013, J PHARM PHARMACOL, V65, P474, DOI 10.1111/j.2042-7158.2012.01601.x; Zhao Y, 2015, J ETHNOPHARMACOL, V169, P210, DOI 10.1016/j.jep.2015.04.030; Zhong ZH, 2013, NEUROSCI LETT, V555, P24, DOI 10.1016/j.neulet.2013.09.023; Zhou Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0094-3; Zhou Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/142458; Zhu XX, 2012, STROKE, V43, P524, DOI 10.1161/STROKEAHA.111.635672; Zhu ZS, 2016, CELL MOL NEUROBIOL, V36, P981, DOI 10.1007/s10571-015-0288-1	61	23	25	0	17	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	AUG	2017	32	4					1133	1145		10.1007/s11011-017-0003-7			13	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	FA3FF	WOS:000405327200023	28401330				2021-06-18	
J	Corrigan, F; Arulsamy, A; Collins-Praino, LE; Holmes, JL; Vink, R				Corrigan, Frances; Arulsamy, Alina; Collins-Praino, Lyndsey E.; Holmes, Joshua L.; Vink, Robert			Toll like receptor 4 activation can be either detrimental or beneficial following mild repetitive traumatic brain injury depending on timing of activation	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Concussion; Chronic traumatic encephalopathy; TLR4; Tau; Neurodegeneration	PROFESSIONAL FOOTBALL PLAYERS; SPINAL-CORD-INJURY; KAPPA-B ACTIVITY; ENDOTOXIN TOLERANCE; ALZHEIMERS-DISEASE; MEDIATED NEURODEGENERATION; MICROGLIAL POLARIZATION; BEHAVIORAL IMPAIRMENTS; INFLAMMATORY RESPONSE; RECURRENT CONCUSSION	A history of repeated concussion has been linked to the later development of neurodegeneration, which is associated with the accumulation of hyperphosphorylated tau and the development of behavioral deficits. However, the role that exogenous factors, such as immune activation, may play in the development of neurodegeneration following repeated mild traumatic brain injury (rmTBI) has not yet been explored. To investigate, male Sprague-Dawley rats were administered three mTBIs 5 days apart using the diffuse impact-acceleration model to generate similar to 100 G. Sham animals underwent surgery only. At 1 or 5 days following the last injury rats were given the TLR4 agonist, lipopolysaccharide (LPS, 0.1 mg/kg), or saline. TLR4 activation had differential effects following rmTBI depending on the timing of activation. When given at 1 day post-injury, LPS acutely activated microglia, but decreased production of pro inflammatory cytoldnes like IL-6. This was associated with a reduction in neuronal injury, both acutely, with a restoration of levels of myelin basic protein (MBP), and chronically, preventing a loss of both MBP and PSD-95. Furthermore, these animals did not develop behavioral deficits with no changes in locomotion, anxiety, depressive-like behavior or cognition at 3 months post-injury. Conversely, when LPS was given at 5 days post-injury, it was associated acutely with an increase in pro-inflammatory cytokine production, with an exacerbation of neuronal damage and increased levels of aggregated and phosphorylated tau. At 3 months post-injury, there was a slight exacerbation of functional deficits, particularly in cognition and depressive-like behavior. This highlights the complexity of the immune response following rmTBI and the need to understand how a history of rmTBI interacts with environmental factors to influence the potential to develop later neurodegeneration. Crown Copyright (C) 2017 Published by Elsevier Inc. All rights reserved.	[Corrigan, Frances; Arulsamy, Alina; Collins-Praino, Lyndsey E.; Holmes, Joshua L.] Univ Adelaide, Adelaide Med Sch, Discipline Anat & Pathol, Adelaide, SA, Australia; [Vink, Robert] Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA, Australia	Corrigan, F (corresponding author), Univ Adelaide, Sch Med, Translat Neuropathol Lab, Discipline Anat & Pathol, Adelaide, SA 5005, Australia.	frances.corrigan@adelaide.edu.au	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019; Collins-Praino, Lyndsey/AAB-3318-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Collins-Praino, Lyndsey/0000-0002-4380-7600; Arulsamy, Alina/0000-0003-0993-5622; Corrigan, Frances/0000-0001-6150-8893	Neurosurgical Research Foundation	This work was supported by a grant from the Neurosurgical Research Foundation.	Ahmed SH, 2000, STROKE, V31, P193, DOI 10.1161/01.STR.31.1.193; Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bala S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096864; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bastide M, 2003, J CEREBR BLOOD F MET, V23, P399, DOI 10.1097/01.WCB.0000050064.57184.F2; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Bingham D, 2013, J NEUROIMMUNOL, V256, P28, DOI 10.1016/j.jneuroim.2012.12.009; Bingham D, 2011, BRAIN RES BULL, V85, P403, DOI 10.1016/j.brainresbull.2011.04.007; Biswas SK, 2007, J IMMUNOL, V179, P4083, DOI 10.4049/jimmunol.179.6.4083; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Bogdanova OV, 2013, PHYSIOL BEHAV, V118, P227, DOI 10.1016/j.physbeh.2013.05.012; Broad A, 2007, IMMUNOLOGY, V120, P103, DOI 10.1111/j.1365-2567.2006.02485.x; Buchanan MM, 2010, J NEUROCHEM, V114, P13, DOI 10.1111/j.1471-4159.2010.06736.x; Caldeira C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00152; Chen XP, 2009, CLIN VACCINE IMMUNOL, V16, P104, DOI 10.1128/CVI.00320-08; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Chongwatpol P, 2015, J INFLAMM RES, V8, P117, DOI 10.2147/JIR.S82261; Chu CH, 2016, BRAIN BEHAV IMMUN, V55, P260, DOI 10.1016/j.bbi.2016.04.015; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cohen-Lahav M, 2006, NEPHROL DIAL TRANSPL, V21, P889, DOI 10.1093/ndt/gfi254; Collins-Praino LE, 2017, BRAIN BEHAV IMMUN, V60, P369, DOI 10.1016/j.bbi.2016.09.027; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Corrigan F, 2014, J NEUROCHEM, V128, P196, DOI 10.1111/jnc.12391; Corrigan F, 2012, CNS NEUROSCI THER, V18, P513, DOI 10.1111/j.1755-5949.2012.00332.x; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Couch Y, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0572-0; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Cruz MT, 2001, NITRIC OXIDE-BIOL CH, V5, P53, DOI 10.1006/niox.2000.0320; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Davis AEM, 2005, EUR J NEUROSCI, V22, P2441, DOI 10.1111/j.1460-9568.2005.04447.x; Dobrovolskaia MA, 2003, J IMMUNOL, V170, P508, DOI 10.4049/jimmunol.170.1.508; Erridge C, 2007, AM J CLIN NUTR, V86, P1286; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Gerson JE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00093; Ghanim H, 2009, DIABETES CARE, V32, P2281, DOI 10.2337/dc09-0979; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Hensley K, 2010, J ALZHEIMERS DIS, V21, P1, DOI 10.3233/JAD-2010-1414; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Koedel U, 2007, AM J PATHOL, V171, P200, DOI 10.2353/ajpath.2007.060821; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Lee DC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-56; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Li YK, 2003, J NEUROSCI, V23, P1605; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Maeda S, 2007, BIOCHEMISTRY-US, V46, P3856, DOI 10.1021/bi061359o; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; McAteer KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160220; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mendez C, 1999, ANN SURG, V229, P843, DOI 10.1097/00000658-199906000-00011; Mendoza J, 2013, J PROTEOME RES, V12, P2654, DOI 10.1021/pr400008f; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Piao W, 2009, J LEUKOCYTE BIOL, V86, P863, DOI 10.1189/jlb.0309189; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Rawji KS, 2016, BRAIN, V139, P653, DOI 10.1093/brain/awv395; Reis J, 2011, CELL BIOCHEM BIOPHYS, V60, P77, DOI 10.1007/s12013-011-9182-8; Rosenzweig HL, 2004, STROKE, V35, P2576, DOI 10.1161/01.STR.0000143450.04438.ae; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Seeger JM, 1999, ANN SURG, V229, P849; Selkirk GA, 2008, AM J PHYSIOL-REG I, V295, pR611, DOI 10.1152/ajpregu.00917.2007; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Sikorski K, 2011, AM J PHYSIOL-CELL PH, V300, pC1337, DOI 10.1152/ajpcell.00276.2010; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Streit WJ, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00138; Sy M, 2011, AM J PATHOL, V178, P2811, DOI 10.1016/j.ajpath.2011.02.012; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Tarassishin L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-187; Tatem KS, 2014, JOVE-J VIS EXP, DOI 10.3791/51785; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vartanian KB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-140; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	97	23	25	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	AUG	2017	64						124	139		10.1016/j.bbi.2017.04.006			16	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	EZ1XR	WOS:000404504600014	28412141				2021-06-18	
J	Kawata, K; Rubin, LH; Takahagi, M; Lee, JH; Sim, T; Szwanki, V; Bellamy, A; Tierney, R; Langford, D				Kawata, Keisuke; Rubin, Leah H.; Takahagi, Masahiro; Lee, Jong Hyun; Sim, Thomas; Szwanki, Victor; Bellamy, Al; Tierney, Ryan; Langford, Dianne			Subconcussive Impact-Dependent Increase in Plasma S100 Levels in Collegiate Football Players	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; concussion; head impact kinematics; subconcussive; traumatic brain injury	NEURON-SPECIFIC ENOLASE; BRAIN-INJURY; BLOOD BIOMARKERS; SERUM; S-100B; VULNERABILITY; MARKER; ADULTS; DAMAGE	The current study investigates whether repetitive subconcussive impacts cause changes in plasma S100 levels, and also tests the associations between S100 changes and frequency/magnitude of impacts sustained. This prospective study of 22 Division-I collegiate football players included baseline and pre-season practices (one helmet-only and four full-gear). Blood samples were obtained and assessed for S100 levels at baseline and pre- to post-practices; symptom scores were assessed at each time-point. An accelerometer-embedded mouthguard was employed to measure the number of impacts (hits), peak linear acceleration (PLA), and peak rotational acceleration (PRA). Because we observed a distinct gap in impact exposure (hits, PLA, and PRA), players were clustered into lower (n=7) or higher (n=15) impact groups based on the sum of impact kinematics from all five practices. S100 levels significantly changed across the study duration. Although S100 levels remained stable from baseline to all pre-practice values, statistically significant acute increases in S100 levels were observed in all post-practice measures compared with the respective pre-practice values (range: 133-246% in the overall sample). Greater number of hits, sum of PLA, and sum of PRA were significantly associated with greater acute increases in S100 levels. There were significant differences in head impact kinematics between lower and higher impact groups (hits, 6 vs. 43 [M-lower - M-higher=35, p<0.001]; PLA, 99.4 vs. 1148.5 g [M-lower - M-higher=1049.1, p<0.001]; PRA, 7589 vs. 68,259rad/s(2) [M-lower - M-higher=60,670, p<0.001]). Players in the higher impact group showed consistently greater increases in plasma S100 levels, but not symptom scores, at each post-practice than the lower impact group. Collectively, these data suggest that although players continued to play without noticeable change in symptoms, a brain-enriched serological factor suggests an acute burden from head impacts. Assessing the effects of repetitive subconcussive head impacts on acute changes in S100 levels may be a clinically useful blood biomarker in tracking real-time acute brain damage in collegiate football players.	[Kawata, Keisuke; Lee, Jong Hyun; Langford, Dianne] Temple Univ, Dept Neurosci, Lewis Katz Sch Med, MERB 750,3500 North Broad St, Philadelphia, PA 19122 USA; [Kawata, Keisuke] Indiana Univ, Dept Kinesiol, Bloomington, IN 47405 USA; [Rubin, Leah H.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; [Takahagi, Masahiro; Szwanki, Victor; Bellamy, Al] Temple Univ, Dept Athlet, Philadelphia, PA 19122 USA; [Sim, Thomas; Tierney, Ryan] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA	Langford, D (corresponding author), Temple Univ, Dept Neurosci, Lewis Katz Sch Med, MERB 750,3500 North Broad St, Philadelphia, PA 19122 USA.	tdl@temple.edu			Pennsylvania Athletic Trainers' Society; Marianne Garman Burton Foundation for Caregivers; Temple University Office of the Vice Provost for Research	This work was supported by the Pennsylvania Athletic Trainers' Society research grant (to K. Kawata), generous support from Athole G. Jacobi, MD, and from the Marianne Garman Burton Foundation for Caregivers (to D. Langford), and a seed grant from Temple University Office of the Vice Provost for Research (to D. Langford). Sponsors had no role in the design or execution of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Daley M, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1131-5; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; Effgen GB, 2017, J NEUROTRAUM, V34, P914, DOI 10.1089/neu.2016.4477; Effgen GB, 2016, J NEUROTRAUM, V33, P1901, DOI 10.1089/neu.2015.4327; Esposito G, 2008, J CELL MOL MED, V12, P914, DOI 10.1111/j.1582-4934.2008.00159.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Higgins M, 2007, J ATHL TRAINING, V42, P5; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Kiechle K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084977; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Tyler CJ, 2010, EUR J APPL PHYSIOL, V110, P1063, DOI 10.1007/s00421-010-1567-7; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Weiner RB, 2013, CIRCULATION, V128, P524, DOI 10.1161/CIRCULATIONAHA.113.003522; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	40	23	23	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2017	34	14					2254	2260		10.1089/neu.2016.4786			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ8RQ	WOS:000404995000008	28181857				2021-06-18	
J	Mukai, T; Mori, Y; Shimazu, T; Takahashi, A; Tsunoda, H; Yamaguchi, S; Kiryu, S; Tojo, A; Nagamura-Inoue, T				Mukai, Takeo; Mori, Yuka; Shimazu, Takahisa; Takahashi, Atsuko; Tsunoda, Hajime; Yamaguchi, Satoru; Kiryu, Shigeru; Tojo, Arinobu; Nagamura-Inoue, Tokiko			INTRAVENOUS INJECTION OF UMBILICAL CORD-DERIVED MESENCHYMAL STROMAL CELLS ATTENUATES REACTIVE GLIOSIS AND HYPOMYELINATION IN A NEONATAL INTRAVENTRICULAR HEMORRHAGE MODEL	NEUROSCIENCE			English	Article						mesenchymal stromal cell; umbilical cord; intraventricular hemorrhage; cerebral palsy; brain-derived neurotrophic factor; Hepatocyte growth factor	HEPATOCYTE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; STEM-CELLS; FUNCTIONAL RECOVERY; PERIVENTRICULAR/INTRAVENTRICULAR HEMORRHAGE; IMMUNOSUPPRESSIVE PROPERTIES; NEUROLOGICAL RECOVERY; BLOOD-BRAIN; THERAPY; MYELINATION	Intraventricular hemorrhage (IVH) is a frequent complication of preterm newborns, resulting in cerebral palsy and cognitive handicap as well as hypoxic ischemic encephalopathy and periventricular leukomalacia. In this study, we investigated the restorative effect on neonatal IVH by umbilical cord-derived mesenchymal stromal cells (UC-MSCs) cultured in serum-free medium (RM medium) for clinical application. UC-MSCs were cultured with alpha MEM medium supplemented with FBS or RM. A neonatal IVH mouse model at postnatal day 5 was generated by intraventricular injection of autologous blood, and mice were intravenously administered 1 x 10(5) UC-MSCs two days after IVH. Brain magnetic resonance imaging was performed at postnatal day 15, 22 and neurological behavioral measurements were performed at postnatal day 23, accompanied by histopathological analysis and cytokine bead assays in serum after IVH with or without UC-MSCs. Both UC-MSCs cultured with aMEM and RM met the criteria of MSCs and improved behavioral outcome of IVH mice. Moreover the RM group exhibited significant behavioral improvement compared to the control group. Histopathological analysis revealed UC-MSCs cultured with RM significantly attenuated periventricular reactive gliosis, hypomyelination, and periventricular cell death observed after IVH. Furthermore, human brain-derived neurotrophic factor and hepatocyte growth factor were elevated in the serum, cerebrospinal fluid and brain tissue of neonatal IVH model mice 24 h after UC-MSCs administration. These results suggest UC-MSCs attenuate neonatal IVH by protecting gliosis and apoptosis of the injured brain, and intravenous injection of UC-MSCs cultured in RM may be feasible for neonatal IVH in clinic. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.	[Mukai, Takeo; Tojo, Arinobu] Univ Tokyo, Inst Med Sci, Ctr Adv Med Res, Div Mol Therapy,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan; [Mukai, Takeo; Mori, Yuka; Shimazu, Takahisa; Takahashi, Atsuko; Tojo, Arinobu; Nagamura-Inoue, Tokiko] Univ Tokyo, Inst Med Sci, Dept Cell Proc & Transfus, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan; [Tsunoda, Hajime] NTT Med Ctr Tokyo Hosp, Dept Obstet, Shinagawa Ku, 5-9-22 Higashigotannda, Tokyo 1410022, Japan; [Yamaguchi, Satoru] Yamaguchi Hosp, Dept Obstet, 5-24-2 Nishifuna, Funabashi, Chiba 2730031, Japan; [Kiryu, Shigeru] Univ Tokyo, Inst Med Sci, Dept Radiol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan	Nagamura-Inoue, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Cell Proc & Transfus, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tokikoni@ims.u-tokyo.ac.jp	Kiryu, Shigeru/B-6867-2019; Mukai, Takeo/H-8335-2019	Kiryu, Shigeru/0000-0003-1440-9483; Mukai, Takeo/0000-0001-6648-1271	Japan Agency for Medical Research and Development/Ministry of Health, Labor and WelfareJapan Agency for Medical Research and Development (AMED) [16Abk0104010h0015]; Ministry of Education, Culture, Sports, Science and Technology (JSPS KAKENHI)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP26293251]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17J02535] Funding Source: KAKEN	This study was supported by Grants-in-Aids for Scientific Research from the Japan Agency for Medical Research and Development/Ministry of Health, Labor and Welfare (16Abk0104010h0015) and from the Ministry of Education, Culture, Sports, Science and Technology (JSPS KAKENHI Grant Number JP26293251). We specially thank Dr. Ota, Y. and Mr. Onoda for his excellent assistance with immunohistochemistry and the staff of NTT Medical Center Hospital and Yamaguchi Hospital, Tokyo, for their assistance with the collection of UC and CB.	Abellaneda JM, 2015, TRANSPL P, V47, P132, DOI 10.1016/j.transproceed.2014.11.016; Ahn So Yoon, 2014, Korean J Pediatr, V57, P251, DOI 10.3345/kjp.2014.57.6.251; Ahn SY, 2013, STROKE, V44, P497, DOI 10.1161/STROKEAHA.112.679092; Bieback Karen, 2007, Curr Stem Cell Res Ther, V2, P310, DOI 10.2174/157488807782793763; Blencowe H, 2013, PEDIATR RES, V74, P17, DOI 10.1038/pr.2013.204; Chua CO, 2009, STROKE, V40, P3369, DOI 10.1161/STROKEAHA.109.549212; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; Cotten CM, 2014, J PEDIATR-US, V164, P973, DOI 10.1016/j.jpeds.2013.11.036; Ding DC, 2007, NEUROBIOL DIS, V27, P339, DOI 10.1016/j.nbd.2007.06.010; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dummula K, 2011, J NEUROSCI, V31, P12068, DOI 10.1523/JNEUROSCI.0013-11.2011; Georgiadis P, 2008, STROKE, V39, P3378, DOI 10.1161/STROKEAHA.107.510883; Gnecchi Massimiliano, 2009, V482, P281, DOI 10.1007/978-1-59745-060-7_18; Gram M, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-100; Gruber HE, 2010, TISSUE ENG PT A, V16, P2843, DOI [10.1089/ten.tea.2009.0709, 10.1089/ten.TEA.2009.0709]; Guo ZY, 2015, NEURAL REGEN RES, V10, P651, DOI 10.4103/1673-5374.155442; Han DM, 2011, CYTOTHERAPY, V13, P913, DOI 10.3109/14653249.2011.579958; He HP, 2015, INT J HEMATOL, V102, P368, DOI 10.1007/s12185-015-1844-7; Heck DH, 2008, HUM MOL GENET, V17, P2181, DOI 10.1093/hmg/ddn117; in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004-0058; Jin JL, 2013, CURR NEUROVASC RES, V10, P11, DOI 10.2174/156720213804805936; Kadoyama K, 2007, NEUROSCI RES, V59, P446, DOI 10.1016/j.neures.2007.08.017; Kienstra KA, 2007, J AM ASSOC LAB ANIM, V46, P50; Kim ES, 2012, PEDIATR RES, V72, P277, DOI 10.1038/pr.2012.71; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Krabbe C, 2005, APMIS, V113, P831, DOI 10.1111/j.1600-0463.2005.apm_3061.x; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Liu AM, 2010, NEUROSURGERY, V67, P357, DOI 10.1227/01.NEU.0000371983.06278.B3; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Ment LR, 2015, SEMIN PERINATOL, V39, P592, DOI 10.1053/j.semperi.2015.09.006; Mori Y, 2015, TISSUE ENG PART C-ME, V21, P367, DOI [10.1089/ten.tec.2014.0385, 10.1089/ten.TEC.2014.0385]; Mukai T, 2015, CYTOTHERAPY; Mukerji A, 2015, PEDIATRICS, V136, P1132, DOI 10.1542/peds.2015-0944; Pan WH, 2006, EXP NEUROL, V201, P99, DOI 10.1016/j.expneurol.2006.03.026; Peckham H, 2016, GLIA, V64, P255, DOI 10.1002/glia.22927; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Pollock K, 2016, MOL THER, V24, P965, DOI 10.1038/mt.2016.12; Qi ZH, 2017, NEUROSCI LETT, V637, P120, DOI 10.1016/j.neulet.2016.11.038; STURROCK RR, 1980, J ANAT, V130, P391; van Velthoven CTJ, 2010, BRAIN BEHAV IMMUN, V24, P387, DOI 10.1016/j.bbi.2009.10.017; Vinukonda G, 2013, EXP NEUROL, V247, P630, DOI 10.1016/j.expneurol.2013.02.018; Vinukonda G, 2010, BRAIN, V133, P2264, DOI 10.1093/brain/awq107; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Wang XD, 2015, CYTOTHERAPY, V17, P224, DOI 10.1016/j.jcyt.2014.09.010; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Wang YY, 2016, MOL NEUROBIOL, V53, P3448, DOI 10.1007/s12035-015-9263-6; Wang Z, 2015, STEM CELLS, V33, P456, DOI 10.1002/stem.1878; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; Xiang JJ, 2009, CYTOTHERAPY, V11, P516, DOI 10.1080/14653240902960429; Xiao JH, 2010, NEUROSIGNALS, V18, P186, DOI 10.1159/000323170; Xue MZ, 2003, J NEUROPATH EXP NEUR, V62, P1154, DOI 10.1093/jnen/62.11.1154; Yan HL, 2002, J NEUROSCI RES, V69, P597, DOI 10.1002/jnr.10323; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423; Zhu Y, 2014, ACTA PHARMACOL SIN, V35, P585, DOI 10.1038/aps.2014.9	56	23	23	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 4	2017	355						175	187		10.1016/j.neuroscience.2017.05.006			13	Neurosciences	Neurosciences & Neurology	EY6EQ	WOS:000404075700015	28504197				2021-06-18	
J	Kelly, M; McDonald, S; Frith, MHJ				Kelly, Michelle; McDonald, Skye; Frith, Matthew H. J.			A Survey of Clinicians Working in Brain Injury Rehabilitation: Are Social Cognition Impairments on the Radar?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; assessment practices; clinician; social cognition; social function; staff; survey; traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; BLUNT HEAD-INJURY; EMOTION RECOGNITION; PERCEPTION DEFICITS; INDIVIDUALS; AWARENESS; VALIDITY; PROSODY; ABILITY; TASIT	Objectives: To examine the social cognition assessment practices of clinicians working with children and adults with traumatic brain injury. Main Measures: Online survey addressing frequency of social cognition impairments, how these are assessed and obstacles to same, and treatment practices. Participants: A total of 443 clinicians worldwide working in inpatient and outpatient settings. Results: While 84% of clinicians reported that more than half of their clients with severe traumatic brain injury had social cognition impairments, 78% of these reported that they infrequently or never assessed these domains using a formal assessment tool. Lack of reliable tests was most frequently (33% of respondents) cited as the greatest barrier to undertaking social cognition assessment. Conclusions and Implications: Improvements are needed in the development and norming of instruments capable of detecting social cognition impairments in the traumatic brain injury population. Additional training and education is needed in the use of social cognition assessment tools.	[Kelly, Michelle] Univ Newcastle, Sch Psychol, Univ Dr, Callaghan, NSW 2308, Australia; [Kelly, Michelle; Frith, Matthew H. J.] Hunter New England Hlth, Paediat Brain Injury Rehabil Team, Newcastle, NSW, Australia; [McDonald, Skye] Univ New South Wales, Sch Psychol, Sydney, NSW, Australia; [Kelly, Michelle; McDonald, Skye] Moving Ahead Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia; [Frith, Matthew H. J.] Hunter New England Hlth, Children Young People & Families, Newcastle, NSW, Australia	Kelly, M (corresponding author), Univ Newcastle, Sch Psychol, Univ Dr, Callaghan, NSW 2308, Australia.	Michelle.Kelly@newcastle.edu.au	Kelly, Michelle/J-9739-2019	Kelly, Michelle/0000-0003-0375-816X	Lifetime Care and Support Authority	This research was funded by Lifetime Care and Support Authority.	Agresti A, 2013, CATEGORICAL DATA ANA; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; [Anonymous], 2006, TRAUM BRAIN INJ DIAG; [Anonymous], 2011, AW SOC INF TEST REV; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Bliksted V, 2014, SCHIZOPHR RES, V153, P9, DOI 10.1016/j.schres.2014.01.010; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Braden C, 2010, BRAIN INJURY, V24, P1298, DOI 10.3109/02699052.2010.506859; Bramham J, 2009, J NEUROPSYCHOL, V3, P125, DOI 10.1348/174866408X293994; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; de Sousa A, 2012, J CLIN EXP NEUROPSYC, V34, P606, DOI 10.1080/13803395.2012.667067; EKMAN P, 1971, J PERS SOC PSYCHOL, V17, P124, DOI 10.1037/h0030377; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Frith M, 2014, BRAIN INJURY, V28, P1657, DOI 10.3109/02699052.2014.947619; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Hofmans J, 2009, QUAL QUANT, V43, P703, DOI 10.1007/s11135-007-9154-7; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hooker C, 2002, PSYCHIAT RES, V112, P41, DOI 10.1016/S0165-1781(02)00177-4; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Howell D.C., 2007, STAT METHODS PSYCHOL, V6th ed.; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Jenkins VA, 2001, QUAL HEALTH CARE, V10, P70, DOI 10.1136/qhc.10.2.70; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Kurtz MM, 2012, SCHIZOPHRENIA BULL, V38, P1092, DOI 10.1093/schbul/sbr036; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 2013, NEUROPSYCHOL REHABIL, V23, P267, DOI 10.1080/09602011.2012.751340; McDonald S, 2009, NEUROPSYCHOL REHABIL, V7, P1; McDonald S, 2014, SOCIAL COMMUNICATION; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McDonald S, 2011, J CLIN EXP NEUROPSYC, V33, P17, DOI 10.1080/13803391003761967; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Mehrabian A., 2000, MANUAL BALANCED EMOT; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Motor Accidents Authority, 2013, NEUR ASS CHILDR AD T; Neumann D, 2015, J HEAD TRAUMA REHAB, V30, pE12, DOI 10.1097/HTR.0000000000000054; Royal College of Physicians and British Society of Rehabilitation Medicine, 2003, REH FOLL ACQ BRAIN I; Rushby JA, 2013, INT J PSYCHOPHYSIOL, V89, P466, DOI 10.1016/j.ijpsycho.2013.06.013; Ryan NP, 2015, HUM BRAIN MAPP, V36, P1677, DOI 10.1002/hbm.22729; Ryan NP, 2015, NEUROPSYCHOLOGIA, V66, P32, DOI 10.1016/j.neuropsychologia.2014.10.040; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Simpson JR, 2014, J AM ACAD PSYCHIATRY, V42, P159; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Ubukata S, 2014, NEUROPSYCH DIS TREAT, V10, P2061, DOI 10.2147/NDT.S68156; Umeasiegbu VI, 2013, AUST J REHABIL COUNS, V19, P155, DOI 10.1017/jrc.2013.18; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Westerhof-Evers HJ, 2014, J CLIN EXP NEUROPSYC, V36, P1031, DOI 10.1080/13803395.2014.966661; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518	68	23	23	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2017	32	4					E55	E65		10.1097/HTR.0000000000000269			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FA2KB	WOS:000405269200007	28489703				2021-06-18	
J	Liu, YL; Bao, ZY; Xu, XP; Chao, HL; Lin, C; Li, Z; Liu, Y; Wang, XM; You, YP; Liu, N; Ji, J				Liu, Yinlong; Bao, Zhongyuan; Xu, Xiupeng; Chao, Honglu; Lin, Chao; Li, Zheng; Liu, Yan; Wang, Xiaoming; You, Yongping; Liu, Ning; Ji, Jing			Extracellular Signal-Regulated Kinase/Nuclear Factor-Erythroid2-like2/Heme Oxygenase-1 Pathway-Mediated Mitophagy Alleviates Traumatic Brain Injury-Induced Intestinal Mucosa Damage and Epithelial Barrier Dysfunction	JOURNAL OF NEUROTRAUMA			English	Article						intestinal dysfunction; intestinal mucosa damage; mitophagy; oxidative stress; TBI	OXIDATIVE STRESS; CELL-DEATH; MITOCHONDRIAL PRODUCTION; AUTOPHAGY PROTECTS; ORGAN DYSFUNCTION; NITRIC-OXIDE; KAPPA-B; PERMEABILITY; ACTIVATION; APOPTOSIS	Gastrointestinal dysfunction is one of several physiologic complications in patients with traumatic brain injury (TBI). TBI can result in increased intestinal permeability resulting from apoptosis of intestinal epithelial cells, which contain a large number of mitochondria for persisting barrier function. Autophagy of damaged mitochondria (mitophagy) controls the quality of the mitochondria and regulates cellular homeostasis. However, the exact mechanism of mitophagy that underlies the pathological changes induced by TBI is unknown. Here, we report that mitophagy decreases the intestinal epithelial cell damage and apoptosis that are activated in a rat model of controlled cortical impact (CCI). CCI-induced mitophagy is associated with an increase in 3-nitrotyrosine and 4-hydroxynonenal, indicating that oxidative stress may increase in response to mitochondrial disturbance. CCI also results in the expression of the tight junction proteins zonula occludens-1 (ZO-1) and occludin, which may regulate the in vivo intestinal hyperpermeability induced by CCI. Additionally, CCIinduced mitophagy was shown to be mediated by the oxidative stress-related extracellular signal-regulated kinase (ERK)/nuclear factor-erythroid2-like2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway, which may serve to reduce the apoptosis induced by oxidative stress. These results suggest that CCI-induced mitophagy serves to diminish apoptosis-mediated intestinal epithelial cell damage and to improve intestinal permeability, via ERK/Nrf2/HO-1 signaling. These findings may be useful in the design of rational approaches for the prevention and treatment of symptoms associated with TBI.	[Liu, Yinlong; Bao, Zhongyuan; Xu, Xiupeng; Chao, Honglu; Lin, Chao; Li, Zheng; You, Yongping; Liu, Ning; Ji, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Liu, Yan] Nanjing Med Univ, Sch Pharm, Inst Stem Cell & Neural Regenerat, Nanjing, Jiangsu, Peoples R China; [Wang, Xiaoming] Nanjing Med Univ, Dept Immunol, Nanjing, Jiangsu, Peoples R China	Ji, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	jijing@njmu.edu.cn			Jiangsu Province's Key Discipline of Medicine. Jiangsu Province [XK201117]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Outstanding Youth of Jiangsu Province [BK20160047, BK20160044]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471269, 81300998, 31570881]	This study was supported by grants from Jiangsu Province's Key Discipline of Medicine (XK201117). Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions (2016, PAPD), Outstanding Youth of Jiangsu Province (BK20160047 and BK20160044), and National Natural Science Foundation of China (81471269, 81300998, and 31570881).	Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Brown D, 1996, J EXP BIOL, V199, P2345; Carchman EH, 2011, HEPATOLOGY, V53, P2053, DOI 10.1002/hep.24324; Castillo L, 1999, REV MED CHILE, V127, P639; Choi HY, 2016, CHEM-BIOL INTERACT, V245, P110, DOI 10.1016/j.cbi.2015.06.024; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Elbrond VS, 2004, COMP BIOCHEM PHYS A, V137, P683, DOI 10.1016/j.cbpb.2004.02.006; Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Grivennikova VG, 2013, BIOCHEMISTRY-MOSCOW+, V78, P1490, DOI 10.1134/S0006297913130087; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Hazeldine J, 2015, INJURY, V46, P975, DOI 10.1016/j.injury.2015.03.028; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jin W, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/502564; Jin W, 2009, J SURG RES, V157, P251, DOI 10.1016/j.jss.2008.08.003; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Kemp CD, 2008, AM SURGEON, V74, P866; Kim I, 2011, AM J PHYSIOL-CELL PH, V300, pC308, DOI 10.1152/ajpcell.00056.2010; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156; LAWRENCE CB, 1986, BIOCHIM BIOPHYS ACTA, V848, P35, DOI 10.1016/0005-2728(86)90157-X; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Maynard AA, 2010, AM J PHYSIOL-GASTR L, V299, pG614, DOI 10.1152/ajpgi.00076.2010; Mei QA, 2011, ACTA PHARMACOL SIN, V32, P495, DOI 10.1038/aps.2010.225; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Moran M, 2012, FREE RADICAL BIO MED, V53, P595, DOI 10.1016/j.freeradbiomed.2012.05.009; Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Sasaki K, 2015, J BIOCHEM, V157, P185, DOI 10.1093/jb/mvv010; Serrano I, 2015, J EXP BOT, V66, P2869, DOI 10.1093/jxb/erv083; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979; Stone JR, 2015, TECH VASC INTERV RAD, V18, P24, DOI 10.1053/j.tvir.2014.12.004; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wang GZ, 2016, ANTIOXID REDOX SIGN, V24, P961, DOI 10.1089/ars.2015.6492; Wang N, 2016, DIGEST DIS SCI, V61, P2522, DOI 10.1007/s10620-016-4184-4; Wang YB, 2011, WORLD J GASTROENTERO, V17, P657, DOI 10.3748/wjg.v17.i5.657; Wang Yan-bin, 2010, Zhonghua Yi Xue Za Zhi, V90, P1716; Xu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072528; Yasuhara H, 2005, SURG TODAY, V35, P185, DOI 10.1007/s00595-004-2924-0; Yu YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069620; Zhang XN, 2014, AUTOPHAGY, V10, P1801, DOI 10.4161/auto.32136; Zhang XN, 2013, AUTOPHAGY, V9, P1321, DOI 10.4161/auto.25132; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057; Zhu KJ, 2014, WORLD J GASTROENTERO, V20, P9585, DOI 10.3748/wjg.v20.i28.9585; Zhu LQ, 2016, ONCOTARGET, V7, P27122, DOI 10.18632/oncotarget.8345	62	23	29	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2119	2131		10.1089/neu.2016.4764			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400450	28093052				2021-06-18	
J	Patel, SP; Cox, DH; Gollihue, JL; Bailey, WM; Geldenhuys, WJ; Gensel, JC; Sullivan, PG; Rabchevsky, AG				Patel, Samir P.; Cox, David H.; Gollihue, Jenna L.; Bailey, William M.; Geldenhuys, Werner J.; Gensel, John C.; Sullivan, Patrick G.; Rabchevsky, Alexander G.			Pioglitazone treatment following spinal cord injury maintains acute mitochondrial integrity and increases chronic tissue sparing and functional recovery	EXPERIMENTAL NEUROLOGY			English	Article						PPAR; mitoNEET; Neuroprotection; Bioenergetics; Locomotor recovery	TRAUMATIC BRAIN-INJURY; PROLIFERATOR-ACTIVATED RECEPTORS; MEMBRANE PROTEIN; LOCOMOTOR RECOVERY; CRYSTAL-STRUCTURE; CONTROLLED-TRIAL; GAMMA AGONISTS; HUMAN MITONEET; METHYLPREDNISOLONE; BIOENERGETICS	Pioglitazone is an FDA-approved PPAR-gamma agonist drug used to treat diabetes, and it has demonstrated neuroprotective effects in multiple models of central nervous system (CNS) injury. Acute treatment after spinal cord injury (SCI) in rats is reported to suppress neuroinflammation, rescue injured tissues, and improve locomotor recovery. In the current study, we additionally assessed the protective efficacy of pioglitazone treatment on acute mitochondrial respiration, as well as functional and anatomical recovery after contusion SCI in adult male C57BL/6 mice. Mice received either vehicle or pioglitazone (10 mg/kg) at either 15 min or 3 h after injury (75 kdyn at T9) followed by a booster at 24 h post-injury. At 25 h, mitochondria were isolated from spinal cord segments centered on the injury epicenters and assessed for their respiratory capacity. Results showed significantly compromised mitochondrial respiration 25 h following SCI, but pioglitazone treatment that was initiated either at 15 min or 3 h post-injury significantly maintained mitochondrial respiration rates near sham levels. A second cohort of injured mice received pioglitazone at 15 min post injury, then once a day for 5 days post-injury to assess locomotor recovery and tissue sparing over 4 weeks. Compared to vehicle, pioglitazone treatment resulted in significantly greater recovery of hind-limb function over time, as determined by serial locomotor BMS assessments and both terminal BMS subscores and gridwalk performance. Such improvements correlated with significantly increased grey and white matter tissue sparing, although pioglitazone treatment did not abrogate long-term injury-induced inflammatory microglia/macrophage responses. In sum, pioglitazone significantly increased functional neuroprotection that was associated with remarkable maintenance of acute mitochondria! bioenergetics after traumatic SCI. This sets the stage for dose-response and delayed administration studies to maximize pioglitazone's efficacy for SCI while elucidating the precise role that mitochondria play in governing its neuroprotection; the ultimate goal to develop novel therapeutics that specifically target mitochondrial dysfunction. (C) 2017 Elsevier Inc. All rights reserved.	[Patel, Samir P.; Cox, David H.; Gollihue, Jenna L.; Bailey, William M.; Gensel, John C.; Sullivan, Patrick G.; Rabchevsky, Alexander G.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Patel, Samir P.; Gollihue, Jenna L.; Gensel, John C.; Rabchevsky, Alexander G.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA; [Sullivan, Patrick G.] Univ Kentucky, Coll Med, Dept Neurosci, Lexington, KY 40536 USA; [Geldenhuys, Werner J.] West Virginia Univ, Dept Pharmaceut Sci, Sch Pharm, Morgantown, WV 26506 USA	Rabchevsky, AG (corresponding author), Spinal Cord & Brain Injury Res Ctr SCoBIRC, B471,Biomed & Biol Sci Res Bldg, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915; Cox, David/0000-0002-9483-5900	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS069633, 2P30NS051220]; KSCHIRT [15-14A]; SCoBIRC Chair Endowment; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS077889, P30NS051220, R01NS069633] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003405] Funding Source: NIH RePORTER	The authors extend special thanks to Dr. Bei Zhang and Mr. Michael Orr for helping with gridwalk, and Mr. Taylor Smith for helping with BMS assessments. This study was supported by NIH/NINDS R01 NS069633 (AGR & PGS); KSCHIRT 15-14A (PGS); SCoBIRC Chair Endowment (AGR); NIH/NINDS 2P30NS051220.	ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Bracken MB, 2001, SPINE, V26, pS47, DOI 10.1097/00007632-200112151-00010; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Center N.S.C.I.S., 2016, SPINAL CORD INJURY S; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Christman JW, 2000, BRAIN PATHOL, V10, P153; Colca JR, 2004, AM J PHYSIOL-ENDOC M, V286, pE252, DOI 10.1152/ajpendo.00424.2003; Conlan AR, 2009, J MOL BIOL, V392, P143, DOI 10.1016/j.jmb.2009.06.079; Cummings BJ, 2007, BEHAV BRAIN RES, V177, P232, DOI 10.1016/j.bbr.2006.11.042; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Drew PD, 2006, NEUROCHEM INT, V49, P183, DOI 10.1016/j.neuint.2006.04.003; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Frazier-Wood AC, 2013, PHARMACOGENOMICS J, V13, P312, DOI 10.1038/tpj.2012.9; Geldenhuys WJ, 2011, BIOORG MED CHEM LETT, V21, P5498, DOI 10.1016/j.bmcl.2011.06.111; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1993, RES P ARNMD, V71, P81; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hou XW, 2007, J BIOL CHEM, V282, P33242, DOI 10.1074/jbc.C700172200; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kusminski CM, 2012, NAT MED, V18, P1539, DOI 10.1038/nm.2899; Landry AP, 2014, J BIOL CHEM, V289, P4307, DOI 10.1074/jbc.M113.542050; Lin JZ, 2007, P NATL ACAD SCI USA, V104, P14640, DOI 10.1073/pnas.0702426104; Liu M, 2017, J NEUROTRAUM, V34, P414, DOI 10.1089/neu.2015.4361; Martin HL, 2012, EXP NEUROL, V235, P528, DOI 10.1016/j.expneurol.2012.02.017; McEwen ML, 2011, NEUROTHERAPEUTICS, V8, P168, DOI 10.1007/s13311-011-0031-7; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Paddock ML, 2007, P NATL ACAD SCI USA, V104, P14342, DOI 10.1073/pnas.0707189104; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Pedada KK, 2014, J CHROMATOGR B, V945, P141, DOI 10.1016/j.jchromb.2013.11.048; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 2011, PHARMACOL THERAPEUT, V132, P15, DOI 10.1016/j.pharmthera.2011.05.001; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Sood HS, 2003, AM J PHYSIOL-LUNG C, V284, pL333, DOI 10.1152/ajplung.00183.2002; Sood V, 2000, Diabetes Technol Ther, V2, P429, DOI 10.1089/15209150050194297; Springer JE, 1997, J NEUROCHEM, V68, P2469; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Wiley SE, 2007, P NATL ACAD SCI USA, V104, P5318, DOI 10.1073/pnas.0701078104; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yonutas HM, 2015, J BIOENERG BIOMEMBR, V47, P149, DOI 10.1007/s10863-014-9593-5; Yonutas HM, 2013, CURR DRUG TARGETS, V14, P733, DOI 10.2174/1389450111314070003; Zhang B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0440-3; Zhang B, 2015, EXP NEUROL, V273, P83, DOI 10.1016/j.expneurol.2015.08.001	59	23	24	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2017	293						74	82		10.1016/j.expneurol.2017.03.021			9	Neurosciences	Neurosciences & Neurology	EV5EC	WOS:000401784300007	28365473	Green Accepted, Green Published			2021-06-18	
J	Pierce, MC; Kaczor, K; Acker, D; Webb, T; Brenzel, A; Lorenz, DJ; Young, A; Thompson, R				Pierce, Mary Clyde; Kaczor, Kim; Acker, Deborah; Webb, Tina; Brenzel, Allen; Lorenz, Douglas J.; Young, Audrey; Thompson, Richard			History, injury, and psychosocial risk factor commonalities among cases of fatal and near-fatal physical child abuse	CHILD ABUSE & NEGLECT			English	Article						Child maltreatment; Recidivism; Homicide; Sentinel injury; Missed abuse	HEAD TRAUMA; SUBSTANCE-ABUSE; UNITED-STATES; MALTREATMENT; PARENTS; COMMUNITY; VIOLENCE; INFANTS; ATTRIBUTIONS; FAMILIES	Failure to recognize child maltreatment results in chronic exposure to high-risk environments where re-injury or death may occur. We analyzed a series (n = 20) of fatal (n = 10) and near fatal (n = 10) physical child abuse cases from the Commonwealth of Kentucky to identify commonalities and determine whether indicators of maltreatment were present prior to the child's fatal or near-fatal event. We conducted retrospective state record reviews involving children < 4 years of age classified as physical child abuse by the Cabinet for Health and Family Services during a 12 month period. Cases were distributed across 17 counties. IRS approvals were obtained. Three reviewers concurrently abstracted case data from medical, social, and legal documents, and descriptive statistics were analyzed. Median age of subjects was 7.5 months (range 1-32 months); 55% were male. Psychosocial risk factors (PRFs) were present in 100% of cases. Traumatic brain injury (95%) and bruising (90%) were the most common injuries. Of the 14 children with available prior medical records, 9 (64%) had sentinel injuries in the form of prior unexplained bruising; all nine suffered subsequent traumatic brain injury resulting in four deaths. A male was caring for the child at the time of the final event in 70% of cases. Our study identified key commonalities across cases of fatal and near-fatal abuse, highlighting the prevalence of psychosocial risk factors and the significance of prior unexplained bruising as a herald of escalating abuse. Further study is warranted to ascertain the predictive value of our findings in the larger population.	[Pierce, Mary Clyde; Kaczor, Kim] Univ Louisville, Dept Pediat, 571 S Floyd St, Louisville, KY 40202 USA; [Acker, Deborah; Brenzel, Allen] Commonwealth Kentucky, Cabinet Hlth & Family Serv, Dept Community Based Serv, 275 East Main St, Frankfort, KY 40621 USA; [Webb, Tina] Commonwealth Kentucky, Cabinet Hlth & Family Serv, Div Protect & Permanency, 275 East Main St, Frankfort, KY 40621 USA; [Brenzel, Allen] Univ Kentucky, Coll Med, Dept Psychiat, 245 Fountain Court, Lexington, KY 40509 USA; [Lorenz, Douglas J.] Univ Louisville, Sch Publ Hlth & Informat Sci, Dept Bioinforrnat & Biostat, 485 E Gray St, Louisville, KY 40202 USA; [Young, Audrey] Northwestern Univ, Feinberg Sch Med, 225 E Chicago Ave, Chicago, IL 60611 USA; [Thompson, Richard] Juvenile Protect Assoc, Richard H Calico Ctr Innovat Children & Family Se, 1707 N Halsted St, Chicago, IL 60614 USA; [Pierce, Mary Clyde; Kaczor, Kim] Ann & Robert H Lurie Childrens Hosp Chicago, Div Emergency Med, 225 E Chicago Ave,Box 62, Chicago, IL 60611 USA; [Pierce, Mary Clyde] Northwestern Univ, Dept Pediat, Feinberg Sch Med, 225 E Chicago Ave, Chicago, IL 60611 USA; [Webb, Tina] Commonwealth Kentucky, Div Maternal & Child Hlth, Dept Publ Hlth, 275 East Main St, Frankfort, KY 40621 USA; [Brenzel, Allen] Commonwealth Kentucky, Dept Behav Hlth, 275 East Main St, Frankfort, KY 40621 USA	Pierce, MC (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, Div Emergency Med, 225 E Chicago Ave,Box 62, Chicago, IL 60611 USA.	MPierce@luriechildrens.org	Pierce, Mary Clyde/AAQ-3509-2021	Kaczor, Kim/0000-0001-8519-1464			Adamsbaum C, 2010, PEDIATRICS, V126, P546, DOI 10.1542/peds.2009-3647; Berlin LJ, 2013, JAMA PEDIATR, V167, P549, DOI 10.1001/jamapediatrics.2013.1212; Bugental DB, 2004, DEV PSYCHOL, V40, P234, DOI 10.1037/0012-1649.40.2.234; Chaffin M, 1996, CHILD ABUSE NEGLECT, V20, P191, DOI 10.1016/S0145-2134(95)00144-1; Children's Bureau, 2016, CHILD AB NEGL FAT 20; Dakil SR, 2011, ARCH PEDIAT ADOL MED, V165, P1006, DOI 10.1001/archpediatrics.2011.129; De Leeuw M, 2013, AM J FOREN MED PATH, V34, P130, DOI 10.1097/PAF.0b013e31828629ca; DiLauro MD, 2004, CHILD WELFARE, V83, P69; Division of Protection and Permanency Department for Community Based Services Cabinet for Health and Family Services, 2014, CHILD AB NEGL ANN RE; EDLESON JL, 1999, VIOLENCE WOMEN, V0005; Fang XM, 2012, CHILD ABUSE NEGLECT, V36, P156, DOI 10.1016/j.chiabu.2011.10.006; Farc MM, 2008, CHILD ABUSE NEGLECT, V32, P177, DOI 10.1016/j.chiabu.2007.06.001; FRYER GE, 1994, CHILD ABUSE NEGLECT, V18, P1063, DOI 10.1016/0145-2134(94)90132-5; Herrenkohl TI, 2008, TRAUMA VIOLENCE ABUS, V9, P84, DOI 10.1177/1524838008314797; Huebner RA, 2010, PROTECT CHILD, V25, P76; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; KELLEHER K, 1994, AM J PUBLIC HEALTH, V84, P1586, DOI 10.2105/AJPH.84.10.1586; King WK, 2006, PEDIATR EMERG CARE, V22, P211, DOI 10.1097/01.pec.0000208180.94166.dd; Kolko D. J., 2002, ASSESSING TREATING P, P1; Kotch JB, 1999, CHILD ABUSE NEGLECT, V23, P305, DOI 10.1016/S0145-2134(99)00003-4; Lamers-Winkelman F, 2012, CHILD ABUSE NEGLECT, V36, P166, DOI 10.1016/j.chiabu.2011.07.006; Lau AS, 2006, CHILD ABUSE NEGLECT, V30, P639, DOI 10.1016/j.chiabu.2005.11.009; Lucas DR, 2002, CHILD ABUSE NEGLECT, V26, P167, DOI 10.1016/S0145-2134(01)00315-5; Maguire S, 2005, ARCH DIS CHILD, V90, P182, DOI 10.1136/adc.2003.044065; Pears KC, 2001, CHILD ABUSE NEGLECT, V25, P1439, DOI 10.1016/S0145-2134(01)00286-1; Phillips SD, 2004, AM J ORTHOPSYCHIAT, V74, P174, DOI 10.1037/0002-9432.74.2.174; Phillips SD, 2010, CHILD YOUTH SERV REV, V32, P544, DOI 10.1016/j.childyouth.2009.11.008; Pierce M. C., 2017, DATA BRIEF UNPUB; Pierce MC, 2010, PEDIATRICS, V125, P67, DOI 10.1542/peds.2008-3632; Saade DN., 2002, ACAD EMERG MED, V9, P524, DOI [10.1197/aemj.9.5.524, DOI 10.1197/AEMJ.9.5.524]; Seng A, 2008, CLIN CHILD FAM PSYCH, V11, P163, DOI 10.1007/s10567-008-0035-y; Serinelli S., 2016, J FORENSIC SCI; Sheets LK, 2013, PEDIATRICS, V131, P701, DOI 10.1542/peds.2012-2780; Sieswerda-Hoogendoorn T, 2013, ACTA PAEDIATR, V102, pE497, DOI 10.1111/apa.12377; Stiffman MN, 2002, PEDIATRICS, V109, P615, DOI 10.1542/peds.109.4.615; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; Thompson R, 2009, CHILD MALTREATMENT, V14, P89, DOI 10.1177/1077559508325317; U. S. Department of Health and Human Services Administration for Children and Families Administration on Children Youth and Families Children's Bureau, 2016, ADM CHILDR FAM ADM C; Walsh C, 2003, CHILD ABUSE NEGLECT, V27, P1409, DOI 10.1016/j.chiabu.2003.07.002; Zolotor AJ, 2008, AM J PREV MED, V35, P364, DOI 10.1016/j.amepre.2008.06.031	40	23	23	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	JUL	2017	69						263	277		10.1016/j.chiabu.2017.04.033			15	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	EY6GO	WOS:000404080700026	28500923				2021-06-18	
J	Raj, R; Kaprio, J; Korja, M; Mikkonen, ED; Jousilahti, P; Siironen, J				Raj, Rahul; Kaprio, Jaakko; Korja, Miikka; Mikkonen, Era D.; Jousilahti, Pekka; Siironen, Jari			Risk of hospitalization with neurodegenerative disease after moderate-to-severe traumatic brain injury in the working- age population: A retrospective cohort study using the Finnish national health registries	PLOS MEDICINE			English	Article							HEAD-INJURY; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; PARKINSON DISEASE; DEMENTIA RISK; EPIDEMIOLOGY	Background Previous epidemiological studies suggest that working-aged persons with a history of moderate-to-severe traumatic brain injury (TBI) may have an increased risk for developing neurodegenerative disease (NDD) while persons with a history of mild TBI do not. In this comprehensive nationwide study in Finland, we assessed the risk of NDD and history of moderate-to-severe TBI in the working-age population. Methods and findings We performed a population-based follow-up study using the Finnish Care Register for Health Care to identify all persons between the ages of 18 and 65 years hospitalized during 1987-2014 due to TBI who did not have a baseline NDD diagnosis. We compared the risk of hospitalization with NDD between persons hospitalized due to moderate-to-severe TBI (intracranial lesions) and persons hospitalized due to mild TBI (no intracranial lesions). Follow-up NDD diagnoses were recorded from 1 year following the TBI to the end of 2014. NDD diagnoses included dementia, Parkinson disease, and amyotrophic lateral sclerosis. We used a Cox proportional hazards model, adjusting for age, sex, education, and socioeconomic group, to assess the association between TBI and NDD. In total, 19,936 and 20,703 persons with a history of moderate-to-severe TBI and mild TBI, respectively, were included. The overall time at risk was 453,079 person-years (median 10 years per person). In total, 3.5% (N = 696) persons in the moderate-to-severe TBI group developed NDD compared to 1.6% (N = 326) in the mild TBI group. After adjusting for covariates, moderate-to-severe TBI was associated with an increased risk for NDD, with a hazard ratio (HR) of 1.8 (95% CI 1.6-2.1) compared to mild TBI. Of the NDD subtypes, only moderate-to-severe TBI was associated with an increased risk for dementia (HR 1.9, 95% CI 1.6-2.2). Yet, this large-scale epidemiological study does not prove that there is a causal relationship between moderate-to-severe TBI and NDD. Further, the Care Register for Health Care includes only hospitalized persons; thus, patients diagnosed with NDD in the outpatient setting may have been missed. Additional limitations include the potential for miscoding and unmeasured confounds. Conclusions In working-aged persons, a history of moderate-to-severe TBI is associated with an increased risk for future dementia but not for Parkinson disease or amyotrophic lateral sclerosis.	[Raj, Rahul; Korja, Miikka; Siironen, Jari] Univ Helsinki, Dept Neurosurg, Helsinki, Finland; [Raj, Rahul; Korja, Miikka; Mikkonen, Era D.; Siironen, Jari] Helsinki Univ Hosp, Helsinki, Finland; [Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; [Kaprio, Jaakko] Inst Mol Med Finland FIMM, Helsinki, Finland; [Mikkonen, Era D.] Univ Helsinki, Dept Anesthesiol Intens Care Emergency Care & Pai, Helsinki, Finland; [Jousilahti, Pekka] Natl Inst Hlth & Welf, Helsinki, Finland	Raj, R (corresponding author), Univ Helsinki, Dept Neurosurg, Helsinki, Finland.; Raj, R (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.	rahul.raj@hus.fi	Kaprio, Jaakko/A-1820-2008; Korja, Miikka/E-4292-2016; Raj, Rahul/K-7693-2012	Kaprio, Jaakko/0000-0002-3716-2455; Korja, Miikka/0000-0002-4463-6954; Raj, Rahul/0000-0003-4243-9591; Mikkonen, Era Daniel/0000-0003-1379-0235	Suomen AkatemiaAcademy of Finland [263278]; Svenska Kulturfonden [17/2921]; Medicinska Understodsforeningen Liv Halsa; Finska Lakaresallskapet; Maud Kuistilan Saatio; Eemil Aaltosen Saatio; Ella & Georg Ehrnroothin Saatio; Suomalais-Norjalainen Laaketieteen Saatio; Suomen Laaketieteen Saatio; Maire Taposen Saatio	JK is supported by the Suomen Akatemia (Grant #263278). RR has received personal research grants from Svenska Kulturfonden (Grant #17/2921), Medicinska Understodsforeningen Liv & Halsa, Finska Lakaresallskapet, Maud Kuistilan Saatio, Eemil Aaltosen Saatio, Ella & Georg Ehrnroothin Saatio, Suomalais-Norjalainen Laaketieteen Saatio, Suomen Laaketieteen Saatio, and Maire Taposen Saatio. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armon C, 2012, AMYOTROPH LATERAL SC, V13, P351, DOI 10.3109/17482968.2012.660954; Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9; Benchimol EI, 2015, PLOS MED, V12, DOI [10.1371/journal.pmed.1001885, 10.1016/j.zefq.2016.07.010]; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fratiglioni L, 2000, NEUROLOGY, V54, pS10; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; Hamer M, 2009, PSYCHOL MED, V39, P3, DOI 10.1017/S0033291708003681; Helakorpi S, ALCOHOL ALCOHOL, V45, P286; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728; Kenborg L, 2015, NEUROLOGY, V84, P1098, DOI 10.1212/WNL.0000000000001362; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Kivipelto M, 2006, LANCET NEUROL, V5, P735, DOI 10.1016/S1474-4422(06)70537-3; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Li YJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169650; Lu FP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004144; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Newgard CD, 2010, ACAD EMERG MED, V17, P142, DOI 10.1111/j.1553-2712.2009.00647.x; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Peters TL, 2013, AMYOTROPH LAT SCL FR, V14, P267, DOI 10.3109/21678421.2012.754043; Prince M, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0188-8; Puljula J, 2016, ANN SURG, V263, P1235, DOI 10.1097/SLA.0000000000001392; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Raj R, 2015, J NEUROTRAUM, V32, P95, DOI 10.1089/neu.2014.3488; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rossor MN, 2010, LANCET NEUROL, V9, P793, DOI 10.1016/S1474-4422(10)70159-9; Rugbjerg K, 2008, BMJ-BRIT MED J, V337, pa2494, DOI [10.1136/bmj.a2494, DOI 10.1136/BMJ.A2494]; Savva GM, 2010, STROKE, V41, pE41, DOI 10.1161/STROKEAHA.109.559880; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vuoksimaa Eero, 2016, Alzheimers Dement (Amst), V4, P118; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015	41	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JUL	2017	14	7							e1002316	10.1371/journal.pmed.1002316			16	Medicine, General & Internal	General & Internal Medicine	FC1QA	WOS:000406611200003	28678790	DOAJ Gold, Green Published			2021-06-18	
J	Tucker, B; Aston, J; Dines, M; Caraman, E; Yacyshyn, M; McCarthy, M; Olson, JE				Tucker, Brian; Aston, Jill; Dines, Megan; Caraman, Elena; Yacyshyn, Marianne; McCarthy, Mary; Olson, James E.			EARLY BRAIN EDEMA IS A PREDICTOR OF IN-HOSPITAL MORTALITY IN TRAUMATIC BRAIN INJURY	JOURNAL OF EMERGENCY MEDICINE			English	Article						logistic regression; mild traumatic brain injury; mortality; secondary insult	GLASGOW COMA SCALE; CRANIAL COMPUTED-TOMOGRAPHY; PROGNOSTIC VALUE; HEAD-INJURY; CELLULAR EDEMA; IMPACT; MILD; VOLUME; MODELS; SCORE	Background: Identifying patients who may progress to a poor clinical outcome will encourage earlier appropriate therapeutic interventions. Brain edema may contribute to secondary injury in traumatic brain injury (TBI) and thus, may be a useful prognostic indicator. Objective: We determined whether the presence of brain edema on the initial computed tomography (CT) scan of TBI patients would predict poor in-hospital outcome. Methods: We performed a retrospective review of all trauma patients with nonpenetrating head trauma at a Level I Trauma Center. International Classification of Diseases, Ninth Revision codes indicated the presence of brain edema and we evaluated the validity of this pragmatic assessment quantitatively in a random subset of patients. In-hospital mortality was the primary outcome variable. Univariate analysis and logistic regression identified predictors of mortality in all TBI patients and those with mild TBI. Results: Over 7200 patients were included in the study, including 6225 with mild TBI. Measurements of gray and white matter CT density verified radiological assessments of brain edema. Patients with documented brain edema had a mortality rate over 10 times that of the entire study population. With logistic regression accounting for Injury Severity Score, Glasgow Coma Scale score, other CT findings, and clinical variables, brain edema predicted an eightfold greater mortality rate in all patients (odds ratio 8.0, 95% confidence interval 4.6-14.0) and fivefold greater mortality rate for mild TBI patients (odds ratio 4.9, 95% confidence interval 2.0-11.7). Conclusions: Brain edema is an independent prognostic variable across all categories of TBI severity. By alerting emergency physicians to patients with poor predicted clinical outcomes, this finding will drive better resource allocation, earlier intervention, and reduced patient mortality. (C) 2017 Elsevier Inc. All rights reserved.	[Tucker, Brian; Aston, Jill; Dines, Megan; Caraman, Elena; Yacyshyn, Marianne; Olson, James E.] Wright State Univ, Boonshoft Sch Med, Dept Emergency Med, Dayton, OH 45435 USA; [McCarthy, Mary] Wright State Univ, Boonshoft Sch Med, Dept Surg, Dayton, OH 45435 USA; [Olson, James E.] Wright State Univ, Boonshoft Sch Med, Dept Neurosci Cell Biol & Physiol, Dayton, OH 45435 USA	Olson, JE (corresponding author), Cox Inst, Dept Emergency Med, 3525 Southern Blvd, Kettering, OH 45429 USA.				Research Fund of the Department of Emergency Medicine, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, USA	This research was supported by the Research Fund of the Department of Emergency Medicine, Wright State University, Boonshoft School of Medicine, Dayton, Ohio, USA.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Battey TWK, 2014, STROKE, V45, P3643, DOI 10.1161/STROKEAHA.114.006884; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P453; Bullock RM, 2000, J NEUROTRAUM, V17, P573; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Gatson JW, 2013, J NEUROSURG, V118, P1336, DOI 10.3171/2013.2.JNS121771; Gomez PA, 2014, J NEUROSURG, V121, P1314, DOI 10.3171/2014.7.JNS131874; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; HOSSMANN KA, 1980, STROKE, V11, P583, DOI 10.1161/01.STR.11.6.583; Huff JS, 2014, AM J EMERG MED, V32, P606, DOI 10.1016/j.ajem.2014.03.010; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Iaccarino C, 2014, J NEUROSURG, V120, P908, DOI 10.3171/2013.12.JNS131090; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kamal Hm, 2007, Libyan J Med, V2, P90, DOI 10.4176/070210; Laalo JP, 2009, J NEUROTRAUM, V26, P2169, DOI 10.1089/neu.2009.1011; Lambert IH, 2003, J MEMBRANE BIOL, V192, P19, DOI 10.1007/s00232-002-1061-1; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou A, 1996, ACT NEUR S, V66, P118; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Metter RB, 2011, RESUSCITATION, V82, P1180, DOI 10.1016/j.resuscitation.2011.04.001; Murray CJL., 1996, GLOBAL HLTH STAT COM; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nelson DW, 2012, J NEUROTRAUM, V29, P2613, DOI 10.1089/neu.2012.2468; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schliess F, 2004, GLIA, V47, P21, DOI 10.1002/glia.20019; Shi HY, 2014, J NEUROSURG, V121, P1323, DOI 10.3171/2014.8.JNS131526; Shi HY, 2013, J NEUROSURG, V118, P732, DOI 10.3171/2012.12.JNS12693; Shi HY, 2013, J NEUROSURG, V118, P746, DOI 10.3171/2013.1.JNS121130; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Stroop R, 1998, ACT NEUR S, V71, P303; TEASDALE G, 1974, LANCET, V2, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P597; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P563; Tierney KJ, 2016, J NEUROSURG, V124, P538, DOI 10.3171/2015.4.JNS142440; UNGER E, 1988, AM J NEURORADIOL, V9, P687; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Varela D, 2004, J BIOL CHEM, V279, P13301, DOI 10.1074/jbc.C400020200; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181	62	23	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	JUL	2017	53	1					18	29		10.1016/j.jemermed.2017.02.010			12	Emergency Medicine	Emergency Medicine	FE0VO	WOS:000407938000008	28343797				2021-06-18	
J	Wang, CF; Zhao, CC; Weng, WJ; Lei, J; Lin, Y; Mao, Q; Gao, GY; Feng, JF; Jiang, JY				Wang, Chuan-fang; Zhao, Cheng-cheng; Weng, Wei-ji; Lei, Jin; Lin, Yong; Mao, Qing; Gao, Guo-yi; Feng, Jun-feng; Jiang, Ji-yao			Alteration in Long Non-Coding RNA Expression after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						co-expression; hippocampus; long non-coding RNA (lncRNA); pathway; traumatic brain injury (TBI)	SPINAL-CORD-INJURY; NEURONAL APOPTOSIS; DEATH; HYPOTHERMIA; MECHANISMS; MODERATE; INFLAMMATION; ASTROCYTES; RESPONSES; TRIGGERS	Traumatic brain injury (TBI) causes a primary insult and initiates a secondary injury cascade. The mechanisms underlying the secondary injury are multifactorial and may include the aberrant expression of long non-coding RNA (lncRNA) post-TBI. Here, lncRNA microarray analysis was performed to profile the altered lncRNAs in the rat hippocampus after TBI. A total of 271 lncRNA probe sets and 1046 messenger RNA (mRNA) probe sets were differentially expressed after TBI. Gene ontology analysis showed that the main components of the most significantly changed categories were inflammation, DNA transcription, apoptosis, and necroptosis. Additionally, the pathway analysis and the pathway relation network revealed correlated pathways mainly involving inflammation, cell cycle, and apoptosis. A co-expression network of these aberrantly expressed lncRNAs and mRNAs was further constructed to predict the potential function of individual lncRNAs. Sub-co-expression networks were formed for the top three lncRNAs: NR_002704, ENSRNOT00000062543, and Zfas1. Thus, our study demonstrated differential expression of a series of lncRNAs in the rat hippocampus after TBI, which may be correlated with post-TBI physiological and pathological processes. The findings also may provide novel targets for further investigation of both the molecular mechanisms underlying TBI and potential therapeutic interventions.	[Wang, Chuan-fang; Zhao, Cheng-cheng; Weng, Wei-ji; Lei, Jin; Lin, Yong; Mao, Qing; Gao, Guo-yi; Feng, Jun-feng; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China; [Wang, Chuan-fang; Zhao, Cheng-cheng; Lin, Yong; Gao, Guo-yi; Feng, Jun-feng; Jiang, Ji-yao] Shanghai Inst Head Trauma, Shanghai, Peoples R China	Gao, GY; Feng, JF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China.	gao3@sina.com; fengjfmail@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30901543, 31371406, 81671198, 81571883]; National Key Basic Research ProgramNational Basic Research Program of China [2012CB518100]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [13ZR1424500]; Shanghai Municipal Health Bureau [XYQ2013094]; SMC-Star Award for Young Scholars	We would like to thank Genminix Informatics and Zhi-han Sun for their excellent technical assistance with the data analysis. We also thank Dr. Lei Wang and other members of the Shanghai Institute of Head Trauma for assistance. We thank Dr. Bruce G. Lyeth, Department of Neurological Surgery, University of California Davis, for his critical English language editing. We gratefully acknowledge the following funding sources: the National Natural Science Foundation of China (30901543, 31371406, 81671198, and 81571883) and the National Key Basic Research Program (2012CB518100). JFF also received funding from the Science and Technology Commission of Shanghai Municipality (13ZR1424500), Shanghai Municipal Health Bureau (XYQ2013094) and SMC-Star Award for Young Scholars (B).	Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Becker EBE, 2004, PROG NEUROBIOL, V72, P1, DOI 10.1016/j.pneurobio.2003.12.005; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bond AM, 2009, NAT NEUROSCI, V12, P1020, DOI 10.1038/nn.2371; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Briggs JA, 2015, NEURON, V88, P861, DOI 10.1016/j.neuron.2015.09.045; Chang L, 2016, MOL MED REP, V13, P1541, DOI 10.3892/mmr.2015.4716; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; Colak T, 2012, INJURY, V43, P1264, DOI 10.1016/j.injury.2012.01.021; Costa FF, 2010, BIOESSAYS, V32, P599, DOI 10.1002/bies.200900112; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; de Bruin A, 2016, NUCLEIC ACIDS RES, V44, P3549, DOI 10.1093/nar/gkv1471; Demircan K, 2013, NEUROSCI LETT, V544, P25, DOI 10.1016/j.neulet.2013.02.064; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; Feng JF, 2010, NEUROSURGERY, V67, P730, DOI 10.1227/01.NEU.0000378023.81727.6E; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Huang XJ, 2013, J NEUROTRAUM, V30, P39, DOI 10.1089/neu.2012.2508; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Kita EM, 2013, DEVELOPMENT, V140, P2933, DOI 10.1242/dev.088286; Li T, 2015, CANCER RES, V75, P3181, DOI 10.1158/0008-5472.CAN-14-3721; Liao Q, 2011, NUCLEIC ACIDS RES, V39, P3864, DOI 10.1093/nar/gkq1348; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Liu R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/470393; Ma CH, 2016, TUMOR BIOL, V37, P1437, DOI 10.1007/s13277-015-4521-9; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mathur S, 2011, SHOCK, V36, P478, DOI 10.1097/SHK.0b013e31822d6442; McKeon RJ, 1999, J NEUROSCI, V19, P10778; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Perez-Polo JR, 2016, J NEUROSCI RES, V94, P27, DOI 10.1002/jnr.23617; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Popescu C, 2015, J Med Life, V8, P272; Quadrato G, 2012, INT REV NEUROBIOL, V105, P71, DOI 10.1016/B978-0-12-398309-1.00005-6; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Shih RH, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00077; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Thorenoor N, 2016, ONCOTARGET, V7, P622, DOI 10.18632/oncotarget.5807; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Tsuruma K, 2006, J BIOL CHEM, V281, P11397, DOI 10.1074/jbc.M510597200; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang HQ, 2014, NEUROPHARMACOLOGY, V86, P9, DOI 10.1016/j.neuropharm.2014.06.018; White TE, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2412-0; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Yu B, 2015, PROG NEUROBIOL, V134, P122, DOI 10.1016/j.pneurobio.2015.09.006; Yu X, 2015, ONCOL LETT, V10, P1953, DOI 10.3892/ol.2015.3553; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078	52	23	27	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2017	34	13					2100	2108		10.1089/neu.2016.4642			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EZ2HM	WOS:000404530400448	28145813				2021-06-18	
J	Gasenzer, ER; Kanat, A; Neugebauer, E				Gasenzer, Elena Romana; Kanat, Ayhan; Neugebauer, Edmund			Neurosurgery and Music; Effect of Wolfgang Amadeus Mozart	WORLD NEUROSURGERY			English	Article						Chronic epidural hematoma; History of neurosurgery; Musician; Skull fracture; Traumatic brain injury	SUBARACHNOID HEMORRHAGE; MECHANICAL VENTILATION; GEORGE GERSHWIN; BRAIN-TUMOR; DID MOZART; DEATH; ILLNESS; RAVEL,MAURICE; DEGENERATION; CREATIVITY	BACKGROUND: The nervous system works like a great orchestra. Specifically, the music of Mozart with its "Mozart effect" is appropriate to use in neurosurgery. We investigated the relationship between Mozart's music and neurosurgery. MATERIAL AND METHODS: We used digital catalogs like "PubMed" and the libraries of universities. Key words were "Wolfgang Amadeus Mozart" and "neurosurgery and music." RESULTS: In the first half of the 20th century, performing neurosurgery on some musicians, such as Maurice Ravel, Josef Hassid, and George Gershwin, resulted in a fatal outcome. The cause of this is probably that neurosurgery had not been developed yet in the first half of the 20th century. In the past 3 decades, the neurosurgical operations of musicians show that musicians have rich associations among auditory, somatic, and sensorial systems. CONCLUSION: It is clear that we have much to learn from studies about music and brain function that derive from our surgical experiences with patients. The neuronal plasticity of musicians' brains may be different from that of nonmusicians' brains. Musicians with enhanced motor skills have greater capacity for plasticity because of enriched interhemispheric connections. Listening to music and the effect of Mozart in neurosurgical practice, intensive care, or rehabilitation were documented in many studies. As authors, we mean something different: Its effectiveness should be studied. We concluded that in current neurosurgical practice, Mozart has an effect. More research and clinical studies are needed.	[Gasenzer, Elena Romana] Univ Witten Herdecke, Dept Med, Cologne, Germany; [Kanat, Ayhan] Recep Tayyip Erdogan Univ, Dept Neurosurg, Rize, Turkey; [Neugebauer, Edmund] Witten Herdecke Univ, Brandenburg Theodor Fontane Hlth Serv Res, Campus Neuruppin, North Rhine Westphalia, Germany	Gasenzer, ER (corresponding author), Univ Witten Herdecke, Dept Med, Cologne, Germany.	elena.gasenzer@uni-wh.de	Kanat, Ayhan/N-2296-2015	Kanat, Ayhan/0000-0002-8189-2877; Gasenzer, Elena Romana/0000-0002-1221-2735			Altenmuller EO, 2001, ANN NY ACAD SCI, V930, P273, DOI 10.1111/j.1749-6632.2001.tb05738.x; Amaducci L, 2002, EUR J NEUROL, V9, P75, DOI 10.1046/j.1468-1331.2002.00351.x; Andrew, 2015, MOL MED MICROBIOLOGY, P517; Apuzzo MLJ, 2001, NEUROSURGERY, V48, P1, DOI 10.1097/00006123-200101000-00001; Ashoori A, 2007, J NEUROL NEUROSUR PS, V78, P1171, DOI 10.1136/jnnp.2007.114520; Baeck E, 2001, Verh K Acad Geneeskd Belg, V63, P543; Baeck E, 2002, EUR J NEUROL, V9, P321, DOI 10.1046/j.1468-1331.2002.t01-5-00389.x; Baeck E, 1996, CLIN NEUROL NEUROSUR, V98, P57, DOI 10.1016/0303-8467(95)00086-0; Bagatti D, 2016, WORLD NEUROSURG, V85, P298, DOI [10.1016/j.wneu.2015.07.054, 10.1016/j.WNEU.2015.07.054]; Bangerter A, 2004, BRIT J SOC PSYCHOL, V43, P605, DOI 10.1348/0144666042565353; Bankl H, 1992, RELIQUIEN MOZARTS TO; Bentivoglio M, 2003, ANN NY ACAD SCI, V999, P234, DOI 10.1196/annals.1284.034; Bhattacharyya KB, 2015, ANN INDIAN ACAD NEUR, V18, P157, DOI 10.4103/0972-2327.145288; Breitenfeld T, 2007, UROLOGE, V46, P172, DOI 10.1007/s00120-006-1260-y; Cabej NR, 2012, ELSEV INSIGHT, P307, DOI 10.1016/B978-0-12-415831-3.00009-4; Chang WTW, 2013, NEUROSURG CLIN N AM, V24, P407, DOI 10.1016/j.nec.2013.02.004; Coorevits E, 2016, MUSIC PERCEPT, V33, P523, DOI 10.1525/MP.2016.33.5.523; Coppola G, 2015, EPILEPSY BEHAV, V50, P18, DOI 10.1016/j.yebeh.2015.05.038; Dastugue J., 2000, ILLUSTRIERTE GESCH M, P19; DAVIES PJ, 1991, J ROY SOC MED, V84, P737; DAVIES PJ, 1983, J ROY SOC MED, V76, P776; de Divitiis E, 2010, WORLD NEUROSURG, V73, P454, DOI 10.1016/j.wneu.2010.03.003; Demarin V, 2016, PSYCHIAT DANUB, V28, P343; Deutsch O, 1963, MOZART DOCUMENT HIS; DRAKE ME, 1993, NEUROLOGY, V43, P2400, DOI 10.1212/WNL.43.11.2400; Duffau H, 2005, LANCET NEUROL, V4, P476, DOI 10.1016/S1474-4422(05)70140-X; Duffau H, 2014, WORLD NEUROSURG, V81, P508, DOI 10.1016/j.wneu.2013.10.006; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Epilepsy Maguire M., 2017, PRACT NEUROL, V17, P86; Eramo Stefano, 2011, J Hist Dent, V59, P129; Foo Francine, 2016, Front Hum Neurosci, V10, P154, DOI 10.3389/fnhum.2016.00154; Freeman W David, 2015, Continuum (Minneap Minn), V21, P1299, DOI 10.1212/CON.0000000000000235; Galarza M, 2014, WORLD NEUROSURG, V81, DOI 10.1016/j.wneu.2013.09.042; Gasenzer E, 2015, ACTA NEUROCHIR WIEN, V157, P1389; Gasenzer E, 2016, J NEUROL SURG A; Gasenzer E, 2016, WORLD NEUROSURG, pS1878; Gasenzer E, 2014, ACTA NEUROCHIR, V156, P1251, DOI 10.1007/s00701-014-2045-5; Geck M., 2009, FELIX MENDELSSOHN BA; Groen RJM, 2015, ACTA NEUROCHIR, V157, P1389, DOI 10.1007/s00701-015-2430-8; Grout J, 1996, HIST W MUSIC, P508; GUILLERY EN, 1992, J AM SOC NEPHROL, V2, P1671; Hatzinger M, 2013, ACTA MED-HIST ADRIAT, V11, P149; Hegde S, 2016, NEUROCASE, V22, P512, DOI 10.1080/13554794.2016.1198815; HENSON RA, 1988, BRIT MED J, V296, P1585, DOI 10.1136/bmj.296.6636.1585; Hetland L, 2000, J AESTHET EDUC, V34, P105, DOI 10.2307/3333640; Hildesheimer W., 1990, MOZART; Ist es Breitinger F., 1941, IDENTIFIZIERUNG MOZA, V1990, P36; Ivkic G, 2011, COLLEGIUM ANTROPOL, V35, P169; Jadavji-Mithani R, 2015, CAN J NEUROL SCI, V42, P7, DOI 10.1017/cjn.2014.127; Jancke L., 2015, MUSIK UND MED, P49; JENKINS JS, 1991, J ROY COLL PHYS LOND, V25, P351; Jenkins JS, 2001, J ROY SOC MED, V94, P170; Jourdain R., 2001, WOHLTEMPERIERTE GEHI; Kaas J., 2015, INT ENCY SOCIAL BEHA, P619; Kanat A, 2010, CLIN NEUROL NEUROSUR, V112, P839, DOI 10.1016/j.clineuro.2010.07.012; Kanat A, 2010, ACTA NEUROCHIR, V152, P737, DOI 10.1007/s00701-009-0507-y; Kanat A, 2009, NEUROL NEUROCHIR POL, V43, P286; KARHAUSEN L, 1987, BRIT MED J, V294, P511, DOI 10.1136/bmj.294.6570.511-b; Karhausen L., 1991, J ROY SOC MED, V84, P743; Karpati F, 2016, BRAIN RES, V8993, P30804; Kasdan M L, 1987, J Ky Med Assoc, V85, P649; Kloppel R., 2003, PSYCHOMOTORIK INSTRU, P24; Kobets Andrew Joshua, 2011, Yale Journal of Biology and Medicine, V84, P161; Laws ER, 2010, WORLD NEUROSURG, V73, P458, DOI 10.1016/j.wneu.2010.03.004; Lebensschule Menuhin Y., 1987, LEBENSSCHULE; Lee CH, 2017, BIOL RES NURS, V19, P137, DOI 10.1177/1099800416669601; Lin LC, 2015, TRANSL PEDIATR, V4, P323, DOI 10.3978/j.issn.2224-4336.2015.09.02; Lin LC, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-17; LJUNGGREN B, 1982, NEUROSURGERY, V10, P733, DOI 10.1227/00006123-198206010-00009; Marini F, 2009, COMPREHENSIVE CHEMOMETRICS: CHEMICAL AND BIOCHEMICAL DATA ANALYSIS, VOLS 1-4, pB477; Massimi L, 2006, CHILD NERV SYST, V22, P451, DOI 10.1007/s00381-006-0098-3; Millichap J., 2015, PEDIATR NEUROL, V29, P9; Mofredj A, 2016, J CRIT CARE, V35, P195, DOI 10.1016/j.jcrc.2016.05.021; Montinaro A, 2010, WORLD NEUROSURG, V73, P442, DOI 10.1016/j.wneu.2010.02.060; Mozart Jenkins J., 1995, J ROY SOC MED, V88, P408; Neumayr A., 1990, WOLFGANG AMADEUS MOZ, P49; Newman J, 1995, PERCEPT MOTOR SKILL, V81, P1379, DOI 10.2466/pms.1995.81.3f.1379; Nudo RJ, 2011, J COMMUN DISORD, V44, P515, DOI 10.1016/j.jcomdis.2011.04.004; Omigie D, 2014, NEUROPSYCHOL REV, V24, P445, DOI 10.1007/s11065-014-9274-5; Ozdemir B, 2017, WORLD NEUROSURG, V99, P409, DOI 10.1016/j.wneu.2016.11.133; Pauwels EKJ, 2014, MED PRIN PRACT, V23, P403, DOI 10.1159/000364873; PERETZ I, 1990, BRAIN, V113, P1185, DOI 10.1093/brain/113.4.1185; Peretz I, 2001, BRAIN, V124, P928, DOI 10.1093/brain/124.5.928; Pietschnig J, 2010, INTELLIGENCE, V38, P314, DOI 10.1016/j.intell.2010.03.001; Popp AJ, 2010, WORLD NEUROSURG, V73, P456, DOI 10.1016/j.wneu.2010.03.030; Potters JW, 2015, CURR OPIN ANESTHESIO, V28, P511, DOI 10.1097/ACO.0000000000000231; Psychosurgery Feinstein A., 1997, HIST PSYCHIATR, V8, P55; PUECH B, 1989, J FORENSIC SCI, V34, P487; PUECH B, 1989, INJURY, V20, P327, DOI 10.1016/0020-1383(89)90004-1; Rauschecker JP, 2001, ANN NY ACAD SCI, V930, P330, DOI 10.1111/j.1749-6632.2001.tb05742.x; RAUSCHER FH, 1993, NATURE, V365, P611, DOI 10.1038/365611a0; Riva M, 2016, WORLD NEUROSURG, V93, DOI 10.1016/j.wneu.2016.06.130; Sarkamo T., 2011, THESIS; Sarkamo T, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00245; Sarkamo T, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00103; Schadeltrepanationen Dastugue J., 2000, ILLUSTRIERTE GESCH M, P35; Schirmer-Mikalsen K, 2016, NEUROCRIT CARE, V24, P332, DOI 10.1007/s12028-015-0208-8; SCHLAUG G, 1995, NEUROPSYCHOLOGIA, V33, P1047, DOI 10.1016/0028-3932(95)00045-5; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; Schlaug G, 2015, PROG BRAIN RES, V217, P37, DOI 10.1016/bs.pbr.2014.11.020; Schmithorst VJ, 2003, NEUROSCI LETT, V348, P65, DOI 10.1016/S0304-3940(03)00714-6; Silverstein A, 1999, SEMIN NEUROL, V19, P3; SIMKIN B, 1992, BRIT MED J, V305, P1563, DOI 10.1136/bmj.305.6868.1563; Supnet C, 2016, CRIT CARE NURSE, V36, pE1, DOI 10.4037/ccn2016413; Tracy Mary Fran, 2015, Music Med, V7, P54; Triarhou LC, 2016, J CHEM NEUROANAT, V77, P143, DOI 10.1016/j.jchemneu.2016.06.002; Unwiderstehlich Sacks O., 2013, EINARMIGE PIANIST MU, P376; Verrusio W, 2015, CONSCIOUS COGN, V35, P150, DOI 10.1016/j.concog.2015.05.005; Vlcek E, 2006, Acta Chir Plast, V48, P133; Wernhard E., 1997, CLARA HASKIL APROPOS; WHEATER M, 1990, J ROY SOC MED, V83, P586; Wolfensberger R., 1962, CLARA HASKIL BEITRAG; Xing YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep18744; Yolas C, 2016, WORLD NEUROSURG, V90, P484, DOI 10.1016/j.wneu.2016.03.049; Yolas C, 2016, WORLD NEUROSURG, V89, P208, DOI 10.1016/j.wneu.2016.01.082; Zegers RHC, 2009, ANN INTERN MED, V151, P274, DOI 10.7326/0003-4819-151-4-200908180-00010	116	23	24	0	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2017	102						313	319		10.1016/j.wneu.2017.02.081			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FA5HA	WOS:000405472500042	28242489				2021-06-18	
J	Krishnamoorthy, V; Rowhani-Rahbar, A; Gibbons, EF; Rivara, FP; Temkin, NR; Pontius, C; Luk, K; Graves, M; Lozier, D; Chaikittisilpa, N; Kiatchai, T; Vavilala, MS				Krishnamoorthy, Vijay; Rowhani-Rahbar, Ali; Gibbons, Edward F.; Rivara, Frederick P.; Temkin, Nancy R.; Pontius, Crystal; Luk, Kevin; Graves, Morgan; Lozier, Danielle; Chaikittisilpa, Nophanan; Kiatchai, Taniga; Vavilala, Monica S.			Early Systolic Dysfunction Following Traumatic Brain Injury: A Cohort Study	CRITICAL CARE MEDICINE			English	Article						echocardiography; stress cardiomyopathy; trauma; traumatic brain injury	VENTRICULAR DIASTOLIC FUNCTION; OF-ECHOCARDIOGRAPHYS GUIDELINES; AMERICAN-SOCIETY; EXTRACRANIAL COMPLICATIONS; CHAMBER QUANTIFICATION; EUROPEAN-ASSOCIATION; STANDARDS COMMITTEE; CARDIAC DYSFUNCTION; RECOMMENDATIONS; SEVOFLURANE	Objective: Prior studies have suggested that traumatic brain injury may affect cardiac function. Our study aims were to determine the frequency, longitudinal course, and admission risk factors for systolic dysfunction in patients with moderate-severe traumatic brain injury. Design: Prospective cohort study. Setting: Level 1 trauma center. Measurements: Transthoracic echocardiogram within 1 day and over the first week after moderate-severe traumatic brain injury; transthoracic echocardiogram within 1 day after mild traumatic brain injury (comparison group). Measurements and Main Results: Systolic function was assessed by transthoracic echocardiogram, and systolic dysfunction was defined as fractional shortening less than 25%. Multivariable Poisson regression models examined admission risk factors for systolic dysfunction. Systolic function in 32 patients with isolated moderate-severe traumatic brain injury and 32 patients with isolated mild traumatic brain injury (comparison group) was assessed with trans thoracic echocardiogram. Seven (22%) moderate-severe traumatic brain injury and 0 (0%) mild traumatic brain injury patients had systolic dysfunction within the first day after injury (p < 0.01). All patients with early systolic dysfunction recovered in 1 week. Younger age (relative risk, 0.87; 95% CI, 0.79-0.94; for 1 yr increase in age) and lower admission Glasgow Coma Scale score (relative risk, 0.34; 95% CI, 0.20-0.58; for one unit increase in Glasgow Coma Scale) were independently associated with the development of systolic dysfunction among moderate-severe traumatic brain injury patients. Conclusions: Early systolic dysfunction can occur in previously healthy patients with moderate-severe traumatic brain injury, and it is reversible over the first week of hospitalization. Younger age and lower admission Glasgow Coma Scale score are independently associated with the development of systolic dysfunction after moderate-severe traumatic brain injury.	[Krishnamoorthy, Vijay; Luk, Kevin; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Krishnamoorthy, Vijay; Rowhani-Rahbar, Ali; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Krishnamoorthy, Vijay; Rowhani-Rahbar, Ali; Gibbons, Edward F.; Rivara, Frederick P.; Temkin, Nancy R.; Graves, Morgan; Lozier, Danielle; Chaikittisilpa, Nophanan; Kiatchai, Taniga; Vavilala, Monica S.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Gibbons, Edward F.; Pontius, Crystal] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA; [Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Graves, Morgan] Georgetown Univ, Sch Med, Washington, DC USA	Krishnamoorthy, V (corresponding author), Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.; Krishnamoorthy, V (corresponding author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.; Krishnamoorthy, V (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA.	vkrish@u.washington.edu			National Institutes of Health National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM086270]; Washington State Society of Anesthesiologists Seafair Research Grant; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Washington State Society of Anesthesiologists; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Foundation for Anesthesia Education and Research; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM086270] Funding Source: NIH RePORTER	Supported, in part, by grants from National Institutes of Health National Research Service Award (T32 GM086270) and Washington State Society of Anesthesiologists Seafair Research Grant.; Dr. Krishnamoorthy's institution received funding from the National Institutes of Health (NIH) and Washington State Society of Anesthesiologists, and he received support for article research from the NIH. Dr. Temkin's institution received funding from multiple grant and applications to different U.S. federal sources, and she received funding from consulting for Data and Safety Monitoring Boards and Statistical Consulting (unrelated to article topic). Mr. Graves received support for article research from the NIH and Foundation for Anesthesia Education and Research. Dr. Vavilala received support for article research from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Alali AS, 2014, NEUROCRIT CARE, V20, P514, DOI 10.1007/s12028-013-9903-5; Ay H, 2006, NEUROLOGY, V66, P1325, DOI 10.1212/01.wnl.0000206077.13705.6d; Banki N, 2006, J NEUROSURG, V105, P15, DOI 10.3171/jns.2006.105.1.15; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bolliger D, 2010, BRIT J ANAESTH, V104, P547, DOI 10.1093/bja/aeq066; Borbely XI, 2015, NEUROCRIT CARE, V23, P66, DOI 10.1007/s12028-014-0101-x; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; EBSTEIN RP, 1985, ISRAEL J MED SCI, V21, P302; Filipovic M, 2005, BRIT J ANAESTH, V94, P186, DOI 10.1093/bja/aei028; Gottdiener JS, 2004, J AM SOC ECHOCARDIOG, V17, P1086, DOI 10.1016/j.echo.2004.07.013; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; Hirsch LJ, 2004, LANCET, V364, P2157, DOI 10.1016/S0140-6736(04)17605-8; Hravnak M, 2009, STROKE, V40, P3478, DOI 10.1161/STROKEAHA.109.556753; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KENDALL MJ, 1982, BRIT J CLIN PHARMACO, V14, P821, DOI 10.1111/j.1365-2125.1982.tb02043.x; Krishnamoorthy V, 2013, CASE REP ANESTHESIOL, V2013; Krishnamoorthy V, 2016, CHEST, V149, P1325, DOI 10.1016/j.chest.2015.12.014; Krishnamoorthy V, 2015, PEDIATR CRIT CARE ME, V16, pE107, DOI 10.1097/PCC.0000000000000397; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; Marr AL., 2004, CENTRAL NERVOUS SYST; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Meng LZ, 2015, ANESTHESIOLOGY, V123, P1198, DOI 10.1097/ALN.0000000000000872; Nagueh SF, 2009, J AM SOC ECHOCARDIOG, V22, P107, DOI 10.1016/j.echo.2008.11.023; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Prabhakar Hemanshu, 2014, J Anaesthesiol Clin Pharmacol, V30, P318, DOI 10.4103/0970-9185.137260; Prathep S, 2014, CRIT CARE MED, V42, P142, DOI 10.1097/CCM.0b013e318298a890; RIMEL RW, 1979, JACEP-J AM COLL EMER, V8, P64, DOI 10.1016/S0361-1124(79)80039-8; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Samuels MA, 2007, CIRCULATION, V116, P77, DOI 10.1161/CIRCULATIONAHA.106.678995; Serri K, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0217-4; Shah AM, 2012, CIRCULATION, V125, pE244, DOI 10.1161/CIRCULATIONAHA.111.086348; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Strzelczyk A, 2011, EPILEPSIA, V52, P2112, DOI 10.1111/j.1528-1167.2011.03266.x; TEASDALE G, 1974, LANCET, V2, P81; Wang TD, 1997, INT J CARDIOL, V58, P308, DOI 10.1016/S0167-5273(96)02879-3; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046; Zafar SN, 2011, J TRAUMA, V71, P1179, DOI 10.1097/TA.0b013e3182140d38	41	23	23	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2017	45	6					1028	1036		10.1097/CCM.0000000000002404			9	Critical Care Medicine	General & Internal Medicine	EV3WO	WOS:000401690000014	28398926	Green Accepted			2021-06-18	
J	Song, JW; Li, K; Liang, ZW; Dai, C; Shen, XF; Gong, YZ; Wang, S; Hu, XY; Wang, Z				Song, Ji Wei; Li, Kun; Liang, Zhuo Wen; Dai, Chen; Shen, Xue Feng; Gong, Yu Ze; Wang, Shuang; Hu, Xue Yu; Wang, Zhe			Low-level laser facilitates alternatively activated macrophage/microglia polarization and promotes functional recovery after crush spinal cord inj\ury in rats	SCIENTIFIC REPORTS			English	Article							MEDIATED AXONAL DIEBACK; INFLAMMATORY RESPONSE; MACROPHAGES; REGENERATION; THERAPY; PHENOTYPE; BARRIER; CNS; MICROGLIA/MACROPHAGES; TRANSPLANTATION	Macrophages and resident microglia play an import role in the secondary neuroinflammation response following spinal cord injury. Reprogramming of macrophage/microglia polarization is an import strategy for spinal cord injury restoration. Low-level laser therapy (LLLT) is a noninvasive treatment that has been widely used in neurotrauma and neurodegenerative diseases. However, the influence of low-level laser on polarization of macrophage/microglia following spinal cord injury remains unknown. The present study applied low-level laser therapy on a crush spinal cord injury rat model. Using immunofluorescence, flow cytometry, RT-qPCR, and western blot assays, we found that low-level laser therapy altered the polarization state to a M2 tendency. A greater number of neurons survived in the pare injury site, which was accompanied by higher BBB scores in the LLLT group. Furthermore, low-level laser therapy elevated expression of interleukin 4 (IL-4) and interleukin 13 (IL-13). Results from this study show that low-level laser therapy has the potential for reducing inflammation, regulating macrophage/microglia polarization, and promoting neuronal survival. These beneficial effects demonstrate that low-level laser therapy may be an effective candidate for clinical treatment of spinal cord injury.	[Song, Ji Wei; Li, Kun; Liang, Zhuo Wen; Dai, Chen; Hu, Xue Yu; Wang, Zhe] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian, Shaanxi, Peoples R China; [Shen, Xue Feng] Fourth Mil Med Univ, Dept Occupat & Environm Hlth, Xian, Shaanxi, Peoples R China; [Shen, Xue Feng] Fourth Mil Med Univ, Minist Educ, Key Lab Hazard Assessment & Control Special Opera, Xian, Shaanxi, Peoples R China; [Gong, Yu Ze; Wang, Shuang] Northwest Univ Xian, Inst Photon & Photon Technol, Dept Phys, Xian, Shaanxi, Peoples R China	Hu, XY; Wang, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian, Shaanxi, Peoples R China.	huxueyu@fmmu.edu.cn; wangzhe@fmmu.edu.cn			National Natural Scientific Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81572151, 81070996, 81101352]; Key Science and Technology Program in Social Development of Shaanxi Province [2016SF-143]	This work was supported by the National Natural Scientific Foundation of China Grant (No. 81572151, No. 81070996, No. 81101352) and Key Science and Technology Program in Social Development of Shaanxi Province (2016SF-143).	Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Ando T, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.9.098002; Barbosa D, 2013, LASER MED SCI, V28, P651, DOI 10.1007/s10103-012-1125-0; Bartus K, 2014, J NEUROSCI, V34, P4822, DOI 10.1523/JNEUROSCI.4369-13.2014; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Boehler RM, 2014, BIOTECHNOL BIOENG, V111, P1210, DOI 10.1002/bit.25175; Busch SA, 2011, J NEUROSCI, V31, P944, DOI 10.1523/JNEUROSCI.3566-10.2011; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Chen YP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086159; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Esposito E, 2011, TRENDS PHARMACOL SCI, V32, P107, DOI 10.1016/j.tips.2010.11.009; Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Gensel JC, 2009, J NEUROSCI, V29, P3956, DOI 10.1523/JNEUROSCI.3992-08.2009; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Gruner JA, 1996, BRAIN RES, V729, P90, DOI 10.1016/S0006-8993(96)00366-6; Guo J, 2015, MOL MED REP, V12, P37, DOI 10.3892/mmr.2015.3390; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Kwon MJ, 2013, J NEUROSCI, V33, P15095, DOI 10.1523/JNEUROSCI.0278-13.2013; Lee SI, 2010, J NEUROSCI RES, V88, P2409, DOI 10.1002/jnr.22411; Liu NK, 2014, ANN NEUROL, V75, P644, DOI 10.1002/ana.24134; Liu XZ, 1997, J NEUROSCI, V17, P5395; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Pinto AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043093; Plemel JR, 2008, J NEUROTRAUM, V25, P350, DOI 10.1089/neu.2007.0426; Plemel JR, 2014, EXP NEUROL, V258, P91, DOI 10.1016/j.expneurol.2014.01.025; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Ren Y, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/945034; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; Sato A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-65; Schwab ME, 1996, PHYSIOL REV, V76, P319; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Vaughn CN, 2013, ANAT REC, V296, P1229, DOI 10.1002/ar.22730; Wang J. M., 2014, CHINESE J LASER, V41, P253; Wang Zhe, 2009, Chinese Journal of Lasers, V36, P3084, DOI 10.3788/CJL20093611.3084; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Zhang Q, 2016, MOL NEUROBIOL, V53, P662, DOI 10.1007/s12035-014-9035-8; Zhu D, 2016, J ALZHEIMERS DIS, V52, P483, DOI 10.3233/JAD-151090	54	23	30	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	APR 4	2017	7								620	10.1038/s41598-017-00553-6			13	Multidisciplinary Sciences	Science & Technology - Other Topics	EQ5ZU	WOS:000398162400031	28377600	DOAJ Gold, Green Published			2021-06-18	
J	Kralik, SF; Yasrebi, M; Supakul, N; Lin, C; Netter, LG; Hicks, RA; Hibbard, RA; Ackerman, LL; Harris, ML; Ho, CY				Kralik, S. F.; Yasrebi, M.; Supakul, N.; Lin, C.; Netter, L. G.; Hicks, R. A.; Hibbard, R. A.; Ackerman, L. L.; Harris, M. L.; Ho, C. Y.			Diagnostic Performance of Ultrafast Brain MRI for Evaluation of Abusive Head Trauma	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLINICAL ARTICLE; CHILDREN; INJURY; HYDROCEPHALUS; INFANTS; QUICK; PREDICTION; CHILDHOOD; CT	BACKGROUND AND PURPOSE: MR imaging with sedation is commonly used to detect intracranial traumatic pathology in the pediatric population. Our purpose was to compare nonsedated ultrafast MR imaging, noncontrast head CT, and standard MR imaging for the detection of intracranial trauma in patients with potential abusive head trauma. MATERIALS AND METHODS: A prospective study was performed in 24 pediatric patients who were evaluated for potential abusive head trauma. All patients received noncontrast head CT, ultrafast brain MR imaging without sedation, and standard MR imaging with general anesthesia or an immobilizer, sequentially. Two pediatric neuroradiologists independently reviewed each technique blinded to other modalities for intracranial trauma. We performed interreader agreement and consensus interpretation for standard MR imaging as the criterion standard. Diagnostic accuracy was calculated for ultrafast MR imaging, noncontrast head CT, and combined ultrafast MR imaging and noncontrast head CT. RESULTS: Interreader agreement was moderate for ultrafast MR imaging (K = 0.42), substantial for noncontrast head CT (K = 0.63), and nearly perfect for standard MR imaging (K = 0.86). Forty-two percent of patients had discrepancies between ultrafast MR imaging and standard MR imaging, which included detection of subarachnoid hemorrhage and subdural hemorrhage. Sensitivity, specificity, and positive and negative predictive values were obtained for any traumatic pathology for each examination: ultrafast MR imaging (50%,100%,100%, 31%), noncontrast head CT (25%,100%,100%, 21%), and a combination of ultrafast MR imaging and noncontrast head CT (60%,100%,100%, 33%). Ultrafast MR imaging was more sensitive than noncontrast head CT for the detection of intraparenchymal hemorrhage (P =.03), and the combination of ultrafast MR imaging and noncontrast head CT was more sensitive than noncontrast head CT alone for intracranial trauma (P =.02). CONCLUSIONS: In abusive head trauma, ultrafast MR imaging, even combined with noncontrast head CT, demonstrated low sensitivity compared with standard MR imaging for intracranial traumatic pathology, which may limit its utility in this patient population.	[Kralik, S. F.; Yasrebi, M.; Supakul, N.; Lin, C.; Netter, L. G.; Ho, C. Y.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [Hicks, R. A.; Hibbard, R. A.] Indiana Univ Sch Med, Child Protect Program, Indianapolis, IN 46202 USA; [Ackerman, L. L.] Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Harris, M. L.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA	Ho, CY (corresponding author), Indiana Univ Sch Med, MRI Dept, 705 Riley Hosp Dr, Indianapolis, IN 46202 USA.	cyho@iupui.edu	Ho, Chang Yueh/Y-9228-2019	Ho, Chang Yueh/0000-0002-2358-1851; Lin, Chen/0000-0002-6146-7347	Siemens; Department of Child Services; Criminaliustice Institute; Payment for Lectures including Service on Speakers Bureaus; Child First Indiana	Grants/Grants Pending: Siemens.* Ralph A. Hicks UNRELATED: Expert Testimony: University Pediatric Associates Inc,* Comments: Dr Hicks has testified as an expert witness in cases involving suspected child abuse/neglect. Roberta A. Hibbard UNRELATED: Expert Testimony: Department of Child Services, State of Indiana, Comments: child abuse consultation for attorneys and child protection services*; Grants/Grants Pending: Department of Child Services, Criminaliustice Institute*: Payment for Lectures including Service on Speakers Bureaus: Child First Indiana, Comments: child abuse interviewing; Royalties. Elsevier, Comments: child abuse chapter in dental text; Payment for Development of Educational Presentations: Indiana University School of Medicine, Comments: part of grants.* *Money paid to the institution.	Adamsbaum C, 2012, PEDIATR RADIOL, V42, P1298, DOI 10.1007/s00247-012-2434-y; Ashley WW, 2005, J NEUROSURG, V103, P124, DOI 10.3171/ped.2005.103.2.0124; Ba-Ssalamah A, 2000, MAGN RESON IMAGING, V18, P237, DOI 10.1016/S0730-725X(99)00140-X; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Bradford R, 2013, J NEUROSURG-PEDIATR, V12, P110, DOI 10.3171/2013.4.PEDS12596; Chevignard MP, 2014, PEDIATR RADIOL, V44, P548, DOI 10.1007/s00247-014-3169-8; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Forbes KP, 2003, AM J NEURORADIOL, V24, P796; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Ginde AA, 2008, ACAD EMERG MED, V15, P780, DOI 10.1111/j.1553-2712.2008.00192.x; Goske MJ, 2008, AM J ROENTGENOL, V190, P273, DOI 10.2214/AJR.07.3526; Griffiths PD, 2000, ACTA RADIOL, V41, P401, DOI 10.1034/j.1600-0455.2000.041005401.x; Hedlund GL, 2009, FORENSIC SCI MED PAT, V5, P280, DOI 10.1007/s12024-009-9132-6; Hedlund GL., 2012, J AM OSTEOPATH COLL, V1, P23; Iskandar BJ, 2004, J NEUROSURG, V101, P147, DOI 10.3171/ped.2004.101.2.0147; Jaspan T, 2003, CLIN RADIOL, V58, P44, DOI 10.1053/crad.2002.1094; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kemp AM, 2011, ARCH DIS CHILD, V96, P1103, DOI 10.1136/archdischild-2011-300630; Mehta H, 2016, AM J NEURORADIOL, V37, P11, DOI 10.3174/ajnr.A4464; Miller JH, 2010, AM J NEURORADIOL, V31, P430, DOI 10.3174/ajnr.A1866; Missios S, 2008, J NEUROS-PEDIATR, V2, P438, DOI 10.3171/PED.2008.2.12.438; Niederkrotenthaler T, 2013, CHILD ABUSE NEGLECT, V37, P446, DOI 10.1016/j.chiabu.2013.02.002; Patel DM, 2014, J NEUROSURG-PEDIATR, V13, P440, DOI 10.3171/2014.1.PEDS13447; Penzkofer AK, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.2.1790509; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rozovsky K, 2013, J CLIN NEUROSCI, V20, P400, DOI 10.1016/j.jocn.2012.02.048; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sieswerda-Hoogendoorn T, 2012, EUR J PEDIATR, V171, P617, DOI 10.1007/s00431-011-1611-6; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Singh RK, 2003, ACTA RADIOL, V44, P550, DOI 10.1034/j.1600-0455.2003.00118.x; Tanoue K, 2013, ACTA PAEDIATR, V102, P805, DOI 10.1111/apa.12281; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Vazquez E, 2014, PEDIATR RADIOL, V44, P589, DOI 10.1007/s00247-014-3216-5; Yu Clara Ky, 2013, F1000Res, V2, P166, DOI 10.12688/f1000research.2-166.v1; Zimmerman RA, 2007, J NEURORADIOLOGY, V34, P109, DOI 10.1016/j.neurad.2007.01.124	39	23	23	1	6	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2017	38	4					807	813		10.3174/ajnr.A5093			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EQ9UD	WOS:000398429800024	28183837	Green Published, Other Gold			2021-06-18	
J	Kurt, M; Laksari, K; Kuo, C; Grant, GA; Camarillo, DB				Kurt, Mehmet; Laksari, Kaveh; Kuo, Calvin; Grant, Gerald A.; Camarillo, David B.			Modeling and Optimization of Airbag Helmets for Preventing Head Injuries in Bicycling	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Concussion; Head trauma; Bicycle helmets; Airbag helmets	FINITE-ELEMENT-ANALYSIS; FOOTBALL; CONCUSSION; ACCIDENTS; CYCLISTS; BARRIERS; SYSTEM; RISK; FOAM; MASS	Bicycling is the leading cause of sports-related traumatic brain injury. Most of the current bike helmets are made of expanded polystyrene (EPS) foam and ultimately designed to prevent blunt trauma, e.g., skull fracture. However, these helmets have limited effectiveness in preventing brain injuries. With the availability of high-rate micro-electrical-mechanical systems sensors and high energy density batteries, a new class of helmets, i.e., expandable helmets, can sense an impending collision and expand to protect the head. By allowing softer liner medium and larger helmet sizes, this novel approach in helmet design provides the opportunity to achieve much lower acceleration levels during collision and may reduce the risk of brain injury. In this study, we first develop theoretical frameworks to investigate impact dynamics of current EPS helmets and airbag helmets-as a form of expandable helmet design. We compared our theoretical models with anthropomorphic test dummy drop test experiments. Peak accelerations obtained from these experiments with airbag helmets achieve up to an 8-fold reduction in the risk of concussion compared to standard EPS helmets. Furthermore, we construct an optimization framework for airbag helmets to minimize concussion and severe head injury risks at different impact velocities, while avoiding excessive deformation and bottoming-out. An optimized airbag helmet with 0.12 m thickness at 72 +/- 8 kPa reduces the head injury criterion (HIC) value to 190 +/- 25 at 6.2 m/s head impact velocity compared to a HIC of 1300 with a standard EPS helmet. Based on a correlation with previously reported HIC values in the literature, this airbag helmet design substantially reduces the risks of severe head injury up to 9 m/s.	[Kurt, Mehmet; Laksari, Kaveh; Camarillo, David B.] Stanford Univ, Dept Bioengn, 443 Via Ortega,Shriram Bldg,Room 202, Stanford, CA 94305 USA; [Kuo, Calvin; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Grant, Gerald A.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA	Kurt, M (corresponding author), Stanford Univ, Dept Bioengn, 443 Via Ortega,Shriram Bldg,Room 202, Stanford, CA 94305 USA.	mkurt@stanford.edu	Kuo, Calvin/AAH-1933-2019	Kuo, Calvin/0000-0001-8401-9136; Kurt, Mehmet/0000-0002-5618-0296	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB0176 1101S1]; Thrasher Research Fund; David and Lucile Packard FoundationThe David & Lucile Packard Foundation [38454]; Child Health Research Institute Transdisciplinary Initiatives Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR000093]; Thrasher Research Fund Early Career Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000093] Funding Source: NIH RePORTER	The study was supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB0176 1101S1, Thrasher Research Fund, David and Lucile Packard Foundation 38454, Child Health Research Institute Transdisciplinary Initiatives Program, and NIH UL1 TR000093 for biostatistics consultation. Dr. Kurt is the recipient of the Thrasher Research Fund Early Career Award. A provisional patent application has been filed for a helmet design using the optimization strategy described in this paper and will be assigned to Stanford University. 26 Royalties gained from any intellectual property granted for this work will be shared among the inventors, the department, and the school, according to Stanfords technology licensing policies.	Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Bourdet N, 2012, P I MECH ENG P-J SPO, V226, P282, DOI 10.1177/1754337112442326; Camacho DLA, 2001, J BIOMECH ENG-T ASME, V123, P432, DOI 10.1115/1.1389086; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cheng ZQ, 1999, SHOCK VIB, V6, P299, DOI 10.1155/1999/146458; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; Croop B, 2009, P 7 EUR LS DYNA C DY; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; de Geus B, 2012, ACCIDENT ANAL PREV, V45, P683, DOI 10.1016/j.aap.2011.09.045; De Vries D.V.W.M., 2009, CHARACTERIZATION POL; Do S, 2012, ACTA ASTRONAUT, V81, P239, DOI 10.1016/j.actaastro.2012.06.022; EilertPetersson E, 1997, ACCIDENT ANAL PREV, V29, P363, DOI 10.1016/S0001-4575(97)00002-X; Esgar J.B., 1960, ANAL STUDY SOFT LAND; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Federal Motor Vehicle Safety Standards (FMVSS), 571202A FMVSS; Finnoff JT, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e4; Folksam, 2015, TECHNICAL REPORT; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Hansen K, 2013, ACCIDENT ANAL PREV, V59, P109, DOI 10.1016/j.aap.2013.05.019; Healy D. G., 2015, ABC SPORTS EXERCISE, P10; Hernandez F., 2014, ANN BIOMED ENG, V43, P1; Hertz E, 1993, 37 ANN P ASS ADV AUT, P303; HOWLAND J, 1989, AM J DIS CHILD, V143, P741, DOI 10.1001/archpedi.1989.02150180123033; Juhra C, 2012, INJURY, V43, P2026, DOI 10.1016/j.injury.2011.10.016; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kurt M., 2015, U.S. Provisional Patent Application, Patent No. [62/141,675, 62141675]; Laksari K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0331; Lamb L, 2009, P I MECH ENG H, V223, P1021, DOI 10.1243/09544119JEIM573; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Marieb E. N., 2007, HUMAN ANATOMY PHYSL; Mertz H. J., 1997, INJURY RISK CURVES C; Mills NJ, 2008, INT J IMPACT ENG, V35, P1087, DOI 10.1016/j.ijimpeng.2007.05.006; Mills NJ, 2006, P I MECH ENG L-J MAT, V220, P167, DOI 10.1243/14644207JMDA100; Moss W. C., 2011, TECHNICAL REPORT; Moss WC, 2014, COMPUT METHOD BIOMEC, V17, P1173, DOI 10.1080/10255842.2012.739162; Nagurka M, 2004, P AMER CONTR CONF, P499; Newman J. A., 2002, BIOMECHANICS HEAD TR, P303; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Ozturk UE, 2011, MATER DESIGN, V32, P773, DOI 10.1016/j.matdes.2010.07.025; Paquette S., 2009, TECHNICAL REPORT; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; RAMON O, 1990, J APPL POLYM SCI, V40, P1683, DOI 10.1002/app.1990.070400922; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; United States Consumer Product Safety Commision (CPSC), 1998, TECHNICAL REPORT; United States Consumer Product Safety Commision (CPSC), 2003, TECHNICAL REPORT; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zhang J, 1998, INT J IMPACT ENG, V21, P369, DOI 10.1016/S0734-743X(97)00087-0; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	48	23	24	4	50	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	APR	2017	45	4					1148	1160		10.1007/s10439-016-1732-1			13	Engineering, Biomedical	Engineering	ER3YV	WOS:000398737100026	27679447				2021-06-18	
J	Wofford, KL; Harris, JP; Browne, KD; Brown, DP; Grovola, MR; Mietus, CJ; Wolf, JA; Duda, JE; Putt, ME; Spiller, KL; Cullen, DK				Wofford, Kathryn L.; Harris, James P.; Browne, Kevin D.; Brown, Daniel P.; Grovola, Michael R.; Mietus, Constance J.; Wolf, John A.; Duda, John E.; Putt, Mary E.; Spiller, Kara L.; Cullen, D. Kacy			Rapid neuroinflammatory response localized to injured neurons after diffuse traumatic brain injury in swine	EXPERIMENTAL NEUROLOGY			English	Article						Neuroinflammation; Microglia reactivity; Diffuse traumatic brain injury; Permeabilized neurons; Concussion	AXONAL INJURY; MICROGLIAL RESPONSE; HEAD-INJURY; IN-VIVO; DAMAGE; PERMEABILITY; IMPACT; MICE; DEGENERATION; INFLAMMATION	Despite increasing appreciation of the critical role that neuroinflammatory pathways play in brain injury and neurodegeneration, little is known about acute microglial reactivity following diffuse traumatic brain injury (TBI) - the most common clinical presentation that includes all concussions. Therefore, we investigated acute microglial reactivity using a porcine model of closed-head rotational velocity/acceleration-induced TBI that closely mimics the biomechanical etiology of inertial TBI in humans. We observed rapid microglial reactivity within 15 min of both mild and severe TBI. Strikingly, microglial activation was restrained to regions proximal to individual injured neurons - as denoted by trauma-induced plasma membrane disruption - which served as epicenters of acute reactivity. Single-cell quantitative analysis showed that in areas free of traumatically permeabilized neurons, microglial density and morphology were similar between sham or following mild or severe TBI. However, microglia density increased and morphology shifted to become more reactive in proximity to injured neurons. Microglial reactivity around injured neurons was exacerbated following repetitive TBI, suggesting further amplification of acute neuroinflammatory responses. These results indicate that neuronal trauma rapidly activates microglia in a highly localized manner, and suggest that activated microglia may rapidly influence neuronal stability and/or pathophysiology after diffuse TBI. (C) 2017 Elsevier Inc. All rights reserved.	[Wofford, Kathryn L.; Harris, James P.; Browne, Kevin D.; Brown, Daniel P.; Grovola, Michael R.; Wolf, John A.; Duda, John E.; Cullen, D. Kacy] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Neurotrauma Neurodegenerat & Restorat, 3900 Woodland Ave, Philadelphia, PA 19104 USA; [Wofford, Kathryn L.; Spiller, Kara L.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA; [Wofford, Kathryn L.; Harris, James P.; Browne, Kevin D.; Brown, Daniel P.; Grovola, Michael R.; Mietus, Constance J.; Wolf, John A.; Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA; [Duda, John E.] Univ Penn, Dept Neurol, 300 Dulles Bldg,3400 Spruce St, Philadelphia, PA 19104 USA; [Putt, Mary E.] Hosp Univ Penn, Dept Biostat & Epidemiol, 621 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA	Cullen, DK (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	kate.wofford@drexel.edu; jph18@case.edu; kbrowne@mail.med.upenn.edu; dbrow@mail.med.upenn.edu; mgrovola@mail.med.upenn.edu; mietusc@gmail.com; wolfjo@upenn.edu; john.duda@va.gov; mputt@mail.med.upenn.edu; kls35@drexel.edu; dkacy@mail.med.upenn.edu	Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303; Harris, James/0000-0002-8458-5434; Wofford, Kathryn/0000-0002-0391-2641; Grovola, Michael/0000-0003-4125-9329	Department of Veterans Affairs(RR&D Merit Review and RR&D Career Development Award) [B1097-I, 1K2-RX001479]; National Institutes of Health(NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32-NS043126, U54-HD086984]; Penn's University Research Foundation [02202014]; National Science Foundation STEM GK-12 program "Catalyzing STEM Education via the NAE Engineering Grand Challenges" through Drexel University [DGE-0947936]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54-HD086984]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD086984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2RX001479, I01RX001097] Funding Source: NIH RePORTER	The authors thank Dr. Victoria Johnson and Carolyn Keating for their technical assistance and guidance. This work was made possible through financial support provided by the Department of Veterans Affairs (RR&D Merit Review #B1097-I and RR&D Career Development Award #1K2-RX001479), the National Institutes of Health (NINDS T32-NS043126; NICHD U54-HD086984), and Penn's University Research Foundation (#02202014). KL. Wofford was supported by a fellowship from the National Science Foundation STEM GK-12 program "Catalyzing STEM Education via the NAE Engineering Grand Challenges", grant #DGE-0947936 through Drexel University. None of the funding sources aided in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. The authors have no conflicts of interest related to this work to disclose.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Clark J. Derrell, 1997, ILAR J, V38, P41; Coronado VG, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cullen DK, 2016, METHODS MOL BIOL, V1462, P289, DOI 10.1007/978-1-4939-3816-2_17; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fitzmaurice GM., 2004, APPL LONGITUDINAL AN; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Harris J. P., 2015, J NEUROTRAUMA C P, V32; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hovens I.B., 2014, NEUROIMMUNOLOGY NEUR, V1, P82, DOI DOI 10.4103/2347-8659.139719; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 2009, IEEE ENG MED BIO, P1113, DOI 10.1109/IEMBS.2009.5334457; Lee M, 2013, CURR PROTEIN PEPT SC, V14, P21, DOI 10.2174/1389203711314010005; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Meaney D. F., 1995, J NEUROTRAUMA, V12; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; R Development Core Team, 2016, R LANG ENV STAT COMP; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shankaran M, 2007, J NEUROSCI RES, V85, P2374, DOI 10.1002/jnr.21389; Simon CM, 2009, J NEUROTRAUM, V26, P563, DOI 10.1089/neu.2008.0523; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Wolf JA, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00043	49	23	24	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2017	290						85	94		10.1016/j.expneurol.2017.01.004			10	Neurosciences	Neurosciences & Neurology	EM5QR	WOS:000395368000008	28081963	Green Accepted, Bronze			2021-06-18	
J	Sharma, R; Rosenberg, A; Bennett, ER; Laskowitz, DT; Acheson, SK				Sharma, Richa; Rosenberg, Alexandra; Bennett, Ellen R.; Laskowitz, Daniel T.; Acheson, Shawn K.			A blood-based biomarker panel to risk-stratify mild traumatic brain injury	PLOS ONE			English	Article							NEW-ORLEANS CRITERIA; C-REACTIVE PROTEIN; CREATINE-KINASE-BB; COMPUTED-TOMOGRAPHY SCANS; NECROSIS-FACTOR-ALPHA; MINOR HEAD TRAUMA; CEREBROSPINAL-FLUID; EXTERNAL VALIDATION; DIAGNOSTIC-TEST; ACUTE-PHASE	Mild traumatic brain injury (TBI) accounts for the vast majority of the nearly two million brain injuries suffered in the United States each year. Mild TBI is commonly classified as complicated (radiographic evidence of intracranial injury) or uncomplicated (radiographically negative). Such a distinction is important because it helps to determine the need for further neuroimaging, potential admission, or neurosurgical intervention. Unfortunately, imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) are costly and not without some risk. The purpose of this study was to screen 87 serum biomarkers to identify a select panel of biomarkers that would predict the presence of intracranial injury as determined by initial brain CT. Serum was collected from 110 patients who sustained a mild TBI within 24 hours of blood draw. Two models were created. In the broad inclusive model, 72kDa type IV collagenase (MMP-2), C-reactive protein (CRP), creatine kinase B type (CKBB), fatty acid binding protein heart (hFABP), granulocyte-macrophage colony-stimulating factor (GM-CSF) and malondialdehyde modified low density lipoprotein (MDA-LDL) significantly predicted injury visualized on CT, yielding an overall c-statistic of 0.975 and a negative predictive value (NPV) of 98.6. In the parsimonious model, MMP-2, CRP, and CKBB type significantly predicted injury visualized on CT, yielding an overall c-statistic of 0.964 and a negative predictive value (NPV) of 97.2. These results suggest that a serum based biomarker panel can accurately differentiate patients with complicated mild TBI from those with uncomplicated mild TBI. Such a panel could be useful to guide early triage decisions, including the need for further evaluation or admission, especially in those environments in which resources are limited.	[Sharma, Richa; Rosenberg, Alexandra; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Sch Med, Durham, NC 27710 USA; [Bennett, Ellen R.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA; [Acheson, Shawn K.] Durham VA Med Ctr, Durham, NC 27705 USA; [Acheson, Shawn K.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA	Sharma, R (corresponding author), Duke Univ, Med Ctr, Sch Med, Durham, NC 27710 USA.; Acheson, SK (corresponding author), Durham VA Med Ctr, Durham, NC 27705 USA.; Acheson, SK (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA.	rsharm23@jhmi.edu; shawn.acheson@duke.edu			Department of Veterans Affairs Biomedical Laboratory Research and Development Career Development [IK2BX001267]; Astute Medical, Inc.	This work was funded in part by Department of Veterans Affairs Biomedical Laboratory Research and Development Career Development Award IK2BX001267 (to SKA). The study was subsidized by a research grant from Astute Medical, Inc., which performed the antibody-based assays used in this study.	Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Arfanakis K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073107; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bouida W, 2013, ANN EMERG MED, V61, P521, DOI 10.1016/j.annemergmed.2012.07.016; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cardali S, 2006, J Neurosurg Sci, V50, P25; Concato J, 1995, J CLIN EPIDEMIOL, V48, P1495, DOI 10.1016/0895-4356(95)00510-2; COOPER PR, 1983, NEUROSURGERY, V12, P536, DOI 10.1227/00006123-198305000-00010; Coplin WM, 1999, ARCH NEUROL-CHICAGO, V56, P1348, DOI 10.1001/archneur.56.11.1348; Dickerson F, 2012, SCHIZOPHR RES, V134, P83, DOI 10.1016/j.schres.2011.10.003; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Ginde AA, 2008, ACAD EMERG MED, V15, P780, DOI 10.1111/j.1553-2712.2008.00192.x; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Hosmer DW, 2000, APPL LOGISTIC REGRES, pxii; Hughes CM, 2014, J AM COLL RADIOLOGY; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; KASTE M, 1981, J NEUROSURG, V55, P511, DOI 10.3171/jns.1981.55.4.0511; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; Keller T, 2011, JAMA-J AM MED ASSOC, V306, P2684, DOI 10.1001/jama.2011.1896; Kelly JP, 1997, NEUROLOGY, V48, P581; Kleinert K, 2010, ZBL CHIR, V135, P277, DOI 10.1055/s-0028-1098766; Koenig W, 2003, AM J EPIDEMIOL, P158; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; Laskowitz DT, 2005, ANN NY ACAD SCI, V1053, P30, DOI 10.1196/annals.1344.051; LEVITT MA, 1995, ACAD EMERG MED, V2, P675, DOI 10.1111/j.1553-2712.1995.tb03617.x; Lynch JR, 2004, STROKE, V35, P57, DOI 10.1161/01.STR.0000105927.62344.4C; McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1097/00006123-200211000-00005; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Parma C, 2014, AM SURGEON, V80, P664; Paul AB, 2015, J AM COLL RADIOL, V12, P453, DOI 10.1016/j.jacr.2014.12.016; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PHILLIPS JP, 1980, BRIT MED J, V281, P777, DOI 10.1136/bmj.281.6243.777; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Planas AM, 2001, NEUROBIOL DIS, V8, P834, DOI 10.1006/nbdi.2001.0435; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Reynolds MA, 2003, CLIN CHEM, V49, P1733, DOI 10.1373/49.10.1733; Reynolds TA, 2013, ANN EMERG MED, V61, P528, DOI 10.1016/j.annemergmed.2012.12.006; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Rohacek M, 2012, INJURY, V43, P1415, DOI 10.1016/j.injury.2012.01.001; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Schachar JL, 2011, PEDIATR RADIOL, V41, P971, DOI 10.1007/s00247-011-2032-4; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Unden Johan, 2013, Lakartidningen, V110, P1868; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Wium-Andersen MK, 2014, BIOL PSYCHIAT, V76, P249, DOI 10.1016/j.biopsych.2013.10.009; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Wright J, 2011, ENCY CLIN NEUROPSYCH, P1149; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Zyluk A, 2015, NEUROL NEUROCHIR POL, V49, P52, DOI 10.1016/j.pjnns.2014.12.007	74	23	25	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2017	12	3							e0173798	10.1371/journal.pone.0173798			18	Multidisciplinary Sciences	Science & Technology - Other Topics	ER9VG	WOS:000399174600027	28355230	DOAJ Gold, Green Published			2021-06-18	
J	Adamczak, J; Aswendt, M; Kreutzer, C; Rotheneichner, P; Riou, A; Selt, M; Beyrau, A; Uhlenkuken, U; Diedenhofen, M; Nelles, M; Aigner, L; Couillard-Despres, S; Hoehn, M				Adamczak, Joanna; Aswendt, Markus; Kreutzer, Christina; Rotheneichner, Peter; Riou, Adrien; Selt, Marion; Beyrau, Andreas; Uhlenkueken, Ulla; Diedenhofen, Michael; Nelles, Melanie; Aigner, Ludwig; Couillard-Despres, Sebastien; Hoehn, Mathias			Neurogenesis upregulation on the healthy hemisphere after stroke enhances compensation for age-dependent decrease of basal neurogenesis	NEUROBIOLOGY OF DISEASE			English	Article						Stroke; Neurogenesis; Age dependence of neurogenesis after stroke; Bioluminescence imaging; Magnetic resonance imaging; Doublecortin	FOCAL CEREBRAL-ISCHEMIA; ENDOGENOUS NEURAL STEM; TRAUMATIC BRAIN-INJURY; SUBVENTRICULAR ZONE; PROGENITOR CELLS; ADULT; PROLIFERATION; EXPRESSION; NEURONS; DOUBLECORTIN	Stroke is a leading cause of death and disability worldwide with no treatment for the chronic phase available. Interestingly, an endogenous repair program comprising inflammation and neurogenesis is known to modulate stroke outcome. Several studies have shown that neurogenesis decreases with age but the therapeutic importance of endogenous neurogenesis for recovery from cerebral diseases has been indicated as its ablation leads to stroke aggravation and worsened outcome. A detailed characterization of the neurogenic response after stroke related to ageing would help to develop novel and targeted therapies. In an innovative approach, we used the DCX-Luc mouse, a transgenic model expressing luciferase in doublecortin-positive neuroblasts, to monitor the neurogenic response following middle cerebral artery occlusion over three weeks in three age groups (2, 6, 12 months) by optical imaging while the stroke lesion was monitored by quantitative MRI. The individual longitudinal and noninvasive time profiles provided exclusive insight into age-dependent decrease in basal neurogenesis and neurogenic upregulation in response to stroke which are not accessible by conventional BrdU-based measures of cell proliferation. For cortico-striatal strokes the maximal upregulation occurred at 4 days post stroke followed by a continuous decrease to basal levels by three weeks post stroke. Older animals effectively compensated for reduced basal neurogenesis by an enhanced sensitivity to the cerebral lesion, resulting in upregulated neurogenesis levels approaching those measured in young mice. In middle aged and older mice, but not in the youngest ones, additional upregulation of neurogenesis was observed in the contralateral healthy hemisphere. This further substantiates the increased propensity of older brains to respond to lesion situation. Our results clearly support the therapeutic relevance of endogenous neurogenesis for stroke recovery and particularly in older brains. (C) 2016 Elsevier Inc. All rights reserved.	[Adamczak, Joanna; Aswendt, Markus; Riou, Adrien; Selt, Marion; Beyrau, Andreas; Uhlenkueken, Ulla; Diedenhofen, Michael; Nelles, Melanie; Hoehn, Mathias] Max Planck Inst Metab Res, In Vivo NMR Lab, Gleuelerstr 50, D-50931 Cologne, Germany; [Kreutzer, Christina; Rotheneichner, Peter; Couillard-Despres, Sebastien] Paracelsus Med Univ Salzburg, Inst Expt Neuroregenerat, Spinal Cord Injury & Tissue Regenerat Ctr, Strubergasse 21, A-5020 Salzburg, Austria; [Aigner, Ludwig] Paracelsus Med Univ Salzburg, Inst Mol Regenerat Med, Spinal Cord Injury & Tissue Regenerat Ctr, Strubergasse 21, A-5020 Salzburg, Austria; [Hoehn, Mathias] Leiden Univ, Med Ctr, Dept Radiol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands; [Hoehn, Mathias] Percuros BV, Drienerlolaan 5 Zuidhorst, NL-7522 NB Enschede, Netherlands; [Kreutzer, Christina; Rotheneichner, Peter; Aigner, Ludwig; Couillard-Despres, Sebastien] Spinal Cord Injury & Tissue Regenerat Ctr Salzbur, Salzburg, Austria	Hoehn, M (corresponding author), Max Planck Inst Metab Res, In Vivo NMR Lab, Gleuelerstr 50, D-50931 Cologne, Germany.	mathias@sf.mpg.de	Aswendt, Markus/L-2743-2019	Aswendt, Markus/0000-0003-1423-0934; Couillard-Despres, Sebastien/0000-0002-8486-6412; Hummer, Joanna/0000-0002-0329-2892; Aigner, Ludwig/0000-0002-1653-8046	European UnionEuropean Commission [HEALTH-F2-2012-279017, PIAPP-GA-2013-612360, HEALTH-F2-2011-278850, HEALTH-F2-2011-279288]; German Research Foundation DFGGerman Research Foundation (DFG) [AS-464/1-1]	This work was financially supported by grants from the European Union Seventh Framework Programme TargetBraln (HEALTH-F2-2012-279017) and BrainPath (PIAPP-GA-2013-612360) and by a grant from the German Research Foundation DFG (AS-464/1-1). In addition, this work received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no HEALTH-F2-2011-278850 (INMiND) and no HEALTH-F2-2011-279288 (IDEA).	Adamczak JM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00274; Ahlenius H, 2009, J NEUROSCI, V29, P4408, DOI 10.1523/JNEUROSCI.6003-08.2009; Aswendt M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055662; Bahmani P, 2011, J CEREBR BLOOD F MET, V31, P1311, DOI 10.1038/jcbfm.2010.233; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Butti E, 2012, BRAIN, V135, P3320, DOI 10.1093/brain/aws194; Couillard-Despres S, 2009, MOL PSYCHIATR, V14, P856, DOI 10.1038/mp.2008.147; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Couillard-Despres S, 2008, MOL IMAGING, V7, P28, DOI 10.2310/7290.2008.0004; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Erlandsson A, 2011, EXP NEUROL, V230, P48, DOI 10.1016/j.expneurol.2010.05.018; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; Hamilton LK, 2013, EUR J NEUROSCI, V37, P1978, DOI 10.1111/ejn.12207; Hammelrath L, 2016, NEUROIMAGE, V125, P144, DOI 10.1016/j.neuroimage.2015.10.009; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jin KL, 2004, AGING CELL, V3, P373, DOI 10.1111/j.1474-9728.2004.00131.x; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Lai B, 2008, NEUROSCI LETT, V442, P305, DOI 10.1016/j.neulet.2008.07.032; Lindvall O, 2011, STROKE, V42, P2369, DOI 10.1161/STROKEAHA.110.599654; Luo J, 2006, AGING CELL, V5, P139, DOI 10.1111/j.1474-9726.2006.00197.x; Mengler L, 2014, NEUROIMAGE, V84, P35, DOI 10.1016/j.neuroimage.2013.08.034; Mezzanotte L, 2013, CONTRAST MEDIA MOL I, V8, P505, DOI 10.1002/cmmi.1549; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Pereira L, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00057; Popa-Wagner A, 2007, ACTA NEUROPATHOL, V113, P277, DOI 10.1007/s00401-006-0164-7; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Sato K, 2001, BRAIN RES, V922, P135, DOI 10.1016/S0006-8993(01)03137-7; Shook BA, 2012, J NEUROSCI, V32, P6947, DOI 10.1523/JNEUROSCI.5987-11.2012; Sun F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046326; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Tang YH, 2014, J CEREBR BLOOD F MET, V34, P1138, DOI 10.1038/jcbfm.2014.61; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Tropepe V, 1997, J NEUROSCI, V17, P7850; Vandeputte C, 2014, NEUROBIOL DIS, V69, P144, DOI 10.1016/j.nbd.2014.05.014; Villeda SA, 2013, AUTOIMMUN REV, V12, P674, DOI 10.1016/j.autrev.2012.10.014; Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036663; Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019	41	23	24	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAR	2017	99						47	57		10.1016/j.nbd.2016.12.015			11	Neurosciences	Neurosciences & Neurology	EL9EP	WOS:000394922800005	28007584				2021-06-18	
J	Clark, MD; Asken, BM; Marshall, SW; Guskiewicz, KM				Clark, Michael D.; Asken, Breton M.; Marshall, Stephen W.; Guskiewicz, Kevin M.			Descriptive Characteristics of Concussions in National Football League Games, 2010-2011 to 2013-2014	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; American football; National Football League; head impacts	HEAD IMPACT EXPOSURE; SPORT-RELATED CONCUSSION; HIGH-SCHOOL SPORTS; PROFESSIONAL FOOTBALL; YOUTH FOOTBALL; INJURIES; EPIDEMIOLOGY; PLAYERS; COLLEGIATE; PERFORMANCE	Background: Despite a high reported incidence rate of concussion, little is known about the on-field characteristics of injurious head impacts in National Football League (NFL) games. Purpose: To characterize on-field features (location, player position, and time during game) and biomechanical features (anticipation status, closing distance, impact location and type) associated with concussions in NFL games over a 4-season period (2010-2011 to 2013-2014). Study Design: Descriptive epidemiology study. Methods: We analyzed video of a subset of reported, in-game concussions for the 2010-2011 to 2013-2014 seasons. These videos represented a sample of injuries that were diagnosed and reported on the same day and that could be clearly associated with an in-game collision as captured on video. We determined anticipation status, closing distance, impact location on the injured player's helmet, and impact type (helmet-to-helmet, helmet-to-body, or helmet-to-ground). Associations between these variables were analyzed by use of descriptive statistics and tests of association. Results: A total of 871 diagnosed concussions were reported as occurring during NFL preseason, regular season, and postseason games for the 2010-2011, 2011-2012, 2012-2013, and 2013-2014 seasons. A total of 1324 games were played during this period, giving a concussion incidence rate of 0.658 per game (95% CI, 0.61-0.70). From the video-reviewed subset (n = 429; 49.3%), the majority of injurious impacts occurred with good anticipation (57.3%) and <10 yards of closing distance (59.0%). An association was found between anticipation status and play type ( <mml:msubsup>32</mml:msubsup> = 27.398, P < .001), largely because injuries occurring on pass plays were more likely to be poorly anticipated than injuries during run plays (43.0% vs 21.4%; <mml:msubsup>12</mml:msubsup> = 14.78, P < .001). Kick returns had the greatest proportion of well-anticipated impacts (78%) and the greatest proportion of impacts with 10 yards of closing distance (80%). The type of impact was approximately equally divided between helmet-to-helmet, helmet-to-body, and helmet-to-ground types. The impact location was broadly distributed over the helmet of the injured player. Conclusion: In-game concussions in the NFL occurred through a diverse variety of mechanisms, surprisingly tended to be well-anticipated, and, also surprisingly, occurred with <10 yards of closing distance. The impacts causing concussion were broadly distributed over the helmet. More concussions occurred during the second half of game play, but we do not have evidence to explain this finding.	[Clark, Michael D.; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, CB 8700, Chapel Hill, NC 27599 USA; [Clark, Michael D.; Guskiewicz, Kevin M.] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Curriculum Human Movement Sci, CB 8700, Chapel Hill, NC 27599 USA; [Asken, Breton M.] Univ Florida, Dept Clin & Hlth Psychol, Neuropsychol Coll Publ Hlth & Hlth Profess, Gainesville, FL USA; [Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, CB 8700, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, CB 8700, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Clark, Michael/0000-0002-5019-0290; Asken, Breton/0000-0001-8419-142X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008719] Funding Source: NIH RePORTER		Badgeley MA, 2013, J PHYS ACT HEALTH, V10, P160, DOI 10.1123/jpah.10.2.160; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Fainaru S, YOUTH FOOTBALL PARTI; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Kerr ZY, 2014, PEDIATRICS, V134, P489, DOI 10.1542/peds.2014-0770; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Mueller F O, 1991, Exerc Sport Sci Rev, V19, P261; Mueller FO, 2001, J ATHL TRAINING, V36, P312; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2	32	23	23	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2017	45	4					929	936		10.1177/0363546516677793			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EP6MD	WOS:000397492700023	28056179				2021-06-18	
J	Narad, ME; Treble-Barna, A; Peugh, J; Yeates, KO; Taylor, HG; Stancin, T; Wade, SL				Narad, Megan E.; Treble-Barna, Amery; Peugh, James; Yeates, Keith O.; Taylor, H. Gerry; Stancin, Terry; Wade, Shari L.			Recovery Trajectories of Executive Functioning After Pediatric TBI: A Latent Class Growth Modeling Analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						executive functioning; latent class growth modeling; pediatric traumatic brain injury	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; COGNITIVE PREDICTORS; EARLY-CHILDHOOD; SHORT-TERM; OUTCOMES; BEHAVIOR; ACHIEVEMENT; RELIABILITY; VALIDITY	Objective: To identify latent trajectories of executive functioning (EF) recovery overtime after childhood traumatic brain injury (TBI) and examine the predictive value of known risk factors within and across recovery trajectories using latent class growth modeling (LCGM). Method: A total of 206 children between the ages of 3 and 7 years with a moderate to severe TBI or orthopedic injury (OI) were included. LCGM was applied to identify longitudinal trajectories of postinjury EF as assessed by the Behavior Rating Inventory of Executive Functioning General Executive Composite (GEC). Separate models were estimated for the TBI and OI groups. Results: Two TBI trajectories-normal limits (70.8%) and clinically elevated (29.2%)-and 3 OI trajectories-normal limits (20.9%), subclinical (49.0%), and clinically elevated (30.17%)-were identified. Baseline GEC was the only predictor of class membership for all models. Both TBI trajectories demonstrated an increase in GEC over time, whereas only 1 of the 3 OI classes demonstrated this pattern. Family variables were associated with GEC across trajectories. Conclusion: The lack of association of injury characteristics with trajectory class membership highlights the heterogeneity in recovery after pediatric TBI. Associations of EF trajectories with family factors underscore the importance of involving the family in interventions for children with traumatic injuries.	[Narad, Megan E.; Treble-Barna, Amery; Peugh, James; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Yeates, Keith O.] Univ Calgary, Hotchkiss Brain Inst, Dept Psychol, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Stancin, Terry] Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Narad, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Megan.narad@cchmc.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human Development and Trauma Research grants from the State of Ohio Emergency Medical Services [R01 HD42729]; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [8 UL1 TR000077]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729, F32HD088011] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER	This publication was supported by grant R01 HD42729 from the National Institute of Child Health and Human Development and Trauma Research grants from the State of Ohio Emergency Medical Services. Additional support was provided through Grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Beauchamp MH, 2013, HAND CLINIC, V112, P913, DOI 10.1016/B978-0-444-52910-7.00013-1; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Forsyth RJ, 2010, ARCH DIS CHILD, V95, P266, DOI 10.1136/adc.2008.147926; Fulton JB, 2012, NEUROPSYCHOLOGY, V26, P314, DOI 10.1037/a0027973; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Nagin D., 2005, GROUP BASED MODELING; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Querido JG, 2002, J CLIN CHILD ADOLESC, V31, P272, DOI 10.1207/S15374424JCCP3102_12; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	39	23	23	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2017	32	2					98	106		10.1097/HTR.0000000000000247			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EN3YU	WOS:000395944700010	27455434	Green Accepted			2021-06-18	
J	Khodaee, M; Currie, DW; Asif, IM; Comstock, RD				Khodaee, Morteza; Currie, Dustin W.; Asif, Irfan M.; Comstock, R. Dawn			Nine-year study of US high school soccer injuries: data from a national sports injury surveillance programme	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CONSENSUS STATEMENT; FOOTBALL; EPIDEMIOLOGY; PLAYERS; CONCUSSIONS; CHILDREN	Background Research on high school soccer injury epidemiology is sparse. Aim To describe high school soccer injury rates, trends and patterns by type of athlete exposure (AE), position and sex. Methods This descriptive epidemiological study used data from a large national high school sports injury surveillance programme to describe rates and patterns of soccer-related injuries including concussion sustained from 2005/2006 to 2013/2014. Injury rates are calculated per 1000 AEs. Results Overall, 6154 soccer injuries occurred during 2 985 991 AEs; injury rate= 2.06 per 1000 AEs. Injury rates were higher during competition (4.42) than practice (1.05; rate ratio (RR)= 4.19; 95% CI 3.98 to 4.41), and in girls (2.33) than boys (1.83; RR= 1.27, 95% CI 1.21 to 1.34). Boys' non-concussion injury rates decreased significantly (p= 0.001) during the study period while reported concussion rates increased significantly (p= 0.002). Girls' non-concussion rates were relatively stable and reported concussion rates increased significantly (p= 0.004). Player-player contact was the injury mechanism that led to the most competition injuries (injury proportion ratio (IPR)= 2.87; 95% CI 2.57 to 3.21), while non-contact injuries were the most common mechanisms among practice injuries (IPR= 2.10; 95% CI 1.86 to 2.38). Recovery from concussion was > 7 days in a third of the cases. Injury patterns were similar between sexes with respect to position played and location on the field at the time of injury. Conclusions High school soccer injury rates vary by sex and type of exposure, while injury patterns are more similar across sexes. Reported concussion rates increased significantly over the study period in male and female athletes.	[Khodaee, Morteza] Univ Colorado, Dept Family Med, Sch Med, Denver, CO USA; [Currie, Dustin W.; Comstock, R. Dawn] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA; [Asif, Irfan M.] Univ South Carolina, Dept Family Med, Greenville Hlth Syst, Greenville Sch Med, Greenville, SC USA; [Comstock, R. Dawn] Univ Colorado, Dept Pediat, Sch Med, Aurora, CO USA	Khodaee, M (corresponding author), Univ Colorado, Dept Family Med, AFW Clin, Sch Med, 3055 Roslyn St, Denver, CO 80238 USA.	morteza.khodaee@ucdenver.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]	The content of this report was funded in part by the Centers for Disease Control and Prevention grants R49/CE000674-01 and R49/CE001172-01.	Adams AL, 2006, ACAD EMERG MED, V13, P571, DOI [10.1111/j.1553-2712.2006.tb01010.x, 10.1197/j.aem.2005.12.015]; Agel J, 2007, J ATHL TRAINING, V42, P270; Brito J, 2012, J ATHL TRAINING, V47, P191; Clausen MB, 2014, AM J SPORT MED, V42, P2487, DOI 10.1177/0363546514541224; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Elias SR, 2001, MED SCI SPORT EXER, V33, P359, DOI 10.1097/00005768-200103000-00004; Faude O, 2010, SCAND J MED SCI SPOR, V20, P103, DOI 10.1111/j.1600-0838.2009.01087.x; Faude O, 2013, SPORTS MED, V43, P819, DOI 10.1007/s40279-013-0061-x; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Giannotti M, 2011, PEDIATR EMERG CARE, V27, P81, DOI 10.1097/PEC.0b013e3182094340; Giza Eric, 2005, Med Sport Sci, V49, P140, DOI 10.1159/000085395; Hunt M, 1990, Br J Sports Med, V24, P265; Injuries in youth soccer: a subject review, 2000, PEDIATRICS 1, V105, P659; Junge A, 2008, BRIT J SPORT MED, V42, P413, DOI 10.1136/bjsm.2008.046631; Kerr ZY, 2011, CLIN PEDIATR, V50, P594, DOI 10.1177/0009922810390513; Khodaee M, 2011, RES SPORTS MED, V19, P129, DOI 10.1080/15438627.2011.556907; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Krustrup P, 2010, SCAND J MED SCI SPOR, V20, P1, DOI 10.1111/j.1600-0838.2010.01108.x; Kucera KL, 2005, BRIT J SPORT MED, V39, P462, DOI 10.1136/bjsm.2004.013672; Le Gall F, 2008, AM J SPORT MED, V36, P276, DOI 10.1177/0363546507307866; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marchi AG, 1999, ARCH DIS CHILD, V81, P324, DOI 10.1136/adc.81.4.324; Mountjoy M, 2016, BRIT J SPORT MED, V50, P590, DOI 10.1136/bjsports-2015-095686; Myer GD, 2013, AM J SPORT MED, V41, P203, DOI 10.1177/0363546512460637; Orchard JW, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.012732; Pluim BM, 2009, BRIT J SPORT MED, V43, P893, DOI 10.1136/bjsm.2009.064915; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rossler R, 2016, AM J SPORT MED, V44, P309, DOI 10.1177/0363546515614816; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schneider AS, 2013, SPORTVERLETZ SPORTSC, V27, P34, DOI 10.1055/s-0032-1330764; Sugimoto Dai, 2015, Curr Phys Med Rehabil Rep, V3, P43; Tourny C, 2014, J SPORT MED PHYS FIT, V54, P526; Walden M, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2014-094573; Walters BS, 2014, J EMERG MED, V46, P650, DOI 10.1016/j.jemermed.2013.11.081; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047	38	23	23	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2017	51	3					185	193		10.1136/bjsports-2015-095946			9	Sport Sciences	Sport Sciences	EL2NF	WOS:000394455800012	28031189	Bronze			2021-06-18	
J	Liu, YM; Hu, CY; Shen, JD; Wu, SH; Li, YC; Yi, LT				Liu, Ya-Min; Hu, Chun-Yue; Shen, Ji-Duo; Wu, Su-Hui; Li, Yu-Cheng; Yi, Li-Tao			Elevation of synaptic protein is associated with the antidepressant-like effects of ferulic acid in a chronic model of depression	PHYSIOLOGY & BEHAVIOR			English	Article						Ferulic acid; Brain-derived neurotrophic factor; Synaptic protein; Depression; Chronic unpredictable mild stress	TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; INVOLVEMENT; STRESS; MTOR; MICE; BDNF; EXPRESSION; HIPPOCAMPUS; ANTAGONISTS	Ferulic acid is a hydroxycinnamic acid that widely presents in plant cell wall components. It has been demonstrated that ferulic acid can reverse depressive-like behaviors in both forced swimming test and tail suspension test. However, it is undear whether chronic ferulic acid treatment can ameliorate the depressive-like behaviors in chronic unpredictable mild stress (CUMS). Because of the putative relationship between neurotrophic system and antidepressant-like activity, we also investigated the effects of chronic ferulic acid on the brain-derived neurotrophic factor (BDNF), postsynaptic protein PSD95, presynaptic protein synapsin I in both prefrontal cortex and hippocampus. The results showed that ferulic acid significantly alleviated CUMS-induced depressive-like behaviors in sucrose preference test and forced swimming test. In addition, ferulic acid significantly up-regulated the levels of BDNF, PSD95 and synapsin I in the prefrontal cortex and hippocampus. The present data indicated that ferulic acid exerted the antidepressant-like effects on behaviors by increasing neurotrophin-related synaptic protein levels in CUMS mice. (C) 2016 Elsevier Inc. All rights reserved.	[Liu, Ya-Min; Hu, Chun-Yue; Shen, Ji-Duo; Wu, Su-Hui; Li, Yu-Cheng] Henan Univ Tradit Chinese Med, Coll Pharm, Zhengzhou 450046, Henan Province, Peoples R China; [Yi, Li-Tao] Huaqiao Univ, Dept Chem & Pharmaceut Engn, Coll Chem Engn, Xiamen 361021, Fujian Province, Peoples R China	Li, YC (corresponding author), Henan Univ Tradit Chinese Med, Coll Pharm, Zhengzhou 450046, Henan Province, Peoples R China.	Liyucheng@hactcm.edu.cn; litao.yi@yahoo.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303278, 81673629]; Provincial Scientific Research Special Foundation of Henan University of Traditional Chinese Medicine [2014KYYWF-QN19]; Talent Project of Science and Technology Innovation of Henan University of Traditional Chinese Medicine [2015XCXRC03]	This work was supported by the National Natural Science Foundation of China (No.81303278, 81673629), the Provincial Scientific Research Special Foundation of Henan University of Traditional Chinese Medicine (2014KYYWF-QN19), and the Talent Project of Science and Technology Innovation of Henan University of Traditional Chinese Medicine (2015XCXRC03).	Akinfiresoye L, 2013, PSYCHOPHARMACOLOGY, V230, P291, DOI 10.1007/s00213-013-3153-2; Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130; Bartkowska K, 2010, ACTA NEUROBIOL EXP, V70, P454; Zeni ALB, 2012, PHARMACOL BIOCHEM BE, V103, P181, DOI 10.1016/j.pbb.2012.08.020; Birkenhager TK, 2012, J PSYCHIATR RES, V46, P285, DOI 10.1016/j.jpsychires.2011.12.006; Bumb JM, 2015, EUR ARCH PSY CLIN N, V265, P227, DOI 10.1007/s00406-014-0543-3; Chen JL, 2015, METAB BRAIN DIS, V30, P129, DOI 10.1007/s11011-014-9635-z; Czeh B, 2016, PROG NEURO-PSYCHOPH, V64, P293, DOI 10.1016/j.pnpbp.2015.04.004; Dell'Osso L, 2010, NEUROPSYCHOBIOLOGY, V62, P207, DOI 10.1159/000319946; Duman RS, 2012, PHILOS T R SOC B, V367, P2475, DOI 10.1098/rstb.2011.0357; Ghosh R, 2015, ASIAN J PSYCHIATR, V18, P37, DOI 10.1016/j.ajp.2015.10.006; Giese M, 2014, J PSYCHIATR RES, V59, P1, DOI 10.1016/j.jpsychires.2014.09.005; Kang HJ, 2012, NAT MED, V18, P1413, DOI 10.1038/nm.2886; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kim MJ, 2007, BIOSCI BIOTECH BIOCH, V71, P1063, DOI 10.1271/bbb.60564; Lakshminarasimhan H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030481; Lenzi J, 2015, METAB BRAIN DIS, V30, P1453, DOI 10.1007/s11011-015-9725-6; Lepack A.E., 2014, INT J NEUROPSYCHOPHA, V18; Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Mizuki D, 2014, J ETHNOPHARMACOL, V156, P16, DOI 10.1016/j.jep.2014.08.014; Mu RH, 2016, PSYCHOPHARMACOLOGY, V233, P3211, DOI 10.1007/s00213-016-4357-z; Nase Sarah, 2016, Neurosignals, V24, P1, DOI 10.1159/000442607; Neis VB, 2016, EUR NEUROPSYCHOPHARM, V26, P959, DOI 10.1016/j.euroneuro.2016.03.009; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Razzoli M, 2011, GENES BRAIN BEHAV, V10, P424, DOI 10.1111/j.1601-183X.2011.00681.x; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; SMITH MA, 1995, J NEUROSCI, V15, P1768; Vigers AJ, 2012, NEUROSCIENCE, V212, P1, DOI 10.1016/j.neuroscience.2012.03.031; Wenk GL, 2004, J NEUROCHEM, V89, P484, DOI 10.1111/j.1471-4159.2004.02359.x; Xie Y, 2013, AMINO ACIDS, V44, P413, DOI 10.1007/s00726-012-1347-2; Yang B, 2016, PSYCHOPHARMACOLOGY; Yasuda S, 2014, CELL MOL NEUROBIOL, V34, P1199, DOI 10.1007/s10571-014-0097-y; Yi LT, 2014, J PSYCHIATR NEUROSCI, V39, P348, DOI 10.1503/jpn.130169; Zhang LM, 2015, EXP THER MED, V9, P972, DOI 10.3892/etm.2014.2157; Zhang YJ, 2011, BRAIN RES BULL, V86, P222, DOI 10.1016/j.brainresbull.2011.07.002; Zhuang FZ, 2016, BEHAV BRAIN RES, V313, P158, DOI 10.1016/j.bbr.2016.06.057	37	23	27	1	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	FEB 1	2017	169						184	188		10.1016/j.physbeh.2016.12.003			5	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	EI8RB	WOS:000392774100025	27940143				2021-06-18	
J	Meier, TB; Bellgowan, PSF; Mayer, AR				Meier, Timothy B.; Bellgowan, Patrick S. F.; Mayer, Andrew R.			Longitudinal assessment of local and global functional connectivity following sports-related concussion	BRAIN IMAGING AND BEHAVIOR			English	Article						fMRI; Mild traumatic brain injury; Regional homogeneity; Resting state	TRAUMATIC BRAIN-INJURY; DEFAULT-MODE NETWORK; RESTING-STATE FMRI; COLLEGIATE FOOTBALL PLAYERS; REGIONAL HOMOGENEITY; ALZHEIMERS-DISEASE; NCAA CONCUSSION; PERFORMANCE; RECOVERY; PHASE	Growing evidence suggests that sports-related concussions (SRC) may lead to acute changes in intrinsic functional connectivity, although most studies to date have been cross-sectional in nature with relatively modest sample sizes. We longitudinally assessed changes in local and global resting state functional connectivity using metrics that do not require a priori seed or network selection (regional homogeneity; ReHo and global brain connectivity; GBC, respectively). A large sample of collegiate athletes (N = 43) was assessed approximately one day (1.74 days post-injury, N = 34), one week (8.44 days, N = 34), and one month post-concussion (32.47 days, N = 30). Healthy contact sport-athletes served as controls (N = 51). Concussed athletes showed improvement in mood symptoms at each time point (p's < 0.05), but had significantly higher mood scores than healthy athletes at every time point (p's < 0.05). In contrast, self-reported symptoms and cognitive deficits improved over time following concussion (p's < 0.001), returning to healthy levels by one week post-concussion. ReHo in sensorimotor, visual, and temporal cortices increased over time post-concussion, and was greatest at one month post-injury. Conversely, ReHo in the frontal cortex decreased over time following SRC, with the greatest decrease evident at one month post-concussion. Differences in ReHo relative to healthy athletes were primarily observed at one month post-concussion rather than the more acute time points. Contrary to our hypothesis, no significant cross-sectional or longitudinal differences in GBC were observed. These results are suggestive of a delayed onset of local connectivity changes following SRC.	[Meier, Timothy B.] Med Coll Wisconsin, Dept Neurosurg, Neurosci Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Meier, Timothy B.; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87106 USA; [Meier, Timothy B.] Laureate Inst Brain Res, Tulsa, OK 74136 USA; [Bellgowan, Patrick S. F.] NINDS, NIH, North Bethesda, MD 20892 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Meier, TB (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Neurosci Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.; Meier, TB (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87106 USA.; Meier, TB (corresponding author), Laureate Inst Brain Res, Tulsa, OK 74136 USA.	tmeier@mcw.edu		Bellgowan, Patrick/0000-0002-6753-8302	Laureate Institute for Brain Research; William K. Warren Foundation	This research was conducted using internal funds from the Laureate Institute for Brain Research, which is supported by The William K. Warren Foundation. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Dr. Meier had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors thank the psychiatric assessment team, the MRI technicians, and Dr. Rashmi Singh at the Laureate Institute for Brain Research for their assistance in data collection and Christopher Nerio, David Polanski, Dr. Thomas Allen, and Dr. Lamont Cavanagh for athlete referral and injury oversight.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Borich M, 2015, J NEUROTRAUM, V32, P265, DOI 10.1089/neu.2013.3269; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buckner RL, 2009, J NEUROSCI, V29, P1860, DOI 10.1523/JNEUROSCI.5062-08.2009; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chen G, 2013, NEUROIMAGE, V73, P176, DOI 10.1016/j.neuroimage.2013.01.047; Cole MW, 2010, NEUROIMAGE, V49, P3132, DOI 10.1016/j.neuroimage.2009.11.001; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Czerniak SM, 2015, BRAIN IMAGING BEHAV, V9, P323, DOI 10.1007/s11682-014-9312-1; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gotts SJ, 2012, BRAIN, V135, P2711, DOI 10.1093/brain/aws160; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Jiang LL, 2015, BRAIN STRUCT FUNCT, V220, P2485, DOI 10.1007/s00429-014-0795-8; Jo HJ, 2010, NEUROIMAGE, V52, P571, DOI 10.1016/j.neuroimage.2010.04.246; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones TB, 2010, NEUROIMAGE, V49, P401, DOI 10.1016/j.neuroimage.2009.07.051; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Mayer AR, 2015, HUM BRAIN MAPP, V36, P4394, DOI 10.1002/hbm.22930; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Meier TB, 2016, HUM BRAIN MAPP, V37, P833, DOI 10.1002/hbm.23072; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Militana AR, 2016, BRAIN IMAGING BEHAV, V10, P559, DOI 10.1007/s11682-015-9407-3; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Roebuck-Spencer TM, 2013, ARCH CLIN NEUROPSYCH, V28, P700, DOI 10.1093/arclin/act055; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Sepulcre J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000808; Sheline YI, 2009, P NATL ACAD SCI USA, V106, P1942, DOI 10.1073/pnas.0812686106; Singh R, 2016, J NEUROL NEUROSUR PS, V87, P670, DOI 10.1136/jnnp-2015-311369; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Taylor PA, 2013, BRAIN CONNECT, V3, P523, DOI 10.1089/brain.2013.0154; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; Urban KJ, 2015, J NEUROTRAUM, V32, P833, DOI 10.1089/neu.2014.3577; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030; Zhan J, 2015, J NERV MENT DIS, V203, P786, DOI 10.1097/NMD.0000000000000368; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang ZQ, 2012, NEUROIMAGE, V59, P1429, DOI 10.1016/j.neuroimage.2011.08.049; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; Zhu SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065884; Zuo XN, 2013, NEUROIMAGE, V65, P374, DOI 10.1016/j.neuroimage.2012.10.017	57	23	23	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	FEB	2017	11	1					129	140		10.1007/s11682-016-9520-y			12	Neuroimaging	Neurosciences & Neurology	ET8TT	WOS:000400575300011	26821253				2021-06-18	
J	Nguyen, TV; Lew, J; Albaugh, MD; Botteron, KN; Hudziak, JJ; Fonov, VS; Collins, DL; Ducharme, S; McCracken, JT				Tuong-Vi Nguyen; Lew, Jimin; Albaugh, Matthew D.; Botteron, Kelly N.; Hudziak, James J.; Fonov, Vladimir S.; Collins, D. Louis; Ducharme, Simon; McCracken, James T.			Sex-specific associations of testosterone with prefrontal-hippocampal development and executive function	PSYCHONEUROENDOCRINOLOGY			English	Article						Gonadarche; Androgen; Cognition; Puberty; Adolescents; Human brain	VERBAL-LEARNING-TEST; BEHAVIOR RATING INVENTORY; TRAUMATIC BRAIN-INJURY; MEDIAL TEMPORAL-LOBE; ADULT MALE RATS; SALIVARY TESTOSTERONE; CORTICAL MATURATION; CONSTRUCT-VALIDITY; CHILDRENS-VERSION; HORMONE LEVELS	Testosterone is thought to play a crucial role in mediating sexual differentiation of brain structures. Examinations of the cognitive effects of testosterone have also shown beneficial and potentially sex-specific effects on executive function and mnemonic processes. Yet these findings remain limited by an incomplete understanding of the critical timing and brain regions most affected by testosterone, the lack of documented links between testosterone-related structural brain changes and cognition, and the difficulty in distinguishing the effects of testosterone from those of related sex steroids such as of estradiol and dehydroepiandrosterone (DHEA). Here we examined associations between testosterone, corticohippocampal structural covariance, executive function (Behavior Rating Inventory of Executive Function) and verbal memory (California Verbal Learning Test-Children's Version), in a longitudinal sample of typically developing children and adolescents 6-22 yo, controlling for the effects of estradiol, DHEA, pubertal stage, collection time, age, handedness, and total brain volume. We found prefrontal-hippocampal covariance to vary as a function of testosterone levels, but only in boys. Boys also showed a specific association between positive prefrontal-hippocampal covariance (as seen at higher testosterone levels) and lower performance on specific components of executive function (monitoring the action process and flexibly shifting between actions). We also found the association between testosterone and a specific aspect of executive function (monitoring) to be significantly mediated by prefrontal-hippocampal structural covariance. There were no significant associations between testosterone-related cortico-hippocampal covariance and verbal memory. Taken together, these findings highlight the developmental importance of testosterone in supporting sexual differentiation of the brain and sex-specific executive function. (C) 2016 Elsevier Ltd. All rights reserved.	[Tuong-Vi Nguyen] McGill Univ, Dept Psychiat, Ctr Hlth, Royal Victoria Hosp Glen Site, Montreal, PQ H4A 3J1, Canada; [Tuong-Vi Nguyen] McGill Univ, Dept Obstet Gynecol, Ctr Hlth, Royal Victoria Hosp Glen Site, Montreal, PQ H4A 3J1, Canada; [Lew, Jimin] McGill Univ, Dept Psychol, Montreal, PQ H4A 3J1, Canada; [Albaugh, Matthew D.; Hudziak, James J.] Univ Vermont, Coll Med, Burlington, VT 05405 USA; [Botteron, Kelly N.] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Fonov, Vladimir S.; Collins, D. Louis; Ducharme, Simon] Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada; [Ducharme, Simon] McGill Univ, Ctr Hlth, Dept Psychiat, Montreal, PQ H3A 1A1, Canada; [Ducharme, Simon] McGill Univ, Ctr Hlth, Dept Neurol & Neurosurg, Montreal, PQ H3A 1A1, Canada; [McCracken, James T.] Univ Calif Los Angeles, Dept Child & Adolescent Psychiat, Los Angeles, CA 90024 USA	Nguyen, TV (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp Glen Site, 1001 Decarie C6-1188-4, Montreal, PQ H4A 3J1, Canada.	tuong.v.nguyen@mcgill.ca	Albaugh, Matthew D/R-4349-2016; Fonov, Vladimir/AAG-9572-2019; Albaugh, Matthew/ABB-5839-2020	Fonov, Vladimir/0000-0003-3402-7749; Albaugh, Matthew/0000-0002-5971-6658; Collins, D. Louis/0000-0002-8432-7021	Brain Development Cooperative Group; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [N01HD023343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [N01MH090002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092317, N01NS092316, N01NS092320, N01NS092314, N01NS092315, N01NS092319] Funding Source: NIH RePORTER	The funding primarily served to support the Brain Development Cooperative Group and was dedicated to protocol development, data collection and image processing.	ABDELGADIR SE, 1994, ENDOCRINOLOGY, V135, P395, DOI 10.1210/en.135.1.395; Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172; Biegon A, 2015, J NUCL MED, V56, P580, DOI 10.2967/jnumed.114.150383; Biegon A, 2010, SYNAPSE, V64, P801, DOI 10.1002/syn.20791; Blakemore SJ, 2010, HUM BRAIN MAPP, V31, P926, DOI 10.1002/hbm.21052; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Brambilla DJ, 2009, J CLIN ENDOCR METAB, V94, P907, DOI 10.1210/jc.2008-1902; Bramen JE, 2011, CEREB CORTEX, V21, P636, DOI 10.1093/cercor/bhq137; Burgess P., 1997, THEORY METHODOLOGY E; Cattie JE, 2012, CLIN NEUROPSYCHOL, V26, P288, DOI 10.1080/13854046.2011.653404; Cherrier MM, 2005, NEUROLOGY, V64, P290, DOI 10.1212/01.WNL.0000149639.25136.CA; Collins DL, 2010, NEUROIMAGE, V52, P1355, DOI 10.1016/j.neuroimage.2010.04.193; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; DABBS JM, 1990, PHYSIOL BEHAV, V48, P83, DOI 10.1016/0031-9384(90)90265-6; Edinger KL, 2004, BEHAV NEUROSCI, V118, P1352, DOI 10.1037/0735-7044.118.6.1352; Evans AC, 2006, NEUROIMAGE, V30, P184, DOI 10.1016/j.neuroimage.2005.09.068; Fernandez G, 2003, J NEUROSCI, V23, P3790; Foradori CD, 2008, FRONT NEUROENDOCRIN, V29, P169, DOI 10.1016/j.yfrne.2007.10.005; Foradori CD, 2007, NEUROSCIENCE, V149, P155, DOI 10.1016/j.neuroscience.2007.06.054; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Gioia GA, 2001, BRAIN COGNITION, V47, P203; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Goldman-Rakic P.S., 1987, CIRCUITRY PRIMATE PR; Goodman AM, 1999, CLIN NEUROPSYCHOL, V13, P274, DOI 10.1076/clin.13.3.274.1748; Granger DA, 2004, PSYCHONEUROENDOCRINO, V29, P1229, DOI 10.1016/j.psyneuen.2004.02.005; Haren MT, 2005, MATURITAS, V50, P124, DOI 10.1016/j.maturitas.2004.05.002; Hill BD, 2012, APPL NEUROPSYCH-ADUL, V19, P198, DOI 10.1080/09084282.2011.643960; Hu SY, 2013, NEUROIMAGE, V74, P276, DOI 10.1016/j.neuroimage.2013.02.032; Huang G, 2015, J ENDOCRINOL INVEST, V38, P455, DOI 10.1007/s40618-014-0213-3; Ishunina TA, 2005, NEUROBIOL AGING, V26, P173, DOI 10.1016/j.neurobiolaging.2004.03.010; Jacobs ML, 2008, ARCH CLIN NEUROPSYCH, V23, P113, DOI 10.1016/j.acn.2007.09.003; Janowsky JS, 2006, TRENDS COGN SCI, V10, P77, DOI 10.1016/j.tics.2005.12.010; KHANDAWOOD FS, 1984, AM J OBSTET GYNECOL, V148, P441; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Koolschijn PCMP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083929; Kritzer MF, 2001, HORM BEHAV, V39, P167, DOI 10.1006/hbeh.2001.1645; McGivern RF, 2002, BRAIN COGNITION, V50, P73, DOI 10.1016/S0278-2626(02)00012-X; Mottram L, 2005, PSYCHOL ASSESSMENT, V17, P212, DOI 10.1037/1040-3590.17.2.212; Muir-Broaddus JE, 2002, ARCH CLIN NEUROPSYCH, V17, P671, DOI 10.1016/S0887-6177(01)00170-6; Muller M, 2005, NEUROLOGY, V64, P866, DOI 10.1212/01.WNL.0000153072.54068.E3; Nakamura N, 2002, NEUROSCIENCE, V109, P473, DOI 10.1016/S0306-4522(01)00513-9; Neufang S, 2009, CEREB CORTEX, V19, P464, DOI 10.1093/cercor/bhn100; Paus T, 2010, HORM BEHAV, V57, P63, DOI 10.1016/j.yhbeh.2009.08.004; Peper JS, 2011, NEUROSCIENCE, V191, P28, DOI 10.1016/j.neuroscience.2011.02.014; PETERSEN AC, 1988, J YOUTH ADOLESCENCE, V17, P117, DOI 10.1007/BF01537962; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Pruessner JC, 2001, J NEUROSCI, V21, P194, DOI 10.1523/JNEUROSCI.21-01-00194.2001; Raznahan A, 2010, P NATL ACAD SCI USA, V107, P16988, DOI 10.1073/pnas.1006025107; Redoute J, 2005, PSYCHONEUROENDOCRINO, V30, P461, DOI 10.1016/j.psyneuen.2004.12.003; Roselli CE, 2001, J STEROID BIOCHEM, V79, P247, DOI 10.1016/S0960-0760(01)00141-8; Sasano H, 1998, CLIN ENDOCRINOL, V48, P325, DOI 10.1046/j.1365-2265.1998.00390.x; Sellers JG, 2007, J RES PERS, V41, P126, DOI 10.1016/j.jrp.2006.02.004; Shallice T., 1991, HIGHER ORDER COGNITI; Shultz S, 2010, J COMP PSYCHOL, V124, P252, DOI 10.1037/a0018894; Sotomayor-Zarate R, 2011, FERTIL STERIL, V96, P1490, DOI 10.1016/j.fertnstert.2011.09.011; Stanczyk FZ, 2006, SEMIN REPROD MED, V24, P78, DOI 10.1055/s-2006-939566; Steckelbroeck S, 1999, J CLIN ENDOCR METAB, V84, P2795, DOI 10.1210/jc.84.8.2795; Stoffel-Wagner B, 1999, J STEROID BIOCHEM, V70, P237, DOI 10.1016/S0960-0760(99)00114-4; Nguyen TV, 2016, PSYCHONEUROENDOCRINO, V63, P109, DOI 10.1016/j.psyneuen.2015.09.021; Nguyen TV, 2013, J NEUROSCI, V33, P10840, DOI 10.1523/JNEUROSCI.5747-12.2013; Nguyen TV, 2013, CEREB CORTEX, V23, P1424, DOI 10.1093/cercor/bhs125; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Witte AV, 2010, NEUROIMAGE, V49, P1205, DOI 10.1016/j.neuroimage.2009.09.046; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P413, DOI 10.1016/j.acn.2006.06.002; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; WORTHMAN CM, 1990, CLIN CHEM, V36, P1769; Yoon T, 2008, LEARN MEMORY, V15, P97, DOI 10.1101/lm.850808; Zuloaga DG, 2008, HORM BEHAV, V53, P613, DOI 10.1016/j.yhbeh.2008.01.013	71	23	24	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	FEB	2017	76						206	217		10.1016/j.psyneuen.2016.12.005			12	Endocrinology & Metabolism; Neurosciences; Psychiatry	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	EK1YL	WOS:000393723600027	27984812	Green Accepted			2021-06-18	
J	Wang, R; Seifert, P; Jakobs, TC				Wang, Rui; Seifert, Philip; Jakobs, Tatjana C.			Astrocytes in the Optic Nerve Head of Glaucomatous Mice Display a Characteristic Reactive Phenotype	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						astrocytes; glial lamina; glaucoma; electron microscopy; confocal microscopy	ELEVATED INTRAOCULAR-PRESSURE; RETROGRADE AXOPLASMIC-TRANSPORT; INDUCED OCULAR HYPERTENSION; RETINAL GANGLION-CELLS; LAMINA-CRIBROSA; DBA/2J MICE; RAT GLAUCOMA; MOUSE MODEL; INHERITED GLAUCOMA; AXONAL-TRANSPORT	PURPOSE. Optic nerve head astrocytes, a subtype of white-matter astrocytes, become reactive early in the course of glaucoma. It was shown recently that in the DBA/2J mouse model of inherited glaucoma optic nerve astrocytes extend new longitudinal processes into the axon bundles before ganglion cell loss becomes apparent. The present study aims at testing whether this behavior of astrocytes is typical of early glaucomatous damage. METHODS. Mice expressing green fluorescent protein in individual astrocytes were used to evaluate the early response of astrocytes in the glial lamina of the optic nerve head after increasing the IOP using the microbead occlusion method. Tissue sections from the glial lamina were imaged consecutively by confocal and electron microscopy. RESULTS. Confocal and electron microscope images show that astrocytes close to the myelination transition zone in the hypertensive nerve heads extend new processes that follow the longitudinal axis of the optic nerve and invade axon bundles in the nerve head. Ultrastructurally, the longitudinal processes were largely devoid of subcellular organelles except for degenerating mitochondria. CONCLUSIONS. The longitudinal processes are a common feature of glaucomatous optic nerve astrocytes, whereas they are not observed after traumatic nerve injury. Thus, astrocytes appear to fine-tune their responses to the nature and/or timing of the injury to the neurons that they surround.	[Wang, Rui] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Wang, Rui; Seifert, Philip; Jakobs, Tatjana C.] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA	Jakobs, TC (corresponding author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	Tatjana_Jakobs@meei.harvard.edu		Wang, Rui/0000-0002-8246-3433; Jakobs, Tatjana/0000-0002-8104-9206	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2R01EY019703, R01EY022092, P30EY003790]; Chinese Scholarship CouncilChina Scholarship Council; Research to Prevent BlindnessResearch to Prevent Blindness (RPB); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY019703, R01EY022092, P30EY014104, P30EY003790] Funding Source: NIH RePORTER	Supported by NIH Grants 2R01EY019703 and R01EY022092, the NIH Core Grant for vision research P30EY003790, and grants from the Chinese Scholarship Council and Research to Prevent Blindness.	Anderson MG, 2005, P NATL ACAD SCI USA, V102, P4566, DOI 10.1073/pnas.0407357102; Balaratnasingam C, 2008, BRAIN RES, V1244, P142, DOI 10.1016/j.brainres.2008.09.044; Baltan S, 2010, J NEUROSCI, V30, P5644, DOI 10.1523/JNEUROSCI.5956-09.2010; Bosco A, 2016, EXP EYE RES, V150, P34, DOI 10.1016/j.exer.2016.01.014; Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602; Burgoyne CF, 2011, EXP EYE RES, V93, P120, DOI 10.1016/j.exer.2010.09.005; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Calkins DJ, 2012, PROG RETIN EYE RES, V31, P702, DOI 10.1016/j.preteyeres.2012.07.001; Chen HH, 2011, INVEST OPHTH VIS SCI, V52, P36, DOI 10.1167/iovs.09-5115; Cone FE, 2012, EXP EYE RES, V99, P27, DOI 10.1016/j.exer.2012.04.006; Cone FE, 2010, EXP EYE RES, V91, P415, DOI 10.1016/j.exer.2010.06.018; Cooper ML, 2016, EXP EYE RES, V150, P22, DOI 10.1016/j.exer.2015.11.016; Coughlin L, 2015, INVEST OPHTH VIS SCI, V56, P1437, DOI 10.1167/iovs.14-16126; Crish SD, 2010, P NATL ACAD SCI USA, V107, P5196, DOI 10.1073/pnas.0913141107; Dai C, 2012, GLIA, V60, P13, DOI 10.1002/glia.21242; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P5151, DOI 10.1167/iovs.02-1101; Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111; Emsley JG, 2006, NEURON GLIA BIOL, V2, P175, DOI 10.1017/S1740925X06000202; Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92; Gao S, 2016, AM J PATHOL, V186, P985, DOI 10.1016/j.ajpath.2015.11.026; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Howell GR, 2012, J CLIN INVEST, V122, P1246, DOI 10.1172/JCI61135; Howell GR, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-429; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Jakobs TC, 2005, J CELL BIOL, V171, P313, DOI 10.1083/jcb.200506099; JOHANSSON JO, 1986, EXP EYE RES, V43, P653, DOI 10.1016/S0014-4835(86)80031-8; JOHANSSON JO, 1983, INVEST OPHTH VIS SCI, V24, P1552; JOHANSSON JO, 1988, EXP EYE RES, V46, P223, DOI 10.1016/S0014-4835(88)80079-4; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Johnson EC, 2015, INVEST OPHTH VIS SCI, V56, P412, DOI 10.1167/iovs.14-15094; Johnson EC, 2011, INVEST OPHTH VIS SCI, V52, P504, DOI 10.1167/iovs.10-5317; Jonas JB, 2003, INVEST OPHTH VIS SCI, V44, P5189, DOI 10.1167/iovs.03-0174; Kiumehr S, 2012, ARCH OPHTHALMOL-CHIC, V130, P552, DOI 10.1001/archopthalmol.2011.1309; Li RX, 2008, MOL VIS, V14, P745; Li Y, 2015, GLIA, V63, P1537, DOI 10.1002/glia.22825; Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130; Liu B, 2006, J NEUROSCI, V26, P7532, DOI 10.1523/JNEUROSCI.1004-06.2006; Longair MH, 2011, BIOINFORMATICS, V27, P2453, DOI 10.1093/bioinformatics/btr390; Lye-Barthel M, 2013, INVEST OPHTH VIS SCI, V54, P909, DOI 10.1167/iovs.12-10109; May CA, 2006, ACTA NEUROPATHOL, V111, P158, DOI 10.1007/s00401-005-0011-2; May CA, 2002, INVEST OPHTH VIS SCI, V43, P2206; McKinnon SJ, 2009, EXP EYE RES, V88, P816, DOI 10.1016/j.exer.2008.12.002; Morcos Y, 2000, J NEUROCYTOL, V29, P665, DOI 10.1023/A:1010835404754; MORRISON J, 1995, EXP EYE RES, V60, P127, DOI 10.1016/S0014-4835(95)80002-6; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; Morrison JC, 2008, PROG BRAIN RES, V173, P285, DOI 10.1016/S0079-6123(08)01121-7; Neufeld AH, 2003, NEUROSCIENTIST, V9, P485, DOI 10.1177/1073858403253460; Nguyen JV, 2011, P NATL ACAD SCI USA, V108, P1176, DOI 10.1073/pnas.1013965108; Nolte C, 2001, GLIA, V33, P72; Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764; QUIGLEY HA, 1980, INVEST OPHTH VIS SCI, V19, P137; Ramirez AI, 2010, INVEST OPHTH VIS SCI, V51, P5690, DOI 10.1167/iovs.10-5248; Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133; Salinas-Navarro M, 2009, MOL VIS, V15, P2578; Sappington RM, 2010, INVEST OPHTH VIS SCI, V51, P207, DOI 10.1167/iovs.09-3947; Schlamp CL, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-66; Sigal IA, 2014, BRIT J OPHTHALMOL, V98, P34, DOI 10.1136/bjophthalmol-2013-304751; Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269; Soto I, 2011, INVEST OPHTH VIS SCI, V52, P434, DOI 10.1167/iovs.10-5856; Strouthidis NG, 2011, INVEST OPHTH VIS SCI, V52, P9431, DOI 10.1167/iovs.11-7922; Sun D, 2013, GLIA, V61, P1218, DOI 10.1002/glia.22507; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Sun D, 2009, J COMP NEUROL, V516, P1, DOI 10.1002/cne.22058; Tehrani S, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14969; Varela HJ, 1997, J GLAUCOMA, V6, P303; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Yang HL, 2011, INVEST OPHTH VIS SCI, V52, P7109, DOI 10.1167/iovs.11-7448	69	23	24	0	3	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404	1552-5783		INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	FEB	2017	58	2								10.1167/iovs.16-20571			9	Ophthalmology	Ophthalmology	EO8LC	WOS:000396939600028	28170536	DOAJ Gold, Green Published			2021-06-18	
J	Herrera, JJ; Bockhorst, K; Kondraganti, S; Stertz, L; Quevedo, J; Narayana, PA				Herrera, Juan J.; Bockhorst, Kurt; Kondraganti, Shakuntala; Stertz, Laura; Quevedo, Joao; Narayana, Ponnada A.			Acute White Matter Tract Damage after Frontal Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; inflammation; mild traumatic brain injury; MRI behavioral assessments	CLOSED-HEAD-INJURY; NECROSIS-FACTOR-ALPHA; RAT SPINAL-CORD; AXONAL INJURY; OUTCOME PREDICTION; IMAGING FINDINGS; BDNF EXPRESSION; MOUSE MODEL; TNF-ALPHA; DIFFUSION	Our understanding of mild traumatic brain injury (mTBI) is still in its infancy and to gain a greater understanding, relevant animal models should replicate many of the features seen in human mTBI. These include changes to diffusion tensor imaging (DTI) parameters, absence of anatomical lesions on conventional neuroimaging, and neurobehavioral deficits. The Maryland closed head TBI model causes anterior-posterior plus sagittal rotational acceleration of the brain, frequently observed with motor vehicle and sports-related TBI injuries. The injury reflects a concussive injury model without skull fracture. The goal of our study was to characterize the acute (72 h) pathophysiological changes occurring following a single mTBI using magnetic resonance imaging (MRI), behavioral assays, and histology. We assessed changes in fractional anisotropy (FA), mean (MD), longitudinal (LD), and radial (RD) diffusivities relative to pre-injury baseline measures. Significant differences were observed in both the longitudinal and radial diffusivities in the fimbria compared with baseline. A significant difference in radial diffusivity was also observed in the splenium of the corpus callosum compared with baseline. The exploratory activity of the mTBI animals was also assessed using computerized activity monitoring. A significant decrease was observed in ambulatory distance, average velocity, stereotypic counts, and vertical counts compared with baseline. Histological examination of the mTBI brain sections indicated a significant decrease in the expression of myelin basic protein in the fimbria, splenium, and internal capsule. Our findings demonstrate the vulnerability of the white matter tracts, specifically the fimbria and splenium, and the ability of DTI to identify changes to the integrity of the white matter tracts following mTBI.	[Herrera, Juan J.; Bockhorst, Kurt; Kondraganti, Shakuntala; Narayana, Ponnada A.] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Diagnost & Intervent Imaging, Houston, TX USA; [Stertz, Laura; Quevedo, Joao] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Psychiat & Behav Sci, Translat Psychiat Program, Houston, TX USA; [Quevedo, Joao] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Psychiat & Behav Sci, Ctr Excellence Mood Disorders, Houston, TX USA	Herrera, JJ (corresponding author), Univ Texas Houston, Med Sch Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin,MSE R102F, Houston, TX 77030 USA.	Juan.Herrera@uth.tmc.edu	de Quevedo, Joao Luciano/E-5491-2013; Stertz, Laura/AAC-7384-2019	de Quevedo, Joao Luciano/0000-0003-3114-6611; Stertz, Laura/0000-0002-1426-6796	Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth); NIH High End Instrumentation Grant [1 S10 RR17205-01]	The Translational Psychiatry Program (USA) is funded by the Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth). The 7T scanner purchase was supported by the NIH High End Instrumentation Grant (1 S10 RR17205-01) awarded to PAN.	Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Cammer W, 2000, BRAIN RES, V864, P213, DOI 10.1016/S0006-8993(00)02178-8; Choy KHC, 2008, HIPPOCAMPUS, V18, P655, DOI 10.1002/hipo.20425; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Council NR, 2011, GUIDE CARE USE LAB A; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gerberding JL, 2003, C MILD TRAUM BRAIN I; Ghadiri T, 2014, J NEUROSCI METH, V233, P18, DOI 10.1016/j.jneumeth.2014.05.035; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HAHN KR, 2005, P 13 ANN M ISMRM MIA, P161; Hall J, 2000, NAT NEUROSCI, V3, P533; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Herrera JJ, 2008, J NEUROSCI RES, V86, P443, DOI 10.1002/jnr.21481; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Madi S, 2005, MAGN RESON MED, V53, P118, DOI 10.1002/mrm.20304; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Narayana PA, 2014, PSYCHIAT RES-NEUROIM, V221, P220, DOI 10.1016/j.pscychresns.2014.01.005; Narayana PA, 2009, PSYCHIAT RES-NEUROIM, V171, P242, DOI 10.1016/j.pscychresns.2008.04.004; Pendlebury ST, 1999, STROKE, V30, P956, DOI 10.1161/01.STR.30.5.956; Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; TRINCHIERI G, 1994, IMMUNOL TODAY, V15, P460, DOI 10.1016/0167-5699(94)90189-9; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	61	23	23	0	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					291	299		10.1089/neu.2016.4407			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800004	27138134	Green Published			2021-06-18	
J	Cui, CM; Cui, JZ; Jin, F; Cui, Y; Li, R; Jiang, XH; Tian, YX; Wang, KJ; Jiang, P; Gao, JL				Cui, Changmeng; Cui, Jianzhong; Jin, Feng; Cui, Ying; Li, Ran; Jiang, Xiaohua; Tian, Yanxia; Wang, Kaijie; Jiang, Pei; Gao, Junling			Induction of the Vitamin D Receptor Attenuates Autophagy Dysfunction-Mediated Cell Death Following Traumatic Brain Injury	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Traumatic brain injury; Vitamin D; Calcitriol; Autophagy; Apoptosis; Function recovery	SPINAL-CORD-INJURY; RAT MODEL; D METABOLISM; D HORMONE; NEUROPROTECTION; ACTIVATION; PROGESTERONE; PATHOGENESIS; COMBINATION; MYOCARDIUM	Background/Aims: Traumatic brain injury (TBI) is a major public health problem in the world and causes high rates of mortality and disability. Recent evidence suggests that vitamin D (VD) has neuroprotective actions and can promote function recovery after TBI. In vitro and in vivo studies have demonstrated that autophagy could be enhanced following supplementation with an active metabolite of VD (calcitriol). However, it is unclear whether autophagy participates in the protective effects of calcitriol after TBI. To test this hypothesis, we examined the protective effects of calcitriol on TBI-induced neurological impairment and further investigated whether calcitriol could modulate autophagy dysfunction-mediated cell death in the cortex region of rat brain. Methods: Eighty-five male rats (250-280 g) were randomly assigned to sham (n = 15), TBI model (TBI, n = 35) and calcitriol treatment (calcitriol, n = 35) groups. Rats were injected intraperitoneally with calcitriol (1 mu g/kg) at 30 min, 24 h and 48 h post-TBI in the calcitriol group. The lysosomal inhibitor, chloroquine (CQ), was used to evaluate autophagic flux in the TBI and calcitriol groups. Neurological functions were evaluated via the modified neurological severity score test at 1-7 days after TBI or sham operation, and the terminal deoxynucleotidyl transferase-mediated FITC-dUTP nick-end labeling method was used to evaluate the ability of calcitriol to inhibit apoptosis. The expression of VDR, LC3 and p62 proteins was measured by western blot analysis at 1, 3 and 7 days post-injury. Results: Calcitriol treatment attenuated mNSS at 2-7 days post-TBI (P < 0.05 versus TBI group). Calcitriol dramatically increased VDR protein expression compared with the untreated counterparts at 1, 3 and 7 days post-TBI (P < 0.05). The rate of apoptotic cells in calcitriol-treated rats was significantly reduced compared to that observed in the TBI group (P < 0.05). The LC3II/LC3I ratio was decreased in the cortex region at 1, 3 and 7 days post-TBI in rats treated with calcitriol (p < 0.05 versus TBI group), and the p62 expression was also attenuated (p < 0.05 versus TBI group). The LC3II/LC3I ratio in the calcitriol group was significantly increased when pretreated with CQ (P < 0.05). Conclusion: Calcitriol treatment activated VDR protein expression and attenuated neurological deficits in this rat TBI model. The protective effects might be associated with the restoration of autophagy flux and the decrease in apoptosis in the cortex region of rat brain. (C) 2017 The Author(s) Published by S. Karger AG, Basel	[Cui, Changmeng; Jin, Feng] Jining Med Univ, Affiliated Hosp, Dept Neurosurg, Jining, Peoples R China; [Cui, Changmeng; Jiang, Pei] Jining Med Univ, Jining Peoples Hosp 1, Inst Clin Pharm & Pharmacol, Jining 272000, Shandong, Peoples R China; [Cui, Jianzhong; Cui, Ying; Wang, Kaijie] Tangshan Gongren Hosp, Tangshan, Peoples R China; [Li, Ran; Jiang, Xiaohua; Tian, Yanxia; Gao, Junling] North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Li, Ran; Jiang, Xiaohua; Tian, Yanxia; Gao, Junling] Tangshan Key Lab Preclin & Basic Res Chron Dis, Hebei Key Lab Chron Dis, Tangshan, Peoples R China	Jiang, P; Gao, JL (corresponding author), Jining Med Univ, Jining Peoples Hosp 1, Inst Clin Pharm & Pharmacol, Jining 272000, Shandong, Peoples R China.; Jiang, P; Gao, JL (corresponding author), North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China.	jiangpeicsu@sina.com; jlgaodr2001@163.com		Jiang, Pei/0000-0002-8360-7427			Aranda A, 2001, PHYSIOL REV, V81, P1269; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Feng Y.C., 2016, CORROS ENG SCI TECHN, P1; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Fu J, 2013, MOL MED REP, V8, P1708, DOI 10.3892/mmr.2013.1734; Galluzzi L, 2016, NAT REV NEUROSCI, V17, P467, DOI 10.1038/nrn.2016.51; He XJ, 2016, CELL PHYSIOL BIOCHEM, V40, P743, DOI 10.1159/000453135; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Jiang P, 2014, PSYCHOPHARMACOLOGY, V231, P3445, DOI 10.1007/s00213-014-3440-6; Jiang P, 2013, PSYCHONEUROENDOCRINO, V38, P2091, DOI 10.1016/j.psyneuen.2013.03.017; Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kalueff AV, 2004, BIOCHEMISTRY-MOSCOW+, V69, P738, DOI 10.1023/B:BIRY.0000040196.65686.2f; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Lawrence DW, 2016, BRAIN INJURY, V30, P960, DOI 10.3109/02699052.2016.1147081; Mustafa G, 2016, NEUROPHARMACOLOGY, V107, P27, DOI 10.1016/j.neuropharm.2016.03.016; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Sheng R, 2010, AUTOPHAGY, V6, P482, DOI 10.4161/auto.6.4.11737; Somjen D, 2017, J STEROID BIOCHEM, V174, P9, DOI 10.1016/j.jsbmb.2017.05.007; TANG H, 2015, BRAIN INJURY, P1; Tung YT, 2012, J BIOSCIENCES, V37, P157, DOI 10.1007/s12038-011-9176-0; Wang P., 2017, OXID MED CELL LONGEV, V2017, DOI DOI 10.1155/2017/1020357; Wang RC, 2011, J INVEST DERMATOL, V131, P990, DOI 10.1038/jid.2010.423; Yan F, 2014, NEUROSCI LETT, V563, P160, DOI 10.1016/j.neulet.2014.01.058; Yao TB, 2015, ANTIOXID REDOX SIGN, V22, P633, DOI 10.1089/ars.2014.5887; Zanatta AP, 2017, BASIC CLIN ANDROL, V27, DOI 10.1186/s12610-017-0053-z; Zhou KL, 2016, SPINAL CORD, V54, P510, DOI 10.1038/sc.2015.217	36	23	26	1	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2017	42	5					1888	1896		10.1159/000479571			9	Cell Biology; Physiology	Cell Biology; Physiology	FL2EB	WOS:000414026500015	28772270	DOAJ Gold			2021-06-18	
J	Dorsett, CR; McGuire, JL; Niedzielko, TL; DePasquale, EAK; Meller, J; Floyd, CL; McCullumsmith, RE				Dorsett, Christopher R.; McGuire, Jennifer L.; Niedzielko, Tracy L.; DePasquale, Erica A. K.; Meller, Jaroslaw; Floyd, Candace L.; McCullumsmith, Robert E.			Traumatic Brain Injury Induces Alterations in Cortical Glutamate Uptake without a Reduction in Glutamate Transporter-1 Protein Expression	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; GLT-1; glutamate; kinome array; membrane vesicles	CELL-SURFACE EXPRESSION; KINASE-C; DIFFERENTIAL REGULATION; NEURONAL DAMAGE; AMINO-ACIDS; RAT-BRAIN; GLT-1; ACTIVATION; AKT; PHOSPHORYLATION	We hypothesize that the primary mechanism for removal of glutamate from the extracellular space is altered after traumatic brain injury (TBI). To evaluate this hypothesis, we initiated TBI in adult male rats using a 2.0 atm lateral fluid percussion injury (LFPI) model. In the ipsilateral cortex and hippocampus, we found no differences in expression of the primary glutamate transporter in the brain (GLT-1) 24 h after TBI. In contrast, we found a decrease in glutamate uptake in the cortex, but not the hippocampus, 24 h after injury. Because glutamate uptake is potently regulated by protein kinases, we assessed global serine-threonine protein kinase activity using a kinome array platform. Twenty-five kinome array peptide substrates were differentially phoshorylated between LFPI and controls in the cortex, whereas 19 peptide substrates were differentially phosphorylated in the hippocampus (fold change >= +/- 1.15). We identified several kinases as likely to be involved in acute TBI, including protein kinase B (Akt) and protein kinase C (PKC), which are well-characterized modulators of GLT-1. Exploratory studies using an inhibitor of Akt suggest selective activation of kinases in LFPI versus controls. Ingenuity pathway analyses of implicated kinases from our network model found apoptosis and cell death pathways as top functions in acute LFPI. Taken together, our data suggest diminished activity of glutamate transporters in the prefrontal cortex, with no changes in protein expression of the primary glutamate transporter GLT-1, and global alterations in signaling networks that include serine-threonine kinases that are known modulators of glutamate transport activity.	[Dorsett, Christopher R.] Univ N Carolina, Biol & Biomed Sci Doctoral Program, Chapel Hill, NC USA; [McGuire, Jennifer L.; DePasquale, Erica A. K.; McCullumsmith, Robert E.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, MSB 5255A,d31 Albert Sabin Way, Cincinnati, OH 45267 USA; [Niedzielko, Tracy L.; Floyd, Candace L.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Meller, Jaroslaw] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Meller, Jaroslaw] Univ Cincinnati, Coll Med, Dept Elect Engn & Comp Syst, Cincinnati, OH USA; [Meller, Jaroslaw] Univ Cincinnati, Coll Med, Dept Biomed Informat, Cincinnati, OH USA; [Meller, Jaroslaw] Cincinnati Childrens Hosp, Med Ctr, Dept Biomed Informat, Cincinnati, OH USA	McCullumsmith, RE (corresponding author), Univ Cincinnati, Dept Psychiat & Behav Neurosci, MSB 5255A,d31 Albert Sabin Way, Cincinnati, OH 45267 USA.	robert.mccullumsmith@uc.edu	Meller, Jaroslaw/A-1971-2011	Meller, Jaroslaw/0000-0002-1162-8253; McGuire, Jennifer/0000-0003-3058-5241	 [R01NS075162]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH094445, R01MH107487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075162] Funding Source: NIH RePORTER	This work was partially supported by R01NS075162 (C.L.F.).	Abe K, 2002, BRAIN RES, V952, P211, DOI 10.1016/S0006-8993(02)03194-3; Adolph O, 2007, GLIA, V55, P1699, DOI 10.1002/glia.20583; Allen NJ, 2004, PFLUG ARCH EUR J PHY, V449, P132, DOI 10.1007/s00424-004-1318-x; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Boston-Howes W, 2006, J BIOL CHEM, V281, P14076, DOI 10.1074/jbc.M600653200; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; Daniels KK, 1999, NEUROCHEM RES, V24, P1017, DOI 10.1023/A:1021004809991; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Garling RJ, 2014, NEURAL REGEN RES, V9, P1891, DOI 10.4103/1673-5374.145355; Gegelashvili G, 2000, NEUROCHEM INT, V37, P163, DOI 10.1016/S0197-0186(00)00019-X; Gibb SL, 2007, J BIOL CHEM, V282, P32480, DOI 10.1074/jbc.M704314200; Gonzalez MI, 2004, MOL INTERV, V4, P48, DOI 10.1124/mi.4.1.48; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Guillet BA, 2005, NEUROCHEM INT, V46, P337, DOI 10.1016/j.neuint.2004.10.006; Jarboe JS, 2012, RADIOTHER ONCOL, V103, P380, DOI 10.1016/j.radonc.2012.03.014; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; Kanai Y, 2003, EUR J PHARMACOL, V479, P237, DOI 10.1016/j.ejphar.2003.08.073; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kobori N, 2015, J NEUROTRAUM, V32, P139, DOI 10.1089/neu.2014.3487; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lauriat TL, 2007, MOL PSYCHIATR, V12, P1065, DOI 10.1038/sj.mp.4002065; Li L, 2006, J ENG FIBER FABR, V1, P1; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; LUDBROOK J, 1994, CLIN EXP PHARMACOL P, V21, P673, DOI 10.1111/j.1440-1681.1994.tb02570.x; LUDBROOK J, 1995, AUST NZ J SURG, V65, P812, DOI 10.1111/j.1445-2197.1995.tb00567.x; McGuire JL, 2014, BRAIN RES, V1568, P42, DOI 10.1016/j.brainres.2014.04.029; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Murphy-Royal C, 2015, NAT NEUROSCI, V18, P219, DOI 10.1038/nn.3901; Muurling T, 2014, OTOL NEUROTOL, V35, P1, DOI 10.1097/MAO.0000000000000254; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Olney J W, 1990, Can Dis Wkly Rep, V16 Suppl 1E, P47; Padmaperuma B, 1996, BRAIN RES, V714, P19, DOI 10.1016/0006-8993(95)01579-5; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Pow DV, 2004, DEV BRAIN RES, V153, P1, DOI 10.1016/j.devbrainres.2004.06.019; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Safaei J, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-S1-S6; Shan D, 2013, SCHIZOPHR RES, V144, P1, DOI 10.1016/j.schres.2012.12.019; Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainresrev.2004.04.004; Sullivan CR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123158; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Susarla BTS, 2008, NEUROCHEM INT, V52, P709, DOI 10.1016/j.neuint.2007.08.020; Tan ZJ, 2013, STROKE, V44, P3490, DOI 10.1161/STROKEAHA.113.002411; Toker Alex, 2014, Advances in Biological Regulation, V55, P28, DOI 10.1016/j.jbior.2014.04.001; Tzingounis AV, 2007, NAT REV NEUROSCI, V8, P935, DOI 10.1038/nrn2274; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Underhill SM, 2015, J NEUROSCI, V35, P5260, DOI 10.1523/JNEUROSCI.4365-14.2015; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Velasco I, 1996, J NEUROSCI RES, V44, P551, DOI 10.1002/(SICI)1097-4547(19960615)44:6<551::AID-JNR5>3.0.CO;2-A; WHITTAKER VP, 1988, J NEUROCHEM, V50, P324, DOI 10.1111/j.1471-4159.1988.tb13270.x; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xue Y, 2011, PROTEIN ENG DES SEL, V24, P255, DOI 10.1093/protein/gzq094; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; Zelenaia O, 2000, MOL PHARMACOL, V57, P667; Zelenaia OA, 2000, J NEUROCHEM, V75, P2252, DOI 10.1046/j.1471-4159.2000.0752252.x; Zhang C., 2014, DISCRETE DYN NAT SOC, V2014, P1, DOI DOI 10.1089/CBR.2014.1653; Zhang J, 2012, CHIN J TRAUMATOL, V15, P338, DOI 10.3760/cma.j.issn.1008-1275.2012.06.004; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhao SF, 2014, NEUROL RES, V36, P483, DOI 10.1179/1743132814Y.0000000353; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001	73	23	23	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					220	234		10.1089/neu.2015.4372			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100024	27312729	Green Published			2021-06-18	
J	Fazio, RL; Denning, JH; Denney, RL				Fazio, Rachel L.; Denning, John H.; Denney, Robert L.			TOMM Trial 1 as a performance validity indicator in a criminal forensic sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Forensic neuropsychology; malingering; performance validity; response bias; Test of Memory Malingering	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; ALBANY CONSISTENCY INDEX; RESPONSE BIAS SCALE; CLASSIFICATION ACCURACY; MENTAL-RETARDATION; COLLEGE-STUDENTS; RETENTION TRIAL; TEST FAILURE; WORD MEMORY	Objective: To determine the effectiveness of the Test of Memory Malingering Trial 1 (TOMM1) as a freestanding Performance Validity Test (PVT) as compared to the full TOMM in a criminal forensic sample. Method: Participants included 119 evaluees in a Midwestern forensic hospital. Criterion groups were formed based on passing/failing scores on other freestanding PVTs. This resulted in three groups: +MND (Malingered Neurocognitive Dysfunction), who failed two or more freestanding PVTs; possible MND (pMND), who failed one freestanding PVT; and -MND, who failed no other freestanding PVTs. All three groups were compared initially, but only+MND and -MND groups were retained for final analyses. TOMM1 performance was compared to standard TOMM performance using Receiver Operating Characteristic (ROC) analyses. Results: TOMM1 was highly predictive of the standard TOMM decision rules (AUC=.92). Overall accuracy rate for TOMM1 predicting failure on 2 PVTs was quite robust as well (AUC=.80), and TOMM139 provided acceptable diagnostic statistics (Sensitivity=.68, Specificity=.89). These results were essentially no different from the standard TOMM accuracy statistics. In addition, by adjusting for those strongly suspected of being inaccurately placed into the -MND group (e.g. false negatives), TOMM1 diagnostics slightly improved (AUC=.84) at a TOMM140 (sensitivity=.71, specificity=.94). Conclusions: Results support use of TOMM1 in a criminal forensic setting where accuracy, shorter evaluation times, and more efficient use of resources are often critical in informing legal decision-making.	[Fazio, Rachel L.] Carter Psychol Ctr, Bradenton, FL 34207 USA; [Denning, John H.] Ralph H Johnson VA Med Ctr, Charleston, SC USA; [Denning, John H.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA; [Denney, Robert L.] Neuropsychol Associates Southwest Missouri, Springfield, MO USA	Fazio, RL (corresponding author), Carter Psychol Ctr, Bradenton, FL 34207 USA.	rlfazio@gmail.com					Allen R., 1997, MANUAL COMPUTERIZED; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2015, APPL NEUROPSYCH-ADUL, V22, P147, DOI 10.1080/23279095.2014.880842; Armistead-Jehle P, 2011, APPL NEUROPSYCHOL, V18, P284, DOI 10.1080/09084282.2011.595455; Benitez A, 2011, ARCH CLIN NEUROPSYCH, V26, P184, DOI 10.1093/arclin/acr001; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Buddin WH, 2014, CLIN NEUROPSYCHOL, V28, P525, DOI 10.1080/13854046.2014.906658; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Davis JJ, 2012, ARCH CLIN NEUROPSYCH, V27, P706, DOI 10.1093/arclin/acs078; Demakis GJ, 2001, PSYCHOL ASSESSMENT, V13, P240, DOI 10.1037//1040-3590.13.2.240; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Denning JH, 2014, APPL NEUROPSYCH-ADUL, V21, P269, DOI 10.1080/23279095.2013.811076; Dennis Richard, 2008, CLIN NEUROPSYCHOLOGY, P1; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Fazio RL, 2015, ARCH CLIN NEUROPSYCH, V30, P293, DOI 10.1093/arclin/acv024; Frederick R. I., 2004, VALIDITY INDICATOR P; Frederick RI, 1998, CLIN NEUROPSYCHOL, V12, P193, DOI 10.1076/clin.12.2.193.2006; Gottfried E, 2016, ASSESSMENT, V23, P672, DOI 10.1177/1073191115599640; Graue LO, 2007, CLIN NEUROPSYCHOL, V21, P929, DOI 10.1080/13854040600932137; Green, 2004, GREENS MED SYMPTOM V; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2005, GREENS WORD MEMORY T; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P, 2011, APPL NEUROPSYCHOL, V18, P18, DOI 10.1080/09084282.2010.523365; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Gunner JH, 2012, ARCH CLIN NEUROPSYCH, V27, P1, DOI 10.1093/arclin/acr089; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heyanka DJ, 2015, ARCH CLIN NEUROPSYCH, V30, P369, DOI 10.1093/arclin/acv025; Jasinski LJ, 2011, CLIN NEUROPSYCHOL, V25, P1415, DOI 10.1080/13854046.2011.630024; Johnstone L, 2003, BRIT J CLIN PSYCHOL, V42, P303, DOI 10.1348/01446650360703401; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.2307/2333011; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kaufmann PM, 2009, CLIN NEUROPSYCHOL, V23, P1130, DOI 10.1080/13854040903107809; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P334; Larrabee G.J., 2012, FORENSIC NEUROPSYCHO; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lindstrom WA, 2009, ARCH CLIN NEUROPSYCH, V24, P659, DOI 10.1093/arclin/acp071; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; McCaffrey R. J., 2003, J FORENSIC NEUROPSYC, V3, P45, DOI [10.1300/J151v03n03_03, DOI 10.1300/J151V03N03_03]; Morgan J. E., 2009, NEUROPSYCHOLOGY MALI; Mossman D, 2012, PSYCHOL ASSESSMENT, V24, P815, DOI 10.1037/a0028195; Musso MW, 2011, ARCH CLIN NEUROPSYCH, V26, P756, DOI 10.1093/arclin/acr078; Nelson N. W., 2013, MILD TRAUMATIC BRAIN, P119; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rey A., 1958, LEXAMEN CLINIQUE PSY; Robles L., 2015, J CLIN EXPT NEUROPSY, P1; Rogers R., 1992, COMMUNICATION; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ruocco AC, 2008, CLIN NEUROPSYCHOL, V22, P547, DOI 10.1080/13854040701336444; Salazar X. F., 2007, ASSESSMENT FEIGNED C, P405; Schroeder RW, 2013, ARCH CLIN NEUROPSYCH, V28, P21, DOI 10.1093/arclin/acs094; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick D., 1997, VICTORIA SYMPTOM VAL; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Sollman MJ, 2010, PSYCHOL ASSESSMENT, V22, P325, DOI 10.1037/a0018857; Stenclik JH, 2013, APPL NEUROPSYCH-ADUL, V20, P243, DOI 10.1080/09084282.2012.704603; Strutt AM, 2012, BRAIN INJURY, V26, P853, DOI 10.3109/02699052.2012.655366; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tarescavage AM, 2013, CLIN NEUROPSYCHOL, V27, P313, DOI 10.1080/13854046.2012.744099; Tombaugh T. N., 2002, DETECTION RESPONSE B, P69; Tombaugh TN, 1996, TEST MEMORY MALINGER; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481; Whiteside DM, 2009, CLIN NEUROPSYCHOL, V23, P523, DOI 10.1080/13854040802389169; Whitney KA, 2013, ARCH CLIN NEUROPSYCH, V28, P222, DOI 10.1093/arclin/act012; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730	78	23	23	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	1					251	267		10.1080/13854046.2016.1213316			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EK2VR	WOS:000393785300016	27456971				2021-06-18	
J	Janak, JC; Cooper, DB; Bowles, AO; Alamgir, AH; Cooper, SP; Gabriel, KP; Perez, A; Orman, JA				Janak, Jud C.; Cooper, Douglas B.; Bowles, Amy O.; Alamgir, Abul H.; Cooper, Sharon P.; Gabriel, Kelley P.; Perez, Adriana; Orman, Jean A.			Completion of Multidisciplinary Treatment for Persistent Postconcussive Symptoms Is Associated With Reduced Symptom Burden	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast injuries; mild traumatic brain injury; military personnel; posttraumatic stress disorder; rehabilitation; treatment	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILITARY SERVICE MEMBERS; GOOD-OLD-DAYS; OPERATION IRAQI FREEDOM; MILD TBI; COMBAT VETERANS; PSYCHOMETRIC PROPERTIES; COMPENSATION SEEKING; NATIONAL-GUARD	Objective: To investigate the pre- to posttreatment changes in both posttraumatic stress disorder (PTSD) and persistent postconcussive symptoms (PPCSs). Setting and Participants: We studied 257 active-duty patients with a history of mild traumatic brain injury (mTBI) who completed multidisciplinary outpatient treatment at Brooke Army Medical Center TBI Clinic from 2008 to 2013. This treatment program included cognitive rehabilitation; vestibular interventions; headache management; and integrated behavioral healthcare to address co-occurring psychiatric conditions such as PTSD, depression, and sleep disturbance. Design: A 1-group; preexperimental, pre- to posttreatment study. Main Measures: The Neurobehavioral Symptom Inventory (NSI) was used to assess PPCSs, and the PTSD Checklist-Military Version (PCL-M) was used to asses PTSD symptoms. Results: Global PPCS resolution (mean NSI: 35.0 pre vs 23.8 post; P < .0001; d = 0.72) and PTSD symptom resolution (mean PCL-M: 43.2 pre vs 37.7 post; P < .0001; d = 0.34) were statistically significant. Compared with those with only mTBI, patients with mTBI and PTSD reported greater global PPCS impairment both pretreatment (mean NSI: 48.7 vs 27.9; P < .0001) and posttreatment (mean NSI: 36.2 vs 17.4; P < .0001). After adjusting for pretreatment NSI scores, patients with comorbid PTSD reported poorer PPCS resolution than those with mTBI alone (mean NSI: 27.9 pre vs 21.7 post; P = .0009). Conclusion: We found a reduction in both self-reported PPCSs and PTSD symptoms; however, future studies are needed to identify specific components of care associated with symptom reduction.	[Janak, Jud C.] US Army, Oak Ridge Inst Sci & Educ, San Antonio, TX USA; [Cooper, Douglas B.] Def & Vet Brain Injury Ctr, San Antonio, TX USA; [Bowles, Amy O.] Brooke Army Med Ctr, San Antonio, TX USA; [Orman, Jean A.] US Army, Inst Surg Res, Stat & Epidemiol, San Antonio, TX USA; [Cooper, Douglas B.; Alamgir, Abul H.] Univ Texas San Antonio, Sch Publ Hlth San Antonio, San Antonio, TX USA; [Gabriel, Kelley P.; Perez, Adriana] Univ Texas Austin, Sch Publ Hlth Austin, Austin, TX 78712 USA	Janak, JC (corresponding author), US Army, Inst Surg Res, Oak Ridge Inst Sci & Educ, 3698 Chambers Pass,Bldg 3611, San Antonio, TX 78234 USA.	judson.c.janak.vol@mail.mil		Perez, Adriana/0000-0002-6859-9916	National Institute of Occupational and Environmental Health/Centers for Disease Control and Prevention [5T42OH008421]; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [T42OH008421] Funding Source: NIH RePORTER	Support and funding for this study was provided by grant No. 5T42OH008421 from the National Institute of Occupational and Environmental Health/Centers for Disease Control and Prevention to the Southwest Center for Occupational and Environmental Health. In addition, this project was supported in part by an appointment to the Internship/Research Participation Program at the United States Army Institute of Surgical Research, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the Environmental Protection Agency. The authors thank the staff at Brooke Army Medical Center Traumatic Brain Injury Clinic for their hard work and dedication. The authors also thank both the service members and their families for their service to the United States.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cernich AN, 2012, J HEAD TRAUMA REHAB, V27, P253, DOI 10.1097/HTR.0b013e3182585cd5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Department of Defense, 2015, DOD WORLDW NUMB TBI; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 2003, PSYCHIATR SERV, V54, P84, DOI 10.1176/appi.ps.54.1.84; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2014, JAMA-J AM MED ASSOC, V312, P1685, DOI 10.1001/jama.2014.6670; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge C, 2015, JAMA INTERN MED, V175, P53, DOI 10.1001/jamainternmed.2014.3375; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jones ML, 2013, ARCH PHYS MED REHAB, V94, pS49, DOI 10.1016/j.apmr.2012.04.038; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Management of Concussion/ mTBI Working Group, 2009, J REHABIL RES DEV, V46, pCP1; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Marshall S, 2012, CAN FAM PHYSICIAN, V58, pE128; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Moye L. A., 2006, STAT REASONING MED I; National Center for PTSD US Department of Veterans Affairs, 2014, US PTSD CHECKL DSM 4; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rosner B, 2010, FUNDAMENTALS BIOSTAT; Ryan PB, 2011, BRAIN INJURY, V25, P1019, DOI 10.3109/02699052.2011.597044; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Whyte J, 2009, NEUROPSYCHOL REHABIL, V19, P807, DOI 10.1080/09602010903031146; Wicklund Alissa H, 2013, Surg Neurol Int, V4, P50, DOI 10.4103/2152-7806.110150; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Yang CC, 2014, J CLIN EXP NEUROPSYC, V36, P399, DOI 10.1080/13803395.2014.903899	74	23	24	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2017	32	1					1	15		10.1097/HTR.0000000000000202			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EI2GH	WOS:000392304400001	26709579				2021-06-18	
J	Martindale, SL; Morissette, SB; Rowland, JA; Dolan, SL				Martindale, Sarah L.; Morissette, Sandra B.; Rowland, Jared A.; Dolan, Sara L.			Sleep Quality Affects Cognitive Functioning in Returning Combat Veterans Beyond Combat Exposure, PTSD, and Mild TBI History	NEUROPSYCHOLOGY			English	Article						neuropsychological tests; veteran; posttraumatic stress disorder; traumatic brain injury; executive function	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL OUTCOMES; PERFORMANCE VALIDITY; BEHAVIORAL THERAPY; IRAQ-WAR; DEPRIVATION; DEPLOYMENT; DEFICITS; DISTURBANCES	Objective: The purpose of this study was to determine how sleep quality affects cognitive functioning in returning combat veterans after accounting for effects of combat exposure, posttraumatic stress disorder (PTSD), and mild traumatic brain injury (mTBI) history. Method: This was a cross-sectional assessment study evaluating combat exposure, PTSD, mTBI history, sleep quality, and neuropsychological functioning. One hundred and nine eligible male Iraq/Afghanistan combat veterans completed an assessment consisting of a structured clinical interview, neuropsychological battery, and self-report measures. Results: Using partial least squares structural equation modeling, combat experiences and mTBI history were not directly associated with sleep quality. PTSD was directly associated with sleep quality, which contributed to deficits in neuropsychological functioning independently of and in addition to combat experiences, PTSD, and mTBI history. Combat experiences and PTSD were differentially associated with motor speed. Conclusions: Sleep affected cognitive function independently of combat experiences, PTSD, and mTBI history. Sleep quality also contributed to cognitive deficits beyond effects of PTSD. An evaluation of sleep quality may be a useful point of clinical intervention in combat veterans with cognitive complaints. Improving sleep quality could alleviate cognitive complaints, improving veterans' ability to engage in treatment.	[Martindale, Sarah L.; Rowland, Jared A.] WG Bill Hefner Vet Affairs Med Ctr, Mid Atlantic Mental Illness Res Educ & Clin Ctr, 1601 Brenner Ave, Salisbury, NC 28144 USA; [Martindale, Sarah L.; Rowland, Jared A.] WG Bill Hefner Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, 1601 Brenner Ave, Salisbury, NC 28144 USA; [Martindale, Sarah L.] Wake Forest Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC USA; [Morissette, Sandra B.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX 78249 USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Neurobiol & Anat, Winston Salem, NC USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Psychiat, Winston Salem, NC USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Behav Med, Winston Salem, NC USA; [Dolan, Sara L.] Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA	Martindale, SL (corresponding author), WG Bill Hefner Vet Affairs Med Ctr, Mid Atlantic Mental Illness Res Educ & Clin Ctr, 1601 Brenner Ave, Salisbury, NC 28144 USA.; Martindale, SL (corresponding author), WG Bill Hefner Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, 1601 Brenner Ave, Salisbury, NC 28144 USA.	sarah.martindale-supak@va.gov	Rowland, Jared A./AAN-3030-2021; Martindale, Sarah L/O-8553-2018	Rowland, Jared A./0000-0002-3655-3411; Martindale, Sarah L/0000-0002-0059-3454	American Psychological Association; VA VISN 17 Center of Excellence for Research on Returning War Veterans; Psychology and Neuroscience Department at Baylor University; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness, Research, and TreatmentUS Department of Veterans Affairs; W. G. "Bill" Hefner Veterans Affairs Medical Center; VA Mid-Atlantic Mental Illness Research Education and Clinical Center	This research was supported in part by a grant to Sarah L. Martindale from the American Psychological Association, funding from the VA VISN 17 Center of Excellence for Research on Returning War Veterans where the research was partially conducted, and a Research Award from the Psychology and Neuroscience Department at Baylor University, where the research was also partially conducted. This research is also supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness, Research, and Treatment, the W. G. "Bill" Hefner Veterans Affairs Medical Center, and the VA Mid-Atlantic Mental Illness Research Education and Clinical Center. We appreciate the contributions of the veterans who participated in this study. A complete list of publications from this project is available upon request from Sarah L. Martindale at sarah.martindale-supak@va.gov. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government.	Aiken L.S., 1991, MULTIPLE REGRESSION; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Ben-David BM, 2011, J INT NEUROPSYCH SOC, V17, P354, DOI 10.1017/S135561771000175X; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Chin W.W., 2009, HDB PARTIAL LEAST SQ, P655, DOI DOI 10.1007/978-3-540-32827-8_29; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Fernandez-Mendoza J, 2010, SLEEP, V33, P459, DOI 10.1093/sleep/33.4.459; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Hair JF, 2011, J MARKET THEORY PRAC, V19, P139, DOI 10.2753/MTP1069-6679190202; Hair JF, 2014, EUR BUS REV, V26, P106, DOI 10.1108/EBR-10-2013-0128; Ho FYY, 2016, CLIN PSYCHOL REV, V43, P90, DOI 10.1016/j.cpr.2015.09.005; Jackson ML, 2011, BRAIN IMAGING BEHAV, V5, P97, DOI 10.1007/s11682-011-9115-6; Jefferson M. L., 2009, MILD TRAUMATIC BRAIN; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kertzman S, 2014, COMPR PSYCHIAT, V55, P1587, DOI 10.1016/j.comppsych.2014.05.004; Kline R. B., 2015, PRINCIPLES PRACTICE; Lucke-Wold BP, 2015, NEUROSCI BIOBEHAV R, V55, P68, DOI 10.1016/j.neubiorev.2015.04.010; Magill RA, 2003, NUTR NEUROSCI, V6, P237, DOI 10.1080/1028415031000120552; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Martin JL, 2011, CHEST, V139, P1514, DOI 10.1378/chest.10-1872; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mohlman J, 2005, BEHAV RES THER, V43, P447, DOI 10.1016/j.brat.2004.03.007; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Neylan TC, 2006, ANN NY ACAD SCI, V1071, P203, DOI 10.1196/annals.1364.015; Orr N., 2010, CHEST, V138, p704A, DOI [10.1378/chest.10975, DOI 10.1378/CHEST.10975]; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Polley M., 2012, NATL VETERANS SLEEP; Ringle C.M., 2015, SMARTPLS 3; Schwab KA, 2006, NEUROLOGY, V66, pA235; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Thompson DG, 2015, AM J GERIAT PSYCHIAT, V23, P13, DOI 10.1016/j.jagp.2014.02.001; Ulmer CS, 2012, J AGGRESS MALTREAT T, V21, P67, DOI DOI 10.1080/10926771.2012.630339; Vaishnavi S, 2010, PSYCHIAT ANN, V40, P553, DOI 10.3928/00485713-20101018-06; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2010, HANDBOOK OF MEDICAL NEUROPSYCHOLOGY: APPLICATIONS OF COGNITIVE NEUROSCIENCE, P447, DOI 10.1007/978-1-4419-1364-7_24; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Verfaellie M, 2016, J HEAD TRAUMA REHAB, V31, P309, DOI 10.1097/HTR.0000000000000197; Vogt D, 2012, DEPLOYMENT RISK RESI; Waters F, 2011, J INT NEUROPSYCH SOC, V17, P571, DOI 10.1017/S1355617711000610; Wechsler D., 2008, WECHSELER ADULT INTE; Wilson, 1991, NATL ADULT READING T; Wisdom NM, 2014, CLIN NEUROPSYCHOL, V28, P128, DOI 10.1080/13854046.2013.863977; Wrocklage KM, 2016, J INT NEUROPSYCH SOC, V22, P399, DOI 10.1017/S1355617716000059; Wu JC, 2006, NEUROPSYCHOPHARMACOL, V31, P2783, DOI 10.1038/sj.npp.1301166	58	23	23	0	15	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2017	31	1					93	104		10.1037/neu0000312			12	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	EH3WI	WOS:000391702300009	27690479				2021-06-18	
J	Reynolds, BB; Patrie, J; Henry, EJ; Goodkin, HP; Broshek, DK; Wintermark, M; Druzgal, TJ				Reynolds, Bryson B.; Patrie, James; Henry, Erich J.; Goodkin, Howard P.; Broshek, Donna K.; Wintermark, Max; Druzgal, T. Jason			Comparative Analysis of Head Impact in Contact and Collision Sports	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; epidemiology; head trauma; pediatric brain injury; subconcussion	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL FOOTBALL; CHRONIC TRAUMATIC ENCEPHALOPATHY; VIDEO INCIDENT ANALYSIS; WHITE-MATTER INTEGRITY; PROFESSIONAL FOOTBALL; BRAIN-INJURY; UNITED-STATES; IN-VIVO; CONCUSSION	As concerns about head impact in American football have grown, similar concerns have started to extend to other sports thought to experience less head impact, such as soccer and lacrosse. However, the amount of head impact experienced in soccer and lacrosse is relatively unknown, particularly compared with the substantial amount of data from football. This pilot study quantifies and compares head impact from four different types of sports teams: college football, high school football, college soccer, and college lacrosse. During the 2013 and 2014 seasons, 61 players wore mastoid patch accelerometers to quantify head impact during official athletic events (i.e., practices and games). In both practices and games, college football players experienced the most or second-most impacts per athletic event, highest average peak resultant linear and rotational acceleration per impact, and highest cumulative linear and rotational acceleration per athletic event. For average peak resultant linear and rotational acceleration per individual impact, college football was followed by high school football, then college lacrosse, and then college soccer, with similar trends in both practices and games. In the four teams under study, college football players experienced a categorically higher burden of head impact. However, for cumulative impact burden, the high school football cohort was not significantly different from the college soccer cohort. The results suggest that head impact in sport substantially varies by both the type of sport (football vs. soccer vs. lacrosse) and level of play (college vs. high school).	[Reynolds, Bryson B.; Henry, Erich J.; Druzgal, T. Jason] Univ Virginia Hlth Syst, Div Neuroradiol, Dept Radiol & Med Imaging, Box 800170, Charlottesville, VA 22908 USA; [Patrie, James] Univ Virginia Hlth Syst, Dept Publ Hlth Sci, Charlottesville, VA USA; [Goodkin, Howard P.] Univ Virginia Hlth Syst, Dept Neurol, Charlottesville, VA USA; [Goodkin, Howard P.] Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA USA; [Broshek, Donna K.] Univ Virginia Hlth Syst, Neurocognit Assessment Lab, Charlottesville, VA USA; [Wintermark, Max] Stanford Univ, Dept Neuroradiol, Stanford, CA 94305 USA	Druzgal, TJ (corresponding author), Univ Virginia Hlth Syst, Div Neuroradiol, Dept Radiol & Med Imaging, Box 800170, Charlottesville, VA 22908 USA.	tjd4m@virginia.edu		Reynolds, Bryson/0000-0001-9196-1461; Druzgal, Jason/0000-0001-7240-9487; Goodkin, Howard/0000-0003-0528-4949	University of Virginia Health System; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2 T32 GM 8328-21]; University of Virginia Department of Radiology and Medical Imaging; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB001628] Funding Source: NIH RePORTER	We thank the athletes, trainers, and coaches of the University of Virginia and football, men's lacrosse, and men's soccer teams and the athletes, trainers, and coaches of St. Anne's Belfield football team for their invaluable assistance in collecting these data. We are also grateful for the financial support that was provided by a University of Virginia Health System Research Award, NIH 2 T32 GM 8328-21, and the University of Virginia Department of Radiology and Medical Imaging. Access to the xPatch impact sensors was obtained through a research agreement with X2 Biosystems.	Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Caswell SV, 2012, AM J SPORT MED, V40, P756, DOI 10.1177/0363546512436647; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Crisco JJ, 2015, J APPL BIOMECH, V31, P122, DOI [10.1123/jab.2014-0102, 10.1123/JAB.2014-0102]; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cummiskey B., 2016, J SPORT ENG TECH; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Huber P.J., 1967, P 5 BERK S MATH STAT, V1; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Johnson BD, 2014, CONCUSSIONS ATHLETIC, P331, DOI DOI 10.1007/978-1-4939-0295-8_19; Kerr Z. Y., 2015, OJSM, V3; King D, 2016, SPORTS MED, V46, P151, DOI 10.1007/s40279-015-0423-7; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lynall RC, 2016, MED SCI SPORT EXER, V48, P1772, DOI 10.1249/MSS.0000000000000951; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Svaldi D. O., 2016, BRAIN IMAGING BEHAV; Swartz EE, 2015, J ATHL TRAINING, V50, P1219, DOI 10.4085/1062-6050-51.1.06; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	74	23	23	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					38	49		10.1089/neu.2015.4308			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100006	27541183	Green Published			2021-06-18	
J	Shen, WB; Anastasiadis, P; Nguyen, B; Yarnell, D; Yarowsky, PJ; Frenkel, V; Fishman, PS				Shen, Wei-Bin; Anastasiadis, Pavlos; Nguyen, Ben; Yarnell, Deborah; Yarowsky, Paul J.; Frenkel, Victor; Fishman, Paul S.			Magnetic Enhancement of Stem Cell-Targeted Delivery into the Brain Following MR-Guided Focused Ultrasound for Opening the Blood-Brain Barrier	CELL TRANSPLANTATION			English	Article						blood-brain barrier; magnetic resonance imaging; focused ultrasound; human neural progenitor cells; magnetic attraction	IN-VIVO; DRUG-DELIVERY; FUNCTIONAL BENEFIT; CONTRAST AGENT; TUMOR-MODEL; RHODAMINE-B; DISRUPTION; RETENTION; THERAPY; MICROBUBBLES	Focused ultrasound (FUS)-mediated blood-brain barrier disruption (BBBD) can enable even large therapeutics such as stem cells to enter the brain from the bloodstream. However, the efficiency is relatively low. Our previous study showed that human neural progenitor cells (hNPCs) loaded with superparamagnetic iron oxide nanoparticles (SPIONs) in culture were attracted by an external magnetic field. In vivo, enhanced brain retention was observed near a magnet mounted on the skull in a rat model of traumatic brain injury, where BBBD also occurs. The goal of the current study was to determine whether magnetic attraction of SPION-loaded hNPCs would also enhance their retention in the brain after FUS-mediated BBBD. A small animal magnetic resonance imaging (MRI)-guided FUS system operating at 1.5 MHz was used to treat rats (similar to 120 g) without tissue damage or hemorrhage. Evidence of successful BBBD was validated with both radiologic enhancement of gadolinium on postsonication TI MRI and whole brain section visualization of Evans blue dye. The procedure was then combined with the application of a powerful magnet to the head directly after intravenous injection of the hNPCs. Validation of cells within the brain was performed by staining with Perls' Prussian blue for iron and by immunohistochemistry with a human-specific antigen. By injecting equal numbers of iron oxide (SPIONs) and noniron oxide nanoparticles-loaded hNPCs, each labeled with a different fluorophore, we found significantly greater numbers of SPIONs-loaded cells retained in the brain at the site of BBBD as compared to noniron loaded cells. This result was most pronounced in regions of the brain closest to the skull (dorsal cortex) in proximity to the magnet surface. A more powerful magnet and a Halbach magnetic array resulted in more effective retention of SPION-labeled cells in even deeper brain regions such as the striatum and ventral cortex. There, up to 90% of hNPCs observed contained SPIONs compared to 60% to 70% with the less powerful magnet. Fewer cells were observed at 24 h posttreatment compared to 2 h (primarily in the dorsal cortex). These results demonstrate that magnetic attraction can substantially enhance the retention of stem cells after FUS-mediated BBBD. This procedure could provide a safer and less invasive approach for delivering stem cells to the brain, compared to direct intracranial injections, substantially reducing the risk of bleeding and infection.	[Shen, Wei-Bin; Yarowsky, Paul J.] Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA; [Anastasiadis, Pavlos; Nguyen, Ben; Frenkel, Victor] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Yarnell, Deborah; Fishman, Paul S.] VA Maryland Healthcare Syst, Neurol Serv, 10 North Greene St, Baltimore, MD 21201 USA; [Yarowsky, Paul J.] VA Maryland Healthcare Syst, Res Serv, Baltimore, MD USA; [Frenkel, Victor] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Fishman, Paul S.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA	Fishman, PS (corresponding author), VA Maryland Healthcare Syst, Neurol Serv, 10 North Greene St, Baltimore, MD 21201 USA.	paul.fishman@va.gov	Anastasiadis, Pavlos/B-3685-2011	Anastasiadis, Pavlos/0000-0002-0230-7925	Focused Ultrasound Surgery Foundation; US Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA154274] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This study was supported by a research grant from the Focused Ultrasound Surgery Foundation (P.S.F.) and to the US Department of Veterans Affairs (P.S.F.).	Alkins R, 2013, CANCER RES, V73, P1892, DOI 10.1158/0008-5472.CAN-12-2609; Arbab AS, 2006, STEM CELLS, V24, P671, DOI 10.1634/stemcells.2005-0017; Arbab AS, 2004, HUM GENE THER, V15, P351, DOI 10.1089/104303404322959506; Barnsley LC, 2015, PHYS MED BIOL, V60, P8303, DOI 10.1088/0031-9155/60/21/8303; Berman SMC, 2011, METHODS MOL BIOL, V711, P435, DOI 10.1007/978-1-61737-992-5_22; Burgess A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027877; Chatterjee S, 2015, AM J PHYSIOL-HEART C, V308, pH1451, DOI 10.1152/ajpheart.00105.2015; Chaudeurge A, 2012, CELL TRANSPLANT, V21, P679, DOI 10.3727/096368911X612440; Cheng K, 2012, CELL TRANSPLANT, V21, P1121, DOI 10.3727/096368911X627381; Cheng K, 2010, CIRC RES, V106, P1570, DOI 10.1161/CIRCRESAHA.109.212589; Chopra R, 2010, ACS CHEM NEUROSCI, V1, P391, DOI 10.1021/cn9000445; Connell JJ, 2015, REGEN MED, V10, P757, DOI 10.2217/rme.15.36; Crake C, 2016, ULTRASOUND MED BIOL, V42, P3022, DOI 10.1016/j.ultrasmedbio.2016.08.002; Deng JM, 2012, J MOL NEUROSCI, V46, P677, DOI 10.1007/s12031-011-9629-9; Dervishi E, 2013, INT J HYPERTHER, V29, P598, DOI 10.3109/02656736.2013.820357; Etame AB, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2011.10.FOCUS11252; Fan CH, 2016, THERANOSTICS, V6, P1542, DOI 10.7150/thno.15297; Gonzalez-Molina J, 2012, J R SOC INTERFACE, V9, P3008, DOI 10.1098/rsif.2012.0316; HALBACH K, 1980, NUCL INSTRUM METHODS, V169, P1, DOI 10.1016/0029-554X(80)90094-4; Hersh DS, 2016, CURR PHARM DESIGN, V22, P1177, DOI 10.2174/1381612822666151221150733; Kinoshita M, 2006, P NATL ACAD SCI USA, V103, P11719, DOI 10.1073/pnas.0604318103; Kyrtatos PG, 2009, JACC-CARDIOVASC INTE, V2, P794, DOI 10.1016/j.jcin.2009.05.014; Li QY, 2013, BIOMATERIALS, V34, P4982, DOI 10.1016/j.biomaterials.2013.03.030; Luciani A, 2009, EUR RADIOL, V19, P1087, DOI 10.1007/s00330-008-1262-9; Magnin R, 2015, J THER ULTRASOUND, V3, DOI 10.1186/s40349-015-0044-5; Marty B, 2012, J CEREBR BLOOD F MET, V32, P1948, DOI 10.1038/jcbfm.2012.100; McDannold N, 2006, PHYS MED BIOL, V51, P793, DOI 10.1088/0031-9155/51/4/003; Mcdannold N, 2008, ULTRASOUND MED BIOL, V34, P930, DOI 10.1016/j.ultrasmedbio.2007.11.009; McDannold N, 2008, ULTRASOUND MED BIOL, V34, P834, DOI 10.1016/j.ultrasmedbio.2007.10.016; Muthana M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9009; Nance E, 2014, J CONTROL RELEASE, V189, P123, DOI 10.1016/j.jconrel.2014.06.031; Oshima S, 2014, J ORTHOP SCI, V19, P478, DOI 10.1007/s00776-014-0548-9; Pardridge WM, 2012, METHOD ENZYMOL, V503, P269, DOI 10.1016/B978-0-12-396962-0.00011-2; Ranjan A, 2012, J CONTROL RELEASE, V158, P487, DOI 10.1016/j.jconrel.2011.12.011; Riegler J, 2011, MED PHYS, V38, P3932, DOI 10.1118/1.3593363; Riegler J, 2010, BIOMATERIALS, V31, P5366, DOI 10.1016/j.biomaterials.2010.03.032; Samiotaki G, 2013, IEEE T ULTRASON FERR, V60, P2257, DOI 10.1109/TUFFC.2013.6644731; She WH, 2016, HONG KONG MED J, V22, P382, DOI 10.12809/hkmj154755; Sheikov N, 2004, ULTRASOUND MED BIOL, V30, P979, DOI 10.1016/j.ultrasmedbio.2004.04.010; Sheikov N, 2008, ULTRASOUND MED BIOL, V34, P1093, DOI 10.1016/j.ultrasmedbio.2007.12.015; Shen WB, 2016, CONTRAST MEDIA MOL I, V11, P222, DOI 10.1002/cmmi.1684; Shen WB, 2016, CELL TRANSPLANT, V25, P1085, DOI 10.3727/096368915X689550; Shen WB, 2013, INT J NANOMED, V8, P4593, DOI 10.2147/IJN.S53012; Shen YL, 2015, CELL TRANSPLANT, V24, P1981, DOI 10.3727/096368914X685302; Silvestrini MT, 2013, STEREOT FUNCT NEUROS, V91, P92, DOI 10.1159/000343213; Song M, 2010, HUM GENE THER, V21, P603, DOI 10.1089/hum.2009.144; Tebebi PA, 2015, STEM CELLS, V33, P1173, DOI 10.1002/stem.1927; Vanecek V, 2012, INT J NANOMED, V7, P3719, DOI 10.2147/IJN.S32824; Wang F, 2012, ADV MATER RES-SWITZ, V411, P7, DOI 10.4028/www.scientific.net/AMR.411.7; Wei KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058995; Wintermark M, 2014, AM J NEURORADIOL, V35, P891, DOI 10.3174/ajnr.A3808; Ziadloo A, 2012, STEM CELLS, V30, P1216, DOI 10.1002/stem.1099	52	23	25	1	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2017	26	7					1235	1246		10.1177/0963689717715824			12	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	EZ4GO	WOS:000404671800011	28933214	DOAJ Gold, Green Published			2021-06-18	
J	Stazyk, K; DeMatteo, C; Moll, S; Missiuna, C				Stazyk, Kathy; DeMatteo, Carol; Moll, Sandra; Missiuna, Cheryl			Depression in youth recovering from concussion: Correlates and predictors	BRAIN INJURY			English	Article						Child; concussion; mild traumatic brain injury; post-concussion syndrome; depression and anxiety; children's depression inventory-2	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; EMERGENCY-DEPARTMENT; MAJOR DEPRESSION; CHILDREN; ADOLESCENTS; SYMPTOMS; PREVALENCE; SCHOOL; RECOMMENDATIONS	Objectives: Although depression can be a serious consequence of concussion, little is known about the factors that predict depression and concussion recovery outcomes in children. The purpose of this study was to explore the risk and possible predictors of developing significant depressive symptoms in children recovering from concussion.Methods: A prospective cohort study was conducted in a paediatric tertiary care clinic. Depression data were collected from 92 children using the Children's Depression Inventory-2 (CDI-2) screening tool. Correlations, t-tests and logistic regression were used to examine the associations between depression scores and demographic as well as injury-related factors.Results: Depressive symptoms were found in 22% of the children (T score on CDI-2 >65). Children with evidence of depressive symptomatology had significantly higher mean post-concussive symptom inventory (PCSI) scores in recovery (p = 0.004) than children who were not depressed. Variables of i) Sex; ii) hospital admission; iii) number of head injuries; iv) post-concussion symptom score and v) experience of prolonged symptoms were predictive of clinically significant CDI T scores, explaining 36% of the variation in the binary logistic model.Conclusion: Depression is commonly reported in this subset of children. High post-concussive symptom scores and hospital admission were strong predictors of depression. Screening for depression should be standard practice in concussion management in children and youth.	[Stazyk, Kathy; DeMatteo, Carol; Moll, Sandra; Missiuna, Cheryl] McMaster Univ, Sch Rehabil Sci, 1400 Main St West,IAHS 403, Hamilton, ON L8S 1C7, Canada; [Stazyk, Kathy; DeMatteo, Carol; Missiuna, Cheryl] McMaster Univ, CanChild Ctr Childhood Disabil Res, Hamilton, ON, Canada	Stazyk, K (corresponding author), McMaster Univ, Sch Rehabil Sci, 1400 Main St West,IAHS 403, Hamilton, ON L8S 1C7, Canada.	stazyk@mcmaster.ca	Moll, Sandra/AAF-5742-2020				Ahmoi C, 1999, DEPRESSIVE DISORDERS, P69; Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Allgaier AK, 2012, J PSYCHOSOM RES, V73, P369, DOI 10.1016/j.jpsychores.2012.08.016; [Anonymous], 2006, IMM POSTCONCUSSION A; Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Avenevoli S., 2008, HDB DEPRESSION CHILD; Avenevoli S, 2015, J AM ACAD CHILD PSY, V54, P37, DOI 10.1016/j.jaac.2014.10.010; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bodin D, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P9, DOI 10.1007/978-0-387-89545-1_2; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carr A, 2008, DEV NEUROREHABIL, V11, P3, DOI 10.1080/17518420701536095; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Duffy A, 2012, CONCUSSIONS RUIN QUA; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Garber J, 2010, VULNERABILITY PSYCHO, P189; Garland J, 2002, BC MED J, V44, P469; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia G.A., 2006, ACUTE CONCUSSION EVA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hankin BL, 2015, J ABNORM PSYCHOL, V124, P803, DOI 10.1037/abn0000089; Hankin BL, 2006, EPILEPSY BEHAV, V8, P102, DOI 10.1016/j.yebeh.2005.10.012; IBM, 2013, IBM SPSS STAT WINDOW; Ilie G, 2014, BULLYING OTHER CONDU, V9, P10, DOI DOI 10.1371/J0URNAL.P0NE.0094936; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kessler RC, 2001, BIOL PSYCHIAT, V49, P1002, DOI 10.1016/S0006-3223(01)01129-5; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Klein DN, 2009, J AM ACAD CHILD PSY, V48, P703, DOI 10.1097/CHI.0b013e3181a56606; Kovacs M., 2011, CHILDRENS DEPRESSION; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; McCrory P, SCAT3 INTERNET; MONROE SM, 1991, PSYCHOL BULL, V110, P406, DOI 10.1037/0033-2909.110.3.406; National Institute of Mental Health, 2014, MAJ DEPR SD INT; Ontario Children's Mental Health, 2001, EV BAS PRACT DEPR CH; Parsons JT, 2013, BRIT J SPORT MED, V47, pe1; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Public Health Agency of Canada, 2011, CHIEF PUBL HLTH OFF; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Smyth K, 2014, DEV MED CHILD NEUROL, V56, P73, DOI 10.1111/dmcn.12263; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	64	23	23	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	5					631	638		10.1080/02699052.2017.1283533			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EV8OA	WOS:000402039900008	28326857				2021-06-18	
J	Clark, JM; Post, A; Hoshizaki, TB; Gilchrist, MD				Clark, J. Michio; Post, Andrew; Hoshizaki, T. Blaine; Gilchrist, Michael D.			Protective Capacity of Ice Hockey Helmets against Different Impact Events	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Ice hockey; Helmet; Concussion; Impact biomechanics; Finite element modeling	INJURY SURVEILLANCE SYSTEM; HEAD IMPACT; INTRACRANIAL-PRESSURE; PROFESSIONAL FOOTBALL; DESCRIPTIVE EPIDEMIOLOGY; ACCIDENT RECONSTRUCTION; ANGULAR ACCELERATION; VIDEO ANALYSIS; BRAIN-INJURY; LEAGUE NHL	In ice hockey, concussions can occur as a result of many different types of impact events, however hockey helmets are certified using a single injury scenario, involving drop tests to a rigid surface. The purpose of this study is to measure the protective capacity of ice hockey helmets for different impact events in ice hockey. A helmeted and unhelmeted Hybrid III headform were impacted simulating falls, elbow, shoulder and puck impacts in ice hockey. Linear and rotational acceleration and maximum principal strain (MPS) were measured. A comparison of helmeted and unhelmeted impacts found significant differences existed in most conditions (p < 0.05), however some shoulder and puck impacts showed no significant difference (p > 0.05). Impacts to the ice hockey helmet tested resulted in acceleration levels below reported ranges of concussion and TBI for falls up to 5 m/s, elbow collisions, and low velocity puck impacts but not for shoulder collisions or high velocity puck impacts and falls. The helmet tested reduced MPS below reported ranges of concussion and TBI for falls up to 5 m/s but not for the other impact events across all velocities and locations. This suggests that the ice hockey helmet tested is unable to reduce engineering parameters below reported ranges of concussion and TBI for impact conditions which do not represent a drop against a rigid surface.	[Clark, J. Michio; Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland; [Clark, J. Michio; Post, Andrew; Hoshizaki, T. Blaine; Gilchrist, Michael D.] Univ Ottawa, Sch Human Kinet, 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada; [Post, Andrew] Childrens Hosp Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada	Clark, JM (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland.; Clark, JM (corresponding author), Univ Ottawa, Sch Human Kinet, 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	michio.clark@ucd.ie					Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Canadian Standards Association, 2009, Z262109 CAN STAND AS; Coulson NR, 2009, J ASTM INT, V6, P1; Delaney JS, 2014, CLIN J SPORT MED, V24, P233, DOI 10.1097/JSM.0000000000000017; DENG YC, 1989, ACCIDENT ANAL PREV, V21, P85, DOI 10.1016/0001-4575(89)90051-1; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Fahlstedt M, 2012, P INT RES COUNC BIOM, V40, P787; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A, 1987, P 31 STAPP CAR CRASH, DOI [10.4271/872197, DOI 10.4271/872197]; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Hardy W. N., 2001, STAPP CAR CRASH J, V51, P17; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Holbourn AHS, 1943, LANCET, V2, P438; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki T Blaine, 2014, Neurosurgery, V75 Suppl 4, pS136, DOI 10.1227/NEU.0000000000000496; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Karton CM, 2014, AM SOC TEST MATER, V1552, P23, DOI 10.1520/STP155220120175; Kendall M., 2012, INT RES COUNC BIOM I, P430, DOI DOI 10.1016/J.JECP.2012.07.001; Kendall M., 2012, J SPORTS ENG TECHNOL, V0, P1; Kendall M, 2014, AM SOC TEST MATER, V1552, P142, DOI 10.1520/STP155220120150; Kleiven S, 2002, P IRCOBI, P161; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller RT, 1998, P 42 STAPP CAR CRASH; Milne G., 2013, P IRC 13 90 IRCOBI C, V33, P735; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Newman J, 2000, P INT RES COUNC BIOM; Nobes KJ, 2003, CAN J APPL PHYSIOL, V28, P1, DOI 10.1139/h03-001; Nusholtz G.S., 1984, 841657 SAE, P41; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ono K., 1980, P 24 STAPP CAR CRASH; Ouckama R., 2014, IRCOBI P, P62; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pearsall D.J., 1999, SPORTS ENG, V2, DOI [10.1046/j.1460-2687.1999.00018.x, DOI 10.1046/J.1460-2687.1999.00018.X]; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A., 2013, J NEUROSURG, V1-9, P1; Post A., 2015, NEUROSURGERY, V51, P325; Post A, 2012, J SPORTS ENG TECHNOL, P1; Post A., 2013, THESIS; Post A., 2011, COMPUT METHOD BIOMEC, P1; Post A, 2015, ACCIDENT ANAL PREV, V79, P33, DOI 10.1016/j.aap.2015.03.017; Post A, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028983; Post A, 2015, J MECH BEHAV BIOMED, V41, P325, DOI 10.1016/j.jmbbm.2014.07.034; Post A, 2014, J BIOMECH, V47, P1074, DOI 10.1016/j.jbiomech.2013.12.026; Post A, 2012, TRAUMA, V14, P327, DOI 10.1177/1460408612446573; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; Rousseau P, 2014, AM SOC TEST MATER, V1552, P196, DOI 10.1520/STP155220120159; Rousseau P, 2009, P I MECH ENG P-J SPO, V223, P159, DOI 10.1243/17543371JSET36; Rousseau P., 2009, J ASTM INT, V6, P1; Rousseau P., 2014, THESIS; Rousseau P, 2015, SPORT BIOMECH, V14, P57, DOI 10.1080/14763141.2015.1025236; Rowson B., 2015, ANN BIOMED IN PRESS, P1; Roy B., 1975, 5 INT C BIOM INT C B; Ruan J, 1994, THESIS; Seemann M. R., 1986, P 30 STAPP CAR CRASH, V30, P291; Smith TA, 2015, SPORTS ENG, V18, P165, DOI 10.1007/s12283-015-0175-5; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Walsh E. S., 2012, ASTM S MECH CONC SPO; Walsh E. S., 2012, J SPORTS ENG, P1; Wayne M., 2014, MECH CONCUSSION SPOR; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R., 1992, P INT IRCOBI C BIOM, P179; Wu T.C., 2003, SPORTS ENG, V6, DOI [10.1007/BF02844158, DOI 10.1007/BF02844158]; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488; Zhou C, 1995, 39 STAPP CAR CRASH C	88	23	23	0	27	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2016	44	12					3693	3704		10.1007/s10439-016-1686-3			12	Engineering, Biomedical	Engineering	EC4MB	WOS:000388103900021	27384941				2021-06-18	
J	Yang, LY; Greig, NH; Huang, YN; Hsieh, TH; Tweedie, D; Yu, QS; Hoffer, BJ; Luo, Y; Kao, YC; Wang, JY				Yang, Ling-Yu; Greig, Nigel H.; Huang, Ya-Ni; Hsieh, Tsung-Hsun; Tweedie, David; Yu, Qian-Sheng; Hoffer, Barry J.; Luo, Yu; Kao, Yu-Chieh; Wang, Jia-Yi			Post-traumatic administration of the p53 inactivator pifithrin-alpha, oxygen analogue reduces hippocampal neuronal loss and improves cognitive deficits after experimental traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury (TBI); p53; Pifithrin-alpha (PFT-alpha); PFT-alpha oxygen analogue (PFT-alpha (o)); Apoptosis; Motor and cognitive deficits; Puma; Controlled cortical impact (CCI)	FLUORO-JADE-C; PEPTIDE-1 RECEPTOR AGONIST; TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; CELL-DEATH; FUNCTIONAL OUTCOMES; UNITED-STATES; UP-REGULATION; HEAD-INJURY; EXPRESSION	Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Neuronal apoptosis in the hippo campus has been detected after TBI. The hippocampal dysfunction may result in cognitive deficits in learning, memory, and spatial information processing. Our previous studies demonstrated that a p53 inhibitor, pifithrin-alpha oxygen analogue (PFT-alpha (O)), significantly reduced cortical cell death, which is substantial following controlled cortical impact (CCI) TBI, and improved neurological functional outcomes via anti-apoptotic mechanisms. In the present study, we examined the effect of PFT-alpha (O) on CCI TBI-induced hippocampal cellular pathophysiology in light of this brain region's role in memory. To investigate whether p53-dependent apoptosis plays a role in hippocampal neuronal loss and associated cognitive deficits and to define underlying mechanisms, SD rats were subjected to experimental CCI TBI followed by the administration of PFT-alpha or PFT-alpha (O) (2 mg/kg, i.v.) or vehicle at 5 h after TBI. Magnetic resonance imaging (MRI) scans were acquired at 24 h and 7 days post-injury to assess evolving structural hippocampal damage. Fluoro-Jade C was used to stain hippocampal sub-regions, including CA1 and dentate gyrus (DG), for cellular degeneration. Neurological functions, including motor and recognition memory, were assessed by behavioral tests at 7 days post injury. p53, p53 upregulated modulator of apoptosis (PUMA), 4-hydroxynonenal (4-HNE), cyclooxygenase-IV (COX IV), annexin V and NeuN were visualized by double immunofluorescence staining with cell-specific markers. Levels of mRNA encoding for caspase-3, p53, PUMA, Bcl-2, Bcl-2-associated X protein (BAX) and superoxide dismutase (SOD) were measured by RT-qPCR. Our results showed that post-injury administration of PFT-alpha and, particularly, PFT-alpha (O) at 5 h dramatically reduced injury volumes in the ipsilateral hippocampus, improved motor outcomes, and ameliorated cognitive deficits at 7 days after TBI, as evaluated by novel object recognition and open-field test. PFT-alpha and especially PFT-alpha (O) significantly reduced the number of FJC-positive cells in hippocampus CA1 and DG subregions, versus vehicle treatment, and significantly decreased caspase-3 and PUMA mRNA expression. PFT-alpha (O), but not PFT-alpha, treatment significantly lowered p53 and elevated SOD2 mRNA expression. Double immunofluorescence staining demonstrated that PFT-alpha (O) treatment decreased p53, annexin V and 4-HNE positive neurons in the hippocampal CA1 region. Furthermore, PUMA co-localization with the mitochondrial maker COX IV, and the upregulation of PUMA were inhibited by PFT-alpha (O) after TBI. Our data suggest that PFT-alpha and especially PFT-alpha (O) significantly reduce hippocampal neuronal degeneration, and ameliorate neurological and cognitive deficits in vivo via antiapoptotic and antioxidative properties. (C) 2016 Published by Elsevier Inc.	[Yang, Ling-Yu; Huang, Ya-Ni; Wang, Jia-Yi] Taipei Med Univ, Grad Inst Med Sci, Coll Med, 250 Wu Hsing St, Taipei 110, Taiwan; [Greig, Nigel H.; Tweedie, David; Yu, Qian-Sheng] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Huang, Ya-Ni] Hsin Sheng Jr Coll Med Care & Management, Dept Nursing, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Coll Med, Dept Phys Therapy, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Coll Med, Grad Inst Rehabil Sci, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Taipei Med Univ, Grad Inst Neural Regenerat Med, Taipei, Taiwan; [Hoffer, Barry J.; Luo, Yu] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Kao, Yu-Chieh] Taipei Med Univ, Sch Med, Translat Imaging Res Ctr, Taipei, Taiwan; [Kao, Yu-Chieh] Taipei Med Univ, Sch Med, Dept Radiol, Taipei, Taiwan; [Wang, Jia-Yi] Taipei Med Univ, Sch Med, Dept Physiol, Coll Med, Taipei, Taiwan	Wang, JY (corresponding author), Taipei Med Univ, Grad Inst Med Sci, Coll Med, 250 Wu Hsing St, Taipei 110, Taiwan.	jywang2010@tmu.edu.tw	Kao, Yu-Chieh Jill/AAW-7050-2020; Hsieh, Tung-Hsun/AAZ-5010-2020	Kao, Yu-Chieh Jill/0000-0001-7416-759X; Hsieh, Tung-Hsun/0000-0002-1794-7941; Luo, Yu/0000-0002-7939-5505; Wang, Jia-Yi/0000-0002-9106-3351	Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [MOST104-2923-B-038-001-MY3 (1-3 2-3)]; National Institutes of Health NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094152]; Intramural Research Program, National Institute on Aging, National Institutes of Health NINDS, USA [R01NS094152]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000994] Funding Source: NIH RePORTER	This study was supported in part by grants from (i) the Ministry of Science and Technology (MOST104-2923-B-038-001-MY3 (1-3 & 2-3) (ii) National Institutes of Health NINDS grant R01NS094152 and by (iii) the Intramural Research Program, National Institute on Aging, National Institutes of Health NINDS grant R01NS094152, USA. The authors thank the Translational Imaging Research Center at Taipei Medical University for technical support in relation to animal setup and MRI imaging. For information relating to PFT-alpha. (O) contact NHG <Greign@mail.nih.gov.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bralic M, 2012, COLLEGIUM ANTROPOL, V36, P1319; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chidlow G, 2009, EXP EYE RES, V88, P426, DOI 10.1016/j.exer.2008.10.015; Chiu WT, 2011, JAMA-J AM MED ASSOC, V306, P267, DOI 10.1001/jama.2011.989; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cregan SP, 2004, J NEUROSCI, V24, P10003, DOI 10.1523/JNEUROSCI.2114-04.2004; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dong XX, 2012, NEUROSCIENCE, V207, P52, DOI 10.1016/j.neuroscience.2012.01.018; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; Engel T, 2010, FASEB J, V24, P853, DOI 10.1096/fj.09-145870; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Golarai G, 2001, J NEUROSCI, V21, P8523; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Gupta S, 2007, Indian J Physiol Pharmacol, V51, P62; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hong MY, 2012, CHINESE MED J-PEKING, V125, P2019, DOI 10.3760/cma.j.issn.0366-6999.2012.11.032; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Leker RR, 2004, EXP NEUROL, V187, P478, DOI 10.1016/j.expneurol.2004.01.030; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lin JW, 2008, ACT NEUR S, V101, P113; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luo Y, 2009, ANN NEUROL, V65, P520, DOI 10.1002/ana.21592; Martin LJ, 2009, CEREB CORTEX, V19, P1273, DOI 10.1093/cercor/bhn167; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; Merchant-Borna K., 2016, ANN BIOMED ENG; Mugwagwa Andrew T, 2015, J Neurodegener Dis, V2015, P242505, DOI 10.1155/2015/242505; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Niizuma K, 2009, STROKE, V40, P618, DOI 10.1161/STROKEAHA.108.524447; Nijboer CH, 2011, ANN NEUROL, V70, P255, DOI 10.1002/ana.22413; Nijboer CHA, 2008, STROKE, V39, P2129, DOI 10.1161/STROKEAHA.107.504175; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tomasevic G, 2010, J NEUROSCI RES, V88, P3414, DOI 10.1002/jnr.22491; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Uo T, 2007, J NEUROSCI, V27, P12198, DOI 10.1523/JNEUROSCI.3222-05.2007; Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005; Wang DB, 2014, BBA-MOL BASIS DIS, V1842, P1186, DOI 10.1016/j.bbadis.2013.12.015; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015; Yonekura I, 2006, J CEREBR BLOOD F MET, V26, P1332, DOI 10.1038/sj.jcbfm.9600293; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	85	23	25	1	18	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2016	96						216	226		10.1016/j.nbd.2016.08.012			11	Neurosciences	Neurosciences & Neurology	EC3WX	WOS:000388058900020	27553877	Green Accepted			2021-06-18	
J	Dadas, A; Washington, J; Marchi, N; Janigro, D				Dadas, Aaron; Washington, Jolewis; Marchi, Nicola; Janigro, Damir			Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers	FLUIDS AND BARRIERS OF THE CNS			English	Article						Physiologically-based pharmacokinetic model; Precision medicine; Traumatic brain injury; Glomerular filtration; Serum markers	PRIMARY CNS LYMPHOMA; BARRIER DISRUPTION; POSSIBLE MARKER; S100B PROTEIN; SERUM-LEVELS; S100-BETA; VOLUME; MILD	Background: Blood biomarkers of neurovascular damage are used clinically to diagnose the presence severity or absence of neurological diseases, but data interpretation is confounded by a limited understanding of their dependence on variables other than the disease condition itself. These include half-life in blood, molecular weight, and marker-specific biophysical properties, as well as the effects of glomerular filtration, age, gender, and ethnicity. To study these factors, and to provide a method for markers' analyses, we developed a kinetic model that allows the integrated interpretation of these properties. Methods: The pharmacokinetic behaviors of S100B (monomer and homodimer), Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 were modeled using relevant chemical and physical properties; modeling results were validated by comparison with data obtained from healthy subjects or individuals affected by neurological diseases. Brain imaging data were used to model passage of biomarkers across the blood-brain barrier. Results: Our results show the following: (1) changes in biomarker serum levels due to age or disease progression are accounted for by differences in kidney filtration; (2) a significant change in the brain-to-blood volumetric ratio, which is characteristic of infant and adult development, contributes to variation in blood concentration of biomarkers; (3) the effects of extracranial contribution at steady-state are predicted in our model to be less important than suspected, while the contribution of blood-brain barrier disruption is confirmed as a significant factor in controlling markers' appearance in blood, where the biomarkers are typically detected; (4) the contribution of skin to the marker S100B blood levels depends on a direct correlation with pigmentation and not ethnicity; the contribution of extracranial sources for other markers requires further investigation. Conclusions: We developed a multi-compartment, pharmacokinetic model that integrates the biophysical properties of a given brain molecule and predicts its time-dependent concentration in blood, for populations of varying physical and anatomical characteristics. This model emphasizes the importance of the blood-brain barrier as a gatekeeper for markers' blood appearance and, ultimately, for rational clinical use of peripherally-detected brain protein.	[Dadas, Aaron; Washington, Jolewis; Janigro, Damir] Flocel Inc, Cleveland, OH 44103 USA; [Dadas, Aaron] Ohio State Univ, Columbus, OH 43210 USA; [Washington, Jolewis] John Carroll Univ, University Hts, OH USA; [Marchi, Nicola] Univ Montpellier, Inst Genom Fonct, Lab Cerebrovasc Mech Brain Disorders, Montpellier, France; [Janigro, Damir] Case Western Reserve Univ, Cleveland, OH 44106 USA	Janigro, D (corresponding author), Flocel Inc, Cleveland, OH 44103 USA.; Janigro, D (corresponding author), Case Western Reserve Univ, Cleveland, OH 44106 USA.	djanigro@flocel.com	Marchi, Nicola/J-8607-2016; Janigro, Damir/P-1750-2018	Marchi, Nicola/0000-0001-9124-0226; Janigro, Damir/0000-0002-9645-0318	 [R01NS078307];  [UH4TR000491];  [R01NS43284];  [R41MH093302];  [R21NS077236];  [R42MH093302];  [R21HD057256]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057256] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UH3TR000491, UH2TR000491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R42MH093302, R41MH093302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078307, R21NS077236, R01NS043284] Funding Source: NIH RePORTER	The work was supported by R01NS078307 (NM, DJ). UH4TR000491, awarded to DJ. R01NS43284, R41MH093302, R21NS077236, R42MH093302, and R21HD057256, awarded to DJ.	Allen JS, 2002, AM J PHYS ANTHROPOL, V118, P341, DOI 10.1002/ajpa.10092; Angelov L, 2009, J CLIN ONCOL, V27, P3503, DOI 10.1200/JCO.2008.19.3789; Astor BC, 2009, J AM SOC NEPHROL, V20, P2214, DOI 10.1681/ASN.2008090980; Bargerstock E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101477; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Ben Abdesselam O, 2003, CLIN CHEM, V49, P836, DOI 10.1373/49.5.836; Bernareggi A, 1998, CLIN PHARMACOKINET, V35, P247, DOI 10.2165/00003088-199835040-00001; BERNAREGGI A, 1991, J PHARMACOKINET BIOP, V19, P21, DOI 10.1007/BF01062191; Biberthaler P, 2002, EUR J MED RES, V7, P164; Boron WF, 2003, MED PHYSL CELLULAR M, P757; Bouvier D, 2016, CLIN CHEM LAB MED, V54, P833, DOI 10.1515/cclm-2015-0771; Falcone T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011089; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Heidari K, 2015, BRAIN INJURY, V29, P33, DOI 10.3109/02699052.2014.948068; Hostetter TH, 2010, CLIN CHEM, V56, P1381, DOI 10.1373/clinchem.2010.147827; Janigro D, 2003, US Patent, Patent No. [20030170747 A1, 20030170747]; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2003, J NEUROSCI, V23, P1949; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Mayer CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062101; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Morera-Fumero AL, 2013, J PSYCHIATR RES, V47, P791, DOI 10.1016/j.jpsychires.2013.03.001; NEUWELT EA, 1991, J CLIN ONCOL, V9, P1580, DOI 10.1200/JCO.1991.9.9.1580; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Orasanu E, 2014, NEUROIMAGE-CLIN, V6, P438, DOI 10.1016/j.nicl.2014.10.007; Peters SA, 2008, CLIN PHARMACOKINET, V47, P261, DOI 10.2165/00003088-200847040-00004; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; ROMANGOLDSTEIN S, 1994, AM J NEURORADIOL, V15, P581; Schiavi Paolo, 2012, Acta Biomed, V83, P5; SISSON TRC, 1959, J PEDIATR-US, V55, P163, DOI 10.1016/S0022-3476(59)80084-6; Steiner J, 2010, PSYCHONEUROENDOCRINO, V35, P321, DOI 10.1016/j.psyneuen.2009.07.012; Stevens LA, 2011, KIDNEY INT, V79, P555, DOI 10.1038/ki.2010.462; Stevens LA, 2009, J AM SOC NEPHROL, V20, P2305, DOI 10.1681/ASN.2009020171; Vogelbaum MA, 2005, CANCER-AM CANCER SOC, V104, P817, DOI 10.1002/cncr.21220; WEISS L, 1980, AM J PATHOL, V101, P101; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149	40	23	23	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-8118			FLUIDS BARRIERS CNS	Fluids Barriers CNS	NOV 30	2016	13								21	10.1186/s12987-016-0045-y			12	Neurosciences	Neurosciences & Neurology	EM4WY	WOS:000395314900001	27903281	DOAJ Gold, Green Published			2021-06-18	
J	Wang, Y; Fan, XG; Tang, T; Fan, R; Zhang, CH; Huang, ZB; Peng, WJ; Gan, PP; Xiong, XG; Huang, W; Huang, X				Wang, Yang; Fan, Xuegong; Tang, Tao; Fan, Rong; Zhang, Chunhu; Huang, Zebing; Peng, Weijun; Gan, Pingping; Xiong, Xingui; Huang, Wei; Huang, Xi			Rhein and rhubarb similarly protect the blood-brain barrier after experimental traumatic brain injury via gp91(phox) subunit of NADPH oxidase/ROS/ERK/MMP-9 signaling pathway	SCIENTIFIC REPORTS			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; TRADITIONAL CHINESE MEDICINE; OXIDATIVE STRESS; KNOCK-OUT; MATRIX-METALLOPROTEINASE-9; NEUROPROTECTION; ASTROCYTES; INHIBITION; RATS; PHARMACOKINETICS	Oxidative stress chiefly contributes to the disruption of the BBB following traumatic brain injury (TBI). The Chinese herbal medicine rhubarb is a promising antioxidant in treating TBI. Here we performed in vivo and in vitro experiments to determine whether rhubarb and its absorbed bioactive compound protected the BBB after TBI by increasing ZO-1 expression through inhibition of gp91(phox) subunit of NADPH oxidase/ROS/ERK/MMP-9 pathway. Rats were subjected to the controlled cortical impact (CCI) model, and primary rat cortical astrocytes were exposed to scratch-wound model. The liquid chromatography with tandem mass spectrometry method showed that rhein was the compound absorbed in the brains of CCI rats after rhubarb administration. The wet-dry weights and Evans blue measurements revealed that rhubarb and rhein ameliorated BBB damage and brain edema in CCI rats. Western blots showed that rhubarb and rhein downregulated GFAP in vitro. RT-PCR, immunohistochemistry, Western blot and dichlorodihydrofluorescein diacetate analysis indicated that rhubarb prevented activation of gp91(phox) subunit of NADPH oxidase induced ROS production, subsequently inhibited ERK/MMP-9 pathway in vivo and in vitro. Interestingly, rhein and rhubarb similarly protected the BBB by inhibiting this signaling cascade. The results provide a novel herbal medicine to protect BBB following TBI via an antioxidative molecular mechanism.	[Wang, Yang; Tang, Tao; Fan, Rong; Zhang, Chunhu; Xiong, Xingui; Huang, Wei; Huang, Xi] Cent S Univ, Inst Integrated Tradit Chinese & Western Med, Xiangya Hosp, Lab Ethnopharmacol, Changsha 410008, Hunan, Peoples R China; [Wang, Yang; Fan, Xuegong; Huang, Zebing] Cent S Univ, Xiangya Hosp, Dept Infect Dis, Key Lab Viral Hepatitis Hunan, Changsha 410008, Hunan, Peoples R China; [Peng, Weijun] Cent S Univ, Xiangya Hosp 2, Dept Integrated Tradit Chinese & Western Med, Changsha 410011, Hunan, Peoples R China; [Gan, Pingping] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Huang, Xi] Nanjing Univ Chinese Med, Inst TCM Related Depress Comorbid, Nanjing 210046, Jiangsu, Peoples R China	Huang, X (corresponding author), Cent S Univ, Inst Integrated Tradit Chinese & Western Med, Xiangya Hosp, Lab Ethnopharmacol, Changsha 410008, Hunan, Peoples R China.; Huang, X (corresponding author), Nanjing Univ Chinese Med, Inst TCM Related Depress Comorbid, Nanjing 210046, Jiangsu, Peoples R China.	tcmhuangx59@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303074, 81673719, 30572339, 81403259]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine)	This study was supported by the National Natural Science Foundation of China (Grant Nos 81303074, 81673719, 30572339 and 81403259), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine).	Abdul-Muneer PM, 2016, MOL NEUROBIOL, V53, P6106, DOI 10.1007/s12035-015-9520-8; Al Ahmad A, 2012, MICROVASC RES, V84, P222, DOI 10.1016/j.mvr.2012.05.008; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Arai K, 2003, GLIA, V43, P254, DOI 10.1002/glia.10255; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bhattacharyya S, 2015, J NEUROCHEM, V134, P728, DOI 10.1111/jnc.13156; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Donkin J. J., CURR OPIN NEUROL; Elmann A, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/157598; Gau BS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-211; Haring RS, 2015, J SURG RES, V195, P1, DOI 10.1016/j.jss.2015.01.017; He SM, 2010, CURR MED CHEM, V17, P4072, DOI 10.2174/092986710793205336; Hsieh HL, 2010, ANTIOXID REDOX SIGN, V13, P1829, DOI 10.1089/ars.2009.2957; Kim HU, 2015, NAT BIOTECHNOL, V33, P264, DOI 10.1038/nbt.3167; Kim MJ, 2005, BRAIN RES, V1040, P178, DOI 10.1016/j.brainres.2005.01.066; Kochanek PM, 2016, LANCET NEUROL, V15, P13, DOI 10.1016/S1474-4422(15)00339-7; Kou K, 2014, WORLD J EMERG MED, V5, P245, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.001; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu CL, 2014, TURK NEUROSURG, V24, P363, DOI 10.5137/1019-5149.JTN.8551-13.0; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Mahmoodpoor A, 2014, NEW ENGL J MED, V371, P971, DOI 10.1056/NEJMc1407775; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Rehman Hina, 2015, J Complement Integr Med, V12, P61, DOI 10.1515/jcim-2014-0004; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Shen QH, 2016, WORLDV EVID-BASED NU, V13, P380, DOI 10.1111/wvn.12167; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stocchetti N, 2016, MINERVA ANESTESIOL, V82, P499; Sun H, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00247; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tyagi N, 2009, J CELL PHYSIOL, V220, P257, DOI 10.1002/jcp.21757; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wang S, 2016, J NUTR BIOCHEM, V36, P42, DOI 10.1016/j.jnutbio.2016.07.008; Wang WZ, 2016, MOL NEUROBIOL, V53, P4809, DOI 10.1007/s12035-015-9385-x; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wang Y, 2015, J SEP SCI, V38, P1100, DOI 10.1002/jssc.201401197; Wang Y, 2012, CHIN J INTEGR MED, V18, P690, DOI 10.1007/s11655-012-1053-7; Watzlawick R, 2016, JAMA NEUROL, V73, P149, DOI 10.1001/jamaneurol.2015.3627; Wv WY, 2014, CHIN J NAT MEDICINES, V12, P241, DOI [10.1016/S1875-5364(14)60050-9, 10.3724/SP.J.1009.2014.00241]; Xing ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep20040; Xue TH, 2003, SCIENCE, V300, P740, DOI 10.1126/science.300.5620.740; Yousefipour Z, 2013, J HEALTH CARE POOR U, V24, P118, DOI 10.1353/hpu.2014.0002; Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559; Zhou YX, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/578107	57	23	28	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 30	2016	6								37098	10.1038/srep37098			13	Multidisciplinary Sciences	Science & Technology - Other Topics	ED4FR	WOS:000388803700001	27901023	DOAJ Gold, Green Published			2021-06-18	
J	Shikov, AN; Pozharitskaya, ON; Makarov, VG				Shikov, Alexander N.; Pozharitskaya, Olga N.; Makarov, Valery G.			Aralia elata var. mandshurica (Rupr. & Maxim.) J.Wen: An overview of pharmacological studies	PHYTOMEDICINE			English	Article						Aralia; Adaptogen; Clinical data; Pharmacology; Toxicity	NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; ELATOSIDE C PROTECTS; MIQ SEEM TASAES; OLEANOLIC ACID; ROOT BARK; ISCHEMIA-REPERFUSION; TRITERPENE SAPONINS; BIOACTIVE SAPONINS; ETHANOL ABSORPTION	Purpose: Aralia elata var. mandshurica (Rupr. & Maxim.) J.Wen syn. A. mandshurica Rupr. & Maxim is evaluated for its medicinal application. The aim of this study is to analyze pharmacological studies on A. data var. mandshurica published until December 2015. Methods: The information regarding the chemistry, safety, effectiveness, and pharmacological and clinical effects of A. elata was systematically collected from the scientific literature through library catalogs; online services such as E-library.ru, Medline/PubMed, Scopus, Web of Science, and Google Scholar. Results: A. elata is often considered an example of a medicinal plant used in Chinese, Korean, and Japanese traditional medicine. However, the contemporary applications of Aralia in officinal medicine result primarily from a large number of pharmacological and clinical investigations carried out in the former USSR in the mid-20th century. Since the 1950s, medicinal preparations from radices of A. elata and radices of A. mandshurica have secured an established position within Russian/USSR medicine as evidenced by the inclusion of the drug in recent editions of the National Pharmacopoeia of the USSR and in the Register of Medicinal Preparations of Russia. Pharmacological studies on animals have shown that Aralia increases physical working capacity and affords a stress-protective effect against a broad spectrum of harmful factors including cold stress, immobilization, UV irradiation, and low air pressure. The phytoadaptogen exerts an effect on the central nervous, reproductive, immune, respiratory, and gastrointestinal systems; the metabolic syndrome including hypolipidemic and antidiabetic effects; and blood coagulation. Together with general properties of adaptogens, Aralia has its own specificity, which manifests in cardioprotective and antiarrhythmic activities. Studies on isolated organs, cells, and enzymes have revealed that Aralia preparations exhibit antioxidant activities and enhance sarcoplasmic reticulum Ca2+-ATPase activity, inhibit endoplasmic reticulum stress-associated apoptosis markers (GRP78, CHOP, Caspase-12, and JNK), and increase phosphorylation of STAT3 and Bc12/Bax ratio; they also show cytotoxic activities against some tumor cell lines; affect NF-kappa B and PPARs activities; and regulate biosynthesis of pro-inflammatory cytokines and inflammation-related protein expression, tissue respiration, and oxygen consumption. In healthy subjects, Aralia increases mental performance, working capacity, and endurance of movement. Numerous clinical trials have shown the efficiency of Aralia preparations in. patients with traumatic brain injury (accompanied with asthenic syndrome and neurotic reactions, depression, neurasthenia, and psychasthenia), neurological diseases (accompanied with astheno-depressive and astheno-hypochondriasis syndromes), myasthenia syndrome (accompanied with chronic post-influenza arachnoiditis), and arterial hypotension. Aralia tincture and "Saparal" are useful as antiviral remedies. Radioprotective properties of Aralia have been reported in pregnant women. Synergistic antiobesity effect was reported for the combination of A. mandshurica and Engelhardtia chrysolepfs extracts and antidiabetic effect for the combination of Aralia and glipizide. Promising stress-relieving effects of Aralia are reported for professionals whose work requires a high level of attention. Its proposed ability to moderate stress-induced damage and dysfunction in the cardiovascular tissue might make Aralia the adaptogen of choice among patients with higher risk for cardiovascular diseases. Because Aralia extract administration appears to affect plasma glucose level and hepatic lipid accumulation and ameliorate hyperinsulinemia, it might also provide benefits and be the adaptogen of choice for patients with obesity and diabetes. Conclusion: This review describes the considerable diversity of pharmacological effects of A. elata reported in numerous studies carried out in the former USSR and other countries, which have been confirmed over >47 years of use of the plant as an official medicinal remedy. The knowledge discussed in this review can be applied to the expansion of the use of this high-value plant in the pharmacotherapy of European and other countries and for the further discovery of new drugs based on the secondary metabolites of this plant. Modern approaches in mechanisms of action, including a study of gene expression profiling, suggest the most up-to-date challenges for the future research of Aralia. (C) 2016 Elsevier GmbH. All rights reserved.	[Shikov, Alexander N.; Pozharitskaya, Olga N.; Makarov, Valery G.] St Petersburg Inst Pharm, P 245, Vsevolozhsky Dist 188663, Kuzmolovo, Russia	Shikov, AN (corresponding author), St Petersburg Inst Pharm, P 245, Vsevolozhsky Dist 188663, Kuzmolovo, Russia.	spb.pharmacy@gmail.com	Pozharitskaya, Olga N/D-9671-2014; Shikov, Alexander/B-1804-2008	Pozharitskaya, Olga N/0000-0003-1061-0665; Shikov, Alexander/0000-0003-4351-0695			Abidov M, 2003, B EXP BIOL MED+, V136, P585, DOI 10.1023/B:BEBM.0000020211.24779.15; Abidov MT, 2006, B EXP BIOL MED+, V141, P343, DOI 10.1007/s10517-006-0167-3; AHUMADA F, 1991, PHYTOTHER RES, V5, P29, DOI 10.1002/ptr.2650050108; Asea A, 2013, PHYTOMEDICINE, V20, P1323, DOI 10.1016/j.phymed.2013.07.001; BARANOV AI, 1982, J ETHNOPHARMACOL, V6, P339, DOI 10.1016/0378-8741(82)90055-1; Barnaulov OD, 2006, PSYCHOPHARMACOL BIOL, V6, P1232; BREKHMAN II, 1969, ANNU REV PHARMACOLOG, V9, P419, DOI 10.1146/annurev.pa.09.040169.002223; Brekhman II, 1963, PRIMORSKOE KNIZHNOE, V5, P219; Brown R.P., 2014, J AM BOT COUNC, V56, P40; BURGOS R, 1994, PHYTOTHER RES, V8, P1, DOI 10.1002/ptr.2650080102; Burgos RA, 1997, PHYTOTHER RES, V11, P59, DOI 10.1002/(SICI)1099-1573(199702)11:1<59::AID-PTR944>3.0.CO;2-8; Chernyak D. M., 2014, PACIFIC MED J, V2, P28; Chung YS, 2005, J ETHNOPHARMACOL, V101, P49, DOI 10.1016/j.jep.2005.03.020; Clement JA, 2014, CURR TOP MED CHEM, V14, P2783; Denisenko P. P., 2000, PSYCHONEUROENDOCRINO, V25, pS57; Dorovskikh V. A., 2015, B PHYSL PATHOL RESP, V55, P95; Duke J. A., 1985, MED PLANTS CHINA, P1; Fedorova M. V., 1994, Rossiiskii Vestnik Perinatologii i Pediatrii, V39, P13; Fruentov N. K., 1974, MED PLANTS FAR E; Garkaev L. H., 1998, ANTISTRESS REACTIONS, P656; Gubchenko PP, 1986, MEW DATA ELEUTHEROCO, P171; Gubina G., 1988, MED PREPARATIONS PLA, P263; GUBINA GP, 1959, ZH NEVROPATOL PSIKH, V59, P1239; HERNANDEZ DE, 1988, J ETHNOPHARMACOL, V23, P109, DOI 10.1016/0378-8741(88)90120-1; Hwang KA, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0871-5; Ishrefova L. R., 2011, PREVENTIVE CLIN MED, V4, P98; ISKENDEROV G B, 1989, Farmatsiya (Moscow), V38, P44; Jung Chun Sik, 1993, Yakhak Hoeji, V37, P581; Kazakevich V. V., 1972, MED SOVIET FAR E; Kazakevich V. V., 1971, BIOL ACTIVE COMPOUND, P119; Kharin S. A., 2011, ADV MODERN SCI, V8, P75; Kochetkov N. K., 1963, B ACAD SCI USSR CH, V12, P1282; KOCHETKOV NK, 1962, TETRAHEDRON LETT, P713; KOLKHIR V K, 1982, Pharmaceutical Chemistry Journal (English Translation of Khimiko-Farmatsevticheskii Zhurnal), V16, P335, DOI 10.1007/BF00762048; KOMISSARENKO B T, 1962, Sov Med, V25, P115; Kuang HX, 2013, CHEM BIODIVERS, V10, P703, DOI 10.1002/cbdv.201200087; Lee EB, 2005, BIOL PHARM BULL, V28, P523, DOI 10.1248/bpb.28.523; Lee JH, 2009, ARCH PHARM RES, V32, P831, DOI 10.1007/s12272-009-1603-5; Li Feng-jin, 2013, Chinese Pharmacological Bulletin, V29, P1663, DOI 10.3969/j.issn.1001-1978.2013.12.009; Liu XH, 2015, J SCI FOOD AGR, V95, P739, DOI 10.1002/jsfa.6829; Liu Y, 2011, AFR J PHARM PHARMACO, V5, P462; Luo Y, 2015, J ETHNOPHARMACOL, V163, P241, DOI 10.1016/j.jep.2015.01.017; Montiel-Ruiz RM, 2012, DRUG DEVELOP RES, V73, P106, DOI 10.1002/ddr.21001; Markin V.V., 2007, SIBERIAN MED REV, V45, P54; Markina L.D., 2008, PACIFIC MED J, V3, P30; Mashkovsky M. D., 2002, MED DRUGS MANUAL PHA, V1, P135; Maslov LN, 2009, B EXP BIOL MED+, V147, P331, DOI 10.1007/s10517-009-0502-6; Maslov L. N., 2007, Eksperimental'naya i Klinicheskaya Farmakologiya, V70, P48; Miroshnichenko I. V., 1985, PHARM CHEM J, V19, P85; MITSUHASHI H, 1976, ECON BOT, V30, P209, DOI 10.1007/BF02909729; Najhin A. N., 1989, VOPROSY VIRUSOLOGII; Namba T., 1980, ENCY WAKAN YAKU COLO, VII, P180; New Medical College of Jiangsu ed, 1977, DICT CHIN MAT MED, P2583; Nhiem NX, 2011, BIOORG MED CHEM LETT, V21, P6143, DOI 10.1016/j.bmcl.2011.08.024; Panossian A, 1999, PHYTOMEDICINE, V6, P287, DOI 10.1016/S0944-7113(99)80023-3; Panossian A., 2003, ALTERNATIVE COMPLEME, V9, P327, DOI DOI 10.1089/107628003322658610; Panossian A, 2008, J ETHNOPHARMACOL, V118, P183, DOI 10.1016/j.jep.2008.04.020; Panossian A, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00016; Panossian A, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00006; Panossian A, 2010, PHARMACEUTICALS, V3, P188, DOI 10.3390/ph3010188; Panossian A, 2009, CURR CLIN PHARMACOL, V4, P198, DOI 10.2174/157488409789375311; Panossian A, 2009, PHYTOMEDICINE, V16, P617, DOI 10.1016/j.phymed.2008.12.003; Panossian AG, 2013, PSYCHIAT CLIN N AM, V36, P49, DOI 10.1016/j.psc.2012.12.005; PARAMONOVA MS, 1994, VOP VIRUSOL+, V39, P131; Perfumi M, 2007, PHYTOTHER RES, V21, P37, DOI 10.1002/ptr.2013; Perry L. M., 1990, MED PLANTS E SE ASIA, P41; Pivovarova A.S., 2003, RASTIT RESUR, V1, P94; Pospelova ML, 2000, HUMAN PHYSL, V26, P86; Poyarkova A.I., 1950, FLORA SSSR, V16, P1; SAITO S, 1993, CHEM PHARM BULL, V41, P1395, DOI 10.1248/cpb.41.1395; Sergeeva N. V., 1977, PHARM CHEM J, V11, P1393; Shikov AN, 2014, J ETHNOPHARMACOL, V154, P481, DOI 10.1016/j.jep.2014.04.007; Shreter Al, 1975, MED FLORA SOVIET FAR; Sim JS, 2005, BIOL PHARM BULL, V28, P1043, DOI 10.1248/bpb.28.1043; Smolyakova G. P., 1997, FAR E MED J, V4, P49; Sokolov S., 1971, BIOL ACTIVE SUBSTANC, P113; Sokolov S. Ya., 1982, MED PREPARATIONS PLA, P270; SOKOLOV SY, 1968, B EXP BIOL MED-USSR, V66, P1353; SOKOLOV SY, 1966, B EXP BIOL MED-USSR, V61, P295, DOI 10.1007/BF00783689; SOKOLOV SY, 1965, B EXP BIOL MED-USSR, V60, P916, DOI 10.1007/BF00805046; Sokolov SY., 2000, PHYTOTHERAPY PHYTOPH; Suh SJ, 2007, ARCH BIOCHEM BIOPHYS, V467, P227, DOI 10.1016/j.abb.2007.08.025; Syrov V. N., 1988, UZBEKSKII BIOL ZH, V3, P61; The State Pharmacopoeia of the USSR, 1990, RAD AR MANDSH RAD 2, P345; Turova AD, 1974, MED PLANTS USSR THEI; Voskanyan V.L., 1983, PHARM CHEM J, V17, P123; Vostrikova G. G., 1973, VOPROSY PHARM DALNEM, V1, P60; Wang M, 2015, INT J CARDIOL, V185, P167, DOI 10.1016/j.ijcard.2015.03.140; Wang M, 2014, APOPTOSIS, V19, P1727, DOI 10.1007/s10495-014-1039-3; Wang M, 2014, J ETHNOPHARMACOL, V155, P240, DOI 10.1016/j.jep.2014.05.024; Wiegant FAC, 2009, BIOGERONTOLOGY, V10, P27, DOI 10.1007/s10522-008-9151-9; WOJCICKI J, 1977, HERBA POL, V23, P285; Xi SG, 2009, EXP MOL MED, V41, P538, DOI 10.3858/emm.2009.41.8.059; Yook C.S., 1981, MED PLANTS KOREA, P272; Yoshikawa M, 1996, CHEM PHARM BULL, V44, P1915, DOI 10.1248/cpb.44.1915; Yoshikawa M, 1996, CHEM PHARM BULL, V44, P1923, DOI 10.1248/cpb.44.1923; YOSHIKAWA M, 1993, CHEM PHARM BULL, V41, P2069, DOI 10.1248/cpb.41.2069; YOSHIKAWA M, 1995, CHEM PHARM BULL, V43, P1878, DOI 10.1248/cpb.43.1878; Zhang Y, 2013, FOOD CHEM, V138, P208, DOI 10.1016/j.foodchem.2012.10.041; Zhuravlev Y N, 1996, ARALIACEAE GINSENG O	100	23	25	1	39	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0944-7113	1618-095X		PHYTOMEDICINE	Phytomedicine	NOV 15	2016	23	12					1409	1421		10.1016/j.phymed.2016.07.011			13	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	EB2KZ	WOS:000387192300016	27765361				2021-06-18	
J	Grima, NA; Ponsford, JL; St Hilaire, MA; Mansfield, D; Rajaratnam, SM				Grima, Natalie A.; Ponsford, Jennie L.; St Hilaire, Melissa A.; Mansfield, Darren; Rajaratnam, Shantha M.			Circadian Melatonin Rhythm Following Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; sleep	SLEEP QUALITY INDEX; DAYTIME SLEEPINESS; DISTURBANCE; INSOMNIA; DISORDERS	Background: Sleep-wake disturbances are highly prevalent following traumatic brain injury (TBI), impeding rehabilitaion and quality of life. However, the mechanisms underlying these sleep disturnbances are unclear, and efficacious treatments are lacking. To investigate possible mechanisms underlying sleep disturbance in TBI, we examined characteristics of the circadian rhythm of melatonin, a hormone involved in sleep-wake regulation. We compared TBI patients reporting sleep disturbance with age- and gender-matched healthy volunteers. Methods: We conducted an overnight observational study with salivary melatonin samples collected hourly in 9 patients with severe TBI and 9 controls. Salivary dim light melatonin onset (DLMO) as well as melatonin synthesis onset (SynOn) and offset (SynOff) were used to determine circadian timing. Total overnight salivary melatonin production was calculated as the area under the curve from melatonin synthesis onset to offset. Results: Compared with healthy individuals, TBI patients showed 42% less melatonin production overnight (d = 0.87; P = .034). The timing of DLMO was delayed by approximately 1.5 hours in patients with TBI compared with controls (d = 1.23; P = .003). Conclusions: In patients with TBI, melatonin production was attenuated overnight, and the timing of melatonin secretion was delayed. We suggest that disruption to the circadian regulation of melatonin synthesis is a feature of severe TBI, possibly contributing to the sleep difficulties that are commonly reported in this population.	[Grima, Natalie A.] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Grima, Natalie A.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA; [Grima, Natalie A.; Ponsford, Jennie L.; Mansfield, Darren; Rajaratnam, Shantha M.] Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia; [Grima, Natalie A.; Ponsford, Jennie L.; Mansfield, Darren; Rajaratnam, Shantha M.] Monash Univ, Inst Cognit & Clin Neurosci, Clayton, Vic 3800, Australia; [Grima, Natalie A.; Ponsford, Jennie L.] Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia; [St Hilaire, Melissa A.; Rajaratnam, Shantha M.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Dept Med, Boston, MA 02115 USA; [St Hilaire, Melissa A.; Rajaratnam, Shantha M.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Dept Neurol, Boston, MA 02115 USA; [St Hilaire, Melissa A.; Rajaratnam, Shantha M.] Harvard Med Sch, Div Sleep Med, Dept Med, Boston, MA USA; [Mansfield, Darren] Monash Hlth, Monash Lung & Sleep, Clayton, Vic, Australia	Rajaratnam, SM (corresponding author), Monash Univ, Sch Psychol Sci, Fac Biomed & Psychol Sci, Med Nursing & Hlth Sci, 18 Innovat Walk,Bldg 17,Clayton Campus, Clayton, Vic 3800, Australia.; Rajaratnam, SM (corresponding author), Monash Univ, Inst Cognit & Clin Neurosci, Fac Biomed & Psychol Sci, Med Nursing & Hlth Sci, 18 Innovat Walk,Bldg 17,Clayton Campus, Clayton, Vic 3800, Australia.	Shantha.rajaratnam@monash.edu		Rajaratnam, Shantha/0000-0001-7527-8558	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1028733]; Australian Postgraduate AwardAustralian Government	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding of the study was supported by an Australian National Health and Medical Research Council project grant (#1028733). NAG was funded by an Australian Postgraduate Award.	American Academy of Sleep Medicine, 2014, INT CLASSIFICATION S, Vthird; Arendt J, 1995, MELATONIN MAMMALIAN; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Dickmeis T, 2009, J ENDOCRINOL, V200, P3, DOI 10.1677/JOE-08-0415; Duffy JF, 1996, J PHYSIOL-LONDON, V495, P289, DOI 10.1113/jphysiol.1996.sp021593; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Lack LC, 2008, SLEEP MED REV, V12, P307, DOI 10.1016/j.smrv.2008.02.003; Leger D, 2004, AM J MED, V116, P91, DOI 10.1016/j.amjmed.2003.07.017; Lewy AJ, 2009, HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION, P2505; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rajaratnam SMW, 2009, SLEEP MED CLIN, V4, P179, DOI 10.1016/j.jsmc.2009.02.007; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Scheer FAJL, 2006, SPINAL CORD, V44, P78, DOI 10.1038/sj.sc.3101784; Seifman MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00237; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; St Hilaire MA, 2007, J PINEAL RES, V43, P294, DOI 10.1111/j.1600-079X.2007.00477.x; Sullivan KA, 2015, J NEUROTRAUM, V32, P474, DOI 10.1089/neu.2013.3284	24	23	23	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV-DEC	2016	30	10					972	977		10.1177/1545968316650279			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DZ0HD	WOS:000385517400007	27221043	Bronze			2021-06-18	
J	Harvey, L; Mitchell, R; Brodaty, H; Draper, B; Close, J				Harvey, Lara; Mitchell, Rebecca; Brodaty, Henry; Draper, Brian; Close, Jacqueline			Differing trends in fall-related fracture and non-fracture injuries in older people with and without dementia	ARCHIVES OF GERONTOLOGY AND GERIATRICS			English	Article						Falls; Injury; Dementia; Hospitalisation	HIP FRACTURE; RISK-FACTORS; ALZHEIMERS-DISEASE; POPULATION; RATES; CARE; MORTALITY; FINLAND; HOME	Objectives: To explore the impact of dementia on the trends in fall-related fracture and non-fracture injuries for older people. Methods: Individuals aged >= 65 years who were admitted to a NSW hospital for at least an over-night stay for a fall-related injury from 2003 to 2012 were identified. Age-standardised hospitalisation rates, length of stay, access to in-hospital rehabilitation, 30-day and 1-year mortality were examined. Annual percentage change (PAC) over time was calculated using negative binomial regression. Results: Of the 228,628 fall-related injury hospitalisations, 20.6% were for people with dementia. People with dementia were more likely to be admitted with a hip fracture, and less likely to be admitted with a fracture of the forearm/wrist, and received less in-hospital rehabilitation than people without dementia. Fall-related hip-fracture rates for people with dementia decreased by 4.2% (95% CI -5.6 to -2.7, p < 0.001) per annum; there was no change over time for people without dementia (PAC-0.2%; 95% CI -0.8 to 0.5, p = 0.643). Rates for other fractures decreased by 1.2% (95% CI -1.9 to -0.5, p < 0.001) per annum in people with dementia, while rates increased by 2.2% (95% CI 1.9-2.5, p < 0.001) for people without dementia. By contrast, non-fracture injuries including traumatic brain injury increased significantly for both people with and without dementia. Conclusion: Rates of fall-related fracture and non-fracture hospitalisations for people with dementia remain higher than for those without dementia. However, fall-related fracture hospitalisation rates have decreased for people with dementia, while there has not been a corresponding decrease in people without dementia. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Harvey, Lara; Mitchell, Rebecca; Close, Jacqueline] UNSW, Neurosci Res Australia, Falls Balance & Injury Res Ctr, Barker St, Randwick, NSW 2031, Australia; [Mitchell, Rebecca] Macquarie Univ, Australian Inst Hlth Innovat, Level 6,75 Talavera Rd, N Ryde, NSW 2109, Australia; [Brodaty, Henry; Draper, Brian] UNSW, Sch Psychiat, Dementia Collaborat Res Ctr Assessment & Better C, Level 3,AGSM Bldg, Sydney, NSW 2052, Australia; [Brodaty, Henry; Draper, Brian] UNSW Med, UNSW, Sch Psychiat, Ctr Hlth Brain Ageing,Euroa Ctr, Randwick, NSW 2031, Australia; [Close, Jacqueline] UNSW Med, Prince Wales Clin Sch, Sydney, NSW 2052, Australia; [Harvey, Lara] UNSW, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia	Harvey, L (corresponding author), Neurosci Res Australia, Barker St, Sydney, NSW 2031, Australia.	l.harvey@neura.edu.au; r.mitchell@mq.edu.au; h.brodaty@unsw.edu.au; b.draper@unsw.edu.au; j.close@neura.edu.au	Mitchell, Rebecca/Z-5476-2019	Mitchell, Rebecca/0000-0003-1939-1761	Dementia Collaborative Research Centre-Assessment and Better Care, UNSW, Australia	This study was funded by the Dementia Collaborative Research Centre-Assessment and Better Care, UNSW, Australia. The authors would like to thank the NSW Ministry of Health and the NSW Registry of Birth Deaths and Marriages for the provision of the hospitalisation and death data extracts, and the Centre for Health Record Linkage (CHeReL) for the provision of the unique patient identifiers used to link the datasets.	Allan LM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005521; Alzheimer's Association, 2015, ALZHEIMERS DEMENTIA, V11; Australian Health Performance Authority, 2013, HOSP PERF LENGTH S S; Australian Insitutute of Health and Welfare, 2015, INJ RES STAT SER, V95; Australian Insitutute of Health and Welfare, 2010, PROBL OST HIP FRACT; Australian Institute of Health and Welfare, 2012, 70 AGE AUSTR I HLTH; Australian Institute of Health and Welfare, 2012, BULLETIN, V110; Baker NL, 2011, AGE AGEING, V40, P49, DOI 10.1093/ageing/afq146; Bergland A, 2004, INJURY PREV, V10, P308, DOI 10.1136/ip.2003.004721; Berry J., 2006, GUIDE STAT METHODS I; Centers for Disease Control and Prevention, 2015, COSTS FALLS OLD AD; Centre for Health Record Linkage, 2012, MAST LINK KEY QUAL A; Chau PH, 2013, AGE AGEING, V42, P229, DOI 10.1093/ageing/afs177; Cirera E, 2014, INJURY, V45, P2076, DOI 10.1016/j.injury.2014.09.016; Cooper C, 2011, OSTEOPOROSIS INT, V22, P1277, DOI 10.1007/s00198-011-1601-6; Deloitte Access Economics, 2011, DEM AUSTR; Draper B, 2011, INT PSYCHOGERIATR, V23, P1649, DOI 10.1017/S1041610211001694; Greenspan SL, 1998, AM J MED, V104, P539, DOI 10.1016/S0002-9343(98)00115-6; Hartholt KA, 2011, J TRAUMA, V71, P255, DOI 10.1097/TA.0b013e31821c36e7; Hartholt KA, 2011, J NEUROTRAUM, V28, P739, DOI 10.1089/neu.2010.1488; Harvey L, 2015, INJURY; Harvey L, 2013, TRENDS FALL RELATED; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Hindmarsh D. M., 2012, AUSTRALASIAN J AGEIN, P1; Jaglal SB, 2005, J BONE MINER RES, V20, P898, DOI 10.1359/JBMR.041231; Jensen J, 2002, SCAND J PUBLIC HEALT, V30, P54, DOI 10.1177/14034948020300011201; Kanis J, 1999, OSTEOPOROSIS INT, V9, P45, DOI 10.1007/s001980050115; King B, 2006, AUSTRALAS J AGEING, V25, P20, DOI 10.1111/j.1741-6612.2006.00135.x; Knopp-Sihota JA, 2014, GERIATR GERONTOL INT, V14, P121, DOI 10.1111/ggi.12069; Korhonen N, 2013, OSTEOPOROSIS INT, V24, P1599, DOI 10.1007/s00198-012-2190-8; Langa KM, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0118-1; Lenze EJ, 2004, INT J GERIATR PSYCH, V19, P472, DOI 10.1002/gps.1116; Leslie WD, 2009, JAMA-J AM MED ASSOC, V302, P883, DOI 10.1001/jama.2009.1231; Lip GYH, 2011, EUROPACE, V13, P723, DOI 10.1093/europace/eur126; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; National Centre for Classification in Health, 2010, INT STAT CLASS DIS R; NSW Ministry of Health, 2010, NEW S WAL FALLS PREV; Nurmi I, 1996, SCAND J CARING SCI, V10, P212; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Requena G, 2014, CALCIFIED TISSUE INT, V94, P580, DOI 10.1007/s00223-014-9850-y; Sachdev P. S., 2014, IS INCIDENCE DEMENTI; Scandol JP, 2013, INJURY, V44, P776, DOI 10.1016/j.injury.2012.11.023; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; VANDIJK PTM, 1993, GERONTOLOGIST, V33, P200, DOI 10.1093/geront/33.2.200; Yiannopoulou KG, 2012, HIP INT, V22, P209, DOI 10.5301/HIP.2012.9229; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	46	23	23	0	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-4943	1872-6976		ARCH GERONTOL GERIAT	Arch. Gerontol. Geriatr.	NOV-DEC	2016	67						61	67		10.1016/j.archger.2016.06.014			7	Geriatrics & Gerontology	Geriatrics & Gerontology	DU5RO	WOS:000382269200010	27434743				2021-06-18	
J	Hoflich, KM; Beyer, C; Clarner, T; Schmitz, C; Nyamoya, S; Kipp, M; Hochstrasser, T				Hoeflich, Katharina Marie; Beyer, Cordian; Clarner, Tim; Schmitz, Christoph; Nyamoya, Stella; Kipp, Markus; Hochstrasser, Tanja			Acute axonal damage in three different murine models of multiple sclerosis: A comparative approach	BRAIN RESEARCH			English	Article						Axonal damage; APP; Experimental autoimmune encephalomyelitis; Cuprizone; Lysolecithin	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CUPRIZONE-INDUCED DEMYELINATION; AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; KINESIN LIGHT-CHAIN; CORPUS-CALLOSUM; C57BL/6 MICE; IN-VIVO; FOCAL DEMYELINATION; GLATIRAMER ACETATE	Axonal damage has been identified as a significant contributor to permanent clinical disability in multiple sclerosis. In the context of demyelinating disorders, this destructive event can be the result of inflammation, demyelination and/or the activation of innate defense cells such as microglia or monocytes. The relative contribution of each of these variables to acute axonal injury is, however, unknown. In the present study, we compared the extent of acute axonal damage in three different murine demyelination models using anti-amyloid precursor protein (APP) immunohistochemistry. T cell dependent (MOG(35-55)-induced experimental autoimmune encephalomyelitis (EAE)) as well as T cell independent demyelination models (cuprizone- and lysolecithin-induced demyelination) were used. APP(+) spheroids were present in all three experimental demyelination models. The number of APP+ spheroids was highest within LPC-induced lesions. Equal amounts were found in the spinal cord of MOG(35-55)-EAE animals and the corpus callosum of cuprizone-intoxicated animals. Moreover, we detected increased immunoreactivity of the pre-synaptic protein vesicular glutamate transporter 1 (VGIuT1) in demyelinated foci. VG1uT1-staining revealed long stretched, ovoid-like axonal structures which co-localized with APP. In summary, we showed that acute axonal damage is evident under various experimental demyelination paradigms. Furthermore, disturbed axonal transport mechanisms, which are responsible for intraaxonal APP accumulation, do not only disturb APP, but also the transport of other synaptic proteins. These results indicate that, despite differences in their characteristics, all three models may serve as valid and suitable systems for investigating responsible mechanisms of axonal damage and potential protective strategies. (C) 2016 Elsevier B.V. All rights reserved.	[Hoeflich, Katharina Marie; Beyer, Cordian; Clarner, Tim; Nyamoya, Stella] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, D-52074 Aachen, Germany; [Schmitz, Christoph; Nyamoya, Stella; Kipp, Markus; Hochstrasser, Tanja] Univ Munich, Dept Neuroanat, D-80336 Munich, Germany	Hochstrasser, T (corresponding author), Univ Munich, Dept Neuroanat, D-80336 Munich, Germany.	tanja.hochstrasser@med.uni-muenchen.de			Doktor Robert Pfleger - Stiftung	We would like to thank H. Helten, P. Ibold and A. Baltruschat for their excellent technical assistance and N. Angstman for English language and grammatical technical support. The present work was supported by the Doktor Robert Pfleger - Stiftung.	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Aharoni R, 2011, J AUTOIMMUN, V37, P228, DOI 10.1016/j.jaut.2011.06.003; ALVORD EC, 1985, NEUROCHEM PATHOL, V3, P195, DOI 10.1007/BF02834271; Berard JL, 2010, GLIA, V58, P434, DOI 10.1002/glia.20935; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brumovsky PR, 2013, J UROLOGY, V189, P2342, DOI 10.1016/j.juro.2012.11.046; Charcot J, 1868, GAZ HOSP, V41, P554; Choi J, 2008, ENDOCRINOLOGY, V149, P6146, DOI 10.1210/en.2008-0432; Clarner T, 2015, J IMMUNOL, V194, P3400, DOI 10.4049/jimmunol.1401459; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Correale J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00180; DOUSSET V, 1995, AM J NEURORADIOL, V16, P225; Fremeau RT, 2004, TRENDS NEUROSCI, V27, P98, DOI 10.1016/j.tins.2003.11.005; Gautier HOB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9518; Gilgun-Sherki Y, 2003, NEUROSCI RES, V47, P201, DOI 10.1016/S0168-0102(03)00217-7; Goldberg J, 2015, J MOL NEUROSCI; Grosse-Veldmann R., 2015, MOL NEUROBIOL; Haider L, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/725370; Hares K, 2016, NEUROPATHOL APPL NEU; Heese K, 1998, J NEUROCHEM, V70, P699; Hendriks JJA, 2005, BRAIN RES REV, V48, P185, DOI 10.1016/j.brainresrev.2004.12.008; Herder V, 2011, NEUROPATH APPL NEURO, V37, P676, DOI 10.1111/j.1365-2990.2011.01168.x; Herrero-Herranz E, 2008, NEUROBIOL DIS, V30, P162, DOI 10.1016/j.nbd.2008.01.001; Hiremath MM, 1998, J NEUROIMMUNOL, V92, P38, DOI 10.1016/S0165-5728(98)00168-4; Imai M, 2008, J NEUROSURG-SPINE, V8, P58, DOI 10.3171/SPI-08/01/058; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Irvine KA, 2006, J NEUROIMMUNOL, V175, P69, DOI 10.1016/j.jneuroim.2006.03.002; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Khademi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063172; Kipp M, 2011, BRAIN BEHAV IMMUN, V25, P1554, DOI 10.1016/j.bbi.2011.05.003; Kipp M, 2009, ACTA NEUROPATHOL, V118, P723, DOI 10.1007/s00401-009-0591-3; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; Lassmann H, 1998, MULT SCLER J, V4, P93, DOI 10.1177/135245859800400301; Lindner M, 2009, NEUROSCI LETT, V453, P120, DOI 10.1016/j.neulet.2009.02.004; Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X; Marik C, 2007, BRAIN, V130, P2800, DOI 10.1093/brain/awm236; Matsuda S, 2003, J BIOL CHEM, V278, P38601, DOI 10.1074/jbc.M304379200; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; Ormel L, 2012, GLIA, V60, P229, DOI 10.1002/glia.21258; Paolillo A, 1999, NEUROLOGY, V53, P751, DOI 10.1212/WNL.53.4.751; Paxinos G., 2001, PAXINOS FRANKLINS MO; Pfeifenbring S, 2015, ANN NEUROL, V77, P655, DOI 10.1002/ana.24364; Pierce JES, 1996, J NEUROSCI, V16, P1083; Scalfari A, 2013, JAMA NEUROL, V70, P214, DOI 10.1001/jamaneurol.2013.599; Scheld M, 2016, J NEUROSCI, V36, P1410, DOI 10.1523/JNEUROSCI.2456-15.2016; Schirmer L, 2013, BRAIN PATHOL, V23, P2, DOI 10.1111/j.1750-3639.2012.00608.x; Schmidt T, 2013, J MOL NEUROSCI, V49, P80, DOI 10.1007/s12031-012-9896-0; Serbinek D, 2010, CARDIOVASC PSYCHIAT, V2010; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Shriver LP, 2006, AM J PATHOL, V169, P999, DOI 10.2353/ajpath.2006.050791; Sidman R. L., 1971, ATLAS MOUSE BRAIN SP; Siffrin V, 2010, IMMUNITY, V33, P424, DOI 10.1016/j.immuni.2010.08.018; Slowik A, 2015, BRIT J PHARMACOL, V172, P80, DOI 10.1111/bph.12938; Smith KJ, 2002, LANCET NEUROL, V1, P232, DOI 10.1016/S1474-4422(02)00102-3; Sun J, 2016, ONCOTARGET, DOI 10.18632/oncotarget.8190; Trapp BD, 1999, CURR OPIN NEUROL, V12, P295, DOI 10.1097/00019052-199906000-00008; van Noort JM, 2011, CNS NEUROL DISORD-DR, V10, P68; WAXMAN SG, 1979, J NEUROL SCI, V44, P45, DOI 10.1016/0022-510X(79)90221-1; Wessig C, 2007, EXP NEUROL, V204, P14, DOI 10.1016/j.expneurol.2006.09.022; Woodruff RH, 1999, GLIA, V25, P216, DOI 10.1002/(SICI)1098-1136(19990201)25:3<216::AID-GLIA2>3.0.CO;2-L	62	23	23	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 1	2016	1650						125	133		10.1016/j.brainres.2016.08.048			9	Neurosciences	Neurosciences & Neurology	DZ9IF	WOS:000386187800014	27592741				2021-06-18	
J	Hallock, H; Collins, D; Lampit, A; Deol, K; Fleming, J; Valenzuela, M				Hallock, Harry; Collins, Daniel; Lampit, Amit; Deol, Kiran; Fleming, Jennifer; Valenzuela, Michael			Cognitive Training for Post-Acute Traumatic Brain Injury: A Systematic Review and Meta-Analysis	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						traumatic brain injury; TBI; closed head injury; cognitive training; cognitive outcome; neuropsychological outcome; rehabilitation	OF-THE-LITERATURE; REHABILITATION; INTERVENTION; IMPAIRMENT; MODERATE; THERAPY; ADULTS; BIAS	Objective: To quantitatively aggregate effects of cognitive training (CT) on cognitive and functional outcome measures in patients with traumatic brain injury (TBI) more than 12 months post-injury. Design: We systematically searched six databases for non-randomized and randomized controlled trials of CT in TBI patients at least 12-months post-injury reporting cognitive and/or functional outcomes. Main Measures: Efficacy was measured as standardized mean difference (Hedges' g) of post-training change. We investigated heterogeneity across studies using subgroup analyses and meta-regressions. Results: Fourteen studies encompassing 575 patients were included. The effect of CT on overall cognition was small and statistically significant (g = 0.22, 95%CI 0.05 to 0.38; p = 0.01), with low heterogeneity (I-2 = 11.71%) and no evidence of publication bias. A moderate effect size was found for overall functional outcomes (g = 0.32, 95%Cl 0.08 to 0.57, p = 0.01) with low heterogeneity (I-2 I= 14.27%) and possible publication bias. Statistically significant effects were also found only for executive function (g = 0.20, 95%CI 0.02 to 0.39, p = 0.03) and verbal memory (g = 0.32, 95%CI 0.14 to 0.50, p < 0.01). Conclusion: Despite limited studies in this field, this meta-analysis indicates that CT is modestly effective in improving cognitive and functional outcomes in patients with post-acute TBI and should therefore play a more significant role in TBI rehabilitation.	[Hallock, Harry; Collins, Daniel; Lampit, Amit; Valenzuela, Michael] Univ Sydney, Brain & Mind Ctr, Regenerat Neurosci Grp, Sydney, NSW, Australia; [Lampit, Amit] Univ Sydney, Sch Psychol, Sydney, NSW, Australia; [Deol, Kiran] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Fleming, Jennifer] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld, Australia; [Fleming, Jennifer] Metro South Hosp & Hlth Serv, Ctr Functioning & Hlth Res, Brisbane, Qld, Australia	Valenzuela, M (corresponding author), Univ Sydney, Brain & Mind Ctr, Regenerat Neurosci Grp, Sydney, NSW, Australia.	michael.valenzuela@sydney.edu.au		Collins, Daniel/0000-0003-2195-9037; Lampit, Amit/0000-0001-6522-8397; Valenzuela, Michael/0000-0001-7162-6607	NHMRCNational Health and Medical Research Council of Australia [1083064]	JF is supported by an NHMRC project grant (ID 1083064). AL is an ARC-NHMRC Dementia Research Development Fellow (ID 1108520). MV is an NHMRC Clinical Career Development Research Fellow (ID 1112813).	Ardila A, 2013, J NEUROLOGICAL DISOR, V1, P1, DOI DOI 10.4172/2329-6895.1000114; Bahar-Fuchs A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003260.pub2; Baribeau J., 1989, J NEUROL REHABIL, V3, P71; Barnett SM, 2002, PSYCHOL BULL, V128, P612, DOI 10.1037//0033-2909.128.4.612; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Borenstein M., 2009, INTRO METAANALYSIS; Buschert V, 2010, NAT REV NEUROL, V6, P508, DOI 10.1038/nrneurol.2010.113; Cantor J, 2014, ARCH PHYS MED REHAB, V95, P1, DOI 10.1016/j.apmr.2013.08.005; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Clare L., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003260; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Dawson DR, 2013, ARCH PHYS MED REHAB, V94, P1959, DOI 10.1016/j.apmr.2013.05.021; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Gates N, 2010, CURR PSYCHIAT REP, V12, P20, DOI 10.1007/s11920-009-0085-y; Gleser L. J., 2009, HDB RES SYNTHESIS ME; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Lampit A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001756; Leung IHK, 2015, NEUROLOGY, V85, P1843, DOI 10.1212/WNL.0000000000002145; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Man DWK, 2006, BRAIN INJURY, V20, P981, DOI 10.1080/13561820600909852; Marshall GA, 2011, ALZHEIMERS DEMENT, V7, P300, DOI 10.1016/j.jalz.2010.04.005; Nelson LA, 2013, NEUROPSYCHOLOGY, V27, P666, DOI 10.1037/a0034117; O'Neil-Pirozzi TM, 2010, J HEAD TRAUMA REHAB, V25, P43, DOI 10.1097/HTR.0b013e3181bf24b1; Pa J, 2009, ANN NEUROL, V65, P414, DOI 10.1002/ana.21591; Potvin MJ, 2011, NEUROPSYCHOL REHABIL, V21, P899, DOI 10.1080/09602011.2011.630882; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Rice-Oxley M, 1999, CLIN REHABIL, V13, P7, DOI 10.1191/026921599668051623; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Strauss ShermanEMS, 2006, COMPENDIUM NEUROPSYC; Thomas-Stonell N, 1994, J HEAD TRAUMA REHAB, V9, P25, DOI DOI 10.1097/00001199-199412000-00005; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Toril P, 2014, PSYCHOL AGING, V29, P706, DOI 10.1037/a0037507; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Wilson M., 2014, SCAND J TRAUMA RE S1, V22, pA7, DOI [10.1186/1757-7241-22-S1-A7, DOI 10.1186/1757-7241-22-S1-A7]; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855	53	23	23	0	20	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 27	2016	10								537	10.3389/fnhum.2016.00537			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	DZ9AL	WOS:000386165200001	27833541	DOAJ Gold, Green Published			2021-06-18	
J	Li, X; Wang, HD; Gao, YY; Li, LW; Tang, C; Wen, GD; Zhou, Y; Zhou, ML; Mao, L; Fan, YW				Li, Xiang; Wang, Handong; Gao, Yongyue; Li, Liwen; Tang, Chao; Wen, Guodao; Zhou, Yuan; Zhou, Mengliang; Mao, Lei; Fan, Youwu			Protective Effects of Quercetin on Mitochondrial Biogenesis in Experimental Traumatic Brain Injury via the Nrf2 Signaling Pathway	PLOS ONE			English	Article							CEREBRAL ISCHEMIA-REPERFUSION; INDUCED OXIDATIVE STRESS; MEMORY-IMPAIRMENT; INDUCED APOPTOSIS; ACTIVATION; MICE; INFLAMMATION; ENHANCEMENT; HEPATITIS; NRF2/HO-1	The present investigation was carried out to elucidate a possible molecular mechanism related to the protective effect of quercetin administration against oxidative stress on various mitochondrial respiratory complex subunits with special emphasis on the role of nuclear factor erythroid 2-related factor 2 (Nrf2) in mitochondrial biogenesis. Recently, quercetin has been proved to have a protective effect against mitochondria damage after traumatic brain injury (TBI). However, its precise role and underlying mechanisms in traumatic brain injury are not yet fully understood. The aim of the present study was to investigate the effect of quercetin on the potential mechanism of these effects in a weight-drop model of TBI in male mice that were treated with quercetin or vehicle via intraperitoneal injection administrated 30 min after TBI. In this experiment, ICR mice were divided into four groups: A sham group, TBI group, TBI + vehicle group, and TBI + quercetin group. Brain samples were collected 24 h later for analysis. Quercetin treatment resulted in an upregulation of Nrf2 expression and cytochrome c, malondialdehyde (MDA) and superoxide dismutase ( SOD) levels were restored by quercetin treatment. Quercetin markedly promoted the translocation of Nrf2 protein from the cytoplasm to the nucleus. These observations suggest that quercetin improves mitochondrial function in TBI models, possibly by activating the Nrf2 pathway.	[Li, Xiang; Wang, Handong; Gao, Yongyue; Li, Liwen; Tang, Chao; Wen, Guodao; Zhou, Yuan; Zhou, Mengliang; Mao, Lei; Fan, Youwu] Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD; Mao, L; Fan, YW (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com; njmaolei@126.com; njywfan@163.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357]; Nanjing Military Region Foundation, PLA Grant [14MS104, 15MS126]	This work was supported by the National Natural Science Foundation of China (81371357) and the Nanjing Military Region Foundation, PLA Grant (14MS104, 15MS126).	Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Baburamani AA, 2015, INT J MOL SCI, V16, P22509, DOI 10.3390/ijms160922509; Bachmetov L, 2012, J VIRAL HEPATITIS, V19, pE81, DOI 10.1111/j.1365-2893.2011.01507.x; Bouitbir J, 2012, EUR HEART J, V33, P1397, DOI 10.1093/eurheartj/ehr224; Bournival J, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/921941; Carrasco-Pozo C, 2016, J NUTR BIOCHEM, V27, P289, DOI 10.1016/j.jnutbio.2015.09.016; Chen C, 2012, J ASIAN NAT PROD RES, V14, P877, DOI 10.1080/10286020.2012.702108; Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Hindy N, 2014, EUR J TRAUMA EMERG S, V40, P481, DOI 10.1007/s00068-013-0337-8; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Go KL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/183469; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Halder S, 2016, BIOL TRACE ELEM RES, V171, P391, DOI 10.1007/s12011-015-0544-8; Halder S, 2016, DRUG CHEM TOXICOL, V39, P272, DOI 10.3109/01480545.2015.1092042; Hu YY, 2015, BRAIN RES, V1605, P39, DOI 10.1016/j.brainres.2015.02.015; Kambe Y, 2016, J MOL NEUROSCI; Kilbaugh TJ, 2015, EXP NEUROL, V271, P136, DOI 10.1016/j.expneurol.2015.05.009; Kimura T, 2016, AMINO ACIDS; Kompanje EJO, 2007, SCI ENG ETHICS, V13, P371, DOI 10.1007/s11948-007-9027-4; Kulkarni GV, 1998, EXP CELL RES, V245, P170, DOI 10.1006/excr.1998.4245; Kysenius K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107129; Lawrence NJ, 2008, DNA REPAIR, V7, P281, DOI 10.1016/j.dnarep.2007.10.005; Lei XF, 2016, MOL MED REP, V13, P412, DOI 10.3892/mmr.2015.4534; Li RR, 2015, INT J MED SCI, V12, P432, DOI 10.7150/ijms.11402; Liu P, 2015, RESTOR NEUROL NEUROS, V33, P143, DOI 10.3233/RNN-140446; Liu WC, 2017, J NEUROSURG, V127, P8, DOI 10.3171/2016.4.JNS152909; Liu Y, 2015, J NEUROL SCI, V351, P88, DOI 10.1016/j.jns.2015.02.045; Marcolin E, 2012, J NUTR, V142, P1821, DOI 10.3945/jn.112.165274; Petzold A, 2007, NEUROL RES, V29, P691, DOI 10.1179/016164107X240080; Sanganahalli BG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063317; Sharma DR, 2015, NEUROTOXICOLOGY, V51, P116, DOI 10.1016/j.neuro.2015.10.002; Sharma DR, 2013, NEUROTOX RES, V23, P336, DOI 10.1007/s12640-012-9351-6; Shen J, 2007, BIOCHEM PHARMACOL, V73, P1901, DOI 10.1016/j.bcp.2007.03.009; Wang L, 2015, INT J CLIN EXP PATHO, V8, P11503; Whitman SA, 2013, EXP CELL RES, V319, P2673, DOI 10.1016/j.yexcr.2013.07.015; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060	40	23	26	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2016	11	10							e0164237	10.1371/journal.pone.0164237			12	Multidisciplinary Sciences	Science & Technology - Other Topics	ED7LQ	WOS:000389046900009	27780244	DOAJ Gold, Green Published			2021-06-18	
J	Saadoun, S; Papadopoulos, MC				Saadoun, Samira; Papadopoulos, Marios C.			Spinal cord injury: is monitoring from the injury site the future?	CRITICAL CARE			English	Article						Blood pressure; CNS injury; Clinical trial; Microdialysis; Monitoring; Neurocritical care; Spinal cord injury; Surgery	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; CLINICAL-TRIALS; INTRASPINAL PRESSURE; PERFUSION-PRESSURE; ICCP PANEL; INTRATHECAL PRESSURE; VASOPRESSOR USAGE; ANIMAL-MODEL; GUIDELINES	This paper challenges the current management of acute traumatic spinal cord injury based on our experience with monitoring from the injury site in the neurointensive care unit. We argue that the concept of bony decompression is inadequate. The concept of optimum spinal cord perfusion pressure, which differs between patients, is introduced. Such variability suggests individualized patient treatment. Failing to optimize spinal cord perfusion limits the entry of systemically administered drugs into the injured cord. We conclude that monitoring from the injury site helps optimize management and should be subjected to a trial to determine whether it improves outcome.	[Saadoun, Samira; Papadopoulos, Marios C.] St Georges Univ London, Acad Neurosurg Unit, Cranmer Terrace, London SW17 0RE, England	Papadopoulos, MC (corresponding author), St Georges Univ London, Acad Neurosurg Unit, Cranmer Terrace, London SW17 0RE, England.	mpapadop@sgul.ac.uk		Papadopoulos, Marios/0000-0001-9174-4176; Saadoun, Samira/0000-0002-5480-5678	Wings for Life spinal cord research foundation; Neurosciences Research Foundation (Fletcher Fund)	Supported by the Wings for Life spinal cord research foundation and the Neurosciences Research Foundation (Fletcher Fund).	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Awwad Waleed, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS261, DOI 10.1007/s00590-013-1409-5; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bydon M, 2014, WORLD NEUROSURG, V82, P848, DOI 10.1016/j.wneu.2013.02.062; Chen S, 2016, J NEUROCHEM IN PRESS; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cozzens JW, 2013, NEUROSURGERY, V72, P2, DOI 10.1227/NEU.0b013e3182772981; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Fehlings MG, 2010, SPINE, V35, pS166, DOI 10.1097/BRS.0b013e3181f386f6; Han JS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002827; Hawryluk G, 2015, J NEUROTRAUM, V32, P1958, DOI 10.1089/neu.2014.3778; Hurlbert RJ, 2008, CAN J NEUROL SCI, V35, P41, DOI 10.1017/S031716710000754X; Iannotti C, 2006, J NEUROTRAUM, V23, P853, DOI 10.1089/neu.2006.23.853; Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061; Jones CF, 2012, SPINE, V37, pE1422, DOI 10.1097/BRS.0b013e31826ba7cd; KATOH S, 1995, PARAPLEGIA, V33, P506, DOI 10.1038/sc.1995.110; Kwon BK, 2009, J NEUROSURG-SPINE, V10, P181, DOI 10.3171/2008.10.SPINE08217; Lammertse D, 2007, SPINAL CORD, V45, P232, DOI 10.1038/sj.sc.3102010; Lassmann H, 2003, J NEUROL SCI, V206, P187, DOI 10.1016/S0022-510X(02)00421-5; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Maas A, 2016, NEUROSURGERY, V78, P368; Nagoshi N, 2015, EXPERT OPIN INV DRUG, V24, P645, DOI 10.1517/13543784.2015.1009629; Papadopoulos MC, 2015, NEUROSURGERY, V77, pE500, DOI 10.1227/NEU.0000000000000862; Phang I, 2016, ANN NEUROL, V80, P522, DOI 10.1002/ana.24750; Phang I, 2016, J NEUROSURG-SPINE, V25, P398, DOI 10.3171/2016.1.SPINE151317; Phang I, 2015, NEUROCRIT CARE, V23, P414, DOI 10.1007/s12028-015-0153-6; Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668; Readdy WJ, 2015, J NEUROSURG-SPINE, V23, P574, DOI 10.3171/2015.2.SPINE14746; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Saadoun S, 2016, BRIT J NEUROSURG, V30, P582, DOI 10.3109/02688697.2016.1173191; Smith JS, 2010, J BONE JOINT SURG AM, V92A, P1206, DOI 10.2106/JBJS.I.00740; Steeves JD, 2007, SPINAL CORD, V45, P206, DOI 10.1038/sj.sc.3102008; Tuszynski MH, 2007, SPINAL CORD, V45, P222, DOI 10.1038/sj.sc.3102009; Valadka AB, 2007, NEUROSURGERY, V61, P203, DOI 10.1227/01.NEU.0000255497.26440.01; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Varsos GV, 2015, J NEUROSURG-SPINE, V23, P763, DOI 10.3171/2015.3.SPINE14870; Vender J, 2011, J CLIN MONIT COMPUT, V25, P231, DOI 10.1007/s10877-011-9300-6; Werndle MC, 2016, ACTA NEUROCHIR SUPPL, V122, P323, DOI 10.1007/978-3-319-22533-3_64; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038; Yuan Q, 2016, NEUROSURGERY, V78, P361, DOI 10.1227/NEU.0000000000001050	45	23	24	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	OCT 5	2016	20								308	10.1186/s13054-016-1490-3			9	Critical Care Medicine	General & Internal Medicine	DX7RZ	WOS:000384588300001	27716379	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Keller, U; van Hedel, HJA; Klamroth-Marganska, V; Riener, R				Keller, Urs; van Hedel, Hubertus J. A.; Klamroth-Marganska, Verena; Riener, Robert			ChARMin: The First Actuated Exoskeleton Robot for Pediatric Arm Rehabilitation	IEEE-ASME TRANSACTIONS ON MECHATRONICS			English	Article						Control engineering; medical robotics; pediatrics; robot kinematics; virtual reality	CEREBRAL-PALSY; MOTOR FUNCTION; CHILDREN; THERAPY; STABILITY	ChARMin is the first actuated exoskeleton robot for pediatric arm rehabilitation. The device was specifically designed to provide intensive rehabilitative training for children with affected arm motor function, e.g., due to cerebral palsy; therewith complementing conventional therapies. This paper gives a comprehensive overview of the ChARMin robot, which provides six actuated degrees of freedom, and is designed to cover the complete target group of children and adolescents aged 5-18 years. Moreover, the new audiovisual game-like interface is presented, which motivates active participation of the child. To support the child's arm movements with the exoskeleton, a patient-cooperative control strategy was implemented. The controller enables free arm movements, assistance-asneeded, and complete guidance of the arm. Five children aged 5-17 years with impaired arm motor function due to cerebral palsy, stroke, and traumatic brain injury tested the various training scenarios with different amounts of support, and robot settings depending on the therapeutic goals and the children's movement capabilities and preferences. These preliminary tests suggest that the ChARMin setup can be used as an advanced exercise tool for arm neurorehabilitation that optimally challenges children and adolescents with severely tomoderately affected armmotor functions.	[Keller, Urs; Klamroth-Marganska, Verena; Riener, Robert] Swiss Fed Inst Technol, Sensory Motor Syst Lab, CH-8092 Zurich, Switzerland; [Keller, Urs; Klamroth-Marganska, Verena; Riener, Robert] Univ Zurich, Univ Hosp Balgrist, CH-8008 Zurich, Switzerland; [Keller, Urs; van Hedel, Hubertus J. A.] Univ Childrens Hosp Zurich, Rehabil Ctr, CH-8910 Affoltern Am Albis, Switzerland	Keller, U (corresponding author), Swiss Fed Inst Technol, Sensory Motor Syst Lab, CH-8092 Zurich, Switzerland.; Keller, U (corresponding author), Univ Zurich, Univ Hosp Balgrist, CH-8008 Zurich, Switzerland.; Keller, U (corresponding author), Univ Childrens Hosp Zurich, Rehabil Ctr, CH-8910 Affoltern Am Albis, Switzerland.	urs.keller@kispi.uzh.ch; hubertus.vanhedel@kispi.uzh.ch; verena.klamroth@hest.ethz.ch; robert.riener@hest.ethz.ch	van Hedel, Hubertus/AAL-3818-2021	van Hedel, Hubertus/0000-0002-9577-5049	Highly-Specialized Medicine Project of the Canton of Zurich; Gottfried und Julia Bangerter-Rhyner Foundation; Maxi Foundation; Gaydoul Foundation; National Centre of Competence in Research (NCCR) Neural Plasticity and RepairSwiss National Science Foundation (SNSF); Clinical Research Priority Program Neuro-Rehabilitation of the Medical Faculty of the University of Zurich; NCCR Robotics, Switzerland	This work was supported by the Highly-Specialized Medicine Project of the Canton of Zurich, by the Gottfried und Julia Bangerter-Rhyner Foundation, by the Maxi Foundation, by the Gaydoul Foundation, by the National Centre of Competence in Research (NCCR) Neural Plasticity and Repair, by the Clinical Research Priority Program Neuro-Rehabilitation of the Medical Faculty of the University of Zurich, and by NCCR Robotics, Switzerland.	Aisen ML, 2011, LANCET NEUROL, V10, P844, DOI 10.1016/S1474-4422(11)70176-4; ARMSTRONGHELOUVRY B, 1994, AUTOMATICA, V30, P1083, DOI 10.1016/0005-1098(94)90209-7; Boyd RN, 2001, EUR J NEUROL, V8, P150, DOI 10.1046/j.1468-1331.2001.00048.x; Colgate J. E., 1988, THESIS; Damiano DL, 2006, PHYS THER, V86, P1534, DOI 10.2522/ptj.20050397; Diolaiti N, 2006, IEEE T ROBOT, V22, P256, DOI 10.1109/TRO.2005.862487; Dominici N, 2012, NAT MED, V18, P1142, DOI 10.1038/nm.2845; Fasoli SE, 2008, AM J PHYS MED REHAB, V87, P929, DOI 10.1097/PHM.0b013e31818a6aa4; Fluet GG, 2010, DEV NEUROREHABIL, V13, P335, DOI 10.3109/17518423.2010.501362; Gilliaux M, 2015, NEUROREHAB NEURAL RE, V29, P183, DOI 10.1177/1545968314541172; Guidali M., 2011, 2011 IEEE INT C REH, P1, DOI DOI 10.1109/ICORR.2011.5975434; Guidali M, 2011, MED BIOL ENG COMPUT, V49, P1213, DOI 10.1007/s11517-011-0809-0; Hanna SE, 2009, DEV MED CHILD NEUROL, V51, P295, DOI 10.1111/j.1469-8749.2008.03196.x; Hogan N, 2006, J REHABIL RES DEV, V43, P605, DOI 10.1682/JRRD.2005.06.0103; Jarrasse N, 2012, IEEE T ROBOT, V28, P697, DOI 10.1109/TRO.2011.2178151; Keller U., 2012, AUT C, V286, P55; Keller U., 2013, REH ROB ICORR 2013 I, P1; Keller U, 2014, P IEEE RAS-EMBS INT, P530, DOI 10.1109/BIOROB.2014.6913832; Keller U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126948; Keller U, 2013, IEEE INT CONF ROBOT, P3908, DOI 10.1109/ICRA.2013.6631127; Kim H, 2012, IEEE T BIO-MED ENG, V59, P1770, DOI 10.1109/TBME.2012.2194489; Lo Albert C, 2012, Am J Phys Med Rehabil, V91, pS204, DOI 10.1097/PHM.0b013e31826bcfa3; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Martin AL, 2014, NEUROL REHABIL, V20, P215; Nef Tobias, 2009, Applied Bionics and Biomechanics, V6, P127, DOI 10.1080/11762320902840179; Nef T, 2007, MED BIOL ENG COMPUT, V45, P887, DOI 10.1007/s11517-007-0226-6; Negrello F, 2015, IEEE-RAS INT C HUMAN, P414, DOI 10.1109/HUMANOIDS.2015.7363567; Olson H. F., 1967, MUSIC PHYS ENG, P249; Oskoui M, 2013, DEV MED CHILD NEUROL, V55, P509, DOI 10.1111/dmcn.12080; Patton JL, 2006, EXP BRAIN RES, V168, P368, DOI 10.1007/s00221-005-0097-8; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Ryu JH, 2005, IEEE T CONTR SYST T, V13, P737, DOI 10.1109/TCST.2005.847336; Sakzewski L, 2014, J CHILD NEUROL, V29, P1077, DOI 10.1177/0883073814533150; Shikako-Thomas Keiko, 2008, Phys Occup Ther Pediatr, V28, P155, DOI 10.1080/01942630802031834; Siciliano Bruno, 2008, SPRINGER HDB ROBOTIC; Stienen AHA, 2010, IEEE T BIO-MED ENG, V57, P728, DOI 10.1109/TBME.2009.2018628; Stienen AHA, 2009, IEEE T ROBOT, V25, P628, DOI 10.1109/TRO.2009.2019147; Ugurlu B, 2015, IEEE T HUM-MACH SYST, V45, P110, DOI 10.1109/THMS.2014.2362816; Vallery H, 2009, INT C REHAB ROBOT, P623, DOI 10.1109/ICORR.2009.5209595; van der Schaft A., 1999, L2 GAIN PASSIVITY NO	41	23	25	1	86	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1083-4435	1941-014X		IEEE-ASME T MECH	IEEE-ASME Trans. Mechatron.	OCT	2016	21	5					2201	2213		10.1109/TMECH.2016.2559799			13	Automation & Control Systems; Engineering, Manufacturing; Engineering, Electrical & Electronic; Engineering, Mechanical	Automation & Control Systems; Engineering	DU8OH	WOS:000382472600001					2021-06-18	
J	Tatel, DF; Wade, BSC; Velez, CS; Drennon, AM; Bolzenius, J; Gutman, BA; Thompson, PM; Lewis, JD; Wilde, EA; Bigler, ED; Shenton, ME; Ritter, JL; York, GE				Tatel, David F.; Wade, Benjamin S. C.; Velez, Carmen S.; Drennon, Ann Marie; Bolzenius, Jacob; Gutman, Boris A.; Thompson, Paul M.; Lewis, Jeffrey D.; Wilde, Elisabeth A.; Bigler, Erin D.; Shenton, Martha E.; Ritter, John L.; York, Gerald E.			Volumetric and shape analyses of subcortical structures in United States service members with mild traumatic brain injury	JOURNAL OF NEUROLOGY			English	Article						Mild traumatic brain injury; Military; mTBI; Subcortical structures; Volumetric measures; Shape analyses; Service members	POSTTRAUMATIC-STRESS-DISORDER; TENSOR IMAGING FINDINGS; HIPPOCAMPAL VOLUME; NUCLEUS-ACCUMBENS; CORTICAL THICKNESS; AMYGDALA; MORPHOMETRY; INTEGRITY; VETERANS; ATROPHY	Mild traumatic brain injury (mTBI) is a significant health concern. The majority who sustain mTBI recover, although similar to 20 % continue to experience symptoms that can interfere with quality of life. Accordingly, there is a critical need to improve diagnosis, prognostic accuracy, and monitoring (recovery trajectory over time) of mTBI. Volumetric magnetic resonance imaging (MRI) has been successfully utilized to examine TBI. One promising improvement over standard volumetric approaches is to analyze high-dimensional shape characteristics of brain structures. In this study, subcortical shape and volume in 76 Service Members with mTBI was compared to 59 Service Members with orthopedic injury (OI) and 17 with post-traumatic stress disorder (PTSD) only. FreeSurfer was used to quantify structures from T1-weighted 3 T MRI data. Radial distance (RD) and Jacobian determinant (JD) were defined vertex-wise on parametric mesh-representations of subcortical structures. Linear regression was used to model associations between morphometry (volume and shape), TBI status, and time since injury (TSI) correcting for age, sex, intracranial volume, and level of education. Volumetric data was not significantly different between the groups. JD was significantly increased in the accumbens and caudate and significantly reduced in the thalamus of mTBI participants. Additional significant associations were noted between RD of the amygdala and TSI. Positive trend-level associations between TSI and the amygdala and accumbens were observed, while a negative association was observed for third ventricle. Our findings may aid in the initial diagnosis of mTBI, provide biological targets for functional examination, and elucidate regions that may continue remodeling after injury.	[Tatel, David F.; Velez, Carmen S.; Bolzenius, Jacob] Univ Missouri, Missouri Inst Mental Hlth, 4633 World Pkwy Circle, Berkeley, MO 63134 USA; [Tatel, David F.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wade, Benjamin S. C.; Gutman, Boris A.; Thompson, Paul M.] Univ So Calif, Imaging Genet Ctr, Marina Del Rey, CA USA; [Drennon, Ann Marie] San Antonio Mil Med Ctr, Def & Vet Brain Injury Ctr, San Antonio, TX USA; [Lewis, Jeffrey D.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Sch Med, Bethesda, MD 20814 USA; [Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat & Radiol, Psychiat Neuroimaging Lab, Boston, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA; [Ritter, John L.] Brooke Army Med Ctr, Dept Radiol, San Antonio, TX USA; [York, Gerald E.] Alaska Radiol Associates, TBI Imaging & Res, Anchorage, AK USA	Tatel, DF (corresponding author), Univ Missouri, Missouri Inst Mental Hlth, 4633 World Pkwy Circle, Berkeley, MO 63134 USA.; Tatel, DF (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA.	David.Tate@mimh.edu	Shenton, Martha/V-8780-2019; Thompson, Paul M/C-4194-2018; Ritter, John/AAG-8899-2020; Tate, David F/I-3963-2013	Thompson, Paul M/0000-0002-4720-8867; Tate, David F/0000-0003-0213-1920	Defense and Veterans Brain Injury Centers; Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0025]; Chronic Effects of Neurotrauma Consortium (CENC) [PT108802-SC104835]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U54 EB020403]; Veterans Administration (VA Merit Grant)US Department of Veterans Affairs; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB020403] Funding Source: NIH RePORTER	The view(s) expressed herein are those of the author and do not reflect the official policy or position of the Defense and Veterans Brain Injury Center, Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, Department of Defense, or the U.S. Government. We gratefully acknowledge the generous time and effort that the Service Members made in supporting this study. We also gratefully acknowledge the clinical effort and expertise of the Brooke Army Medical Center Brain Injury and Rehabilitation Service staff in the identification, recruitment, consenting, and treatment of Service Members who are a part of this study. This work is supported in part by the Defense and Veterans Brain Injury Centers, the Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC; W81XWH-13-2-0025), the Chronic Effects of Neurotrauma Consortium (CENC; PT108802-SC104835), the National Institutes of Health (NIH U54 EB020403), and the Veterans Administration (VA Merit Grant).	Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; [Anonymous], 2016, CLIN PRACT GUID; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Berger-Sweeney J, 2003, NEUROSCI BIOBEHAV R, V27, P401, DOI 10.1016/S0149-7634(03)00070-8; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler E, 2015, NEUROPSYCHOL REV, V25, P224, DOI 10.1007/s11065-015-9290-0; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075; Castro DC, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00090; Chan RCK, 2016, NEUROPSYCHOLOGY, V30, P274, DOI 10.1037/neu0000233; Chen YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048298; Combs HL, 2015, J NEUROTRAUM, V32, P956, DOI 10.1089/neu.2014.3585; Dennis EL, 2016, J NEUROTRAUM, V33, P840, DOI 10.1089/neu.2015.4012; Depue BE, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/691505; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Esopenko C, 2015, J NEUROTRAUM, V32, P209, DOI 10.1089/neu.2014.3506; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gooijers J, 2015, NEUROREHABIL NEURAL; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Gutman Boris A., 2013, Multimodal Brain Image Analysis. Third International Workshop, MBIA 2013. Held in Conjunction with MICCAI 2013. Proceedings: LNCS 8159, P246, DOI 10.1007/978-3-319-02126-3_24; Gutman BA, 2015, I S BIOMED IMAGING, P1402, DOI 10.1109/ISBI.2015.7164138; Gutman BA, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P716, DOI 10.1109/ISBI.2012.6235648; Han K, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00231; Haran FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079595; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2014, LANCET PSYCHIAT, V1, P269, DOI 10.1016/S2215-0366(14)70235-4; Hoge CW, 2014, JAMA-J AM MED ASSOC, V312, P1685, DOI 10.1001/jama.2014.6670; Jaramillo CA, 2015, BRAIN IMAGING BEHAV, V9, P445, DOI 10.1007/s11682-015-9402-8; JONES EG, 1976, BRAIN RES, V104, P142, DOI 10.1016/0006-8993(76)90654-5; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Joshi SH, 2016, BIOL PSYCHIAT, V79, P282, DOI 10.1016/j.biopsych.2015.02.029; Karmonik C, 2013, IEEE ENG MED BIO, P1366, DOI 10.1109/EMBC.2013.6609763; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; King JB, 2016, NEUROIMAGE-CLIN, V11, P81, DOI 10.1016/j.nicl.2016.01.003; Kuhn S, 2011, J AFFECT DISORDERS, V134, P315, DOI 10.1016/j.jad.2011.06.003; Leunissen I, 2014, CORTEX, V51, P67, DOI 10.1016/j.cortex.2013.10.009; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lutkenhoff ES, 2013, NEUROIMAGE-CLIN, V3, P396, DOI 10.1016/j.nicl.2013.09.010; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maller JJ, 2014, BEHAV BRAIN RES, V271, P147, DOI 10.1016/j.bbr.2014.05.047; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Ohman A, 2005, PSYCHONEUROENDOCRINO, V30, P953, DOI 10.1016/j.psyneuen.2005.03.019; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.09.004; Pietrzak RH, 2015, JAMA PSYCHIAT, V72, P396, DOI 10.1001/jamapsychiatry.2014.2470; Prasad MR, 2016, J HEAD TRAUMA REHABI; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Roozendaal B, 2001, J NEUROSCI, V21, P2518; Sarkar A, 2013, INT J EMERG MULTIDIS, V3, P135; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; Tator CH, 2016, J NEUROSURG, V26, P1; van Rooij SJH, 2015, PSYCHOL MED, V45, P2737, DOI 10.1017/S0033291715000707; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Wade BSC, 2015, NEUROIMAGE-CLIN, V9, P564, DOI 10.1016/j.nicl.2015.10.006; Wang L, 2016, P NATL ACAD SCI USA, V113, P2750, DOI 10.1073/pnas.1514682113; Wilde EA, 2015, BRAIN IMAGING BEHAV, V9, P367, DOI 10.1007/s11682-015-9444-y; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilke M, 2013, J COGNITIVE NEUROSCI, V25, P1270, DOI 10.1162/jocn_a_00399	74	23	23	0	14	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	OCT	2016	263	10					2065	2079		10.1007/s00415-016-8236-7			15	Clinical Neurology	Neurosciences & Neurology	DY5WA	WOS:000385173900019	27435967	Green Accepted			2021-06-18	
J	Palmer, BW; Harmell, AL				Palmer, Barton W.; Harmell, Alexandrea L.			Assessment of Healthcare Decision-making Capacity	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Schizophrenia; Alzheimer's disease	MILD COGNITIVE IMPAIRMENT; DIFFERENT LEGAL STANDARDS; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; MEDICAL DECISIONS; CLINICAL-RESEARCH; BIPOLAR DISORDER; INFORMED-CONSENT; OLDER PATIENTS	It is often necessary for neuropsychologists, clinical psychologists, and other healthcare professionals to assess an individual's capacity to consent to treatment related to healthcare. This task can be challenging and requires a delicate balance of both respect for individuals' autonomy, as well as the protection of individuals with diminished capacity to make an autonomous decision. The purpose of the present review is to provide an overview of the conceptual model of decisional capacity as well as a brief summary of some of the currently available instruments designed to help evaluate medical decision making. In addition, current empirical literature on the relationship between neuropsychological abilities and decision-making capacity is discussed and a brief set of recommendations is provided to further aid clinicians or consultants when they are required to complete the ethically important but difficult task of making determinations about healthcare decision-making capacity.	[Palmer, Barton W.; Harmell, Alexandrea L.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Palmer, Barton W.] Vet Med Res Fdn, San Diego, CA USA; [Palmer, Barton W.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Palmer, Barton W.; Harmell, Alexandrea L.] Univ Calif San Diego, Stein Inst Res Aging, Ctr Hlth Aging, San Diego, CA 92093 USA; [Harmell, Alexandrea L.] San Diego State Univ, Univ Calif San Diego Joint Doctoral Program Clin, San Diego, CA 92182 USA	Palmer, BW (corresponding author), Univ Calif San Diego, 9500 Gilman Dr,MC 0993, La Jolla, CA 92093 USA.	bpalmer@ucsd.edu	Palmer, Barton/ABA-7519-2020	Palmer, Barton/0000-0002-7618-3144	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AG028827, R01MH097274, T32MH019934]; Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019934, R01MH097274] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health (R01AG028827, R01MH097274, and T32MH019934) and by the Department of Veterans Affairs.	Alvarez M. I., 2014, MED CLIN, V143, P201; Amalraj S, 2009, ONCOLOGY-NY, V23, P369; American Bar Association Commission on Law and Aging & American Psychological Association, 2008, ASS OLD AD DIM CAP H; Anastasi A, 1997, PSYCHOL TESTING, V7th; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; Bambara JK, 2007, EPILEPSY BEHAV, V10, P63, DOI 10.1016/j.yebeh.2006.10.003; BEAN G, 1994, CAN J PSYCHIAT, V39, P368, DOI 10.1177/070674379403900804; BRANSFORD JD, 1972, J VERB LEARN VERB BE, V11, P717, DOI 10.1016/S0022-5371(72)80006-9; Braun MM, 2009, GENERATIONS, V33, P78; Burton CZ, 2012, AM J GERIAT PSYCHIAT, V20, P306, DOI 10.1097/JGP.0b013e3182436987; Cairns R, 2005, BRIT J PSYCHIAT, V187, P379, DOI 10.1192/bjp.187.4.379; Carney MT, 2001, J CLIN ETHIC, V12, P17; Carpenter WT, 2000, ARCH GEN PSYCHIAT, V57, P533, DOI 10.1001/archpsyc.57.6.533; Cea CD, 2003, MENT RETARD, V41, P78, DOI 10.1352/0047-6765(2003)041<0078:HCDMBA>2.0.CO;2; CHAPMAN LJ, 1973, PSYCHOL BULL, V79, P380, DOI 10.1037/h0034541; Chapman LJ, 2001, J ABNORM PSYCHOL, V110, P31, DOI 10.1037/0021-843X.110.1.31; Childress JF., 2001, PRINCIPLES BIOMEDICA; Cochrane Database of Systematic Reviews, 2015, WITHDR PUBL ACC ASS; Cohen J., 2003, APPL MULTIPLE CORREL; da Silva RD, 2015, PSYCHIAT QUART, V86, P395, DOI 10.1007/s11126-015-9340-z; Doyle KL, 2016, J CLIN PSYCHOL MED S, V23, P135, DOI 10.1007/s10880-016-9455-x; Dreer LE, 2008, REHABIL PSYCHOL, V53, P486, DOI 10.1037/a0013798; Dunn LB, 2006, AM J PSYCHIAT, V163, P1323, DOI 10.1176/appi.ajp.163.8.1323; Dunn LB, 2007, HUMAN FRONTAL LOBES, P335; Dymek MP, 2001, NEUROLOGY, V56, P17, DOI 10.1212/WNL.56.1.17; Edelstein B, 2000, J AGING STUD, V14, P423, DOI 10.1016/S0890-4065(00)80006-7; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gerstenecker A, 2016, ASSESSMENT, V23, P232, DOI 10.1177/1073191115599053; Gerstenecker A, 2015, CANCER-AM CANCER SOC, V121, P2013, DOI 10.1002/cncr.29326; Griffith HR, 2010, AGING NEUROPSYCHOL C, V17, P492, DOI 10.1080/13825581003646135; Grisso T, 1997, PSYCHIATR SERV, V48, P1415; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P127, DOI 10.1007/BF01499322; Grisso T., 1998, ASSESSING COMPETENCE; Grisso T, 1998, MACARTHUR COMPETENCE; Gurrera RJ, 2007, AM J GERIAT PSYCHIAT, V15, P168, DOI 10.1097/JGP.0b013e31802e705c; Gurrera RJ, 2014, AM J GERIAT PSYCHIAT, V22, P1200, DOI 10.1016/j.jagp.2013.03.010; Hafen B. C., 1976, BYU LAW REV, V605; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Hein I. M., 2014, COCHRANE DATABASE SY; Jeste DV, 2008, J PSYCHIATR RES, V42, P1, DOI 10.1016/j.jpsychires.2006.10.004; Jeste DV, 2007, ARCH GEN PSYCHIAT, V64, P966, DOI 10.1001/archpsyc.64.8.966; Jurica P. L., 1991, DEMENTIA RATING SCAL; Karel MJ, 2010, J CLIN ETHIC, V21, P58; Karel MJ, 2000, J AGING STUD, V14, P403, DOI 10.1016/S0890-4065(00)80005-5; Kim SYH, 2011, ARCH GEN PSYCHIAT, V68, P214, DOI 10.1001/archgenpsychiatry.2010.191; Kitamura T, 2000, PSYCHIAT CLIN NEUROS, V54, P515, DOI 10.1046/j.1440-1819.2000.00746.x; Kontos N, 2015, PSYCHOSOMATICS, V56, P217, DOI 10.1016/j.psym.2014.11.004; Lamont S, 2013, J CLIN NURS, V22, P2387, DOI 10.1111/jocn.12215; Mackenzie C, 2013, INT J LAW CONTEXT, V9, P37, DOI 10.1017/S174455231200047X; Marson D., 1993, Journal of the American Geriatrics Society, V41, pSA43; Marson D, 1999, Semin Clin Neuropsychiatry, V4, P41; Marson DC, 2000, J AM GERIATR SOC, V48, P911, DOI 10.1111/j.1532-5415.2000.tb06887.x; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P949, DOI 10.1001/archneur.1995.00540340029010; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P955, DOI 10.1001/archneur.1995.00540340035011; Marson DC, 1996, NEUROLOGY, V46, P666, DOI 10.1212/WNL.46.3.666; Marson DC, 1997, J AM GERIATR SOC, V45, P453, DOI 10.1111/j.1532-5415.1997.tb05170.x; Marson DC, 2001, INT J LAW PSYCHIAT, V24, P267, DOI 10.1016/S0160-2527(01)00064-4; Martin RC, 2008, MOVEMENT DISORD, V23, P1867, DOI 10.1002/mds.22170; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MOYE J, 1999, ADV MED PSYCHOTHERAP, V10, P71; Moye J, 2006, CLIN PSYCHOL REV, V26, P1054, DOI 10.1016/j.cpr.2005.04.013; Moye J, 2013, AM J GERIAT PSYCHIAT, V21, P326, DOI 10.1016/j.jagp.2012.09.001; Moye J, 2007, CLIN GERONTOLOGIST, V31, P37, DOI 10.1080/07317110802072140; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Norman D. A, 1980, ATTENTION ACTION WIL; Nutbeam D, 2008, SOC SCI MED, V67, P2072, DOI 10.1016/j.socscimed.2008.09.050; O'Callaghan C, 2014, PSYCHO-ONCOLOGY, V23, P1391, DOI 10.1002/pon.3576; Okonkwo O, 2007, NEUROLOGY, V69, P1528, DOI 10.1212/01.wnl.0000277639.90611.d9; Okonkwo OC, 2008, J INT NEUROPSYCH SOC, V14, P297, DOI 10.1017/S1355617708080338; Palmer B. W., 2012, CIVIL CAPACITIES CLI, P69; Palmer BW, 2007, J INT NEUROPSYCH SOC, V13, P1047, DOI 10.1017/S1355617707071299; Palmer BW, 2007, J CLIN PSYCHIAT, V68, P689, DOI 10.4088/JCP.v68n0505; Palmer BW, 2013, AM J GERIAT PSYCHIAT, V21, P373, DOI 10.1016/j.jagp.2012.11.008; Palmer Barton W, 2012, IRB, V34, P1; Palmer BW, 2006, SCHIZOPHRENIA BULL, V32, P98; Palmer BW, 2004, ARCH GEN PSYCHIAT, V61, P230, DOI 10.1001/archpsyc.61.3.230; ROTH LH, 1977, AM J PSYCHIAT, V134, P279; Savla GN, 2012, SCHIZOPHRENIA BULL, V38, P760, DOI 10.1093/schbul/sbq149; SCHANK RC, 1980, CONTEMP PSYCHOL, V25, P814; Schmand B, 1999, ALZ DIS ASSOC DIS, V13, P80, DOI 10.1097/00002093-199904000-00004; Sessums LL, 2011, JAMA-J AM MED ASSOC, V306, P420, DOI 10.1001/jama.2011.1023; Stroup S, 2005, SCHIZOPHR RES, V80, P1, DOI 10.1016/j.schres.2005.08.007; Sturman ED, 2005, CLIN PSYCHOL REV, V25, P954, DOI 10.1016/j.cpr.2005.04.010; The National Commission for the Protection of Human Subjects of Biomedical and Bevahioral Research, 1979, BELM REP ETH PRINC G; THOMPSON B, 1995, EDUC PSYCHOL MEAS, V55, P525, DOI 10.1177/0013164495055004001; Tomoda A, 1997, J CLIN PSYCHOL, V53, P443, DOI 10.1002/(SICI)1097-4679(199708)53:5<443::AID-JCLP4>3.0.CO;2-O; Triebel KL, 2009, NEUROLOGY, V73, P2086, DOI 10.1212/WNL.0b013e3181c67bce; Vellinga A, 2004, INT J GERIATR PSYCH, V19, P645, DOI 10.1002/gps.1139; Whittingham MJ, 2006, J ANIM ECOL, V75, P1182, DOI 10.1111/j.1365-2656.2006.01141.x	90	23	23	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	SEP	2016	31	6					530	540		10.1093/arclin/acw051			11	Psychology, Clinical; Psychology	Psychology	DZ7AU	WOS:000386016000006	27551024	Bronze, Green Published			2021-06-18	
J	Wang, SN; Xu, TY; Wang, X; Guan, YF; Zhang, SL; Wang, P; Miao, CY				Wang, Shu-Na; Xu, Tian-Ying; Wang, Xia; Guan, Yun-Feng; Zhang, Sai-Long; Wang, Pei; Miao, Chao-Yu			Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke	CNS NEUROSCIENCE & THERAPEUTICS			English	Article						Aminopropyl carbazole chemical; Ischemic stroke; Neuroprotection; Nicotinamide adenine dinucleotide; Nicotinamide phosphoribosyltransferase; P7C3-A20	TARGETING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL NEUROGENESIS; MOUSE MODEL; RATS; DISCOVERY; ACTIVATION; AUTOPHAGY; VISFATIN	AimNAMPT is a novel therapeutic target of ischemic stroke. The aim of this study was to investigate the effect of a potential NAMPT activator, P7C3-A20, an aminopropyl carbazole derivative, on ischemic stroke. MethodsIn vitro study, neuron protection effect of P7C3-A20 was investigated by co-incubation with primary neurons subjected to oxygen-glucose deprivation (OGD) or oxygen-glucose deprivation/reperfusion (OGD/R) injury. In vivo experiment, P7C3-A20 was administrated in middle cerebral artery occlusion (MCAO) rats and infarct volume was examined. Lastly, the brain tissue nicotinamide adenine dinucleotide (NAD) levels were detected in P7C3-A20 treated normal or MCAO mice. ResultsCell viability, morphology, and Tuj-1 staining confirmed the neuroprotective effect of P7C3-A20 in OGD or OGD/R model. P7C3-A20 administration significantly reduced cerebral infarction in MCAO rats. Moreover, brain NAD levels were elevated both in normal and MCAO mice after P7C3-A20 treatment. ConclusionsP7C3-A20 has neuroprotective effect in cerebral ischemia. The study contributes to the development of NAMPT activators against ischemic stroke and expands the horizon of the neuroprotective effect of aminopropyl carbazole chemicals.	[Wang, Shu-Na; Xu, Tian-Ying; Wang, Xia; Guan, Yun-Feng; Zhang, Sai-Long; Wang, Pei; Miao, Chao-Yu] Second Mil Med Univ, Dept Pharmacol, 325 Guo He Rd, Shanghai 200433, Peoples R China; [Miao, Chao-Yu] Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China	Miao, CY (corresponding author), Second Mil Med Univ, Dept Pharmacol, 325 Guo He Rd, Shanghai 200433, Peoples R China.	cymiao@smmu.edu.cn	WANG, PEI/AAH-3926-2019	WANG, PEI/0000-0002-1650-3353; Miao, Chao-Yu/0000-0002-8176-3434	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81130061, 81373414, 81422049]; National Science and Technology Major Project [2009ZX09303-002]; National 863 Plan Young Scientist Program of ChinaNational High Technology Research and Development Program of China [2015AA020943]	This work was supported by grants from the National Natural Science Foundation of China (81130061 and 81373414 to C.-Y.M.), the National Science and Technology Major Project (2009ZX09303-002 to C.-Y.M), the National Natural Science Foundation of China (81422049 to P.W.), and the National 863 Plan Young Scientist Program of China (2015AA020943 to P.W.). We thank Ming-Jun Zheng for technical assistance.	Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Chen J, 2015, CNS NEUROSCI THER, V21, P301, DOI 10.1111/cns.12392; Chen WF, 2015, CNS NEUROSCI THER, V21, P698, DOI 10.1111/cns.12429; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; Dirnagl U, 2014, STROKE, V45, P1510, DOI 10.1161/STROKEAHA.113.004075; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Guo XB, 2015, ACTA PHARMACOL SIN, V36, P1266, DOI 10.1038/aps.2015.25; Guo ZL, 2015, ACTA PHARMACOL SIN, V36, P748, DOI 10.1038/aps.2014.167; Jiang BM, 2013, CARDIOVASC RES, V99, P92, DOI 10.1093/cvr/cvt085; Kemp SWP, 2015, NEUROSCIENCE, V284, P202, DOI 10.1016/j.neuroscience.2014.10.005; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Latchney SE, 2015, NEUROSCI LETT, V591, P86, DOI 10.1016/j.neulet.2015.02.008; Li Y, 2015, CNS NEUROSCI THER, V21, P905, DOI 10.1111/cns.12469; Lin Y, 2016, CNS NEUROSCI THER, V22, P477, DOI 10.1111/cns.12519; Liu ZJ, 2016, CNS NEUROSCI THER, V22, P43, DOI 10.1111/cns.12448; Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Pacher P, 2002, J PHARMACOL EXP THER, V300, P862, DOI 10.1124/jpet.300.3.862; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Sampath D, 2015, PHARMACOL THERAPEUT, V151, P16, DOI 10.1016/j.pharmthera.2015.02.004; Shen L, 2016, ACTA PHARMACOL SIN, V37, P312, DOI 10.1038/aps.2015.106; Su Y, 2015, CNS NEUROSCI THER, V21, P870, DOI 10.1111/cns.12419; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Walker AK, 2015, MOL PSYCHIATR, V20, P500, DOI 10.1038/mp.2014.34; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wang P, 2015, CNS NEUROSCI THER, V21, P475, DOI 10.1111/cns.12388; Wang P, 2014, CARDIOVASC RES, V104, P477, DOI 10.1093/cvr/cvu220; Wang P, 2014, AUTOPHAGY, V10, P1535, DOI 10.4161/auto.29203; Wang P, 2012, DIABETES, V61, P1051, DOI 10.2337/db11-1180; Wang P, 2012, AUTOPHAGY, V8, P77, DOI 10.4161/auto.8.1.18274; Wang P, 2012, J CARDIOVASC PHARM, V59, P1, DOI 10.1097/FJC.0b013e31820eb8f6; Wang P, 2011, ANN NEUROL, V69, P360, DOI 10.1002/ana.22236; Wang P, 2009, CARDIOVASC RES, V81, P370, DOI 10.1093/cvr/cvn288; Wang P, 2015, MAT SCI SEMICON PROC, V36, P36, DOI 10.1016/j.mssp.2015.03.022; Wang SN, 2016, CNS NEUROSCI THER, V22, P431, DOI 10.1111/cns.12539; Wang X, 2015, SCI REP-UK, V5, DOI 10.1038/srep12657; Xie H, 2014, ACTA PHARMACOL SIN, V35, P1504, DOI 10.1038/aps.2014.78; Xu TY, 2015, SCI REP-UK, V5, DOI 10.1038/srep10043; Xu TY, 2015, ACTA PHARMACOL SIN, V36, P429, DOI 10.1038/aps.2015.5; Yang D, 2015, CNS NEUROSCI THER, V21, P367, DOI 10.1111/cns.12365; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Zhang RY, 2011, ANAL BIOCHEM, V412, P18, DOI 10.1016/j.ab.2010.12.035; Zhang XH, 2011, CNS NEUROSCI THER, V17, P590, DOI 10.1111/j.1755-5949.2011.00271.x; Zhao Y, 2015, STROKE, V46, P1966, DOI 10.1161/STROKEAHA.115.009216; Zhao Y, 2014, CNS NEUROSCI THER, V20, P539, DOI 10.1111/cns.12273	47	23	24	0	17	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	SEP	2016	22	9					782	788		10.1111/cns.12576			7	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	DS8ER	WOS:000381016600006	27333812	Green Published, Bronze			2021-06-18	
J	Li, Q; Han, XN; Wang, J				Li, Qian; Han, Xiaoning; Wang, Jian			Organotypic Hippocampal Slices as Models for Stroke and Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Organotypic hippocampal slice cultures; Stoke; Traumatic brain injury	IN-VITRO MODEL; OXYGEN-GLUCOSE DEPRIVATION; NEURONAL CELL-DEATH; KAINIC ACID; CEREBRAL-ISCHEMIA; POLY(ADP-RIBOSE) POLYMERASE; GLUTAMATE RECEPTORS; ELECTRICAL-ACTIVITY; NEURAL PROGENITORS; LIPID-PEROXIDATION	Organotypic hippocampal slice cultures (OHSCs) have been used as a powerful ex vivo model for decades. They have been used successfully in studies of neuronal death, microglial activation, mossy fiber regeneration, neurogenesis, and drug screening. As a pre-animal experimental phase for physiologic and pathologic brain research, OHSCs offer outcomes that are relatively closer to those of whole-animal studies than outcomes obtained from cell culture in vitro. At the same time, mechanisms can be studied more precisely in OHSCs than they can be in vivo. Here, we summarize stroke and traumatic brain injury research that has been carried out in OHSCs and review classic experimental applications of OHSCs and its limitations.	[Li, Qian; Han, Xiaoning; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA	Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA.	jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Li, Qian/0000-0003-0359-5604	AHAAmerican Heart Association [13GRNT15730001]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078026, R01AT007317]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG031926] Funding Source: NIH RePORTER	This work was supported by an AHA Mid-Atlantic Affiliate Grant-in-Aid 13GRNT15730001, NIH grants R01NS078026 and R01AT007317 (JW), and an AHA Mid-Atlantic Affiliate Postdoctoral Fellowship Award (XH).	AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Ahlgren H, 2011, CELL TISSUE RES, V345, P329, DOI 10.1007/s00441-011-1218-2; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Allard J, 2015, HIPPOCAMPUS, V25, P197, DOI 10.1002/hipo.22364; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Avaliani N, 2014, STEM CELLS, V32, P3088, DOI 10.1002/stem.1823; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Bai JZ, 2014, NEUROTOXICOLOGY, V41, P64, DOI 10.1016/j.neuro.2014.01.001; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Barth A, 1996, EXP NEUROL, V141, P330, DOI 10.1006/exnr.1996.0168; Barth A, 1996, NEUROREPORT, V7, P1461, DOI 10.1097/00001756-199606170-00003; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Benakis C, 2010, BRAIN BEHAV IMMUN, V24, P800, DOI 10.1016/j.bbi.2009.11.001; Bernard A, 1999, EUR J NEUROSCI, V11, P604, DOI 10.1046/j.1460-9568.1999.00479.x; Bernardi A, 2010, NEUROCHEM INT, V57, P629, DOI 10.1016/j.neuint.2010.07.012; Bickler PE, 2009, ANESTHESIOLOGY, V111, P258, DOI 10.1097/ALN.0b013e3181a8647f; Birgbauer E, 2004, J NEUROSCI RES, V78, P157, DOI 10.1002/jnr.20248; BRUCE AJ, 1995, EXP NEUROL, V132, P209, DOI 10.1016/0014-4886(95)90026-8; Budd SL, 1998, PHARMACOL THERAPEUT, V80, P203, DOI 10.1016/S0163-7258(98)00029-1; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chip S, 2013, J CEREBR BLOOD F MET, V33, P508, DOI 10.1038/jcbfm.2012.190; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Cho SG, 2004, NEUROCHEM INT, V45, P117, DOI 10.1016/j.neuint.2003.11.012; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Cooke Sam F, 2005, Curr Opin Investig Drugs, V6, P25; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cui HS, 2009, BIOL PHARM BULL, V32, P79, DOI 10.1248/bpb.32.79; Daviaud N, 2013, EXP NEUROL, V248, P429, DOI 10.1016/j.expneurol.2013.07.012; De Simoni A, 2003, J PHYSIOL-LONDON, V550, P135, DOI 10.1113/jphysiol.2003.039099; De Simoni A, 2006, NAT PROTOC, V1, P1439, DOI 10.1038/nprot.2006.228; del Zoppo GJ, 2001, ARCH NEUROL-CHICAGO, V58, P669, DOI 10.1001/archneur.58.4.669; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Feiner JR, 2005, ANESTH ANALG, V100, P215, DOI 10.1213/01.ANE.0000142129.17005.73; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Fujimoto S, 2006, NEUROBIOL DIS, V22, P130, DOI 10.1016/j.nbd.2005.10.008; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; Gatherer M, 1998, NEUROSCI LETT, V253, P119, DOI 10.1016/S0304-3940(98)00619-3; Gerace Elisabetta, 2012, Methods Mol Biol, V846, P343, DOI 10.1007/978-1-61779-536-7_29; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gill R, 2013, EUR J NEUROSCI, V38, P3554, DOI 10.1111/ejn.12367; Gogolla N, 2006, NAT PROTOC, V1, P2452, DOI 10.1038/nprot.2006.180; Gong QZ, 1996, INT J DEV NEUROSCI, V14, P841, DOI 10.1016/S0736-5748(96)00056-1; Granziera C, 2007, BRAIN RES, V1148, P217, DOI 10.1016/j.brainres.2007.02.025; Gregersen M, 2013, THER HYPOTHERMIA TEM, V3, P178, DOI 10.1089/ther.2013.0017; Hassen GW, 2004, BRAIN RES PROTOC, V13, P135, DOI 10.1016/j.brainresprot.2004.03.004; Hellwig S, 2011, J NEUROSCI, V31, P2352, DOI 10.1523/JNEUROSCI.3984-10.2011; HOGUE MJ, 1947, J EXP ZOOL, V106, P85, DOI 10.1002/jez.1401060104; Holopainen IE, 2004, NEUROCHEM INT, V45, P1, DOI 10.1016/j.neuint.2004.01.005; Hong J, 2010, J BIOL CHEM, V285, P39447, DOI 10.1074/jbc.M110.132522; Horn AP, 2011, STEM CELLS DEV, V20, P1171, DOI 10.1089/scd.2010.0157; Huang Yunke, 2014, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V39, P195, DOI 10.11817/j.issn.1672-7347.2014.02.015; Hughes RH, 2014, BRAIN RES, V1543, P308, DOI 10.1016/j.brainres.2013.11.020; Ikeda-Matsuo Y, 2010, BRIT J PHARMACOL, V160, P847, DOI 10.1111/j.1476-5381.2010.00711.x; Jakobsen B, 2002, AMINO ACIDS, V23, P37, DOI 10.1007/s00726-001-0107-5; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; Jung YJ, 2012, KOREAN J PHYSIOL PHA, V16, P423, DOI 10.4196/kjpp.2012.16.6.423; Kao C, 2012, J NEUROSURG, V117, P316, DOI 10.3171/2012.4.JNS111170; Kim HA, 2014, INT J MOL SCI, V15, P5940, DOI 10.3390/ijms15045940; KIRINO T, 1984, ACTA NEUROPATHOL, V64, P139, DOI 10.1007/BF00695577; Ko HK, 2001, BRAIN RES, V894, P297, DOI 10.1016/S0006-8993(00)03188-7; Koch H, 2010, J NEUROSCI, V30, P11678, DOI 10.1523/JNEUROSCI.4665-09.2010; Kovacs R, 2009, J NEUROSCI, V29, P8565, DOI 10.1523/JNEUROSCI.5698-08.2009; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Kristensen BW, 2001, BRAIN RES, V896, P1, DOI 10.1016/S0006-8993(00)03304-7; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Kurihara D, 2012, J BIOL CHEM, V287, P13822, DOI 10.1074/jbc.M111.314070; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Lamprecht MR, 2014, BRAIN RES, V1563, P131, DOI 10.1016/j.brainres.2014.03.037; Leonardo CC, 2009, NEUROSCIENCE, V160, P755, DOI 10.1016/j.neuroscience.2009.02.080; Li CT, 2009, J NEUROSCI RES, V87, P991, DOI 10.1002/jnr.21913; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Lossi L, 2009, PROG NEUROBIOL, V88, P221, DOI 10.1016/j.pneurobio.2009.01.002; Maisano X, 2012, J NEUROSCI, V32, P46, DOI 10.1523/JNEUROSCI.2683-11.2012; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McManus T, 2004, J NEUROCHEM, V91, P327, DOI 10.1111/j.1471-4159.2004.02711.x; Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003; Meli E, 2003, TOXICOL LETT, V139, P153, DOI 10.1016/S0378-4274(02)00429-0; Mielke JG, 2013, NEUROSCI LETT, V553, P13, DOI 10.1016/j.neulet.2013.07.050; Mirante O, 2013, INT J MOL SCI, V14, P16719, DOI 10.3390/ijms140816719; Molnar Z, 1999, EXP NEUROL, V156, P363, DOI 10.1006/exnr.1999.7032; Montero M, 2009, BRAIN RES, V1291, P140, DOI 10.1016/j.brainres.2009.06.097; Morin-Brureau M, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-11; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Moroni F, 2009, BRIT J PHARMACOL, V157, P854, DOI 10.1111/j.1476-5381.2009.00232.x; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; NEWELL DW, 1995, J NEUROSCI, V15, P7702; NEWELL DW, 1990, NEUROSCI LETT, V116, P325, DOI 10.1016/0304-3940(90)90095-Q; NITSCH C, 1989, BRAIN RES, V495, P243, DOI 10.1016/0006-8993(89)90218-7; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; Ohashi H, 2002, Z NATURFORSCH C, V57, P348; Pacher P, 2012, J MOL MED, V90, P347, DOI 10.1007/s00109-012-0884-1; Peng Y, 2010, NEUROPATHOLOGY, V30, P565, DOI 10.1111/j.1440-1789.2010.01102.x; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PHILLIS JW, 1994, BRAIN RES BULL, V34, P457, DOI 10.1016/0361-9230(94)90019-1; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; Rau TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040881; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; RIMVALL K, 1987, ACTA NEUROPATHOL, V74, P183, DOI 10.1007/BF00692850; RIVERA S, 1994, MOL BRAIN RES, V27, P12, DOI 10.1016/0169-328X(94)90179-1; Rosenblad C, 1998, NEUROSCIENCE, V82, P129; Runden E, 1998, J NEUROSCI, V18, P7296; Rytter A, 2003, J CEREBR BLOOD F MET, V23, P23, DOI 10.1097/01.WCB.0000034361.37277.1B; Sarnowska A, 2009, EXP NEUROL, V215, P317, DOI 10.1016/j.expneurol.2008.10.023; Sarntinoranont M, 2012, J NEUROTRAUM, V29, P418, DOI 10.1089/neu.2011.1772; Schoeler M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-20; Shetty AK, 2008, J NEUROSCI RES, V86, P3062, DOI 10.1002/jnr.21764; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Strassburger M, 2008, EUR J PHARMACOL, V592, P55, DOI 10.1016/j.ejphar.2008.06.099; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Suuronen T, 2003, J NEUROCHEM, V87, P407, DOI 10.1046/j.1471-4159.2003.02004.x; Takano T, 2014, GLIA, V62, P78, DOI 10.1002/glia.22588; Tanabe M, 1998, J NEUROPHYSIOL, V80, P2268; TASKER RC, 1992, J NEUROSCI, V12, P4298; Thevenet J, 2009, J NEUROCHEM, V111, P828, DOI 10.1111/j.1471-4159.2009.06369.x; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; VALLEE L, 1994, EUR J PEDIATR, V153, P598, DOI 10.1007/BF02190669; Van Kanegan MJ, 2014, J NEUROSCI, V34, P963, DOI 10.1523/JNEUROSCI.2700-13.2014; de Almeida LMV, 2008, ARCH BIOCHEM BIOPHYS, V480, P27, DOI 10.1016/j.abb.2008.09.006; VORNOV JJ, 1994, STROKE, V25, P457, DOI 10.1161/01.STR.25.2.457; WAHL P, 1989, J NEUROCHEM, V53, P1316, DOI 10.1111/j.1471-4159.1989.tb07430.x; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; Xiang ZM, 2000, J NEUROSCI METH, V98, P145, DOI 10.1016/S0165-0270(00)00197-7; Yoon JJ, 2010, EPILEPSY RES, V92, P153, DOI 10.1016/j.eplepsyres.2010.08.014; Yoshinaga H, 2003, CAN J PHYSIOL PHARM, V81, P683, DOI 10.1139/Y03-060; Yu Z, 2009, IEEE ENG MED BIO, P4210, DOI 10.1109/IEMBS.2009.5333791; Yu Z, 2009, IEEE ENG MED BIO, P1135; Yu Z, 2009, J NEUROTRAUM, V26, P1135, DOI 10.1089/neu.2008.0810; Zehendner CM, 2014, METHODS MOL BIOL, V1135, P403, DOI 10.1007/978-1-4939-0320-7_33; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038; Ziemka-Nalecz M, 2013, ACTA NEUROBIOL EXP, V73, P130	152	23	23	1	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2016	53	6					4226	4237		10.1007/s12035-015-9362-4			12	Neurosciences	Neurosciences & Neurology	DR2AO	WOS:000379707600061	26223803	Green Accepted			2021-06-18	
J	Zador, Z; Sperrin, M; King, AT				Zador, Zsolt; Sperrin, Matthew; King, Andrew T.			Predictors of Outcome in Traumatic Brain Injury: New Insight Using Receiver Operating Curve Indices and Bayesian Network Analysis	PLOS ONE			English	Article							HEAD-INJURY; VALIDATION; MORTALITY; DESIGN; MODELS; CRASH; COMA	Background Traumatic brain injury remains a global health problem. Understanding the relative importance of outcome predictors helps optimize our treatment strategies by informing assessment protocols, clinical decisions and trial designs. In this study we establish importance ranking for outcome predictors based on receiver operating indices to identify key predictors of outcome and create simple predictive models. We then explore the associations between key outcome predictors using Bayesian networks to gain further insight into predictor importance. Methods We analyzed the corticosteroid randomization after significant head injury (CRASH) trial database of 10008 patients and included patients for whom demographics, injury characteristics, computer tomography (CT) findings and Glasgow Outcome Scale (GCS) were recorded (total of 13 predictors, which would be available to clinicians within a few hours following the injury in 6945 patients). Predictions of clinical outcome (death or severe disability at 6 months) were performed using logistic regression models with 5-fold cross validation. Predictive performance was measured using standardized partial area (pAUC) under the receiver operating curve (ROC) and we used Delong test for comparisons. Variable importance ranking was based on pAUC targeted at specificity (pAUC(SP)) and sensitivity (pAUC(SE)) intervals of 90-100%. Probabilistic associations were depicted using Bayesian networks. Results Complete AUC analysis showed very good predictive power (AUC = 0.8237, 95% CI: 0.8138-0.8336) for the complete model. Specificity focused importance ranking highlighted age, pupillary, motor responses, obliteration of basal cisterns/3rd ventricle and midline shift. Interestingly when targeting model sensitivity, the highest-ranking variables were age, severe extracranial injury, verbal response, hematoma on CT and motor response. Simplified models, which included only these key predictors, had similar performance (pAUC(SP) = 0.6523, 95% CI: 0.6402-0.6641 and pAUC(SE) = 0.6332, 95% CI: 0.62-0.6477) compared to the complete models (pAUC(SP) = 0.6664, 95% CI: 0.6543-0.679, pAUC(SE) = 0.6436, 95% CI: 0.6289-0.6585, de Long p value 0.1165 and 0.3448 respectively). Bayesian networks showed the predictors that did not feature in the simplified models were associated with those that did. Conclusion We demonstrate that importance based variable selection allows simplified predictive models to be created while maintaining prediction accuracy. Variable selection targeting specificity confirmed key components of clinical assessment in TBI whereas sensitivity based ranking suggested extracranial injury as one of the important predictors. These results help refine our approach to head injury assessment, decision-making and outcome prediction targeted at model sensitivity and specificity. Bayesian networks proved to be a comprehensive tool for depicting probabilistic associations for key predictors giving insight into why the simplified model has maintained accuracy.	[Zador, Zsolt; King, Andrew T.] Salford Royal Fdn Trust, Dept Neurosurg, Salford, Greater Manches, England; [Zador, Zsolt] Univ Manchester, Ctr Vasc & Stroke Res, Inst Cardiovasc Sci, Manchester, Lancs, England; [Sperrin, Matthew] Univ Manchester, Manchester Acad Hlth Sci Ctr, Hlth eRes Ctr, Farr Inst, Manchester, Lancs, England	Zador, Z (corresponding author), Salford Royal Fdn Trust, Dept Neurosurg, Salford, Greater Manches, England.; Zador, Z (corresponding author), Univ Manchester, Ctr Vasc & Stroke Res, Inst Cardiovasc Sci, Manchester, Lancs, England.	zadzso@gmail.com	King, Andrew/AAR-1656-2020	Zador, Zsolt/0000-0001-9767-3372; Sperrin, Matthew/0000-0002-5351-9960; King, Andrew/0000-0002-6546-7248	National Institute for Health and Research; University of Manchester's Health eResearch Centre (HeRC) - Medical Research Council Grant [MR/K006665/1]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_13042, MR/K006665/1] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2014-06-004] Funding Source: researchfish	ZZ is an Academic Clinical Lecturer Funded by the National Institute for Health and Research. MS is supported by the University of Manchester's Health eResearch Centre (HeRC) funded by the Medical Research Council Grant MR/K006665/1.	Akaike H, 1973, P 2 INTERNTERNATIONA, P267, DOI 10.1007/978-1-4612-1694-0; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Bateman DE, 2001, J NEUROL NEUROSUR PS, V71, P13; Cai ZQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120805; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Edwards P, 2005, LANCET, V365, P1957; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Kehoe A, 2016, EMERG MED J, V33, P381, DOI 10.1136/emermed-2015-205180; Korb Kevin B, 2010, BAYESIAN ARTIFICIAL; Lecky F, 2015, EMERG MED J, V32, P906, DOI 10.1136/emermed-2015-205460; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marion DW, 2006, NEUROSURGERY, V58, P655; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nagarajan R., 2013, BAYESIAN NETWORKS R; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; R Core Team, 2017, R LANG ENV STAT COMP; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sesen MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082349; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; TEASDALE G, 1974, LANCET, V2, P81; The CRASH trial management group, 2001, BMC Emerg Med, V1, P1; Turck N, 2010, INTENS CARE MED, V36, P107, DOI 10.1007/s00134-009-1641-y; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Wong George K C, 2011, J Emerg Trauma Shock, V4, P346, DOI 10.4103/0974-2700.83861; Wong GKC, 2013, J CLIN NEUROSCI, V20, P1693, DOI 10.1016/j.jocn.2012.12.032	39	23	23	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2016	11	7							e0158762	10.1371/journal.pone.0158762			18	Multidisciplinary Sciences	Science & Technology - Other Topics	DR3OC	WOS:000379811500043	27388421	DOAJ Gold, Green Published			2021-06-18	
J	Lyon, DE; Cohen, R; Chen, HH; Kelly, DL; Starkweather, A; Ahn, HC; Jackson-Cook, CK				Lyon, Debra E.; Cohen, Ronald; Chen, Huaihou; Kelly, Debra L.; Starkweather, Angela; Ahn, Hyo-Chol; Jackson-Cook, Colleen K.			The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY			English	Article						Breast cancer; Cognition; Memory; Adjuvant; Chemotherapy	TRAUMATIC BRAIN-INJURY; ADJUVANT CHEMOTHERAPY; ENDOCRINE THERAPY; WORKING-MEMORY; FATIGUE; IMPAIRMENT; SURVIVORS; ASSOCIATION; DYSFUNCTION; IMPACT	Cognitive dysfunction in women with breast cancer continues to be an area of intense research interest. The prevalence, severity, timing, and cognitive domains that are most affected, as well as the contribution of cancer and its treatments to cognition, remain unresolved. Thus, longitudinal studies are needed that examine cognitive function during different stages of breast cancer treatment and survivorship. This longitudinal trial followed women with early-stage breast cancer, prior to chemotherapy through 2 years survivorship. In women with early-stage breast cancer (N = -75), performance-based assessment of nine cognitive domains was performed at five time points beginning prior to chemotherapy and finishing 24 months after initial chemotherapy. Linear mixed effects models were used to examine the temporal changes in cognitive performance domains, while adjusting for cofactors, including those related to individuals, tumor attributes, chemotherapy (adjuvant or neoadjuvant), radiation, endocrine therapy, and concurrent symptoms. At baseline, scores on reaction time, complex attention, cognitive flexibility, executive function, and visual memory were lower than 90. At 2 years, all domains improved except for the memory domains (verbal, visual, and composite). Scores on six domains (psychomotor speed, reaction time, complex attention, cognitive flexibility, and visual memory) remained lower than 100 at 2 years. Neoadjuvant chemotherapy and fatigue had strong inverse relationship with cognitive functioning at multiple time points. The low performance-based cognitive scores at baseline and over time warrant further study. Although most scores improved over time, memory did not improve. In all, the level of cognitive function is lower than expected for a majority college-educated sample. Thus, future studies are warranted to replicate these findings and to develop methods for identifying women with cognitive dysfunction pretreatment and into survivorship.	[Lyon, Debra E.; Cohen, Ronald; Chen, Huaihou; Kelly, Debra L.; Ahn, Hyo-Chol] Univ Florida, Gainesville, FL USA; [Starkweather, Angela] Univ Connecticut, Storrs Hall,Room 112B,231 Glenbrook Rd,Unit 4026, Storrs, CT 06269 USA; [Jackson-Cook, Colleen K.] Virginia Commonwealth Univ, Sch Med, 1101 E Marshall St, Richmond, VA 23298 USA	Lyon, DE (corresponding author), Univ Florida, Gainesville, FL USA.	delyon@ufl.edu		Ahn, Hyochol/0000-0002-9998-4876	National Institute of Nursing Research (MPI) [R01 NR012667]; NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG037986, R01 NR013932]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR012667, R01NR013932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG037986] Funding Source: NIH RePORTER	This research was supported by the National Institute of Nursing Research (Jackson-Cook/Lyon; MPI; R01 NR012667). Dr. Jackson-Cook (NIH/NIA R01AG037986) and Dr. A. Starkweather (R01 NR013932) are currently receiving grants. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research (NINR), National Institute on Aging (NIA), or the National Institutes of Health (NIH).	Aboalela N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133380; Ahles TA, 2012, PSYCHO-ONCOLOGY, V21, P1141, DOI 10.1002/pon.3196; Ahles TA, 2012, J CLIN ONCOL, V30, P3675, DOI 10.1200/JCO.2012.43.0116; Alosco ML, 2014, OBESITY, V22, P32, DOI 10.1002/oby.20494; Alosco ML, 2013, PSYCHOGERIATRICS, V13, P35, DOI 10.1111/j.1479-8301.2012.00424.x; Andreotti C, 2016, PSYCHO-ONCOLOGY, V25, P43, DOI 10.1002/pon.3799; Arpino G, 2015, BREAST CANCER RES TR, V154, P127, DOI 10.1007/s10549-015-3586-x; Bakoyiannis I, 2016, CLIN DRUG INVEST, V36, P109, DOI 10.1007/s40261-015-0364-9; Barker-Collo S, 2015, BRAIN INJURY, V29, P1604, DOI 10.3109/02699052.2015.1075143; Bender CM, 2015, CANCER-AM CANCER SOC, V121, P2627, DOI 10.1002/cncr.29393; Bower JE, 2000, J CLIN ONCOL, V18, P743, DOI 10.1200/JCO.2000.18.4.743; Breckenridge LM, 2012, PSYCHO-ONCOLOGY, V21, P43, DOI 10.1002/pon.1860; Buchanan ND, 2015, AM J PREV MED, V49, pS498, DOI 10.1016/j.amepre.2015.08.013; Calvio L, 2010, J OCCUP ENVIRON MED, V52, P219, DOI 10.1097/JOM.0b013e3181d0bef7; Cheung YT, 2015, ANN ONCOL, V26, P1446, DOI 10.1093/annonc/mdv206; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S., 1988, SOCIAL PSYCHOL HLTH, P123; Crawford RD, 2016, J ADV NURS, V72, P1409, DOI 10.1111/jan.12755; Fan HGM, 2005, J CLIN ONCOL, V23, P8025, DOI 10.1200/JCO.2005.01.6550; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gunstad J, 2013, EAT WEIGHT DISORD-ST, V11, pe15; Henneghan A, 2016, SUPPORT CARE CANCER, V24, P481, DOI 10.1007/s00520-015-2927-y; Hermelink K, 2007, CANCER, V109, P1905, DOI 10.1002/cncr.22610; Hermelink Kerstin, 2015, Journal of the National Cancer Institute Monographs, P67, DOI 10.1093/jncimonographs/lgv009; Jansen CE, 2011, SUPPORT CARE CANCER, V19, P1647, DOI 10.1007/s00520-010-0997-4; Jenkins V, 2006, BRIT J CANCER, V94, P828, DOI 10.1038/sj.bjc.6603029; Kesler SR, 2016, JAMA ONCOL, V2, P185, DOI 10.1001/jamaoncol.2015.4333; Kool M, 2015, BREAST, V24, P224, DOI 10.1016/j.breast.2015.01.010; Kyranou M, 2014, CANCER NURS, V37, P406, DOI 10.1097/NCC.0000000000000131; Lyon D, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1151-z; Mandelblatt JS, 2014, J CLIN ONCOL, V32, P1909, DOI 10.1200/JCO.2013.54.2050; McDonald BC, 2012, J CLIN ONCOL, V30, P2500, DOI 10.1200/JCO.2011.38.5674; McDonald BC, 2010, BREAST CANCER RES TR, V123, P819, DOI 10.1007/s10549-010-1088-4; Meeske K, 2007, QUAL LIFE RES, V16, P947, DOI 10.1007/s11136-007-9215-3; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Meskal I, 2015, J NEURO-ONCOL, V121, P617, DOI 10.1007/s11060-014-1679-8; Myers JS, 2012, ONCOL NURS FORUM, V39, P1; Ono M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00059; Opdebeeck C, 2015, REV CLIN GERONTOL, V25, P181, DOI 10.1017/S0959259815000155; Perez S, 2014, J TRAUMA STRESS, V27, P224, DOI 10.1002/jts.21901; Ramaiah Ramesh, 2009, Anesthesiol Clin, V27, P485, DOI 10.1016/j.anclin.2009.07.011; Rele S, 2015, PRIM CARE COMPANION, V17, DOI [10.4088/PCC.4014m01734, DOI 10.4088/PCC.4014M01734]; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Scherling C, 2012, J CLIN EXP NEUROPSYC, V34, P543, DOI 10.1080/13803395.2012.666227; Scherling C, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00122; Schrepf A, 2015, BRAIN BEHAV IMMUN, V49, P1, DOI 10.1016/j.bbi.2015.04.010; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Theadom A, 2015, J NEUROTRAUM, V32, P674, DOI 10.1089/neu.2014.3579; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Wefel JS, 2011, LANCET ONCOL, V12, P703, DOI 10.1016/S1470-2045(10)70294-1; Zwart W, 2015, NAT REV CLIN ONCOL, V12, P597, DOI 10.1038/nrclinonc.2015.124; Zygouris S, 2015, AM J ALZHEIMERS DIS, V30, P13, DOI 10.1177/1533317514522852	52	23	24	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0171-5216	1432-1335		J CANCER RES CLIN	J. Cancer Res. Clin. Oncol.	JUL	2016	142	7					1461	1474		10.1007/s00432-016-2163-y			14	Oncology	Oncology	DN9VS	WOS:000377429400007	27102492	Green Accepted			2021-06-18	
J	Pignat, JM; Mauron, E; Johr, J; de Keranflec'h, CG; Van De Ville, D; Preti, MG; Meskaldji, DE; Homberg, V; Laureys, S; Draganski, B; Frackowiak, R; Diserens, K				Pignat, Jean-Michel; Mauron, Etienne; Johr, Jane; de Keranflec'h, Charlotte Gilart; Van De Ville, Dimitri; Preti, Maria Giulia; Meskaldji, Djalel E.; Hoemberg, Volker; Laureys, Steven; Draganski, Bogdan; Frackowiak, Richard; Diserens, Karin			Outcome Prediction of Consciousness Disorders in the Acute Stage Based on a Complementary Motor Behavioural Tool	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; VEGETATIVE STATE; UNRESPONSIVE WAKEFULNESS; DIAGNOSTIC-ACCURACY; FOLLOW-UP; RECOVERY; REHABILITATION; PROGNOSIS; COMA	Introduction Attaining an accurate diagnosis in the acute phase for severely brain-damaged patients presenting Disorders of Consciousness (DOC) is crucial for prognostic validity; such a diagnosis determines further medical management, in terms of therapeutic choices and end-of-life decisions. However, DOC evaluation based on validated scales, such as the Revised Coma Recovery Scale (CRS-R), can lead to an underestimation of consciousness and to frequent misdiagnoses particularly in cases of cognitive motor dissociation due to other aetiologies. The purpose of this study is to determine the clinical signs that lead to a more accurate consciousness assessment allowing more reliable outcome prediction. Methods From the Unit of Acute Neurorehabilitation (University Hospital, Lausanne, Switzerland) between 2011 and 2014, we enrolled 33 DOC patients with a DOC diagnosis according to the CRS-R that had been established within 28 days of brain damage. The first CRS-R assessment established the initial diagnosis of Unresponsive Wakefulness Syndrome (UWS) in 20 patients and a Minimally Consciousness State (MCS) in the remaining13 patients. We clinically evaluated the patients over time using the CRS-R scale and concurrently from the beginning with complementary clinical items of a new observational Motor Behaviour Tool (MBT). Primary endpoint was outcome at unit discharge distinguishing two main classes of patients (DOC patients having emerged from DOC and those remaining in DOC) and 6 subclasses detailing the outcome of UWS and MCS patients, respectively. Based on CRS-R and MBT scores assessed separately and jointly, statistical testing was performed in the acute phase using a non-parametric Mann-Whitney U test; longitudinal CRS-R data were modelled with a Generalized Linear Model. Results Fifty-five per cent of the UWS patients and 77% of the MCS patients had emerged from DOC. First, statistical prediction of the first CRS-R scores did not permit outcome differentiation between classes; longitudinal regression modelling of the CRS-R data identified distinct outcome evolution, but not earlier than 19 days. Second, the MBT yielded a significant outcome predictability in the acute phase (p<0.02, sensitivity>0.81). Third, a statistical comparison of the CRS-R subscales weighted by MBT became significantly predictive for DOC outcome (p<0.02). Discussion The association of MBT and CRS-R scoring improves significantly the evaluation of consciousness and the predictability of outcome in the acute phase. Subtle motor behaviour assessment provides accurate insight into the amount and the content of consciousness even in the case of cognitive motor dissociation.	[Pignat, Jean-Michel; Johr, Jane; de Keranflec'h, Charlotte Gilart; Diserens, Karin] Univ Lausanne Hosp, Dept Clin Neurosci, Acute Neurorehabil Unit, Lausanne, Switzerland; [Pignat, Jean-Michel; Draganski, Bogdan; Frackowiak, Richard; Diserens, Karin] Univ Lausanne Hosp, Dept Clin Neurosci, Lausanne, Switzerland; [Mauron, Etienne] Univ Lausanne, Fac Med, Lausanne, Switzerland; [Laureys, Steven] Univ Liege, Coma Sci Grp, Liege, Belgium; [Van De Ville, Dimitri; Preti, Maria Giulia; Meskaldji, Djalel E.] Ecole Polytech Fed Lausanne, Inst Bioengn, Lausanne, Switzerland; [Van De Ville, Dimitri; Preti, Maria Giulia; Meskaldji, Djalel E.] Univ Geneva, Fac Med, Geneva, Switzerland; [Hoemberg, Volker] SRH Gesundheitszentrum, Dept Neurol, Bad Wimpfen, Germany	Pignat, JM (corresponding author), Univ Lausanne Hosp, Dept Clin Neurosci, Acute Neurorehabil Unit, Lausanne, Switzerland.; Pignat, JM (corresponding author), Univ Lausanne Hosp, Dept Clin Neurosci, Lausanne, Switzerland.	jean-michel.pignat@chuv.ch	Van De Ville, Dimitri/A-5364-2008; Laureys, Steven/A-3349-2011; Laureys, Steven/AAN-2097-2021; Frackowiak, Richard/H-4383-2011; Draganski, Bodgan/C-3096-2016; Johr, Jane/AAL-3611-2021; Preti, Maria Giulia/X-9430-2019	Van De Ville, Dimitri/0000-0002-2879-3861; Laureys, Steven/0000-0002-3096-3807; Frackowiak, Richard/0000-0002-3151-822X; Draganski, Bodgan/0000-0002-5159-5919; Preti, Maria Giulia/0000-0002-5323-5327; Johr, Jane/0000-0003-4280-9310	German Research FoundationGerman Research Foundation (DFG); National Fund for Scientific Research (NFSR); Foundation Parkinson Switzerland; Foundation Synapsis; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Fondation Roger de Spoelberch; Partridge Foundation; Gianni Biaggi de Blasys Foundation; Schumacher Foundation; company Merz; company AllerganAbbVieAllergan	V. Homberg received funding from the German Research Foundation. S. Laureys received funding from National Fund for Scientific Research (NFSR). B. Draganski received funding from the Foundation Parkinson Switzerland, the Foundation Synapsis, the German Research Foundation and the Swiss National Science Foundation. R. Frackowiak received funding from the Fondation Roger de Spoelberch, the Partridge Foundation and for the LREN research neuroimaging platform. K. Diserens received funding from the Gianni Biaggi de Blasys Foundation and the Schumacher Foundation. K. Diserens received also funding from the companies Merz and Allergan for research on botulinum toxin treatment. This study was financially supported by the peer reviewed Gianni Biaggi de Blasys Foundation, which had no role in study design, in data collection, analysis and interpretation, nor in writing the final report. All the aforementioned institutions and companies had no role in study design, in data collection, analysis and interpretation, nor in writing the final report.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bagnato S, 2015, CLIN NEUROPHYSIOL, V126, P959, DOI 10.1016/j.clinph.2014.08.005; Bodart O, 2013, SEMIN NEUROL, V33, P83, DOI 10.1055/s-0033-1348965; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Cavanna AE, 2011, BEHAV NEUROL, V24, P107, DOI [10.1155/2011/645159, 10.3233/BEN-2011-0322]; Chatelle C, 2012, BRAIN INJURY, V26, P1510, DOI 10.3109/02699052.2012.698362; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Di Perri C, 2014, WORLD J RADIOL, V6, P589, DOI 10.4329/wjr.v6.i8.589; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Fernandez-Espejo D., 2015, JAMA NEUROL, P1, DOI [10.1001/jamaneurol.2015.2614, DOI 10.1001/JAMANEUROL.2015.2614]; Forgacs PB, 2014, ANN NEUROL, V76, P869, DOI 10.1002/ana.24283; Formisano R, 2011, FUNCT NEUROL, V26, P15; Gerrard P, 2014, ARCH PHYS MED REHAB, V95, P2335, DOI 10.1016/j.apmr.2014.06.018; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; Holler Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080479; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lechinger J, 2013, J NEUROL, V260, P2348, DOI 10.1007/s00415-013-6982-3; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; Lupi A, 2014, CURR RADIOPHARM, V7, P57, DOI 10.2174/1874471007666140411103819; Owen AM, 2014, NAT REV NEUROL, V10, P370, DOI 10.1038/nrneurol.2014.102; Posner J., 2007, PLUM POSNERS DIAGNOS, V4; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; Schiff ND, 2015, JAMA NEUROL, V72, P1413, DOI 10.1001/jamaneurol.2015.2899; Schnakers C, 2015, NEUROREHAB NEURAL RE, V29, P41, DOI 10.1177/1545968314528067; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Serrao M, 2006, J NEUROSCI, V26, P3505, DOI 10.1523/JNEUROSCI.5160-05.2006; Silva S, 2015, NEUROLOGY, V85, P2036, DOI 10.1212/WNL.0000000000002196; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; 1994, NEW ENGL J MED, V330, P1572, DOI DOI 10.1056/NEJM199406023302206	45	23	24	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2016	11	6							e0156882	10.1371/journal.pone.0156882			16	Multidisciplinary Sciences	Science & Technology - Other Topics	DQ0CH	WOS:000378865200004	27359335	DOAJ Gold, Green Published			2021-06-18	
J	Tan, JKY; Pham, B; Zong, YJ; Perez, C; Maris, DO; Hemphill, A; Miao, CH; Matula, TJ; Mourad, PD; Wei, H; Sellers, DL; Horner, PJ; Pun, SH				Tan, James-Kevin Y.; Binhan Pham; Zong, Yujin; Perez, Camilo; Maris, Don O.; Hemphill, Ashton; Miao, Carol H.; Matula, Thomas J.; Mourad, Pierre D.; Wei, Hua; Sellers, Drew L.; Horner, Philip J.; Pun, Suzie H.			Microbubbles and ultrasound increase intraventricular polyplex gene transfer to the brain	JOURNAL OF CONTROLLED RELEASE			English	Article; Proceedings Paper	13th Nanomedicine and Drug Delivery Symposium (NanoDDS)	SEP 16-18, 2015	Univ Washington, Seattle, WA	Precision NanoSystems, Inc, Sigma Aldrich, Izon Sci, Perkin Elmer, Univ Washington, Coll Engn, UW Bioengineering, UW Mol Engn & Sci Inst, Bio Pact, iThera Med, Quidel, Wyatt Technol, Miltenyi Biotec	Univ Washington	Gene delivery; Microbubble; Polyplex; Ultrasound; In vivo; Choroid plexus epithelium	CONTRAST AGENT MICROBUBBLES; MEDIATED DRUG-DELIVERY; FOCUSED ULTRASOUND; CHOROID-PLEXUS; FLOW-CYTOMETRY; ADULT BRAIN; IN-VITRO; BARRIER; NEUROGENESIS; CAVITATION	Neurons in the brain can be damaged or lost from neurodegenerative disease, stroke, or traumatic injury. Although neurogenesis occurs in mammalian adult brains, the levels of natural neurogenesis are insufficient to restore function in these cases. Gene therapy has been pursued as a promising strategy to induce differentiation of neural progenitor cells into functional neurons. Non-viral vectors are a preferred method of gene transfer due to potential safety and manufacturing benefits but suffer from lower delivery efficiencies compared to viral vectors. Since the neural stem and progenitor cells reside in the subventricular zone of the brain, intraventricular injection has been used as an administration route for gene transfer to these cells. However, the choroid plexus epithelium remains an obstacle to delivery. Recently, transient disruption of the blood-brain barrier by microbubble-enhanced ultrasound has been used to successfully improve drug delivery to the brain after intravenous injection. In this work, we demonstrate that microbubble-enhanced ultrasound can similarly improve gene transfer to the subventricular zone after intraventricular injection. Microbubbles of different surface charges (neutral, slightly cationic, and cationic) were prepared, characterized by acoustic flow cytometry, and evaluated for their ability to increase the permeability of immortalized choroid plexus epithelium monolayers in vitro. Based on these results, slightly cationic microbubbles were evaluated for microbubble and ultrasound-mediated enhancement of non-viral gene transfer in vivo. When coupled with our previously reported gene delivery vehicles, the slightly cationic microbubbles significantly increased ultrasound-mediated transfection of the murine brain when compared to commercially available Definity (R) microbubbles. Temporary disruption of the choroid plexus by microbubble-enhanced ultrasound is therefore a viable way of enhancing gene delivery to the brain and merits further research. (C) 2016 Elsevier B.V. All rights reserved.	[Tan, James-Kevin Y.; Binhan Pham; Perez, Camilo; Hemphill, Ashton; Sellers, Drew L.; Pun, Suzie H.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Tan, James-Kevin Y.; Binhan Pham; Hemphill, Ashton; Sellers, Drew L.; Pun, Suzie H.] Univ Washington, Mol Engn & Sci Inst, Seattle, WA 98195 USA; [Zong, Yujin; Perez, Camilo; Matula, Thomas J.] Univ Washington, Ctr Ind & Med Ultrasound, Seattle, WA 98195 USA; [Zong, Yujin] Xi An Jiao Tong Univ, Dept Biomed Engn, Xian 710049, Peoples R China; [Maris, Don O.; Mourad, Pierre D.; Horner, Philip J.] Univ Washington, Dept Neurol Surg, Seattle, WA 98109 USA; [Miao, Carol H.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Wei, Hua] Lanzhou Univ, Dept Chem, Lanzhou 730000, Peoples R China	Horner, PJ (corresponding author), Houston Methodist Res Inst, Ctr Neuroregenerat Med, 6670 Bertner Ave,MSR10-112, Houston, TX 77030 USA.; Pun, SH (corresponding author), Univ Washington, Dept Bioengn, Mol Engn & Sci Inst, William H Foege Bldg,Box 355061, Seattle, WA 98195 USA.	pjhorner@houstonmethodist.org; spun@uw.edu	Wei, Hua-liang/AAX-4771-2020; Horner, Philip J./AAF-7012-2021	Wei, Hua-liang/0000-0002-4704-7346; Pham, Binhan/0000-0002-1989-4169	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL128139] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS064404, R01 NS066357] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL128139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS066357, R01NS064404] Funding Source: NIH RePORTER		Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Cavalieri F, 2013, ACS APPL MATER INTER, V5, P10920, DOI 10.1021/am403108y; Chodobski A, 2001, MICROSC RES TECHNIQ, V52, P65; Choi JJ, 2007, ULTRASOUND MED BIOL, V33, P95, DOI 10.1016/j.ultrasmedbio.2006.07.018; Choi JJ, 2011, J CEREBR BLOOD F MET, V31, P725, DOI 10.1038/jcbfm.2010.155; Choi JJ, 2010, ULTRASOUND MED BIOL, V36, P58, DOI 10.1016/j.ultrasmedbio.2009.08.006; Choi JL, 2015, BIOMATERIALS, V54, P87, DOI 10.1016/j.biomaterials.2015.03.008; Dass CR, 2004, BIOTECHNOL APPL BIOC, V40, P113, DOI 10.1042/BA20040005; De Cock I, 2015, J CONTROL RELEASE, V197, P20, DOI 10.1016/j.jconrel.2014.10.031; Delalande A., 2015, ULTRASOUND MED BIOL, P1; Dicker S., 2010, Bubble Science, Engineering & Technology, V2, P55, DOI 10.1179/1758897910Y.0000000001; Dicker S, 2013, ULTRASOUND MED BIOL, V39, P1292, DOI 10.1016/j.ultrasmedbio.2013.02.462; Dodge JC, 2010, MOL THER, V18, P2075, DOI 10.1038/mt.2010.206; Doinikov AA, 2009, ULTRASONICS, V49, P269, DOI 10.1016/j.ultras.2008.09.007; Fan Z, 2013, J CONTROL RELEASE, V170, P401, DOI 10.1016/j.jconrel.2013.05.039; Feshitan JA, 2009, J COLLOID INTERF SCI, V329, P316, DOI 10.1016/j.jcis.2008.09.066; Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119; Greenleaf WJ, 1998, ULTRASOUND MED BIOL, V24, P587, DOI 10.1016/S0301-5629(98)00003-9; Guo XS, 2013, J ACOUST SOC AM, V134, P1622, DOI 10.1121/1.4812887; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014; Matsuoka N, 2003, STROKE, V34, P1519, DOI 10.1161/01.STR.0000070840.56414.3B; Matula T. J., 2011, 2011 IEEE International Ultrasonics Symposium (IUS), P156, DOI 10.1109/ULTSYM.2011.0039; McDannold N, 2012, CANCER RES, V72, P3652, DOI 10.1158/0008-5472.CAN-12-0128; Meairs S, 2007, PROG BIOPHYS MOL BIO, V93, P354, DOI 10.1016/j.pbiomolbio.2006.07.019; Meairs S, 2009, MED BIOL ENG COMPUT, V47, P839, DOI 10.1007/s11517-009-0468-6; Mortazavi MM, 2014, CHILD NERV SYST, V30, P205, DOI 10.1007/s00381-013-2326-y; Panje CM, 2013, INVEST RADIOL, V48, P755, DOI 10.1097/RLI.0b013e3182982cc1; Pardridge WM, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-7; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Rychak JJ, 2014, ADV DRUG DELIVER REV, V72, P82, DOI 10.1016/j.addr.2014.01.009; Saha B, 2013, STEM CELL RES, V11, P965, DOI 10.1016/j.scr.2013.06.006; Samiotaki G., 2015, J CEREB BLOOD FLOW M, P1; Sawada Masato, 2013, Keio Journal of Medicine, V62, P13, DOI 10.2302/kjm.2012-0005-RE; Sheikov N, 2004, ULTRASOUND MED BIOL, V30, P979, DOI 10.1016/j.ultrasmedbio.2004.04.010; Shi LZ, 2008, TOXICOL IN VITRO, V22, P190, DOI 10.1016/j.tiv.2007.07.007; Sugiura S, 2005, STROKE, V36, P859, DOI 10.1161/01.STR.0000158905.22871.95; Sun RR, 2014, J CONTROL RELEASE, V182, P111, DOI 10.1016/j.jconrel.2014.03.002; Tan JKY, 2015, BIOMATER SCI-UK, V3, P112, DOI 10.1039/c4bm00240g; Tu J, 2011, IEEE T ULTRASON FERR, V58, P955, DOI 10.1109/TUFFC.2011.1896; Wang DS, 2012, RADIOLOGY, V264, P721, DOI 10.1148/radiol.12112368; Wang S, 2015, GENE THER, V22, P104, DOI 10.1038/gt.2014.91; Wang ST, 2014, ULTRASOUND MED BIOL, V40, P130, DOI 10.1016/j.ultrasmedbio.2013.09.015; Weber-Adrian D., 2015, GENE THER, P1; Wei H, 2013, ANGEW CHEM INT EDIT, V52, P5377, DOI 10.1002/anie.201301896; Wu SY, 2015, J CONTROL RELEASE, V212, P30, DOI 10.1016/j.jconrel.2015.06.007; Xie F, 2008, ULTRASOUND MED BIOL, V34, P2028, DOI 10.1016/j.ultrasmedbio.2008.05.004; Zheng W, 2002, BRAIN RES, V958, P371, DOI 10.1016/S0006-8993(02)03683-1; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579; Zhou Y, 2012, J CONTROL RELEASE, V157, P103, DOI 10.1016/j.jconrel.2011.09.068	50	23	23	0	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-3659	1873-4995		J CONTROL RELEASE	J. Control. Release	JUN 10	2016	231						86	93		10.1016/j.jconrel.2016.02.003			8	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	DM6EY	WOS:000376444600010	26860281	Green Accepted			2021-06-18	
J	Delbary-Gossart, S; Lee, S; Baroni, M; Lamarche, I; Arnone, M; Canolle, B; Lin, A; Sacramento, J; Salegio, EA; Castel, MN; Delesque-Touchard, N; Alam, A; Laboudie, P; Ferzaz, B; Savi, P; Herbert, JM; Manley, GT; Ferguson, AR; Bresnahan, JC; Bono, F; Beattie, MS				Delbary-Gossart, Sandrine; Lee, Sangmi; Baroni, Marco; Lamarche, Isabelle; Arnone, Michele; Canolle, Benoit; Lin, Amity; Sacramento, Jeffrey; Salegio, Ernesto A.; Castel, Marie-Noelle; Delesque-Touchard, Nathalie; Alam, Antoine; Laboudie, Patricia; Ferzaz, Badia; Savi, Pierre; Herbert, Jean-Marc; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Bono, Francoise; Beattie, Michael S.			A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury	BRAIN			English	Article						p75NTR; TBI; EVT901; neuron; oligodendrocyte	P75 NEUROTROPHIN RECEPTOR; SPINAL-CORD-INJURY; CELL-DEATH; IN-VITRO; P75(NTR); LIGAND; APOPTOSIS; DOMAIN; OLIGODENDROCYTES; RECOVERY	The p75 neurotrophin receptor (p75NTR) is a member of the TNF-receptor superfamily. Delbary-Gossart, Lee et al. describe the neuroprotective effects of a novel piperizine derivative that blocks p75NTR. In two rodent models of traumatic brain injury, EVT901 protects neurons and glia, reduces inflammation and seizure susceptibility, and improves neurological outcomes.The p75 neurotrophin receptor (p75NTR) is a member of the TNF-receptor superfamily. Delbary-Gossart, Lee et al. describe the neuroprotective effects of a novel piperizine derivative that blocks p75NTR. In two rodent models of traumatic brain injury, EVT901 protects neurons and glia, reduces inflammation and seizure susceptibility, and improves neurological outcomes.The p75 neurotrophin receptor is important in multiple physiological actions including neuronal survival and neurite outgrowth during development, and after central nervous system injury. We have discovered a novel piperazine-derived compound, EVT901, which interferes with p75 neurotrophin receptor oligomerization through direct interaction with the first cysteine-rich domain of the extracellular region. Using ligand binding assays with cysteine-rich domains-fused p75 neurotrophin receptor, we confirmed that EVT901 interferes with oligomerization of full-length p75 neurotrophin receptor in a dose-dependent manner. Here we report that EVT901 reduces binding of pro-nerve growth factor to p75 neurotrophin receptor, blocks pro-nerve growth factor induced apoptosis in cells expressing p75 neurotrophin receptor, and enhances neurite outgrowth in vitro. Furthermore, we demonstrate that EVT901 abrogates p75 neurotrophin receptor signalling by other ligands, such as prion peptide and amyloid-beta. To test the efficacy of EVT901 in vivo, we evaluated the outcome in two models of traumatic brain injury. We generated controlled cortical impacts in adult rats. Using unbiased stereological analysis, we found that EVT901 delivered intravenously daily for 1 week after injury, reduced lesion size, protected cortical neurons and oligodendrocytes, and had a positive effect on neurological function. After lateral fluid percussion injury in adult rats, oral treatment with EVT901 reduced neuronal death in the hippocampus and thalamus, reduced long-term cognitive deficits, and reduced the occurrence of post-traumatic seizure activity. Together, these studies provide a new reagent for altering p75 neurotrophin receptor actions after injury and suggest that EVT901 may be useful in treatment of central nervous system trauma and other neurological disorders where p75 neurotrophin receptor signalling is affected.	[Delbary-Gossart, Sandrine; Bono, Francoise] Evotec, 195 Route Espagne, F-31036 Toulouse, France; [Lee, Sangmi; Lin, Amity; Sacramento, Jeffrey; Salegio, Ernesto A.; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, 1001 Potrero Ave, San Francisco, CA 94110 USA; [Baroni, Marco] Sanofi Rech, Exploratory Unit, Via Gaetano Sbodio 2, I-20134 Milan, Italy; [Lamarche, Isabelle; Arnone, Michele; Canolle, Benoit; Castel, Marie-Noelle; Delesque-Touchard, Nathalie; Alam, Antoine; Laboudie, Patricia; Ferzaz, Badia; Savi, Pierre; Herbert, Jean-Marc] Sanofi Rech, 195 Route Espagne, F-31036 Toulouse, France	Beattie, MS (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, Box 0899,1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94143 USA.	Michael.Beattie@ucsf.edu	Beattie, Michael S/A-8953-2009	Ferguson, Adam/0000-0001-7102-1608	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038079]; UCSF/BASIC; Sanofi R and D; UCSF; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038079, R01NS067092] Funding Source: NIH RePORTER	This work was supported by NIH NS038079, with statistical support from NIH NS067092, UCSF/BASIC pilot funds, and a sponsored research agreement (SRA) between Sanofi R and D and UCSF.	Anastasia A, 2015, J NEUROSCI, V35, P11911, DOI 10.1523/JNEUROSCI.0591-15.2015; BALDWIN AN, 1995, J BIOL CHEM, V270, P4594, DOI 10.1074/jbc.270.9.4594; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bunone G, 1997, ONCOGENE, V14, P1463, DOI 10.1038/sj.onc.1200972; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chan FKM, 2007, CYTOKINE, V37, P101, DOI 10.1016/j.cyto.2007.03.005; Covolan L, 2000, EPILEPSY RES, V39, P133, DOI 10.1016/S0920-1211(99)00119-9; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Deinhardt K, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002060; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Deng GM, 2005, NAT MED, V11, P1066, DOI 10.1038/nm1304; Diarra Adama, 2009, Biochem Biophys Res Commun, V390, P352, DOI 10.1016/j.bbrc.2009.09.116; Domeniconi M, 2007, MOL CELL NEUROSCI, V34, P271, DOI 10.1016/j.mcn.2006.11.005; Gentry JJ, 2004, PROG BRAIN RES, V146, P25, DOI 10.1016/S0079-6123(03)46002-0; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Inoue T, 2013, EXP NEUROL, V248, P136, DOI 10.1016/j.expneurol.2013.06.006; Langevin C, 2002, J BIOL CHEM, V277, P37655, DOI 10.1074/jbc.M201374200; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Miller BA, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-28; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Routbort MJ, 1999, NEUROSCIENCE, V94, P755, DOI 10.1016/S0306-4522(99)00358-9; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Schor NF, 2005, PROG NEUROBIOL, V77, P201, DOI 10.1016/j.pneurobio.2005.10.006; Sebastiani A, 2015, J NEUROTRAUM, V32, P1599, DOI 10.1089/neu.2014.3751; Shi J, 2013, STEM CELLS, V31, P2561, DOI 10.1002/stem.1516; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Sun F, 2010, GLIA, V58, P1304, DOI 10.1002/glia.21009; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Turner BJ, 2004, J NEUROSCI RES, V78, P193, DOI 10.1002/jnr.20256; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Veiga S, 2011, NEUROSCI LETT, V503, P10, DOI 10.1016/j.neulet.2011.07.053; Vilar M, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001918; Vilar M, 2009, NEURON, V62, P72, DOI 10.1016/j.neuron.2009.02.020; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wang JJL, 2000, J NEUROSCI RES, V60, P587, DOI 10.1002/(SICI)1097-4547(20000601)60:5<587::AID-JNR3>3.0.CO;2-1; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yang JM, 2014, CELL REP, V7, P796, DOI 10.1016/j.celrep.2014.03.040; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Zhang HQ, 2011, J NEUROSCI, V31, P15894, DOI 10.1523/JNEUROSCI.3943-11.2011; Zhao YY, 2011, ACTA NEUROBIOL EXP, V71, P322	45	23	26	1	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN	2016	139		6				1762	1782		10.1093/brain/aww074			21	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DN9WA	WOS:000377430200023	27084575	Other Gold, Green Published			2021-06-18	
J	Douiri, S; Bandoudi, S; Hamdi, Y; Cubi, R; Basille, M; Fournier, A; Vaudry, H; Tonon, MC; Amri, M; Vaudry, D; Masmoudi-Kouki, O				Douiri, Salma; Bandoudi, Seyma; Hamdi, Yosra; Cubi, Roger; Basille, Magali; Fournier, Alain; Vaudry, Hubert; Tonon, Marie-Christine; Amri, Mohamed; Vaudry, David; Masmoudi-Kouki, Olfa			Involvement of endogenous antioxidant systems in the protective activity of pituitary adenylate cyclase-activating polypeptide against hydrogen peroxide-induced oxidative damages in cultured rat astrocytes	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; astroglial cells; catalase; oxidative stress; PACAP; superoxide dismutase	CEREBELLAR GRANULE NEURONS; STRESS-INDUCED APOPTOSIS; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; NERVE GROWTH-FACTOR; SUPEROXIDE-DISMUTASE; NEURODEGENERATIVE DISEASES; SIGNALING PATHWAYS; GENE-EXPRESSION; FOCAL ISCHEMIA	Astroglial cells possess an array of cellular defense mechanisms, including superoxide dismutase (SOD) and catalase antioxidant enzymes, to prevent damages caused by oxidative stress. Nevertheless, astroglial cell viability and functionality can be affected by significant oxidative stress. We have previously shown that pituitary adenylate cyclase-activating polypeptide (PACAP) is a potent glioprotective agent that prevents hydrogen peroxide (H2O2)-induced apoptosis in cultured astrocytes. The purpose of this study was to investigate the potential protective effect of PACAP against oxidative-generated alteration of astrocytic antioxidant systems. Incubation of cells with subnanomolar concentrations of PACAP inhibited H2O2-evoked reactive oxygen species accumulation, mitochondrial respiratory burst, and caspase-3 mRNA level increase. PACAP also stimulated SOD and catalase activities in a concentration-dependent manner, and counteracted the inhibitory effect of H2O2 on the activity of these two antioxidant enzymes. The protective action of PACAP against H2O2-evoked inhibition of antioxidant systems in astrocytes was protein kinase A, PKC, and MAP-kinase dependent. In the presence of H2O2, the SOD blocker NaCN and the catalase inhibitor 3-aminotriazole, both suppressed the protective effects of PACAP on SOD and catalase activities, mitochondrial function, and cell survival. Taken together, these results indicate that the anti-apoptotic effect of PACAP on astroglial cells can account for the activation of endogenous antioxidant enzymes and reduction in respiration rate, thus preserving mitochondrial integrity and preventing caspase-3 expression provoked by oxidative stress. Considering its powerful anti-apoptotic and anti-oxidative properties, the PACAPergic signaling system should thus be considered for the development of new therapeutical approaches to cure various pathologies involving oxidative neurodegeneration.	[Douiri, Salma; Bandoudi, Seyma; Hamdi, Yosra; Amri, Mohamed; Masmoudi-Kouki, Olfa] Univ Tunis El Manar, Fac Sci Tunis, Dept Biol Sci, Lab Funct Neurophysiol & Pathol,Res Unit UR 11ES0, Tnis 2092, Tunisia; [Bandoudi, Seyma; Cubi, Roger; Basille, Magali; Vaudry, Hubert; Tonon, Marie-Christine; Vaudry, David] Univ Rouen, IRIB, INSERM, U982,Lab Neuronal & Neuroendocrine Commun & Diffe, F-76128 Mont St Aignan, France; [Basille, Magali; Vaudry, Hubert; Tonon, Marie-Christine; Vaudry, David] Univ Rouen, Inst Biomed Res & Innovat, Reg Platform Cell Imaging Normandie PRIMACEN, Mont St Aignan, France; [Fournier, Alain] Inst Armand Frappier, INRS, Laval, PQ, Canada; [Fournier, Alain] Inst Armand Frappier, Lab Int Associe Samuel de Champlain, Laval, PQ, Canada; [Fournier, Alain; Vaudry, Hubert; Vaudry, David] Univ Rouen, Int Associated Lab Samuel de Champlain, Mont St Aignan, France	Masmoudi-Kouki, O (corresponding author), Univ Tunis El Manar, Fac Sci Tunis, Dept Biol Sci, Lab Funct Neurophysiol & Pathol,Res Unit UR 11ES0, Tnis 2092, Tunisia.; Vaudry, D (corresponding author), Univ Rouen, IRIB, INSERM, U982,Lab Neuronal & Neuroendocrine Commun & Diffe, F-76128 Mont St Aignan, France.; Vaudry, D (corresponding author), Univ Rouen, Inst Biomed Res & Innovat, Reg Platform Cell Imaging Normandie PRIMACEN, Mont St Aignan, France.	david.vaudry@univ-rouen.fr; olfa.masmoudi@fst.rnu.tn	VAUDRY, David/M-1454-2018	VAUDRY, David/0000-0003-3567-7452; Cubi, Roger/0000-0003-2762-9928; Amri, Mohamed/0000-0001-5309-7633	University of Tunis El Manar; France-Tunisia exchange program Inserm-DGRS; CMCU-Utique program [UR/11ES09, 07G0822]; Inserm-DGRS program [M10/M]; InsermInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission [U982]; Institute for Medical Research and Innovation (IRIB); Normandy region; PeReNE Interreg project	Salma Douiri and Seyma Bandoudi were recipients of fellowships from the University of Tunis El Manar and a France-Tunisia exchange program Inserm-DGRS. This study was supported by the Research Unit UR/11ES09, a CMCU-Utique program (to Mohamed Amri and Marie-Christine Tonon; grant number 07G0822), an Inserm-DGRS program (to Mohamed Amri and Marie-Christine Tonon; grant number M10/M), Inserm (U982), the Institute for Medical Research and Innovation (IRIB) and the Normandy region, and the Normandy region and the PeReNE Interreg project. Authors declare that they have no conflict of interest.	Baraibar MA, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/919832; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Botia B, 2008, J MOL NEUROSCI, V36, P61, DOI 10.1007/s12031-008-9075-5; Bourgault S, 2011, CURR PHARM DESIGN, V17, P1002, DOI 10.2174/138161211795589337; Cabezas R, 2012, NEUROSCI RES, V74, P80, DOI 10.1016/j.neures.2012.07.008; Chen YM, 2001, GLIA, V33, P343, DOI 10.1002/1098-1136(20010315)33:4<343::AID-GLIA1033>3.0.CO;2-H; Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432; Dasuri K, 2013, FREE RADICAL BIO MED, V62, P170, DOI 10.1016/j.freeradbiomed.2012.09.016; Dejda A, 2005, PHARMACOL REP, V57, P307; Dokic I, 2012, GLIA, V60, P1785, DOI 10.1002/glia.22397; Dumont M, 2009, FASEB J, V23, P2459, DOI 10.1096/fj.09-132928; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Fang KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015299; Feeney CJ, 2008, BRAIN RES, V1198, P1, DOI 10.1016/j.brainres.2007.12.049; Fernandez-Fernandez S, 2012, BIOCHEM J, V443, P3, DOI 10.1042/BJ20111943; Ferrero-Gutierrez A, 2008, FREE RADICAL BIO MED, V44, P1806, DOI 10.1016/j.freeradbiomed.2008.01.029; Gaspar T, 2008, J CEREBR BLOOD F MET, V28, P1090, DOI 10.1038/sj.jcbfm.9600611; Gyulkhandanyan AV, 2003, J NEUROCHEM, V87, P448, DOI 10.1046/j.1471-4159.2003.02029.x; Hamdi Y, 2015, PEPTIDES, V71, P56, DOI 10.1016/j.peptides.2015.06.010; Hamdi Yosra, 2012, Front Endocrinol (Lausanne), V3, P138, DOI 10.3389/fendo.2012.00138; Hamdi Y, 2011, J NEUROCHEM, V118, P416, DOI 10.1111/j.1471-4159.2011.07315.x; Harmar AJ, 2012, BRIT J PHARMACOL, V166, P4, DOI 10.1111/j.1476-5381.2012.01871.x; HSU MJ, 2009, BIOCHIM BIOPHYS ACTA, V1800, P290; Huang WC, 2001, CLIN EXP PHARMACOL P, V28, P822, DOI 10.1046/j.1440-1681.2001.03529.x; Jolivel V, 2009, NEUROSCIENCE, V160, P434, DOI 10.1016/j.neuroscience.2009.02.028; Kaddour H, 2013, J NEUROCHEM, V125, P620, DOI 10.1111/jnc.12140; Kupershmidt L, 2011, NEUROSCIENCE, V189, P345, DOI 10.1016/j.neuroscience.2011.03.040; Lamine A, 2016, NEUROPHARMACOLOGY, V108, P440, DOI 10.1016/j.neuropharm.2015.05.014; Leem YH, 2009, J NEUROSCI RES, V87, P2561, DOI 10.1002/jnr.22075; Liu JB, 2013, NEUROSCI LETT, V555, P91, DOI 10.1016/j.neulet.2013.09.011; Mao XY, 2014, NEUROL SCI, V35, P1261, DOI 10.1007/s10072-014-1695-7; Masmoudi O, 2005, J NEUROCHEM, V94, P561, DOI 10.1111/j.1471-4159.2005.03076.x; Masmoudi O, 2003, FASEB J, V17, P17, DOI 10.1096/fj.02-0317com; Masmoudi-Kouki O, 2007, PEPTIDES, V28, P1753, DOI 10.1016/j.peptides.2007.05.015; Masmoudi-Kouki O, 2011, J NEUROCHEM, V117, P403, DOI 10.1111/j.1471-4159.2011.07185.x; Mei Y, 1999, HEARING RES, V135, P169, DOI 10.1016/S0378-5955(99)00103-3; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; Miyama A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027883; Miyamoto K, 2014, J MOL NEUROSCI, V54, P370, DOI 10.1007/s12031-014-0309-4; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Mullenbrock S, 2011, J BIOL CHEM, V286, P45131, DOI 10.1074/jbc.M111.274076; Lopez MVN, 2007, BBA-GEN SUBJECTS, V1770, P1308, DOI 10.1016/j.bbagen.2007.06.008; Negre-Salvayre A, 2010, FREE RADICAL RES, V44, P1125, DOI 10.3109/10715762.2010.498478; Ouyang YB, 2004, NEUROCHEM INT, V45, P371, DOI 10.1016/j.neuint.2003.07.006; Peng TI, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/159567; Priyanka HP, 2013, NEUROCHEM RES, V38, P141, DOI 10.1007/s11064-012-0902-2; Quesada A, 2011, J NEUROSCI RES, V89, P394, DOI 10.1002/jnr.22543; Radjendirane V., 1998, ONCOGENE, V17, P3145; Ramalingam M, 2014, FREE RADICAL RES, V48, P347, DOI 10.3109/10715762.2013.869588; Ravni A, 2006, J NEUROCHEM, V98, P321, DOI 10.1111/J.1471-4159.2006.03884.X; Reglodi D, 2006, NEUROPEPTIDES, V40, P265, DOI 10.1016/j.npep.2006.06.001; Resch JM, 2014, SYNAPSE, V68, P604, DOI 10.1002/syn.21772; Saito A, 2003, J NEUROSCI, V23, P1710; Sanders LH, 2013, FREE RADICAL BIO MED, V62, P111, DOI 10.1016/j.freeradbiomed.2013.01.003; Schuessel K, 2005, NEUROBIOL DIS, V18, P89, DOI 10.1016/j.nbd.2004.09.003; Seaborn T, 2011, CURR PHARM DESIGN, V17, P204, DOI 10.2174/138161211795049679; Shibata Noriyuki, 2008, Brain and Nerve (Tokyo), V60, P157; Smith PS, 2007, FREE RADICAL BIO MED, V42, P787, DOI 10.1016/j.freeradbiomed.2006.11.032; Steele M. L., 2010, NEUROBIOL AGING, V33, pe421; Stetler RA, 2010, P NATL ACAD SCI USA, V107, P3204, DOI 10.1073/pnas.1000030107; Stumm R, 2007, J NEUROCHEM, V103, P1666, DOI 10.1111/j.1471-4159.2007.04895.x; Sun GY, 2014, MOL NEUROBIOL, V50, P6, DOI 10.1007/s12035-014-8662-4; Suzuki R, 2003, MOL BRAIN RES, V115, P10, DOI 10.1016/S0169-328X(03)00172-4; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Takuma K, 2001, YAKUGAKU ZASSHI, V121, P663, DOI 10.1248/yakushi.121.663; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 1998, NEUROSCIENCE, V84, P801, DOI 10.1016/S0306-4522(97)00545-9; Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Wang JF, 2014, NEUROCHEM INT, V64, P37, DOI 10.1016/j.neuint.2013.11.002; Yang SF, 2006, J PHARMACOL EXP THER, V319, P595, DOI 10.1124/jpet.106.102236; Zhou YC, 2015, INT J MOL MED, V36, P43, DOI 10.3892/ijmm.2015.2205; Zhu H, 2012, EXP BIOL MED, V237, P143, DOI 10.1258/ebm.2011.011152	74	23	23	2	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2016	137	6					913	930		10.1111/jnc.13614			18	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DS0BZ	WOS:000380261500009	26991551	Green Accepted, Bronze			2021-06-18	
J	Flygt, J; Gumucio, A; Ingelsson, M; Skoglund, K; Holm, J; Alafuzoff, I; Marklund, N				Flygt, Johanna; Gumucio, Astrid; Ingelsson, Martin; Skoglund, Karin; Holm, Jonatan; Alafuzoff, Irina; Marklund, Niklas			Human Traumatic Brain Injury Results in Oligodendrocyte Death and Increases the Number of Oligodendrocyte Progenitor Cells	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Apoptosis; Human; Immunohistochemistry; Oligodendrocyte; Oligodendrocyte progenitor cells; Traumatic brain injury	DIFFUSE AXONAL INJURY; CENTRAL-NERVOUS-SYSTEM; RAT SPINAL-CORD; MULTIPLE-SCLEROSIS LESIONS; SITU DNA FRAGMENTATION; FACTOR-ALPHA-RECEPTOR; FATAL HEAD-INJURY; WHITE-MATTER; ADULT CNS; INCREASED EXPRESSION	Oligodendrocyte (OL) death may contribute to white matter pathology, a common cause of network dysfunction and persistent cognitive problems in patients with traumatic brain injury (TBI). Oligodendrocyte progenitor cells (OPCs) persist throughout the adult CNS and may replace dead OLs. OL death and OPCs were analyzed by immunohistochemistry of human brain tissue samples, surgically removed due to life-threatening contusions and/or focal brain swelling at 60.6 +/- 75 hours (range 4-192 hours) postinjury in 10 severe TBI patients (age 51.7 +/- 18.5 years). Control brain tissue was obtained postmortem from 5 age-matched patients without CNS disorders. TUNEL and CC1 co-labeling was used to analyze apoptotic OLs, which were increased in injured brain tissue (p < 0.05), without correlation with time from injury until surgery. The OPC markers Olig2, A2B5, NG2, and PDGFR-alpha were used. In contrast to the number of single-labeled Olig2, A2B5, NG2, and PDGFR-alpha-positive cells, numbers of Olig2 and A2B5 co-labeled cells were increased in TBI samples (p < 0.05); this was inversely correlated with time from injury to surgery (r = -0.8, p < 0.05). These results indicate that severe focal human TBI results in OL death and increases in OPCs postinjury, which may influence white matter function following TBI.	[Flygt, Johanna; Skoglund, Karin; Holm, Jonatan; Marklund, Niklas] Uppsala Univ, Dept Neurosci, Neurosurg, Uppsala, Sweden; [Gumucio, Astrid; Ingelsson, Martin] Uppsala Univ, Dept Publ Hlth & Caring Sci, Geriatr, Uppsala, Sweden; [Alafuzoff, Irina] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, Ing 85,2 Tr, SE-75185 Uppsala, Sweden.	Niklas.Marklund@neuro.uu.se		Marklund, Niklas/0000-0002-9797-5626			Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Baumann N, 2001, PHYSIOL REV, V81, P871; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; Boulanger JJ, 2014, NEUROSCIENCE, V269, P343, DOI 10.1016/j.neuroscience.2014.03.063; Bradl M, 2010, ACTA NEUROPATHOL, V119, P37, DOI 10.1007/s00401-009-0601-5; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; Chari DM, 2007, INT REV NEUROBIOL, V79, P589, DOI 10.1016/S0074-7742(07)79026-8; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Clark RSB, 1999, FASEB J, V13, P813; Clarke LE, 2012, J NEUROSCI, V32, P8173, DOI 10.1523/JNEUROSCI.0928-12.2012; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Conti AC, 1998, J NEUROSCI, V18, P5663; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cudrici C, 2006, J REHABIL RES DEV, V43, P123, DOI 10.1682/JRRD.2004.08.0111; Cui QL, 2013, AM J PATHOL, V183, P516, DOI 10.1016/j.ajpath.2013.04.016; Czepiel M, 2015, GLIA, V63, P513, DOI 10.1002/glia.22769; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Di Bello IC, 1999, J NEUROCYTOL, V28, P365, DOI 10.1023/A:1007069815302; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Geha S, 2010, BRAIN PATHOL, V20, P399, DOI 10.1111/j.1750-3639.2009.00295.x; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Horner PJ, 2000, J NEUROSCI, V20, P2218; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Jadasz JJ, 2012, CELL TISSUE RES, V349, P331, DOI 10.1007/s00441-012-1331-x; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnstone JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080975; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Lojewski X, 2014, STEM CELL TRANSL MED, V3, P458, DOI 10.5966/sctm.2013-0117; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; LUDWIN SK, 1978, LAB INVEST, V39, P597; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maeda Y, 2001, ANN NEUROL, V49, P776, DOI 10.1002/ana.1015; MAJOCHA RE, 1989, J NEUROCHEM, V53, P953, DOI 10.1111/j.1471-4159.1989.tb11798.x; Maki T, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00275; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Merrill JE, 1999, NEUROPATH APPL NEURO, V25, P435; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Miller BA, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-28; Moransard M, 2011, BRAIN, V134, P1315, DOI 10.1093/brain/awr070; Morelli PI, 2006, ATHEROSCLEROSIS, V184, P39, DOI 10.1016/j.atherosclerosis.2005.03.026; Oliver-De La Cruz J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099253; Oumesmar BN, 1997, J NEUROSCI, V17, P125; Piaton G, 2010, J NEUROCHEM, V114, P1243, DOI 10.1111/j.1471-4159.2010.06831.x; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rhee W, 2009, GLIA, V57, P510, DOI 10.1002/glia.20780; Sahinkaya FR, 2014, EXP NEUROL, V255, P113, DOI 10.1016/j.expneurol.2014.02.025; Sanchez I, 1996, J NEUROSCI, V16, P5095; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Simpson JE, 2007, NEUROPATH APPL NEURO, V33, P410, DOI 10.1111/j.1365-2990.2007.00828.x; Skoglund K, 2012, CRIT CARE MED, V40, P216, DOI 10.1097/CCM.0b013e31822d7dbd; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Sun F, 2010, GLIA, V58, P1304, DOI 10.1002/glia.21009; Takahashi C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.335; Trotter J, 2010, BRAIN RES REV, V63, P72, DOI 10.1016/j.brainresrev.2009.12.006; Uschkureit T, 2000, J NEUROSCI, V20, P5225, DOI 10.1523/JNEUROSCI.20-14-05225.2000; VIGNAIS L, 1995, NEUROREPORT, V6, P1993, DOI 10.1097/00001756-199510010-00010; Wegner M, 2001, MICROSC RES TECHNIQ, V52, P746, DOI 10.1002/jemt.1059; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wilson HC, 2006, J NEUROIMMUNOL, V176, P162, DOI 10.1016/j.jneuroim.2006.04.014; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Yeung MSY, 2014, CELL, V159, P766, DOI 10.1016/j.cell.2014.10.011; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006	99	23	24	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUN	2016	75	6					503	515		10.1093/jnen/nlw025			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DO3FC	WOS:000377665000003	27105664	Bronze			2021-06-18	
J	Fuller, CW; Taylor, AE; Raftery, M				Fuller, Colin W.; Taylor, Aileen E.; Raftery, Martin			Should player fatigue be the focus of injury prevention strategies for international rugby sevens tournaments?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							WORLD-CUP; MUSCLE FATIGUE; MATCH ANALYSIS; PROPRIOCEPTION; PERFORMANCE; PATTERNS; SERIES; SENSE	Objective To assess the incidence, severity and nature of injuries, to determine risk factors for injury and to identify potential injury prevention strategies in men's international Rugby-7s tournaments. Design A prospective cohort study. Participants Players from core teams competing in matches at 6 Sevens World Series from 2008/2009 to 2014/2015. Results The incidence of injury across all Series was 108.3 injuries/1000 player-match-hours (backs: 121.0; forwards: 91.5) with a mean severity of 44.2 days (backs: 46.1; forwards: 40.9) and a median severity of 28 days (backs: 29; forwards: 26). The proportion of injuries sustained in the second half was significantly higher (60%; p<0.001) than the first half of matches and the proportion increased from match to match and day to day in a tournament. The knee (17.4%), ankle (15.9%) and posterior thigh (13.2%) were the most common injury locations for backs and the knee (18.5%), head/face (17.3%) and shoulder/clavicle (13.0%) for forwards. The four most common injuries across all players were knee ligament (13.0%), ankle ligament (12.8%), concussion (10.4%) and posterior thigh muscle strains (9.8%). Conclusions The incidence of injury in Rugby-7s suggests that teams require squads of around 20 players for a Sevens World Series. The higher incidence of injury in the second half of matches is probably the result of player fatigue; therefore, injury prevention strategies for teams and the Governing Body should address this issue. The results presented support the World Rugby trial allowing 'rolling substitutes' during Sevens World Series matches, as this approach may help to mitigate the effects of player fatigue during the second half of matches.	[Fuller, Colin W.; Taylor, Aileen E.; Raftery, Martin] World Rugby, World Rugby House,8-10 Pembroke St Lower, Dublin 2, Ireland	Fuller, CW (corresponding author), World Rugby, World Rugby House,8-10 Pembroke St Lower, Dublin 2, Ireland.	ColinFullerConsultancy@gmail.com			World Rugby, Dublin, Ireland	The study was funded by World Rugby, Dublin, Ireland.	Aughey RJ, 2010, INT J SPORT PHYSIOL, V5, P394, DOI 10.1123/ijspp.5.3.394; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Bruckner P, 2007, CLIN SPORTS MED, P8; Cortes N, 2014, GAIT POSTURE, V39, P888, DOI 10.1016/j.gaitpost.2013.11.020; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2015, BRIT J SPORT MED, V49, P458, DOI 10.1136/bjsports-2014-094369; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2010, CLIN J SPORT MED, V20, P179, DOI 10.1097/JSM.0b013e3181df1eea; Furlan N, 2015, INT J SPORT PHYSIOL, V10, P802, DOI 10.1123/ijspp.2014-0315; Granatelli G, 2014, J STRENGTH COND RES, V28, P728, DOI 10.1519/JSC.0b013e31829d23c3; Herrington L, 2008, PHYS THER SPORT, V9, P67, DOI 10.1016/j.ptsp.2008.01.001; Hiemstra LA, 2001, J ORTHOP SPORT PHYS, V31, P598, DOI 10.2519/jospt.2001.31.10.598; Higham DG, 2016, J STRENGTH COND RES, V30, P1287, DOI [10.1519/JSC.0b013e3182a9536f, 10.1097/JSC.0000000000000212]; Higham DG, 2013, INT J SPORT PHYSIOL, V8, P19, DOI 10.1123/ijspp.8.1.19; Higham DG, 2012, J SCI MED SPORT, V15, P277, DOI 10.1016/j.jsams.2011.11.256; Kibler WB, 2007, CLIN SPORTS MED, P243; Kirkwood B., 2003, ESSENTIAL MED STAT, V2nd; Lee HM, 2003, CLIN BIOMECH, V18, P843, DOI 10.1016/S0268-0033(03)00151-7; Mair SD, 1996, AM J SPORT MED, V24, P137, DOI 10.1177/036354659602400203; Myers JB, 2000, J ATHL TRAINING, V35, P351; Orchard J., 1995, SPORT HLTH, V11, P39; Pedersen J, 1999, MED SCI SPORT EXER, V31, P1047, DOI 10.1097/00005768-199907000-00019; Rampinini E, 2009, J SCI MED SPORT, V12, P227, DOI 10.1016/j.jsams.2007.10.002; Ross A, 2015, J SPORT SCI, V33, P1035, DOI 10.1080/02640414.2014.979858; Ross A, 2014, SPORTS MED, V44, P357, DOI 10.1007/s40279-013-0123-0; Takarada Y, 2003, BRIT J SPORT MED, V37, P416, DOI 10.1136/bjsm.37.5.416; Weinhandl JT, 2014, CLIN BIOMECH, V29, P752, DOI 10.1016/j.clinbiomech.2014.05.013; Wojtys EM, 1996, AM J SPORT MED, V24, P615, DOI 10.1177/036354659602400509; World Rugby, GAM AN SEV WORLD SER; World Rugby, WHAT IS RUGB	32	23	23	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2016	50	11					682	U72		10.1136/bjsports-2016-096043			7	Sport Sciences	Sport Sciences	DN0NX	WOS:000376761700014	27190230				2021-06-18	
J	Giannoudi, M; Harwood, P				Giannoudi, M.; Harwood, P.			Damage control resuscitation: lessons learned	EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY			English	Article						Polytrauma; Damage control surgery; Severe haemorrhage; Resuscitation	ACUTE TRAUMATIC COAGULOPATHY; ENDOVASCULAR BALLOON OCCLUSION; HEMOSTATIC RESUSCITATION; PERMISSIVE HYPOTENSION; MASSIVE TRANSFUSION; FLUID RESUSCITATION; PELVIC TRAUMA; BRAIN-INJURY; HEMORRHAGE; HYPOTHERMIA	Background Damage control resuscitation describes an approach to the early care of very seriously injured patients. The aim is to keep the patient alive whilst avoiding interventions and situations that risk worsening their situation by driving the lethal triad of hypothermia, coagulopathy and acidosis or excessively stimulating the immune-inflammatory system. It is critical that the concepts and practicalities of this approach are understood by all those involved in the early management of trauma patients. This review aims to summarise this and discusses current knowledge on the subject. Interventions Damage control resuscitation forms part of an overall approach to patient care rather than a specific intervention and has evolved from damage control surgery. It is characterised by early blood product administration, haemorrhage arrest and restoration of blood volume aiming to rapidly restore physiologic stability. The infusion of large volumes of crystalloid is no longer appropriate, instead the aim is to replace lost blood and avoid dilution and coagulopathy. In specific situations, permissive hypotension may also be of benefit, particularly in patients with severe haemorrhage from an arterial source. As rapid arrest of haemorrhage is so important, team-based protocols that deliver patients rapidly but safely, via CT scan where appropriate, to operating theatres or interventional radiology suites form a critical part of this process. Conclusions Given that interventions are so time dependent in the severely injured, it is likely that by further improving trauma systems and protocols, improvements in outcome can still be made. Further research work in this area will allow us to target these approaches more accurately to those patients who can benefit most.	[Giannoudi, M.; Harwood, P.] Leeds Gen Infirm, Clarendon Wing,Level A,Great George St, Leeds LS1 3EX, W Yorkshire, England	Harwood, P (corresponding author), Leeds Gen Infirm, Clarendon Wing,Level A,Great George St, Leeds LS1 3EX, W Yorkshire, England.	pauljharwood@me.com	Harwood, Paul/I-2360-2019	Harwood, Paul/0000-0003-4564-4689			Bailey AM, 2014, ADV EMERG NURS J, V36, P123, DOI 10.1097/TME.0000000000000018; Ball CG, 2014, CAN J SURG, V57, P55, DOI 10.1503/cjs.020312; Beekley AC, 2008, CRIT CARE MED, V36, pS267, DOI 10.1097/CCM.0b013e31817da7dc; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Brenner ML, 2013, J TRAUMA ACUTE CARE, V75, P506, DOI 10.1097/TA.0b013e31829e5416; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Chesser TJS, 2012, INJURY, V43, P667, DOI 10.1016/j.injury.2012.04.003; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Cohen MJ, 2011, J TRAUMA, V70, pS47, DOI 10.1097/TA.0b013e31821a5c24; Davenport R, 2013, TRANSFUSION, V53, p23S, DOI 10.1111/trf.12032; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Dutton RP, 2012, BRIT J ANAESTH, V109, pI39, DOI 10.1093/bja/aes389; Feinman M, 2014, CURR OPIN CRIT CARE, V20, P366, DOI 10.1097/MCC.0000000000000104; Fox Charles J, 2011, Perspect Vasc Surg Endovasc Ther, V23, P112, DOI 10.1177/1531003511400627; Gantner D, 2014, CURR OPIN CRIT CARE, V20, P385, DOI 10.1097/MCC.0000000000000114; Geeraedts LMG, 2009, INJURY, V40, P11, DOI 10.1016/j.injury.2008.10.007; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Giannoudis PV, 2006, INJURY, V37, pS3, DOI 10.1016/S0020-1383(07)70005-0; Giannoudis PV, 2009, INJURY, V40, pS47, DOI 10.1016/j.injury.2009.10.036; Giannoudis PV, 2003, J BONE JOINT SURG BR, V85B, P478, DOI 10.1302/0301-620X.85B4.14217; Hamilton H, 2014, J CARDIOVASC SURG, V55, P151; Hildebrand F, 2009, UNFALLCHIRURG, V112, P959, DOI 10.1007/s00113-009-1683-1; HIRSHBERG A, 1994, J TRAUMA, V37, P365, DOI 10.1097/00005373-199409000-00005; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Hsu Jeremy M, 2011, Int J Crit Illn Inj Sci, V1, P66, DOI 10.4103/2229-5151.79285; Jansen JO, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1778; Kaafarani HMA, 2014, SCAND J SURG, V103, P81, DOI 10.1177/1457496914524388; Khan S, 2014, J TRAUMA ACUTE CARE, V76, P561, DOI 10.1097/TA.0000000000000146; Kim Y, 2014, J KOREAN MED SCI, V29, P1007, DOI 10.3346/jkms.2014.29.7.1007; Kobbe P, 2009, UNFALLCHIRURG, V112, P1055, DOI 10.1007/s00113-009-1711-1; Kornblith LZ, 2014, J TRAUMA ACUTE CARE, V77, P818, DOI 10.1097/TA.0000000000000354; Kragh JF, 2011, J EMERG MED, V41, P590, DOI 10.1016/j.jemermed.2009.07.022; Lamb CM, 2014, BRIT J ANAESTH, V113, P242, DOI 10.1093/bja/aeu233; Langan NR, 2014, JAMA SURG, V149, P904, DOI 10.1001/jamasurg.2014.940; Lasanianos NG, 2011, INJURY, V42, P617, DOI 10.1016/j.injury.2011.02.011; Lasanianos NG, 2010, CLIN ORTHOP RELAT R, V468, P2514, DOI 10.1007/s11999-009-1191-1; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; McDaniel LM, 2014, TRANSFUSION MED, V24, P138, DOI 10.1111/tme.12125; Mitra B, 2014, SHOCK, V42, P307, DOI 10.1097/SHK.0000000000000219; Mizushima Y, 2000, ARCH SURG-CHICAGO, V135, P175, DOI 10.1001/archsurg.135.2.175; Pape Hans-Christoph, 2005, J Orthop Trauma, V19, P551, DOI 10.1097/01.bot.0000161712.87129.80; Perel P, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001664; Roberts Craig S, 2005, Instr Course Lect, V54, P447; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Scharbert G, 2010, PLATELETS, V21, P44, DOI 10.3109/09537100903420269; Schmidt BM, 2012, WORLD J EMERG SURG, V7, DOI 10.1186/1749-7922-7-S1-S9; Schwartz DA, 2014, J TRAUMA ACUTE CARE, V76, P134, DOI 10.1097/TA.0b013e3182ab0cfc; Shapiro MB, 2000, J TRAUMA, V49, P969, DOI 10.1097/00005373-200011000-00033; Smith A, 2013, CAN J SURG, V56, pE154, DOI 10.1503/cjs.020012; Spahn DR, 2010, BRIT J ANAESTH, V105, P103, DOI 10.1093/bja/aeq166; Spinella PC, 2014, SHOCK, V41, P1, DOI 10.1097/SHK.0000000000000059; Stannard A, 2011, J TRAUMA, V71, P1869, DOI 10.1097/TA.0b013e31823fe90c; Taylor DM, 2013, MIL MED, V178, P1196, DOI 10.7205/MILMED-D-13-00223; Tobin JM, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2013.11.017; Tosounidis TI, 2013, SURG-J R COLL SURG E, V11, P344, DOI 10.1016/j.surge.2013.07.004; Zipfel B, 2014, ANN THORAC SURG, V97, P774, DOI 10.1016/j.athoracsur.2013.09.034	56	23	25	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-9933	1863-9941		EUR J TRAUMA EMERG S	Eur. J. Trauma Emerg. Surg.	JUN	2016	42	3					273	282		10.1007/s00068-015-0628-3			10	Emergency Medicine	Emergency Medicine	DS3SR	WOS:000380703500002	26847110	Green Published, Other Gold			2021-06-18	
J	Rowe, RK; Ellis, GI; Harrison, JL; Bachstetter, AD; Corder, GF; Van Eldik, LJ; Taylor, BK; Marti, F; Lifshitz, J				Rowe, Rachel K.; Ellis, Gavin I.; Harrison, Jordan L.; Bachstetter, Adam D.; Corder, Gregory F.; Van Eldik, Linda J.; Taylor, Bradley K.; Marti, Francesc; Lifshitz, Jonathan			Diffuse traumatic brain injury induces prolonged immune dysregulation and potentiates hyperalgesia following a peripheral immune challenge	MOLECULAR PAIN			English	Article						Traumatic brain injury; pain; hyperalgesia; regulatory T cells; immunology	REGULATORY T-CELLS; NECROSIS-FACTOR-ALPHA; CHRONIC PAIN; NEUROPATHIC PAIN; P38-ALPHA MAPK; RETINOIC ACID; UP-REGULATION; ACTIVATION; MECHANISMS; NEUROINFLAMMATION	Background: Nociceptive and neuropathic pain occurs as part of the disease process after traumatic brain injury (TBI) in humans. Central and peripheral inflammation, a major secondary injury process initiated by the traumatic brain injury event, has been implicated in the potentiation of peripheral nociceptive pain. We hypothesized that the inflammatory response to diffuse traumatic brain injury potentiates persistent pain through prolonged immune dysregulation. Results: To test this, adult, male C57BL/6 mice were subjected to midline fluid percussion brain injury or to sham procedure. One cohort of mice was analyzed for inflammation-related cytokine levels in cortical biopsies and serum along an acute time course. In a second cohort, peripheral inflammation was induced seven days after surgery/injury with an intraplantar injection of carrageenan. This was followed by measurement of mechanical hyperalgesia, glial fibrillary acidic protein and Iba1 immunohistochemical analysis of neuroinflammation in the brain, and flow cytometric analysis of T-cell differentiation in mucosal lymph. Traumatic brain injury increased interleukin-6 and chemokine ligand 1 levels in the cortex and serum that peaked within 1-9 h and then resolved. Intraplantar carrageenan produced mechanical hyperalgesia that was potentiated by traumatic brain injury. Further, mucosal T cells from brain-injured mice showed a distinct deficiency in the ability to differentiate into inflammation-suppressing regulatory T cells (Tregs). Conclusions: We conclude that traumatic brain injury increased the inflammatory pain associated with cutaneous inflammation by contributing to systemic immune dysregulation. Regulatory T cells are immune suppressors and failure of T cells to differentiate into regulatory T cells leads to unregulated cytokine production which may contribute to the potentiation of peripheral pain through the excitation of peripheral sensory neurons. In addition, regulatory T cells are identified as a potential target for therapeutic rebalancing of peripheral immune homeostasis to improve functional outcome and decrease the incidence of peripheral inflammatory pain following traumatic brain injury.	[Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Phoenix Veteran Affairs Healthcare Syst, Phoenix, AZ USA; [Ellis, Gavin I.] Univ Kentucky, Coll Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY USA; [Harrison, Jordan L.; Lifshitz, Jonathan] Arizona State Univ, Tempe, AZ USA; [Bachstetter, Adam D.; Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Bachstetter, Adam D.; Van Eldik, Linda J.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Corder, Gregory F.; Taylor, Bradley K.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY USA	Lifshitz, J (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA.	jlifshitz@email.arizona.edu		Rowe, Rachel/0000-0002-9034-3159; Bachstetter, Adam/0000-0003-4646-6757	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K02 DA19656, R01 DA037621, R01 NS065052, F31 NS09092]; Bisgrove Scholar Award from Science Foundation Arizona; Diane and Bruce Halle Foundation; Office of the Vice President for Research; Markey Cancer Center; NIH Shared Instrument ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10 RR026827]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR026827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA037621, K02DA019656] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by NIH grants K02 DA19656 and R01 DA037621 (BKT) and R01 NS065052 (JL). Dr. Rowe is funded by a Bisgrove Scholar Award from Science Foundation Arizona. Mr. Harrison was partially supported by the Diane and Bruce Halle Foundation and NIH F31 NS09092. Flow cytometry was carried out at the University of Kentucky Flow Cytometry and Cell Sorting Core Facility, which is supported in part by the Office of the Vice President for Research, the Markey Cancer Center and a grant from the NIH Shared Instrument Program (S10 RR026827).	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Austin PJ, 2012, PAIN, V153, P1916, DOI 10.1016/j.pain.2012.06.005; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Beggs S, 2013, NEUROSCI LETT, V557, P37, DOI 10.1016/j.neulet.2013.08.037; Bosco MA, 2013, HEADACHE, V53, P1518, DOI 10.1111/head.12172; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carson WF, 2010, EUR J IMMUNOL, V40, P998, DOI 10.1002/eji.200939739; Corder G, 2013, SCIENCE, V341, P1394, DOI 10.1126/science.1239403; Cunha F Q, 1992, Mediators Inflamm, V1, P397, DOI 10.1155/S0962935192000607; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; DePaolo RW, 2011, NATURE, V471, P220, DOI 10.1038/nature09849; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Eakin K, 2015, BRAIN NEUROTRAUMA MO, P1; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128; Ellis GI, 2012, JOVE-J VIS EXP, DOI 10.3791/3738; Feliciano DP, 2014, NEUROSCI LETT, V583, P55, DOI 10.1016/j.neulet.2014.09.030; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Hall JA, 2011, IMMUNITY, V34, P435, DOI 10.1016/j.immuni.2011.03.003; Harrison JL, 2015, BRAIN BEHAV IMMUN, V47, P131, DOI 10.1016/j.bbi.2015.01.001; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Huang H, 2013, J IMMUNOL, V191, P1136, DOI 10.4049/jimmunol.1201899; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Liu ZM, 2015, CELL MOL IMMUNOL, V12, P553, DOI 10.1038/cmi.2014.133; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Murphy TJ, 2005, J IMMUNOL, V174, P2957, DOI 10.4049/jimmunol.174.5.2957; Myers RR, 2006, DRUG DISCOV TODAY, V11, P8, DOI 10.1016/S1359-6446(05)03637-8; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; NAPOLITANO LM, 1994, ARCH SURG-CHICAGO, V129, P1276; NAPOLITANO LM, 1995, J TRAUMA, V39, P104, DOI 10.1097/00005373-199507000-00014; Old EA, 2015, HANDB EXP PHARMACOL, V227, P145, DOI 10.1007/978-3-662-46450-2_8; Posadas I, 2004, BRIT J PHARMACOL, V142, P331, DOI 10.1038/sj.bjp.0705650; Reichling DB, 2009, TRENDS NEUROSCI, V32, P611, DOI 10.1016/j.tins.2009.07.007; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Sandkuhler J, 2009, PHYSIOL REV, V89, P707, DOI 10.1152/physrev.00025.2008; Schafers M, 2003, J NEUROSCI, V23, P2517; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007; Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; Zelenka M, 2005, PAIN, V116, P257, DOI 10.1016/j.pain.2005.04.018; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	56	23	23	2	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		1744-8069		MOL PAIN	Mol. Pain	MAY 13	2016	12								1744806916647055	10.1177/1744806916647055			12	Neurosciences	Neurosciences & Neurology	DM9YY	WOS:000376722800001	27178244	DOAJ Gold, Green Published			2021-06-18	
J	Richards, RI; Robertson, SA; O'Keefe, LV; Fornarino, D; Scott, A; Lardelli, M; Baune, BT				Richards, Robert I.; Robertson, Sarah A.; O'Keefe, Louise V.; Fornarino, Dani; Scott, Andrew; Lardelli, Michael; Baune, Bernhard T.			The Enemy within: Innate Surveillance-Mediated Cell Death, the Common Mechanism of Neurodegenerative Disease	FRONTIERS IN NEUROSCIENCE			English	Article						dementia; innate autoimmunity; inflammation; neurodegeneration; Alzheimer's; Parkinson's; Huntington's	AMYOTROPHIC-LATERAL-SCLEROSIS; UNFOLDED PROTEIN RESPONSE; TOLL-LIKE RECEPTOR; ENDOPLASMIC-RETICULUM STRESS; AMYLOID CASCADE HYPOTHESIS; AICARDI-GOUTIERES SYNDROME; MOTOR-NEURON DEGENERATION; TERM COGNITIVE IMPAIRMENT; ONSET ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY	Neurodegenerative diseases comprise an array of progressive neurological disorders all characterized by the selective death of neurons in the central nervous system. Although, rare (familial) and common (sporadic) forms can occur for the same disease, it is unclear whether this reflects several distinct pathogenic pathways or the convergence of different causes into a common form of nerve cell death. Remarkably, neurodegenerative diseases are increasingly found to be accompanied by activation of the innate immune surveillance system normally associated with pathogen recognition and response. Innate surveillance is the cell's quality control system for the purpose of detecting such danger signals and responding in an appropriate manner. Innate surveillance is an "intelligent system," in that the manner of response is relevant to the magnitude and duration of the threat. If possible, the threat is dealt with within the cell in which it is detected, by degrading the danger signal(s) and restoring homeostasis. If this is not successful then an inflammatory response is instigated that is aimed at restricting the spread of the threat by elevating degradative pathways, sensitizing neighboring cells, and recruiting specialized cell types to the site. If the danger signal persists, then the ultimate response can include not only the programmed cell death of the original cell, but the contents of this dead cell can also bring about the death of adjacent sensitized cells. These responses are clearly aimed at destroying the ability of the detected pathogen to propagate and spread. Innate surveillance comprises intracellular, extracellular, non-cell autonomous and systemic processes. Recent studies have revealed how multiple steps in these processes involve proteins that, through their mutation, have been linked to many familial forms of neurodegenerative disease. This suggests that individuals harboring these mutations may have an amplified response to innate-mediated damage in neural tissues, and renders innate surveillance mediated cell death a plausible common pathogenic pathway responsible for neurodegenerative diseases, in both familial and sporadic forms. Here we have assembled evidence in favor of the hypothesis that neurodegenerative disease is the cumulative result of chronic activation of the innate surveillance pathway, triggered by endogenous or environmental danger or damage associated molecular patterns in a progressively expanding cascade of inflammation, tissue damage and cell death.	[Richards, Robert I.; O'Keefe, Louise V.; Fornarino, Dani; Scott, Andrew; Lardelli, Michael] Univ Adelaide, Dept Genet & Evolut, Ctr Mol Pathol, Sch Biol Sci, Adelaide, SA, Australia; [Robertson, Sarah A.] Univ Adelaide, Sch Paediat & Reprod Hlth, Robinson Res Inst, Adelaide, SA, Australia; [Baune, Bernhard T.] Univ Adelaide, Discipline Psychiat, Sch Med, Adelaide, SA, Australia	Richards, RI (corresponding author), Univ Adelaide, Dept Genet & Evolut, Ctr Mol Pathol, Sch Biol Sci, Adelaide, SA, Australia.	robert.richards@adelaide.edu.au	Richards, Robert/ABE-6423-2020; Robertson, Sarah A/C-8182-2009; O'Keefe, Louise V/B-9856-2008	Robertson, Sarah A/0000-0002-9967-0084; Lardelli, Michael/0000-0002-4289-444X	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [APP1069348]; National Ataxia Foundation (USA)	This research is funded in part by Project Grant (APP1069348) from the National Health and Medical Research Council of Australia and a grant from the National Ataxia Foundation (USA).	Ahmad ST, 2009, P NATL ACAD SCI USA, V106, P12168, DOI 10.1073/pnas.0903134106; Ahrens S, 2012, IMMUNITY, V36, P635, DOI 10.1016/j.immuni.2012.03.008; Aikawa T, 2015, HUM MOL GENET, V24, P4780, DOI 10.1093/hmg/ddv202; Andries O, 2013, J CONTROL RELEASE, V167, P157, DOI 10.1016/j.jconrel.2013.01.033; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; Asakura T, 2015, GENES CELLS, V20, P153, DOI 10.1111/gtc.12206; Azuma Y, 2014, HUM MOL GENET, V23, P3467, DOI 10.1093/hmg/ddu055; Banez-Coronel M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002481; Barbaro BA, 2015, HUM MOL GENET, V24, P913, DOI 10.1093/hmg/ddu504; Batra R., 2016, BIORXIV, DOI [10.1101/038448, DOI 10.1101/038448]; Batra R, 2010, HUM MOL GENET, V19, pR77, DOI 10.1093/hmg/ddq132; Bentmann E, 2013, FEBS J, V280, P4348, DOI 10.1111/febs.12287; Bernard JJ, 2012, NAT MED, V18, P1286, DOI 10.1038/nm.2861; Bettens K, 2013, LANCET NEUROL, V12, P92, DOI 10.1016/S1474-4422(12)70259-4; Beutler B, 2007, NAT REV IMMUNOL, V7, P753, DOI 10.1038/nri2174; Bjorkqvist M, 2008, J EXP MED, V205, P1869, DOI 10.1084/jem.20080178; Blin J, 2015, CYTOKINE, V74, P175, DOI 10.1016/j.cyto.2015.03.005; Bortoluci KR, 2010, CELL MOL LIFE SCI, V67, P1643, DOI 10.1007/s00018-010-0335-5; Brinkmann MM, 2007, J CELL BIOL, V177, P265, DOI 10.1083/jcb.200612056; Buchan JR, 2013, CELL, V153, P1461, DOI 10.1016/j.cell.2013.05.037; Buchon N, 2014, NAT REV IMMUNOL, V14, P796, DOI 10.1038/nri3763; Catala-Lopez F, 2014, PSYCHOTHER PSYCHOSOM, V83, P89, DOI 10.1159/000356498; Caulin AF, 2011, TRENDS ECOL EVOL, V26, P175, DOI 10.1016/j.tree.2011.01.002; Celardo I, 2014, BRIT J PHARMACOL, V171, P1943, DOI 10.1111/bph.12433; Chan G, 2015, NAT NEUROSCI, V18, P1556, DOI 10.1038/nn.4126; Chavan SS, 2012, MOL MED, V18, P930, DOI 10.2119/molmed.2012.00195; Cho JA, 2013, CELL HOST MICROBE, V13, P558, DOI 10.1016/j.chom.2013.03.011; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Cox LE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009872; Crow YJ, 2015, CURR OPIN IMMUNOL, V32, P7, DOI 10.1016/j.coi.2014.10.005; Crow YJ, 2014, NEUROPEDIATRICS, V45, P386, DOI 10.1055/s-0034-1389161; Crow YJ, 2011, ANN NY ACAD SCI, V1238, P91, DOI 10.1111/j.1749-6632.2011.06220.x; Crow YJ, 2009, HUM MOL GENET, V18, pR130, DOI 10.1093/hmg/ddp293; Dou ZX, 2015, NATURE, V527, P105, DOI 10.1038/nature15548; Driver JA, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e1442; Dunys J, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-35; Eckard SC, 2014, NAT IMMUNOL, V15, P839, DOI 10.1038/ni.2948; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Escott-Price V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094661; Fang L, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00016; Feng Y, 2015, NAT REV CANCER, V15, P556, DOI 10.1038/nrc3979; Fonseca ACRG, 2013, BBA-MOL BASIS DIS, V1832, P2191, DOI 10.1016/j.bbadis.2013.08.007; Francisco NM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0345-1; Freibaum BD, 2015, NATURE, V525, P129, DOI 10.1038/nature14974; Gardner BM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013169; Gelderblom M, 2015, AGEING RES REV, V24, P77, DOI 10.1016/j.arr.2015.07.004; Goedert M, 2015, SCIENCE, V349, DOI 10.1126/science.1255555; Goldwurm S, 2007, NEUROLOGY, V68, P1141, DOI 10.1212/01.wnl.0000254483.19854.ef; Gottschalk W. K., 2015, J PARKINSONS DIS ALZ, V1, DOI 10.13188/2376-922X; Goubau D, 2014, NATURE, V514, P372, DOI 10.1038/nature13590; Goubau D, 2010, NAT IMMUNOL, V11, P984, DOI 10.1038/ni1110-984; Greene JC, 2005, HUM MOL GENET, V14, P799, DOI 10.1093/hmg/ddi074; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Guardia-Laguarta C, 2014, J NEUROSCI, V34, P249, DOI 10.1523/JNEUROSCI.2507-13.2014; Guillot-Sestier MV, 2015, TRENDS NEUROSCI, V38, P674, DOI 10.1016/j.tins.2015.08.008; Haeusler AR, 2014, NATURE, V507, P195, DOI 10.1038/nature13124; Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910; HAMILTON JA, 1980, ENVIRON HEALTH PERSP, V34, P69, DOI 10.1289/ehp.803469; Harbauer AB, 2014, CELL METAB, V19, P357, DOI 10.1016/j.cmet.2014.01.010; Hardy J, 2014, J INTERN MED, V275, P296, DOI 10.1111/joim.12192; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Harijith A, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00352; Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222; Hausler M, 2003, HUM PATHOL, V34, P253, DOI 10.1053/hupa.2003.35; Haynes CM, 2010, J CELL SCI, V123, P3849, DOI 10.1242/jcs.075119; Haywood AFM, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-14; Hefendehl JK, 2014, AGING CELL, V13, P60, DOI 10.1111/acel.12149; Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Herrup K, 2015, NAT NEUROSCI, V18, P794, DOI 10.1038/nn.4017; Hetz C, 2009, GENE DEV, V23, P2294, DOI 10.1101/gad.1830709; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hofer MJ, 2013, CYTOKINE GROWTH F R, V24, P257, DOI 10.1016/j.cytogfr.2013.03.006; Hornung V, 2014, NAT REV IMMUNOL, V14, P521, DOI 10.1038/nri3719; Hu SQ, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005367; Cornejo VH, 2013, SEMIN IMMUNOPATHOL, V35, P277, DOI 10.1007/s00281-013-0373-9; IQBAL K, 1977, J NEUROCHEM, V29, P417, DOI 10.1111/j.1471-4159.1977.tb10689.x; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Iqbal K, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.225; Ito D, 2011, NEUROLOGY, V77, P1636, DOI 10.1212/WNL.0b013e3182343365; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Juranek JK, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3289/fncel.2015.00435, 10.3389/fncel.2015.00485]; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Kauppinen TM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-152; Khoo JJ, 2011, J INTERF CYTOK RES, V31, P13, DOI 10.1089/jir.2010.0095; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kim YK, 2016, YONSEI MED J, V57, P5, DOI 10.3349/ymj.2016.57.1.5; Kiningham KK, 1999, FASEB J, V13, P1601; Kitada T, 1998, NATURE, V392, P605; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kubes P, 2012, GASTROENTEROLOGY, V143, P1158, DOI 10.1053/j.gastro.2012.09.008; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lattante S, 2015, TRENDS GENET, V31, P263, DOI 10.1016/j.tig.2015.03.005; Lawlor KT, 2011, HUM MOL GENET, V20, P3757, DOI 10.1093/hmg/ddr292; Lee JY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0310-z; Lee JH, 2010, EXP MOL MED, V42, P386, DOI 10.3858/emm.2010.42.5.040; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li JM, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0211-2; Li YR, 2013, J CELL BIOL, V201, P361, DOI 10.1083/jcb.201302044; Liddicoat BJ, 2015, SCIENCE, V349, P1115, DOI 10.1126/science.aac7049; Liu Y, 2014, NATURE, V508, P406, DOI 10.1038/nature13204; Livingston JH, 2014, J MED GENET, V51, P76, DOI 10.1136/jmedgenet-2013-102038; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Lu JV, 2014, SEMIN CELL DEV BIOL, V35, P33, DOI 10.1016/j.semcdb.2014.07.003; Lui PCW, 2009, HUM PATHOL, V40, P1611, DOI 10.1016/j.humpath.2009.04.016; MacKay CR, 2014, CURR OPIN IMMUNOL, V26, P49, DOI 10.1016/j.coi.2013.10.015; Mackenzie IRA, 2015, ACTA NEUROPATHOL, V130, P845, DOI 10.1007/s00401-015-1476-2; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Mann DMA, 2015, NEUROBIOL AGING, V36, P1224, DOI 10.1016/j.neurobiolaging.2014.10.011; Martire S, 2015, MECH AGEING DEV, V146, P53, DOI 10.1016/j.mad.2015.04.001; Masters CL, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.56; McGlasson S, 2015, NAT REV NEUROL, V11, P515, DOI 10.1038/nrneurol.2015.143; McLeod CJ, 2005, HUM MOL GENET, V14, P1041, DOI 10.1093/hmg/ddi096; Meyer SN, 2014, SCIENCE, V346, P1199, DOI 10.1126/science.1258236; Michels M, 2015, BRAIN BEHAV IMMUN, V43, P54, DOI 10.1016/j.bbi.2014.07.002; Miller JRC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141793; Mino T, 2015, CELL, V161, P1058, DOI 10.1016/j.cell.2015.04.029; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; Moehle MS, 2012, J NEUROSCI, V32, P1602, DOI 10.1523/JNEUROSCI.5601-11.2012; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166-2236(00)02031-2; Muller-Schiffmann A, 2016, BRAIN, V139, P509, DOI 10.1093/brain/awv355; Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109; Musicco M, 2013, NEUROLOGY, V81, P322, DOI 10.1212/WNL.0b013e31829c5ec1; Nakano S, 2010, RHEUMATOLOGY, V49, P876, DOI 10.1093/rheumatology/keq001; Nallagatla SR, 2008, RNA BIOL, V5, P140, DOI 10.4161/rna.5.3.6839; Nasirudeen AMA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000926; Norris KL, 2015, J BIOL CHEM, V290, P13862, DOI 10.1074/jbc.M114.634063; Nystrom S, 2013, EMBO J, V32, P86, DOI 10.1038/emboj.2012.328; Olmos-Alonso A, 2016, BRAIN, V139, P891, DOI 10.1093/brain/awv379; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788; Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191; Pellegrino MW, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0129-1; Pellegrino MW, 2014, NATURE, V516, P414, DOI 10.1038/nature13818; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Pestal K, 2015, IMMUNITY, V43, P933, DOI 10.1016/j.immuni.2015.11.001; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Piccoli C, 2008, J MED GENET, V45, P596, DOI 10.1136/jmg.2008.058628; Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824; Radian AD, 2015, MOL IMMUNOL, V67, P294, DOI 10.1016/j.molimm.2015.06.013; Radian AD, 2013, MICROBES INFECT, V15, P630, DOI 10.1016/j.micinf.2013.04.001; Ray R, 2016, NEUROSCI BIOBEHAV R, V62, P48, DOI 10.1016/j.neubiorev.2015.12.006; Rhodes JD, 2012, HUM MOL GENET, V21, P852, DOI 10.1093/hmg/ddr515; Rice GI, 2014, NAT GENET, V46, P503, DOI 10.1038/ng.2933; Rice GI, 2012, NAT GENET, V44, P1243, DOI 10.1038/ng.2414; Rigby RE, 2015, TRENDS IMMUNOL, V36, P179, DOI 10.1016/j.it.2015.02.001; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Rock KL, 2010, ANNU REV IMMUNOL, V28, P321, DOI 10.1146/annurev-immunol-030409-101311; Rodriguez-Vieitez E, 2016, BRAIN, V139, P922, DOI 10.1093/brain/awv404; Roses AD, 2010, PHARMACOGENOMICS J, V10, P375, DOI 10.1038/tpj.2009.69; Russo I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-52; Ryan SM, 2016, NEUROSCI BIOBEHAV R, V61, P121, DOI 10.1016/j.neubiorev.2015.12.004; Ryoo J, 2014, NAT MED, V20, P936, DOI 10.1038/nm.3626; Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002; Samaraweera SE, 2013, HUM MOL GENET, V22, P2811, DOI 10.1093/hmg/ddt130; Sasaki T, 2016, EXP NEUROL, V275, P220, DOI 10.1016/j.expneurol.2015.11.003; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Schapansky J, 2015, NEUROSCIENCE, V302, P74, DOI 10.1016/j.neuroscience.2014.09.049; Schapansky J, 2014, HUM MOL GENET, V23, P4201, DOI 10.1093/hmg/ddu138; Schellenberg GD, 2012, ACTA NEUROPATHOL, V124, P305, DOI 10.1007/s00401-012-0996-2; Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002; Sharshar T, 2014, LANCET NEUROL, V13, P534, DOI 10.1016/S1474-4422(14)70064-X; Shichita T, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00319; Simola N, 2007, NEUROTOX RES, V11, P151, DOI 10.1007/BF03033565; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; Talbot K, 2006, HUM MOL GENET, V15, pR182, DOI 10.1093/hmg/ddl202; Tan MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.348; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Tanzi RE, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006296; Tekkok I H, 2000, Brain Tumor Pathol, V17, P97, DOI 10.1007/BF02484280; Thaiss CA, 2016, TRENDS IMMUNOL, V37, P84, DOI 10.1016/j.it.2015.12.003; Thundyil J, 2015, AGEING RES REV, V24, P17, DOI 10.1016/j.arr.2014.11.003; Valanne S, 2011, J IMMUNOL, V186, P649, DOI 10.4049/jimmunol.1002302; Valdes-Ferrer SI, 2013, J INTERN MED, V274, P381, DOI 10.1111/joim.12104; van Eyk CL, 2011, HUM MOL GENET, V20, P2783, DOI 10.1093/hmg/ddr177; Vanha-aho LM, 2016, IMMUNOL LETT, V170, P42, DOI 10.1016/j.imlet.2015.12.005; Venderova K, 2009, HUM MOL GENET, V18, P4390, DOI 10.1093/hmg/ddp394; Venereau E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00422; von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x; Wan JJ, 2012, NAT GENET, V44, P704, DOI 10.1038/ng.2254; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037; West RJH, 2015, J CELL BIOL, V208, P931, DOI 10.1083/jcb.201404066; Whitworth AJ, 2005, P NATL ACAD SCI USA, V102, P8024, DOI 10.1073/pnas.0501078102; Widmann CN, 2014, LANCET NEUROL, V13, P630, DOI 10.1016/S1474-4422(14)70017-1; Wu W, 2012, CRIT REV ONCOL HEMAT, V82, P249, DOI 10.1016/j.critrevonc.2011.08.004; Xu ZH, 2013, P NATL ACAD SCI USA, V110, P7778, DOI 10.1073/pnas.1219643110; Ye X, 2015, HUM MOL GENET, V24, P2938, DOI 10.1093/hmg/ddv056; Yoneyama M, 2016, J BIOCHEM, V159, P279, DOI 10.1093/jb/mvv122; Yu AK, 2015, HUM MOL GENET, V24, P2848, DOI 10.1093/hmg/ddv045; Yu ZM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001340; Yuan FH, 2015, J BIOL CHEM, V290, P13344, DOI 10.1074/jbc.M115.653915; Zeng L, 2010, J IMMUNOL, V185, P2324, DOI 10.4049/jimmunol.0903052; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030; Zhang K, 2015, NATURE, V525, P56, DOI 10.1038/nature14973; Zhou R, 2011, CELL MOL IMMUNOL, V8, P371, DOI 10.1038/cmi.2011.19	202	23	23	0	28	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	MAY 10	2016	10								193	10.3389/fnins.2016.00193			20	Neurosciences	Neurosciences & Neurology	DL3QO	WOS:000375548500002	27242399	DOAJ Gold, Green Published			2021-06-18	
J	Chagdes, JR; Rietdyk, S; Haddad, JM; Zelaznik, HN; Cinelli, ME; Denomme, LT; Powers, KC; Raman, A				Chagdes, James R.; Rietdyk, Shirley; Haddad, Jeffrey M.; Zelaznik, Howard N.; Cinelli, Michael E.; Denomme, Luke T.; Powers, Kaley C.; Raman, Arvind			Limit cycle oscillations in standing human posture	JOURNAL OF BIOMECHANICS			English	Article						Balance; Model; Time-delay; Bifurcations; Limit cycle; Neuromuscular disease	DIFFERENTIAL-DELAY EQUATIONS; OF-PRESSURE TRAJECTORIES; MULTIPLE-SCLEROSIS; SENSORIMOTOR INTEGRATION; DYNAMICAL STRUCTURE; VISUAL-STIMULATION; SWAY; STABILITY; BALANCE; SYSTEM	Limit cycle oscillations (LCOs) are a hallmark of dynamic instability in time-delayed and nonlinear systems such as climate change models, biological oscillators, and robotics. Here we study the links between the human neuromuscular system and LCOs in standing posture. First, we demonstrate through a simple mathematical model that the observation of LCOs in posture is indicative of excessive neuromuscular time-delay. To test this hypothesis we study LCOs in the postural sway of individuals with multiple sclerosis and concussed athletes representing two different populations with chronically and acutely increased neuromuscular time-delays. Using a wavelet analysis method we demonstrate that 67% of individuals with multiple sclerosis and 44% of individuals with concussion exhibit intermittent LCOs; 8% of MS-controls, 0% of older adults, and 0% of concussion-controls displayed LCOs. Thus, LCOs are not only key to understanding postural instability but also may have important applications for the detection of neuromuscular deficiencies. (C) 2016 Published by Elsevier Ltd.	[Chagdes, James R.] Miami Univ, Dept Mech & Mfg Engn, 650 East High St, Oxford, OH 45056 USA; [Rietdyk, Shirley; Haddad, Jeffrey M.; Zelaznik, Howard N.] Purdue Univ, Dept Hlth & Kinesiol, 800 West Stadium Ave, W Lafayette, IN 47907 USA; [Cinelli, Michael E.; Denomme, Luke T.; Powers, Kaley C.] Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, 75 Univ Ave West, Waterloo, ON N2L 3C5, Canada; [Raman, Arvind] Purdue Univ, Sch Mech Engn, 585 Purdue Mall, W Lafayette, IN 47907 USA	Raman, A (corresponding author), Purdue Univ, Sch Mech Engn, 585 Purdue Mall, W Lafayette, IN 47907 USA.	raman@purdue.edu	Chagdes, James/R-9241-2019; Cinelli, Michael/ABE-7625-2020	Chagdes, James/0000-0001-5307-7608; Cinelli, Michael/0000-0002-5802-2590	National Science FoundationNational Science Foundation (NSF) [CMMI-1300632]	The authors are grateful to the National Science Foundation for partial financial support for this project provided through the Grant CMMI-1300632.	Addison P, 2002, ILLUSTRATED WAVELET; ALBRECHT F, 1973, SCIENCE, V181, P1073, DOI 10.1126/science.181.4104.1073; [Anonymous], 2009, BR J SPORTS MED S1, V43, pi85; Asai H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007371; Barauskas R, 2007, J SOUND VIB, V308, P612, DOI 10.1016/j.jsv.2007.03.051; Batzel JJ, 2000, J MATH BIOL, V41, P45, DOI 10.1007/s002850000044; Benedetti MG, 1999, MULT SCLER J, V5, P363, DOI 10.1177/135245859900500510; Cameron MH, 2008, SOMATOSENS MOT RES, V25, P113, DOI 10.1080/08990220802131127; CAMPBELL SA, 1995, J DYN DIFFER EQU, V7, DOI DOI 10.1007/BF02218819; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chagdes JR, 2009, EXP BRAIN RES, V197, P297, DOI 10.1007/s00221-009-1915-1; COLLINS JJ, 1994, PHYS REV LETT, V73, P764, DOI 10.1103/PhysRevLett.73.764; DEGREGORIO S, 1992, J NONLINEAR SCI, V2, P293, DOI 10.1007/BF01208927; Denomme L., 2014, EXP BRAIN RES, P1; Donker SF, 2007, EXP BRAIN RES, V181, P1, DOI 10.1007/s00221-007-0905-4; Dowell EH, 1975, AEROELASTICITY PLATE; Duarte M, 2001, PHYS LETT A, V283, P124, DOI 10.1016/S0375-9601(01)00188-8; Eckner JT, 2012, MED SCI SPORT EXER, V44, P411; Engelborghs K., 2001, TW330 KU LEUVEN DEP; EPSTEIN IR, 1991, J CHEM PHYS, V95, P244, DOI 10.1063/1.461481; EPSTEIN IR, 1992, INT REV PHYS CHEM, V11, P135, DOI 10.1080/01442359209353268; Eurich CW, 1996, PHYS REV E, V54, P6681, DOI 10.1103/PhysRevE.54.6681; Fukuoka Y, 2001, IEEE T NEUR SYS REH, V9, P145, DOI 10.1109/7333.928574; Gawthrop P., 2014, BIOL CYBERN, P1; Haddad JM, 2008, EXP BRAIN RES, V190, P431, DOI 10.1007/s00221-008-1483-9; Haddad JM, 2013, EXERC SPORT SCI REV, V41, P123, DOI 10.1097/JES.0b013e3182877cc8; Haddad JM, 2011, J MOTOR BEHAV, V43, P345, DOI 10.1080/00222895.2011.596169; HOLMES PJ, 1977, J SOUND VIB, V53, P471, DOI 10.1016/0022-460X(77)90521-1; Insperger T, 2000, CISM COURSES LECT, V422, P197; Insperger T., 2011, SEMIDISCRETIZATION T; Jankovic J, 2006, NEUROLOGY, V66, P1286; Kinsella-Shaw JM, 2006, J MOTOR BEHAV, V38, P251, DOI 10.3200/JMBR.38.4.251-264; Kirchner M, 2012, PHYSICA A, V391, P4692, DOI 10.1016/j.physa.2012.05.034; Kowalczyk P, 2012, J R SOC INTERFACE, V9, P234, DOI 10.1098/rsif.2011.0212; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Ladislao L, 2007, MED BIOL ENG COMPUT, V45, P679, DOI 10.1007/s11517-007-0213-y; Liang ZQ, 2014, GAIT POSTURE, V39, P397, DOI 10.1016/j.gaitpost.2013.08.007; MacDonald N., 1978, TIME LAGS IN BIOLOGI; MACKEY MC, 1977, SCIENCE, V197, P287, DOI 10.1126/science.267326; Masani K, 2006, GAIT POSTURE, V23, P164, DOI 10.1016/j.gaitpost.2005.01.006; Masani K, 2003, J NEUROPHYSIOL, V90, P3774, DOI 10.1152/jn.00730.2002; Maurer C, 2005, J NEUROPHYSIOL, V93, P189, DOI 10.1152/jn.00221.2004; Maurer C, 2004, EXP BRAIN RES, V157, P369, DOI 10.1007/s00221-004-1852-y; Maurer C, 2003, BRAIN, V126, P1146, DOI 10.1093/brain/awg100; MAY RM, 1972, SCIENCE, V177, P900, DOI 10.1126/science.177.4052.900; Orosz G, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.046205; Peterka RJ, 2004, J NEUROPHYSIOL, V91, P410, DOI 10.1152/jn.00516.2003; Peterka RJ, 2000, BIOL CYBERN, V82, P335, DOI 10.1007/s004220050587; Peterka RJ, 2003, IEEE ENG MED BIOL, V22, P63, DOI 10.1109/MEMB.2003.1195698; Peterka RJ, 2002, J NEUROPHYSIOL, V88, P1097, DOI 10.1152/jn.2002.88.3.1097; Porter B., 1967, STABILITY CRITERIA L; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; Rhea CK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017696; Rocchi L, 2002, J NEUROL NEUROSUR PS, V73, P267, DOI 10.1136/jnnp.73.3.267; Roerdink M, 2006, EXP BRAIN RES, V174, P256, DOI 10.1007/s00221-006-0441-7; Schmit JM, 2006, EXP BRAIN RES, V168, P357, DOI 10.1007/s00221-005-0094-y; STEPAN G, 1986, NONLINEAR ANAL-THEOR, V10, P913, DOI 10.1016/0362-546X(86)90078-7; Stepan G, 2009, PHILOS T R SOC A, V367, P1195, DOI 10.1098/rsta.2008.0278; Suarez H, 2001, ACTA OTO-LARYNGOL, V121, P220; Suarez H, 2000, ACTA OTO-LARYNGOL, V120, P168; Suzuki T, 2002, CNS DRUGS, V16, P165, DOI 10.2165/00023210-200216030-00003; Ting LH, 2009, CHAOS, V19, DOI 10.1063/1.3142245; TOBIAS SA, 1965, MACHINE TOOL VIBRATI; Verdaasdonk BW, 2004, BIOL CYBERN, V91, P48, DOI 10.1007/s00422-004-0494-2; Vette AH, 2010, IEEE T NEUR SYS REH, V18, P86, DOI 10.1109/TNSRE.2009.2037891; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Winter D.A., 1995, ABC ANATOMY BIOMECHA; Winter DA, 1998, J NEUROPHYSIOL, V80, P1211; WINTERS JM, 1985, IEEE T BIO-MED ENG, V32, P826, DOI 10.1109/TBME.1985.325498; Yamada N, 1995, HUM MOVEMENT SCI, V14, P711, DOI 10.1016/0167-9457(95)00032-1; Yao W, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.021902	72	23	23	1	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	MAY 3	2016	49	7					1170	1179		10.1016/j.jbiomech.2016.03.005			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	DM0RB	WOS:000376052400026	27018157	Bronze			2021-06-18	
J	Chaturvedi, J; Botta, R; Prabhuraj, AR; Shukla, D; Bhat, DI; Devi, BI				Chaturvedi, Jitender; Botta, Ragasudha; Prabhuraj, A. R.; Shukla, Dhaval; Bhat, Dahnanjay I.; Devi, B. Indira			Complications of cranioplasty after decompressive craniectomy for traumatic brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						complications; cranioplasty; decompressive craniectomy	MULTICENTER	Introduction. Decompressive craniectomy (DC)a potentially life-saving intervention following traumatic brain injury (TBI) with medically refractory brain swellingonce performed, surviving patients, more often than not, undergo a second procedure with cranioplasty (CP) in the future. This study analyzes complications following CP after DC, as the beneficial effects of the DC can't be extrapolated in long run over a population unless one adds into it the complications associated with the CP in the survivors of TBI. Materials and methods. An observational study was performed retrospectively, with the review of case records. Demographic, clinical, and outcome data were collected, and complications were studied for any predictive parameters. A multivariate analysis was performed to identify factors that influenced these complications. Results. Data were collected for a total of 74 patients who underwent CP with a median age of 32, and a mean follow-up time of 2 years and 8 months. The mortality rate was 1.35% and overall complication rate 31%. The most significant factor determining complications were operating time more than 90 min Odds ratio (OR) 4.77 (1.61-14.20); timing of CP less than 3 months after craniectomy, OR 2.86 (1.48-8.11); age more than 20 years, OR 2.59 (1.20-6.53); and female gender, OR 1.91 (1.13-4.17). Conclusions. Although considered as a straight-forward procedure, the risks associated with this elective procedure should be kept in mind by the surgeon so that the patients and families can be apprised judiciously. It should be ascertained that patient and/or family consents for the procedure after being appropriately informed about the benefits and risks associated with the procedure.	[Chaturvedi, Jitender; Prabhuraj, A. R.; Shukla, Dhaval; Bhat, Dahnanjay I.; Devi, B. Indira] NIMHANS, Dept Neurosurg, Bengaluru 560029, Karnataka, India; [Botta, Ragasudha] NIMHANS, Dept Clin Neurosci, Bengaluru 560029, Karnataka, India	Chaturvedi, J (corresponding author), NIMHANS, Dept Neurosurg, Bengaluru 560029, Karnataka, India.	drjittu28@gmail.com					Bobinski L, 2013, CLIN NEUROL NEUROSUR, V115, P1788, DOI 10.1016/j.clineuro.2013.04.013; Broughton E, 2014, BRIT J NEUROSURG, V28, P34, DOI 10.3109/02688697.2013.815319; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Heo J, 2014, J NEUROSURG, V121, P313, DOI 10.3171/2014.2.JNS131480; Joffe J, 1999, BRIT J NEUROSURG, V13, P576, DOI 10.1080/02688699943088; Klinger DR, 2014, WORLD NEUROSURG, V82, pE525, DOI 10.1016/j.wneu.2013.08.005; Lee MK, 2010, J CRANIO MAXILL SURG, V38, P494, DOI 10.1016/j.jcms.2010.02.001; Shaffrey ME, 1993, BRAIN SURG COMPLICAT, V1, P1373; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	16	23	24	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	MAY 3	2016	30	2					264	268		10.3109/02688697.2015.1054356			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI3LK	WOS:000373399900019	26083136				2021-06-18	
J	Kokiko-Cochran, O; Ransohoff, L; Veenstra, M; Lee, S; Saber, M; Sikora, M; Teknipp, R; Xu, GX; Bemiller, S; Wilson, G; Crish, S; Bhaskar, K; Lee, YS; Ransohoff, RM; Lamb, BT				Kokiko-Cochran, Olga; Ransohoff, Lena; Veenstra, Mike; Lee, Sungho; Saber, Maha; Sikora, Matt; Teknipp, Ryan; Xu, Guixiang; Bemiller, Shane; Wilson, Gina; Crish, Samuel; Bhaskar, Kiran; Lee, Yu-Shang; Ransohoff, Richard M.; Lamb, Bruce T.			Altered Neuroinflammation and Behavior after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease	JOURNAL OF NEUROTRAUMA			English	Article						Alzheimer's disease; traumatic brain injury; neuroinflammation; macrophage	AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; A-BETA DEPOSITION; HEAD-INJURY; TRANSGENIC MICE; RISK-FACTOR; FRONTOTEMPORAL DEMENTIA; MICROGLIAL ACTIVATION	Traumatic brain injury (TBI) has acute and chronic sequelae, including an increased risk for the development of Alzheimer's disease (AD). TBI-associated neuroinflammation is characterized by activation of brain-resident microglia and infiltration of monocytes; however, recent studies have implicated beta-amyloid as a major manipulator of the inflammatory response. To examine neuroinflammation after TBI and development of AD-like features, these studies examined the effects of TBI in the presence and absence of beta-amyloid. The R1.40 mouse model of cerebral amyloidosis was used, with a focus on time points well before robust AD pathologies. Unexpectedly, in R1.40 mice, the acute neuroinflammatory response to TBI was strikingly muted, with reduced numbers of CNS myeloid cells acquiring a macrophage phenotype and decreased expression of inflammatory cytokines. At chronic time points, macrophage activation substantially declined in non-Tg TBI mice; however, it was relatively unchanged in R1.40 TBI mice. The persistent inflammatory response coincided with significant tissue loss between 3 and 120 days post-injury in R1.40 TBI mice, which was not observed in non-Tg TBI mice. Surprisingly, inflammatory cytokine expression was enhanced in R1.40 mice compared with non-Tg mice, regardless of injury group. Although R1.40 TBI mice demonstrated task-specific deficits in cognition, overall functional recovery was similar to non-Tg TBI mice. These findings suggest that accumulating beta-amyloid leads to an altered post-injury macrophage response at acute and chronic time points. Together, these studies emphasize the role of post-injury neuroinflammation in regulating long-term sequelae after TBI and also support recent studies implicating beta-amyloid as an immunomodulator.	[Kokiko-Cochran, Olga; Ransohoff, Lena; Veenstra, Mike; Lee, Sungho; Saber, Maha; Sikora, Matt; Teknipp, Ryan; Xu, Guixiang; Bemiller, Shane; Lee, Yu-Shang; Lamb, Bruce T.] Cleveland Clin, Dept Neurosci, NC30,9500 Euclid Ave, Cleveland, OH 44195 USA; [Wilson, Gina; Crish, Samuel] Northeast Ohio Med Univ, Dept Pharmaceut Sci, Rootstown, OH USA; [Bhaskar, Kiran] Univ New Mexico, Dept Mol Genet Microbiol & Neurol, Albuquerque, NM 87131 USA; [Ransohoff, Richard M.] Biogen Idec Inc, Cambridge, MA USA; [Lamb, Bruce T.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; [Lamb, Bruce T.] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA	Lamb, BT (corresponding author), Cleveland Clin, Dept Neurosci, NC30,9500 Euclid Ave, Cleveland, OH 44195 USA.	lambb@ccf.org	Bhaskar, Kiran/AAF-2755-2020	Lee, Sungho/0000-0003-2111-5504	NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY022358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS083704, R01NS069765] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY022358, R01 EY022358] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RF1 NS083704, R01 NS069765] Funding Source: Medline		Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Bhaskar K, 2014, NEUROBIOL DIS, V62, P273, DOI 10.1016/j.nbd.2013.10.007; Bhaskar K, 2010, NEURON, V68, P19, DOI 10.1016/j.neuron.2010.08.023; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Cady J, 2014, JAMA NEUROL, V71, P449, DOI 10.1001/jamaneurol.2013.6237; Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Corrigan F, 2014, J NEUROCHEM, V128, P196, DOI 10.1111/jnc.12391; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Grant JL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004145; Griciuc A, 2013, NEURON, V78, P631, DOI 10.1016/j.neuron.2013.04.014; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Guerreiro RJ, 2013, JAMA NEUROL, V70, P78, DOI 10.1001/jamaneurol.2013.579; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kawabori M, 2015, J NEUROSCI, V35, P3384, DOI 10.1523/JNEUROSCI.2620-14.2015; Krabbe G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060921; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; Lamb BT, 1997, HUM MOL GENET, V6, P1535, DOI 10.1093/hmg/6.9.1535; Lee CYD, 2010, J NEURAL TRANSM, V117, P949, DOI 10.1007/s00702-010-0433-4; Lill C.M., 2015, ALZHEIMERS DEMENT; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LUBERNAROD J, 1988, NEUROSCI LETT, V94, P17, DOI 10.1016/0304-3940(88)90263-7; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; MCGEER PL, 1988, ACTA NEUROPATHOL, V76, P550, DOI 10.1007/BF00689592; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ferreira APO, 2014, PSYCHOPHARMACOLOGY, V231, P1935, DOI 10.1007/s00213-013-3336-x; Pajoohesh-Ganji A, 2014, BRAIN RES, V1560, P73, DOI 10.1016/j.brainres.2014.02.049; Pan XD, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-45; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rayaprolu S, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-19; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Sieber MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052982; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Thal DR, 2000, ACTA NEUROPATHOL, V100, P608, DOI 10.1007/s004010000242; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Whiting M. D., INJURY MODELS CENTRA	79	23	23	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2016	33	7					625	640		10.1089/neu.2015.3970			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DI6QK	WOS:000373624700002	26414955	Green Published			2021-06-18	
J	Kroshus, E; Baugh, CM				Kroshus, Emily; Baugh, Christine M.			Concussion Education in US Collegiate Sport: What Is Happening and What Do Athletes Want?	HEALTH EDUCATION & BEHAVIOR			English	Article						college health; dissemination and implementation; health communications; injury prevention; safety; school-based	ICE HOCKEY; KNOWLEDGE; PLAYERS; BRAIN; EPIDEMIOLOGY; SYMPTOMS; INJURIES; MEDICINE; BEHAVIOR; POLICY	Concussion education for athletes has the potential to play a role in reducing the health burden of concussions from sport by modifying individual risk-related behaviors. In U.S. collegiate sport, decisions about content and delivery of concussion education are left up to the individual institution. This may result in a high degree of variability in what educational materials athletes receive and is particularly problematic as few concussion education programs have demonstrated efficacy. Health educators can play an important role in working collaboratively with sports medicine clinicians to design and evaluate evidence-based concussion education materials for athletes that meet their learning needs. As a first step in this process, the present study characterizes the content, source, and delivery modalities of concussion currently being provided to U.S. collegiate athletes. It also describes the reported concussion education preferences of a sample of U.S. collegiate athletes. Participants were 789 athletic trainers from 276 schools and 325 athletes from four schools. Results indicated that education is most frequently provided by athletic trainers but that many athletes would also like coaches and physicians to be involved in this process. Athletes also indicated a preference for content provision across a range of topics, including athletic and academic consequences of continued play with a concussion. Implications for the design and delivery of concussion education for athletes are discussed.	[Kroshus, Emily] Univ Washington, Dept Pediat, 2001 Eighth Ave,Suite 400, Seattle, WA 98121 USA; [Kroshus, Emily] Ctr Child Hlth Behav & Dev, Seattle Childrens Res Inst, Seattle, WA USA; [Kroshus, Emily] Natl Collegiate Athlet Assoc, Indianapolis, IN USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.] Boston Childrens Hosp, Micheli Ctr Sports Injury Prevent, Boston, MA USA	Kroshus, E (corresponding author), Univ Washington, Dept Pediat, 2001 Eighth Ave,Suite 400, Seattle, WA 98121 USA.	ekroshus@u.washington.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338	National Institute of Mental Health of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Christine Baugh was supported by the National Institute of Mental Health of the National Institutes of Health under Award No. T32MH019733.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Chan DKC, 2012, SPORTS MED, V42, P725, DOI 10.2165/11633040-000000000-00000; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dickinson D, 2003, BRIT MED J, V327, P861, DOI 10.1136/bmj.327.7419.861-a; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Gilmore G, 2005, NEEDS CAPACITY ASSES; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kroshus E, 2015, ANN BEHAV MED, V49, P532, DOI 10.1007/s12160-014-9683-y; Kroshus E, 2015, CLIN J SPORT MED, V25, P243, DOI 10.1097/JSM.0000000000000137; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, EAT DISORD, V22, P136, DOI 10.1080/10640266.2013.867744; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; LaBrie JW, 2010, ADDICT BEHAV, V35, P1094, DOI 10.1016/j.addbeh.2010.08.003; Manasse-Cohick NJ, 2014, COMMUN DISORD Q, V35, P182, DOI 10.1177/1525740113506605; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; National Collegiate Athletic Association, CONC FACT SHEET STUD; National Collegiate Athletic Association, 2013, NCAA SPORTS MED HDB; National Collegiate Athletic Association, 2014, DIV I STEER COMM GOV; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rivara FP, 2014, JAMA-J AM MED ASSOC, V311, P239, DOI 10.1001/jama.2013.282985; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Verhagen EALM, 2010, SPORTS MED, V40, P899, DOI 10.2165/11536890-000000000-00000	42	23	23	0	30	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1090-1981	1552-6127		HEALTH EDUC BEHAV	Health Educ. Behav.	APR	2016	43	2					182	190		10.1177/1090198115599380			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	DI7RN	WOS:000373699600009	26293460	Green Accepted			2021-06-18	
J	Dall'Acqua, P; Johannes, S; Mica, L; Simmen, HP; Glaab, R; Fandino, J; Schwendinger, M; Meier, C; Ulbrich, EJ; Muller, A; Jancke, L; Hanggi, J				Dall'Acqua, Patrizia; Johannes, Soenke; Mica, Ladislav; Simmen, Hans-Peter; Glaab, Richard; Fandino, Javier; Schwendinger, Markus; Meier, Christoph; Ulbrich, Erika J.; Mueller, Andreas; Jaencke, Lutz; Haenggi, Juergen			Connectomic and Surface-Based Morphometric Correlates of Acute Mild Traumatic Brain Injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						mild traumatic brain injury; structural connectome; connectivity analysis; cortical surface area; multimodal MRI; subjective symptoms	POST-CONCUSSION SYMPTOMS; TENSOR IMAGING FINDINGS; HUMAN CEREBRAL-CORTEX; GRAPH-THEORETICAL ANALYSIS; ANTERIOR CINGULATE CORTEX; MAGNETIC-RESONANCE IMAGES; DIFFUSE AXONAL INJURY; POSTCONCUSSION SYMPTOMS; CORTICAL SURFACE; MATTER ABNORMALITIES	Reduced integrity of white matter (WM) pathways and subtle anomalies in gray matter (GM) morphology have been hypothesized as mechanisms in mild traumatic brain injury (mTBI). However, findings on structural brain changes in early stages after mTBI are inconsistent and findings related to early symptoms severity are rare. Fifty-one patients were assessed with multimodal neuroimaging and clinical methods exclusively within 7 days following mTBI and compared to 53 controls. Whole-brain connectivity based on diffusion tensor imaging was subjected to network-based statistics, whereas cortical surface area, thickness, and volume based on T1-weighted MRI scans were investigated using surface-based morphometric analysis. Reduced connectivity strength within a subnetwork of 59 edges located predominantly in bilateral frontal lobes was significantly associated with higher levels of self-reported symptoms. In addition, cortical surface area decreases were associated with stronger complaints in five clusters located in bilateral frontal and postcentral cortices, and in the right inferior temporal region. Alterations in WM and GM were localized in similar brain regions and moderately-to-strongly related to each other. Furthermore, the reduction of cortical surface area in the frontal regions was correlated with poorer attentive-executive performance in the mTBI group. Finally, group differences were detected in both the WM and GM, especially when focusing on a subgroup of patients with greater complaints, indicating the importance of classifying mTBI patients according to severity of symptoms. This study provides evidence that mTBI affects not only the integrity of WM networks by means of axonal damage but also the morphology of the cortex during the initial post-injury period. These anomalies might be greater in the acute period than previously believed and the involvement of frontal brain regions was consistently pronounced in both findings. The dysconnected subnetwork suggests that mTBI can be conceptualized as a dysconnection syndrome. It remains unclear whether reduced WM integrity is the trigger for changes in cortical surface area or whether tissue deformations are the direct result of mechanical forces acting on the brain. The findings suggest that rapid identification of high-risk patients with the use of clinical scales should be assessed acutely as part of the mTBI protocol.	[Dall'Acqua, Patrizia; Johannes, Soenke] Bellikon Rehabil Clin, Bellikon, Switzerland; [Johannes, Soenke; Jaencke, Lutz; Haenggi, Juergen] Univ Zurich, Dept Psychol, Div Neuropsychol, Zurich, Switzerland; [Mica, Ladislav; Simmen, Hans-Peter] Univ Zurich Hosp, Div Trauma Surg, CH-8091 Zurich, Switzerland; [Glaab, Richard] Cantonal Hosp Aarau, Dept Traumatol, Aarau, Switzerland; [Fandino, Javier] Cantonal Hosp Aarau, Dept Neurosurg, Aarau, Switzerland; [Schwendinger, Markus] Baden Cantonal Hosp, Interdisciplinary Emergency Ctr, Baden, Switzerland; [Meier, Christoph] Waid Hosp Zurich, Dept Surg, Zurich, Switzerland; [Ulbrich, Erika J.] Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, CH-8091 Zurich, Switzerland; [Mueller, Andreas] Brain & Trauma Fdn Grison, Chur, Switzerland; [Jaencke, Lutz] Univ Zurich, Int Normal Aging & Plast Imaging Ctr, Zurich, Switzerland; [Jaencke, Lutz] Univ Zurich, Ctr Integrat Human Physiol, Zurich, Switzerland; [Jaencke, Lutz] Univ Zurich, Univ Res Prior Program, Dynam Hlth Aging, Zurich, Switzerland	Dall'Acqua, P (corresponding author), Bellikon Rehabil Clin, Bellikon, Switzerland.	patrizia.dallacqua@rehabellikon.ch		Hanggi, Jurgen/0000-0001-8124-6018; Simmen, Hans-Peter/0000-0002-5201-4549	Research Fund of the Swiss Accident Insurance (SUVA)	This work has been supported by the Research Fund of the Swiss Accident Insurance (SUVA).	Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck A.T., 1993; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; da Costa L, 2015, J NEUROL NEUROSUR PS, V86, P1008, DOI 10.1136/jnnp-2014-308571; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Eagle DM, 2008, PSYCHOPHARMACOLOGY, V199, P439, DOI 10.1007/s00213-008-1127-6; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Floden D, 2006, J COGNITIVE NEUROSCI, V18, P1843, DOI 10.1162/jocn.2006.18.11.1843; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gosselin N, 2012, J NEUROTRAUM, V29, P2625, DOI 10.1089/neu.2012.2312; Hanggi J, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00915; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Hansen K, 2013, ACCIDENT ANAL PREV, V59, P109, DOI 10.1016/j.aap.2013.05.019; Hautzinger M., 2006, BDI 2 BECK DEPRESSIO; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Margraf J, 2007, BAI BECK ANGST INVEN; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Menon V, 2001, HUM BRAIN MAPP, V12, P131, DOI 10.1002/1097-0193(200103)12:3<131::AID-HBM1010>3.0.CO;2-C; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Vink M, 2005, HUM BRAIN MAPP, V25, P336, DOI 10.1002/hbm.20111; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wiebking C, 2014, NEUROIMAGE, V86, P10, DOI 10.1016/j.neuroimage.2013.04.042; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Winkler AM, 2012, NEUROIMAGE, V61, P1428, DOI 10.1016/j.neuroimage.2012.03.026; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Yuan WH, 2015, HUM BRAIN MAPP, V36, P779, DOI 10.1002/hbm.22664; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zalesky A, 2009, IEEE T MED IMAGING, V28, P1023, DOI 10.1109/TMI.2008.2012113; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhan J, 2015, J NERV MENT DIS, V203, P786, DOI 10.1097/NMD.0000000000000368; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhu Y., 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/548392	94	23	23	0	17	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 29	2016	10								127	10.3389/fnhum.2016.00127			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	DH6UR	WOS:000372928100001	27065831	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Mountney, A; Bramlett, HM; Dixon, CE; Mondello, S; Dietrich, WD; Wang, KKW; Caudle, K; Empey, PE; Poloyac, SM; Hayes, RL; Povlishock, JT; Tortella, FC; Kochanek, PM; Shear, DA				Mountney, Andrea; Bramlett, Helen M.; Dixon, C. Edward; Mondello, Stefania; Dietrich, W. Dalton; Wang, Kevin K. W.; Caudle, Krista; Empey, Philip E.; Poloyac, Samuel M.; Hayes, Ronald L.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.; Shear, Deborah A.			Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						penetrating ballistic-like brain injury; therapy; micropig; biomarker; controlled cortical impact; neuroprotection; statin; fluid percussion; rat	ANEURYSMAL SUBARACHNOID HEMORRHAGE; COA REDUCTASE INHIBITOR; COMBINATION THERAPY; COGNITIVE DEFICITS; NEURONAL SURVIVAL; GENE-EXPRESSION; STATINS; ATORVASTATIN; MODEL; RAT	Simvastatin, the fourth drug selected for testing by Operation Brain Trauma Therapy (OBTT), is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor used clinically to reduce serum cholesterol. In addition, simvastatin has demonstrated potent antineuroinflammatory and brain edema reducing effects and has shown promise in promoting functional recovery in pre-clinical models of traumatic brain injury (TBI). The purpose of this study was to assess the potential neuroprotective effects of oral administration of simvastatin on neurobehavioral, biomarker, and histopathological outcome measures compared across three pre-clinical TBI animal models. Adult male Sprague-Dawley rats were exposed to either moderate fluid percussion injury (FPI), controlled cortical impact injury (CCI), or penetrating ballistic-like brain injury (PBBI). Simvastatin (1 or 5 mg/kg) was delivered via oral gavage at 3 h post-injury and continued once daily out to 14 days post-injury. Results indicated an intermediate beneficial effect of simvastatin on motor performance on the gridwalk (FPI), balance beam (CCI), and rotarod tasks (PBBI). No significant therapeutic benefit was detected, however, on cognitive outcome across the OBTT TBI models. In fact, Morris water maze (MWM) performance was actually worsened by treatment in the FPI model and scored full negative points for low dose in the MWM latency and swim distance to locate the hidden platform. A detrimental effect on cortical tissue loss was also seen in the FPI model, and there were no benefits on histology across the other models. Simvastatin also produced negative effects on circulating glial fibrillary acidic protein biomarker outcomes that were evident in the FPI and PBBI models. Overall, the current findings do not support the beneficial effects of simvastatin administration over 2 weeks post-TBI using the oral route of administration and, as such, it will not be further pursued by OBTT.	[Mountney, Andrea; Caudle, Krista; Tortella, Frank C.; Shear, Deborah A.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Empey, Philip E.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15260 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Empey, Philip/L-9604-2019; Mondello, Stefania/A-1813-2012	Empey, Philip/0000-0001-7474-2339; Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Boimel M, 2009, J NEUROPATH EXP NEUR, V68, P314, DOI 10.1097/NEN.0b013e31819ac3cb; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; Bulsara Ketan R, 2006, Neurosurg Focus, V21, pE11; Chauhan NB, 2011, RESTOR NEUROL NEUROS, V29, P23, DOI 10.3233/RNN-2011-0573; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Cimino A, 2005, NEUROTOXICOLOGY, V26, P929, DOI 10.1016/j.neuro.2005.03.009; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Glushakova OY, 2012, TOXICOL SCI, V130, P158, DOI 10.1093/toxsci/kfs224; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Jung KH, 2004, STROKE, V35, P1744, DOI 10.1161/01.STR.0000131270.45822.85; Kirkpatrick PJ, 2014, LANCET NEUROL, V13, P666, DOI 10.1016/S1474-4422(14)70084-5; Kobayashi M, 2006, INT J PHARMACEUT, V317, P19, DOI 10.1016/j.ijpharm.2006.02.043; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Lee G, 2001, PHARMACOL REV, V53, P569; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; McGirt MJ, 2006, J NEUROSURG, V105, P671, DOI 10.3171/jns.2006.105.5.671; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Nagasawa K, 2002, J PHARM SCI, V91, P2605, DOI 10.1002/jps.10246; Ogasawara A, 2009, DRUG METAB DISPOS, V37, P122, DOI 10.1124/dmd.108.022574; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Vonder Haar C, 2014, J NEUROTRAUM, V31, P961, DOI 10.1089/neu.2013.3119; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2011, NEUROSURGERY, V68, P1363, DOI 10.1227/NEU.0b013e31820c06b9; Wu HT, 2012, BRAIN RES, V1486, P121, DOI 10.1016/j.brainres.2012.09.039; Xie HZ, 2014, CORONARY ARTERY DIS, V25, P565, DOI 10.1097/MCA.0000000000000148	50	23	23	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					567	580		10.1089/neu.2015.4130			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800006	26541177	Green Published			2021-06-18	
J	Armstead, WM; Riley, J; Vavilala, MS				Armstead, William M.; Riley, John; Vavilala, Monica S.			Preferential Protection of Cerebral Autoregulation and Reduction of Hippocampal Necrosis With Norepinephrine After Traumatic Brain Injury in Female Piglets*	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						extracellular signal-regulated kinase; mitogen-activated protein kinase; cerebral autoregulation; traumatic brain injury; interleukin-6; vasopressor	TRANSIENT HYPEREMIC RESPONSE; PERFUSION-PRESSURE; NITROUS-OXIDE; INTRACRANIAL-PRESSURE; HYPOTENSION; IMPAIRMENT; CHILDREN; NEWBORN; PHENYLEPHRINE; INTERLEUKIN-6	Objectives: Traumatic brain injury contributes to morbidity in children and boys is disproportionately represented. Cerebral autoregulation is impaired after traumatic brain injury, contributing to poor outcome. Cerebral perfusion pressure is often normalized by the use of vasopressors to increase mean arterial pressure. In prior studies, we observed that phenylephrine prevented impairment of autoregulation in female but exacerbated in male piglets after fluid percussion injury. In contrast, dopamine prevented impairment of autoregulation in both sexes after fluid percussion injury, suggesting that pressor choice impacts outcome. The extracellular signal-regulated kinase isoform of mitogen-activated protein kinase produces hemodynamic impairment after fluid percussion injury, but the role of the cytokine interleukin-6 is unknown. We investigated whether norepinephrine sex-dependently protects autoregulation and limits histopathology after fluid percussion injury and the role of extracellular signal-regulated kinase and interleukin-6 in that outcome. Design: Prospective, randomized animal study. Setting: University laboratory. Subjects: Newborn (1-5 d old) pigs. Interventions: Cerebral perfusion pressure, cerebral blood flow, and pial artery diameter were determined before and after fluid percussion injury in piglets equipped with a closed cranial window and post-treated with norepinephrine. Cerebrospinal fluid extracellular-signal-regulated kinase mitogen-activated protein kinase was determined by enzyme-linked immunosorbent assay. Measurements and Main Results: Norepinephrine does not protect autoregulation or prevent reduction in cerebral blood flow in male but fully protects autoregulation in female piglets after fluid percussion injury. Papaverine-induced dilation was unchanged by fluid percussion injury and norepinephrine. Norepinephrine increased extracellular signal-regulated kinase mitogen-activated protein kinase up-regulation in male but blocked such up-regulation in female piglets after fluid percussion injury. Norepinephrine aggravated interleukin-6 upregulation in males in an extracellular signal-regulated kinase mitogen-activated protein kinase-dependent mechanism but blocked interleukin-6 up-regulation in females after fluid percussion injury. Norepinephrine augments loss of neurons in CA1 and CA3 hippocampus of male piglets after fluid percussion injury in an extracellular signal-regulated kinase mitogen-activated protein kinase-dependent and interleukin-6-dependent manner but prevents loss of neurons in females after fluid percussion injury. Conclusion: Norepinephrine protects autoregulation and limits hippocampal neuronal cell necrosis via modulation of extracellular signal-regulated kinase mitogen-activated protein kinase and interleukin-6 after fluid percussion injury in a sex-dependent manner.	[Armstead, William M.; Riley, John] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.; Armstead, WM (corresponding author), Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS090998]; University of Pennsylvania Research Foundation; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090998] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health (NIH) RO1 NS090998.; Dr. Armstead received support for article research from the University of Pennsylvania Research Foundation. Dr. Riley received support for article research from the National Institutes of Health (NIH). Dr. Vavilala received support for article research from the NIH.	Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2013, PEDIATR CRIT CARE ME, V14, pE103, DOI 10.1097/PCC.0b013e3182712b44; Armstead WM, 2012, J NEUROTRAUM, V29, P1794, DOI 10.1089/neu.2012.2328; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1038/sj.mn.7300110; Bedford NM, 1999, ANESTH ANALG, V89, P170; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Biestro A, 1998, ACT NEUR S, V71, P5; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Girling KJ, 1999, ANESTH ANALG, V89, P175, DOI 10.1097/00000539-199907000-00031; Ishikawa S, 2009, ANESTH ANALG, V108, P1631, DOI 10.1213/ane.0b013e31819d94e3; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS24, DOI 10.1097/PCC.0b013e31823f4450; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Newacheck PW, 2004, PEDIATRICS, V114, P79, DOI 10.1542/peds.114.1.79; Oto J, 2008, J ANESTH, V22, P207, DOI 10.1007/s00540-008-0639-x; Sharma D, 2010, J NEUROSURG ANESTH, V22, P132, DOI 10.1097/ANA.0b013e3181c9fbf1; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Tibble RK, 2001, ANESTH ANALG, V93, P171; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037	31	23	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2016	17	3					e130	e137		10.1097/PCC.0000000000000603			8	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	DG0ID	WOS:000371747600005	26741414	Green Accepted			2021-06-18	
J	Lucke-Wold, BP; Turner, RC; Logsdon, AF; Nguyen, L; Bailes, JE; Lee, JM; Robson, MJ; Omalu, BI; Huber, JD; Rosen, CL				Lucke-Wold, Brandon P.; Turner, Ryan C.; Logsdon, Aric F.; Nguyen, Linda; Bailes, Julian E.; Lee, John M.; Robson, Matthew J.; Omalu, Bennet I.; Huber, Jason D.; Rosen, Charles L.			Endoplasmic reticulum stress implicated in chronic traumatic encephalopathy	JOURNAL OF NEUROSURGERY			English	Article						chronic traumatic encephalopathy; blast traumatic brain injury; endoplasmic reticulum stress; hyperphosphorylated tau; docosahexaenoic acid; trauma	UNFOLDED PROTEIN RESPONSE; REPETITIVE BRAIN TRAUMA; ER STRESS; CELL-DEATH; TAU; INJURY; DISEASE; MODEL; OMEGA-3-FATTY-ACIDS; ACTIVATION	OBJECTIVE Chronic traumatic encephalopathy is a progressive neurodegenerative disease characterized by neurofibrillary tau tangles following repetitive neurotrauma. The underlying mechanism linking traumatic brain injury to chronic traumatic encephalopathy has not been elucidated. The authors investigate the role of endoplasmic reticulum stress as a link between acute neurotrauma and chronic neurodegeneration. METHODS The authors used pharmacological, biochemical, and behavioral tools to assess the role of endoplasmic reticulum stress in linking acute repetitive traumatic brain injury to the development of chronic neurodegeneration. Data from the authors' clinically relevant and validated rodent blast model were compared with those obtained from postmortem human chronic traumatic encephalopathy specimens from a National Football League player and World Wrestling Entertainment wrestler. RESULTS The results demonstrated strong correlation of endoplasmic reticulum stress activation with subsequent tau hyperphosphorylation. Various endoplasmic reticulum stress markers were increased in human chronic traumatic encephalopathy specimens, and the endoplasmic reticulum stress response was associated with an increase in the tau kinase, glycogen synthase kinase-3 beta. Docosahexaenoic acid, an endoplasmic reticulum stress inhibitor, improved cognitive performance in the rat model 3 weeks after repetitive blast exposure. The data showed that docosahexaenoic acid administration substantially reduced tau hyperphosphorylation (t = 4.111, p < 0.05), improved cognition (t = 6.532, p < 0.001), and inhibited C/EBP homology protein activation (t = 5.631, p < 0.01). Additionally the data showed, for the first time, that endoplasmic reticulum stress is involved in the pathophysiology of chronic traumatic encephalopathy. CONCLUSIONS Docosahexaenoic acid therefore warrants further investigation as a potential therapeutic agent for the prevention of chronic traumatic encephalopathy.	[Lucke-Wold, Brandon P.; Turner, Ryan C.; Rosen, Charles L.] W Virginia Univ, Dept Neurosurg, Sch Med, One Med Ctr Dr,POB 9183 Hlth Sci Ctr, Morgantown, WV 26506 USA; [Lucke-Wold, Brandon P.; Turner, Ryan C.; Logsdon, Aric F.; Nguyen, Linda; Huber, Jason D.; Rosen, Charles L.] W Virginia Univ, Ctr Neurosci, Sch Med, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Nguyen, Linda; Robson, Matthew J.; Huber, Jason D.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Bailes, Julian E.; Lee, John M.] Univ Chicago, Pritzker Sch Med, Dept Neurosurg, NorthShore Univ HealthSyst, Evanston, IL USA; [Robson, Matthew J.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA; [Omalu, Bennet I.] Univ Calif Davis, Med Ctr, Dept Med Pathol & Lab Med, Sacramento, CA USA	Rosen, CL (corresponding author), W Virginia Univ, Dept Neurosurg, Sch Med, One Med Ctr Dr,POB 9183 Hlth Sci Ctr, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu	Robson, Matthew/H-3127-2013; Nguyen, Linda/AAQ-1755-2021	Robson, Matthew/0000-0002-3277-3062; Turner, Ryan/0000-0001-5523-0645	West Virginia University Health Sciences Center Office of Research and Graduate Education; West Virginia University Department of Neurosurgery; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM08174, NS007491]; American Foundation of Pharmaceutical Education Predoctoral Grant; American Medical Association Foundation Seed Grant; Neurosurgery Research and Education Foundation Medical Student Summer Research Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942] Funding Source: NIH RePORTER	A Research Funding and Development Grant from the West Virginia University Health Sciences Center Office of Research and Graduate Education supported this work along with the West Virginia University Department of Neurosurgery. Drs. Turner and Robson were supported by NIH training grants (GM08174 and NS007491). Brandon Lucke-Wold was supported by an American Foundation of Pharmaceutical Education Predoctoral Grant, an American Medical Association Foundation Seed Grant, and a Neurosurgery Research and Education Foundation Medical Student Summer Research Fellowship.	Abisambra JF, 2013, J NEUROSCI, V33, P9498, DOI 10.1523/JNEUROSCI.5397-12.2013; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Cavallini A, 2013, J BIOL CHEM, V288, P23331, DOI 10.1074/jbc.M113.463984; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; Dapul HR, 2013, J NEUROTRAUM, V30, P382, DOI 10.1089/neu.2012.2536; DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fonseca ACRG, 2013, BBA-MOL BASIS DIS, V1832, P2191, DOI 10.1016/j.bbadis.2013.08.007; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hetz C, 2014, NAT REV NEUROSCI, V15, P233, DOI 10.1038/nrn3689; Hiramatsu N, 2014, MOL BIOL CELL, V25, P1411, DOI 10.1091/mbc.E13-11-0664; Hoozemans JJM, 2012, INT J BIOCHEM CELL B, V44, P1295, DOI 10.1016/j.biocel.2012.04.023; Kang EB, 2013, APOPTOSIS, V18, P1332, DOI 10.1007/s10495-013-0884-9; Kaufman RJ, 2014, BBA-MOL CELL RES, V1843, P2233, DOI 10.1016/j.bbamcr.2014.03.022; Kester MI, 2014, JAMA NEUROL, V71, P855, DOI 10.1001/jamaneurol.2014.754; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Lebbadi M, 2011, J ALZHEIMERS DIS, V27, P853, DOI 10.3233/JAD-2011-111010; Levi YF, 2014, J INTERN MED, V275, P428, DOI 10.1111/joim.12166; Liu ZC, 2012, J ALZHEIMERS DIS, V29, P727, DOI 10.3233/JAD-2012-111898; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Miyauchi T, 2014, J NEUROTRAUM, V31, P773, DOI 10.1089/neu.2013.3181; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Placido AI, 2015, MOL NEUROBIOL, V51, P571, DOI 10.1007/s12035-014-8819-1; Plattner F, 2006, J BIOL CHEM, V281, P25457, DOI 10.1074/jbc.M603469200; Pooler AM, 2013, EMBO REP, V14, P389, DOI 10.1038/embor.2013.15; Robson MJ, 2014, EXP NEUROL, V254, P180, DOI 10.1016/j.expneurol.2014.01.020; Ron D, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a013177; Rubovitch V, 2011, NEUROCHEM INT, V58, P443, DOI 10.1016/j.neuint.2011.01.009; Sadik G, 2009, J NEUROCHEM, V108, P33, DOI 10.1111/j.1471-4159.2008.05716.x; Shoulders MD, 2013, CELL REP, V3, P1279, DOI 10.1016/j.celrep.2013.03.024; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Song J, 2014, INT J MOL SCI, V15, P2119, DOI 10.3390/ijms15022119; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stutzbach LD, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-31; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Watanabe T, 2010, PM&R, V2, P671, DOI 10.1016/j.pmrj.2010.06.002; Yang CC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/108486; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yokobori S, 2013, TRANSL STROKE RES, V4, P25, DOI 10.1007/s12975-012-0226-1; Zhou SS, 2014, TOXICOL LETT, V227, P113, DOI 10.1016/j.toxlet.2014.03.011; Zhu X, 2014, J BIOL CHEM, V289, P30567, DOI 10.1074/jbc.M114.562868	60	23	23	0	29	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2016	124	3					687	702		10.3171/2015.3.JNS141802			16	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DE8VQ	WOS:000370915200013	26381255	Bronze			2021-06-18	
J	Samantaray, S; Das, A; Matzelle, DC; Yu, SP; Wei, L; Varma, A; Ray, SK; Banik, NL				Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Yu, Shan P.; Wei, Ling; Varma, Abhay; Ray, Swapan K.; Banik, Naren L.			Administration of low dose estrogen attenuates gliosis and protects neurons in acute spinal cord injury in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						acute spinal cord injury; calpain; estrogen; estrogen receptors; gliosis; neuroprotection	APOPTOTIC CELL-DEATH; TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-VESSELS; RECEPTOR-ALPHA; UP-REGULATION; NEUROPROTECTIVE AGENT; FUNCTIONAL RECOVERY; SIGNAL-TRANSDUCTION; CALPAIN INHIBITORS; CORTICAL-NEURONS	Spinal cord injury (SCI) is a debilitating condition with neurological deficits and loss of motor function that, depending on the severity, may lead to paralysis. The only treatment currently available is methylprednisolone, which is widely used and renders limited efficacy in SCI. Therefore, other therapeutic agents must be developed. The neuroprotective efficacy of estrogen in SCI was studied with a pre-clinical and pro-translational perspective. Acute SCI was induced in rats that were treated with low doses of estrogen (1, 5, 10, or 100g/kg) and compared with vehicle-treated injured rats or laminectomy control (sham) rats at 48h post-SCI. Changes in gliosis and other pro-inflammatory responses, expression and activity of proteolytic enzymes (e.g., calpain, caspase-3), apoptosis of neurons in SCI, and cell death were monitored via Western blotting and immunohistochemistry. Negligible pro-inflammatory responses or proteolytic events and very low levels of neuronal death were found in sham rats. In contrast, vehicle-treated SCI rats showed profound pro-inflammatory responses with reactive gliosis, elevated expression and activity of calpain and caspase-3, elevated Bax:Bcl-2 ratio, and high levels of neuronal death in lesion and caudal regions of the injured spinal cord. Estrogen treatment at each dose reduced pro-inflammatory and proteolytic activities and protected neurons in the caudal penumbra in acute SCI. Estrogen treatment at 10g was found to be as effective as 100g in ameliorating the above parameters in injured animals. Results from this investigation indicated that estrogen at a low dose could be a promising therapeutic agent for treating acute SCI.	[Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Varma, Abhay; Banik, Naren L.] Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,Suite 309 CSB,MSC 606, Charleston, SC 29425 USA; [Yu, Shan P.; Wei, Ling] Emory Univ, Sch Med, Dept Anesthesia, Atlanta, GA USA; [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA; [Banik, Naren L.] Ralph H Johnson Vet Adm, Med Ctr, Charleston, SC USA	Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,Suite 309 CSB,MSC 606, Charleston, SC 29425 USA.	baniknl@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS31622, R01 NS45967]; Veterans AdministrationUS Department of Veterans Affairs [1IOBX00126 and 1IOBX002349]; South Carolina State Spinal Cord Research Fund [SCIRF-2015-P-01, SCIRF-2015-P-04, SCIRF-2015-I-01]; Department of Neurosurgery, MUSC; MUSC-CTSA program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045967, R01NS031622] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002349, I01BX001262] Funding Source: NIH RePORTER	This work was supported in part by funding from NIH (R01-NS31622 and R01 NS45967); Veterans Administration (1IOBX00126 and 1IOBX002349); South Carolina State Spinal Cord Research Fund (SCIRF-2015-P-01, SCIRF-2015-P-04, and SCIRF-2015-I-01); Department of Neurosurgery, MUSC; and MUSC-CTSA program. We also thank Dr. Kelly Guyton for her valuable contribution to this work. Authors declare no conflict of interests.	Alkayed NJ, 2001, J NEUROSCI, V21, P7543; BANIK NL, 1983, NEUROCHEM RES, V8, P1389, DOI 10.1007/BF00964996; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Battaglia F, 2003, J MOL NEUROSCI, V20, P357, DOI 10.1385/JMN:20:3:357; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Cox A, 2015, J NEUROTRAUM, V32, P1413, DOI 10.1089/neu.2014.3730; Cuzzocrea S, 2008, SHOCK, V29, P362, DOI 10.1097/shk.0b013e31814545dc; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Duckles SP, 2003, NEURONAL AND VASCULAR PLASTICITY: ELUCIDATING BASIC CELLULAR MECHANISMS FOR FUTURE THERAPEUTIC DISCOVERY, P95; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2009, CELL MOL NEUROBIOL, V29, P27, DOI 10.1007/s10571-008-9291-0; Guyton MK, 2005, ANN NY ACAD SCI, V1053, P48, DOI 10.1196/annals.1344.005; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hu R, 2012, CRIT CARE MED, V40, P3230, DOI 10.1097/CCM.0b013e3182657560; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Kachadroka S, 2010, J NEUROTRAUM, V27, P611, DOI 10.1089/neu.2009.1069; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; Lee JY, 2012, ENDOCRINOLOGY, V153, P3815, DOI 10.1210/en.2012-1068; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Perot P.L., 1987, J AM PARALYSIS ASS, V4, P149, DOI DOI 10.1089/cns.1987.4.149; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Ritz MF, 2008, BRAIN RES, V1203, P177, DOI 10.1016/j.brainres.2008.01.091; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sakurai M, 2003, J VASC SURG, V37, P446, DOI 10.1067/mva.2003.100; Samantaray S, 2007, NEUROSCIENCE, V146, P741, DOI 10.1016/j.neuroscience.2007.01.056; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Samantaray S, 2013, J NEUROCHEM, V127, P880, DOI 10.1111/jnc.12374; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Shields DC, 1998, EXP EYE RES, V67, P403, DOI 10.1006/exer.1998.0537; Shields DC, 1998, BRAIN RES, V794, P68, DOI 10.1016/S0006-8993(98)00193-0; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Shields DC, 2000, J NEUROSCI RES, V61, P146; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2004, NEUROCHEM RES, V29, P2007, DOI 10.1007/s11064-004-6874-0; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2010, J NEUROSCI RES, V88, P1738, DOI 10.1002/jnr.22337; Sribnick EA, 2009, BRAIN RES, V1276, P159, DOI 10.1016/j.brainres.2009.04.022; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Stirone C, 2003, EUR J PHARMACOL, V478, P35, DOI 10.1016/j.ejphar.2003.08.037; Stirone C, 2003, AM J PHYSIOL-ENDOC M, V284, pE184, DOI 10.1152/ajpendo.00165.2002; Sur P, 2005, GLIA, V50, P160, DOI 10.1002/glia.20168; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tiwari-Woodruff S, 2007, P NATL ACAD SCI USA, V104, P14813, DOI 10.1073/pnas.0703783104; Wei Ling, 2005, Pathophysiology, V12, P47, DOI 10.1016/j.pathophys.2004.11.002; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xie LP, 2002, EUR J IMMUNOL, V32, P2837, DOI 10.1002/1521-4141(2002010)32:10<2837::AID-IMMU2837>3.0.CO;2-V; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086	73	23	23	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2016	136	5					1064	1073		10.1111/jnc.13464			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DE5BT	WOS:000370646500016	26662641	Bronze, Green Accepted			2021-06-18	
J	Wang, HC; Lin, YJ; Shih, FY; Chang, HW; Su, YJ; Cheng, BC; Su, CM; Tsai, NW; Chang, YT; Kwan, AL; Lu, CH				Wang, Hung-Chen; Lin, Yu-Jun; Shih, Fu-Yuan; Chang, Hsueh-Wen; Su, Yu-Jih; Cheng, Ben-Chung; Su, Chih-Min; Tsai, Nai-Wen; Chang, Ya-Ting; Kwan, Aij-Lie; Lu, Cheng-Hsien			The Role of Serial Oxidative Stress Levels in Acute Traumatic Brain Injury and as Predictors of Outcome	WORLD NEUROSURGERY			English	Article						Glutathione; Outcome; Oxidative stress; Traumatic brain injury	ENTRAPPED SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; HEAD-INJURY; IN-VIVO; RATS; INFLAMMATION; MECHANISMS; ISCHEMIA; CHILDREN; MODERATE	BACKGROUND: Oxidative stress is thought to participate in the pathobiology of secondary brain injury after acute traumatic brain injury (TBI). This study posits that oxidative stress levels in acute TBI are predictive of outcome. METHODS: Two hundred and twenty-nine blood samples from 88 patients admitted within 24 hours after TBI were obtained on admission and on days 4 and 7. Serial plasma oxidative level and antioxidant were examined in 88 patients with acute TBI and 27 control individuals. RESULTS: Compared with controls, patients with TBI had significantly increased serum glutathione (GSH) levels on presentation and significantly decreased erythrocyte superoxide dismutase levels. Outcome was assessed on discharge using the Glasgow Outcome Scale. Serum GSH and erythrocyte superoxide dismutase levels were significantly higher in the good outcome group than in the poor outcome group on day 1 (P = 0.008 and P = 0.026, respectively). In the logistic regression analysis, only motor deficits and GSH levels on presentation were independently associated with outcome. A GSH cutoff value of 1.106 mu mol/L on presentation was associated with good outcome in patients with acute TBI. CONCLUSIONS: Quantifying biomarkers of oxidative stress and antioxidant status of serum correlate with trauma severity and may be used to predict outcomes after TBI. Higher serum GSH levels on admission are associated with better outcome.	[Wang, Hung-Chen; Lin, Yu-Jun; Shih, Fu-Yuan] Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung, Taiwan; [Chang, Hsueh-Wen; Su, Yu-Jih; Cheng, Ben-Chung] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Su, Chih-Min] Kaohsiung Chang Gung Mem Hosp, Dept Emergency Med, Kaohsiung, Taiwan; [Tsai, Nai-Wen; Chang, Ya-Ting; Lu, Cheng-Hsien] Kaohsiung Chang Gung Mem Hosp, Dept Neurol, Kaohsiung, Taiwan; Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Lin, Yu-Jun; Chang, Hsueh-Wen; Cheng, Ben-Chung; Chang, Ya-Ting; Lu, Cheng-Hsien] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan; [Kwan, Aij-Lie] Kaohsiung Med Univ, Dept Neurosurg, Coll Med, Kaohsiung, Taiwan; [Lu, Cheng-Hsien] Xiamen Chang Gung Mem Hosp, Dept Neurol, Xiamen, Fujian, Taiwan	Lu, CH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Neurol, Kaohsiung, Taiwan.; Lu, CH (corresponding author), Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan.; Lu, CH (corresponding author), Xiamen Chang Gung Mem Hosp, Dept Neurol, Xiamen, Fujian, Taiwan.	chlu99@ms44.url.com.tw		WANG, HUNG-CHEN/0000-0003-3962-1958; Su, Yu-Jih/0000-0002-7274-3458			Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Awasthi D, 1997, SURG NEUROL, V47, P581; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HERBERT V, 1994, STEM CELLS, V12, P289, DOI 10.1002/stem.5530120305; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Johnston SC, 1998, NEUROLOGY, V51, P411, DOI 10.1212/WNL.51.2.411; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Ma Anlun, 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P20; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; OYESIKU NM, 1993, NEUROSURGERY, V32, P518; Oyesiku NM, 1993, NEUROSURGERY, V32, P525; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Zimmermann M, 2011, METHODS MOL BIOL, V740, P57, DOI 10.1007/978-1-61779-108-6_8	28	23	23	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR	2016	87						463	470		10.1016/j.wneu.2015.10.010			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI3HR	WOS:000373390200060	26481337				2021-06-18	
J	Arnould, A; Dromer, E; Rochat, L; Van der Linden, M; Azouvi, P				Arnould, A.; Dromer, E.; Rochat, L.; Van der Linden, M.; Azouvi, P.			Neurobehavioral and self-awareness changes after traumatic brain injury: Towards new multidimensional approaches	ANNALS OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Apathy; Impulsivity; Anosognosia; Traumatic brain injury; Multidimensional approach	APATHY; IMPULSIVITY; MODERATE; ANOSOGNOSIA; PERSONALITY; CAREGIVERS; MODEL; HEMIPLEGIA; INVENTORY; SEVERITY	Neurobehavioral and self-awareness changes are frequently observed following traumatic brain injury (TBI). These disturbances have been related to negative consequences on functional outcomes, caregiver distress and social reintegration, representing therefore a challenge for clinical research. Some studies have recently been conducted to specifically explore apathetic and impulsive manifestations, as well as self-awareness impairments in patients with TBI. These findings underlined the heterogeneity of clinical manifestations for each behavioral disturbance and the diversity of psychological processes involved. In this context, new multidimensional approaches taking into account the various processes at play have been proposed to better understand and apprehend the complexity and dynamic nature of these problematic behaviors. In addition, the involvement of social and environmental factors as well as premorbid personality traits have increasingly been addressed. These new multidimensional frameworks have the potential to ensure targeted and effective rehabilitation by allowing a better identification and therefore consideration of the various mechanisms involved in the onset of problematic behaviors. In this context, the main objective of this position paper was to demonstrate the interest of multidimensional approaches in the understanding and rehabilitation of problematic behaviors in patients with TBI. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Arnould, A.; Dromer, E.; Azouvi, P.] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France; [Arnould, A.; Rochat, L.; Van der Linden, M.] Univ Geneva, Unite Psychopathol & Neuropsychol Cognit, Geneva, Switzerland; [Arnould, A.; Dromer, E.; Azouvi, P.] Univ Versailles St Quentin En Yvelines, HANDIReSP, EA 4047, F-78000 Versailles, France; [Rochat, L.; Van der Linden, M.] Univ Geneva, Swiss Ctr Affect Sci, Geneva, Switzerland; [Van der Linden, M.] Univ Liege, Unite Psychopathol Cognit, Liege, Belgium	Arnould, A (corresponding author), Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France.; Arnould, A (corresponding author), Univ Geneva, Unite Psychopathol & Neuropsychol Cognit, Geneva, Switzerland.; Arnould, A (corresponding author), Univ Versailles St Quentin En Yvelines, HANDIReSP, EA 4047, F-78000 Versailles, France.	annabelle.arnould@rpc.aphp.fr		Rochat, Lucien/0000-0002-9992-2720			Arnould A, 2015, BRAIN INJURY, P1; Arnould A, 2013, NEUROPSYCHOL REV, V23, P210, DOI 10.1007/s11065-013-9236-3; Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; Billieux J., 2008, TRAITE PSYCHOPATHOLO, V1, P137; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Coben R.A., 1995, ARCH CLIN NEUROPSYCH, V10, P310; Coben RA, 1995, ARCH CLIN NEUROPSYCH, V10, P309; Crosson B, 1989, J HEAD TRAUMA REHAB, V4, P91; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Desmurget M, 2009, SCIENCE, V324, P811, DOI 10.1126/science.1169896; Ennis N, 2013, NEUROPSYCHOL REHABIL, V23, P1, DOI 10.1080/09602011.2012.712871; Esposito F, 2014, AGING MENT HEALTH, V18, P521, DOI 10.1080/13607863.2013.856865; Esposito F, 2014, ARCH GERONTOL GERIAT, V58, P43, DOI 10.1016/j.archger.2013.09.002; Esposito F, 2012, DEMENT GER COGN D EX, V2, P456, DOI 10.1159/000345037; Esposito F, 2010, ALZ DIS ASSOC DIS, V24, P131, DOI 10.1097/WAD.0b013e3181c9c168; FEINBERG TE, 1990, NEUROLOGY, V40, P1391, DOI 10.1212/WNL.40.9.1391; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gay P, 2008, ACTA PSYCHOL, V129, P332, DOI 10.1016/j.actpsy.2008.08.010; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GOLD M, 1994, NEUROLOGY, V44, P1804, DOI 10.1212/WNL.44.10.1804; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Jumisko E, 2007, J FAM NURS, V13, P353, DOI 10.1177/1074840707303842; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Karnath HO, 2005, J NEUROSCI, V25, P7134, DOI 10.1523/JNEUROSCI.1590-05.2005; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lane-Brown AT, 2009, BRAIN INJURY, V23, P999, DOI 10.3109/02699050903379347; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McAllister TW, 2007, BRAIN INJURY MED, P815; Meulemans T, 2000, TRAITE NEUROPSYCHOLO, V1, P301; Miller J, 2003, PERS INDIV DIFFER, V34, P1403, DOI 10.1016/S0191-8869(02)00122-8; Mulin E, 2011, INT J GERIATR PSYCH, V26, P158, DOI 10.1002/gps.2508; Robert PH, 2002, INT J GERIATR PSYCH, V17, P1099, DOI 10.1002/gps.755; Rochat L, 2013, J INT NEUROPSYCH SOC, V19, P890, DOI 10.1017/S1355617713000672; Rochat L, 2011, PSYCHOPATHOLOGY, V44, P158, DOI 10.1159/000322454; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Sela-Kaufman M, 2013, J CLIN EXP NEUROPSYC, V35, P584, DOI 10.1080/13803395.2013.799123; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sinha N, 2013, J NEUROPSYCHOL, V7, P255, DOI 10.1111/jnp.12013; Sockeel P, 2006, J NEUROL NEUROSUR PS, V77, P579, DOI 10.1136/jnnp.2005.075929; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Vocat R, 2010, BRAIN, V133, P3578, DOI 10.1093/brain/awq297; Vuilleumier P, 2004, CORTEX, V40, P9, DOI 10.1016/S0010-9452(08)70918-3; Vuilleumier P, 2000, BEHAVIOR AND MOOD DISORDERS IN FOCAL BRAIN LESIONS, P465; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Wilson BA, 1993, BEHAV ASSESSMENT DYS; Zasler Nathan D, 2013, Handb Clin Neurol, V110, P377, DOI 10.1016/B978-0-444-52901-5.00032-0; Zermatten A, 2005, J NERV MENT DIS, V193, P647, DOI 10.1097/01.nmd.0000180777.41295.65	60	23	25	2	8	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	1877-0657	1877-0665		ANN PHYS REHABIL MED	Ann. Phys. Rehabil. Med.	FEB	2016	59	1			SI		18	22		10.1016/j.rehab.2015.09.002			5	Rehabilitation	Rehabilitation	FO5JF	WOS:000416890700004	26585583	Bronze			2021-06-18	
J	Despins, EH; Turkstra, LS; Struchen, MA; Clark, AN				Despins, Emily H.; Turkstra, Lyn S.; Struchen, Margaret A.; Clark, Allison N.			Sex-Based Differences in Perceived Pragmatic Communication Ability of Adults With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Communication; Rehabilitation; Sex factors; Social behavior	CLOSED-HEAD-INJURY; FACIAL EXPRESSION; EMOTION RECOGNITION; GENDER-DIFFERENCES; DISCOURSE; MIND; CONVERSATION; COMPETENCE; PERCEPTION; CHILDREN	Objective: To identify sex-based differences in self-reported and close other reported perceptions of communication behaviors in adults with traumatic brain injury (TBI). Design: Between-groups comparison of questionnaire data from men and women with TBI and their close others. Setting: University academic department. Participants: Adults with medically documented TBI (n=160) and adults without TBI (n=81; control group) (N=241). Interventions: Not applicable. Main Outcome Measure: La Trobe Communication Questionnaire, a standardized measure of communication problems in everyday life. Results: Participants with TBI endorsed more communication problems than controls (P<.001). There were no significant differences in self-ratings (P=.20) or in the ratings of close others (P=.09) in communication behaviors of men with TBI compared with women with TBI. There was no difference between the self-ratings of women with TBI and their close others (P=.59). However, men with TBI significantly underreported communication problems compared with reports of close others (P<.001). Conclusions: Women with TBI might be more accurate than men with TBI in recognizing their own pragmatic communication problems. (C) 2016 by the American Congress of Rehabilitation Medicine	[Despins, Emily H.; Turkstra, Lyn S.] Univ Wisconsin, Dept Commun Sci & Disorders, 1975 Willow Dr, Madison, WI 53706 USA; [Struchen, Margaret A.; Clark, Allison N.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Struchen, Margaret A.; Clark, Allison N.] Texas Inst Rehabil Res Mem Hermann, Brain Injury Res Ctr, Houston, TX USA	Turkstra, LS (corresponding author), Univ Wisconsin, Dept Commun Sci & Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu			National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [111330010152, H133B031117, H133A070043]; Walker Foundation	Supported in part by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. 111330010152, Assessment of Pragmatic communication Abilities after Traumatic Brain Injury; H133B031117, Rehabilitation Research and Training Center on Community Integration of Persons with Traumatic Brain Injury; H133A070043, Texas Traumatic Brain Injury Model System at Texas Institute of Rehabilitation Research Memorial Hermann) and the Walker Foundation.	Auster CJ, 2000, SEX ROLES, V43, P499, DOI 10.1023/A:1007119516728; Bach LJ, 2006, BRAIN COGNITION, V60, P196; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; BEM SL, 1981, PSYCHOL REV, V88, P354, DOI 10.1037/0033-295X.88.4.354; BEM SL, 1985, NEBR SYM MOTIV, V32, P179; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bosacki S, 1999, SOC DEV, V8, P237, DOI 10.1111/1467-9507.00093; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Centers for Disease Control and Prevention, 2014, TRAUM BRAIN INJ US F; CLARK MS, 1988, ANNU REV PSYCHOL, V39, P609, DOI 10.1146/annurev.ps.39.020188.003141; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Douglas J., 2011, BRAIN IMPAIR, V11, P171; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Friedland D, 1998, BRAIN INJURY, V12, P1, DOI 10.1080/026990598122818; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HALL JA, 1978, PSYCHOL BULL, V85, P845, DOI 10.1037/0033-2909.85.4.845; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Jennett B., 1986, MED N AM, V36, P5210; Johnson JE, 2012, BRAIN INJURY, V26, P1118, DOI 10.3109/02699052.2012.666370; Jones CA, 2011, BRAIN INJURY, V25, P844, DOI 10.3109/02699052.2011.585507; Kessels RPC, 2014, J NEUROPSYCHOL, V8, P75, DOI 10.1111/jnp.12009; Krach S, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-9; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Russell TA, 2012, COG EMOT, V21, P1554; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Schrijnemaekers AC, 2014, J HEAD TRAUMA REHAB, V29, pE9, DOI 10.1097/01.HTR.0000438117.63852.b4; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; SNOW P, 2000, BRAIN IMPAIR, V1, P57; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Tannen D., 1994, GENDER DISCOURSE; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Willard VW, 2009, PSYCHO-ONCOLOGY, V18, P893, DOI 10.1002/pon.1502; Yamasue H, 2009, PSYCHIAT CLIN NEUROS, V63, P129, DOI 10.1111/j.1440-1819.2009.01944.x	55	23	24	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2016	97	2		1			S26	S32		10.1016/j.apmr.2014.06.023			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DC4RI	WOS:000369207600004	25662398	Bronze			2021-06-18	
J	Kirkwood, MW; Peterson, RL; Connery, AK; Baker, DA; Forster, J				Kirkwood, Michael W.; Peterson, Robin L.; Connery, Amy K.; Baker, David A.; Forster, Jeri			A Pilot Study Investigating Neuropsychological Consultation as an Intervention for Persistent Postconcussive Symptoms in a Pediatric Sample	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; POST-CONCUSSIVE SYMPTOMS; MILD HEAD-INJURY; PSYCHOLOGICAL-ASSESSMENT; NEUROCOGNITIVE OUTCOMES; SUBOPTIMAL EFFORT; CHILDREN; PREDICTORS; RECOVERY; ADOLESCENTS	Objective To examine the efficacy of a one-time neuropsychological consultation as an intervention for youth with persistent postconcussive symptoms following mild traumatic brain injury. Study design Using a prospective interrupted time series design, we enrolled 80 patients aged 8-17 years referred consecutively for clinical neuropsychological consultation. Patients needed to have sustained injury between 2 and 12 months prior to enrollment. Parent and child postconcussive symptom ratings were used as the primary outcome measures and were collected at 6 time points, 3 before the neuropsychological consultation and 3 after. Repeated measure ANOVA was used to estimate the magnitude of change in symptom ratings before and after the neuropsychological intervention. Results The decrease in symptoms for the week prior to consultation was nonsignificant by both child (P = .63) and parent (P = .19) report. In contrast, for both reporters, the decrease in symptoms at 1 week and 3 months postconsultation was significant (P < .0001). The difference in reported change was also significant when comparing the week before the intervention to the 3 months after (child: P < .0001; parent: P = .0009). Conclusions Postconcussive symptoms decreased significantly following the neuropsychological consultation. The primary limitation of the study is that it lacked randomization and a control group. The results warrant further research into the benefits of neuropsychological consultation after mild traumatic brain injury and provide justification for clinical providers to consider referring to neuropsychologists in the face of persistent postconcussive symptoms.	[Kirkwood, Michael W.; Peterson, Robin L.; Connery, Amy K.; Baker, David A.; Forster, Jeri] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.; Peterson, Robin L.; Connery, Amy K.; Baker, David A.; Forster, Jeri] Childrens Hosp Colorado, Aurora, CO 80045 USA; [Forster, Jeri] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA	Kirkwood, MW (corresponding author), Childrens Hosp Colorado, Dept Rehabil Med, 13123 E 16th Ave, Aurora, CO 80045 USA.	Michael.Kirkwood@childrenscolorado.org			Children's Hospital Colorado Research Institute	Supported by the Children's Hospital Colorado Research Institute. M.K. receives royalties from, Mild Traumatic Brain Injury in Children and Adolescents: From Basic Science to Clinical Management, which is cited in the article. The other authors declare no conflicts of interest.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Araujo GC, 2014, CLIN NEUROPSYCHOL, V28, P786, DOI 10.1080/13854046.2014.896415; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; Bercaw EL, 2011, CLIN NEUROPSYCHOL, V25, P72, DOI 10.1080/13854046.2010.532813; BIJUR PE, 1990, PEDIATRICS, V86, P337; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Gaynor ST, 2003, J CONSULT CLIN PSYCH, V71, P386, DOI 10.1037/0022-006X.71.2.386; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Leininger S, 2014, J HEAD TRAUMA REHAB, V29, P109, DOI 10.1097/HTR.0b013e3182860506; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nygren-de Boussard Catharina, 2014, Arch Phys Med Rehabil, V95, pS257, DOI 10.1016/j.apmr.2013.10.009; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Peterson RL, 2015, J NEUROPSYCH CLIN N, V27, P280, DOI 10.1176/appi.neuropsych.14120373; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Vu JA, 2011, EXCEPT CHILDREN, V77, P263, DOI 10.1177/001440291107700301; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates K. O., 2012, MILD TRAUMATIC BRAIN, P124; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	51	23	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	FEB	2016	169						244	+		10.1016/j.jpeds.2015.10.014			7	Pediatrics	Pediatrics	DB6AK	WOS:000368595300046	26541427				2021-06-18	
J	Pang, EW; Dunkley, BT; Doesburg, SM; da Costa, L; Taylor, MJ				Pang, Elizabeth W.; Dunkley, Benjamin T.; Doesburg, Sam M.; da Costa, Leodante; Taylor, Margot J.			Reduced brain connectivity and mental flexibility in mild traumatic brain injury	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							CARD SORTING TEST; MINOR HEAD-INJURIES; FUNCTIONAL CONNECTIVITY; PREFRONTAL CORTEX; IMAGING APPROACH; MEG; CONCUSSION; NETWORKS; MAGNETOENCEPHALOGRAPHY; MRI	ObjectiveA mild traumatic brain injury (mTBI), or concussion, has known neuropsychological sequelae, and neuroimaging shows disturbed brain connectivity during the resting state. We hypothesized that task-based functional connectivity measures, using magnetoencephalography (MEG), would better link the neurobiological underpinnings of cognitive deficits to specific brain damage. MethodsWe used a mental flexibility task in the MEG and compared brain connectivity between adults with and without mTBI. ResultsAffected individuals showed significant reductions in connectivity. When challenged with a more difficult task, these individuals were not able to boost their connectivity, and as such, showed deterioration in performance. InterpretationWe discuss these findings in the context of limitations in cognitive reserve as a consequence of a mTBI.	[Pang, Elizabeth W.] Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5J 1X8, Canada; [Pang, Elizabeth W.; Taylor, Margot J.] Sick Kids Res Inst, Program Neurosci & Mental Hlth, Toronto, ON, Canada; [Pang, Elizabeth W.; Dunkley, Benjamin T.; da Costa, Leodante; Taylor, Margot J.] Univ Toronto, Fac Med, Toronto, ON, Canada; [Dunkley, Benjamin T.] Hosp Sick Children, Diagnost Imaging, Toronto, ON M5J 1X8, Canada; [Doesburg, Sam M.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada; [da Costa, Leodante] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Taylor, Margot J.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada	Pang, EW (corresponding author), Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5J 1X8, Canada.	elizabeth.pang@sickkids.ca	da Costa, Leodante/F-7474-2010	da Costa, Leodante/0000-0002-3222-4944; Dunkley, Ben/0000-0001-6173-1171			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Brookes MJ, 2011, P NATL ACAD SCI USA, V108, P16783, DOI 10.1073/pnas.1112685108; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; da Costa L, 2015, J NEUROL NEUROSUR PS, V86, P1008, DOI 10.1136/jnnp-2014-308571; Hamalainen Matti S., 1992, Brain Topography, V5, P95, DOI 10.1007/BF01129036; Hari R, 2012, NEUROIMAGE, V61, P386, DOI 10.1016/j.neuroimage.2011.11.074; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Henaff MA, 2010, CLIN NEUROPHYSIOL, V121, P508, DOI 10.1016/j.clinph.2009.11.082; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Konishi S, 1999, CEREB CORTEX, V9, P745, DOI 10.1093/cercor/9.7.745; Lalancette M, 2011, PHYS MED BIOL, V56, P5621, DOI 10.1088/0031-9155/56/17/010; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lie CH, 2006, NEUROIMAGE, V30, P1038, DOI 10.1016/j.neuroimage.2005.10.031; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Monchi O, 2001, J NEUROSCI, V21, P7733; Nagahama Y, 2001, CEREB CORTEX, V11, P85, DOI 10.1093/cercor/11.1.85; Nagahama Y, 1999, NEUROIMAGE, V10, P193, DOI 10.1006/nimg.1999.0451; Oh A, 2014, BRAIN COGNITION, V86, P90, DOI 10.1016/j.bandc.2014.02.006; Onnela JP, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.065103; Palva S, 2007, TRENDS NEUROSCI, V30, P150, DOI 10.1016/j.tins.2007.02.001; Palva S, 2012, TRENDS COGN SCI, V16, P219, DOI 10.1016/j.tics.2012.02.004; Perianez JA, 2004, NEUROIMAGE, V21, P687, DOI 10.1016/j.neuroimage.2003.10.008; Quraan MA, 2010, NEUROIMAGE, V49, P2387, DOI 10.1016/j.neuroimage.2009.10.012; Rogers RD, 2000, J COGNITIVE NEUROSCI, V12, P142, DOI 10.1162/089892900561931; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stam CJ, 2007, HUM BRAIN MAPP, V28, P1178, DOI 10.1002/hbm.20346; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wang LH, 2001, COGNITIVE BRAIN RES, V12, P19, DOI 10.1016/S0926-6410(01)00022-2; Wechsler D., 2011, WECHLSER ABBREVIATED; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wilmsmeier A, 2010, J PSYCHIATR NEUROSCI, V35, P321, DOI 10.1503/jpn.090181; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Yu S, 2008, CEREB CORTEX, V18, P2891, DOI 10.1093/cercor/bhn047; Zalesky A, 2012, NEUROIMAGE, V60, P1055, DOI 10.1016/j.neuroimage.2012.01.068; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	56	23	23	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	FEB	2016	3	2					124	131		10.1002/acn3.280			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DD9SA	WOS:000370264700006	26900581	DOAJ Gold, Green Published			2021-06-18	
J	Taher, A; Pilehvari, Z; Poorolajal, J; Aghajanloo, M				Taher, Abbas; Pilehvari, Zahra; Poorolajal, Jalal; Aghajanloo, Mashhood			Effects of Normobaric Hyperoxia in Traumatic Brain Injury: A Randomized Controlled Clinical Trial	TRAUMA MONTHLY			English	Article						Brain Injuries; Oxygen Inhalation Therapy; Hyperbaric Oxygenation; Glasgow Outcome Scale	HYPERBARIC-OXYGEN THERAPY; ACUTE ISCHEMIC-STROKE; HEAD-INJURY; CEREBRAL METABOLISM; INSPIRED OXYGEN; TISSUE OXYGEN; PENUMBRA; GLUCOSE; IMPROVEMENT; PRESSURE	Background: Traumatic brain injury (TBI) is one of the important causes of morbidity and mortality throughout the world, especially in young people. In recent years normobaric hyperoxia has become an important and useful step for recovery and improvement of outcome in TBI. Objectives: The purpose of this study was to evaluate the effects of normobaric hyperoxia on clinical neurological outcomes of patients with severe traumatic brain injuries. We used the Glasgow outcome scale (GOS), barthel index, and modified rankin scale (mRS) to measure the outcomes of patients with TBI. Patients and Methods: Sixty-eight consecutive patients with severe TBI (mean Glasgow coma scale [GCS] score: 7.4) who met the inclusion criteria were entered in this randomized controlled clinical trial. The patients were randomized into two groups, as follows: 1) experimental: received 80% oxygen via mechanical ventilator in the first 6 hours of admission, 2) control: received 50% oxygen by mechanical ventilator in the first 6 hours of admission and then standard medical care. We measured the GOS, Barthel Index, and mRS at the time of discharge from hospital and reassessed these measurements at the 6-month follow-up after injury. Results: According to our study, there were no significant sex or age differences between the two groups (P = 0.595 and 0.074). The number of days in the intensive care unit (ICU) in the control group and experimental group were 11.4 and 9.4 days, respectively (P = 0.28), while the numbers of days of general ward admission were 13.9 and 11.4 days (P = 0.137) respectively. The status of GOS at time of discharge were severe = 13 and 10, moderate = 16 and 19, and low = 5 and 5 in the control and experimental groups, respectively (P = 0.723); 6 months after injury, the scores were as follows: moderate = 16 and 9, low = 15 and 25, and severe = 3 and 0 (P = 0.024). The Barthel index scores in the control and experimental groups were 59.7 and 63.9 at time of discharge (P = 0.369) and 82.7 and 91.3 at 6 months after injury (P = 0.018), respectively. The mRS results were 2.6 and 2.3 at time of discharge (P = 0.320) and 1.6 and 0.7 at 6 months after injury (P = 0.006) for the control and experimental groups, respectively. Conclusions: According to the results of this study, oxygen therapy by mechanical ventilator in the first 6 hours after injury in patients with severe TBI can improve the final GOS, Barthel index, and mRS scores. It could also improve long-term outcomes and enhance rehabilitation and the quality of life.	[Taher, Abbas; Pilehvari, Zahra] Hamadan Univ Med Sci, Dept Anesthesiol & Crit Care, Hamadan, Iran; [Poorolajal, Jalal] Hamadan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Modeling Noncommunicable Dis Res Ctr, Hamadan, Iran; [Aghajanloo, Mashhood] Hamadan Univ Med Sci, Dept Neurosurg, Hamadan, Iran	Pilehvari, Z (corresponding author), Hamadan Univ Med Sci, Besat Hosp, Dept Anesthesiol & Crit Care, Hamadan, Iran.	dr_manijeh@yahoo.com	aghajanloo, mashhood/O-8047-2017; taher, abbas/G-4808-2017; Poorolajal, Jalal/D-3506-2013	aghajanloo, mashhood/0000-0002-9462-2200; taher, abbas/0000-0002-8977-9350; 			Abate MG, 2008, NEUROCRIT CARE, V9, P319, DOI 10.1007/s12028-008-9119-2; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bennett MH, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD004609.PUB3; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; Bulte DP, 2007, J CEREBR BLOOD F MET, V27, P69, DOI 10.1038/sj.jcbfm.9600319; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Kellert L, 2012, CEREBROVASC DIS EXTR, V2, P99, DOI 10.1159/000343731; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Martin DS, 2013, CRIT CARE MED, V41, P423, DOI 10.1097/CCM.0b013e31826a44f6; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Narotam PK, 2013, CRIT CARE, V17, DOI 10.1186/cc13065; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Raj R, 2013, CRIT CARE, V17, DOI 10.1186/cc12856; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson CA, 2011, J CEREBR BLOOD F MET, V31, P1778, DOI 10.1038/jcbfm.2011.66; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rusyniak DE, 2003, STROKE, V34, P571, DOI 10.1161/01.STR.0000050644.48393.D0; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Strong AJ, 2005, ADV TECH STAND NEUR, V30, P3, DOI 10.1007/3-211-27208-9_1; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377	32	23	26	0	8	NATL CENTER TRAUMA RESEARCH	TEHRAN	NATL CENTER TRAUMA RESEARCH, TEHRAN, IRAN	2251-7464	2251-7472		TRAUMA MON	Trauma Mon.	FEB	2016	21	1							e26772	10.5812/traumamon.26772			5	Emergency Medicine	Emergency Medicine	DV5NI	WOS:000382974200020	27218057	Green Published			2021-06-18	
J	Di Stefano, C; Rinaldesi, ML; Quinquinio, C; Ridolfi, C; Vallasciani, M; Sturiale, C; Piperno, R				Di Stefano, Cristina; Rinaldesi, Maria Luisa; Quinquinio, Cristina; Ridolfi, Chiara; Vallasciani, Massimo; Sturiale, Carmelo; Piperno, Roberto			Neuropsychological changes and cranioplasty: A group analysis	BRAIN INJURY			English	Article						Cognitive changes; Clinical improvement; Cranioplasty; Decompressive craniectomy; Neuropsychological improvement	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; SINKING SKIN FLAP; DECOMPRESSIVE CRANIECTOMY; CRANIAL DEFECTS; CASE SERIES; IMPACT; HEMICRANIECTOMY; REHABILITATION; MULTICENTER	Background: Cranioplasty is the surgical answer to cranial defect due to decompressive craniectomy in order to increase patient's safety and for cosmetic reasons. Two main neurological sequelae of skull breaches have been described and cranioplasty has been suggested as a way to treat these neurological symptoms, but its effects on cognitive and motor functions are still unclear. Materials and methods: In order to better elucidate if and to what extent the cranioplasty affects the whole array of cognitive functions or just some specific domains, 29 patients were studied pre- and post-cranioplasty, with structured assessments of memory, attention, language and executive functioning performed ~ 4 months and 1 month before cranioplasty and 1 month and 6 months after surgery. Results and conclusion: Cranioplasty affects the cognitive profile with a non-specific pattern of change. Timing of the cranioplasty plays a key role to enucleate cognitive improvement, indeed greater cognitive changes were seen in patients who had cranioplasty within 6 months following the injury. Thus, cranioplasty must be considered a key factor in neuropsychological recovery and should be performed as soon as possible following the injury in order to take advantage of the window of opportunity for rehabilitation.	[Di Stefano, Cristina; Piperno, Roberto] Ctr Studi Ric Coma, Bologna, Italy; [Di Stefano, Cristina; Piperno, Roberto] Ausl, Casa Risvegli Luca De Nigris, Dipartimento Emergenza, Bologna, Italy; [Rinaldesi, Maria Luisa; Quinquinio, Cristina; Ridolfi, Chiara; Vallasciani, Massimo] Ist Riabilitaz Santo Stefano, Porto Potenza Picena, Macerata, Italy; [Sturiale, Carmelo] Ausl Bologna, IRCCS, Unita Operat Neurochirurg, Bologna, Italy	Di Stefano, C (corresponding author), Casa Risvegli Luca De Nigris Bologna, Ctr Studi Ric Coma, Via G Gaist 6, I-40100 Bologna, Italy.	c.distefano@ausl.bologna.it	Piperno, Roberto/AAC-3000-2021	Piperno, Roberto/0000-0002-2251-9191	Fondazionedel Monte di Bologna e Ravenna; Centro Studi per la Ricerca sul Coma - Bologna	This work has been supported by a grant from the Fondazionedel Monte di Bologna e Ravenna and Centro Studi per la Ricerca sul Coma - Bologna. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Archavlis E, 2012, NERVENARZT, V83, P751, DOI 10.1007/s00115-011-3424-2; Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972; Chibbaro S, 2013, REV NEUROL-FRANCE, V169, P240, DOI 10.1016/j.neurol.2012.06.016; Cho Hyun, 2006, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V40, P51; CHRISTENSEN L, 1986, BEHAV THER, V17, P305, DOI 10.1016/S0005-7894(86)80060-0; Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Erdogan E, 2003, NEUROL INDIA, V51, P479; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Huang YH, 2013, INT J SURG, V11, P886, DOI 10.1016/j.ijsu.2013.07.013; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Janzen C, 2012, BRAIN INJURY, V26, P101, DOI 10.3109/02699052.2011.635357; Kumar GSS, 2004, NEUROL INDIA, V52, P504; Ng D, 1997, J CLIN NEUROSCI, V4, P346, DOI 10.1016/S0967-5868(97)90103-X; Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008; Piedra Mark P, 2014, Surg Neurol Int, V5, P25, DOI 10.4103/2152-7806.127762; Piedra MP, 2013, J NEUROSURG, V118, P109, DOI 10.3171/2012.10.JNS121037; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sancisi E, 2009, BRAIN INJURY, V23, P163, DOI 10.1080/02699050802660446; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Seo Won-Duck, 2006, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V40, P434; Servadei F, 2015, WORLD NEUROSURG, V83, P133, DOI 10.1016/j.wneu.2014.08.031; Sivaramakrishnan A, 2004, NEUROSURGERY, V55, P1344, DOI 10.1227/01.NEU.0000143612.60114.2D; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43	38	23	23	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN 28	2016	30	2					164	171		10.3109/02699052.2015.1090013			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DF3MM	WOS:000371248400006	26647093				2021-06-18	
J	Ahdidan, J; Raji, CA; Deyoe, EA; Mathis, J; Noe, KO; Rimestad, J; Kjeldsen, TK; Mosegaard, J; Becker, JT; Lopez, O				Ahdidan, Jamila; Raji, Cyrus A.; DeYoe, Edgar A.; Mathis, Jedidiah; Noe, Karsten O.; Rimestad, Jens; Kjeldsen, Thomas K.; Mosegaard, Jesper; Becker, James T.; Lopez, Oscar			Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Hippocampus; magnetic resonance imaging; quantification	TEMPORAL-LOBE EPILEPSY; ADNI HARMONIZED PROTOCOL; VOXEL-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; MAGNETIC-RESONANCE; ENTORHINAL CORTEX; BRAIN ATROPHY; MANUAL SEGMENTATION; PHYSICAL-ACTIVITY; SUBFIELD VOLUMES	Background: Multiple neurological disorders including Alzheimer's disease (AD), mesial temporal sclerosis, and mild traumatic brain injury manifest with volume loss on brain MRI. Subtle volume loss is particularly seen early in AD. While prior research has demonstrated the value of this additional information from quantitative neuroimaging, very few applications have been approved for clinical use. Here we describe a US FDA cleared software program, Neuroreader (TM), for assessment of clinical hippocampal volume on brain MRI. Objective: To present the validation of hippocampal volumetrics on a clinical software program. Method: Subjects were drawn (n = 99) from the Alzheimer Disease Neuroimaging Initiative study. Volumetric brain MR imaging was acquired in both 1.5 T (n = 59) and 3.0 T (n = 40) scanners in participants with manual hippocampal segmentation. Fully automated hippocampal segmentation and measurement was done using a multiple atlas approach. The Dice Similarity Coefficient (DSC) measured the level of spatial overlap between Neuroreader (TM) and gold standard manual segmentation from 0 to 1 with 0 denoting no overlap and 1 representing complete agreement. DSC comparisons between 1.5 T and 3.0 T scanners were done using standard independent samples T-tests. Results: In the bilateral hippocampus, mean DSC was 0.87 with a range of 0.78-0.91 (right hippocampus) and 0.76-0.91 (left hippocampus). Automated segmentation agreement with manual segmentation was essentially equivalent at 1.5 T (DSC = 0.879) versus 3.0 T (DSC = 0.872). Conclusion: This work provides a description and validation of a software program that can be applied in measuring hippocampal volume, a biomarker that is frequently abnormal in AD and other neurological disorders.	[Ahdidan, Jamila] Brainreader, Horsens, Denmark; [Raji, Cyrus A.] UCLA Med Ctr, Los Angeles, CA USA; [DeYoe, Edgar A.; Mathis, Jedidiah] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA; [Noe, Karsten O.; Rimestad, Jens; Kjeldsen, Thomas K.; Mosegaard, Jesper] Alexandra Inst, Aarhus, Denmark; [Becker, James T.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; [Becker, James T.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Becker, James T.; Lopez, Oscar] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA	Raji, CA (corresponding author), UCLA Med Ctr, Dept Radiol, Los Angeles, CA 90095 USA.	cyrusraji@gmail.com			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG005133] Funding Source: Medline		Abdallah CG, 2015, J PSYCHOPHARMACOL, V29, P591, DOI 10.1177/0269881114544776; Ahdidan J, 2011, ACTA PSYCHIAT SCAND, V123, P211, DOI 10.1111/j.1600-0447.2010.01644.x; Alzheimer's Association, HEALTHC PROF FREQ AS; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Barnes J, 2009, NEUROBIOL AGING, V30, P1711, DOI 10.1016/j.neurobiolaging.2008.01.010; Benedict RHB, 2009, J NEUROL NEUROSUR PS, V80, P201, DOI 10.1136/jnnp.2008.148403; Boccardi M, 2015, ALZHEIMERS DEMENT, V11, P175, DOI 10.1016/j.jalz.2014.12.002; Boccardi M, 2015, ALZHEIMERS DEMENT, V11, P184, DOI 10.1016/j.jalz.2013.03.001; Boccardi M, 2014, J NEUROIMAGING, V24, P509, DOI 10.1111/jon.12065; Boccardi M, 2011, J ALZHEIMERS DIS, V26, P61, DOI 10.3233/JAD-2011-0004; Bocchetta M, 2015, ALZHEIMERS DEMENT, V11, P151, DOI 10.1016/j.jalz.2013.12.019; Boyle CP, 2015, NEUROBIOL AGING, V36, pS194, DOI 10.1016/j.neurobiolaging.2014.05.036; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.3233/BEN-2009-0226, 10.1155/2009/616581]; Carmichael OT, 2005, NEUROIMAGE, V27, P979, DOI 10.1016/j.neuroimage.2005.05.005; Cherbuin N, 2009, DEMENT GERIATR COGN, V28, P47, DOI 10.1159/000229025; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; de Lanerolle NC, 2005, EPILEPSY BEHAV, V7, P190, DOI 10.1016/j.yebeh.2005.06.003; Desikan RS, 2013, AM J NEURORADIOL, V34, P2075, DOI 10.3174/ajnr.A3644; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Duchesne S, 2015, ALZHEIMERS DEMENT, V11, P161, DOI 10.1016/j.jalz.2015.01.002; Erickson KI, 2010, NEUROLOGY, V75, P1415, DOI 10.1212/WNL.0b013e3181f88359; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Ezekiel F, 2004, ALZ DIS ASSOC DIS, V18, P196; Farid N, 2012, RADIOLOGY, V264, P542, DOI 10.1148/radiol.12112638; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fotuhi M, 2012, NAT REV NEUROL, V8, P189, DOI 10.1038/nrneurol.2012.27; Frisoni GB, 2015, ALZHEIMERS DEMENT, V11, P111, DOI 10.1016/j.jalz.2014.05.1756; Goodkind M, 2015, JAMA PSYCHIAT, V72, P305, DOI 10.1001/jamapsychiatry.2014.2206; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Haukvik UK, 2015, BIOL PSYCHIAT, V77, P581, DOI 10.1016/j.biopsych.2014.06.020; Hirata Y, 2005, NEUROSCI LETT, V382, P269, DOI 10.1016/j.neulet.2005.03.038; Hoef LWV, 2013, EPILEPSY RES, V106, P155, DOI 10.1016/j.eplepsyres.2013.05.008; Hughes S, 2013, MEDSCAPE; Ishiwata A, 2014, DEMENT GERIATR COGN, V38, P170, DOI 10.1159/000358510; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Jack CR, 2010, ALZHEIMERS DEMENT, V6, P212, DOI 10.1016/j.jalz.2010.03.004; Jack CR, 2011, ALZHEIMERS DEMENT, V7; KESSLAK JP, 1991, NEUROLOGY, V41, P51, DOI 10.1212/WNL.41.1.51; Killiany RJ, 2002, NEUROLOGY, V58, P1188, DOI 10.1212/WNL.58.8.1188; Kirson N, 2013, ALZHEIMERS DEMENT, V9, pP845; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Lehmann M, 2010, NEUROIMAGE, V49, P2264, DOI 10.1016/j.neuroimage.2009.10.056; Modat M, 2010, COMPUT METH PROG BIO, V98, P278, DOI 10.1016/j.cmpb.2009.09.002; Moran NF, 2001, BRAIN, V124, P167, DOI 10.1093/brain/124.1.167; Mueller SG, 2009, EPILEPSIA, V50, P1474, DOI 10.1111/j.1528-1167.2009.02010.x; Mulder ER, 2014, NEUROIMAGE, V92, P169, DOI 10.1016/j.neuroimage.2014.01.058; Nenadic I, 2015, SCHIZOPHR RES, V161, P169, DOI 10.1016/j.schres.2014.10.041; Ochs AL, 2015, J NEUROIMAGING, V25, P721, DOI 10.1111/jon.12229; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Ourselin S, 2001, IMAGE VISION COMPUT, V19, P25, DOI 10.1016/S0262-8856(00)00052-4; Pennanen C, 2004, NEUROBIOL AGING, V25, P303, DOI 10.1016/S0197-4580(03)00084-8; Perez-Miralles FC, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000132; Raji CA, 2015, AM J NEURORADIOL, V36, P1803, DOI 10.3174/ajnr.A4409; Raji CA, 2014, AM J PREV MED, V47, P444, DOI 10.1016/j.amepre.2014.05.037; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Ramani A, 2006, RADIOLOGY, V241, P26, DOI 10.1148/radiol.2411050628; Redlich R, 2014, JAMA PSYCHIAT, V71, P1222, DOI 10.1001/jamapsychiatry.2014.1100; Ringman JM, 2010, J NEUROL, V257, P839, DOI 10.1007/s00415-009-5436-4; Rodrigue KM, 2004, J NEUROSCI, V24, P956, DOI 10.1523/JNEUROSCI.4166-03.2004; Sanchez-Benavides G, 2010, PSYCHIAT RES-NEUROIM, V181, P219, DOI 10.1016/j.pscychresns.2009.10.011; Shen Q, 2011, THESIS; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tellez-Zenteno Jose F, 2012, Epilepsy Res Treat, V2012, P630853, DOI 10.1155/2012/630853; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Varma VR, 2015, HIPPOCAMPUS, V25, P605, DOI 10.1002/hipo.22397; Varon D, 2015, INT J GERIATR PSYCH, V30, P192, DOI 10.1002/gps.4126; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Wignall EL, 2004, BIOL PSYCHIAT, V56, P832, DOI 10.1016/j.biopsych.2004.09.015; Winston GP, 2013, EPILEPSIA, V54, P2166, DOI 10.1111/epi.12408; Wisse LEM, 2015, J AFFECT DISORDERS, V175, P1, DOI 10.1016/j.jad.2014.12.052; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760; Zou KH, 2004, ACAD RADIOL, V11, P178, DOI 10.1016/S1076-6332(03)00671-8	76	23	24	0	9	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	49	3					723	732		10.3233/JAD-150559			10	Neurosciences	Neurosciences & Neurology	CZ4WS	WOS:000367104100012	26484924	Green Published, Bronze, Green Accepted			2021-06-18	
J	Gao, JL; Grill, RJ; Dunn, TJ; Bedi, S; Labastida, JA; Hetz, RA; Xue, HS; Thonhoff, JR; DeWitt, DS; Prough, DS; Cox, CS; Wu, P				Gao, Junling; Grill, Raymond J.; Dunn, Tiffany J.; Bedi, Supinder; Labastida, Javier Allende; Hetz, Robert A.; Xue, Hasen; Thonhoff, Jason R.; DeWitt, Douglas S.; Prough, Donald S.; Cox, Charles S., Jr.; Wu, Ping			Human Neural Stem Cell Transplantation-Mediated Alteration of Microglial/Macrophage Phenotypes After Traumatic Brain Injury	CELL TRANSPLANTATION			English	Article						Neural stem cells (NSCs); Microglia; Traumatic brain injury (TBI); Transplantation; Immunomodulation	SPINAL-CORD-INJURY; MACROPHAGE ACTIVATION; INFLAMMATORY RESPONSE; STEM/PROGENITOR CELLS; M2 MICROGLIA; THERAPY; POLARIZATION; SYSTEM; NEUROINFLAMMATION; IMMUNOGENICITY	Neural stem cells (NSCs) promote recovery from brain trauma, but neuronal replacement is unlikely the sole underlying mechanism. We hypothesize that grafted NSCs enhance neural repair at least partially through modulating the host immune response after traumatic brain injury (TBI). C57BL/6 mice were intracerebrally injected with primed human NSCs (hNSCs) or vehicle 24 h after a severe controlled cortical impact injury. Six days after transplantation, brain tissues were collected for Western blot and immunohistochemical analyses. Observations included indicators of microglia/macrophage activation, M1 and M2 phenotypes, axonal injury detected by amyloid precursor protein (APP), lesion size, and the fate of grafted hNSCs. Animals receiving hNSC transplantation did not show significant decreases of brain lesion volumes compared to transplantation procedures with vehicle alone, but did show significantly reduced injury-dependent accumulation of APP. Furthermore, intracerebral transplantation of hNSCs reduced microglial activation as shown by a diminished intensity of Ibal immunostaining and a transition of microglia/macrophages toward the M2 anti-inflammatory phenotype. The latter was represented by an increase in the brain M2/M1 ratio and increases of M2 microglial proteins. These phenotypic switches were accompanied by the increased expression of anti-inflammatory interleukin-4 receptor alpha and decreased proinflammatory interferon-gamma receptor beta. Finally, grafted hNSCs mainly differentiated into neurons and were phagocytized by either M1 or M2 microglia/macrophages. Thus, intracerebral transplantation of primed hNSCs efficiently leads host microglia/macrophages toward an anti-inflammatory phenotype that presumably contributes to stem cell-mediated neuroprotective effects after severe TBI in mice.	[Gao, Junling; Dunn, Tiffany J.; Labastida, Javier Allende; Thonhoff, Jason R.; Wu, Ping] Univ Texas Med Branch Galveston, Dept Neurosci & Cell Biol, 301 Univ Blvd,Res Bldg 17, Galveston, TX 77555 USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Bedi, Supinder; Hetz, Robert A.; Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [DeWitt, Douglas S.; Prough, Donald S.] Univ Texas Med Branch Galveston, Dept Anesthesiol, Galveston, TX USA; [Wu, Ping] Beijing Inst Brain Disorders, Beijing, Peoples R China	Wu, P (corresponding author), Univ Texas Med Branch Galveston, Dept Neurosci & Cell Biol, 301 Univ Blvd,Res Bldg 17, Galveston, TX 77555 USA.; Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu; piwu@utmb.edu	Labastida, Javier Allende/AAA-4500-2021; Prough, Donald S/G-5793-2013	Labastida, Javier Allende/0000-0001-6372-3300; Prough, Donald S/0000-0001-7994-532X	TIRR Foundation Mission Connect; Coalition for Brain Injury Research; Gilson Longenbaugh Foundation; Moody Project; J. S. Dunn Foundation	The work was supported by grants from the TIRR Foundation Mission Connect to P.W., C.S.C., and R.J.G.; the Coalition for Brain Injury Research to P.W.; the Gilson Longenbaugh Foundation to P.W; the Moody Project to P.W, D.S.D., and D.S.P.; and the J. S. Dunn Foundation to P.W. The authors thank Dr. Yongjia Yu and Dr. Richard Coggeshall for the critical reading of the manuscript. The authors declare no conflicts of interest.	Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Ben-Hur T, 2008, J NEUROL SCI, V265, P102, DOI 10.1016/j.jns.2007.05.007; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Canton J, 2014, J LEUKOCYTE BIOL, V96, P729, DOI 10.1189/jlb.1MR0114-021R; Capetian P, 2011, SEMIN IMMUNOPATHOL, V33, P619, DOI 10.1007/s00281-011-0272-x; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu J, 2013, STEM CELL RES, V10, P325, DOI 10.1016/j.scr.2013.01.001; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martino G, 2011, PHYSIOL REV, V91, P1281, DOI 10.1152/physrev.00032.2010; McManus MM, 2011, JOVE-J VIS EXP, V58, P3246; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mosher KI, 2012, NAT NEUROSCI, V15, P1485, DOI 10.1038/nn.3233; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Payne Natalie, 2011, Curr Stem Cell Res Ther, V6, P50, DOI 10.2174/157488811794480735; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2013, GLIA, V61, P1379, DOI 10.1002/glia.22500; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Snyder EY, 2012, NEW ENGL J MED, V366, P1940, DOI 10.1056/NEJMcibr1200138; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wang EY, 2012, J NEUROTRAUM, V29, P295, DOI 10.1089/neu.2011.2043; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	51	23	23	0	9	COGNIZANT COMMUNICATION CORP	PUTNAM VALLEY	18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2016	25	10					1863	1877		10.3727/096368916X691150			15	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	DY4FV	WOS:000385055300010	26980267	Bronze			2021-06-18	
J	Jackson, ACW; Roche, SL; Byrne, AM; Ruiz-Lopez, AM; Cotter, TG				Jackson, Alice C. Wyse; Roche, Sarah L.; Byrne, Ashleigh M.; Ruiz-Lopez, Ana M.; Cotter, Thomas G.			Progesterone receptor signalling in retinal photoreceptor neuroprotection	JOURNAL OF NEUROCHEMISTRY			English	Article						neuroprotection; Norgestrel; PGRMC1; photoreceptor; progesterone; retinal degeneration	BREAST-CANCER CELLS; MEMBRANE COMPONENT-1 PGRMC1; TRAUMATIC BRAIN-INJURY; TIME QUANTITATIVE PCR; RETINITIS-PIGMENTOSA; ANTIAPOPTOTIC ACTION; GRANULOSA-CELLS; UP-REGULATION; 661W CELLS; PROTEIN	Norgestrel', a synthetic form of the female hormone progesterone has been identified as potential drug candidate for the treatment of the degenerative eye disease retinitis pigmentosa. However, to date, no work has looked at the compound's specific cellular target. Therefore, this study aimed to identify the receptor target of Norgestrel and begin to examine its potential mechanism of action in the retina. In this work, we identify and characterize the expression of progesterone receptors present in the C57 wild type and rd10 mouse model of retinitis pigmentosa. Classical progesterone receptors A and B (PR A/B), progesterone receptor membrane components 1 and 2 (PGRMC1, PGRMC2) and membrane progesterone receptors , and were found to be expressed. All receptors excluding PR A/B were also found in the 661W photoreceptor cell line. PGRMC1 is a key regulator of apoptosis and its expression is up-regulated in the degenerating rd10 mouse retina. Activated by Norgestrel through nuclear trafficking, siRNA knock down of PGRMC1 abrogated the protective properties of Norgestrel on damaged photoreceptors. Furthermore, specific inhibition of PGRMC1 by AG205 blocked Norgestrel-induced protection in stressed retinal explants. Therefore, we conclude that PGRMC1 is crucial to the neuroprotective effects of Norgestrel on stressed photoreceptors.	[Jackson, Alice C. Wyse; Roche, Sarah L.; Byrne, Ashleigh M.; Ruiz-Lopez, Ana M.; Cotter, Thomas G.] Natl Univ Ireland Univ Coll Cork, Biosci Res Inst, Dept Biochem, Cell Dev & Dis Lab, Cork, Ireland	Cotter, TG (corresponding author), Natl Univ Ireland Univ Coll Cork, Biosci Res Inst, Dept Biochem, Cell Dev & Dis Lab, Cork, Ireland.	t.cotter@ucc.ie		Cotter, Thomas/0000-0003-4626-5613	Fighting Blindness Ireland; Science Foundation Ireland (SFI)Science Foundation Ireland	The authors would like to thank Ms Jennifer Moloney for useful discussions relating to this work. The authors also gratefully acknowledge all members of the Biological Services Unit (BSU) for their assistance. This work was supported by Fighting Blindness Ireland and Science Foundation Ireland (SFI).	Ait-Hmyed O, 2013, EUR J NEUROSCI, V37, P1048, DOI 10.1111/ejn.12103; Ashley RL, 2006, ENDOCRINOLOGY, V147, P4151, DOI 10.1210/en.2006-0002; Barone I, 2014, MOL VIS, V20, P1545; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; Borowicz Kinga K, 2011, Front Endocrinol (Lausanne), V2, P50, DOI 10.3389/fendo.2011.00050; BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223; Cahill MA, 2007, J STEROID BIOCHEM, V105, P16, DOI 10.1016/j.jsbmb.2007.02.002; Choksuchat C, 2009, CONTRACEPTION, V79, P139, DOI 10.1016/j.contraception.2008.08.008; Compagnone NA, 2008, J STEROID BIOCHEM, V109, P307, DOI 10.1016/j.jsbmb.2008.03.022; Crudden G, 2006, J PHARMACOL EXP THER, V316, P448, DOI 10.1124/jpet.105.094631; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Diederen RMH, 2008, MOL VIS, V14, P255; Doonan F, 2012, EXPERT OPIN INV DRUG, V21, P579, DOI 10.1517/13543784.2012.667400; Doonan F, 2011, J NEUROCHEM, V118, P915, DOI 10.1111/j.1471-4159.2011.07354.x; Doonan F, 2009, J NEUROCHEM, V109, P631, DOI 10.1111/j.1471-4159.2009.05995.x; Dressing GE, 2007, STEROIDS, V72, P111, DOI 10.1016/j.steroids.2006.10.006; Dressing GE, 2012, HORM CANCER-US, V3, P101, DOI 10.1007/s12672-012-0106-x; Espinosa-Garcia C, 2014, BRAIN RES, V1545, P23, DOI 10.1016/j.brainres.2013.11.030; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Friberg PA, 2009, BIOL REPROD, V80, P1160, DOI 10.1095/biolreprod.108.073932; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gomez-Vicente V, 2005, CELL DEATH DIFFER, V12, P796, DOI 10.1038/sj.cdd.4401621; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Guerin MB, 2011, CLIN EXP OPHTHALMOL, V39, P243, DOI 10.1111/j.1442-9071.2011.02496.x; Hanna RN, 2010, BIOL REPROD, V82, P112, DOI 10.1095/biolreprod.109.078527; Intlekofer KA, 2011, NEUROSCIENCE, V176, P86, DOI 10.1016/j.neuroscience.2010.12.033; Kupchak BR, 2009, BIOCHEMISTRY-US, V48, P5504, DOI 10.1021/bi9006258; Lange CA, 2008, J STEROID BIOCHEM, V108, P203, DOI 10.1016/j.jsbmb.2007.09.019; Li YC, 1997, J MOL NEUROSCI, V8, P145, DOI 10.1007/BF02736779; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Losel RM, 2008, STEROIDS, V73, P929, DOI 10.1016/j.steroids.2007.12.017; Lu Na, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P2026; Mackey AM, 2008, CELL DEATH DIFFER, V15, P1291, DOI 10.1038/cdd.2008.43; Mastrodimou N, 2008, INVEST OPHTH VIS SCI, V49, P342, DOI 10.1167/iovs.07-0341; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Meyer C, 1996, EUR J BIOCHEM, V239, P726, DOI 10.1111/j.1432-1033.1996.0726u.x; Moussatche P, 2012, BIOCHEM SOC T, V40, P200, DOI 10.1042/BST20110638; Mygind T, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-17; Okumichi H, 2008, EXP EYE RES, V86, P727, DOI 10.1016/j.exer.2008.01.019; Pang YF, 2011, STEROIDS, V76, P921, DOI 10.1016/j.steroids.2011.01.008; Peluso JJ, 2006, ENDOCRINOLOGY, V147, P3133, DOI 10.1210/en.2006-0114; Peluso JJ, 2008, J CLIN ENDOCR METAB, V93, P1592, DOI 10.1210/jc.2007-2771; Peluso JJ, 2008, ENDOCRINOLOGY, V149, P534, DOI 10.1210/en.2007-1050; Peluso JJ, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.122986; Peluso JJ, 2012, STEROIDS, V77, P1007, DOI 10.1016/j.steroids.2012.01.013; Penha FM, 2013, OPHTHALMOLOGICA, V230, P41, DOI 10.1159/000354251; Petersen SL, 2013, J NEUROENDOCRINOL, V25, P991, DOI 10.1111/jne.12060; Qin YB, 2015, J STEROID BIOCHEM, V154, P302, DOI 10.1016/j.jsbmb.2015.01.002; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; Rohe HJ, 2009, PHARMACOL THERAPEUT, V121, P14, DOI 10.1016/j.pharmthera.2008.09.006; Samadi A, 2002, PFLUG ARCH EUR J PHY, V444, P700, DOI 10.1007/s00424-002-0889-7; Samardzija M, 2012, EXP EYE RES, V99, P17, DOI 10.1016/j.exer.2012.04.004; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sobolewska B, 2013, CURR EYE RES, V38, P662, DOI 10.3109/02713683.2012.746991; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Swiatek-De Lange M, 2007, GLIA, V55, P1061, DOI 10.1002/glia.20523; Thomas P, 2007, ENDOCRINOLOGY, V148, P705, DOI 10.1210/en.2006-0974; Thomas P, 2012, NEUROENDOCRINOLOGY, V96, P162, DOI 10.1159/000339822; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; Wendler A, 2013, STEROIDS, V78, P555, DOI 10.1016/j.steroids.2012.12.002; Wickham LA, 2000, ACTA OPHTHALMOL SCAN, V78, P146, DOI 10.1034/j.1600-0420.2000.078002146.x; WONG F, 1993, ARCH OPHTHALMOL-CHIC, V111, P754, DOI 10.1001/archopht.1993.01090060042020; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; Yousuf S, 2014, PSYCHOPHARMACOLOGY, V231, P3313, DOI 10.1007/s00213-014-3556-8; Yu HJ, 2010, NEUROSCI LETT, V476, P42, DOI 10.1016/j.neulet.2010.03.079; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	70	23	26	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2016	136	1					63	77		10.1111/jnc.13388			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CZ6DZ	WOS:000367192700006	26447367	Bronze			2021-06-18	
J	Khan, M; Dhammu, TS; Matsuda, F; Annamalai, B; Dhindsa, TS; Singh, I; Singh, AK				Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Annamalai, Balasubramaniam; Dhindsa, Tejbir Singh; Singh, Inderjit; Singh, Avtar K.			Targeting the nNOS/peroxynitrite/calpain system to confer neuroprotection and aid functional recovery in a mouse model of TBI	BRAIN RESEARCH			English	Article						TBI; GSNO; Calpain; Peroxynitrite; nNOS; Neurodegeneration	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; S-NITROSOGLUTATHIONE; EXPERIMENTAL STROKE; RAT MODEL; CYTOSKELETAL DEGRADATION; PEROXYNITRITE FORMATION	Traumatic brain injury (TB!) derails nitric oxide (NO)-based anti-inflammatory and anti-excitotoxicity mechanisms. NO is consumed by superoxide to form peroxynitrite, leading to decreased NO bioavailability for S-nitrosoglutathione (GSNO) synthesis and regulation of neuroprotective pathways. Neuronal peroxynitrite is implicated in neuronal loss and functional deficits following TBI. Using a contusion mouse model of TBI, we investigated mechanisms for the opposed roles of GSNO versus peroxynitrite for neuroprotection and functional recovery. TBI was induced by controlled cortical impact (CCI) in adult male mice. GSNO treatment at 2 h after CCI decreased the expression levels of phospho neuronal nitric oxide synthase (pnNOS), alpha II spectrin degraded products, and 3-NT, while also decreasing the activities of nNOS and calpains. Treatment of TBI with FeTPPS, a peroxynitrite scavenger, had effects similar to GSNO treatment. GSNO treatment of TBI also reduced neuronal degeneration and improved neurobehavioral function in a two-week TB! study. In a cell free system, SIN-1 (a peroxynitrite donor and 3-nitrotyrosinating agent) increased whereas GSNO (an S-nitrosylating agent) decreased calpain activity, and these activities were reversed by, respectively, FeTPPS and mercuric chloride, a cysteine-NO bond cleaving agent. These data indicate that peroxynitrite-mediated activation and GSNO-mediated inhibition of the deleterious nNOS/calpain system play critical roles in the pathobiology of neuronal protection and functional recovery in TBI disease. Given GSNO's safety record in other diseases, its neuroprotective efficacy and promotion of functional recovery in this TBI study make low-dose GSNO a potential candidate for preclinical evaluation. (C) 2015 Elsevier B.V. All rights reserved.	[Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Annamalai, Balasubramaniam; Dhindsa, Tejbir Singh; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan; [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Khan, M (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	khanm@musc.edu; dhammu@musc.edu; fumiyo@health.nop.kagoshima-u.ac.jp; annamal@musc.edu; dhindsat@musc.edu; singhi@musc.edu; singha@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511]; VA Merit AwardUS Department of Veterans Affairs [BX001062, BX002829]; NIH from the Extramural Research Facilities Program of the National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018823, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072511] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001062, I01BX002829] Funding Source: NIH RePORTER	This work was supported by grants from NIH (NS-72511) and VA Merit Award (BX001062 and BX002829). This work was also supported by the NIH, Grants C06 RR018823 and No. C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan and Ms. Terry Hope for their technical help and secretarial assistance. We are grateful to Ms. Danielle Lowe (MD/PhD student at the MUSC) for statistical analysis. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing of the manuscript.	Annamalai B, 2015, BIOCHEM BIOPH RES CO, V458, P214, DOI 10.1016/j.bbrc.2015.01.093; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Chiueh CC, 1999, FREE RADICAL RES, V31, P641, DOI 10.1080/10715769900301211; Chou PCT, 2011, J MAGN RESON IMAGING, V33, P1301, DOI 10.1002/jmri.22574; Coert BA, 2003, AM J PHYSIOL-HEART C, V284, pH151, DOI 10.1152/ajpheart.00580.2002; Cook JA, 1996, ANAL BIOCHEM, V238, P150, DOI 10.1006/abio.1996.0268; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dhawan J, 2011, FUTUR NEUROL, V6, P823, DOI 10.2217/FNL.11.55; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Hess DT, 2012, J BIOL CHEM, V287, P4411, DOI 10.1074/jbc.R111.285742; Huang TN, 2014, NAT NEUROSCI, V17, P240, DOI 10.1038/nn.3626; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ju TC, 2005, FREE RADICAL BIO MED, V38, P938, DOI 10.1016/j.freeradbiomed.2004.12.019; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0179-x; Khan M, 2015, DRUG DES DEV THER, V9, P2233, DOI 10.2147/DDDT.S77115; Khan M, 2012, J NEUROCHEM, V123, P86, DOI 10.1111/j.1471-4159.2012.07947.x; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim J., 2013, ANTIOXID REDOX SIGNA; Koh TJ, 2000, AM J PHYSIOL-CELL PH, V279, pC806; Kruk-Slomka M, 2014, PHARMACOL REP, V66, P638, DOI 10.1016/j.pharep.2014.02.002; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Prasad KN, 2015, BRAIN RES, V1599, P103, DOI 10.1016/j.brainres.2014.12.038; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; Qu ZW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052788; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Rameau GA, 2007, J NEUROSCI, V27, P3445, DOI 10.1523/JNEUROSCI.4799-06.2007; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sakakima H, 2012, RESTOR NEUROL NEUROS, V30, P383, DOI 10.3233/RNN-2012-110209; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Samengo G, 2012, AGING CELL, V11, P1036, DOI 10.1111/acel.12003; Schonhoff CM, 2006, P NATL ACAD SCI USA, V103, P2404, DOI 10.1073/pnas.0507243103; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Shunmugavel A, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-17; SIGNORE P, 1991, PHYSIOL BEHAV, V49, P701, DOI 10.1016/0031-9384(91)90305-8; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; Venna VR, 2014, EUR J NEUROSCI, V39, P2129, DOI 10.1111/ejn.12556; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yoon JS, 2011, NEUROBIOL DIS, V41, P624, DOI 10.1016/j.nbd.2010.11.011; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093334	63	23	23	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 1	2016	1630						159	170		10.1016/j.brainres.2015.11.015			12	Neurosciences	Neurosciences & Neurology	CZ4YU	WOS:000367109900016	26596859	Green Accepted			2021-06-18	
J	Ma, J; Shui, SF; Han, XW; Guo, D; Li, TF; Yan, L				Ma, Ji; Shui, Shaofeng; Han, Xinwei; Guo, Dong; Li, Tengfei; Yan, Lei			microRNA-22 attenuates neuronal cell apoptosis in a cell model of traumatic brain injury	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Traumatic brain injury; microRNA-22; neuronal cell apoptosis; caspase 3; apoptosis factor	IN-VITRO; BAX/BCL-2 RATIO; UP-REGULATION; DEATH; BCL-2; EXPRESSION; MODERATE; PATHWAY	Traumatic brain injury (TBI) is a major cause of injury-related deaths, and the mechanism of TBI has become a research focus, but little is known about the mechanism of microRNAs in TBI. The aim of this study is the role of microRNA-22 (miR-22) in TBI-induced neuronal cell apoptosis. Rat cortical neurons were cultured and the TBI model was induced by scratch injury in vitro, before which miR-22 level was altered by transfection of agomir or antagomir. Lactate dehydrogenase (LDH) release and TUNEL assays were performed to examine neuronal cell injury and apoptosis. The activity of caspase 3 (CASP3) and level changes of several apoptosis factors including B-cell lymphoma 2 (BCL2), BCL2-associated X protein (BAX), phosphatase and tensin homolog (PTEN) and v-AKT murine thymoma viral oncogene homolog 1 (AKT1) were detected. Results showed that TBI model cells possessed a downregulated miR-22 level (P < 0.001) and more LDH release and apoptotic cells indicating the aggravated neuronal cell injury and apoptosis induced by TBI. miR-22 agomir attenuated neuronal cell injury and apoptosis of the TBI model. It also caused the corresponding changes in CASP3 activity and other apoptosis factors, with cleaved CASP3, BAX and PTEN inhibited and BCL2 and phosphorylated AKT1 promoted, while miR-22 antagomir had the opposite effects. So miR-22 has neuroprotective roles of attenuating neuronal cell injury and apoptosis induced by TBI, which may be associated with its regulation on apoptosis factors. This study reveals miR-22 as a potential approach to TBI treatment and detailed mechanism remains to be uncovered.	[Ma, Ji; Shui, Shaofeng; Han, Xinwei; Guo, Dong; Li, Tengfei; Yan, Lei] Zhengzhou Univ, Affiliated Hosp 1, Dept Intervent Radiol, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China	Han, XW (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Intervent Radiol, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China.	hanxinwei516@126.com					Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fabian MR, 2009, MOL CELL, V35, P868, DOI 10.1016/j.molcel.2009.08.004; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Gong QH, 2007, ACTA PHARMACOL SIN, V28, P1724, DOI 10.1111/j.1745-7254.2007.00666.x; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Jiang H, 2014, MOL MED REP, V9, P2265, DOI 10.3892/mmr.2014.2108; Jovicic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054222; Liu LH, 2010, TOXICOL IN VITRO, V24, P1168, DOI 10.1016/j.tiv.2010.02.016; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Omer AD, 2009, MOL CELL, V35, P739, DOI 10.1016/j.molcel.2009.09.003; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Richman JE, 2007, J BEHAV OPTOMETRY, V18, P149; Roy MJ, 2014, BRIT J PHARMACOL, V171, P1973, DOI 10.1111/bph.12431; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Stechschulte LA, 2014, J BIOL CHEM, V289, P17885, DOI 10.1074/jbc.M113.544072; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Wu B, 2012, ARCH PHARM RES, V35, P543, DOI 10.1007/s12272-012-0318-1; Yang J, 2014, MOL BIOL REP, V41, P555, DOI 10.1007/s11033-013-2891-x; Yu HY, 2015, J CELL BIOCHEM, V116, P233, DOI 10.1002/jcb.24960; Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	30	23	25	0	3	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2016	8	4					1895	1902					8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	DN5GP	WOS:000377094900009	27186313				2021-06-18	
J	Majdan, M; Brazinova, A; Mauritz, W				Majdan, Marek; Brazinova, Alexandra; Mauritz, Walter			Epidemiology of traumatic spinal cord injuries in Austria 2002-2012	EUROPEAN SPINE JOURNAL			English	Article						Traumatic spinal cord injury; Spinal cord injury; Epidemiology; Incidence; Mortality	GLOBAL INCIDENCE; BRAIN-INJURY; COUNTRIES	The aim of this study was to analyse the epidemiological patterns (mortality, incidence of non-fatal cases and overall incidence), of traumatic spinal cord injuries (TSCI) in 2002-2012 in Austria. TSCI-related deaths and hospital admissions in Austria 2002-2012 were obtained from Statistics Austria and analysed. Mortality rates, as well as non-fatal and overall incidence rates were calculated and compared across the age spectrum and by sex. Additionally, the main causes and demographic characteristics of victims were analysed. The crude overall incidence rate of TSCI was 16.96, CI 95 % 16.95-16.97 and the standardized incidence rate was 13.98, CI 95 % 13.97-13.99 per million (annual average rate). An annual increase in fatality rates was observed occurring mostly in the age group > 65 years (Kendall's Tau = 0.1). Falls (mortality rate 19.58, CI 95 % 19.57-19.59) and injuries at home (incidence rate 56.57, CI 95 % 56.56-56.58) were the principal causes of fatal and non-fatal TSCI, respectively. Injuries to the neck region were the most common. All indicators were the highest for the age group > 65 years: non-fatal incidence rate 23.55, CI 95 % 23.54-23.56; mortality rate 21.4, CI 95 % 21.39-21.41; and overall incidence rate 47.9, CI 95 % 47.89-47.91. A clear male dominance was observed (incidence rate ratio 1.9, CI 95 % 1.4-2.7). The population > 65 years has been at the highest risk of TSCI in Austria for the analysed period and therefore preventive activities should be focused on this group. The increasing overall incidence of TSCI was driven by the increasing mortality rates that were highest in the age group > 65 years. We advocate harmonization of epidemiological reporting especially regarding aetiology of TSCI in order to better inform policy makers and prevention.	[Majdan, Marek; Brazinova, Alexandra] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia; [Majdan, Marek; Brazinova, Alexandra; Mauritz, Walter] INRO, Moelkergasse 4-3, A-1080 Vienna, Austria	Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia.; Majdan, M (corresponding author), INRO, Moelkergasse 4-3, A-1080 Vienna, Austria.	mmajdan@igeh.org; abrazinova@igeh.org; walter.mauritz@igeh.org	Majdan, Marek/K-5017-2012; Brazinova, Alexandra/C-4265-2016	Majdan, Marek/0000-0001-8037-742X; Brazinova, Alexandra/0000-0003-0625-256X			Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Ahmad O. B., 2001, GPE DISCUSSION PAPER, V31; Aragon TJ, 2012, EP EP TOOLS R PACK V; Fitzharris M, 2014, SPINAL CORD, V52, P117, DOI 10.1038/sc.2013.135; Furlan JC, 2013, CAN J NEUROL SCI, V40, P456, DOI 10.1017/S0317167100014530; Hagen EM, 2009, SPINAL CORD, V47, P367, DOI 10.1038/sc.2008.118; Hagen EM, 2010, J NEUROL NEUROSUR PS, V81, P368, DOI 10.1136/jnnp.2009.178798; Jazayeri SB, 2015, EUR SPINE J, V24, P905, DOI 10.1007/s00586-014-3424-6; Knutsdottir S, 2012, SPINAL CORD, V50, P123, DOI 10.1038/sc.2011.105; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Mauritz W, 2014, WIEN KLIN WOCHENSCHR, V126, P278, DOI 10.1007/s00508-014-0521-9; Mauritz W, 2014, WIEN KLIN WOCHENSCHR, V126, P42, DOI 10.1007/s00508-013-0456-6; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1402, DOI 10.1016/S0003-9993(99)90251-4; McLeod AI, 2011, KEND KEND RANK CORR; Pickett GE, 2006, SPINE, V31, P799, DOI 10.1097/01.brs.0000207258.80129.03; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; R Core Team, 2013, R LANG ENV STAT COMP; Rahimi-Movaghar V, 2013, NEUROEPIDEMIOLOGY, V41, P65, DOI 10.1159/000350710; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Van Den Berg M, 2011, J NEUROTRAUM, V28, P469, DOI 10.1089/neu.2010.1608; van den Berg MEL, 2010, J NEUROTRAUM, V27, P1517, DOI 10.1089/neu.2009.1138; WHO, 2013, INTERNATIONAL PERSPECTIVES ON SPINAL CORD INJURY, P1; World Health Organization, 2010, INT STAT CLASS DIS R	25	23	23	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0940-6719	1432-0932		EUR SPINE J	Eur. Spine J.	JAN	2016	25	1					62	73		10.1007/s00586-015-3985-z			12	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	DB6FI	WOS:000368608900006	25957283				2021-06-18	
J	Moore, DR; Pindus, DM; Raine, LB; Drollette, ES; Scudder, MR; Ellemberg, D; Hillman, CH				Moore, Davis R.; Pindus, Dominika M.; Raine, Lauren B.; Drollette, Eric S.; Scudder, Mark R.; Ellemberg, Dave; Hillman, Charles H.			The persistent influence of concussion on attention, executive control and neuroelectric function in preadolescent children	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Sport-concussion; Children; Brain function; Event related potentials; Cognition	TRAUMATIC BRAIN-INJURY; COGNITIVE CONTROL; WORKING-MEMORY; HEAD-INJURIES; NEUROPSYCHOLOGICAL FUNCTION; PEDIATRIC CONCUSSION; ADOLESCENTS; PERFORMANCE; OUTCOMES; TASK	The aim of this investigation was to examine the influence of pediatric sport-related concussion on brain and cognitive function. To do so, we used a between-participants design, measures of executive control, and event related potentials (ERPs). The findings demonstrate that children with a history of concussion exhibit behavioral deficits in attention, working memory and impulse control, as well as neuroelectric alterations in ERP indices of visual attention (N1), conflict resolution (N2) and attentional resource allocation (P3). Furthermore, the age at injury related to the magnitude of several concussion-related deficits. Accordingly, a single sports-related concussive incident during childhood (m = 2.1 years prior to testing) may lead to subtle, yet pervasive alterations in the behavioral and neural indices of attention and executive control, and age at injury may moderate injury outcomes. (C) 2015 Elsevier B.V. All rights reserved.	[Moore, Davis R.; Raine, Lauren B.; Drollette, Eric S.; Scudder, Mark R.; Hillman, Charles H.] Univ Illinois, Urbana, IL 61801 USA; [Pindus, Dominika M.] Univ Loughborough, Loughborough, Leics, England; [Ellemberg, Dave] Univ Montreal, Montreal, PQ H3C 3J7, Canada; [Ellemberg, Dave] 2100 Blvd Edouard Montpetit, Montreal, PQ H3T 1J4, Canada; [Pindus, Dominika M.] Ashby Rd, Loughborough LE11 3TU, Leics, England; [Raine, Lauren B.; Drollette, Eric S.; Scudder, Mark R.; Hillman, Charles H.] 906 S Goodwin Ave, Urbana, IL 61801 USA	Moore, DR (corresponding author), 2100 Blvd Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	robert.moore@umontreal.ca; D.M.Pindus@lboro.ac.uk; lraine19@gmail.com; droeri@gmail.com; mscudde2@illinois.edu; dave.ellemberg@umontreal.ca; chhillma@gmail.com	Hillman, Charles/AAD-4828-2019; Meijer, Anna/K-5118-2016	Hillman, Charles/0000-0002-3722-5612; Pindus, Dominika M/0000-0001-7288-7921			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Bar-Or O., 1983, PEDIATRIC SPORTS MED, P1; Beste C, 2010, NEUROPSYCHOLOGIA, V48, P366, DOI 10.1016/j.neuropsychologia.2009.09.023; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Birnbaum AS, 2002, AM J HEALTH BEHAV, V26, P284, DOI 10.5993/AJHB.26.4.5; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Centers for Disease Control and Prevention, 1997, INT J TRAUMA NURS, V3, P88; Chaddock L, 2012, J SPORT SCI, V30, P421, DOI 10.1080/02640414.2011.647706; Chatrian G. E., 1985, American Journal of EEG Technology, V25, P83; Conners C.K., 2001, CONNERS CHILD ADHD D; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FREEDSON PS, 1993, PEDIATRIC LABORATORY EXERCISE TESTING, P91; Gajewski PD, 2013, INT J PSYCHOPHYSIOL, V87, P273, DOI 10.1016/j.ijpsycho.2012.08.007; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Gothe N, 2013, J PHYS ACT HEALTH, V10, P488, DOI 10.1123/jpah.10.4.488; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hessen E, 2009, BRAIN INJURY, V23, P234, DOI 10.1080/02699050902748349; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Hillman CH, 2014, PEDIATRICS, V134, pE1063, DOI 10.1542/peds.2013-3219; Hillman CH, 2012, DEV COGN NEUROS-NETH, V2, pS90, DOI 10.1016/j.dcn.2011.07.004; HILLYARD SA, 1984, PERCEPT PSYCHOPHYS, V36, P185, DOI 10.3758/BF03202679; Hillyard SA, 1998, P NATL ACAD SCI USA, V95, P781, DOI 10.1073/pnas.95.3.781; Hoffman B, 2009, LEARN INDIVID DIFFER, V19, P91, DOI 10.1016/j.lindif.2008.08.001; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kamijo K, 2012, OBESITY, V20, P2406, DOI 10.1038/oby.2012.112; Kamijo K, 2011, DEVELOPMENTAL SCI, V14, P1046, DOI 10.1111/j.1467-7687.2011.01054.x; Kaufman A., 1990, AM GUIDANCE SERVICE; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Keightley ML, 2012, CURR OPIN PEDIATR, V24, P709, DOI 10.1097/MOP.0b013e3283599a55; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; Kiesel A, 2010, PSYCHOL BULL, V136, P849, DOI 10.1037/a0019842; Kirkwood M, 2012, MILD TRAUMATIC BRAIN; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Larson MJ, 2012, J INT NEUROPSYCH SOC, V18, P323, DOI 10.1017/S1355617711001779; Luna B, 2009, ADV CHILD DEV BEHAV, V37, P233, DOI 10.1016/S0065-2407(09)03706-9; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; Mayr U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091379; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P., 2009, S AFRICAN J SPORTS M, V21; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Moore RD, 2015, BIOL PSYCHOL, V109, P93, DOI 10.1016/j.biopsycho.2015.04.008; Moore RD, 2014, J ATHL TRAINING, V49, P24, DOI 10.4085/1062-6050-49.1.01; Neuroscan C., 2003, OFFLINE ANAL ACQUIRE; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; Ornstein TJ, 2013, J NEUROPSYCHOL, V7, P1, DOI 10.1111/j.1748-6653.2012.02027.x; Ozen LJ, 2013, BRAIN INJURY, V27, P1244, DOI 10.3109/02699052.2013.804207; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Rueda MR, 2004, NEUROPSYCHOLOGIA, V42, P1029, DOI 10.1016/j.neuropsychologia.2003.12.012; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Schmitt BM, 2000, PSYCHOPHYSIOLOGY, V37, P473, DOI 10.1111/1469-8986.3740473; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Smith JL, 2010, INT J PSYCHOPHYSIOL, V75, P217, DOI 10.1016/j.ijpsycho.2009.11.002; Taylor SJC, 2001, PAEDIATR PERINAT EP, V15, P88; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; THOMAS S, 1992, CAN J SPORT SCI, V17, P338; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Utter AC, 2002, MED SCI SPORT EXER, V34, P139, DOI 10.1097/00005768-200201000-00021; Vogel EK, 2000, PSYCHOPHYSIOLOGY, V37, P190, DOI 10.1111/1469-8986.3720190; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	78	23	24	0	37	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	JAN	2016	99						85	95		10.1016/j.ijpsycho.2015.11.010			11	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	DC4MA	WOS:000369193800011	26608697				2021-06-18	
J	Olabarrieta-Landa, L; Caracuel, A; Perez-Garcia, M; Panyavin, I; Morlett-Paredes, A; Arango-Lasprilla, JC				Olabarrieta-Landa, Laiene; Caracuel, Alfonso; Perez-Garcia, Miguel; Panyavin, Ivan; Morlett-Paredes, Alejandra; Carlos Arango-Lasprilla, Juan			The profession of neuropsychology in Spain: results of a national survey	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neuropsychology survey; Spain; professional development	NEURONORMA PROJECT NORMS; BOSTON NAMING TEST; UNITED-STATES; CLINICAL NEUROPSYCHOLOGISTS; NORMATIVE DATA; SALARY SURVEY; SPANISH; BELIEFS; INCOMES; TESTS	Objective: To examine the current status of professional neuropsychology in Spain, with particular focus on the areas of professional training, current work situation, evaluation and diagnostic practice, rehabilitation, teaching, and research. Methods: Three hundred and thirty-nine self-identified professionals in neuropsychology from Spain completed an online survey between July and December of 2013. Respondents had an average age of 35.8years and 77% were women. Results: Ninety-seven percent of the respondents identified as psychologists; 82% of the sample had a master's degree, and 33% a doctoral degree. The majority (91%) received their neuropsychological training at a graduate level; 88% engaged in neuropsychological evaluation, 59% in rehabilitation, 50% in research, and 40% in teaching. Average number of hours per week dedicated to work in neuropsychology was 29.7, with 28% of the respondents reporting working in hospitals, 17% in not-for-profit rehabilitation centers, 15% in universities, and 14% in private clinics. Clinicians primarily work with individuals with stroke, traumatic brain injury, and dementia. The top perceived barriers to development of neuropsychology in Spain included lack of clinical and academic training opportunities, and negative attitude toward professional collaboration. Conclusions: The field of neuropsychology in Spain is young and rapidly growing. There is a need to regulate professional neuropsychology, improve graduate curricula, enhance existing clinical training, develop professional certification programs, validate and create normative data for existing neuropsychological tests, and create new, culturally relevant instruments.	[Olabarrieta-Landa, Laiene; Panyavin, Ivan] Univ Deusto, Dept Psychol, Bilbao, Spain; [Caracuel, Alfonso; Perez-Garcia, Miguel] Univ Granada, CIMCYC, Granada, Spain; [Perez-Garcia, Miguel] Comis Neuropsicol Colegio Oficial Psicol Andaluci, Granada, Spain; [Morlett-Paredes, Alejandra] Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USA; [Carlos Arango-Lasprilla, Juan] Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Carlos Arango-Lasprilla, Juan] Cruces Univ Hosp, BioCruces Hlth Res Inst, Baracaldo, Spain	Arango-Lasprilla, JC (corresponding author), Basque Fdn Sci, Ikerbasque, Bilbao, Spain.; Arango-Lasprilla, JC (corresponding author), Cruces Univ Hosp, BioCruces Hlth Res Inst, Baracaldo, Spain.	jcalasprilla@gmail.com	Garcia, Miguel Perez/F-9630-2010; Landa, Laiene Olabarrieta/V-6207-2017; Arango-Lasprilla, Juan Carlos/AAB-5407-2019; Caracuel, Alfonso/V-3695-2019	Garcia, Miguel Perez/0000-0003-4775-7556; Landa, Laiene Olabarrieta/0000-0002-8305-8720; Arango-Lasprilla, Juan Carlos/0000-0002-7184-8311; Caracuel, Alfonso/0000-0002-9738-8456			Aceituno P., 2014, NOVENO INFORM INNOVA; Alegret M, 2012, J CLIN EXP NEUROPSYC, V34, P209, DOI 10.1080/13803395.2011.630652; [Anonymous], 2014, EF ENGL PROF IND; Carrobles JA, 2014, BEHAV PSYCHOL, V22, P161; Arango-Lasprilla J. C., APPL NEUROP IN PRESS; Arango-Lasprilla J. C. O., 2015, NEUROPSICOLOGIA COLO, P21; Ardila A, 2013, ARCH CLIN NEUROPSYCH, V28, P751, DOI 10.1093/arclin/act036; Bandres J., 1989, REV HIST PSICOLOGIA, V10, P131; Bauermeister J. J., 2010, ADHD REPORT, V18, P12, DOI [10.1521/adhd.2010.18.1.12, DOI 10.1521/ADHD.2010.18.1.12]; Beaumont J., 2008, INTRO NEUROPSYCHOLOG; Campos-Bueno J. J., 2002, REV HIST PSICOLOGIA, V23, P85; Carpintero H, 2014, L SIMARRO PSICOLOGIA; Elbulok-Charcape MM, 2014, CULT DIVERS ETHN MIN, V20, P353, DOI 10.1037/a0035023; Fonseca-Aguilar Paola, 2015, Psicol. caribe, V32, P344, DOI 10.14482/psdc.32.3.7896; Garcia EG, 2009, REV HIST PSICOL, V30, P107; Hartlage LC, 2011, HANDBOOK OF CLINICAL CHILD NEUROPSYCHOLOGY, THIRD EDITION, P3, DOI 10.1007/978-0-387-78867-8_1; Heilbronner RL, 2004, CLIN NEUROPSYCHOL, V18, P312, DOI 10.1080/13854040490501574; Instituto Nacional de Estadistica, 2015, ENC POBL ACT EPA SER; Instituto Nacional de Estadistica, 2014, PROYECC POBL ESP 201; Instituto Nacional de Estadistica, 2015, EST ACT I D RES DEF; Instituto Nacional de Estadistica, 2015, DEF SEG CAUS MUERT A; Junque Plaja C., 2011, HIST NEUROLOGIA CATA, P211; Kolb B., 2015, FUNDAMENTALS HUMAN N; Martinez Riera Jose Ramon, 2012, Rev Enferm, V35, P6; Pena-Casanova J, 2012, NEUROLOGIA, V27, P253, DOI 10.1016/j.nrl.2011.12.019; Pena-Casanova J., 1991, PROGRAMA INTEGRADO E; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P413, DOI 10.1093/arclin/acp043; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P343, DOI 10.1093/arclin/acp039; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P371, DOI 10.1093/arclin/acp041; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P321, DOI 10.1093/arclin/acp038; Quijano TD, 2004, MED CLIN-BARCELONA, V122, P727, DOI 10.1157/13062190; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rabin LA, 2014, PROF PSYCHOL-RES PR, V45, P368, DOI 10.1037/a0037987; Rami L, 2007, REV NEUROLOGIA, V45, P268, DOI 10.33588/rn.4505.2007112; Rami L, 2008, J CLIN EXP NEUROPSYC, V30, P1, DOI 10.1080/13803390701743954; Rivera D., 2015, NEUROPSICOLOGIA COLO; SCImago Journal and Country Rank, 2015, COUNTR SEARCH W EUR; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P325, DOI 10.1080/13854040600760488; Sweet JJ, 2011, CLIN NEUROPSYCHOL, V25, P12, DOI 10.1080/13854046.2010.544165; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P109, DOI 10.1076/clin.16.2.109.13237; Trincado-Alonso F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/904985; Wilson B.A., 2004, CLIN NEUROPSYCHOLOGY, P345; Wykes T, 2015, LANCET PSYCHIAT, V2, P1036, DOI 10.1016/S2215-0366(15)00332-6	43	23	24	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2016	30	8					1335	1355		10.1080/13854046.2016.1183049			21	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EA8NR	WOS:000386893100014	27684408				2021-06-18	
J	Raithatha, R; Carrico, C; Powell, ES; Westgate, PM; Chelette, KC; Lee, K; Dunsmore, L; Salles, S; Sawaki, L				Raithatha, Ravi; Carrico, Cheryl; Powell, Elizabeth Salmon; Westgate, Philip M.; Chelette, Kenneth C., II; Lee, Kara; Dunsmore, Laura; Salles, Sara; Sawaki, Lumy			Non-invasive brain stimulation and robot-assisted gait training after incomplete spinal cord injury: A randomized pilot study	NEUROREHABILITATION			English	Article						Lower extremity; motor function; neuroplasticity; treadmill training; transcranial direct current stimulation	MOTOR FUNCTION; CHRONIC STROKE; CORTICAL EXCITABILITY; MUSCLE STRENGTH; TRAUMATIC BRAIN; DC STIMULATION; REHABILITATION; RELIABILITY; VALIDITY; PLASTICITY	BACKGROUND: Locomotor training with a robot-assisted gait orthosis (LT-RGO) and transcranial direct current stimulation (tDCS) are interventions that can significantly enhance motor performance after spinal cord injury (SCI). No studies have investigated whether combining these interventions enhances lower extremity motor function following SCI. OBJECTIVE: Determine whether active tDCS paired with LT-RGO improves lower extremity motor function more than a sham condition, in subjects with motor incomplete SCI. METHODS: Fifteen adults with SCI received 36 sessions of either active (n = 9) or sham (n = 6) tDCS (20 minutes) preceding LT-RGO (1 hour). Outcome measures included manual muscle testing (MMT; primary outcome measure); 6-Minute Walk Test (6MinWT); 10-Meter Walk Test (10MWT); Timed Up and Go Test (TUG); Berg Balance Scale (BBS); and Spinal Cord Independence Measure-III (SCIM-III). RESULTS: MMT showed significant improvements after active tDCS, with the most pronounced improvement in the right lower extremity. 10MWT, 6MinWT, and BBS showed improvement for both groups. TUG and SCIM-III showed improvement only for the sham tDCS group. CONCLUSION: Pairing tDCS with LT-RGO can improve lower extremity motor function more than LT-RGO alone. Future research with a larger sample size is recommended to determine longer-term effects on motor function and activities of daily living.	[Raithatha, Ravi] Univ Pikeville, Kentucky Coll Osteopath Med, Pikeville, KY USA; [Carrico, Cheryl; Powell, Elizabeth Salmon; Chelette, Kenneth C., II; Salles, Sara; Sawaki, Lumy] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY 40504 USA; [Westgate, Philip M.] Univ Kentucky, Dept Biostat, Coll Publ Hlth, Lexington, KY 40504 USA; [Lee, Kara] Univ Kentucky, Coll Hlth Sci, Lexington, KY 40504 USA; [Dunsmore, Laura; Sawaki, Lumy] HealthSouth Cardinal Hill Rehabil Hosp, Lexington, KY USA	Sawaki, L (corresponding author), Univ Kentucky, Dept Phys Med & Rehabil, HealthSouth Cardinal Hill Hosp, 2050 Versailles Rd, Lexington, KY 40504 USA.	lsawa2@uky.edu			Christopher and Dana Reeve Foundation [SAC1-1001-2]; Cardinal Hill Stroke and Spinal Cord Endowment [1215375670]	This study was funded by Christopher and Dana Reeve Foundation (SAC1-1001-2) and the Cardinal Hill Stroke and Spinal Cord Endowment (1215375670). There are no financial benefits to the authors. Partial results of this study were first presented in poster form at Reeve Foundation's fourth Spinal Cord Symposium: August 2010; Phoenix, AZ. There are no conflicts of interest related to this research or this manuscript.	[Anonymous], 2014, J Spinal Cord Med, V37, P117, DOI 10.1179/1079026813Z.000000000249; Behrman AL, 2006, PHYS THER, V86, P1406, DOI 10.2522/ptj.20050212; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Cabral ME, 2015, NEUROREPORT, V26, P618, DOI 10.1097/WNR.0000000000000397; Carda S, 2012, NEUROREHAB NEURAL RE, V26, P1027, DOI 10.1177/1545968312446753; Chang MC, 2015, BRAIN STIMUL, V8, P561, DOI 10.1016/j.brs.2015.01.411; Chen G, 2006, J REHABIL RES DEV, V43, P485, DOI 10.1682/JRRD.2005.04.0063; Grecco LAC, 2014, RES DEV DISABIL, V35, P2840, DOI 10.1016/j.ridd.2014.07.030; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; Cuthbert Scott C, 2007, Chiropr Osteopat, V15, P4, DOI 10.1186/1746-1340-15-4; Danzl MM, 2013, NEUROREHABILITATION, V33, P67, DOI 10.3233/NRE-130929; Dietz V, 2009, BRAIN RES BULL, V78, pI, DOI 10.1016/S0361-9230(08)00410-3; Dietz V, 2012, EXP NEUROL, V235, P110, DOI 10.1016/j.expneurol.2011.04.007; Dobkin BH, 2009, CURR OPIN NEUROL, V22, P563, DOI 10.1097/WCO.0b013e3283314b11; Downs S, 2013, J PHYSIOTHER, V59, P93, DOI 10.1016/S1836-9553(13)70161-9; Edwards DJ, 2009, RESTOR NEUROL NEUROS, V27, P199, DOI 10.3233/RNN-2009-0470; Fan E, 2010, INTENS CARE MED, V36, P1038, DOI 10.1007/s00134-010-1796-6; Field-Fote EC, 2011, PHYS THER, V91, P62, DOI 10.2522/ptj.20090359.ar; Fregni F, 2007, NAT CLIN PRACT NEURO, V3, P383, DOI 10.1038/ncpneuro0530; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Geroin C, 2011, CLIN REHABIL, V25, P537, DOI 10.1177/0269215510389497; Giacobbe V, 2013, NEUROREHABILITATION, V33, P49, DOI 10.3233/NRE-130927; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1508, DOI 10.1016/j.apmr.2011.01.024; Hesse S, 2007, RESTOR NEUROL NEUROS, V25, P9; Hesse S, 2003, CURR OPIN NEUROL, V16, P705, DOI 10.1097/00019052-200312000-00010; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hornby TG, 2010, PM&R, V2, P214, DOI 10.1016/j.pmrj.2010.02.013; Hummel F, 2005, NEUROREHAB NEURAL RE, V19, P14, DOI 10.1177/1545968304272698; Itzkovich M, 2007, DISABIL REHABIL, V29, P1926, DOI 10.1080/09638280601046302; Jackson AB, 2008, J SPINAL CORD MED, V31, P487, DOI 10.1080/10790268.2008.11753644; Jeffery DT, 2007, EXP BRAIN RES, V182, P281, DOI 10.1007/s00221-007-1093-y; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Kaski D, 2014, CLIN REHABIL, V28, P1115, DOI 10.1177/0269215514534277; Knikou M, 2010, CLIN NEUROPHYSIOL, V121, P1655, DOI 10.1016/j.clinph.2010.01.039; Koenig AC, 2009, IEEE ENG MED BIO, P1758, DOI 10.1109/IEMBS.2009.5333096; Koganemaru S, 2015, NEUROSCI RES, V92, P29, DOI 10.1016/j.neures.2014.10.004; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Krewer C, 2007, GAIT POSTURE, V26, P372, DOI 10.1016/j.gaitpost.2006.10.003; Labruyere R, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-4; Lammertse D, 2007, SPINAL CORD, V45, P232, DOI 10.1038/sj.sc.3102010; Lapitskaya N, 2011, BRAIN INJURY, V25, P1070, DOI 10.3109/02699052.2011.607782; Dumont AJL, 2015, J PHYS THER SCI, V27, P955, DOI 10.1589/jpts.27.955; Lynskey JV, 2008, J REHABIL RES DEV, V45, P229, DOI 10.1682/JRRD.2007.03.0047; Martinez M, 2009, EUR J NEUROSCI, V30, P2356, DOI 10.1111/j.1460-9568.2009.07019.x; Mehrholz Jan, 2008, Spine (Phila Pa 1976), V33, pE768, DOI 10.1097/BRS.0b013e3181849747; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; MERZENICH MM, 1982, TRENDS NEUROSCI, V5, P434, DOI 10.1016/0166-2236(82)90235-1; Neckel N, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2698; Nitsche MA, 2002, NERVENARZT, V73, P332, DOI 10.1007/s00115-002-1272-9; Nudo Randolph J, 2003, Phys Med Rehabil Clin N Am, V14, pS57, DOI 10.1016/S1047-9651(02)00054-2; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Nudo RJ, 1996, J NEUROSCI, V16, P785; Paternostro-Sluga T, 2008, J REHABIL MED, V40, P665, DOI 10.2340/16501977-0235; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Rossignol S, 2011, ANNU REV NEUROSCI, V34, P413, DOI 10.1146/annurev-neuro-061010-113746; Scivoletto G, 2011, SPINAL CORD, V49, P736, DOI 10.1038/sc.2010.180; Shin JC, 2014, ANN REHABIL MED-ARM, V38, P719, DOI 10.5535/arm.2014.38.6.719; Stephenson JL, 2010, GAIT POSTURE, V31, P109, DOI 10.1016/j.gaitpost.2009.09.008; Sullivan J, 2011, NEUROLOGY SECTION ST; Swinnen E, 2010, J REHABIL MED, V42, P520, DOI 10.2340/16501977-0538; van Hedel HJ, 2005, ARCH PHYS MED REHAB, V86, P190, DOI 10.1016/j.apmr.2004.02.010; van Hedelt HJA, 2008, NEUROL RES, V30, P61, DOI 10.1179/016164107X230775; Vaney C, 2012, NEUROREHAB NEURAL RE, V26, P212, DOI 10.1177/1545968311425923; WADSWORTH CT, 1987, PHYS THER, V67, P1342, DOI 10.1093/ptj/67.9.1342; Williams JA, 2009, J REHABIL MED, V41, P305, DOI 10.2340/16501977-0356; Wirz M, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-60	72	23	23	2	21	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2016	38	1					15	25		10.3233/NRE-151291			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DE6CC	WOS:000370719800003	26889794				2021-06-18	
J	Robinson, C; Apgar, C; Shapiro, LA				Robinson, Clark; Apgar, Christopher; Shapiro, Lee A.			Astrocyte Hypertrophy Contributes to Aberrant Neurogenesis after Traumatic Brain Injury	NEURAL PLASTICITY			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; DENTATE GRANULE CELLS; HILAR BASAL DENDRITES; POSTTRAUMATIC EPILEPSY; SEIZURE SUSCEPTIBILITY; MICROGLIAL ACTIVATION; CIRCUIT MECHANISMS; NEURONS; BORN; INFLAMMATION	Traumatic brain injury (TBI) is a widespread epidemic with severe cognitive, affective, and behavioral consequences. TBIs typically result in a relatively rapid inflammatory and neuroinflammatory response. A major component of the neuroinflammatory response is astrocytes, a type of glial cell in the brain. Astrocytes are important in maintaining the integrity of neuronal functioning, and it is possible that astrocyte hypertrophy after TBIs might contribute to pathogenesis. The hippocampus is a unique brain region, because neurogenesis persists in adults. Accumulating evidence supports the functional importance of these newborn neurons and their associated astrocytes. Alterations to either of these cell types can influence neuronal functioning. To determine if hypertrophied astrocytes might negatively influence immature neurons in the dentate gyrus, astrocyte and newborn neurons were analyzed at 30 days following a TBI in mice. The results demonstrate a loss of radial glial-like processes extending through the granule cell layer after TBI, as well as ectopic growth and migration of immature dentate neurons. The results further show newborn neurons in close association with hypertrophied astrocytes, suggesting a role for the astrocytes in aberrant neurogenesis. Future studies are needed to determine the functional significance of these alterations to the astrocyte/immature neurons after TBI.	[Robinson, Clark; Apgar, Christopher; Shapiro, Lee A.] Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX 76504 USA; [Robinson, Clark; Apgar, Christopher; Shapiro, Lee A.] Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA; [Shapiro, Lee A.] Scott & White Mem Hosp & Clin, Neurosci Res Inst, Dept Neurosurg, Temple, TX 76508 USA	Shapiro, LA (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX 76504 USA.; Shapiro, LA (corresponding author), Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA.; Shapiro, LA (corresponding author), Scott & White Mem Hosp & Clin, Neurosci Res Inst, Dept Neurosurg, Temple, TX 76508 USA.	lshapiro@medicine.tamhsc.edu			Central Texas Veterans Health Care System, Temple, TX, USA	The authors are grateful for the technical contributions of Sanjib Mukherjee, Jessica Kain, and Jaclyn Jenkins. This material is the result of work supported by the use of facilities at the Central Texas Veterans Health Care System, Temple, TX, USA.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Ashton RS, 2012, NAT NEUROSCI, V15, P1399, DOI 10.1038/nn.3212; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Boccazzi M, 2014, GLIA, V62, P428, DOI 10.1002/glia.22614; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Briellmann RS, 2002, NEUROLOGY, V58, P265, DOI 10.1212/WNL.58.2.265; Case M, 2011, EPILEPSIA, V52, P12, DOI 10.1111/j.1528-1167.2011.03225.x; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Diamond ML, 2015, EPILEPSIA, V56, P991, DOI 10.1111/epi.13100; Ehninger D, 2008, CELL TISSUE RES, V331, P243, DOI 10.1007/s00441-007-0478-3; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Foresti ML, 2011, BRAIN RES REV, V66, P115, DOI 10.1016/j.brainresrev.2010.09.002; Foresti ML, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-40; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Golarai G, 2001, J NEUROSCI, V21, P8523; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kuzumaki N, 2010, SYNAPSE, V64, P721, DOI 10.1002/syn.20800; Lagace DC, 2010, P NATL ACAD SCI USA, V107, P4436, DOI 10.1073/pnas.0910072107; Lei ZG, 2012, J NEUROTRAUM, V29, P235, DOI 10.1089/neu.2010.1537; Li Y, 2015, NEUROBIOL DIS, V74, P240, DOI 10.1016/j.nbd.2014.11.021; Liu XS, 2007, J NEUROSCI RES, V85, P2120, DOI 10.1002/jnr.21359; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Mukherjee S., 2014, J NEUROLOGICAL DISOR, V2, P1; Mukherjee S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00028; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Parent JM, 1997, J NEUROSCI, V17, P3727; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Peragine DE, 2014, NEUROSCIENCE, V268, P10, DOI 10.1016/j.neuroscience.2014.02.044; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pierce JP, 2005, EXP NEUROL, V196, P316, DOI 10.1016/j.expneurol.2005.08.007; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ribak CE, 2007, BRAIN RES REV, V55, P390, DOI 10.1016/j.brainresrev.2006.12.005; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Sanchez RM, 2012, EPILEPSIA, V53, P109, DOI 10.1111/j.1528-1167.2012.03481.x; Scharfman H., 2006, DEV NEUROSCIENCE, V29, P14; Scharfman HE, 2003, J NEUROPHYSIOL, V90, P2536, DOI 10.1152/jn.00251.2003; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Shapiro LA, 2006, EPILEPSY RES, V69, P53, DOI 10.1016/j.eplepsyres.2005.12.003; Shapiro LA, 2005, NEUROSCIENCE, V136, P823, DOI 10.1016/j.neuroscience.2005.03.059; Shapiro LA, 2005, BRAIN RES, V1040, P81, DOI 10.1016/j.brainres.2005.01.098; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; Shapiro LA, 2008, EPILEPSIA, V49, P33, DOI 10.1111/j.1528-1167.2008.01491.x; Shapiro LA, 2007, EUR J NEUROSCI, V26, P583, DOI 10.1111/j.1460-9568.2007.05662.x; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tobin RP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0143-5; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Villasana LE, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0056-15.2015; Vivar C, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00015; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; Yan YP, 2007, J CEREBR BLOOD F MET, V27, P1213, DOI 10.1038/sj.jcbfm.9600432; Yang F, 2010, J NEUROSCI RES, V88, P519, DOI 10.1002/jnr.22224; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020	72	23	24	0	3	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-5904	1687-5443		NEURAL PLAST	Neural. Plast.		2016	2016								1347987	10.1155/2016/1347987			10	Neurosciences	Neurosciences & Neurology	DM0FN	WOS:000376018600001	27274873	DOAJ Gold, Green Published			2021-06-18	
J	Vas, A; Chapman, S; Aslan, S; Spence, J; Keebler, M; Rodriguez-Larrain, G; Rodgers, B; Jantz, T; Martinez, D; Rakic, J; Krawczyk, D				Vas, Asha; Chapman, Sandra; Aslan, Sina; Spence, Jeffrey; Keebler, Molly; Rodriguez-Larrain, Gisella; Rodgers, Barry; Jantz, Tiffani; Martinez, David; Rakic, Jelena; Krawczyk, Daniel			Reasoning training in veteran and civilian traumatic brain injury with persistent mild impairment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain plasticity and repair; CBF; Cognitive training; Gist reasoning; Mild-spectrum TBI in adults; Veterans	COGNITIVE REHABILITATION; WORKING-MEMORY; SUSTAINED-ATTENTION; DEFICITS; DISABILITY; DEPRESSION; NETWORK; ADULTS	Traumatic brain injury (TBI) is a chronic health condition. The prevalence of TBI, combined with limited advances in protocols to mitigate persistent TBI-related impairments in higher order cognition, present a significant challenge. In this randomised study (n=60), we compared the benefits of Strategic Memory Advanced Reasoning Training (SMART, n=31), a strategy-based programme shown to improve cognitive control, versus an active learning programme called Brain Health Workshop (BHW, n=29) in individuals with TBI with persistent mild functional deficits. Outcomes were measured on cognitive, psychological health, functional, and imaging measures. Repeated measures analyses of immediate post-training and 3-month post-training demonstrated gains on the cognitive control domain of gist reasoning (ability to abstract big ideas/goals from complex information/tasks) in the SMART group as compared to BHW. Gains following the SMART programme were also evident on improved executive function, memory, and daily function as well as reduced symptoms associated with depression and stress. The SMART group showed an increase in bilateral precuneus cerebral blood flow (CBF). Improvements in gist reasoning in the SMART group were also associated with an increase in CBF in the left inferior frontal region, the left insula and the bilateral anterior cingulate cortex. These results add to prior findings that the SMART programme provides an efficient set of strategies that have the potential to improve cognitive control performance and associated executive functionsand daily function, to enhance psychological health, and facilitate positive neural plasticity in adults with persistent mild impairment after TBI.	[Vas, Asha; Chapman, Sandra; Aslan, Sina; Spence, Jeffrey; Keebler, Molly; Rodriguez-Larrain, Gisella; Rodgers, Barry; Jantz, Tiffani; Martinez, David; Rakic, Jelena; Krawczyk, Daniel] Univ Texas Dallas, Ctr BrainHlth, 2200 West Mockingbird Lane, Dallas, TX 75235 USA; [Aslan, Sina] Adv MRI LLC, Frisco, TX USA	Chapman, S (corresponding author), Univ Texas Dallas, Ctr BrainHlth, 2200 West Mockingbird Lane, Dallas, TX 75235 USA.	schapman@utdallas.edu		Rodgers, Barry/0000-0003-1673-874X	Meadows Foundation; Dee Wyly Endowed Chair fund; US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) [W81XWH-11-2-0194, W81XWH-11-2-01945]	We would like to thank Lyda Hill, the Meadows Foundation, and Dee Wyly Endowed Chair fund for their support with various aspects of the study including advocacy and recruitments efforts.; This study received funding from the US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) [Award W81XWH-11-2-0194 to DCK] and [Award W81XWH-11-2-01945 to SBC]. The funding agency has not had a direct role in the design, data collection, analysis, or interpretation of the data for this study, nor have they had a direct role in the preparation of this manuscript or the decision to submit it.	Alsop DC, 1996, J CEREBR BLOOD F MET, V16, P1236, DOI 10.1097/00004647-199611000-00019; Anand R, 2011, INT J GERIATR PSYCH, V26, P961, DOI 10.1002/gps.2633; Aslan S, 2010, MAGN RESON IMAGING, V28, P928, DOI 10.1016/j.mri.2010.03.037; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barratt W., 2005, BARRATT SIMPLIFIED M; Beck A.T., 1996, MANUAL BECK DEPRESSI; Binder D, 2008, BRAIN HLTH WORKSH; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buck PW, 2011, HEALTH SOC WORK, V36, P299, DOI 10.1093/hsw/36.4.299; Burgess PW., 1997, HAYLING SENTENCE COM; Buschkuehl M, 2014, COGN AFFECT BEHAV NE, V14, P147, DOI 10.3758/s13415-013-0244-9; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chapman S. B., TEST STRATE IN PRESS; Chapman SB, 2015, CEREB CORTEX, V25, P396, DOI 10.1093/cercor/bht234; Chapman SB, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00069; Chapman Sandra B., 2012, ADOLESCENT BRAIN LEA, P123, DOI DOI 10.1037/13493-005; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Chen JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056733; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cook LG, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00087; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; D'Esposito M, 2006, PROG BRAIN RES, V157, P123, DOI 10.1016/S0079-6123(06)57008-6; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DESPOSITO M, 2006, TXB NEURAL REPAIR RE; Detre JA, 2012, J MAGN RESON IMAGING, V35, P1026, DOI 10.1002/jmri.23581; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Ferguson R. J., 1996, SOURCEBOOK PSYCHOL T, P615; Gabrieli John D E, 2004, Cerebrum, V6, P39; Gamino JF, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00924; Gamino JF, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00188; Gazzaley A, 2005, J COGNITIVE NEUROSCI, V17, P507, DOI 10.1162/0898929053279522; Helgeson S. R., 2010, BRAIN INJURY PROFESS, V7, P18; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Krawczyk DC, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-29; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Lloyd FJ, 2009, JAMA-J AM MED ASSOC, V302, P1332, DOI 10.1001/jama.2009.1383; Marshall S, 2012, CAN FAM PHYSICIAN, V58, pE128; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rutherford GW, 2009, J HEAD TRAUMA REHAB, V24, P421, DOI 10.1097/HTR.0b013e3181c13439; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Soman S., 2014, NEUROLOGY, V82, P329; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Tops M, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00330; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Wechsler D., 2011, WECHLSER ABBREVIATED; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yan XD, 2013, NEUROSCI LETT, V547, P1, DOI 10.1016/j.neulet.2013.04.032; Zwaan RA, 1998, PSYCHOL BULL, V123, P162, DOI 10.1037/0033-2909.123.2.162	64	23	23	0	15	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2016	26	4					502	531		10.1080/09602011.2015.1044013			30	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	DL8HK	WOS:000375881600003	26018041				2021-06-18	
J	Brown, JA; Dalecki, M; Hughes, C; Macpherson, AK; Sergio, LE				Brown, Jeffrey A.; Dalecki, Marc; Hughes, Cindy; Macpherson, Alison K.; Sergio, Lauren E.			Cognitive-motor integration deficits in young adult athletes following concussion	BMC SPORTS SCIENCE MEDICINE AND REHABILITATION			English	Article						Mild traumatic brain injury; Prediction model; Movement control; Return to play protocol; Eye-hand coordination		Background: The ability to perform visually-guided motor tasks requires the transformation of visual information into programmed motor outputs. When the guiding visual information does not align spatially with the motor output, the brain processes rules to integrate the information for an appropriate motor response. Here, we look at how performance on such tasks is affected in young adult athletes with concussion history. Methods: Participants displaced a cursor from a central to peripheral targets on a vertical display by sliding their finger along a touch sensitive screen in one of two spatial planes. The addition of a memory component, along with variations in cursor feedback increased task complexity across conditions. Results: Significant main effects between participants with concussion history and healthy controls without concussion history were observed in timing and accuracy measures. Importantly, the deficits were distinctly more pronounced for participants with concussion history compared to healthy controls, especially when the brain had to control movements having two levels of decoupling between vision and action. A discriminant analysis correctly classified athletes with a history of concussion based on task performance with an accuracy of 94 %, despite the majority of these athletes being rated asymptomatic by current standards. Conclusions: These findings correspond to our previous work with adults at risk of developing dementia, and support the use of cognitive motor integration as an enhanced assessment tool for those who may have mild brain dysfunction. Such a task may provide a more sensitive metric of performance relevant to daily function than what is currently in use, to assist in return to play/work/learn decisions.	[Brown, Jeffrey A.; Dalecki, Marc; Hughes, Cindy; Macpherson, Alison K.; Sergio, Lauren E.] York Univ, Sch Kinesiol & Hlth Sci, 357 Bethune Coll,4700 Keele St, Toronto, ON M3J 1P3, Canada; [Dalecki, Marc; Sergio, Lauren E.] York Univ, Ctr Vis Res, Toronto, ON, Canada; [Hughes, Cindy; Macpherson, Alison K.; Sergio, Lauren E.] York Univ, Sport Med Team, Toronto, ON, Canada; [Sergio, Lauren E.] Southlake Reg Hlth Ctr, Newmarket, ON, Canada	Sergio, LE (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, 357 Bethune Coll,4700 Keele St, Toronto, ON M3J 1P3, Canada.	lsergio@yorku.ca	Sergio, Lauren/AAK-3274-2020	Brown, Jeffrey/0000-0002-5661-1172	Ontario Neurotrauma Foundation; Canadian Institutes of Health Research operating grantCanadian Institutes of Health Research (CIHR) [125915]; Donald Sanderson Memorial Trust	The authors gratefully acknowledge Laura Cruz, MD and Tracey Meloche, CATA for their assistance with the athletes, and the York University Lions organization. Funding provided by the Ontario Neurotrauma Foundation (JB), Canadian Institutes of Health Research operating grant # 125915 (LS, AM), and the Donald Sanderson Memorial Trust (LS, AM, CH).	Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; Gail A, 2009, J NEUROSCI, V29, P9490, DOI 10.1523/JNEUROSCI.1095-09.2009; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gorbet DJ, 2007, EUR J NEUROSCI, V25, P1228, DOI 10.1111/j.1460-9568.2007.05358.x; Gorbet DJ, 2009, BRAIN RES, V1284, P77, DOI 10.1016/j.brainres.2009.05.057; Gorbet DJ, 2004, NEUROIMAGE, V23, P1100, DOI 10.1016/j.neuroimage.2004.07.043; Granek J, 2013, PLOS ONE, V8, P1; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hawkins KM, 2015, J ALZHEIMERS DIS, V44, P867, DOI 10.3233/JAD-142079; Hawkins KM, 2014, J ALZHEIMERS DIS, V42, P607, DOI 10.3233/JAD-140051; Hawkins KM, 2013, J COGNITIVE NEUROSCI, V25, P436, DOI 10.1162/jocn_a_00318; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Locklin J, 2010, SPORTS MED, V40, P183, DOI 10.2165/11319440-000000000-00000; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Salek Y, 2011, EUR NEUROL, V66, P283, DOI 10.1159/000331049; Sayegh PF, 2014, J NEUROPHYSIOL, V111, P2210, DOI 10.1152/jn.00793.2013; Sayegh PF, 2013, J NEUROPHYSIOL, V110, P952, DOI 10.1152/jn.00764.2012; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Tippett WJ, 2007, EUR NEUROL, V58, P1, DOI 10.1159/000102160; Tippett WJ, 2006, BRAIN RES, V1102, P92, DOI 10.1016/j.brainres.2006.04.049; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Verweij BH, 1997, CLIN NEUROL NEUROSUR, V99, P102; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wise SP, 1996, CAN J PHYSIOL PHARM, V74, P469, DOI 10.1139/cjpp-74-4-469; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	38	23	23	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2052-1847			BMC SPORTS SCI MED R	BMC Sports Sci. Med. Rehabil.	DEC	2015	7	1							25	10.1186/s13102-015-0019-4			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V30RK	WOS:000215579500024	26491541	DOAJ Gold, Green Published			2021-06-18	
J	Gibb, SL; Zhao, YH; Potter, D; Hylin, MJ; Bruhn, R; Baimukanova, G; Zhao, J; Xue, HS; Abdel-Mohsen, M; Pillai, SK; Moore, AN; Johnson, EM; Cox, CS; Dash, PK; Pati, S				Gibb, Stuart L.; Zhao, Yuhai; Potter, Daniel; Hylin, Michael J.; Bruhn, Roberta; Baimukanova, Gyulnar; Zhao, Jing; Xue, Hasen; Abdel-Mohsen, Mohamed; Pillai, Satish K.; Moore, Anthony N.; Johnson, Evan M.; Cox, Charles S., Jr.; Dash, Pramod K.; Pati, Shibani			TIMP3 Attenuates the Loss of Neural Stem Cells, Mature Neurons and Neurocognitive Dysfunction in Traumatic Brain Injury	STEM CELLS			English	Article						Tissue inhibitor of matrix metalloproteinase-3; Mesenchymal stem cell; Neural stem cell; Traumatic brain injury; Hippocampus	HIPPOCAMPAL NEUROGENESIS; RAPAMYCIN; INHIBITION; MOTOR; DEFICITS; KINASE; TARGET; SURVEILLANCE; EXPRESSION; SURVIVAL	Mesenchymal stem cells (MSCs) have been shown to have potent therapeutic effects in a number of disorders including traumatic brain injury (TBI). However, the molecular mechanism(s) underlying these protective effects are largely unknown. Herein we demonstrate that tissue inhibitor of matrix metalloproteinase-3 (TIMP3), a soluble protein released by MSCs, is neuroprotective and enhances neuronal survival and neurite outgrowth in vitro. In vivo in a murine model of TBI, intravenous recombinant TIMP3 enhances dendritic outgrowth and abrogates loss of hippocampal neural stem cells and mature neurons. Mechanistically we demonstrate in vitro and in vivo that TIMP3-mediated neuroprotection is critically dependent on activation of the Akt-mTORC1 pathway. In support of the neuroprotective effect of TIMP3, we find that intravenous delivery of recombinant TIMP3 attenuates deficits in hippocampal-dependent neurocognition. Taken together, our data strongly suggest that TIMP3 has direct neuroprotective effects that can mitigate the deleterious effects associated with TBI, an area with few if any therapeutic options.	[Gibb, Stuart L.; Potter, Daniel; Bruhn, Roberta; Baimukanova, Gyulnar; Abdel-Mohsen, Mohamed; Pillai, Satish K.; Pati, Shibani] Blood Syst Res Inst, San Francisco, CA 94118 USA; [Gibb, Stuart L.; Potter, Daniel; Bruhn, Roberta; Baimukanova, Gyulnar; Abdel-Mohsen, Mohamed; Pillai, Satish K.; Pati, Shibani] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Zhao, Yuhai; Hylin, Michael J.; Zhao, Jing; Moore, Anthony N.; Johnson, Evan M.; Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol, Houston, TX 77030 USA; [Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX 77030 USA	Pati, S (corresponding author), Blood Syst Res Inst, 270 Mason Ave, San Francisco, CA 94118 USA.	spati@bloodsystems.org	Hylin, Michael/U-2878-2019	Bruhn, Roberta/0000-0002-5898-8168	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K18HL102256-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K18HL102256] Funding Source: NIH RePORTER	This work was made possible in part by Mission Connect; the Texas Institute for Rehabilitation and Research; the Bentsen Foundation, Houston, Texas; and National Heart, Lung, and Blood Institute K18 award (K18HL102256-01).	Ahn YJ, 2014, FOOD CHEM TOXICOL, V64, P210, DOI 10.1016/j.fct.2013.11.033; Atkins CM, 2011, TRANSL STROKE RES, V2, P546, DOI 10.1007/s12975-011-0123-z; Benarroch EE, 2013, NEUROLOGY, V81, P1079, DOI 10.1212/WNL.0b013e3182a4a577; Bohbot VD, 2000, ANN NY ACAD SCI, V911, P355; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; BREW K, 2010, MOL CELL RES, V1803, P55, DOI DOI 10.1016/J.BBAMCR.2010.01.003; Brewster AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057808; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Burke RE, 2007, PHARMACOL THERAPEUT, V114, P261, DOI 10.1016/j.pharmthera.2007.02.002; Carloni S, 2010, AUTOPHAGY, V6, P366, DOI 10.4161/auto.6.3.11261; CHEN S, 2006, J CEREB BLOOD FLOW M, V27, P939; Christensen J, 2012, EPILEPSIA, V53, P43, DOI 10.1111/j.1528-1167.2012.03612.x; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eckhouse SR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007244; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; Feng JF, 2012, J NEUROTRAUM, V29, P1167, DOI 10.1089/neu.2011.1867; Gerlai R, 2001, BEHAV BRAIN RES, V125, P269, DOI 10.1016/S0166-4328(01)00296-0; Golarai G, 2001, J NEUROSCI, V21, P8523; Guo D, 2013, PLOS ONE, V8, P1; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; Hasin T, 2011, BASIC RES CARDIOL, V106, P175, DOI 10.1007/s00395-010-0145-9; Huusko N, 2015, BRAIN STRUCT FUNCT, V220, P153, DOI 10.1007/s00429-013-0644-1; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kallio JP, 2011, INT J CANCER, V128, P991, DOI 10.1002/ijc.25404; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kjelstrup KG, 2002, P NATL ACAD SCI USA, V99, P10825, DOI 10.1073/pnas.152112399; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Leuner B, 2013, NEUROSCIENCE, V251, P108, DOI 10.1016/j.neuroscience.2012.04.021; Lin H, 2012, CANCER GENE THER, V19, P845, DOI 10.1038/cgt.2012.70; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Malkesman O, 2013, FRONT NEUROSCI, P1; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Mersmann J, 2012, RESUSCITATION, V83, P1404, DOI 10.1016/j.resuscitation.2012.04.001; Ning K, 2010, HUM MOL GENET, V19, P3159, DOI 10.1093/hmg/ddq226; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Okada K, 2011, NEUROSCI LETT, V495, P201, DOI 10.1016/j.neulet.2011.03.065; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Raman L, 2013, NEUROSCI LETT, V541, P9, DOI 10.1016/j.neulet.2013.01.045; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Urbanska M, 2012, J BIOL CHEM, V287, P30240, DOI 10.1074/jbc.M112.374405; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yassa MA, 2011, TRENDS NEUROSCI, V34, P515, DOI 10.1016/j.tins.2011.06.006; Zhang W-N, 2013, BRIT J NEUROSURG, P1; Zhang Y, 2008, GYNECOL ONCOL, V108, P234, DOI 10.1016/j.ygyno.2007.09.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhou SL, 2015, NEUROSCI LETT, V586, P43, DOI 10.1016/j.neulet.2014.12.006	64	23	23	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	DEC	2015	33	12			SI		3530	3544		10.1002/stem.2189			15	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	CW5PR	WOS:000365049000018	26299440	Bronze			2021-06-18	
J	Dash, PK; Hylin, MJ; Hood, KN; Orsi, SA; Zhao, J; Redell, JB; Tsvetkov, AS; Moore, AN				Dash, Pramod K.; Hylin, Michael J.; Hood, Kimberly N.; Orsi, Sara A.; Zhao, Jing; Redell, John B.; Tsvetkov, Andrey S.; Moore, Anthony N.			Inhibition of Eukaryotic Initiation Factor 2 Alpha Phosphatase Reduces Tissue Damage and Improves Learning and Memory after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CHOP; ER stress; hippocampus; phosphatase; TBI	UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; CONTROLLED CORTICAL IMPACT; AMYOTROPHIC-LATERAL-SCLEROSIS; WATER MAZE PERFORMANCE; ER STRESS; COGNITIVE DEFICITS; TRANSCRIPTION FACTOR; HEMORRHAGIC-SHOCK; NEURONAL INJURY	Patients who survive traumatic brain injury (TBI) are often faced with persistent memory deficits. The hippocampus, a structure critical for learning and memory, is vulnerable to TBI and its dysfunction has been linked to memory impairments. Protein kinase RNA-like ER kinase regulates protein synthesis (by phosphorylation of eukaryotic initiation factor 2 alpha [eIF2]) in response to endoplasmic reticulum (ER) stressors, such as increases in calcium levels, oxidative damage, and energy/glucose depletion, all of which have been implicated in TBI pathophysiology. Exposure of cells to guanabenz has been shown to increase eIF2 phosphorylation and reduce ER stress. Using a rodent model of TBI, we present experimental results that indicate that postinjury administration of 5.0mg/kg of guanabenz reduced cortical contusion volume and decreased hippocampal cell damage. Moreover, guanabenz treatment attenuated TBI-associated motor, vestibulomotor, recognition memory, and spatial learning and memory dysfunction. Interestingly, when the initiation of treatment was delayed by 24h, or the dose reduced to 0.5mg/kg, some of these beneficial effects were still observed. Taken together, these findings further support the involvement of ER stress signaling in TBI pathophysiology and indicate that guanabenz may have translational utility.	[Dash, Pramod K.; Hood, Kimberly N.; Orsi, Sara A.; Zhao, Jing; Redell, John B.; Tsvetkov, Andrey S.; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hylin, Michael J.] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA	Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, POB 20036, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS087149]; Gillson-Longenbaugh Foundation; TIRR Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090935, R01NS087149] Funding Source: NIH RePORTER	This project was made possible by funds provided to P.K.D. by the NIH (NS087149), the Gillson-Longenbaugh Foundation, and the TIRR Foundation.	Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chakrabarti A, 2011, BIOTECHNOL BIOENG, V108, P2777, DOI 10.1002/bit.23282; Chaudhari N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00213; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Colla E, 2012, J NEUROSCI, V32, P3301, DOI 10.1523/JNEUROSCI.5368-11.2012; DASH PK, 1995, J NEUROSCI, V15, P2030; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; HOLMES B, 1983, DRUGS, V26, P212, DOI 10.2165/00003495-198326030-00003; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jiang HQ, 2014, NEUROSCIENCE, V277, P132, DOI 10.1016/j.neuroscience.2014.03.047; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Lin JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004170; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; McAllister TW, 2011, INT J PSYCHOPHYSIOL, V82, P107, DOI 10.1016/j.ijpsycho.2011.06.022; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Mei Y., 2013, J PHARM BIOMED ANAL, V1; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; Olivari S, 2005, J BIOL CHEM, V280, P2424, DOI 10.1074/jbc.C400534200; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046; Pouzet B, 1999, EUR J NEUROSCI, V11, P123, DOI 10.1046/j.1460-9568.1999.00413.x; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Ron D, 2008, CELL, V132, P24, DOI 10.1016/j.cell.2007.12.017; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Smith CJ, 2012, JOVE-J VIS EXP, DOI 10.3791/4411; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Teske BF, 2011, MOL BIOL CELL, V22, P4390, DOI 10.1091/mbc.E11-06-0510; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tribouillard-Tanvier D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001981; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Tsvetkov AS, 2013, NAT CHEM BIOL, V9, P586, DOI [10.1038/NCHEMBIO.1308, 10.1038/nchembio.1308]; Van Der Vlies D, 2003, ANTIOXID REDOX SIGN, V5, P381, DOI 10.1089/152308603768295113; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang LJ, 2014, NEUROBIOL DIS, V71, P317, DOI 10.1016/j.nbd.2014.08.010; Wang Y, 2000, J BIOL CHEM, V275, P27013; Whishaw IQ, 1997, HIPPOCAMPUS, V7, P361, DOI 10.1002/(SICI)1098-1063(1997)7:4<361::AID-HIPO2>3.0.CO;2-M; Wilson DI, 2013, HIPPOCAMPUS, V23, P352, DOI 10.1002/hipo.22095; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	72	23	24	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2015	32	20					1608	1620		10.1089/neu.2014.3772			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CS6VH	WOS:000362220500009	25843479	Green Published			2021-06-18	
J	Ojo, JO; Bachmeier, C; Mouzon, BC; Tzekov, R; Mullan, M; Davies, H; Stewart, MG; Crawford, F				Ojo, Joseph O.; Bachmeier, Corbin; Mouzon, Benoit C.; Tzekov, Radouil; Mullan, Michael; Davies, Heather; Stewart, Michael G.; Crawford, Fiona			Ultrastructural Changes in the White and Gray Matter of Mice at Chronic Time Points After Repeated Concussive Head Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal injury; Concussion; Electron microscopy; Microvasculature; Neuroglial activation; Repetitive TBI; Synapses	TRAUMATIC BRAIN-INJURY; MOUSE MODEL; PATHOLOGICAL ALTERATIONS; CEREBRAL VASCULATURE; COGNITIVE DEFICITS; GLIAL ACTIVATION; AXONAL INJURY; ENCEPHALOPATHY; NEUROPATHOLOGY; DEGENERATION	Mild traumatic brain injury is a risk factor for neurodegenerative disease. We recently developed a model of repetitive concussive injury in mice that we have extensively characterized from 24 hours to 24 months after injury. Animals show evidence of progressive spatial memory deficits, thinning of the corpus callosum, axonal injury, and neuroglial activation. Here, we extended our neuropathologic characterization to the ultrastructural level in both a qualitative and a quantitative study. We focused on chronic (3 and 6 months) postinjury time points when the earliest stages of degenerative secondary changes were previously observed. In both C57BL/6 and hTau mice, we found white matter damage typified by axonal degeneration, microglial phagocytosis, and increased neuroglial cell density. In the cerebral cortex, we observed evidence of synaptic degeneration, dark neurons, altered dendritic microfilaments, subtle changes to the microvasculature, a mild augmentation of age-related features such as lipofuscin deposition, and electron-dense inclusions in microglial and perivascular cells. The majority of these ultrastructural features seemed to be more prominent at 3 versus 6 months after injury. Similar patterns were observed in C57BL/6 and hTau mice. These findings further support the relevance of our concussive injury model to the consequences of repetitive mild traumatic brain injury in humans.	[Ojo, Joseph O.; Bachmeier, Corbin; Mouzon, Benoit C.; Tzekov, Radouil; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Dept Neuropathol, Sarasota, FL 34234 USA; [Davies, Heather; Stewart, Michael G.] Open Univ, Dept Life Sci, London, England; [Mouzon, Benoit C.; Tzekov, Radouil; Crawford, Fiona] James A Haley Hosp, Tampa, FL USA	Ojo, JO (corresponding author), Roskamp Inst, Dept Neuropathol, Sarasota, FL 34234 USA.	bojo@roskampinstitute.net		Tzekov, Radouil/0000-0002-3662-9818	Department of DefenseUnited States Department of Defense [W81XWH-13-1-0759]; Roskamp Foundation; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/I020330/1, BB/J021687/1] Funding Source: researchfish	This work was supported by Department of Defense award W81XWH-13-1-0759 (Fiona Crawford) and by the Roskamp Foundation.	ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Bouras C, 1997, EUR NEUROL, V38, P53, DOI 10.1159/000112903; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Castejon OJ, 1997, BRAIN INJURY, V11, P363, DOI 10.1080/026990597123520; CASTEJON OJ, 1985, J SUBMICR CYTOL PATH, V17, P703; Castejon OJ, 2013, ULTRASTRUCT PATHOL, V37, P417, DOI 10.3109/01913123.2013.831157; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Liu J, 2012, NAT NEUROSCI, V15, P1621, DOI 10.1038/nn.3263; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ojo Bunmi, 2013, Neurosci J, V2013, P839535, DOI 10.1155/2013/839535; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Peters A, 1991, FINE STRUCTURE NERVO; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Popov VI, 2008, EUR J NEUROSCI, V27, P301, DOI 10.1111/j.1460-9568.2007.06004.x; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Sandell JH, 2003, J COMP NEUROL, V466, P14, DOI 10.1002/cne.10859; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	61	23	23	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	OCT	2015	74	10					1012	1035		10.1097/NEN.0000000000000247			24	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DC2VQ	WOS:000369076600007	26360375	Bronze			2021-06-18	
J	Sekhon, MS; Griesdale, DE; Czosnyka, M; Donnelly, J; Liu, X; Aries, MJ; Robba, C; Lavinio, A; Menon, DK; Smielewski, P; Gupta, AK				Sekhon, Mypinder S.; Griesdale, Donald E.; Czosnyka, Marek; Donnelly, Joseph; Liu, Xia; Aries, Marcel J.; Robba, Chiara; Lavinio, Andrea; Menon, David K.; Smielewski, Peter; Gupta, Arun K.			The Effect of Red Blood Cell Transfusion on Cerebral Autoregulation in Patients with Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Vascular reactivity; Cerebral blood flow; Autoregulation; Traumatic brain injury; Pressure reactivity index	PERFUSION-PRESSURE; CEREBROVASCULAR AUTOREGULATION; CRITICALLY-ILL; ANEMIA; OXYGENATION; MORTALITY; ASSOCIATION; METABOLISM; TRIAL; AGE	Red blood cell (RBC) transfusion is associated with inconsistent changes in brain tissue oxygenation (PbO2). Previous studies have failed to consider alterations in cerebral autoregulation. Our objective was to investigate the effect of RBC transfusion on cerebral autoregulation, as measured by pressure reactivity index (PRx). Retrospective analysis of 28 severe traumatic brain injury (TBI) patients from a prospective registry between 2007 and 2014. We recorded hemoglobin (Hb) concentration, intracranial pressure, PbO2, cerebral perfusion pressure, PRx, and cerebral lactate/pyruvate ratio for 6 h before and after RBC transfusion. We also recorded body temperature, PaO2, PCO2, pH, and fraction of inspired oxygen. Subgroups of normoxia (PbO2 > 20 mmHg) and hypoxia (PbO2 < 20 mmHg) prior to transfusion were defined a priori. The median age was 36 years [interquartile range (IQR) 27-49], 32 % were female. The median admission Glasgow Coma score was 5 (IQR 4-9) and injury severity score was 16 (IQR 9-21). Overall, mean Hb concentration [80 g/L (SD 7) to 89 g/L (SD 8), p < 0.001] and PbO2 increased [23.5 mmHg (SD 8) to 25.0 mmHg (SD 9), p = 0.033] following transfusion. PRx increased post-transfusion [0.028 (SD 0.29) to 0.11 (SD 0.24), p = 0.034], indicating worsening cerebrovascular pressure reactivity. In patients with mean PbO2 > 20 mmHg pre-transfusion (n = 20), the PRx increased significantly [-0.052 (SD 0.24) to 0.079 (SD 0.22), p = 0.007] but did not change in patients with PbO2 < 20 mmHg: PRx [0.22 (SD 0.34) to 0.18 (SD 0.30), p = 0.36]. RBC transfusion in severe TBI patients results in worsening PRx, indicating impaired cerebral autoregulation.	[Sekhon, Mypinder S.; Griesdale, Donald E.] Univ British Columbia, Vancouver Gen Hosp, Dept Med, Div Crit Care Med, Vancouver, BC V5Z 1M9, Canada; [Czosnyka, Marek; Donnelly, Joseph; Liu, Xia; Aries, Marcel J.; Robba, Chiara; Lavinio, Andrea; Menon, David K.; Smielewski, Peter; Gupta, Arun K.] Univ Cambridge, Cambridge Univ Hosp Trust, Addenbrookes Hosp, Neurocrit Care Unit, Cambridge CB2 0QQ, England; [Sekhon, Mypinder S.] Vancouver Gen Hosp, Crit Care Med, Vancouver, BC V5Z 1M9, Canada	Sekhon, MS (corresponding author), Univ British Columbia, Vancouver Gen Hosp, Dept Med, Div Crit Care Med, West 12th Ave, Vancouver, BC V5Z 1M9, Canada.	mypindersekhon@gmail.com	Donnelly, Joseph/E-9235-2018; Lavinio, Andrea/M-1778-2016; Donnelly, Joseph/N-6803-2019; Robba, Chiara/AAS-7421-2020	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Smielewski, Peter/0000-0001-5096-3938; czosnyka, marek/0000-0003-2446-8006; Griesdale, Donald/0000-0001-5985-8624	Cambridge Enterprise Ltd, UK; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	Mypinder S. Sekhon, Donald E. Griesdale, Joseph Donnelly, Xia Liu, Marcel J. Aries, Chiara Robba, Andrea Lavinio, David K. Menon, Peter Smielewski, Arun K. Gupta have no conflict of interest. Marek Czosnyka and Peter Smielewski are co-founders of the ICM+ software (www.neurosurg.cam.ac.uk/icmplus) and receives licensing fees (Cambridge Enterprise Ltd, UK).	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Bisschops LLA, 2014, CRIT CARE MED, V42, P632, DOI 10.1097/CCM.0000000000000027; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Czosnyka M, 2007, NEUROL RES, V29, P672, DOI 10.1179/016164107X240053; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kramer AH, 2009, CRIT CARE, V13, DOI 10.1186/cc7916; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; LeRoux P, 2013, CURR OPIN CRIT CARE, V19, P83, DOI 10.1097/MCC.0b013e32835eba43; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Neuman R, 2015, TRANSFUSION, V55, P782, DOI 10.1111/trf.12919; Oddo M, 2012, INTENS CARE MED, V38, P1497, DOI 10.1007/s00134-012-2593-1; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Sekhon MS, 2014, NEUROCRIT CARE, V21, P245, DOI 10.1007/s12028-014-0003-y; Sekhon MS, 2012, CRIT CARE, V16, DOI 10.1186/cc11431; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Sriram K, 2012, AM J PHYSIOL-HEART C, V303, pH1096, DOI 10.1152/ajpheart.00438.2012; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Weinberg JA, 2011, TRANSFUSION, V51, P867, DOI 10.1111/j.1537-2995.2011.03098.x; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	33	23	25	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2015	23	2					210	216		10.1007/s12028-015-0141-x			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CQ6FU	WOS:000360700700010	25894454				2021-06-18	
J	Villapol, S; Kryndushkin, D; Balarezo, MG; Campbell, AM; Saavedra, JM; Shewmaker, FP; Symes, AJ				Villapol, Sonia; Kryndushkin, Dmitry; Balarezo, Maria G.; Campbell, Ashley M.; Saavedra, Juan M.; Shewmaker, Frank P.; Symes, Aviva J.			Hepatic Expression of Serum Amyloid A1 Is Induced by Traumatic Brain Injury and Modulated by Telmisartan	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ACUTE-PHASE RESPONSE; NF-KAPPA-B; PROTEIN-COUPLED RECEPTOR; RENIN-ANGIOTENSIN SYSTEM; GENE-EXPRESSION; LIVER-INJURY; TRANSCRIPTIONAL REGULATION; HUMAN NEUTROPHILS; OXIDATIVE STRESS; GAMMA ACTIVATION	Traumatic brain injury affects the whole body in addition to the direct impact on the brain. The systemic response to trauma is associated with the hepatic acute-phase response. To further characterize this response, we performed controlled cortical impact injury on male mice and determined the expression of serum amyloid A1 (SAA1), an apolipoprotein, induced at the early stages of the acute-phase response in liver and plasma. After cortical impact injury, induction of SAA1 was detectable in plasma at 6 hours post-injury and in liver at 1 day post-injury, followed by gradual diminution over time. In the liver, cortical impact injury increased neutrophil and macrophage infiltration, apoptosis, and expression of mRNA encoding the chemokines CXCL1 and CXCL10. An increase in angiotensin II AT1 receptor mRNA at 3 days post-injury was also observed. Administration of the AT1 receptor antagonist telmisartan 1 hour post-injury significantly decreased Liver SAA1 levels and CXCL10 mRNA expression, but did not affect CXCL1 expression or the number of apoptotic cells or infiltrating leukocytes. To our knowledge, this is the first study to demonstrate that SAA1 is induced in the liver after traumatic brain injury and that telmisartan prevents this response. Elucidating the molecular pathogenesis of the Liver after brain injury will assist in understanding the efficacy of therapeutic approaches to brain injury.	[Villapol, Sonia; Balarezo, Maria G.; Campbell, Ashley M.; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Villapol, Sonia; Kryndushkin, Dmitry; Balarezo, Maria G.; Campbell, Ashley M.; Shewmaker, Frank P.; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Villapol, Sonia] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; [Saavedra, Juan M.] Georgetown Univ, Med Ctr, Dept Pharmacol & Physiol, Washington, DC 20057 USA	Villapol, S (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bldg,Room WG20,3970 Reservoir Rd NW, Washington, DC 20057 USA.	sonia.villapol@georgetown.edu; aviva.symes@usuhs.edu	Villapol, Sonia/D-1949-2014; Saavedra, Juan/AAO-7149-2020; Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Villapol, Sonia/0000-0002-6174-4113	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; National Institute of Mental Health/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 002762-16]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH002762] Funding Source: NIH RePORTER	Supported by Center for Neuroscience and Regenerative Medicine grants (A.J.S.), a postdoctoral fellowship (S.V.) and the Intramural Research Program at the National Institute of Mental Health/NIH (MH 002762-16; J.M.S.).	Anthony DC, 2012, BRAIN BEHAV IMMUN, V26, P534, DOI 10.1016/j.bbi.2011.10.011; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; Bataller R, 2005, ANTIOXID REDOX SIGN, V7, P1346, DOI 10.1089/ars.2005.7.1346; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Bundzikova J, 2011, Endocr Regul, V45, P163; Campbell SJ, 2008, NEUROPHARMACOLOGY, V55, P780, DOI 10.1016/j.neuropharm.2008.06.074; Campbell SJ, 2008, J NEUROPATH EXP NEUR, V67, P223, DOI 10.1097/NEN.0b013e3181654957; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Cheng N, 2008, J IMMUNOL, V181, P22, DOI 10.4049/jimmunol.181.1.22; Chiba T, 2011, ARTERIOSCL THROM VAS, V31, P1326, DOI 10.1161/ATVBAHA.111.226159; Christenson K, 2008, J LEUKOCYTE BIOL, V83, P139, DOI 10.1189/jlb.0507276; Cowling RT, 2002, J BIOL CHEM, V277, P5719, DOI 10.1074/jbc.M107515200; DeLegge MH, 2008, NUTR CLIN PRACT, V23, P35, DOI 10.1177/011542650802300135; Eikelenboom P, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt118; El Bekay R, 2003, BLOOD, V102, P662, DOI 10.1182/blood-2002-09-2785; Enjoji M, 2008, INT J MOL MED, V22, P521, DOI 10.3892/ijmm_00000051; Fouad AA, 2012, TOXICOLOGY, V300, P149, DOI 10.1016/j.tox.2012.06.015; Gao WM, 2014, PEDIATR RES, V76, P280, DOI 10.1038/pr.2014.86; Gorevic PD, 2013, P NATL ACAD SCI USA, V110, P16291, DOI 10.1073/pnas.1315112110; Hatanaka E, 2003, FEMS IMMUNOL MED MIC, V38, P81, DOI 10.1016/S0928-8244(03)00112-3; He R, 2003, BLOOD, V101, P1572, DOI 10.1182/blood-2002-05-1431; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Home PD, 2008, DIABETES OBES METAB, V10, P699, DOI 10.1111/j.1463-1326.2007.00761.x; Huet O, 2014, CLIN SCI, V126, P31, DOI 10.1042/CS20120668; Jaeschke H, 2006, LIVER INT, V26, P912, DOI 10.1111/j.1478-3231.2006.01327.x; Jensen LE, 1998, BIOCHEM J, V334, P489, DOI 10.1042/bj3340489; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kryndushkin D, 2013, PRION, V7, P464, DOI 10.4161/pri.27503; Kryndushkin D, 2013, J BIOL CHEM, V288, P27100, DOI 10.1074/jbc.M113.485359; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Li HZ, 2013, ATHEROSCLEROSIS, V227, P72, DOI 10.1016/j.atherosclerosis.2012.12.007; LIAO F, 1994, ARTERIOSCLER THROMB, V14, P1475, DOI 10.1161/01.ATV.14.9.1475; Lindhorst E, 1997, BBA-PROTEIN STRUCT M, V1339, P143, DOI 10.1016/S0167-4838(96)00227-0; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; Lubel JS, 2008, J GASTROEN HEPATOL, V23, P1327, DOI 10.1111/j.1440-1746.2008.05461.x; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; Mitra AK, 2010, AM J PHYSIOL-CELL PH, V299, pC561, DOI 10.1152/ajpcell.00127.2010; MOZES G, 1989, J TRAUMA, V29, P71, DOI 10.1097/00005373-198901000-00014; National Research Council (US), 2011, COMM UPD GUID CAR US; Niemi K, 2011, J IMMUNOL, V186, P6119, DOI 10.4049/jimmunol.1002843; O'Brien Kevin D, 2006, Curr Atheroscler Rep, V8, P62, DOI 10.1007/s11883-006-0066-0; Obici L, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13580; Okamoto H, 2008, J RHEUMATOL, V35, P752; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; Rodriguez-Perez AI, 2015, GLIA, V63, P466, DOI 10.1002/glia.22765; RON D, 1990, MOL CELL ENDOCRINOL, V74, pC97, DOI 10.1016/0303-7207(90)90221-S; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; Sandri S, 2008, J LEUKOCYTE BIOL, V83, P1174, DOI 10.1189/jlb.0407203; SELINGER MJ, 1980, NATURE, V285, P498, DOI 10.1038/285498a0; SHIMIZU H, 1994, GENE, V149, P305; Simons JP, 2013, P NATL ACAD SCI USA, V110, P16115, DOI 10.1073/pnas.1306621110; Steckelings UM, 2009, FUND CLIN PHARMACOL, V23, P693, DOI 10.1111/j.1472-8206.2009.00780.x; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6; Tobin RP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0143-5; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Vallon R, 2001, J IMMUNOL, V166, P2801, DOI 10.4049/jimmunol.166.4.2801; Villapol S, 2015, BRAIN IN PRESS, DOI [10.1093/brain/awv172, DOI 10.1093/BRAIN/AWV172]; Villapol S, 2015, AM J HYPERTENS, V28, P289, DOI 10.1093/ajh/hpu197; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Villapol S, 2009, AM J PATHOL, V175, P2111, DOI 10.2353/ajpath.2009.090257; Wang J, 2014, NEUROPHARMACOLOGY, V79, P249, DOI 10.1016/j.neuropharm.2013.11.022; Weber DJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009443; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; XU LL, 1995, J IMMUNOL, V155, P1184; Yokote H, 2013, J NEUROIMMUNOL, V259, P92, DOI 10.1016/j.jneuroim.2013.03.004; Yoneda M, 2001, J GASTROENTEROL, V36, P361, DOI 10.1007/s005350170079; Yu Y, 2014, J ALZHEIMERS DIS, V38, P133, DOI 10.3233/JAD-130818; Zhang LP, 2009, J AM SOC NEPHROL, V20, P604, DOI 10.1681/ASN.2008060628	77	23	24	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2015	185	10					2641	2652		10.1016/j.ajpath.2015.06.016			12	Pathology	Pathology	CT3HR	WOS:000362698300006	26435412	Green Published			2021-06-18	
J	Cox, A; Varma, A; Barry, J; Vertegel, A; Banik, N				Cox, April; Varma, Abhay; Barry, John; Vertegel, Alexey; Banik, Naren			Nanoparticle Estrogen in Rat Spinal Cord Injury Elicits Rapid Anti-Inflammatory Effects in Plasma, Cerebrospinal Fluid, and Tissue	JOURNAL OF NEUROTRAUMA			English	Article						spinal cord injury; MCP-1; IL-6; GRO-KC; S100 beta; nanoparticle; estrogen; CSF	TRAUMATIC BRAIN-INJURY; INFLAMMATORY CYTOKINES; CLINICAL-TRIALS; POSTMENOPAUSAL WOMEN; FUNCTIONAL RECOVERY; LOCOMOTOR FUNCTION; SEX STEROIDS; CELL-DEATH; 17-BETA-ESTRADIOL; NEUROPROTECTION	Persons with spinal cord injury (SCI) are in need of effective therapeutics. Estrogen (E2), as a steroid hormone, is a highly pleiotropic agent; with anti-inflammatory, anti-apoptotic, and neurotrophic properties, it is ideal for use in treatment of patients with SCI. Safety concerns around the use of high doses of E2 have limited clinical application, however. To address these concerns, low doses of E2 (25 mu g and 2.5 mu g) were focally delivered to the injured spinal cord using nanoparticles. A per-acute model (6 h after injury) was used to assess nanoparticle release of E2 into damaged spinal cord tissue; in addition, E2 was evaluated as a rapid anti-inflammatory. To assess inflammation, 27-plex cytokine/chemokine arrays were conducted in plasma, cerebrospinal fluid (CSF), and spinal cord tissue. A particular focus was placed on IL-6, GRO-KC, and MCP-1 as these have been identified from CSF in human studies as potential biomarkers in SCI. S100 beta, an additional proposed biomarker, was also assessed in spinal cord tissue only. Tissue concentrations of E2 were double those found in the plasma, indicating focal release. E2 showed rapid anti-inflammatory effects, significantly reducing interleukin (IL)-6, GRO-KC, MCP-1, and S100 beta in one or all compartments. Numerous additional targets of rapid E2 modulation were identified including: leptin, MIP-1 alpha, IL-4, IL-2, IL-10, IFN gamma, tumor necrosis factor-alpha, etc. These data further elucidate the rapid anti-inflammatory effects E2 exerts in an acute rat SCI model, have identified additional targets of estrogen efficacy, and suggest nanoparticle delivered estrogen may provide a safe and efficacious treatment option in persons with acute SCI.	[Cox, April; Varma, Abhay; Banik, Naren] Med Univ S Carolina, Dept Neurol & Neurosurg, Charleston, SC 29425 USA; [Barry, John; Vertegel, Alexey] Clemson Univ, Dept Bioengn, Clemson, SC USA; [Banik, Naren] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Cox, A (corresponding author), Med Univ S Carolina, Dept Neurosci, 96 Jonathan Lucas St,MSC 606, Charleston, SC 29412 USA.	coxaa@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS-RO1 NS-31622, NS-45967]; Office of Research and Development, Medical Research Service, Department of Veterans Affairs, at Ralph H. Johnson VA Medical Center, Charleston, SC, the Department of Neurosurgery, MUSC [1IOBX001262]; South Carolina Spinal Cord Injury Research Fund; National Institutes of Health from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045967, R01NS031622] Funding Source: NIH RePORTER	The funding for this project was provided in part by NIH, NINDS-RO1 NS-31622 and NS-45967; also by 1IOBX001262 from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, at Ralph H. Johnson VA Medical Center, Charleston, SC, the Department of Neurosurgery, MUSC, and South Carolina Spinal Cord Injury Research Fund. This work was conducted in a facility constructed with support from the National Institutes of Health, Grant Number C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We would like to acknowledge Dr. Supriti Samantaray and Nakul Thakore for help in organizing this article.	Ardelt AA, 2012, BRAIN RES, V1461, P76, DOI 10.1016/j.brainres.2012.04.024; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Bank M, 2015, ARCH PHYS MED REHAB, V96, P633, DOI 10.1016/j.apmr.2014.10.021; Bao F, 2011, J NEUROTRAUM, V28, P1035, DOI 10.1089/neu.2010.1575; Bracken MB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001046.pub2; Breslin K, 2012, PEDIATR EMERG CARE, V28, P1238, DOI 10.1097/PEC.0b013e3182724434; Cao F, 2008, J CLIN NEUROSCI, V15, P541, DOI 10.1016/j.jocn.2007.05.014; Cox A, 2015, METAB BRAIN DIS, V30, P473, DOI 10.1007/s11011-014-9547-y; Cuzzocrea S, 2008, SHOCK, V29, P362, DOI 10.1097/shk.0b013e31814545dc; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Eifler AC, 2011, METHODS MOL BIOL, V726, P325, DOI 10.1007/978-1-61779-052-2_21; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Evsen MS, 2013, EUR REV MED PHARMACO, V17, P1869; Fehlings MG, 2005, INJURY, V36, P113, DOI 10.1016/j.injury.2005.06.022; Gatson JW, 2012, J NEUROTRAUM, V29, P2209, DOI 10.1089/neu.2011.2274; Hall ED, 2003, J REHABIL RES DEV, V40, P81, DOI 10.1682/JRRD.2003.08.0081; Perez-Alvarez MJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-157; Kachadroka S, 2010, J NEUROTRAUM, V27, P611, DOI 10.1089/neu.2009.1069; Kipp M, 2012, J NEUROENDOCRINOL, V24, P62, DOI 10.1111/j.1365-2826.2011.02163.x; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kumar S, 2010, BBA-GEN SUBJECTS, V1800, P1127, DOI 10.1016/j.bbagen.2010.04.011; Kwon BK, 2010, SPINE, V35, pS263, DOI 10.1097/BRS.0b013e3181f3286d; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Lammertse DP, 2013, SPINAL CORD, V51, P2, DOI 10.1038/sc.2012.137; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Lee JY, 2012, ENDOCRINOLOGY, V153, P3815, DOI 10.1210/en.2012-1068; Lee YL, 2000, NEUROCHEM INT, V36, P417, DOI 10.1016/S0197-0186(99)00133-3; Lidegaard O, 2002, CONTRACEPTION, V65, P187, DOI 10.1016/S0010-7824(01)00307-9; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2; Ma JJ, 2001, SCAND J PLAST RECONS, V35, P355; Maximov VD, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/26/265103; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; Mosquera L, 2014, BRAIN RES, V1561, P11, DOI 10.1016/j.brainres.2014.03.002; Neirinckx V, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0150-2; Perot P.L., 1987, J AM PARALYSIS ASS, V4, P149, DOI DOI 10.1089/cns.1987.4.149; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Ritz MF, 2008, BRAIN RES, V1203, P177, DOI 10.1016/j.brainres.2008.01.091; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Saddick SY, 2014, SAUDI J BIOL SCI, V21, P232, DOI 10.1016/j.sjbs.2014.02.004; Samantaray S, 2013, NEUROCHEM RES, V38, P1734, DOI 10.1007/s11064-013-1077-1; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Satishkumar R, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/50/505103; Schroeder GD, 2014, SPINE, V39, P971, DOI 10.1097/BRS.0000000000000297; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Spence RD, 2013, J NEUROSCI, V33, P10924, DOI 10.1523/JNEUROSCI.0886-13.2013; Sribnick EA, 2004, NEUROCHEM RES, V29, P2007, DOI 10.1007/s11064-004-6874-0; Sribnick EA, 2010, J NEUROSCI RES, V88, P1738, DOI 10.1002/jnr.22337; Sribnick EA, 2009, BRAIN RES, V1276, P159, DOI 10.1016/j.brainres.2009.04.022; Stammers AT, 2012, J NEUROSCI RES, V90, P782, DOI 10.1002/jnr.22820; Strom JO, 2008, SCAND J CLIN LAB INV, V68, P806, DOI 10.1080/00365510802254638; Taylor AR, 2014, J NEUROTRAUM, V31, P1561, DOI 10.1089/neu.2014.3405; Tsai EC, 2005, CURR PHARM DESIGN, V11, P1211, DOI 10.2174/1381612053507404; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zlotnik A, 2012, INTENS CARE MED, V38, P137, DOI 10.1007/s00134-011-2401-3	67	23	24	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 15	2015	32	18					1413	1421		10.1089/neu.2014.3730			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CQ8AR	WOS:000360828900004	25845398	Green Published			2021-06-18	
J	Honeybul, S; Ho, KM; Gillett, G				Honeybul, Stephen; Ho, Kwok Ming; Gillett, Grant			Outcome Following Decompressive Hemicraniectomy for Malignant Cerebral Infarction Ethical Considerations	STROKE			English	Article						brain; decompressive craniectomy; ethics; outcome; stroke	CRANIECTOMY; ARTERY; NEUROTRAUMA		[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6000, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok Ming] Univ Western Australia, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok Ming] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Gillett, Grant] Dunedin Publ Hosp, Div Hlth Sci, Dunedin, New Zealand; [Gillett, Grant] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Hosp Ave, Perth, WA 6000, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Back L, 2015, INTERN MED J, V45, P711, DOI 10.1111/imj.12724; Cooper P R, 1976, Surg Neurol, V5, P25; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; Dworkin R, 1993, LIFES DOMINION, P218; Frank JI, 2014, STROKE, V45, P781, DOI 10.1161/STROKEAHA.113.003200; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2011, J MED ETHICS, V37, P707, DOI 10.1136/medethics-2011-100081; Honeybul S, 2013, NEUROSURGERY, V73, P917, DOI 10.1227/NEU.0000000000000014; Honeybul S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032375; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367; Larach DR, 2009, NEUROCRIT CARE, V11, P106, DOI 10.1007/s12028-008-9180-x; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Puetz V, 2007, LANCET NEUROL, V6, P580, DOI 10.1016/S1474-4422(07)70160-6; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yang MH, 2015, SURG-J R COLL SURG E, V13, P230, DOI 10.1016/j.surge.2014.12.002	27	23	23	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	SEP	2015	46	9					2695	2698		10.1161/STROKEAHA.115.010078			4	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	CQ9FZ	WOS:000360919700060	26243228	Bronze			2021-06-18	
J	Khaksari, M; Abbasloo, E; Dehghan, F; Soltani, Z; Asadikaram, G				Khaksari, Mohammad; Abbasloo, Elham; Dehghan, Fatemeh; Soltani, Zahra; Asadikaram, Gholamreza			The brain cytokine levels are modulated by estrogen following traumatic brain injury: Which estrogen receptor serves as modulator?	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Estrogen receptors; ICI182 780; Brain cytokines; Traumatic brain injury; Edema	INFLAMMATORY RESPONSE; MEDIATED ATTENUATION; PURE ANTIESTROGEN; STEROID-HORMONES; IMMUNE-RESPONSE; EDEMA FORMATION; ANIMAL-MODELS; YOUNG-ADULT; ICI 182,780; MICROGLIA	The present study was designed to explore whether administration of estrogen affects brain cytokine levels in TBI. We also sought determine which one of type of classical estrogen receptors (ERs) is involved. Ovariectomized female rats were divided in to eight groups. Estrogen or vehicle was administered following TBI (E2 and oil groups). Antagonist of ER(ICI 182, 780) or vehicle was also administered following TBI (ICI and DMSO groups). The ICI or vehicle was administered either before induction of TBI and administration of estrogen (ICI+E2 and DMSO+E2 groups). TBI was induced by Marmarou's method. In addition to brain water content, the levels of brain proinflammatory and anti-inflammatory cytokines were measured 24 hours post-TBI. Present results demonstrated that, estrogen reduced TBI- induced brain edema. The antiedema effect of estrogen was attenuated by ICI. The brain measures of IL-1 beta, IL-6 and TNF-alpha in TBI were also reduced by estrogen. The anti-inflammatory effect of estrogen was attenuated by ICI. The inhibition level of estrogen by ICI was 53.2%, 12.09% and 48.45% for IL-1 beta, IL-6 and INF-alpha, respectively. Estrogen also elevated IL-10 in TBI. ICI inversely controlled the effect of estrogen on IL-10, by 33.84%. This effect was not observed once ICI was used alone. The estrogen administration following TBI probably results in proinflammatoty cytokines reduction, and inversely enhancement of anti-inflammatory cytokines. In our study, the neuroprotective effect of estrogen is proposed to be mediated by both BR alpha and ER alpha, and accordingly the inhibition of neuroprotective effect of estrogen by ICI. (C) 2015 Elsevier B.V. All rights reserved.	[Khaksari, Mohammad] Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran; [Abbasloo, Elham; Dehghan, Fatemeh] Kerman Univ Med Sci, Inst Neuropharmacol, Physiol Res Ctr, Kerman, Iran; [Soltani, Zahra] Kerman Univ Med Sci, Inst Basic & Clin Physiol Sci, Endocrinol & Metab Res Ctr, Kerman, Iran; [Asadikaram, Gholamreza] Kerman Univ Med Sci, Med Sch Afzalipour, Dept Biochem, Kerman, Iran	Khaksari, M (corresponding author), Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran.		Haddad, Mohammad Khaksari/AAB-9025-2019; Asadikaram, Gholamreza/AAG-4437-2021; Soltani, Zahra/AAC-1350-2019	Haddad, Mohammad Khaksari/0000-0003-0770-4281; Asadikaram, Gholamreza/0000-0002-9100-0756; Soltani, Zahra/0000-0002-8423-6189; Asadi karam, Gholamreza/0000-0002-6417-5200	Neuroscience research center of Kerman University of Medical Sciences	We thanked Dr. Mahmoudi of the Department of Biochemistry, Medical School of Afzalipour, Kerman University of Medical Sciences, and Kerman, Iran for providing language. The present study was financially supported by Neuroscience research center of Kerman University of Medical Sciences. We thanked the manager of this center, Prof. Shaibani.	Abdul-Muneer P., 2014, MOL NEUROBIOL, P1; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Cao L, 2007, J NEUROCHEM, V102, P408, DOI 10.1111/j.1471-4159.2007.04588.x; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Castro CC, 2014, NEUROL RES, V36, P198, DOI 10.1179/1743132813Y.0000000286; Cotran R.S., 2003, BASIC PATHOLOGY, P47; Cotroneo MS, 2005, FOOD CHEM TOXICOL, V43, P637, DOI 10.1016/j.fct.2004.12.022; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Di Liberto V, 2012, NEUROPHARMACOLOGY, V62, P1011, DOI 10.1016/j.neuropharm.2011.10.010; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; DUKES M, 1992, J ENDOCRINOL, V135, P239, DOI 10.1677/joe.0.1350239; Ferreira L.C.B., 2014, BRAIN INJURY, P1; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gonzales RJ, 2007, J CEREBR BLOOD F MET, V27, P1841, DOI 10.1038/sj.jcbfm.9600483; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Haour F., 1992, BRAIN INTERLEUKIN 1, P13; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Howell A, 2000, CANCER, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Hsu JT, 2007, J LEUKOCYTE BIOL, V82, P1019, DOI 10.1189/jlb.0607355; Hu R, 2012, CRIT CARE MED, V40, P3230, DOI 10.1097/CCM.0b013e3182657560; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Kawasaki T, 2008, MOL IMMUNOL, V45, P376, DOI 10.1016/j.molimm.2007.06.148; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kimura T, 2003, INT IMMUNOPHARMACOL, V3, P1519, DOI 10.1016/S1567-5769(03)00179-6; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Lewis DK, 2008, J NEUROIMMUNOL, V195, P47, DOI 10.1016/j.jneuroim.2008.01.006; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luchetti S, 2014, J NEUROPATH EXP NEUR, V73, P123, DOI 10.1097/NEN.0000000000000037; Miller AP, 2004, CIRCULATION, V110, P1664, DOI 10.1161/01.CIR.0000142050.19488.C7; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nebel D., 2012, FUNCTIONAL IMPORTANC; Nordell VL, 2003, NEUROBIOL AGING, V24, P733, DOI 10.1016/S0197-4580(02)00193-8; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002; Raz L, 2008, NEUROSIGNALS, V16, P140, DOI 10.1159/000111559; Rivera HM, 2010, ENDOCRINOLOGY, V151, P5680, DOI 10.1210/en.2010-0731; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Santos-Galindo M., 2011, BIOL SEX DIFFER, V2; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039-128X(98)00054-3; Suuronen T, 2005, INFLAMM RES, V54, P194, DOI 10.1007/s00011-005-1343-z; Vegeto E, 2006, ENDOCRINOLOGY, V147, P2263, DOI 10.1210/en.2005-1330; WAKELING AE, 1991, CANCER RES, V51, P3867; WAKELING AE, 1995, BIOCHEM PHARMACOL, V49, P1545, DOI 10.1016/0006-2952(94)00528-T; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xing DQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036890; Yang LS, 2006, MOL IMMUNOL, V43, P357, DOI 10.1016/j.molimm.2005.02.012; Yu HP, 2012, CHINESE J PHYSIOL, V55, P229, DOI 10.4077/CJP.2012.BAA023; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zweckberger K, 2011, NEUROSCI LETT, V499, P189, DOI 10.1016/j.neulet.2011.05.059	65	23	23	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	SEP	2015	28	1					279	287		10.1016/j.intimp.2015.05.046			9	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	CR5VW	WOS:000361413500036	26112336	Green Accepted			2021-06-18	
J	Sanchez-Vallejo, V; Benlloch-Navarro, S; Lopez-Pedrajas, R; Romero, FJ; Miranda, M				Sanchez-Vallejo, V.; Benlloch-Navarro, S.; Lopez-Pedrajas, R.; Romero, F. J.; Miranda, M.			Neuroprotective actions of progesterone in an in vivo model of retinitis pigmentosa	PHARMACOLOGICAL RESEARCH			English	Article						Progesterone; Retinitis pigmentosa; Gliosis; Glutamate; Glutathione	TRAUMATIC BRAIN-INJURY; CONE CELL-DEATH; CILIARY NEUROTROPHIC FACTOR; OXIDATIVE STRESS; RETINAL-DEGENERATION; INDUCED APOPTOSIS; GENE-EXPRESSION; MOUSE MODEL; PROTECTS; PHOTORECEPTORS	Progesterone has been shown to have neuroprotective effects in experimental acute brain injury models, but little is known about the effects of steroid sex hormones in models of retinitis pigmentosa (RP). The aim of this study was to asses whether progesterone had a protective effect in one animal model of RP (the rd1 mice), and whether its action was due at least in part, to its ability to reduce free radical damage or to increase antioxidant defences. Rd1 and wild type (wt) mice received an oral administration of 100 mg/kg body/weight of progesterone on alternate days starting at postnatal day 7 (PN7) and were sacrificed at different postnatal days. Our results show that progesterone decreases cell death, as the number of TUNEL-positive cells were decreased in the ONL of the retina from treated rd1 mice. At PN15, treatment with progesterone increased values of ERG b-wave amplitude (p < 0,5) when compared with untreated mice. Progesterone also decreased the observed gliosis in RP, though this effect was transient. Treatment with progesterone significantly reduced retinal glutamate concentrations at PN15 and PN17. To clarify the mechanism by which progesterone is able to decrease retinal glutamate concentration, we examined expression levels of glutamine synthase (GS). Our results showed a significant increase in GS in rd1 treated retinas at PN13. Treatment with progesterone, significantly increase not only GSH but also oxidized glutathione retinal concentrations, probably because progesterone is able to partially increase glutamate cysteine ligase c subunit (GCLC) at PN15 and PN17 (p < 0,05). In summary, our results demonstrate that oral administration of progesterone appears to act on multiple levels to delay photoreceptor death in this model of RP. (C) 2015 Elsevier Ltd. All rights reserved.	[Sanchez-Vallejo, V.; Benlloch-Navarro, S.; Lopez-Pedrajas, R.; Miranda, M.] Univ CEU Cardenal Herrera, Dept Ciencias Biomed, Inst Ciencias Biomed, Valencia 46113, Spain; [Romero, F. J.] Univ Catolica Valencia San Vicente Martir, Fac Med, Valencia, Spain	Miranda, M (corresponding author), Univ CEU Cardenal Herrera, Dept Ciencias Biomed, Inst Ciencias Biomed, Avda Seminario S-N, Valencia 46113, Spain.	mmiranda@uch.ceu.es	Miranda, Maria/ABG-5343-2020; Lopez-Pedrajas, Rosa/L-2734-2014; Miranda, Maria/L-3471-2014; Benlloch-Navarro, Soledad/K-8255-2014	Miranda, Maria/0000-0002-3738-367X; Lopez-Pedrajas, Rosa/0000-0003-4845-6544; Miranda, Maria/0000-0002-3738-367X; Benlloch-Navarro, Soledad/0000-0001-5748-0082	Ministerio de Ciencia e InnovacionInstituto de Salud Carlos IIISpanish GovernmentEuropean Commission [SAF 2010-21317]; Fundacion Mutua Madrilena, Proyecto de Investigacion Preconsolidado CEU-UCH [PRCEU-UCH 16/12]; Consolidacion de Indicadores CEU-UCH	This work was partially supported by grants from Ministerio de Ciencia e Innovacion (SAF 2010-21317) to FJR, and Fundacion Mutua Madrilena, Proyecto de Investigacion Preconsolidado CEU-UCH (PRCEU-UCH 16/12) and Consolidacion de Indicadores CEU-UCH 2014-2015 to MM.	Aggarwal R, 2008, J PHARM PHARMACOL, V60, P731, DOI 10.1211/jpp.60.6.0008; Arroba AI, 2014, ADV EXP MED BIOL, V801, P373, DOI 10.1007/978-1-4614-3209-8_47; Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176; Cayouette M, 1998, J NEUROSCI, V18, P9282; Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418; Corrochano S, 2008, INVEST OPHTH VIS SCI, V49, P4188, DOI 10.1167/iovs.08-2182; Crupi R, 2013, PHARMACOL RES, V70, P80, DOI 10.1016/j.phrs.2012.12.009; Dalkara D, 2014, CR BIOL, V337, P185, DOI 10.1016/j.crvi.2014.01.002; Delyfer MN, 2005, MOL VIS, V11, P688; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Doonan F, 2011, J NEUROCHEM, V118, P915, DOI 10.1111/j.1471-4159.2011.07354.x; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; Fletcher EL, 1996, J COMP NEUROL, V376, P343; Fletcher EL, 2000, MICROSC RES TECHNIQ, V50, P89, DOI 10.1002/1097-0029(20000715)50:2<89::AID-JEMT1>3.0.CO;2-9; Ghosh F, 2012, CURR EYE RES, V37, P704, DOI 10.3109/02713683.2012.663856; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; Gouix E, 2014, PHARMACOL RES, V87, P8, DOI 10.1016/j.phrs.2014.06.002; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gu LM, 2014, INVEST OPHTH VIS SCI, V55, P8208, DOI 10.1167/iovs.14-14435; Guarneri P, 2003, ANN NY ACAD SCI, V1007, P117, DOI 10.1196/annals.1286.012; Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; He YX, 2015, CURR STEM CELL RES T, V10, P258, DOI 10.2174/1574888X09666141027103552; HERRMANN H, 1945, J BIOL CHEM, V158, P33; Hoang YD, 2009, BIOL REPROD, V81, P636, DOI 10.1095/biolreprod.109.078378; Hwang JY, 2009, CELL CALCIUM, V45, P233, DOI 10.1016/j.ceca.2008.10.006; Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144; Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949; Kaldi I, 2004, EUR J OPHTHALMOL, V14, P306, DOI 10.5301/EJO.2008.1363; Kalloniatis M, 1999, PROG RETIN EYE RES, V18, P811, DOI 10.1016/S1350-9462(98)00036-6; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Kennan A, 2005, TRENDS GENET, V21, P103, DOI 10.1016/j.tig.2004.12.001; Kern TS, 2014, DIABETES METAB J, V38, P163, DOI 10.4093/dmj.2014.38.3.163; Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152; Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103; Kumar DM, 2005, FREE RADICAL BIO MED, V38, P1152, DOI 10.1016/j.freeradbiomed.2004.12.007; Lei BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103969; Li C, 2006, GLIA, V53, P392, DOI 10.1002/glia.20291; Liu M, 2010, MINERVA ENDOCRINOL, V35, P127; Liu S, 2013, NEURAL REGEN RES, V8, P2800, DOI 10.3969/j.issn.1673-5374.2013.30.002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu Na, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P2026; Mancini M, 2014, PHARMACOL RES, V87, P80, DOI 10.1016/j.phrs.2014.06.010; Martin KR, 2015, CURR OPIN OPHTHALMOL, P26; Meyer M, 2010, CELL MOL NEUROBIOL, V30, P123, DOI 10.1007/s10571-009-9437-8; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Miranda M, 2010, FREE RADICAL BIO MED, V48, P216, DOI 10.1016/j.freeradbiomed.2009.10.042; Miyamoto N, 1999, J IMMUNOL, V163, P374; Nakazawa T, 2006, BRAIN RES, V1093, P141, DOI 10.1016/j.brainres.2006.03.084; Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756-200205070-00018; Nixon E, 2012, INVEST OPHTH VIS SCI, V53, P4739, DOI 10.1167/iovs.12-9517; Ola MS, 2011, NEUROCHEM INT, V59, P656, DOI 10.1016/j.neuint.2011.06.010; OSTEEN WK, 1977, EXP EYE RES, V25, P361, DOI 10.1016/0014-4835(77)90103-8; Paquet-Durand F, 2006, J NEUROCHEM, V96, P802, DOI 10.1111/j.1471-4159.2005.03628.x; Paquet-Durand F, 2009, J NEUROCHEM, V108, P796, DOI 10.1111/j.1471-4159.2008.05822.x; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; Petersen SL, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00164; POW DV, 1995, NEUROSCI LETT, V193, P25, DOI 10.1016/0304-3940(95)11657-I; Pulido JE, 2007, EXP DIABETES RES, DOI 10.1155/2007/36150; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027; Robertson CL, 2015, J BIOENERG BIOMEMBR, V47, P43, DOI 10.1007/s10863-014-9585-5; Roesch Karin, 2012, Mol Vis, V18, P1197; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221; Sanvicens N, 2006, J NEUROCHEM, V98, P1432, DOI 10.1111/j.1471-4159.2006.03977.x; Sanz MM, 2007, NEUROSCIENCE, V145, P1120, DOI 10.1016/j.neuroscience.2006.12.034; Schutte M, 1998, NEUROSCI LETT, V246, P53, DOI 10.1016/S0304-3940(98)00229-8; Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Sotic E., 1992, NEUROSCI LETT, V142, P128; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; ULSHAFER RJ, 1990, BRAIN RES, V531, P350, DOI 10.1016/0006-8993(90)90800-Q; Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47; Verdier L, 2002, AM J PHYSIOL-ENDOC M, V282, pE215, DOI 10.1152/ajpendo.00117.2001; Wang YQ, 2015, GRAEF ARCH CLIN EXP, V253, P17, DOI 10.1007/s00417-014-2657-8; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Yang HP, 2005, MOL CELL BIOL, V25, P5933, DOI 10.1128/MCB.25.14.5933-5946.2005; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yu DY, 2000, INVEST OPHTH VIS SCI, V41, P3999	84	23	23	0	5	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	SEP	2015	99						276	288		10.1016/j.phrs.2015.06.019			13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CR8DA	WOS:000361580100030	26158501				2021-06-18	
J	Greenham, M; Hearps, S; Gomes, A; Rinehart, N; Gonzalez, L; Gordon, A; Mackay, M; Lo, W; Yeates, K; Anderson, V				Greenham, Mardee; Hearps, Stephen; Gomes, Alison; Rinehart, Nicole; Gonzalez, Linda; Gordon, Anne; Mackay, Mark; Lo, Warren; Yeates, Keith; Anderson, Vicki			Environmental Contributions to Social and Mental Health Outcomes Following Pediatric Stroke	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; PROBLEM-SOLVING INTERVENTION; ARTERIAL ISCHEMIC-STROKE; FRIENDSHIP QUALITY; CHILDHOOD; PREDICTORS; COMPETENCE; CHILDREN; RECOVERY	Mental health and social outcomes following acquired brain injury (ABI) in children are often considered to be due to brain insult, but other factors, such as environment, may also play a role. We assessed mental health and social function in children with chronic illness, with and without stroke (a form of ABI), and typically developing (TD) controls to examine environmental influences on these outcomes. We recruited 36 children diagnosed with stroke, 15 with chronic asthma, and 43 TD controls. Children and parents completed questionnaires rating child mental health and social function and distal and proximal environment. TD children had significantly less internalizing and social problems than stroke and asthma groups, and engaged in more social activities than children with stroke. Poorer parent mental health predicted more internalizing and social problems and lower social participation. Family dysfunction was associated with internalizing problems. Lower parent education contributed to children's social function. Children with chronic illness are at elevated risk of poorer mental health and social function. Addition of brain insult leads to poorer social participation. Quality of home environment contributes to children's outcomes, suggesting that supporting parent and family function provides an opportunity to optimize child mental health and social outcomes.	[Greenham, Mardee; Hearps, Stephen; Gomes, Alison; Rinehart, Nicole; Mackay, Mark; Anderson, Vicki] Murdoch Childrens Res Inst, Clin Sci, Melbourne, Vic 3052, Australia; [Greenham, Mardee; Anderson, Vicki] Univ Melbourne, Sch Psychol Sci, Melbourne, Vic, Australia; [Gomes, Alison; Gonzalez, Linda] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Rinehart, Nicole] Deakin Univ, Sch Psychol, Melbourne, Vic, Australia; [Gordon, Anne] Evelina London Childrens Hosp, Paediat Neurol, London, England; [Gordon, Anne] Kings Coll London, Inst Psychol Psychiat & Neurosci, London, England; [Mackay, Mark] Royal Childrens Hosp, Dept Neurol, Melbourne, Vic, Australia; [Mackay, Mark] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Lo, Warren; Yeates, Keith] Nationwide Childrens Hosp, Neurosci Ctr, Columbus, OH USA	Greenham, M (corresponding author), Murdoch Childrens Res Inst, 50 Flemington Rd, Parkville, Vic 3052, Australia.	mardee.greenham@mcri.edu.au	Lo, Warren/E-3531-2011; Yeates, Keith/AAJ-4223-2020; Greenham, Mardee/AAR-1711-2020; Hearps, Stephen/L-6853-2016	Yeates, Keith/0000-0001-7680-2892; Rinehart, Nicole/0000-0001-6109-3958	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Research Institute, Nationwide Children's HospitalOhio State University [231308]; Murdoch Childrens Research Institute; Victorian Governmental Operational Infrastructure Scheme	This study was supported by grants from the Australian National Health and Medical Research Council (Anderson), the Research Institute, Nationwide Children's Hospital (# 231308), Murdoch Childrens Research Institute, and Victorian Governmental Operational Infrastructure Scheme.	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson V, 2014, SOC NEUROSCI-UK, V9, P471, DOI 10.1080/17470919.2014.932308; Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bedell G, 2009, DEV NEUROREHABIL, V12, P342, DOI 10.3109/17518420903087277; BRESLAU N, 1990, ARCH GEN PSYCHIAT, V47, P15; De Schryver ELLM, 2000, DEV MED CHILD NEUROL, V42, P313, DOI 10.1017/S0012162200000554; deVeber GA, 2000, J CHILD NEUROL, V15, P316, DOI 10.1177/088307380001500508; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Evans GW, 2004, AM PSYCHOL, V59, P77, DOI 10.1037/0003-066X.59.2.77; Everts R, 2008, CHILD NEUROPSYCHOL, V14, P323, DOI 10.1080/09297040701792383; Friefeld S, 2004, CNS SPECTRUMS, V9, P465; Gaertner AE, 2010, J CHILD FAM STUD, V19, P101, DOI 10.1007/s10826-009-9289-3; Galvin J, 2010, AUST OCCUP THER J, V57, P152, DOI 10.1111/j.1440-1630.2010.00853.x; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Gordon AL, 2002, J CHILD NEUROL, V17, P429, DOI 10.1177/088307380201700606; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Hajek CA, 2014, J CHILD NEUROL, V29, P887, DOI 10.1177/0883073813491828; Hartel C, 2004, EUR J NEUROL, V11, P431, DOI 10.1111/j.1468-1331.2004.00861.x; Hurvitz Edward, 2004, Top Stroke Rehabil, V11, P51; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Kolb B, 2007, DEV PSYCHOBIOL, V49, P107, DOI 10.1002/dev.20199; Langley AK, 2004, J CHILD ADOL PSYCHOP, V14, P105, DOI 10.1089/104454604773840544; Leventer RJ, 1999, NEUROLOGY, V53, P715, DOI 10.1212/WNL.53.4.715; Lo W, 2014, INT J STROKE, V9, P1037, DOI 10.1111/ijs.12222; Long B, 2011, J CHILD NEUROL, V26, P279, DOI 10.1177/0883073810380049; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; McLoyd VC, 1998, AM PSYCHOL, V53, P185, DOI 10.1037/0003-066X.53.2.185; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Merrel K. W., 1998, SOCIAL SKILLS CHILDR; Nassau JH, 1997, J PEDIATR PSYCHOL, V22, P771, DOI 10.1093/jpepsy/22.6.771; Neuner B, 2011, ANN NEUROL, V70, P70, DOI 10.1002/ana.22381; O'Keeffe F, 2012, BRAIN INJURY, V26, P1072, DOI 10.3109/02699052.2012.661117; PARKER JG, 1993, DEV PSYCHOL, V29, P611, DOI 10.1037/0012-1649.29.4.611; Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI 10.1037/0033-2909.128.2.330; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Steinlin M, 2004, EUR J PEDIATR, V163, P245, DOI 10.1007/s00431-003-1357-x; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; Terrell-Deutsch B., 1999, LONELINESS CHILDHOOD, P11; Trauner D., 1996, ASSESSMENT, V3, P265, DOI DOI 10.1177/1073191196003003007; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wechsler D, 1999, WASI WECHSLER ABBREV; Woods D, 2015, SOCIAL CARE NEURODIS, V5, P70, DOI [DOI 10.1108/SCN-01-2014-0001, 10.1108/SCN-01-2014-0001]; Woods D., 2014, SOCIAL CARE NEURODIS, V5, P51, DOI [10.1108/SCN-01-2013-0002, DOI 10.1108/SCN-01-2013-0002]; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015	56	23	23	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	AUG 18	2015	40	6					348	362		10.1080/87565641.2015.1095191			15	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CU1YW	WOS:000363319300002	26491988				2021-06-18	
J	Kram, BL; Kram, SJ; Brooks, KR				Kram, Bridgette L.; Kram, Shawn J.; Brooks, Kelli R.			Implications of atypical antipsychotic prescribing in the intensive care unit	JOURNAL OF CRITICAL CARE			English	Article						Delirium; Antipsychotic agents; Care transitions	TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; TERM COGNITIVE IMPAIRMENT; CAM-ICU; CLINICAL-OUTCOMES; CRITICAL ILLNESS; RISK-FACTORS; DOUBLE-BLIND	Purpose: The purpose of the study was to determine the downstream implications of atypical antipsychotic (AAP) prescribing in the intensive care unit (ICU), including discharge prescribing practices, monitoring, and attributable adverse drug events. Materials and methods: This retrospective cohort study included patients at least 18 years of age admitted to an ICU that received at least 2 doses of an AAP for documented delirium or avoidance of a deliriogenic medication. Exclusion criteria were documentation of an AAP as a home medication or initiation for a psychiatric indication unrelated to delirium (eg, schizophrenia). Results: During the 8-month study period, 156 patients were included and 133 (85.2%) patients survived to hospital discharge. Of the survivors, AAP therapy was continued for 112 (84.2%) patients upon ICU transfer and for 38 (28.6%) patients upon hospital discharge. A majority of these patients had evidence of delirium resolution or no indication for continuation documented at discharge. Of the 127 patients with an electrocardiogram ordered during AAP therapy, QTc prolongation occurred in 49 (31.4%) patients. An adverse drug event leading to drug discontinuation was documented in 16 (10.2%) patients. Conclusions: Because of significant patient-centered implications, AAPs initiated in the ICU require continued evaluation for indication to avoid prolonged and possibly unnecessary use. (C) 2015 Elsevier Inc. All rights reserved.	[Kram, Bridgette L.; Kram, Shawn J.; Brooks, Kelli R.] Duke Univ Hosp, Durham, NC 27710 USA	Kram, BL (corresponding author), Duke Univ Hosp, DUMC Box 3089, Durham, NC 27710 USA.	Bridgette.Kram@duke.edu; Shawn.Kram@duke.edu; Kelli.Brooks@dm.duke.edu					Agawal V, 2010, J BURN CARE RES, V31, P706; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Brummel N.E., 2013, CRIT CARE MED; Brummel NE, 2013, CRIT CARE MED, V41, P2196, DOI 10.1097/CCM.0b013e31829a6f1e; Cha DS, 2012, EXPERT OPIN PHARMACO, V13, P1587, DOI 10.1517/14656566.2012.656590; Devlin JW, 2007, CRIT CARE MED, V35, P2721, DOI 10.1097/01.CCM.0000292011.93074.82; Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Girard TD, 2010, CRIT CARE MED, V38, P428, DOI 10.1097/CCM.0b013e3181c58715; Han CS, 2004, PSYCHOSOMATICS, V45, P297, DOI 10.1016/S0033-3182(04)70170-X; Huybrechts KF, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e977; Jasiak Karalea D, 2013, J Pharm Pract, V26, P253, DOI 10.1177/0897190012465987; Kim E, 2006, J NEUROPSYCH CLIN N, V18, P547, DOI 10.1176/appi.neuropsych.18.4.547; Lat I, 2009, CRIT CARE MED, V37, P1898, DOI 10.1097/CCM.0b013e31819ffe38; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; Mizoguchi Y, 2002, J NEUROPSYCH CLIN N, V14, P87, DOI 10.1176/appi.neuropsych.14.1.87-a; Modrykamien AM, 2012, RESP CARE, V57, P764, DOI 10.4187/respcare.01461; Morandi A, 2013, J AM GERIATR SOC, V61, P1128, DOI 10.1111/jgs.12329; Noe E, 2007, BEHAV NEUROL, V18, P7, DOI 10.1155/2007/529076; Olafson K, 2012, ANN PHARMACOTHER, V46, P9, DOI 10.1345/aph.1Q446; Oster TJ, 2007, CNS SPECTRUMS, V12, P764, DOI 10.1017/S1092852900015455; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Patel RP, 2009, CRIT CARE MED, V37, P825, DOI 10.1097/CCM.0b013e31819b8608; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Schreiber S, 1998, INT CLIN PSYCHOPHARM, V13, P273, DOI 10.1097/00004850-199811000-00006; Silver BV, 2003, BRAIN INJURY, V17, P237, DOI 10.1080/0269905021000013192; Skrobik YK, 2004, INTENS CARE MED, V30, P444, DOI 10.1007/s00134-003-2117-0; Swan JT, 2012, CRIT CARE, V16, DOI 10.1186/cc11342; Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729; Tomasi CD, 2012, J CRIT CARE, V27, P212, DOI 10.1016/j.jcrc.2011.05.015; van Eijk MMJ, 2010, AM J RESP CRIT CARE, V181, P419, DOI 10.1164/ajrccm.181.4.419b; van Eijk MM, 2010, AM J RESP CRIT CARE, V181; Wang PS, 2005, NEW ENGL J MED, V353, P2335, DOI 10.1056/NEJMoa052827; Wilcox ME, 2013, CRIT CARE MED, V41, pS81, DOI 10.1097/CCM.0b013e3182a16946	40	23	23	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	AUG	2015	30	4					814	818		10.1016/j.jcrc.2015.03.030			5	Critical Care Medicine	General & Internal Medicine	CK2TO	WOS:000356066100028	25887805				2021-06-18	
J	Petranovich, CL; Wade, SL; Taylor, HG; Cassedy, A; Stancin, T; Kirkwood, MW; Brown, TM				Petranovich, Christine L.; Wade, Shari L.; Taylor, H. Gerry; Cassedy, Amy; Stancin, Terry; Kirkwood, Michael W.; Brown, Tanya Maines			Long-Term Caregiver Mental Health Outcomes Following a Predominately Online Intervention for Adolescents With Complicated Mild to Severe Traumatic Brain Injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						caregiver outcomes; psychopathology; traumatic brain injury	BEHAVIOR PROBLEMS; FAMILY INTERVENTION; RANDOMIZED-TRIAL; CHILDREN; ADAPTATION; PREDICTORS; SYMPTOMS; EPILEPSY; EFFICACY; BURDEN	Objective To examine the efficacy of counselor-assisted problem solving (CAPS) in improving long-term caregiver psychological functioning following traumatic brain injury (TBI) in adolescents. Methods This randomized clinical trial compared CAPS (n = 65), a predominantly online problem-solving intervention, with an Internet resource comparison (n = 67) program. Families of adolescents with TBI completed a baseline assessment and follow-up assessments 6, 12, and 18 months later. General linear mixed models were used to examine longitudinal changes in caregiver global psychological distress, depressive symptoms, and caregiving self-efficacy. Family income and injury severity were examined as moderators of treatment efficacy. Results Family income moderated long-term changes in caregiver psychological distress. For lower-income caregivers, the CAPS intervention was associated with lower levels of psychological distress at 6, 12, and 18 months post baseline. Conclusions These findings support the utility of Web-based interventions in improving long-term caregiver psychological distress, particularly for lower-income families.	[Petranovich, Christine L.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Petranovich, Christine L.; Wade, Shari L.] Cincinnati Childrens Hosp, Div Phys Med & Rehabil, Med Ctr, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Univ Hosp Case, Med Ctr, Cleveland, OH 44106 USA; [Cassedy, Amy] Cincinnati Childrens Hosp, Div Biostat & Epidemiol, Med Ctr, Cincinnati, OH USA; [Stancin, Terry] Case Western Reserve Univ, MetroHealth Med Ctr, Cleveland, OH 44106 USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Boulder, CO 80309 USA; [Brown, Tanya Maines] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Brown, Tanya Maines] Mayo Clin & Mayo Grad Sch Med, Rochester, MN USA	Petranovich, CL (corresponding author), Univ Cincinnati, Dept Psychol, 1 Edwards Ctr,ML 0376, Cincinnati, OH 45221 USA.	karvercl@mail.uc.edu	Stancin, Terry/L-7993-2019		National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01-MH073764]; National Institute of Disability and Rehabilitation Research [H133G050239]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	This work was supported by grant R01-MH073764 from the National Institute of Mental Health, grant H133G050239 from the National Institute of Disability and Rehabilitation Research, and the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Blaha RZ, 2015, J HEAD TRAUMA REHAB, V30, pE33, DOI 10.1097/HTR.0000000000000059; Bothroyd R, 1997, PRELIMINARY MANUAL C; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Collins C. L., 2014, INJURY EPIDEMIOLOGY, V1, P1; Connell AM, 2002, PSYCHOL BULL, V128, P746, DOI 10.1037//0033-2909.128.5.746; D'Zurilla T. J., 2006, HDB COGNITIVE BEHAV, P211; Deonandan R., 2000, CHRONIC DIS CANADA, V21, P93; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Hastings RP, 2002, AM J MENT RETARD, V107, P222, DOI 10.1352/0895-8017(2002)107<0222:BPOCWA>2.0.CO;2; Hegewald J., 2003, P N E SAS US GROUP W; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Jones TL, 2005, CLIN PSYCHOL REV, V25, P341, DOI 10.1016/j.cpr.2004.12.004; Karver CL, 2014, CHILD NEUROPSYCHOL, V20, P343, DOI 10.1080/09297049.2013.796918; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Maruish M.E., 1994, USE PSYCHOL TESTING, P217; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reeves William C., 2011, Morbidity and Mortality Weekly Report, V60, P1; Stancin T, 2010, J DEV BEHAV PEDIATR, V31, P317, DOI 10.1097/DBP.0b013e3181dbaf32; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2014, REHABIL PSYCHOL, V59, P1, DOI 10.1037/a0034911; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082	40	23	23	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2015	40	7					680	688		10.1093/jpepsy/jsv001			9	Psychology, Developmental	Psychology	CP1UH	WOS:000359661200008	25682211	Green Published, Bronze			2021-06-18	
J	Aloizos, S; Evodia, E; Gourgiotis, S; Isaia, EC; Seretis, C; Baltopoulos, GJ				Aloizos, Stavros; Evodia, Efimia; Gourgiotis, Stavros; Isaia, Eleni-Christina; Seretis, Charalampos; Baltopoulos, George J.			Neuroprotective Effects of Erythropoietin in Patients with Severe Closed Brain Injury	TURKISH NEUROSURGERY			English	Article						Brain; Injury; Erythropoietin; Mortality; Outcome	RECOMBINANT-HUMAN-ERYTHROPOIETIN; NITRIC-OXIDE; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CONTROLLED-TRIAL; SPATIAL MEMORY; IN-VITRO; RATS; ISCHEMIA; CELLS	AIM: Our research was focused on the neuroprotective function of erythropoietin (Epo) in patients with severe closed traumatic brain injury (TBI). MATERIAL and METHODS: Our model examined the influence of the outcome and neurological recovery in 42 adults with TBI who were admitted to ICU within 6 hours of their injury and were recruited into a randomized controlled study of two groups; only the patients of the intervention group received 10,000 i.u. of Epo for 7 consecutive days. A prognostic model based on CRASH II injury model and outcome was measured by survival and Glasgow Outcome Scale-Extended version (GOS-E) score at 6 months post-injury. RESULTS: Six patients (18.7%) died during the first two weeks; 4 of the control group and 2 of the intervention group. A mortality rate of 22.2% and 8.3% for the control and intervention group respectively was observed. A lower rate of good outcome (GOS-E score >4) at 6 months was mentioned among patients of the control group. CONCLUSION: The study provides evidence of lower mortality and better neurological outcome for the patients who received Epo increasing the possibility that Epo therapy could be used in clinical practice, limiting neuronal damage induced by TBI.	[Aloizos, Stavros; Gourgiotis, Stavros; Isaia, Eleni-Christina; Seretis, Charalampos] 401 Gen Army Hosp Athens, ICU, Athens, Greece; [Evodia, Efimia; Baltopoulos, George J.] Univ Athens, KAT Gen Hosp, Sch Nursing ICU, Athens, Greece	Gourgiotis, S (corresponding author), 401 Gen Army Hosp Athens, ICU, Athens, Greece.	drgourgiotis@yahoo.gr	Gourgiotis, Stavros/AAD-8696-2019	Gourgiotis, Stavros/0000-0002-7923-6395			Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Banerjee D, 2000, KIDNEY INT, V57, P1895, DOI 10.1046/j.1523-1755.2000.00039.x; Bouzat P, 2011, CRIT CARE MED, V39, P2099, DOI 10.1097/CCM.0b013e31821cb7b2; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Campana WM, 1998, INT J MOL MED, V1, P235; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Casadevall N, 2003, NEPHROL DIAL TRANSPL, V18, P37, DOI 10.1093/ndt/gfg1091; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Edwards P, 2005, LANCET, V365, P1957; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Food and Drug Adminstration, SAF AL HUM MED PROD; Genc S, 2002, NEUROSCI LETT, V321, P73, DOI 10.1016/S0304-3940(02)00041-1; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2001, J Neurosurg Sci, V45, P7; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Haiden N, 2006, PEDIATRICS, V118, P180, DOI 10.1542/peds.2005-2475; Juul SE, 2004, BIOL NEONATE, V85, P138, DOI 10.1159/000074970; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Kellert BA, 2007, PEDIATR RES, V61, P451, DOI 10.1203/pdr.0b013e3180332cec; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Nirula R, 2003, J TRAUMA, V55, P844, DOI 10.1097/01.TA.0000087645.62474.91; Palmer C, 1999, J NEUROSCI RES, V56, P60, DOI 10.1002/(SICI)1097-4547(19990401)56:1<60::AID-JNR8>3.0.CO;2-A; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; STATLER PA, 2007, PEDIATR RES, V61, P1; Sun Y, 2005, STROKE, V36, P1672, DOI 10.1161/01.STR.0000173406.04891.8c; Tsukahara H, 1997, SCAND J CLIN LAB INV, V57, P487, DOI 10.3109/00365519709084598; Ulusal I, 2010, ACTA NEUROCHIR, V152, P2161, DOI 10.1007/s00701-010-0775-6; Vairano M, 2002, EUR J NEUROSCI, V16, P584, DOI 10.1046/j.1460-9568.2002.02125.x; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wu XC, 1999, CLIN SCI, V97, P639, DOI 10.1042/CS19990070	41	23	24	0	2	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	JUL	2015	25	4					552	558		10.5137/1019-5149.JTN.9685-14.4			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CQ0YN	WOS:000360324600007	26242331	Bronze			2021-06-18	
J	Cheng, T; Yang, B; Li, DP; Ma, SS; Tian, Y; Qu, RN; Zhang, WJ; Zhang, YT; Hu, K; Guan, FX; Wang, J				Cheng, Tian; Yang, Bo; Li, Dongpeng; Ma, Shanshan; Tian, Yi; Qu, Ruina; Zhang, Wenjin; Zhang, Yanting; Hu, Kai; Guan, Fangxia; Wang, Jian			Wharton's Jelly Transplantation Improves Neurologic Function in a Rat Model of Traumatic Brain Injury	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Cognition; Traumatic brain injury; Wharton's jelly; Transplantation; BDNF	MESENCHYMAL STEM-CELLS; CEREBRAL-ISCHEMIA; HEMORRHAGIC BRAIN; CORD; EXPRESSION	Traumatic brain injury (TBI), which can lead to disability, dysfunction, and even death, is a prominent health problem worldwide. Effective therapy for this serious and debilitating condition is needed. Human umbilical cord matrix, known as Wharton's jelly (WJ), provides a natural, interface scaffold that is enriched in mesenchymal stem cells. In this study, we tested the efficacy of WJ tissue transplantation in a weight-drop model of TBI in rats. WJ tissue was cultured and transplanted into the injury site 24 h after TBI. The modified neurologic severity score, body weight, brain edema, and lesion volume were evaluated at various time points after TBI. Cognitive behavior was assessed by the novel object recognition test and the Morris water maze test. Expression of brain-derived neurotrophic factor (BDNF) in the perilesional brain area was measured at day 14 after TBI. We found that WJ tissue transplantation lessened TBI-induced brain edema (day 3), reduced lesion volume (day 28), improved neurologic function (days 21-28), and promoted memory and cognitive recovery. Additionally, expression of BDNF mRNA and protein was higher in WJ tissue-treated rats than in sham-operated or vehicle-treated rats. These data suggest that WJ tissue transplantation can reduce TBI-induced brain injury and may have therapeutic potential for the treatment of TBI.	[Cheng, Tian; Yang, Bo; Li, Dongpeng; Tian, Yi; Zhang, Wenjin; Guan, Fangxia] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China; [Cheng, Tian; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Ma, Shanshan; Qu, Ruina; Zhang, Yanting; Guan, Fangxia] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Henan, Peoples R China; [Hu, Kai] Henan Acad Med Sci, Zhengzhou 450003, Henan, Peoples R China	Guan, FX (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.	13613813972@126.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X	Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471306, U1404313]; Innovative Research Team (in Science and Technology); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01AG031926, R01NS078026, R01AT007317]; China Scholarship CouncilChina Scholarship Council; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG031926] Funding Source: NIH RePORTER	This study was supported by Natural Science Foundation of China (81471306, U1404313), Innovative Research Team (in Science and Technology) and NIH K01AG031926, R01NS078026, and R01AT007317. T.C. is the recipient of the China Scholarship Council Joint PhD Training award. We thank Jiarui Wang and Claire Levine for assistance with this manuscript.	Arien-Zakay H, 2012, J MOL NEUROSCI, V48, pS66; Bakhtiary M, 2011, IRAN J BASIC MED SCI, V14, P327; Bennett MH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004609.pub3; Camussi G, 2010, CURR OPIN NEPHROL HY, V19, P7, DOI 10.1097/MNH.0b013e328332fb6f; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Fang B, 2014, INT J MOL SCI, V15, P6378, DOI 10.3390/ijms15046378; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Jiang C, 2013, BEHAV BRAIN RES, V250, P222, DOI 10.1016/j.bbr.2013.05.011; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006-0286; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Liu SJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-66; Lu B, 2014, Handb Exp Pharmacol, V220, P223, DOI 10.1007/978-3-642-45106-5_9; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Malkowski A, 2007, ACTA BIOCHIM POL, V54, P357, DOI 10.18388/abp.2007_3257; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Shen XF, 2013, INT J MOL SCI, V14, P21598, DOI 10.3390/ijms141121598; Sobolewski K, 2005, PLACENTA, V26, P747, DOI 10.1016/j.placenta.2004.10.008; Vatansever F, 2013, PROC SPIE, V8569, DOI 10.1117/12.2001900; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2010, NEUROCHEM INT, V57, P248, DOI 10.1016/j.neuint.2010.06.002; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; Zan L, 2014, NEUROSCIENCE, V262, P118, DOI 10.1016/j.neuroscience.2013.12.060; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhou CH, 2011, CELL IMMUNOL, V272, P33, DOI 10.1016/j.cellimm.2011.09.010; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423	27	23	23	0	18	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUL	2015	35	5					641	649		10.1007/s10571-015-0159-9			9	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	CL2JJ	WOS:000356769400005	25638565	Green Accepted			2021-06-18	
J	Moore, RD; Pindus, DM; Drolette, ES; Scudder, MR; Raine, LB; Hillman, CH				Moore, Robert D.; Pindus, Dominika M.; Drolette, Eric S.; Scudder, Mark R.; Raine, Lauren B.; Hillman, Charles H.			The persistent influence of pediatric concussion on attention and cognitive control during flanker performance	BIOLOGICAL PSYCHOLOGY			English	Article						Child; Concussion; Brain function; Cognition	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; RESPONSE CONFLICT; CHILDREN; ERP; QUESTIONNAIRE; ADOLESCENTS; POTENTIALS; ACTIVATION; COMPONENT	This study investigated the influence of concussion history on children's neurocognitive processing. Thirty-two children ages 8-10 years (16 with a concussion history, 16 controls) completed compatible and incompatible conditions of a flanker task while behavioral and neuroelectric data were collected. Relative to controls, children with a concussion history exhibited alterations in the sequential congruency effect, committed more omission errors, and exhibited decreased post-error accuracy. Children with a concussion history exhibited longer N2 latency across task conditions, increased N2 amplitude during the incompatible condition of the task, and decreased P3b amplitude across task conditions. Children with a history of concussion also exhibited decreased ERN and Pe amplitudes, with group difference increasing for the incompatible condition of the task. The current results indicate that pediatric concussion may lead to subtle, but pervasive deficits in attention and cognitive control. These results serve to inform a poorly understood but significant public health concern. (C) 2015 Elsevier B. V. All rights reserved.	[Moore, Robert D.; Drolette, Eric S.; Scudder, Mark R.; Raine, Lauren B.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol, Urbana, IL 61801 USA; [Moore, Robert D.] Univ Montreal, Dept Kinesiol, Montreal, PQ, Canada; [Pindus, Dominika M.] Univ Loughborough, Sch Sport Exercise & Hlth Sci, Loughborough, Leics, England	Moore, RD (corresponding author), 2100 Boul Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	robert.moore@umontreal.ca	Hillman, Charles/AAD-4828-2019	Hillman, Charles/0000-0002-3722-5612; Pindus, Dominika M/0000-0001-7288-7921	National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1 HD055352]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055352] Funding Source: NIH RePORTER	Partial support for this research and the preparation of this manuscript was provided by a grant from the National Institute of Child Health and Human Development (NICHD) to Charles Hillman (RO1 HD055352).	Alexander WH, 2010, TOP COGN SCI, V2, P658, DOI 10.1111/j.1756-8765.2010.01085.x; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Birnbaum AS, 2002, AM J HEALTH BEHAV, V26, P284, DOI 10.5993/AJHB.26.4.5; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Broglio S.P., 2009, J NEUROTRAUM, V23, P899; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Caggiano DM, 2004, PSYCHON B REV, V11, P932, DOI 10.3758/BF03196724; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Chatrian G. E., 1985, American Journal of EEG Technology, V25, P83; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2013, J CLIN EXP NEUROPSYC, V35, P596, DOI 10.1080/13803395.2013.800023; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; FISK AD, 1981, HUM FACTORS, V23, P737; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Friedman D, 2009, COGN AFFECT BEHAV NE, V9, P91, DOI 10.3758/CABN.9.1.91; Gajewski PD, 2008, BRAIN RES, V1189, P127, DOI 10.1016/j.brainres.2007.10.076; Gajewski PD, 2013, INT J PSYCHOPHYSIOL, V87, P273, DOI 10.1016/j.ijpsycho.2012.08.007; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; Hajcak G, 2009, PSYCHOPHYSIOLOGY, V46, pS15; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Hillyard SA, 1998, P NATL ACAD SCI USA, V95, P781, DOI 10.1073/pnas.95.3.781; Hilti CC, 2013, BRAIN COGNITION, V81, P193, DOI 10.1016/j.bandc.2012.10.013; Holmes J, 2009, DEVELOPMENTAL SCI, V12, pF9, DOI 10.1111/j.1467-7687.2009.00848.x; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Kaufman A.S., 1990, KAUFMAN BRIEF INTELL; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Luna B, 2009, ADV CHILD DEV BEHAV, V37, P233, DOI 10.1016/S0065-2407(09)03706-9; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Moore R. D., 2015, PERSISTENT INF UNPUB; Moore RD, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00258; Moore RD, 2014, J ATHL TRAINING, V49, P24, DOI 10.4085/1062-6050-49.1.01; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nieuwenhuis S, 2005, PSYCHOL BULL, V131, P510, DOI 10.1037/0033-2909.131.4.510; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Pontifex MB, 2012, NEUROPSYCHOLOGY, V26, P407, DOI 10.1037/a0028795; Pontifex MB, 2011, J COGNITIVE NEUROSCI, V23, P1332, DOI 10.1162/jocn.2010.21528; Pontifex MB, 2010, PSYCHOPHYSIOLOGY, V47, P767, DOI 10.1111/j.1469-8986.2010.00974.x; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Reid R., 1998, ADHD RATING SCALE 4; Rueda MR, 2004, NEUROPSYCHOLOGIA, V42, P1029, DOI 10.1016/j.neuropsychologia.2003.12.012; Sarter M, 2001, BRAIN RES REV, V35, P146, DOI 10.1016/S0165-0173(01)00044-3; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P364, DOI 10.1017/S0048577299970749; Taylor SJC, 2001, PAEDIATR PERINAT EP, V15, P88; THOMAS S, 1992, CAN J SPORT SCI, V17, P338; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	64	23	23	1	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0301-0511	1873-6246		BIOL PSYCHOL	Biol. Psychol.	JUL	2015	109						93	102		10.1016/j.biopsycho.2015.04.008			10	Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental	Psychology; Behavioral Sciences	CN4XQ	WOS:000358434200011	25951782				2021-06-18	
J	Rosenberg, H; Dethier, M; Kessels, RPC; Westbrook, RF; McDonald, S				Rosenberg, Hannah; Dethier, Marie; Kessels, Roy P. C.; Westbrook, R. Frederick; McDonald, Skye			Emotion Perception After Moderate-Severe Traumatic Brain Injury: The Valence Effect and the Role of Working Memory, Processing Speed, and Nonverbal Reasoning	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; emotion recognition; valence; working memory; processing speed	FACIAL AFFECT RECOGNITION; BLUNT HEAD-INJURY; SOCIAL-PERCEPTION; STROKE PATIENTS; HUMAN AMYGDALA; WECHSLER TEST; EXPRESSIONS; DEFICITS; IMPAIRMENTS; PERFORMANCE	Objective: Traumatic brain injury (TBI) impairs emotion perception. Perception of negative emotions (sadness, disgust, fear, and anger) is reportedly affected more than positive (happiness and surprise) ones. It has been argued that this reflects a specialized neural network underpinning negative emotions that is vulnerable to brain injury. However, studies typically do not equate for differential difficulty between emotions. We aimed to examine whether emotion recognition deficits in people with TBI were specific to negative emotions, while equating task difficulty, and to determine whether perception deficits might be accounted for by other cognitive processes. Method: Twenty-seven people with TBI and 28 matched control participants identified 6 basic emotions at 2 levels of intensity (a) the conventional 100% intensity and (b) "equated intensity"-that is, an intensity that yielded comparable accuracy rates across emotions in controls. Results: (a) At 100% intensity, the TBI group was impaired in recognizing anger, fear, and disgust but not happiness, surprise, or sadness and performed worse on negative than positive emotions. (b) At equated intensity, the TBI group was poorer than controls overall but not differentially poorer in recognizing negative emotions. Although processing speed and nonverbal reasoning were associated with emotion accuracy, injury severity by itself was a unique predictor. Conclusions: When task difficulty is taken into account, individuals with TBI show impairment in recognizing all facial emotions. There was no evidence for a specific impairment for negative emotions or any particular emotion. Impairment was accounted for by injury severity rather than being a secondary effect of reduced neuropsychological functioning.	[Rosenberg, Hannah; McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Dethier, Marie] Univ Liege, Dept Psychol Cognit & Behav, B-4000 Liege, Belgium; [Kessels, Roy P. C.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Venray, Netherlands; [Kessels, Roy P. C.] Radboud Univ Nijmegen, Dept Med Psychol, Venray, Netherlands; [Kessels, Roy P. C.] Vincent van Gogh Inst Psychiat, Korsakoff Clin, Venray, Netherlands	Rosenberg, H (corresponding author), Univ New S Wales, Sch Psychol, Mathews Bldg, Sydney, NSW 2052, Australia.	hannah.rosenberg@unsw.edu.au	Kessels, Roy P.C./D-1902-2010	Kessels, Roy P.C./0000-0001-9500-9793	Australian Research CouncilAustralian Research Council [DP0988689]	This research was funded by Australian Research Council Discovery Project Grant DP0988689. We thank the individuals with brain injuries, their families, and community controls for their interest and participation in this study. We are also grateful to Jacob Rosenberg for assistance with data processing and technical support.	ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2004, J COGNITIVE NEUROSCI, V16, P453, DOI 10.1162/089892904322926782; Adolphs R, 1999, PSYCHOL SCI, V10, P167, DOI 10.1111/1467-9280.00126; Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Ammerlaan EJG, 2008, ACTA NEUROBIOL EXP, V68, P214; Anderson AK, 2000, PSYCHOL SCI, V11, P106, DOI 10.1111/1467-9280.00224; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; BENSON PJ, 1991, IMAGE VISION COMPUT, V9, P123, DOI 10.1016/0262-8856(91)90022-H; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bird KD, 2011, PSYCHOL METHODS, V16, P432, DOI 10.1037/a0024447; Bornhofen C., 2010, READING SMILES OTHER; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Braun M, 2005, BRAIN COGNITION, V58, P193, DOI 10.1016/j.bandc.2004.11.003; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Callahan BL, 2011, BRAIN COGNITION, V77, P412, DOI 10.1016/j.bandc.2011.08.017; Calvo MG, 2008, BEHAV RES METHODS, V40, P109, DOI 10.3758/BRM.40.1.109; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P345, DOI 10.1080/13854049708400463; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Dethier M, 2013, J INT NEUROPSYCH SOC, V19, P367, DOI 10.1017/S1355617712001555; Dethier M, 2012, J CLIN EXP NEUROPSYC, V34, P936, DOI 10.1080/13803395.2012.702734; Dimoska A, 2010, J INT NEUROPSYCH SOC, V16, P369, DOI 10.1017/S1355617709991445; Ekman P., 1976, PICTURES FACIAL AFFE; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; ESLINGER PJ, 1995, NEUROREHABILITATION, V5, P161, DOI 10.3233/NRE-1995-5206; Fernandez-Duque D, 2005, NEUROPSYCHOLOGIA, V43, P1673, DOI 10.1016/j.neuropsychologia.2005.01.005; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Graham R, 2007, NEUROPSYCHOLOGIA, V45, P42, DOI 10.1016/j.neuropsychologia.2006.04.021; Grattan LM, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P266; Gray John, 2006, Cogn Neuropsychiatry, V11, P505, DOI 10.1080/13546800544000028; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; Harmer CJ, 2001, NAT NEUROSCI, V4, P17, DOI 10.1038/82854; Hennenlotter A, 2006, PROG BRAIN RES, V156, P443, DOI 10.1016/S0079-6123(06)56024-8; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kessels RPC, 2007, BEHAV NEUROL, V18, P31, DOI 10.1155/2007/868431; Kessels RPC, 2014, J NEUROPSYCHOL, V8, P75, DOI 10.1111/jnp.12009; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Kohler CG, 2005, AM J GERIAT PSYCHIAT, V13, P926, DOI 10.1176/appi.ajgp.13.11.926; Kreibig SD, 2010, BIOL PSYCHOL, V84, P394, DOI 10.1016/j.biopsycho.2010.03.010; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lovibond SH, 1995, MANUAL DEPRESSION AN; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mandal MK, 1998, SCHIZOPHRENIA BULL, V24, P399, DOI 10.1093/oxfordjournals.schbul.a033335; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Montagne B, 2008, EUR PSYCHIAT, V23, P26, DOI 10.1016/j.eurpsy.2007.07.007; Montagne B, 2007, ACTA NEUROPSYCHIATR, V19, P279, DOI 10.1111/j.1601-5215.2007.00235.x; Montagne B, 2007, BRIT J PSYCHOL, V98, P517, DOI 10.1348/000712606X160669; Montagne Barbara, 2006, Cogn Neuropsychiatry, V11, P389, DOI 10.1080/13546800444000254; Montagne B, 2006, CORTEX, V42, P705, DOI 10.1016/S0010-9452(08)70408-8; Montagne B, 2006, EUR NEUROL, V55, P151, DOI 10.1159/000093215; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Palermo R, 2004, BEHAV RES METH INS C, V36, P634, DOI 10.3758/BF03206544; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Phillips ML, 1997, NATURE, V389, P495, DOI 10.1038/39051; Poljac E, 2011, CORTEX, V47, P974, DOI 10.1016/j.cortex.2010.10.002; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Rapcsak SZ, 2000, NEUROLOGY, V54, P575, DOI 10.1212/WNL.54.3.575; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; Rosenberg H, 2014, J INT NEUROPSYCH SOC, V20, P994, DOI 10.1017/S1355617714000940; RUSSELL JA, 1994, PSYCHOL BULL, V115, P102, DOI 10.1037/0033-2909.115.1.102; Sato W, 2002, CORTEX, V38, P727, DOI 10.1016/S0010-9452(08)70040-6; Scholten MRM, 2005, SCHIZOPHR RES, V78, P61, DOI 10.1016/j.schres.2005.06.019; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Smith MJL, 2010, NEUROPSYCHOLOGIA, V48, P2777, DOI 10.1016/j.neuropsychologia.2010.03.008; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spikman JM, 2013, NEUROPSYCHOL REHABIL, V23, P824, DOI 10.1080/09602011.2013.826138; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tottenham N, 2002, J COGNITIVE NEUROSCI, P74; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408; Yim J, 2013, BRAIN INJURY, V27, P1155, DOI 10.3109/02699052.2013.804203; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Zupan B, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e31829dded6; Zupan B, 2014, BRAIN INJURY, V28, P1087, DOI 10.3109/02699052.2014.901560	101	23	25	2	37	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2015	29	4					509	521		10.1037/neu0000171			13	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	CL5CA	WOS:000356976200002	25643220				2021-06-18	
J	Awwad, HO; Gonzalez, LP; Tompkins, P; Lerner, M; Brackett, DJ; Awasthi, V; Standifer, KM				Awwad, Hibah O.; Gonzalez, Larry P.; Tompkins, Paul; Lerner, Megan; Brackett, Daniel J.; Awasthi, Vibhudutta; Standifer, Kelly M.			Blast overpressure waves induce transient anxiety and regional changes in cerebral glucose metabolism and delayed hyperarousal in rats	FRONTIERS IN NEUROLOGY			English	Article						blast injury; traumatic brain injury; anxiety; fluorodeoxyglucose; positron emission tomography imaging; glucose metabolism; acoustic startle response	TRAUMATIC BRAIN-INJURY; CORTICAL CONTUSION; AXONAL INJURY; PLUS-MAZE; EXPOSURE; PRESSURE; MODEL; MECHANISMS; REACTIVITY; INFLAMMATION	Physiological alterations, anxiety, and cognitive disorders are strongly associated with blast-induced traumatic brain injury (blast TBI), and are common symptoms in service personnel exposed to blasts. Since 2006, 25,000-30,000 new TBI cases are diagnosed annually in U.S. Service members; increasing evidence confirms that primary blast exposure causes diffuse axonal injury and is often accompanied by altered behavioral outcomes. Behavioral and acute metabolic effects resulting from blast to the head in the absence of thoracic contributions from the periphery were examined, following a single blast wave directed to the head of male Sprague-Dawley rats protected by a lead shield over the torso. An 80 psi head blast produced cognitive deficits that were detected in working memory. Blast TBI rats displayed increased anxiety as determined by elevated plus maze at day 9 post-blast compared to sham rats; blast TBI rats spent significantly more time than the sham controls in the closed arms (p < 0.05; n = 8-11). Interestingly, anxiety symptoms were absent at days 22 and 48 post-blast. Instead, blast TBI rats displayed increased rearing behavior at day 48 post-blast compared to sham rats. Blast TBI rats also exhibited suppressed acoustic startle responses, but similar pre-pulse inhibition at day 15 post-blast compared to sham rats. Acute physiological alterations in cerebral glucose metabolism were determined by positron emission tomography 1 and 9 days post-blast using F-18-fluorodeoxyglucose (F-18-FDG). Global glucose uptake in blast TBI rat brains increased at day 1 post-blast (p < 0.05; n = 4-6) and returned to sham levels by day 9. Our results indicate a transient increase in cerebral metabolism following a blast injury. Markers for reactive astrogliosis and neuronal damage were noted by immunoblotting motor cortex tissue from day 10 post-blast in blast TBI rats compared to sham controls (p < 0.05; n = 5-6).	[Awwad, Hibah O.; Awasthi, Vibhudutta; Standifer, Kelly M.] Univ Oklahoma, Hlth Sci Ctr, Coll Pharm, Dept Pharmaceut Sci, Oklahoma City, OK 73117 USA; [Awwad, Hibah O.; Gonzalez, Larry P.; Standifer, Kelly M.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Oklahoma Ctr Neurosci, Oklahoma City, OK 73117 USA; [Gonzalez, Larry P.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Psychiat & Behav Sci, Oklahoma City, OK 73117 USA; [Tompkins, Paul] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Neurosurg, Oklahoma City, OK 73117 USA; [Lerner, Megan; Brackett, Daniel J.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Surg, Oklahoma City, OK 73117 USA; [Lerner, Megan] Oklahoma City VA Med Ctr, Oklahoma City, OK USA; [Standifer, Kelly M.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Cell Biol, Oklahoma City, OK 73117 USA	Awwad, HO (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Coll Pharm, Dept Pharmaceut Sci, 1110 N Stonewall Ave,Suite 315, Oklahoma City, OK 73117 USA.	hawwad@ouhsc.edu	Gonzalez, Larry P/A-4362-2008		Department of the Army [W81XWH-09-1-0443]	The authors would like to acknowledge: Cindy Simpson-Durand for her excellent technical assistance, Patrick Dib and Robert Stover for help with PET image layouts, Dr. Charles Vorhees for helpful discussions regarding MWM paradigms, and Dr. Ethan Stolzenberg for his expertise on histopathology. Special acknowledgments to Dr. Namas Chandra and Aaron Alai from the University of Nebraska-Lincoln for their input and discussions related to blast loading mechanics and parameters. This work was supported by the Department of the Army W81XWH-09-1-0443 to KMS.	Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; [Anonymous], 2009, BRAIN NAVIGATOR RELE; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Awasthi V, 2010, NUCL MED COMMUN, V31, P152, DOI 10.1097/MNM.0b013e3283339f92; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bonnet MH, 2010, SLEEP MED REV, V14, P9, DOI 10.1016/j.smrv.2009.05.002; Borta A, 2005, PHYSIOL BEHAV, V84, P387, DOI 10.1016/j.physbeh.2005.01.009; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; CARNEVALE UAG, 1990, BEHAV BRAIN RES, V39, P187, DOI 10.1016/0166-4328(90)90104-M; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DeLellis Stephen M, 2009, J Spec Oper Med, V9, P36; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Glenn Thomas C, 2012, Acta Neurochir Suppl, V114, P11, DOI 10.1007/978-3-7091-0956-4_3; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Grillon C, 2002, BIOL PSYCHIAT, V52, P958, DOI 10.1016/S0006-3223(02)01665-7; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; Hattori N, 2004, J NUCL MED, V45, P775; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huckans M, 2010, J REHABIL RES DEV, V47, P43, DOI 10.1682/JRRD.2009.02.0019; Irwin R J, 1998, J Okla State Med Assoc, V91, P387; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; Jaffee MS, 2009, J REHABIL RES DEV, V46, P655, DOI 10.1682/JRRD.2008.09.0114; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lamarche LJ, 2007, J CLIN PSYCHIAT, V68, P1257, DOI 10.4088/JCP.v68n0813; Li L, 2009, NEUROSCI BIOBEHAV R, V33, P1157, DOI 10.1016/j.neubiorev.2009.02.001; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nelson NW, 2011, BRAIN INJURY, V25, P511, DOI 10.3109/02699052.2011.558040; Pang KCH, 2015, J NEUROTRAUM, V32, P801, DOI 10.1089/neu.2014.3451; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; Riemann D, 2010, SLEEP MED REV, V14, P19, DOI 10.1016/j.smrv.2009.04.002; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; Scherer MR, 2011, EXP BRAIN RES, V208, P399, DOI 10.1007/s00221-010-2490-1; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Schrauwen JTC, 2012, J STRUCT BIOL, V180, P335, DOI 10.1016/j.jsb.2012.06.007; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Uys JDK, 2006, ANN NY ACAD SCI, V1071, P542, DOI 10.1196/annals.1364.060; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; VandeVord PJ, 2008, NEUROSCI LETT, V434, P247, DOI 10.1016/j.neulet.2008.01.056; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Veltkamp R, 2005, STROKE, V36, P1679, DOI 10.1161/01.STR.0000173408.94728.79; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Warden DL, 2005, NEW ENGL J MED, V353, P633; Wright MJ, 2013, BRAIN IMAGING BEHAV, V7, P307, DOI 10.1007/s11682-013-9231-6; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	95	23	24	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUN 17	2015	6								132	10.3389/fneur.2015.00132			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU9FG	WOS:000363848900001	26136722	DOAJ Gold, Green Published			2021-06-18	
J	Czerniak, SM; Sikoglu, EM; Navarro, AAL; McCafferty, J; Eisenstock, J; Stevenson, JH; King, JA; Moore, CM				Czerniak, Suzanne M.; Sikoglu, Elif M.; Navarro, Ana A. Liso; McCafferty, Joseph; Eisenstock, Jordan; Stevenson, J. Herbert; King, Jean A.; Moore, Constance M.			A resting state functional magnetic resonance imaging study of concussion in collegiate athletes	BRAIN IMAGING AND BEHAVIOR			English	Article						Concussion; fMRI; Resting state; Functional connectivity; Neurocognition	DORSOLATERAL PREFRONTAL CORTEX; ANTERIOR CINGULATE CORTEX; DEFAULT NETWORK; HIGH-SCHOOL; BRAIN; CONNECTIVITY; IMPACT; INTERFERENCE; METAANALYSIS; INJURY	Sports-related concussions are currently diagnosed through multi-domain assessment by a medical professional and may utilize neurocognitive testing as an aid. However, these tests have only been able to detect differences in the days to week post-concussion. Here, we investigate a measure of brain function, namely resting state functional connectivity, which may detect residual brain differences in the weeks to months after concussion. Twenty-one student athletes (9 concussed within 6 months of enrollment; 12 non-concussed; between ages 18 and 22 years) were recruited for this study. All participants completed the Wisconsin Card Sorting Task and the Color-Word Interference Test. Neuroimaging data, specifically resting state functional Magnetic Resonance Imaging data, were acquired to examine resting state functional connectivity. Two sample t-tests were used to compare the neurocognitive scores and resting state functional connectivity patterns among concussed and non-concussed participants. Correlations between neurocognitive scores and resting state functional connectivity measures were also determined across all subjects. There were no significant differences in neurocognitive performance between concussed and non-concussed groups. Concussed subjects had significantly increased connections between areas of the brain that underlie executive function. Across all subjects, better neurocognitive performance corresponded to stronger brain connectivity. Even at rest, brains of concussed athletes may have to 'work harder' than their healthy peers to achieve similar neurocognitive results. Resting state brain connectivity may be able to detect prolonged brain differences in concussed athletes in a more quantitative manner than neurocognitive test scores.	[Czerniak, Suzanne M.; Sikoglu, Elif M.; Navarro, Ana A. Liso; McCafferty, Joseph; King, Jean A.; Moore, Constance M.] Univ Massachusetts, Sch Med, Dept Psychiat, Ctr Comparat NeuroImaging, Worcester, MA 01604 USA; [Sikoglu, Elif M.; Navarro, Ana A. Liso; Eisenstock, Jordan; King, Jean A.; Moore, Constance M.] Univ Massachusetts, Mem Med Sch, Dept Psychiat, Worcester, MA 01605 USA; [Navarro, Ana A. Liso] Univ Geneva, Sch Med, Dept Psychiat, Off Med Pedag, CH-1211 Geneva 8, Switzerland; [Eisenstock, Jordan] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA; [Stevenson, J. Herbert] Univ Massachusetts, Mem Med Sch, Dept Sports Med, Worcester, MA 01605 USA; [King, Jean A.; Moore, Constance M.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA USA	Czerniak, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, Ctr Comparat NeuroImaging, 303 Belmont St, Worcester, MA 01604 USA.	suzanne.czerniak@umassmed.edu; muazzez.sikoglu@umassmed.edu; aliso@bluewin.ch; jpm059@bucknell.edu; jordan.eisenstock@umassmemorial.org; john.stevenson@umassmemorial.org; jean.king@umassmed.edu; Constance.Moore@umassmed.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH073998]; University of Massachusetts Medical School; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBGEP3-134252]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM107000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073998] Funding Source: NIH RePORTER	National Institute of Mental Health to CMM (MH073998), and start-up funds to CMM from the University of Massachusetts Medical School. Swiss National Science Foundation (PBGEP3-134252) to AAL.	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Buchsbaum BR, 2005, HUM BRAIN MAPP, V25, P35, DOI 10.1002/hbm.20128; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chai XQJ, 2011, NEUROPSYCHOPHARMACOL, V36, P2009, DOI 10.1038/npp.2011.88; Conklin SM, 2007, NEUROSCI LETT, V421, P209, DOI 10.1016/j.neulet.2007.04.086; Cullen KR, 2009, NEUROSCI LETT, V460, P227, DOI 10.1016/j.neulet.2009.05.022; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Friston Karl J., 1994, Human Brain Mapping, V2, P56, DOI 10.1002/hbm.460020107; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hayama HR, 2009, NEUROPSYCHOLOGIA, V47, P2409, DOI 10.1016/j.neuropsychologia.2009.04.010; Hebb DO., 1949, ORG BEHAV NEUROPSYCH; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kelly AMC, 2009, CEREB CORTEX, V19, P640, DOI 10.1093/cercor/bhn117; Laird AR, 2005, HUM BRAIN MAPP, V25, P6, DOI 10.1002/hbm.20129; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leung HC, 2000, CEREB CORTEX, V10, P552, DOI 10.1093/cercor/10.6.552; Lie CH, 2006, NEUROIMAGE, V30, P1038, DOI 10.1016/j.neuroimage.2005.10.031; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mahaffey Bran L, 2012, Mo Med, V109, P445; Margulies DS, 2007, NEUROIMAGE, V37, P579, DOI 10.1016/j.neuroimage.2007.05.019; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Monchi O, 2001, J NEUROSCI, V21, P7733; Qin SZ, 2009, BIOL PSYCHIAT, V66, P25, DOI 10.1016/j.biopsych.2009.03.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Silton RL, 2010, NEUROIMAGE, V50, P1292, DOI 10.1016/j.neuroimage.2009.12.061; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Staudinger MR, 2011, CEREB CORTEX, V21, P2578, DOI 10.1093/cercor/bhr041; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tsushima WT, 2013, APPL NEUROPSYCH-CHIL, V2, P13, DOI 10.1080/09084282.2011.643967	47	23	23	2	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2015	9	2					323	332		10.1007/s11682-014-9312-1			10	Neuroimaging	Neurosciences & Neurology	CI7TB	WOS:000354966600017	25112544	Green Accepted			2021-06-18	
J	Dixon, KJ; Theus, MH; Nelersa, CM; Mier, J; Travieso, LG; Yu, TS; Kernie, SG; Liebl, DJ				Dixon, Kirsty J.; Theus, Michelle H.; Nelersa, Claudiu M.; Mier, Jose; Travieso, Lissette G.; Yu, Tzong-Shiue; Kernie, Steven G.; Liebl, Daniel J.			Endogenous Neural Stem/Progenitor Cells Stabilize the Cortical Microenvironment after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						gliosis; neural stem; progenitor cell ablation; neurogenesis; neuronal survival; traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; STEM-CELLS; INTERMEDIATE-FILAMENT; NEURONAL PRECURSORS; REACTIVE ASTROCYTES; ADULT BRAIN; NEUROGENESIS; RAT; PROLIFERATION; EXPRESSION	Although a myriad of pathological responses contribute to traumatic brain injury (TBI), cerebral dysfunction has been closely linked to cell death mechanisms. A number of therapeutic strategies have been studied in an attempt to minimize or ameliorate tissue damage; however, few studies have evaluated the inherent protective capacity of the brain. Endogenous neural stem/progenitor cells (NSPCs) reside in distinct brain regions and have been shown to respond to tissue damage by migrating to regions of injury. Until now, it remained unknown whether these cells have the capacity to promote endogenous repair. We ablated NSPCs in the subventricular zone to examine their contribution to the injury microenvironment after controlled cortical impact (CCI) injury. Studies were performed in transgenic mice expressing the herpes simplex virus thymidine kinase gene under the control of the nestin promoter exposed to CCI injury. Two weeks after CCI injury, mice deficient in NSPCs had reduced neuronal survival in the perilesional cortex and fewer Iba-1-positive and glial fibrillary acidic protein-positive glial cells but increased glial hypertrophy at the injury site. These findings suggest that the presence of NSPCs play a supportive role in the cortex to promote neuronal survival and glial cell expansion after TBI injury, which corresponds with improvements in motor function. We conclude that enhancing this endogenous response may have acute protective roles after TBI.	[Dixon, Kirsty J.; Nelersa, Claudiu M.; Mier, Jose; Travieso, Lissette G.; Liebl, Daniel J.] Univ Miami, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Dixon, Kirsty J.; Nelersa, Claudiu M.; Mier, Jose; Travieso, Lissette G.; Liebl, Daniel J.] Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA; [Theus, Michelle H.] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA; [Yu, Tzong-Shiue; Kernie, Steven G.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA	Liebl, DJ (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, 1095 NW 14th Terrace,R-48, Miami, FL 33136 USA.	dliebl@med.miami.edu	Kernie, Steven/AAT-9912-2020	Yu, Tzong-Shiue/0000-0003-4277-6213; Kernie, Steven/0000-0003-1371-0549	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049545, R01 NS048192, NS064699, NS007459, NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192, P50NS030291, R01NS049545, T32NS007459, F32NS064699] Funding Source: NIH RePORTER		Ahlemeyer B, 2013, J NEUROSCI METH, V212, P156, DOI 10.1016/j.jneumeth.2012.09.016; Gomez-Climent MA, 2011, CEREB CORTEX, V21, P1028, DOI 10.1093/cercor/bhq177; Arias-Carrion O, 2006, J NEUROSCI RES, V84, P1425, DOI 10.1002/jnr.21068; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Bernal GM, 2011, AGING CELL, V10, P466, DOI 10.1111/j.1474-9726.2011.00694.x; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Budinich CS, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/378307; Butti E, 2012, BRAIN, V135, P3320, DOI 10.1093/brain/aws194; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chiu CC, 2005, CANCER DETECT PREV, V29, P286, DOI 10.1016/j.cdp.2005.02.001; Cromwell HC, 1996, J NEUROSCI, V16, P3444; Dang MT, 2006, P NATL ACAD SCI USA, V103, P15254, DOI 10.1073/pnas.0601758103; Doyon J, 1996, EUR J NEUROSCI, V8, P637, DOI 10.1111/j.1460-9568.1996.tb01249.x; Ehninger D, 2011, CELL TISSUE RES, V345, P69, DOI 10.1007/s00441-011-1200-z; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Faiz M, 2008, MOL CELL NEUROSCI, V38, P170, DOI 10.1016/j.mcn.2008.02.002; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Guerra-Crespo M, 2009, NEUROSCIENCE, V160, P470, DOI 10.1016/j.neuroscience.2009.02.029; Heymach Jr. J. V., 1995, NATURE, P374; HEYMACH JV, 1995, NATURE, V374, P405, DOI 10.1038/374405a0; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Lai B, 2008, NEUROSCI LETT, V442, P305, DOI 10.1016/j.neulet.2008.07.032; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Li B, 2010, BRAIN RES, V1327, P91, DOI 10.1016/j.brainres.2010.02.030; Liu YP, 2009, ACTA NEUROPATHOL, V117, P469, DOI 10.1007/s00401-009-0516-1; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Luo Chun, 2002, Chin J Traumatol, V5, P24; Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007; Mizuno Y, 2006, J NEUROL SCI, V246, P131, DOI 10.1016/j.jns.2006.02.019; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nakano K, 2000, BRAIN DEV-JPN, V22, pS5; Neves SS, 2006, BBA-BIOMEMBRANES, V1758, P1703, DOI 10.1016/j.bbamem.2006.08.021; Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Petridis AK, 2011, J CLIN NEUROSCI, V18, P265, DOI 10.1016/j.jocn.2010.06.021; Proia P, 2008, INT J MOL MED, V21, P63; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rani SB, 2006, INDIAN J MED RES, V124, P269; Ricard J, 2006, MOL CELL NEUROSCI, V31, P713, DOI 10.1016/j.mcn.2006.01.002; Salhia B, 2000, BRAIN RES, V883, P87, DOI 10.1016/S0006-8993(00)02825-0; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Sun CR, 2013, J NEUROSCI, V33, P17314, DOI 10.1523/JNEUROSCI.2129-13.2013; Sun F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046326; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Taupin Philippe, 2008, Int J Med Sci, V5, P127; Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170; Theus M. H., 2012, CURR PROTOC STEM CEL; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036663; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008	60	23	25	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					753	764		10.1089/neu.2014.3390			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700001	25290253	Green Published			2021-06-18	
J	Xiao, Y; Faucherre, A; Pola-Morell, L; Heddleston, JM; Liu, TL; Chew, TL; Sato, F; Sehara-Fujisawa, A; Kawakami, K; Lopez-Schier, H				Xiao, Yan; Faucherre, Adele; Pola-Morell, Laura; Heddleston, John M.; Liu, Tsung-Li; Chew, Teng-Leong; Sato, Fuminori; Sehara-Fujisawa, Atsuko; Kawakami, Koichi; Lopez-Schier, Hernan			High-resolution live imaging reveals axon-glia interactions during peripheral nerve injury and repair in zebrafish	DISEASE MODELS & MECHANISMS			English	Article						High-resolution imaging; Neurotrauma; Regeneration; Schwann cells; Haptotaxis	SCHWANN-CELL DENERVATION; TARGETED GENE-EXPRESSION; BEAM PLANE ILLUMINATION; LATERAL-LINE; MYELINATED AXONS; EXPERIMENTAL STRATEGIES; FUNCTIONAL RECOVERY; REGENERATION; GROWTH; ADULT	Neural damage is a devastating outcome of physical trauma. The glia are one of the main effectors of neuronal repair in the nervous system, but the dynamic interactions between peripheral neurons and Schwann cells during injury and regeneration remain incompletely characterized. Here, we combine laser microsurgery, genetic analysis, high-resolution intravital imaging and lattice light-sheet microscopy to study the interaction between Schwann cells and sensory neurons in a zebrafish model of neurotrauma. We found that chronic denervation by neuronal ablation leads to Schwann-cell death, whereas acute denervation by axonal severing does not affect the overall complexity and architecture of the glia. Neuronal-circuit regeneration begins when Schwann cells extend bridging processes to close the injury gap. Regenerating axons grow faster and directionally after the physiological clearing of distal debris by the Schwann cells. This might facilitate circuit repair by ensuring that axons are guided through unoccupied spaces within bands of Bungner towards their original peripheral target. Accordingly, in the absence of Schwann cells, regenerating axons are misrouted, impairing the re-innervation of sensory organs. Our results indicate that regenerating axons use haptotaxis as a directional cue during the reconstitution of a neural circuit. These findings have implications for therapies aimed at neurorepair, which will benefit from preserving the architecture of the peripheral glia during periods of denervation.	[Xiao, Yan; Lopez-Schier, Hernan] Helmholtz Zentrum Munchen, Res Unit Sensory Biol Organogenesis, D-85764 Munich, Germany; [Faucherre, Adele; Pola-Morell, Laura; Lopez-Schier, Hernan] Ctr Genom Regulat, Cell & Dev Biol, Barcelona 08003, Spain; [Heddleston, John M.; Liu, Tsung-Li; Chew, Teng-Leong] Howard Hughes Med Inst, Ashburn, VA 20147 USA; [Sato, Fuminori; Sehara-Fujisawa, Atsuko] Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; [Kawakami, Koichi] Grad Univ Adv Studies Sokendai, Natl Inst Genet, Div Mol & Dev Biol, Mishima, Shizuoka 4118540, Japan; [Kawakami, Koichi] Grad Univ Adv Studies Sokendai, Dept Genet, Mishima, Shizuoka 4118540, Japan	Lopez-Schier, H (corresponding author), Helmholtz Zentrum Munchen, Res Unit Sensory Biol Organogenesis, D-85764 Munich, Germany.	hernan.lopez-schier@helmholtz-muenchen.de	Kawakami, Koichi/AAF-1380-2019; Liu, Tsung-li/M-4473-2015	Faucherre, Adele/0000-0002-6099-3898	HDC Diabetes Portfolio of the Helmholtz Gemeinschaft; Program Grant of the Human Frontier Science Program [RGP0033/2014]; National BioResource Project (NBRP)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Ministry of Education, Science, Sports and Technology (MEXT) of Japan [23241063]; Gordon and Betty Moore FoundationGordon and Betty Moore Foundation; Howard Hughes Medical InstituteHoward Hughes Medical Institute; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15H05935, 15K21745, 22122007, 15H02370] Funding Source: KAKEN	This work was funded by the HDC Diabetes Portfolio of the Helmholtz Gemeinschaft, and by a Program Grant of the Human Frontier Science Program (RGP0033/2014) to H.L.-S.; and by the National BioResource Project (NBRP) and Grants-in-Aid for Scientific Research (23241063 to K.K. and 2212207 to A.F.-S.) from the Ministry of Education, Science, Sports and Technology (MEXT) of Japan. The AIC at Janelia is sponsored by the Gordon and Betty Moore Foundation and by the Howard Hughes Medical Institute.	Allodi I, 2012, PROG NEUROBIOL, V98, P16, DOI 10.1016/j.pneurobio.2012.05.005; Arthur-Farraj PJ, 2012, NEURON, V75, P633, DOI 10.1016/j.neuron.2012.06.021; Asakawa K, 2008, DEV GROWTH DIFFER, V50, P391, DOI [10.1111/j.1440-169x.2008.01044.x, 10.1111/j.1440-169X.2008.01044.x]; Asakawa K, 2008, P NATL ACAD SCI USA, V105, P1255, DOI 10.1073/pnas.0704963105; BASTMEYER M, 1994, GLIA, V11, P300, DOI 10.1002/glia.440110403; Beirowski B, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00256; Bradke F, 2012, NAT REV NEUROSCI, V13, P183, DOI 10.1038/nrn3176; Brosamle C, 2002, GLIA, V39, P47, DOI 10.1002/glia.10088; BUETTNER HM, 1994, DEV BIOL, V163, P407, DOI 10.1006/dbio.1994.1158; Cashman C. R., 2015, NEUROSCI LETT; Chada S, 1997, J CELL SCI, V110, P1179; Chen BC, 2014, SCIENCE, V346, P439, DOI 10.1126/science.1257998; Court FA, 2004, NATURE, V431, P191, DOI 10.1038/nature02841; Czopka T, 2011, METHOD CELL BIOL, V105, P25, DOI 10.1016/B978-0-12-381320-6.00002-3; David G, 1997, J PHYSIOL-LONDON, V498, P295, DOI 10.1113/jphysiol.1997.sp021858; Dedkov EI, 2002, ACTA NEUROPATHOL, V103, P565, DOI 10.1007/s00401-001-0504-6; Erturk A, 2012, NAT MED, V18, P166, DOI 10.1038/nm.2600; Faber C. G., 2015, NEUROSCI LETT; Faucherre A, 2014, METHODS MOL BIOL, V1082, P187, DOI 10.1007/978-1-62703-655-9_13; Faucherre A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016587; Faucherre A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004477; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FENELEY MR, 1991, EXP NEUROL, V114, P275, DOI 10.1016/0014-4886(91)90153-4; Gao L, 2014, NAT PROTOC, V9, P1083, DOI 10.1038/nprot.2014.087; Ghysen A, 2007, GENE DEV, V21, P2118, DOI 10.1101/gad.1568407; Gilmour DT, 2002, NEURON, V34, P577, DOI 10.1016/S0896-6273(02)00683-9; Goedhart J, 2010, NAT METHODS, V7, P137, DOI [10.1038/NMETH.1415, 10.1038/nmeth.1415]; Goessling W, 2014, DIS MODEL MECH, V7, P769, DOI 10.1242/dmm.016352; Gordon T, 2003, J PERIPHER NERV SYST, V8, P236, DOI 10.1111/j.1085-9489.2003.03029.x; Graciarena M, 2014, P NATL ACAD SCI USA, V111, P1610, DOI 10.1073/pnas.1319405111; Grant KA, 2005, NEURON, V45, P69, DOI 10.1016/j.neuron.2004.12.020; Hall SM, 1999, ANN NY ACAD SCI, V883, P215, DOI 10.1111/j.1749-6632.1999.tb08584.x; Halpern ME, 2008, ZEBRAFISH, V5, P97, DOI 10.1089/zeb.2008.0530; Harrisingh MC, 2004, EMBO J, V23, P3061, DOI 10.1038/sj.emboj.7600309; Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746; Jung SH, 2010, DEV DYNAM, V239, P592, DOI 10.1002/dvdy.22166; Kang H, 2014, J NEUROSCI, V34, P6323, DOI 10.1523/JNEUROSCI.4673-13.2014; Kang H, 2013, J NEUROSCI, V33, P19480, DOI 10.1523/JNEUROSCI.4067-13.2013; Kawakami K, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-105; Kidd GJ, 2013, HAND CLINIC, V115, P55, DOI 10.1016/B978-0-444-52902-2.00005-9; LAFONT F, 1994, PERSPECT DEV NEUROBI, V2, P259; Lewis G. M., 2013, JOVE; Lombardo FL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086405; Lopez-Schier H, 2005, P NATL ACAD SCI USA, V102, P1496, DOI 10.1073/pnas.0409361102; Lush ME, 2014, ELIFE, V3, DOI 10.7554/eLife.01832; Lyons DA, 2005, CURR BIOL, V15, P513, DOI 10.1016/j.cub.2005.02.030; Martin SM, 2010, DEVELOPMENT, V137, P3985, DOI 10.1242/dev.053611; Meier C, 1999, J NEUROSCI, V19, P3847; Misgeld T, 2007, NAT PROTOC, V2, P263, DOI 10.1038/nprot.2007.24; Monk KR, 2013, DIS MODEL MECH, V6, P135, DOI 10.1242/dmm.009217; Monk KR, 2009, SCIENCE, V325, P1402, DOI 10.1126/science.1173474; Munzel EJ, 2012, GLIA, V60, P253, DOI 10.1002/glia.21260; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; Painter MW, 2014, NEURON, V83, P331, DOI 10.1016/j.neuron.2014.06.016; Parrinello S, 2010, CELL, V143, P145, DOI 10.1016/j.cell.2010.08.039; Patton EE, 2014, DIS MODEL MECH, V7, P731, DOI 10.1242/dmm.017004; Perlin JR, 2011, DEVELOPMENT, V138, P4639, DOI 10.1242/dev.068072; Planchon TA, 2011, NAT METHODS, V8, P417, DOI [10.1038/NMETH.1586, 10.1038/nmeth.1586]; Pogoda HM, 2006, DEV BIOL, V298, P118, DOI 10.1016/j.ydbio.2006.06.021; Pujol-Marti J, 2012, J NEUROSCI, V32, P2976, DOI 10.1523/JNEUROSCI.5157-11.2012; Raphael AR, 2011, CURR TOP DEV BIOL, V97, P1, DOI 10.1016/B978-0-12-385975-4.00007-3; Rodrigues F, 2011, CELL MOL LIFE SCI, V68, P55, DOI 10.1007/s00018-010-0512-6; Ruohonen S, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-26; Scheer N, 1999, MECH DEVELOP, V80, P153, DOI 10.1016/S0925-4773(98)00209-3; Scherer SS, 1997, CURR OPIN NEUROL, V10, P386, DOI 10.1097/00019052-199710000-00006; Scherer SS, 2008, GLIA, V56, P1578, DOI 10.1002/glia.20751; Scott EK, 2007, NAT METHODS, V4, P323, DOI 10.1038/NMETH1033; Sharghi-Namini S, 2006, J NEUROSCI, V26, P6364, DOI 10.1523/JNEUROSCI.0157-06.2006; SHEPPARD CJR, 1981, J MICROSC-OXFORD, V124, P107, DOI 10.1111/j.1365-2818.1981.tb00304.x; Shy ME, 2009, ADV EXP MED BIOL, V652, P171, DOI 10.1007/978-90-481-2813-6_11; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; Soares L, 2014, SCI REP-UK, V4, DOI 10.1038/srep06199; SPIRA ME, 1993, J NEUROBIOL, V24, P300, DOI 10.1002/neu.480240304; Stankovic K, 2004, J NEUROSCI, V24, P8651, DOI 10.1523/JNEUROSCI.0733-04.2004; Sulaiman OAR, 2002, EXP NEUROL, V176, P342, DOI 10.1006/exnr.2002.7928; Sulaiman OAR, 2009, NEUROSURGERY, V65, pA105, DOI 10.1227/01.NEU.0000358537.30354.63; Toyama BH, 2013, CELL, V154, P971, DOI 10.1016/j.cell.2013.07.037; Villegas R, 2012, NEURAL DEV, V7, DOI 10.1186/1749-8104-7-19; WEINBERG HJ, 1978, J NEUROCYTOL, V7, P555, DOI 10.1007/BF01260889; Wuhr M, 2011, METHOD CELL BIOL, V101, P1, DOI 10.1016/B978-0-12-387036-0.00001-3; Xiao T, 2005, DEVELOPMENT, V132, P2955, DOI 10.1242/dev.01861	81	23	23	0	31	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	1754-8403	1754-8411		DIS MODEL MECH	Dis. Model. Mech.	JUN	2015	8	6					553	564		10.1242/dmm.018184			12	Cell Biology; Pathology	Cell Biology; Pathology	CJ5VD	WOS:000355559100004	26035865	DOAJ Gold, Green Published			2021-06-18	
J	Berger, RP; Parks, S; Fromkin, J; Rubin, P; Pecora, PJ				Berger, Rachel P.; Parks, Sharyn; Fromkin, Janet; Rubin, Pamela; Pecora, Peter J.			Assessing the accuracy of the International Classification of Diseases codes to identify abusive head trauma: a feasibility study	INJURY PREVENTION			English	Article							OPERATIONAL CASE-DEFINITION; HOSPITAL INPATIENT DATA; SHAKEN BABY SYNDROME; BRAIN-INJURY; CHILDREN; SURVEILLANCE; USA	Objective To assess the accuracy of an International Classification of Diseases (ICD) code-based operational case definition for abusive head trauma (AHT). Methods Subjects were children <5 years of age evaluated for AHT by a hospital-based Child Protection Team (CPT) at a tertiary care paediatric hospital with a completely electronic medical record (EMR) system. Subjects were designated as non-AHT traumatic brain injury (TBI) or AHT based on whether the CPT determined that the injuries were due to AHT. The sensitivity and specificity of the ICD-based definition were calculated. Results There were 223 children evaluated for AHT: 117 AHT and 106 non-AHT TBI. The sensitivity and specificity of the ICD-based operational case definition were 92% (95% CI 85.8 to 96.2) and 96% (95% CI 92.3 to 99.7), respectively. All errors in sensitivity and three of the four specificity errors were due to coder error; one specificity error was a physician error. Conclusions In a paediatric tertiary care hospital with an EMR system, the accuracy of an ICD-based case definition for AHT was high. Additional studies are needed to assess the accuracy of this definition in all types of hospitals in which children with AHT are cared for.	[Berger, Rachel P.; Fromkin, Janet; Rubin, Pamela] Childrens Hosp Pittsburgh UPMC, Dept Pediat, Pittsburgh, PA 15224 USA; [Parks, Sharyn] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Pecora, Peter J.] Univ Washington, Sch Social Work, Casey Family Programs, Seattle, WA 98195 USA	Berger, RP (corresponding author), Childrens Hosp Pittsburgh UPMC, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	Rachel.berger@chp.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD055986]; Matty Eappen Foundation; Casey Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055986] Funding Source: NIH RePORTER	This project was funded, in part, by NIH R01HD055986 (RB), the Matty Eappen Foundation (RB) and the Casey Family Foundation. Neither NIH nor Matty Eappen Foundation had any role in (1) the study design; (2) the collection, analysis and interpretation of the data; (3) the writing of the report and (4) the decision to submit the article for publication. Casey Family Foundation assisted with study design, interpretation of the data, writing of the report and gave approval for submission.	Aboa-Eboule C, 2013, J NEUROL, V260, P605, DOI 10.1007/s00415-012-6686-0; [Anonymous], 2012, KIDS INPATIENT DATAB; Bennett S, 2011, CHILD ABUSE NEGLECT, V35, P930, DOI 10.1016/j.chiabu.2011.05.018; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Duffy SO, 2011, PEDIATRICS, V127, pE47, DOI 10.1542/peds.2010-0298; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Fujiwara T, 2012, AM J PREV MED, V43, P215, DOI 10.1016/j.amepre.2012.04.028; Hooft A, 2013, J PEDIATR-US, V162, P80, DOI 10.1016/j.jpeds.2012.06.037; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kelly P, 2008, J PAEDIATR CHILD H, V44, P99, DOI 10.1111/j.1440-1754.2007.01234.x; Laskey AL, 2007, CHILD ABUSE NEGLECT, V31, P329, DOI 10.1016/j.chiabu.2006.02.017; Lindberg DM, 2008, PEDIATRICS, V121, pE945, DOI 10.1542/peds.2007-2485; McKenzie K, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-8; Parks S, 2012, INJURY PREV, V18, P392, DOI 10.1136/injuryprev-2011-040234; Parks SE, 2012, INJURY PREV, V18, P193, DOI 10.1136/injuryprev-2011-040128; Ryan MAK, 2008, AM J PREV MED, V34, pS143, DOI 10.1016/j.amepre.2007.12.020; Scott D, 2009, CHILD ABUSE NEGLECT, V33, P791, DOI 10.1016/j.chiabu.2009.08.005; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Stavrou E, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-331; U. S. Department of Health and Human Services Administration for Children and Families Administration on Children Youth and Families Children's Bureau, 2011, CHILD MALTR 2011; Wirtz SJ, 2008, AM J PREV MED, V34, pS134, DOI 10.1016/j.amepre.2007.11.004	24	23	23	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	APR	2015	21	E1					E133	E137		10.1136/injuryprev-2013-040924			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CE2ZS	WOS:000351693200024	24167034	Green Accepted			2021-06-18	
J	Krohn, M; Dressler, J; Bauer, M; Schober, K; Franke, H; Ondruschka, B				Krohn, Michael; Dressler, Jan; Bauer, Manfred; Schober, Kristin; Franke, Heike; Ondruschka, Benjamin			Immunohistochemical Investigation of S100 and NSE in Cases of Traumatic Brain Injury and Its Application for Survival Time Determination	JOURNAL OF NEUROTRAUMA			English	Article						NSE; traumatic brain injury; immunohistochemistry; S100; survival time	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; NERVOUS-SYSTEM; HIPPOCAMPAL NEUROGENESIS; GLUCOSE DEPRIVATION; NEUROTROPHIC FACTOR; COGNITIVE RECOVERY; TRANSGENIC MICE; CEREBRAL-CORTEX; GLIAL-CELLS	The availability of markers able to provide insight into protein changes in the central nervous system after fatal traumatic brain injury (TBI) is limited. The present study reports on the semi-quantitative assessments of the immunopositive neuroglial cells (both astrocytes and oligodendrocytes) and neurons for S100 protein (S100), as well as neuronal specific enolase (NSE), in the cerebral cortex, hippocampus, and cerebellum with regard to survival time and cause of death. Brain tissues of 47 autopsy cases with TBI (survival times ranged between several minutes and 34 d) and 10 age- and gender-matched controls (natural deaths) were examined. TBI cases were grouped according to their survival time in acute death after brain injury (ABI, n=25), subacute death after brain injury (SBI, n=18) and delayed death after brain injury (DBI, n=4). There were no significant changes in the percentages of S100-stained astrocytes between TBI and control cases. The percentages of S100-positive oligodendrocytes in the pericontusional zone (PCZ) in cases with SBI were significantly lower than in controls (p<0.05) and in the ABI group (p<0.05). In the hippocampus, S100-positive oligodendrocytes were significantly lower in cases with ABI and SBI (both, p<0.05), compared with controls. It is of particular interest that there were also S100-positive neurons in the PCZ and hippocampus in TBI cases after more than 2 h survival but not in ABI cases or controls. The percentages of NSE-positive neurons in the hippocampus were likewise significantly lower in cases with ABI, compared with controls (p<0.05) but increased in cases with SBI in PCZ (p<0.05). In conclusion, the present findings emphasize that S100 and NSE-immunopositivity might be useful for detecting the cause and process of death due to TBI. Further, S100-positivity in neurons may be helpful to estimate the survival time of fatal injuries in legal medicine.	[Krohn, Michael; Dressler, Jan; Ondruschka, Benjamin] Univ Leipzig, Inst Legal Med, D-04103 Leipzig, Germany; [Bauer, Manfred] Univ Leipzig, Dept Neuropathol, D-04103 Leipzig, Germany; [Franke, Heike] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, D-04103 Leipzig, Germany; [Schober, Kristin] German Air Force Ctr Aerosp Med, Furstenfeldbruck, Germany	Ondruschka, B (corresponding author), Univ Leipzig, Inst Legal Med, Johannisallee 28, D-04103 Leipzig, Germany.	b.ondruschka@medizin.uni-leipzig.de			German Ministry of Defense	This work was partly supported by the German Ministry of Defense. The authors declare that no competing financial interests exist.	Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; AZMITIA EC, 1995, BRAIN RES, V677, P181, DOI 10.1016/0006-8993(95)00051-Q; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Castagna C, 2003, J CHEM NEUROANAT, V25, P195, DOI 10.1016/S0891-0618(03)00009-7; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dmytriyeva O, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2202; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; FISCHER I, 1986, DEV BRAIN RES, V25, P99, DOI 10.1016/0165-3806(86)90156-2; Franke H, 2013, PURINERG SIGNAL, V9, P451, DOI 10.1007/s11302-013-9366-3; Furutani R, 2012, J NEUROTRAUM, V29, P1266, DOI 10.1089/neu.2010.1630; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Gerlach R, 2006, NEUROSCIENCE, V141, P1697, DOI 10.1016/j.neuroscience.2006.05.008; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; Hu JR, 1997, J NEUROCHEM, V69, P2294; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnstone JT, 2013, J NEUROSCI RES, V91, P828, DOI 10.1002/jnr.23208; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P1351, DOI 10.1007/s00701-013-1720-2; Li Dong-Ri, 2006, Legal Medicine, V8, P78, DOI 10.1016/j.legalmed.2005.09.002; Li DR, 2012, LEGAL MED-TOKYO, V14, P84, DOI 10.1016/j.legalmed.2011.12.007; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Mao HJ, 2013, J NEUROTRAUM, V30, P1521, DOI 10.1089/neu.2012.2520; MATSUMOTO M, 1987, MAYO CLIN PROC, V62, P460, DOI 10.1016/S0025-6196(12)65471-8; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Moore CS, 2011, J NEUROSCI RES, V89, P13, DOI 10.1002/jnr.22482; MURRAY GI, 1993, J CLIN PATHOL, V46, P993, DOI 10.1136/jcp.46.11.993; Nobs L, 2013, GLIA, V61, P1443, DOI 10.1002/glia.22533; Nogami M, 1998, ACTA HISTOCHEM, V100, P371, DOI 10.1016/S0065-1281(98)80034-2; Nogami M, 1998, FORENSIC SCI INT, V94, P97, DOI 10.1016/S0379-0738(98)00060-7; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; Ondruschka B, 2013, J NEUROTRAUM, V30, P1862, DOI 10.1089/neu.2013.2895; PELC S, 1986, J NEUROL SCI, V73, P289, DOI 10.1016/0022-510X(86)90153-X; Quintyn JC, 2005, GRAEF ARCH CLIN EXP, V243, P1167, DOI 10.1007/s00417-005-1175-0; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; RICKMANN M, 1995, NEUROSCIENCE, V67, P977, DOI 10.1016/0306-4522(94)00615-C; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Sabattini E, 1998, J CLIN PATHOL, V51, P506, DOI 10.1136/jcp.51.7.506; Savigni DL, 2013, NEUROPHARMACOLOGY, V75, P380, DOI 10.1016/j.neuropharm.2013.07.034; Schiavi Paolo, 2012, Acta Biomed, V83, P5; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Sen J, 2007, J NEUROSCI RES, V85, P1373, DOI 10.1002/jnr.21211; Staffa K, 2012, J NEUROTRAUM, V29, P2716, DOI 10.1089/neu.2011.2246; Steiner J, 2008, NEUROSCIENCE, V154, P496, DOI 10.1016/j.neuroscience.2008.03.060; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; Tiesman HM, 2011, AM J PREV MED, V41, P61, DOI 10.1016/j.amepre.2011.03.007; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; UZAN M, 1995, ACTA NEUROCHIR, V135, P141, DOI 10.1007/BF02187758; VICK RS, 1992, J NEUROTRAUM, V9, pS93; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wajima D, 2013, BRAIN RES, V1519, P127, DOI 10.1016/j.brainres.2013.05.002; Wang S, 2012, CLIN CHEM LAB MED, V50, P525, DOI [10.1515/CCLM.2011.794, 10.1515/cclm.2011.794]; WATANABE M, 1990, DEV BRAIN RES, V53, P89, DOI 10.1016/0165-3806(90)90127-K; Whitaker-Azmitia PM, 1997, BRAIN RES, V776, P51, DOI 10.1016/S0006-8993(97)01002-0; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Xiong Y, 2010, DISCOV MED, V10, P434; Yan EB, 2014, J NEUROTRAUM, V31, P618, DOI 10.1089/neu.2013.3087; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zimmer DB, 2005, CELL MOL BIOL, V51, P201, DOI 10.1170/T620	79	23	26	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					430	440		10.1089/neu.2014.3524			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400003	25211554				2021-06-18	
J	Li, K; Zhao, H; Liu, WJ; Yin, ZY				Li, Kui; Zhao, Hui; Liu, Wenjun; Yin, Zhiyong			Material Properties and Constitutive Modeling of Infant Porcine Cerebellum Tissue in Tension at High Strain Rate	PLOS ONE			English	Article							BRAIN-TISSUE; MECHANICAL-PROPERTIES; IN-VIVO; DEFORMATION; COMPRESSION; ELASTICITY; WHITE	Background The mechanical characterization of infant porcine cerebellum tissue in tension at high strain rate is crucial for modeling traumatic cerebellum injury, which is in turn helpful for understanding the biomechanics of such injuries suffered in traffic accidents. Material and Method In this study, the infant porcine cerebellum tissue was given three loading velocities, ie, 2s(-1), 20s(-1) and 100s(-1) with up to 30% strain to investigate the tensile properties. At least six tensile tests for each strain rate were validly performed. Fung, Gent, Ogden and exponential models were applied to fit the constitutive equations, so as to obtain material parameters from the experimental data. Results The Lagrange stress of infant porcine cerebellum tissue in tension appeared to be no more than 3000Pa at each loading velocity. More specifically, the Lagrange stress at 30% strain was (393.7 +/- 84.4) Pa, (928.3 +/- 56.3) Pa and (2582.4 +/- 282.2) Pa at strain rates of 2s(-1), 20s(-1) and 100s(-1), respectively. Fung (0.833 <= R-2 <= 0.924), Gent (0.797 <= R-2 <= 0.875), Ogden (0.859 <= R-2 <= 0.944) and exponential (0.930 <= R-2 <= 0.972) models provided excellent fitting to experimental data up to 30% strain. Conclusions The infant cerebellum tissue shows a stiffer response with increase of the loading speed, indicating a strong strain-rate sensitivity. This study will enrich the knowledge on the material properties of infant brain tissue, which may augment the biofidelity of finite element model of human pediatric cerebellum.	[Li, Kui; Zhao, Hui; Liu, Wenjun; Yin, Zhiyong] Third Mil Med Univ, Inst Surg Res, Daping Hosp, Inst Traff Med,Dept 4, Chongqing 400042, Peoples R China	Yin, ZY (corresponding author), Third Mil Med Univ, Inst Surg Res, Daping Hosp, Inst Traff Med,Dept 4, Chongqing 400042, Peoples R China.	yinzhiyong86@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [1271006, 31470913]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education MinistryScientific Research Foundation for the Returned Overseas Chinese Scholars	This paper was supported by grants from National Natural Science Foundation of China (No. 1271006, No. 31470913), and the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 2011, BIOL MED PHYS BIOMED, P69, DOI 10.1007/978-1-4419-9997-9_4; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; FUNG YC, 1979, AM J PHYSIOL, V237, pH620; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gent AN, 1996, RUBBER CHEM TECHNOL, V69, P59, DOI 10.5254/1.3538357; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; Margulies S, 2013, PEDIAT INJURY BIOMEC, P157; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2001, J BIOMECH, V34, P651, DOI 10.1016/S0021-9290(00)00236-0; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Ogden R., 1997, NONLINEAR ELASTIC DE; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Pervin F, 2011, NEUROIMAGE, V54, pS98, DOI 10.1016/j.neuroimage.2010.03.077; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Rashid B, 2013, J BIOMECH, V46, P1276, DOI 10.1016/j.jbiomech.2013.02.014; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tamura A., 2008, J BIOMECH SCI ENG, V3, P263, DOI DOI 10.1299/JBSE.3.263; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Zhang JY, 2011, J BIOMECH, V44, P391, DOI 10.1016/j.jbiomech.2010.10.024; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034	28	23	23	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2015	10	4							e0123506	10.1371/journal.pone.0123506			12	Multidisciplinary Sciences	Science & Technology - Other Topics	CE9AM	WOS:000352135600148	25830545	DOAJ Gold, Green Published			2021-06-18	
J	Leonard, AV; Thornton, E; Vink, R				Leonard, Anna V.; Thornton, Emma; Vink, Robert			The Relative Contribution of Edema and Hemorrhage to Raised Intrathecal Pressure after Traumatic Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						hemorrhage; spinal cord injury; edema; intrathecal pressure	BLOOD-FLOW; BARRIER PERMEABILITY; VASCULAR MECHANISMS; COMPRESSION INJURY; BRAIN-INJURY; RAT; ISCHEMIA; BALLOON; PATHOPHYSIOLOGY; REPAIR	Raised intrathecal pressure (ITP) after traumatic spinal cord injury (SCI) is a critically important aspect of injury development that may result in significantly greater tissue damage and worsened functional outcome. Raised ITP is caused by the accumulation of blood and/or water (edema), and while their occurrence after traumatic SCI has been well established, the relative contribution of both processes to the development of ITP after SCI has not yet been determined. Accordingly, the current study investigates the temporal profile of raised ITP after traumatic SCI in relation to both hemorrhage and edema development. A closed balloon compression injury was induced at T10 in New Zealand White rabbits. Animals were thereafter assessed for spinal water content (edema), ITP, lesion and hemorrhage volume, and albumin immunoreactivity from 5 h to 1 week post-SCI. Early increases in ITP at 5 h post-injury were associated with significant increases in blood volume. ITP, however, was maximal at 3 days post-SCI, at which time there was an associated significant increase in edema that persisted for 1 week. We conclude that raised ITP after traumatic SCI is initially driven by volumetric increases in hemorrhage, while edema becomes the primary driver of ITP at 3 days post-injury.	[Leonard, Anna V.; Thornton, Emma] Univ Adelaide, Sch Med Sci, Adelaide Ctr Neurosci Res, Adelaide, SA 5005, Australia; [Vink, Robert] Univ S Australia, Div Hlth Sci, Adelaide, SA 5001, Australia	Leonard, AV (corresponding author), Univ Adelaide, Sch Med Sci, Level 4 Med Sch South,Frome Rd, Adelaide, SA 5005, Australia.	anna.leonard@adelaide.edu.au	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667	Neil Sacshe Foundation Fellowship; Neurosurgical Research Foundation (Australia)	Funded, in part, by a Neil Sacshe Foundation Fellowship to AVL, and by the Neurosurgical Research Foundation (Australia).	Ates O, 2007, J CLIN NEUROSCI, V14, P658, DOI 10.1016/j.jocn.2006.03.023; Batchelor PE, 2011, J NEUROTRAUM, V28, P809, DOI 10.1089/neu.2010.1622; Bilgen M, 2002, MAGN RESON IMAGING, V20, P337, DOI 10.1016/S0730-725X(02)00504-0; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; Demediuk P, 1990, Adv Neurol, V52, P225; Goldsmith HS, 2009, J AM COLL SURGEONS, V208, P289, DOI 10.1016/j.jamcollsurg.2008.10.021; GOODMAN JH, 1976, J NEUROSURG, V44, P418, DOI 10.3171/jns.1976.44.4.0418; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Helps SC, 2012, APPL IMMUNOHISTO M M, V20, P82, DOI 10.1097/PAI.0b013e31821fc8cd; Horn EM, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E12; JACOBS TP, 1992, STROKE, V23, P367, DOI 10.1161/01.STR.23.3.367; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Kwon BK, 2009, J NEUROSURG-SPINE, V10, P181, DOI 10.3171/2008.10.SPINE08217; Leonard AV, 2013, J NEUROTRAUM, V30, P1812, DOI 10.1089/neu.2013.2993; LEVI L, 1993, NEUROSURGERY, V33, P1007, DOI 10.1097/00006123-199312000-00008; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; NEMECEK S, 1977, ACTA NEUROCHIR, V37, P7, DOI 10.1007/BF01401922; Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Popovich PG, 2012, EXP NEUROL, V233, P615, DOI 10.1016/j.expneurol.2010.11.016; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; SHARMA HS, 1993, NEUROSCIENCE, V57, P443, DOI 10.1016/0306-4522(93)90076-R; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; SYPERT GW, 1990, CLIN NEUR, V36, P186; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Vink R, 2003, ACT NEUR S, V86, P257; WANG R, 1993, SURG NEUROL, V39, P348, DOI 10.1016/0090-3019(93)90198-A; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; WINKLER T, 1994, NEUROSCI RES, V21, P91, DOI 10.1016/0168-0102(94)90072-8; YOUNG W, 1982, J NEUROSURG, V56, P706, DOI 10.3171/jns.1982.56.5.0706	38	23	25	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2015	32	6					397	402		10.1089/neu.2014.3543			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CC9DQ	WOS:000350668400004	25111333				2021-06-18	
J	Lin, AC; Salzman, GA; Bachman, SL; Burke, RV; Zaslow, T; Piasek, CZ; Edison, BR; Hamilton, A; Upperman, JS				Lin, Ann C.; Salzman, Garrett A.; Bachman, Shelby L.; Burke, Rita V.; Zaslow, Tracy; Piasek, Carolina Z.; Edison, Bianca R.; Hamilton, Anita; Upperman, Jeffrey S.			Assessment of Parental Knowledge and Attitudes Toward Pediatric Sports-Related Concussions	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						brain concussion; knowledge; parents; pediatric sports injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; LEGISLATION; EDUCATION; PLAYERS; COACHES	Background: Parents of young athletes play a major role in the identification and management of sports-related concussions. However, they are often unaware of the consequences of concussions and recommended management techniques. Hypothesis: This study quantitatively assessed parental understanding of concussions to identify specific populations in need of additional education. We predicted that parents with increased education and prior sports- and concussion-related experience would have more knowledge and safer attitudes toward concussions. Study Design: Cross-sectional survey. Methods: Participants were parents of children brought to a pediatric hospital and 4 satellite clinics for evaluation of orthopaedic injuries. Participants completed a validated questionnaire that assessed knowledge of concussion symptoms, attitudes regarding diagnosis and return-to-play guidelines, and previous sports-and concussion-related experience. Results: Over 8 months, 214 parents completed surveys. Participants scored an average of 18.4 (possible, 0-25) on the Concussion Knowledge Index and 63.1 (possible, 15-75) on the Concussion Attitude Index. Attitudes were safest among white women, and knowledge increased with income and education levels. Previous sports experience did not affect knowledge or attitudes, but parents who reported experiencing an undiagnosed concussion had significantly better concussion knowledge than those who did not. Conclusion: Parents with low income and education levels may benefit from additional concussion-related education.	[Lin, Ann C.; Salzman, Garrett A.; Bachman, Shelby L.; Burke, Rita V.; Zaslow, Tracy; Upperman, Jeffrey S.] Childrens Hosp Los Angeles, Div Pediat Surg, 4650 Sunset Blvd,Mailstop 100, Los Angeles, CA 90027 USA; [Lin, Ann C.; Burke, Rita V.; Zaslow, Tracy; Edison, Bianca R.; Hamilton, Anita; Upperman, Jeffrey S.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Zaslow, Tracy; Piasek, Carolina Z.; Edison, Bianca R.; Hamilton, Anita] Childrens Hosp Los Angeles, Childrens Orthoped Ctr Sports Med & Concuss Progr, Los Angeles, CA 90027 USA; [Zaslow, Tracy; Piasek, Carolina Z.; Edison, Bianca R.; Hamilton, Anita] Childrens Hosp Los Angeles, Concuss Program, Los Angeles, CA 90027 USA	Upperman, JS (corresponding author), Childrens Hosp Los Angeles, Div Pediat Surg, 4650 Sunset Blvd,Mailstop 100, Los Angeles, CA 90027 USA.	jupperman@chla.usc.edu		Edison, Bianca/0000-0003-3181-5758; Bachman, Shelby/0000-0002-4460-4661			Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Centers for Disease Control and Prevention, HEADS CONC; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Coghlin Craig J, 2009, J Can Chiropr Assoc, V53, P233; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gordon KE, 2010, PEDIATR NEUROL, V43, P253, DOI 10.1016/j.pediatrneurol.2010.05.012; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Upshaw JE, 2012, PEDIATR EMERG CARE, V28, P926, DOI 10.1097/PEC.0b013e318267f674	20	23	23	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAR-APR	2015	7	2					124	129		10.1177/1941738115571570			6	Sport Sciences	Sport Sciences	V20HU	WOS:000214878500004	25984257	Green Published			2021-06-18	
J	Mata-Mbemba, D; Mugikura, S; Nakagawa, A; Murata, T; Kato, Y; Tatewaki, Y; Li, L; Takase, K; Ishii, K; Kushimoto, S; Tominaga, T; Takahashi, S				Mata-Mbemba, Daddy; Mugikura, Shunji; Nakagawa, Atsuhiro; Murata, Takaki; Kato, Yumiko; Tatewaki, Yasuko; Li, Li; Takase, Kei; Ishii, Kiyoshi; Kushimoto, Shigeki; Tominaga, Teiji; Takahashi, Shoki			Intraventricular Hemorrhage on Initial Computed Tomography as Marker of Diffuse Axonal Injury after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; intraventricular hemorrhage; diffuse axonal injury; computed tomography; corpus callosum	CLOSED-HEAD INJURY; MAGNETIC-RESONANCE; INTRACRANIAL-PRESSURE; CT; MR; PROGNOSIS; CLASSIFICATION; MODERATE; LESIONS	Intraventricular hemorrhage (IVH) on initial computed tomography (CT) was reported to predict lesions of diffuse axonal injury (DAI) in the corpus callosum (CC) on subsequent magnetic resonance imaging (MRI). We aimed to examine the relationship between initial CT findings and DAI lesions detected on MRI as well as the relationship between the severity of IVH (IVH score) and severity of DAI (DAI staging). A consecutive 140 patients with traumatic brain injury (TBI) who underwent MRI within 30 days after onset were revisited. We reviewed their initial CT for the following six findings: Status of basal cistern, status of mid-line shift, epidural hematoma, IVH, subarachnoid hemorrhage, and volume of hemorrhagic mass and IVH score were assigned in each patient. Based on MRI findings, patients were divided into DAI and non-DAI groups and were assigned a DAI staging. Then, to confirm that the IVH on initial CT predicts DAI lesions on MRI, we used multi-variate analysis of the six CT findings, including IVH, and examined the relationship between IVH score and DAI staging. The IVH detected on CT was the only predictor of DAI (p=0.0139). The IVH score and DAI staging showed significant positive correlation (p<0.0003). IVH score in DAI stage 3 (with DAI involving the brain stem; p=0.0025) or stage 2 (with DAI involving CC; p=0.0042) was significantly higher than that of DAI stage 0 (no DAI lesions). In conclusion, IVH on initial CT is the only marker of DAI on subsequent MRI, specifically severe DAI (stage 2 or 3).	[Mata-Mbemba, Daddy; Mugikura, Shunji; Murata, Takaki; Kato, Yumiko; Tatewaki, Yasuko; Li, Li; Takase, Kei; Takahashi, Shoki] Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Sendai, Miyagi 9808574, Japan; [Nakagawa, Atsuhiro; Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 9808574, Japan; [Kushimoto, Shigeki] Tohoku Univ, Grad Sch Med, Div Emergency Med, Sendai, Miyagi 9808574, Japan; [Ishii, Kiyoshi] Sendai City Hosp, Dept Radiol, Sendai, Miyagi, Japan	Mugikura, S (corresponding author), Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	mugi@rad.med.tohoku.ac.jp	Mata-Mbemba, Daddy/AAP-3184-2020		Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [13F03410] Funding Source: KAKEN		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Atzema C, 2006, J TRAUMA, V60, P1010, DOI 10.1097/01.ta.0000218038.28064.9d; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Huang YH, 2012, NEUROSURGERY, V71, P80, DOI 10.1227/NEU.0b013e3182517aa1; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; JAYAKUMAR PN, 1990, ACTA NEUROCHIR, V106, P48, DOI 10.1007/BF01809332; Katsnelson M, 2012, NEUROSURGERY, V70, P1095, DOI 10.1227/NEU.0b013e318240c1ed; Lagares A, 2006, NEUROCIRUGIA, V17, P105; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; LEE JP, 1991, ACTA NEUROL SCAND, V84, P85, DOI 10.1111/j.1600-0404.1991.tb04913.x; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; Matsukawa H, 2012, J NEUROSURG, V117, P334, DOI 10.3171/2012.5.JNS112318; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Provenzale JM, 2010, AM J ROENTGENOL, V194, P16, DOI 10.2214/AJR.09.3687; SATO M, 1987, ACTA NEUROCHIR, V88, P95, DOI 10.1007/BF01404144; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	33	23	25	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					359	365		10.1089/neu.2014.3453			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700008	25026366				2021-06-18	
J	Rodger, J; Sherrard, RM				Rodger, Jennifer; Sherrard, Rachel M.			Optimising repetitive transcranial magnetic stimulation for neural circuit repair following traumatic brain injury	NEURAL REGENERATION RESEARCH			English	Article									[Rodger, Jennifer] Univ Western Australia, Sch Anim Biol, Expt & Regenerat Neurosci, Perth, WA 6009, Australia; [Sherrard, Rachel M.] Univ Paris 06, Sorbonne Univ, Paris, France; [Sherrard, Rachel M.] CNRS, Inst Biol Paris Seine B2A, UMR Biol Adaptat & Ageing 8256, Paris, France	Rodger, J (corresponding author), Univ Western Australia, Sch Anim Biol, Expt & Regenerat Neurosci, Perth, WA 6009, Australia.	jennifer.rodger@uwa.edu.au	Sherrard, Rachel/Y-1355-2019; Sherrard, Rachel M/D-5446-2013; Rodger, Jennifer/H-5735-2014	Sherrard, Rachel/0000-0002-6595-3545; Rodger, Jennifer/0000-0003-3413-4229			Deng ZD, 2013, BRAIN STIMUL, V6, P1, DOI 10.1016/j.brs.2012.02.005; Di Lazzaro V, 2013, BRAIN STIMUL, V6, P469, DOI 10.1016/j.brs.2013.01.004; Ellaway PH, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00042; Grehl S, 2015, BRAIN STIMUL, V8, P114, DOI 10.1016/j.brs.2014.09.012; Henrich-Noack P, 2013, NEUROSCI LETT, V543, P1, DOI 10.1016/j.neulet.2013.03.013; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Makowiecki K, 2014, J NEUROSCI, V34, P10780, DOI 10.1523/JNEUROSCI.0723-14.2014; Mix A, 2015, DEV NEUROBIOL, V75, P1, DOI 10.1002/dneu.22205; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; Rodger J, 2012, FASEB J, V26, P1593, DOI 10.1096/fj.11-194878; Vlachos A, 2012, J NEUROSCI, V32, P17514, DOI 10.1523/JNEUROSCI.0409-12.2012; Wiltschko R., 1995, MAGNETIC ORIENTATION	12	23	23	0	11	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	MAR	2015	10	3					357	359		10.4103/1673-5374.153676			3	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	CH0VH	WOS:000353740000007	25878575	DOAJ Gold, Green Published			2021-06-18	
J	Troyanskaya, M; Pastorek, NJ; Scheibel, RS; Petersen, NJ; McCulloch, K; Wilde, EA; Henson, HK; Levin, HS				Troyanskaya, Maya; Pastorek, Nicholas J.; Scheibel, Randall S.; Petersen, Nancy J.; McCulloch, Katie; Wilde, Elisabeth A.; Henson, Helene K.; Levin, Harvey S.			Combat Exposure, PTSD Symptoms, and Cognition Following Blast-Related Traumatic Brain Injury in OEF/OIF/OND Service Members and Veterans	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SELECTIVE REMINDING TEST; ENDURING FREEDOM; TEST-PERFORMANCE; VALIDITY TEST; IRAQ WAR; DEPLOYMENT; SOLDIERS; PERSONNEL	Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are frequently documented among the Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans. This study will investigate both combat exposure and PTSD as factors that may influence objective cognitive outcomes following blast-related mild TBI (mTBI). Participants included 54 OEF/OIF/OND veterans who had been exposed to blast and reported symptoms consistent with mTBI and 43 combat-deployed control participants who had no history of blast exposure or TBI. Raw scores from the Controlled Oral Word Association Test, Trail Making Test, Color-Word Interference Test, and Verbal Selective Reminding Test were used to measure cognitive functioning. All participants demonstrated adequate effort on the Word Memory Test. Demographics, injury characteristics, overall intellectual functioning, and total scores from the PTSD Checklist-Civilian Version (PCL-C) and Combat Exposure Scale (CES) were used as the predictors for each cognitive measure. History of mTBI was significantly associated with higher PCL-C and CES scores. Multivariable linear regression, however, showed no significant differences in cognitive performance between groups. The absence of effect of mTBI, PTSD, and combat exposure on cognitive functioning noted in this study may be partially explained by the inclusion of only those participants who passed performance validity testing.	[Troyanskaya, Maya; Pastorek, Nicholas J.; Scheibel, Randall S.; Petersen, Nancy J.; McCulloch, Katie; Wilde, Elisabeth A.; Henson, Helene K.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Troyanskaya, Maya; Pastorek, Nicholas J.; Scheibel, Randall S.; Wilde, Elisabeth A.; Henson, Helene K.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Petersen, Nancy J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [McCulloch, Katie] Univ Houston, Dept Psychol, Houston, TX 77204 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Troyanskaya, M (corresponding author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.			McCulloch, Katie/0000-0003-0385-6536	Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs [B6812C]; Veterans AffairsUS Department of Veterans Affairs [I01RX001062, I01RX001320] Funding Source: NIH RePORTER	This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, B6812C (PI-Levin HS) VA RR&D "Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks"; O1062I (PIs-Scheibel RS and Wilde EA) VA RR&D "A Longitudinal Study of Chronic TBI in OEF/OIF/OND Veterans and Service Members"; B7241R (PIs-Levin HS and Scheibel RS) "An FMRI Study of TBI Associated with Blast Injury"; and CIN 13-413 (PI-Petersen LA) VA HSR&D Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, TX.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT, P424; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Benton AL, 1978, MULTILINGUAL APHASIA; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bliese PD, 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; Brown L., 2010, TEST NONVERBAL INTEL; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2005, WORD MEMORY TEST WIN; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020	31	23	23	0	11	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	MAR	2015	180	3					285	289		10.7205/MILMED-D-14-00256			5	Medicine, General & Internal	General & Internal Medicine	CD3OI	WOS:000350987700013	25735018	Bronze			2021-06-18	
J	DeMatteo, C; Stazyk, K; Singh, SK; Giglia, L; Hollenberg, R; Malcolmson, CH; Mahoney, W; Harper, JA; Missiuna, C; Law, M; McCauley, D				DeMatteo, Carol; Stazyk, Kathy; Singh, Sheila K.; Giglia, Lucy; Hollenberg, Robert; Malcolmson, Charles H.; Mahoney, William; Harper, Jessica A.; Missiuna, Cheryl; Law, Mary; McCauley, Dayle			Development of a Conservative Protocol to Return Children and Youth to Activity Following Concussive Injury	CLINICAL PEDIATRICS			English	Article						child; mild traumatic brain injury; concussion; return to play; return to activity; postconcussion syndrome; recovery	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; TO-PLAY; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; POSTCONCUSSION SYNDROME; RECURRENT CONCUSSION; CONSENSUS STATEMENT; PATHOPHYSIOLOGY; ADOLESCENTS	Background. Consensus-based guidelines exist for adult athletes returning to play after concussion, but there are no protocols developed specifically for children. The goal of this knowledge translation research was to develop evidence-based materials to inform physicians about pediatric concussion. Methods. A pediatric concussion protocol was developed based on the National Institute for Health and Care Excellence procedures. Results. This return to activity protocol was developed to guide management when children/youth sustain a concussion. The protocol incorporated 3 main themes: (a) a protocol must include return to all activity, including sport and school; (b) existing consensus-based adult protocols are not appropriate for children; and (c) a more conservative protocol is needed. After pilot testing, the developed protocol is being used across Ontario. Conclusion. Implementation of these new pediatric recommendations is an important addition to prevention of subsequent concussions during vulnerable recovery periods, with potential to facilitate recovery by preventing prolonged symptomatology, and secondary sequelae.	[DeMatteo, Carol; Stazyk, Kathy; Singh, Sheila K.; Giglia, Lucy; Hollenberg, Robert; Malcolmson, Charles H.; Mahoney, William; Harper, Jessica A.; Missiuna, Cheryl; Law, Mary] McMaster Univ, Hamilton, ON L8S 1C7, Canada; [Singh, Sheila K.; Giglia, Lucy; Hollenberg, Robert; Malcolmson, Charles H.; McCauley, Dayle] McMaster Childrens Hosp, Hamilton, ON, Canada	DeMatteo, C (corresponding author), McMaster Univ, Sch Rehabil Sci, 1400 Main St West,IAHS 403, Hamilton, ON L8S 1C7, Canada.	dematteo@mcmaster.ca	Singh, Sheila K/W-2799-2018	Singh, Sheila K/0000-0003-1272-5300	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [115228]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Canadian Institute of Health Research (Grant No. 115228).	[Anonymous], 2010, THINKFIRST SPORT SMA; Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Berlin AA, 2006, PSYCHOSOM MED, V68, pA; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; *CDCP, WHAT IS TRAUM BRAIN; Centre for Evidence Based Medicine, FIND THE EV; Colorado Medical Society School and Sports Medicine Committee, 1990, COLO MED, V87, P4; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DeMatteo C, 2015, DISABIL REHABIL, V37, P1107, DOI 10.3109/09638288.2014.952452; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Johnson LSM, 2012, J SCHOOL HEALTH, V82, P180, DOI 10.1111/j.1746-1561.2011.00684.x; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kelly JP, 1997, NEUROLOGY, V48, P581; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Laker SR, 2011, PHYS MED REH CLIN N, V22, P619, DOI 10.1016/j.pmr.2011.08.004; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGrath N, 2013, BRAIN INJURY, V27, P103, DOI 10.3109/02699052.2012.729282; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Morin D, 2011, AM AC PED NAT C OCT; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; National Institute for Health and Care Excellence (NICE), WHO WE AR; Ontario Neurotrauma Foundation, GUID CONC MTBI PERS; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Vidal PG, 2012, PEDIATR ANN, V41, pE186, DOI 10.3928/00904481-20120827-10; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	70	23	23	0	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	FEB	2015	54	2					152	163		10.1177/0009922814558256			12	Pediatrics	Pediatrics	AZ4NA	WOS:000348197200008	25422524				2021-06-18	
J	Stasolla, F; Caffo, AO; Damiani, R; Perilli, V; Di Leone, A; Albano, V				Stasolla, Fabrizio; Caffo, Alessandro O.; Damiani, Rita; Perilli, Viviana; Di Leone, Antonia; Albano, Vincenza			Assistive technology-based programs to promote communication and leisure activities by three children emerged from a minimal conscious state	COGNITIVE PROCESSING			English	Article						Assistive technology; Traumatic brain injury; Post-coma; Minimal conscious state; Quality of life; Social validation	AUTISM SPECTRUM DISORDERS; TRAUMATIC BRAIN-INJURY; SCANNING KEYBOARD EMULATOR; MICROSWITCH-BASED PROGRAMS; QUALITY-OF-LIFE; MOTOR DISABILITIES; MULTIPLE DISABILITIES; ALZHEIMERS-DISEASE; 2 BOYS; ENGAGEMENT	This study proposed the use of assistive technology (AT) to promote communication and leisure opportunities by three children with traumatic brain injury (TBI). Furthermore, it assessed the effects of such technology on the indices of positive participation and provided a social validation procedure. Three children emerged from a minimal conscious state and presenting extensive motor disabilities were involved. The intervention program allowed the participants to request and to choice preferred items independently and to perform literacy through a keyboard emulator. A multiple probe design across behaviors with post-intervention check was employed. Outcome measures were correct requests, understandable words, intervals with positive participation, and scores of social validation assessment. Request and choice behaviors and literacy improved significantly during intervention phases. During post-intervention check, all participants consolidated their performance. Moreover, indices of positive participation increased during intervention phases. Scores of social validation assessment showed that the combination of both behaviors was preferable to the same considered separately. AT program showed to be suitable for promoting constructive engagement and literacy behaviors by children with TBI. Future research is needed to generalize this data to a larger sample and to develop new technology for people with different levels of disabilities due to TBI.	[Stasolla, Fabrizio] Lega Filo dOro Res Ctr, Molfetta, Italy; [Caffo, Alessandro O.; Damiani, Rita; Di Leone, Antonia; Albano, Vincenza] Univ Bari, Dept Educ Sci, Bari, Italy; [Perilli, Viviana] Lega Filo dOro Res Ctr, Lesmo, Italy	Stasolla, F (corresponding author), Lega Filo dOro Res Ctr, Molfetta, Italy.	f.stasolla@psico.uniba.it	Stasolla, Fabrizio/I-5418-2019	Stasolla, Fabrizio/0000-0003-1626-9664; Caffo, Alessandro O./0000-0003-3973-8152			Anderson V, 2012, J HEAD TRAUMA REHAB, V27, P199, DOI 10.1097/HTR.0b013e31821a9d2b; Caffo AO, 2014, RES DEV DISABIL, V35, P572, DOI 10.1016/j.ridd.2013.12.003; Chiapparino C, 2011, LIFE SPAN DISABIL, V14, P45; Crawford MR, 1993, J DEV PHYS DISABIL, V5, P349, DOI DOI 10.1007/BF01046391; FELCE D, 1995, RES DEV DISABIL, V16, P51, DOI 10.1016/0891-4222(94)00028-8; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Hagen C, 1998, LEVELS COGNITIVE FUN; Kramer ME, 2013, J HEAD TRAUMA REHAB, V28, P361, DOI 10.1097/HTR.0b013e31824da031; Lancioni GE, 2007, PERCEPT MOTOR SKILL, V105, P47, DOI 10.2466/PMS.105.1.47-54; Lancioni GE, 2006, J INTELL DISABIL RES, V50, P739, DOI 10.1111/j.1365-2788.2006.00839.x; Lancioni GE, 2014, AUT CHILD PSYCHO, P1, DOI 10.1007/978-1-4899-8029-8; Lancioni G, 2010, DEV NEUROREHABIL, V13, P248, DOI 10.3109/17518423.2010.485596; Lancioni GE, 2007, J DEV PHYS DISABIL, V19, P593, DOI 10.1007/s10882-007-9073-5; Lancioni Giulio E, 2005, Cogn Process, V6, P177, DOI 10.1007/s10339-005-0003-0; Lancioni GE, 2013, RES DEV DISABIL, V34, P2959, DOI 10.1016/j.ridd.2013.06.006; Lancioni GE, 2013, J DEV PHYS DISABIL, V25, P273, DOI 10.1007/s10882-012-9301-5; Lancioni GE, 2012, RES DEV DISABIL, V33, P1605, DOI 10.1016/j.ridd.2012.03.028; Lancioni GE, 2010, RES DEV DISABIL, V31, P1121, DOI 10.1016/j.ridd.2010.06.019; Lancioni GE, 2009, RES DEV DISABIL, V30, P203, DOI 10.1016/j.ridd.2008.03.001; Lancioni GE, 2006, J DEV PHYS DISABIL, V18, P383, DOI 10.1007/s10882-006-9024-6; Lidstrom H, 2012, DISABIL REHABIL-ASSI, V7, P287, DOI 10.3109/17483107.2011.635332; Ratliffe KT, 2012, INFORM TECHNOL DEV, V18, P209, DOI 10.1080/02681102.2011.643207; Sasse N, 2013, J HEAD TRAUMA REHAB, V28, P464, DOI 10.1097/HTR.0b013e318263977d; Stasolla F, 2014, NEUROREHABILITATION, V35, P253, DOI 10.3233/NRE-141112; Stasolla F, 2014, RES AUTISM SPECT DIS, V8, P1071, DOI 10.1016/j.rasd.2014.05.016; Stasolla F, 2014, RES AUTISM SPECT DIS, V8, P472, DOI 10.1016/j.rasd.2014.01.007; Stasolla F, 2014, RES AUTISM SPECT DIS, V8, P376, DOI 10.1016/j.rasd.2013.12.020; Stasolla F, 2013, RES AUTISM SPECT DIS, V7, P1265, DOI 10.1016/j.rasd.2013.07.010; Stasolla F, 2013, RES DEV DISABIL, V34, P2694, DOI 10.1016/j.ridd.2013.05.029	29	23	23	0	12	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1612-4782	1612-4790		COGN PROCESS	Cogn. Process.	FEB	2015	16	1					69	78		10.1007/s10339-014-0625-1			10	Psychology, Experimental	Psychology	AZ3GS	WOS:000348116100007	25077461				2021-06-18	
J	Trotman, M; Vermehren, P; Gibson, CL; Fern, R				Trotman, Melissa; Vermehren, Philipp; Gibson, Claire L.; Fern, Robert			The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						glutamate; ischemia; memantine; NMDA receptor; stroke	NMDA RECEPTOR ANTAGONIST; TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; GLUTAMATE RECEPTORS; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; CLINICAL-TRIALS; CHANNEL BLOCK; WHITE-MATTER; RAT	Excitotoxicity is a major contributor to cell death during the acute phase of ischemic stroke but aggressive pharmacological targeting of excitotoxicity has failed clinically. Here we investigated whether pretreatment with low doses of memantine, within the range currently used and well tolerated for the treatment of Alzheimer's disease, produce a protective effect in stroke. A coculture preparation exposed to modeled ischemia showed cell death associated with rapid glutamate rises and cytotoxic Ca2+ influx. Cell death was significantly enhanced in the presence of high memantine concentrations. However, low memantine concentrations significantly protected neurons and glia via excitotoxic cascade interruption. Mice were systemically administered a range of memantine doses (0.02, 0.2, 2, 10, and 20 mg/kg/day) starting 24 hours before 60 minutes reversible focal cerebral ischemia and continuing for a 48-hour recovery period. Low dose (0.2 mg/kg/day) memantine treatment significantly reduced lesion volume (by 30% to 50%) and improved behavioral outcomes in stroke lesions that had been separated into either small/striatal or large/striatocortical infarcts. However, higher doses of memantine (20 mg/kg/day) significantly increased injury. These results show that clinically established low doses of memantine should be considered for patients 'at risk' of stroke, while higher doses are contraindicated.	[Trotman, Melissa; Vermehren, Philipp] Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; [Gibson, Claire L.] Univ Leicester, Sch Psychol, Leicester, Leics, England; [Fern, Robert] Univ Plymouth, Peninsula Sch Med & Dent, Plymouth PL6 8BU, Devon, England	Fern, R (corresponding author), Univ Plymouth, Peninsula Sch Med & Dent, John Bull Bldg,Res Way, Plymouth PL6 8BU, Devon, England.	robert.fern@plymouth.ac.uk	trotman-lucas, melissa/Y-5096-2019	trotman-lucas, melissa/0000-0002-7735-7476; Gibson, Claire/0000-0002-3358-7341; fern, robert/0000-0002-0625-3434			Aarts MM, 2005, PFLUG ARCH EUR J PHY, V451, P243, DOI 10.1007/s00424-005-1439-x; Ahlgren H, 2011, CELL TISSUE RES, V345, P329, DOI 10.1007/s00441-011-1218-2; Allgaier M, 2014, FRONT BIOSCI-LANDMRK, V19, P1344; Bakiri Y, 2008, GLIA, V56, P233, DOI 10.1002/glia.20608; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Besancon E, 2008, TRENDS PHARMACOL SCI, V29, P268, DOI 10.1016/j.tips.2008.02.003; Blanpied TA, 1997, J NEUROPHYSIOL, V77, P309; Block F, 1996, NEUROSCI LETT, V208, P41, DOI 10.1016/0304-3940(96)12545-3; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; Bonde C, 2005, NEUROSCIENCE, V136, P779, DOI 10.1016/j.neuroscience.2005.07.020; Chen HSV, 1998, NEUROSCIENCE, V86, P1121, DOI 10.1016/S0306-4522(98)00163-8; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; Coull AJ, 2004, STROKE, V35, P1925, DOI 10.1161/01.STR.0000133129.58126.67; Creeley C, 2006, J NEUROSCI, V26, P3923, DOI 10.1523/JNEUROSCI.4883-05.2006; Culmsee C, 2004, STROKE, V35, P1197, DOI 10.1161/01.STR.0000125855.17686.6d; Dale N, 2005, TRENDS BIOTECHNOL, V23, P420, DOI 10.1016/j.tibtech.2005.05.010; Danysz W, 2012, BRIT J PHARMACOL, V167, P324, DOI 10.1111/j.1476-5381.2012.02057.x; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Elijovich L, 2010, CURR ATHEROSCLER REP, V12, P316, DOI 10.1007/s11883-010-0121-8; Fern R, 1998, J NEUROSCI, V18, P7232; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Ginsberg MD, 2009, STROKE, V40, pS111, DOI 10.1161/STROKEAHA.108.528877; Gorgulu A, 2000, ACTA NEUROCHIR, V142, P1287, DOI 10.1007/s007010070027; Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Johnson JW, 2006, CURR OPIN PHARMACOL, V6, P61, DOI 10.1016/j.coph.2005.09.007; Kalia LV, 2008, LANCET NEUROL, V7, P742, DOI 10.1016/S1474-4422(08)70165-0; Klyubin I, 2011, NEUROBIOL AGING, V32, P614, DOI 10.1016/j.neurobiolaging.2009.04.005; KORNHUBER J, 1995, NEUROSCI LETT, V195, P137, DOI 10.1016/0304-3940(95)11785-U; KRIEGSTEIN AR, 1983, J NEUROSCI, V3, P1634; Lapchak PA, 2006, BRAIN RES, V1088, P141, DOI 10.1016/j.brainres.2006.02.093; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8; Lipton Stuart A, 2004, NeuroRx, V1, P101, DOI 10.1007/BF03206570; Liu FD, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/464701; Loihl AK, 1999, BRAIN RES, V830, P155, DOI 10.1016/S0006-8993(99)01388-8; Longuemare MC, 1996, AM J PHYSIOL-CELL PH, V270, pC1398; Lubitz SA, 2013, J AM GERIATR SOC, V61, P1798, DOI 10.1111/jgs.12456; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Orgogozo JM, 2002, STROKE, V33, P1834, DOI 10.1161/01.STR.0000020094.08790.49; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Rammes G, 2001, NEUROSCI LETT, V306, P81, DOI 10.1016/S0304-3940(01)01872-9; REISER G, 1989, EUR J PHARM-MOLEC PH, V172, P199, DOI 10.1016/0922-4106(89)90011-4; Rogawski MA, 2003, CNS DRUG REV, V9, P275, DOI 10.1111/j.1527-3458.2003.tb00254.x; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Sperlagh B, 2007, NEUROSCIENCE, V149, P99, DOI 10.1016/j.neuroscience.2007.07.035; Sun HX, 2013, J STROKE, V15, P109, DOI 10.5853/jos.2013.15.2.109; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; Yaksh TL, 2008, ANESTHESIOLOGY, V108, P938, DOI 10.1097/ALN.0b013e31816c902a	52	23	25	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2015	35	2					230	239		10.1038/jcbfm.2014.188			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CA2QS	WOS:000348753100010	25407270	Green Published, Bronze			2021-06-18	
J	Mohn, TC; Koob, AO				Mohn, Tal C.; Koob, Andrew O.			Adult Astrogenesis and the Etiology of Cortical Neurodegeneration	JOURNAL OF EXPERIMENTAL NEUROSCIENCE			English	Article						astrocyte; gliogenesis; neurogenesis; gliosis; Alzheimer's disease; dementia with Lewy bodies	NEURAL STEM-CELLS; ASTROGLIAL INTERLAMINAR PROCESSES; ASTROCYTE-MEDIATED CONTROL; AMYLOID PRECURSOR PROTEIN; MULTIPLE SYSTEM ATROPHY; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; CEREBRAL-CORTEX	As more evidence points to a clear role for astrocytes in synaptic processing, synaptogenesis and cognition, continuing research on astrocytic function could lead to strategies for neurodegenerative disease prevention. Reactive astrogliosis results in astrocyte proliferation early in injury and disease states and is considered neuroprotective, indicating a role for astrocytes in disease etiology. This review describes the different types of human cortical astrocytes and the current evidence regarding adult cortical astrogenesis in injury and degenerative disease. A role for disrupted astrogenesis as a cause of cortical degeneration, with a focus on the tauopathies and synucleinopathies, will also be considered.	[Mohn, Tal C.; Koob, Andrew O.] Univ Wisconsin, Biol Dept, River Falls, WI 54022 USA	Koob, AO (corresponding author), Univ Wisconsin, Biol Dept, River Falls, WI 54022 USA.	andrew.koob@uwrf.edu		Koob, Andrew/0000-0003-3381-6770			Alonso G, GLIA; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALTMAN J, 1964, NATURE, V204, P1161, DOI 10.1038/2041161a0; Anderson CM, 2003, TRENDS NEUROSCI, V26, P340, DOI 10.1016/S0166-2236(03)00141-3; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Attems J, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0206-2; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Bayraktar OA, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020362; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Bhardwaj RD, 2006, P NATL ACAD SCI USA, V103, P12564, DOI 10.1073/pnas.0605177103; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Boda E, 2010, ARCH ITAL BIOL, V148, P119; Braak H, 2007, ACTA NEUROPATHOL, V114, P231, DOI 10.1007/s00401-007-0244-3; Brennan KC, 2007, J NEUROPHYSIOL, V97, P4143, DOI 10.1152/jn.00028.2007; Broe M, 2004, BRAIN, V127, P2214, DOI 10.1093/brain/awh250; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Burns KA, 2009, GLIA, V57, P1115, DOI 10.1002/glia.20835; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butt AM, 2005, J ANAT, V207, P695, DOI 10.1111/j.1469-7580.2005.00458.x; Capilla-Gonzalez V, 2014, GLIA, V62, P790, DOI 10.1002/glia.22642; Casal C, 2004, NEUROSCI RES, V48, P315, DOI 10.1016/j.neures.2003.11.006; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chow SK, 2010, ASN NEURO, V2, DOI 10.1042/AN20090035; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Colombo JA, 2004, BRAIN RES, V1006, P126, DOI 10.1016/j.brainres.2004.02.003; Colombo JA, 1997, INT J DEV NEUROSCI, V15, P823, DOI 10.1016/S0736-5748(97)00043-9; COLOMBO JA, 1995, J NEUROSCI RES, V40, P551, DOI 10.1002/jnr.490400414; Colombo JA, 1997, J NEUROSCI RES, V48, P352, DOI 10.1002/(SICI)1097-4547(19970515)48:4<352::AID-JNR7>3.0.CO;2-A; Colombo JA, 1998, ANAT EMBRYOL, V197, P369, DOI 10.1007/s004290050147; Cotrina ML, 2002, J NEUROSCI RES, V67, P1; Crouch EE, 2015, J NEUROSCI, V35, P4528, DOI 10.1523/JNEUROSCI.1188-14.2015; Dabir DV, 2006, J NEUROSCI, V26, P644, DOI 10.1523/JNEUROSCI.3861-05.2006; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Keyser J, 2008, J NEUROL SCI, V267, P3, DOI 10.1016/j.jns.2007.08.044; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Dore-Duffy P, 2011, METHODS MOL BIOL, V686, P49, DOI 10.1007/978-1-60761-938-3_2; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Ehninger D, 2003, CEREB CORTEX, V13, P845, DOI 10.1093/cercor/13.8.845; Fabricius K, 2013, NEUROBIOL AGING, V34, P91, DOI 10.1016/j.neurobiolaging.2012.06.009; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Forman MS, 2005, J NEUROSCI, V25, P3539, DOI 10.1523/JNEUROSCI.0081-05.2005; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Fung KM, 2003, ACTA NEUROPATHOL, V106, P167, DOI 10.1007/s00401-003-0718-x; Garcia-Marques J, 2013, CEREB CORTEX, V23, P1463, DOI 10.1093/cercor/bhs134; Ge WP, 2012, NATURE, V484, P376, DOI 10.1038/nature10959; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Gotz M, 2015, GLIA, V63, P1452, DOI 10.1002/glia.22850; Gu XL, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-12; Halliday GM, 2011, MOVEMENT DISORD, V26, P6, DOI 10.1002/mds.23455; Han XN, 2013, CELL STEM CELL, V12, P342, DOI 10.1016/j.stem.2012.12.015; HANSEN LA, 1987, NEUROBIOL AGING, V8, P1, DOI 10.1016/0197-4580(87)90051-0; Haydon PG, 2001, NAT REV NEUROSCI; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; Holmin S, 2001, NEUROSCI LETT, V314, P151, DOI 10.1016/S0304-3940(01)02292-3; Hu XY, 2013, CELL REP, V4, P40, DOI 10.1016/j.celrep.2013.06.005; Ihrie RA, 2008, CELL TISSUE RES, V331, P179, DOI 10.1007/s00441-007-0461-z; Iliff JJ, 2013, STROKE, V44, pS93, DOI 10.1161/STROKEAHA.112.678698; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jellinger KA, 1997, J NEURAL TRANSM-SUPP, P57; Kamphuis W, 2015, GLIA, V63, P1036, DOI 10.1002/glia.22800; Kamphuis W, 2012, GLIA, V60, P615, DOI 10.1002/glia.22295; Kang SH, 2010, NEURON, V68, P668, DOI 10.1016/j.neuron.2010.09.009; Kim KS, 2013, HUM MOL GENET, V22, P4805, DOI 10.1093/hmg/ddt332; Kimelberg HK, 2010, NEUROTHERAPEUTICS, V7, P338, DOI 10.1016/j.nurt.2010.07.006; KIMELBERG HK, 1995, NEUROCHEM INT, V26, P27, DOI 10.1016/0197-0186(94)00118-E; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; Koob AO, 2008, INT J DEV NEUROSCI, V26, P641, DOI 10.1016/j.ijdevneu.2008.04.001; Koob AO, 2014, BRAIN RES, V1591, P102, DOI 10.1016/j.brainres.2014.10.013; Koob AO, 2010, NEUROSCI LETT, V469, P11, DOI 10.1016/j.neulet.2009.11.034; KRAIG RP, 1991, J NEUROSCI, V11, P2187; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Kronenberg G, 2007, BRAIN STRUCT FUNCT, V212, P19, DOI 10.1007/s00429-007-0141-5; Kulijewicz-Nawrot M, 2012, J ANAT, V221, P252, DOI 10.1111/j.1469-7580.2012.01536.x; LeComte MD, 2015, P NATL ACAD SCI USA, V112, P8726, DOI 10.1073/pnas.1501029112; Lee HJ, 2014, NAT REV NEUROL, V10, P92, DOI 10.1038/nrneurol.2013.275; Lee HJ, 2010, J BIOL CHEM, V285, P9262, DOI 10.1074/jbc.M109.081125; Lee IS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.125; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Li L, 2010, GLIA, V58, P1610, DOI 10.1002/glia.21033; Lim DA, 2014, TRENDS NEUROSCI, V37, P563, DOI 10.1016/j.tins.2014.08.006; Lim D, 2014, REV PHYSIOL BIOCH P, V167, P45, DOI 10.1007/112_2014_19; Luccarini I, 2012, NEUROSCI LETT, V506, P94, DOI 10.1016/j.neulet.2011.10.056; LUSE SA, 1956, J BIOPHYS BIOCHEM CY, V2, P531, DOI 10.1083/jcb.2.5.531; Magnus T, 2007, J NEUROSCI RES, V85, P2126, DOI 10.1002/jnr.21368; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Mandyam CD, 2007, J NEUROSCI, V27, P11442, DOI 10.1523/JNEUROSCI.2505-07.2007; Mathur R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118463; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Moh C, 2011, RESULTS PROBL CELL D, V53, P565, DOI 10.1007/978-3-642-19065-0_23; Mukaetova-Ladinska EB, 2008, DEMENT GERIATR COGN, V26, P32, DOI 10.1159/000141039; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Ninkina N, 2009, HUM MOL GENET, V18, P1779, DOI 10.1093/hmg/ddp090; Nishiyama A, 2005, J ANAT, V207, P687, DOI 10.1111/j.1469-7580.2005.00489.x; O'Flanagan CH, 2014, BBA-REV CANCER, V1846, P590, DOI 10.1016/j.bbcan.2014.10.006; Oberheim NA, 2012, METHODS MOL BIOL, V814, P23, DOI 10.1007/978-1-61779-452-0_3; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Olsson B, 2013, MOVEMENT DISORD, V28, P1882, DOI 10.1002/mds.25589; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 1997, J NEUROSCI, V17, P7817; Peinado MA, 1997, ANAT REC, V247, P420; Peinado MA, 1998, MICROSC RES TECHNIQ, V43, P34, DOI 10.1002/(SICI)1097-0029(19981001)43:1<34::AID-JEMT6>3.0.CO;2-G; Pelvig DP, 2008, NEUROBIOL AGING, V29, P1754, DOI 10.1016/j.neurobiolaging.2007.04.013; Peng L, 2014, CURR NEUROPHARMACOL, V12, P303, DOI 10.2174/1570159X12999140829152550; PETERS A, 1994, CEREB CORTEX, V4, P621, DOI 10.1093/cercor/4.6.621; PETERS A, 1991, ANAT REC, V229, P384, DOI 10.1002/ar.1092290311; Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Psachoulia K, 2009, NEURON GLIA BIOL, V5, P57, DOI 10.1017/S1740925X09990354; Radford R, 2015, MOL CELL NEUROSCI, V65, P68, DOI 10.1016/j.mcn.2015.02.015; Raina AK, 2004, ACTA NEUROBIOL EXP, V64, P107; Rapanelli M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014713; Reyes RC, 2012, ASN NEURO, V4, P33, DOI 10.1042/AN20110059; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Rhodes KE, 2003, NEUROSCIENCE, V120, P41, DOI 10.1016/S0306-4522(03)00285-9; Richardson WD, 2011, NEURON, V70, P661, DOI 10.1016/j.neuron.2011.05.013; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Robel S, 2009, GLIA, V57, P1630, DOI 10.1002/glia.20876; Rodriguez JJ, 2014, NEUROBIOL AGING, V35, P15, DOI 10.1016/j.neurobiolaging.2013.07.002; Rodriguez-Arellano J.J., 2015, NEUROSCIENCE; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rozovsky I, 1998, NEUROBIOL AGING, V19, P97, DOI 10.1016/S0197-4580(97)00169-3; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Sampedro-Piquero P, 2014, NEUROBIOL LEARN MEM, V114, P16, DOI 10.1016/j.nlm.2014.04.002; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; SCHECHTER R, 1981, J NEUROPATH EXP NEUR, V40, P95, DOI 10.1097/00005072-198103000-00002; Seidenfaden R, 2006, MOL CELL NEUROSCI, V32, P187, DOI 10.1016/j.mcn.2006.04.003; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shibuya K, 2011, BRAIN RES, V1404, P50, DOI 10.1016/j.brainres.2011.06.014; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Sirko S, 2009, BRAIN, V132, P2252, DOI 10.1093/brain/awp043; Sizonenko SV, 2008, INT J DEV NEUROSCI, V26, P37, DOI 10.1016/j.ijdevneu.2007.08.014; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sofroniew MV, 2015, GLIA; Sohn JH, 2015, J NEUROSCI, V35, P3756, DOI 10.1523/JNEUROSCI.3454-14.2015; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Steiner B, 2004, GLIA, V46, P41, DOI 10.1002/glia.10337; Surgucheva I, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0132-8; Surguchov A, 2001, CELL MOTIL CYTOSKEL, V49, P218, DOI 10.1002/cm.1035; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Takano T, 2006, NAT NEUROSCI, V9, P260, DOI 10.1038/nn1623; Tamura Y, 2012, J CEREBR BLOOD F MET, V32, P1879, DOI 10.1038/jcbfm.2012.98; Tatsumi K, 2008, J NEUROSCI RES, V86, P3494, DOI 10.1002/jnr.21862; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Toledano A., 2004, Current Alzheimer Research, V1, P189, DOI 10.2174/1567205043332117; Tong JC, 2015, NEUROBIOL DIS, V82, P243, DOI 10.1016/j.nbd.2015.06.010; Trazzi S, 2013, J BIOL CHEM, V288, P20817, DOI 10.1074/jbc.M113.451088; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Urbach A, 2006, EUR J NEUROSCI, V24, P841, DOI 10.1111/j.1460-9568.2006.04862.x; Urbach A, 2015, J CEREBR BLOOD F MET, V35, P576, DOI 10.1038/jcbfm.2014.232; van den Berge SA, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/420957; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; Verkhratsky A., 2013, GLIAL PHYSL PATHOPHY; Verkhratsky A, 2014, NEUROSCIENTIST, V21, P562; Verkhratsky A, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0595; Verkhratsky A, 2014, BIOCHEM SOC T, V42, P1291, DOI 10.1042/BST20140107; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wang SM, 2015, MOL NEUROBIOL, V51, P370, DOI 10.1007/s12035-014-8714-9; Xue JH, 2009, STROKE, V40, pE606, DOI 10.1161/STROKEAHA.109.560334; Yang L, 2013, J TRANSL MED, V1, P11; Yeh CY, 2011, ASN NEURO, V3, DOI 10.1042/AN20110025; Yurov YB, 2011, THESCIENTIFICWORLDJO, V11, P2602, DOI 10.1100/2011/625690; Zhang Y., 2015, J NANOMATER, V2015, P1, DOI DOI 10.1080/10298436.2015.1019502; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895; Zhu XQ, 2011, DEVELOPMENT, V138, P745, DOI 10.1242/dev.047951	184	23	26	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1179-0695			J EXP NEUROSCI	J. Exp. Neurosci.		2015	9			2			25	34	UNSP JEn.S25520	10.4137/JEn.S25520			10	Neurosciences	Neurosciences & Neurology	V30XG	WOS:000215594700003	26568684	DOAJ Gold, Green Published			2021-06-18	
J	Neville, C; Ludlow, C; Rieger, B				Neville, Christopher; Ludlow, Caleb; Rieger, Brian			Measuring postural stability with an inertial sensor: validity and sensitivity	MEDICAL DEVICES-EVIDENCE AND RESEARCH			English	Article						balance; concussion; forceplate; posturography; accelerometer		Introduction/purpose: To examine the concurrent validity, and sensitivity, of an inertial sensor for use in the assessment of postural sway. Methods: This was a laboratory-based, repeated-measures design with ten healthy participants. Concurrent validity was tested between an inertial sensor, forceplate, and rigid-body kinematics across three commonly used balance tests. Further, the inertial sensor measures were compared across eight commonly used tests of balance. Variables manipulated include stance position, surface condition, and eyes-open versus eyes-closed. Results: The inertial sensor was correlated to both the forceplate-derived measures (r=0.793) and rigid-body kinematics (r=0.887). Significant differences between the balance tests were observed when tested with the inertial sensor. In general, there was a three-way interactions between the three balance factors (surface, stance, and vision) leading to pairwise comparisons between each balance test. The root-mean-square showed an increase across tasks of greater difficulty ranging from an average of 0.0368 with two legs, eyes-open to 0.911 when tested during tandem stance, eyes-closed tested on a foam pad. Conclusion: The new inertial sensor shows promise for use in the assessment of postural sway. Additionally, the inertial sensor appears sensitive to differences in balance tasks of varying degrees of difficulty when tested in a healthy sample of young adults. This inertial sensor may provide new opportunities for further research in the assessment of balance changes in the mild traumatic brain injury population.	[Neville, Christopher; Ludlow, Caleb] SUNY Upstate Med Univ, Dept Phys Therapy Educ, 2225 Silvermann Hall,750 East Adams St, Syracuse, NY 13210 USA; [Rieger, Brian] SUNY Upstate Med Univ, Upstate Concuss Ctr, Syracuse, NY 13210 USA	Neville, C (corresponding author), SUNY Upstate Med Univ, Dept Phys Therapy Educ, 2225 Silvermann Hall,750 East Adams St, Syracuse, NY 13210 USA.	nevillec@upstate.edu		Neville, Christopher/0000-0002-8601-976X	Upstate Medical University and Motion Intelligence, Inc.	Research reported in this publication was solely the responsibility of the authors. The inertial sensors used in the study were provided by Motion Intelligence, Inc. (Ithaca, NY), and Upstate Medical University and Motion Intelligence, Inc. provided financial support of the clinical research.	Adlerton Anna-Karin, 2003, Physiother Res Int, V8, P187, DOI 10.1002/pri.289; Baltich J, 2014, GAIT POSTURE, V40, P327, DOI 10.1016/j.gaitpost.2014.04.208; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bonfim TR, 2008, NEUROSCI LETT, V441, P257, DOI 10.1016/j.neulet.2008.06.039; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Chang JO, 2014, CLIN J SPORT MED, V24, P256, DOI 10.1097/JSM.0000000000000016; Chaudhry H, 2004, J REHABIL RES DEV, V41, P713, DOI 10.1682/JRRD.2003.09.0140; Cicchetti DV, 2001, J CLIN EXP NEUROPSYC, V23, P695, DOI 10.1076/jcen.23.5.695.1249; Doheny EP, 2012, IEEE ENG MED BIO, P3300, DOI 10.1109/EMBC.2012.6346670; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Jorgensen MG, 2014, DAN MED J, V61; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; MAKI BE, 1994, J GERONTOL, V49, pM72, DOI 10.1093/geronj/49.2.M72; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2012, GAIT POSTURE, V36, P471, DOI 10.1016/j.gaitpost.2012.04.010; McCall Andrew A, 2011, Front Neurol, V2, P88, DOI 10.3389/fneur.2011.00088; McCollum G, 1996, J THEOR BIOL, V180, P257, DOI 10.1006/jtbi.1996.0101; Moe-Nilssen R, 2002, GAIT POSTURE, V16, P60, DOI 10.1016/S0966-6362(01)00200-4; Moe-Nilssen R, 1998, ARCH PHYS MED REHAB, V79, P1377, DOI 10.1016/S0003-9993(98)90231-3; NASHNER LM, 1971, ACTA OTO-LARYNGOL, V72, P429, DOI 10.3109/00016487109122504; O'Sullivan M, 2009, AGE AGEING, V38, P308, DOI 10.1093/ageing/afp009; Palmerini L, 2011, IEEE T INF TECHNOL B, V15, P481, DOI 10.1109/TITB.2011.2107916; Pereira Tiago, 2013, Percept Mot Skills, V117, P1150; Piirtola M, 2006, GERONTOLOGY, V52, P1, DOI 10.1159/000089820; SCHUMANN T, 1995, J BIOMECH, V28, P603, DOI 10.1016/0021-9290(94)00113-I; Seimetz Christina, 2012, Biomed Sci Instrum, V48, P386; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015; WINTER DA, 1990, MED PROG TECHNOL, V16, P31	32	23	23	0	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1179-1470			MED DEVICES-EVID RES	MED. DEVICES-EVID. RES.		2015	8						447	454		10.2147/MDER.S91719			8	Engineering, Biomedical	Engineering	V05TQ	WOS:000213895300048	26604839	DOAJ Gold, Green Published			2021-06-18	
J	Ooi, YY; Dheen, ST; Tay, SSW				Ooi, Yin Yin; Dheen, S. Thameem; Tay, Samuel Sam Wah			Paracrine Effects of Mesenchymal Stem Cells-Conditioned Medium on Microglial Cytokines Expression and Nitric Oxide Production	NEUROIMMUNOMODULATION			English	Article						Mesenchymal stem cells; Microglia; Conditioned medium; Cytokines	TRAUMATIC BRAIN-INJURY; UMBILICAL-CORD BLOOD; BONE-MARROW; INTRACEREBRAL TRANSPLANTATION; ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; BV2 MICROGLIA; SYNTHASE; MECHANISMS; LIPOPOLYSACCHARIDE	Background/Aim: Microglia, the resident macrophages in the central nervous system, secrete various proinflammatory cytokines and undergo proliferation upon activation in various neurodegenerative diseases. Activation of microglia has been implicated in exacerbation of various neurodegenerative diseases. Recently, it has been proposed that mesenchymal stem cells (MSC) have immunosuppressive properties and the potential to moderate inflammation. This study aimed to elucidate the effects of MSC-conditioned medium (MSC-CM) in modulating microglial activation by analyzing microglial proinflammatory and anti-inflammatory factors [interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS) and IL-10], signaling pathway molecules [NF kappa B, c-Jun N-terminal kinase (JNK) and MKP-1) and NO production. Methods: Immortalized murine microglia cell line, BV2 microglia and primary microglia isolated from C57BL/6 mouse pup brains were used in this study. Mouse MSC were isolated from the male C57BL/6 mouse tibia and fibula. The effects of MSC-CM on the expression of inflammatory cytokines and signaling molecules in microglia were elucidated using RT-PCR, immunofluorescence analysis and Western blot analysis. NO production in microglia was assessed using a Griess kit. Results: MSC-CM significantly reduced the mRNA and protein expression levels of proinflammatory cytokines (IL-6 and TNF-alpha) in microglia activated by lipopolysaccharide (LPS). In addition, MSC-CM significantly reduced the protein expression of NF kappa B, JNK and c-Jun, but increased the expression levels of IL-10 and MKP-1 in activated BV2 microglia. NO production and iNOS expression by BV2 microglia in MSC-CM were increased. Conclusions: Overall, our findings suggest that MSC immunomodulate microglial activities through paracrine effects. (C) 2014 S. Karger AG, Basel	[Ooi, Yin Yin; Dheen, S. Thameem; Tay, Samuel Sam Wah] Natl Univ Singapore, Dept Anat, Yong Loo Lin Sch Med, Singapore 117594, Singapore	Tay, SSW (corresponding author), Natl Univ Singapore, Dept Anat, Yong Loo Lin Sch Med, MD10,4 Med Dr, Singapore 117594, Singapore.	samuel_tay@nuhs.edu.sg	Dheen, S. Thameem/AAU-8627-2020	Dheen, S. Thameem/0000-0001-9600-6789	Singapore Ministry of EducationMinistry of Education, Singapore [R-181-000-128-112]; Singapore National University Health System Seed Grant [R-181-000-151-750]	This study was supported by the Singapore Ministry of Education (R-181-000-128-112) and Singapore National University Health System Seed Grant (R-181-000-151-750). We thank Parakalan Rangarajan for providing critical comments about the manuscript.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Cipriani R, 2011, J NEUROSCI, V31, P16327, DOI 10.1523/JNEUROSCI.3611-11.2011; Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932; DEMERLEPALLARDY C, 1993, LIFE SCI, V52, P1883, DOI 10.1016/0024-3205(93)90009-R; Emborg ME, 2013, CELL TRANSPLANT, V22, P831, DOI 10.3727/096368912X647144; Fouraschen SMG, 2012, STEM CELLS DEV, V21, P2410, DOI 10.1089/scd.2011.0560; Gaetani P, 2013, J NEUROSURG SCI, V57, P55; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Huo YQ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-49; Karussis D, 2008, J NEUROL SCI, V265, P131, DOI 10.1016/j.jns.2007.05.005; Kim YJ, 2009, GLIA, V57, P13, DOI 10.1002/glia.20731; Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lee HJ, 2012, NEUROBIOL AGING, V33, P588, DOI 10.1016/j.neurobiolaging.2010.03.024; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341; Ling E A, 2001, Prog Brain Res, V132, P61; Magnusson S, 1996, NEUROREPORT, V7, P2046, DOI 10.1097/00001756-199608120-00039; Muller I, 2008, CURR OPIN ORGAN TRAN, V13, P639, DOI 10.1097/MOT.0b013e328317a462; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Nikolic WV, 2008, STEM CELLS DEV, V17, P423, DOI 10.1089/scd.2008.0018; Ooi YY, 2010, INT IMMUNOPHARMACOL, V10, P1532, DOI 10.1016/j.intimp.2010.09.001; Ousman SS, 2012, NAT NEUROSCI, V15, P1096, DOI 10.1038/nn.3161; Parekkadan B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000941; Peunova N, 1996, COLD SPRING HARB SYM, V61, P417; Rafei M, 2009, J IMMUNOL, V182, P5994, DOI 10.4049/jimmunol.0803962; Rahmat Z, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt160; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Sarojini H, 2008, J CELL BIOCHEM, V104, P1793, DOI 10.1002/jcb.21748; Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood-2006-02-002246; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Singer NG, 2011, ANNU REV PATHOL-MECH, V6, P457, DOI 10.1146/annurev-pathol-011110-130230; Stansley B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-115; Sun H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072926; Timmers L, 2011, STEM CELL RES, V6, P206, DOI 10.1016/j.scr.2011.01.001; Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-52; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Walter MNM, 2010, EXP CELL RES, V316, P1271, DOI 10.1016/j.yexcr.2010.02.026; Wieseler-Frank J, 2005, NEUROSIGNALS, V14, P166, DOI 10.1159/000087655; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhou Y, 2007, J NEUROCHEM, V102, P667, DOI 10.1111/j.1471-4159.2007.04535.x; Zhu CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035125	51	23	24	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401	1423-0216		NEUROIMMUNOMODULAT	Neuroimmunomodulation		2015	22	4					233	242		10.1159/000365483			10	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	CG8NE	WOS:000353564000003	25341618				2021-06-18	
J	Salgado, ASI; Zangaro, RA; Parreira, RB; Kerppers, II				Salgado, Afonso S. I.; Zangaro, Renato A.; Parreira, Rodolfo B.; Kerppers, Ivo I.			The effects of transcranial LED therapy (TCLT) on cerebral blood flow in the elderly women	LASERS IN MEDICAL SCIENCE			English	Article						Cerebrovascular blood flow; Elderly people; Light emitting diode; Transcranial Doppler ultrasound	TRAUMATIC BRAIN-INJURY; LEVEL LASER THERAPY; NEAR-INFRARED LIGHT; DOPPLER ULTRASOUND; PERFORMANCE; STROKE; INDEX; MICE; DEPRESSION; PRESSURE	During aging processes, there is a range of functional changes, where we can highlight the disease related to the central nervous system, such as Alzheimer disease and others forms of dementia. This study investigated the effects of transcranial light emitting diode (LED) on cerebral blood flow in healthy elderly women analyzed by transcranial Doppler ultrasound (TCD) of the right and left middle cerebral artery and basilar artery. Twenty-five noninstitutionalized elderly women (mean age 72 years old), with a cognitive status > 24, were assessed using transcranial Doppler ultrasound on two separate occasions: pre-irradiation and post-transcranial LED therapy (TCLT). Prior to this, they answered two questionnaires: the perceived stress scale and the general health questionnaire. TCLT (627 nm, 70 mW/cm(2), 10 J/cm(2)) was performed at four points of the frontal and parietal region for 30 s each, totaling 120 s two times per week for 4 weeks. Paired t-test results showed that there was a significant improvement after TCLT with increase in the systolic and diastolic velocity of the left middle cerebral artery (25 and 30 %, respectively) and basilar artery (up to 17 and 25 %), as well as a decrease in the pulsatility index and resistance index values of the three cerebral arteries analyzed (p < 0.05). TCD parameters showed improvement in the blood flow on the arteries analyzed. TCLT promoted a blood and vasomotor behavior of the basilar and middle cerebral arteries in healthy elderly women.	[Salgado, Afonso S. I.; Zangaro, Renato A.] Univ Camilo Castelo Branco, Inst Biomed Engn, Unicastelo, BR-12247004 Sao Paulo, Brazil; [Salgado, Afonso S. I.; Parreira, Rodolfo B.] Sch Postural & Manual Therapy, BR-86015300 Londrina, Parana, Brazil; [Zangaro, Renato A.] CITE, BR-12245650 Sao Paulo, Brazil; [Kerppers, Ivo I.] Univ Estadual Centro Oeste, Physiotherapy Course, Lab Neuroanat & Neurophysiol, BR-85040080 Guarapuava, Parana, Brazil	Salgado, ASI (corresponding author), Univ Camilo Castelo Branco, Inst Biomed Engn, Unicastelo, BR-12247004 Sao Paulo, Brazil.	afonsosisalgado@yahoo.com.br	Parreira, Rodolfo B/L-9793-2016; Parreira, Rodolfo/AAH-6459-2019; Kerppers, Ivo Ilvan/ABF-8157-2020; Kerppers, Ivo Ilvan/AAF-2075-2019	Parreira, Rodolfo B/0000-0003-2597-1172; Parreira, Rodolfo/0000-0003-2597-1172; 			Akinyemi RO, 2013, CURR ALZHEIMER RES, V10, P642; Akiyama H, 1997, J NEUROL SCI, V152, P39, DOI 10.1016/S0022-510X(97)00141-X; Alexandrov AV, 2007, J NEUROIMAGING, V17, P11, DOI 10.1111/j.1552-6569.2006.00088.x; Ball KA, 2011, J PHOTOCH PHOTOBIO B, V102, P182, DOI 10.1016/j.jphotobiol.2010.12.002; Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014; Chen JJ, 2011, NEUROIMAGE, V55, P468, DOI 10.1016/j.neuroimage.2010.12.032; Demidova-Rice TN, 2007, LASER SURG MED, V39, P706, DOI 10.1002/lsm.20549; Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; ELIAS MF, 1995, EXP AGING RES, V21, P369, DOI 10.1080/03610739508253991; FARMER ME, 1990, J CLIN EPIDEMIOL, V43, P475, DOI 10.1016/0895-4356(90)90136-D; Gouveia Valdiney V., 2003, Psic.: Teor. e Pesq., V19, P241, DOI 10.1590/S0102-37722003000300006; Gsell W, 2000, J CHEM NEUROANAT, V20, P215, DOI 10.1016/S0891-0618(00)00095-8; Hutsler J, 2003, TRENDS NEUROSCI, V26, P429, DOI 10.1016/S0166-2236(03)00198-X; Jagdeo JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047460; KAY DWK, 1985, PSYCHOL MED, V15, P771, DOI 10.1017/S0033291700005006; KELLEY RE, 1992, STROKE, V23, P9, DOI 10.1161/01.STR.23.1.9; Knecht S, 2000, BRAIN, V123, P2512, DOI 10.1093/brain/123.12.2512; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Li M, 2014, NEUROSCI RES, V14, P33; Lim MH, 2009, STROKE, V40, P3216, DOI 10.1161/STROKEAHA.109.558403; Luft CD, 2007, REV SAUDE PUBL, V41, P606, DOI 10.1590/S0034-89102007000400015; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Okamoto Y, 2012, ACTA NEUROPATHOL, V123, P381, DOI 10.1007/s00401-011-0925-9; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; ROBERTSON LC, 1991, COGNITIVE PSYCHOL, V23, P299, DOI 10.1016/0010-0285(91)90012-D; Roher AE, 2011, ALZHEIMERS DEMENT, V7, P445, DOI 10.1016/j.jalz.2010.09.002; Samoilova KA, 2004, PHOTOCH PHOTOBIO SCI, V3, P96, DOI 10.1039/b305738k; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Sejdic E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055405; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; SPERRY R, 1982, SCIENCE, V217, P1223, DOI 10.1126/science.7112125; Staub D, 2006, STROKE, V37, P800, DOI 10.1161/01.STR.0000202589.47401.c6; Suter OC, 2002, STROKE, V33, P1986, DOI 10.1161/01.STR.0000024523.82311.77; Tanaka Kortaro, 1996, Keio Journal of Medicine, V45, P14; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Vicenzini E, 2007, EUR NEUROL, V58, P84, DOI 10.1159/000103642; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003	44	23	23	1	12	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-8921	1435-604X		LASER MED SCI	Lasers Med. Sci.	JAN	2015	30	1					339	346		10.1007/s10103-014-1669-2			8	Engineering, Biomedical; Surgery	Engineering; Surgery	AZ5ZS	WOS:000348297900045	25277249				2021-06-18	
J	Salinsky, M; Storzbach, D; Goy, E; Evrard, C				Salinsky, Martin; Storzbach, Daniel; Goy, Elizabeth; Evrard, Collette			Traumatic Brain Injury and Psychogenic Seizures in Veterans	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						epilepsy; psychogenic seizures; PTSD; TBI; Veterans	POSTTRAUMATIC-STRESS-DISORDER; NONEPILEPTIC SEIZURES; EPILEPSY; HEALTH; COMORBIDITY; SYMPTOMS; SEQUELAE	Objective: To evaluate a proposed seizure etiology of traumatic brain injury (TBI) as a risk factor for psychogenic nonepileptic seizures (PNESs), the effect of reported TBI severity on the diagnosis of PNES versus epileptic seizures (ESs), and the potential moderating role of posttraumatic stress disorder (PTSD). Participants, Setting: Veterans with a diagnosis of PNES or ES during epilepsy monitoring at a Veterans Affairs Medical Center. Design: Retrospective review of seizure type, proposed seizure etiology, TBI severity, and PTSD. Main Outcomes: Both PNES and ES groups were compared for TBI history and severity, and prior diagnosis of PTSD. Results: Traumatic brain injury was the proposed seizure etiology for 57% of 67 PNES patients versus 35% of 54 ES patients (P < .05). It was mild in 87% of PNES patients and 37% of ES patients (P < .001). Posttraumatic stress disorder increased the likelihood of diagnosing PNES versus ES in Veterans with mild TBI as the proposed seizure etiology. Conclusions: Veterans with PNES commonly cite a TBI as the cause for seizures. Mild TBI was strongly associated with PNES versus ES. Posttraumatic stress disorder may moderate the development of PNES in Veterans with a history of mild TBI. Clinicians caring for Veterans with seizures may use these results in selecting patients for early diagnostic evaluation.	[Salinsky, Martin; Storzbach, Daniel; Goy, Elizabeth; Evrard, Collette] Portland VA Med Ctr, Portland, OR USA; [Salinsky, Martin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Salinsky, M (corresponding author), Portland VAMC Epilepsy Ctr, 3710 SWUS Vet Hosp Rd P3ECOE, Portland, OR 97239 USA.	Salinsky@ohsu.edu					Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Annegers JF, 1996, TREATMENT EPILEPSY P, P166; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Benbadis SR, 2004, EPILEPSIA, V45, P1150, DOI 10.1111/j.0013-9580.2004.14504.x; Bowman ES, 1996, AM J PSYCHIAT, V153, P57; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlson K, 2009, ASSESSMENT TREATMENT, P1; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Goldstein LH, 2010, NEUROLOGY, V74, P1986, DOI 10.1212/WNL.0b013e3181e39658; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Krawetz P, 2001, J NERV MENT DIS, V189, P38, DOI 10.1097/00005053-200101000-00007; LaFrance WC, 2010, NEUROLOGY, V75, P1166, DOI 10.1212/WNL.0b013e3181f4d5a9; LaFrance WC, 2013, EPILEPSIA, V54, P718, DOI 10.1111/epi.12053; LaFrance WC, 2013, EPILEPSIA, V54, P53, DOI 10.1111/epi.12106; LaFrance WC, 2006, NEUROLOGY, V66, P1620, DOI 10.1212/01.wnl.0000224953.94807.be; Lippa SM, 2012, J INT NEUROPSYCH SOC, V16, P856; Litz B. T., 2009, PTSD RES Q, V20, P1; Martin R, 2003, NEUROLOGY, V61, P1791, DOI 10.1212/01.WNL.0000098890.13946.F5; Martin RC, 1998, SEIZURE-EUR J EPILEP, V7, P385, DOI 10.1016/S1059-1311(05)80007-X; Nelson N. W., 2012, J INT NEUROPSYCH SOC, V18, P1, DOI DOI 10.1017/S1355617711001548; PIERELLI F, 1989, EPILEPSIA, V30, P513, DOI 10.1111/j.1528-1157.1989.tb05465.x; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Pugh MJV, 2015, J HEAD TRAUMA REHAB, V30, P29, DOI 10.1097/HTR.0000000000000045; R Development Core Team, 2012, R LANG ENV STAT COMP; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rosenberg HJ, 2000, EPILEPSIA, V41, P447, DOI 10.1111/j.1528-1157.2000.tb00187.x; Salinsky M, 2012, EPILEPSY BEHAV, V25, P345, DOI 10.1016/j.yebeh.2012.07.013; Salinsky M, 2011, NEUROLOGY, V77, P945, DOI 10.1212/WNL.0b013e31822cfc46; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sigurdardottir KR, 1998, EPILEPSIA, V39, P749, DOI 10.1111/j.1528-1157.1998.tb01161.x; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tingley D, 2012, MEDIATION R PACKAGE; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	38	23	25	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					E65	E70		10.1097/HTR.0000000000000057			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400008	24901325				2021-06-18	
J	Solomon, GS; Zuckerman, SL				Solomon, Gary S.; Zuckerman, Scott L.			Chronic traumatic encephalopathy in professional sports: Retrospective and prospective views	BRAIN INJURY			English	Article						Chronic traumatic encephalopathy; concussion; sports; traumatic brain injury	ALZHEIMERS-DISEASE; FOOTBALL; CONCUSSION; RISK; TAU; PLAYERS; INJURY	Primary objective: The purposes of this paper are to review: (1) the history of chronic traumatic encephalopathy (CTE) in sports, (2) the similarities and differences between historic and current definitions of CTE, (3) recent epidemiology and cohort studies of CTE and (4) controversies regarding the current CTE positions. Research design: Not applicable. Methods and procedures: Selective review of published articles relevant to CTE. Main outcome and results: The current definitions of CTE have evolved from its original definition and now rely heavily on the post-mortem detection of hyperphosphorylated tau for diagnosis. As of 2013, there is a blended cohort of 110 professional athletes diagnosed with CTE. It is being assumed that concussions and/or sub-concussive impacts in contact sports are the sole cause of CTE. Conclusions: There are multiple causes of abnormal tau protein deposition in the human brain and the pathogenesis of CTE may not be related solely to concussion and/or sub-concussive injury. In all likelihood, the causes of CTE are a multivariate, as opposed to a univariate, phenomenon.	[Solomon, Gary S.; Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Nashville, TN 37212 USA; [Solomon, Gary S.; Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Dept Orthoped Surg & Rehabil, Nashville, TN 37212 USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA	Solomon, GS (corresponding author), Neurosurg Clin, 1500 21st Ave South,Suite 1506, Nashville, TN 37232 USA.	gary.solomon@vanderbilt.edu	Solomon, Gary/K-9011-2019		Nashville Predators; Tennessee Titans	Solomon receives royalties from book sales. He receives consulting fees for clinical services from the Nashville Predators and the Tennessee Titans. He is a member of the ImPACT Professional Advisory Board and receives free use of the ImPACT test when beta testing, as well as expense reimbursement for attendance at Board meetings. Dr Zuckerman has no competing interests to disclose.	Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Braak E, 1999, EUR ARCH PSY CLIN N, V249, P14; Braak H, 2012, ALZHEIMERS DEMENT, V8, P227, DOI 10.1016/j.jalz.2012.01.011; Casson I, 2010, NEUROLOGY TODAY, V10, P6, DOI DOI 10.1097/01.NT.0000380917.17552.b7; Casson I, 2006, NEUROSURGERY, V58, pE1152; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; COURVILLE CYRIL B., 1962, BULL LOS ANGELES NEUROL SOC, V27, P160; Critchley M., 1949, NEUROCHIRURG HOMMAGE, P131; Fodero-Tavoletti MT, 2011, BRAIN, V134, P1089, DOI 10.1093/brain/awr038; Forman M, 2006, ANN NEUROL, V59, P592; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Handratta V, 2010, NEUROCASE, V16, P125, DOI 10.1080/13554790903329166; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Josephs KA, 2008, ANN NEUROL, V64, P4, DOI 10.1002/ana.21426; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lesort M, 1999, J NEURAL TRANSM, V106, P1217, DOI 10.1007/s007020050235; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McKee A, 2012, BRAIN A J NEUROL, V1, P1; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Omalu B, 2006, NEUROSURGERY, V58, pE1152; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Osnato M, 1927, ARCH NEURO PSYCHIATR, V18, P181, DOI 10.1001/archneurpsyc.1927.02210020025002; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Ramage SN, 2005, NEUROPATH APPL NEURO, V31, P439, DOI 10.1111/j.1365-2990.2005.00670.x; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Weir D. R., 2009, STUDY RETIRED NFL PL	40	23	23	0	27	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	2					164	170		10.3109/02699052.2014.965205			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AZ4OI	WOS:000348201500005	25314314				2021-06-18	
J	Westfall, DR; West, JD; Bailey, JN; Arnold, T; Kersey, PA; Saykin, AJ; McDonald, BC				Westfall, Daniel R.; West, John D.; Bailey, Jessica N.; Arnold, Toddw.; Kersey, Patrick A.; Saykin, Andrew J.; McDonald, Brenna C.			Increased brain activation during working memory processing after pediatric mild traumatic brain injury (mTBI)	JOURNAL OF PEDIATRIC REHABILITATION MEDICINE			English	Article						Concussion; mild traumatic brain injury; mTBI; pediatric; functional magnetic resonance imaging; fMRI; working memory	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; FUNCTIONAL MRI; RECOVERY; DYSFUNCTION; INHIBITION; CHALLENGE; FOOTBALL; CHILDREN; IMPACT	PURPOSE: The neural substrate of post-concussive symptoms following the initial injury period after mild traumatic brain injury (mTBI) in pediatric populations remains poorly elucidated. This study examined neuropsychological, behavioral, and brain functioning in adolescents post-mTBI to assess whether persistent differences were detectable up to a year post-injury. METHODS: Nineteen adolescents on average 7.5 months post-mTBI completed neuropsychological testing and an fMRI auditory-verbal N-back working memory task. Parents completed behavioral ratings. The comparison group included 19 healthy controls matched to the mTBI group for demographic variables and N-back task performance. RESULTS: There were no between-group differences for cognition or behavior ratings. The expected decreased accuracy and increased reaction time as N-back task difficulty increased were apparent. The mTBI group showed significantly greater brain activation than controls during the most difficult working memory load condition. CONCLUSION: Greater working memory task-related activation was found in adolescents up to one year post-mTBI relative to controls, potentially indicating compensatory activation to support normal task performance. Differences in brain activation in the mTBI group so long after injury may indicate residual alterations in brain function much later than would be expected based on the typical pattern of symptom recovery, which could have important clinical implications.	[Westfall, Daniel R.; West, John D.; Bailey, Jessica N.; Saykin, Andrew J.; McDonald, Brenna C.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, 355 W 16th St,GH Suite 4100, Indianapolis, IN 46202 USA; [Arnold, Toddw.; Kersey, Patrick A.] St Vincent Sports Performance, Carmel, IN USA	McDonald, BC (corresponding author), Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, 355 W 16th St,GH Suite 4100, Indianapolis, IN 46202 USA.	mcdonalb@iupui.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	Indiana State Department of Health Spinal Cord and Brain Injury Fund Research Grant Program; Project Development Team within the ICTSI NIH/NCRR Grant [RR025761]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108, UL1TR002529] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010133] Funding Source: NIH RePORTER	The authors thank our MRI technologist colleagues at the Indiana Institute for Biomedical Imaging Sciences for their assistance in assuring successful MRI scans, and also thank Lindsey Shine and Kimberly Campbell for their contributions to this project. We are also very grateful to our participants and their families for their time and effort. This work was supported by a grant from the Indiana State Department of Health Spinal Cord and Brain Injury Fund Research Grant Program and by a Project Development Team within the ICTSI NIH/NCRR Grant Number RR025761.	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Ahles TA, 2008, BREAST CANCER RES TR, V110, P143, DOI 10.1007/s10549-007-9686-5; Ahles TA, 2010, J CLIN ONCOL, V28, P4434, DOI 10.1200/JCO.2009.27.0827; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Baddeley A, 2012, ANNU REV PSYCHOL, V63, P1, DOI 10.1146/annurev-psych-120710-100422; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Brett M., 2002, NEUROIMAGE, V16, P2, DOI [10.1016/S1053-8119(02)90010-8, DOI 10.1016/S1053-8119(02)90010-8]; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; CDC, 2010, TRAUM BRAIN INJ US; Chen CJ, 2012, RADIOLOGY, V264, P844, DOI 10.1148/radiol.12112154; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Conroy SK, 2013, BRAIN IMAGING BEHAV, V7, P491, DOI 10.1007/s11682-013-9240-5; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Elbin RJ, 2012, BRAIN INJURY, V26, P1217, DOI 10.3109/02699052.2012.672788; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gordon M., 1996, GORDON DIAGNOSTIC SY; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kearney-Ramos TE, 2014, J INT NEUROPSYCH SOC, P1; Keightley ML, 2012, CURR OPIN PEDIATR, V24, P709, DOI 10.1097/MOP.0b013e3283599a55; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Lafayette Instrument, 1989, GROOV PEGB INSTR OWN; Loher S, 2014, APPL NEUROPSYCH-CHIL, V3, P103, DOI 10.1080/21622965.2012.716752; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2011, INT J PSYCHOPHYSIOL, V82, P107, DOI 10.1016/j.ijpsycho.2011.06.022; McAllister TW, 2011, J NEUROPSYCH CLIN N, V23, P277, DOI 10.1176/appi.neuropsych.23.3.277; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Meyers J., 1995, REY COMPLEX FIGURE T; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395	56	23	24	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1874-5393	1875-8894		J PEDIATR REHAB MED	J. Pediatr. Rehab. Med.		2015	8	4					297	308		10.3233/PRM-150348			12	Pediatrics	Pediatrics	VG7LK	WOS:000448290900004	26684070	Green Accepted			2021-06-18	
J	Gomez, PA; de-la-Cruz, J; Lora, D; Jimenez-Roldan, L; Rodriguez-Boto, G; Sarabia, R; Sahuquillo, J; Lastra, R; Morera, J; Lazo, E; Dominguez, J; Ibanez, J; Brell, M; de-la-Lama, A; Lobato, RD; Lagares, A				Gomez, Pedro A.; de-la-Cruz, Javier; Lora, David; Jimenez-Roldan, Luis; Rodriguez-Boto, Gregorio; Sarabia, Rosario; Sahuquillo, Juan; Lastra, Roberto; Morera, Jesus; Lazo, Eglis; Dominguez, Jaime; Ibanez, Javier; Brell, Marta; de-la-Lama, Adolfo; Lobato, Ramiro D.; Lagares, Alfonso			Validation of a prognostic score for early mortality in severe head injury cases	JOURNAL OF NEUROSURGERY			English	Article						severe traumatic brain injury; prognosis; early death; external validation	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; CLINICAL-TRIALS; OUTCOME PREDICTION; MODELS; DISABILITY; DEATHS; DESIGN; AGE	Object. Traumatic brain injury (TBI) represents a large health and economic burden. Because of the inability of previous randomized controlled trials (RCTs) on TBI to demonstrate the expected benefit of reducing unfavorable outcomes, the IMPACT (International Mission on Prognosis and Analysis of Clinical Trials in TBI) and CRASH (Corticosteroid Randomisation After Significant Head Injury) studies provided new methods for performing prognostic studies of TBI. This study aimed to develop and externally validate a prognostic model for early death (within 48 hours). The secondary aim was to identify patients who were more likely to succumb to an early death to limit their inclusion in RCTs and to improve the efficiency of RCTs. Methods. The derivation cohort was recruited at 1 center, Hospital 12 de Octubre, Madrid (1990-2003,925 patients). The validation cohort was recruited in 2004-2006 from 7 study centers (374 patients). The eligible patients had suffered closed severe TBIs. The study outcome was early death (within 48 hours post-TBI). The predictors were selected using logistic regression modeling with bootstrapping techniques, and a penalized reduction was used. A risk score was developed based on the regression coefficients of the variables included in the final model. Results. In the validation set, the final model showed a predictive ability of 50% (Nagelkerke R-2), with an area under the receiver operating characteristic curve of 89% and an acceptable calibration (goodness-of-fit test, p = 0.32). The final model included 7 variables, and it was used to develop a risk score with a range from 0 to 20 points. Age provided 0,1,2, or 3 points depending on the age group; motor score provided 0 points, 2 (untestable), or 3 (no response); pupillary reactivity, 0,2(1 pupil reacted), or 6 (no pupil reacted); shock, 0 (no) or 2 (yes); subarachnoid hemorrhage, 0 or 1 (severe deposit); cisternal status, 0 or 3 (compressed/absent); and epidural hematoma, 0 (yes) or 2 (no). Based on the risk of early death estimated with the model, 4 risk of early death groups were established: low risk, sum score 0-3 (< 1% predicted mortality); moderate risk, sum score 4-8 (predicted mortality between 1% and 10%); high risk, sum score 9-12 (probability of early death between 10% and 50%); and very high risk, sum score 13-20 (early mortality probability > 50%). This score could be used for selecting patients for clinical studies. For example, if patients with very high risk scores were excluded from our study sample, the patients included (eligibility score < 13) would represent 80% of the original sample and only 23% of the patients who died early. Conclusions. The combination of Glasgow Coma Scale score, CT scanning results, and secondary insult data into a prognostic score improved the prediction of early death and the classification of TBI patients.	[Gomez, Pedro A.; Jimenez-Roldan, Luis; Lobato, Ramiro D.; Lagares, Alfonso] Univ Complutense, Fac Med, Univ Hosp Octubre 12, Dept Neurosurg, Madrid 20841, Spain; [de-la-Cruz, Javier; Lora, David] Univ Complutense, Fac Med, Univ Hosp Octubre 12, Clin Res Unit,CIBERESP IMAS12, Madrid 20841, Spain; [Rodriguez-Boto, Gregorio] Clin Univ Hosp, Dept Neurosurg, Madrid, Spain; [Sarabia, Rosario] Clin Univ Hosp Rio Ortega, Dept Neurosurg, Valladolid, Spain; [Sahuquillo, Juan; Lastra, Roberto] Clin Univ Hosp Val dHebron, Dept Neurosurg, Barcelona, Spain; [Morera, Jesus] Clin Univ Hosp Dr Negrin, Dept Neurosurg, Las Palmas Gran Canaria, Spain; [Lazo, Eglis; Dominguez, Jaime] Clin Univ Hosp Virgen de la Candelaria, Dept Neurosurg, Tenerife, Spain; [Ibanez, Javier; Brell, Marta] Clin Univ Hosp Son Dureta, Dept Neurosurg, Palma De Mallorca, Spain; [de-la-Lama, Adolfo] Hosp Xeral Vigo, Clin Univ Hosp, Dept Neurosurg, Vigo, Spain	Gomez, PA (corresponding author), Univ Complutense, Fac Med, Univ Hosp Octubre 12, Dept Neurosurg, Carretera Andalucia S-N, Madrid 20841, Spain.	pagolopez@gmail.com	Jimenez-Roldan, Luis/K-2298-2017; Sahuquillo, Juan/B-3577-2008; Gomez, Pedro/N-5051-2019; Lagares, Alfonso/B-2969-2011	Jimenez-Roldan, Luis/0000-0002-9864-0385; Sahuquillo, Juan/0000-0003-0713-5875; Gomez, Pedro/0000-0002-4185-5238; Lagares, Alfonso/0000-0003-3996-0554; Ibanez, Javier/0000-0003-3735-8332	Fondo de Investigacion Sanitaria (FIS)Instituto de Salud Carlos III [PI-030318]; Fundacion Mutua Madrilena (FMM) [2010-007]	Funding was provided by the following: Fondo de Investigacion Sanitaria (FIS) PI-030318 (2004-2006) and Fundacion Mutua Madrilena (FMM) No. 2010-007. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell Frank E., 2001, REGRESSION MODELING; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Moons KGM, 2004, J CLIN EPIDEMIOL, V57, P1262, DOI 10.1016/j.jclinepi.2004.01.020; Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	43	23	24	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2014	121	6					1314	1322		10.3171/2014.7.JNS131874			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AU3CP	WOS:000345490700003	25237737				2021-06-18	
J	Okasha, AS; Fayed, AM; Saleh, AS				Okasha, Ahmed Said; Fayed, Akram Muhammad; Saleh, Ahmad Sabry			The FOUR Score Predicts Mortality, Endotracheal Intubation and ICU Length of Stay After Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Glasgow Coma Scale; FOUR score; Glasgow outcome score; Outcome assessment; Length of stay	GLASGOW COMA SCALE; INTENSIVE-CARE-UNIT; HEAD-INJURY; UNRESPONSIVENESS SCORE; SEVERITY SCORE; FULL OUTLINE; VALIDATION; IMPACT; OUTCOMES; VERSION	The Glasgow Coma Scale (GCS) is the most widely accepted scale for assessing levels of consciousness, clinical status, as well as prognosis of traumatic brain injury (TBI) patients. The Full Outline of UnResponsiveness (FOUR) score is a new coma scale developed addressing the limitations of the GCS. The aim of this prospective cohort study was to compare the performance of the FOUR score vs. the GCS in predicting TBI outcomes. From April to July 2011, 60 consecutive adult patients with TBI admitted to the Alexandria Main University Hospital intensive care units (ICU) were enrolled in the study. GCS and FOUR score were documented on arrival to emergency room. Outcomes were in-hospital mortality, unfavorable outcome [Glasgow outcome scale extended (GOSE) 1-4], endotracheal intubation, and ICU length of stay (LOS). Fifteen (25 %) patients died and 35 (58 %) had unfavorable outcome. When predicting mortality, the FOUR score showed significantly higher area under receiver operating characteristic curve (AUC) than the GCS score (0.850 vs. 0.796, p = 0.025). The FOUR score and the GCS score were not different in predicting unfavorable outcome (AUC 0.813 vs. 0.779, p = 0.136) and endotracheal intubation (AUC 0.961 vs. 0.982, p = 0.06). Both scores were good predictors of ICU LOS (r (2) = 0.40 [FOUR score] vs. 0.41 [GCS score]). The FOUR score was superior to the GCS in predicting in-hospital mortality in TBI patients. There was no difference between both scores in predicting unfavorable outcome, endotracheal intubation, and ICU LOS.	[Okasha, Ahmed Said] Univ Alexandria, Fac Med, Dept Anesthesia & Surg Intens Care, Alexandria, Egypt; [Fayed, Akram Muhammad] Univ Alexandria, Fac Med, Dept Crit Care Med, Alexandria, Egypt; [Saleh, Ahmad Sabry] Kom el Shoqafa Chest Hosp, Intens Care Unit, Alexandria 21572, Egypt	Saleh, AS (corresponding author), Kom el Shoqafa Chest Hosp, Intens Care Unit, Khufu St, Alexandria 21572, Egypt.	sabryccm@gmail.com	Saleh, Ahmad Sabry/AAG-9732-2019	Saleh, Ahmad/0000-0001-9791-1086; Fayed, Akram/0000-0001-6991-4407			Adnet F, 1996, LANCET, V348, P123, DOI 10.1016/S0140-6736(05)64630-2; Agrawal Deepak, 2012, J Emerg Trauma Shock, V5, P217, DOI 10.4103/0974-2700.99685; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Basso A., 2006, NEUR DIS PUBL HLTH C, P164; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Champion HR, 1996, J TRAUMA, V40, P42, DOI 10.1097/00005373-199601000-00009; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chen BX, 2013, ACTA NEUROCHIR, V155, P2133, DOI 10.1007/s00701-013-1854-2; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Frontera JA, 2011, NEUROCRIT CARE, V14, P260, DOI 10.1007/s12028-010-9418-2; Gruenberg DA, 2006, AM J CRIT CARE, V15, P502; Hoffmann M, 2012, BRIT J SURG, V99, P122, DOI 10.1002/bjs.7707; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Idrovo L, 2010, EUR NEUROL, V63, P364, DOI 10.1159/000292498; Kim YJ, 2011, J EMERG NURS, V37, P328, DOI 10.1016/j.jen.2010.04.017; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; Kramer AA, 2012, CRIT CARE MED, V40, P2671, DOI 10.1097/CCM.0b013e318258fd88; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Marcati E, 2012, INTERN EMERG MED, V7, P145, DOI 10.1007/s11739-011-0583-x; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Matis G, 2008, ACTA NEUROL BELG, V108, P75; McNett M, 2014, NEUROCRIT CARE, V21, P52, DOI 10.1007/s12028-013-9947-6; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Qualls M, 2010, ACAD EMERG MED, V17, P1113, DOI 10.1111/j.1553-2712.2010.00874.x; Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sadaka F, 2012, NEUROCRIT CARE, V16, P95, DOI 10.1007/s12028-011-9617-5; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Sitsapesan HA, 2013, WORLD NEUROSURG, V79, P568, DOI 10.1016/j.wneu.2012.09.018; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Vivien B, 2012, AM J EMERG MED, V30, P1032, DOI 10.1016/j.ajem.2011.06.022; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wisborg T, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-62	40	23	24	0	13	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2014	21	3					496	504		10.1007/s12028-014-9995-6			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AT2TY	WOS:000344790100016	24865273				2021-06-18	
J	Larrabee, GJ				Larrabee, Glenn J.			Minimizing False Positive Error With Multiple Performance Validity Tests: Response to Bilder, Sugar, and Hellemann (2014 this issue)	CLINICAL NEUROPSYCHOLOGIST			English	Article						False positive rate.; Performance and symptom validity tests; Multiple scores	TRAUMATIC BRAIN-INJURY; INADEQUATE EFFORT; CLINICAL-SAMPLE; TEST FAILURE; HEAD-INJURY; INTELLIGENCE; VALIDATION; INDICATORS; SCALE	Bilder, Sugar, and Hellemann (2014 this issue) contend that empirical support is lacking for use of multiple performance validity tests (PVTs) in evaluation of the individual case, differing from the conclusions of Davis and Millis (2014), and Larrabee (2014), who found no substantial increase in false positive rates using a criterion of failure of >= 2 PVTs and/or Symptom Validity Tests (SVTs) out of multiple tests administered. Reconsideration of data presented in Larrabee (2014) supports a criterion of >= 2 out of up to 7 PVTs/SVTs, as keeping false positive rates close to and in most cases below 10% in cases with bona fide neurologic, psychiatric, and developmental disorders. Strategies to minimize risk of false positive error are discussed, including (1) adjusting individual PVT cutoffs or criterion for number of PVTs failed, for examinees who have clinical histories placing them at risk for false positive identification (e.g., severe TBI, schizophrenia), (2) using the history of the individual case to rule out conditions known to result in false positive errors, (3) using normal performance in domains mimicked by PVTs to show that sufficient native ability exists for valid performance on the PVT(s) that have been failed, and (4) recognizing that as the number of PVTs/SVTs failed increases, the likelihood of valid clinical presentation decreases, with a corresponding increase in the likelihood of invalid test performance and symptom report.		Larrabee, GJ (corresponding author), 2650 Bahia Vista St,Suite 308, Sarasota, FL 34239 USA.	glarrabee@aol.com					BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; Boone, 2007, ASSESSMENT FEIGNED C; Boone K., 2002, B TEST MANUAL; Boone K. B., 2002, DOT COUNTING TEST MA; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heaton RK, 2004, REVISED COMPREHENSIV; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P334; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Pearson, 2009, ADV CLIN SOLUTIONS U; Pella RD, 2012, ARCH CLIN NEUROPSYCH, V27, P45, DOI 10.1093/arclin/acr090; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Silverberg N, 2005, J CLIN EXP NEUROPSYC, V27, P907, DOI 10.1080/13803390490919326; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682	33	23	23	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2014	28	8					1230	1242		10.1080/13854046.2014.988754			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AY0KY	WOS:000347286600003	25491180				2021-06-18	
J	Dias, C; Silva, MJ; Pereira, E; Silva, S; Cerejo, A; Smielewski, P; Rocha, AP; Gaio, AR; Paiva, JA; Czosnyka, M				Dias, Celeste; Silva, Maria Joao; Pereira, Eduarda; Silva, Sofia; Cerejo, Antonio; Smielewski, Peter; Rocha, Ana Paula; Rita Gaio, A.; Paiva, Jose-Artur; Czosnyka, Marek			Post-Traumatic Multimodal Brain Monitoring: Response to Hypertonic Saline	JOURNAL OF NEUROTRAUMA			English	Article						Cerebral blood flow; cerebral perfusion pressure; cerebrovascular reactivity; hypertonic saline; intracranial pressure	CEREBRAL PERFUSION-PRESSURE; INTENSIVE-CARE-UNIT; INTRACRANIAL-PRESSURE; HEAD-INJURY; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; HYPERTENSION; TISSUE; OXYGENATION; MANNITOL	Emerging evidence suggests that hypertonic saline (HTS) is efficient in decreasing intracranial pressure (ICP). However there is no consensus about its interaction with brain hemodynamics and oxygenation. In this study, we investigated brain response to HTS bolus with multimodal monitoring after severe traumatic brain injury (TBI). We included 18 consecutive TBI patients during 10 days after neurocritical care unit admission. Continuous brain monitoring applied included ICP, tissue oxygenation (PtO2) and cerebral blood flow (CBF). Cerebral perfusion pressure (CPP), cerebrovascular resistance (CVR), and reactivity indices related to pressure (PRx) and flow (CBFx) were calculated. ICM + software was used to collect and analyze monitoring data. Eleven of 18 (61%) patients developed 99 episodes of intracranial hypertension (IHT) greater than 20 mm Hg that were managed with 20% HTS bolus. Analysis over time was performed with linear mixed-effects regression modelling. After HTS bolus, ICP and CPP improved over time (p < 0.001) following a quadratic model. From baseline to 120 min, ICP had a mean decrease of 6.2 mm Hg and CPP a mean increase of 3.1 mmHg. Mean increase in CBF was 7.8 mL/min/100 g (p < 0.001) and mean decrease in CVR reached 0.4 mm Hg*min*100 g/mL (p = 0.01). Both changes preceded pressures improvement. PtO2 exhibited a marginal increase and no significant models for time behaviour could be fitted. PRx and CBFx were best described by a linear decreasing model showing autoregulation recover after HTS (p = 0.01 and p = 0.04 respectively). During evaluation, CO2 remained constant and sodium level did not exhibit significant variation. In conclusion, management of IHT with 20% HTS significantly improves cerebral hemodynamics and cerebrovascular reactivity with recovery of CBF appearing before rise in CPP and decrease in ICP. In spite of cerebral hemodynamic improvement, no significant changes in brain oxygenation were identified.	[Dias, Celeste; Pereira, Eduarda; Silva, Sofia; Paiva, Jose-Artur] Univ Hosp Sao Joao, Dept Intens Care, Oporto, Portugal; [Cerejo, Antonio] Univ Hosp Sao Joao, Dept Neurosurg, Oporto, Portugal; [Silva, Maria Joao; Rocha, Ana Paula; Rita Gaio, A.] Univ Porto, Dept Math, P-4100 Oporto, Portugal; [Smielewski, Peter; Czosnyka, Marek] Addenbrookes Hosp, Dept Clin Neurosci, Cambridge, England	Dias, C (corresponding author), Univ Hosp Sao Joao, Neurocrit Care Unit, Dept Intens Care, Oporto, Portugal.	mceleste.dias@gmail.com	Rocha, Ana Paula/D-2813-2012; Dias, Celeste/L-9901-2014; Paiva, Jose-Artur/AAO-9730-2021; Dias, Celeste/AAD-8711-2019; Dias, Celeste/AAV-3820-2020; Cerejo, Antonio/AAT-7863-2020	Rocha, Ana Paula/0000-0003-3218-7001; Dias, Celeste/0000-0003-0340-9808; Dias, Celeste/0000-0003-0340-9808; Cerejo, Antonio/0000-0001-9136-873X; Gaio, Rita/0000-0003-3906-0775; Smielewski, Peter/0000-0001-5096-3938; Paiva, Jose-Artur/0000-0003-4323-0220	European Regional Development Fund through program COMPETE; Portuguese Government through FCT - Fundacao para a Ciencia e a Tecnologia [PEst-C/MAT/UI0144/2013]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	Ana Rita Gaio and Ana Paula Rocha were partially funded by the European Regional Development Fund through the program COMPETE and by the Portuguese Government through the FCT - Fundacao para a Ciencia e a Tecnologia under the project PEst-C/MAT/UI0144/2013.	Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bourdeaux C, 2010, NEUROCRIT CARE, V13, P24, DOI 10.1007/s12028-010-9368-8; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Diringer MN, 2013, CURR OPIN CRIT CARE, V19, P77, DOI 10.1097/MCC.0b013e32835eba30; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hinson HE, 2013, J INTENSIVE CARE MED, V28, P3, DOI 10.1177/0885066611400688; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Latorre JGS, 2009, NEUROLOGIST, V15, P193, DOI 10.1097/NRL.0b013e31819f956a; Lazaridis C, 2013, CRIT CARE MED, V41, P1353, DOI 10.1097/CCM.0b013e31827ca4b3; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; MAZZONI MC, 1990, CIRC SHOCK, V31, P407; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Orban JC, 2007, ANN FR ANESTH, V26, P440, DOI 10.1016/j.annfar.2007.03.001; Paredes-Andrade E, 2012, NEUROCRIT CARE, V17, P204, DOI 10.1007/s12028-011-9574-z; Pinheiro J., 2000, MIXED EFFECTS MODELS; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; R Development Core Team, 2011, R LANG ENV STAT COMP; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Scalfani M. T., 2012, J CRIT CARE, V27, pe527; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Stein DM, 2013, NEUROCRIT CARE, V18, P332, DOI 10.1007/s12028-013-9832-3; Strandvik GF, 2009, ANAESTHESIA, V64, P990, DOI 10.1111/j.1365-2044.2009.05986.x; Suarez Jose I, 2004, Cleve Clin J Med, V71 Suppl 1, pS9; Toung TJ, 2008, CRIT CARE MED, V36, P256, DOI 10.1097/01.CCM.0000295306.52783.1E; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Varsos GV, 2013, NEUROCRIT CARE, V18, P341, DOI 10.1007/s12028-013-9830-5; Wells DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11678; White H, 2008, EUR J ANAESTH, V25, P104, DOI 10.1017/S0265021507003420; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WOLF MB, 1971, AM J PHYSIOL, V221, P1392	50	23	23	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1872	1880		10.1089/neu.2014.3376			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400006	24915462				2021-06-18	
J	Snyder, AR; Bauer, RM				Snyder, Aliyah R.; Bauer, Russell M.		Hlth IMPACTS Florida Network	A Normative Study of the Sport Concussion Assessment Tool (SCAT2) in Children and Adolescents	CLINICAL NEUROPSYCHOLOGIST			English	Article						SCAT2; Standardized Assessment of Concussion; BESS.; Child; Concussion assessment; Balance Error Scoring System; Adolescent; SAC; Sport-related concussion	TRAUMATIC BRAIN-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; STANDARDIZED ASSESSMENT; CONSENSUS STATEMENT; SYMPTOMS; AGE; MANAGEMENT; ZURICH; SEX	Recent clinical practice parameters encourage systematic use of concussion surveillance/management tools that evaluate participating athletes at baseline and after concussion. Office-based tools (Sports Concussion Assessment Tool; SCAT2) require accurate baseline assessment to maximize utility but no normative data exist for children on the SCAT2, limiting identification of "normal" or "impaired" score ranges. The purpose of this study was to develop child and adolescent baseline norms for the SCAT2 to provide reference values for different age groups. A community-based approach was implemented to compile baseline performance data on the SCAT2 in 761 children aged 9 to 18 to create age- and sex-graded norms. Findings indicate a significant age effect on SCAT2 performance such that older adolescents and teenagers produced higher (better) total scores than younger children (ages 9 to 11) driven by age differences on individual components measuring cognition (SAC), postural stability (BESS), and symptom report. Females endorsed greater numbers of symptoms at baseline than males. Normative data tables are presented. Findings support the SCAT2 as a useful clinical tool for assessing baseline functioning in teenagers, but suggest clinical utility may be limited in children under age 11. Follow-up studies after incident concussion are needed to confirm this assumption.	[Snyder, Aliyah R.; Bauer, Russell M.] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32610 USA; Univ Florida, Clin & Translat Sci Inst, Jacksonville, FL 32209 USA; [Hlth IMPACTS Florida Network] Florida State Univ, Coll Med, Clin Res Network, Tallahassee, FL 32306 USA	Snyder, AR (corresponding author), Univ Florida, POB 100165, Gainesville, FL 32610 USA.	aliyahsnyder@phhp.ufl.edu	Meijer, Anna/K-5118-2016; Snyder, Aliyah/AAT-6250-2020	Snyder, Aliyah/0000-0003-1185-7424	State of Florida [NCATS UL1 RR029890-03S3]; NIH/NCATS Clinical and Translational Science AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000064]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR000066, UL1TR000064] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029890] Funding Source: NIH RePORTER	This work was supported by State of Florida under Grant number NCATS UL1 RR029890-03S3; NIH/NCATS Clinical and Translational Science Award to the University of Florida under Grant number UL1 TR000064.	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; Mayfield R. M., 2013, BRIT J SPORT MED, V47, pe1; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Steindl R, 2006, DEV MED CHILD NEUROL, V48, P477, DOI 10.1017/S0012162206001022; Storrow AB, 1997, AM J EMERG MED, V15, P700, DOI 10.1016/S0735-6757(97)90190-X; VanWijk CMTG, 1997, SOC SCI MED, V45, P231, DOI 10.1016/S0277-9536(96)00340-1	33	23	23	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	OCT 3	2014	28	7					1091	1103		10.1080/13854046.2014.952667			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AR2MK	WOS:000343421300002	25244434	Green Accepted			2021-06-18	
J	Lafrenaye, AD; Krahe, TE; Povlishock, JT				Lafrenaye, Audrey D.; Krahe, Thomas E.; Povlishock, John T.			Moderately elevated intracranial pressure after diffuse traumatic brain injury is associated with exacerbated neuronal pathology and behavioral morbidity in the rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						behavioral morbidity; histopathology; intracranial pressure; membrane poration; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; CONTROLLED CORTICAL IMPACT; HIPPOCAMPAL-NEURONS; MEMBRANE PORATION; HEMORRHAGIC-SHOCK; LATE-ONSET; CELLS; MICE; CONTUSION	Traumatic brain injury (TBI)-induced elevated intracranial pressure (ICP) is correlated with ensuing morbidity/mortality in humans. This relationship is assumed to rely mostly on the recognition that extremely elevated ICP either indicates hematoma/contusions capable of precipitating herniation or alters cerebral perfusion pressure (CPP), which precipitates global ischemia. However, whether subischemic levels of elevated ICP without hematoma/contusion contribute to increased morbidity/mortality remains unknown. To address this knowledge gap, we utilized a model of moderate diffuse TBI in rats followed by either intraventricular ICP monitoring or manual ICP elevation to 20 mm Hg, in which CPP was above ischemic levels. The effects of ICP elevation after TBI on acute and chronic histopathology, as well as on behavioral morbidity, were evaluated. ICP elevation after TBI resulted in increased acute neuronal membrane perturbation and was also associated with reduced neuronal density at 4 weeks after injury. Somatosensory hypersensitivity was exacerbated by ICP elevation and was correlated to the observed neuronal loss. In conclusion, this study indicates that morbidity and increased neuronal damage/death associated with elevated ICP can occur without concurrent global ischemia. Therefore, understanding the pathologies associated with subischemic levels of elevated ICP could lead to the development of better therapeutic strategies for the treatment and management of TBI patients.	[Lafrenaye, Audrey D.; Krahe, Thomas E.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Lafrenaye, AD (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	forrestad@mymail.vcu.edu	Krahe, Thomas E/H-1695-2013	Krahe, Thomas E/0000-0002-4686-9284	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045824, 5P30NS047463]; NIH-NINDS centerUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045824, P30NS047463] Funding Source: NIH RePORTER	This work was supported by NIH grants NS045824 and 5P30NS047463. This work was supported by NIH grant NS045824. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS center core grant, 5P30NS047463.	Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Bouzat P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-23; Bragin DE, 2013, STROKE, V44, P177, DOI 10.1161/STROKEAHA.112.668293; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chesnut RM, 2008, J TRAUMA, V65, P500, DOI 10.1097/TA.0b013e31818020b3; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Curley G, 2010, CRIT CARE MED, V38, P1348, DOI 10.1097/CCM.0b013e3181d8cf2b; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Di Ieva A, 2013, NEUROSCIENTIST, V19, P592, DOI 10.1177/1073858412474845; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Folgering JHA, 2008, PROG BIOPHYS MOL BIO, V97, P180, DOI 10.1016/j.pbiomolbio.2008.02.006; Fujita M, 2011, J NEUROTRAUM, V28, P1209, DOI 10.1089/neu.2011.1852; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Liapi A, 2005, EUR J NEUROSCI, V22, P825, DOI 10.1111/j.1460-9568.2005.04270.x; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Mukherjee D, 2013, NEW ENGL J MED, V368, P1748, DOI 10.1056/NEJMc1301076; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Romner B, 2013, NAT REV NEUROL, V9, P185, DOI 10.1038/nrneurol.2013.37; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Thomas TC, 2012, J NEUROTRAUM, V29, P187, DOI 10.1089/neu.2011.2091; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yacoub A, 2006, MOL PHARMACOL, V70, P589, DOI 10.1124/mol.106.025007; Zhang HL, 2009, J IMMUNOL, V182, P6993, DOI 10.4049/jimmunol.0802502; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	49	23	23	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2014	34	10					1628	1636		10.1038/jcbfm.2014.122			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AQ1IV	WOS:000342536000007	25027309	Bronze, Green Published			2021-06-18	
J	Tanabe, K; Matsushima-Nishiwaki, R; Kozawa, O; Iida, H				Tanabe, Kumiko; Matsushima-Nishiwaki, Rie; Kozawa, Osamu; Iida, Hiroki			Dexmedetomidine suppresses interleukin-1 beta-induced interleukin-6 synthesis in rat glial cells	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						alpha(2)-adrenoceptor; dexmedetomidine; interleukin-1 beta; interleukin-6; intracellular signaling	C6 GLIOMA-CELLS; SEDATION; RELEASE; EXPRESSION; KINASE	Dexmedetomidine, an alpha(2)-adrenoceptor agonist, is used as a sedative medication for criticalyl ill patients and is known to exert neuroprotective effects by direct action on neurons and indirect action on neurons through astrocytes. Interleukin (IL)-6 plays a key role in neuroinflammation, which accompanies infection, traumatic brain injury, ischemia, neurodegenerative disorders, as both a pro-inflammatory cytokine and an anti-inflammatory cytokine. Dexmedetomidine suppresses immune function. However, the effects of dexmedetomidine on cytokine synthesis in the central nervous system (CNS) remain elusive. We previously reported that IL-1 beta stimulates IL-6 synthesis in the rat C6 glioma cell line through the phosphorylation of p38 mitogen-activated protein (MAP) kinase, stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) and I kappa B. In the present study, we investigated the effects of dexmedetomidine on the IL-1 beta-induced IL-6 synthesis in C6 cells. Dexmedetomidine inhibited the IL-1 beta-stimulated IL-6 release and mRNA expression in C6 cells. 8-Bromo-adenosine-3',5'-cyclic monophosphate, but not 8-bromo-guanosine 3',5'-cyclic monophosphate, significantly enhanced the IL-1 beta-induced IL-6 release and mRNA expression. However, dexmedetomidine failed to affect cAMP accumulation in the cells treated with IL-1 beta or forskolin, an activator of adenylyl cyclase. Yohimbine, an alpha(2)-adrenoceptor antagonist, did not reverse the suppressive effects of dexmedetomidine on the IL-1 beta-induced IL-6 release. Dexmedetomidine did not affect the IL-1 beta-induced phosphorylation of p38 MAP kinase, SAPK/JNK, I kappa B, nuclear factor (NF)-kappa B or c-Jun. Our findings strongly suggest that dexmedetomidine inhibits the IL-1 beta-induced IL-6 synthesis independently of the adenylyl cyclase-cAMP pathway through alpha(2)-adrenoceptors in C6 glioma cells. It is possible that dexmedetomidine may affect the immune system in the CNS by regulating the production of IL-6.	[Tanabe, Kumiko; Iida, Hiroki] Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Gifu 5011194, Japan; [Matsushima-Nishiwaki, Rie; Kozawa, Osamu] Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu 5011194, Japan	Tanabe, K (corresponding author), Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Yanagido 1-1, Gifu 5011194, Japan.	kumiko-t@m2.gyao.ne.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [23592248]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26462334] Funding Source: KAKEN	We are very grateful to Yumiko Kurokawa for her skillful technical assistance. The present study was supported in part by a Grant-in-Aid for Scientific Research (23592248) from the Ministry of Education, Science, Sports and Culture of Japan.	AANTAA R, 1995, ANN MED, V27, P439, DOI 10.3109/07853899709002452; Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Bekker A, 2013, J NEUROSURG ANESTH, V25, P16, DOI 10.1097/ANA.0b013e31826318af; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Chen Y, 2000, ANESTH ANALG, V91, P353, DOI 10.1097/00000539-200008000-00022; Edwards LP, 2012, CARDIOVASC THER, V30, P199, DOI 10.1111/j.1755-5922.2011.00268.x; Eser O, 2008, BRAIN RES, V1218, P250, DOI 10.1016/j.brainres.2008.04.045; Gallagher HC, 2004, NEUROTOXICOL TERATOL, V26, P73, DOI 10.1016/j.ntt.2003.07.013; Huang R, 2000, BRAIN RES, V873, P297, DOI 10.1016/S0006-8993(00)02525-7; Iirola T, 2012, BRIT J ANAESTH, V108, P460, DOI 10.1093/bja/aer441; Kang SH, 2013, ACTA ANAESTH SCAND, V57, P480, DOI 10.1111/aas.12039; Kawashima A, 2008, PROSTAG LEUKOTR ESS, V79, P59, DOI 10.1016/j.plefa.2008.07.002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Ma DQ, 2004, BRIT MED BULL, V71, P77, DOI 10.1093/bmb/ldh036; Memis D, 2007, BRIT J ANAESTH, V98, P550, DOI 10.1093/bja/aem017; Morioka N, 2010, J PHARMACOL SCI, V113, P234, DOI 10.1254/jphs.10031FP; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Qiao H, 2009, CRIT CARE, V13, DOI 10.1186/cc8012; Saavedra A, 2008, PROG NEUROBIOL, V86, P186, DOI 10.1016/j.pneurobio.2008.09.006; Sanders RD, 2007, CURR OPIN INVEST DR, V8, P25; Sanders Robert D, 2011, Anesthesiol Clin, V29, P687, DOI 10.1016/j.anclin.2011.09.008; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Talke P, 1996, ANESTHESIOLOGY, V85, P551, DOI 10.1097/00000542-199609000-00014; Tanabe K, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-68; Venn RM, 2001, BRIT J ANAESTH, V86, P650, DOI 10.1093/bja/86.5.650; Yan M, 2011, NEUROCHEM INT, V58, P549, DOI 10.1016/j.neuint.2011.01.013; Zhang FJ, 2012, J PHARM PHARMACOL, V64, P120, DOI 10.1111/j.2042-7158.2011.01382.x; Zhang Yonghua, 2005, Current Neuropharmacology, V3, P317, DOI 10.2174/157015905774322534; Zumwalt JW, 1999, ENDOCRINOLOGY, V140, P888, DOI 10.1210/en.140.2.888	33	23	26	0	14	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	OCT	2014	34	4					1032	1038		10.3892/ijmm.2014.1863			7	Medicine, Research & Experimental	Research & Experimental Medicine	AQ4AL	WOS:000342734500014	25069417	Bronze			2021-06-18	
J	Bachynski, KE; Goldberg, DS				Bachynski, Kathleen E.; Goldberg, Daniel S.			Youth Sports & Public Health: Framing Risks of Mild Traumatic Brain Injury in American Football and Ice Hockey	JOURNAL OF LAW MEDICINE & ETHICS			English	Article							PLAY GUIDELINES; CONCUSSION; IMPACT; RETURN	The framing of the risks of experiencing mild traumatic brain injury in American football and ice hockey has an enormous impact in defining the scope of the problem and the remedies that are prioritized. According to the prevailing risk frame, an acceptable level of safety can be maintained in these contact sports through the application of technology, rule changes, and laws. An alternative frame acknowledging that these sports carry significant risks would produce very different ethical, political, and social debates.	[Bachynski, Kathleen E.] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY 10027 USA; [Goldberg, Daniel S.] E Carolina Univ, Brody Sch Med, Dept Bioeth & Interdisciplinary Studies, Greenville, NC USA	Bachynski, KE (corresponding author), Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY 10027 USA.						Anderson AJ, 2000, PEDIATRICS, V105, P657; [Anonymous], 2009, CLOSING GAP GENERATI; Bachynski KE, 2012, AM J PUBLIC HEALTH, V102, P2214, DOI 10.2105/AJPH.2012.300721; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Belson K, 2013, NY TIMES; Breslow J. M., COMMUNICATION; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Chokshi DA, 2012, NEW ENGL J MED, V367, P295, DOI 10.1056/NEJMp1206268; Chou R, 2009, LANCET, V373, P463, DOI 10.1016/S0140-6736(09)60172-0; Crouse Karen, 2013, NY TIMES; CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Deyo RA, 2009, J AM BOARD FAM MED, V22, P62, DOI 10.3122/jabfm.2009.01.080102; Dixon J. L., 1989, SAFETY ICE HOCKEY, P207; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Fainaru-Wada M, 2013, LEAGUE DENIAL N F L; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GEERTZ C, 1972, DAEDALUS, P1; Goldberg DS, 2013, J LEGAL MED, V34, P157, DOI 10.1080/01947648.2013.800792; Goldberg DS, 2008, HEC FORUM, V20, P337, DOI 10.1007/s10730-008-9079-0; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hofmann B, 2002, INT J TECHNOL ASSESS, V18, P675; Hulse William F., 1981, SPORTS INJURIES UNTH, P378; Johnson LSM, 2012, J SCHOOL HEALTH, V82, P180, DOI 10.1111/j.1746-1561.2011.00684.x; Jonas MF, 2011, PUBLIC HEALTH ETH-UK, V4, P129, DOI 10.1093/phe/phr023; Kreck C., 2014, COMMUNICATION; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Markowitz J. S., 2013, PIGSKIN CROSSROADS E, P50; Maske M., 2007, WASHINGTON POST; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGrew CA, 2011, CURR SPORT MED REP, V10, P394, DOI 10.1249/JSR.0b013e318237c2a5; McGUIRE A, 2009, EC NEW HLTH TECHNOLO, P3; Molcho M, 2011, INJURY PREV, V17, P147, DOI 10.1136/ip.2010.030023; Munthe C., 2012, PRICE PRECAUTION ETH; National Operating Committee for Standards on Athletic Equipment, FAQS; NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3; Noble D. F., 1997, RELIG TECHNOLOGY DIV; Partridge B., 2013, NEUROETHICS, DOI 10.1007/s12152-013-9182-z; Pop Warner Little Scholars Inc., FOOTB SAF; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rothman David, 1997, BEGINNINGS COUNT TEC; Ryan Allan J., 1968, NAT C PROT EQ SPORTS, P12; Schankman S., 2013, ESPN            0501; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schwarz A, 2007, NY TIMES; Schwarz A, 2010, NY TIMES; Smith M. D., POLAMALU SAYS PLAYER; Smith M. D., STEELRES R CLARK IM; Starfield B, 2008, J EPIDEMIOL COMMUN H, V62, P580, DOI 10.1136/jech.2007.071027; Thompson H., 2009, US HOCKEY MAGAZI SEP; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; Van Dellen T. R., 1950, CHICAGO TRIBUNE; Walter K. D., 2013, AAP NEWS, V34, P17, DOI DOI 10.1542/AAPNEWS.20133410-17	62	23	23	0	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1105	1748-720X		J LAW MED ETHICS	J. Law Med. Ethics	FAL	2014	42	3			SI		323	333		10.1111/jlme.12149			11	Ethics; Law; Medical Ethics; Medicine, Legal	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	AQ4ED	WOS:000342745000007	25264090				2021-06-18	
J	McLean, RL; Harrison, AJ; Zimak, E; Joseph, RM; Morrow, EM				McLean, Rebecca L.; Harrison, Ashley Johnson; Zimak, Eric; Joseph, Robert M.; Morrow, Eric M.			Executive Function in Probands With Autism With Average IQ and Their Unaffected First-Degree Relatives	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						autism spectrum disorder; executive functioning; adaptive functioning; IQ; pedigree	TRAUMATIC BRAIN-INJURY; SPECTRUM DISORDERS; COGNITIVE PHENOTYPE; CHILDREN; INDIVIDUALS; PARENTS; IMPAIRMENTS; DYSFUNCTION; CHILDHOOD; PROFILES	Objective: This study aimed to characterize executive function (EF) in pedigrees of children with autism spectrum disorder (ASD) and average IQ. The authors examined the hypothesis that deficits in EF relate to lower levels of adaptive functioning, and they assessed evidence for a cognitive extended phenotype in unaffected relatives in a large, well-characterized sample. Method: Proband EF was assessed by parent-report questionnaires (Behavior Rating Inventory of Executive Functioning [BRIEF], n = 109) and child neuropsychological tests (Delis-Kaplan Executive Functioning System [D-KEFS], n = 35). EF also was examined in parents (D-KEFS, n = 335) and unaffected siblings (BRIEF, n = 114; D-KEFS, n = 57). Adaptive functioning was assessed by the Vineland Adaptive Behavior Scales-II (n = 155). All data were obtained from the Autism Consortium Clinical Genetics Database. Results: Individuals with ASD showed important EF weaknesses. Multiple regression analyses showed that parent-reported EF deficits were related to profound decreases in adaptive functioning even after controlling for age, IQ and severity of ASD symptoms. Parent-reported EF also was related to adaptive skills in preschoolers. First-degree unaffected relatives did not demonstrate difficulties with EF compared with normative data. Conclusion: In this study, EF impairments do not appear to relate to broad familial risk factors for ASD but may be associated with factors relevant to the expression of ASD in probands. Results support the benefits of EF assessment as a way to identify potential therapeutic targets that could lead to improved adaptive behavior in children with ASD and average IQ.	[McLean, Rebecca L.; Morrow, Eric M.] Brown Univ, Sch Med, Emma Pendleton Bradley Hosp, Dev Disorders Genet Res Program, Providence, RI 02912 USA; [McLean, Rebecca L.] Mem Hosp Rhode Isl, Neurodev Ctr, Pawtucket, RI USA; [Harrison, Ashley Johnson; Zimak, Eric] Emma Pendleton Bradley Hosp, Dev Disorders Genet Res Program, East Providence, RI USA; [Harrison, Ashley Johnson; Zimak, Eric] Brown Univ, Med Sch, Providence, RI 02912 USA; [Joseph, Robert M.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Joseph, Robert M.; Morrow, Eric M.] Autism Consortium, Boston, MA USA; [Morrow, Eric M.] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA	Morrow, EM (corresponding author), Brown Univ, Mol Med Lab, 70 Ship St, Providence, RI 02912 USA.	eric_morrow@brown.edu	Morrow, Eric/J-2767-2013	Morrow, Eric/0000-0003-3430-3520; Joseph, Robert/0000-0001-6879-0254	Dr. Morrow's Career Award in Medical Science from the Burroughs Wellcome Fund; National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103645 01A1]; Autism Consortium; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1R01MH085143, 1R01MH083565]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH083565, R01MH085143, K23MH080954] Funding Source: NIH RePORTER	This research was supported by Dr. Morrow's Career Award in Medical Science from the Burroughs Wellcome Fund and the National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS) grant P20GM103645 01A1 : Project Award under Neuroscience COBRE Project. The collection of data and biomaterials comes from the Phenotypic and Genetic Factors in Autism Spectrum Disorders Study. Since 2008, this project has been supported by the Autism Consortium and by NIMH grants (1R01MH085143, principal investigator, Louis M. Kunkel, PhD; 1R01MH083565, principal investigator, Christopher Walsh, MD, PhD)	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; BaronCohen S, 1997, J COGNITIVE NEUROSCI, V9, P548, DOI 10.1162/jocn.1997.9.4.548; Bishop SL, 1999, AUTISM DIAGNOSTIC OB; Bolte S, 2002, CHILD PSYCHIAT HUM D, V33, P165, DOI 10.1023/A:1020734325815; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delorme R, 2007, EUR PSYCHIAT, V22, P32, DOI 10.1016/j.eurpsy.2006.05.002; Duncan AW, 2013, AUTISM; Fein, 2011, NEUROPSYCHOLOGY AUTI, P185; Gilotty L, 2002, CHILD NEUROPSYCHOL, V8, P241, DOI 10.1076/chin.8.4.241.13504; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 1996, BEHAV RATING INVENTO; Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Hughes C, 1999, J CHILD PSYCHOL PSYC, V40, P705, DOI 10.1111/1469-7610.00487; Hughes C, 1997, PSYCHOL MED, V27, P209, DOI 10.1017/S0033291796004308; Ikuta T, 2014, PSYCHIAT RES-NEUROIM, V221, P63, DOI 10.1016/j.pscychresns.2013.08.002; Isquith PK, 2005, MENT RETARD DEV D R, V11, P209, DOI 10.1002/mrdd.20075; Joseph R.M., 2011, NEUROPSYCHOLOGY AUTI, P281; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P1007, DOI 10.1007/s10803-010-1126-4; Kenworthy L, 2014, J CHILD PSYCHOL PSYC, V55, P374, DOI 10.1111/jcpp.12161; Kenworthy L, 2009, CHILD NEUROPSYCHOL, V15, P425, DOI 10.1080/09297040802646983; Kenworthy LE, 2005, DEV NEUROPSYCHOL, V28, P809, DOI 10.1207/s15326942dn2803_4; Klin A, 2007, J AUTISM DEV DISORD, V37, P748, DOI 10.1007/s10803-006-0229-4; Latzman RD, 2010, ASSESSMENT, V17, P172, DOI 10.1177/1073191109356254; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Losh M, 2009, ARCH GEN PSYCHIAT, V66, P518, DOI 10.1001/archgenpsychiatry.2009.34; MacAllister WS, 2012, CHILD NEUROPSYCHOL, V18, P404, DOI 10.1080/09297049.2011.613812; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Payne JM, 2011, CHILD NEUROPSYCHOL, V17, P313, DOI 10.1080/09297049.2010.542746; Pellicano E, 2012, AUTISM RES TREAT, V2012, P146; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Risi S, 2006, J AM ACAD CHILD PSY, V45, P1094, DOI 10.1097/01.chi.0000227880.42780.0e; Rosenthal M, 2013, NEUROPSYCHOLOGY, V27, P13, DOI 10.1037/a0031299; Rozga A., 2011, NEUROPSYCHOLOGY AUTI, P97; Rutter M., 2003, AUTISM DIAGNOSTIC IN; Sayers N, 2011, J INTELL DISABIL RES, V55, P699, DOI 10.1111/j.1365-2788.2010.01370.x; Semrud-Clikeman M, 2010, J AUTISM DEV DISORD, V40, P1017, DOI 10.1007/s10803-010-0951-9; Smithson PE, 2013, J AUTISM DEV DISORD, V43, P1967, DOI 10.1007/s10803-012-1747-x; Sparrow S, 2005, VINELAND ADAPTIVE BE; Sumiyoshi C, 2011, NEUROSCI RES, V69, P252, DOI 10.1016/j.neures.2010.11.007; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Wecshler D, 2002, WECHSLER PRESCHOOL P; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wong D, 2006, GENES BRAIN BEHAV, V5, P561, DOI 10.1111/j.1601-183X.2005.00199.x	46	23	23	1	31	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	SEP	2014	53	9					1001	1009		10.1016/j.jaac.2014.05.019			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	AO3HW	WOS:000341221300010	25151423	Green Accepted			2021-06-18	
J	Salentijn, EG; Peerdeman, SM; Boffano, P; van den Bergh, B; Forouzanfar, T				Salentijn, Erik G.; Peerdeman, Saskia M.; Boffano, Paolo; van den Bergh, Bart; Forouzanfar, Tymour			A ten-year analysis of the traumatic maxillofacial and brain injury patient in Amsterdam: Incidence and aetiology	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article						Maxillofacial trauma; Neurotrauma; Brain injury; Incidence; Aetiology; Treatment	CLOSED-HEAD INJURIES; FACIAL FRACTURES; MANAGEMENT; SEVERITY; IMPACT	In the literature it is questioned if the presence of maxillofacial trauma is associated with the presence of brain injury. The aim of this study is to present a 10-year retrospective study of the incidence and aetiology of maxillofacial trauma associated with brain injury that required both oral and maxillofacial and neurosurgical intervention during the same hospital stay. Forty-seven patients from a population of 579 trauma patients undergoing maxillofacial surgery were identified. The main cause of injury was road traffic collision, followed by falls. Interpersonal violence correlated less well with traumatic brain injury. Most of the patients were males, aged 20-39 years. Frontal sinus fractures were the most common maxillofacial fractures (21.9%) associated with neurosurgical input, followed by mandibular fractures and zygomatic complex fractures. In the general maxillofacial trauma population, frontal sinus fractures were only found in 2.2% of the cases. At presentation to the Emergency Department the majority of the patients were diagnosed with severe traumatic brain injury and a Marshall CT class 2. Intracranial pressure monitoring was the most common neurosurgical intervention, followed by reconstruction of a bone defect and haematoma evacuation. Although it is a small population, our data suggest that maxillofacial trauma does have an association with traumatic brain injury that requires neurosurgical intervention (8.14 In comparison with the overall maxillofacial trauma population, our results demonstrate that frontal sinus fractures are more commonly diagnosed in association with brain injury, most likely owing to the location of the impact of the trauma. In these cases the frontal sinus seems not specifically to act as a barrier to protect the brain. This report provides useful data concerning the joint management of oral and maxillofacial surgeons and neurosurgeons for the treatment of cranio-maxillofacial trauma and brain injury patients in Amsterdam. (C) 2014 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.	[Salentijn, Erik G.; Boffano, Paolo; van den Bergh, Bart; Forouzanfar, Tymour] Vrije Univ Amsterdam, Med Ctr, Dept Oral & Maxillofacial Surg Oral Pathol, Acad Ctr Dent Amsterdam ACTA, NL-1007 MB Amsterdam, Netherlands; [Peerdeman, Saskia M.] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, NL-1007 MB Amsterdam, Netherlands	Salentijn, EG (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Oral & Maxillofacial Surg Oral Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	e.salentijn@vumc.nl	Boffano, Paolo/J-1094-2016	Boffano, Paolo/0000-0002-0782-9933			Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Bogusiak K, 2010, J CRANIOFAC SURG, V21, P1018, DOI 10.1097/SCS.0b013e3181e62e47; BRANDT KE, 1991, J TRAUMA, V31, P15, DOI 10.1097/00005373-199101000-00003; Calderoni DR, 2011, J CRANIO MAXILL SURG, V39, P593, DOI 10.1016/j.jcms.2010.11.018; CHANG CJ, 1994, J TRAUMA, V37, P807, DOI 10.1097/00005373-199411000-00017; Chrcanovic BR, 2010, J TRAUMA, V69, pE73, DOI 10.1097/TA.0b013e3181cc847b; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; Fasola AO, 2003, DENT TRAUMATOL, V19, P2, DOI 10.1034/j.1600-9657.2003.00073.x; Forouzanfar T, 2013, J CRANIO MAXILL SURG, V41, P616, DOI 10.1016/j.jcms.2012.12.004; Gassner R, 2003, J CRANIO MAXILL SURG, V31, P51, DOI 10.1016/S1010-5182(02)00168-3; Giuliani G., 1997, Revue de Stomatologie et de Chirurgie Maxillo-Faciale, V98, P100; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Katzen JT, 2003, J TRAUMA, V54, P1026, DOI 10.1097/01.TA.0000066180.14666.8B; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; Lee KH, 2009, J ORAL MAXIL SURG, V67, P1878, DOI 10.1016/j.joms.2009.04.117; Lee Kai H., 2009, New Zealand Dental Journal, V105, P4; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; Lee TT, 1998, J TRAUMA, V44, P665, DOI 10.1097/00005373-199804000-00018; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Naveen Shankar A, 2011, J CRANIOMAXILLOFAC S, V40, P675; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Salentijn EG, 2013, J CRANIOMAXILLOFAC S; Salentijn EG, 2013, J CRANIO MAXILL SURG, V41, P630, DOI 10.1016/j.jcms.2012.11.043; Servadei F, 2002, ACT NEUR S, V81, P81; Singh Vibha, 2012, Natl J Maxillofac Surg, V3, P166, DOI 10.4103/0975-5950.111372; van Beek GJ, 1999, INT J ORAL MAX SURG, V28, P424, DOI 10.1016/S0901-5027(99)80055-1; van den Bergh B, 2011, J CRANIOMAXILLOFAC S, V40, pe165; Weider L, 1999, AM SURGEON, V65, P790	30	23	24	0	12	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1010-5182	1878-4119		J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	SEP	2014	42	6					705	710		10.1016/j.jcms.2013.12.008			6	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	AO6LG	WOS:000341463000001	24703508				2021-06-18	
J	Jepsen, CH; deMoya, MA; Perner, A; Sillesen, M; Ostrowski, SR; Alam, HB; Johansson, PI				Jepsen, Cecilie Heerdegen; deMoya, Marc A.; Perner, Anders; Sillesen, Martin; Ostrowski, Sisse R.; Alam, Hasan B.; Johansson, Paer I.			Effect of valproic acid and injury on lesion size and endothelial glycocalyx shedding in a rodent model of isolated traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; endothelial dysfunction; valproic acid; S100 beta; rats	PROTEIN; DAMAGE; S100B; DEGRADATION; BIOMARKERS; EXPRESSION; MARKER; SERUM; COAGULOPATHY	BACKGROUND: In isolated traumatic brain injury (TBI), little is known about the endothelial response and the effects of endothelial glycocalyx shedding. We have previously shown that treatment with valproic acid (VPA) improves outcomes following TBI and hemorrhagic shock. In this model, we hypothesized that severe isolated TBI would cause shedding of the endothelial glycocalyx, as measured by serum syndecan-1 (sSDC-1) levels. We further hypothesized that VPA treatment would reduce this response and reduce lesion size volume. METHODS: Forty Sprague-Dawley rats were allocated to TBI + VPA (n = 8), TBI + saline vehicle control infusion (n = 8), sham + saline vehicle control infusion (n = 6), or sham + VPA (n = 8). TBI animals were subjected to severe controlled cortical impact and killed 6 hours after injury. VPA 300 mg/kg was given as an intravenous bolus 30 minutes after injury. Serum samples were analyzed for sSDC-1, and lesion size was determined on Nissl-stained cryosections. RESULTS: sSDC-1 was significantly elevated in injured compared with uninjured animals at 3 hours (p = 0.0009) and 6 hours (p = 0.0007) after injury. This effect was significantly more pronounced in the animals treated with VPA (p = 0.019) 3 hours after injury, in which sSDC-1 levels were also significantly inversely correlated with lesion size (Q = -0.55, p = 0.038). Lesion size was significantly smaller in TBI + VPA (40.45 mm(3) +/- 13.83 mm(3)) as compared with vehicle control (59.57 mm(3) +/- 16.83 mm(3)) (p = 0.023). CONCLUSION: Severe isolated TBI caused shedding of the endothelial glycocalyx. Treatment with VPA was associated with increased glycocalyx shedding and reduced lesion size volume in injured animal Copyright (C) 2014 by Lippincott Williams & Wilkins	[Jepsen, Cecilie Heerdegen; deMoya, Marc A.; Sillesen, Martin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, Boston, MA 02114 USA; [Jepsen, Cecilie Heerdegen; Sillesen, Martin; Ostrowski, Sisse R.; Johansson, Paer I.] Rigshosp, Copenhagen Univ Hosp, Capital Reg Blood Bank, DK-2100 Copenhagen, Denmark; [Perner, Anders] Rigshosp, Copenhagen Univ Hosp, Dept Intens Care, DK-2100 Copenhagen, Denmark; [Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Johansson, Paer I.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX USA	Jepsen, CH (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.	ceciliehjepsen@gmail.com	Ostrowski, Sisse R/E-7423-2011; Johansson, Par I/P-9283-2015	Ostrowski, Sisse R/0000-0001-5288-3851; Johansson, Par I/0000-0001-9778-5964; Sillesen, Martin/0000-0001-9494-5475; Perner, Anders/0000-0002-4668-0123	Polsky family	The authors declare no conflicts of interest. This study was supported by the Polsky family.	Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Babcock L, 2012, BRAIN INJURY, V26, P1372, DOI 10.3109/02699052.2012.694565; Causey MW, 2012, J VASC SURG, V55, P1096, DOI 10.1016/j.jvs.2011.08.060; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Henrich M, 2010, THESCIENTIFICWORLDJO, V10, P917, DOI 10.1100/tsw.2010.88; Iseki K, 2002, GLIA, V39, P1, DOI 10.1002/glia.10078; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Johansson PI, 2010, MED HYPOTHESES, V75, P564, DOI 10.1016/j.mehy.2010.07.031; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Li YQ, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/523481; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Properzi F, 2008, EUR J NEUROSCI, V27, P593, DOI 10.1111/j.1460-9568.2008.06042.x; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149	23	23	25	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2014	77	2					292	297		10.1097/TA.0000000000000333			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AN0EJ	WOS:000340255700018	25058256				2021-06-18	
J	Ratcliff, JJ; Adeoye, O; Lindsell, CJ; Hart, KW; Pancioli, A; McMullan, JT; Yue, JK; Nishijima, DK; Gordon, WA; Valadka, AB; Okonkwo, DO; Lingsma, HF; Maas, AIR; Manley, GT				Ratcliff, Jonathan J.; Adeoye, Opeolu; Lindsell, Christopher J.; Hart, Kimberly W.; Pancioli, Arthur; McMullan, Jason T.; Yue, John K.; Nishijima, Daniel K.; Gordon, Wayne A.; Valadka, Alex B.; Okonkwo, David O.; Lingsma, Hester F.; Maas, Andrew I. R.; Manley, Geoffrey T.		TRACK-TBI Investigators	ED disposition of the Glasgow Coma Scale 13 to 15 traumatic brain injury patient: analysis of the Transforming Research and Clinical Knowledge in TBI study	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							INTRACRANIAL HEMORRHAGE; ADULT PATIENTS; HEAD-INJURY; CT; SATISFACTION; RELIABILITY; RULE	Objective: Mild traumatic brain injury (mTBI) patients are frequently admitted to high levels of care despite limited evidence suggesting benefit. Such decisions may contribute to the significant cost of caring for mTBI patients. Understanding the factors that drive disposition decision making and how disposition is associated with outcomes is necessary for developing an evidence-base supporting disposition decisions. We evaluated factors associated with emergency department triage of mTBI patients to 1 of 3 levels of care: home, inpatient floor, or intensive care unit (ICU). Methods: This multicenter, prospective, cohort study included patients with isolated head trauma, a cranial computed tomography as part of routine care, and a Glasgow Coma Scale (GCS) score of 13 to 15. Data analysis was performed using multinomial logistic regression. Results: Of the 304 patients included, 167 (55%) were discharged home, 76 (25%) were admitted to the inpatient floor, and 61 (20%) were admitted to the ICU. In the multivariable model, admission to the ICU, compared with floor admission, varied by study site, odds ratio (OR) 0.18 (95% confidence interval [CI], 0.06-0.57); antiplatelet/anticoagulation therapy, OR 7.46 (95% CI, 1.79-31.13); skull fracture, OR 7.60 (95% CI, 2.44-23.73); and lower GCS, OR 2.36 (95% CI, 1.05-5.30). No difference in outcome was observed between the 3 levels of care. Conclusion: Clinical characteristics and local practice patterns contribute to mTBI disposition decisions. Level of care was not associated with outcomes. Intracranial hemorrhage, GCS 13 to 14, skull fracture, and current antiplatelet/anticoagulant therapy influenced disposition decisions. (C) 2014 Elsevier Inc. All rights reserved.	[Ratcliff, Jonathan J.; Adeoye, Opeolu; Lindsell, Christopher J.; Hart, Kimberly W.; Pancioli, Arthur; McMullan, Jason T.] Univ Cincinnati, Cincinnati, OH 45267 USA; [Yue, John K.] Univ Calif San Francisco, San Francisco, CA 94110 USA; [Nishijima, Daniel K.; Manley, Geoffrey T.] Univ Calif Davis, Sacramento, CA 95817 USA; [Gordon, Wayne A.] Mt Sinai Sch Med, New York, NY 10029 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; [Lingsma, Hester F.] Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp, Univ Antwerp Hosp, B-102650 Edegem, Belgium	Ratcliff, JJ (corresponding author), Univ Cincinnati, 231 Albert Sabin Way,POB 670769, Cincinnati, OH 45267 USA.	ratclijn@uc.edu; adeoyeo@uc.edu; lindsecj@ucmail.uc.edu; hartkb@ucmail.uc.edu; arthur.pancioli@uc.edu; jason.mcmullan@uc.edu; yuej@neurosurg.ucsf.edu; daniel.nishijima@ucdmc.ucdavis.edu; wayne.gordon@mssm.edu; avaladka@gmail.com; okonkwodo@upmc.edu; h.lingsma@erasmusmc.nl; andrew.maas@uza.be; manleyg@neurosurg.ucsf.edu	McMullan, Jason/ABB-9691-2020; Yue, John K/P-1348-2015	McMullan, Jason/0000-0002-7656-7447; Yue, John K/0000-0001-9694-7722	NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001425] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS047996, RC2 NS069409] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, T32NS047996] Funding Source: NIH RePORTER		AAAM, 2008, ABBR INJ SCAL 2005 R; af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M., 2010, TRAUMATIC BRAIN US E; Franschman G, 2012, J NEUROTRAUM, V29, P128, DOI 10.1089/neu.2011.2044; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Homnick A, 2012, INJURY, V43, P2122, DOI 10.1016/j.injury.2012.04.013; Jagoda AS, 2010, PSYCHIAT CLIN N AM, V33, P797, DOI 10.1016/j.psc.2010.09.004; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Nishijima DK, 2013, ANN EMERG MED, V61, P509, DOI 10.1016/j.annemergmed.2012.08.024; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	31	23	23	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	AUG	2014	32	8					844	850		10.1016/j.ajem.2014.04.003			7	Emergency Medicine	Emergency Medicine	AR1AK	WOS:000343311000004	24857248	Green Accepted			2021-06-18	
J	Voicu, S; Deye, N; Malissin, I; Vigue, B; Brun, PY; Haik, W; Champion, S; Megarbane, B; Sideris, G; Mebazaa, A; Carli, P; Manivet, P; Baud, FJ				Voicu, Sebastian; Deye, Nicolas; Malissin, Isabelle; Vigue, Bernard; Brun, Pierre-Yves; Haik, William; Champion, Sebastien; Megarbane, Bruno; Sideris, Georgios; Mebazaa, Alexandre; Carli, Pierre; Manivet, Philippe; Baud, Frederic J.			Influence of alpha-Stat and pH-Stat Blood Gas Management Strategies on Cerebral Blood Flow and Oxygenation in Patients Treated With Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest: A Crossover Study	CRITICAL CARE MEDICINE			English	Article						blood gases; carbon dioxide; cardiac arrest; cerebral blood flow; cerebral oxygen extraction; therapeutic hypothermia	2010 INTERNATIONAL CONSENSUS; CARDIOVASCULAR CARE SCIENCE; ARTERIAL CARBON-DIOXIDE; TRAUMATIC BRAIN-INJURY; CARDIOPULMONARY BYPASS; CIRCULATORY ARREST; MILD HYPOTHERMIA; CEREBROVASCULAR REACTIVITY; TREATMENT RECOMMENDATIONS; INTRACRANIAL-PRESSURE	Objectives: In patients treated with therapeutic hypothermia after out-of-hospital cardiac arrest, two blood gas management strategies are used regarding the Paco(2) target: alpha-stat or pH-stat. We aimed to compare the effects of these strategies on cerebral blood flow and oxygenation. Design: Prospective observational single-center crossover study. Setting: ICU of University hospital. Patients: Twenty-one therapeutic hypothermia-treated patients after out-of-hospital cardiac arrest more than 18 years old without history of cerebrovascular disease were included. Interventions: Cerebral perfusion and oxygenation variables were compared in a-stat (Paco(2) measured at 37 degrees C) versus pH-stat (Paco(2) measured at 32-34 degrees C), both strategies maintaining physiological Paco(2) values: 4.8-5.6 kPa (36-42 torr). Measurements and Main Results: Bilateral transcranial middle cerebral artery flow velocities using Doppler and jugular vein oxygen saturation were measured in both strategies 18 hours (14-23 hr) after the return of spontaneous circulation. Pulsatility and resistance indexes and cerebral oxygen extraction were calculated. Data are expressed as median (interquartile range 25-75) in alpha-stat versus pH-stat. No differences were found in temperature, arterial blood pressure, and oxygenation between alpha-stat and pH-stat. Significant differences were found in minute ventilation (p = 0.006), temperature-corrected Paco(2) (4.4 kPa [4.1-4.6 kPa] vs 5.1 kPa [5.0-5.3 kPa], p = 0.0001), and temperature-uncorrected Paco(2) (p = 0.0001). No differences were found in cerebral blood velocities and pulsatility and resistance indexes in the overall population. Significant differences were found in jugular vein oxygen saturation (83.2% [79.2-87.6%] vs 86.7% [83.2-88.2%], p = 0.009) and cerebral oxygen extraction (15% [11-20%] vs 12% [10-16%], p = 0.01), respectively. In survivors, diastolic blood velocities were 25 cm/s (19-30 cm/s) versus 29 cm/s (23-35 cm/s) (p = 0.004), pulsatility index was 1.10 (0.97-1.18) versus 0.94 (0.89-1.05) (p = 0.027), jugular vein oxygen saturation was 79.2 (71.1-81.8) versus 83.3% (76.6-87.8) (p = 0.033), respectively. However, similar results were not found in nonsurvivors. Conclusions: In therapeutic hypothermia-treated patients after out-of-hospital cardiac arrest at physiological Paco(2), alpha-stat strategy increases jugular vein blood desaturation and cerebral oxygen extraction compared with pH-stat strategy and decreases cerebral blood flow velocities in survivors.	[Voicu, Sebastian; Deye, Nicolas; Malissin, Isabelle; Brun, Pierre-Yves; Haik, William; Champion, Sebastien; Megarbane, Bruno; Baud, Frederic J.] Lariboisiere Univ Hosp, APHP, Med & Toxicol Intens Care Dept, Paris, France; [Voicu, Sebastian; Deye, Nicolas; Sideris, Georgios; Mebazaa, Alexandre; Manivet, Philippe] Univ Paris Diderot, INSERM, U942, Paris, France; [Voicu, Sebastian; Sideris, Georgios] Lariboisiere Univ Hosp, APHP, Dept Cardiol, Paris, France; [Vigue, Bernard] CHU Bicetre, APHP, Dept Anesthesiol & Crit Care, Le Kremlin Bicetre, France; [Megarbane, Bruno; Baud, Frederic J.] Univ Paris Denis Diderot, INSERM, U705, Paris, France; [Mebazaa, Alexandre] Lariboisiere Univ Hosp, APHP, Dept Anaesthesia & Intens Care, Paris, France; [Carli, Pierre] Paris Descartes Univ, Necker Hosp, APHP, Med Sch,SAMU 75, Paris, France; [Carli, Pierre] Paris Descartes Univ, Necker Hosp, APHP, Dept Anesthesiol,Med Sch, Paris, France; [Manivet, Philippe] Lariboisiere Univ Hosp, APHP, Biochem Lab, Paris, France; Lariboisiere Univ Hosp, Intens Care Unit Dept, Paris, France	Deye, N (corresponding author), Lariboisiere Univ Hosp, APHP, Med & Toxicol Intens Care Dept, Paris, France.	nicolas.deye@lrb.aphp.fr	voicu, sebastian/AAM-5348-2020; Manivet, Philippe/AAA-1884-2021	Megarbane, Bruno/0000-0002-2522-2764; Mebazaa, Alexandre/0000-0001-8715-7753	Thermofischer; Ministere Francais de la Sante	Dr. Vigue lectured for Laboratoire francais du Fractionnement et de Biotechnologie (LFB) and Octapharma. Dr. Vigue and his institution consulted for LFB and received grant support from Thermofischer. Dr. Mebazaa consulted for Bayer, Cardiorentis, and Vifor and lectured for Alere, Edwards, Novartis, and Orion. Dr. Baud received support for article research from the Ministere Francais de la Sante. The remaining authors have disclosed that they do not have any potential conflicts of interest.	AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aziz KAA, 2010, INTERACT CARDIOV TH, V10, P271, DOI 10.1510/icvts.2009.214130; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bhatia A, 2007, INTENS CARE MED, V33, P1263, DOI 10.1007/s00134-007-0678-z; Bisschops LLA, 2012, CRIT CARE MED, V40, P2362, DOI 10.1097/CCM.0b013e318255d983; Bisschops LLA, 2010, CRIT CARE MED, V38, P1542, DOI 10.1097/CCM.0b013e3181e2cc1e; Buunk G, 1997, STROKE, V28, P1569, DOI 10.1161/01.STR.28.8.1569; Chamorro C, 2010, ANESTH ANALG, V110, P1328, DOI 10.1213/ANE.0b013e3181d8cacf; Curley G, 2010, CRIT CARE, V14, DOI 10.1186/cc8926; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Deakin CD, 2010, RESUSCITATION, V81, pE93, DOI 10.1016/j.resuscitation.2010.08.027; Duebener LF, 2002, CIRCULATION, V106, pI103, DOI 10.1161/01.cir.0000032916.33237.a9; Falkenbach P, 2009, RESUSCITATION, V80, P990, DOI 10.1016/j.resuscitation.2009.04.044; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HENRIKSEN L, 1983, J THORAC CARDIOV SUR, V86, P202; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hoover LR, 2009, ANESTH ANALG, V108, P1389, DOI 10.1213/ane.0b013e318187c39d; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JENNETT B, 1975, LANCET, V1, P480; Joshi B, 2010, ANESTH ANALG, V110, P321, DOI 10.1213/ANE.0b013e3181c6fd12; Kiziltan HT, 2003, ANESTH ANALG, V96, P644, DOI 10.1213/01.ANE.000048826.67870.85; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; Kollmar R, 2009, NEUROCRIT CARE, V10, P173, DOI 10.1007/s12028-008-9162-z; Krejza J, 1999, AM J ROENTGENOL, V172, P213, DOI 10.2214/ajr.172.1.9888770; Laffey JG, 2002, NEW ENGL J MED, V347, P43, DOI 10.1056/NEJMra012457; Laussen PC, 2002, PAEDIATR ANAESTH, V12, P199, DOI 10.1046/j.1460-9592.2002.00779.x; Lemiale V, 2008, RESUSCITATION, V76, P17, DOI 10.1016/j.resuscitation.2007.06.028; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; Marti-Fabregas J, 2003, NEUROLOGY, V61, P1051, DOI 10.1212/01.WNL.0000090520.67254.14; Millar SA, 1999, BRIT J ANAESTH, V83, P936, DOI 10.1093/bja/83.6.936; Morrison LJ, 2010, CIRCULATION, V122, P8345, DOI 10.1161/CIRCULATIONAHA.110.971051; MURKIN JM, 1987, ANESTH ANALG, V66, P825; Nauphal M, 2007, EUR J ANAESTH, V24, P15, DOI 10.1017/S0265021506000998; Pokela M, 2003, ANN THORAC SURG, V76, P1215, DOI 10.1016/S0003-4975(03)00834-8; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Priestley MA, 2001, J THORAC CARDIOV SUR, V121, P336, DOI 10.1067/mtc.2001.112338; Pynnonen L, 2011, RESUSCITATION, V82, P1174, DOI 10.1016/j.resuscitation.2011.04.022; Roberts BW, 2013, CIRCULATION, V127, P2107, DOI 10.1161/CIRCULATIONAHA.112.000168; Schneider AG, 2013, RESUSCITATION, V84, P927, DOI 10.1016/j.resuscitation.2013.02.014; Sideris G, 2011, RESUSCITATION, V82, P1148, DOI 10.1016/j.resuscitation.2011.04.023; SORTEBERG W, 1990, J ULTRAS MED, V9, P403; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Sundgreen C, 2001, STROKE, V32, P128, DOI 10.1161/01.STR.32.1.128; van Genderen ME, 2012, CRIT CARE MED, V40, P2287, DOI 10.1097/CCM.0b013e31825333b2; Vigue B, 2000, INTENS CARE MED, V26, P722, DOI 10.1007/s001340051238; Wessels T, 2006, ULTRASOUND MED BIOL, V32, P1845, DOI 10.1016/j.ultrasmedbio.2006.06.023	46	23	23	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2014	42	8					1849	1861		10.1097/CCM.0000000000000339			13	Critical Care Medicine	General & Internal Medicine	AL7QV	WOS:000339330700034	24717455				2021-06-18	
J	Walter, KH; Dickstein, BD; Barnes, SM; Chard, KM				Walter, Kristen H.; Dickstein, Benjamin D.; Barnes, Sean M.; Chard, Kathleen M.			Comparing Effectiveness of CPT to CPT-C Among US Veterans in an Interdisciplinary Residential PTSD/TBI Treatment Program	JOURNAL OF TRAUMATIC STRESS			English	Article							COGNITIVE-PROCESSING THERAPY; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CLINICAL-TRIAL; SCALE; VICTIMS	Cognitive processing therapy (CPT) is a leading cognitive-behavioral treatment for posttraumatic stress disorder (PTSD) and a front-line intervention according to the U.S. Department of Veterans Affairs treatment guidelines. The original CPT protocol entails the creation of a written trauma account and use of cognitive therapy. Cognitive processing therapy-cognitive therapy only (CPT-C) does not involve a written account and in a previous study resulted in faster symptom improvement and fewer dropouts than standard CPT. This study sought to replicate these findings by comparing the effectiveness of CPT to CPT-C in a sample of 86 U. S. male veterans receiving treatment in a PTSD residential program for individuals with a history of traumatic brain injury. CPT and CPT-C were delivered in a combined individual and group format as part of a comprehensive, interdisciplinary treatment program. Outcomes were self-and clinician-reported PTSD and self-reported depression symptoms. Multilevel analysis revealed no significant difference for PTSD symptoms, but did show a greater decrease in depression at posttreatment (d = 0.63) for those receiving CPT. When an experiment-wise a correction was applied, this effect did not remain significant.	[Walter, Kristen H.; Dickstein, Benjamin D.; Chard, Kathleen M.] Cincinnati VA Med Ctr, Trauma Recovery Ctr, Cincinnati, OH USA; [Barnes, Sean M.] VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Barnes, Sean M.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA; [Chard, Kathleen M.] Univ Cincinnati, Sch Med, Dept Psychiat, Cincinnati, OH USA	Walter, KH (corresponding author), Vet Med Res Fdn, 3350 La Jolla Village Dr 111-N1,Bldg 13, San Diego, CA 92161 USA.	Kristen.Walter@va.gov	Walter, Kristen H/S-1827-2019				Alvarez J, 2011, J CONSULT CLIN PSYCH, V79, P590, DOI 10.1037/a0024466; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890423349, DOI 10.1176/APPI.BOOKS.9780890423349]; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Chard KM, 2005, J CONSULT CLIN PSYCH, V73, P965, DOI 10.1037/0022-006X.73.5.965; Chard KM, 2009, COGNITIVE PROCESSING; First M.B., 1996, STRUCTURED CLIN INTE; Foa E.B., 2008, EFFECTIVE TREATMENTS; Foa EB, 2007, PROLONGED EXPOSURE T; Forbes D, 2012, J ANXIETY DISORD, V26, P442, DOI 10.1016/j.janxdis.2012.01.006; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Heck RH, 2010, QUANT METH SER, P1; Hox J.J., 2010, MULTILEVEL ANAL TECH, V2nd ed.; Institute of Medicine, 2008, TREATM PTSD ASS EV; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; McCarthy E, 2011, J TRAUMA STRESS, V24, P474, DOI 10.1002/jts.20660; McIlvain SM, 2013, COGN BEHAV PRACT, V20, P375, DOI 10.1016/j.cbpra.2012.09.002; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Resick P. A, 2007, COGNITIVE PROCESSING; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Shear MK, 2000, AM J PSYCHIAT, V157, P581, DOI 10.1176/appi.ajp.157.4.581; SPSS, 2008, SPSS STAT BAS 17 0 U; Suris A, 2013, J TRAUMA STRESS, V26, P28, DOI 10.1002/jts.21765; Twamley E. W., 2008, COGNITIVE SYMP UNPUB; U. S. Department of Veterans Affairs, 2010, VHA HDB; U. S. Department of Veterans Affairs & U. S. Department of Defense, 2004, VA DOD CLIN PRACT GU; United States Department of Veterans Affairs & Department of Defense, 2009, VA DOD CLIN PRACT GU; Weathers F. W., 1993, 9 ANN C INT SOC TRAU; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029	32	23	23	0	21	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	AUG	2014	27	4					438	445		10.1002/jts.21934			8	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	AO2ZQ	WOS:000341198000008	25158637				2021-06-18	
J	Almolda, B; Villacampa, N; Manders, P; Hidalgo, J; Campbell, IL; Gonzalez, B; Castellano, B				Almolda, Beatriz; Villacampa, Nadia; Manders, Peter; Hidalgo, Juan; Campbell, Iain L.; Gonzalez, Berta; Castellano, Bernardo			Effects of astrocyte-targeted production of interleukin-6 in the mouse on the host response to nerve injury	GLIA			English	Article						lymphocytes; microglia; facial nerve axotomy; osteopontin; CD44; transgenic animal	FACIAL MOTOR NUCLEUS; APPEARING WHITE-MATTER; SPINAL-CORD-INJURY; OSTEOPONTIN EXPRESSION; TRANSGENIC MICE; UP-REGULATION; IN-VIVO; MEDIATED NEUROPROTECTION; MACROPHAGE INFILTRATION; LYMPHOCYTE RECRUITMENT	Interleukin-6 (IL-6) is a pleiotropic cytokine with a key role in the control of inflammatory/immune responses. In the central nervous system (CNS), an increase in IL-6 occurs in a wide range of pathological conditions such as excitotoxicity and traumatic brain injury. We evaluated the effects of astrocyte-targeted production of IL-6 in the CNS in the sterile-nerve injury model of facial nerve axotomy. To accomplish this, facial nerve transection was performed in transgenic mice (glial fibrillary acidic protein [GFAP]-IL6Tg) with IL-6 production under the GFAP promoter. Neuronal death, glial activation, lymphocyte recruitment, and integrin expression were evaluated by immunohistochemistry and flow cytometry from 3 to 28 days postinjury. Our findings revealed an increase in motor neuron cell death in GFAP-IL6Tg mice correlating with changes in the microglial activation pattern, characterized principally by less attachment to neurons and reduced expression of both CD11b and CD18. We also found a higher CD4(+) T-lymphocyte recruitment in GFAP-IL6Tg mice. In addition, changes in the expression pattern of different integrins and their receptors were observed in transgenic animals. Specifically, alterations in osteopontin expression in motor neurons and its receptors CD44 and CD49e in lymphocytes and microglia, respectively, which may account for the variations related to glial reactivity and lymphocyte infiltration. In conclusion, our results indicated that forced local production of IL-6 has a direct impact on the outcome of nerve injury in the CNS inducing an increase in neurodegeneration, changes in glial response, and lymphocyte recruitment as well as in the expression of different integrins and their receptors. GLIA 2014;62:1142-1161	[Almolda, Beatriz; Villacampa, Nadia; Hidalgo, Juan; Gonzalez, Berta; Castellano, Bernardo] Univ Autonoma Barcelona, Inst Neurosci, Dept Cell Biol Physiol & Immunol, Bellaterra 08193, Spain; [Manders, Peter; Campbell, Iain L.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia	Almolda, B (corresponding author), Univ Autonoma Barcelona, Unitat Histol, Torre M5, Bellaterra 08193, Spain.	beatriz.almolda@uab.cat	Hidalgo, Juan/C-9082-2011; Castellano, Bernardo/G-1428-2010; Villacampa, Dr Nadia/K-5304-2014; Almolda, Beatriz/L-6920-2014; Gonzalez, Berta/G-1428-2010	Hidalgo, Juan/0000-0003-0921-1122; Castellano, Bernardo/0000-0003-1976-971X; Villacampa, Dr Nadia/0000-0001-6513-0250; Almolda, Beatriz/0000-0001-6631-4385; Gonzalez, Berta/0000-0002-1860-3980	Spanish Ministry of Science and InnovationSpanish Government [BFU2011-27400]; SAF [2008-00435, 2011-23272]; NHMRC projectNational Health and Medical Research Council of Australia [632754]	Grant sponsor: Spanish Ministry of Science and Innovation; Grant numbers: BFU2011-27400 (to BC); Grant sponsor: SAF; Grant numbers: 2008-00435 and 2011-23272 (to JH); Grant sponsor: NHMRC project; Grant number: 632754 (to ILC).	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Almolda Beatriz, 2013, Methods Mol Biol, V1041, P243, DOI 10.1007/978-1-62703-520-0_22; Almolda B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027473; Almolda B, 2010, J NEUROIMMUNOL, V223, P39, DOI 10.1016/j.jneuroim.2010.03.021; Almolda B, 2009, J NEUROIMMUNOL, V209, P65, DOI 10.1016/j.jneuroim.2009.01.026; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Borges K, 2008, EPILEPSIA, V49, P1675, DOI 10.1111/j.1528-1167.2008.01613.x; Brunello AG, 2000, AM J PATHOL, V157, P1485, DOI 10.1016/S0002-9440(10)64787-6; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cao ZX, 2006, J NEUROSCI, V26, P5565, DOI 10.1523/JNEUROSCI.0815-06.2006; Carecchio M, 2011, J ALZHEIMERS DIS, V25, P179, DOI 10.3233/JAD-2011-102151; CASTELLANO B, 1991, J COMP NEUROL, V311, P434, DOI 10.1002/cne.903110312; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Choi JS, 2007, BRAIN RES, V1151, P195, DOI 10.1016/j.brainres.2007.03.016; Conroy SM, 2004, J NEUROIMMUNOL, V155, P43, DOI 10.1016/j.jneuroim.2004.06.014; Dauer DJ, 2011, BRAIN BEHAV IMMUN, V25, P77, DOI 10.1016/j.bbi.2010.08.005; Deboy CA, 2006, EXP NEUROL, V201, P212, DOI 10.1016/j.expneurol.2006.04.028; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Fisher J, 2001, J NEUROIMMUNOL, V119, P1, DOI 10.1016/S0165-5728(01)00342-3; Fu YF, 2004, ACTA NEUROPATHOL, V107, P8, DOI 10.1007/s00401-003-0775-1; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; Giachelli CM, 1998, AM J PATHOL, V152, P353; Giralt M, 2013, GLIA, V61, P587, DOI 10.1002/glia.22457; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Ha GK, 2006, J NEUROIMMUNOL, V172, P1, DOI 10.1016/j.jneuroim.2005.10.012; Ha GK, 2008, J NEUROIMMUNOL, V199, P18, DOI 10.1016/j.jneuroim.2008.04.027; Hao HP, 2007, J NEUROSCI RES, V85, P2196, DOI 10.1002/jnr.21357; Hashimoto M, 2003, J NEUROTRAUM, V20, P287, DOI 10.1089/089771503321532879; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Iczkiewicz J, 2005, EUR J NEUROSCI, V21, P1911, DOI 10.1111/j.1460-9568.2005.04009.x; Ikeda K, 1996, J NEUROL SCI, V135, P109, DOI 10.1016/0022-510X(95)00263-2; Jin JK, 2006, BRAIN RES, V1072, P227, DOI 10.1016/j.brainres.2005.12.013; Jones KJ, 2005, BRAIN BEHAV IMMUN, V19, P12, DOI 10.1016/j.bbi.2004.05.004; Jones LL, 1997, EUR J NEUROSCI, V9, P1854, DOI 10.1111/j.1460-9568.1997.tb00752.x; Kalla R, 2001, J COMP NEUROL, V436, P182; Kazanecki CC, 2007, J CELL BIOCHEM, V102, P912, DOI 10.1002/jcb.21558; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim SY, 2002, MOL CELLS, V13, P429; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Krady JK, 2008, J NEUROSCI RES, V86, P1538, DOI 10.1002/jnr.21620; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Lee JY, 2010, ACTA NEUROBIOL EXP, V70, P1; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; Makwana M, 2010, J COMP NEUROL, V518, P699, DOI 10.1002/cne.22240; Milner R, 2006, MOL CELL NEUROSCI, V33, P429, DOI 10.1016/j.mcn.2006.09.004; Moran LB, 2004, BRAIN RES REV, V44, P154, DOI 10.1016/j.brainresrev.2003.11.004; Mukaino M, 2010, EXP NEUROL, V224, P403, DOI 10.1016/j.expneurol.2010.04.020; MURABE Y, 1981, CELL TISSUE RES, V216, P557, DOI 10.1007/BF00238651; Murphy PG, 1999, J NEUROSCI, V19, P3791; Nakamura M, 2005, CLIN REV ALLERG IMMU, V28, P197, DOI 10.1385/CRIAI:28:3:197; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Pekny M, 2014, NEUROSCI LETT S, VS0304-3940, DOI 00008-00001; Petito CK, 2003, J NEUROVIROL, V9, P36, DOI 10.1080/13550280390173391; Quintana A, 2013, BRAIN BEHAV IMMUN, V27, P162, DOI 10.1016/j.bbi.2012.10.011; Quintana A, 2009, J IMMUNOL, V183, P2079, DOI 10.4049/jimmunol.0900242; Raivich G, 1998, J NEUROSCI, V18, P5804; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Sander LE, 2008, J IMMUNOL, V181, P3586, DOI 10.4049/jimmunol.181.5.3586; Selvaraju R, 2004, MOL CELL NEUROSCI, V25, P707, DOI 10.1016/j.mcn.2003.12.014; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.3.CO;2-3; Serpe CJ, 1999, J NEUROSCI, V19; Shin SL, 1999, NEUROSCI LETT, V273, P73, DOI 10.1016/S0304-3940(99)00516-9; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Shin T, 2004, NEUROSCI LETT, V356, P72, DOI 10.1016/j.neulet.2003.11.023; Sinclair C, 2005, NEUROPATH APPL NEURO, V31, P292, DOI 10.1111/j.1365-2990.2004.00638.x; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Stanke M, 2006, DEVELOPMENT, V133, P141, DOI 10.1242/dev.02189; Suzuki S, 2009, J CEREBR BLOOD F MET, V29, P464, DOI 10.1038/jcbfm.2008.141; Suzuki T, 2012, CELL MOL NEUROBIOL, V32, P1265, DOI 10.1007/s10571-012-9851-1; SVENSSON M, 1993, EXP NEUROL, V120, P123, DOI 10.1006/exnr.1993.1046; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tilgner J, 2001, GLIA, V35, P234, DOI 10.1002/glia.1088; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; van Horssen J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-156; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Villacampa Nadia, 2013, Methods Mol Biol, V1041, P261, DOI 10.1007/978-1-62703-520-0_23; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Werner A, 1998, J NEUROCYTOL, V27, P219, DOI 10.1023/A:1006928830251; Wung JK, 2007, CURR ALZHEIMER RES, V4, P67, DOI 10.2174/156720507779939869; Zhong J, 1999, J NEUROSCI, V19, P4305	94	23	25	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2014	62	7					1142	1161		10.1002/glia.22668			20	Neurosciences	Neurosciences & Neurology	AH3DF	WOS:000336001100010	24691898				2021-06-18	
J	Gouveia, TLF; Scorza, FA; Iha, HA; Frangiotti, MIB; Perosa, SR; Cavalheiro, EA; Silva, JA; Feliciano, RS; de Almeida, AC; Naffah-Mazzacoratti, MG				Gouveia, T. L. F.; Scorza, F. A.; Iha, H. A.; Frangiotti, M. I. B.; Perosa, S. R.; Cavalheiro, E. A.; Silva, J. A., Jr.; Feliciano, R. S.; de Almeida, A. C.; Naffah-Mazzacoratti, M. G.			Lovastatin decreases the synthesis of inflammatory mediators during epileptogenesis in the hippocampus of rats submitted to pilocarpine-induced epilepsy	EPILEPSY & BEHAVIOR			English	Article						Lovastatin; Pilocarpine; Epileptogenesis; Cytokines; Temporal lobe epilepsy	TEMPORAL-LOBE EPILEPSY; TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; STATUS-EPILEPTICUS; KININ B1; REDUCTASE INHIBITORS; NEURONAL DEATH; B2 RECEPTORS; CELL-DEATH	Statins may act on inflammatory responses, decreasing oxidative stress and also reducing brain inflammation in several brain disorders. Epileptogenesis is a process in which a healthy brain becomes abnormal and predisposed to generating spontaneous seizures. We previously reported that lovastatin could prevent neuroinflammation in pilocarpine-induced status epilepticus (SE). In this context, this study investigated the long-lasting effects of lovastatin on mRNA expression of proinflammatoty cytokines (interleukin-1 beta, tumor necrosis factor alpha, interleukin-6) and the antiinflammatoty cytokine IL-10 in the hippocampus during epileptogenesis by immunohistochemistry and real time polymerase chain reaction (RT-PCR) during the latent and chronic phases in the epilepsy model induced by pilocarpine in rats. For these purposes, four groups of rats were employed: saline (CONTROL), lovastatin (LOVA), pilocarpine (PILO), and pilocarpine plus lovastatin (PILO + LOVA). After pilocarpine injection (350 mg/kg, i.p.), the rats were treated with 20 mg/kg of lovastatin via an esophagic probe 2 h after SE onset All surviving rats were continuously treated during 15 days, twice/day. The pilocarpine plus lovastatin group showed a significant decrease in the levels of IL-1 beta, TNF-alpha, and IL-6 during the latent phase and a decreased expression of IL-1 beta and TNF-alpha in the chronic phase when compared with the PILO group. Moreover, lovastatin treatment also induced an increased expression of the antiinflammatory cytokine, IL-10, in the PILO + LOVA group when compared with the PILO group in the chronic phase. Thus, our data suggest that lovastin may reduce excitotoxicity during epileptogenesis induced by pilocarpine by increasing the synthesis of IL-10 and decreasing proinflammatory cytokines in the hippocampus. (C) 2014 Elsevier Inc All rights reserved.	[Gouveia, T. L. F.; Scorza, F. A.; Iha, H. A.; Frangiotti, M. I. B.; Perosa, S. R.; Cavalheiro, E. A.; Naffah-Mazzacoratti, M. G.] Univ Fed Sao Paulo UNIFESP, Dept Neurol & Neurosurg, Sao Paulo, Brazil; [Silva, J. A., Jr.; Feliciano, R. S.] Univ Nave Julho, Rehabil Dept, Sao Paulo, Brazil; [de Almeida, A. C.] Univ Fed Sao Joao del Rei, Dept Biomed Engn, Sao Joao Del Rei, Brazil; [Naffah-Mazzacoratti, M. G.] Univ Fed Sao Paulo UNIFESP, Dept Biochem, Sao Paulo, Brazil	Naffah-Mazzacoratti, MG (corresponding author), Rua Pedro de Toledo 669,04039-032 Vila Clementino, Sao Paulo, Brazil.	naffahmazz.nexp@epm.br	Cavalheiro, Esper A/I-3084-2016; ALMEIDA, ANTONIO-CARLOS G/B-8028-2008; Scorza, Carla Alessandra/C-4199-2013; Scorza, Fulvio/C-7048-2013; da Graca Naffah Mazzacoratti, Maria/N-9934-2014; Cavalheiro, Esper A/F-4325-2014; Silva, Jose Antonio/AAA-8100-2019; Cavalheiro, Esper/N-3985-2019	Cavalheiro, Esper A/0000-0002-0854-3582; ALMEIDA, ANTONIO-CARLOS G/0000-0003-4893-338X; Scorza, Carla Alessandra/0000-0001-7810-4748; Scorza, Fulvio/0000-0002-0694-8674; da Graca Naffah Mazzacoratti, Maria/0000-0002-3468-360X; Cavalheiro, Esper A/0000-0002-0854-3582; Silva, Jose Antonio/0000-0001-6904-9185; Cavalheiro, Esper/0000-0002-0854-3582; Iha, Higor/0000-0002-7034-6678	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Ministerio da Ciencia e Tecnologia, Instituto Nacional de Neurociencia Translacional (INNT); Cooperacao Interinstitucional de Apoio a Pesquisa sobre o Cerebro (CInAPCe), Brazil	This research was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Ministerio da Ciencia e Tecnologia, Instituto Nacional de Neurociencia Translacional (INNT), and Cooperacao Interinstitucional de Apoio a Pesquisa sobre o Cerebro (CInAPCe), Brazil.	Agnello D, 2000, BRAIN RES, V869, P241, DOI 10.1016/S0006-8993(00)02392-1; Arganaraz GA, 2004, BRAIN RES, V1013, P30, DOI 10.1016/j.brainres.2004.03.046; Arganaraz GA, 2004, BRAIN RES, V1006, P114, DOI 10.1016/j.brainres.2003.12.050; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; Chen CP, 2005, DRUG METAB DISPOS, V33, P537, DOI 10.1124/dmd.104.002477; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Choi H, 2008, JAMA-J AM MED ASSOC, V300, P2497, DOI 10.1001/jama.2008.771; Cimino M, 2007, NEUROSCIENTIST, V13, P208, DOI 10.1177/1073858406297121; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; Dolga AM, 2008, J ALZHEIMERS DIS, V13, P111; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Gouveia TLF, 2011, EPILEPSY BEHAV, V20, P1, DOI 10.1016/j.yebeh.2010.10.001; Ginsberg HN, 1998, AM J CARDIOL, V81, p32B, DOI 10.1016/S0002-9149(98)00035-6; Griffin JL, 2006, PHARMACOGENOMICS, V7, P1095, DOI 10.2217/14622416.7.7.1095; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Hering H, 2003, J NEUROSCI, V23, P3262; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; Li G, 2007, NEUROLOGY, V69, P878, DOI 10.1212/01.wnl.0000277657.95487.1c; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; McTaggart F, 2001, AM J CARDIOL, V87, p28B; Neuhaus O, 2004, LANCET NEUROL, V3, P369, DOI 10.1016/S1474-4422(04)00770-7; Pahan K, 2000, J NEUROCHEM, V75, P576, DOI 10.1046/j.1471-4159.2000.0750576.x; Perosa SR, 2007, HIPPOCAMPUS, V17, P26, DOI 10.1002/hipo.20239; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Ravizza T, 2006, NEUROSCIENCE, V137, P301, DOI 10.1016/j.neuroscience.2005.07.063; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; Sewnath ME, 2001, J IMMUNOL, V166, P6323, DOI 10.4049/jimmunol.166.10.6323; Silva JA, 2008, INT IMMUNOPHARMACOL, V8, P197, DOI 10.1016/j.intimp.2007.09.003; Strle K, 2002, J NEUROIMMUNOL, V122, P9, DOI 10.1016/S0165-5728(01)00444-1; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Varella PPV, 2011, ARQ NEURO-PSIQUIAT, V69, P91, DOI 10.1590/S0004-282X2011000100018; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Wang Y, 2010, APOPTOSIS, V15, P1382, DOI 10.1007/s10495-010-0481-0; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	42	23	29	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	JUL	2014	36						68	73		10.1016/j.yebeh.2014.04.009			6	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	AL4WW	WOS:000339136500014	24857811				2021-06-18	
J	Vaughan, CG; Gerst, EH; Sady, MD; Newman, JB; Gioia, GA				Vaughan, Christopher G.; Gerst, Elyssa H.; Sady, Maegan D.; Newman, Julie B.; Gioia, Gerard A.			The Relation Between Testing Environment and Baseline Performance in Child and Adolescent Concussion Assessment	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						baseline testing; concussion testing; neurocognitive testing; computerized testing	SPORTS; SCHOOL; IMPACT	Background: Previous research has demonstrated differences in cognitive performance when baseline concussion assessment is performed in a group versus an individual setting. Accurate baseline assessment is imperative when such data are used to make clinical decisions regarding cognitive and symptom recovery after concussion. Hypothesis: The use of similar standardized test administration procedures and test conditions across group and individual settings results in no differences in cognitive performance or symptom reporting. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 939 participants (aged 5-18 years), including 313 tested individually and 626 tested in a group setting, matched on age, sex, and attention-deficit/hyperactivity disorder status, were administered concussion baseline assessment using the desktop version of the Immediate Post-Concussion Assessment and Cognitive Testing and a new pediatric measure, the Multimodal Assessment of Cognition & Symptoms for Children. Cognitive performance, symptom reports, and rates of invalid performance were compared between settings. Results: No significant differences were found between individual and group testing settings for the age-based Learning and Memory Accuracy composite and Response Speed composite standard scores on the Multimodal Assessment of Cognition & Symptoms for Children. Accounting for age and sex, adolescents' performance on the Immediate Post-Concussion Assessment and Cognitive Testing revealed no differences between settings on the 4 composite raw scores (Verbal Memory, Visual Memory, Visual Motor Speed, and Reaction Time). Furthermore, symptom reporting was similar between settings on both measures. Rates of invalid performance did not differ between the 2 administration groups for either age group. There was an interaction effect for invalid performance between attention-deficit/hyperactivity disorder and setting in younger children (aged 5-12 years), with higher rates of invalid performance for children in the group setting with attention-deficit/hyperactivity disorder compared with those without, although there were no differences in the individual setting. Conclusion: In this sample, children given a baseline assessment in a group setting performed no differently than children tested individually when standardized administration procedures were used by trained test administrators. Previous evidence suggesting differences between settings may be attributable to the variability in test administration and supervision rather than the environment itself. The importance of standardized procedures and proper supervision during baseline concussion assessment is supported by these findings.	[Vaughan, Christopher G.; Gerst, Elyssa H.; Sady, Maegan D.; Newman, Julie B.; Gioia, Gerard A.] Childrens Natl Hlth Syst, Rockville, MD 20850 USA	Vaughan, CG (corresponding author), Childrens Natl Hlth Syst, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	cvaughan@childrensnational.org			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352-01]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5-M01-RR-020359-02, P30/HDO40677-07]; USA Hockey at Children's National Health System	One or more of the authors has declared the following potential conflict of interest or source of funding: C. G. V. is a test author of the Multimodal Assessment of Cognition & Symptoms, with royalties expected. G. A. G. is a test author of several measures, including the Multimodal Assessment of Cognition & Symptoms, with royalties expected. Research support has been provided through several grants for test and measure development for the assessment of pediatric concussion by the Centers for Disease Control and Prevention (grant U17/CCU323352-01) and the National Institutes of Health (grants 5-M01-RR-020359-02 and P30/HDO40677-07). USA Hockey has sponsored broader implementation of the concussion program (research and education, predominantly with ice hockey organizations) at Children's National Health System.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Lovell MR., 2000, IMPACT IMMEDIATE POS; Lovell MR, IMPACT 2007 6 0 CLIN; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Podell K, 2004, STUD NEUROPSYCHOL DE, P375; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Vaughan C., 2009, J INT NEUROPSYCH SOC, V15, P189; Woodard JL, 2012, J CLIN SPORT PSYCH, V57, P524	20	23	23	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2014	42	7					1716	1723		10.1177/0363546514531732			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AN6QT	WOS:000340721900031	24787043				2021-06-18	
J	Gu, YL; Zhang, LW; Ma, N; Ye, LL; Wang, DX; Gao, X				Gu, Ying Li; Zhang, Li Wei; Ma, Ning; Ye, Lin Lin; Wang, De Xin; Gao, Xu			Cognitive improvement of mice induced by exercise prior to traumatic brain injury is associated with cytochrome c oxidase	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Cognitive; Cytochrome c oxidase; Exercise	EXPRESSION; HIPPOCAMPUS; PLASTICITY; PROTEINS; INCREASE; DEFICITS; CORTEX	Though the evidence demonstrated that voluntary exercise programs could be implemented to enhance recovery of cognitive function induced by traumatic brain injury (TBI), the exact mechanisms were still not known. We proposed that the cognitive improvement induced by exercise in TBI mice is associated with cytochrome c oxidase (COX). To demonstrate this hypothesis, adult mice were housed with or without access to a running wheel (RW) for three weeks followed by TBI operation. Acquisition of spatial learning and memory retention was assessed by using the Morris Water Maze (MWM) on days 15 post TBI. The synaptic density was measured by Golji staining. Immunohistochemistry (IHC) for NeuN, GFAP and growth associated protein 43 (GAP43) were also performed. Using Western blot, the expressions of COX I, II, III, BDNF, synapsin I, synaptophysin (SYP) and GAP43 in hippocampus of TBI mice were determinated. Lastly, CcO activity and ATP amount were also detected. Results showed that voluntary exercise prior TBI: (i) counteracted the cognitive deficits and neuron and synaptic density loss associated with the injury; (ii) increased the levels of COX I, II, III, BDNF, synapsin I, SYP and GAP43; (iii) switched the mitochondrial CcO activity and ATP amounts. These studies demonstrated that the COX plays an important role in exercise's cognitive effects in TBI model and also provide evidence that RW training is a promise exercise for traumatically injured mice. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Gu, Ying Li; Zhang, Li Wei; Ye, Lin Lin] Harbin Med Univ, Affiliated Hosp 4, Dept Neurol, Harbin 150001, Peoples R China; [Ma, Ning; Gao, Xu] Harbin Med Univ, Dept Biochem & Mol Biol, Harbin 150081, Peoples R China; [Wang, De Xin] Beichen Hosp Tradit Chinese Med, Dept Neurol, Tianjin 300400, Peoples R China	Gao, X (corresponding author), Harbin Med Univ, Dept Biochem & Mol Biol, Harbin 150081, Peoples R China.	gaoxu2014@126.com	Ye, Linlin/Y-7497-2018; GU, YINGLI/AAQ-3591-2021; GU, YINGLI/ABA-6790-2020; gao, xu/U-4765-2019		Health Department of Heilongjiang Province [2013097]	We thank Dr. M.J.. Keven for his valuable comments on this manuscript. This research was supported by the Health Department of Heilongjiang Province (No. 2013097).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ashman TA, 2006, MT SINAI J MED, V73, P999; Balaratnasingam C, 2009, J NEUROSCI RES, V87, P2973, DOI 10.1002/jnr.22120; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Dai W, 2009, BRAIN RES, V1251, P287, DOI 10.1016/j.brainres.2008.11.034; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guarnieri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053267; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoffman AN, 2011, EUR J NEUROSCI, V34, P1023, DOI 10.1111/j.1460-9568.2011.07820.x; Huttemann M, 2008, NEUROSCIENCE, V151, P148, DOI 10.1016/j.neuroscience.2007.09.029; JASLOVE SW, 1992, NEUROSCIENCE, V47, P495, DOI 10.1016/0306-4522(92)90161-T; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; Loane David J, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P136; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Rosi S, 2012, HIPPOCAMPUS, V22, P544, DOI 10.1002/hipo.20920; Tanaka JI, 2008, SCIENCE, V319, P1683, DOI 10.1126/science.1152864; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; XiYang YB, 2013, BMC BIOCHEM, V14, DOI 10.1186/1471-2091-14-21; Xu T, 2014, INT J MOL SCI, V15, P3299, DOI 10.3390/ijms15023299	25	23	23	1	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 6	2014	570						86	91		10.1016/j.neulet.2014.04.004			6	Neurosciences	Neurosciences & Neurology	AI6VM	WOS:000337015100019	24746931				2021-06-18	
J	Maruta, J; Heaton, KJ; Mau, AL; Ghajar, J				Maruta, Jun; Heaton, Kristin J.; Mau, Alexis L.; Ghajar, Jamshid			Predictive Visual Tracking: Specificity in Mild Traumatic Brain Injury and Sleep Deprivation	MILITARY MEDICINE			English	Article							PURSUIT EYE-MOVEMENTS; SMOOTH-PURSUIT; ATTENTION; SYNCHRONIZATION	We tested whether reduced cognitive function associated with mild traumatic brain injury (mTBI) and sleep deprivation can be detected and distinguished using indices of predictive visual tracking. A circular visual tracking test was given to 13 patients with acute mTBI (recruited within 2 weeks of injury), 127 normal control subjects, and 43 healthy subjects who were fatigued by 26-hour sleep deprivation. Eye movement was monitored with video-oculography. In the mTBI-related portion of the study, visual tracking performance of acute mTBI patients was significantly worse than normal subjects (p < 0.001). In the sleep-deprivation-related portion of the study, no change was detected between the two baseline measures separated by 2 to 3 weeks, but the 26-hour sleep deprivation significantly degraded the visual tracking performance (p < 0.001). The mTBI subjects had substantially worse visual tracking than sleep-deprived subjects that could also be identified with different visual tracking indices, indicating possible different neurophysiological mechanisms. Results suggest that cognitive, impairment associated with mTBI and fatigue may be triaged with the aid of visual tracking measures.	[Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, World Trade Ctr 7, New York, NY 10007 USA; [Heaton, Kristin J.; Mau, Alexis L.] US Army, Inst Environm Med, Mil Performance Div, Natick, MA 01760 USA; [Heaton, Kristin J.; Mau, Alexis L.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; [Ghajar, Jamshid] Stanford Univ, Med Ctr, Dept Neurosurg, Stanford, CA 94305 USA	Maruta, J (corresponding author), Brain Trauma Fdn, World Trade Ctr 7, 34th Floor,250 Greenwich St, New York, NY 10007 USA.		Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605	CDMRPUnited States Department of Defense [W81XWH-08-2-0646]; USAMRMCU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-1-0021]; James S. McDonnell Foundation	This work was supported by CDMRP W81XWH-08-2-0646, USAMRMC W81XWH-08-1-0021, and James S. McDonnell Foundation.	Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Baumann O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007110; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Chen Y, 2002, PROG BRAIN RES, V140, P255; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Ghajar J, 2009, NEUROSCIENTIST, V15, P232, DOI 10.1177/1073858408326429; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HENN V, 1984, EXP BRAIN RES, V54, P166; Katsanis J, 1998, PSYCHOPHYSIOLOGY, V35, P64; Maruta J, 2013, BEHAV RES METHODS, V45, P289, DOI 10.3758/s13428-012-0248-3; Maruta J, 2012, PROC SPIE, V8371, DOI 10.1117/12.927790; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; Salman MS, 2006, EXP BRAIN RES, V169, P139, DOI 10.1007/s00221-005-0292-7; Suzuki Y, 1997, INVEST OPHTH VIS SCI, V38, P2103; Thomas M, 2000, J SLEEP RES, V9, P335, DOI 10.1046/j.1365-2869.2000.00225.x; VANGELDER P, 1995, VISION RES, V35, P667, DOI 10.1016/0042-6989(94)00161-E	18	23	23	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	JUN	2014	179	6					619	625		10.7205/MILMED-D-13-00420			7	Medicine, General & Internal	General & Internal Medicine	AN7UM	WOS:000340806500006	24902128	Bronze			2021-06-18	
J	Pang, T; Sun, LX; Wang, T; Jiang, ZZ; Liao, H; Zhang, LY				Pang, Tao; Sun, Li-xin; Wang, Tao; Jiang, Zhen-zhou; Liao, Hong; Zhang, Lu-yong			Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARy and the Akt/GSK-beta pathway	ACTA PHARMACOLOGICA SINICA			English	Article						cerebellar granule cell; nutrient deprivation; apoptosis; angiotensin II receptor blocker; telmisartan; AT(1a) receptor; Akt; GSK-3 beta; PPARy; neurotoxicity	GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR-GAMMA ACTIVATION; TRAUMATIC BRAIN-INJURY; ANGIOTENSINOGEN MESSENGER-RNA; FOCAL CEREBRAL-ISCHEMIA; CELL-DEATH; INFLAMMATORY RESPONSE; PARKINSONS-DISEASE; NERVOUS-SYSTEM; DIABETIC MICE	Aim: To determine whether angiotensin II receptor blockers (ARBs) could protect central neurons against nutrient deprivation-induced apoptosis in vitro and to elucidate the underlying mechanisms. Methods: Primary rat cerebellar granule cells (CGCs) underwent B27 (a serum substitute) deprivation for 24 h to induce neurotoxicity, and cell viability was analyzed using LDH assay and WST-1 assay. DNA laddering assay and TUNEL assay were used to detect cell apoptosis. The expression of caspase-3 and Bcl-2, and the phosphorylation of Akt and GSK-3 beta were detected using Western blot analysis. AT,a mRNA expression was determined using RT-PCR analysis. Results: B27 deprivation significantly increased the apoptosis of CGCs, as demonstrated by LDH release, DNA laddering, caspase-3 activation and positive TUNEL staining. Pretreatment with 10 mu mol/L ARBs (telmisartan, candesartan or losartan) partially blocked B27 deprivation-induced apoptosis of CGCs with telmisartan being the most effective one. B27 deprivation markedly increased the expression of AT(1a) receptor in CGCs, inhibited Akt and GSK-3 beta activation, decreased Bcl-2 level, and activated caspase-3, which were reversed by pretreatment with 1 mu mol/L telmisartan. In addition, pretreatment with 10 mu mol/L PPARy agonist pioglitazone was more effective in protecting CGCs against B27 deprivation-induced apoptosis, whereas pretreatment with 20 mu mol/L PPARy antagonist GW9662 abolished all the effects of telmisartan in CGCs deprived of B27. Conclusion: ARBs, in particular telmisartan, can protect the nutrient deprivation-induced apoptosis of CGCs in vitro through activation of PPARy and the Akt/GSK-3 beta pathway.	[Pang, Tao; Sun, Li-xin; Wang, Tao; Jiang, Zhen-zhou; Liao, Hong; Zhang, Lu-yong] China Pharmaceut Univ, New Drug Screening Ctr, Nanjing 210009, Jiangsu, Peoples R China; [Pang, Tao; Liao, Hong; Zhang, Lu-yong] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China; [Pang, Tao] China Pharmaceut Univ, Minist Educ, Key Lab Drug Qual Control & Pharmacovigilance, Nanjing 210009, Jiangsu, Peoples R China	Liao, H (corresponding author), China Pharmaceut Univ, New Drug Screening Ctr, Nanjing 210009, Jiangsu, Peoples R China.	liaohong56@hotmail.com; lyzhang@cpu.edu.cn			Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20130653, BK2010433]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [JKZD2013006]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070967, 81271338]; Specialized Research Fund for the Doctoral Program of Higher Education of ChinaSpecialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [20130096110011]; China Pharmaceutical University	This study was supported by the Natural Science Foundation of Jiangsu Province (BK20130653, BK2010433), the Fundamental Research Funds for the Central Universities (JKZD2013006), the National Natural Science Foundation of China (81070967, 81271338), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20130096110011) and the Initial Fund of China Pharmaceutical University to Dr Tao PANG.	AbdAlla S, 2009, J BIOL CHEM, V284, P6554, DOI 10.1074/jbc.M807746200; An JB, 2010, HYPERTENS RES, V33, P831, DOI 10.1038/hr.2010.79; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen YC, 2012, MOL NEUROBIOL, V46, P114, DOI 10.1007/s12035-012-8259-8; Chiong M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.130; Chuang DM, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00015; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DZAU VJ, 1986, HYPERTENSION, V8, P544, DOI 10.1161/01.HYP.8.6.544; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Erbe DV, 2006, VASC PHARMACOL, V45, P154, DOI 10.1016/j.vph.2006.05.002; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fuenzalida K, 2007, J BIOL CHEM, V282, P37006, DOI 10.1074/jbc.M700447200; Garrido-Gil P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-38; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GYURKO R, 1993, REGUL PEPTIDES, V49, P167, DOI 10.1016/0167-0115(93)90438-E; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Inaba S, 2009, STROKE, V40, P597, DOI 10.1161/STROKEAHA.108.519801; Iwanami J, 2010, J HYPERTENS, V28, P1730, DOI 10.1097/HJH.0b013e32833a551a; Jantas D, 2011, NEUROTOXICOLOGY, V32, P845, DOI 10.1016/j.neuro.2011.05.013; Jin N, 2005, NEUROPHARMACOLOGY, V48, P576, DOI 10.1016/j.neuropharm.2004.11.010; Jing G, 2004, BRAIN RES BULL, V62, P397, DOI 10.1016/j.brainresbull.2003.10.011; Joglar B, 2009, J NEUROCHEM, V109, P656, DOI 10.1111/j.1471-4159.2009.05999.x; Kasahara Y, 2010, BRAIN RES, V1340, P70, DOI 10.1016/j.brainres.2010.03.101; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kehoe PG, 2009, TRENDS NEUROSCI, V32, P619, DOI 10.1016/j.tins.2009.07.006; Kelly S, 2004, EXP NEUROL, V188, P378, DOI 10.1016/j.expneurol.2004.04.004; Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007; Kiaei M, 2008, PPAR RES, V2008, DOI 10.1155/2008/418765; Koh EJ, 2013, BRIT J PHARMACOL, V169, P1404, DOI 10.1111/bph.12229; Krikov M, 2008, J HYPERTENS, V26, P544, DOI 10.1097/HJH.0b013e3282f2dac9; Kumari S, 2001, MOL BRAIN RES, V96, P157, DOI 10.1016/S0006-8993(01)03045-1; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Liang MH, 2007, J BIOL CHEM, V282, P3904, DOI 10.1074/jbc.M605178200; Liu F, 2005, J NEUROCHEM, V95, P1363, DOI 10.1111/j.1471-4159.2005.03474.x; Min LJ, 2012, HYPERTENSION, V59, P1079, DOI 10.1161/HYPERTENSIONAHA.112.192401; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Neldam S, 2010, FUTUR CARDIOL, V6, P129, DOI [10.2217/fca.09.61, 10.2217/FCA.09.61]; Pang T, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-102; Pang T, 2012, J HYPERTENS, V30, P87, DOI 10.1097/HJH.0b013e32834dde5f; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Park DS, 1997, J NEUROSCI, V17, P8975; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rotman N, 2010, PHYSIOLOGY, V25, P176, DOI 10.1152/physiol.00018.2010; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Schelman WR, 2004, MOL BRAIN RES, V128, P20, DOI 10.1016/j.molbrainres.2004.06.001; Schrader J, 2005, STROKE, V36, P1218, DOI 10.1161/01.STR.0000166048.35740.a9; Schrader J, 2003, STROKE, V34, P1699, DOI 10.1161/01.STR.0000075777.18006.89; Seneff S, 2011, EUR J INTERN MED, V22, P134, DOI 10.1016/j.ejim.2010.12.017; Stangier J, 2000, J INT MED RES, V28, P149, DOI 10.1177/147323000002800401; Tsukuda K, 2009, HYPERTENSION, V54, P782, DOI 10.1161/HYPERTENSIONAHA.109.136879; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Wang LX, 2009, CHINESE MED J-PEKING, V122, P1380, DOI 10.3760/cma.j.issn.0366-6999.2009.12.005; Wright JW, 2008, PROG NEUROBIOL, V84, P157, DOI 10.1016/j.pneurobio.2007.10.009; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhao XR, 2006, BRAIN RES, V1073, P460, DOI 10.1016/j.brainres.2005.12.061; Zhao Y, 2006, FASEB J, V20, P1162, DOI 10.1096/fj.05-5007com; Zhu DM, 2004, NEUROTOX RES, V6, P281, DOI 10.1007/BF03033438; Zorad S, 2006, EUR J PHARMACOL, V552, P112, DOI 10.1016/j.ejphar.2006.08.062; Zuhayra M, 2011, NEUROPATH APPL NEURO, V37, P738, DOI 10.1111/j.1365-2990.2011.01169.x	66	23	25	0	14	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	JUN	2014	35	6					727	737		10.1038/aps.2013.199			11	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	AI9QM	WOS:000337267800003	24793312	Green Published, Bronze			2021-06-18	
J	Qiao, Y; Zhang, PP; Wang, CM; Ma, LY; Su, M				Qiao, Yong; Zhang, Peipei; Wang, Chaoming; Ma, Liyuan; Su, Ming			Reducing X-Ray Induced Oxidative Damages in Fibroblasts with Graphene Oxide	NANOMATERIALS			English	Article						X-ray; graphene oxide; DNA damage; oxidative; reactive oxygen species (ROS)	TRAUMATIC BRAIN-INJURY; RADIATION-THERAPY; CEREBROVASCULAR DYSFUNCTION; IONIZING-RADIATION; IN-VITRO; DNA; RADIOTHERAPY; ASSAY; RADIOSENSITIZERS; NANOCARRIER	A major issue of X-ray radiation therapy is that normal cells can be damaged, limiting the amount of X-rays that can be safely delivered to a tumor. This paper describes a new method based on graphene oxide (GO) to protect normal cells from oxidative damage by removing free radicals generated by X-ray radiation using grapheme oxide (GO). A variety of techniques such as cytotoxicity, genotoxicity, oxidative assay, apoptosis, gamma-H2AX expression, and micro-nucleus assay have been used to assess the protective effect of GO in cultured fibroblast cells. It is found that although GO at higher concentration (100 and 500 mu g/mL) can cause cell death and DNA damage, it can effectively remove oxygen free radicals at a lower concentration of 10 mu g/mL. The level of DNA damage and cell death is reduced by 48%, and 39%, respectively. Thus, low concentration GO can be used as an effective radio-protective agent in occupational and therapeutic settings.	[Qiao, Yong; Zhang, Peipei; Wang, Chaoming; Ma, Liyuan; Su, Ming] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA	Ma, LY (corresponding author), Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA.	qiaoyong83@gmail.com; pzhang2@wpi.edu; cwang4@wpi.edu; lma2@wpi.edu; msu2@wpi.edu	Su, Ming/F-4001-2014		National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1DP2EB016572]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [DP2EB016572] Funding Source: NIH RePORTER	This work is supported with a Director's New Innovator Award (1DP2EB016572) from National Institute of Health.	Ali H, 1999, CHEM REV, V99, P2379, DOI 10.1021/cr980439y; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Borek C, 2004, J NUTR, V134, p3207S; Box HC, 1999, RADIAT RES, V152, P575, DOI 10.2307/3580252; Bucci MK, 2005, CA-CANCER J CLIN, V55, P117, DOI 10.3322/canjclin.55.2.117; Cabiscol Elisa, 2000, International Microbiology, V3, P3; Chandra A, 2005, RADIOTHER ONCOL, V77, P247, DOI 10.1016/j.radonc.2005.10.017; Chang YL, 2011, TOXICOL LETT, V200, P201, DOI 10.1016/j.toxlet.2010.11.016; COMPORTI M, 1989, CHEM-BIOL INTERACT, V72, P1, DOI 10.1016/0009-2797(89)90016-1; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Elshaikh M, 2006, ANNU REV MED, V57, P19, DOI 10.1146/annurev.med.57.121304.131431; Fang Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep02811; Fischer TW, 2008, EXP DERMATOL, V17, P713, DOI 10.1111/j.1600-0625.2008.00767.x; Harrison LB, 2002, ONCOLOGIST, V7, P492, DOI 10.1634/theoncologist.7-6-492; He JL, 2000, CHINESE MED J-PEKING, V113, P911; Hosseinimehr SJ, 2007, DRUG DISCOV TODAY, V12, P794, DOI 10.1016/j.drudis.2007.07.017; Huang P, 2011, THERANOSTICS, V1, P240, DOI 10.7150/thno/v01p0240; Lawrence Theodore S, 2003, Oncology (Williston Park), V17, P23; Liu GD, 2013, ACS APPL MATER INTER, V5, P6909, DOI 10.1021/am402128s; Lobo V, 2010, Pharmacogn Rev, V4, P118, DOI 10.4103/0973-7847.70902; Maity AR, 2014, NANOSCALE, V6, P2752, DOI 10.1039/c3nr05431d; Marcano DC, 2013, J NEUROTRAUM, V30, P789, DOI 10.1089/neu.2011.2301; MARK F, 1989, RADIAT ENVIRON BIOPH, V28, P81, DOI 10.1007/BF01210293; MILAS L, 1988, PHARMACOL THERAPEUT, V39, P179, DOI 10.1016/0163-7258(88)90059-9; NAKANO H, 1994, RADIAT RES, V140, P1, DOI 10.2307/3578561; Qiao Y, 2013, ANAL CHEM, V85, P4107, DOI 10.1021/ac400242w; Qiao Y, 2012, ANAL CHEM, V84, P1112, DOI 10.1021/ac202773g; Qin XC, 2013, J PHOTOCH PHOTOBIO B, V120, P156, DOI 10.1016/j.jphotobiol.2012.12.005; Redon CE, 2009, ADV SPACE RES, V43, P1171, DOI 10.1016/j.asr.2008.10.011; Rydberg B, 1996, RADIAT RES, V145, P200, DOI 10.2307/3579175; Salas EC, 2010, ACS NANO, V4, P4852, DOI 10.1021/nn101081t; Teh B S, 1999, Oncologist, V4, P433; Wardman P, 2007, CLIN ONCOL-UK, V19, P397, DOI 10.1016/j.clon.2007.03.010; Wu J, 2013, CLIN CANCER RES, V19, P721, DOI 10.1158/1078-0432.CCR-12-2529; Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680	35	23	23	0	24	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2079-4991			NANOMATERIALS-BASEL	Nanomaterials	JUN	2014	4	2					522	534		10.3390/nano4020522			13	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	AP6QJ	WOS:000342202000019	25530873	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Sima, XT; Xu, JG; Li, JM; Zhong, WY; You, C				Sima, Xiutian; Xu, Jianguo; Li, Jinmei; Zhong, Weiying; You, Chao			Expression of beta-amyloid precursor protein in refractory epilepsy	MOLECULAR MEDICINE REPORTS			English	Article						refractory epilepsy; beta-amyloid precursor protein	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; TAU PHOSPHORYLATION; INDUCED SEIZURES; HIPPOCAMPUS; TRAFFICKING; PATHOLOGY; NEURONS; CORTEX	beta-amyloid precursor protein (beta-APP), also known as A beta peptide, has a key role in the pathogenesis of Alzheimer's disease, and is also likely to be involved in the development of refractory epilepsy. The mechanism behind the association between beta-APP and refractory epilepsy remains to be elucidated. The aim of the present study was to examine the levels of APP mRNA and beta-APP protein in patients with refractory epilepsy. Tissue samples were obtained from patients with chronic pharmacoresistant epilepsy who underwent surgery. Levels of APP mRNA and beta-APP protein in epileptic temporal lobe and hippocampal tissue were assessed using quantitative polymerase chain reaction, immunohistochemistry and immunofluorescence. The expression levels of protein significantly increased in the temporal cortex and the hippocampus of the patients with epilepsy. beta-APP may thus contribute to the pathogenesis of refractory epilepsy.	[Sima, Xiutian; Xu, Jianguo; Zhong, Weiying; You, Chao] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Sichuan, Peoples R China; [Li, Jinmei] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu 610041, Sichuan, Peoples R China	You, C (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China.	youchao1977@163.com			National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30872646, 30973082]	This study was supported by the National Natural Science Foundation (nos 30872646 and 30973082).	Blurton-Jones Mathew, 2006, Current Alzheimer Research, V3, P437, DOI 10.2174/156720506779025242; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Del Vecchio RA, 2004, NEUROSCI LETT, V367, P164, DOI 10.1016/j.neulet.2004.05.107; FERREIRA A, 1993, J NEUROSCI, V13, P3112; Ghribi O, 2006, EXP NEUROL, V200, P460, DOI 10.1016/j.expneurol.2006.03.019; Gordon-Krajcer W, 2001, FOLIA NEUROPATHOL, V39, P163; KALARIA RN, 1993, ANN NY ACAD SCI, V695, P190, DOI 10.1111/j.1749-6632.1993.tb23050.x; Kins S, 2006, NEURODEGENER DIS, V3, P218, DOI 10.1159/000095259; LARNER AJ, 1995, SEIZURE, V4, P249, DOI 10.1016/S1059-1311(95)80001-8; Lozsadi DA, 2006, DEMENT GERIATR COGN, V22, P121, DOI 10.1159/000093664; Nadler JV, 2003, NEUROCHEM RES, V28, P1649, DOI 10.1023/A:1026004904199; Pavia J, 1998, FUNDAM CLIN PHARM, V12, P473, DOI 10.1111/j.1472-8206.1998.tb00975.x; Peel AL, 2004, NEUROMOL MED, V5, P205, DOI 10.1385/NMM:5:3:205; Perez RG, 1997, J NEUROSCI, V17, P9407; POLLARD H, 1994, NEUROSCIENCE, V61, P773, DOI 10.1016/0306-4522(94)90401-4; Radhakrishnan VV, 1999, NEUROL INDIA, V47, P196; SHENG JG, 1994, J NEUROCHEM, V63, P1872; Shoham S, 1997, EXP NEUROL, V147, P361, DOI 10.1006/exnr.1997.6622; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Wang ZF, 2006, J NEUROCHEM, V98, P1167, DOI 10.1111/j.1471-4159.2006.03956.x; Wieser HG, 2001, EPILEPSIA, V42, P282, DOI 10.1046/j.1528-1157.2001.4220282.x; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Zhu Jin-long, 2005, Fa Yi Xue Za Zhi, V21, P165	24	23	23	0	8	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	APR	2014	9	4					1242	1248		10.3892/mmr.2014.1977			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	AE9RD	WOS:000334345300023	24566726	Bronze			2021-06-18	
J	Chen, D; Bao, L; Lu, SQ; Xu, F				Chen, Du; Bao, Long; Lu, Shi-qi; Xu, Feng			Serum Albumin and Prealbumin Predict the Poor Outcome of Traumatic Brain Injury	PLOS ONE			English	Article							GLYCEMIC CONTROL; HYPERGLYCEMIA; RESUSCITATION; PROGNOSIS; CHILDREN	Background: Serum albumin and prealbumin are both negative acute-phase reactants, and usually at low levels in stress. We aim to determine their predictive values for poor outcome of traumatic brain injury (TBI). Methods: A total of 326 patients of TBI were enrolled and followed-up by telephone 6 months after discharge. They were divided into a favorable group (GOS: 3 to 5) and an unfavorable group (GOS: 1 to 2). Serum albumin and prealbumin were measured from vein blood within 24 h after admission. Results: Ninety one (27.9%) patients were with poor outcome (GOS: 1 to 2). The unfavorable group had lower albumin and prealbumin (P, 0.001). Albumin and prealbumin were both positively correlated with GCS (r = 0.489, P < 0.001; r = 0.222, P < 0.001, respectively) and GOS (r = 0.518, P < 0.001; r = 0.314, P < 0.001, respectively). After adjustment for confounding factors, the odds ratios of albumin and prealbumin were 0.866, 95% CI: 0.829 to 0.904 and 0.990, 95% CI: 0.985 to 0.995, respectively. In subgroup of GCS <= 8 (n = 101), the crude and adjusted odds ratios of serum albumin were both statistically significant (P = 0.027, P = 0.033, respectively), while prealbumin were not (P = 0.553, P = 0.576, respectively). The AUC of albumin for predicting poor outcome was 0.762, 95% CI: 0.712 to 0.807, which was significantly higher than that of prealbumin (0.664, 95% CI: 0.610 to 0.715). In analyses of all patients and subgroup of GCS <= 8, the AUCs of serum albumin were both significantly higher than those of prealbumin (P = 0.001, P = 0.045, respectively). Conclusions: Both serum albumin and prealbumin could predict the poor outcome of TBI, but the former is much better, especially, in patients with severe TBI.	[Chen, Du; Bao, Long; Lu, Shi-qi; Xu, Feng] Soochow Univ, Affiliated Hosp 1, Dept Emergency Med, Suzhou, Peoples R China	Xu, F (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Emergency Med, Suzhou, Peoples R China.	sdfyycd@foxmail.com	Chen, Du/AAM-8789-2021	Chen, Du/0000-0001-6990-3310			Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bernard F, 2008, J TRAUMA, V64, P872, DOI 10.1097/TA.0b013e31803428cc; Cabassi A, 2013, INT J CARDIOL; Collins N, 2001, Adv Skin Wound Care, V14, P235, DOI 10.1097/00129334-200109000-00009; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Gao C, 2011, CLIN EXP MED, V11, P49, DOI 10.1007/s10238-010-0103-8; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kawai H, 2012, WORLD J SURG, V36, P2853, DOI 10.1007/s00268-012-1766-y; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Matsushima K, 2012, J CRIT CARE, V27, P125, DOI 10.1016/j.jcrc.2011.08.012; Melo JRT, 2010, ACTA NEUROCHIR, V152, P1559, DOI 10.1007/s00701-010-0680-z; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nelson DW, 2012, J NEUROTRAUM, V29, P2613, DOI 10.1089/neu.2012.2468; ROCCA B, 1987, Annales Francaises d'Anesthesie et de Reanimation, V6, P476, DOI 10.1016/S0750-7658(87)80091-6; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rossi JL, 2011, J NEUROSCI RES, V89, P852, DOI 10.1002/jnr.22600; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Saadat SMS, 2012, CHILD NERV SYST, V28, P1773, DOI 10.1007/s00381-012-1753-5; Sharma Deepak, 2012, Anesthesiol Clin, V30, P333, DOI 10.1016/j.anclin.2012.04.003; Shutter L, 2012, CRIT CARE MED, V40, P1995, DOI 10.1097/CCM.0b013e3182514c15; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Wahlstrom MR, 2009, ACTA ANAESTH SCAND, V53, P18, DOI 10.1111/j.1399-6576.2008.01798.x; Yang Tian-jun, 2013, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V25, P301, DOI 10.3760/cma.j.issn.2095-4352.2013.05.016; YURCHENCO PD, 1990, FASEB J, V4, P1577	28	23	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e93167	10.1371/journal.pone.0093167			7	Multidisciplinary Sciences	Science & Technology - Other Topics	AE0SR	WOS:000333677000123	24671050	DOAJ Gold, Green Published			2021-06-18	
J	Roberts, BW; Kilgannon, JH; Chansky, ME; Trzeciak, S				Roberts, Brian W.; Kilgannon, J. Hope; Chansky, Michael E.; Trzeciak, Stephen			Association between initial prescribed minute ventilation and post-resuscitation partial pressure of arterial carbon dioxide in patients with post-cardiac arrest syndrome	ANNALS OF INTENSIVE CARE			English	Article						Cardiac arrest; Heart arrest; Cardiopulmonary resuscitation; Resuscitation; Anoxic brain injury; Shock; Hypocapnia; Hypercapnia; Minute ventilation	INTERNATIONAL LIAISON COMMITTEE; EUROPEAN RESUSCITATION COUNCIL; AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; STROKE FOUNDATION; CEREBRAL-ISCHEMIA; BRAIN; HYPERVENTILATION; SURVIVAL; INJURY	Background: Post-cardiac arrest hypocapnia/hypercapnia have been associated with poor neurological outcome. However, the impact of arterial carbon dioxide (CO2) derangements during the immediate post-resuscitation period following cardiac arrest remains uncertain. We sought to test the correlation between prescribed minute ventilation and post-resuscitation partial pressure of CO2 (PaCO2), and to test the association between early PaCO2 and neurological outcome. Methods: We retrospectively analyzed a prospectively compiled single-center cardiac arrest registry. We included adult (age >= 18 years) patients who experienced a non-traumatic cardiac arrest and required mechanical ventilation. We analyzed initial post-resuscitation ventilator settings and initial arterial blood gas analysis (ABG) after initiation of post-resuscitation ventilator settings. We calculated prescribed minute ventilation: MV (mL/kg/min) = [[tidal volume (TV)/ideal body weight (IBW)] x respiratory rate (RR)] for each patient. We then used Pearson's correlation to test the correlations between prescribed MV and PaCO2. We also determined whether patients had normocapnia (PaCO2 between 30 and 50 mmHg) on initial ABG and tested the association between normocapnia and good neurological function (Cerebral Performance Category 1 or 2) at hospital discharge using logistic regression analyses. Results: Seventy-five patients were included. The majority of patients were in-hospital arrests (85%). Pulseless electrical activity/asystole was the initial rhythm in 75% of patients. The median (IQR) TV, RR, and MV were 7 (7 to 8) mL/kg, 14 (14 to 16) breaths/minute, and 106 (91 to 125) mL/kg/min, respectively. Hypocapnia, normocapnia, and hypercapnia were found in 15%, 62%, and 23% of patients, respectively. Good neurological function occurred in 32% of all patients, and 18%, 43%, and 12% of patients with hypocapnia, normocapnia, and hypercapnia respectively. We found prescribed MV had only a weak correlation with initial PaCO2, R = -0.40 (P < 0.001). Normocapnia was associated with good neurological function, odds ratio 4.44 (95% CI 1.33 to 14.85). Conclusions: We found initial prescribed MV had only a weak correlation with subsequent PaCO2 and that early Normocapnia was associated with good neurological outcome. These data provide rationale for future research to determine the impact of PaCO2 management during mechanical ventilation in post-cardiac arrest patients.	[Roberts, Brian W.; Kilgannon, J. Hope; Chansky, Michael E.; Trzeciak, Stephen] Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Emergency Med, Camden, NJ 08103 USA; [Trzeciak, Stephen] Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Med,Div Crit Care Med, Camden, NJ 08103 USA	Roberts, BW (corresponding author), Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Emergency Med, One Cooper Plaza,K152, Camden, NJ 08103 USA.	roberts-brian-w@cooperhealth.edu					ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; Ausina A, 1998, ACT NEUR S, V71, P1; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Buunk G, 1997, STROKE, V28, P1569, DOI 10.1161/01.STR.28.8.1569; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; del Castillo J, 2012, RESUSCITATION, V83, P1456, DOI 10.1016/j.resuscitation.2012.07.019; Falkenbach P, 2009, RESUSCITATION, V80, P990, DOI 10.1016/j.resuscitation.2009.04.044; Gaul GB, 1996, RESUSCITATION, V32, P169, DOI 10.1016/0300-9572(96)00956-2; GREISEN G, 1987, ACTA PAEDIATR SCAND, V76, P401, DOI 10.1111/j.1651-2227.1987.tb10489.x; Hajbaghery MA, 2005, RESUSCITATION, V66, P317, DOI 10.1016/j.resuscitation.2005.04.004; Hodgman EI, 2012, J TRAUMA ACUTE CARE, V72, P844, DOI 10.1097/TA.0b013e31824ef9d2; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JENNETT B, 1975, LANCET, V1, P480; KAGSTROM E, 1983, ACTA PHYSIOL SCAND, V118, P281, DOI 10.1111/j.1748-1716.1983.tb07272.x; Kilgannon JH, 2008, RESUSCITATION, V79, P410, DOI 10.1016/j.resuscitation.2008.07.019; Krep H, 2000, CRIT CARE MED, V28, P2873, DOI 10.1097/00003246-200008000-00031; Krep H, 2000, CRIT CARE MED, V28, P2866, DOI 10.1097/00003246-200008000-00030; Langhelle A, 2005, RESUSCITATION, V66, P271, DOI 10.1016/j.resuscitation.2005.06.005; Langhelle A, 2003, RESUSCITATION, V56, P247, DOI 10.1016/S0300-9572(02)00409-4; Lee CC, 2011, EMERG MED J, V28, P432, DOI 10.1136/emj.2009.087593; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray SB, 2006, ACAD EMERG MED, V13, P530, DOI [10.1111/j.1553-2712.2006.tb01004.x, 10.1197/j.aem.2005.11.084]; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; NEMOTO EM, 1975, STROKE, V6, P425, DOI 10.1161/01.STR.6.4.425; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; PLUM F, 1972, ANN INTERN MED, V76, P328, DOI 10.7326/0003-4819-76-2-328; Roberts BW, 2013, CIRCULATION, V127, P2107, DOI 10.1161/CIRCULATIONAHA.112.000168; Roberts BW, 2013, CRIT CARE MED, V41, P1492, DOI 10.1097/CCM.0b013e31828a39e9; ROUT MW, 1971, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5765.7; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Schneider AG, 2013, RESUSCITATION, V84, P927, DOI 10.1016/j.resuscitation.2013.02.014; Tok D, 2004, TOHOKU J EXP MED, V202, P265, DOI 10.1620/tjem.202.265; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Trzeciak S, 2009, CRIT CARE MED, V37, P2895, DOI 10.1097/CCM.0b013e3181b01d8c; Trzeciak S, 2009, RESUSCITATION, V80, P617, DOI 10.1016/j.resuscitation.2009.03.014; VANNUCCI RC, 1995, PEDIATRICS, V95, P868; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	45	23	26	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	2110-5820			ANN INTENSIVE CARE	Ann. Intensive Care	MAR 7	2014	4								9	10.1186/2110-5820-4-9			9	Critical Care Medicine	General & Internal Medicine	AT8DR	WOS:000345164700001	24602367	DOAJ Gold, Green Published			2021-06-18	
J	Addington, CP; Pauken, CM; Caplan, MR; Stabenfeldt, SE				Addington, Caroline P.; Pauken, Christine M.; Caplan, Michael R.; Stabenfeldt, Sarah E.			The role of SDF-1 alpha-ECM crosstalk in determining neural stem cell fate	BIOMATERIALS			English	Article						Neural stem cell; ECM; Chemotaxis; Laminin; Progenitor cell	TRAUMATIC BRAIN-INJURY; ADULT-RAT BRAIN; EXTRACELLULAR-MATRIX; SUBVENTRICULAR ZONE; PROGENITOR CELLS; IN-VITRO; NEUROSPHERE CULTURES; CEREBRAL-ISCHEMIA; SIGNALING PATHWAY; CANCER CELLS	The consequences of central nervous system injury are far-reaching and debilitating and, while an endogenous repair response to neural injury has been observed in recent years, the mechanisms behind this response remain unclear. Neural progenitor/stem cell (NPSC) migration to the site of injury from the neural stem cell niches (e.g. subventricular zone and hippocampus) has been observed to be vasophilic in nature. While the chemotactic stimuli directing NPSC homing to injury is not well established, it is thought to be due in part to an increasing gradient of chemotactic cytokines, such as stromal cell-derived factor Ice (SDF-1 alpha). Based on these recent findings, we hypothesize that critical crosstalk between SDF-1 alpha and the extracellular matrix (ECM) drives injury-induced NPSC behavior. In this study, we investigated the effect of SDF-1 alpha and ECM substrates (Matrigel, laminin, and vitronectin) on the migration, differentiation, and proliferation of NPSCs in vitro using standard assays. The results demonstrated that SDF-1 alpha and laminin-based ECM (Matrigel and laminin) significantly and synergistically enhanced NPSC migration and acute neuronal differentiation. These effects were significantly attenuated with the addition of AMD3100 (an antagonist against the SDF-1 alpha receptor, CXCR4). SDF-1 alpha alone significantly increased NPSC proliferation regardless of ECM substrate, however no synergy was observed between SDF-1 alpha and the ECM. These results serve to elucidate the relationship between adhesive and soluble signaling factors of interest and their effect on NPSC behavior following neural injury. Furthermore, these results better inform the next generation of biomaterials aimed at stimulating endogenous neural regeneration for neural injury and neurodegenerative diseases. (C) 2014 Elsevier Ltd. All rights reserved.	[Addington, Caroline P.; Pauken, Christine M.; Caplan, Michael R.; Stabenfeldt, Sarah E.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85287 USA	Stabenfeldt, SE (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, POB 879709, Tempe, AZ 85287 USA.	sarah.stabenfeldt@asu.edu		Addington, Caroline/0000-0003-4534-8222	Mayo Clinic Center for Regenerative Medicine; Arizona State University Start-Up Funding; Ira A. Fulton Schools of Engineering Dean's Fellowship	This work was supported by the Mayo Clinic Center for Regenerative Medicine, Arizona State University Start-Up Funding, and the Ira A. Fulton Schools of Engineering Dean's Fellowship.	Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140-6736(06)68438-9; Azari H, 2011, JOVE-J VIS EXP, DOI 10.3791/2457; Badylak SE, 2002, SEMIN CELL DEV BIOL, V13, P377, DOI 10.1016/S1084952102000940; Banisadr G, 2011, NEUROBIOL DIS, V44, P19, DOI 10.1016/j.nbd.2011.05.019; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Barker TH, 2011, BIOMATERIALS, V32, P4211, DOI 10.1016/j.biomaterials.2011.02.027; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Campos LS, 2004, DEVELOPMENT, V131, P3433, DOI 10.1242/dev.01199; Carbajal KS, 2010, P NATL ACAD SCI USA, V107, P11068, DOI 10.1073/pnas.1006375107; Christie KJ, 2013, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00070; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Garzon-Muvdi T, 2010, ILAR J, V51, P3, DOI 10.1093/ilar.51.1.3; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Grossman H, 2006, MT SINAI J MED, V73, P985; Grzesiak JJ, 2007, SURGERY, V141, P804, DOI 10.1016/j.surg.2006.12.016; Hall Margaret Jean, 2012, NCHS Data Brief, P1; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Hartman NW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015856; Hou SW, 2008, STROKE, V39, P2837, DOI 10.1161/STROKEAHA.107.510982; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Ishido M, 2010, TOXICOL IN VITRO, V24, P552, DOI 10.1016/j.tiv.2009.11.005; Jacques TS, 1998, DEVELOPMENT, V125, P3167; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Kokovay E, 2010, CELL STEM CELL, V7, P163, DOI 10.1016/j.stem.2010.05.019; Kucia M, 2004, J MOL HISTOL, V35, P233; Leong SY, 2011, STEM CELLS, V29, P332, DOI 10.1002/stem.577; Li MZ, 2011, GLIA, V59, P108, DOI 10.1002/glia.21080; Li WW, 2000, DEV NEUROSCI-BASEL, V22, P68, DOI 10.1159/000017428; LIN CQ, 1993, FASEB J, V7, P737; Magavi SS, 2000, NATURE, V405, P951; Magnon C, 2011, METHODS MOL BIOL, V750, P3, DOI 10.1007/978-1-61779-145-1_1; Maheshwari G, 2000, J CELL SCI, V113, P1677; Mani N, 2010, J NEUROSCI RES, V88, P248, DOI 10.1002/jnr.22197; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mercier F, 2002, J COMP NEUROL, V451, P170, DOI 10.1002/cne.10342; NOBLE PB, 1987, J CELL SCI, V87, P241; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Olstorn H, 2011, NEUROSURGERY, V68, P213, DOI 10.1227/NEU.0b013e3181fd2c11; Park DS, 1998, YONSEI MED J, V39, P130, DOI 10.3349/ymj.1998.39.2.130; Parmar M, 2003, MOL CELL NEUROSCI, V24, P741, DOI 10.1016/S1044-7431(03)00239-2; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Peng H, 2007, J NEUROIMMUNE PHARM, V2, P251, DOI 10.1007/s11481-007-9081-3; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Rudiger C, 2005, BIOCHEM BIOPH RES CO, V335, P1107, DOI 10.1016/j.bbrc.2005.08.006; Shanley DK, 2006, BRAIN RES, V1067, P85, DOI 10.1016/j.brainres.2005.10.008; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Stabenfeldt SE, 2010, TISSUE ENG PT A, V16, P3747, DOI [10.1089/ten.tea.2009.0837, 10.1089/ten.TEA.2009.0837]; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Sun YX, 2007, PROSTATE, V67, P61, DOI 10.1002/pros.20500; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tran PB, 2007, J COMP NEUROL, V500, P1007, DOI 10.1002/cne.21229; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Vishnubhotla Ramana, 2012, Int J Cell Biol, V2012, P259142, DOI 10.1155/2012/259142; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; Wachs FP, 2006, J NEUROPATH EXP NEUR, V65, P358, DOI 10.1097/01.jnen.0000218444.53405.f0; Wang JH, 2005, CELL SIGNAL, V17, P1578, DOI 10.1016/j.cellsig.2005.03.022; Wang LL, 2010, MOL BIOL REP, V37, P1971, DOI 10.1007/s11033-009-9645-9; Wei L, 2012, NEUROBIOL DIS, V46, P635, DOI 10.1016/j.nbd.2012.03.002; White DE, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002952; Whittemore SR, 1999, EXP CELL RES, V252, P75, DOI 10.1006/excr.1999.4621; Wojcik-Stanaszek L, 2011, ACTA NEUROBIOL EXP, V71, P103; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yanagawa Y, 2001, IMMUNOLOGY, V104, P43, DOI 10.1046/j.1365-2567.2001.01292.x; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yu YQ, 2007, J NEUROL SCI, V255, P81, DOI 10.1016/j.jns.2007.01.076; Zhang Q, 2011, MOLECULES, V16, P10146, DOI 10.3390/molecules161210146	77	23	23	1	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	MAR	2014	35	10					3263	3272		10.1016/j.biomaterials.2013.12.102			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	AC0MC	WOS:000332188400013	24438907				2021-06-18	
J	Mohseni, S; Talving, P; Wallin, G; Ljungqvist, O; Riddez, L				Mohseni, Shahin; Talving, Peep; Wallin, Goran; Ljungqvist, Olle; Riddez, Louis			Preinjury A- blockade is protective in isolated severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; preinjury; -blocker; mortality	ORGAN DYSFUNCTION; UNITED-STATES; SURVIVAL; NOREPINEPHRINE; TRENDS; DEATH	BACKGROUND The purpose of this study was to investigate the effect of preinjury -blockade in patients experiencing isolated severe traumatic brain injury (TBI). We hypothesized that -blockade before TBI is associated with improved survival. METHODS The trauma registry of an urban academic trauma center was queried to identify patients with an isolated severe TBI between January 2007 and December 2011. Isolated severe TBI was defined as an intracranial injury with an Abbreviated Injury Scale (AIS) score of 3 or greater excluding all extracranial injuries AIS score of 3 or greater. Patient demographics, clinical characteristics on admission, injury profile, Injury Severity Score (ISS), AIS score, in-hospital morbidity, and -blocker exposure were abstracted for analysis. The primary outcome evaluated was in-hospital mortality stratified by preinjury -blockade exposure. RESULTS Overall, a total of 662 patients met the study criteria. Of these, 25% (n = 159) were exposed to -blockade before their traumatic insult. When comparing the demographics and injury characteristics between the groups, the sole difference was age, with the -blocked group being older (69 [12] years vs. 63 [13] years, p < 0.001). -blocked patients had a higher rate of infectious complications (30% vs. 19%, p = 0.04), with no difference in cardiac or pulmonary complications between the cohorts. Patients exposed to -blockade versus no -blockade experienced 13% and 22% mortality, respectively (p = 0.01). Stepwise logistic regression predicted the absence of -blockade exposure as a risk factor for mortality (odds ratio, 2.7; 95% confidence interval, 1.5-4.8; p = 0.002). After adjustment for significant differences between the groups, patients not exposed to -blockade experienced twofold increased risk of mortality (adjusted odds ratio, 2.2; 95% confidence interval, 1.3-3.7; p = 0.004). CONCLUSION Preinjury -blockade improves survival following isolated severe TBI. The role of prophylactic -blockade and the timing of initiation of such therapy after TBI warrant further investigations. LEVEL OF EVIDENCE Therapeutic study, level III; prognostic study, level II.	[Mohseni, Shahin; Wallin, Goran; Ljungqvist, Olle] Orebro Univ Hosp, Dept Surg, Div Acute Care Surg, Orebro, Sweden; [Talving, Peep; Riddez, Louis] Karolinska Univ Hosp, Dept Surg, Div Acute Care Surg & Trauma, Stockholm, Sweden	Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles Cty Gen Hosp LAC USC, 2051 Marengo Str,C5L100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Talving, Peep/E-6015-2013; Talving, Peep/G-8621-2015	Talving, Peep/0000-0002-9741-2073			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ALEXANDER RW, 1975, NATURE, V258, P437, DOI 10.1038/258437a0; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CLIFTON G L, 1989, Neurosurgical Review, V12, P465, DOI 10.1007/BF01790692; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Enderson BL, 2007, J TRAUMA, V62, P33; Gerrard P, 2012, J TRAUMA ACUTE CARE, V73, P1242, DOI 10.1097/TA.0b013e318265d234; Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kemp CD, 2008, AM SURGEON, V74, P866; KRAUS J, 1985, J NEUROSURG, V63, P537, DOI 10.3171/jns.1985.63.4.0537; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P489; MALING HM, 1958, AM J PHYSIOL, V194, P590; Mann NC, 2001, J TRAUMA, V50, P1111, DOI 10.1097/00005373-200106000-00022; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; MEYER JS, 1976, STROKE, V7, P158, DOI 10.1161/01.STR.7.2.158; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Poulat P, 1998, EUR J PHARMACOL, V344, P251, DOI 10.1016/S0014-2999(97)01569-0; Pryor JP, 2007, J TRAUMA, V62, P61; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	32	23	24	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2014	76	3					804	808		10.1097/TA.0000000000000139			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AB8YW	WOS:000332077100048	24553552				2021-06-18	
J	Rao, AT; Degnan, AJ; Levy, LM				Rao, A. T.; Degnan, A. J.; Levy, L. M.			Genetics of Alzheimer Disease	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article								Alzheimer disease prevails as a major cause of disability in the elderly population and ranks as the most common form of dementia that affects 1 of 8 individuals older than 65 years of age. Most AD cases are late in onset and are probably influenced by both genetic and environmental factors. Apart from age, the risk factors include family history; brain injury, both traumatic and vascular; and metabolic diseases, such as diabetes, hypercholesterolemia, and obesity. Based on twin studies, inheritance plays a role in approximately 80% of cases (familial and sporadic).	[Rao, A. T.; Levy, L. M.] George Washington Univ, Med Ctr, Washington, DC 20037 USA; [Degnan, A. J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Levy, LM (corresponding author), George Washington Univ, Med Ctr, 901 23rd St NW, Washington, DC 20037 USA.	llevy@mfa.gwu.edu		Degnan, Andrew/0000-0002-7373-0990			Alagiakrishnan K, 2012, POSTGRAD MED J, V88, P522, DOI 10.1136/postgradmedj-2011-130363; Bekris LM, 2010, J GERIATR PSYCH NEUR, V23, P213, DOI 10.1177/0891988710383571; Bird TD, 2008, GENET MED, V10, P231, DOI 10.1097/GIM.0b013e31816b64dc; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Jack CR, 2012, RADIOLOGY, V263, P343, DOI 10.1148/radiol.12110433; Williamson J, 2009, NEUROLOGIST, V15, P80, DOI 10.1097/NRL.0b013e318187e76b	6	23	24	0	5	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2014	35	3					457	458		10.3174/ajnr.A3545			2	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AD9IU	WOS:000333579400011	23538412	Other Gold, Green Published			2021-06-18	
J	Rasmussen, KW; Berntsen, D				Rasmussen, Katrine W.; Berntsen, Dorthe			Autobiographical memory and episodic future thinking after moderate to severe traumatic brain injury	JOURNAL OF NEUROPSYCHOLOGY			English	Article							MENTAL TIME-TRAVEL; CLOSED-HEAD-INJURY; HIPPOCAMPAL DAMAGE; CONSTRUCTION; EVENTS; EXPERIENCE; DEFICITS; IMAGINE; MIND; CONSCIOUSNESS	Converging evidence suggests that autobiographical memory and episodic future thinking share a common neurocognitive basis. Although previous research has shown that traumatic brain injury (TBI) can impair the ability to remember the personal past, episodic future thinking has not previously been systematically examined within this population. In this study, we examined the ability to remember events in the personal past and the ability to imagine possible events in the personal future in a sample of moderate-to-severe TBI patients. We present data on nine patients and nine healthy controls, who were asked to report a series of events that had happened to them in the past and a series of events that might happen to them in the future. Transcriptions were scored according to a reliable system for categorizing internal (episodic) and external (semantic) information. For each event described, participants also completed two modified Autobiographical Memory Questionnaire items to assess self-reported phenomenal qualities associated with remembering and imagining. In addition, TBI patients underwent neuropsychological assessment. Results revealed that TBI patients recalled/imagined proportionally fewer episodic event-specific details for both past and future events compared to healthy controls ((2)(p)=0.78). In contrast, there were no group differences in ratings of phenomenal characteristics. These results are discussed in relation to theories suggesting that remembering and imagining the future are the expression of the same underlying neurocognitive system.	[Rasmussen, Katrine W.; Berntsen, Dorthe] Aarhus Univ, Dept Psychol & Behav Sci, Ctr Autobiog Memory Res, DK-8000 Aarhus C, Denmark	Rasmussen, KW (corresponding author), Aarhus Univ, Bartholins Alle 9, DK-8000 Aarhus C, Denmark.	katrine@psy.au.dk			Danish National Research FoundationDanmarks Grundforskningsfond; Danish Council for Independent Research for the Humanities	We thank the patients for giving their time; the Regional Hospital Hammel Neurocenter and in particular Eva Lind for clinical assistance and helpful suggestions. We also thank Lise Fischer-Mogensen and Nadia Nielsen for their help. This work was supported by the Danish National Research Foundation as well as the Danish Council for Independent Research for the Humanities.	Addis DR, 2008, PSYCHOL SCI, V19, P33, DOI 10.1111/j.1467-9280.2008.02043.x; Addis DR, 2007, BRAIN, V130, P2327, DOI 10.1093/brain/awm166; Addis DR, 2007, NEUROPSYCHOLOGIA, V45, P1363, DOI 10.1016/j.neuropsychologia.2006.10.016; Addis DR, 2009, NEUROPSYCHOLOGIA, V47, P2660, DOI 10.1016/j.neuropsychologia.2009.05.018; Andelman F, 2010, NEUROCASE, V16, P426, DOI 10.1080/13554791003623318; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Barsalou L. W., 1988, REMEMBERING RECONSID, P193, DOI DOI 10.1017/CBO9780511664014.009; Berntsen D, 2004, MEM COGNITION, V32, P427, DOI 10.3758/BF03195836; Berryhill ME, 2010, NEUROPSYCHOLOGIA, V48, P1385, DOI 10.1016/j.neuropsychologia.2010.01.004; Botzung A, 2008, BRAIN COGNITION, V66, P202, DOI 10.1016/j.bandc.2007.07.011; Buckner RL, 2007, TRENDS COGN SCI, V11, P49, DOI 10.1016/j.tics.2006.11.004; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Cooper JM, 2011, NEUROPSYCHOLOGIA, V49, P1843, DOI 10.1016/j.neuropsychologia.2011.03.008; D'Argembeau A, 2004, CONSCIOUS COGN, V13, P844, DOI 10.1016/j.concog.2004.07.007; Dalla Barba G, 1997, NEUROCASE, V3, P425, DOI 10.1093/neucas/3.6.425; Dalsgaard I., 1998, DANISH ADULT R UNPUB; de Vito S, 2012, NEUROPSYCHOLOGIA, V50, P1494, DOI 10.1016/j.neuropsychologia.2012.03.001; Gade A., 1994, S 81 UDVIDET N UNPUB, P81; Gaesser B, 2011, PSYCHOL AGING, V26, P80, DOI 10.1037/a0021054; Gamboz N, 2010, NEUROPSYCHOLOGIA, V48, P2091, DOI 10.1016/j.neuropsychologia.2010.03.030; Golden C. J., 1998, STROOP COLOR WORLD T; Hassabis D, 2007, TRENDS COGN SCI, V11, P299, DOI 10.1016/j.tics.2007.05.001; Hassabis D, 2009, PHILOS T R SOC B, V364, P1263, DOI 10.1098/rstb.2008.0296; Hassabis D, 2007, P NATL ACAD SCI USA, V104, P1726, DOI 10.1073/pnas.0610561104; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Klein SB, 2002, SOC COGNITION, V20, P353, DOI 10.1521/soco.20.5.353.21125; Knight RG, 2009, J CLIN EXP NEUROPSYC, V31, P575, DOI 10.1080/13803390802363710; Kwan D, 2010, NEUROPSYCHOLOGIA, V48, P3179, DOI 10.1016/j.neuropsychologia.2010.06.011; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; Levine B, 2002, PSYCHOL AGING, V17, P677, DOI 10.1037//0882-7974.17.4.677; Maguire EA, 2011, P NATL ACAD SCI USA, V108, pE39, DOI 10.1073/pnas.1018876108; Maguire EA, 2010, NEUROPSYCHOLOGIA, V48, P3187, DOI 10.1016/j.neuropsychologia.2010.06.037; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Mortensen I. K., 1994, STAND MAT S 94 UNPUB; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Okuda J, 2003, NEUROIMAGE, V19, P1369, DOI 10.1016/S1053-8119(03)00179-4; Piolino P, 2007, CORTEX, V43, P176, DOI 10.1016/S0010-9452(08)70474-X; Ponsford J., 1995, TRAUMATIC BRAIN INJU, P1; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Race E, 2011, J NEUROSCI, V31, P10262, DOI 10.1523/JNEUROSCI.1145-11.2011; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rubin DC, 2003, MEM COGNITION, V31, P887, DOI 10.3758/BF03196443; Schacter DL, 2007, NAT REV NEUROSCI, V8, P657, DOI 10.1038/nrn2213; Schacter DL, 2007, PHILOS T R SOC B, V362, P773, DOI 10.1098/rstb.2007.2087; Schacter DL, 2008, ANN NY ACAD SCI, V1124, P39, DOI 10.1196/annals.1440.001; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Spreng RN, 2006, MEM COGNITION, V34, P1644, DOI 10.3758/BF03195927; Spreng RN, 2009, J COGNITIVE NEUROSCI, V21, P489, DOI 10.1162/jocn.2008.21029; Squire LR, 2010, P NATL ACAD SCI USA, V107, P19044, DOI 10.1073/pnas.1014391107; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suddendorf T, 2005, LEARN MOTIV, V36, P110, DOI 10.1016/j.lmot.2005.02.010; Suddendorf T, 1997, GENET SOC GEN PSYCH, V123, P133; Suddendorf T, 2007, BEHAV BRAIN SCI, V30, P299, DOI 10.1017/S0140525X07001975; Szpunar KK, 2008, CONSCIOUS COGN, V17, P330, DOI 10.1016/j.concog.2007.04.006; Szpunar KK, 2007, P NATL ACAD SCI USA, V104, P642, DOI 10.1073/pnas.0610082104; Szpunar KK, 2010, PERSPECT PSYCHOL SCI, V5, P142, DOI 10.1177/1745691610362350; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Trope Y, 2003, PSYCHOL REV, V110, P403, DOI 10.1037/0033-295X.110.3.403; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114; TULVING E, 1988, BRAIN COGNITION, V8, P3, DOI 10.1016/0278-2626(88)90035-8; Tulving E., 1985, CANADIAN PSYCHOL, V25, P1, DOI DOI 10.1037/H0080017; Wechsler D., 1997, WECHSLERS MEMORY SCA; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; Williams JMG, 1996, MEM COGNITION, V24, P116, DOI 10.3758/BF03197278; Wilson BA, 1996, BEHAV ASSESSMENT DYS	71	23	23	0	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	MAR	2014	8	1					34	52		10.1111/jnp.12003			19	Psychology; Psychology, Experimental	Psychology	AA9YD	WOS:000331448100003	23253283				2021-06-18	
J	Singh, R; Venkateshwara, G; Nair, KPS; Khan, M; Saad, R				Singh, Rajiv; Venkateshwara, Guru; Nair, Krishnan P. S.; Khan, Muhammed; Saad, Rafat			Agitation after traumatic brain injury and predictors of outcome	BRAIN INJURY			English	Article						Agitation; CT scans; neuropsychology; outcome; traumatic brain injury	CLOSED HEAD-INJURY; AGGRESSIVE-BEHAVIOR; REHABILITATION; SEQUELAE; RESTLESSNESS; VIOLENCE; SCALE	Objectives: To measure the incidence of agitation after traumatic brain injury (TBI) in an inpatient population and to identify any features associated with an adverse outcome Design: Prospective study of TBI admissions over 30 months in consecutive admissions with TBI to a regional neurorehabilitation unit. Outcome of agitation was compared to patient, injury and treatment features and any associations were sought. The presence of agitation was measured by the Agitation Behaviour Score. A good outcome for agitation was defined as a return to independent living with minimal care requirement at 6 months using an Extended Glasgow Outcome Scale (GOSE) score > 4. Results: Over 30 months, there were 146 TBI admissions, of whom 53 cases had agitation (36.3%). Achieving 100% follow-up, 27 (51%) had a good outcome. On a multivariable logistic regression analysis, a good outcome was associated with the type of lesions seen on CT scan, the severity of agitation and the duration of the behaviour. Alcohol excess and type of treatment used for the behaviour were initially significant on univariate testing but dropped out of the logistic regression model. Conclusions: Over a third of TBI admissions, developed agitation and poor functional outcome was associated with CT scan findings, severity and duration of agitation.	[Singh, Rajiv; Venkateshwara, Guru; Nair, Krishnan P. S.; Khan, Muhammed; Saad, Rafat] No Gen Hosp, Osborn Neurorehabil Unit, Sheffield S5 7AU, S Yorkshire, England	Singh, R (corresponding author), No Gen Hosp, Osborn Neurorehabil Unit, Sheffield S5 7AU, S Yorkshire, England.	rajiv.singh@sth.nhs.uk	Nair, Krishnan/AAE-3474-2020	Nair, Krishnan/0000-0002-4004-2315; singh, rajiv/0000-0002-3173-9591			Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CASSIDY JW, 1994, J HEAD TRAUMA REHAB, V9, P43, DOI 10.1097/00001199-199409000-00005; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fleminger S, 2003, BMJ-BRIT MED J, V327, P4, DOI 10.1136/bmj.327.7405.4; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Maryniak O, 2001, BRAIN INJURY, V15, P167, DOI 10.1080/026990501458399; Miller L., 1990, COGN REHABIL, V8, P14; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tonkonogy J M, 1991, J Neuropsychiatry Clin Neurosci, V3, P189; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	23	23	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2014	28	3					336	340		10.3109/02699052.2013.873142			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AC0RI	WOS:000332202100011	24377492				2021-06-18	
J	Zeng, S; Jiang, JX; Xu, MH; Xu, LS; Shen, GJ; Zhang, AQ; Wang, XH				Zeng, Shi; Jiang, Jian-Xin; Xu, Min-Hui; Xu, Lun-Shan; Shen, Guang-Jian; Zhang, An-Qiang; Wang, Xu-Hui			Prognostic Value of Apolipoprotein E Epsilon4 Allele in Patients with Traumatic Brain Injury: A Meta-Analysis and Meta-Regression	GENETIC TESTING AND MOLECULAR BIOMARKERS			English	Article							HEAD-INJURY; E POLYMORPHISM; ALZHEIMERS-DISEASE; UNITED-STATES; E GENOTYPE; ASSOCIATION; APOE; PROTEIN; EPIDEMIOLOGY; VOLUME	Aims: Current scientific evidence suggests that the apolipoprotein E epsilon4 (APOE4) allele may be associated with a good prognosis for patients with traumatic brain injury (TBI); however, many existing studies have yielded inconclusive results. This meta-analysis aims to obtain a more precise estimation of the association between APOE4 allele and prognosis of TBI patients.Methods: A literature search of PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, CNKI and CBM databases was conducted for articles published before July 1st, 2013. Crude odds ratios (OR) with 95% confidence intervals (CI) were calculated. Results: Thirteen cohort studies were included with a total of 662 TBI patients with APOE4 (+) and 1614 TBI patients with APOE4 (-). The meta-analysis results revealed that the APOE4 allele was associated with a poor prognosis in TBI patients (OR=0.68, 95% CI: 0.48-0.96, p=0.027). Subgroup analysis by ethnicity indicated that TBI patients with APOE4 (+) had a worse prognosis than those with APOE4 (-) in Asian populations (OR=0.46, 95% CI: 0.21-0.99, p=0.046), but not in Caucasian populations (OR=0.75, 95% CI: 0.53-1.08, p=0.120). A further subgroup analysis by TBI grade showed that the APOE4 allele was associated with poor prognosis in severe TBI patients (OR=0.43, 95% CI: 0.21-0.87, p=0.020). However, there was no evidence for any association between the APOE4 allele and poor prognosis in patients with other grades of TBI (all p>0.05). Conclusion: The current meta-analysis indicates that the APOE4 allele may be associated with a poor prognosis in severe TBI patients and in Asian populations. The APOE4 allele may be used as a biomarker in predicting the prognosis of TBI patients.	[Zeng, Shi; Xu, Min-Hui; Xu, Lun-Shan; Shen, Guang-Jian; Wang, Xu-Hui] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Neurosurg, Chongqing 400042, Peoples R China; [Jiang, Jian-Xin; Zhang, An-Qiang] Third Mil Med Univ, Daping Hosp, Inst Surg Res, State Key Lab Trauma Burns & Combined Injury, Chongqing 400042, Peoples R China	Jiang, JX (corresponding author), Third Mil Med Univ, Daping Hosp, Inst Surg Res, State Key Lab Trauma Burns & Combined Injury, Branch Rd 10, Chongqing 400042, Peoples R China.	tmmu_jjx@163.com; xuminhui8@163.com			army medical science and technology major projects during the 12th Five Year Plan [AWS11J008]	We would like to acknowledge the helpful comments on this article received from our reviewers. The work is funded by the army medical science and technology major projects during the 12th Five Year Plan (AWS11J008).	Bekris LM, 2010, J GERIATR PSYCH NEUR, V23, P213, DOI 10.1177/0891988710383571; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cervantes S, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2011.05.023; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cun W, 2010, J VIROL, V84, P11532, DOI 10.1128/JVI.01021-10; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; [GU Yi 顾奕], 2007, [中国神经精神疾病杂志, Chinese Journal of Nervous and Mental Diseases], V33, P385; Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008; Hauser PS, 2011, PROG LIPID RES, V50, P62, DOI 10.1016/j.plipres.2010.09.001; Ioannidis JPA, 2008, BMJ-BRIT MED J, V336, P1413, DOI 10.1136/bmj.a117; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Li FQ, 2010, J PHARMACOL EXP THER, V334, P106, DOI 10.1124/jpet.110.167882; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lo TYM, 2009, CHILD NERV SYST, V25, P47, DOI 10.1007/s00381-008-0723-4; Mahley RW, 2012, NEURON, V76, P871, DOI 10.1016/j.neuron.2012.11.020; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Maysinger D, 2008, J NEUROSCI, V28, P7891, DOI 10.1523/JNEUROSCI.1461-08.2008; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Pearson-Fuhrhop KM, 2012, CURR OPIN NEUROL, V25, P682, DOI 10.1097/WCO.0b013e32835a360a; Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sun XC, 2008, CHIN J TRAUMATOL, V11, P247, DOI 10.1016/S1008-1275(08)60051-6; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takeda M, 2010, PSYCHIAT CLIN NEUROS, V64, P592, DOI 10.1111/j.1440-1819.2010.02148.x; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Xue P, 2012, PLOS ONE, V7; Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536	50	23	24	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1945-0265	1945-0257		GENET TEST MOL BIOMA	Genet. Test. Mol. Biomark.	MAR 1	2014	18	3					202	210		10.1089/gtmb.2013.0421			9	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	AC2HL	WOS:000332320400010	24475734				2021-06-18	
J	Nhac-Vu, HT; Hours, M; Chossegros, L; Charnay, P; Tardy, H; Martin, JL; Mazaux, JM; Laumon, B				Hoang-Thy Nhac-Vu; Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Martin, Jean-Louis; Mazaux, Jean-Michel; Laumon, Bernard			Prognosis of Outcome in Adult Survivors of Road Accidents in France: One-Year Follow-Up in the ESPARR Cohort	TRAFFIC INJURY PREVENTION			English	Article						outcome prediction; road crash; homogeneous outcome groups; Injury Impairment Scale; WHOQOL-BREF; ESPARR	POSTTRAUMATIC-STRESS-DISORDER; INJURY SEVERITY SCORE; TRAFFIC ACCIDENTS; PSYCHOLOGICAL TRAUMA; IMPROVES ACCURACY; MAJOR TRAUMA; RISK-FACTORS; HEALTH; CONSEQUENCES; COMPENSATION	Objective: The consequences of road crashes are various, and few studies have dealt with the multidimensionality of outcomes. The aim of the present study was to assess the multidimensional nature of outcomes one year after a crash and to determine predictive factors that could help in adapting medical and social care to prevent such consequences to improve road crash victims' prognosis. Methods: The study population was the 886 respondents to the one-year follow-up from the ESPARR (Etude et Suivi d'une Population d'Accidentes de la Route du Rhone) cohort, aged 16years; the analysis was carried out only on the 616 subjects who fully completed a self-report questionnaire on health, social, emotional, and financial status one year after a crash. Multiple correspondence analysis and hierarchical clustering was implemented to produce homogeneous groups according to differences in outcome. Groups were compared using the World Health Organization Quality of Life Assessment (WHOQOL-BREF, a standard instrument of quality of life, assessing physical health, psychological health, social relationships, and environment) and the Injury Impairment Scale (IIS), a tool to predict road crash sequelae. Baseline predictive factors for group attribution were analyzed by weighted multinomial logistic regression models. Results: Three hundred seventeen of the 616 subjects (60.1%) were men. Mean age was 36.9years (SD = 16.5). Five victim groups were identified in terms of consequences at one year: one group (206 subjects, 33.4%) with few problems, one with essentially physical sequelae, one with problems that were essentially both physical and social, and 2 groups with a wider range of problems (one including psychological problems but fewer environmental problems; the last one reported negative physical, psychological, social, and environmental impact; notably, all had post-concussion syndrome [PCS]). There were significant differences between groups in terms of family status, injury severity, and certain types of injury (thorax, spine, lower limbs). Comparison on the WHOQOL-BREF confirmed that groups reporting more adverse outcomes had a lower quality of life. Description of the 5 groups by IIS indicators showed that IIS underestimated physical consequences one year after the crash. In addition to the known prognostic factors such as age, initial injury severity, and injury type, socioeconomic fragility and having a relative involved in the accident emerged as predictive of poor outcome at one year. Conclusions: One year after the crash, victims may still be experiencing multiple problems in terms of not only physical health but also of mental health, social life, and environment. Poor outcome may be predicted from both accident-related factors and socioeconomic fragility. Our results are useful in catching the attention of both clinicians and the public administration regarding victims at risk of suffering from important consequences after an accident. If those suffering head injuries are recognized, it would be very important to better consider and treat posttraumatic stress disorder (PTSD) or PCS. Furthermore, subjects from lower socioeconomic backgrounds, with or without lower limb injuries, have numerous difficulties after an accident, notably for returning to work. An objective would be to provide them with more specific support. Supplemental materials are available for this article. Go to the publisher's online edition of Traffic Injury Prevention to view the supplemental file.	[Hoang-Thy Nhac-Vu; Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Martin, Jean-Louis; Laumon, Bernard] Univ Lyon, UMRESTTE, IFSTTAR, Lyon, France; [Mazaux, Jean-Michel] Bordeaux Univ, Rehabil & Phys Med Unit, St Andre Hosp, Bordeaux, France; [Mazaux, Jean-Michel] Bordeaux Univ, Rehabil & Phys Med Unit, Pellegrin Hosp, Bordeaux, France	Hours, M (corresponding author), IFSTTAR, UMRESTTE, Case 24,25 Ave F Mitterand, F-69675 Bron, France.	martine.hours@ifsttar.fr	TARDY, HELENE/AAE-6287-2019; Martin, Jean-Louis/X-6588-2019	TARDY, HELENE/0000-0001-8351-9825; Martin, Jean-Louis/0000-0002-3426-9601	French Ministry of Equipment, Transport, Housing, Tourism and Sea [SU0400066]; National Agency for ResearchFrench National Research Agency (ANR) [ANR-07-TSFA-007-01]; French Ministry of Health [PHRC-N03, PHRC-N051]	We acknowledge funding from the French Ministry of Equipment, Transport, Housing, Tourism and Sea (Predit 3 Program, "New Knowledge in the Field of Road Safety," No. SU0400066); the National Agency for Research (Program Predit 4, "Safe, Reliable and Adapted Transport," No. ANR-07-TSFA-007-01); and the French Ministry of Health (PHRC 2003 Program: PHRC-N03 and PHRC 2005: PHRC-N051).	AMOROS E., 2008, B EPIDEMIOLOGIQUE HE, V19, P157; Arnold R, 2005, SOC SCI MED, V61, P2144, DOI 10.1016/j.socscimed.2005.04.025; Association for the Advancement of Automotive Medicine, 1990, ABBR INH SCAL 1990 R; Barnes Jo, 2009, Ann Adv Automot Med, V53, P195; Barnes Jo, 2006, Annu Proc Assoc Adv Automot Med, V50, P253; Chossegros L, 2011, ACCIDENT ANAL PREV, V43, P471, DOI 10.1016/j.aap.2010.10.004; CORNES P, 1992, INJURY, V23, P256, DOI 10.1016/S0020-1383(05)80011-7; Cunningham C, 2001, Ir Med J, V94, P169; Gaulle-Anthonioz GD, 1995, J OFFICIEL; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris IA, 2008, J ORTHOP TRAUMA, V22, P216, DOI 10.1097/BOT.0b013e31815c11dc; Nhac-Vu HT, 2012, TRAFFIC INJ PREV, V13, P239, DOI 10.1080/15389588.2011.647139; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Hours M, 2008, ACCIDENT ANAL PREV, V40, P1789, DOI 10.1016/j.aap.2008.06.017; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; Hudek-Knezevic J, 2009, CROAT MED J, V50, P394, DOI 10.3325/cmj.2009.50.394; Jeavons S, 2000, J TRAUMA STRESS, V13, P359, DOI 10.1023/A:1007797904536; Jeavons S, 2000, BEHAV RES THER, V38, P499, DOI 10.1016/S0005-7967(99)00073-X; Koren D, 1999, AM J PSYCHIAT, V156, P367; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; Laumon B, 1999, P 41 ANN M ASS ADV A, P127; Lecomte T, 1996, PRECARITE SOCIALE CU; Li L, 2001, EUR J PUBLIC HEALTH, V11, P81, DOI 10.1093/eurpub/11.1.81; Mayou R, 2003, INJURY, V34, P197, DOI 10.1016/S0020-1383(02)00285-1; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; Mayou R, 2002, BRIT J PSYCHIAT, V180, P441, DOI 10.1192/bjp.180.5.441; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ottosson C, 2005, J TRAUMA, V58, P553, DOI 10.1097/01.TA.0000152634.66513.AF; Saevareid HI, 2007, AGING MENT HEALTH, V11, P658, DOI 10.1080/13607860701368513; Soderstrom CA, 1997, J TRAUMA, V43, P925; Spicer Rebecca S, 2011, Ann Adv Automot Med, V55, P365; Valent F, 2002, ACCIDENT ANAL PREV, V34, P71, DOI 10.1016/S0001-4575(00)00104-4; Vorko-Jovic A, 2006, J SAFETY RES, V37, P93, DOI 10.1016/j.jsr.2005.08.009; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967	37	23	24	0	24	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.	FEB 17	2014	15	2					138	147		10.1080/15389588.2013.804180			10	Public, Environmental & Occupational Health; Transportation	Public, Environmental & Occupational Health; Transportation	277IU	WOS:000328813000005	24345015				2021-06-18	
J	Agrawal, RG; Owen, JA; Levin, PS; Hewetson, A; Berman, AE; Franklin, SR; Hogue, RJ; Chen, YK; Walz, C; Colvard, BD; Nguyen, J; Velasquez, O; Al-Hasan, Y; Blednov, YA; Fowler, AK; Syapin, PJ; Bergeson, SE				Agrawal, Rajiv G.; Owen, Julie A.; Levin, Patricia S.; Hewetson, Aveline; Berman, Ari E.; Franklin, Scott R.; Hogue, Ryan J.; Chen, Yukun; Walz, Chris; Colvard, Benjamin D.; Nguyen, Jonathan; Velasquez, Oscar; Al-Hasan, Yazan; Blednov, Yuri A.; Fowler, Anna-Kate; Syapin, Peter J.; Bergeson, Susan E.			Bioinformatics Analyses Reveal Age-Specific Neuroimmune Modulation as a Target for Treatment of High Ethanol Drinking	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						Alcoholism; Drinking-in-Dark; FVB; NJxC57BL; 6J F1 Mouse; Medications Development; Minocycline; Bioinformatics	RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; ALCOHOL-USE DISORDERS; GENE-EXPRESSION; C57BL/6J MICE; MICROGLIAL ACTIVATION; RECEPTOR ACTIVATION; MICROARRAY ANALYSIS; IMMUNE FUNCTION; BINGE DRINKING	BackgroundUse of in silico bioinformatics analyses has led to important leads in the complex nature of alcoholism at the genomic, epigenomic, and proteomic level, but has not previously been successfully translated to the development of effective pharmacotherapies. In this study, a bioinformatics approach led to the discovery of neuroimmune pathways as an age-specific druggable target. Minocycline, a neuroimmune modulator, reduced high ethanol (EtOH) drinking in adult, but not adolescent, mice as predicted a priori. MethodsAge and sex-divergent effects in alcohol consumption were quantified in FVB/NJxC57BL/6J F1 mice given access to 20% alcohol using a 4h/d, 4-day drinking-in-dark (DID) paradigm. In silico bioinformatics pathway overrepresentation analysis for age-specific effects of alcohol in brain was performed using gene expression data collected in control and DID-treated, adolescent and adult, male mice. Minocycline (50mg/kg i.p., once daily) or saline alone was tested for an effect on EtOH intake in the F1 and C57BL/6J (B6) mice across both age and gender groups. Effects of minocycline on the pharmacokinetic properties of alcohol were evaluated by comparing the rates of EtOH elimination between the saline- and minocycline-treated F1 and B6 mice. ResultsAge and gender differences in DID consumption were identified. Only males showed a clear developmental increase difference in drinking over time. In silico analyses revealed neuroimmune-related pathways as significantly overrepresented in adult, but not in adolescent, male mice. As predicted, minocycline treatment reduced drinking in adult, but not adolescent, mice. The age effect was present for both genders, and in both the F1 and B6 mice. Minocycline had no effect on the pharmacokinetic elimination of EtOH. ConclusionsOur results are a proof of concept that bioinformatics analysis of brain gene expression can lead to the generation of new hypotheses and a positive translational outcome for individualized pharmacotherapeutic treatment of high alcohol consumption.	[Agrawal, Rajiv G.; Owen, Julie A.; Hewetson, Aveline; Franklin, Scott R.; Hogue, Ryan J.; Chen, Yukun; Al-Hasan, Yazan; Fowler, Anna-Kate; Syapin, Peter J.; Bergeson, Susan E.] Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, South Plains Alcohol & Addict Res Ctr, Lubbock, TX 79430 USA; [Levin, Patricia S.; Berman, Ari E.; Walz, Chris; Colvard, Benjamin D.; Nguyen, Jonathan; Velasquez, Oscar; Blednov, Yuri A.] Univ Texas Austin, Waggoner Ctr Alcohol & Addict Res, Austin, TX 78712 USA	Bergeson, SE (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, South Plains Alcohol & Addict Res Ctr, 3601 4th St,MS 6592, Lubbock, TX 79430 USA.	Susan.Bergeson@TTUHSC.edu	Colvard, Benjamin/ABA-1814-2020; Chen, Yu/Y-3292-2019		NIAAA INIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U01AA13475, U01AA13520]; South Plains Alcohol and Addiction Research Center; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U01AA013475, U01AA013520, R21AA021142] Funding Source: NIH RePORTER	Supported by NIAAA INIA grants U01AA13475 (SEB), U01AA13520 (YAB), and the South Plains Alcohol and Addiction Research Center.	Agrawal RG, 2011, BRAIN BEHAV IMMUN, V25, pS165, DOI 10.1016/j.bbi.2011.03.002; Ai ZH, 2013, J OBSTET GYNAECOL RE, V39, P1052, DOI 10.1111/jog.12022; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003; BABOR TF, 1992, ARCH GEN PSYCHIAT, V49, P599; Bahrami F, 2012, MINI-REV MED CHEM, V12, P44, DOI 10.2174/138955712798868977; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett ME, 1999, J STUD ALCOHOL, V60, P605, DOI 10.15288/jsa.1999.60.605; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Blednov YA, 2005, ALCOHOL CLIN EXP RES, V29, P1949, DOI 10.1097/01.alc.0000187605.91468.17; Blednov YA, 2005, BEHAV BRAIN RES, V165, P110, DOI 10.1016/j.bbr.2005.06.026; Blednov YA, 2012, ADDICT BIOL, V17, P108, DOI 10.1111/j.1369-1600.2010.00284.x; Brown SA, 2004, ANN NY ACAD SCI, V1021, P234, DOI 10.1196/annals.1308.028; Brown SA, 2001, RECENT DEV ALCOHOL, V15, P307; Cippitelli A, 2010, BIOL PSYCHIAT, V67, P823, DOI 10.1016/j.biopsych.2009.12.018; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Crews FT, 2012, ALCOHOL RES-CURR REV, V34, P355; Crews FT, 2009, ALCOHOL ALCOHOLISM, V44, P115, DOI 10.1093/alcalc/agn079; Daniels GM, 2002, GENES BRAIN BEHAV, V1, P35, DOI 10.1046/j.1601-1848.2001.00008.x; Davis RL, 2005, BRAIN RES REV, V49, P494, DOI 10.1016/j.brainresrev.2005.01.008; Dawes MA, 2004, ALCOHOL ALCOHOLISM, V39, P166, DOI 10.1093/alcalc/agh045; Edenberg HJ, 2005, GENES BRAIN BEHAV, V4, P20, DOI 10.1111/j.1601-183X.2004.00091.x; Fernandez-Lizarbe S, 2009, J IMMUNOL, V183, P4733, DOI 10.4049/jimmunol.0803590; Finn DA, 2007, ALCOHOL CLIN EXP RES, V31, P939, DOI 10.1111/j.1530-0277.2007.00379.x; Garrido-Mesa N, 2013, PHARMACOL RES, V67, P18, DOI 10.1016/j.phrs.2012.10.006; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Grant BF, 1997, J SUBST ABUSE, V9, P103, DOI 10.1016/S0899-3289(97)90009-2; Greenfield SF, 2010, ALCOHOL CLIN EXP RES, V34, P1803, DOI 10.1111/j.1530-0277.2010.01267.x; Guasti L, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-35; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Huang TY, 2009, TOXICOL APPL PHARM, V237, P69, DOI 10.1016/j.taap.2009.02.026; Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3; Kapsimali M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r173; Kerns Robnet T., 2008, V447, P395, DOI 10.1007/978-1-59745-242-7_26; Key J, 2006, CANCER CAUSE CONTROL, V17, P759, DOI 10.1007/s10552-006-0011-0; Kielian T, 2007, AM J PATHOL, V171, P1199, DOI 10.2353/ajpath.2007.070231; Kloppenburg M, 1996, ANTIMICROB AGENTS CH, V40, P934, DOI 10.1128/AAC.40.4.934; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kranzler HR, 2001, ALCOHOL CLIN EXP RES, V25, P1335, DOI 10.1097/00000374-200109000-00014; Lewohl JM, 2000, ALCOHOL CLIN EXP RES, V24, P1873, DOI 10.1111/j.1530-0277.2000.tb01993.x; Liu JA, 2011, P NATL ACAD SCI USA, V108, P4465, DOI 10.1073/pnas.1019020108; Medina KL, 2008, ALCOHOL CLIN EXP RES, V32, P386, DOI 10.1111/j.1530-0277.2007.00602.x; Melon LC, 2013, PHARMACOL BIOCHEM BE, V104, P177, DOI 10.1016/j.pbb.2013.01.005; Mulligan MK, 2008, GENES BRAIN BEHAV, V7, P677, DOI 10.1111/j.1601-183X.2008.00405.x; Mulligan MK, 2011, ALCOHOL CLIN EXP RES, V35, P659, DOI 10.1111/j.1530-0277.2010.01384.x; Mulligan MK, 2006, P NATL ACAD SCI USA, V103, P6368, DOI 10.1073/pnas.0510188103; Nikodemova M, 2010, J NEUROIMMUNOL, V219, P33, DOI 10.1016/j.jneuroim.2009.11.009; Orio L, 2010, NEUROTOX RES, V18, P187, DOI 10.1007/s12640-009-9120-3; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Qin HW, 2005, BLOOD, V106, P3114, DOI 10.1182/blood-2005-02-0759; R Development Core Team, 2006, R LANG ENV STAT COMP; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rhodes JS, 2005, PHYSIOL BEHAV, V84, P53, DOI 10.1016/j.physbeh.2004.10.007; Scheffel J, 2012, GLIA, V60, P1930, DOI 10.1002/glia.22409; Sewell KL, 1996, CELL IMMUNOL, V167, P195, DOI 10.1006/cimm.1996.0027; Soliman GM, 2010, MACROMOL BIOSCI, V10, P278, DOI 10.1002/mabi.200900259; Squeglia Lindsay M, 2012, Psychopharmacology (Berl), V220, P529, DOI 10.1007/s00213-011-2500-4; Sullivan EV, 2008, EXP NEUROL, V213, P10, DOI 10.1016/j.expneurol.2008.05.016; Tabakoff B, 2003, J NEUROSCI, V23, P4491; URBANOMARQUEZ A, 1995, JAMA-J AM MED ASSOC, V274, P149, DOI 10.1001/jama.274.2.149; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; Yang LP, 2007, MOL VIS, V13, P1083; Yoon SY, 2012, NEUROSCIENCE, V221, P214, DOI 10.1016/j.neuroscience.2012.06.024; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007	67	23	24	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0145-6008	1530-0277		ALCOHOL CLIN EXP RES	Alcoholism (NY)	FEB	2014	38	2					428	437		10.1111/acer.12288			10	Substance Abuse	Substance Abuse	297PC	WOS:000330266400017	24125126	Green Accepted			2021-06-18	
J	Huang, APH; Tsai, JC; Kuo, LT; Lee, CW; Lai, HS; Tsai, LK; Huang, SJ; Chen, CM; Chen, YS; Chuang, HY; Wintermark, M				Huang, Abel Po-Hao; Tsai, Jui-Chang; Kuo, Lu-Ting; Lee, Chung-Wei; Lai, Hong-Shiee; Tsai, Li-Kai; Huang, Sheng-Jean; Chen, Chien-Min; Chen, Yuan-Shen; Chuang, Hao-Yu; Wintermark, Max			Clinical application of perfusion computed tomography in neurosurgery Clinical article	JOURNAL OF NEUROSURGERY			English	Article						aneurysmal subarachnoid hemorrhage; perfusion CT; blood-brain barrier	MIDDLE CEREBRAL-ARTERY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; BRAIN-BARRIER PERMEABILITY; SINKING SKIN FLAP; EXTRACRANIAL-INTRACRANIAL BYPASS; POSITRON-EMISSION-TOMOGRAPHY; ACUTE ISCHEMIC-STROKE; DYNAMIC CT PERFUSION; SEVERE HEAD TRAUMA; INTRACEREBRAL HEMORRHAGE	Object. Currently, perfusion CT (PCT) is a valuable imaging technique that has been successfully applied to the clinical management of patients with ischemic stroke and aneurysmal subarachnoid hemorrhage (SAH). However, recent literature and the authors' experience have shown that PCT has many more important clinical applications in a variety of neurosurgical conditions. Therefore, the authors share their experiences of its application in various diseases of the cerebrovascular, neurotraumatology, and neurooncology fields and review the pertinent literature regarding expanding PCT applications for neurosurgical conditions, including pitfalls and future developments. Methods. A pertinent literature search was conducted of English-language articles describing original research, case series, and case reports from 1990 to 2011 involving PCT and with relevance and applicability to neurosurgical disorders. Results. In the cerebrovascular field, PCT is already in use as a diagnostic tool for patients suspected of having an ischemic stroke. Perfusion CT can be used to identify and define the extent of the infarct core and ischemic penumbra core, and thus aid patient selection for acute reperfusion therapy. For patients with aneurysmal SAH, PCT provides assessment of early brain injury, cerebral ischemia, and infarction, in addition to vasospasm. It may also be used to aid case selection for aggressive treatment of patients with poor SAH grade. In terms of oncological applications, PCT can be used as an imaging biomarker to assess angiogenesis and response to antiangiogenetic treatments, differentiate between glioma grades, and distinguish recurrent tumor from radiation necrosis. In the setting of traumatic brain injury, PCT can detect and delineate contusions at an early stage. In patients with mild head injury, PCT results have been shown to correlate with the severity and duration of postconcussion syndrome. In patients with moderate or severe head injury, PCT results have been shown to correlate with patients' functional outcome. Conclusions. Perfusion CT provides quantitative and qualitative data that can add diagnostic and prognostic value in a number of neurosurgical disorders, and also help with clinical decision making. With emerging new technical developments in PCT, such as characterization of blood-brain barrier permeability and whole-brain PCT, this technique is expected to provide more and more insight into the pathophysiology of many neurosurgical conditions.	[Huang, Abel Po-Hao; Tsai, Jui-Chang; Kuo, Lu-Ting; Lee, Chung-Wei; Tsai, Li-Kai; Huang, Sheng-Jean; Chen, Yuan-Shen] Natl Taiwan Univ Hosp, Div Neurosurg, Taipei, Taiwan; [Huang, Abel Po-Hao; Kuo, Lu-Ting; Lai, Hong-Shiee; Chen, Yuan-Shen] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Tsai, Jui-Chang] Natl Taiwan Univ, Coll Med, Ctr Optoelect Biomed, Taipei, Taiwan; [Huang, Abel Po-Hao; Kuo, Lu-Ting; Huang, Sheng-Jean; Chen, Yuan-Shen] Natl Taiwan Univ Hosp, Dept Surg, Yun Lin Branch, Div Neurosurg, Yunlin, Taiwan; [Chen, Chien-Min] Chang Hau Christian Hosp, Dept Neurosurg, Chang Ha, Taiwan; [Chuang, Hao-Yu] China Med Univ, Dept Neurosurg, Bei Gang Hosp, Yunlin, Taiwan; [Wintermark, Max] Univ Virginia, Med Ctr, Dept Radiol, Neuroradiol Div, Charlottesville, VA 22908 USA	Wintermark, M (corresponding author), Univ Virginia, Med Ctr, Dept Radiol, Neuroradiol Div, 1215 Lee St New Hosp,POB 800170, Charlottesville, VA 22908 USA.	max.wintermark@virginia.edu		HUANG, ABEL PO-HAO/0000-0002-5689-6761; Wintermark, Max/0000-0002-6726-3951; LEE, CHUNG-WEI/0000-0002-3573-2506; Tsai, Li-Kai/0000-0001-8420-6951; TSAI, JUI-CHANG/0000-0003-2723-6841; Kuo, Lu-Ting/0000-0002-1405-8700	GE HealthcareGE Healthcare	Dr. Wintermark has received clinical or research support for this study from GE Healthcare.	Abou-Chebl A, 2010, STROKE, V41, P1996, DOI 10.1161/STROKEAHA.110.578997; Aviv RI, 2009, RADIOLOGY, V250, P867, DOI 10.1148/radiol.2503080257; BARTOLINI A, 1994, COMPUT MED IMAG GRAP, V18, P145, DOI 10.1016/0895-6111(94)90023-X; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; Bektas H, 2010, STROKE, V41, P2539, DOI 10.1161/STROKEAHA.110.591362; Bhujwalla ZM, 2003, CLIN CANCER RES, V9, P355; Broome DR, 2007, AM J ROENTGENOL, V188, P586, DOI 10.2214/AJR.06.1094; Cahill J, 2009, STROKE, V40, pS86, DOI 10.1161/STROKEAHA.108.533315; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Chang CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019886; Cheung A, 2005, NEUROCRIT CARE, V3, P216, DOI 10.1385/NCC:3:3:216; Cianfoni A, 2006, J NEURORADIOLOGY, V33, P164, DOI 10.1016/S0150-9861(06)77254-6; Dittrich R, 2008, J NEUROL, V255, P896, DOI 10.1007/s00415-008-0802-1; Donnan GA, 2009, LANCET NEUROL, V8, P261, DOI 10.1016/S1474-4422(09)70041-9; Ellika SK, 2007, AM J NEURORADIOL, V28, P1981, DOI 10.3174/ajnr.A0688; Escudero D, 2007, Med. Intensiva, V31, P335; Escudero D, 2009, NEUROCRIT CARE, V11, P261, DOI 10.1007/s12028-009-9243-7; Etminan N, 2012, STROKE, V43, P759, DOI 10.1161/STROKEAHA.111.616730; Frolich AMJ, 2012, STROKE, V43, P97, DOI 10.1161/STROKEAHA.111.630954; Galvez M, 2004, AM J NEURORADIOL, V25, P1205; Gass A, 2007, CEREBROVASC DIS, V23, P4, DOI 10.1159/000096298; Han JS, 2011, STROKE, V42, P3047, DOI 10.1161/STROKEAHA.111.615955; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Herweh C, 2007, STROKE, V38, P2941, DOI 10.1161/STROKEAHA.107.486977; Herweh C, 2010, J NEUROIMAGING, V20, P350, DOI 10.1111/j.1552-6569.2009.00408.x; Hopyan JJ, 2008, AM J NEURORADIOL, V29, P1826, DOI 10.3174/ajnr.A1257; Huang APH, 2011, J TRAUMA, V71, P1593, DOI 10.1097/TA.0b013e31822c8865; Huang APH, 2011, J TRAUMA, V70, P1578, DOI 10.1097/TA.0b013e3182178c71; Huang APH, 2010, NEUROSURGERY, V67, P964, DOI 10.1227/NEU.0b013e3181ee359c; Huang APH, 2009, CEREBROVASC DIS, V28, P247, DOI 10.1159/000228254; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Ivens S, 2010, J NEUROL, V257, P615, DOI 10.1007/s00415-009-5384-z; Jain R, 2011, AM J NEURORADIOL, V32, P1570, DOI 10.3174/ajnr.A2263; Jain R, 2011, AM J NEURORADIOL, V32, P388, DOI 10.3174/ajnr.A2280; Jongen LM, 2010, CEREBROVASC DIS, V29, P538, DOI 10.1159/000306639; Kang KH, 2008, AM J NEURORADIOL, V29, P1487, DOI 10.3174/ajnr.A1129; Kemmling A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-80; Kirkman MA, 2011, BRIT J NEUROSURG, V25, P523, DOI 10.3109/02688697.2011.578773; Komotar RJ, 2009, NEUROSURGERY, V64, P397, DOI 10.1227/01.NEU.0000338946.42939.C7; Kostov DB, 2012, WORLD NEUROSURG, V78, P480, DOI 10.1016/j.wneu.2011.12.080; Kudo K, 2003, AM J NEURORADIOL, V24, P419; Kuroda S, 2001, STROKE, V32, P2110, DOI 10.1161/hs0901.095692; Leclerc X, 2006, J NEURORADIOLOGY, V33, P90, DOI 10.1016/S0150-9861(06)77237-6; Levy EI, 2009, STROKE, V40, P3552, DOI 10.1161/STROKEAHA.109.561274; Lin K, 2007, AM J NEURORADIOL, V28, P1292, DOI 10.3174/ajnr.A0539; Mandell DM, 2011, AM J NEURORADIOL, V32, P721, DOI 10.3174/ajnr.A2365; Martin ET, 2004, J AM COLL CARDIOL, V43, P1315, DOI 10.1016/j.jacc.2003.12.016; Metting Z, 2010, J NEUROTRAUM, V27, P2183, DOI 10.1089/neu.2010.1395; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Mordasini P, 2012, AM J NEURORADIOL, V33, P154, DOI 10.3174/ajnr.A2715; Muehlschlegel S, 2007, NEUROLOGY, V68, P1437, DOI 10.1212/01.wnl.0000260621.86593.39; NARIAI T, 1995, AM J NEURORADIOL, V16, P563; Nemoto EM, 2003, STROKE, V34, P2, DOI 10.1161/01.STR.0000041048.33908.18; Oppenheim C, 2000, STROKE, V31, P2175, DOI 10.1161/01.STR.31.9.2175; Park JC, 2010, CEREBROVASC DIS, V30, P547, DOI 10.1159/000319026; Parsons MW, 2007, NEUROLOGY, V68, P730, DOI 10.1212/01.wnl.0000256366.86353.ff; Patel HC, 2010, BRIT J NEUROSURG, V24, P179, DOI 10.3109/02688690903536603; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Pellon R, 2010, NEUROPEDIATRICS, V41, P189, DOI 10.1055/s-0030-1267209; Pham M, 2007, NEUROLOGY, V69, P762, DOI 10.1212/01.wnl.0000267641.08958.1b; Provenzale JM, 2005, AM J ROENTGENOL, V185, P763, DOI 10.2214/ajr.185.3.01850763; Rim NJ, 2008, AM J NEURORADIOL, V29, P1658, DOI 10.3174/ajnr.A1229; Roberts HC, 2001, AM J NEURORADIOL, V22, P1077; Rosand J, 2002, CEREBROVASC DIS, V14, P214, DOI 10.1159/000065681; Sakamoto S, 2006, ACTA NEUROCHIR, V148, P77, DOI 10.1007/s00701-005-0634-z; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Salomon EJ, 2009, CLIN NEURORADIOL, V19, P187, DOI 10.1007/s00062-009-9019-7; Sanelli PC, 2011, AM J NEURORADIOL, V32, P2047, DOI 10.3174/ajnr.A2693; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Sarrafzadeh AS, 2010, J CEREBR BLOOD F MET, V30, P36, DOI 10.1038/jcbfm.2009.199; Sato K, 2010, J CEREBR BLOOD F MET, V30, P1110, DOI 10.1038/jcbfm.2009.264; Schaefer PW, 2008, STROKE, V39, P2986, DOI 10.1161/STROKEAHA.107.513358; Schichor C, 2010, J NEUROSURG, V112, P722, DOI 10.3171/2009.9.JNS081255; Shankar JJS, 2012, NEURORADIOLOGY, V54, P197, DOI 10.1007/s00234-011-0876-9; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith LM, 2008, J NEURORADIOLOGY, V35, P157, DOI 10.1016/j.neurad.2007.11.002; So Y, 2005, STROKE, V36, P1485, DOI 10.1161/01.STR.0000170709.95185.b1; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Stiver SI, 2008, ACTA NEUROCHIR SUPPL, V102, P273, DOI 10.1007/978-3-211-85578-2_51; Vagal AS, 2009, AM J NEURORADIOL, V30, P876, DOI 10.3174/ajnr.A1538; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Vernieri F, 1999, STROKE, V30, P593, DOI 10.1161/01.STR.30.3.593; Vespa PM, 2009, STROKE, V40, P1547, DOI 10.1161/STROKEAHA.108.542803; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark M, 2002, STROKE, V33, P2025, DOI 10.1161/01.STR.0000023579.61630.AC; Wintermark M, 2001, AM J NEURORADIOL, V22, P905; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257	89	23	31	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2014	120	2					473	488		10.3171/2013.10.JNS13103			16	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	301UA	WOS:000330556400031	24266541				2021-06-18	
J	Li, W; Ling, HP; You, WC; Liu, HD; Sun, Q; Zhou, ML; Shen, W; Zhao, JB; Zhu, L; Hang, CH				Li, Wei; Ling, Hai-Ping; You, Wan-Chun; Liu, Huan-Dong; Sun, Qing; Zhou, Meng-Liang; Shen, Wei; Zhao, Jin-Bing; Zhu, Lin; Hang, Chun-Hua			Elevated Cerebral Cortical CD24 Levels in Patients and Mice with Traumatic Brain Injury: A Potential Negative Role in Nuclear Factor Kappa B/Inflammatory Factor Pathway	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; CD24; Inflammatory response; Short hairpin RNA; Knockdown	CLOSED-HEAD INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PROTEIN 88 MYD88; INFLAMMATORY RESPONSE; IMMUNE-RESPONSES; T-CELLS; EXPRESSION; ACTIVATION; ADULT; MODEL	Increasing evidence indicates that sterile inflammatory response contributes to secondary brain injury following traumatic brain injury (TBI). However, the specific mechanisms remain largely unknown, as is whether CD24, known as an important regulator in the non-infectious inflammatory response, plays a role in secondary brain injury after TBI. Here, the expression of CD24 was detected in samples from patients with TBI by quantitative real-time polymerase chain reaction (PCR), western blotting, immunohistochemistry and immunofluorescence. RNA interference was used to investigate the effects of CD24 on inflammatory response in a mouse model of TBI. Nuclear factor kappa B (NF-kappa B) DNA-binding activity was measured by electrophoretic mobility shift assay, and the levels of downstream pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and Interleukin 1 beta (IL-1 beta) were detected by real-time PCR. The results indicated that both the mRNA and protein levels of CD24 were markedly elevated after TBI in humans and mice, showing a time-dependent expression. The expression of CD24 could be observed in neurons, astrocytes and microglia in both humans and mice. Meanwhile, downregulation of CD24 significantly induced an increase of NF-kappa B DNA-binding activity and mRNA levels of TNF-alpha and IL-1 beta. These findings indicated that CD24 expression could negatively regulate the NF-kappa B/inflammatory factor pathway after experimental TBI in mice, thus providing a novel target for therapeutic intervention of TBI.	[Li, Wei; You, Wan-Chun; Sun, Qing; Zhou, Meng-Liang; Zhu, Lin; Hang, Chun-Hua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Ling, Hai-Ping; Liu, Huan-Dong; Zhou, Meng-Liang; Shen, Wei; Zhu, Lin; Hang, Chun-Hua] Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Zhao, Jin-Bing] Nanjing Med Univ, Nanjing Brain Hosp, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hang_neurosurgery@163.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170, 8100053, 81271377]	We gratefully acknowledge the generous technical assistance from Dr. Gen-bao Feng. This study was supported by grants from the National Natural Science Foundation, China (no. 81171170 for C. H. Hang, no. 8100053 for M. L. Zhou, and no. 81271377 for L. Zhu).	Ahmed MAH, 2010, INFLAMM BOWEL DIS, V16, P795, DOI 10.1002/ibd.21134; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Bai XF, 2004, J EXP MED, V200, P447, DOI 10.1084/jem.20040131; Bai XF, 2000, J CLIN INVEST, V105, P1227, DOI 10.1172/JCI9012; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Belvindrah R, 2002, J NEUROSCI, V22, P3594; Bianchi ME, 2009, SCIENCE, V323, P1683, DOI 10.1126/science.1172794; Bleckmann C, 2009, J PROTEOME RES, V8, P567, DOI 10.1021/pr800729r; Calaora V, 1996, NEUROSCIENCE, V73, P581, DOI 10.1016/0306-4522(96)00042-5; Cavassani KA, 2008, J EXP MED, V205, P2609, DOI 10.1084/jem.20081370; Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fukushima T, 2007, J BIOL CHEM, V282, P18634, DOI 10.1074/jbc.M609567200; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Graeber MB, 2011, FEBS LETT, V585, P3798, DOI 10.1016/j.febslet.2011.08.033; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Jiang W, 2011, STEM CELLS, V29, P609, DOI 10.1002/stem.608; KAY R, 1991, J IMMUNOL, V147, P1412; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Lescot T, 2007, PRESSE MED, V36, P1117, DOI 10.1016/j.lpm.2007.01.017; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li W, 2013, NEUROL SCI, V34, P847, DOI 10.1007/s10072-012-1131-9; Ling HP, 2013, J SURG RES, V179, pE227, DOI 10.1016/j.jss.2012.03.030; Liu YQ, 2009, J MATER RES, V24, P24, DOI 10.1557/JMR.2009.0034; Liu Y, 2007, TRENDS IMMUNOL, V28, P315, DOI 10.1016/j.it.2007.05.001; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Qiu Q, 2011, STEM CELLS DEV, V20, P2177, DOI 10.1089/scd.2010.0352; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Warger T, 2006, J BIOL CHEM, V281, P22545, DOI 10.1074/jbc.M502900200; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001	39	23	23	1	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	FEB	2014	49	1					187	198		10.1007/s12035-013-8509-4			12	Neurosciences	Neurosciences & Neurology	AA4EC	WOS:000331046800016	23881416				2021-06-18	
J	Geddes, RI; Sribnick, EA; Sayeed, I; Stein, DG				Geddes, Rastafa I.; Sribnick, Eric A.; Sayeed, Iqbal; Stein, Donald G.			Progesterone Treatment Shows Benefit in a Pediatric Model of Moderate to Severe Bilateral Brain Injury	PLOS ONE			English	Article							IMMATURE RATS; RECEPTOR KNOCKOUT; SEX-DIFFERENCES; FEMALE RATS; RECOVERY; BEHAVIOR; EDEMA; YOUNG; GABA; MICE	Purpose: Controlled cortical impact (CCI) models in adult and aged Sprague-Dawley (SD) rats have been used extensively to study medial prefrontal cortex (mPFC) injury and the effects of post-injury progesterone treatment, but the hormone's effects after traumatic brain injury (TBI) in juvenile animals have not been determined. In the present proof-of-concept study we investigated whether progesterone had neuroprotective effects in a pediatric model of moderate to severe bilateral brain injury. Methods: Twenty-eight-day old (PND 28) male Sprague Dawley rats received sham (n = 24) or CCI (n = 47) injury and were given progesterone (4, 8, or 16 mg/kg per 100 g body weight) or vehicle injections on post-injury days (PID) 1-7, subjected to behavioral testing from PID 9-27, and analyzed for lesion size at PID 28. Results: The 8 and 16 mg/kg doses of progesterone were observed to be most beneficial in reducing the effect of CCI on lesion size and behavior in PND 28 male SD rats. Conclusion: Our findings suggest that a midline CCI injury to the frontal cortex will reliably produce a moderate TBI comparable to what is seen in the adult male rat and that progesterone can ameliorate the injury-induced deficits.	[Geddes, Rastafa I.; Sribnick, Eric A.; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020; Sribnick, Eric/AAH-6693-2020	Geddes, Rastafa/0000-0002-7313-761X	Allen and Company; Centers for Injury Control [R49CE001494-04]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001494] Funding Source: NIH RePORTER	This work was supported by gifts in support of research from Allen and Company and by the Centers for Injury Control Grant No. R49CE001494-04. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baykara B, 2013, BIOTECH HISTOCHEM, V88, P250, DOI 10.3109/10520295.2013.769630; Blumberg MS, 1998, DEV PSYCHOBIOL, V33, P107, DOI 10.1002/(SICI)1098-2302(199809)33:2<107::AID-DEV2>3.0.CO;2-N; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Clancy B, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.020.2009; Conti F, 2004, BRAIN RES REV, V45, P196, DOI 10.1016/j.brainresrev.2004.03.003; Coomber B, 2010, BRAIN RES, V1361, P124, DOI 10.1016/j.brainres.2010.09.037; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Espinoza TR, 2011, J HEAD TRAUMA REHAB, V26, P497, DOI 10.1097/HTR.0b013e31823088fa; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frye CA, 2011, J PSYCHOPHARMACOL, V25, P421, DOI 10.1177/0269881109349836; Galanopoulou AS, 2008, EPILEPSY RES, V80, P99, DOI 10.1016/j.eplepsyres.2008.04.013; GAYTAN F, 1988, ANDROLOGIA, V20, P450; Gerrish CJ, 1998, PHYSIOL BEHAV, V64, P463, DOI 10.1016/S0031-9384(98)00077-8; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Golub MS, 2006, BIRTH DEFECTS RES B, V77, P455, DOI 10.1002/bdrb.20089; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOLMES GL, 1984, DEV BRAIN RES, V16, P45, DOI 10.1016/0165-3806(84)90061-0; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Kosten TA, 2012, NEUROSCI BIOBEHAV R, V36, P1985, DOI 10.1016/j.neubiorev.2012.07.003; Liu D, 2000, NAT NEUROSCI, V3, P799; McCarthy MM, 2002, TRENDS NEUROSCI, V25, P307, DOI 10.1016/S0166-2236(02)02182-3; Nold C, 2013, AM J OBSTET GYNECOL, V208, pS26, DOI 10.1016/j.ajog.2012.10.216; Norwitz Errol R, 2011, Rev Obstet Gynecol, V4, P60; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Reddy DS, 2005, BRAIN RES, V1033, P96, DOI 10.1016/j.brainres.2004.11.026; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Rodgers RJ, 1997, BRAZ J MED BIOL RES, V30, P289, DOI 10.1590/S0100-879X1997000300002; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Russell KL, 2011, J NEUROSCI METH, V199, P214, DOI 10.1016/j.jneumeth.2011.05.008; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Silva-Gomez AB, 2003, BRAIN RES, V973, P285, DOI 10.1016/S0006-8993(03)02537-X; Soderpalm AHV, 2004, PSYCHONEUROENDOCRINO, V29, P339, DOI 10.1016/S0306-4530(03)00033-7; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Uysal N, 2013, TURK NEUROSURG, V23, P129, DOI 10.5137/1019-5149.JTN.5582-11.1; Varty GB, 2000, BIOL PSYCHIAT, V47, P864, DOI 10.1016/S0006-3223(99)00269-3; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	50	23	23	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2014	9	1							e87252	10.1371/journal.pone.0087252			10	Multidisciplinary Sciences	Science & Technology - Other Topics	301CJ	WOS:000330510000120	24489882	DOAJ Gold, Green Published			2021-06-18	
J	Mayer, AR; Toulouse, T; Klimaj, S; Ling, JM; Pena, A; Bellgowan, PSF				Mayer, Andrew R.; Toulouse, Trent; Klimaj, Stefan; Ling, Josef M.; Pena, Amanda; Bellgowan, Patrick S. F.			Investigating the Properties of the Hemodynamic Response Function after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						fMRI; hemodynamic response function; sensorimotor; traumatic brain injury	CEREBRAL-BLOOD-FLOW; BOLD POSTSTIMULUS UNDERSHOOT; OXIDATIVE-METABOLISM; WORKING-MEMORY; OXYGEN-METABOLISM; FOOTBALL PLAYERS; FMRI; ACTIVATION; MRI; RECOVERY	Although several functional magnetic resonance imaging (fMRI) studies have been conducted in human models of mild traumatic brain injury (mTBI), to date no studies have explicitly examined how injury may differentially affect both the positive phase of the hemodynamic response function (HRF) as well as the post-stimulus undershoot (PSU). Animal models suggest that the acute and semi-acute stages of mTBI are associated with significant disruptions in metabolism and to the microvasculature, both of which could impact on the HRF. Therefore, fMRI data were collected on a cohort of 30 semi-acute patients with mTBI (16 males; 27.83 +/- 9.97 years old; 13.00 +/- 2.18 years of education) and 30 carefully matched healthy controls (HC; 16 males; 27.17 +/- 10.08 years old; 13.37 +/- 2.31 years of education) during a simple sensory-motor task. Patients reported increased cognitive, somatic, and emotional symptoms relative to controls, although no group differences were detected on traditional neuropsychological examination. There were also no differences between patients with mTBI and controls on fMRI data using standard analytic techniques, although mTBI exhibited a greater volume of activation during the task qualitatively. A significant GroupxTime interaction was observed in the right supramarginal gyrus, bilateral primary and secondary visual cortex, and the right parahippocampal gyrus. The interaction was the result of an earlier time-to-peak and positive magnitude shift throughout the estimated HRF in patients with mTBI relative to HC. This difference in HRF shape combined with the greater volume of activated tissue may be indicative of a potential compensatory mechanism to injury. The current study demonstrates that direct examination and modeling of HRF characteristics beyond magnitude may provide additional information about underlying neuropathology that is not available with more standard fMRI analyses.	[Mayer, Andrew R.; Toulouse, Trent; Klimaj, Stefan; Ling, Josef M.; Pena, Amanda] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Bellgowan, Patrick S. F.] Laureate Inst Brain Res, Tulsa, OK USA; [Bellgowan, Patrick S. F.] Univ Tulsa, Fac Community Med, Tulsa, OK 74104 USA	Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020				Ances BM, 2009, HUM BRAIN MAPP, V30, P1120, DOI 10.1002/hbm.20574; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Behzadi Y, 2005, NEUROIMAGE, V25, P1100, DOI 10.1016/j.neuroimage.2004.12.057; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bellgowan PSF, 2006, NEUROIMAGE, V29, P1244, DOI 10.1016/j.neuroimage.2005.08.042; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BOUMA GJ, 1992, J NEUROTRAUMA S1, V9, P333; Box G.E.P., 1994, TIME SERIES ANAL FOR; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Buxton RB, 2004, NEUROIMAGE, V23, pS220, DOI 10.1016/j.neuroimage.2004.07.013; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Frackowiak R S, 1988, Am J Physiol Imaging, V3, P24; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Harshbarger TB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002914; Hua J, 2011, J CEREBR BLOOD F MET, V31, P1599, DOI 10.1038/jcbfm.2011.35; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lu HZ, 2004, J CEREBR BLOOD F MET, V24, P764, DOI 10.1097/01.WCB.0000124322.60992.5C; Mangia S, 2007, J CEREBR BLOOD F MET, V27, P1055, DOI 10.1038/sj.jcbfm.9600401; Mayer AR, 2007, J INT NEUROPSYCH SOC, V13, P839, DOI 10.1017/S1355617707071081; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Palmer HS, 2010, J NEUROTRAUM, V27, P853, DOI 10.1089/neu.2009.1225; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Poser BA, 2011, HUM BRAIN MAPP, V32, P141, DOI 10.1002/hbm.21003; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schroeter ML, 2006, NEUROIMAGE, V30, P349, DOI 10.1016/j.neuroimage.2005.09.048; Shen Q, 2008, J MAGN RESON IMAGING, V27, P599, DOI 10.1002/jmri.21203; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Talairach J., 1988, COPLANAR STERIOTOXIC; van Zijl PCM, 2012, NEUROIMAGE, V62, P1092, DOI 10.1016/j.neuroimage.2012.01.029; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	66	23	23	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					189	197		10.1089/neu.2013.3069			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600005	23965000	Green Published			2021-06-18	
J	Weeks, D; Sullivan, S; Kilbaugh, T; Smith, C; Margulies, SS				Weeks, Dianne; Sullivan, Sarah; Kilbaugh, Todd; Smith, Colin; Margulies, Susan S.			Influences of Developmental Age on the Resolution of Diffuse Traumatic Intracranial Hemorrhage and Axonal Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; hemorrhage; pediatric traumatic brain injury; swine; time course	ROTATIONAL HEAD-INJURY; BRAIN-INJURY; CEREBRAL CONCUSSION; COGNITIVE FUNCTION; CORPUS-CALLOSUM; CORTICAL IMPACT; ANIMAL-MODELS; VULNERABILITY; CHILDREN; PIGLET	This study investigated the age-dependent injury response of diffuse traumatic axonal injury (TAI) and regional subdural and subarachnoid intracranial hemorrhage (ICH) in two pediatric age groups using a porcine head injury model. Fifty-five 5-day-old and 40 four-week-old pigletswhich developmentally correspond to infants and toddlers, respectivelyunderwent either a sham injury or a single rapid non-impact rotational injury in the sagittal plane and were grouped by post-TBI survival time (sham, 3-8h, one day, 3-4 days, and 5-6 days). Both age groups exhibited similar initial levels of ICH and a significant reduction of ICH over time (p<0.0001). However, ICH took longer to resolve in the five-day-old age group. At 5-6 days post-injury, ICH in the cerebrum had returned to sham levels in the four-week-old piglets, while the five-day-olds still had significantly elevated cerebral ICH (p=0.012). Both ages also exhibited similar resolution of axonal injury with a peak in TAI at one day post-injury (p<0.03) and significantly elevated levels even at 5-6 days after the injury (p<0.008), which suggests a window of vulnerability to a second insult at one day post-injury that may extend for a prolonged period of time. However, five-day-old piglets had significantly more TAI than four-week-olds overall (p=0.016), which presents some evidence for an increased vulnerability to brain injury in this age group. These results provide insight into an optimal window for clinical intervention, the period of increased susceptibility to a second injury, and an age dependency in brain injury tolerance within the pediatric population.	[Weeks, Dianne; Sullivan, Sarah; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Kilbaugh, Todd] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA; [Smith, Colin] Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 South 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu		Smith, Colin/0000-0002-4507-5132; Kilbaugh, Todd/0000-0002-4959-3092	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS039679, U01 NS069545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069545, R01NS039679] Funding Source: NIH RePORTER	The authors gratefully acknowledge the technical assistance of Michelle Skettini, Melissa Byro, Jill Ralston, Shreya Reddy, and Sharon Martinez. Studies were supported by NIH R01 NS039679 and NIH U01 NS069545.	Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bruce D A, 1990, Curr Probl Pediatr, V20, P61; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Conrad MS, 2012, DEV NEUROSCI-BASEL, V34, P291, DOI 10.1159/000339311; Dobbing J, 1968, Prog Brain Res, V29, P417; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Hagberg H, 2002, DEV NEUROSCI-BASEL, V24, P364, DOI 10.1159/000069040; Ibrahim N.G., J NEUROTRAUMA, V27, P1021; Ibrahim NG, 2012, INT J DEV NEUROSCI, V30, P201, DOI 10.1016/j.ijdevneu.2011.10.007; Kilbaugh T.J., J NEUROTRAUMA, V28, P763; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pinto PS, 2012, J NEUROIMAGING, V22, pe18, DOI 10.1111/j.1552-6569.2011.00690.x; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Snyder R.C., 1977, UMHSRI77 CONS PROD S; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zakaria N, 2012, BRAIN RES, V1467, P81, DOI 10.1016/j.brainres.2012.05.046	41	23	25	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					206	214		10.1089/neu.2013.3113			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600007	23984914	Green Published			2021-06-18	
J	Tohme, S; Delhumeau, C; Zuercher, M; Haller, G; Walder, B				Tohme, Sophia; Delhumeau, Cecile; Zuercher, Mathias; Haller, Guy; Walder, Bernhard			Prehospital risk factors of mortality and impaired consciousness after severe traumatic brain injury: an epidemiological study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Out-of-hospital emergency medical services; Prehospital emergency medicine; Head injury; Short term outcome	GLASGOW COMA SCALE; PROGNOSTIC VALUE; HEAD-INJURY; CARE; CATECHOLAMINES; ASPIRATION; MANAGEMENT; OUTCOMES; FAILURE; SYSTEM	Background: Severe traumatic brain injury (TBI) is a significant health concern and a major burden for society. The period between trauma event and hospital admission in an emergency department (ED) could be a determinant for secondary brain injury and early survival. The aim was to investigate the relationship between prehospital factors associated with secondary brain injury (arterial hypotension, hypoxemia, hypothermia) and the outcomes of mortality and impaired consciousness of survivors at 14 days. Methods: A multicenter, prospective cohort study was performed in dedicated trauma centres of Switzerland. Adults with severe TBI (Abbreviated Injury Scale score of head region (HAIS) >3) were included. Main outcome measures were death and impaired consciousness (Glasgow Coma Scale (GCS) <= 13) at 14 days. The associations between risk factors and outcome were assessed with univariate and multivariate regression models. Results: 589 patients were included, median age was 55 years (IQR 33, 70). The median GCS in ED was 4 (IQR 3-14), with abnormal pupil reaction in 167 patients (29.2%). Median ISS was 25 (IQR 21, 34). Three hundred seven patients sustained their TBI from falls (52.1%) and 190 from a road traffic accidents (32.3%). Median time from Out-of-hospital Emergency Medical Service (OHEMS) departure on scene to arrival in ED was 50 minutes (IQR 37-72); 451 patients had a direct admission (76.6%). Prehospital hypotension was observed in 24 (4.1%) patients, hypoxemia in 73 (12.6%) patients and hypothermia in 146 (24.8%). Prehospital hypotension and hypothermia (apart of age and trauma severity) was associated with mortality. Prehospital hypoxemia (apart of trauma severity) was associated with impaired consciousness; indirect admission was a protective factor. Conclusion: Mortality and impaired consciousness at 14 days do not have the same prehospital risk factors; prehospital hypotension and hypothermia is associated with mortality, and prehospital hypoxemia with impaired consciousness.	[Tohme, Sophia; Delhumeau, Cecile; Haller, Guy; Walder, Bernhard] Univ Hosp Geneva, Div Anaesthesiol, Geneva, Switzerland; [Zuercher, Mathias] Univ Basel Hosp, Dept Anaesthesia & Intens Care Med, CH-4031 Basel, Switzerland; [Haller, Guy] Univ Hosp Geneva, Div Clin Epidemiol, Geneva, Switzerland	Walder, B (corresponding author), Univ Hosp Geneva, Div Anaesthesiol, Geneva, Switzerland.	bernhard.walder@hcuge.ch			Swiss Accident Company; Bangerter-Rhyner Foundation, Switzerland	The authors declare no conflicts of interest. B. W. received support from the Swiss Accident Company and the Bangerter-Rhyner Foundation, Switzerland, for this project. The founding agencies had no role in the preparation, review or approval of the manuscript.	Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Berry C, 2012, INJURY, V43, P1833, DOI 10.1016/j.injury.2011.08.014; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Bukur M, 2012, J SURG RES, V175, P24, DOI 10.1016/j.jss.2011.07.003; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; de Ribaupierre S, 2011, NEUROL CLIN, V29, P883, DOI 10.1016/j.ncl.2011.07.012; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Franschman G, 2011, J TRAUMA, V71, P826, DOI 10.1097/TA.0b013e31820cebf0; Garthe E, 1999, J TRAUMA, V47, P309, DOI 10.1097/00005373-199908000-00016; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Haut ER, 2011, ANN SURG, V253, P371, DOI 10.1097/SLA.0b013e318207c24f; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Kalia LV, 2008, LANCET NEUROL, V7, P742, DOI 10.1016/S1474-4422(08)70165-0; Kool B, 2012, NEUROEPIDEMIOLOGY, V38, P179, DOI 10.1159/000337261; Kouloulas EJ, 2013, INT J REHABIL RES, V36, P260, DOI 10.1097/MRR.0b013e32835fd99a; Leon-Carrion J, 2012, BRAIN RES, V1476, P22, DOI 10.1016/j.brainres.2012.03.055; Lockey DJ, 1999, ANAESTHESIA, V54, P1097, DOI 10.1046/j.1365-2044.1999.00754.x; Lundgren P, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-59; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mosconi P, 2011, PATIENT, V4, P55, DOI 10.2165/11535550-000000000-00000; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Pielmaier L, 2011, BRAIN INJURY, V25, P259, DOI 10.3109/02699052.2010.542429; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Vadeboncoeur TF, 2006, J EMERG MED, V30, P131, DOI 10.1016/j.jemermed.2005.04.019; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; von Elm E, 2008, SWISS MED WKLY, V138, P327, DOI 2008/23/smw-12025; Walder B, 2013, J NEUROTRAUM, V30, P1934, DOI 10.1089/neu.2013.2955; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	39	23	26	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	JAN 7	2014	22								1	10.1186/1757-7241-22-1			9	Emergency Medicine	Emergency Medicine	AB3VO	WOS:000331718500001	24393519	DOAJ Gold, Green Published			2021-06-18	
J	Carone, DA				Carone, Dominic A.			Young Child With Severe Brain Volume Loss Easily Passes the Word Memory Test and Medical Symptom Validity Test: Implications for Mild TBI	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; Symptom validity testing; Malingering; Word Memory Test; Medical Symptom Validity Test	TEST-PERFORMANCE; RESPONSE BIAS; TEST-SCORES; INJURY; ADOLESCENTS; FAILURE; ADULTS; TOMM	The Word Memory Test (WMT) and Medical Symptom Validity Test (MSVT) are two commonly used free-standing measures of test-taking effort. The use of any test as a measure of effort is enhanced when evidence shows that it can be easily passed by patients with severe neurological conditions. The opportunity arose to administer the WMT and MSVT to a 9-year-old girl (referred to as CJ) with severe congenital bilateral brain tissue loss (shown via a compelling brain MRI image), chronic epilepsy, an extremely low Full Scale IQ, extremely low adaptive functioning, developmental delays, numerous severe cognitive impairments, and treatment with multiple high-dose benzodiazepines. She received extensive early intervention services and numerous academic accommodations. Despite this set of problems, CJ passed the WMT and MSVT at perfect to near perfect levels. Implications for failure on these tests among patients with known or alleged mild traumatic brain injury are discussed.	[Carone, Dominic A.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA	Carone, DA (corresponding author), 505 Irving Ave,Room 2012, Syracuse, NY USA.	caroned@upstate.edu					Adams W., 2005, WIDE RANGE ASSESSMEN; An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Beery K.E, 2010, BEERY BUKTENICA DEV, V6th; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Carone D. A., 2009, APPL NEUROPSYCHOLOGY, V16; Carone D. A., APPL NEUROP IN PRESS; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2012, CLIN NEUROPSYCHOL, V26, P1358, DOI 10.1080/13854046.2012.730674; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Donders J, 2007, BRAIN INJURY, V21, P319, DOI 10.1080/02699050701253129; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Graver C.J, 2012, MIL MED, V176, P1426; Graver CJ, 2012, MIL MED, V177, pVII; Green, 2004, GREENS MED SYMPTOM V; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P, 2012, DETECTION OF MALINGERING DURING HEAD INJURY LITIGATION, SECOND EDITION, P201, DOI 10.1007/978-1-4614-0442-2_6; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Harrison P. L., 2003, ADAPATIVE BEHAV ASSE; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; Kaplan E., 2001, Boston naming test; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Korkman M, 1998, NEPSY DEV NEUROPSYCH; Larochette AC, 2012, APPL NEUROPSYCH-CHIL, V1, P38, DOI 10.1080/21622965.2012.665777; Loring DW, 2011, CLIN NEUROPSYCHOL, V25, P799, DOI 10.1080/13854046.2011.583279; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Meyers JE, 1996, REY COMPLEX FIGURE S; Reitan RM, 2000, ARCH CLIN NEUROPSYCH, V15, P433, DOI 10.1016/S0887-6177(99)00038-4; Rienstra A, 2009, ARCH CLIN NEUROPSYCH, V24, P255, DOI 10.1093/arclin/acp035; Rienstra A, 2013, ARCH CLIN NEUROPSYCH, V28, P463, DOI 10.1093/arclin/act026; Rohling M. L., 2013, 53 ANN C AM SOC CLIN; Rohling M. L., 2011, CLIN NEUROPSYCHOL, V25, P1; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sheslow D., 2003, WIDE RANGE ASSESSMEN, V2nd; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D, 2003, WISC 4 TECHNICAL INT; Wechsler D., 2011, WECHSLER ABBREVIATED; Wilkinson G.S., 2006, WRAT4 WIDE RANGE ACH; Williamson D. J., 2003, J FORENSIC NEUROPSYC, V3, P19; Williamson DJ, 2012, CLIN NEUROPSYCHOL, V26, P588, DOI 10.1080/13854046.2012.670266; Willis PF, 2011, MIL MED, V176, P1426, DOI 10.7205/MILMED-D-11-00168; Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE	60	23	23	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2014	28	1					146	162		10.1080/13854046.2013.861019			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AA0AF	WOS:000330756800010	24266623				2021-06-18	
J	Cottingham, ME; Victor, TL; Boone, KB; Ziegler, EA; Zeller, M				Cottingham, Maria Easter; Victor, Tara L.; Boone, Kyle B.; Ziegler, Elizabeth A.; Zeller, Michelle			Apparent Effect of Type of Compensation Seeking (Disability Versus Litigation) on Performance Validity Test Scores may be due to Other Factors	CLINICAL NEUROPSYCHOLOGIST			English	Article						Compensation; Performance validity; Neuropsychology; Disability; mTBI	SOCIAL-SECURITY DISABILITY; TRAUMATIC BRAIN-INJURY; WORD RECOGNITION TEST; MILD HEAD TRAUMA; SUSPECT EFFORT; RESPONSE BIAS; SYMPTOM EXAGGERATION; CONSULTATIVE EXAM; CROSS-VALIDATION; BASE RATES	Neuropsychologists use performance validity tests (PVTs; Larrabee, 2012) to ensure that results of testing are reflective of the test taker's true neurocognitive ability, and their use is recommended in all compensation-seeking settings. However, whether the type of compensation context (e.g., personal injury litigation versus disability seeking) impacts the nature and extent of neurocognitive symptom feigning has not been adequately investigated. PVT performance was compared in an archival data set of noncredible individuals in either a personal injury litigation (n = 163) or a disability-seeking context (n = 201). Individuals were deemed noncredible based on meeting Slick, Sherman, and Iverson's (1999) criteria including failure on at least two PVTs and a lack of congruency between their low cognitive scores and normal function in activities of daily living (ADLs). In general, disability seekers tended to perform in a less sophisticated manner than did litigants (i.e., they failed more indicators and did so more extensively). Upon further investigation, these differences were in part accounted for by type of diagnoses feigned; those seeking compensation for mental health diagnoses were more likely to feign or exaggerate a wide variety of cognitive deficits, whereas those with claimed medical diagnoses (i.e., traumatic brain injury) were more targeted in their attempts to feign and/or exaggerate neurocognitive compromise.	[Cottingham, Maria Easter] Olive View UCLA Med Ctr, Dept Psychiat, Sylmar, CA 91342 USA; [Victor, Tara L.] Calif State Univ, Dept Psychol, Carson, CA USA; [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA USA; [Ziegler, Elizabeth A.] Spokane Vet Adm Med Ctr, Dept Mental Behav Hlth, Spokane, WA USA; [Zeller, Michelle] Greater Los Angeles Vet Healthcare Syst, Dept Psychol, Los Angeles, CA USA	Cottingham, ME (corresponding author), TBI Clin, 11050 Mt Belvedere Blvd,Bldg 25, Ft Drum, NY 13601 USA.	mecottingham@gmail.com	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bell-Sprinkel TL, 2013, CLIN NEUROPSYCHOL, V27, P516, DOI 10.1080/13854046.2012.744853; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Boone K. B., 2002, DOT COUNTING TEST MA; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Buddin R., 2012, IS MILITARY COMPENSA; Buddin R, 2005, ANAL MILITARY DISABI; Chafetz M. D, 2013, MILD TRAUMATIC BRAIN; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Chafetz MD, 2011, ARCH CLIN NEUROPSYCH, V26, P306, DOI 10.1093/arclin/acr030; Chafetz MD, 2010, CLIN NEUROPSYCHOL, V24, P1045, DOI 10.1080/13854046.2010.481637; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Denning J., 2012, ANN M AM AC CLIN NEU; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Green, 2004, GREENS MED SYMPTOM V; Green P, 2013, MILD TRAUMATIC BRAIN; Green P., 2003, MANUAL WORD MEMORY T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein M. F., 2008, TXB CLIN NEUROPSYCHO, P905; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Kaufmann PM, 2009, CLIN NEUROPSYCHOL, V23, P1130, DOI 10.1080/13854040903107809; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Langton Lynn, 2005, CIVIL BENCH JURY TRI; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; McNally RJ, 2013, J ANXIETY DISORD, V27, P520, DOI 10.1016/j.janxdis.2013.07.002; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morton III D. A, 2010, NOLOS GUIDE SOCIAL S; Nakagawa S, 2004, BEHAV ECOL, V15, P1044, DOI 10.1093/beheco/arh107; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Roberson CJ, 2013, CLIN NEUROPSYCHOL, V27, P495, DOI 10.1080/13854046.2012.737027; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith K., CLIN NEUROP IN PRESS; *SOC SEC ADV BOARD, 2003, SOC SEC DEF DIS; Social Security Administration, 2013, NUMB PEOPL US SEEK R; Solomon RE, 2010, CLIN NEUROPSYCHOL, V24, P1243, DOI 10.1080/13854046.2010.514864; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Victor T. L., 2007, ASSESSMENT FEIGNED C, P310, DOI 10.1076/jcen.25.7.979.16481; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	51	23	24	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	6					1030	1047		10.1080/13854046.2014.951397			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AP4MR	WOS:000342051600010	25157537				2021-06-18	
J	Douglas-Escobar, MV; Heaton, SC; Bennett, J; Young, LJ; Glushakova, O; Xu, XH; Barbeau, DY; Rossignol, C; Miller, C; Crow, AMO; Hayes, RL; Weiss, MD				Douglas-Escobar, Martha V.; Heaton, Shelley C.; Bennett, Jeffrey; Young, Linda J.; Glushakova, Olena; Xu, Xiaohui; Barbeau, Daphna Yasova; Rossignol, Candice; Miller, Cindy; Crow, Alissa M. Old; Hayes, Ronald L.; Weiss, Michael D.			UCH-L1 and GFAP serum levels in neonates with hypoxic-ischemic encephalopathy: a single center pilot study	FRONTIERS IN NEUROLOGY			English	Article						biomarkers; HIE; UCH-L1; GFAP	TRAUMATIC BRAIN-INJURY; C-TERMINAL HYDROLASE-L1; WHOLE-BODY HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; PERINATAL ASPHYXIA; BIOMARKERS; BLOOD; ELECTROENCEPHALOGRAM; PREDICTION; OUTCOMES	Objective: We examined two potential biomarkers of brain damage in hypoxic ischemic encephalopathy (HIE) neonates: glial fibrillary acidic protein (GFAP; a marker of gliosis) and ubiquitin C-terminal hydrolase L1 (UCH-L1; a marker of neuronal injury). We hypothesized that the biomarkers would be measurable in cord blood of healthy neonates and could serve as a normative reference for brain injury in HIE infants. We further hypothesized that higher levels would be detected in serum samples of HIE neonates and would correlate with brain damage on magnetic resonance imaging (MRI) and later developmental outcomes.? Study Design: Serum UCH-L1 and GFAP concentrations from HIE neonates (n=16) were compared to controls (n=11). The relationship between biomarker concentrations of HIE neonates and brain damage (MRI) and developmental outcomes (Bayley-III) was examined using Pearson correlation coefficients and a mixed model design. Result: Both biomarkers were detectable in cord blood from control subjects. UCH-L1 concentrations were higher in HIE neonates (p < 0.001), and associated with cortical injury (p < 0.055) and later motor and cognitive developmental outcomes (p < 0.05). The temporal change in GFAP concentrations during (from birth to 96 h of age) predicted motor developmental outcomes (p < 0.05) and injury to the basal ganglia and white matter. Conclusion: Ubiquitin C-terminal hydrolase L1 and GFAP should be explored further as promising serum biomarkers of brain damage and later neurodevelopmental outcomes in neonates with HIE.	[Douglas-Escobar, Martha V.; Barbeau, Daphna Yasova; Rossignol, Candice; Miller, Cindy; Weiss, Michael D.] Univ Florida, Dept Pediat, Gainesville, FL USA; [Douglas-Escobar, Martha V.] Univ Calif San Francisco, Dept Pediat, 505 Parnassus Ave,Moffitt Room M 680, San Francisco, CA 94143 USA; [Heaton, Shelley C.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Bennett, Jeffrey; Crow, Alissa M. Old] Univ Florida, Dept Radiol, Gainesville, FL 32610 USA; [Young, Linda J.] Univ Florida, Dept Stat, Gainesville, FL 32611 USA; [Glushakova, Olena; Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Xu, Xiaohui] Univ Florida, Dept Biostat, Gainesville, FL USA	Douglas-Escobar, MV (corresponding author), Univ Calif San Francisco, Dept Pediat, 505 Parnassus Ave,Moffitt Room M 680, San Francisco, CA 94143 USA.	martha.douglas-escobar@ucsf.edu	Xu, Xiaohui/H-5397-2019	Xu, Xiaohui/0000-0001-7269-4089; Young, Linda/0000-0002-3541-4313			Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P143; Bayley N., 2006, BAYLEY SCALES INFANT; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Boichot C, 2006, RADIOLOGY, V239, P839, DOI 10.1148/radiol.2393050027; Bonifacio SL, 2011, NAT REV NEUROL, V7, P485, DOI 10.1038/nrneurol.2011.119; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Chalak LF, 2014, J PEDIATR-US, V164, P468, DOI 10.1016/j.jpeds.2013.10.067; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Day INM, 2010, PROG NEUROBIOL, V90, P327, DOI 10.1016/j.pneurobio.2009.10.020; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Douglas-Escobar M, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00185; Douglas-Escobar Martha, 2012, Front Neurol, V3, P144, DOI 10.3389/fneur.2012.00144; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Ennen CS, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.025; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; Garfinkle J, 2013, EUR J PAEDIATR NEURO, V17, P492, DOI 10.1016/j.ejpn.2013.03.006; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; Gunn AJ, 2008, J PEDIATR-US, V152, P55, DOI 10.1016/j.jpeds.2007.06.003; Jouvet P, 1999, AM J NEURORADIOL, V20, P1343; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Leijser LM, 2007, NEUROPEDIATRICS, V38, P219, DOI 10.1055/s-2007-992815; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Low JA, 1997, AM J OBSTET GYNECOL, V177, P1391, DOI 10.1016/S0002-9378(97)70080-2; MACDONALD HM, 1980, J PEDIATR-US, V96, P898, DOI 10.1016/S0022-3476(80)80574-9; Massaro AN, 2013, PEDIATR CRIT CARE ME, V14, P310, DOI 10.1097/PCC.0b013e3182720642; Mondello S, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-85; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; van Laerhoven H, 2013, PEDIATRICS, V131, P88, DOI 10.1542/peds.2012-1297; Vannucci R.C, 1997, NEONATAL PERINATAL M, P856; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	43	23	27	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								273	10.3389/fneur.2014.00273			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QW	WOS:000209629300256	25566179	DOAJ Gold, Green Published			2021-06-18	
J	Menn, SJ; Yang, R; Lankford, A				Menn, Stuart J.; Yang, Ronghua; Lankford, Alan			Armodafinil for the Treatment of Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury: A 12-Week, Randomized, Double-Blind Study followed by a 12-Month Open-Label Extension	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						traumatic brain injury; excessive sleepiness; armodafinil	SHIFT WORK DISORDER; GLOBAL IMPRESSION SCALE; DAYTIME SLEEPINESS; LATENCY TEST; EFFICACY; TOLERABILITY; DISTURBANCES; WAKEFULNESS; PREVALENCE; NARCOLEPSY	Objective: To evaluate the efficacy and tolerability of armodafinil in patients with excessive sleepiness following mild or moderate closed traumatic brain injury (TBI). Design: Randomized, placebo-controlled, double-blind trial followed by open-label extension. Setting: 40 US centers. Patients: Adults with closed TBI (N = 117), Glasgow Coma Scale score > 8 at time of injury; baseline Epworth Sleepiness Scale (ESS) >= 10; sleep latency < 8 minutes on multiple sleep latency test (MSLT); and Clinical Global Impression-Severity of Illness (CGI-S) score >= 4 for excessive sleepiness. Intervention: Patients received armodafinil (50, 150, or 250 mg/day) or placebo for 12 weeks followed by an optional 12-month open-label extension. Measurements and Results: Outcomes included MSLT, ESS, Clinical Global Impression-Change (CGI-C), TBI-Work Instability Scale (TBI-WIS), CGI-S, and tolerability. The study was terminated early due to low enrollment. Patients receiving 250 mg armodafinil showed significant improvement in sleep latency from baseline to final visit versus placebo (+7.2 minutes vs. +2.4 minutes; p = 0.0010). CGI-C ratings were much/very much improved in approximately 50% of patients receiving 150 and 250 mg armodafinil, compared to 38% on placebo. ESS and TBI-WIS scores were not significantly different between groups. In the open-label extension (N = 49), patients demonstrated gradual improvement in ESS, TBI-WIS, and CGI-S scores up to 48 weeks post-baseline. Armodafinil was generally well tolerated, with headache the most common adverse event in both double-blind and open-label portions. Conclusions: Armodafinil 250 mg significantly improved sleep latency in patients with excessive sleepiness associated with mild or moderate TBI. Efficacy and tolerability of armodafinil were sustained throughout the open-label extension.	[Menn, Stuart J.] Pacific Sleep Med Serv, Palm Springs, CA USA; [Yang, Ronghua] Teva Pharmaceut Ind Ltd, Frazer, PA USA; [Lankford, Alan] Sleep Disorders Ctr Georgia, Atlanta, GA USA	Menn, SJ (corresponding author), 5 Dominion Court, Palm Springs, CA 92270 USA.	stuartjmenn@cs.com			Teva Pharmaceutical Industries Ltd.	The authors thank Craig Q. Earl, Ph. D., formerly of Cephalon, Inc, for his contribution to the study design and Sarah Mizne, PharmD, and David Christiansen, Ph. D., of MedVal Scientific Information Services, LLC, for professional medical writing and editorial support. This manuscript was prepared according to the International Society for Medical Publication Professionals' Good Publication Practice for Communicating Company-Sponsored Medical Research: the GPP2 Guidelines. Funding for this study and to support the preparation of this manuscript was provided by Teva Pharmaceutical Industries Ltd.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, SLEEP MED CLIN, V7, P609, DOI 10.1016/j.jsmc.2012.08.002; Black JE, 2010, J CLIN SLEEP MED, V6, P458; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Czeisler CA, 2009, MAYO CLIN PROC, V84, P958, DOI 10.1016/S0025-6196(11)60666-6; Erman MK, 2011, J OCCUP ENVIRON MED, V53, P1460, DOI 10.1097/JOM.0b013e318237a17e; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Forkmann T, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-83; Gilworth G, 2006, BRAIN INJURY, V20, P835, DOI 10.1080/02699050600832221; Greenwald B, 2011, PM&R, V3, P480, DOI 10.1016/j.pmrj.2011.04.010; Guy W., 1976, ECDEU ASSESSMENT MAN; Harsh J, 2014, CURR MED RES OPIN, V30, P945, DOI 10.1185/03007995.2014.884490; Harsh JR, 2006, CURR MED RES OPIN, V22, P761, DOI 10.1185/030079906X100050; Heres S, 2014, PROG NEURO-PSYCHOPH, V48, P207, DOI 10.1016/j.pnpbp.2013.09.015; Hirshkowitz M, 2007, RESP MED, V101, P616, DOI 10.1016/j.rmed.2006.06.007; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Jiang Qin, 2009, Ann Gen Psychiatry, V8, P4, DOI 10.1186/1744-859X-8-4; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; Kadouri A, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-7; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ohayon MM, 2008, SLEEP MED REV, V12, P129, DOI 10.1016/j.smrv.2008.01.001; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Roth T, 2006, CLIN THER, V28, P689, DOI 10.1016/j.clinthera.2006.05.013; Schwartz JRL, 2010, J CLIN SLEEP MED, V6, P450; Sheng P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081802; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249	40	23	23	0	2	AMER ACAD SLEEP MEDICINE	DARIEN	2510 N FRONTAGE RD, DARIEN, IL 60561 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2014	10	11					1181	1191		10.5664/jcsm.4196			11	Clinical Neurology	Neurosciences & Neurology	AT8XT	WOS:000345213100004	25325609	Green Published, Bronze			2021-06-18	
J	Moore, RD; Broglio, SP; Hillman, CH				Moore, Robert D.; Broglio, Steven P.; Hillman, Charles H.			Sport-Related Concussion and Sensory Function in Young Adults	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injuries; visual processing; event-related potentials; pattern-reversal visual evoked potentials	TRAUMATIC BRAIN-INJURY; VISUAL-EVOKED POTENTIALS; INTERNATIONAL-CONFERENCE; SELECTIVE ATTENTION; OPTIC NEURITIS; HISTORY; LONG; ABNORMALITIES; PERFORMANCE; STATEMENT	Context: The long-term implications of concussive injuries for brain and cognitive health represent a growing concern in the public consciousness. As such, identifying measures sensitive to the subtle yet persistent effects of concussive injuries is warranted. Objective: To investigate how concussion sustained early in life influences visual processing in young adults. We predicted that young adults with a history of concussion would show decreased sensory processing, as noted by a reduction in P1 event-related potential component amplitude. Design: Cross-sectional study. Setting: Research laboratory. Patients or Other Participants: Thirty-six adults (18 with a history of concussion, 18 controls) between the ages of 20 and 28 years completed a pattern-reversal visual evoked potential task while event-related potentials were recorded. Main Outcome Measure(s): The groups did not differ in any demographic variables (all P values > .05), yet those with a concussive history exhibited reduced P1 amplitude compared with the control participants (P =.05). Conclusions: These results suggest that concussion history has a negative effect on visual processing in young adults. Further, upper-level neurocognitive deficits associated with concussion may, in part, result from less efficient downstream sensory capture.	[Moore, Robert D.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA	Broglio, SP (corresponding author), ATC, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Meijer, Anna/K-5118-2016; Hillman, Charles/AAD-4828-2019	Hillman, Charles/0000-0002-3722-5612	National Athletic Trainers' Association Research & Education Foundation	Funding for this project was provided by the National Athletic Trainers' Association Research & Education Foundation.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BRIGELL M, 1994, DOC OPHTHALMOL, V86, P65, DOI 10.1007/BF01224629; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; Brusa A, 2001, BRAIN, V124, P468, DOI 10.1093/brain/124.3.468; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chatrian G. E., 1985, American Journal of EEG Technology, V25, P83; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dockree PM, 2011, INT J PSYCHOPHYSIOL, V82, P53, DOI 10.1016/j.ijpsycho.2011.01.004; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Halliday A M., 1982, EVOKED POTENTIALS CL; Hecht S, 2005, CLIN J SPORT MED, V15, P281, DOI DOI 10.1097/01.jsm.0000172669.85640.05; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hillyard SA, 1998, PHILOS T ROY SOC B, V353, P1257, DOI 10.1098/rstb.1998.0281; HILLYARD SA, 1984, PERCEPT PSYCHOPHYS, V36, P185, DOI 10.3758/BF03202679; Hillyard SA, 1998, P NATL ACAD SCI USA, V95, P781, DOI 10.1073/pnas.95.3.781; Hugdahl K, 1995, J CLIN EXP NEUROPSYC, V17, P833, DOI 10.1080/01688639508402432; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Key APF, 2005, DEV NEUROPSYCHOL, V27, P183, DOI 10.1207/s15326942dn2702_1; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mellow TB, 2011, DOC OPHTHALMOL, V122, P133, DOI 10.1007/s10633-011-9267-0; Moore RD, 2014, J ATHL TRAIN, V49; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; National Center for Injury Prevention and Control, 2002, INJ FACT BOOK 2001 2; Odom JV, 2010, DOC OPHTHALMOL, V120, P111, DOI 10.1007/s10633-009-9195-4; OKEN BS, 1987, ELECTROEN CLIN NEURO, V68, P153, DOI 10.1016/0168-5597(87)90042-6; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Sarnthein J, 2009, CLIN NEUROPHYSIOL, V120, P1835, DOI 10.1016/j.clinph.2009.08.014; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Trip SA, 2006, NEUROIMAGE, V31, P286, DOI 10.1016/j.neuroimage.2005.11.051; Turgeon C, 2011, EAR HEARING, V32, P667, DOI 10.1097/AUD.0b013e31821209d6	57	23	23	1	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2014	49	1					36	41		10.4085/1062-6050-49.1.02			6	Sport Sciences	Sport Sciences	AQ3LX	WOS:000342696500005	24377961	Green Published			2021-06-18	
J	Neipert, L; Pastorek, NJ; Troyanskaya, M; Scheibel, RS; Petersen, NJ; Levin, HS				Neipert, Leslie; Pastorek, Nicholas J.; Troyanskaya, Maya; Scheibel, Randall S.; Petersen, Nancy J.; Levin, Harvey S.			Effect of clinical characteristics on cognitive performance in service members and veterans with histories of blast-related mild traumatic brain injury	BRAIN INJURY			English	Article						Blast; cognitive function; concussion; mild traumatic brain injury; post-traumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; EXECUTIVE FUNCTION; CHRONIC PAIN; MEMORY; SLEEP; AFGHANISTAN; ATTENTION; DEFICITS; IRAQ	Objective: To examine the relationship between clinical characteristics and cognitive performance in service members and veterans with histories of blast-related mild traumatic brain injury (mTBI). Design: This study consisted of 40 Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) service members and veterans; 20 participants reported blast exposure and alteration of mental status consistent with mTBI and 20 participants denied blast exposure and had no history of traumatic brain injury (TBI), but could have experienced extra-cranial injuries. Measures of simple reaction time, processing speed, visual attention, working memory and mathematical processing were used to assess long-term effects of mTBI. Measures of post-traumatic stress symptom severity, pain intensity, sleep difficulty and subjective appraisal of cognition at time of testing were also obtained. Multivariate analyses were conducted with clinical characteristics and mTBI history as predictors of cognitive performance. Results: There was no evidence of an effect of mTBI history on cognitive performance in this sample. However, post-traumatic stress symptom severity was significantly related to two measures of cognitive performance. Conclusions: This study demonstrated the importance of considering the effects of current clinical symptoms (e. g. post-traumatic stress) as possibly having greater influence on current cognitive functioning than the effects of a remote history of mTBI.	[Neipert, Leslie; Pastorek, Nicholas J.; Troyanskaya, Maya; Scheibel, Randall S.; Petersen, Nancy J.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Neipert, Leslie] Univ Houston, Dept Psychol, Houston, TX USA; [Pastorek, Nicholas J.; Troyanskaya, Maya; Scheibel, Randall S.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Petersen, Nancy J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	Pastorek, NJ (corresponding author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd RCL 117, Houston, TX 77030 USA.	nicholas.pastorek@va.gov			Department of Veterans Affairs, Veterans Health AdministrationUS Department of Veterans Affairs; Department of Veterans AffairsUS Department of Veterans Affairs [RRDS B6812C]; Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks Center for Rehabilitation Research; Veterans AffairsUS Department of Veterans Affairs [I01RX000326] Funding Source: NIH RePORTER	This research was supported by the Department of Veterans Affairs, Veterans Health Administration and was funded by: RRDS B6812C (PI- Levin HS) Department of Veterans Affairs; Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks Center for Rehabilitation Research. This research was also supported in part with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX. The authors report no conflicts of interest. The opinions and assumptions described by the authors herein are those of the authors alone and should not be interpreted as being reflective of the official position or policy of the Department of Veterans Affairs or the US government.	[Anonymous], 2007, AUT NEUR ASS METR VE; Bandura A., 1997, SELF EFFICACY EXERCI; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Blackwood HD, 1996, ARCH CLIN NEUROPSYCH, V11, P93; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bremner JD, 2007, PROG BRAIN RES, V167, P171, DOI 10.1016/S0079-6123(07)67012-5; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cleeland CS, 2009, BRIEF PAIN INVENTORY; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P1; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Field A. P, 2009, DISCOVERING STAT USI; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; Heyer EJ, 2000, J CLIN EXP NEUROPSYC, V22, P633; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jorge RE, 1999, NEUROLOGY, V53, P543, DOI 10.1212/WNL.53.3.543; King PR, 2012, J REHABILITATION RES, V49, P79; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; McCrea M, 2008, MILD TRAUMATIC BRAIN; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rath JF, 2011, REHABIL PSYCHOL, V56, P320, DOI 10.1037/a0025817; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Stahle L, 2011, WILD ENVIRON MED, V22, P202, DOI 10.1016/j.wem.2011.02.018; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tanielian T, 2008, INVISIBLE SOUNDS WAR; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Weathers FW, 1993, P ANN C INT SOC TRAU	43	23	23	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	13-14					1667	1674		10.3109/02699052.2014.947623			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT1LY	WOS:000344696600005	25180439				2021-06-18	
J	Reistetter, TA; Karmarkar, AM; Graham, JE; Eschbach, K; Kuo, YF; Granger, CV; Freeman, J; Ottenbacher, KJ				Reistetter, Timothy A.; Karmarkar, Amol M.; Graham, James E.; Eschbach, Karl; Kuo, Yong-Fang; Granger, Carl V.; Freeman, Jean; Ottenbacher, Kenneth J.			Regional Variation in Stroke Rehabilitation Outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Health services; Quality of health care; Rehabilitation	SKILLED NURSING FACILITIES; TRAUMATIC BRAIN-INJURY; LENGTH-OF-STAY; INPATIENT REHABILITATION; GEOGRAPHIC-VARIATION; THERAPY ACTIVITIES; CARE; QUALITY; REPLACEMENT; REIMBURSEMENT	Objective: To examine and describe regional variation in outcomes for persons with stroke receiving inpatient medical rehabilitation. Design: Retrospective cohort design. Setting: Inpatient rehabilitation units and facilities contributing to the Uniform Data System for Medical Rehabilitation from the United States. Participants: Patients (N=143,036) with stroke discharged from inpatient rehabilitation during 2006 and 2007. Interventions: Not applicable. Main Outcome Measures: Community discharge, length of stay (LOS), and discharge functional status ratings (motor, cognitive) across 10 geographic service regions defined by the Centers for Medicare and Medicaid Services (CMS). Results: Approximately 71% of the sample was discharged to the community. After adjusting for covariates, the percentage discharged to the community varied from 79.1% in the Southwest (CMS region 9) to 59.4% in the Northeast (CMS region 2). Adjusted LOS varied by 2.1 days, with CMS region 1 having the longest LOS at 18.3 days and CMS regions 5 and 9 having the shortest at 16.2 days. Conclusions: Rehabilitation outcomes for persons with stroke varied across CMS regions. Substantial variation in discharge destination and LOS remained after adjusting for demographic and clinical characteristics. Archives of Physical Medicine and Rehabilitation 2014;95:29-38 (c) 2014 by the American Congress of Rehabilitation Medicine	[Reistetter, Timothy A.] Univ Texas Med Branch, Dept Occupat Therapy, Galveston, TX 77555 USA; [Karmarkar, Amol M.; Graham, James E.; Ottenbacher, Kenneth J.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Eschbach, Karl; Kuo, Yong-Fang; Freeman, Jean] Univ Texas Med Branch, Dept Internal Med, Sealy Ctr Aging, Galveston, TX 77555 USA; [Eschbach, Karl; Kuo, Yong-Fang; Freeman, Jean] Univ Texas Med Branch, Dept Internal Med, Div Geriatr, Galveston, TX 77555 USA; [Granger, Carl V.] Uniform Data Syst Med Rehabil, Buffalo, NY USA	Reistetter, TA (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	tareiste@utmb.edu	Karmarkar, Amol/E-6030-2011	Karmarkar, Amol/0000-0001-8355-1585; Ottenbacher, Kenneth/0000-0001-5990-3982	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01-HD068513, R24 H12065702, R01-HD069443]; Institute for Translational Sciences at University of Texas Medical Branch; National Institutes of Health Clinical and Translational Science AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ULITR000071]; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1R24HS022134-01]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R24HS022134] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD065702, K01HD068513, R01HD069443] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024832] Funding Source: NIH RePORTER	Supported by the National Institute of Child Health and Human Development, National Institutes of Health (grant nos. K01-HD068513, R24 H12065702); the Institute for Translational Sciences at University of Texas Medical Branch with support in part by a National Institutes of Health Clinical and Translational Science Award (grant no. ULITR000071); the Agency for Healthcare Research and Quality (grant no. 1R24HS022134-01); and the National Institutes of Health (grant no. R01-HD069443). The funding organizations had no role in the design and conduct of the study or the collection, management, analysis, interpretation, and preparation of the manuscript.	Anderson J G, 1973, Med Care, V11, P104, DOI 10.1097/00005650-197303000-00003; Ashton CM, 1999, NEW ENGL J MED, V340, P32, DOI 10.1056/NEJM199901073400106; Atalay A, 2009, INT J REHABIL RES, V32, P48, DOI 10.1097/MRR.0b013e32830d3689; Beninato M, 2006, ARCH PHYS MED REHAB, V87, P32, DOI 10.1016/j.apmr.2005.08.130; Berkowitz SA, 2009, RISK MANAG HEALTHC P, V2, P91, DOI 10.2147/RMHP.S6583; Bhandari VK, 2005, ARCH PHYS MED REHAB, V86, P2081, DOI 10.1016/j.apmr.2005.05.008; Birkmeyer JD, 1998, SURGERY, V124, P917, DOI 10.1016/S0039-6060(98)70017-0; Buntin MB, 2007, ARCH PHYS MED REHAB, V88, P1488, DOI 10.1016/j.apmr.2007.07.023; Buntin MB, 2010, MED CARE, V48, P776, DOI 10.1097/MLR.0b013e3181e359df; Carod-Artal FJ, 2005, BRAIN INJURY, V19, P667, DOI 10.1080/02699050400013626; Carter G. M., 2005, PRELIMINARY ANAL REF; Cooper RA, 2009, HEALTH AFFAIR, V28, pW103, DOI 10.1377/hlthaff.28.1.w103; DeJong G, 2011, PHYS THER, V91, P1826, DOI 10.2522/ptj.20100424; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1284, DOI 10.1016/j.apmr.2009.02.009; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1269, DOI 10.1016/j.apmr.2008.11.021; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1306, DOI 10.1016/j.apmr.2009.04.003; Denti L, 2008, EUR J PHYS REHAB MED, V44, P3; Department of Health and Human Services, 2005, FED REGISTER, V70, P47880; Deutsch A, 2006, STROKE, V37, P1477, DOI 10.1161/01.STR.0000221172.99375.5a; Domanski M, 2004, CONTROL CLIN TRIALS, V25, P553, DOI 10.1016/j.cct.2004.08.005; Donabedian A, 2005, MILBANK Q, V83, P691, DOI 10.1111/j.1468-0009.2005.00397.x; Dowla N, 2010, TOP STROKE REHABIL, V17, P230, DOI 10.1310/tsr1704-230; Fisher E, 2010, TRENDS REGIONAL VIBR; Fisher ES, 2009, NEW ENGL J MED, V360, P849, DOI 10.1056/NEJMp0809794; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FitzGerald JD, 2009, HEALTH SERV RES, V44, P1232, DOI 10.1111/j.1475-6773.2009.00983.x; Foley N, 2012, DISABIL REHABIL, V34, P2132, DOI 10.3109/09638288.2012.676145; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; Freburger JK, 2011, ARCH PHYS MED REHAB, V92, P1220, DOI 10.1016/j.apmr.2011.03.019; Freburger JK, 2011, ARTHRIT CARE RES, V63, P1020, DOI 10.1002/acr.20477; Gage B, 2008, EXAMINING RELATIONSH; Graham JE, 2009, ARCH PHYS MED REHAB, V90, P1110, DOI 10.1016/j.apmr.2009.01.014; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; Hoenig H, 2010, TOP STROKE REHABIL, V17, P239, DOI 10.1310/tsr1704-239; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Howard VJ, 2005, NEUROEPIDEMIOLOGY, V25, P135, DOI 10.1159/000086678; Ilet PA, 2010, ARCH PHYS MED REHAB, V91, P788, DOI 10.1016/j.apmr.2009.11.028; Kane RL, 2002, HEALTH SERV RES, V37, P667, DOI 10.1111/1475-6773.00043; Kane RL, 2013, MODELS CAUSAL THINKI, P25; Krupski TL, 2005, J CLIN ONCOL, V23, P7881, DOI 10.1200/JCO.2005.08.755; Latham NK, 2006, AM J OCCUP THER, V60, P369, DOI 10.5014/ajot.60.4.369; Medicare Payment Advisory Commission, 2011, REP C MED PAYM POL; MedPAC, 2012, REP C MED PAYM POL; Mutai H, 2012, GERIATR GERONTOL INT, V12, P215, DOI 10.1111/j.1447-0594.2011.00747.x; Ottenbacher KJ, 2004, JAMA-J AM MED ASSOC, V292, P1687, DOI 10.1001/jama.292.14.1687; Ottenbacher KJ, 2001, ARCH PHYS MED REHAB, V82, P1367, DOI 10.1053/apmr.2001.26088; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Reistetter TA, 2011, DIABETES CARE, V34, P1375, DOI 10.2337/dc10-2220; Reistetter TA, 2010, ARCH PHYS MED REHAB, V91, P345, DOI 10.1016/j.apmr.2009.11.010; Rosenthal T, 2012, ANNU REV MED, V63, P493, DOI 10.1146/annurev-med-050710-134438; Sporer SM, 2006, J AM ACAD ORTHOP SUR, V14, P246, DOI 10.5435/00124635-200604000-00006; Strasser DC, 2010, TOP STROKE REHABIL, V17, P225, DOI 10.1310/tsr1704-225; Tian WQ, 2009, ARCH PHYS MED REHAB, V90, P1260, DOI 10.1016/j.apmr.2008.10.035; Turhan N, 2009, NEUROREHABILITATION, V24, P321, DOI 10.3233/NRE-2009-0485; UB Foundation Activities, INP REH FAC PAT ASS; US Department of Education, 2007, FED REG, V72, P44284; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; Wennberg DE, 2003, HLTH AFF MILWO S JUL; Wennberg John E, 2002, Health Aff (Millwood), VSuppl Web Exclusives, pW96; Wennberg John E, 2004, Spec Law Dig Health Care Law, P9; Zhang YT, 2012, NEW ENGL J MED, V367, P1724, DOI 10.1056/NEJMsa1203980	61	23	23	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2014	95	1					29	38		10.1016/j.apmr.2013.07.018			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	289KI	WOS:000329681000004	23921200	Green Accepted			2021-06-18	
J	Tsaousides, T; D'Antonio, E; Varbanova, V; Spielman, L				Tsaousides, Theodore; D'Antonio, Emily; Varbanova, Vladimira; Spielman, Lisa			Delivering group treatment via videoconference to individuals with traumatic brain injury: A feasibility study	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Telerehabilitation; Emotion regulation; Group treatment; Cognitive-behavioural therapy; Videoconferencing	SCHEDULED TELEPHONE INTERVENTION; COGNITIVE-BEHAVIOR THERAPY; EXECUTIVE DYSFUNCTION; EMOTION REGULATION; REHABILITATION; PROGRAM; EFFICACY; TELEREHABILITATION; SATISFACTION; ADOLESCENTS	The objective was to assess the feasibility of delivering a group treatment to improve emotional regulation via videoconferencing to individuals with traumatic brain injury (TBI). A pre-post feasibility study was undertaken. Seven individuals with TBI were recruited at a brain injury research centre in an urban medical centre. The main measures were therapist assessment of session-by-session progress and feasibility, Difficulties in Emotion Regulation Scale (DERS), Brain Injury Rehabilitation Trust Regulation of Emotions Questionnaire (BREQ), Satisfaction with Therapy and Therapist Scale (STTS), and exit interview. Attendance across sessions and participants was over 90%. Adequate skill acquisition and ease of use of the technology were demonstrated. Self-reported satisfaction with treatment was high. Participants noted several benefits in terms of the treatment delivery modality. There was no change is self-reported emotional dysregulation. This is the first study to report the use of videoconferencing for the delivery of group treatment to individuals with TBI. The exceptional compliance and self-reported satisfaction suggest that this treatment delivery option could be a viable alternative for increasing access to healthcare in this population. The findings of the study supported the development of a large clinical trial to assess treatment effectiveness.	[Tsaousides, Theodore; D'Antonio, Emily; Varbanova, Vladimira; Spielman, Lisa] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA	Tsaousides, T (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, One Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	theodore.tsaousides@mountsinai.org			National Institute on Disability and Rehabilitation Research [H133P100016, H133A070033]	This research was funded by National Institute on Disability and Rehabilitation Research (grants H133P100016 and H133A070033) carried out at the Brain Injury Research Center, Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai.	Arundine A, 2012, J HEAD TRAUMA REHAB, V27, P104, DOI 10.1097/HTR.0b013e3182125591; Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bell KR, 2011, ARCH PHYS MED REHAB, V92, P1552, DOI 10.1016/j.apmr.2011.05.018; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bergquist T, 2008, BRAIN INJURY, V22, P891, DOI 10.1080/02699050802405487; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Brennan David M, 2011, Telemed J E Health, V17, P662, DOI 10.1089/tmj.2011.0036; Cantor J, 2014, ARCH PHYS MED REHAB, V95, P1, DOI 10.1016/j.apmr.2013.08.005; Cattran C, 2011, J CLIN EXP NEUROPSYC, V33, P672, DOI 10.1080/13803395.2010.550603; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; DZurilla T. J., 2002, SOCIAL PROBLEM SOLVI; First M., 1997, USERS GUIDE STRUCTUR; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; GLADSTEIN GA, 1974, COUNS PSYCHOL, V4, P34, DOI 10.1177/001100007400400307; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Greene CJ, 2010, J CONSULT CLIN PSYCH, V78, P746, DOI 10.1037/a0020158; Harrison A, 2010, PSYCHOL MED, V40, P1887, DOI 10.1017/S0033291710000036; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Johnstone B, 2003, NEUROREHABILITATION, V18, P197; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kazantzis N, 2004, J CLIN PSYCHOL, V60, P627, DOI 10.1002/jclp.10239; King VL, 2009, J SUBST ABUSE TREAT, V36, P331, DOI 10.1016/j.jsat.2008.06.011; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Man DWK, 2006, BRAIN INJURY, V20, P959, DOI 10.1080/02699050600909789; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Morland LA, 2010, J CLIN PSYCHIAT, V71, P855, DOI 10.4088/JCP.09m05604blu; Ng EMW, 2013, BRAIN INJURY, V27, P548, DOI 10.3109/02699052.2013.766927; Oei TPS, 1999, AUST NZ J PSYCHIAT, V33, P748, DOI 10.1080/j.1440-1614.1999.00628.x; Radley DC, 2012, NEW ENGL J MED, V367, P3, DOI 10.1056/NEJMp1204516; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Schoenberg MR, 2008, PROF PSYCHOL-RES PR, V39, P169, DOI 10.1037/0735-7028.39.2.169; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Simpson GK, 2011, J HEAD TRAUMA REHAB, V26, P290, DOI 10.1097/HTR.0b013e3182225250; Soong W, 2005, INT J REHABIL RES, V28, P341, DOI 10.1097/00004356-200512000-00006; Staples AM, 2012, J ANXIETY DISORD, V26, P385, DOI 10.1016/j.janxdis.2012.01.005; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Tsaousides T, 2011, 2011 INT NEUR SOC MI; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Wechsler D., 2011, WECHLSER ABBREVIATED; Williams AD, 2012, BRIT J CLIN PSYCHOL, V51, P223, DOI 10.1111/j.2044-8260.2011.02022.x; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Yalom I.D., 1995, THEORY PRACTICE GROU	51	23	24	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2014	24	5					784	803		10.1080/09602011.2014.907186			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AN1UE	WOS:000340368400007	24810148				2021-06-18	
J	Graves, JM; Whitehill, JM; Stream, JO; Vavilala, MS; Rivara, FP				Graves, Janessa M.; Whitehill, Jennifer M.; Stream, Joshua O.; Vavilala, Monica S.; Rivara, Frederick P.			Emergency department reported head injuries from skiing and snowboarding among children and adolescents, 1996-2010	INJURY PREVENTION			English	Article							TRAUMATIC BRAIN-INJURY; HELMET USE; RISK-FACTORS; SKIERS; CONCUSSION; OUTCOMES; PARKS; NECK	Objectives To evaluate the incidence of snow-sports-related head injuries among children and adolescents reported to emergency departments (EDs), and to examine the trend from 1996 to 2010 in ED visits for snow-sports-related traumatic brain injury (TBI) among children and adolescents. Methods A retrospective, population-based cohort study was conducted using data from the National Electronic Injury Surveillance System for patients (aged 17years) treated in EDs in the USA from 1996 to 2010, for TBIs associated with snow sports (defined as skiing or snowboarding). National estimates of snow sports participation were obtained from the National Ski Area Association and utilised to calculate incidence rates. Analyses were conducted separately for children (aged 4-12years) and adolescents (aged 13-17 years). Results An estimated number of 78538 (95% CI 66350 to 90727) snow sports-related head injuries among children and adolescents were treated in EDs during the 14-year study period. Among these, 77.2% were TBIs (intracranial injury, concussion or fracture). The annual average incidence rate of TBI was 2.24 per 10000 resort visits for children compared with 3.13 per 10000 visits for adolescents. The incidence of TBI increased from 1996 to 2010 among adolescents (p<0.003). Conclusions Given the increasing incidence of TBI among adolescents and the increased recognition of the importance of concussions, greater awareness efforts may be needed to ensure safety, especially helmet use, as youth engage in snow sports.	[Graves, Janessa M.; Whitehill, Jennifer M.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Graves, Janessa M.; Whitehill, Jennifer M.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98104 USA; [Stream, Joshua O.] Univ Utah, Sch Med, Dept Anesthesiol, Salt Lake City, UT USA; [Vavilala, Monica S.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA; [Rivara, Frederick P.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98104 USA	Graves, JM (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, 325 9th Ave,Box 359960, Seattle, WA 98104 USA.	janessa@uw.edu	Graves, Janessa M./J-2596-2019	Graves, Janessa M./0000-0002-7659-2634	Wilderness Medical Society Research-in-Training Award; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD057822-01A2]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD057822] Funding Source: NIH RePORTER	This research is supported in part by the Wilderness Medical Society Research-in-Training Award (Graves). JMG and JMW receive fellowship support from National Institute of Child Health and Human Development (T32 HD057822-01A2).	Ackery A, 2007, INJURY PREV, V13, P368, DOI 10.1136/ip.2007.017285; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brooks MA, 2010, INJURY PREV, V16, P119, DOI 10.1136/ip.2009.022608; Burtscher M, 2008, CLIN J SPORT MED, V18, P355, DOI 10.1097/MJT.0b013e31815fd0fe; Cusimano MD, 2010, BRIT J SPORT MED, V44, P781, DOI 10.1136/bjsm.2009.070573; Cusimano MD, 2010, JAMA-J AM MED ASSOC, V303, P661, DOI 10.1001/jama.2010.147; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goulet C, 2007, CAN J PUBLIC HEALTH, V98, P402, DOI 10.1007/BF03405428; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hagel BE, 2003, CAN J PUBLIC HEALTH, V94, P458, DOI 10.1007/BF03405085; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harlos S, 1999, Inj Prev, V5, P183; Hentschel S, 2001, CAN J NEUROL SCI, V28, P42; Klein KS, 2005, INJURY PREV, V11, P288, DOI 10.1136/ip.2004.007013; Lawrence L, 2008, PEDIATR EMERG CARE, V24, P219, DOI 10.1097/PEC.0b013e31816a9f0a; Levy AS, 2007, HEALTH PROMOT PRACT, V8, P257, DOI 10.1177/1524839906292178; McBeth PB, 2009, AM J SURG, V197, P560, DOI [10.1016/j.amjsurg.2008.12.016, 10.1016/j.amjsurg.2008.08.010]; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; National Ski Area Association (NSAA), STUD SHOWS MOST SKIE; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Stata Statistics/Data Analysis Software, 2011, STAT STAT DAT AN SOF; State of New Jersey, 2011, HELM REQ DOWNH SKIER, P1; State of Washington, 1928, YOUTH SPORTS CONC HE; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Todis B, 2011, J HEAD TRAUMA REHAB, V26, P138, DOI 10.1097/HTR.0b013e3181e5a87a; US Consumer Product Safety Commission, 1999, SKIING HELM EV POT R; Wasden CC, 2009, J TRAUMA, V67, P1022, DOI 10.1097/TA.0b013e3181b0d559; Xiang HY, 2007, BRAIN INJURY, V21, P293, DOI 10.1080/02699050701311034; Xiang HY, 2005, J TRAUMA, V58, P112, DOI 10.1097/01.TA.0000151270.26634.DD; Yang J, 2008, BRIT J SPORT MED, V42, P664, DOI 10.1136/bjsm.2007.040923	39	23	24	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	DEC	2013	19	6					399	404		10.1136/injuryprev-2012-040727			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	255OG	WOS:000327249100006	23513009	Green Accepted			2021-06-18	
J	Lemke, S; Cockerham, GC; Glynn-Milley, C; Cockerham, KP				Lemke, Sonne; Cockerham, Glenn C.; Glynn-Milley, Catherine; Cockerham, Kimberly P.			Visual Quality of Life in Veterans With Blast-Induced Traumatic Brain Injury	JAMA OPHTHALMOLOGY			English	Article							FUNCTION QUESTIONNAIRE; MULTIPLE-SCLEROSIS; EYE; VISION; DYSFUNCTION; PEOPLE; NEI-VFQ-25; TYPE-1; VFQ-25	IMPORTANCE Traumatic brain injury (TBI) is an important cause of morbidity worldwide, with increasing awareness of the role of blast exposure in military and civilian casualties. Visual problems have been reported in TBI and may affect functioning and quality of life. OBJECTIVE To evaluate the 25-item National Eye Institute Visual Functioning Questionnaire and Neuro-Ophthalmic Supplement for utility in assessing the effect of blast exposure on perceived visual functioning among veterans with TBI. DESIGN, SETTING, AND PARTICIPANTS Observational cohort study from a tertiary care Veterans Health Administration hospital. Reported visual quality of life was compared with existing norms, and relationships between perceived visual quality and ocular injury, diplopia, visual performance, and blast exposure characteristics were examined. Participants included inpatients with blast-induced TBI who underwent baseline examination between December 7, 2006, and January 11, 2012, at a multiple-trauma rehabilitation center and who had at least 1 intact eye and were able to undergo psychometric testing and ocular examination. Among 64 sequentially eligible patients, 60 completed visual quality testing,1 declined study participation, and 3 were evaluated prior to inclusion of visual quality testing in the protocol. Thirty-nine patients returned for outpatient follow-up, with a median test-retest interval of 11 months. EXPOSURE Combat blast exposure with documented TBI. MAIN OUTCOMES AND MEASURES Composite and subscale scores on the 25-item National Eye Institute Visual Functioning Questionnaire and Neuro-Ophthalmic Supplement. RESULTS Both tests had high test-retest reliability. Blast-exposed veterans reported significantly poorer visual quality compared with healthy samples and some patient samples with known eye disease. Scores tended to be worse for participants with identified visual performance deficits (poorer visual acuity or spatial contrast sensitivity, visual field depression or defects). Scores were not related to the extent of ocular injury or to blast exposure characteristics such as use of protective eyewear or TBI severity level. CONCLUSIONS AND RELEVANCE Individuals with blast-induced TBI reliably completed both tests and reported significant decrements in their subjective visual experiences. Measures of subjective visual quality may be useful to identify patients needing additional visual or neurologic evaluation and to monitor the effect of visual rehabilitation on patients with blast-related visual disabilities.	[Lemke, Sonne] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA; [Cockerham, Glenn C.] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA; [Cockerham, Glenn C.; Glynn-Milley, Catherine; Cockerham, Kimberly P.] VA Palo Alto Hlth Care Syst, Ophthalmol Serv, Palo Alto, CA 94304 USA; [Cockerham, Glenn C.; Cockerham, Kimberly P.] Stanford Univ, Sch Med, Dept Ophthalmol, Palo Alto, CA 94304 USA	Cockerham, GC (corresponding author), VA Palo Alto Hlth Care Syst, Ophthalmol Serv, 112-B1,3801 Miranda Ave, Palo Alto, CA 94304 USA.	glenn.cockerham@va.gov	Cockerham, Kimberly/AAR-5917-2021		Veterans AdministrationUS Department of Veterans Affairs [C5O18R]	This work was supported by Merit Review Award C5O18R from the Veterans Administration.	Bradley EA, 2006, OPHTHALMOLOGY, V113, P1450, DOI 10.1016/j.ophtha.2006.02.060; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Clemons TE, 2008, INVEST OPHTH VIS SCI, V49, P4340, DOI 10.1167/iovs.08-1749; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Cusick M, 2005, AM J OPHTHALMOL, V139, P1042, DOI 10.1016/j.ajo.2005.01.008; Defense and Veterans Brain Injury Center, DOD WORLDWIDE NUMBER; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gal RL, 2008, OPHTHALMOLOGY, V115, P1079, DOI 10.1016/j.ophtha.2007.08.004; Gall C, 2009, INVEST OPHTH VIS SCI, V50, P2765, DOI 10.1167/iovs.08-2519; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Holmes JM, 2005, OPHTHALMOLOGY, V112, P2035, DOI 10.1016/j.ophtha.2005.06.013; Hyman LG, 2005, OPHTHALMOLOGY, V112, P1505, DOI 10.1016/j.ophtha.2005.03.028; Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P733, DOI 10.1001/archopht.119.5.733; Kymes SM, 2008, AM J OPHTHALMOL, V145, P611, DOI 10.1016/j.ajo.2007.11.017; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Ma SL, 2002, AM J OPHTHALMOL, V133, P686, DOI 10.1016/S0002-9394(02)01337-5; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maguire M, 2004, OPHTHALMOLOGY, V111, P1307; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Murray CJ, 1996, GLOBAL HEALTH STATIS; Noble J, 2006, AM J OPHTHALMOL, V142, P464, DOI 10.1016/j.ajo.2006.04.051; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Optic Neuritis Study Group, 2008, OPHTHALMOLOGY, V115, pe5; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Papageorgiou E, 2007, GRAEF ARCH CLIN EXP, V245, P1749, DOI 10.1007/s00417-007-0644-z; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Pineles SL, 2011, AM J OPHTHALMOL, V152, P133, DOI 10.1016/j.ajo.2011.01.023; Raphael BA, 2006, AM J OPHTHALMOL, V142, P1026, DOI 10.1016/j.ajo.2006.06.060; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schimiti RB, 2002, OPHTHALMOLOGY, V109, P2084, DOI 10.1016/S0161-6420(02)01253-8; Shao X, 2011, J CLIN EXP OPHTHALMO, V2, DOI [10.4172/2155-9570.1000117, DOI 10.4172/2155-9570.1000117]; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; VectorVision, CONTRAST SENSITIVITY; Veterans Health Administration, 2008, PERFORMANCE OF TRAUM; Vitale Susan, 2004, Health Qual Life Outcomes, V2, P44, DOI 10.1186/1477-7525-2-44; Vitale Susan, 2003, International Ophthalmology Clinics, V43, P17; Walline JJ, 2000, OPTOMETRY VISION SCI, V77, P648, DOI 10.1097/00006324-200012000-00011; Walter SD, 2012, OPHTHALMOLOGY, V119, P1250, DOI 10.1016/j.ophtha.2011.11.032; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	47	23	23	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6165	2168-6173		JAMA OPHTHALMOL	JAMA Ophthalmol.	DEC	2013	131	12					1602	1609		10.1001/jamaophthalmol.2013.5028			8	Ophthalmology	Ophthalmology	291SU	WOS:000329850600017	24136237	Bronze			2021-06-18	
J	Wang, HQ; Xin, T; Sun, XB; Wang, SZ; Guo, H; Holton-Burke, C; Pang, Q				Wang, Huaqing; Xin, Tao; Sun, Xiubin; Wang, Shuzhen; Guo, Hua; Holton-Burke, Conor; Pang, Qi			Post-traumatic seizures-A prospective, multicenter, large case study after head injury in China	EPILEPSY RESEARCH			English	Article						Post-traumatic seizures; Prospective; Multicenter; Risk factors	BRAIN-INJURY; RISK-FACTORS; EPILEPSY; EPIDEMIOLOGY; MODEL	Background: Post-traumatic seizures (PTS) is a well-known sequela of traumatic brain injury (TBI). The risk factors for PTS are still controversial. Studies on PTS in China are rare and no large prospective, multicenter-based studies are available. Methods: Data were collected from 15 hospitals prospectively using standardized structured questionnaires in Shandong, a province in China with a follow-up of 2 years. Results: A total of 3093 traumatic brain injury patients were validated and entered in this analysis. After 6 months of follow-up, 181 (59.9%) patients were identified as having PTS. The number were 236 (78.1%) and 302 after 1 year and 2 years' follow-up, respectively. The cumulative 24-month-rate of PTS is 9.8%. Among these 302 patients, 242 were male (80.1%) and 60 female (19.9%). A marked peak was seen in the young people group aged 15-24 (27.8%). Three factors were identified as significant in the multivariate model of PTS: Frontal-temporal lobar contusion, Linear fracture and Severity of TBI measured by initial Glasgow Coma Scale (GCS). Conclusion: This prospective cohort study shows the epidemiologic features and risk factors of PTS in China. Frontal-temporal lobar contusion, linear fracture and severity of TBI measured by initial Glasgow Coma Scale (GCS) are risk factors for PTS. It is essential to establish a standard surveillance system for PTS. (C) 2013 Elsevier B.V. All rights reserved.	[Wang, Huaqing; Xin, Tao; Guo, Hua; Pang, Qi] Shandong Univ, Prov Hosp, Dept Neurosurg, Jinan 250021, Shandong, Peoples R China; [Sun, Xiubin] Shandong Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Jinan 250012, Shandong, Peoples R China; [Wang, Shuzhen] Shandong Univ, Qianfoshan Hosp, Dept Paediat, Jinan 250014, Shandong, Peoples R China; [Holton-Burke, Conor] Whitman Coll, Dept Biochem Biophys & Mol Biol, Walla Walla, WA 99362 USA	Pang, Q (corresponding author), Shandong Univ, Prov Hosp, Dept Neurosurg, 324 Jin Wu Wei Qi Rd, Jinan 250021, Shandong, Peoples R China.	pangqisdu@yahoo.com			Chinese national critical neuro-psychiatrical illness early warning system: risk factors and model development; Chinese Government [2008BAR52B03]	This study was supported by a grant called "Chinese national critical neuro-psychiatrical illness early warning system: risk factors and model development" which was funded by the Chinese Government (Grant no. 2008BAR52B03). The authors thank the doctors and patients in 15 hospitals of Shandong province in China. The authors also thank Dr. Anna Da Fonseca for editorial support.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Dakin K A, 1993, Seizure, V2, P21, DOI 10.1016/S1059-1311(05)80098-6; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; Jiang Taipeng, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P392; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Schutze M, 1999, ZBL NEUROCHIR, V60, P163; Sharma V, 2007, SEIZURE-EUR J EPILEP, V16, P680, DOI 10.1016/j.seizure.2007.05.012; Thapa A, 2010, SEIZURE-EUR J EPILEP, V19, P211, DOI 10.1016/j.seizure.2010.02.004; Wang HC, 2008, J TRAUMA, V64, P883, DOI 10.1097/TA.0b013e31804a7fa4; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; Zhao YQ, 2012, SEIZURE-EUR J EPILEP, V21, P322, DOI 10.1016/j.seizure.2012.02.007	19	23	28	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	DEC	2013	107	3					272	278		10.1016/j.eplepsyres.2013.10.006			7	Clinical Neurology	Neurosciences & Neurology	295DP	WOS:000330097100009	24239245				2021-06-18	
J	Ondruschka, B; Pohlers, D; Sommer, G; Schober, K; Teupser, D; Franke, H; Dressler, J				Ondruschka, Benjamin; Pohlers, Dirk; Sommer, Gerald; Schober, Kristin; Teupser, Daniel; Franke, Heike; Dressler, Jan			S100B and NSE as Useful Postmortem Biochemical Markers of Traumatic Brain Injury in Autopsy Cases	JOURNAL OF NEUROTRAUMA			English	Article						NSE; postmortem biochemistry; S100B; survival time; traumatic brain injury	NEURON-SPECIFIC ENOLASE; FIBRILLARY ACIDIC PROTEIN; SERUM S-100B PROTEIN; MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; CHEMISTRY UPDATE; HEAD-INJURY; NEUROENDOCRINE CELLS; MOLECULAR MARKER; DAMAGE	Postmortem analysis of relevant biomarkers might aid in characterizing causes of death and survival times in legal medicine. However, there are still no sufficiently established results of practical postmortem biochemical investigations in cases of traumatic brain injury (TBI). The two biomarkersS100 protein subunit B (S100B) and neuronal specific enolase (NSE)could be of special interest. Therefore, the aim of the present study was to investigate changes in their postmortem levels for further determination of brain damage in TBI. In 17 cases of TBI (average age, 58 years) and in 23 controls with different causes of death (average age, 59 years), serum and cerebrospinal fluid (CSF) samples were analyzed with a chemiluminescence immunoassay for marker expression. An increase in serum S100B, as well as a subsequent decrease after survival times>4 days, were detected in TBI cases (p<0.01). CSF NSE values >6,000ng/mL and CSF S100B levels >10,000ng/mL seem to indicate a TBI survival time of at least 15min (p<0.01). It is of particular interest that CSF S100B levels (p<0.01) and serum S100B levels (p<0.05) as well as CSF NSE values (p<0.01) were significantly higher in TBI cases in comparison to the controls, especially when compared with fatal non-head injuries. In conclusion, the present findings emphasize that S100B and NSE are useful markers in postmortem biochemistry in cases of suspected TBI. Further, S100B may be helpful to estimate the survival time of fatal injuries in legal medicine.	[Ondruschka, Benjamin; Schober, Kristin; Dressler, Jan] Univ Leipzig, Inst Legal Med, D-04109 Leipzig, Germany; [Sommer, Gerald] Univ Leipzig, Innovat Ctr Comp Assisted Surg, D-04109 Leipzig, Germany; [Franke, Heike] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, Fac Med, D-04109 Leipzig, Germany; [Pohlers, Dirk] Klinikum Chemnitz, Ctr Diagnost GmbH, Chemnitz, Germany; [Schober, Kristin] German Airforce Inst Aviat Med, Furstenfeldbruck, Germany; [Teupser, Daniel] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany; [Teupser, Daniel] Univ Munich, Inst Lab Med, Munich, Germany	Ondruschka, B (corresponding author), Univ Leipzig, Inst Legal Med, D-04109 Leipzig, Germany.	benjamin.ondruschka@medizin.uni-leipzig.de					Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BARGER SW, 1992, J BIOL CHEM, V267, P9689; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baydas G, 2003, FREE RADICAL BIO MED, V35, P797, DOI 10.1016/S0891-5849(03)00408-8; Beaudeux JL, 2000, CLIN CHEM, V46, P989; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Casmiro M, 2005, EUR J NEUROL, V12, P369, DOI 10.1111/j.1468-1331.2004.01021.x; COE JI, 1993, AM J FOREN MED PATH, V14, P91, DOI 10.1097/00000433-199306000-00001; Cooper E. H., 1987, LUNG CANCER, V3, P61, DOI DOI 10.1016/S0169-5002(87)80001-6; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAIMOTO H, 1985, LAB INVEST, V52, P257; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Janeczko K., 1991, BRAIN RES, V565, P86; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Li D. R., 2006, LEGAL MED, V8, P78; Li Dong-Ri, 2006, Legal Medicine, V8, P71, DOI 10.1016/j.legalmed.2005.07.004; Li Dong-Ri, 2009, Leg Med (Tokyo), V11 Suppl 1, pS273, DOI 10.1016/j.legalmed.2009.02.042; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; Maeda H, 2011, LEGAL MED-TOKYO, V13, P55, DOI 10.1016/j.legalmed.2010.12.005; Maeda Hitoshi, 2009, Leg Med (Tokyo), V11 Suppl 1, pS46, DOI 10.1016/j.legalmed.2009.01.048; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; MURRAY GI, 1993, J CLIN PATHOL, V46, P993, DOI 10.1136/jcp.46.11.993; Nogami M, 1999, Leg Med (Tokyo), V1, P76, DOI 10.1016/S1344-6223(99)80016-9; Oehmichen Manfred, 2003, Leg Med (Tokyo), V5, P190, DOI 10.1016/S1344-6223(03)00077-4; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; Ohrt-Nissen S, 2011, EMERG MED J, V28, P941, DOI 10.1136/emj.2010.091363; OSUNA E, 1992, FORENSIC SCI INT, V52, P193, DOI 10.1016/0379-0738(92)90107-8; Palmiere C, 2012, INT J LEGAL MED, V126, P199, DOI 10.1007/s00414-011-0614-1; Palmiere C, 2012, INT J LEGAL MED, V126, P187, DOI 10.1007/s00414-011-0625-y; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Raabe A, 2003, CLIN CHEM LAB MED, V41, P700, DOI 10.1515/CCLM.2003.106; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Reali C, 2005, J NEUROSCI RES, V81, P677, DOI 10.1002/jnr.20584; Romero-Aleman MD, 2003, J NEUROBIOL, V57, P54, DOI 10.1002/neu.10258; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schiavi Paolo, 2012, Acta Biomed, V83, P5; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Sen J, 2007, J NEUROSCI RES, V85, P1373, DOI 10.1002/jnr.21211; Sorci G, 2004, J CELL PHYSIOL, V199, P274, DOI 10.1002/jcp.10462; Staffa K, 2012, J NEUROTRAUM, V29, P2716, DOI 10.1089/neu.2011.2246; STEINBERG R, 1983, NEUROCHEM INT, V5, P145, DOI 10.1016/0197-0186(83)90021-9; Steiner J, 2006, J NEUROL NEUROSUR PS, V77, P1284, DOI 10.1136/jnnp.2006.093427; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; SUZUKI F, 1983, J BIOCHEM-TOKYO, V94, P1707; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vasquez M. D., 1995, AM J FOREN MED PATH, V16, P210; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Wojtczak-Soska K, 2010, CARDIOL J, V17, P532; WYLER D, 1994, INT J LEGAL MED, V106, P194, DOI 10.1007/BF01371336; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	81	23	33	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2013	30	22					1862	1871		10.1089/neu.2013.2895			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	243PH	WOS:000326328400004	23796187				2021-06-18	
J	Clerc, P; Young, CA; Bordt, EA; Grigore, AM; Fiskum, G; Polster, BM				Clerc, Pascaline; Young, Christina A.; Bordt, Evan A.; Grigore, Alina M.; Fiskum, Gary; Polster, Brian M.			Magnesium Sulfate Protects Against the Bioenergetic Consequences of Chronic Glutamate Receptor Stimulation	PLOS ONE			English	Article							SPARE RESPIRATORY CAPACITY; TRAUMATIC BRAIN-INJURY; NEURONAL CULTURES; OXIDATIVE STRESS; EXCITOTOXICITY; CALCIUM; DEATH; ACTIVATION; APOPTOSIS; MITOCHONDRIA	Extracellular glutamate is elevated following brain ischemia or trauma and contributes to neuronal injury. We tested the hypothesis that magnesium sulfate (MgSO4, 3 mM) protects against metabolic failure caused by excitotoxic glutamate exposure. Rat cortical neuron preparations treated in medium already containing a physiological concentration of Mg2+ (1 mM) could be segregated based on their response to glutamate (100 mu M). Type I preparations responded with a decrease or small transient increase in oxygen consumption rate (OCR). Type II neurons responded with >50% stimulation in OCR, indicating a robust response to increased energy demand without immediate toxicity. Pre-treatment with MgSO4 improved the initial bioenergetic response to glutamate and ameliorated subsequent loss of spare respiratory capacity, measured following addition of the uncoupler FCCP, in Type I but not Type II neurons. Spare respiratory capacity in Type I neurons was also improved by incubation with MgSO4 or NMDA receptor antagonist MK801 in the absence of glutamate treatment. This finding indicates that the major difference between Type I and Type II preparations is the amount of endogenous glutamate receptor activity. Incubation of Type II neurons with 5 mM glutamate prior to excitotoxic (100 mM) glutamate exposure recapitulated a Type I phenotype. MgSO4 protected against an excitotoxic glutamate-induced drop in neuronal ATP both with and without prior 5 mu M glutamate exposure. Results indicate that MgSO4 protects against chronic moderate glutamate receptor stimulation and preserves cellular ATP following treatment with excitotoxic glutamate.	[Polster, Brian M.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA	Polster, BM (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.	bpolster@anes.umm.edu		Polster, Brian/0000-0003-2571-7510	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS064978, P01HD016596]; National Institute of Child Health and Human Development/United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064978] Funding Source: NIH RePORTER	This research was supported by the National Institute of Neurological Disorders and Stroke/the National Institutes of Health (www.nih.gov, grant number R01NS064978) and by the National Institute of Child Health and Human Development/the National Institutes of Health (www.nih.gov, grant number P01HD016596). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramov AY, 2008, BBA-BIOENERGETICS, V1777, P953, DOI 10.1016/j.bbabio.2008.04.017; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Altura BT, 1997, NEUROSCI LETT, V230, P37, DOI 10.1016/S0304-3940(97)00471-0; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Blitzblau R, 1996, EUR J NEUROSCI, V8, P1840, DOI 10.1111/j.1460-9568.1996.tb01328.x; Castilho RF, 1998, J NEUROSCI, V18, P10277; Chen YC, 2008, J NEUROSCI METH, V171, P239, DOI 10.1016/j.jneumeth.2008.03.013; Clerc P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034465; Deshpande LS, 2008, EUR J PHARMACOL, V583, P73, DOI 10.1016/j.ejphar.2008.01.025; Gerencser AA, 2009, J NEUROCHEM, V110, P990, DOI 10.1111/j.1471-4159.2009.06194.x; Gleichmann M, 2009, J NEUROCHEM, V109, P644, DOI 10.1111/j.1471-4159.2009.05997.x; Greene MF, 2003, NEW ENGL J MED, V348, P275, DOI 10.1056/NEJMp020166; Hallak M, 1998, MAGNESIUM RES, V11, P117; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Jekabsons MB, 2004, J BIOL CHEM, V279, P32989, DOI 10.1074/jbc.M401540200; Kovac S, 2012, J CELL SCI, V125, P1796, DOI 10.1242/jcs.099176; Lampl Y, 1998, J NEUROL, V245, P584, DOI 10.1007/s004150050249; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; Nicholls DG, 2009, BIOCHEM SOC T, V37, P1385, DOI 10.1042/BST0371385; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Panov A, 1996, BIOCHEMISTRY-US, V35, P427, DOI 10.1021/bi952101t; Rodriguez-Zavala JS, 1998, J BIOL CHEM, V273, P7850, DOI 10.1074/jbc.273.14.7850; Stoica BA, 2005, MOL CELL NEUROSCI, V29, P355, DOI 10.1016/j.mcn.2005.02.009; Stout AK, 1998, NAT NEUROSCI, V1, P366; van den Bergh WM, 2003, NEUROSURGERY, V52, P276, DOI 10.1227/01.NEU.0000043984.42487.0E; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Xu Minhui, 2002, Chin J Traumatol, V5, P361; Yadava N, 2007, J NEUROSCI, V27, P7310, DOI 10.1523/JNEUROSCI.0212-07.2007; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Zhu HD, 2005, EXP NEUROL, V193, P361, DOI 10.1016/j.expneurol.2005.01.022	31	23	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2013	8	11							e79982	10.1371/journal.pone.0079982			11	Multidisciplinary Sciences	Science & Technology - Other Topics	255QK	WOS:000327254700168	24236167	DOAJ Gold, Green Published			2021-06-18	
J	Casey-Trott, TM; Millman, ST; Turner, PV; Nykamp, SG; Widowski, TM				Casey-Trott, T. M.; Millman, S. T.; Turner, P. V.; Nykamp, S. G.; Widowski, T. M.			Effectiveness of a nonpenetrating captive bolt for euthanasia of piglets less than 3 d of age	JOURNAL OF ANIMAL SCIENCE			English	Article						animal welfare; captive bolt; euthanasia; insensibility; neonate; piglet	DETERMINING BRAIN-DEATH; CERVICAL DISLOCATION; BLUNT TRAUMA; LAYING HENS; WELFARE; PIGS; NEUROPHYSIOLOGY; INSENSIBILITY; DEPOPULATION; CESSATION	The objective of this study was to determine the effectiveness of a nonpenetrating captive bolt (NPCB), the Zephyr-Euthanasia (Zephyr-E), for euthanasia of neonatal piglets < 72 h of age using signs of insensibility and death, as well as postmortem assessment of traumatic brain injury (TBI). The Zephyr-E was used by 10 stock people to euthanize 100 low viability neonatal piglets from 3 commercial farrowing units and 1 research farm. Brainstem reflexes, convulsions, and heartbeat were used to assess insensibility, time of brain death, and cardiac arrest after Zephyr-E application. Hemorrhage severity and skull fracture displacement (FD) were quantified from computed tomography scans (n = 10), macroscopic scoring was used to assess brain hemorrhage and skull fracture (SK) severity (n = 100), and microscopic scoring was used to assess subdural (SDH) and parenchymal (PH) hemorrhage within specific brain regions that are responsible for consciousness and vital function (n = 10). All 100 piglets were rendered immediately insensible without return to sensibility. On average, clonic convulsions (CC) ceased in 101 s (+/- 7.4 SE), brain death was achieved in 229 s (+/- 9.18 SE), and cardiac arrest occurred in 420 s (+/- 13.57 SE). Time of cardiac arrest differed significantly among stock people when either body weight (BW: P = 0.0053) or body mass index (BMI: P = 0.0059) was used as a covariate. The BMI was inversely related to the duration of CC (P = 0.0227). Moderate to severe hemorrhage severity was reported in 9 of 10 piglets. There was no relationship between FD and BW (P = 0.8408) or BMI (P = 0.6439). Macroscopic analyses indicated moderate to severe hemorrhage and SK in all piglets. No differences were found among brain sections for SDH (P = 0.2302); PH was greater in the cerebral cortex than in the midbrain and brainstem (P = 0.0328). The Zephyr-E NPCB reliably caused immediate, sustained insensibility followed by death in neonatal piglets. Postmortem assessment confirmed that application of the Zephyr-E caused widespread, irreversible brain damage.	[Casey-Trott, T. M.; Widowski, T. M.] Univ Guelph, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada; [Millman, S. T.] Iowa State Univ, Ames, IA 50011 USA; [Turner, P. V.] Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [Nykamp, S. G.] Ontario Vet Coll, Hlth Sci Ctr, Primary Healthcare Ctr, Guelph, ON N1G 2W1, Canada	Widowski, TM (corresponding author), Univ Guelph, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada.	twidowsk@uoguelph.ca		Millman, Suzanne/0000-0001-5752-4647	National Pork Board, Des Moines, IA, USA	Funding was provided by the National Pork Board, Des Moines, IA, USA. The authors wish to thank the dedicated stock people from the farm in Ontario and Elite Pork Partnership LLC, Carroll, IA, who were willing to take on this task. We are also grateful to the students and staff from the University of Guelph and Iowa State University; in particular, Dr. Ray Brooks and research associate Rebecca Parsons, for their contributions to data collection, and to Michelle Edwards for her statistical advice.	AKRITAS MG, 1990, J AM STAT ASSOC, V85, P73, DOI 10.2307/2289527; American Association of Swine Veterinarians (AASV) and National Pork Board (NPB), 2009, AASV PUBL; ANIL MH, 1991, MEAT SCI, V30, P13, DOI 10.1016/0309-1740(91)90030-T; AVMA, 2007, J AM VET MED ASSOC, V218, P669; Baxter EM, 2008, THERIOGENOLOGY, V69, P773, DOI 10.1016/j.theriogenology.2007.12.007; Chevillon P., 2004, P INT SOC ANIM HYG, P45; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; Dawson MD, 2007, J APPL POULTRY RES, V16, P583, DOI 10.3382/japr.2007-00023; Dawson MD, 2009, J APPL POULTRY RES, V18, P135, DOI 10.3382/japr.2008-00072; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Erasmus MA, 2010, VET REC, V167, P850, DOI 10.1136/vr.c5051; Erasmus MA, 2010, J APPL POULTRY RES, V19, P288, DOI 10.3382/japr.2009-00103; Erasmus MA, 2010, POULTRY SCI, V89, P1345, DOI 10.3382/ps.2009-00445; Finnie JW, 2003, AUST VET J, V81, P153, DOI 10.1111/j.1751-0813.2003.tb11078.x; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; HANNA JP, 1995, NEUROLOGY, V45, P985, DOI 10.1212/WNL.45.5.985; Hills Teresa E, 2010, Nursing, V40, P34, DOI 10.1097/01.NURSE.0000390667.52579.8e; IRWIN C.K., 2010, AASV ANN M IMPL KNOW, P441; Lee PH, 2005, PARKINSONISM RELAT D, V11, P105, DOI 10.1016/j.parkreldis.2004.09.005; McKeegan DEF, 2011, BRIT POULTRY SCI, V52, P645, DOI 10.1080/00071668.2011.640307; McKinstry JL, 2004, MEAT SCI, V67, P121, DOI 10.1016/j.meatsci.2003.10.002; Millman ST, 2010, AASV ANN M IMPL KNOW, P443; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; OIE, 2011, TERR AN HLTH COD; Raj ABM, 1996, ANIM WELFARE, V5, P71; Sadler LJ, 2013, THESIS IOWA STATE U; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sutherland M., 2010, 08145 NAT PORK BOARD; Tseng WC, 2011, J TRAUMA, V71, P1611, DOI 10.1097/TA.0b013e31823a8a60; Turner PV, 2012, POULTRY SCI, V91, P1558, DOI 10.3382/ps.2012-02139; Viano DC, 2012, ANN BIOMED ENG, V40, P213, DOI 10.1007/s10439-011-0386-2; Vogel KD, 2011, J ANIM SCI, V89, P1412, DOI 10.2527/jas.2010-2920; Whiting TL, 2011, CAN VET J, V52, P753; Widowski T., 2008, P AD LEM SWIN C ST P, P107; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1003, DOI 10.1212/WNL.45.5.1003; Woods J. A., 2011, P HUM SLAUGHT ASS CE; Young RJ, 2002, NEUROIMAG CLIN N AM, V12, P189, DOI 10.1016/S1052-5149(02)00003-5	39	23	24	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0021-8812	1525-3163		J ANIM SCI	J. Anim. Sci.	NOV	2013	91	11					5477	5484		10.2527/jas.2013-6320			8	Agriculture, Dairy & Animal Science	Agriculture	246CZ	WOS:000326515900043	24045471				2021-06-18	
J	Larrabee, GJ; Rohling, ML				Larrabee, Glenn J.; Rohling, Martin L.			Neuropsychological Differential Diagnosis of Mild Traumatic Brain Injury	BEHAVIORAL SCIENCES & THE LAW			English	Article							COGNITIVE PERFORMANCE; BASE RATES; POSTCONCUSSIVE SYMPTOMS; MISERABLE MINORITY; MEMORY COMPLAINTS; HEAD-INJURY; CONCUSSION; DISORDER; OUTCOMES; DEPRESSION	The diagnosis and evaluation of mild traumatic brain injury (mTBI) is reviewed from the perspective of meta-analyses of neuropsychological outcome, showing full recovery from a single, uncomplicated mTBI by 90 days post-trauma. Persons with history of complicated mTBI characterized by day-of-injury computed tomography or magnetic resonance imaging abnormalities, and those who have suffered prior mTBIs may or may not show evidence of complete recovery similar to that experienced by persons suffering a single, uncomplicated mTBI. Persistent post-concussion syndrome (PCS) is considered as a somatoform presentation, influenced by the non-specificity of PCS symptoms which commonly occur in non-TBI samples and co-vary as a function of general life stress, and psychological factors including symptom expectation, depression and anxiety. A model is presented for forensic evaluation of the individual mTBI case, which involves open-ended interview, followed by structured interview, record review, and detailed neuropsychological testing. Differential diagnosis includes consideration of other neurologic and psychiatric disorders, symptom expectation, diagnosis threat, developmental disorders, and malingering. Copyright (c) 2013 John Wiley & Sons, Ltd.	[Rohling, Martin L.] Univ S Alabama, Mobile, AL 36688 USA	Larrabee, GJ (corresponding author), 2650 Bahia Vista St,Suite 308, Sarasota, FL 34239 USA.	glarrabee@aol.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brulot MM, 1997, CLIN NEUROPSYCHOL, V11, P391, DOI 10.1080/13854049708400468; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Granacher RP, 2008, J AM ACAD PSYCHIATRY, V36, P323; Greiffenstein M., 2012, FORENSIC NEUROPSYCHO, P23; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 2007, ASSESSMENT MALINGERE, P100; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Hanlon RE, 1999, BRAIN INJURY, V13, P873; HANNINEN T, 1994, J AM GERIATR SOC, V42, P1; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Larrabee G. J., 2012, FORENSIC NEUROPSYCHO, P3; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LARRABEE GJ, 1991, J CLIN EXP NEUROPSYC, V13, P466, DOI 10.1080/01688639108401064; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lipsey M.W., 2001, PRACTICAL META ANAL; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Putnam S. H., 1996, NEUROPSYCHOLOGICAL A, P529; Putnam S. H., 1994, ADV MED PSYCHOTHERAP, V7, P1; Rohling Martin L, 2002, CNS Spectr, V7, P387; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Roth R. S., 2013, J PALLIATIVE CARE ME, V1, P2; Ruff RM, 1999, STUD NEUROPSYCHOL DE, P315; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; Weiser M, 2004, ACTA PSYCHIAT SCAND, V110, P471, DOI 10.1111/j.1600-0447.2004.00385.x; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS JM, 1987, J CONSULT CLIN PSYCH, V55, P595, DOI 10.1037/0022-006X.55.4.595	81	23	23	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0735-3936	1099-0798		BEHAV SCI LAW	Behav. Sci. Law	NOV	2013	31	6			SI		686	701		10.1002/bsl.2087			16	Psychology, Applied; Law	Psychology; Government & Law	262KI	WOS:000327733400002	24105915				2021-06-18	
J	Li, AH; Sun, XL; Ni, YH; Chen, X; Guo, AS				Li, Aihong; Sun, Xiaolei; Ni, Yaohui; Chen, Xin; Guo, Aisong			HIF-1 alpha Involves in Neuronal Apoptosis after Traumatic Brain Injury in Adult Rats	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Traumatic brain injury; HIF-1 alpha; Neuronal apoptosis; Rat	HYPOXIA-INDUCIBLE FACTOR-1; SECONDARY INSULTS; CORTICAL IMPACT; UP-REGULATION; BCL-2 FAMILY; EXPRESSION; P53; GLUTAMATE; PROTEIN; DEATH	Hypoxia-inducible factor-1 alpha (HIF-1 alpha), a well-identified hypoxia-related protein, is involved in regulating the biological functions of various cell types including neurons. The traditional biological function of HIF-1 alpha is promoting the transcription of some pro-survival genes when exposing to low oxygen conditions. Meanwhile, some studies also point out that HIF-1 alpha shows the detrimental role in several central nervous system (CNS) disorders. Up to now, the knowledge of HIF-1 alpha function in CNS is still limited. To investigate whether HIF-1 alpha is involved in CNS impairment and repair, we employed a traumatic brain injury model in adult rats. Upregulation of HIF-1 alpha was observed in the injured brain cortex by western blot analysis and immunohistochemistry staining. Terminal deoxynucleotidyl transferase deoxy-UTP nick-end labeling (TUNEL) and 4',6-diamidino-2-phenylindole (DAPI) staining suggested that HIF-1 alpha was relevant to neuronal apoptosis after brain injury. In addition, glutamate excitotoxic model of primary cortex neurons was introduced to further investigate the role of HIF-1 alpha in neuronal apoptosis; the result implied HIF-1 alpha was associated with the regulation of p53 and BNIP3 in the apoptotic neurons. Based on our data, we suggested that HIF-1 alpha might play an important role in neuronal apoptosis after traumatic brain injury in rat, which might also provide a basis for the further study on its role in regulating the transcription of target genes in apoptotic neurons, and might gain a novel strategy for the clinical therapy for traumatic brain injury.	[Li, Aihong; Ni, Yaohui; Chen, Xin] Nantong Univ, Dept Neurol, Affiliated Hosp, Nantong 226002, Jiangsu, Peoples R China; [Sun, Xiaolei] Nantong Univ, Coll Med, Dept Pathogen Biol, Nantong 226001, Jiangsu, Peoples R China; [Guo, Aisong] Nantong Univ, Dept Rehabil Med, Affiliated Hosp, Nantong 226002, Jiangsu, Peoples R China	Guo, AS (corresponding author), Nantong Univ, Dept Rehabil Med, Affiliated Hosp, Nantong 226002, Jiangsu, Peoples R China.	AisongGuo@hotmail.com			Open Science Foundation of the Jiangsu Province [KF200953]	The project was funded by the Open Science Foundation of the Jiangsu Province (KF200953).	Agostinho P, 2003, EUR J NEUROSCI, V17, P1189, DOI 10.1046/j.1460-9568.2003.02546.x; Badawi Y, 2012, ASN NEURO, V4, P231, DOI 10.1042/AN20120006; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cregan SP, 1999, J NEUROSCI, V19, P7860; Di Giovanni S, 2006, EMBO J, V25, P4084, DOI 10.1038/sj.emboj.7601292; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Endo H, 2006, J NEUROSCI, V26, P7974, DOI 10.1523/JNEUROSCI.0897-06.2006; Feng JF, 2012, BRAIN RES, V1469, P144, DOI 10.1016/j.brainres.2012.06.021; Ha YM, 2012, APOPTOSIS, V17, P463, DOI 10.1007/s10495-011-0688-8; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Hota KB, 2012, J CEREBR BLOOD F MET, V32, P1046, DOI 10.1038/jcbfm.2012.21; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim TH, 2011, CANCER RES, V71, P2260, DOI 10.1158/0008-5472.CAN-10-3007; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Mangat Halinder S, 2012, Continuum (Minneap Minn), V18, P532, DOI 10.1212/01.CON.0000415426.76524.e1; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mellergard P, 2012, J NEUROTRAUM, V29, P112, DOI 10.1089/neu.2010.1732; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Prabhakaran K, 2007, NEUROSCIENCE, V150, P159, DOI 10.1016/j.neuroscience.2007.07.033; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shi HL, 2009, CURR MED CHEM, V16, P4593, DOI 10.2174/092986709789760779; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tedeschi A, 2009, CELL DEATH DIFFER, V16, P543, DOI 10.1038/cdd.2008.175; Trollmann R, 2009, BRAIN DEV-JPN, V31, P503, DOI 10.1016/j.braindev.2009.03.007; Vazquez-Valls E, 2011, J NEUROIMMUNOL, V238, P12, DOI 10.1016/j.jneuroim.2011.06.001; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zhang HM, 2003, APOPTOSIS, V8, P229, DOI 10.1023/A:1023616620970; Zhang ZF, 2011, FEBS J, V278, P134, DOI 10.1111/j.1742-4658.2010.07939.x	38	23	25	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	NOV	2013	51	3					1052	1062		10.1007/s12031-013-0084-7			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	235IH	WOS:000325710500048	23979836				2021-06-18	
J	Rosenthal, JF; Erickson, JC				Rosenthal, Jacqueline F.; Erickson, Jay C.			Post-Traumatic Stress Disorder in US Soldiers With Post-Traumatic Headache	HEADACHE			English	Article						post-traumatic headache; post-traumatic stress disorder; concussion; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENTS; SERVICE MEMBERS; MIGRAINE; PREVALENCE; CONCUSSION; IRAQ; ASSOCIATION; DEPRESSION; VETERANS	ObjectiveTo determine the impact of post-traumatic stress disorder (PTSD) on headache characteristics and headache prognosis in U.S. soldiers with post-traumatic headache. BackgroundPTSD and post-concussive headache are common conditions among U.S. Army personnel returning from deployment. The impact of comorbid PTSD on the characteristics and outcomes of post-traumatic headache has not been determined in U.S. Army soldiers. MethodsA retrospective cohort study was conducted among 270 consecutive U.S. Army soldiers diagnosed with post-traumatic headache at a single Army neurology clinic. All subjects were screened for PTSD at baseline using the PTSD symptom checklist. Headache frequency and characteristics were determined for post-traumatic headache subjects with and without PTSD at baseline. Headache measures were reassessed 3 months after the baseline visit, and were compared between groups with and without PTSD. ResultsOf 270 soldiers with post-traumatic headache, 105 (39%) met screening criteria for PTSD. There was no significant difference between subjects with PTSD and those without PTSD with regard to headache frequency (17.2 vs 15.7 headache days per month; P=.15) or chronic daily headache (58.1% vs 52.1%; P=.34). Comorbid PTSD was associated with higher headache-related disability as measured by the Migraine Disability Assessment Score. Three months after the baseline neurology clinic visit, the number of subjects with at least 50% reduction in headache frequency was similar among post-traumatic headache cases with and without PTSD (25.9% vs 26.8%). ConclusionPTSD is prevalent among U.S. Army soldiers with post-traumatic headache. Comorbid PTSD is not associated with more frequent headaches or chronic daily headache in soldiers evaluated at a military neurology clinic for chronic post-traumatic headache. Comorbid PTSD does not adversely affect short-term headache outcomes, although prospective controlled trials are needed to better assess this relationship.	[Rosenthal, Jacqueline F.; Erickson, Jay C.] Madigan Army Med Ctr, Neurol Serv, Tacoma, WA 98431 USA	Rosenthal, JF (corresponding author), Martin Army Community Hosp, 7950 Martin Loop, Ft Benning, GA 31905 USA.	jacqueline.f.rosenthal.mil@mail.mil			Comprehensive National Neuroscience Program at the Uniformed Services University of Health Sciences, Bethesda, MD, USA	This study was supported by the Comprehensive National Neuroscience Program at the Uniformed Services University of Health Sciences, Bethesda, MD, USA.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; [Anonymous], 2004, CEPHALALGIA, V24, p2nd, DOI DOI 10.1111/J.1468-2982.2003.00824.X; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; CHIBNALL JT, 1994, HEADACHE, V34, P357, DOI 10.1111/j.1526-4610.1994.hed3406357.x; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; Hickling EJ, 1992, HEADACHE Q-CURR TREA, V3, P285; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Management of Concussion/mTBI Working Group, 2009, J REHABIL RES DEV, V46, pCP1; Packard RC, 2008, CURR PAIN HEADACHE R, V12, P67, DOI 10.1007/s11916-008-0013-6; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Peterlin BL, 2011, HEADACHE, V51, P860, DOI 10.1111/j.1526-4610.2011.01907.x; Peterlin BL, 2011, CEPHALALGIA, V31, P235, DOI 10.1177/0333102410378051; Peterlin BL, 2009, HEADACHE, V49, P541, DOI 10.1111/j.1526-4610.2009.01368.x; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Rosenthal JF, 2011, HEADACHE, V51, P3; Ruff Robert L, 2010, F1000 Med Rep, V2, P64, DOI 10.3410/M2-64; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tatrow K, 2003, HEADACHE, V43, P755, DOI 10.1046/j.1526-4610.2003.03133.x; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Theeler BJ, 2012, CURR TREAT OPTION NE, V14, P36, DOI 10.1007/s11940-011-0157-2; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Waung MW, 2012, CURR PAIN HEADACHE R, V16, P533, DOI 10.1007/s11916-012-0294-7; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604	33	23	24	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	NOV	2013	53	10					1564	1572		10.1111/head.12200			9	Clinical Neurology	Neurosciences & Neurology	255PZ	WOS:000327253600005	24001181				2021-06-18	
J	Okuma, Y; Wang, FF; Toyoshima, A; Kameda, M; Hishikawa, T; Tokunaga, K; Sugiu, K; Liu, KY; Haruma, J; Nishibori, M; Yasuhara, T; Date, I				Okuma, Yu; Wang, Feifei; Toyoshima, Atsuhiko; Kameda, Masahiro; Hishikawa, Tomohito; Tokunaga, Koji; Sugiu, Kenji; Liu, Keyue; Haruma, Jun; Nishibori, Masahiro; Yasuhara, Takao; Date, Isao			Mannitol enhances therapeutic effects of intra-arterial transplantation of mesenchymal stem cells into the brain after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Mesenchymal stem cells; Hypertonic solution	BONE-MARROW; RATS; PRESSURE; DELIVERY; BARRIER; STROKE	Traumatic brain injury (TBI) sustained in a traffic accident or a fall is a major cause of death that affects a broad range of ages. The aim of this study was to investigate the therapeutic effects of intra-arterial transplantation of mesenchymal stem cells (MSCs) combined with hypertonic glycerol (25%) or mannitol (25%) in a TBI model of rats. TBI models were produced with a fluid percussion device. At 24 h after TBI, MSCs (1 x 10(6) cells/100 mu l) with glycerol or mannitol were administered via the right internal carotid artery. Rats were evaluated behaviorally and immunohistochemically, and hyperpermeability of the blood-brain barrier (BBB) induced by hypertonic solutions was explored. Compared to PBS or glycerol, the administration of mannitol resulted in increased BBB disruption. The mannitol-treated rats showed significant improvement in motor function. Intra-arterial transplantation of MSCs caused no thromboembolic ischemia. Immunohistochemically, more MSCs were observed in the injured brain tissues of mannitol-treated rats than in glycerol or PBS-treated rats at 24 h after transplantation. Intra-arterial transplantation of MSCs combined with mannitol is an effective treatment in a TBI model of rats. This technique might be used for patients with diseases of the central nervous system including TBI. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Okuma, Yu; Wang, Feifei; Toyoshima, Atsuhiko; Kameda, Masahiro; Hishikawa, Tomohito; Tokunaga, Koji; Sugiu, Kenji; Haruma, Jun; Yasuhara, Takao; Date, Isao] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan; [Okuma, Yu; Liu, Keyue; Haruma, Jun; Nishibori, Masahiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Okayama, Japan; [Wang, Feifei] Kochi Univ, Sch Med, Ctr Innovat & Translat Med, Kochi 7838505, Japan	Wang, FF (corresponding author), Kochi Univ, Sch Med, Ctr Innovat & Translat Med, Nanko Ku, Oko Cho, Kochi 7838505, Japan.	f-wang@kochi-u.ac.jp		Okuma, Yu/0000-0003-4769-8111	Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24390061, 23791602] Funding Source: KAKEN	The authors thank Ms. Masako Arao and Ms. Natsuki Uemori for their assistance. This work was supported in part by Grants-in-Aid for Scientific Research and Health Science Research Grants for Research on Brain Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Armin SS, 2008, ACTA NEUROCHIR SUPPL, V104, P421; Borlongan CV, 2012, CURR PHARM DESIGN, V18, P3670; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; COSOLO WC, 1989, AM J PHYSIOL, V256, pR443; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Lee HS, 2003, STEM CELLS, V21, P190, DOI 10.1634/stemcells.21-2-190; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Scalfani MT, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.10.008; Schierhout G., 2000, COCHRANE DB SYST REV, V2; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Seyfried DM, 2008, BRAIN RES, V1224, P12, DOI 10.1016/j.brainres.2008.05.080; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Wang FF, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-52; WISE BL, 1961, ARCH NEUROL-CHICAGO, V4, P200, DOI 10.1001/archneur.1961.00450080082009; Yasuhara T, 2010, J CELL MOL MED, V14, P914, DOI 10.1111/j.1582-4934.2008.00671.x	22	23	24	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 25	2013	554						156	161		10.1016/j.neulet.2013.08.058			6	Neurosciences	Neurosciences & Neurology	261ON	WOS:000327674600030	24016413				2021-06-18	
J	Roberts, DJ; Jenne, CN; Leger, C; Kramer, AH; Gallagher, CN; Todd, S; Parney, IF; Doig, CJ; Yong, VW; Kubes, P; Zygun, DA				Roberts, Derek J.; Jenne, Craig N.; Leger, Caroline; Kramer, Andreas H.; Gallagher, Clare N.; Todd, Stephanie; Parney, Ian F.; Doig, Christopher J.; Yong, V. Wee; Kubes, Paul; Zygun, David A.			A Prospective Evaluation of the Temporal Matrix Metalloproteinase Response after Severe Traumatic Brain Injury in Humans	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; cerebrospinal fluid; craniocerebral trauma; matrix metalloproteinase; microdialysis	BARRIER DISRUPTION; BLOOD; MATRIX-METALLOPROTEINASE-9; EXPRESSION; EDEMA; INHIBITION; OVEREXPRESSION; MICRODIALYSIS; INFLAMMATION; MEDIATORS	Accumulating pre-clinical data suggests that matrix metalloproteinase (MMP) expression plays a critical role in the pathophysiology of secondary brain injury. We conducted a prospective multimodal monitoring study in order to characterize the temporal MMP response after severe traumatic brain injury (TBI) in eight critically ill humans and its relationship with outcomes. High-cutoff, cerebral microdialysis (n=8); external ventricular drainage (n=3); and arterial and jugular venous bulb catheters were used to collect microdialysate, cerebrospinal fluid, and arterial and jugular bulb blood over 6 days. Levels of MMP-8 and -9 were initially high in microdialysate and then gradually declined over time. After these MMPs decreased, a spike in the microdialysate levels of MMP-2 and -3 occurred, followed by a gradual rise in the microdialysate concentration of MMP-7. Use of generalized estimating equations suggested that MMP-8 concentration in microdialysate was associated with mortality (p=0.019) and neurological outcome at hospital discharge (p=0.013). Moreover, the mean microdialysate concentration of MMP-8 was 2.4-fold higher among those who died after severe TBI than in those who survived. Mean microdialysate levels of MMP-8 also rose with increasing intracranial pressure (ICP), whereas those of MMP-7 decreased with increasing cerebral perfusion pressure (CPP). Significant changes in the mean microdialysate concentrations of MMP-1, -2, -3, and -9 and MMP-1, -2, -3, -7, and -9 also occurred with increases in microdialysate glucose and the lactate/pyruvate ratio, respectively. These results imply that monitoring of MMPs following severe TBI in humans is feasible, and that their expression may be associated with clinical outcomes, ICP, CPP, and cerebral metabolism.	[Roberts, Derek J.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Roberts, Derek J.; Doig, Christopher J.; Zygun, David A.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Roberts, Derek J.; Jenne, Craig N.; Leger, Caroline; Kramer, Andreas H.; Todd, Stephanie; Doig, Christopher J.; Kubes, Paul] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Kramer, Andreas H.; Gallagher, Clare N.; Yong, V. Wee] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Kramer, Andreas H.; Gallagher, Clare N.; Yong, V. Wee; Kubes, Paul] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Yong, V. Wee] Univ Calgary, Dept Oncol, Calgary, AB, Canada; [Kubes, Paul] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Jenne, Craig N.; Leger, Caroline; Kubes, Paul] Univ Calgary, Calvin Phoebe & Joan Snyder Inst Chron Dis, Calgary, AB, Canada; Foothills Med Ctr, Calgary, AB, Canada; [Parney, Ian F.] Mayo Clin, Coll Med, Dept Neurol Surg, Rochester, MN USA; [Zygun, David A.] Univ Alberta, Div Crit Care Med, Edmonton, AB T6G 2B7, Canada	Zygun, DA (corresponding author), Univ Alberta, Div Crit Care Med, 8440-112 St, Edmonton, AB T6G 2B7, Canada.	zygun@ualberta.ca	Roberts, Derek J./L-6229-2019; Doig, Christopher/AAC-7949-2020	Roberts, Derek J./0000-0001-6111-6291; Doig, Christopher/0000-0002-8576-9139; Parney, Ian/0000-0002-9702-8047; Yong, V. Wee/0000-0002-2600-3563	Alberta Innovates Health Solutions; Canadian Intensive Care Foundation; Snyder Chair for Translational Research in Critical Care Medicine; Alberta Innovates - Health Solutions Clinician Fellowship Award; Clinician Investigator and Surgeon Scientist Programs at the University of Calgary	This work was supported by grants from Alberta Innovates Health Solutions (formally the Alberta Heritage Foundation for Medical Research [awarded to Dr. Zygun]), the Canadian Intensive Care Foundation (awarded to Dr. Zygun), and the Snyder Chair for Translational Research in Critical Care Medicine (awarded to Dr. Kubes). Dr. Roberts is supported by an Alberta Innovates - Health Solutions Clinician Fellowship Award and funding from the Clinician Investigator and Surgeon Scientist Programs at the University of Calgary. Dr. Jenne is funded by an Alberta Innovates Health Solutions Postdoctoral Fellowship Award.	Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bilousova TV, 2006, J NEUROCHEM, V97, P44, DOI 10.1111/j.1471-4159.2006.03701.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chen JL, 2011, STROKE, V42, P445, DOI 10.1161/STROKEAHA.110.596486; duPont NC, 2005, J REPROD IMMUNOL, V66, P175, DOI 10.1016/j.jri.2005.03.005; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Falo MC, 2008, J NEUROTRAUM, V25, P769, DOI 10.1089/neu.2008.0511; Folgueras AR, 2008, J BIOL CHEM, V283, P9465, DOI 10.1074/jbc.M709522200; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hutchinson PJA, 2002, ACT NEUR S, V81, P359; JENNETT B, 1975, LANCET, V1, P480; Kawai N, 2003, J NEUROTRAUM, V20, P649, DOI 10.1089/089771503322144563; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Kumari R, 2011, J NEUROCHEM, V119, P1029, DOI 10.1111/j.1471-4159.2011.07487.x; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Nygardas PT, 2002, CLIN EXP IMMUNOL, V128, P245, DOI 10.1046/j.1365-2249.2002.01855.x; Reyes R, 2009, J NEUROSURG, V110, P1218, DOI 10.3171/2008.8.JNS08382; Roberts DJ, 2008, EXPERT OPIN DRUG MET, V4, P1245, DOI [10.1517/17425255.4.10.1245, 10.1517/17425255.4.10.1245 ]; ROSENBERG GA, 1992, BRAIN RES, V576, P203, DOI 10.1016/0006-8993(92)90681-X; Szklarczyk A, 2008, FASEB J, V22, P3757, DOI 10.1096/fj.07-101402; TEASDALE G, 1974, LANCET, V2, P81; Van Hove I, 2012, J NEUROCHEM, V123, P203, DOI 10.1111/j.1471-4159.2012.07900.x; Vilalta A, 2008, ACTA NEUROCHIR SUPPL, V102, P415, DOI 10.1007/978-3-211-85578-2_81; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Vittinghoff E, 2012, REGRESSION METHODS B, P261; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zhang HQ, 2010, NEUROSCIENTIST, V16, P156, DOI 10.1177/1073858409355830	42	23	24	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1717	1726		10.1089/neu.2012.2841			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000004	23725031				2021-06-18	
J	Cook, AM; Arora, S; Davis, J; Pittman, T				Cook, Aaron M.; Arora, Shaily; Davis, Justin; Pittman, Thomas			Augmented Renal Clearance of Vancomycin and Levetiracetam in a Traumatic Brain Injury Patient	NEUROCRITICAL CARE			English	Article						Closed head injury; Pharmacokinetics; Antibiotic; Antiepileptic; Creatinine clearance	INTENSIVE-CARE-UNIT; CREATININE CLEARANCE; GLOMERULAR-FILTRATION; PHARMACOKINETICS	Increased creatinine clearance and subsequent elevated antimicrobial clearance is evident in many traumatic brain injury (TBI) patients due to augmented renal clearance (ARC). Little is known about the effects of ARC on other renally-eliminated medications, such as the anti-epileptic drug levetiracetam. This is a case report of serum monitoring of vancomycin and levetiracetam in a 22 year old female with ARC after severe TBI. The patient exhibited ARC of vancomycin as evidenced by her low serum concentrations with standard vancomycin dosing. Her estimated creatinine clearance based on vancomycin clearance was 243.9 ml/min. Serum concentrations also suggested ARC of levetiracetam. No toxicities for either medication were noted, even after dose adjustment to account for possible ARC. Vancomycin and levetiracetam both appear to be subject to ARC after TBI. Clinicians should be mindful that standard dosing of these agents may not achieve typical target concentrations in this clinical scenario.	[Cook, Aaron M.; Arora, Shaily] Univ Kentucky, Serv Pharm, Lexington, KY USA; [Davis, Justin; Pittman, Thomas] Univ Kentucky, Dept Neurosurg, Lexington, KY USA	Cook, AM (corresponding author), Univ Kentucky, Serv Pharm, Lexington, KY USA.	amcook0@email.uky.edu		Cook, Aaron/0000-0001-8539-902X			Baptista JP, 2011, CRIT CARE, V15, DOI 10.1186/cc10262; Benedetti MS, 2003, EUR J CLIN PHARMACOL, V59, P621, DOI 10.1007/s00228-003-0655-6; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Fay MA, 2005, CLIN THER, V27, P594, DOI 10.1016/j.clinthera.2005.05.010; Herrera-Gutierrez ME, 2007, INTENS CARE MED, V33, P1900, DOI 10.1007/s00134-007-0745-5; http://www.hosp.uky.edu/pharmacy/formulary/criteria/Clinical_PKS_Manual-July_2010.pdf, 2010, CLIN PHARMACOKINETIC; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Klein P, 2012, EPILEPSY BEHAV, V24, P457, DOI 10.1016/j.yebeh.2012.05.011; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; MATZKE GR, 1984, ANTIMICROB AGENTS CH, V25, P433, DOI 10.1128/AAC.25.4.433; Patsalos PN, 2004, CLIN PHARMACOKINET, V43, P707, DOI 10.2165/00003088-200443110-00002; Rybak MJ, 2009, CLIN INFECT DIS, V49, P325, DOI 10.1086/600877; RYBAK MJ, 1990, ANTIMICROB AGENTS CH, V34, P792, DOI 10.1128/AAC.34.5.792; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Udy A, 2010, ANESTH ANALG, V111, P1505, DOI 10.1213/ANE.0b013e3181f7107d; Udy AA, 2012, CHEST, V142, P30, DOI 10.1378/chest.11-1671; Udy AA, 2011, NAT REV NEPHROL, V7, P539, DOI 10.1038/nrneph.2011.92; Udy AA, 2010, INT J ANTIMICROB AG, V35, P606, DOI 10.1016/j.ijantimicag.2010.02.013; Udy AA, 2010, CLIN PHARMACOKINET, V49, P1, DOI 10.2165/11318140-000000000-00000; ZASKE DE, 1976, J TRAUMA, V16, P824, DOI 10.1097/00005373-197610000-00014	23	23	24	1	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2013	19	2					210	214		10.1007/s12028-013-9837-y			5	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	221GB	WOS:000324644800012	23907742				2021-06-18	
J	Fins, JJ				Fins, Joseph J.			Disorders of Consciousness and Disordered Care: Families, Caregivers, and Narratives of Necessity	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Affordable Care Act; Brain injury; Disability and civil rights; Disorders of consciousness; Family narratives; Neuroethics; Rehabilitation; Vegetative State	TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; PLACEBO-CONTROLLED TRIAL; MEDICAL ASPECTS; RECOVERY; COMA; OPPORTUNITIES; STIMULATION; RESPONSES; ACCESS	By their nature, care decisions for patients with severe disorders of consciousness must involve surrogates. Patients, so impaired, have lost their decision-making capacity and the ability to direct their own care. Surrogates-family members, friends, or other intimates-must step in and make decisions about ongoing care or its withdrawal. This article shares the narrative experiences of these surrogate decision makers as they encounter the American health care system and accompany patients from injury through rehabilitation. Through their perspectives, the article considers challenges to ongoing care and rehabilitation that are a function of a prevailing medical infrastructure and reimbursement framework better suited to patients with acute care needs. Specific attention is paid to the ethical challenges posed by reimbursement strategies such as "medical necessity" as well as those proposed for the Affordable Care Act. The argument concludes that when it comes to care for a disorder related to consciousness, its provision is not discretionary, and its receipt is not an entitlement but a civil right. (c) 2013 by the American Congress of Rehabilitation Medicine	[Fins, Joseph J.] Weill Cornell Med Coll, Div Med Eth, New York, NY USA; [Fins, Joseph J.] Rockefeller Univ, New York, NY 10021 USA	Fins, JJ (corresponding author), Rockefeller Univ, Weill Cornell Med Coll, Div Med Eth, 435 East 70th St,Ste 4-J, New York, NY 10021 USA.	jjfins@med.cornell.edu			Investigator Award in Health Policy Research from the Robert Wood Johnson Foundation; Buster Foundation; Jerold B. Katz Foundation	Supported by an Investigator Award in Health Policy Research from the Robert Wood Johnson Foundation, and grants from the Buster and Jerold B. Katz Foundations.	[Anonymous], 1994, N ENGL J MED, V330, P1499; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Berkowitz SA, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1100076; Berube J, 2006, MOHONK REPORT REPORT; Brody H., 2009, STORIES SICKNESS; Carusone P., 2011, COMMUNICATION; Connors S, 2012, BRAIN INJURY ASS AM; Fins J, 2010, T AM CLIN CLIMAT ASS, V122, P336; Fins J. J., 2011, TRANSFORMING HLTH CA, P21; Fins JJ, 1999, J PAIN SYMPTOM MANAG, V17, P6, DOI 10.1016/S0885-3924(98)00109-2; Fins JJ, 2004, ARCH NEUROL-CHICAGO, V61, P1354, DOI 10.1001/archneur.61.9.1354; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fins JJ, 2005, HASTINGS CENT REP, V35, P22, DOI 10.1353/hcr.2005.0020; FINS JJ, 2010, LAW NEUROSCIENCE CUR, V13, P367, DOI DOI 10.1093/ACPROF:OSO/9780199599844.003.0018; Fins JJ, 2006, PALLIATIVE ETHIC CAR; Fins JJ., 2007, PLUM POSNERS DIAGNOS; Fins Joseph J, 2006, Palliat Support Care, V4, P169; Fins JJ, 2007, NEUROLOGY, V68, P304, DOI 10.1212/01.wnl.0000252376.43779.96; Fins Joseph J, 2012, Virtual Mentor, V14, P221, DOI 10.1001/virtualmentor.2012.14.3.stas1-1203; Fins JJ, 2011, SOC RES, V78, P731; Fins JJ, 2012, ARCH NEUROL-CHICAGO, V69, P158, DOI 10.1001/archneurol.2011.1211; Fins JJ, 2009, PROG BRAIN RES, V177, P371, DOI 10.1016/S0079-6123(09)17726-9; Fins JJ, 2009, CAMB Q HEALTHC ETHIC, V18, P7, DOI 10.1017/S0963180108090038; Fins JJ, 2009, ANN NY ACAD SCI, V1157, P131, DOI 10.1111/j.1749-6632.2009.04473.x; Giacino J, 2012, NEUROMODULATION, V15, P339, DOI 10.1111/j.1525-1403.2012.00458.x; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Granger CV, 2009, AM J PHYS MED REHAB, V88, P755, DOI 10.1097/PHM.0b013e3181aa71a8; Kastor JA, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1013221; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; Luft HS, 2010, NEW ENGL J MED, V363, P1389, DOI 10.1056/NEJMp1009380; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nolan JP, 2010, CURR OPIN CRIT CARE, V16, P216, DOI 10.1097/MCC.0b013e3283383dca; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Pascrell B., 2011, COMMUNICATION; Relyea-Chew A, 2009, ARCH PHYS MED REHAB, V90, P413, DOI 10.1016/j.apmr.2008.07.031; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2012, PRINCIPLES PRACTICE, P1724; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; the Multi-Society Task Force on PVS, 1994, N ENGL J MED, V330, P1572; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wijdicks EFM, 2007, NEUROLOGY, V68, P1092, DOI 10.1212/01.wnl.0000259401.36220.1a	49	23	24	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1934	1939		10.1016/j.apmr.2012.12.028			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100011	23770277				2021-06-18	
J	Hou, LJ; Han, X; Sheng, P; Tong, WS; Li, ZQ; Xu, DY; Yu, MK; Huang, LQ; Zhao, ZX; Lu, YC; Dong, Y				Hou, Lijun; Han, Xi; Sheng, Ping; Tong, Wusong; Li, Zhiqiang; Xu, Dayuan; Yu, Mingkun; Huang, Liuqing; Zhao, Zhongxin; Lu, Yicheng; Dong, Yan			Risk Factors Associated with Sleep Disturbance following Traumatic Brain Injury: Clinical Findings and Questionnaire Based Study	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; EXCESSIVE DAYTIME SLEEPINESS; INSOMNIA; COMPLAINTS; PREVALENCE	Background: Sleep disturbance is very common following traumatic brain injury (TBI), which may initiate or exacerbate a variety of co-morbidities and negatively impact rehabilitative treatments. To date, there are paradoxical reports regarding the associations between inherent characteristics of TBI and sleep disturbance in TBI population. The current study was designed to explore the relationship between the presence of sleep disturbance and characteristics of TBI and identify the factors which are closely related to the presence of sleep disturbance in TBI population. Methods: 98 TBI patients (72 males, mean age +/- SD, 47 +/- 13 years, range 18-70) were recruited. Severity of TBI was evaluated based on Glasgow Coma Scale (GCS). All participants performed cranial computed tomography and were examined on self-reported sleep quality, anxiety, and depression. Results: TBI was mild in 69 (70%), moderate in 15 (15%) and severe in 14 (15%) patients. 37 of 98 patients (38%) reported sleep disturbance following TBI. Insomnia was diagnosed in 28 patients (29%) and post-traumatic hypersomnia in 9 patients (9%). In TBI with insomnia group, 5 patients (18%) complained of difficulty falling asleep only, 8 patients (29%) had difficulty maintaining sleep without difficulty in initial sleep and 15 patients (53%) presented both difficulty falling asleep and difficulty maintaining sleep. Risk factors associated with insomnia were headache and/or dizziness and more symptoms of anxiety and depression rather than GCS. In contrast, GCS was independently associated with the presence of hypersomnia following TBI. Furthermore, there was no evidence of an association between locations of brain injury and the presence of sleep disturbance after TBI. Conclusion: Our data support and contribute to a growing body of evidence which indicates that TBI patients with insomnia are prone to suffer from concomitant headache and/or dizziness, report more symptoms of anxiety and depression and severe TBI patients are likely to experience hypersomnia.	[Hou, Lijun; Sheng, Ping; Yu, Mingkun; Lu, Yicheng; Dong, Yan] Second Mil Med Univ, Dept Neurosurg, Shanghai Inst Neurosurg, PLA Inst Neurosurg,Changzhang Hosp, Shanghai, Peoples R China; [Han, Xi] Fudan Univ, Dept Neurosurg, Huashan Hosp, Shanghai 200433, Peoples R China; [Tong, Wusong] Pudong New Area Peoples Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Li, Zhiqiang; Xu, Dayuan] Fengxian Cent Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Huang, Liuqing; Zhao, Zhongxin] Second Mil Med Univ, Dept Neurol, Changzhang Hosp, Shanghai, Peoples R China	Hou, LJ (corresponding author), Second Mil Med Univ, Dept Neurosurg, Shanghai Inst Neurosurg, PLA Inst Neurosurg,Changzhang Hosp, Shanghai, Peoples R China.	lj_hou@hotmail.com; dongyan2006@yahoo.com			Natural Science Foundation from Science and Technology Commission of Shanghai Municipality [11ZR1448700]; Research Foundation for Returned Scholars from Ministry of Education of China	Dr. Yan Dong is supported by Natural Science Foundation from Science and Technology Commission of Shanghai Municipality (11ZR1448700) and Research Foundation for Returned Scholars from Ministry of Education of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, P298; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Boivin DB, 2003, NEUROLOGY, V60, P1841, DOI 10.1212/01.WNL.0000061482.24750.7C; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Flesher MR, 2001, BRAIN INJURY, V15, P879, DOI 10.1080/02699050110065682; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Hossain Jamil L, 2002, Sleep Breath, V6, P85, DOI 10.1055/s-2002-32322; Johnson VE, 2012, EXP NEUROL; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Liang Siyu, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P370, DOI 10.3969/j.issn.1672-7347.2013.04.006; Liu Y, 2013, CHINA MED HERALD, V10, P60; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mayers AG, 2006, INT J PSYCHIAT CLIN, V10, P2, DOI 10.1080/13651500500328087; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Plante DT, 2009, SLEEP MED CLIN, V4, P407, DOI 10.1016/j.jsmc.2009.04.008; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Tobe EH, 1999, J NEUROPSYCH CLIN N, V11, P504, DOI 10.1176/jnp.11.4.504; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wu SQ, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-849	40	23	25	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2013	8	10							e76087	10.1371/journal.pone.0076087			8	Multidisciplinary Sciences	Science & Technology - Other Topics	231OR	WOS:000325427100040	24098425	DOAJ Gold, Green Published			2021-06-18	
J	Chan, V; Zagorski, B; Parsons, D; Colantonio, A				Chan, Vincy; Zagorski, Brandon; Parsons, Daria; Colantonio, Angela			Older adults with acquired brain injury: a population based study	BMC GERIATRICS			English	Article						Brain injury; Epidemiology; Outcomes	ALZHEIMERS-DISEASE; MAJOR DEPRESSION; EPIDEMIOLOGY; TRENDS; SYSTEM; TUMORS; RISK; AGE	Background: Acquired brain injury (ABI), which includes traumatic (TBI) and non-traumatic brain injury (nTBI), is a leading cause of death and disability worldwide. The objective of this study was to examine the trends, characteristics, cause of brain injury, and discharge destination of hospitalized older adults aged 65 years and older with an ABI diagnosis in a population with universal access to hospital care. The profile of characteristics of patients with TBI and nTBI causes of injury was also compared. Methods: A population based retrospective cohort study design with healthcare administrative databases was used. Data on acute care admissions were obtained from the Discharge Abstract Database and patients were identified using the International Classification of Diseases - Version 10 codes for Ontario, Canada from April 1, 2003 to March 31, 2010. Older adults were examined in three age groups -65 to 74, 75 to 84, and 85+ years. Results: From 2003/04 to 2009/10, there were 14,518 episodes of acute care associated with a TBI code and 51, 233 episodes with a nTBI code. Overall, the rate of hospitalized TBI and nTBI episodes increased with older age groups. From 2007/08 to 2009/10, the percentage of patients that stayed in acute care for 12 days or more and the percentage of patients with delayed discharge from acute care increased with age. The most common cause of TBI was falls while the most common type of nTBI was brain tumours. The percentage of patients discharged to long term care and complex continuing care increased with age and the percentage discharged home decreased with age. In-hospital mortality also increased with age. Older adults with TBI and nTBI differed significantly in demographic and clinical characteristics and discharge destination from acute care. Conclusions: This study showed an increased rate of acute care admissions for both TBI and nTBI with age. It also provided additional support for falls prevention strategies to prevent injury leading to cognitive disability with costly human and economic consequences. Implications for increased numbers of people with ABI are discussed.	[Chan, Vincy; Colantonio, Angela] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Chan, Vincy; Colantonio, Angela] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Zagorski, Brandon] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5T 3M6, Canada; [Parsons, Daria] Ontario Neurotrauma Fdn, Toronto, ON M4P 2Y3, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5G 1V7, Canada	Colantonio, A (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	angela.colantonio@utoronto.ca	Chan, Vincy/AAA-7813-2020	Chan, Vincy/0000-0002-6884-044X; Colantonio, Angela/0000-0003-2094-4765	Ontario Neurotrauma Foundation [2010-ABI-TRAJECT-869]; Toronto Rehabilitation Institute Foundation; Ministry of Health and Long-Term Care (MOHLTC)Ministry of Health and Long-Term Care, Ontario; Saunderson Family Chair in Acquired Brain Injury Research; Canadian Institutes of Health Research Chair in Gender, Work and HealthCanadian Institutes of Health Research (CIHR) [CGW-126580]; Jane Gillett Pediatric ABI Studentship through the Ontario Neurotrauma Foundation; Canadian Institutes of Health Research and Pediatric Oncology Group of Ontario; Brain Canada-CIBC Brain Cancer Training Award from Brain Canada; CIBC	Funding for this study was obtained from the Ontario Neurotrauma Foundation (#2010-ABI-TRAJECT-869), the Toronto Rehabilitation Institute Foundation, and a grant from the Ministry of Health and Long-Term Care (MOHLTC) to the Toronto Rehabilitation Institute, University Health Network. Dr. Colantonio received support through the Saunderson Family Chair in Acquired Brain Injury Research and through a Canadian Institutes of Health Research Chair in Gender, Work and Health (#CGW-126580). Vincy Chan received support from the Jane Gillett Pediatric ABI Studentship through the Ontario Neurotrauma Foundation, the Doctoral Research Award from the Canadian Institutes of Health Research and Pediatric Oncology Group of Ontario, and a Brain Canada-CIBC Brain Cancer Training Award from Brain Canada and CIBC. We would like to thank the MOHLTC for providing us with the data and Ms. Sandra Sokoloff for her comments and assistance in the editing process of this manuscript.	Arora RS, 2010, EUR J CANCER, V46, P1607, DOI 10.1016/j.ejca.2010.02.007; Canadian Institute for Health Information, DISCH ABSTR DAT MET; Canadian Institute for Health Information, 2009, ALT LEV CAR CAN; Cancer Care Ontario, CANC FACT AG DISTR B; Cancer Care Ontario, CANC ONT OV STAT REP; Centers for Disease Control and Prevention, INJ DAT RES TOOLS FR; Chan V, 2013, CAN J AGING, V32, P278, DOI 10.1017/S0714980813000317; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen AY, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-16; Chen AY, 2011, EMERG THEMES EPIDEMI, V8, DOI 10.1186/1742-7622-8-4; Colantonio A, 2012, LHIN REPORTS; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Colantonio A, 2011, J REHABIL MED, V43, P311, DOI 10.2340/16501977-0783; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Harvey LA, 2012, INJURY, V7, P188; Juurlink D., 2006, Canadian Institute for Health Information Discharge Abstract Database: a validation study; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Lonn S, 2004, INT J CANCER, V108, P450, DOI 10.1002/ijc.11578; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MAO Y, 1991, CAN MED ASSOC J, V145, P1583; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; National Cancer Institute, 1975, AG ADJ SEER INC RAT; Pickett William, 2004, Chronic Dis Can, V25, P32; Raad J, 2007, ARCH PHYS MED REHAB, V94, P1426; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; *STAT CAN, POP YEAR PROV TERR; *STAT CAN, POP SEX AG GROUP PRO; *STAT CAN, PROJ POP AG GROUP AC; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; World Health Organization, 2006, TRAUM BRAIN INJ NEUR, P164	41	23	23	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2318			BMC GERIATR	BMC Geriatr.	SEP 23	2013	13								97	10.1186/1471-2318-13-97			12	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	228RX	WOS:000325206900001	24060144	DOAJ Gold, Green Published			2021-06-18	
J	Brockman, EC; Bayir, H; Blasiole, B; Shein, SL; Fink, EL; Dixon, CE; Clark, RSB; Vagni, VA; Ma, L; Hsia, CJC; Tisherman, SA; Kochanek, PM				Brockman, Erik C.; Bayir, Huelya; Blasiole, Brian; Shein, Steven L.; Fink, Ericka L.; Dixon, C. Edward; Clark, Robert S. B.; Vagni, Vincent A.; Ma, Li; Hsia, Carleton J. C.; Tisherman, Samuel A.; Kochanek, Patrick M.			Polynitroxylated-pegylated hemoglobin attenuates fluid requirements and brain edema in combined traumatic brain injury plus hemorrhagic shock in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood substitute; cerebral edema; hemoglobin blood oxygen carrier; intracranial pressure; nitroxide; resuscitation	CEREBRAL-BLOOD-FLOW; INTRACRANIAL-PRESSURE; OXYGEN DELIVERY; RESUSCITATION; HYPOTENSION; CONSEQUENCES; SUBSTITUTES; EXPRESSION; ALBUMIN; DAMAGE	Polynitroxylated-pegylated hemoglobin (PNPH), a bovine hemoglobin decorated with nitroxide and polyethylene glycol moieties, showed neuroprotection vs. lactated Ringer's (LR) in experimental traumatic brain injury plus hemorrhagic shock (TBI+HS). Hypothesis: Resuscitation with PNPH will reduce intracranial pressure (ICP) and brain edema and improve cerebral perfusion pressure (CPP) vs. LR in experimental TBI+HS. C57/BL6 mice (n = 20) underwent controlled cortical impact followed by severe HS to mean arterial pressure (MAP) of 25 to 27 mm Hg for 35 minutes. Mice (n = 10/group) were then resuscitated with a 20 mL/kg bolus of 4% PNPH or LR followed by 10 mL/kg boluses targeting MAP>70 mm Hg for 90 minutes. Shed blood was then reinfused. Intracranial pressure was monitored. Mice were killed and % brain water (%BW) was measured (wet/dry weight). Mice resuscitated with PNPH vs. LR required less fluid (26.0 +/- 0.0 vs. 167.0 +/- 10.7 mL/kg, P<0.001) and had a higher MAP (79.4 +/- 0.40 vs. 59.7 +/- 0.83mmHg, P<0.001). The PNPH-treated mice required only 20 mL/kg while LR-resuscitated mice required multiple boluses. The PNPH-treated mice had a lower peak ICP (14.5 +/- 0.97 vs. 19.7 +/- 1.12mmHg, P = 0.002), higher CPP during resuscitation (69.2 +/- 0.46 vs. 45.5 +/- 0.68mmHg, P<0.001), and lower % BW vs. LR (80.3 +/- 0.12 vs. 80.9 +/- 0.12%, P = 0.003). After TBI+HS, resuscitation with PNPH lowers fluid requirements, improves ICP and CPP, and reduces brain edema vs. LR, supporting its development.	[Brockman, Erik C.; Bayir, Huelya; Shein, Steven L.; Fink, Ericka L.; Clark, Robert S. B.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Brockman, Erik C.; Bayir, Huelya; Blasiole, Brian; Shein, Steven L.; Fink, Ericka L.; Dixon, C. Edward; Clark, Robert S. B.; Vagni, Vincent A.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Brockman, Erik C.; Bayir, Huelya; Shein, Steven L.; Fink, Ericka L.; Clark, Robert S. B.; Kochanek, Patrick M.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Bayir, Huelya] Univ Pittsburgh, Sch Med, Pittsburgh Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA; [Blasiole, Brian] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Ma, Li] Georgia So Univ, Dept Phys, Statesboro, GA 30460 USA; [Hsia, Carleton J. C.] SynZyme Technol LLC, Irvine, CA USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Tisherman, Samuel A./AAK-9377-2020; Kochanek, Patrick M/D-2371-2015; Shein, Steven/I-7763-2019	Tisherman, Samuel A./0000-0003-3810-3729; Kochanek, Patrick M/0000-0002-2627-913X; Shein, Steven/0000-0003-3382-5159; Fink, Ericka/0000-0002-3683-4571	 [U44 NS070324];  [T32 HD040686];  [K12 HD047349]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686, K12HD047349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U44NS070324] Funding Source: NIH RePORTER	This study was supported by U44 NS070324, T32 HD040686, and K12 HD047349.	Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Buehler PW, 2004, TRANSFUSION, V44, P1516, DOI 10.1111/j.1537-2995.2004.04081.x; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Burhop K, 2004, ARTIF CELL BLOOD SUB, V32, P353, DOI 10.1081/LABB-200027429; Chesnut R M, 1995, New Horiz, V3, P366; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; DeAngeles DA, 1997, J TRAUMA, V42, P406, DOI 10.1097/00005373-199703000-00007; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Foley LM, 2013, J CEREBR BLOOD F MET, V33, P129, DOI 10.1038/jcbfm.2012.145; GRAHAM DI, 1971, LANCET, V1, P265; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hsia Carleton Jen Chang, 2012, Artif Organs, V36, P215, DOI 10.1111/j.1525-1594.2011.01307.x; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jungner M, 2010, ANESTHESIOLOGY, V112, P1194, DOI 10.1097/ALN.0b013e3181d94d6e; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Okayama N, 1999, FREE RADICAL RES, V31, P53, DOI 10.1080/10715769900300591; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Reid TJ, 2003, TRANSFUSION, V43, P280, DOI 10.1046/j.1537-2995.2003.00314.x; Resta TC, 2002, J APPL PHYSIOL, V93, P1327, DOI 10.1152/japplphysiol.00175.2002; RICHES AC, 1973, J PHYSIOL-LONDON, V228, P279, DOI 10.1113/jphysiol.1973.sp010086; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Saetzler RK, 1999, FREE RADICAL BIO MED, V27, P1, DOI 10.1016/S0891-5849(99)00037-4; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Stoyanovsky DA, 2010, BIOCHEM BIOPH RES CO, V399, P139, DOI 10.1016/j.bbrc.2010.07.030; Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754	40	23	23	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2013	33	9					1457	1464		10.1038/jcbfm.2013.104			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	214IQ	WOS:000324126400018	23801241	Green Published, Bronze			2021-06-18	
J	Head, J; Helton, WS				Head, James; Helton, William S.			Perceptual decoupling or motor decoupling?	CONSCIOUSNESS AND COGNITION			English	Article						Motor control; Motor decoupling; Perceptual decoupling; Response inhibition; SART; Sustained attention	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; RESPONSE-INHIBITION; VIGILANCE; MIND; TASK; LAPSES; EXPERIENCE; AWARENESS; FAILURES	The current investigation was conducted to elucidate whether errors of commission in the Sustained Attention to Response Task (SARI) are indicators of perceptual or motor decoupiing. Twenty-eight participants completed SARTs with motor and perceptual aspects of the task manipulated. The participants completed four different SART blocks whereby stimuli location uncertainty and stimuli acquisition were manipulated. In previous studies of more traditional sustained attention tasks stimuli location uncertainty reduces sustained attention performance. In the case of the SARI the motor manipulation (stimuli acquisition), but not the perceptual manipulation (stimuli location uncertainty) significantly reduced commission errors. The results suggest that the majority of SARI commission errors are likely to be indicators of motor decoupling not necessarily perceptual decoupling. (C) 2013 Elsevier Inc. All rights reserved.	[Head, James; Helton, William S.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand	Helton, WS (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	Deak.Helton@canterbury.ac.nz					ADAMS JA, 1964, J EXP PSYCHOL, V67, P127, DOI 10.1037/h0046473; Boulinguez P, 2008, J NEUROPHYSIOL, V99, P1572, DOI 10.1152/jn.01198.2007; Boulinguez P, 2009, CLIN NEUROPHYSIOL, V120, P730, DOI 10.1016/j.clinph.2009.02.167; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Chun MM, 2011, ANNU REV PSYCHOL, V62, P73, DOI 10.1146/annurev.psych.093008.100427; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Head J, 2012, CONSCIOUS COGN, V21, P1617, DOI 10.1016/j.concog.2012.08.009; Head J, 2012, EXP BRAIN RES, V216, P103, DOI 10.1007/s00221-011-2914-6; Helton WS, 2008, ACTA PSYCHOL, V129, P18, DOI 10.1016/j.actpsy.2008.04.002; Helton WS, 2011, EXP BRAIN RES, V212, P429, DOI 10.1007/s00221-011-2749-1; Helton WS, 2011, EXP BRAIN RES, V209, P401, DOI 10.1007/s00221-011-2563-9; Helton WS, 2011, PSYCHOL RES-PSYCH FO, V75, P384, DOI 10.1007/s00426-010-0316-1; Helton WS, 2010, CONSCIOUS COGN, V19, P77, DOI 10.1016/j.concog.2010.01.006; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Hong SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011461; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2004, NEUROPSYCHOL REHABIL, V14, P89, DOI 10.1080/09602010343000110; Mrazek MD, 2011, J EXP SOC PSYCHOL, V47, P1243, DOI 10.1016/j.jesp.2011.05.011; O'Connell RG, 2006, NEUROPSYCHOL REHABIL, V16, P653, DOI 10.1080/09602010500200250; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Peebles D, 2004, PROCEEDINGS OF THE SIXTH INTERNATIONAL CONFERENCE ON COGNITIVE MODELING, P231; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Seli P., 2012, BEHAV RES METHODS; Seli P, 2012, CAN J EXP PSYCHOL, V66, P44, DOI 10.1037/a0025111; Seli P, 2012, CONSCIOUS COGN, V21, P277, DOI 10.1016/j.concog.2011.09.017; Smallwood J, 2004, CONSCIOUS COGN, V13, P657, DOI 10.1016/j.concog.2004.06.003; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Smallwood J, 2007, PSYCHON B REV, V14, P527, DOI 10.3758/BF03194102; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Stevenson H, 2011, BRAIN COGNITION, V77, P215, DOI 10.1016/j.bandc.2011.08.007; Wardack C., 2012, EUROPEAN J NEUROSCIE, P1; Warm J. S., 1993, WORKLOAD TRANSITION, P139; Warm JS, 2008, HUM FACTORS, V50, P433, DOI 10.1518/001872008X312152; WARM JS, 1996, HUM FAC TRANSP, P183	41	23	23	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100	1090-2376		CONSCIOUS COGN	Conscious. Cogn.	SEP	2013	22	3					913	919		10.1016/j.concog.2013.06.003			7	Psychology, Experimental	Psychology	235SG	WOS:000325740400025	23838467				2021-06-18	
J	Jamora, CW; Schroeder, SC; Ruff, RM				Jamora, Christina Weyer; Schroeder, Sara C.; Ruff, Ronald M.			Pain and mild traumatic brain injury: The implications of pain severity on emotional and cognitive functioning	BRAIN INJURY			English	Article						Chronic pain; cognition; mild traumatic brain injury; neuropsychological assessement; pain; postconcussional disorder; Ruff neurobehavioural inventory	ATTENTION; DEPRESSION; COMPLAINTS; HEALTH; IMPACT	Primary objective: The aim of this study was to examine the effect of high chronic pain on (a) neuropsychological test performance and (b) self-reported emotional complaints in persons suffering from Postconcussional Disorders (PCD) after a mild traumatic brain injury (TBI). Research design: A two-group comparative research design was employed. Methods and procedure: An outpatient sample of 66 patients with mild TBI and PCD using the Ruff Neurobehavioural Inventory (RNBI) and a neuropsychological test battery. Main outcomes and results: According to ANOVAs, no significant between-group differences were found on neuropsychological test performances; however, the high pain group had significantly more emotional residuals; particularly elevated on the RNBI were the Anger and Aggression, Anxiety, Depression and Paranoia and Suspicion sub-scales. Furthermore, an ANOVA found participants of the high pain group reporting significantly higher impairments on the RNBI Cognitive, Physical and Quality-of-Life composite scores and several RNBI sub-scales compared to their pre-morbid functioning. Conclusions: High chronic pain exacerbates the emotional aspect of PCD and, therefore, should be given special observance in treatment settings.	[Jamora, Christina Weyer] San Francisco Clin Neurosci, San Francisco, CA USA; [Jamora, Christina Weyer; Ruff, Ronald M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Schroeder, Sara C.] Univ Zurich, Zurich, Switzerland	Jamora, CW (corresponding author), 909 Hyde St,Suite 620, San Francisco, CA 94109 USA.	cyweyer@aol.com			RNBI	Dr Ruff receives royalties for the RNBI. All other authors had no conflicts of interest.	American Congress of Rehabilitation Medicine, 2003, J HEAD TRAUMA REHAB, V8, P86; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Benton A., 1994, MULTILINGUAL APHASIA; Boone K., 2002, DOT COUNTING TEST; Brown SC, 2002, PAIN, V96, P279, DOI 10.1016/S0304-3959(01)00457-2; Buffington ALH, 2005, PAIN, V113, P172, DOI 10.1016/j.pain.2004.10.006; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Demyttenaere K, 2007, PAIN, V129, P332, DOI 10.1016/j.pain.2007.01.022; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; Eccleston C, 1997, PAIN, V72, P209, DOI 10.1016/S0304-3959(97)00030-4; Edwards CL, 2001, PAIN, V94, P133, DOI 10.1016/S0304-3959(01)00408-0; FISHBAIN DA, 1986, PAIN, V26, P181, DOI 10.1016/0304-3959(86)90074-6; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; Hart Robert P, 2003, Curr Pain Headache Rep, V7, P116, DOI 10.1007/s11916-003-0021-5; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Jensen MP, 2001, J CONSULT CLIN PSYCH, V69, P655, DOI 10.1037/0022-006X.69.4.655; Johansson SH, 2008, BRAIN INJURY, V22, P999, DOI 10.1080/02699050802530573; Klein TA, 2007, NEUROIMAGE, V34, P1774, DOI 10.1016/j.neuroimage.2006.11.014; Kouneiher F, 2009, NAT NEUROSCI, V12, P939, DOI 10.1038/nn.2321; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Matthews C, 1964, INSTRUCTION MANUAL A; Meyers J., 1995, REY COMPLEX FIGURE T; Moriarty O, 2011, PROG NEUROBIOL, V93, P385, DOI 10.1016/j.pneurobio.2011.01.002; Mueller J., 2007, NEUROPSYCHIATRIC PRO; Murray RF, 2007, SPINAL CORD, V45, P429, DOI 10.1038/sj.sc.3102022; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Okifuji A, 1999, J PSYCHOSOM RES, V47, P1, DOI 10.1016/S0022-3999(99)00006-9; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Reitan RM., 1969, MANUAL ADM NEUROPSYC; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Riley JL, 2002, PAIN, V100, P291, DOI 10.1016/S0304-3959(02)00306-8; Robbins TW, 1996, PHILOS T ROY SOC B, V351, P1463, DOI 10.1098/rstb.1996.0131; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruff R. M., 1999, RUFF LIGHT TRAIL LEA; Ruff R.M., 1996, RUFF 2 7 SELECTIVE A; Ruff R. M., 1996, RUFF FIGURAL FLUENCY; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vernon-Wilkinson R, 1993, ARCH CLIN NEUROPSYCH, V8, P211; Wechsler D, 1997, WECHSLER MEMORY SCAL; Wechsler D., 2000, WECHSLER ADULT INTEL	51	23	23	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2013	27	10					1134	1140		10.3109/02699052.2013.804196			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	204KW	WOS:000323365200005	23895398				2021-06-18	
J	Kramer, ME; Suskauer, SJ; Christensen, JR; DeMatt, EJ; Trovato, MK; Salorio, CF; Slomine, BS				Kramer, Megan E.; Suskauer, Stacy J.; Christensen, James R.; DeMatt, Ellen J.; Trovato, Melissa K.; Salorio, Cynthia F.; Slomine, Beth S.			Examining Acute Rehabilitation Outcomes for Children With Total Functional Dependence After Traumatic Brain Injury: A Pilot Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children and adolescents; functional independence measure; outcome; rehabilitation; traumatic brain injury	INPATIENT REHABILITATION; DEVELOPMENTAL-DISABILITIES; INDEPENDENCE MEASURE; WEEFIM; CONSCIOUSNESS; PREDICTORS; DISORDERS; RECOVERY; SAMPLE; SCALE	Objective: To examine in a pilot cohort factors associated with functional outcome at discharge and 3-month follow-up after discharge from inpatient rehabilitation in children with severe traumatic brain injury (TBI) who entered rehabilitation with the lowest level of functional skills. Participants: Thirty-nine children and adolescents (3-18 years old) who sustained a severe TBI and had the lowest possible rating at rehabilitation admission on the Functional Independence Measure for Children (total score = 18). Methods: Retrospective review of data collected as part of routine clinical care. Results: At discharge, 59% of the children were partially dependent for basic activities, while 41% remained dependent for basic activities. Initial Glasgow Coma Scale score, time to follow commands, and time from injury to rehabilitation admission were correlated with functional status at discharge. Time to follow commands and time from injury to rehabilitation admission were correlated with functional status at 3-month follow-up. Changes in functional status during the first few weeks of admission were associated with functional status at discharge and follow-up. Conclusions: Even children with the most severe brain injuries, who enter rehabilitation completely dependent for all daily activities, have the potential to make significant gains in functioning by discharge and in the following few months. Assessment of functional status early in the course of rehabilitation contributes to the ability to predict outcome from severe TBI.	[Kramer, Megan E.; Suskauer, Stacy J.; Christensen, James R.; DeMatt, Ellen J.; Trovato, Melissa K.; Salorio, Cynthia F.] Kennedy Krieger Inst, Baltimore, MD 21205 USA; [Salorio, Cynthia F.; Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Suskauer, Stacy J.; Christensen, James R.; Trovato, Melissa K.; Salorio, Cynthia F.; Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Suskauer, Stacy J.; Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Suskauer, SJ (corresponding author), Kennedy Krieger Inst, 707 North Broadway, Baltimore, MD 21205 USA.	suskauer@kennedykrieger.org		Kramer, Megan/0000-0002-8813-7217	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Eunice Kennedy Shriver National Institute of Child Health & Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD061611]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD061611] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health and award K23HD061611 (Dr Suskauer) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health.	Ashwal Stephen, 2002, Semin Pediatr Neurol, V9, P19, DOI 10.1053/spen.2002.30334; Azaula M, 2000, ARCH PHYS MED REHAB, V81, P307, DOI 10.1053/apmr.2000.0810307; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Chelune GJ, 2010, CLIN NEUROPSYCHOL, V24, P454, DOI 10.1080/13854040802360574; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; Forsyth RJ, 2010, ARCH DIS CHILD, V95, P266, DOI 10.1136/adc.2008.147926; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Msall ME, 1999, AM J MED GENET, V89, P62, DOI 10.1002/(SICI)1096-8628(19990625)89:2<62::AID-AJMG3>3.0.CO;2-T; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Niedzwecki CM, 2008, J HEAD TRAUMA REHAB, V23, P209, DOI 10.1097/01.HTR.0000327253.61751.29; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Slomine B, 2008, J HEAD TRAUMA REHAB, V23, P286, DOI 10.1097/01.HTR.0000336841.53338.2f; Suskauer SJ, 2009, J PEDIATR REHAB MED, V2, P297, DOI 10.3233/PRM-2009-0092; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91, DOI 10.1080/J006v21n02_08	25	23	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2013	28	5					361	370		10.1097/HTR.0b013e31824da031			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZU	WOS:000330364600082	22613944	Green Accepted			2021-06-18	
J	Mao, HJ; Elkin, BS; Genthikatti, VV; Morrison, B; Yang, KH				Mao, Haojie; Elkin, Benjamin S.; Genthikatti, Vinay V.; Morrison, Barclay, III; Yang, King H.			Why Is CA3 More Vulnerable Than CA1 in Experimental Models of Controlled Cortical Impact-Induced Brain Injury?	JOURNAL OF NEUROTRAUMA			English	Article						brain injury biomechanics; brain material; controlled cortical impact; finite element method; heterogeneous hippocampus injury; rat brain modeling	FINITE-ELEMENT MODEL; IN-VITRO MODEL; LIVING BRAIN; RAT; HIPPOCAMPUS; CULTURES; STRETCH; STRAIN	One interesting finding of controlled cortical impact (CCI) experiments is that the CA3 region of the hippocampus, which is positioned further from the impact than the CA1 region, is reported as being more injured. The current literature has suggested a positive correlation between brain tissue stretch and neuronal cell loss. However, it is counterintuitive to assume that CA3 is stretched more during CCI injury. Recent mechanical studies of the brain have reported on a level of spatial heterogeneity not previously appreciated-the finding that CA1 was significantly stiffer than all other regions tested and that CA3 was one of the most compliant. We hypothesized that mechanical heterogeneity of anatomical structures could underlie the proposed heterogeneous mechanical response and hence the pattern of cell death. As such, we developed a three-dimensional finite element (FE) rat brain model representing detailed hippocampal structures and simulated various CCI experiments. Four groups of material properties based on recent experiments were tested. In group 1, hyperelastic material properties were assigned to various hippocampal structures, with CA3 more compliant than CA1. In group 2, linear viscoelastic material properties were assigned to hippocampal structures, with CA3 more compliant than CA1. In group 3, the hippocampus was represented by homogenous linear viscoelastic material properties. In group 4, a homogeneous nonlinear hippocampus was adopted. Simulation results demonstrated that for CCI with a 5-mm diameter, flat shape impactor, CA3 experienced increased tensile strains over a larger area and to a greater magnitude than did CA1 for group 1, which best explained why CA3 is more sensitive to CCI injury. However, for groups 2-4, the total volume with high strain (>30%) in CA3 was smaller than that in CA1. The FE rat brain model, with detailed hippocampal structures presented here, will help to engineer desired experimental neurotrauma models by virtually characterizing brain biomechanics before testing.	[Mao, Haojie; Genthikatti, Vinay V.; Yang, King H.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Elkin, Benjamin S.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY USA	Yang, KH (corresponding author), Wayne State Univ, Ctr Bioengn, 818 West Hancock, Detroit, MI 48201 USA.	king.yang@wayne.edu	Morrison, Barclay/B-7132-2008; Mao, Haojie/Q-7514-2018	Morrison, Barclay/0000-0001-7676-0864; Mao, Haojie/0000-0002-7563-9234	National Highway Traffic Safety Administration [DTNH22-08-C-00088]	The authors appreciate Dr. Michelle LaPlaca's help in describing CCI experiments. The authors thank Mr. Amandeep Gill, Mr. Gurdeep Jandir, Mr. Amrinder Singh, and Mr. Chintan Shelat for their help, in part, with meshing and simulation. The authors acknowledge Mr. Abrar Wazir for proofreading. This work was supported, in part, by the National Highway Traffic Safety Administration (DTNH22-08-C-00088).	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Baumgartner D, 2011, COMPUT METHOD BIOMEC, V14, P273, DOI 10.1080/10255842.2011.595240; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2011, J NEUROTRAUM, V28, P2235, DOI 10.1089/neu.2010.1604; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kreisman NR, 2000, J NEUROPHYSIOL, V83, P1031; Lamy M, 2013, MED BIOL ENG COMPUT, V51, P353, DOI 10.1007/s11517-012-1004-7; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shreiber D.I., 1997, 41 STAPP CAR CRASH C; Stemper B.D., 2011, J NEUROTRAUM, V28, pA; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yeoh S., 2011, ASME 2011 SUMM BIOEN	28	23	25	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1521	1530		10.1089/neu.2012.2520			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800008	23557208	Green Published			2021-06-18	
J	Amick, MM; Clark, A; Fortier, CB; Esterman, M; Rasmusson, AM; Kenna, A; Milberg, WP; McGlinchey, R				Amick, Melissa M.; Clark, Alexandra; Fortier, Catherine B.; Esterman, Michael; Rasmusson, Ann M.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina			PTSD Modifies Performance on a Task of Affective Executive Control among Deployed OEF/OIF Veterans with Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Post-traumatic stress disorder; Attention; Brain injury; Military; Cognition; Deployment	POSTTRAUMATIC-STRESS-DISORDER; LARGE-SAMPLE; HEAD-INJURY; ATTENTION; IRAQ; INFORMATION; AFGHANISTAN; INHIBITION; MILITARY; EMOTION	Individuals with post-traumatic stress disorder (PTSD) show a cognitive bias for threatening information, reflecting dysregulated executive control for affective stimuli. This study examined whether comorbid mild Traumatic Brain Injury (mTBI) with PTSD exacerbates this bias. A computer-administered Affective Go/No-Go task measured reaction times (RTs) and errors of omission and commission to words with a non-combat-related positive or negative valence in 72 deployed United States service members from the wars in Iraq and Afghanistan. Incidents of military-related mTBI were measured with the Boston Assessment of Traumatic Brain Injury-Lifetime. PTSD symptoms were measured with the Clinician-Administered PTSD Scale. Participants were divided into those with (mTBI+, n = 34) and without a history of military-related mTBI (mTBI-, n = 38). Valence of the target stimuli differentially impacted errors of commission and decision bias (criterion) in the mTBI+ and mTBI- groups. Specifically, within the mTBI+ group, increasing severity of PTSD symptoms was associated with an increasingly liberal response pattern (defined as more commission errors to negative distractors and greater hit rate for positive stimuli) in the positive compared to the negative blocks. This association was not observed in the mTBI- group. This study underscores the importance of considering the impact of a military-related mTBI and PTSD severity upon affective executive control.	[Amick, Melissa M.; Clark, Alexandra; Fortier, Catherine B.; Esterman, Michael; Rasmusson, Ann M.; Kenna, Alexandra; Milberg, William P.; McGlinchey, Regina] VA Boston Healthcare Syst, Translat Res Ctr Traumat Brain Injury & Stress Di, Boston, MA 02130 USA; [Amick, Melissa M.; Esterman, Michael; Rasmusson, Ann M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Fortier, Catherine B.; Milberg, William P.; McGlinchey, Regina] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Milberg, William P.; McGlinchey, Regina] VA Boston Healthcare Syst, Ctr Geriatr Res Educ & Clin, Boston, MA USA	Amick, MM (corresponding author), VA Boston Healthcare Syst 182 JP, Translat Res Ctr Traumat Brain Injury & Stress Di, 150 South Huntington Ave, Boston, MA 02130 USA.	melissa.amick@va.gov		Milberg, William/0000-0002-6078-7066; Esterman, Michael/0000-0002-9000-3920	RR&D TBI Center of Excellence at VA Boston Healthcare System, The Translational Research Center for TBI and Stress Disorders; VA Rehabilitation Research and Development Center [B6796-C]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG034258] Funding Source: NIH RePORTER	This work was supported by the RR&D TBI Center of Excellence at VA Boston Healthcare System, The Translational Research Center for TBI and Stress Disorders. We thank all of the individuals who participated in this study. We thank Dr. Gheorghe Doros for his advisement in our statistical approach. We are grateful to all members of the Human Characterization Core of TRACTS: Marge Alhquist, BS, Brad Brummett, PhD, Racheal Dayton, BS, Andrea Levine, MA, Kathleen Moriarty, BS, Lindsay Morra, BA, Roxanne Moyer, BS, Erica Scioli, PhD, Jonathan Venne, BS, Ruby Ward, BA, David Zade PhD for their expert assessment skills. We would also like to thank Walter Musto for his extraordinary recruitment efforts and Joe Degutis, PhD, Jennifer Vasterling, PhD, and Mieke Verfaellie PhD, for valuable feedback in the interpretation of our results. These findings were presented in part at the annual meetings of the International Neuropsychological Society, 2011, the International Trauma and Stress Society, 2011, the Federal Interagency Conference on TBI, 2011, and the American Psychological Association, 2012. The authors report no conflicts of interest. This research was supported by a VA Rehabilitation Research and Development Center Grant B6796-C awarded to Dr. Regina McGlinchey.	Amir N, 2009, J CONSULT CLIN PSYCH, V77, P961, DOI 10.1037/a0016685; Atkinson MP, 2009, MANAGE SCI, V55, P1454, DOI 10.1287/mnsc.1090.1042; Aupperle RL, 2012, ARCH GEN PSYCHIAT, V69, P360, DOI 10.1001/archgenpsychiatry.2011.1539; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLAKE DD, 1993, BEHAV THER, V18, P187; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Calhoun PS, 2010, PSYCHIAT RES, V178, P330, DOI 10.1016/j.psychres.2009.11.009; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; Cisler JM, 2010, J PSYCHOPATHOL BEHAV, V32, P68, DOI 10.1007/s10862-009-9161-1; Constans JI, 2004, J ABNORM PSYCHOL, V113, P315, DOI 10.1037/0021-843X.113.2.315; Constans JJ, 2005, NEUROPSYCHOLOGY PTSD, P105; Crawford MA, 2007, J INT NEUROPSYCH SOC, V13, P178, DOI 10.1017/S135561770707021X; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; DeGutis J, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.044.2009; DeGutis JM, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00060; Eldar S, 2010, PSYCHOL MED, V40, P667, DOI 10.1017/S0033291709990766; Esterman M., 2012, CEREBRAL CORTEX; Falconer E, 2008, J PSYCHIATR NEUROSCI, V33, P413; Fortier C.B., 2013, J HEAD TRAUMA REHABI; Green P, 2003, GREENS MED SYMPTOM V; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hayes JP, 2009, PSYCHIAT RES-NEUROIM, V172, P7, DOI 10.1016/j.pscychresns.2008.05.005; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kimble MO, 2010, J ANXIETY DISORD, V24, P293, DOI 10.1016/j.janxdis.2009.12.006; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Pineles SL, 2009, BEHAV RES THER, V47, P1050, DOI 10.1016/j.brat.2009.08.001; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; ROBBINS TW, 1994, DEMENTIA, V5, P266, DOI 10.1159/000106735; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; THRASHER SM, 1994, BEHAV RES THER, V32, P247, DOI 10.1016/0005-7967(94)90119-8; Van Zomeren AH, 1984, ATTENTIONAL DEFICITS; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Walilko T, 2009, J TRAUMA, V67, P1311, DOI 10.1097/TA.0b013e31819adc36	58	23	24	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	AUG	2013	19	7					792	801		10.1017/S1355617713000544			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	186CI	WOS:000322018900006	23823533	Green Accepted			2021-06-18	
J	Eskandari, R; Filtz, MR; Davis, GE; Hoesch, RE				Eskandari, Ramin; Filtz, Michael R.; Davis, Gary E.; Hoesch, Robert E.			Effective treatment of refractory intracranial hypertension after traumatic brain injury with repeated boluses of 14.6% hypertonic saline Clinical article	JOURNAL OF NEUROSURGERY			English	Article						hypertonic saline solution; traumatic brain injury; intracranial pressure; refractory; intracranial hypertension; neurocritical care	SEVERE HEAD-INJURY; TRANSTENTORIAL HERNIATION; SODIUM-CHLORIDE; UNITED-STATES; MANNITOL; PRESSURE; CHILDREN; RESUSCITATION; THERAPY; MANAGEMENT	Object. Normal intracranial pressure (ICP) and cerebral perfusion pressure (CPP) have been identified as favorable prognostic factors in the outcome of patients with traumatic brain injuries (TBIs). Osmotic diuretics and hypertonic saline (HTS) are commonly used to treat elevated ICP in patients with TBI; however, sustained effects of repeated high-concentration HTS boluses for severely refractory ICP elevation have not been studied. The authors' goal in this study was to determine whether repeated 14.6% HTS boluses were efficacious in treating severely refractory intracranial hypertension in patients with TBI. Methods. In a prospective cohort study in a neurocritical care unit, adult TBI patients with sustained ICP > 30 mm Hg for more than 30 minutes after exhaustive medical and/or surgical therapy received repeated 15-minute boluses of 14.6% HTS over 12 hours through central venous access. Results. Response to treatment was evaluated in 11 patients. Within 5 minutes of bolus administration, mean ICP decreased from 40 to 33 mm Hg (30% reduction, p < 0.05). Intracranial pressure lowering effects were sustained for 12 hours (41% reduction, p < 0.05) with multiple boluses (mean number of boluses 7 +/- 5.5). The mean CPP increased 22% and 32% from baseline at 15 and 30 minutes, respectively (p < 0.05). The mean serum sodium level (S-Na) at baseline was 155 +/- 7.1 mEq/L, and after multiple boluses of 14.6% HTS, S-Na at 12 hours was 154 +/- 7.1 mEq/L. The mean heart rate, systolic blood pressure, blood urea nitrogen, and creatinine demonstrated no significant change throughout the study. Conclusions. The subset of TBI patients with intracranial hypertension that is completely refractory to all other medical therapies can be treated effectively and safely with repeated boluses of 14.6% HTS rather than a one-time dose.	[Eskandari, Ramin] Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA; [Hoesch, Robert E.] Univ Utah, Dept Neurol, Div Neurocrit Care, Salt Lake City, UT 84132 USA; [Filtz, Michael R.; Davis, Gary E.] Univ Utah Hosp, Dept Pharm Serv, Salt Lake City, UT USA	Hoesch, RE (corresponding author), Univ Utah, Dept Neurol, Div Neurocrit Care, 175 N Med Dr East, Salt Lake City, UT 84132 USA.	robert.hoesch@hsc.utah.edu					Balbino M, 2010, J TRAUMA, V68, P859, DOI 10.1097/TA.0b013e3181af69d3; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Beaumont A, 1999, CRIT REV NEUROSURG, V9, P207, DOI 10.1007/s003290050135; Bell Scott E, 2006, Curr Treat Options Neurol, V8, P167, DOI 10.1007/s11940-006-0007-9; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Castillo LB, 2009, CRIT CARE RESUSC, V11, P151; Cohen H, 1924, BRIT MED J, V1924, P420, DOI 10.1136/bmj.1.3297.420; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; da Silva JC, 2010, NEUROL RES, V32, P139, DOI 10.1179/174313209X405119; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Hartl R, 2008, CRIT CARE MED, V36, P1005, DOI 10.1097/CCM.0B013E318166FCF8; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Himmelseher S, 2007, CURR OPIN ANESTHESIO, V20, P414, DOI 10.1097/ACO.0b013e3282eff9ea; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Keyrouz SG, 2008, NEUROCRIT CARE, V9, P204, DOI 10.1007/s12028-008-9118-3; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Luostarinen T, 2011, NEUROCRIT CARE, V14, P238, DOI 10.1007/s12028-010-9475-6; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Paredes-Andrade E, 2012, NEUROCRIT CARE, V17, P204, DOI 10.1007/s12028-011-9574-z; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 2002, J NEUROSURG ANESTH, V14, P22, DOI 10.1097/00008506-200201000-00005; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; Schatzmann C, 1998, ACT NEUR S, V71, P31; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; Strandvik GF, 2009, ANAESTHESIA, V64, P990, DOI 10.1111/j.1365-2044.2009.05986.x; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Sutherland WD, 1911, BIOCHEM J, V5, P1; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; Yilmaz N, 2007, BRAIN RES, V1164, P132, DOI 10.1016/j.brainres.2007.06.017	50	23	23	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2013	119	2					338	346		10.3171/2013.4.JNS121541			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	187CL	WOS:000322094400013	23706055				2021-06-18	
J	Eskridge, SL; Macera, CA; Galarneau, MR; Holbrook, TL; Woodruff, SI; MacGregor, AJ; Morton, DJ; Shaffer, RA				Eskridge, Susan L.; Macera, Caroline A.; Galarneau, Michael R.; Holbrook, Troy L.; Woodruff, Susan I.; MacGregor, Andrew J.; Morton, Deborah J.; Shaffer, Richard A.			Influence of Combat Blast-Related Mild Traumatic Brain Injury Acute Symptoms on Mental Health and Service Discharge Outcomes	JOURNAL OF NEUROTRAUMA			English	Article						combat blast injury; functional outcomes; mental health; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; US SOLDIERS; IRAQ; PREDICTORS; REGISTRY; RISK	Assessment of acute mild traumatic brain injury (mTBI) symptoms after a combat blast could aid diagnosis and guide follow-up care. Our objective was to document acute mTBI symptoms following a combat blast and to examine associations between acute symptoms and mental health and service discharge outcomes. A retrospective cohort study was conducted with 1656 service personnel who experienced a combat blast-related mTBI in Iraq. Acute mTBI symptoms were ascertained from point-of-injury medical records. The associations between acute symptoms and posttraumatic stress disorder (PTSD), postconcussion syndrome (PCS), and type of service discharge were examined. Disability discharge occurred in 11% of patients, while 36% had a non-disability discharge and 52% had no recorded discharge. A PTSD and PCS diagnosis was made in 19% and 15% of the sample, respectively. The most common acute mTBI symptoms were headache (62.8%), loss of consciousness (LOC) (34.5%), and tinnitus (33.2%). LOC was predictive of PTSD (odds ratio [OR] 1.54; 95% confidence interval [CI] 1.18, 2.00) and PCS (OR 2.08; 95% CI 1.56, 2.77), while altered mental status (OR 1.53; 95% CI 1.07, 2.17) and previous blast history (OR 1.83; 95% CI 1.15, 2.90) also were predictive of PCS. While no acute mTBI symptoms were associated with discharge outcomes, injury severity was associated with disability discharge. LOC after blast-related mTBI was associated with PTSD and PCS, and injury severity was predictive of disability discharge. The assessment of cognitive status immediately after a blast could assist in diagnosing mTBI and indicate a need for follow-up care.	[Eskridge, Susan L.; Galarneau, Michael R.; MacGregor, Andrew J.] Naval Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA; [Macera, Caroline A.; Shaffer, Richard A.] Naval Hlth Res Ctr, Dept Def, HIV AIDS Prevent Program, San Diego, CA 92106 USA; [Macera, Caroline A.; Shaffer, Richard A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA; [Holbrook, Troy L.] San Diego State Univ, Sch Social Work, San Diego, CA 92182 USA; [Woodruff, Susan I.] EPI SOAR Consulting Inc, San Diego, CA USA; [Morton, Deborah J.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA	Eskridge, SL (corresponding author), Naval Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, 140 Sylvester Rd, San Diego, CA 92106 USA.	susan.eskridge@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390; Eskridge, Susan/0000-0002-1817-8355	U.S. Navy Bureau of Medicine and Surgery [60808]	This work was supported by the U.S. Navy Bureau of Medicine and Surgery under the Wounded, Ill, and Injured/Psychological Health/Traumatic Brain Injury Program under work unit 60808. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U.S. Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (protocol NHRC. 2009.0023).	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Defense and Veteran Brain Injury (DVBIC), 2008, DEF VET BRAIN INJ CT; Department of Defense, 2010, OP IR FREED OIF US C; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Helmick K., 2007, FEDERAL PRACTITIONER, P58; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCracken DL, 2005, TRAUMATIC BRAIN INJU; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2008, MILD TRAUMATIC BRAIN; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Zoroya G, 2009, US TODAY	29	23	23	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2013	30	16					1391	1397		10.1089/neu.2012.2537			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	199JB	WOS:000322989500002	23489170				2021-06-18	
J	Nishijima, DK; Shahlaie, K; Sarkar, K; Rudisill, N; Holmes, JF				Nishijima, Daniel K.; Shahlaie, Kiarash; Sarkar, Korak; Rudisill, Nancy; Holmes, James F.			Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							HEAD-INJURY; PREINJURY WARFARIN; ELDERLY-PATIENTS; BRAIN-INJURY; MANAGEMENT; THERAPY; TRIALS; SCALES	Study objective: The objective was to compare neurological outcomes at 6 months in older patients with preinjury warfarin or clopidogrel use and mild traumatic intracranial hemorrhage with those without prior use of these medications. Methods: This was a retrospective study conducted at a Level 1 trauma center from April 2009 to July 2010. Patients older than 55 years with isolated mild head injury (Glasgow Coma Scale score 13-15 and Abbreviated Injury Score <3 in nonhead body region) were included. Demographic, clinical, and outcome data were abstracted from an existing traumatic brain injury database. The primary end point of unfavorable extended Glasgow Outcome Score at 6 months was compared between patients with and without preinjury warfarin or clopidogrel use. Results: Seventy-seven eligible patients were identified: 27 (35%) with preinjury warfarin or clopidogrel use and 50 (65%) without. Baseline characteristics (sex, Glasgow Coma Scale score, Injury Severity Score, computed tomography score, and in-hospital mortality) were similar between cohorts, although the preinjury warfarin or clopidogrel cohort was older than the control group (P < .05). Patients in the preinjury warfarin or clopidogrel cohort were more likely to have an unfavorable outcome (16/27; 59.3%; 95% confidence interval, 40.7%-77.8%) as compared with those without (18/50; 36.0%; 95% confidence interval, 22.7%-49.3%) (P = .05). Conclusion: Older adults with preinjury warfarin or clopidogrel use and mild traumatic intracranial hemorrhage may be at an increased risk for unfavorable long-term neurological outcomes compared with similar patients without preinjury use of these medications. (C) 2013 Elsevier Inc. All rights reserved.	[Nishijima, Daniel K.; Holmes, James F.] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Shahlaie, Kiarash; Rudisill, Nancy] Univ Calif Davis, Sch Med, Dept Neurol Surg, Sacramento, CA 95817 USA; [Sarkar, Korak] Univ Calif Davis, Sch Med, Dept Neurol, Sacramento, CA 95817 USA	Nishijima, DK (corresponding author), Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA.	daniel.nishijima@ucdmc.ucdavis.edu			National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002, KL2TR000134]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002, KL2TR000134] Funding Source: NIH RePORTER	DN was supported through a Mentored Clinical Research Training Program Award (grant UL1TR000002 and linked award KL2TR000134) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NCATS and NIH had no role in the design and conduct of the study, in the analysis or interpretation of the data, or in the preparation of the data. The views expressed in this article are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH. Information on NCATS is available at http://www.ncats.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.	Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Karni A, 2001, AM SURGEON, V67, P1098; Kawamata T, 1995, SURG NEUROL, V44, P438, DOI 10.1016/0090-3019(95)00249-9; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yasuda CL, 2003, ARQ NEURO-PSIQUIAT, V61, P1011, DOI 10.1590/S0004-282X2003000600023	17	23	24	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	AUG	2013	31	8					1244	1247		10.1016/j.ajem.2013.04.035			4	Emergency Medicine	Emergency Medicine	201SN	WOS:000323163400017	23759685	Green Accepted			2021-06-18	
J	Raj, R; Siironen, J; Kivisaari, R; Hernesniemi, J; Tanskanen, P; Handolin, L; Skrifvars, MB				Raj, Rahul; Siironen, Jari; Kivisaari, Riku; Hernesniemi, Juha; Tanskanen, Paivi; Handolin, Lauri; Skrifvars, Markus B.			External Validation of the International Mission for Prognosis and Analysis of Clinical Trials Model and the Role of Markers of Coagulation	NEUROSURGERY			English	Article						Coagulation; Prognosis; Prognostic model; Traumatic brain injury; Validation	TRAUMATIC BRAIN-INJURY; ANTICOAGULATION; IMPACT; COAGULOPATHY; MODERATE; MORTALITY; INCREASE; DESIGN; SCORE	BACKGROUND: Markers of coagulation have shown to have important value in predicting traumatic brain injury outcome. OBJECTIVE: To externally validate and investigate the role of markers of coagulation for outcome prediction by using the International Mission for Prognosis and Analysis of Clinical Trials (IMPACT) model while adjusting for overall injury severity. METHODS: A retrospective chart analysis of traumatic brain injury patients admitted to Helsinki University Central Hospital between 2009 and 2010 was performed. Outcome was estimated by using the criteria of the IMPACT model. Admission international normalized ratio (INR) and platelet count were used as markers of coagulation. Overall injury severity was categorized with the injury severity score (ISS). Variables were added to the calculated IMPACT risk, generating new models. Model performance was assessed by analyzing and comparing the area under the curve (AUC) of the models. RESULTS: For 342 included patients, 6-month mortality was 32% and unfavorable neurological outcome was 36%. Patients with a poor outcome had lower platelets and higher INR and ISS than those with good outcome (P < .001). The IMPACT model had an AUC of 0.85 for predicting mortality and 0.81 for neurological outcome. Addition of INR but not ISS or platelets to the IMPACT predicted risk improved the predictive validity for mortality (Delta AUC 0.02, P = .034) but not neurological outcome (Delta AUC 0.00, P = .401). In multivariate analysis, INR remained significant for mortality but not for neurological outcome when adjusting for IMPACT risk and ISS (P = .012). CONCLUSION: The IMPACT model showed excellent performance, and INR was an independent predictor for mortality, independent of overall injury severity.	[Raj, Rahul; Siironen, Jari; Kivisaari, Riku; Hernesniemi, Juha] Univ Helsinki, Cent Hosp, Dept Neurosurg, FIN-00029 Helsinki, Finland; [Raj, Rahul; Tanskanen, Paivi; Skrifvars, Markus B.] Univ Helsinki, Cent Hosp, Dept Anaesthesiol & Intens Care Med, FIN-00029 Helsinki, Finland; [Handolin, Lauri] Univ Helsinki, Cent Hosp, Dept Orthoped & Traumatol, FIN-00029 Helsinki, Finland	Raj, R (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurosurg, C-O Markus Skrifvars,Topeliuksenkatu 5,PL 266, FIN-00029 Helsinki, Finland.	rahul.raj@helsinki.fi	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591	Division Of Mathematical SciencesNational Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS) [1106891] Funding Source: National Science Foundation		Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Franschman G, 2012, J NEUROTRAUM, V29, P128, DOI 10.1089/neu.2011.2044; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Ott MM, 2010, J TRAUMA, V68, P560, DOI 10.1097/TA.0b013e3181ad6600; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348	26	23	23	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2013	73	2					305	311		10.1227/01.neu.0000430326.40763.ec			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	299GD	WOS:000330383100045	23867260				2021-06-18	
J	Yi, X; Jin, GH; Zhang, XH; Mao, WF; Li, HM; Qin, JB; Shi, JH; Dai, K; Zhang, F				Yi, Xin; Jin, Guohua; Zhang, Xinhua; Mao, Weifeng; Li, Haoming; Qin, Jianbing; Shi, Jinhong; Dai, Kui; Zhang, Fan			Cortical Endogenic Neural Regeneration of Adult Rat after Traumatic Brain Injury	PLOS ONE			English	Article							STEM-CELLS; SUBVENTRICULAR ZONE; COGNITIVE FUNCTION; GENERATED NEURONS; CEREBRAL-CORTEX; RADIAL GLIA; NEUROGENESIS; NEOCORTEX; PROGENITOR; MIGRATION	Focal and diffuse neuronal loss happened after traumatic brain injury (TBI). With little in the way of effective repair, recent interest has focused on endogenic neural progenitor cells (NPCs) as a potential method for regeneration. Whether endogenic neural regeneration happened in the cortex of adult rat after TBI remains to be determined. In this study, rats were divided into a sham group and a TBI group, and the rat model of medium TBI was induced by controlled cortical impact. Rats were injected with BrdU at 1 to 7 days post-injury (dpi) to allow identification of differentiated cells and sacrificed at 1, 3, 7, 14 and 28 dpi for immunofluorescence. Results showed nestin(+)/sox-2(+) NPCs and GFAP(+)/sox-2(+) radial glial (RG)-like cells emerged in peri-injured cortex at 1, 3, 7, 14 dpi and peaked at 3 dpi. The number of GFAP(+)/sox-2(+) cells was less than that of nestin(+)/sox-2(+) cells. Nestin(+)/sox-2(+) cells from posterior periventricle (pPV) immigrated into peri-injured cortex through corpus callosum (CC) were found. DCX+/BrdU(+) newborn immature neurons in peri-injured cortex were found only at 3, 7, 14 dpi. A few MAP-2(+)/BrdU(+) newborn neurons in peri-injured cortex were found only at 7 and 14 dpi. NeuN(+)/BrdU(+) mature neurons were not found in peri-injured cortex at 1, 3, 7, 14 and 28 dpi. While GFAP(+)/BrdU(+) astrocytes emerged in peri-injured cortex at 1, 3, 7, 14, 28 dpi and peaked at 7 dpi then kept in a stable state. In the corresponding time point, the percentage of GFAP(+)/BrdU(+) astrocytes in BrdU(+) cells was more than that of NPCs or newborn neurons. No CNP+/BrdU(+) oligodendrocytes were found in peri-injured cortex. These findings suggest that NPCs from pPV and reactive RG-like cells emerge in peri-injured cortex of adult rats after TBI. It can differentiate into immature neurons and astrocytes, but the former fail to grow up to mature neurons.	[Yi, Xin] Soochow Univ, Coll Med, Dept Anat & Cytoneurobiol, Suzhou, Peoples R China; [Yi, Xin; Jin, Guohua; Zhang, Xinhua; Mao, Weifeng; Li, Haoming; Qin, Jianbing; Shi, Jinhong] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Dept Anat & Neurobiol, Nantong, Peoples R China; [Dai, Kui; Zhang, Fan] Nantong Univ, Xinglin Coll, Nantong, Peoples R China	Jin, GH (corresponding author), Nantong Univ, Jiangsu Key Lab Neuroregenerat, Dept Anat & Neurobiol, Nantong, Peoples R China.	jguohua@ntu.edu.cn		Zhang, Xin-hua/0000-0002-5702-6733	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31271138]; Jiangsu Natural Science FoundationNatural Science Foundation of Jiangsu Province [BK2012659]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by grants from the National Natural Science Foundation of China (Grant No. 31271138), the Jiangsu Natural Science Foundation (Grant No. BK2012659), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed AI, 2012, J NEUROTRAUM, V29, P828, DOI 10.1089/neu.2011.1923; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Ghashghaei HT, 2007, GENE DEV, V21, P3258, DOI 10.1101/gad.1580407; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li HM, 2011, IN VITRO CELL DEV-AN, V47, P431, DOI 10.1007/s11626-011-9422-7; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Magavi SS, 2000, NATURE, V405, P951; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Otero L, 2012, HISTOL HISTOPATHOL, V27, P303, DOI 10.14670/HH-27.303; Oya S, 2009, NEUROSCIENCE, V158, P683, DOI 10.1016/j.neuroscience.2008.10.043; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Rakic P, 2004, NATURE, V427, P685, DOI 10.1038/427685a; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2006, ACTA NEUROCHIR, V148, P773, DOI 10.1007/s00701-006-0778-5; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Zhao CS, 2008, EPILEPSIA, V49, P3, DOI 10.1111/j.1528-1167.2008.01632.x	38	23	25	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2013	8	7							e70306	10.1371/journal.pone.0070306			13	Multidisciplinary Sciences	Science & Technology - Other Topics	204MP	WOS:000323369700168	23922973	DOAJ Gold, Green Published			2021-06-18	
J	Bose, P; Hou, JM; Nelson, R; Nissim, N; Parmer, R; Keener, J; Wacnik, PW; Thompson, FJ				Bose, Prodip; Hou, Jiamei; Nelson, Rachel; Nissim, Nicole; Parmer, Ron; Keener, Jonathon; Wacnik, Paul W.; Thompson, Floyd J.			Effects of Acute Intrathecal Baclofen in an Animal Model of TBI-Induced Spasticity, Cognitive, and Balance Disabilities	JOURNAL OF NEUROTRAUMA			English	Article						ankle torque; EMG, GABA(b); ITB; TBI spasticity	TRAUMATIC BRAIN-INJURY; MOTONEURONS IN-VIVO; PERSISTENT INWARD CURRENT; DEPENDENT ANKLE TORQUE; DIFFUSE AXONAL INJURY; SPINAL-CORD; LOCUS-CERULEUS; VESTIBULAR COMPENSATION; OVERGROUND LOCOMOTION; SYSTEMATIC VARIATIONS	Spasticity is a major health problem for patients with traumatic brain injury (TBI). In addition to spasticity, TBI patients exhibit enduring cognitive, balance, and other motor impairments. Although the use of antispastic medications, particularly ITB, can decrease the severity of TBI-induced spasticity, current guidelines preclude the use of ITB during the first year after TBI. Therefore, the present study was performed to quantitate disability in an animal model of closed-head TBI (cTBI; Mararou's model) after ITB treatment. After cTBI, significant deficits in spasticity and gait, cognitive, balance, and anxiety-like behaviors were detected. ITB (Lioresal (R)) or saline was administered using Alzet pumps (0.8 mu g/hour for 4 weeks). Spasticity measures using velocity-dependent ankle torque and ankle extensor muscle electromyography recordings, footprints (gait), balance performance tests, serial learning, and anxiety-like behaviors were performed at multiple post-treatment and -withdrawal of ITB time points. Our data indicated that 1 month of ITB treatment initiated at post-TBI week 1 blocked the early onset of spasticity and significantly attenuated late-onset spasticity and anxiety-like behavior with no significant adverse effects on cognitive and balance performance. This improved spasticity outcome was accompanied by marked up-regulation of gamma-aminobutyric acid (GABA)/GABA(b), norepinephrine, and brain-derived neurotrophic factor expression in spinal cord tissue. Early intervention with ITB treatment was safe, feasible, and effective in this cTBI animal model. Collectively, these data provide a strong molecular footprint of enhanced expression of reflex regulation by presynaptic inhibition. The possibility that acute ITB treatment may decrease maladaptive segmental and descending plasticity is discussed. The data provided by the present animal model initiates a pre-clinical platform for safety, feasibility, and efficacy of early ITB intervention after TBI.	[Bose, Prodip; Nelson, Rachel; Nissim, Nicole; Parmer, Ron; Thompson, Floyd J.] North Florida South Georgia VA Hlth Syst, Brain Rehabil Res Ctr 151, Gainesville, FL USA; [Bose, Prodip; Hou, Jiamei; Keener, Jonathon; Thompson, Floyd J.] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA; [Bose, Prodip] Univ Florida, Dept Neurol, Gainesville, FL USA; [Thompson, Floyd J.] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; [Wacnik, Paul W.] Medtronic Inc, Neuromodulat Targeted Drug Delivery, Minneapolis, MN USA	Bose, P (corresponding author), Malcom Randal VA Med Ctr, Brain Rehabil Res Ctr 151, 1601 Southwest Archer Rd, Gainesville, FL 32608 USA.	prodip.bose@va.gov			Medtronic Inc.Medtronic; Department of Veteran AffairsUS Department of Veterans Affairs [B6570R, B78071, B7345S]; Veterans AffairsUS Department of Veterans Affairs [I01RX000502] Funding Source: NIH RePORTER	This work was supported by Medtronic Inc. and the Department of Veteran Affairs (Rehabilitation R&D Merit Review B6570R; R&D Merit B78071; R&D RCS B7345S).	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Arolfo MP, 1998, HIPPOCAMPUS, V8, P109, DOI 10.1002/(SICI)1098-1063(1998)8:2<109::AID-HIPO2>3.0.CO;2-G; Balaban CD, 2000, NEUROSCIENCE, V99, P669, DOI 10.1016/S0306-4522(00)00232-3; Beaumont A, 2000, NEUROL RES, V22, P665; Bennett DJ, 1996, J PHYSIOL-LONDON, V495, P835, DOI 10.1113/jphysiol.1996.sp021636; Bennett DJ, 1998, J NEUROPHYSIOL, V80, P2023; BETTS RP, 1978, J NEUROL NEUROSUR PS, V41, P791, DOI 10.1136/jnnp.41.9.791; Bose P, 2002, J NEUROTRAUM, V19, P1231, DOI 10.1089/08977150260338029; Bose P.K., 2002, J NEUROTRAUM, V19, P1229; Bose PK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00258; BOWERY NG, 1980, NATURE, V283, P92, DOI 10.1038/283092a0; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CLARKE KA, 1992, BEHAV RES METH INSTR, V24, P407, DOI 10.3758/BF03203570; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DENNIS T, 1985, N-S ARCH PHARMACOL, V331, P225, DOI 10.1007/BF00634242; Drake RG, 2003, ANN PHARMACOTHER, V37, P1177, DOI 10.1345/aph.1C465; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FOSTER GA, 1989, BRAIN RES BULL, V22, P131, DOI 10.1016/0361-9230(89)90137-8; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Francisco GE, 2005, BRAIN INJURY, V19, P359, DOI 10.1080/02699050400003999; FUKUDA H, 1977, EUR J PHARMACOL, V44, P17; Garcia C, 2003, NEUROSCIENCE, V119, P721, DOI 10.1016/S0306-4522(03)00192-1; Gladden MH, 2000, J PHYSIOL-LONDON, V527, P213, DOI 10.1111/j.1469-7793.2000.00213.x; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Heskin-Sweezie R, 2010, NEUROSCIENCE, V169, P302, DOI 10.1016/j.neuroscience.2010.04.008; HOUNSGAARD J, 1984, EXP BRAIN RES, V55, P391; JANKOWSKA E, 1993, J PHYSIOL-LONDON, V461, P705, DOI 10.1113/jphysiol.1993.sp019537; JIMENEZ I, 1991, EXP BRAIN RES, V85, P103; KERNELL D, 1979, BRAIN RES, V160, P159, DOI 10.1016/0006-8993(79)90612-7; Khoshbouei H, 2002, PHARMACOL BIOCHEM BE, V71, P407, DOI 10.1016/S0091-3057(01)00683-9; KROIN JS, 1993, J NEUROSURG, V79, P544, DOI 10.3171/jns.1993.79.4.0544; Lee RH, 2003, J NEUROPHYSIOL, V89, P27, DOI 10.1152/jn.00137.2002; Lee RH, 1998, J NEUROPHYSIOL, V80, P572; Lee RH, 1998, J NEUROPHYSIOL, V80, P583; Lee RH, 1999, J NEUROPHYSIOL, V81, P2164; Lee RH, 2000, J NEUROSCI, V20, P6734, DOI 10.1523/JNEUROSCI.20-17-06734.2000; Li Y, 2004, J NEUROPHYSIOL, V92, P2694, DOI 10.1152/jn.00164.2004; Loy DN, 2002, EXP NEUROL, V177, P575, DOI 10.1006/exnr.2002.7959; Luft AR, 2002, EXP BRAIN RES, V142, P562, DOI 10.1007/s00221-001-0952-1; Luft AR, 2001, EXP BRAIN RES, V140, P112, DOI 10.1007/s002210100805; Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016; Magnusson AK, 1998, BRAIN RES, V795, P307, DOI 10.1016/S0006-8993(98)00329-1; Magnusson AK, 2000, EXP BRAIN RES, V134, P32, DOI 10.1007/s002210000438; MALCANGIO M, 1993, NEUROSCI LETT, V158, P189, DOI 10.1016/0304-3940(93)90261-I; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matsuyama K, 2004, PROG BRAIN RES, V143, P239, DOI 10.1016/S0079-6123(03)43024-0; McGuire L., 2011, EPIDEMIOLOGY TRAUMAT; McNamara RK, 1996, PHARMACOL BIOCHEM BE, V53, P303, DOI 10.1016/0091-3057(95)02025-X; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 2003, ARCH PHYS MED REHAB, V84, P638, DOI 10.1016/S0003-9993(03)00105-9; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; POMPEIANO O, 1990, NEUROSCIENCE, V35, P227, DOI 10.1016/0306-4522(90)90078-I; POMPEIANO O, 1989, PROG BRAIN RES, V80, P329; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; PRICE GW, 1984, NATURE, V307, P71, DOI 10.1038/307071a0; QUEVEDO J, 1992, EXP BRAIN RES, V91, P29; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; Rifici C, 1994, Funct Neurol, V9, P29; SALTUARI L, 1989, LANCET, V2, P503; SAWYNOK J, 1987, PHARMACOL BIOCHEM BE, V26, P463, DOI 10.1016/0091-3057(87)90148-1; SAWYNOK J, 1986, BRAIN RES, V386, P341, DOI 10.1016/0006-8993(86)90171-X; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SCHUERGER RJ, 1993, EXP BRAIN RES, V92, P351; SCHWINDT P, 1980, J NEUROPHYSIOL, V43, P1296; SCHWINDT PC, 1980, J NEUROPHYSIOL, V43, P1700; Singer BJ, 2004, ARCH PHYS MED REHAB, V85, P1465, DOI 10.1016/j.apmr.2003.08.103; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Theiss RD, 2005, NEUROSCIENCE, V134, P803, DOI 10.1016/j.neuroscience.2005.04.041; Thompson F.J., 2002, J NEUROTRAUM, V19, P233; THOMPSON FJ, 1992, J NEUROPHYSIOL, V68, P1473; Thompson FJ, 1996, NEUROREPORT, V7, P2273; THOMPSON FJ, 1993, ADV NEUROL, V59, P175; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang DC, 2002, J NEUROTRAUM, V19, P875, DOI 10.1089/08977150260190465; WINOCUR G, 1990, CAN J PSYCHOL, V44, P435, DOI 10.1037/h0084270; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93; Zarrindast MR, 2001, EUR J PHARMACOL, V411, P283, DOI 10.1016/S0014-2999(00)00906-7	88	23	23	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	13					1177	1191		10.1089/neu.2012.2740			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	174WB	WOS:000321186400009	23268729				2021-06-18	
J	Johnson, BS; Boudiab, LD; Freundl, M; Anthony, M; Gmerek, GB; Carter, J				Johnson, Barbara S.; Boudiab, Lina D.; Freundl, Margaret; Anthony, Maureen; Gmerek, Gregory B.; Carter, Jemica			Enhancing VETERAN-CENTERED CARE: A Guide for Nurses in Non-VA Settings	AMERICAN JOURNAL OF NURSING			English	Article						chronic pain; hazardous exposure; homelessness; military sexual trauma; military veteran; polytrauma; posttraumatic stress disorder; substance use disorder; suicide; traumatic brain injury; veteran	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILITARY SEXUAL TRAUMA; MENTAL-HEALTH; CHRONIC PAIN; IRAQI FREEDOM; AUDIT-C; WAR; POLYTRAUMA; PREVALENCE	There are currently 22.5 million living U.S. military veterans, and this number is expected to increase dramatically as military personnel return from Iraq and Afghanistan. Although honorably discharged veterans may qualify for health care through the U.S. Department of Veterans Affairs (VA), only about 25% of all veterans take advantage of this benefit; a majority seek services in non-VA settings. It's imperative for nurses in all civilian care settings to understand the impact that military service has on veterans' health. This article provides an overview of veterans' unique health care issues, focusing particularly on traumatic brain injury, polytrauma, hazardous exposures, chronic pain, posttraumatic stress disorder, military sexual trauma, substance use disorders, suicide, and homelessness. Evidence-based assessment tools and treatment guidelines for these health issues are discussed. A resource table provides telephone numbers and Web sites offering tools, educational materials, and veteran services. A second table provides detailed veteran-centered health assessment and screening questions.	[Johnson, Barbara S.; Boudiab, Lina D.] Aleda E Lutz VA Med Ctr, VA Nursing Acad, Saginaw, MI USA; [Freundl, Margaret; Gmerek, Gregory B.; Carter, Jemica] John Dingell VA Med Ctr, VA Nursing Acad, Detroit, MI USA; [Anthony, Maureen] Univ Detroit, Mercy McAuley Sch Nursing, Detroit, MI USA	Johnson, BS (corresponding author), Aleda E Lutz VA Med Ctr, VA Nursing Acad, Saginaw, MI USA.	barbara.johnson19@va.gov			Department of Veterans AffairsUS Department of Veterans Affairs	This project was funded by an unrestricted educational grant in whole through federal funds from the Department of Veterans Affairs and administered through the Veterans Health Administration Office of Academic Affiliations. The opinions expressed herein do not necessarily reflect the views of the Department of Veterans Affairs or its affiliates, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.	Adkins RE, 1967, MEDICAL CARE OF VETE; American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; American Psychiatric Association, 1980, DIAGNOSTIC AND STATI; Bagalman E, 2011, SUICIDE PTSD AND SUB; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Chan BL, 2007, NEW ENGL J MED, V357, P2206, DOI 10.1056/NEJMc071927; Clark JD, 2002, J PAIN SYMPTOM MANAG, V23, P131, DOI 10.1016/S0885-3924(01)00396-7; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Cobb Anne M, 2008, J Trauma Nurs, V15, P192, DOI 10.1097/01.JTN.0000343326.93204.0b; Committee on the Initial Assessment of Readjustment Needs of Military Personnel Veterans and their Families Board on the Health of Select Populations Institute of Medicine of the National Academies, 2010, RETURNING HOME FROM; Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides Board on the Health of Select Populations Institute of Medicine of the National Academies, 2010, VETERANS AND AGENT O; Daniron-Rodriguez J, 2004, MIL MED, V169, P243, DOI 10.7205/MILMED.169.3.243; Defense and Veterans Brain Injury Center, 2013, DEPARTMENT OF DEFENS; Defense and Veterans Brain Injury Center, CONCUSSION MTBI SCRE; Defense Manpower Data Center Human Resources Strategic Assessment Program (HRSAP), 2012, 2012 WORKPLACE AND G; Demers A, 2011, J LOSS TRAUMA, V16, P160, DOI 10.1080/15325024.2010.519281; Denneson LM, 2011, J REHABIL RES DEV, V48, P1119, DOI 10.1682/JRRD.2010.12.0243; Department of Veterans Affairs Veterans Health Administration, 2010, VHA HANDBOOK 117204; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Galloway K. T., 2011, AM NURSE TODAY S, V6, P8; Gamache G, 2003, AM J PUBLIC HEALTH, V93, P1132, DOI 10.2105/AJPH.93.7.1132; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Geiling J, 2012, MIL MED, V177, P1235, DOI 10.7205/MILMED-D-12-00031; Gierisch JM, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110131; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Hannah G, 2011, GETTING TO OUTCOMES; Harada ND, 2002, MED CARE, V40, P117; Haskell SG, 2012, CLIN J PAIN, V28, P163, DOI 10.1097/AJP.0b013e318223d951; HealthyPeople.gov, 2012, 2020 TOPICS AND OBJE; Hovanitz CA, 2002, APPL PSYCHOPHYS BIOF, V27, P29, DOI 10.1023/A:1014524521152; Jakupcak M, 2010, DEPRESS ANXIETY, V27, P1001, DOI 10.1002/da.20722; Kaplan MS, 2009, J TRAUMA, V67, P503, DOI 10.1097/TA.0b013e3181b36521; Kemp J, 2012, SUICIDE DATA REPORT; Kimerling R, 2008, PSYCHIAT SERV, V59, P635, DOI 10.1176/appi.ps.59.6.635; Kimerling R, 2007, AM J PUBLIC HEALTH, V97, P2160, DOI 10.2105/AJPH.2006.092999; Kulka RA, 1990, TRAUMA AND THE VIETN; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Maestas KL, 2011, REHABIL PSYCHOL, V56, P366, DOI 10.1037/a0025447; Magruder KM, 2012, AM J PUBLIC HEALTH, V102, pS118, DOI 10.2105/AJPH.2011.300451; McNamee MJ, 2006, ENCYCLOPEDIA OF NURS, P277; Miles D., 2010, AMERICAN FORCES PRES; Miller M, 2008, NEW ENGL J MED, V359, P989, DOI 10.1056/NEJMp0805923; [National Center for Veterans Analysis and Statistics United States Department of Veterans Affairs], 2013, PROFILE OF VETERANS; National Coalition for Homeless Veterans, BACKGROUND AND STATI; Neason Kathleen, 2006, RN, V69, P30; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Olszewski TM, 2005, J PSYCHOSOC NURS MEN, V43, P40; Otis JD, 2009, PAIN MED, V10, P1300, DOI 10.1111/j.1526-4637.2009.00715.x; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Petzel RA, 2010, VHA DIRECTIVE MILITA; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Probst C, 2010, J TRAUMA, V68, P706, DOI 10.1097/TA.0b013e3181a8b21c; Richardson C, 2003, C2KBR 22 CENSUS 2000; Riggs DS, 2012, MIL MED, V177, P14, DOI 10.7205/MILMED-D-12-00140; Saxon A. J., 2011, PSYCHIAT TIMES, V28, P49; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Siddharthan K, 2008, REHABIL NURS, V33, P221, DOI 10.1002/j.2048-7940.2008.tb00231.x; Skidmore WC, 2011, SOC WORK HEALTH CARE, V50, P85, DOI 10.1080/00981389.2010.522913; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Solomon Z, 2008, PSYCHOL MED, V38, P1427, DOI 10.1017/S0033291708002808; Spelman JF, 2012, J GEN INTERN MED, V27, P1200, DOI 10.1007/s11606-012-2061-1; Suris A, 2008, TRAUMA VIOLENCE ABUS, V9, P250, DOI 10.1177/1524838008324419; U.S. Census Bureau, 2012, VETERANS BY SELECTED, P340; U.S. Department of Defense Task Force on the Prevention of Suicide by Members of the Armed Forces, 2010, FINAL REPORT; U.S. Department of Labor Women's Bureau, 2011, TRAUMA INFORMED CARE; U.S. Department of the Army, 2012, ADRP 6 22 C1, pC1; U.S. Department of Veterans Affairs, 2012, PUBLIC HEALTH MILI T; U.S. Department of Veterans Affairs, 2013, PUBLIC HEALTH HEALTH; U.S. Department of Veterans Affairs, 2012, PUBLIC HEALTH MILITA; U.S. Department of Veterans Affairs, 2011, SUICIDE RISK ASSESSM; U.S. Department of Veterans Affairs, 2012, GERIATRICS AND EXTEN; U.S. Department of Veterans Affairs, 2012, GREAT AMERICAN SMOKE; U.S. Department of Veterans Affairs, 2012, POLYTRAUMA TBI SYSTE; U.S. Department of Veterans Affairs, 2013, PUBLIC HEALTH MILITA; U.S. Department of Veterans Affairs and U.S. Department of Defense, 2000, CLINICAL PRACTICE GU; U.S. Department of Veterans Affairs and U.S. Department of Defense, 2010, CLINICAL PRACTICE GU; U.S. Department of Veterans Affairs and U.S. Department of Defense, 2009, CLINICAL PRACTICE GU; U.S. Department of Veterans Affairs National Center for PTSD, 2007, MILITARY SEXUAL TRAU; U.S. Department of Veterans Affairs National Center for PTSD, 2007, AGING VETERANS AND P; U.S. Department of Veterans Affairs National Center for PTSD, 2007, TRAUMATIC BRAIN INJU; U.S. Department of Veterans Affairs National Center for PTSD, UNDERSTANDING PTSD; U.S. Department of Veterans Affairs National Center for PTSD, 2012, PTSD SCREENING INSTR; U.S. Department of Veterans Affairs National Center for PTSD, 2007, CHRONIC PAIN AND PTS; U.S. Department of Veterans Affairs National Center for Veterans Analysis and Statistics, 2013, VA BENEFITS AND HEAL; U.S. Department of Veterans Affairs National Center for Veterans Analysis and Statistics, 2010, VETERAN POPULATION P; U.S. Department of Veterans Affairs National Center for Veterans Analysis and Statistics, 2013, DEPARTMENT OF VETERA; U.S. Department of Veterans Affairs Office of Academic Affiliations, 2012, MILITARY HEALTH HIST; U.S. Department of Veterans Affairs Office of Patient Care Services and Office of Mental Health Services, 2012, FACT SHEET VA SUICID; U.S. Department of Veterans Affairs Office of Public and Intergovernmental Affairs, 2013, HOMELESS VETERANS AB; U.S. Department of Veterans Affairs Office of Public Health and Environmental Hazards, 2010, ANALYSIS OF VA HEALT; U.S. Department of Veterans Affairs Office of Public Health and Environmental Hazards, 2010, VHA TOBACCO USE CESS; U.S. Department of Veterans Affairs Veterans Health Administration Research and Development Cooperative Studies Program (CSP), 2010, CSP 579 HEALTH VIEWS; United States Government Accountability Office, 2008, GAO 08 276; United States Interagency Council on Homelessness, 2010, OPENING DOORS FEDERA; Uomoto JM, 2009, REHABIL PSYCHOL, V54, P259, DOI 10.1037/a0016907; Valente S, 2007, MIL MED, V172, P259, DOI 10.7205/MILMED.172.3.259; WAGNER TH, 2007, PSYCHOL SERVICES, V0004; Watts DD, 2011, J NEUROSCI NURS, V43, P122, DOI 10.1097/JNN.0b013e3182135af6; Wieland Diane M, 2011, Pa Nurse, V66, P17; Wieland DM, 2011, PA NURSE, V66, P21; Wisco BE, 2012, MIL MED, V177, P7, DOI 10.7205/MILMED-D-12-00111; World Health Organization, 2012, RABIES A NEGLECTED Z; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	105	23	23	1	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0002-936X	1538-7488		AM J NURS	Am. J. Nurs.	JUL	2013	113	7					24	39		10.1097/01.NAJ.0000431913.50226.83			16	Nursing	Nursing	299AI	WOS:000330366200015	23764699				2021-06-18	
J	Oyetunji, TA; Jackson, HT; Obirieze, AC; Moore, D; Branche, MJ; Greene, WR; Cornwell, EE; Siram, SM				Oyetunji, Tolulope A.; Jackson, Hope T.; Obirieze, Augustine C.; Moore, Danier; Branche, Marc J.; Greene, Wendy R.; Cornwell, Edward E., III; Siram, Suryanarayana M.			Associated Injuries in Traumatic Sternal Fractures: A Review of the National Trauma Data Bank	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Scientific Meeting and Postgraduate Course Program of the Southeastern-Surgical-Congress	FEB 09-13, 2013	Jacksonville, FL	SE Surg Congress			RETROSPECTIVE ANALYSIS; CHEST TRAUMA; MANAGEMENT	Sternal fractures occur infrequently with blunt force trauma. The demographics and epidemiology of associated injuries have not been well characterized from a national trauma database. The National Trauma Data Bank was queried for patients with closed sternal fractures. The demographics were analyzed by age, gender, mechanism and indicators of anatomic and physiologic injuries. Types of commonly associated injuries were also determined. A total of 23,985 records were analyzed. Males accounted for 68.3 per cent and whites 70.9 per cent. Motor vehicle crash was the leading mechanism. More than 56 per cent had severe injuries based on Injury Severity Score (greater than 15) and 17 per cent with Glasgow Coma Score 8 or less. Crude mortality was 7.9 per cent. The majority (57.8%) and approximately one-third (33.7%) of the patients had rib fractures and lung contusions, respectively, 22.0 per cent with closed pneumothorax, 21.6 per cent had a closed thoracic vertebra fracture, 16.9 per cent with lumbar spine fracture, 3.9 per cent with concussion, and blunt cardiac injury in 3.6 per cent. Sternal fractures are usually associated with severe blunt trauma. Lung contusion remains the leading associated injury followed by vertebral spine fractures. Cardiac injuries are less frequent and vascular injuries less so. Mechanism of injury and presence of sternal fractures should alert providers to these potential associated injuries.	[Oyetunji, Tolulope A.; Obirieze, Augustine C.; Moore, Danier; Branche, Marc J.; Greene, Wendy R.; Cornwell, Edward E., III; Siram, Suryanarayana M.] Howard Univ, Coll Med, Dept Surg, Washington, DC 20060 USA; [Jackson, Hope T.] George Washington Univ, Sch Med & Hlth Sci, Dept Surg, Washington, DC 20052 USA	Oyetunji, TA (corresponding author), Howard Univ, Coll Med, Dept Surg, 2041 Georgia Ave NW, Washington, DC 20060 USA.	toyetunji@howard.edu		Oyetunji, Tolulope/0000-0003-3039-7195			Athanassiadi K, 2002, WORLD J SURG, V26, P1243, DOI 10.1007/s00268-002-6511-5; BROOKES JG, 1993, J TRAUMA, V35, P46, DOI 10.1097/00005373-199307000-00008; Chiu WC, 1997, AM J EMERG MED, V15, P252, DOI 10.1016/S0735-6757(97)90007-3; Clancy K, 2012, J TRAUMA ACUTE CARE, V73, pS301, DOI 10.1097/TA.0b013e318270193a; Hankins J R, 1973, Am Surg, V39, P309; HILLS MW, 1993, J TRAUMA, V35, P55, DOI 10.1097/00005373-199307000-00009; Knobloch K, 2006, ANN THORAC SURG, V82, P444, DOI 10.1016/j.athoracsur.2006.03.046; Kulshrestha P, 2004, J TRAUMA, V57, P576, DOI 10.1097/01.TA.0000091107.00699.C7; National Highway Traffic Safety Administration, 2011, 2011 MOT VEH CRASH O; OTREMSKI I, 1990, INJURY, V21, P81, DOI 10.1016/0020-1383(90)90059-4; Rashid MA, 2001, EUR J SURG, V167, P243; Recinos G, 2009, AM SURGEON, V75, P401; RICHARDSON JD, 1975, J TRAUMA, V15, P156, DOI 10.1097/00005373-197502000-00009; Sadaba JR, 2000, ANN ROY COLL SURG, V82, P162; Shott RM, 1987, ANN SURG, V206, P200; Tyburski JG, 1999, J TRAUMA, V46, P833, DOI 10.1097/00005373-199905000-00011; Velissaris T, 2003, INJURY, V34, P924, DOI 10.1016/S0020-1383(02)00415-1; von Garrel T, 2004, J TRAUMA, V57, P837, DOI 10.1097/01.TA.0000091112.02703.D8; Wiener Y, 2001, AM J EMERG MED, V19, P403, DOI 10.1053/ajem.2001.24463; Yiadom MYMAB, 2008, J EMERG MED, V35, P199, DOI 10.1016/j.jemermed.2008.05.014	20	23	24	0	1	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JUL	2013	79	7					702	705					4	Surgery	Surgery	AI6ED	WOS:000336962600014	23816003				2021-06-18	
J	Rabinowitz, AR; Arnett, PA				Rabinowitz, Amanda R.; Arnett, Peter A.			Intraindividual Cognitive Variability Before and After Sports-Related Concussion	NEUROPSYCHOLOGY			English	Article						concussion; intraindividual variability; traumatic brain injury	PERFORMANCE; IMPACT; AGE; DEFICITS; DECLINE; SPEED	Objective: Inconsistent performance is associated with cognitive dysfunction in a number of clinical populations. However, intraindividual cognitive variability in healthy individuals is poorly understood. Inconsistency poses a challenge to clinicians when interpreting change over time. This study examined intraindividual cognitive variability within a sample of college athletes tested at baseline and postconcussion. Method: Athletes (n = 71) and control participants (n = 42) were tested with a comprehensive neuropsychological battery at baseline and postconcussion (athletes) or one month later (controls). A subset of indices with high internal consistency was used to calculate overall performance and performance variability. A k-means cluster analysis of baseline and postconcussion performance variability examined heterogeneity within the sample. Results: In the athlete sample, performance variability was significantly greater than zero, and was negatively correlated with overall performance at both time points (p < .001). Wechsler Test of Adult Reading Full Scale IQ estimate was significantly correlated with overall performance (p < .01), but not with performance variability. Cluster analysis revealed low-variability (n = 46) and high-variability (n = 25) cluster groups. Whereas the low-variability cluster group exhibited a pattern of performance similar to that of control participants, membership in the high-variability cluster group was associated with postconcussion cognitive dysfunction. Conclusion: These findings suggest that normative cognitive performance in college athletes is characterized by significant intraindividual variation across tests. Cross-test intraindividual variability may impart clinically meaningful information, as higher levels of variability were related to poorer overall performance and postconcussion cognitive dysfunction.	[Rabinowitz, Amanda R.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	Rabinowitz, AR (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 370 Stemmler Hall, Philadelphia, PA 19104 USA.	rabinowitz.a@gmail.com					Anstey KJ, 2007, NEUROPSYCHOLOGIA, V45, P1911, DOI 10.1016/j.neuropsychologia.2006.11.020; Backman L, 2006, NEUROSCI BIOBEHAV R, V30, P791, DOI 10.1016/j.neubiorev.2006.06.005; Bailey C. M., 2005, 33 ANN M INT NEUR SO; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT., 1989, MILD HEAD INJURY, P257; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BRITTON TC, 1991, ELECTROEN CLIN NEURO, V81, P186, DOI 10.1016/0168-5597(91)90071-5; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; BUNCE DJ, 1993, PSYCHOL AGING, V8, P26, DOI 10.1037/0882-7974.8.1.26; Cegalis J., 1991, VIGIL SOFTWARE ASSES; CONDER R, 1992, COMPUTERIZED ASSESSM; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Halpern DF, 1997, AM PSYCHOL, V52, P1091, DOI 10.1037/0003-066X.52.10.1091; Holtzer R, 2008, JAMA-J AM MED ASSOC, V300, P823, DOI 10.1001/jama.300.7.823; Hultsch D. F., 2008, HDB AGING COGNITION, P491, DOI DOI 10.4324/9780203837665.CH10; Hultsch D.F., 2004, NEW FRONTIERS COGNIT, P65, DOI DOI 10.1093/ACPROF:OSO/9780198525691.003.0004; Hultsch DF, 2000, NEUROPSYCHOLOGY, V14, P588, DOI 10.1037/0894-4105.14.4.588; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kliegel M, 2004, GERONTOLOGY, V50, P39, DOI 10.1159/000074388; Lovden M, 2007, NEUROPSYCHOLOGIA, V45, P2827, DOI 10.1016/j.neuropsychologia.2007.05.005; Lovell MR., 2000, IMPACT IMMEDIATE POS; MacDonald SWS, 2009, PSYCHOL AGING, V24, P792, DOI 10.1037/a0017798; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ragan BG, 2007, ATHLET THER TODAY, V12, P2; Ram N, 2005, PSYCHOL AGING, V20, P623, DOI 10.1037/0882-7974.20.4.623; Randolph C, 2005, J ATHL TRAINING, V40, P139; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Smith A., 1982, SYMBOL DIGIT MODALIT; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Walhovd KB, 2007, NEUROPSYCHOLOGIA, V45, P2277, DOI 10.1016/j.neuropsychologia.2007.02.022; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507	43	23	23	0	22	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2013	27	4					481	490		10.1037/a0033023			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	185SC	WOS:000321989600008	23876120				2021-06-18	
J	Stubberud, J; Langenbahn, D; Levine, B; Stanghelle, J; Schanke, AK				Stubberud, Jan; Langenbahn, Donna; Levine, Brian; Stanghelle, Johan; Schanke, Anne-Kristine			Goal Management Training of Executive Functions in Patients with Spina Bifida: A Randomized Controlled Trial	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Executive functioning; Brain injury; Cognitive rehabilitation; Myelomeningocele; Goal management; Evidence-based	TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; COGNITIVE REHABILITATION; SUSTAINED ATTENTION; FRONTAL-LOBE; CLINICAL NEUROPSYCHOLOGY; DYSFUNCTION; HYDROCEPHALUS; DEFICITS; PLASTICITY	Executive dysfunction causes significant real-life disability for patients with spina bifida (SB). However, no previous research has been directed toward the amelioration of executive functioning deficits amongst persons with SB. Goal Management Training (GMT) is a compensatory cognitive rehabilitation approach, addressing underlying deficits in sustained attention to improve executive function. GMT has received empirical support in studies of other patient groups. The purpose of the present study was to determine the efficacy of GMT in treating subjects with SB, using inpatient intervention periods. We hypothesized post-intervention changes in scores on neuropsychological measures to reflect improved attentional control, including sustained attention and inhibitory control. Thirty-eight adult subjects with SB were included in this randomized controlled trial. Inclusion was based upon the presence of executive functioning complaints. Experimental subjects (n = 24) received 21 hr of GMT, with efficacy of GMT being compared to results of subjects in a wait-list condition (n = 14). All subjects were assessed at baseline, post-intervention, and at 6-month follow-up. Findings indicated superior effects of GMT on domain-specific neuropsychological measures and on a functional "real-life" measure, all lasting at least 6 months post-treatment. These results show that deficits in executive functioning can be ameliorated in patients with congenital brain dysfunction.	[Stubberud, Jan; Stanghelle, Johan; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; [Langenbahn, Donna] NYU, Sch Med, Rusk Inst Rehabil Med, New York, NY USA; [Levine, Brian] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON, Canada; [Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Levine, Brian] Univ Toronto, Dept Med, Toronto, ON, Canada; [Stanghelle, Johan] Univ Oslo, Dept Med, Oslo, Norway; [Schanke, Anne-Kristine] Univ Oslo, Dept Psychol, Oslo, Norway	Stubberud, J (corresponding author), Sunnaas Rehabil Hosp, Bjornemyrveien 11, N-1450 Nesoddtangen, Norway.	jan.stubberud@sunnaas.no	Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Stubberud, Jan/0000-0001-9592-8589	South-Eastern Norway Regional Health Authority [2011041]	This work was supported by The South-Eastern Norway Regional Health Authority (grant number 2011041). The authors thank all patients, caregivers, and staff, especially Astri Andersen, Lisbeth Brondberg, Gunnar Riemer, Lena Haugen, Karen Grimsrud, Brede Dammann, Pal-Erik Plaum, Helene Barder, Per Frydenborg, and Solveig Skou who helped to carry out the study. We also thank Marianne Lovstad and Jan Egil Nordvik for the discussions concerning this study. The authors report no conflict of interest.	Alfonso JP, 2011, DRUG ALCOHOL DEPEN, V117, P78, DOI 10.1016/j.drugalcdep.2010.12.025; Andres P, 2003, CORTEX, V39, P871, DOI 10.1016/S0010-9452(08)70868-2; Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288; Barkovich A.J., 2000, PAEDIAT NEUROIMAGING; Benedict R., 1997, BRIEF VISUOSPATIAL M; Blake DT, 2006, NEURON, V52, P371, DOI 10.1016/j.neuron.2006.08.009; Boelen DHE, 2011, J NEUROPSYCHOL, V5, P73, DOI 10.1348/174866410X516434; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Burmeister R, 2005, CHILD NEUROPSYCHOL, V11, P265, DOI 10.1080/092970490911324; Charney Edward B., 1992, P471; Chen AJW, 2011, BRAIN, V134, P1541, DOI 10.1093/brain/awr067; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CONNERS CK, 2000, CONNERS CPT 2 CONTIN; Coull J. T., 1995, THESIS CAMBRIDGE U; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Dennis M, 2006, J INT NEUROPSYCH SOC, V12, P285, DOI 10.1017/S1355617706060371; Dennis M, 2010, DEV DISABIL RES REV, V16, P31, DOI 10.1002/ddrr.89; Dumville JC, 2006, CONTEMP CLIN TRIALS, V27, P1, DOI 10.1016/j.cct.2005.08.003; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; Evans J, 2005, EFFECTIVENESS REHABI, P247; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fletcher JM, 2005, J NEUROSURG, V102, P268, DOI 10.3171/ped.2005.102.3.0268; Fletcher JM, 1996, DEV NEUROPSYCHOL, V12, P53, DOI 10.1080/87565649609540640; Gioia G.A., 2000, BEHAV RATING INVENTO; Gleichgerrcht E, 2010, J INT NEUROPSYCH SOC, V16, P687, DOI 10.1017/S1355617710000482; Grant M, 2012, NEUROPSYCHOL REHABIL, V22, P852, DOI 10.1080/09602011.2012.693455; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Hampton LE, 2011, J NEUROSURG-PEDIATR, V8, P289, DOI 10.3171/2011.6.PEDS10584; Jackson JC, 2012, CRIT CARE MED, V40, P1088, DOI 10.1097/CCM.0b013e3182373115; Kabat-Zinn J, 1990, FULL CATASTROPHE LIV; Kelly NC, 2012, CHILD NEUROPSYCHOL, V18, P417, DOI 10.1080/09297049.2011.613814; Levaux M. N., 2012, CASE REPORTS PSYCHIA, V2012; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2008, COGNITIVE NEUROREHAB, P464; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McDonnell GV, 2000, CHILD NERV SYST, V16, P222, DOI 10.1007/s003810050502; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; Metzler-Baddeley C, 2010, APPL NEUROPSYCHOL, V17, P299, DOI 10.1080/09084282.2010.523394; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Norman DA, 1986, CONSCIOUSNESS SELF R; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Connor C, 2011, NEUROPSYCHOLOGY, V25, P535, DOI 10.1037/a0022767; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Raz A, 2006, NAT REV NEUROSCI, V7, P367, DOI 10.1038/nrn1903; Raz N, 2009, NEUROPSYCHOL REV, V19, P411, DOI 10.1007/s11065-009-9122-1; Reason J., 1990, HUMAN ERROR; RECANZONE GH, 1993, J NEUROSCI, V13, P87; Robertson IH, 2004, COGNITIVE NEUROSCIENCES III, THIRD EDITION, P631; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Robertson IH, 1996, GOAL MANAGEMENT TRAI; Roca M, 2008, MULT SCLER, V14, P364, DOI 10.1177/1352458507084270; Roca M, 2010, BRAIN, V133, P234, DOI 10.1093/brain/awp269; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rose BM, 2007, J PEDIATR PSYCHOL, V32, P983, DOI 10.1093/jpepsy/jsm042; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Schweizer TA, 2008, NEUROREHAB NEURAL RE, V22, P72, DOI 10.1177/1545968307305303; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Smith A, 1996, NATURE, V380, P291, DOI 10.1038/380291a0; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Stubberud J, 2012, DISABIL REHABIL, V34, P740, DOI 10.3109/09638288.2011.619617; Stuss DT, 2007, J INT NEUROPSYCH SOC, V13, P120, DOI 10.1017/S1355617707070154; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Torralva T, 2013, J ATTEN DISORD, V17, P11, DOI 10.1177/1087054710389988; Tuminello ER, 2012, CHILD NEUROPSYCHOL, V18, P105, DOI 10.1080/09297049.2011.590470; van Hooren SAH, 2007, PATIENT EDUC COUNS, V65, P205, DOI 10.1016/j.pec.2006.07.010; Wechsler D., 1999, MANUAL WECHSLER ABBR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson BA, 2009, NEUROPSYCHOLOGICAL REHABILITATION: THEORY, MODELS, THERAPY AND OUTCOME, P1, DOI 10.1017/CBO9780511581083; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	95	23	23	1	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2013	19	6					672	685		10.1017/S1355617713000209			14	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	170QY	WOS:000320869700006	23575309				2021-06-18	
J	Suffoletto, B; Wagner, AK; Arenth, PM; Calabria, J; Kingsley, E; Kristan, J; Callaway, CW				Suffoletto, Brian; Wagner, Amy K.; Arenth, Patricia M.; Calabria, Jaclyn; Kingsley, Evan; Kristan, Jeffrey; Callaway, Clifton W.			Mobile Phone Text Messaging to Assess Symptoms After Mild Traumatic Brain Injury and Provide Self-Care Support: A Pilot Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; mild; mobile phone; postconcussive symptoms	HEAD-INJURY; SCREENING SCALE; RAPID SCREEN; ADULTS; QUESTIONNAIRE; DEPRESSION; SEVERITY; ALCOHOL; ANXIETY; TRIAL	Purpose: To examine whether patients with mild traumatic brain injury (mTBI) receiving text messaging based education and behavioral support had fewer and less severe postconcussive symptoms than those not receiving text-message support. Our secondary objective was to determine the feasibility of using text messaging to assess daily symptoms and provide support to patients with mTBI. Design: Randomized controlled trial with 14-day follow-up. Participants: Convenience sample of 43 adult emergency department patients with mTBI. Intervention: Fourteen days of timed SMS (short-message service) symptom assessments (9 AM: headaches; 1 PM: difficulty concentrating; 5 PM: irritability or anxiety) with self-care support messages. Main Measures: SMS symptom reports, Rivermead Postconcussion Symptoms Questionnaire. Results: Compared with the control group, intervention participants trended to lower odds of reporting headaches (odds ratio [OR] = 0.38; 95% confidence interval [CI]: 0.07-1.99), concentration difficulty (OR = 0.32; 95% CI: 0.04-2.24), and irritability or anxiety (OR = 0.33; 95% CI: 0.05-2.35). There were also trends of lower mean scores for headaches (0.99 vs 1.19; P = .5), difficulty concentrating (0.88 vs 1.23; P = .2), and irritability/anxiety (1.00 vs 1.62; P = .06). There were high response rate to SMS symptom assessments and high satisfaction with the intervention. Conclusion: Those receiving the text messaging based education and support had fewer and less severe postconcussive symptoms than the controls but none of the differences reached statistical significance. Further evaluation of more robust mobile interventions and larger sample of participants are still needed.	[Suffoletto, Brian; Calabria, Jaclyn; Kingsley, Evan; Kristan, Jeffrey; Callaway, Clifton W.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA; [Wagner, Amy K.; Arenth, Patricia M.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA	Suffoletto, B (corresponding author), Univ Pittsburgh, Dept Emergency Med, Iroquois Bldg,Ste 400A,3600 Forbes Ave, Pittsburgh, PA 15261 USA.	suffbp@upmc.edu		Callaway, Clifton/0000-0002-3309-1573			Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; De Monte VE, 2010, J CLIN EXP NEUROPSYC, V32, P28, DOI 10.1080/13803390902806519; DeSalvo KB, 2006, QUAL LIFE RES, V15, P191, DOI 10.1007/s11136-005-0887-2; Humeniuk R, 2008, ADDICTION, V103, P1039, DOI 10.1111/j.1360-0443.2007.02114.x; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kimerling R, 2006, J GEN INTERN MED, V21, P65, DOI 10.1111/j.1525-1497.2005.00292.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Snell DL, 2010, BRAIN INJURY, V24, P1595, DOI 10.3109/02699052.2010.523048; Suffoletto B, 2012, ACAD EMERG MED, V19, P949, DOI 10.1111/j.1553-2712.2012.01411.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Wei J, 2011, J TELEMED TELECARE, V17, P41, DOI 10.1258/jtt.2010.100322	26	23	23	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					302	312		10.1097/HTR.0b013e3182847468			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900008	23474882				2021-06-18	
J	Huang, YH; Lee, TC; Lee, TH; Liao, CC; Sheehan, J; Kwan, AL				Huang, Yu-Hua; Lee, Tao-Chen; Lee, Tsung-Han; Liao, Chen-Chieh; Sheehan, Jason; Kwan, Aij-Lie			Thirty-day mortality in traumatically brain-injured patients undergoing decompressive craniectomy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; decompressive craniectomy mortality; age; Glasgow Coma Scale	SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; AGE	Object. Decompressive craniectomy is a life-saving measure for patients who have sustained traumatic brain injury (TBI), but patients undergoing this procedure may still die during an early phase of head injury. The aim of this study was to investigate the incidence, causes, and risk factors of 30-day mortality in traumatically brain-injured patients undergoing decompressive craniectomy. Methods. The authors included 201 head-injured patients undergoing decompressive craniectomy in this 3-year retrospective study. The main outcome evaluated was 30-day mortality in patients who had undergone craniectomy after TBI. Demographic and clinical data, including information on death, were obtained for subsequent analysis. The authors identified differences between survivors and nonsurvivors in terms of clinical parameters; multivariate logistic regression was used to adjust for independent risk factors of short-term death. Results. The 30-day mortality rate was 26.4% in traumatically brain-injured patients undergoing decompressive craniectomy. The majority of deaths following decompression resulted from uncontrollable brain swelling and extensive brain infarction, which accounted for 79.2% of mortality. In the multivariate logistic regression mode, the 2 independent risk factors for 30-day mortality were age (OR 1.035 [95% CI 1.006-1.064]; p = 0.018) and Glasgow Coma Scale (GCS) score before decompressive craniectomy (OR 0.769 [95% CI 0.597-0.990]; p = 0.041). Conclusions. There is a high 30-day mortality rate in traumatically brain-injured patients undergoing decompressive craniectomy. Most of the deaths are attributed to ongoing brain damage, even after decompression. Risk factors of short-term death, including age and preoperative GCS score, are important in patient selection for decompressive craniectomy, and these factors should be considered together to ensure the highest chance of surviving TBI.	[Huang, Yu-Hua; Lee, Tao-Chen; Lee, Tsung-Han; Liao, Chen-Chieh] Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung, Taiwan; [Huang, Yu-Hua; Lee, Tao-Chen; Lee, Tsung-Han; Liao, Chen-Chieh] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Huang, Yu-Hua; Lee, Tsung-Han] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan; [Kwan, Aij-Lie] Kaohsiung Med Univ, Coll Med, Dept Surg, Kaohsiung, Taiwan; [Kwan, Aij-Lie] Kaohsiung Med Univ Hosp, Dept Neurosurg, Kaohsiung 807, Taiwan; [Sheehan, Jason; Kwan, Aij-Lie] Univ Virginia Hlth Syst, Dept Neurosurg, Charlottesville, VA USA	Kwan, AL (corresponding author), Kaohsiung Med Univ Hosp, Dept Neurosurg, 100,Tzyou 1st Rd, Kaohsiung 807, Taiwan.	a_lkwan@yahoo.com					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Ciesla DJ, 2006, SURGERY, V140, P640, DOI 10.1016/j.surg.2006.06.015; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Meier U, 2006, ACTA NEUROCHIR SUPPL, V96, P373; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Munch E, 2000, NEUROSURGERY, V47, P315; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134	23	23	27	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1329	1335		10.3171/2013.1.JNS121775			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400033	23472847				2021-06-18	
J	Siegel, BS; Davis, BE				Siegel, Benjamin S.; Davis, Beth Ellen		Comm Psychosocial Aspects Child; Family Hlth & Sect Uniformed Serv	Health and Mental Health Needs of Children in US Military Families	PEDIATRICS			English	Article						military; families; children; deployment; mental health; health maintenance	FACING WARTIME DEPLOYMENTS; CENTERED PREVENTION; YOUNG-CHILDREN; DESERT-STORM; COMBAT; ARMY; IRAQ; INTERVENTION; PEDIATRICIAN; MALTREATMENT	The wars in Afghanistan and Iraq have been challenging for US uniformed service families and their children. Almost 60% of US service members have family responsibilities. Approximately 2.3 million active duty, National Guard, and Reserve service members have been deployed since the beginning of the wars in Afghanistan and Iraq (2001 and 2003, respectively), and almost half have deployed more than once, some for up to 18 months' duration. Up to 2 million US children have been exposed to a wartime deployment of a loved one in the past 10 years. Many service members have returned from combat deployments with symptoms of posttraumatic stress disorder, depression, anxiety, substance abuse, and traumatic brain injury. The mental health and well-being of spouses, significant others, children (and their friends), and extended family members of deployed service members continues to be significantly challenged by the experiences of wartime deployment as well as by combat mortality and morbidity. The medical system of the Department of Defense provides health and mental health services for active duty service members and their families as well as activated National Guard and Reserve service members and their families. In addition to military pediatricians and civilian pediatricians employed by military treatment facilities, nonmilitary general pediatricians care for >50% of children and family members before, during, and after wartime deployments. This clinical report is for all pediatricians, both active duty and civilian, to aid in caring for children whose loved ones have been, are, or will be deployed.					Siegel, Benjamin/0000-0003-3572-2575			American Psychological Association, 2007, PSYCH NEEDS US MIL S; [Anonymous], 2009, HON OUR BAB TODDL SU; Applewhite LW, 1986, CHILD ADOLESC SOCIAL, V13, P23; Aranda MC, 2011, MIL MED, V176, P402, DOI 10.7205/MILMED-D-10-00202; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Barker LH, 2009, MIL MED, V174, P1033, DOI 10.7205/MILMED-D-04-1108; Beardslee W, 2011, PREV SCI, V12, P339, DOI 10.1007/s11121-011-0234-5; Chandra A., 2008, UNDERSTANDING IMPACT; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Chartrand MM, 2008, ARCH PEDIAT ADOL MED, V162, P1009, DOI 10.1001/archpedi.162.11.1009; Coleman WL, 2009, PEDIATRICS, V124, P410, DOI 10.1542/peds.2009-1061; Cozza SJ, 2005, PSYCHIAT QUART, V76, P371, DOI 10.1007/s11126-005-4973-y; Cozza SJ, 2010, J TRAUMA STRESS, V23, P112, DOI 10.1002/jts.20488; Davis BE, 2012, PEDIATRICS, V129, pS3, DOI 10.1542/peds.2010-3797c; Department of Defense, 2009, DEM PROF MIL COMM; Drummet AR, 2003, FAM RELAT, V52, P279, DOI 10.1111/j.1741-3729.2003.00279.x; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Foy Jane Meschan, 2010, Pediatrics, V125 Suppl 3, pS109, DOI 10.1542/peds.2010-0788F; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Gorman GH, 2010, PEDIATRICS, V126, P1058, DOI 10.1542/peds.2009-2856; Gorman LA, 2011, PSYCHIAT SERV, V62, P28, DOI 10.1176/ps.62.1.pss6201_0028; Hagan JF, 2005, PEDIATRICS, V116, P787, DOI 10.1542/peds.2005-1498; Hill R, 1971, FAMILIES STRESS ADJU; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Howell Alison, 2011, WAR COMES HOME TOLL; Huebner A. J., 2005, ADJUSTMENTS MONG FAM, P1; Jensen PS, 1996, J AM ACAD CHILD PSY, V35, P433, DOI 10.1097/00004583-199604000-00009; KELLEY ML, 1994, AM J ORTHOPSYCHIAT, V64, P103, DOI 10.1037/h0079499; LAGRONE DM, 1978, AM J PSYCHIAT, V135, P1040; Lester P, 2012, AM J PUBLIC HEALTH, V102, pS48, DOI 10.2105/AJPH.2010.300088; Lester P, 2011, MIL MED, V176, P19, DOI 10.7205/MILMED-D-10-00122; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Levetown M, 2008, PEDIATRICS, V121, pE1441, DOI 10.1542/peds.2008-0565; Lozano P, 2010, ARCH PEDIAT ADOL MED, V164, P561, DOI 10.1001/archpediatrics.2010.86; Mansfield AJ, 2011, ARCH PEDIAT ADOL MED, V165, P999, DOI 10.1001/archpediatrics.2011.123; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; National Military Family Association, 2005, REP CYCL DEPL SURV A; National Scientific Council on the Developing Child, 2010, PERS FEAR ANX CAN AF; Orthner DK, 2005, SAF 5 SURVEY REPORT; PATTERSON JM, 1984, J MARRIAGE FAM, V46, P95, DOI 10.2307/351868; Pincus SH, 2001, EMOTIONAL CYCLE DEPL; RAND, 2008, INVISIBLE WOUNDS WAR; Rentz ED, 2007, AM J EPIDEMIOL, V165, P1199, DOI 10.1093/aje/kwm008; ROSEN LN, 1993, MIL MED, V158, P465; Saltzman WR, 2011, CLIN CHILD FAM PSYCH, V14, P213, DOI 10.1007/s10567-011-0096-1; Smith DC, 2010, OBSTET GYNECOL, V116, P679, DOI 10.1097/AOG.0b013e3181eb6c84; Strategic Outreach to Families of All Reservists (SOFAR), SOFAR GUID HELP CHIL; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Waterhouse M, 2008, CRS C; Wessel MA, 2003, PEDIATR REV, V24, P183, DOI 10.1542/pir.24-6-183; Wolraich ML, 2000, PEDIATRICS, V105, P445; Woolston J L, 1986, Pediatr Rev, V8, P169, DOI 10.1542/pir.8-6-169	54	23	23	0	27	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2013	131	6					E2002	E2015		10.1542/peds.2013-0940			14	Pediatrics	Pediatrics	197HH	WOS:000322840200040	23713100	Bronze			2021-06-18	
J	Zhang, YL; Chopp, M; Meng, YL; Zhang, ZG; Doppler, E; Mahmood, A; Xiong, Y				Zhang, Yanlu; Chopp, Michael; Meng, Yuling; Zhang, Zheng Gang; Doppler, Edith; Mahmood, Asim; Xiong, Ye			Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury	JOURNAL OF NEUROSURGERY			English	Article						Cerebrolysin; closed head injury; neuroprotection; rat; sensorimotor; spatial learning	TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GROWTH-FACTOR; MARROW STROMAL CELLS; ALZHEIMERS-DISEASE; MATRIX METALLOPROTEINASES; NEUROTROPHIC TREATMENT; CEREBROSPINAL-FLUID; ADULT NEUROGENESIS; THERAPEUTIC WINDOW; GENE-EXPRESSION	Object. Cerebrolysin is a unique peptide preparation that mimics the action of neurotrophic factors. This study was designed to investigate the effects of acute treatment of experimental closed head injury (CHI) in rats with Cerebrolysin on neurological function. Methods. Adult male Wistar rats (n = 60) were subjected to impact acceleration induced CHI. Closed head injured rats received intraperitoneal injection of saline (n = 30) or Cerebrolysin (2.5 ml/kg, n = 30) starting 1 hour postinjury and administered once daily until they were killed (2 or 14 days after CHI). To evaluate functional outcome, the modified neurological severity score (mNSS), foot fault, adhesive removal, and Morris water maze (MWM) tests were performed. Animals were killed on Day 14 (n = 20) after injury, and their brains were removed and processed for measurement of neuronal cells, axonal damage, apoptosis, and neuroblasts. The remaining rats (n = 40) were killed 2 days postinjury to evaluate cerebral microvascular patency by fluorescein isothiocyanate (FITC) dextran perfusion (n = 16) and to measure the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) by using real-time reverse transcriptase-polymerase chain reaction (RT-PCR, n = 8) and by immunohistochemical analysis (n = 16). Results. At 14 days post-CHI, the Cerebrolysin treatment group exhibited significant improvements in functional outcomes (the adhesive removal, mNSS, foot-fault, and MWM tests), and significantly more neurons and neuroblasts were present in the dentate gyms (DG) (p < 0.05) compared with the saline-treated group (p < 0.05). At 2 days post-CM, the Cerebrolysin group exhibited a significantly higher percentage of phosphorylated neurofilament H (pNF-H)-positive staining area in the striatum (p < 0.05), a significant increase in the percentage of FITC-dextran perfused vessels in the brain cortex (p < 0.05), a significant increase in the number of VEGF-positive cells (p < 0.05), and a significant reduction in the MMP-9 staining area (p < 0.05) compared with the saline-treated group. There was no significant difference in mRNA levels of MMP-9 and VEGF in the hippocampus and cortex 48 hours postinjury between Cerebrolysin-and saline-treated rats that sustained CHI. Conclusions. Acute Cerebrolysin treatment improves functional recovery in rats after CHI. Cerebrolysin is neuroprotective for CHI (increased neurons in the dentate gyms and the CA3 regions of the hippocampus and increased neuroblasts in the dentate gyms) and may preserve axonal integrity in the striatum (significantly increased percentage of pNF-H-positive tissue in the striatum). Reduction of MMP-9 and elevation of VEGF likely contribute to enhancement of vascular patency and integrity as well as neuronal survival induced by Cerebrolysin. These promising results suggest that Cerebrolysin may be a useful treatment in improving the recovery of patients with CHI.	[Zhang, Yanlu; Meng, Yuling; Mahmood, Asim; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael; Zhang, Zheng Gang] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Doppler, Edith] EVER Neuro Pharma GmbH, Clin Res & Pharmacol, Unterach, Austria	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 West Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	EVER Neuro Pharma GmbH	EVER Neuro Pharma GmbH provided financial support for this study. Edith Doppler is an employee of Clinical Research and Pharmacology, EVER Neuro Pharma GmbH, Unterach, Austria.	Alvarez XA, 2011, EUR J NEUROL, V18, P59, DOI 10.1111/j.1468-1331.2010.03092.x; Alvarez XA, 2011, DRUG TODAY, V47, P487, DOI 10.1358/dot.2011.47.7.1656496; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P281; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bitto A, 2012, CRIT CARE MED, V40, P945, DOI 10.1097/CCM.0b013e318236efde; Bornstein N, 2012, DRUG TODAY, V48, P43, DOI 10.1358/dot.2012.48(Suppl.A).1739723; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen HH, 2007, NEUROBIOL AGING, V28, P1148, DOI 10.1016/j.neurobiolaging.2006.05.036; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Eder P, 2001, HISTOCHEM J, V33, P605, DOI 10.1023/A:1016394031947; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Goldie BJ, 2012, MOL NEUROBIOL, V45, P99, DOI 10.1007/s12035-011-8222-0; Grant P, 2000, J NEUROCYTOL, V29, P843, DOI 10.1023/A:1010999509251; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gschanes A, 1997, J NEURAL TRANSM, V104, P1319, DOI 10.1007/BF01294733; Gutmann B, 2002, NEUROTOX RES, V4, P59, DOI 10.1080/10298420290007637; Hanson LR, 2009, AM J NEUROPROTEC NEU, V1, P60, DOI [DOI 10.1166/AJNN.2009.1010, 10.1166/ajnn.2009.1010]; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Imer M, 2009, NEUROL RES, V31, P977, DOI 10.1179/174313209X385617; Kawamata T, 1999, EXP NEUROL, V158, P89, DOI 10.1006/exnr.1999.7101; Liu XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023461; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Logan Ann, 1994, Progress in Growth Factor Research, V5, P379, DOI 10.1016/0955-2235(94)00008-9; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masliah E, 2012, DRUG TODAY, V48, P3, DOI 10.1358/dot.2012.48(Suppl.A).1739716; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Oomen CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0003675; Pardridge WM, 2002, ADV EXP MED BIOL, V513, P397; Park CO, 2001, YONSEI MED J, V42, P518, DOI 10.3349/ymj.2001.42.5.518; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Plosker GL, 2009, DRUG AGING, V26, P893, DOI 10.2165/11203320-000000000-00000; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rockenstein E, 2007, ACTA NEUROPATHOL, V113, P265, DOI 10.1007/s00401-006-0166-5; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Schauer E, 2006, J NEURAL TRANSM, V113, P855, DOI 10.1007/s00702-005-0384-3; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P95, DOI 10.1196/annals.1403.007; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Thau-Zuchman O, 2012, NEUROSCIENCE, V202, P334, DOI 10.1016/j.neuroscience.2011.11.071; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Ubhi K, 2009, ACTA NEUROPATHOL, V117, P699, DOI 10.1007/s00401-009-0505-4; Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wada K, 2003, STROKE, V34, P2722, DOI 10.1161/01.STR.0000094421.61917.71; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yasuhara T, 2004, REV NEUROSCIENCE, V15, P293; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495; Zhang L, 2003, CIRCULATION, V107, P2837, DOI 10.1161/01.CIR.0000068374.57764.EB; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	71	23	27	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUN	2013	118	6					1343	1355		10.3171/2013.3.JNS122061			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	150BY	WOS:000319366400035	23581594				2021-06-18	
J	Itoh, T; Tabuchi, M; Mizuguchi, N; Imano, M; Tsubaki, M; Nishida, S; Hashimoto, S; Matsuo, K; Nakayama, T; Ito, A; Munakata, H; Satou, T				Itoh, Tatsuki; Tabuchi, Masaki; Mizuguchi, Nobuyuki; Imano, Motohiro; Tsubaki, Masahiro; Nishida, Shozo; Hashimoto, Shigeo; Matsuo, Kazuhiko; Nakayama, Takashi; Ito, Akihiko; Munakata, Hiroshi; Satou, Takao			Neuroprotective effect of (-)-epigallocatechin-3-gallate in rats when administered pre- or post-traumatic brain injury	JOURNAL OF NEURAL TRANSMISSION			English	Article						(-)-Epigallocatechin gallate; Traumatic brain injury; Apoptosis; Green tea treatment; Cerebral function	GREEN TEA POLYPHENOL; CENTRAL-NERVOUS-SYSTEM; IMPROVES CEREBRAL FUNCTION; NEURONAL CELL-DEATH; NEURAL STEM-CELLS; MITOCHONDRIAL DYSFUNCTION; EXPERIMENTAL-ISCHEMIA; OXYGEN RADICALS; DAMAGE; PROTECTS	Our previous study indicated that consuming (-)-epigallocatechin gallate (EGCG) before or after traumatic brain injury (TBI) eliminated free radical generation in rats, resulting in inhibition of neuronal degeneration and apoptotic death, and improvement of cognitive impairment. Here we investigated the effects of administering EGCG at various times pre- and post-TBI on cerebral function and morphology. Wistar rats were divided into five groups and were allowed access to (1) normal drinking water, (2) EGCG pre-TBI, (3) EGCG pre- and post-TBI, (4) EGCG post-TBI, and (5) sham-operated group with access to normal drinking water. TBI was induced with a pneumatic controlled injury device at 10 weeks of age. Immunohistochemistry and lipid peroxidation studies revealed that at 1, 3, and 7 days post-TBI, the number of 8-Hydroxy-2'-deoxyguanosine-, 4-Hydroxy-2-nonenal- and single-stranded DNA (ssDNA)-positive cells, and levels of malondialdehyde around the damaged area were significantly decreased in all EGCG treatment groups compared with the water group (P < 0.05). Although there was a significant increase in the number of surviving neurons after TBI in each EGCG treatment group compared with the water group (P < 0.05), significant improvement of cognitive impairment after TBI was only observed in the groups with continuous and post-TBI access to EGCG (P < 0.05). These results indicate that EGCG inhibits free radical-induced neuronal degeneration and apoptotic death around the area damaged by TBI. Importantly, continuous and post-TBI access to EGCG improved cerebral function following TBI. In summary, consumption of green tea may be an effective therapy for TBI patients.	[Itoh, Tatsuki; Ito, Akihiko; Satou, Takao] Kinki Univ, Fac Med, Dept Pathol, Osaka 5898511, Japan; [Tabuchi, Masaki; Munakata, Hiroshi] Kinki Univ, Fac Med, Dept Biochem, Osaka 5898511, Japan; [Mizuguchi, Nobuyuki] Kinki Univ, Life Sci Res Inst, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Fac Med, Dept Surg, Osaka 5898511, Japan; [Tsubaki, Masahiro; Nishida, Shozo; Matsuo, Kazuhiko; Nakayama, Takashi] Kinki Univ, Fac Pharmaceut Sci, Osaka 5898511, Japan; [Hashimoto, Shigeo] PL Hosp, Dept Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ Hosp, Fac Med, Div Hosp Pathol, Osaka, Japan	Itoh, T (corresponding author), Kinki Univ, Fac Med, Dept Pathol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			Kao Research Council for the Study of Healthcare Science;  [23500629];  [24501009]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24501009, 23700934] Funding Source: KAKEN	This work was supported by Grants-in-Aid for Scientific Research (23500629 and 24501009) and a 2012 research grant of the Kao Research Council for the Study of Healthcare Science. The authors thank Mari Yachi for technical assistance.	Aktas O, 2004, J IMMUNOL, V173, P5794, DOI 10.4049/jimmunol.173.9.5794; Amemiya S, 2005, EUR J PHARMACOL, V516, P125, DOI 10.1016/j.ejphar.2005.04.036; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; CHAN PH, 1985, PROG BRAIN RES, V63, P227; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Herges K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025456; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hong JT, 2000, BRAIN RES BULL, V53, P743, DOI 10.1016/S0361-9230(00)00348-8; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2012, J NEURAL TRANSM, V119, P877, DOI 10.1007/s00702-011-0764-9; Itoh T, 2011, NEUROMOL MED, V13, P300, DOI 10.1007/s12017-011-8162-x; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Itoh T, 2009, NEUROTOX RES, V16, P378, DOI 10.1007/s12640-009-9081-6; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; Jang S, 2010, BRAIN RES, V1313, P25, DOI 10.1016/j.brainres.2009.12.012; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kim CY, 2009, ARCH PHARM RES, V32, P869, DOI 10.1007/s12272-009-1609-z; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Lee H, 2004, J NEUROSCI RES, V77, P892, DOI 10.1002/jnr.20193; Lee SR, 2000, NEUROSCI LETT, V287, P191, DOI 10.1016/S0304-3940(00)01159-9; Lee SY, 2003, BRAIN RES BULL, V61, P399, DOI 10.1016/S0361-9230(03)00139-4; Lin LC, 2007, J AGR FOOD CHEM, V55, P1517, DOI 10.1021/jf062816a; Loren DJ, 2005, PEDIATR RES, V57, P858, DOI 10.1203/01.PDR.0000157722.07810.15; Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x; Mandel SA, 2005, NEUROSIGNALS, V14, P46, DOI 10.1159/000085385; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Nakagawa K, 1999, J AGR FOOD CHEM, V47, P3967, DOI 10.1021/jf981195l; Park JW, 2009, J NEUROSCI RES, V87, P567, DOI 10.1002/jnr.21847; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Sakurai M, 2003, J VASC SURG, V37, P446, DOI 10.1067/mva.2003.100; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Suganuma M, 1998, CARCINOGENESIS, V19, P1771, DOI 10.1093/carcin/19.10.1771; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; Walton KM, 1998, J NEUROCHEM, V70, P1764; Wang XY, 2001, BIOL NEONATE, V79, P172; Weinreb O, 2009, GENES NUTR, V4, P283, DOI 10.1007/s12263-009-0143-4; Weissman L, 2007, NEUROSCIENCE, V145, P1318, DOI 10.1016/j.neuroscience.2006.08.061; Won MH, 2001, NEUROSCI LETT, V301, P139, DOI 10.1016/S0304-3940(01)01625-1; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Yu JX, 2010, FEBS LETT, V584, P2921, DOI 10.1016/j.febslet.2010.05.011	51	23	24	0	13	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564			J NEURAL TRANSM	J. Neural Transm.	MAY	2013	120	5					767	783		10.1007/s00702-012-0918-4			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	131IH	WOS:000317986000007	23180302				2021-06-18	
J	Leopold, E; Gefen, A				Leopold, Efrat; Gefen, Amit			Changes in permeability of the plasma membrane of myoblasts to fluorescent dyes with different molecular masses under sustained uniaxial stretching	MEDICAL ENGINEERING & PHYSICS			English	Article						Fluorescence-activated cell sorting; Dextran; Deformation-diffusion; Skeletal muscle cells; Confocal imaging	DEEP TISSUE-INJURY; SUB-DERMAL TISSUES; MECHANICAL STRETCH; MODEL; STRAINS; MACROMOLECULES; DEFORMATIONS; COMPRESSION; REPERFUSION; CALCIUM	Deep tissue injury (DTI) is a serious pressure ulcer which onsets in skeletal muscle tissues adjacent to weight-bearing bony prominences. Recent literature points at sustained large deformations in muscle tissue, which translate to static stretching of the plasma membrane (PM) at the cell-scale, as the primary cause of accumulated cell death in DTI. It has been specifically suggested that prolonged exposure to large tensional PM strains interferes with normal cellular homeostasis, primarily by affecting transport through the PM which could become more permeable when stretched. In this context, using confocal imaging and fluorescence-activated cell sorter (FACS), we visualized and quantified here the uptake of fluorescent Dextran dye by myoblasts that were statically stretched uniaxially, up to physiological strains of 3%, 6% and 9%, using two different molecular masses for the Dextran (4 kDa and 20 kDa). The confocal and FACS studies provided consistent evidence that the permeability of the PM increased at large static deformations. Furthermore, the FACS data indicated that the kinetics of the PM permeability very likely depends on the size of the biomolecular marker. Both results were consistent with reports published in the neurotrauma literature on the kinetics of uptake of fluorescent biomolecules by dynamically stretched neurons; hence there are some analogues in the biomechanical pathways of cellular-level injury between DTI and impact insults. The present work provides additional empirical support to the theory of cell-scale deformation-diffusion damage in the etiology of DTI, and may lead to better understanding of time courses for onset of cellular damage in DTI, by exploring mass transport processes across the PM of the involved cells. (C) 2012 IPEM. Published by Elsevier Ltd. All rights reserved.	[Leopold, Efrat; Gefen, Amit] Tel Aviv Univ, Fac Engn, Dept Biomed Engn, IL-69978 Tel Aviv, Israel	Gefen, A (corresponding author), Tel Aviv Univ, Fac Engn, Dept Biomed Engn, IL-69978 Tel Aviv, Israel.	gefen@eng.tau.ac.il	Gefen, Amit/M-4720-2015	Gefen, Amit/0000-0002-0223-7218	Ministry of Science & Technology, Israel; Ministry of Research, TaiwanMinistry of Education, Taiwan	We are thankful to the following personnel from the Department of Biomedical Engineering at Tel Aviv University: Dr. Uri Zaretsky for helping with the design of the UCSD, Ms. Naama Shoham for assisting with calibration of the UCSD, and Ms. Riki Levkovitch for helping with the pre-confocal staining. This research is being supported by a grant from the Ministry of Science & Technology, Israel & the Ministry of Research, Taiwan (A.G.).	Agam L, 2007, J Wound Care, V16, P336; Apodaca G, 2002, AM J PHYSIOL-RENAL, V282, pF179; BOHRER MP, 1979, J GEN PHYSIOL, V74, P583, DOI 10.1085/jgp.74.5.583; Ceelen KK, 2009, EXP MECH, V49, P25, DOI 10.1007/s11340-007-9093-1; Freitas Jr RA, 1999, NANOMEDICINE; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gefen Amit, 2007, Int Wound J, V4, P222, DOI 10.1111/j.1742-481X.2007.00330.x; Gefen A, 2008, J BIOMECH, V41, P845, DOI 10.1016/j.jbiomech.2007.10.023; Lee AA, 1996, AM J PHYSIOL-CELL PH, V271, pC1400; Leopold E, 2012, J TISSUE VIABILITY, V21, P27, DOI 10.1016/j.jtv.2011.11.002; Leopold E, 2011, MED ENG PHYS, V33, P1072, DOI 10.1016/j.medengphy.2011.04.008; Levy A, 2012, ANN BIOMED ENG, V40, P1052, DOI 10.1007/s10439-011-0496-x; Linder-Ganz E, 2008, J BIOMECH, V41, P567, DOI 10.1016/j.jbiomech.2007.10.011; Linder-Ganz E, 2007, J BIOMECH, V40, P1443, DOI 10.1016/j.jbiomech.2006.06.020; Loerakker S, 2011, J APPL PHYSIOL, V111, P1168, DOI 10.1152/japplphysiol.00389.2011; Loerakker S, 2010, ANN BIOMED ENG, V38, P2577, DOI 10.1007/s10439-010-0002-x; Mak AFT, 2011, J THEOR BIOL, V289, P65, DOI 10.1016/j.jtbi.2011.08.022; Mak AFT, 2010, ANNU REV BIOMED ENG, V12, P29, DOI 10.1146/annurev-bioeng-070909-105223; Morris CE, 2001, J MEMBRANE BIOL, V179, P79, DOI 10.1007/s002320010040; OLIVER JD, 1992, J AM SOC NEPHROL, V3, P214; Shabshin N, 2010, CLIN BIOMECH, V25, P402, DOI 10.1016/j.clinbiomech.2010.01.019; Shabshin N, 2010, J REHABIL RES DEV, V47, P31, DOI 10.1682/JRRD.2009.07.0105; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Shoham N, 2012, AM J PHYSIOL-CELL PH, V302, pC429, DOI 10.1152/ajpcell.00167.2011; Siu PM, 2009, J APPL PHYSIOL, V107, P1266, DOI 10.1152/japplphysiol.90897.2008; Slomka N, 2012, ANN BIOMED ENG, V40, P606, DOI 10.1007/s10439-011-0423-1; Slomka N, 2009, CELL MOL BIOENG, V2, P118, DOI 10.1007/s12195-009-0046-x; Sopher R, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003325; Stekelenburg A, 2008, ARCH PHYS MED REHAB, V89, P1410, DOI 10.1016/j.apmr.2008.01.012; Thery M, 2008, HFSP J, V2, P65, DOI 10.2976/1.2895661; Venturoli D, 2005, AM J PHYSIOL-RENAL, V288, pF605, DOI 10.1152/ajprenal.00171.2004	33	23	23	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533	1873-4030		MED ENG PHYS	Med. Eng. Phys.	MAY	2013	35	5					601	607		10.1016/j.medengphy.2012.07.004			7	Engineering, Biomedical	Engineering	137SH	WOS:000318457200006	22854841				2021-06-18	
J	Marmarelis, VZ; Shin, DC; Orme, ME; Zhang, R				Marmarelis, V. Z.; Shin, D. C.; Orme, M. E.; Zhang, R.			Closed-Loop Dynamic Modeling of Cerebral Hemodynamics	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Cerebral autoregulation; Nonlinear modeling; Modeling cerebral hemodynamics; Closed-loop modeling; Cerebral flow autoregulation; Cerebral vasomotor reactivity	AUTONOMIC NEURAL-CONTROL; BLOOD-FLOW; AUTOREGULATION; PRESSURE; METHODOLOGY; SYSTEMS	The dynamics of cerebral hemodynamics have been studied extensively because of their fundamental physiological and clinical importance. In particular, the dynamic processes of cerebral flow autoregulation (CFA) and CO2 vasomotor reactivity have attracted broad attention because of their involvement in a host of pathologies and clinical conditions (e.g., hypertension, syncope, stroke, traumatic brain injury, vascular dementia, Alzheimer's disease, mild cognitive impairment etc.). This raises the prospect of useful diagnostic methods being developed on the basis of quantitative models of cerebral hemodynamics, if cerebral vascular dysfunction can be quantified reliably from data collected within practical clinical constraints. This paper presents a modeling method that utilizes beat-to-beat measurements of mean arterial blood pressure, cerebral blood flow velocity and end-tidal CO2 (collected non-invasively under resting conditions) to quantify the dynamics of CFA and cerebral vasomotor reactivity (CVMR). The unique and novel aspect of this dynamic model is that it is nonlinear and operates in a closed-loop configuration.	[Marmarelis, V. Z.; Shin, D. C.] Univ So Calif, Los Angeles, CA 90089 USA; [Orme, M. E.] Sonovation, Los Angeles, CA USA; [Zhang, R.] Univ Texas Dallas, SW Med Ctr, Dallas, TX USA	Marmarelis, VZ (corresponding author), Univ So Calif, Los Angeles, CA 90089 USA.	vzm@usc.edu			Biomedical Simulations Resource at the University of Southern California under NIH/NIBIB [P41-EB001978]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033106-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB001978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033106] Funding Source: NIH RePORTER	This work was supported in part by the Biomedical Simulations Resource at the University of Southern California under NIH/NIBIB grant P41-EB001978 and NIA R01AG033106-01 grant to the UT-Southwestern Medical Center.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Bellapart J., ULTRASOUND MED BIOL, DOI [10.1016/j.ultrasmedbio.2009, DOI 10.1016/J.ULTRASMEDBI0.2009]; BUSSE R, 1985, BASIC RES CARDIOL, V80, P475, DOI 10.1007/BF01907912; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Giller CA, 2003, MED ENG PHYS, V25, P633, DOI 10.1016/S1350-4533(03)00028-6; Hu K, 2008, CARDIOVASC ENG, V8, P60, DOI 10.1007/s10558-007-9045-5; Iadecola C, 2004, NAT REV NEUROSCI, V5, P347, DOI 10.1038/nrn1387; Marmarelis Vz, 2012, Open Biomed Eng J, V6, P42, DOI 10.2174/1874230001206010042; Marmarelis VZ, 1997, ANN BIOMED ENG, V25, P239, DOI 10.1007/BF02648038; MARMARELIS VZ, 1993, ANN BIOMED ENG, V21, P573, DOI 10.1007/BF02368639; Marmarelis VZ, 2004, NONLINEAR DYNAMIC MO; Mitsis GD, 2004, IEEE T BIO-MED ENG, V51, P1932, DOI 10.1109/TBME.2004.834272; Mitsis GD, 2002, ANN BIOMED ENG, V30, P555, DOI 10.1114/1.1477448; Mitsis GD, 2006, J APPL PHYSIOL, V101, P354, DOI 10.1152/japplphysiol.00548.2005; Mitsis GD, 2009, IEEE ENG MED BIOL, V28, P54, DOI 10.1109/MEMB.2009.934908; Panerai RB, 2000, IEEE T BIO-MED ENG, V47, P419, DOI 10.1109/10.827312; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089; Panerai RB, 2008, CARDIOVASC ENG, V8, P42, DOI 10.1007/s10558-007-9044-6; van Beek AHEA, 2008, J CEREBR BLOOD F MET, V28, P1071, DOI 10.1038/jcbfm.2008.13; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zhang R, 2002, CIRCULATION, V106, P1814, DOI 10.1161/01.CIR.0000031798.07790.FE; Zhang R, 2007, HYPERTENSION, V49, P1149, DOI 10.1161/HYPERTENSIONAHA.106.084939; Zhang R, 2009, J PHYSIOL-LONDON, V587, P2567, DOI 10.1113/jphysiol.2008.168302	23	23	23	0	24	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2013	41	5					1029	1048		10.1007/s10439-012-0736-8			20	Engineering, Biomedical	Engineering	124LJ	WOS:000317465000014	23292615	Green Accepted			2021-06-18	
J	Nishijima, DK; Haukoos, JS; Newgard, CD; Staudenmayer, K; White, N; Slattery, D; Maxim, PC; Gee, CA; Hsia, RY; Melnikow, JA; Holmes, JF				Nishijima, Daniel K.; Haukoos, Jason S.; Newgard, Craig D.; Staudenmayer, Kristan; White, Nathan; Slattery, David; Maxim, Preston C.; Gee, Christopher A.; Hsia, Renee Y.; Melnikow, Joy A.; Holmes, James F.			Variability of ICU Use in Adult Patients With Minor Traumatic Intracranial Hemorrhage	ANNALS OF EMERGENCY MEDICINE			English	Article							BRAIN-INJURY; EMERGENCY-DEPARTMENT; AMERICAN-COLLEGE; ADMISSION; TOMOGRAPHY; UTILITY; RULE	Study objective: Patients with minor traumatic intracranial hemorrhage are frequently admitted to the ICU, although many never require critical care interventions. To describe ICU resource use in minor traumatic intracranial hemorrhage, we assess (1) the variability of ICU use in a cohort of patients with minor traumatic intracranial hemorrhage across multiple trauma centers, and (2) the proportion of adult patients with traumatic intracranial hemorrhage who are admitted to the ICU and never receive a critical care intervention during hospitalization. In addition, we evaluate the association between ICU admission and key independent variables. Methods: A structured, historical cohort study of adult patients (aged 18 years and older) with minor traumatic intracranial hemorrhage was conducted within a consortium of 8 Level I trauma centers in the western United States from January 2005 to June 2010. The study population included patients with minor traumatic intracranial hemorrhage, defined as an emergency department (ED) Glasgow Coma Scale (GCS) score of 15 (normal mental status) and an Injury Severity Score less than 16 (no other major organ injury). The primary outcome measure was initial ICU admission. The secondary outcome measure was a critical care intervention during hospitalization. Critical care interventions included mechanical ventilation, neurosurgical intervention, transfusion of blood products, vasopressor or inotrope administration, and invasive hemodynamic monitoring. ED disposition and the proportion of ICU patients not receiving a critical care intervention were compared across sites with descriptive statistics. The association between ICU admission and predetermined independent variables was analyzed with multivariable regression. Results: Among 11,240 adult patients with traumatic intracranial hemorrhage, 1,412 (13%) had minor traumatic intracranial hemorrhage and complete ED disposition data (mean age 48 years; SD 20 years). ICU use within this cohort across sites ranged from 50% to 97%. Overall, 847 of 888 patients (95%) with minor traumatic intracranial hemorrhage who were admitted to the ICU did not receive a critical care intervention during hospitalization (range between sites 80% to 100%). Three of 524 (0.6%) patients discharged home or admitted to the observation unit or ward received a critical care intervention. After controlling for severity of injury (age, blood pressure, and Injury Severity Score), study site was independently associated with ICU admission (odds ratios ranged from 1.5 to 30; overall effect P<.001). Conclusion: Across a consortium of trauma centers in the western United States, there was wide variability in ICU use within a cohort of patients with minor traumatic intracranial hemorrhage. Moreover, a large proportion of patients admitted to the ICU never required a critical care intervention, indicating the potential to improve use of critical care resources in patients with minor traumatic intracranial hemorrhage.	[Nishijima, Daniel K.; Holmes, James F.] UC Davis Sch Med, Dept Emergency Med, Sacramento, CA USA; [Melnikow, Joy A.] UC Davis Sch Med, Dept Family & Community Med, Sacramento, CA USA; [Haukoos, Jason S.] Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO USA; [Newgard, Craig D.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; [Staudenmayer, Kristan] Stanford Univ, Sch Med, Dept Surg, Palo Alto, CA 94304 USA; [White, Nathan] Univ Washington, Sch Med, Div Emergency Med, Seattle, WA USA; [Slattery, David] Univ Nevada, Sch Med, Dept Emergency Med, Las Vegas, NV 89154 USA; [Maxim, Preston C.; Hsia, Renee Y.] UCSF Sch Med, Dept Emergency Med, San Francisco, CA USA; [Gee, Christopher A.] Univ Utah, Sch Med, Div Emergency Med, Salt Lake City, UT USA	Nishijima, DK (corresponding author), UC Davis Sch Med, Dept Emergency Med, Sacramento, CA USA.	daniel.nishijima@ucdmc.ucdavis.edu		White, Nathan/0000-0002-3752-310X	UC Davis Clinical and Translational Science Center [UL1 RR024146]; Colorado Clinical and Translational Science Institute [UL1 RR025780]; Oregon Clinical and Translational Research Institute [UL1 RR024140]; Stanford Center for Clinical and Translational Education and Research [1UL1 RR025744]; Institute of Translational Health Sciences at the University of Washington [UL1 RR025014]; University of Utah Center for Clinical and Translational Science [UL1-RR025764, C06-RR11234]; UCSF Clinical and Translational Science Institute [UL1 RR024131]; Robert Wood Johnson Foundation (RWJF) Physician Faculty Scholars ProgramRobert Wood Johnson Foundation (RWJF); National Center for Advancing Translational Sciences [NCATS], a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000421] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025780, UL1RR024140, UL1RR024131, C06RR011234, UL1RR025764, UL1RR025744, UL1RR024146, UL1RR025014] Funding Source: NIH RePORTER	Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This project was supported by the UC Davis Clinical and Translational Science Center (grant UL1 RR024146), Colorado Clinical and Translational Science Institute (grant UL1 RR025780), Oregon Clinical and Translational Research Institute (grant UL1 RR024140), Stanford Center for Clinical and Translational Education and Research (grant 1UL1 RR025744), Institute of Translational Health Sciences at the University of Washington (grant UL1 RR025014), University of Utah Center for Clinical and Translational Science (grants UL1-RR025764 and C06-RR11234), UCSF Clinical and Translational Science Institute (grant UL1 RR024131), and the Robert Wood Johnson Foundation (RWJF) Physician Faculty Scholars Program. All Clinical and Translational Science Awards are from the National Center for Research Resources (now National Center for Advancing Translational Sciences [NCATS]), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The NIH and the RWJF had no role in the design and conduct of the study, in the analysis or interpretation of the data, or in the preparation of the data. Dr. Nishijima had full access to all the data and had final responsibility for the decision to submit for publication. The views expressed in this article are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH. Information on NCATS is available at http://www.ncats.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translationalasp.	[Anonymous], HEAD INJ TRIAG ASS I; Baker N, 2010, REDUCING COSTS APPRO; Barker DE, 2006, AM SURGEON, V72, P1166; Bolorunduro OB, 2011, J SURG RES, V166, P40, DOI 10.1016/j.jss.2010.04.012; BONE RC, 1993, CHEST, V104, P1806, DOI 10.1378/chest.104.6.1806; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Egol A, 1999, CRIT CARE MED, V27, P633; Escher M, 2004, BRIT MED J, V329, P425, DOI 10.1136/bmj.329.7463.425; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Huynh T, 2006, AM SURGEON, V72, P1162; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; Newgard CD, 2011, J AM COLL SURGEONS, V213, P709, DOI 10.1016/j.jamcollsurg.2011.09.012; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; Robert R, 2012, AM J RESP CRIT CARE, V185, P1081, DOI 10.1164/rccm.201104-0729OC; Salottolo K, 2009, INJURY, V40, P999, DOI 10.1016/j.injury.2009.05.013; Schaller B, 2010, EMERG MED J, V27, P537, DOI 10.1136/emj.2009.073031; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; U.S. Department of Health and Human Services, 1997, INT CLASS DIS 9 REV; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Viera AJ, 2005, FAM MED, V37, P360; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Welch RD, 2001, EMERG MED CLIN N AM, V19, P137, DOI 10.1016/S0733-8627(05)70172-3; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021; Zehtabchi S, 2011, ACAD EMERG MED, V18, P637, DOI 10.1111/j.1553-2712.2011.01083.x	36	23	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAY	2013	61	5					509	517		10.1016/j.annemergmed.2012.08.024			9	Emergency Medicine	Emergency Medicine	145OW	WOS:000319027500003	23021347	Green Accepted, Other Gold			2021-06-18	
J	Ragsdale, KA; Neer, SM; Beidel, DC; Frueh, BC; Stout, JW				Ragsdale, Katie A.; Neer, Sandra M.; Beidel, Deborah C.; Frueh, B. Christopher; Stout, Jeremy W.			Posttraumatic stress disorder in OEF/OIF veterans with and without traumatic brain injury	JOURNAL OF ANXIETY DISORDERS			English	Article						Posttraumatic stress disorder; Traumatic brain injury; OEF/OIF; Veteran	PERSISTENT POSTCONCUSSIVE SYMPTOMS; PSYCHOMETRIC PROPERTIES; PTSD; MILITARY; AFGHANISTAN; DEPLOYMENT; IRAQ; PREVALENCE; DEPRESSION; SEVERITY	Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) are presenting with high rates of co-occurring posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI). The purpose of this study was to compare the clinical presentations of combat-veterans with PTSD and TBI (N=40) to those with PTSD only (N=56). Results suggest that the groups present two distinct clinical profiles, with the PTSD+TBI group endorsing significantly higher PTSD scores, higher overall anxiety, and more functional limitations. The higher PTSD scores found for the PTSD+TBI group appeared to be due to higher symptom intensity, but not higher frequency, across PTSD clusters and symptoms. Groups did not differ on additional psychopathology or self-report of PTSD symptoms or executive functioning. Further analysis indicated PTSD severity, and not TBI, was responsible for group differences, suggesting that treatments implicated for PTSD would likely be effective for this population. (C) 2013 Elsevier Ltd. All rights reserved.	[Ragsdale, Katie A.; Neer, Sandra M.; Beidel, Deborah C.; Stout, Jeremy W.] Univ Cent Florida, Dept Psychol, Orlando, FL 32816 USA; [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA	Ragsdale, KA (corresponding author), Univ Cent Florida, Anxiety Disorders Clin, Dept Psychol, 4000 Cent Florida Blvd, Orlando, FL 32816 USA.	KatieRagsdale@knights.ucf.edu; Sandra.Neer@ucf.edu; Deborah.Beidel@ucf.edu; frueh@hawaii.edu; jwstout@knights.ucf.edu					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Bunnell B. E., 2013, J ABNORMAL PSYCHOL; Callahan BL, 2011, BRAIN COGNITION, V77, P412, DOI 10.1016/j.bandc.2011.08.017; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Department of Defense, 2012, DOD WORLDW NUMB TRAU; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Epidemiology Program Post Deployment Health Strategic Healthcare Group Office of Public Health Veterans Health Administration Department of Veterans Affairs, 2012, AN VA HLTH CAR UT OP; Ferrier-Auerbach AG, 2010, J PSYCHIATR RES, V44, P470, DOI 10.1016/j.jpsychires.2009.10.010; First M.B., 1996, STRUCTURED CLIN INTE; Forbes D., 2012, PSYCHIAT RES, V44, P470; FOY DW, 1984, J CONSULT CLIN PSYCH, V52, P79, DOI 10.1037/0022-006X.52.1.79; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Herman D., 1993, ANN CONV INT SOC TRA; Hermann BA, 2012, MIL MED, V177, P1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lauterbach D, 2001, J TRAUMA STRESS, V14, P29; Marshall KR, 2012, MIL MED, V177, P67, DOI 10.7205/MILMED-D-12-00110; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Roth R.M., 2005, BEHAV RATING INVENTO; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Waid-Ebbs JK, 2012, BRAIN INJURY, V26, P1646, DOI 10.3109/02699052.2012.700087; Walker RL, 2010, PSYCHOL SERV, V7, P136, DOI 10.1037/a0019684; Ware J, 2003, VERSION 2 SF 36 HLTH; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 2000, SCORE VERSION 2 SF 3; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Zawadzki B, 2012, J INDIVID DIFFER, V33, P257, DOI 10.1027/1614-0001/a000074	46	23	23	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6185	1873-7897		J ANXIETY DISORD	J. Anxiety Disord.	MAY	2013	27	4					420	426		10.1016/j.janxdis.2013.04.003			7	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	184IJ	WOS:000321883000008	23746495				2021-06-18	
